Wild-type BRAF indicates that no mutation has been detected within the BRAF gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,13
"BRAF V600E (previously reported as V599) lies within the activation segment of the kinase domain of the Braf protein (PMID: 15035987). V600E confers a gain of function to the Braf protein as demonstrated by increased Braf kinase activity, downstream signaling, and the ability to transform cells in culture (PMID: 15035987).",146,15035987,Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.,http://www.ncbi.nlm.nih.gov/pubmed/15035987,49
"BRAF V600K (previously reported as V599) lies within the activation segment of the kinase domain of the Braf protein (PMID: 15035987). V600K confers a gain of function to the Braf protein as demonstrated by increased kinase activity, downstream signaling, and the ability to transform cells in vitro (PMID: 15035987).",146,15035987,Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.,http://www.ncbi.nlm.nih.gov/pubmed/15035987,50
NRAS mutant indicates an unspecified mutation in the NRAS gene. ,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,51
"PIK3CA H1047R is a hotspot mutation that lies within the kinase domain of the Pik3ca protein (UniProt.org). H1047R results in increased phosphorylation of Akt and Mek1/2, growth factor-independent cell survival, and is transforming in cell culture (PMID: 26627007).",295,,,www.uniprot.org,4255,26627007,Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26627007,53
Wild-type EGFR indicates that no mutation has been detected within the EGFR gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,163
Wild-type KDR (VEGFR2) indicates that no mutation has been detected within the KDR (VEGFR2) gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,270
EGFR exon 19 deletions result in increased EGFR kinase activity and induce oncogenic transformation of cells  (PMID: 16912195; PMID:17495523).,21,16912195,"Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib.",http://www.ncbi.nlm.nih.gov/pubmed/16912195,271
"EGFR L858R lies within the protein kinase domain of the Egfr protein (UniProt.org). L858R results in increased kinase activity, is transforming in cell culture, and promotes tumor formation in mouse models (PMID: 16187797).",410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,295,,,www.uniprot.org,273
"EGFR T790M is a gatekeeper mutation that lies within the ATP-binding pocket of the Egfr protein (PMID: 20026433). T790M results increased Egfr kinase activity, and is a frequently occurring secondary somatic mutation that results in resistance to reversible tyrosine kinase inhibitors (PMID: 18227510, PMID: 20026433).",442,18227510,The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.,http://www.ncbi.nlm.nih.gov/pubmed/18227510,443,20026433,Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20026433,274
Wild-type AKT1 indicates that no mutation has been detected within the AKT1 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,276
Wild-type ALK indicates that no mutation has been detected within the ALK gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,295
"DNMT3A inact mut indicates that this variant results in a loss of function of the DNMT3A protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,314
"DNMT3A act mut indicates that this variant results in a gain of function in the DNMT3A protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,315
"EGFR act mut indicates that this variant results in a gain of function in the Egfr protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,327
PIK3CA mutant indicates an unspecified mutation within the PIK3CA gene. ,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,333
Wild-type PIK3CA indicates that no mutation has been detected within the PIK3CA gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,334
TP53 mutant indicates an unspecified mutation within the TP53 gene. ,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,338
Wild-type BRCA2 indicates that no mutation has been detected within the BRCA2 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,346
"EGFR amp indicates an increased number of copies of the EGFR gene. However, the mechanism causing the increase is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,352
KRAS mutant indicates an unspecified mutation in the KRAS gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,353
BRAF mutant indicates an unspecified mutation in the BRAF gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,370
"KIT amp indicates an increased number of copies of the KIT gene. However, the mechanism causing the increase is unspecified. ",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,378
"PTEN loss indicates a loss of the PTEN gene, mRNA, or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,384
"Wild-type NRAS indicates that no mutation has been detected within the NRAS gene.
",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,386
"TP53 inact mut indicates that this variant results in a loss of function of the Tp53 protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,394
Wild-type KRAS indicates that no mutation has been detected within the KRAS gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,401
404
"KRAS G12R is a hotspot mutation that lies within a GTP binding region of the Kras protein (UniProt.org). G12R results in decreased Kras GTPase activity and increased activation of downstream signaling in cell culture (PMID: 23455880, PMID: 26037647).",295,,,www.uniprot.org,3052,26037647,Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26037647,26,23455880,KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23455880,408
"KDR (VEGFR2) Q472H does not lie within any known functional domains of the Kdr (Vegfr2) protein (UniProt.org). Q472H confers a gain of function to the Kdr (Vegfr2) protein, resulting in increased phosphorylation of Kdr (Vegfr2) in cell culture, increased serum VEGF levels, and increased microvessel density in tumor samples (PMID: 21712447, PMID: 26631613).",4818,26631613,Identification of a Novel Pathogenic Germline KDR Variant in Melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/26631613,295,,,www.uniprot.org,20,21712447,Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21712447,412
"GNAS R201C (corresponding to R844C in isoform XLas-1) lies within the GTP binding domain of the Gnas short isoform 1 (UniProt.org). R201C results in a loss of the GTPase activity of Gnas leading to constitutive downstream pathway activation, cell proliferation, and tumor formation in mouse models (PMID: 20531296, PMID: 24498230).",2540,20531296,The activating mutation R201C in GNAS promotes intestinal tumourigenesis in Apc(Min/+) mice through activation of Wnt and ERK1/2 MAPK pathways.,http://www.ncbi.nlm.nih.gov/pubmed/20531296,2541,24498230,"GNAS mutations identify a set of right-sided, RAS mutant, villous colon cancers.",http://www.ncbi.nlm.nih.gov/pubmed/24498230,295,,,www.uniprot.org,413
Wild-type TP53 indicates that no mutation has been detected within the TP53 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,414
"AKT1 E17K lies within the PH domain of the Akt1 protein (UniProt.org). E17K leads to constitutive activation of Akt1, activates downstream signaling, and is transforming in culture (PMID: 17611497).",9005,17611497,A transforming mutation in the pleckstrin homology domain of AKT1 in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17611497,295,,,www.uniprot.org,415
Wild-type APC indicates that no mutation has been detected within the APC gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,416
Wild-type ATM indicates that no mutation has been detected within the ATM gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,417
Wild-type ASXL1 indicates that no mutation has been detected within the ASXL1 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,419
Wild-type ATRX indicates that no mutation has been detected within the ATRX gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,420
"ALK I1461V lies within the cytoplasmic domain of the Alk protein (UniProt.org). I1461V has not been characterized in the scientific literature and therefore, its effect on Alk protein function is unknown (PubMed, Oct 2017).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,421
"NRAS Q61K lies within a GTP-binding region of the Nras protein (UniProt.org). Q61K induces cell survival, results in increased activation of downstream pathway signaling, and is transforming in cell culture (PMID: 22718121).",295,,,www.uniprot.org,10132,22718121,"Activated mutant NRas(Q61K) drives aberrant melanocyte signaling, survival, and invasiveness via a Rac1-dependent mechanism.",http://www.ncbi.nlm.nih.gov/pubmed/22718121,423
MAP2K1 K57N does not lie within any known functional domains of the Map2k1 protein (UniProt.org). K57N results in increased Erk phosphorylation and oncogenesis in cell culture (PMID: 18632602).,119,18632602,Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18632602,295,,,www.uniprot.org,425
Wild-type ABL1 indicates that no mutation has been detected within the ABL1 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,426
BRCA1 wild-type indicates that no mutation has been detected within the BRCA1 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,434
Wild-type CBL indicates that no mutation has been detected within the CBL gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,435
"MAP2K1 Q56P does not lie within any known functional domains of the Map2k1 protein (UniProt.org). Q56P confers a gain of function to the Map2k1 protein as indicated by increased kinase activity and the ability to transform cultured cells (PMID: 22327936, PMID: 7651428).",135,22327936,Oncogenic MAP2K1 mutations in human epithelial tumors.,http://www.ncbi.nlm.nih.gov/pubmed/22327936,260,7651428,RAS signalling is abnormal in a c-raf1 MEK1 double mutant.,http://www.ncbi.nlm.nih.gov/pubmed/7651428,436
ATM N1650S does not lie within any known functional domains of the Atm protein (UniProt.org). N1650S results in impaired Atm phosphorylation of Tp53 and Chek2 in cultured cells (PMID: 12969974).,136,12969974,Identification and characterization of polymorphic variations of the ataxia telangiectasia mutated (ATM) gene in childhood Hodgkin disease.,http://www.ncbi.nlm.nih.gov/pubmed/12969974,295,,,www.uniprot.org,437
"ATM inact mut indicates that this variant results in a loss of function of the Atm protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,438
Wild-type CDKN2A indicates that no mutation has been detected within the CDKN2A gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,439
Wild-type CSF1R indicates that no mutation has been detected within the CSF1R gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,440
Wild-type CTNNB1 indicates that no mutation has been detected within the CTNNB1 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,441
Wild-type DNMT3A indicates that no mutation has been detected within the DNMT3A gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,443
"DNMT3A R882H lies within the dimer interface region of the Dnmt3a protein (PMID: 22722925). R882H disrupts the tetramerization ability of the Dnmt3a protein, resulting in reduced DNA binding affinity, reduced methylation activity, and altered catalytic activity (PMID: 22722925).",2887,22722925,Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation.,http://www.ncbi.nlm.nih.gov/pubmed/22722925,444
"EGFR G719S lies within the phosphate-binding “P loop” in the protein kinase domain of the Egfr protein (PMID: 17349580). G719S results in constitutive ligand-independent phosphorylation of Egfr and activation of STAT5, ERK1/2, and AKT, and is transforming in cell culture (PMID: 16204070, PMID: 24894453, PMID: 18573086).",9916,18573086,Structure-based view of epidermal growth factor receptor regulation.,http://www.ncbi.nlm.nih.gov/pubmed/18573086,438,17349580,Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.,http://www.ncbi.nlm.nih.gov/pubmed/17349580,445
Wild-type ERBB2 (HER2) indicates that no mutation has been detected within the ERBB2 (HER2) gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,447
"ERBB2 (HER2) amplification indicates an increased number of copies of the ERBB2 (HER2) gene. However, the mechanism causing the increase is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,448
Wild-type ERBB4 indicates that no mutation has been detected within the ERBB4 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,450
"BRAF G469A lies within the protein kinase domain of the Braf protein (UniProt.org). G469A results in increased Braf kinase activity and downstream activation of Erk, and is transforming in cell culture (PMID: 19010912, PMID: 12068308).",636,19010912,Genetic predictors of MEK dependence in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19010912,637,12068308,Mutations of the BRAF gene in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/12068308,295,,,www.uniprot.org,452
"BRAF V600D (previously reported as V599) lies within the activation segment of the kinase domain of the Braf protein (PMID: 15035987). V600D confers a gain of function to the Braf protein as demonstrated by increased kinase activity, downstream signaling, and the ability to transform cells in vitro (PMID: 15035987).",146,15035987,Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.,http://www.ncbi.nlm.nih.gov/pubmed/15035987,454
"BRAF V600R (previously reported as V599) lies within the activation segment of the kinase domain of the Braf protein (PMID: 15035987). V600R confers a gain of function to the Braf protein as demonstrated by increased Braf kinase activity, downstream signaling, and the ability to transform cells in culture (PMID: 15035987).",146,15035987,Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.,http://www.ncbi.nlm.nih.gov/pubmed/15035987,455
"BRAF K601E lies within the activation segment in the kinase domain of the Braf protein (PMID: 15343278). K601E results in increased Braf kinase activity and downstream activation of MEK and ERK in cell culture (PMID: 22798288, PMID: 28783719).",9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,3,22798288,BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/22798288,9694,15343278,Switching on kinases: oncogenic activation of BRAF and the PDGFR family.,http://www.ncbi.nlm.nih.gov/pubmed/15343278,456
BRAF L597V lies within the protein kinase domain of the Braf protein (UniProt.org). L597V results in activation of Braf as indicated by increased phosphorylation of Mek and Erk in cell culture (PMID: 22798288).,3,22798288,BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/22798288,464
"BRAF G464V (also reported as G463V) lies within the protein kinase domain of the Braf protein (UniProt.org). G464V results in increased Braf kinase activity, and increased downstream Erk signaling (PMID: 12068308).",637,12068308,Mutations of the BRAF gene in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/12068308,295,,,www.uniprot.org,465
"BRAF G469E lies within the protein kinase domain of the Braf protein (UniProt.org). G469E has been described having low Braf kinase activity (PMID: 28783719) and intermediate Braf kinase activity (PMID: 15035987), and results in Ras-dependent activation of ERK signaling in cell culture (PMID: 28783719).",295,,,www.uniprot.org,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,146,15035987,Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.,http://www.ncbi.nlm.nih.gov/pubmed/15035987,467
"BRAF G466V lies within the protein kinase domain of the Braf protein (UniProt.org). G466V results in impaired Braf kinase activity, however, paradoxically activates MEK and ERK through transactivation of c-RAF in cell culture (PMID: 22649091, PMID: 28783719).",9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,423,22649091,Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.,http://www.ncbi.nlm.nih.gov/pubmed/22649091,470
Wild-type EZH2 indicates that no mutation has been detected within the EZH2 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,472
EZH2 Y641X is an activating mutation which increases the catalytic efficiency for H3K27me3 (PMID: 24362326).,149,24362326,"EZH2: biology, disease, and structure-based drug discovery.",http://www.ncbi.nlm.nih.gov/pubmed/24362326,473
EZH2 Y641F lies within the SET domain of the Ezh2 protein (UniProt.org). Y641F alters the substrate specificity of the Ezh2 protein and increases the catalytic efficiency for H3K27 trimethylation (PMID: 21190999).,505,21190999,"Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.",http://www.ncbi.nlm.nih.gov/pubmed/21190999,295,,,www.uniprot.org,474
"EZH2 Y641N lies within the SET domain of the Ezh2 protein (PMID: 24362326). Y641N confers a gain-of-function on Ezh2, leading to increased trimethylation of H3K27 in B-cell lymphoma cells in culture (PMID: 21190999).",149,24362326,"EZH2: biology, disease, and structure-based drug discovery.",http://www.ncbi.nlm.nih.gov/pubmed/24362326,505,21190999,"Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.",http://www.ncbi.nlm.nih.gov/pubmed/21190999,475
EZH2 Y641S lies within the SET domain of the Ezh2 protein (UniProt.org). Y641S alters the substrate specificity of the Ezh2 protein and increases the catalytic efficiency for H3K27 trimethylation (PMID: 21190999).,505,21190999,"Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.",http://www.ncbi.nlm.nih.gov/pubmed/21190999,295,,,www.uniprot.org,476
EZH2 Y641H lies within the SET domain of the Ezh2 protein (UniProt.org). Y641H alters the substrate specificity of the Ezh2 protein and increases the catalytic efficiency for H3K27 trimethylation (PMID: 21078963).,295,,,www.uniprot.org,2703,21078963,Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas.,http://www.ncbi.nlm.nih.gov/pubmed/21078963,477
"EZH2 Y641C lies within the SET domain of the Ezh2 protein (UniProt.org). Y641C alters the substrate specificity of the Ezh2 protein and increases the catalytic efficiency for H3K27 trimethylation (PMID: 24362326).
",295,,,www.uniprot.org,149,24362326,"EZH2: biology, disease, and structure-based drug discovery.",http://www.ncbi.nlm.nih.gov/pubmed/24362326,478
"ABL1 T315I is a gatekeeper mutation that lies within the hinge region of the protein kinase domain of the Abl1 protein (PMID: 18794843). T315I has been demonstrated to occur as a secondary resistance mutation in the context of BCR-ABL and results in increased kinase activity and transformation in cultured cells (PMID: 11423618, PMID: 18794843). ",644,18794843,Activation of tyrosine kinases by mutation of the gatekeeper threonine.,http://www.ncbi.nlm.nih.gov/pubmed/18794843,2379,11423618,Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.,http://www.ncbi.nlm.nih.gov/pubmed/11423618,480
"ALK L1196M is a gatekeeper mutation, which confers resistance to crizotinib and results in activation of the Alk protein in cultured cells (PMID: 24768039, PMID: 21613408, PMID: 20979473).",912,20979473,EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/20979473,151,24768039,Standardized decision support in next generation sequencing reports of somatic cancer variants.,http://www.ncbi.nlm.nih.gov/pubmed/24768039,2442,21613408,Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/21613408,481
Wild-type FBXW7 indicates that no mutation has been detected within the FBXW7 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,484
Wild-type FGFR1 indicates that no mutation has been detected within the FGFR1 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,485
Wild-type FGFR2 indicates that no mutation has been detected within the FGFR2 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,486
Wild-type FGFR3 indicates that no mutation has been detected within the FGFR3 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,487
Wild-type FLT3 indicates that no mutation has been detected within the FLT3 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,488
"FGFR2 N549K lies within the protein kinase domain of the FGFR2 protein (UniProt.org). N549K confers a gain of function to the Fgfr2 protein, resulting in oncogenic transformation in cell-based studies (PMID: 18552176, PMID: 17803937).",252,18552176,Drug-sensitive FGFR2 mutations in endometrial carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18552176,1905,17803937,A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases.,http://www.ncbi.nlm.nih.gov/pubmed/17803937,490
Wild-type GNA11 indicates that no mutation has been detected within the GNA11 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,491
"GNA11 Q209P lies within a GTP binding region of the Gna11 protein (UniProt.org). Q209P is hotspot mutation in Gna11, which has not been biochemically characterized, but is predicted to result in loss of Gna11 GTPase activity and activation of downstream signaling based on the effects of other Q209 mutations (PMID: 23640210, PMID: 21083380).",8762,21083380,Mutations in GNA11 in uveal melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/21083380,253,23640210,The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23640210,295,,,www.uniprot.org,492
"GNA11 Q209L lies within a GTP binding region of the Gna11 protein (UniProt.org). Q209L is a hotspot mutation in Gna11, which interferes with Gna11 GTPase activity and results in increased downstream signaling in culture, and increased tumor growth in mouse models (PMID: 21083380, PMID: 24141786, PMID: 23640210).",772,24141786,Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24141786,8762,21083380,Mutations in GNA11 in uveal melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/21083380,253,23640210,The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23640210,295,,,www.uniprot.org,493
"GNA11 Q209R lies within a GTP binding region of the Gna11 protein (UniProt.org). Q209R is hotspot mutation in Gna11, which has not been biochemically characterized, but is predicted to result in loss of Gna11 GTPase activity and activation of downstream signaling based on the effects of other Q209 mutations (PMID: 23640210, PMID: 21083380).",295,,,www.uniprot.org,8762,21083380,Mutations in GNA11 in uveal melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/21083380,253,23640210,The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23640210,494
"GNA11 Q209K lies within a GTP binding region of the Gna11 protein (UniProt.org). Q209K is a hotspot mutation in Gna11, which has not been biochemically characterized, but is predicted to result in loss of Gna11 GTPase activity and activation of downstream signaling based on the effects of other Q209 mutations (PMID: 23640210, PMID: 21083380).",295,,,www.uniprot.org,8762,21083380,Mutations in GNA11 in uveal melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/21083380,253,23640210,The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23640210,495
"GNA11 Q209X indicates any amino acid change at position 209 within a GTP binding region of the Gnaq protein (UniProt.org). Q209 mutations are hotspot mutations in Gna11, which impair the intrinsic GTPase function of Gna11, resulting in constitutive activation of downstream signaling (PMID: 23640210).",253,23640210,The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23640210,295,,,www.uniprot.org,496
"GNA11 R183Q lies within a GTP binding region of the Gna11 protein (UniProt.org). R183Q is a hotspot mutation in Gna11, which has not been biochemically characterized, but is predicted to interfere with Gna11 GTPase activity resulting in activation of downstream signaling based on the effects of other R183 mutations (PMID: 21083380, PMID: 26778290, PMID: 22307269).",295,,,www.uniprot.org,8762,21083380,Mutations in GNA11 in uveal melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/21083380,8769,26778290,Mosaic Activating Mutations in GNA11 and GNAQ Are Associated with Phakomatosis Pigmentovascularis and Extensive Dermal Melanocytosis.,http://www.ncbi.nlm.nih.gov/pubmed/26778290,453,22307269,GNAQ and GNA11 mutations in melanocytomas of the central nervous system.,http://www.ncbi.nlm.nih.gov/pubmed/22307269,497
"GNA11 R183C lies within a GTP binding region of the Gna11 protein (UniProt.org). R183C is a hotspot mutation in Gna11, which interferes with Gna11 GTPase activity and results in increased downstream signaling in culture and increased tumor growth in mouse models (PMID: 21083380, PMID: 26778290, PMID: 23640210).",253,23640210,The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23640210,8769,26778290,Mosaic Activating Mutations in GNA11 and GNAQ Are Associated with Phakomatosis Pigmentovascularis and Extensive Dermal Melanocytosis.,http://www.ncbi.nlm.nih.gov/pubmed/26778290,295,,,www.uniprot.org,8762,21083380,Mutations in GNA11 in uveal melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/21083380,498
"GNA11 R183H lies within a GTP binding region of the Gna11 protein (UniProt.org). R183H is a hotspot mutation in Gna11, which has not been biochemically characterized, but is predicted to interfere with Gna11 GTPase activity resulting in activation of downstream signaling based on the effects of other R183 mutations (PMID: 21083380, PMID: 26778290, PMID: 23640210).",8762,21083380,Mutations in GNA11 in uveal melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/21083380,8769,26778290,Mosaic Activating Mutations in GNA11 and GNAQ Are Associated with Phakomatosis Pigmentovascularis and Extensive Dermal Melanocytosis.,http://www.ncbi.nlm.nih.gov/pubmed/26778290,253,23640210,The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23640210,295,,,www.uniprot.org,499
"GNA11 R183X indicates any amino acid change at position 183 within a GTP binding region of the Gnaq protein (UniProt.org). R183 mutations are hotspot mutations in Gna11, which impair the intrinsic GTPase function of Gna11, resulting in constitutive activation of downstream signaling (PMID: 23640210).",253,23640210,The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23640210,295,,,www.uniprot.org,500
Wild-type GNAQ indicates that no mutation has been detected within the GNAQ gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,501
"GNAQ R209X indicates any amino acid change at position 209 within a GTP binding region of the Gnaq protein (UniProt.org). R209 mutations are hotspot mutations in Gnaq, which impair GTPase function, resulting in constitutive activation of Gnaq and downstream signaling (PMID: 23640210).",253,23640210,The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23640210,295,,,www.uniprot.org,502
"GNAQ Q209P lies within a GTP binding region of the Gnaq protein (UniProt.org). Q209P is a hotspot mutation in Gnaq, which interferes with Gna11 GTPase activity and results in increased downstream signaling in cell culture (PMID: 23640210, PMID: 23904987, PMID: 24504448).",8771,24504448,Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/24504448,253,23640210,The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23640210,8772,23904987,GNAQ and BRAF mutations show differential activation of the mTOR pathway in human transformed cells.,http://www.ncbi.nlm.nih.gov/pubmed/23904987,503
"GNAQ Q209L lies within the GTPase domain of the Gnaq protein (PMID: 19936769). Q209L is a hotspot mutation in Gnaq, which interferes with Gnaq GTPase activity and results in downstream pathway activation and transformation in cell culture, and increased tumor growth in mouse models (PMID: 23640210, PMID: 19936769, PMID: 21083380).",253,23640210,The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23640210,909,19936769,Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system.,http://www.ncbi.nlm.nih.gov/pubmed/19936769,8762,21083380,Mutations in GNA11 in uveal melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/21083380,504
"GNAQ Q209R lies within the GTPase domain of the Gnaq protein (PMID: 19936769). Q209R is a ""hotspot"" mutation, which impairs GTPase function, rendering Gnaq and downstream pathways constitutively active (PMID: 23640210).",253,23640210,The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23640210,909,19936769,Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system.,http://www.ncbi.nlm.nih.gov/pubmed/19936769,505
"GNAQ Q209H lies within the GTPase domain of the Gnaq protein (PMID: 19936769). Q209H is a ""hotspot"" mutation, which impairs GTPase function, rendering Gnaq and downstream pathways constitutively active (PMID: 23640210, PMID: 28084343 ).",253,23640210,The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23640210,909,19936769,Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system.,http://www.ncbi.nlm.nih.gov/pubmed/19936769,9917,28084343,Recurrent GNAQ mutations in anastomosing hemangiomas.,http://www.ncbi.nlm.nih.gov/pubmed/28084343,506
"GNAQ Q209K lies within a GTP binding region of the Gnaq protein (UniProt.org). Q209K is a hotspot mutation in Gnaq, which has not been biochemically characterized, but is predicted to interfere with Gna11 GTPase activity resulting in activation of downstream signaling based on the effects of other Q209 mutations (PMID: 23640210, PMID: 21083380, PMID: 24504448).",8762,21083380,Mutations in GNA11 in uveal melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/21083380,253,23640210,The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23640210,8771,24504448,Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/24504448,295,,,www.uniprot.org,507
"GNAQ Q209Y lies within a GTP binding region of the Gnaq protein (UniProt.org). Q209Y is a hotspot mutation in Gnaq, which has not been biochemically characterized, but is predicted to interfere with Gna11 GTPase activity resulting in activation of downstream signaling based on the effects of other Q209 mutations (PMID: 23640210, PMID: 21083380, PMID: 24504448).",8762,21083380,Mutations in GNA11 in uveal melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/21083380,253,23640210,The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23640210,295,,,www.uniprot.org,8771,24504448,Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/24504448,508
"GNAQ R183X indicates any amino acid change at position 183 within a GTP binding region of the Gnaq protein (UniProt.org). R183 mutations are hotspot mutations in Gnaq, which impair GTPase function, resulting in constitutive activation of Gnaq and downstream signaling (PMID: 23640210).",253,23640210,The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23640210,295,,,www.uniprot.org,509
"GNAQ R183Q lies within the GTP binding region of the Gnaq protein (UniProt.org). R183Q is a hotspot mutation that interferes with Gnaq GTPase activity, leading to activation of downstream signaling, such as YAP, in cell culture (PMID: 23640210, PMID: 24882516, PMID: 23656586).",8773,23656586,Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ.,http://www.ncbi.nlm.nih.gov/pubmed/23656586,1808,24882516,Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP.,http://www.ncbi.nlm.nih.gov/pubmed/24882516,253,23640210,The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23640210,510
"GNAQ G64V does not lie within any known functional domains of the Gnaq protein (UniProt.org). G64V has not been characterized in the scientific literature and therefore, its effect on Gnaq protein function is unknown (PubMed, Feb 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,511
Wild-type GNAS indicates that no mutation has been detected within the GNAS gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,512
"GNAS Q227X (corresponding to Q870X in isoform XLas-1) mutations lie within the GTP conformational domain of the Gnas short isoform 1 (UniProt.org, PMID: 23640210). Q227X are hotspot mutations, which impair GTPase function, rendering Gnas and downstream pathways constitutively active (PMID: 23640210).",253,23640210,The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23640210,295,,,www.uniprot.org,513
"GNAS Q227L (corresponding to Q870L in isoform XLas-1) lies within the GTP conformational domain of the Gnas short isoform 1 (UniProt.org, PMID: 23640210). Q227L is a hotspot mutation, which impairs GTPase function, rendering Gnas and downstream pathways constitutively active (PMID: 23640210).",253,23640210,The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23640210,295,,,www.uniprot.org,514
"GNAQ R183* results in a premature truncation of the Gnaq protein at amino acid 183 of 359 (UniProt.org).  Due to the loss of the majority of key residues that make up the GTP binding region (UniProt.org), R183* is predicted to lead to a loss of Gnaq protein function.",295,,,www.uniprot.org,515
"Wild-type HRAS indicates that no mutation has been detected within the HRAS gene.

",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,517
"Wild-type IDH1 indicates that no mutation has been detected within the IDH1 gene.

",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,518
"Wild-type IDH2 indicates that no mutation has been detected within the IDH2 gene.

",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,519
"Wild-type JAK2 indicates that no mutation has been detected within the JAK2 gene.

",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,522
"Wild-type JAK3 indicates that no mutation has been detected within the JAK3 gene.

",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,523
"Wild-type KIT indicates that no mutation has been detected within the KIT gene.

",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,524
"Wild-type MAP2K1 indicates that no mutation has been detected within the MAP2K1 gene.

",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,525
"Wild-type MET indicates that no mutation has been detected within the MET gene.

",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,528
"Wild-type MPL indicates that no mutation has been detected within the MPL gene.

",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,529
MPL W515L lies within the cytoplasmic domain of the Mpl protein (UniProt.org). MPL W515L has been shown to constitutively activate JAK/STAT signaling to promote cytokine-independent proliferation of hematopoietic cells (PMID: 16834459).,263,16834459,MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16834459,530
"MPL W515K lies within the cytoplasmic domain of the Mpl protein (UniProt.org). W515K results in activation of Mpl signaling as indicated by constitutive activation of Jak/Stat, Ras/Mapk, and Pi3k signaling, and is transforming in cell culture (PMID: 18528423).",295,,,www.uniprot.org,9810,18528423,New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition.,http://www.ncbi.nlm.nih.gov/pubmed/18528423,531
"JAK2 V617F lies within the protein kinase domain 1 of the Jak2 protein (UniProt.org). V617F results in constitutive activation of Jak2 and downstream Stat5 and Erk, is transforming in cell culture, and leads to development of erythrocytosis in mouse models PMID: 15858187, PMID: 15837627, PMID: 15793561).",295,,,www.uniprot.org,9808,15793561,A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.,http://www.ncbi.nlm.nih.gov/pubmed/15793561,699,15858187,A gain-of-function mutation of JAK2 in myeloproliferative disorders.,http://www.ncbi.nlm.nih.gov/pubmed/15858187,9809,15837627,"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.",http://www.ncbi.nlm.nih.gov/pubmed/15837627,532
"Wild-type MYD88 indicates that no mutation has been detected within the MYD88 gene.

",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,534
"Wild-type NOTCH1 indicates that no mutation has been detected within the NOTCH1 gene.

",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,538
"NOTCH1 D469G lies within the calcium-binding, EGF-like domain 12 of the Notch1 protein (UniProt.org). D469G results in impaired ligand-dependent activation of Notch1 signaling in culture (PMID: 22006338).",269,22006338,Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22006338,295,,,www.uniprot.org,539
"NOTCH1 P1770S lies within the RAM domain of the Notch1 protein (PMID: 22006338). P1770S has not been characterized individually however, results in a loss of Notch1 signaling in the context of a truncated form of Notch1 protein in culture (PMID: 22006338).",269,22006338,Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22006338,540
Wild-type PDGFRA indicates that no mutation has been detected within the PDGFRA gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,543
PDGFRA V561D lies within the juxtamembrane domain of the Pdgfra protein (PMID: 12949711). V561D confers a gain of function to the Pdgfra protein resulting in constitutive tyrosine phosphorylation in cell culture (PMID: 12949711).,2161,12949711,Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/12949711,544
PDGFRA D842V lies within the protein kinase domain of the Pdgfra protein (UniProt.org). D842V confers a gain of function to the Pdgfra protein resulting in transformation activity and phosphorylation of downstream targets (PMID: 23752188).,295,,,www.uniprot.org,476,23752188,PDGFRA alterations in cancer: characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations.,http://www.ncbi.nlm.nih.gov/pubmed/23752188,545
"TP53 P72R lies within a region of the Tp53 protein that interacts wtih WWOX (UniProt.org). P72R is a common Tp53 polymorphism, but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PMID: 19165225, PubMed, Nov 2016).",4002,19165225,p53 polymorphisms: cancer implications.,http://www.ncbi.nlm.nih.gov/pubmed/19165225,295,,,www.uniprot.org,562
"EGFR E746_A750del is an exon 19 deletion that results in the deletion of five amino acids in the kinase domain of the Egfr protein from amino acids 746 to 750 (PMID: 17318210). E746_A750del results in increased Egfr kinase activity, activation of p44/42 MAPK and AKT in cell culture, and promotes tumor growth in xenograft models (PMID: 16373402, PMID: 16912195 ).",21,16912195,"Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib.",http://www.ncbi.nlm.nih.gov/pubmed/16912195,1881,17318210,Epidermal growth factor receptor mutations in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17318210,1804,16373402,Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16373402,565
"TP53 loss indicates loss of the TP53 gene, mRNA, or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,571
"KDR act mut indicates that this variant results in a gain of function in the Kdr (Vegfr2) protein. However, the specific amino acid change has not been identified. ",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,576
"BRAF act mut indicates that this variant results in a gain of function in the Braf protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,578
Wild-type PTEN indicates that no mutation has been detected within the PTEN gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,579
Wild-type PTPN11 indicates that no mutation has been detected within the PTPN11 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,580
Wild-type RET indicates that no mutation has been detected within the RET gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,582
Wild-type ROS1 indicates that no mutation has been detected within the ROS1 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,583
Wild-type RUNX1 indicates that no mutation has been detected within the RUNX1 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,584
Wild-type SMAD4 indicates that no mutation has been detected within the SMAD4 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,585
Wild-type SMARCB1 indicates that no mutation has been detected within the SMARCB1 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,586
Wild-type SMO indicates that no mutation has been detected within the SMO gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,587
Wild-type SRC indicates that no mutation has been detected within the Src gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,588
Wild-type STK11 indicates that no mutation has been detected within the STK11 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,589
Wild-type VHL indicates that no mutation has been detected within the VHL gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,591
"ALK H1030P lies within the extracellular domain of the ALK protein (UniProt.org). H1030P has been identified in sequencing studies (PMID: 25275298), but has not been biochemically characterized and therefore, its effect on Alk protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1586,25275298,The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies.,http://www.ncbi.nlm.nih.gov/pubmed/25275298,592
"ALK F1174L lies within the protein kinase domain of the Alk protein (UniProt.org). F1174L confers a gain of function to the Alk protein as indicated by transformation activity and increased cell proliferation in culture and has been demonstrated to occur as a secondary resistance mutation in the context of ALK fusions (PMID: 18923525, PMID: 21030459).",295,,,www.uniprot.org,296,18923525,Activating mutations in ALK provide a therapeutic target in neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/18923525,3660,21030459,The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.,http://www.ncbi.nlm.nih.gov/pubmed/21030459,593
"ABL1 P328fs likely results in a truncation of the 1130 aa Abl1 protein at aa 328. Due to the loss of a portion of the protein kinase domain (UniProt.org), P328fs is predicted to lead to a loss of function.",295,,,www.uniprot.org,594
"ABL1 P309fs likely results in a truncation of the 1130 aa Abl1 protein at aa 309. Due to the loss of a portion of the protein kinase domain (UniProt.org), P309fs is predicted to lead to a loss of function.",295,,,www.uniprot.org,595
"ALK P1543S lies within the cytoplasmic domain of the Alk protein (UniProt.org). P1543S has not been characterized in the scientific literature and therefore, its effect on Alk protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,596
"APC S2685G does not lie within any known functional domains of the Apc protein (UniProt.org). S2685G has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,598
"APC R2714C does not lie within any known functional domains of the Apc protein (UniProt.org). R2714C has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,599
"APC S31fs results in a change in the amino acid sequence of the Apc protein beginning at aa 31 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of most known functional domains (UniProt.org), S31fs is predicted to result in a loss of Apc function.",295,,,www.uniprot.org,600
"ATM L546V does not lie within any known functional domains of the Atm protein (UniProt.org). L546V results in Atm kinase activity similar to wild-type in culture as demonstrated by phosphorylation of ATM target proteins and thus, is predicted to have no effect on the Atm protein (PMID: 18573109).
",1709,18573109,Pathogenic ATM mutations occur rarely in a subset of multiple myeloma patients.,http://www.ncbi.nlm.nih.gov/pubmed/18573109,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,602
"BRAF R347* results in a premature truncation of the of the 766 aa Braf protein at aa 347 (UniProt.org). Due to the loss of a portion of the protein kinase domain (UniProt.org), R347* is predicted to lead to a loss of Braf protein function.",295,,,www.uniprot.org,603
"BRCA1 S1634G (present in isoform 7) lies within the BRCT 1 domain of Brca1 protein (UniProt.org). S1634G has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,604
"BRCA1 S1613G does not lie within any known functional domains of the Brca1 protein (UniProt.org). S1613G is a common Brca1 polymorphism, and does not impact on Brca1 protein function in cell culture (PMID: 17308087).",298,17308087,Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis.,http://www.ncbi.nlm.nih.gov/pubmed/17308087,295,,,www.uniprot.org,605
"BRCA1 S1566G does not lie within any known functional domains of the Brca1 protein (UniProt.org). S1566G has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,606
"BRCA2 Q1782fs results in a change in the amino acid sequence of the Brca2 protein beginning at aa 1782 of 3418, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the nuclear localization sequence (PMID: 10570174), Q1782fs is predicted to lead to a loss of Brca2 protein function. ",3274,10570174,Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations.,http://www.ncbi.nlm.nih.gov/pubmed/10570174,295,,,www.uniprot.org,607
"BRCA2 V2466A lies within the FANCD2-interacting region of the Brca2 protein (UniProt.org). V2466A has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,608
"BRCA2 K1574fs results in a change in the amino acid sequence of the Brca2 protein beginning at aa 1574 of 3418, likely resulting in premature truncation of the functional protein (UniProt.org). K1574fs has not been characterized, however, due to the effects of other truncations downstream of K1574 (PMID: 12619154, PMID: 15695382), K1574fs is predicted to lead to a loss of Brca2 protein function.",2582,15695382,Functional evaluation and cancer risk assessment of BRCA2 unclassified variants.,http://www.ncbi.nlm.nih.gov/pubmed/15695382,295,,,www.uniprot.org,2580,12619154,"Deletion of Brca2 exon 27 causes hypersensitivity to DNA crosslinks, chromosomal instability, and reduced life span in mice.",http://www.ncbi.nlm.nih.gov/pubmed/12619154,609
"BRCA2 I1977fs results in a change in the amino acid sequence of the Brca2 protein beginning at aa 1977 of 3418, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the nuclear localization sequence (PMID: 10570174), I1977fs is predicted to lead to a loss of Brca2 protein function. ",3274,10570174,Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations.,http://www.ncbi.nlm.nih.gov/pubmed/10570174,295,,,www.uniprot.org,610
"EGFR Y1016H lies within a site in the Egfr protein important for interaction with PIK3C2B (UniProt.org). Y1016H has not been characterized in the scientific literature and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,611
"BRAF Y538H lies within the protein kinase domain of the Braf protein (Uniprot.org). Y538H has not been characterized in the scientific literature and therefore, its effect on Braf protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,613
"ERBB2 (HER2) G804D lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). G804D has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,614
"ERBB2 (HER2) G774D (corresponds to G804 in the canonical isoform) lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). G774D has not been characterized in the scientific literature and therefore its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,615
"CDKN2A E33fs results in a change in the amino acid sequence of the Cdkn2a protein beginning at aa 33 of 156, likely resulting in premature truncation of the functional protein (UniProt.org). E33fs has not been characterized, however, nonsense mutations downstream of E33 are inactivating (PMID: 9053859, PMID: 8668202), thus E33fs is predicted to lead to a loss of Cdkn2a protein function. ",3108,8668202,Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/8668202,295,,,www.uniprot.org,3063,9053859,Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma.,http://www.ncbi.nlm.nih.gov/pubmed/9053859,616
APC V1822D does not lie within any known functional domains of the Apc protein (UniProt.org). There is conflicting evidence on the effect of V1822D on Apc protein function (PMID: 20844743).,3559,20844743,Single nucleotide polymorphisms in the Wnt and BMP pathways and colorectal cancer risk in a Spanish cohort.,http://www.ncbi.nlm.nih.gov/pubmed/20844743,295,,,www.uniprot.org,617
"RET G691S lies within the cytoplasmic domain of the Ret protein (UniProt.org). G691S is an activating mutation, which has been shown to increase phosphorylation and activation of downstream signaling pathways in response to GDNF in cultured cells (PMID: 16357163, PMID: 19561646).",295,,,www.uniprot.org,1882,19561646,Functional RET G691S polymorphism in cutaneous malignant melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/19561646,299,16357163,The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling.,http://www.ncbi.nlm.nih.gov/pubmed/16357163,619
"ASXL1 L815P does not lie within any known functional domains of the Asxl1 protein (UniProt.org). L815P has not been characterized and therefore, its effect on Asxl1 protein function is unknown (PubMed, Oct 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,625
"ASXL1 L810P does not lie within any known functional domains of the Asxl1 protein (UniProt.org). L810P has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Oct 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,626
"ATM N1983S lies within the FAT domain of the Atm protein (UniProt.org). N1983S has been identified in sequencing studies (PMID: 25275298), but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1586,25275298,The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies.,http://www.ncbi.nlm.nih.gov/pubmed/25275298,627
BRCA2 N372H does not lie within any known functional domains of the Brca2 protein (UniProt.org). N372H rescues Brca2-null cell survival at a level comparable to wild-type Brca2 in culture (PMID: 15695382).,295,,,www.uniprot.org,2582,15695382,Functional evaluation and cancer risk assessment of BRCA2 unclassified variants.,http://www.ncbi.nlm.nih.gov/pubmed/15695382,636
"PIK3CA act mut indicates that this variant results in a gain of function in the Pik3ca protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,638
"PIK3CA E542K is a hotspot mutation that lies within the PIK helical domain of the Pik3ca protein (UniProt.org). E542K results in increased phosphorylation of Akt, growth factor-independent cell survival, and is transforming in cell culture (PMID: 16533766, PMID: 26627007).",102,16533766,PIK3CA mutations in head and neck squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/16533766,295,,,www.uniprot.org,4255,26627007,Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26627007,639
"ALK K1491R lies within the cytoplasmic domain of the Alk protein (UniProt.org). K1491R has been identified in sequencing studies (PMID: 26249178) but has not been biochemically characterized and therefore, its effect on Alk protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7823,26249178,A Molecular Portrait of High-Grade Ductal Carcinoma In Situ.,http://www.ncbi.nlm.nih.gov/pubmed/26249178,640
"KRAS G12D is a hotspot mutation that lies within a GTP binding region of the Kras protein (UniProt.org). G12D results in decreased Kras GTPase activity and increased activation of downstream signaling, and promotes tumor formation in mouse models (PMID: 16474405, PMID: 26037647, PMID: 22871572).",3052,26037647,Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26037647,295,,,www.uniprot.org,840,16474405,Germline KRAS mutations cause Noonan syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/16474405,3442,22871572,KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22871572,642
"PTEN R233* results in a premature truncation of the Pten protein at amino acid 233 of 403 (UniProt.org). PTEN R233* has not been characterized, however C-terminal deletion mutants downstream of R233 are inactivating (PMID: 10468583), thus R233* is predicted to lead to a loss of Pten protein function.",326,9598803,Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers.,http://www.ncbi.nlm.nih.gov/pubmed/9598803,295,,,www.uniprot.org,644
"ATM D1853N does not lie within any known functional domains of the Atm protein (Uniprot.org). D1853N is a common Atm polymorphism, but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PMID: 20799949, PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7883,20799949,The association between ATM D1853N polymorphism and breast cancer susceptibility: a meta-analysis.,http://www.ncbi.nlm.nih.gov/pubmed/20799949,654
"ATRX E607K does not lie within any known functional domains of the Atrx protein (UniProt.org). E607K has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,657
"ATRX H865Q does not lie within any known functional domains of the Atrx protein (UniProt.org). H865Q has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,658
"NOTCH1 D568N lies within the calcium-binding, EGF-like domain 15 of the Notch1 protein (UniProt.org). D568N has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,659
"NOTCH1 D571A lies within the calcium-binding, EGF-like domain 15 of the Notch1 protein (UniProt.org). D571A has been identified in the scientific literature (PMID: 25406187, PMID: 25275298), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",1586,25275298,The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies.,http://www.ncbi.nlm.nih.gov/pubmed/25275298,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8136,25406187,Notch1 mutations are drivers of oral tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/25406187,660
"NOTCH1 D571Y lies within the calcium-binding, EGF-like domain 15 of the Notch1 protein (UniProt.org). D571Y has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,661
"NOTCH1 D573E lies within the calcium-binding, EGF-like domain 15 of the Notch1 protein (UniProt.org). D573E has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,662
"NOTCH1 D573H lies within the calcium-binding, EGF-like domain 15 of the Notch1 protein (UniProt.org). D573H has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,663
"NOTCH1 E694G lies within the calcium-binding, EGF-like domain 18 of the Notch1 protein (UniProt.org). E694G has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,664
"NOTCH1 E694Q lies within the calcium-binding, EGF-like domain 18 of the Notch1 protein (UniProt.org). E694Q has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,665
"NOTCH1 G583R lies within the calcium-binding, EGF-like domain 15 of the Notch1 protein (UniProt.org). G583R has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,666
"NOTCH1 G696S lies within the calcium-binding, EGF-like domain 18 of the Notch1 protein (UniProt.org). G696S has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,115,0,,http://www.ncbi.nlm.nih.gov/pubmed,667
"NOTCH1 H165D lies within the EGF-like domain 4 of the Notch1 protein (UniProt.org). H165D has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,668
"NOTCH1 H165L lies within the EGF-like domain 4 of the Notch1 protein (UniProt.org). H165L has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,669
"NOTCH1 H576R lies within the calcium-binding, EGF-like domain 15 of the Notch1 protein (UniProt.org). H576R has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,670
"NOTCH1 H688D lies within the calcium-binding, EGF-like domain 18 of the Notch1 protein (UniProt.org). H688D has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,671
"NOTCH1 H688L lies within the calcium-binding, EGF-like domain 18 of the Notch1 protein (UniProt.org). H688L has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,672
"NOTCH1 I163L lies within the EGF-like domain 4 of the Notch1 protein (UniProt.org). I163L has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,673
"NOTCH1 I163S lies within the EGF-like domain 4 of the Notch1 protein. I163S has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,674
NOTCH1 I1680N lies within the extracellular domain of the Notch1 protein. I1680N (also referred to as I1681N) results in a loss of Notch1 dimer stability (PMID: 16738328),2752,16738328,Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes.,http://www.ncbi.nlm.nih.gov/pubmed/16738328,295,,,www.uniprot.org,675
"NOTCH1 I697L lies within the calcium-binding, EGF-like domain 18 of the Notch1 protein (UniProt.org). I697L has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,676
"NOTCH1 K581Q lies within the calcium-binding, EGF-like domain 15 of the Notch1 protein. K581Q has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,677
"NOTCH1 N689H lies within the calcium-binding, EGF-like domain 18 of the Notch1 protein. N689H has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,678
"NOTCH1 P1377S lies within the EGF-like domain 35 of the Notch1 protein. P1377S has been identified in sequencing studies (PMID: 25589003), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6992,25589003,Sporadic hemangioblastomas are characterized by cryptic VHL inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/25589003,679
"NOTCH1 P572R lies within the calcium-binding, EGF-like domain 15 of the Notch1 protein. P572R has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,680
"NOTCH1 P572R lies within the calcium-binding, EGF-like domain 15 of the Notch1 protein. P572T has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,681
"NOTCH1 Q290E lies within the calcium-binding, EGF-like domain 7 of the Notch1 protein. Q290E has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,682
"NOTCH1 S579T lies within the calcium-binding, EGF-like domain 15 of the Notch1 protein. S579T has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,683
"NOTCH1 T174N lies within the EGF-like domain 4 of the Notch1 protein. T174N has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,684
"NOTCH1 T293S lies within the calcium-binding, EGF-like domain 7 of the Notch1 protein. T293S has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,685
"NOTCH1 V2285I lies within the Notch1 intracellular domain of the Notch1 protein. V2285I has been identified in sequencing studies (PMID: 25589003, PMID: 22547598), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6992,25589003,Sporadic hemangioblastomas are characterized by cryptic VHL inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/25589003,8166,22547598,"Clinical impact of NOTCH1 and/or FBXW7 mutations, FLASH deletion, and TCR status in pediatric T-cell lymphoblastic lymphoma.",http://www.ncbi.nlm.nih.gov/pubmed/22547598,686
"NOTCH1 V296M lies within the calcium-binding, EGF-like domain 8 of the Notch1 protein. V296M has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,687
"NOTCH1 V565A lies within the extracellular domain of the Notch1 protein (UniProt.org). V565A has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,688
"NOTCH1 V565M lies within the extracellular domain of the Notch1 protein (UniProt.org). V565M has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,689
"NOTCH1 Y291D lies within the EGF-like 7, calcium-binding domain of the Notch1 protein (UniProt.org). Y291D has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,690
"NOTCH1 Y577H lies within the EGF-like 15, calcium-binding domain of the Notch1 protein (UniProt.org). Y577H has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,691
PTEN R15S lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). R15S results in a loss of Pten phosphatase activity and is unable to suppress cell proliferation in culture (PMID: 9823298).,295,,,www.uniprot.org,2305,9823298,The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells.,http://www.ncbi.nlm.nih.gov/pubmed/9823298,703
"PTEN V290* results in a premature truncation of the Pten protein at amino acid 290 of 403 (UniProt.org). V290* has not been characterized, however, other C-terminal deletion mutants downstream of V290 are inactivating (PMID: 10468583), thus V290* is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,704
"MET R988C (corresponds to R970C in isoform 1) lies within the juxtamembrane domain of the Met protein (PMID: 14559814, UniProt.org). R988C does not increase Met phosphorylation, but results in increased phosphorylation of cellular proteins and increased proliferation and migration of cultured cells (PMID: 14559814, PMID: 20670955, PMID: 22973954).",332,14559814,c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.,http://www.ncbi.nlm.nih.gov/pubmed/14559814,2198,20670955,MET receptor sequence variants R970C and T992I lack transforming capacity.,http://www.ncbi.nlm.nih.gov/pubmed/20670955,295,,,www.uniprot.org,2053,22973954,Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors.,http://www.ncbi.nlm.nih.gov/pubmed/22973954,706
"KRAS G13C is a hotspot mutation that lies within a GTP binding region of the Kras protein (UniProt.org). G13C results in decreased Kras GTPase activity, as indicated by increased Ras-GTP, and leads to activation of downstream signaling in cell culture (PMID: 25705018, PMID: 21079152).",546,21079152,Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis.,http://www.ncbi.nlm.nih.gov/pubmed/21079152,295,,,www.uniprot.org,2129,25705018,"Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines.",http://www.ncbi.nlm.nih.gov/pubmed/25705018,707
"FGFR1 amp indicates an increased number of copies of the FGFR1 gene. However, the mechanism causing the increase is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,708
"TP53 Y163C lies within the DNA binding domain of the Tp53 protein (PMID: 22713868). Y163C results in decreased transactivation of Tp53 target genes, increased cellular growth rate, and failure to induce apoptosis in cell culture (PMID: 23246812).",371,23246812,Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.,http://www.ncbi.nlm.nih.gov/pubmed/23246812,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,709
"FBXW7 R465C lies within the WD 3 repeat region of the Fbxw7 protein (UniProt.org). R465C confers a loss of FBXW7-substrate interaction and impairs substrate degradation by FBXW7, resulting in sustained NICD and MYC expression (PMID: 17646409).",295,,,www.uniprot.org,379,17646409,FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/17646409,710
"FGFR1 K656E lies within the cytoplasmic domain of the Fgfr1 protein (UniProt.org). K656E confers a gain of function to the Fgfr1 protein resulting in constitutive activation of MAPK signaling, and is transforming in cultured cells (PMID: 23817572).",295,,,www.uniprot.org,1902,23817572,Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.,http://www.ncbi.nlm.nih.gov/pubmed/23817572,711
"FGFR1 R538H (corresponds to R507H in the canonical isoform) lies within the protein kinase domain of the Fgfr1 protein (UniProt.org). R538H has not been characterized and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,712
"FGFR2 C382R (also referred to as C383R) lies within the helical domain of the Fgfr2 protein (UniProt.org). C382R confers a gain of function to the Fgfr2 protein resulting in constitutive MAPK pathway activation, and is transforming in cultured cells (PMID: 24993163).",1904,24993163,Activating FGFR2-RAS-BRAF mutations in ameloblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/24993163,295,,,www.uniprot.org,713
"FGFR3 K652E is a missense mutation in the protein kinase domain of the Fgfr3 protein (UniProt.org). K652E was demonstrated to induce transformation of mouse fibroblasts, but had a lesser degree of signaling and phenotypic effect in immortalized normal human urothelial cells (PMID: 19749790).",373,19749790,Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner.,http://www.ncbi.nlm.nih.gov/pubmed/19749790,295,,,www.uniprot.org,714
"FLT3 T227M lies within the extracellular domain of the Flt3 protein (UniProt.org). T227M has been identified in sequencing studies (PMID: 26999641), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7347,26999641,Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.,http://www.ncbi.nlm.nih.gov/pubmed/26999641,717
"TP53 R273H is a hotspot mutation that lies within the DNA binding domain of the Tp53 protein (PMID: 22713868). R273H results in decreased activation of Tp53 target gene expression, and also confers a gain of function to Tp53, resulting in aberrant transcriptional activation and increased cell migration (PMID: 22114072, PMID: 14743206).",2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,378,22114072,Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.,http://www.ncbi.nlm.nih.gov/pubmed/22114072,2154,18701504,"Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations.",http://www.ncbi.nlm.nih.gov/pubmed/18701504,2153,14743206,Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.,http://www.ncbi.nlm.nih.gov/pubmed/14743206,734
"TP53 R175H is a hotspot mutation that lies within the DNA binding domain of the Tp53 protein (PMID: 22713868). R175H results in decreased activation of Tp53 targets, and additionally confers a gain of function to Tp53, resulting in aberrant activation of gene transcription and enhanced cell migration (PMID: 10713666, PMID: 22114072).",1939,10713666,Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/10713666,378,22114072,Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.,http://www.ncbi.nlm.nih.gov/pubmed/22114072,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,2162,8062826,Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation.,http://www.ncbi.nlm.nih.gov/pubmed/8062826,735
"TP53 D281G lies within the DNA interaction domain of the Tp53 protein (UniProt.org). D281G results in decreased transactivation of wild-type Tp53 targets, and also confers a gain of function to Tp53, which leads to aberrant gene transcription and cell migration (PMID: 22114072).",378,22114072,Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.,http://www.ncbi.nlm.nih.gov/pubmed/22114072,295,,,www.uniprot.org,736
"FBXW7 R505L lies within the WD repeat 4 of the Fbxw7 protein (UniProt.org). R505L confers a loss of function on Fbxw7, resulting in activation of the NOTCH pathway in cultured cells (PMID: 17646409).",295,,,www.uniprot.org,379,17646409,FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/17646409,737
"BRCA1 E1038G does not lie within any known functional domains of the Brca1 protein (UniProt.org). E1038G is a common Brca1 polymorphism, but has not been biochemically characterized and therefore, its effect on Brca1 protein function is unknown (PMID: 23674270, PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5422,23674270,BRCA1 polymorphisms and breast cancer epidemiology in the Western New York exposures and breast cancer (WEB) study.,http://www.ncbi.nlm.nih.gov/pubmed/23674270,738
"BRCA1 K1183R does not lie within any known functional domains of the Brca1 protein (UniProt.org). K1183R has been identified in the scientific literature (PMID: 17341484), but has not been biochemically characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8744,17341484,"Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility.",http://www.ncbi.nlm.nih.gov/pubmed/17341484,739
"BRCA1 P871L does not lie within any known functional domains of the Brca1 protein (UniProt.org). P871L is a common Brca1 polymorphism, but has not been biochemically characterized and therefore, its effect on Brca1 protein function is unknown (PMID: 14555511, PubMed, Apr 2017).",5421,14555511,Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/14555511,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,740
"SMO P647S lies within the C-terminal cytoplasmic tail of the Smo protein (PMID: 20207148). P647S has not been characterized in the scientific literature and therefore, its effect on Smo protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2471,20207148,Evaluating Smoothened as a G-protein-coupled receptor for Hedgehog signalling.,http://www.ncbi.nlm.nih.gov/pubmed/20207148,743
"MAP2K1 K57E does not lie within any known functional domains of the Map2k1 protein (UniProt.org). K57E results in activation of Map2k1 as indicated by increased activation of downstream Erk1/2, and has been associated with BRAF inhibitor resistance in cell culture (PMID: 24463458, PMID: 25370473).",384,24463458,BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.,http://www.ncbi.nlm.nih.gov/pubmed/24463458,295,,,www.uniprot.org,6439,25370473,Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.,http://www.ncbi.nlm.nih.gov/pubmed/25370473,744
"NOTCH1 L2457V does not lie within any known functional domains of the Notch1 protein (UniProt.org). L2457V has been identified in the scientific literature (PMID: 19258443, PMID: 24345752, PMID: 18322257), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",8210,19258443,Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19258443,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7350,24345752,A targeted mutational landscape of angioimmunoblastic T-cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/24345752,295,,,www.uniprot.org,8211,18322257,In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/18322257,745
CDKN2A A148T does not lie within any known functional domains of the Cdkn2a protein (UniProt.org). A148T was shown to display similar activity to wild-type Cdkn2a including inhibition of cell growth in culture and binding to Cdk4 and Cdk6 (PMID: 10389768).,385,10389768,Functional reassessment of P16 variants using a transfection-based assay.,http://www.ncbi.nlm.nih.gov/pubmed/10389768,295,,,www.uniprot.org,746
"TP53 I254N lies within the DNA-binding domain of the Tp53 protein (PMID: 11902578). I254N results in decreased Tp53 transactivation activity yeast assays, and is associated with Tp53 over expression in patient-derived samples (PMID: 17724467, PMID: 26564006).",3142,11902578,Assessing TP53 status in human tumours to evaluate clinical outcome.,http://www.ncbi.nlm.nih.gov/pubmed/11902578,3143,17724467,Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast.,http://www.ncbi.nlm.nih.gov/pubmed/17724467,4401,26564006,"Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type.",http://www.ncbi.nlm.nih.gov/pubmed/26564006,747
"TP53 G279V lies within the DNA-binding domain of the Tp53 protein (UniProt.org). G279V has not been biochemically characterized in human cells, but results in decreased Tp53 transcriptional activity in a yeast assay (PMID: 11429700). ",295,,,www.uniprot.org,4395,11429700,Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay.,http://www.ncbi.nlm.nih.gov/pubmed/11429700,748
"EGFR over exp indicates an over expression of the Egfr protein and/or mRNA.  However, the mechanism causing the over expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,749
"ERBB2 (HER2) over exp indicates an over expression of the Erbb2 (Her2) protein. However, the mechanism causing the over expression is unknown.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,750
"KIT positive indicates the presence of the KIT gene, mRNA, and/or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,752
"KIT over exp indicates an over expression of the KIT protein. However, the mechanism causing the over expression is unspecified. ",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,753
"FBXW7 S582L lies within the WD repeat 6 of the Fbxw7 protein (UniProt.org). S582L has been identified in the scientific literature (PMID: 25450649, PMID: 27852700, PMID: 28120820), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,8065,27852700,Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/27852700,295,,,www.uniprot.org,10055,28120820,DNA copy number changes define spatial patterns of heterogeneity in colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28120820,7964,25450649,FBXW7 mutation analysis and its correlation with clinicopathological features and prognosis in colorectal cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/25450649,754
"ERBB4 R488W lies within the extracellular domain of the Erbb4 protein (UniProt.org). R488W has been identified in sequencing studies (PMID: 25822088), but has not been biochemically characterized and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7022,25822088,Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.,http://www.ncbi.nlm.nih.gov/pubmed/25822088,295,,,www.uniprot.org,755
"JAK2 R683* results in a premature truncation of the Jak2 protein at amino acid 683 of 1182 (UniProt.org). Due to the loss of a portion of protein kinase domain 1 and all of protein kinase domain 2 (UniProt.org), R683* is predicted to lead to a loss of Jak2 protein function.",295,,,www.uniprot.org,757
"ERBB4 S774G lies within the protein kinase domain of the Erbb4 protein (UniProt.org). S774G has been identified in sequencing studies (PMID: 23525077), but has not been biochemically characterized and therefore, its effect on Erbb4 protein function is unknown (PubMed, May 2017).",7021,23525077,Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity.,http://www.ncbi.nlm.nih.gov/pubmed/23525077,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,758
JAK3 P151R lies within the FERM domain of the Jak3 protein (UniProt.org). P151R confers a loss of function and has been observed in patients with hematological malignancies (PMID:17456055).,295,,,www.uniprot.org,395,17456055,Loss-of-function JAK3 mutations in TMD and AMKL of Down syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/17456055,763
"KRAS A59T lies within a GTP binding region of the Kras protein (UniProt.org). A59T has been identified in the scientific literature (PMID: 26924569, PMID: 28404754), but has not been biochemically characterized and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).
",8729,28404754,Therapeutic Response of Metastatic Colorectal Cancer Harboring a KRAS Missense Mutation After Combination Chemotherapy With the EGFR Inhibitor Panitumumab.,http://www.ncbi.nlm.nih.gov/pubmed/28404754,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4878,26924569,Frequent PTPRK-RSPO3 fusions and RNF43 mutations in colorectal traditional serrated adenoma.,http://www.ncbi.nlm.nih.gov/pubmed/26924569,764
"PDGFRA L221F lies within an extracellular domain of the Pdgfra protein (UniProt.org). L221F has been identified in the scientific literature (PMID: 22718859), but has not been biochemically characterized and therefore, its effect on Pdgfra protein function is unknown (PubMed, Aug 2017).
",396,22718859,Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.,http://www.ncbi.nlm.nih.gov/pubmed/22718859,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,765
"CSF1R  G413S lies within the Ig-like C2-type domain 5 of the Csf1r protein (UniProt.org). G413S has been identified in the scientific literature (PMID: 23889897, PMID: 18971950), but has not been biochemically characterized and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017). ",7275,23889897,Colony stimulation factor 1 receptor (CSF1R) is not a common cause of multiple sclerosis.,http://www.ncbi.nlm.nih.gov/pubmed/23889897,285,,,http://www.ncbi.nlm.nih.gov/pubmed,397,18971950,Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1.,http://www.ncbi.nlm.nih.gov/pubmed/18971950,295,,,www.uniprot.org,766
RB1 K740* results in a premature truncation of the Rb1 protein at amino acid 740 of 928 (UniProt.org). K740* lies within the B domain of the Rb1 protein and leads to a loss of function (PMID: 23895135).,398,23895135,Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities.,http://www.ncbi.nlm.nih.gov/pubmed/23895135,295,,,www.uniprot.org,767
"RB1 Q504* results in a premature truncation of the Rb1 protein at amino acid 504 of 928 and is a known break point for the formation of Pcm1/Jak2 fusion proteins (UniProt.org). Due to the loss of multiple functional domains, Q504* leads to a loss of Rb1 protein function (PMID:23895135, UniProt.org).",295,,,www.uniprot.org,398,23895135,Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities.,http://www.ncbi.nlm.nih.gov/pubmed/23895135,768
"SMAD4 G510E lies within the MH2 domain of the Smad4 protein (UniProt.org). G510E has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,770
EZH2 H530N lies within the CXC domain of the Ezh2 protein (UniProt.org). H530N is predicted to destabilize Ezh2 protein structure resulting in loss of function (PMID:24367637).,295,,,www.uniprot.org,399,24367637,Structural context of disease-associated mutations and putative mechanism of autoinhibition revealed by X-ray crystallographic analysis of the EZH2-SET domain.,http://www.ncbi.nlm.nih.gov/pubmed/24367637,771
EZH2 C571Y lies within the CXC domain of the Ezh2 protein (UniProt.org). C571Y is predicted to destabilize Ezh2 protein structure resulting in loss of function (PMID:24367637).,295,,,www.uniprot.org,399,24367637,Structural context of disease-associated mutations and putative mechanism of autoinhibition revealed by X-ray crystallographic analysis of the EZH2-SET domain.,http://www.ncbi.nlm.nih.gov/pubmed/24367637,772
"EZH2 V626M lies within the SET domain of the Ezh2 protein (UniProt.org). V626M has not been biochemically characterized, however, because of its location in the cofactor binding pocket, V626M is predicted to impair the active state of Ezh2, resulting in a loss of function (PMID:24367637).",295,,,www.uniprot.org,399,24367637,Structural context of disease-associated mutations and putative mechanism of autoinhibition revealed by X-ray crystallographic analysis of the EZH2-SET domain.,http://www.ncbi.nlm.nih.gov/pubmed/24367637,773
EZH2 K639E lies within the SET domain of the Ezh2 protein (UniProt.org). K639E is associated with Weaver syndrome and likely results from some subtle destabilizing effect on Ezh2 protein function (PMID:24367637).,295,,,www.uniprot.org,399,24367637,Structural context of disease-associated mutations and putative mechanism of autoinhibition revealed by X-ray crystallographic analysis of the EZH2-SET domain.,http://www.ncbi.nlm.nih.gov/pubmed/24367637,774
"RB1 R566* results in a premature truncation of the Rb1 protein within the PK1 domain (UniProt.org). Due to the loss of multiple function domains (UniProt.org), RB1 R566* is predicted to lead to a loss of Rb1 protein function.",295,,,www.uniprot.org,775
"EZH2 R583* results in a premature truncation of the RB protein at amino acid 583 of 746 (UniProt.org). Due to the loss of multiple functional domains (UniProt.org), R583* is predicted to lead to a loss of Ezh2 protein function. ",295,,,www.uniprot.org,776
"EZH2 Q539* results in a premature truncation of the RB protein at amino acid 539 of 746 (UniProt.org). Due to the loss of mulitple functional domains (UniProt.org), Q539* is predicted to lead to a loss of Ezh2 protein function. 
",295,,,www.uniprot.org,777
"EZH2 C534fs likely results in a truncation of the Ezh2 protein at aa 534 of 746, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of multiple functional domains (UniProt.org), C534fs is predicted to result in a loss of function in the Ezh2 protein.",295,,,www.uniprot.org,778
"RET G601W lies within the extracellular domain of the Ret protein (UniProt.org). G601W has not been characterized in the scientific literature and therefore, its effect on Ret protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,779
"RET R721W does not lie within any known functional domains of the Ret protein (UniProt.org). R721W has not been characterized in the scientific literature and therefore, its effect on Ret protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,780
"VHL P25S lies within tandem repeat 3 of the Vhl protein (UniProt.org). P25S has been identified in sequencing studies (PMID: 11536052), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",7436,11536052,VHL gene alterations in renal cell carcinoma patients: novel hotspot or founder mutations and linkage disequilibrium.,http://www.ncbi.nlm.nih.gov/pubmed/11536052,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,781
NOTCH1 V1676I lies within the negative regulatory region of the Notch1 protein (PMID: 25104330). V1676I results in increased Notch1 signaling in a Luciferase reporter assay in cell culture (PMID: 25104330).,3550,25104330,Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25104330,295,,,www.uniprot.org,782
"CTNNB1 S23R lies within a phosphorylation site of the Ctnnb1 protein (UniProt.org). The functional effect of S23R is conflicting, as S23R has been reported to increase Ctnnb1 transcriptional activity (Cancer Res April 15, 2012 72:2249) and to have no effect on transcriptional activity (PMID: 12027456).",2328,12027456,Identification of two novel regulated serines in the N terminus of beta-catenin.,http://www.ncbi.nlm.nih.gov/pubmed/12027456,400,,Abstract 2249: Mutations to the GSK3-beta regulatory region of CTNNB1 increase TCF transcription activity and are resistant to degradation by GSK3-beta,http://cancerres.aacrjournals.org/content/72/8_Supplement/2249.short,295,,,www.uniprot.org,783
CTNNB1 I35S does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). I35S is predicted to confer a gain of function to the Ctnnb1 protein as demonstrated by nuclear accumulation of Ctnnb1 (PMID: 18282277).,295,,,www.uniprot.org,401,18282277,Correlation between beta-catenin mutations and expression of Wnt-signaling target genes in hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18282277,784
"CTNNB1 H36P does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). H36P confers a gain of function to the Ctnnb1 protein as demonstrated by stabilization of the Ctnnb1 protein, increased transcription of target genes, and nuclear accumulation of Ctnnb1 (PMID: 18282277).",295,,,www.uniprot.org,401,18282277,Correlation between beta-catenin mutations and expression of Wnt-signaling target genes in hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18282277,785
"CTNNB1 S45P lies within a Gsk3b phosphorylation site on the Ctnnb1 protein (UniProt.org). S45P confers a gain of function to the Ctnnb1 protein as demonstrated by stabilization of the Ctnnb1 protein and increased transcription of Ctnnb1 target genes (PMID: 9065403, PMID:15133491).",295,,,www.uniprot.org,402,9065403,Stabilization of beta-catenin by genetic defects in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/9065403,403,15133491,Genetic and epigenetic alterations of the APC gene in malignant melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/15133491,786
APC N813S does not lie within any known functional domains of the Apc protein (UniProt.org). N813S is predicted to result in no effect on the Apc protein as demonstrated by lack of increase in both Axin2 signaling and Tcf/Lef transcriptional activity in cultured cells (PMID: 15133491).,295,,,www.uniprot.org,403,15133491,Genetic and epigenetic alterations of the APC gene in malignant melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/15133491,787
"APC G2502S does not lie within any known functional domains of the Apc protein (UniProt.org). G2502S has been identified in the scientific literature (PMID: 18612690, PMID: 24790607, PMID: 20233475), but has not been characterized and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).  ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,9806,24790607,Identification of an APC Variant in a Patient with Clinical Attenuated Familial Adenomatous Polyposis.,http://www.ncbi.nlm.nih.gov/pubmed/24790607,295,,,www.uniprot.org,9805,18612690,Missense polymorphisms in the adenomatous polyposis coli gene and colorectal cancer risk.,http://www.ncbi.nlm.nih.gov/pubmed/18612690,9807,20233475,Germline Missense Changes in the APC Gene and Their Relationship to Disease.,http://www.ncbi.nlm.nih.gov/pubmed/20233475,788
APC S130G lies within a coiled-coil domain of the Apc protein (UniProt.org). S130G does not result in increased Wnt signaling by Apc in cell culture (PMID: 15133491).,403,15133491,Genetic and epigenetic alterations of the APC gene in malignant melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/15133491,295,,,www.uniprot.org,789
"ERBB2 (HER2) K716Q lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). K716Q has not been characterized in the scientific literature and therefore, its effect on Erb2 (Her2) protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,800
"ERBB2 (HER2) L720V lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). L720V has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,801
"ERBB2 (HER2) P1170A lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). P1170A is a common polymorphism (PMID: 15743501), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3573,15743501,Common ERBB2 polymorphisms and risk of breast cancer in a white British population: a case-control study.,http://www.ncbi.nlm.nih.gov/pubmed/15743501,802
ERBB4 (HER4) E542K lies within the extracellular (growth factor receptor) domain of the Erbb4 (Her4) protein (UniProt.org). E542K has been shown to be activating as it increases Erbb4 (Her4) kinase activity and confers transformation ability in cultured cells (PMID: 19718025).,295,,,www.uniprot.org,566,19718025,Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.,http://www.ncbi.nlm.nih.gov/pubmed/19718025,803
"EZH2 D185H lies within the DNMT1, DNMT3A and DNMT3B interaction region of the Ezh2 protein (UniProt.org). D185H has not been characterized and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,805
"HNF1A I27L does not lie within any known functional domains of the Hnf1a protein (UniProt.org). I27L has not been characterized and therefore, its effect on Hnf1a protein function is unknown  (Pubmed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,807
"HNF1A R503H does not lie within any known functional domains of the Hnf1a protein (UniProt.org). R503H has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (Pubmed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,808
"HNF1A S487N does not lie within any known functional domains of the Hnf1a protein (UniProt.org). S487N has not been characterized and therefore, its effect on Hnf1a protein function is unknown (Pubmed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,809
"HNF1A S574G does not lie within any known functional domains of the Hnf1a protein (UniProt.org). S574G has not been characterized and therefore, its effect on Hnf1a protein function is unknown (Pubmed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,810
HNF1A T196A does not lie within any known functional domains of the Hnf1a protein (UniProt.org). T196A has no effect on DNA binding or transcriptional activity of Hnf1a (PMID: 21170474).,4195,21170474,Differential effects of HNF-1α mutations associated with familial young-onset diabetes on target gene regulation.,http://www.ncbi.nlm.nih.gov/pubmed/21170474,295,,,www.uniprot.org,811
"IDH1 V178I does not lie within any known functional domains of the Idh1 protein (UniProt.org). IDH1 V178I retains wild-type Idh1 enzymatic activity, and does not increase 2HG levels in cell culture (PMID: 21996744).",2651,21996744,Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.,http://www.ncbi.nlm.nih.gov/pubmed/21996744,295,,,www.uniprot.org,813
"JAK3 P132A lies within the FERM domain of the Jak3 protein (UniProt.org). P132A does not result in constitutive phosphorylation of Jak3 or downstream Stat5 or Erk, and is not transforming in cell culture, however, promotes tumor formation in mouse models (PMID: 21599579).",295,,,www.uniprot.org,406,21599579,Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects.,http://www.ncbi.nlm.nih.gov/pubmed/21599579,816
"CTNNB1 D32N lies within the ubiquitination recognition motif of the Ctnnb1 protein (PMID: 15064718). D32N confers a gain of function on the Ctnnb1 protein as demonstrated by a loss of ubiquitin ligase interaction leading to decreased ubiquitination and increased Ctnnb1-dependent transcription (PMID: 15064718, PMID: 11955436).",408,15064718,Phosphorylation and ubiquitination of oncogenic mutants of beta-catenin containing substitutions at Asp32.,http://www.ncbi.nlm.nih.gov/pubmed/15064718,2316,11955436,Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism.,http://www.ncbi.nlm.nih.gov/pubmed/11955436,828
MLH1 A20V does not lie within any known functional domains of the Mlh1 protein (UniProt.org). A20V does not alter Mlh1 amino acid polarity and is not predicted to be disease causing (PMID: 21901162).,295,,,www.uniprot.org,404,21901162,Molecular genetic analysis of 103 sporadic colorectal tumours in Czech patients.,http://www.ncbi.nlm.nih.gov/pubmed/21901162,851
MLH1 I219V lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). I219V is a common polymorphism with activity comparable to wild-type MLH1 (PMID: 20020535).,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,5161,20020535,A cell-free assay for the functional analysis of variants of the mismatch repair protein MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/20020535,852
"MLH1 Q26R does not lie within any known functional domains of the Mlh1 protein (UniProt.org). Q26R has not been characterized in the scientific literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,853
"TP53 R158L lies within the DNA-binding domain of the Tp53 protein (UniProt.org). R158L results decreased Tp53 transactivation activity, but does not interfere with wild-type Tp53 activity in cell culture (PMID: 16861262, PMID: 25584008).",295,,,www.uniprot.org,411,16861262,Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/16861262,4424,25584008,Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study.,http://www.ncbi.nlm.nih.gov/pubmed/25584008,855
"CSF1R Y571D lies within the regulatory juxtamembrane domain of the Csf1r protein (UniProt.org). Y571D was shown to result in constitutive activation of the Csf1r protein, increased colony growth, and elevated Csf1r signaling in cultured cells (PMID: 18971950).",397,18971950,Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1.,http://www.ncbi.nlm.nih.gov/pubmed/18971950,295,,,www.uniprot.org,856
"APC Q1447* results in a premature truncation of the Apc protein at aa 1447 of 2843 (UniProt.org). Q1447* has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), Q1447* is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,857
RB1 L607I lies within the spacer region of the Rb1 protein (UniProt.org). L607I confers a loss of function to the Rb1 protein as demonstrated by the inability to induce apoptosis in cultured cells (PMID:20594292).,412,20594292,Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers.,http://www.ncbi.nlm.nih.gov/pubmed/20594292,295,,,www.uniprot.org,858
RB1 R689W lies within the spacer region of the Rb1 protein (UniProt.org). R689W confers a loss of function to the Rb1 protein as demonstrated by the inability to induce apoptosis in cultured cells (PMID: 20594292).,412,20594292,Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers.,http://www.ncbi.nlm.nih.gov/pubmed/20594292,295,,,www.uniprot.org,859
RB1 R621C lies within the spacer region of the Rb1 protein (UniProt.org). R621C confers a loss of function to the Rb1 protein as demonstrated by the inability to induce apoptosis in cultured cells (PMID: 20594292).,412,20594292,Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers.,http://www.ncbi.nlm.nih.gov/pubmed/20594292,295,,,www.uniprot.org,860
"RB1 S567L lies within Domain A of the Rb1 protein (UniProt.org). S567L has been identified in the scientific literature (PMID: 10671068), but has not been biochemically characterized and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",8561,10671068,Twelve novel RB1 gene mutations in patients with hereditary retinoblastoma. Mutations in brief no. 206. Online.,http://www.ncbi.nlm.nih.gov/pubmed/10671068,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,861
"KRAS L19F does not lie within any known functional domain of the Kras protein (UniProt.org). L19F inhibits GTPase activity of Kras leading to increased activation of downstream signaling pathways (PMID: 17150185).
",550,17150185,Characterization of a novel oncogenic K-ras mutation in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17150185,295,,,www.uniprot.org,862
"MET M1268T lies within the protein kinase domain and RANBP9 interaction region of the Met protein (UniProt.org). M1268T results in constitutive phosphorylation of Met and activation of Src, and is transforming in cell culture (PMID: 10871851).",295,,,www.uniprot.org,414,10871851,Tumorigenesis mediated by MET mutant M1268T is inhibited by dominant-negative Src.,http://www.ncbi.nlm.nih.gov/pubmed/10871851,871
"PDGFRA H650Q lies within the protein kinase domain of the Pdgfra protein (UniProt.org). H650Q results in constitutive activation of Pdgfra, is transforming in culture, and induces leukemia-like disease in animal models (PMID: 21224473).",295,,,www.uniprot.org,418,21224473,Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.,http://www.ncbi.nlm.nih.gov/pubmed/21224473,886
BRAF V600M (previously reported as V599) lies within the activation segment of the kinase domain of the Braf protein (PMID: 15035987). V600M results in intermediate Braf kinase activity in cell culture (PMID: 28783719).,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,146,15035987,Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.,http://www.ncbi.nlm.nih.gov/pubmed/15035987,893
"BRAF Y472C lies within the protein kinase domain of the Braf protein (UniProt.org), Y472C results in impaired Braf kinase activity, however, paradoxically activates Mek and Erk through transactivation of CRAF (PMID: 22649091).",295,,,www.uniprot.org,423,22649091,Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.,http://www.ncbi.nlm.nih.gov/pubmed/22649091,894
"BRAF D594N lies within the protein kinase domain of the Braf protein (UniProt.org). D594N results in impaired Braf kinase activity, however, leads to activation of Erk signaling through CRAF in cell culture (PMID: 28783719).",295,,,www.uniprot.org,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,895
"BRAF D594H lies within the protein kinase domain of the Braf protein (UniProt.org). D594H results in a loss of Braf kinase activity, however, leads to Ras-dependent activation of Erk signaling in cell culture (PMID: 28783719).",295,,,www.uniprot.org,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,896
"BRAF D594G lies within the protein kinase domain of the Braf protein (UniProt.org). D594G results in impaired Braf kinase activity, however, has been demonstrated to lead to increased activation of Erk signaling through CRAF in cell culture (PMID: 18794803, PMID: 28783719).",7,18794803,CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations.,http://www.ncbi.nlm.nih.gov/pubmed/18794803,295,,,www.uniprot.org,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,897
"BRAF D594V lies within the protein kinase domain of the Braf protein (UniProt.org). D594V results in impaired Braf kinase activity, and decreased activation of Erk, Mek, and CRAF in cell culture (PMID: 27577079, PMID: 15035987).",295,,,www.uniprot.org,7322,27577079,Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.,http://www.ncbi.nlm.nih.gov/pubmed/27577079,146,15035987,Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.,http://www.ncbi.nlm.nih.gov/pubmed/15035987,898
"BRAF D594E lies within the protein kinase domain of the Braf protein (UniProt.org). D594E results in impaired Braf kinase activity, however, results in increased Mek and Erk phosphorylation in the presence of CRAF in cell culture (PMID: 28783719).",295,,,www.uniprot.org,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,899
BRAF L597R lies within the protein kinase domain of the Braf protein (UniProt.org). L597R results in activation of Braf as indicated by increased phosphorylation of Mek and Erk in cell culture (PMID: 22798288).,3,22798288,BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/22798288,900
BRAF L597Q lies within the protein kinase domain of the Braf protein (UniProt.org). L597Q results in activation of Braf as indicated by increased phosphorylation of Mek and Erk in cell culture (PMID: 22798288).,3,22798288,BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/22798288,295,,,www.uniprot.org,901
BRAF L597S lies within the protein kinase domain of the Braf protein (UniProt.org). L597S results in activation of Braf as indicated by increased phosphorylation of Mek and Erk in cell culture (PMID: 22798288).,3,22798288,BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/22798288,902
KIT W557R lies within the juxtamembrane domain of the Kit protein (PMID: 15790786). W557R results in increased KIT kinase activity and is transforming in cell culture (PMID: 15790786).,425,15790786,Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.,http://www.ncbi.nlm.nih.gov/pubmed/15790786,903
"RB1 C712R lies within Domain B of the Rb1 protein (UniProt.org). C712R results in a loss of function of the Rb1 protein as demonstrated by reduced Rb1 phosphorylation in cell culture, reduced temperature-sensitive Rb1 interaction with large T antigen in cell culture, and inability to bind E2f1 in vitro (PMID: 10486322).",8559,10486322,Temperature-sensitive RB mutations linked to incomplete penetrance of familial retinoblastoma in 12 families.,http://www.ncbi.nlm.nih.gov/pubmed/10486322,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,904
"RB1 L662P lies within Domain B of the Rb1 protein (UniProt.org). L662P has been identified in the scientific literature (PMID: 10671068), but has not been biochemically characterized and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,8561,10671068,Twelve novel RB1 gene mutations in patients with hereditary retinoblastoma. Mutations in brief no. 206. Online.,http://www.ncbi.nlm.nih.gov/pubmed/10671068,295,,,www.uniprot.org,905
"RB1 W99* results in a premature truncation of the Rb1 protein at amino acid 99 of 928 (UniProt.org). Due to the loss of all functional domains (UniProt.org), W99* leads to loss of Rb1 protein function (PMID:24406863).",426,24406863,Retinoblastoma gene mutations detected by whole exome sequencing of Merkel cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24406863,295,,,www.uniprot.org,906
NOTCH1 L1594P lies within the HD domain of the Notch1 protein (PMID: 17646409).  L1594P results in weak activation of Notch1-driven reporter activity in cell culture (PMID: 16738328). ,379,17646409,FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/17646409,2752,16738328,Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes.,http://www.ncbi.nlm.nih.gov/pubmed/16738328,907
"NOTCH1 L1575P lies within the HD domain of the Notch1 protein (PMID: 17646409).  L1575P results in activation of Notch1 as evidenced by elevated Notch-driven reporter activity in cell culture (PMID: 15472075, PMID: 20393564).",379,17646409,FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/17646409,2814,15472075,Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/15472075,4206,20393564,Therapeutic antibody targeting of individual Notch receptors.,http://www.ncbi.nlm.nih.gov/pubmed/20393564,908
NOTCH1 L1601P lies within the HD domain of the Notch1 protein (PMID: 17646409).  L1601P weakly activates Notch-driven MYC transcription in cell culture (PMID: 18677410).,379,17646409,FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/17646409,4207,18677410,Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/18677410,909
"NOTCH1 V1605E lies within the HD domain of the Notch1 protein (PMID: 17646409). V1605E has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",379,17646409,FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/17646409,285,,,http://www.ncbi.nlm.nih.gov/pubmed,910
"NOTCH1 L1586P lies within the HD domain of the Notch1 protein (PMID: 17646409).  L1586P has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",379,17646409,FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/17646409,285,,,http://www.ncbi.nlm.nih.gov/pubmed,911
"NOTCH1 F1748S lies within the HD domain of the Notch1 protein (PMID: 17646409).  F1748S has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",379,17646409,FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/17646409,285,,,http://www.ncbi.nlm.nih.gov/pubmed,912
"FBXW7 R465H (corresponds to R385H in isoform 2) lies within the WD repeat 3 of the Fbxw7 protein (UniProt.org). R465H confers a loss of FBXW7-substrate interaction and impairs substrate degradation by FBXW7, resulting in sustained NICD and MYC expression (PMID: 17646409).",295,,,www.uniprot.org,379,17646409,FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/17646409,914
FBXW7 del indicates a deletion of the FBXW7 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,915
"FBXW7 R505C lies within the WD 4 repeat region of the Fbxw7 protein (UniProt.org). R505C confers a loss of FBXW7-substrate interation and impairs substrate degradation by FBXW7, resulting in sustained NICD and MYC expression (PMID: 17646409).",295,,,www.uniprot.org,379,17646409,FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/17646409,916
"FBXW7 R479Q lies within the WD 3 repeat region of the Fbxw7 protein (UniProt.org). R479Q confers a loss of FBXW7-substrate interation and impairs substrate degradation by FBXW7, resulting in sustained NICD and MYC expression (PMID: 17646409, PMID: 25450649).",295,,,www.uniprot.org,379,17646409,FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/17646409,7964,25450649,FBXW7 mutation analysis and its correlation with clinicopathological features and prognosis in colorectal cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/25450649,917
"MAP2K1 P124S lies within the protein kinase domain of the Map2k1 protein (UniProt.org). P124S results in increased ERK1/2 phosphorylation and confers resistance to Mek and Braf inhibitors in melanoma cells (PMID: 19915144, PMID:22197931).",134,19915144,MEK1 mutations confer resistance to MEK and B-RAF inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/19915144,429,22197931,Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22197931,295,,,www.uniprot.org,918
"RET Y791F lies within the protein kinase domain of the Ret protein (UniProt.org). Y791F confers a gain of function to the Ret protein, resulting in ligand independent kinase activity and activation of downstream signaling pathways (PMID: 15753368).",295,,,www.uniprot.org,1871,15753368,"RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor.",http://www.ncbi.nlm.nih.gov/pubmed/15753368,919
"CTNNB1 S45del results in the deletion of an amino acid at a Gsk3b phosphorylation site of the Ctnnb1 protein at amino acid 45 (PMID: 9065402). S45del confers a gain of function to the Ctnnb1 protein as demonstrated by stabilization and nuclear accumulation of Ctnnb1 (PMID: 9065402, PMID: 21084400).",415,9065402,Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC.,http://www.ncbi.nlm.nih.gov/pubmed/9065402,2649,21084400,"Wnt/β-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors.",http://www.ncbi.nlm.nih.gov/pubmed/21084400,920
"RB1 E137* results in a premature truncation of the Rb1 protein at amino acid 137 of 928. Due to the loss of all known functional domains (UniProt.org), E137* is predicted to lead to a loss of Rb1 protein function.",295,,,www.uniprot.org,922
"RB1 R251* results in a premature truncation of the Rb1 protein at amino acid 251 of 928 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), R251* is predicted to lead to a loss of Rb1 protein function.",295,,,www.uniprot.org,923
"RB1 R255* results in a premature truncation of the Rb1 protein at amino acid 255 of 928 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), R255* is predicted to lead to a loss of Rb1 protein function.",295,,,www.uniprot.org,924
"RB1 R266* results in a premature truncation of the Rb1 protein at amino acid 266 of 928 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), R266* is predicted to lead to a loss of Rb1 protein function.",295,,,www.uniprot.org,925
"RB1 R320* results in a premature truncation of the Rb1 protein at amino acid 320 of 928 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), R320* is predicted to lead to a loss of Rb1 protein function.",295,,,www.uniprot.org,926
"RB1 Q354* results in a premature truncation of the Rb1 protein at amino acid 354 of 928 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), Q354* is predicted to lead to a loss of Rb1 protein function.",295,,,www.uniprot.org,927
"RB1 R358* results in a premature truncation of the Rb1 protein at amino acid 358 of 928 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), R358* is predicted to lead to a loss of Rb1 protein function.",295,,,www.uniprot.org,928
"RB1 R445* results in a premature truncation of the Rb1 protein within the A domain at amino acid 445 of 928 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), R445* is predicted to lead to a loss of Rb1 protein function.",295,,,www.uniprot.org,929
"RB1 R455* results in a premature truncation of the Rb1 protein within the A domain at amino acid 455 of 928 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), R455* is predicted to lead to a loss of Rb1 protein function.",295,,,www.uniprot.org,930
"RB1 R467* results in a premature truncation of the Rb1 protein within the A domain at amino acid 467 of 928 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), R467* is predicted to lead to a loss of Rb1 protein function.",295,,,www.uniprot.org,931
"RB1 R552* results in a premature truncation of the Rb1 protein within the A domain at amino acid 552 of 928 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), R552* is predicted to lead to a loss of Rb1 protein function.",295,,,www.uniprot.org,932
"RB1 C553* results in a premature truncation of the Rb1 protein within the A domain at amino acid 553 of 928 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), C553* is predicted to lead to a loss of Rb1 protein function.",295,,,www.uniprot.org,933
"RET C634R lies within the extracellular domain of the Ret protein (UniProt.org). C634R confers a gain of function to the Ret protein, as evidenced by autophosphorylation, and is transforming in cultured cells (PMID: 9242375).",432,9242375,Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain.,http://www.ncbi.nlm.nih.gov/pubmed/9242375,295,,,www.uniprot.org,934
RET R982C lies within the protein kinase domain of the Ret protein (UniProt.org). R982C demonstrated GDNF-dependent Mapk activation to similar level of wild-type Ret in culture (PMID: 22729463).,6809,22729463,"Traditional and targeted exome sequencing reveals common, rare and novel functional deleterious variants in RET-signaling complex in a cohort of living US patients with urinary tract malformations.",http://www.ncbi.nlm.nih.gov/pubmed/22729463,295,,,www.uniprot.org,935
"ROS1 S1109L lies within the fibronectin type-III 5 domain of the Ros1 protein (UniProt.org). S1109L has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,941
"ROS1 T145P lies within the fibronectin type-III 1 domain of the Ros1 protein (UniProt.org). T145P has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,942
"SMO D25G does not lie within any known functional domains of the Smo protein (UniProt.org). D25G has not been characterized and therefore, its effect on Smo protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,945
"SMO W535L lies within the seventh transmembrane domain of the Smo protein (PMID: 9422511). W535L results in constitutive activation of Smo and is transforming in cell culture, and has been demonstrated to confer Hh pathway inhibitor resistance (PMID: 9422511, PMID: 10607393, PMID: 25759020).",433,9422511,Activating Smoothened mutations in sporadic basal-cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/9422511,2677,25759020,Smoothened variants explain the majority of drug resistance in basal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25759020,4691,10607393,The seven-transmembrane receptor smoothened cell-autonomously induces multiple ventral cell types.,http://www.ncbi.nlm.nih.gov/pubmed/10607393,946
"RB1 S816* results in a premature truncation of the Rb1 protein at amino acid 816 of 928 (UniProt.org). Due to the loss of the C domain and nuclear localization signal (UniProt.org), S816* is predicted to lead to a loss of Rb1 protein function.",295,,,www.uniprot.org,955
"RB1 Q575* results in a premature truncation of the Rb1 protein within the A domain at amino acid 575 of 928. Due to the loss of all known functional domains (UniProt.org), Q575* is predicted to lead to a loss of Rb1 protein function.",295,,,www.uniprot.org,956
"RB1 R579* results in a premature truncation of the Rb1 protein within the A domain at amino acid 579 of 928 (UniProt.org). Due to the loss of multiple functional domains (UniProt.org), R579* is predicted to lead to a loss of Rb1 protein function.",295,,,www.uniprot.org,957
"RB1 Q639* results in a premature truncation of the Rb1 protein within the spacer domain at amino acid 639 of 928 (UniProt.org). Due to the loss of multiple functional domains (UniProt.org), Q639* is predicted to lead to a loss of Rb1 protein function.",295,,,www.uniprot.org,958
"RB1 S634* results in a premature truncation of the Rb1 protein within the spacer domain at amino acid 634 of 928 (UniProt.org). Due to the loss of multiple functional domains (UniProt.org), S634* is predicted to lead to a loss of Rb1 protein function.",295,,,www.uniprot.org,959
"RB1 Y728* results in a premature truncation of the Rb1 protein within the B domain at amino acid 728 of 928 (UniProt.org). Due to the loss of multiple functional domains (UniProt.org), Y728* is predicted to lead to a loss of Rb1 protein function.",295,,,www.uniprot.org,960
"RB1 R787* results in a premature truncation of the Rb1 protein within its B domain at amino acid 787 of 928 (UniProt.org). Due to the loss of multiple functional domains (UniProt.org), R787* is predicted to lead to a loss of Rb1 protein function.",295,,,www.uniprot.org,961
"RB1 R661W lies within the B domain of the Rb1 protein (UniProt.org). R661W is unable to bind E2F, however tumor suppression function is similar to wild-type Rb1 (PMID: 15688068).",4269,15688068,"RNA polymerases I and III, growth control and cancer.",http://www.ncbi.nlm.nih.gov/pubmed/15688068,962
"KRAS G12C is a hotspot mutation that lies within a GTP binding region of the Kras protein (UniProt.org). G12C results in decreased Kras GTPase activity and activation of downstream signaling in cell culture and mouse models (PMID: 26037647 PMID: 16051643, PMID: 23455880).",3052,26037647,Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26037647,26,23455880,KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23455880,295,,,www.uniprot.org,436,16051643,Conditional expression of the mutant Ki-rasG12C allele results in formation of benign lung adenomas: development of a novel mouse lung tumor model.,http://www.ncbi.nlm.nih.gov/pubmed/16051643,979
"TP53 Y220C is a hotspot mutation that lies within the DNA-binding domain (PMID: 17401432). Y220C confers a loss of function to Tp53, as indicated by decreased Tp53 transcriptional activity in cell culture (PMID: 16861262, PMID: 23630318).",2163,17401432,Structure-function-rescue: the diverse nature of common p53 cancer mutants.,http://www.ncbi.nlm.nih.gov/pubmed/17401432,4410,23630318,Small molecule induced reactivation of mutant p53 in cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/23630318,411,16861262,Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/16861262,980
"G719A lies within the P-loop in the kinase domain of the Egfr protein (PMID: 17349580). G719A is predicted to confer a gain of function to Egfr by destabilizing the P loop, weakening the inactive conformation, and is transforming in cell culture (PMID: 17349580, PMID: 26206867).",4031,26206867,EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.,http://www.ncbi.nlm.nih.gov/pubmed/26206867,438,17349580,Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.,http://www.ncbi.nlm.nih.gov/pubmed/17349580,981
"EGFR G719C lies within the phosphate-binding P-loop in the protein kinase domain of the Egfr protein (PMID: 17349580). G719C confers a gain of function to Egfr, as indicated by constitutive autophosphorylation in cell culture (PMID: 19671738).",438,17349580,Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.,http://www.ncbi.nlm.nih.gov/pubmed/17349580,1878,19671738,Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations.,http://www.ncbi.nlm.nih.gov/pubmed/19671738,982
"EGFR A763_Y764insFQEA results in the insertion of four amino acids in the C-helix region of the Egfr protein between amino acids 763 and 764 (PMID: 24353160). A763_Y764insFQEA confers a gain of function to Egfr, as indicated by increased kinase activity, and is transforming in cell culture (PMID: 24353160).",440,24353160,"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24353160,983
"EGFR L861Q lies within the protein kinase domain of the Egfr protein (UniProt.org). L861Q confers a gain of function to Egfr, as indicated by increased Egfr kinase activity in cell culture (PMID: 23387505).",441,23387505,Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/23387505,984
EGFR D770_N771insSVD (equivalent to S768_D770dupSVD) is an exon 20 mutation that results in the insertion of the three amino acids into the protein kinase domain of the Egfr protein (UniProt.org). EGFR D770_N771insSVD results in increased Egfr phosphorylation and activation of downstream signaling in cell culture (PMID: 24353160).,440,24353160,"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24353160,985
"EGFR V769_D770insASV (also called A767_V769dup) is a exon 20 mutation resulting in insertion of 3 amino acids in the protein kinase domain of the Egfr protein between amino acids 769 and 770 (UniProt.org). V769_D770insASV results in constitutive Egfr phosphorylation, downstream signaling activation, and transformation of cultured cells (PMID: 24353160, PMID: 28363995).",295,,,www.uniprot.org,440,24353160,"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24353160,8567,28363995,Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/28363995,986
EGFR H773_V774insH is an exon 20 insertion that results in the insertion of a histidine (H) in the protein kinase domain of the Egfr protein between amino acids 773 and 774 (UniProt.org). H773_V774insH results in constitutive phosphorylation of Egfr and activation of downstream signaling in cell culture (PMID: 24353160). ,295,,,www.uniprot.org,440,24353160,"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24353160,987
"MET amp indicates an increased number of copies of the MET gene. However, the mechanism causing the increase is unspecified. ",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1002
"MET over exp indicates an over expression of the Met protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1003
"MET H1112Y lies within the protein kinase domain and ATP nucleotide binding region of the Met protein (UniProt.org). H1112Y confers a gain of function to Met, resulting in constitutive Met phosphorylation and activation of downstream signaling, and is transforming in cell culture (PMID: 15064724, PMID: 24061647).",295,,,www.uniprot.org,2196,24061647,The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variants.,http://www.ncbi.nlm.nih.gov/pubmed/24061647,452,15064724,The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants.,http://www.ncbi.nlm.nih.gov/pubmed/15064724,1004
"NOTCH1 E1583_Q1584insPVELMPPE results in the insertion of eight amino acids in the extracellular heterodimerization domain of the Notch1 protein between amino acids 1583 and 1584 (PMID: 17646409). E1583_Q1584insPVELMPPE has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,379,17646409,FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/17646409,1011
"MET L1213V lies within the protein kinase domain and RANBP9 interaction region of the Met protein (UniProt.org). L1213V confers a gain of function to Met, resulting in constitutive Met phosphorylation and transformation of cultured cells (PMID: 15064724, PMID: 24061647).",295,,,www.uniprot.org,452,15064724,The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants.,http://www.ncbi.nlm.nih.gov/pubmed/15064724,1012
"MET Y1248H lies within the protein kinase domain and RANBP9 interaction region of the Met protein (UniProt.org). Y1248H results in constitutive Met phosphorylation, is transforming in cell culture, and promotes tumor formation in mice (PMID: 15064724, PMID: 9326629).",295,,,www.uniprot.org,452,15064724,The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants.,http://www.ncbi.nlm.nih.gov/pubmed/15064724,1013
"MET H1112L lies within the protein kinase domain and ATP nucleotide binding region of the Met protein (UniProt.org). H1112L confers a gain of function to Met, resulting in increased Met phosphorylation and activation of downstream signaling, and is transforming in cell culture (PMID: 19783361, PMID: 24061647).",295,,,www.uniprot.org,455,19783361,Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274.,http://www.ncbi.nlm.nih.gov/pubmed/19783361,2196,24061647,The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variants.,http://www.ncbi.nlm.nih.gov/pubmed/24061647,1014
"MET V1110I lies within the protein kinase domain and ATP nucleotide binding region of the Met protein (UniProt.org). V1110I confers a gain of function to Met, resulting in constitutive Met phosphorylation and is transforming in cell culture  (PMID: 19783361).",295,,,www.uniprot.org,455,19783361,Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274.,http://www.ncbi.nlm.nih.gov/pubmed/19783361,1015
"MET V1238I lies within the protein kinase domain and RANBP9 interaction region of the Met protein (UniProt.org). V1238I confers a gain of function to Met, resulting in increased Met phosphorylation in cell culture and promotes tumor formation in mice (PMID: 1978336, PMID: 9326629).",295,,,www.uniprot.org,455,19783361,Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274.,http://www.ncbi.nlm.nih.gov/pubmed/19783361,2199,9326629,Activating mutations for the met tyrosine kinase receptor in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/9326629,1016
"MET V1206L lies within the protein kinase domain and RANBP9 interaction region of the Met protein (UniProt.org). V1206L confers a gain of function to Met, resulting in increased Met phosphorylation in cell culture (PMID: 19783361, PMID: 24061647).",295,,,www.uniprot.org,455,19783361,Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274.,http://www.ncbi.nlm.nih.gov/pubmed/19783361,2196,24061647,The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variants.,http://www.ncbi.nlm.nih.gov/pubmed/24061647,1017
Wild-type RB1 indicates that no mutations have been detected within the RB1 gene. ,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1046
"EGFR positive indicates the presence of the EGFR gene, mRNA, and/or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1047
Wild-type TET2 indicates that no mutations have been detected within the TET2 gene. ,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1053
MET mutant indicates an unspecified mutation in the MET gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1057
"STK11 K78I lies within the protein kinase domain of the Stk11 protein (UniProt.org).  K78I results in a loss of Stk11 kinase activity i cell culture (PMID: 15731909, PMID: 9837816).

",295,,,www.uniprot.org,456,15731909,"Peutz-Jeghers LKB1 mutants fail to activate GSK-3beta, preventing it from inhibiting Wnt signaling.",http://www.ncbi.nlm.nih.gov/pubmed/15731909,457,9837816,"Loss of LKB1 kinase activity in Peutz-Jeghers syndrome, and evidence for allelic and locus heterogeneity.",http://www.ncbi.nlm.nih.gov/pubmed/9837816,1058
TET2 I1762V does not lie within any known functional domains of the Tet2 protein (UniProt.org). I1762V produced amounts of 5hmC equivalent to Tet2 wild-type (J Cancer 2015; 6(9):832-842).,3344,,Genetic Characterization of Ten-Eleven-Translocation Methylcytosine Dioxygenase Alterations in Human Glioma,http://www.jcancer.org/v06p0832.htm,295,,,www.uniprot.org,1059
"TET2 L1721W does not lie within any known functional domains of the Tet2 protein (UniProt.org). L1721W and has not been characterized and therefore, its effect on Tet2 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1060
"VHL S65L does not lie within any known functional domains of the Vhl protein (UniProt.org). S65L results in a loss of Vhl binding to Hif1a and failure to mediate Hif2a degradation in culture (PMID: 15611064). 

",458,15611064,Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1alpha complex.,http://www.ncbi.nlm.nih.gov/pubmed/15611064,295,,,www.uniprot.org,1065
"JAK3 V722I lies within the protein kinase domain 1 of the Jak3 protein (UniProt.org). V722I results in constitutive phosphorylation of Jak3, and activation of downstream signaling in cell culture and in patient samples, and is transforming in cell culture (PMID: 23689514, PMID: 16843266).",459,23689514,JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/23689514,6795,16843266,Activating alleles of JAK3 in acute megakaryoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/16843266,295,,,www.uniprot.org,1066
"KIT M541L lies within the helical domain of the Kit protein (UniProt.org). M541L has been demonstrated to increase proliferation in the presence of ligand when compared to wild-type Kit (PMID: 18795925; PMID: 25015329), but is not predicted to be pathogenic (PMID: 16307017, PMID: 21757432).",462,25015329,"Identification of kit(M541L) somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response.",http://www.ncbi.nlm.nih.gov/pubmed/25015329,460,18795925,Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT.,http://www.ncbi.nlm.nih.gov/pubmed/18795925,1795,21757432,"The prevalence of the c-kit exon 10 variant, M541L, in aggressive fibromatosis does not differ from the general population.",http://www.ncbi.nlm.nih.gov/pubmed/21757432,1796,16307017,"The c-kit (CD117) sequence variation M541L, but not N564K, is frequent in the general population, and is not associated with CML in Caucasians.",http://www.ncbi.nlm.nih.gov/pubmed/16307017,1067
PDGFRA S478P lies within the extracellular domain and the Ig-like C2-type 5 domain of the Pdgfra protein (UniProt.org). S478P results in ligand-dependent phosphorylation of Pdgfra similar to wild-type Pdgfra (PMID: 12949711).,2161,12949711,Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/12949711,295,,,www.uniprot.org,1068
CTNNB1 S33A does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). S33A is predicted to confers a gain of function to Ctnnb1 as demonstrated by weak transforming properties and cell invasion in cell culture (PMID: 15829978).,461,15829978,Functional correlates of mutation of the Asp32 and Gly34 residues of beta-catenin.,http://www.ncbi.nlm.nih.gov/pubmed/15829978,295,,,www.uniprot.org,1069
"DNMT3A R598* results in a premature truncation of the Dnmt3a protein at amino acid 598 of 912 (UniProt.org).  Q598* is predicted to result in a loss of  Dnmt3a function. 

",295,,,www.uniprot.org,1071
"DNMT3A L805* results in a premature truncation of the Dnmt3a protein at amino acid 805 of 912 (UniProt.org). L805* has not been characterized in the scientific literature and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1072
"DNMT3A R882P lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (UniProt.org). R882P has been identified in sequencing studies (PMID: 23135354), but has not been biochemically characterized and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jul 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7333,23135354,"Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/23135354,1073
"DNMT3A P904L lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (UniProt.org). P904L has been identified in sequencing studies (PMID: 21067377), but has not been biochemically characterized and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jul 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7314,21067377,DNMT3A mutations in acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/21067377,1074
"DNMT3A A741V lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (UniProt.org). A741V has been identified in sequencing studies (PMID: 21067377), but has not been biochemically characterized and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7314,21067377,DNMT3A mutations in acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/21067377,1075
"DNMT3A E505* results in a premature truncation within the ADD domain of the Dnmt3a protein at amino acid 505 of 912 (UniProt.org). Due to the loss of multiple domains (UniProt.org), Q505* is predicted to result in a loss of Dnmt3a protein function.",295,,,www.uniprot.org,1076
"DNMT3A F909C lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (UniProt.org). F909C has been identified in sequencing studies (PMID: 22817890), but has not been biochemically characterized and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7329,22817890,The origin and evolution of mutations in acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/22817890,1077
"DNMT3A K829R lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (UniProt.org). K829R has not been characterized in the scientific literature and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1078
"DNMT3A K841Q lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (UniProt.org). K841Q has been identified in sequencing studies (PMID: 21067377), but has not been biochemically characterized and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jun 2017). ",7314,21067377,DNMT3A mutations in acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/21067377,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1079
"ATM S1403fs*3 likely results in a truncation of the 3056 aa Atm protein at aa 1403, followed by 3 nonsense amino acids (UniProt.org). Due to the loss of 2 protein kinase domains and the FATC domain (UniProt.org), S1403fs*3 is predicted to lead to a loss of Atm function.",295,,,www.uniprot.org,1086
"KRAS G12S is a hotspot mutation that lies within a GTP binding region of the Kras protein (UniProt.org). G12S results in decreased Kras GTP-GDP exchange rate and leads to increased Ras-GTP and activation of downstream signaling in cell culture (PMID: 23455880, PMID: 28484014, PMID: 26184075).",9854,28484014,Selective targeting of point-mutated KRAS through artificial microRNAs.,http://www.ncbi.nlm.nih.gov/pubmed/28484014,9853,26184075,Interaction of a novel fluorescent GTP analogue with the small G-protein K-Ras.,http://www.ncbi.nlm.nih.gov/pubmed/26184075,26,23455880,KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23455880,295,,,www.uniprot.org,1087
"KRAS G12V is a hotspot mutation that lies within a GTP binding region of the Kras protein (UniProt.org). G12V results in decreased Kras GTPase activity and increased activation of downstream signaling in cell culture, and leads to increased tumor growth in mouse models (PMID: 23455880, PMID: 26037647, PMID: 24642870).",295,,,www.uniprot.org,2127,24642870,Characterization of rare transforming KRAS mutations in sporadic colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24642870,3052,26037647,Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26037647,26,23455880,KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23455880,1088
"CTNNB1 E54K does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). E54K has not been biochemically characterized however, it is predicted to confer a gain of function to Ctnnb1 as demonstrated by nuclear accumulation of Ctnnb1 (PMID: 12474227).",2347,12474227,Cribriform-morular variant of papillary thyroid carcinoma: a pathological and molecular genetic study with evidence of frequent somatic mutations in exon 3 of the beta-catenin gene.,http://www.ncbi.nlm.nih.gov/pubmed/12474227,295,,,www.uniprot.org,1101
"CTNNB1 G50D does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). G50D has been identified in the scientific literature (PMID: 12824925, PMID: 9515795), but has not been biochemically characterized and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Mar 2017).",8344,9515795,Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/9515795,8343,12824925,"Analysis of p53, K-ras, c-kit, and beta-catenin gene mutations in sinonasal NK/T cell lymphoma in northeast district of China.",http://www.ncbi.nlm.nih.gov/pubmed/12824925,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1102
"KDR (VEGFR2) G509E lies within the Ig-like C2-type domain 5 of the Kdr (Vegfr2) protein (UniProt.org). G509E has been identified in sequencing studies (PMID: 22842228), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",7109,22842228,Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22842228,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1103
"EZH2 G266E does not lie within any known functional domains of the Ezh2 protein (UniProt.org). G266E has been identified in sequencing studies (PMID: 22237151), but has not been biochemically characterized and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1104
"EZH2 R78H lies within the region of the Ezh2 protein which interacts with DNMT1, DNMT3A and DNMT3B (UniProt.org). R78H has been identified in sequencing studies (PMID: 24755471), but has not been biochemically characterized and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).
",295,,,www.uniprot.org,6962,24755471,Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24755471,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1105
"EZH2 Q62R lies within the region of the Ezh2 protein which interacts with DNMT1, DNMT3A and DNMT3B (UniProt.org). Q62R has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1106
"JAK2 I540T does not lie within any known functional domains of the Jak2 protein (UniProt.org). I540T has been identified in sequencing studies (PMID: 21497288), but has not been biochemically characterized and therefore, its effect on Jak2 protein function is unknown (PubMed, Dec 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7393,21497288,"Nested high-resolution melting curve analysis a highly sensitive, reliable, and simple method for detection of JAK2 exon 12 mutations--clinical relevance in the monitoring of polycythemia.",http://www.ncbi.nlm.nih.gov/pubmed/21497288,295,,,www.uniprot.org,1107
"KDR (VEGFR2) D985N lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). D985N has been identified in sequencing studies (PMID: 22842228), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1108
"ERBB4 C234Y lies within the extracellular domain of the Erbb4 protein (UniProt.org). C234Y has been identified in sequencing studies (PMID: 23525077), but has not been biochemically characterized and therefore, its effect on Erbb3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7021,23525077,Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity.,http://www.ncbi.nlm.nih.gov/pubmed/23525077,1109
"GNA11 D333N does not lie within any known functional domains of the Gna11 protein (UniProt.org). D333N has not been characterized in the scientific literature and therefore, its effect on Gna11 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1111
" JAK3 S720N lies within the protein kinase domain 1 of the Jak3 protein (UniProt.org). S720N has not been characterized in the scientific literature and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1112
"SMAD4 L104F lies within the MH1 domain of the Smad4 protein (UniProt.org). L104F has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1113
"FLT3 S454L lies within the extracellular domain of the Flt3 protein (UniProt.org). S454L has been identified in sequencing studies (PMID: 25056374), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",7205,25056374,Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/25056374,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1114
"RET A756V lies within the protein kinase domain of the Ret protein (UniProt.org). A756V has been identified in sequencing studies (PMID:     27683183), but has not been characterized and therefore, its effect on Ret protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,8676,27683183,"RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients.",http://www.ncbi.nlm.nih.gov/pubmed/27683183,295,,,www.uniprot.org,1115
BRAF G478C lies within the protein kinase domain of the Braf protein (UniProt.org). G478C results in a loss of Braf kinase activity in cell culture (PMID: 22926515).,463,22926515,ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers.,http://www.ncbi.nlm.nih.gov/pubmed/22926515,295,,,www.uniprot.org,1116
"DNMT3A P718L lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (UniProt.org). P718L has been identified in sequencing studies (PMID: 21067377), but has not been biochemically characterized and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jul 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7314,21067377,DNMT3A mutations in acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/21067377,1122
"DNMT3A R803S lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (UniProt.org). R803S has been identified in sequencing studies (PMID: 21067377), but has not been biochemically characterized and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jun 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7314,21067377,DNMT3A mutations in acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/21067377,1123
"DNMT3A R792H lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (UniProt.org). R792H has been identified in sequencing studies (PMID: 21067377), but has not been biochemically characterized and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jul 2017).
",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7314,21067377,DNMT3A mutations in acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/21067377,1124
DNMT3A R736H lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (UniProt.org). R736H confers a loss of function to the Dnmt3a protein as demonstrated by decreased methylation activity (PMID: 22722925). ,2887,22722925,Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation.,http://www.ncbi.nlm.nih.gov/pubmed/22722925,295,,,www.uniprot.org,1125
"DNMT3A H873A lies within the dimer interface region of the Dnmt3a protein (PMID: 22722925). H873A disrupts the teramerization ability of the Dnmt3a protein, resulting in reduced DNA binding affinity, reduced methylation activity, and altered catalytic activity (PMID: 22722925).",2887,22722925,Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation.,http://www.ncbi.nlm.nih.gov/pubmed/22722925,1126
"DNMT3A H873R lies within the dimer interface region of the Dnmt3a protein (PMID: 22722925). H873R disrupts the teramerization ability of the Dnmt3a protein, resulting in reduced DNA binding affinity, reduced methylation activity, and altered catalytic activity (PMID: 22722925).",2887,22722925,Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation.,http://www.ncbi.nlm.nih.gov/pubmed/22722925,1127
"DNMT3A W860A lies within the dimer interface region of the Dnmt3a protein (PMID: 22722925). W860A disrupts the tetramerization ability of the Dnmt3a protein, resulting in reduced DNA binding affinity, reduced methylation activity, and altered catalytic activity (PMID: 22722925).",2887,22722925,Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation.,http://www.ncbi.nlm.nih.gov/pubmed/22722925,1128
"DNMT3A N879A lies within the dimer interface region of the Dnmt3a protein (PMID: 22722925). N879A disrupts the teramerization ability of the Dnmt3a protein, resulting in reduced DNA binding affinity, reduced methylation activity, and altered catalytic activity (PMID: 22722925).",2887,22722925,Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation.,http://www.ncbi.nlm.nih.gov/pubmed/22722925,1129
"DNMT3A D876G lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (UniProt.org). D876G has not been characterized in the scientific literature and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jul 2014).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1130
DNMT3A R885A lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (UniProt.org). R885A confers a loss of function to the Dnmt3a protein as demonstrated by loss of methylation activity (PMID: 22722925).,2887,22722925,Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation.,http://www.ncbi.nlm.nih.gov/pubmed/22722925,295,,,www.uniprot.org,1131
DNMT3A R771L lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (UniProt.org). R771L confers a loss of function to the Dnmt3a protein as demonstrated by loss of methylation activity (PMID: 22722925). ,295,,,www.uniprot.org,2887,22722925,Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation.,http://www.ncbi.nlm.nih.gov/pubmed/22722925,1132
DNMT3A R729W lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (UniProt.org). R729W confers a loss of function to the Dnmt3a protein as demonstrated by loss of methylation activity (PMID: 22722925). ,2887,22722925,Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation.,http://www.ncbi.nlm.nih.gov/pubmed/22722925,295,,,www.uniprot.org,1133
"DNMT3A R729Q lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (UniProt.org). R729Q has been identified in sequencing studies (PMID: 21067377), but has not been biochemically characterized and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jul 2017).
",7314,21067377,DNMT3A mutations in acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/21067377,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1134
DNMT3A Q304A lies within the PWWP domain and the interaction with DNMT1 and DNMT3B region of the Dnmt3a protein (UniProt.org). Q304A is predicted to confer a loss of function to the Dnmt3a protein due to inhibition of allosteric activation of the Dnmt3a protein resulting in decreased methylation activity (PMID: 21606950).,3271,21606950,Histone tails regulate DNA methylation by allosterically activating de novo methyltransferase.,http://www.ncbi.nlm.nih.gov/pubmed/21606950,295,,,www.uniprot.org,1135
DNMT3A R580A lies within the ADD domain and the GATA-type zinc finger region of the Dnmt3a protein (UniProt.org). R580A is predicted to confer a loss of function to the Dnmt3a protein due to inhibition of allosteric activation of the Dnmt3a protein resulting in decreased methylation activity (PMID: 21606950).,295,,,www.uniprot.org,3271,21606950,Histone tails regulate DNA methylation by allosterically activating de novo methyltransferase.,http://www.ncbi.nlm.nih.gov/pubmed/21606950,1136
DNMT3A Q615* results in a premature truncation of the Dnmt3a protein at amino acid 615 of 912 (UniProt.org). Q615* is predicted to result in a loss of  Dnmt3a function.,295,,,www.uniprot.org,1137
"DNMT3A Q515* results in a premature truncation within the ADD domain of the Dnmt3a protein at amino acid 515 of 912 (UniProt.org). Due to the loss of multiple domains (UniProt.org), Q515* is predicted to result in a loss of Dnmt3a protein function.",295,,,www.uniprot.org,1138
"PIK3CA K179T does not lie within any known functional domains of the Pik3ca protein (UniProt.org). K179T has not been characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1139
"EZH2 S21A lies within a interaction with DNMT1, DNMT3A and DNMT3B region of the Ezh2 protein (UniProt.org). S21A confers a loss of function to the Ezh2 protein as demonstrated by reduced methylation of the Ezh2 target protein, Stat3 (PMID: 23684459).",3664,23684459,Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells.,http://www.ncbi.nlm.nih.gov/pubmed/23684459,295,,,www.uniprot.org,1140
"EZH2 S21D lies within a interaction with DNMT1, DNMT3A and DNMT3B region of the Ezh2 protein (UniProt.org). S21D results in increased Stat3 methylation and activation, is transforming in culture, and promotes tumor growth in animal models (PMID: 23239736, PMID: 16224021, PMID: 23684459).",3664,23684459,Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells.,http://www.ncbi.nlm.nih.gov/pubmed/23684459,4374,16224021,Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3.,http://www.ncbi.nlm.nih.gov/pubmed/16224021,295,,,www.uniprot.org,4373,23239736,EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent.,http://www.ncbi.nlm.nih.gov/pubmed/23239736,1141
"EZH2 C576W lies within a CXC domain and Cys-rich region of the Ezh2 protein (UniProt.org). C576W confers a loss of function to the Ezh2 protein as demonstrated by reduced H3K27 trimethylation activity (PMID: 20601953).
",3332,20601953,Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders.,http://www.ncbi.nlm.nih.gov/pubmed/20601953,295,,,www.uniprot.org,1142
"EZH2 P577L (corresponds to P572 in the canonical isoform) lies within a CXC domain and Cys-rich region of the Ezh2 protein (UniProt.org). P577L has been identified in sequencing studies (PMID: 22237151), but has not been biochemically characterized and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",7338,22237151,Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/22237151,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1143
"EZH2 Y646N (also reported as Y641N) lies within a SET domain  of the Ezh2 protein (UniProt.org). Y646N confers a gain of function on Ezh2, as indicated by increased trimethylation at H3K27 (PMID: 22194861).",937,22194861,EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas.,http://www.ncbi.nlm.nih.gov/pubmed/22194861,295,,,www.uniprot.org,1144
EZH2 Y646H (corresponds to Y641H in the canonical isoform) lies within a SET domain  of the Ezh2 protein (UniProt.org). Y646H alters the substrate specificity of the Ezh2 protein and increases the catalytic efficiency for H3K27 trimethylation (PMID: 21078963).,2703,21078963,Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas.,http://www.ncbi.nlm.nih.gov/pubmed/21078963,295,,,www.uniprot.org,1145
"EZH2 Y646F (corresponds to Y641F in the canonical isoform) lies within a SET domain  of the Ezh2 protein (UniProt.org). Y646F alters the substrate specificity of the Ezh2 protein and increases the catalytic efficiency for H3K27 trimethylation (PMID: 21190999, PMID: 24563539).",2725,24563539,Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/24563539,505,21190999,"Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.",http://www.ncbi.nlm.nih.gov/pubmed/21190999,295,,,www.uniprot.org,1146
EZH2 Y646S (corresponds to Y641S in the canonical isoform) lies within a SET domain  of the Ezh2 protein (UniProt.org). Y646S alters the substrate specificity of the Ezh2 protein and increases the catalytic efficiency for H3K27 trimethylation (PMID: 21190999).,505,21190999,"Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.",http://www.ncbi.nlm.nih.gov/pubmed/21190999,295,,,www.uniprot.org,1147
EZH2 Y646C lies within a SET domain  of the Ezh2 protein (UniProt.org). Y646C confers a loss of function to the Ezh2 protein as demonstrated by reduced downstream H3K27 trimethylation activity (PMID: 20601953).,295,,,www.uniprot.org,3332,20601953,Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders.,http://www.ncbi.nlm.nih.gov/pubmed/20601953,1148
"EZH2 D664E (corresponds to D659 in the canonical isoform) lies within a SET domain of the Ezh2 protein (UniProt.org). D664E has been identified in sequencing studies (PMID: 20601953), but has not been biochemically characterized and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3332,20601953,Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders.,http://www.ncbi.nlm.nih.gov/pubmed/20601953,295,,,www.uniprot.org,1149
"EZH2 D664V (corresponds to D659 in the canonical isoform) lies within a SET domain of the Ezh2 protein (UniProt.org). D664V has been identified in sequencing studies (PMID: 27276561), but has not been biochemically characterized and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",7052,27276561,Genomic Classification and Prognosis in Acute Myeloid Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27276561,115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1150
"EZH2 D664fs (corresponds to D659 in the canonical isoform) results in a change in the amino acid sequence of the Ezh2 protein beginning at aa 664 of 751, likely resulting in premature truncation of the functional protein (UniProt.org). D664fs has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1151
"EZH2 N673S (corresponds to N668 in the canonical isoform) lies within a SET domain  of the Ezh2 protein (UniProt.org). N673S has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1152
JAK2 mutant indicates and unspecified mutation in the JAK2 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1156
"ERBB2 (HER2) negative indicates a lack of the ERBB2 (HER2) gene, mRNA, or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1159
FGFR2 mutant indicates an unspecified mutation in the FGFR2 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1160
BRAF V600X indicates any Braf missense mutation that results in replacement of the the valine (V) at amino acid 600 by a different amino acid. BRAF V600 mutations are hotspot mutations that often result in increased Braf kinase activity (PMID: 15035987).,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,146,15035987,Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.,http://www.ncbi.nlm.nih.gov/pubmed/15035987,1161
"ERBB2 (HER2) positive indicates the presence of the ERBB2 (HER2) gene, mRNA, and/or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1162
"PIK3CA amplification indicates an increased number of copies of the PIK3CA gene. However, the mechanism causing the increase is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1166
"KRAS G12X indicates any amino acid change at codon 12 of the Kras protein. KRAS codon 12 variants are hotspot mutations that often interfere with Ras GTPase activity, resulting in downstream pathway activation (PMID: 28666118, PMID: 22589270).",2097,22589270,A comprehensive survey of Ras mutations in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22589270,9843,28666118,RAS Proteins and Their Regulators in Human Disease.,http://www.ncbi.nlm.nih.gov/pubmed/28666118,1167
"KRAS G13X indicates any amino acid change at codon 13 of the Kras protein. KRAS codon 13 variants are hotspot mutations that often interfere with Ras GTPase activity, resulting in downstream pathway activation (PMID: 21993244, PMID: 22589270).",2097,22589270,A comprehensive survey of Ras mutations in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22589270,2102,21993244,RAS oncogenes: weaving a tumorigenic web.,http://www.ncbi.nlm.nih.gov/pubmed/21993244,9843,28666118,RAS Proteins and Their Regulators in Human Disease.,http://www.ncbi.nlm.nih.gov/pubmed/28666118,1168
"KRAS Q61X indicates any amino acid change at codon 61 of the Kras protein. KRAS codon 61 variants often interfere with Ras GTPase activity, resulting in downstream pathway activation (PMID: 28666118, PMID: 22589270, PMID: 26902995).",2097,22589270,A comprehensive survey of Ras mutations in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22589270,9843,28666118,RAS Proteins and Their Regulators in Human Disease.,http://www.ncbi.nlm.nih.gov/pubmed/28666118,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,9846,26902995,"The Structural Basis of Oncogenic Mutations G12, G13 and Q61 in Small GTPase K-Ras4B.",http://www.ncbi.nlm.nih.gov/pubmed/26902995,1169
"NRAS G12X indicates any NRAS missense mutation, which results in the glycine (G) at amino acid 12 being replaced by a different amino acid.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1171
"NRAS G13X indicates any NRAS missense mutation, which results in the glycine (G) at amino acid 13 being replaced by a different amino acid. ",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1172
"NRAS Q61X indicates any NRAS missense mutation, which results in the glutamine (Q) at amino acid 61 being replaced by a different amino acid. NRAS Q61 mutations are hotspot mutations resulting in a loss of Nras GTPase activity and activation of downstream pathways (PMID: 27664710).",9838,27664710,"NRAS, NRAS, Which Mutation Is Fairest of Them All?",http://www.ncbi.nlm.nih.gov/pubmed/27664710,1173
MAP2K1 D67N does not lie within any known functional domains of the Map2k1 protein (UNiProt.org). D67N results in constitutive activation of Erk signaling in cell culture (PMID: 25049390).,3163,25049390,Next-generation sequencing identifies rare variants associated with Noonan syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/25049390,1177
EGFR mut indicates an unspecified mutation in the EGFR gene. ,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1178
PDGFRA V536E lies within the transmembrane of the Pdgfra protein (UniProt.org). V536E confers a gain of function to the Pdgfra protein resulting in constitutive activation of Pdgfr and cell proliferation in cultured cells (PMID: 23752188).,476,23752188,PDGFRA alterations in cancer: characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations.,http://www.ncbi.nlm.nih.gov/pubmed/23752188,1179
PDGFRA F808L lies within the protein kinase domain of the Pdgfra protein (UniProt.org). F808L confers a loss of function to the Pdgfra protein as indicated by a lack of phosphorylation and kinase activity (PMID: 23752188).,476,23752188,PDGFRA alterations in cancer: characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations.,http://www.ncbi.nlm.nih.gov/pubmed/23752188,1180
BRCA1 mutant indicates an unspecified mutation in the BRCA1 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1181
BRCA2 mutant indicates an unspecified mutation in the BRCA2 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1182
"G719X indicates a single amino acid change in the phosphate-binding “P loop” of the kinase domain. The substitution (usually A, C, or S) likely destabilizes the P loop, weakening the inactive conformation (PMID: 17349580).",438,17349580,Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.,http://www.ncbi.nlm.nih.gov/pubmed/17349580,1183
HRAS mutant indicates an unspecified mutation in the HRAS gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1184
AKT1 mutant indicates an unspecified mutation in the AKT1 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1185
TP53 M246K lies within the DNA binding domain of the Tp53 protein (UniProt.org). M246K results in decreased activation of Tp53 target gene expression and increased tumor formation in zebrafish models (PMID: 15630097).,2643,15630097,tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15630097,1186
PTEN mutant indicates an unspecified mutation in the PTEN gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1189
KIT mutant indicates an unspecified mutation in the KIT gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1190
PDGFRA mutant indicates an unspecified mutation in the PDGFRA gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1191
ERBB2 (HER2) mutant indicates an unspecified mutation in the ERBB2 (HER2) gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1192
"FGFR1 act mut indicates that this variant results in a gain of function in the FGFR1 protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1193
"FGFR2 act mut indicates that this variant results in a gain of function in the FGFR2 protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1194
"FGFR3 act mut indicates that this variant results in a gain of function in the FGFR3 protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1195
FGFR1 mutant indicates an unspecified mutation in the FGFR1 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1197
FGFR3 mutant indicates an unspecified mutation in the FGFR3 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1198
FLT3 mutant indicates an unspecified mutation in the FLT3 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1203
CSF1R mutant indicates an unspecified mutation in the CSF1R gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1204
RET mutant indicates and unspecified mutation in the RET gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1208
"MYD88 A6fs results in a change in the amino acid sequence of the Myd88 protein beginning at aa 6 of 296, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of all known functional domains (UniProt.org), A6fs is predicted to lead to a loss of function.",295,,,www.uniprot.org,1209
MAP2K1 mutant indicates an unspecified mutation in the MAP2K1 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1215
"MET positive indicates the presence of the MET gene, mRNA, and/or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1217
"ERBB2 (HER2) act mut indicates that this variant results in a gain of function in the Erbb2 (Her2) protein. However, the specific amino acid change has not been identified.

",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1219
"STK11 mutant indicates and unspecified mutation in the STK11 gene.
",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1223
ALK rearrangement indicates an unspecified rearrangement of the ALK gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1225
"BRAF inact mut indicates that this variant results in a loss of function of the Braf protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1226
"IDH1 R132H lies within the active site of the IDH1 protein (PMID: 19228619). R132H confers a loss-of-function to use isocitrate as substrate, and a concomitant gain-of-function to convert alpha-ketoglutarate to onco-metabolite 2HG (R(-)-2-hydroxyglutarate). High levels of 2HG confers tumor formation and progression (PMID: 19935646).",486,19228619,IDH1 and IDH2 mutations in gliomas.,http://www.ncbi.nlm.nih.gov/pubmed/19228619,487,19935646,Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.,http://www.ncbi.nlm.nih.gov/pubmed/19935646,1228
"IDH1 R132C lies within the active site of the IDH1 protein (PMID: 19228619). R132C confers a loss-of-function to use isocitrate as substrate, and a concomitant gain-of-function to convert alpha-ketoglutarate to onco-metabolite 2HG (R(-)-2-hydroxyglutarate). High levels of 2HG confers tumor formation and progression (PMID: 19935646).",486,19228619,IDH1 and IDH2 mutations in gliomas.,http://www.ncbi.nlm.nih.gov/pubmed/19228619,487,19935646,Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.,http://www.ncbi.nlm.nih.gov/pubmed/19935646,1229
"IDH1 R132S lies within the active site of the Idh1 protein (PMID: 19228619). R132S results in a loss of the ability of Idh1 to use isocitrate as a substrate and a gain-of-function in conversion of alpha-ketoglutarate to 2-hydroxyglutarate (2HG), leading to accumulation of 2HG, which is associated with tumor formation and progression (PMID: 19935646).",486,19228619,IDH1 and IDH2 mutations in gliomas.,http://www.ncbi.nlm.nih.gov/pubmed/19228619,487,19935646,Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.,http://www.ncbi.nlm.nih.gov/pubmed/19935646,1230
"IDH1 R132L lies within the active site of the IDH1 protein (PMID: 19228619). R132L confers a loss-of-function to use isocitrate as substrate, and a concomitant gain-of-function to convert alpha-ketoglutarate to onco-metabolite 2HG (R(-)-2-hydroxyglutarate). High levels of 2HG confers tumor formation and progression (PMID: 19935646).",487,19935646,Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.,http://www.ncbi.nlm.nih.gov/pubmed/19935646,486,19228619,IDH1 and IDH2 mutations in gliomas.,http://www.ncbi.nlm.nih.gov/pubmed/19228619,1231
"IDH2 R172K lies within the active site of the IDH2 protein (PMID: 19228619). R172K confers a loss-of-function to use isocitrate as substrate, and a concomitant gain-of-function to convert alpha-ketoglutarate to onco-metabolite 2HG (R(-)-2-hydroxyglutarate). High levels of 2HG confers tumor formation and progression (PMID: 20171147, 19935646).",487,19935646,Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.,http://www.ncbi.nlm.nih.gov/pubmed/19935646,488,20171147,The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.,http://www.ncbi.nlm.nih.gov/pubmed/20171147,486,19228619,IDH1 and IDH2 mutations in gliomas.,http://www.ncbi.nlm.nih.gov/pubmed/19228619,1232
"IDH2 R140Q lies within the substrate binding region of the Idh2 protein (UniProt.org). R140Q confers a gain of function to Idh2, enabling conversion of alpha-ketoglutarate to the oncometabolite 2HG, results in increased 2HG levels in patient samples, and is transforming in cell culture (PMID: 20171147, PMID: 23558173).",295,,,www.uniprot.org,881,23558173,Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.,http://www.ncbi.nlm.nih.gov/pubmed/23558173,488,20171147,The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.,http://www.ncbi.nlm.nih.gov/pubmed/20171147,1233
"IDH1 R132G lies within the active site of the Idh1 protein (PMID: 19228619). R132G confers a gain of function to Idh1, as indicated by production of 2-hydroxyglutarate (2HG) in patient tissue and in vitro assays (PMID: 28330869, PMID: 24529257, PMID: 19935646).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,487,19935646,Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.,http://www.ncbi.nlm.nih.gov/pubmed/19935646,2894,24529257,D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma.,http://www.ncbi.nlm.nih.gov/pubmed/24529257,486,19228619,IDH1 and IDH2 mutations in gliomas.,http://www.ncbi.nlm.nih.gov/pubmed/19228619,9218,28330869,Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiency.,http://www.ncbi.nlm.nih.gov/pubmed/28330869,1234
IDH2 R172G lies within the active site of the Idh2 protein (PMID: 19228619). R172G activates HIF-1alpha and beta-catenin signaling and is likely to confer tumor invasion and chemo-resistance (PMID: 22309944).,489,22309944,Glioma derived isocitrate dehydrogenase-2 mutations induced up-regulation of HIF-1α and β-catenin signaling: possible impact on glioma cell metastasis and chemo-resistance.,http://www.ncbi.nlm.nih.gov/pubmed/22309944,486,19228619,IDH1 and IDH2 mutations in gliomas.,http://www.ncbi.nlm.nih.gov/pubmed/19228619,1235
IDH2 R172M lies within the active site of the Idh2 protein (PMID: 19228619). R172M confers a gain of function to the Idh2 protein as demonstrated by accumulation of the onco-metabolite 2HG (R(-)-2-hydroxyglutarate) in cultured cells (PMID: 21326614).,486,19228619,IDH1 and IDH2 mutations in gliomas.,http://www.ncbi.nlm.nih.gov/pubmed/19228619,2755,21326614,"2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.",http://www.ncbi.nlm.nih.gov/pubmed/21326614,1236
"FBXW7 D560G lies within the WD repeat 5 of the Fbxw7 protein (UniProt.org). D560G has been identified in sequencing studies (PMID: 22895193), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4597,22895193,Recurrent R-spondin fusions in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22895193,1237
"NOTCH1 V1578del results in the deletion of one amino acid in the extracellular domain of the Notch1 protein at amino acid 1578 (UniProt.org). V1578del has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1238
"FBXW7 R441W lies within the WD 2 repeat domain of the Fbxw7 protein (UniProt.org). R441W has been identified in sequencing studies (PMID: 25233892), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7231,25233892,Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes.,http://www.ncbi.nlm.nih.gov/pubmed/25233892,1239
"NOTCH1 R1633C lies within the extracellular domain of the Notch1 protein (UniProt.org). R1633C has been identified in sequencing studies (PMID: 22225590), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7067,22225590,Impact of complex NOTCH1 mutations on survival in paediatric T-cell leukaemia.,http://www.ncbi.nlm.nih.gov/pubmed/22225590,1241
"TP53 T377S lies within the region of the Tp53 protein which interacts with CARM1 (UniProt.org). T377S has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1242
"TP53 A353V lies within the HIPK2-interacting region of the Tp53 protein (UniProt.org). A353V has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1243
"TP53 F338Y lies within the HIPK1-interacting region of the Tp53 protein (UniProt.org). F338Y has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1244
ALK mutant indicates an unspecified mutation in the ALK gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1245
"CTNNB1 K335I lies within the ARM repeat 5 of the Ctnnb1 protein (UniProt.org). K335I is weakly activating as compared to Ctnnb1 wild-type in cultured cells (PMID: 24735922, PMID: 15579438) and thus, is predicted lead to a gain of Ctnnb1 protein function.",496,24735922,Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation.,http://www.ncbi.nlm.nih.gov/pubmed/24735922,586,15579438,CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15579438,295,,,www.uniprot.org,1248
EGFR R521K lies within the repeat region of the Egfr protein (UniProt.org). R521K (also reported as R497K) has been demonstrated to result in decreased Egfr response in cultured cells (PMID: 7937865). ,295,,,www.uniprot.org,497,7937865,A variant epidermal growth factor receptor exhibits altered type alpha transforming growth factor binding and transmembrane signaling.,http://www.ncbi.nlm.nih.gov/pubmed/7937865,1249
"SMO act mut indicates that this variant results in a gain of function in the SMO protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1250
BRAF rearrangement indicates an unspecified rearrangement of the BRAF gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1252
"FGFR1 rearrangement indicates an unspecified rearrangement of the FGFR1 gene.

",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1255
"TP53 R335H lies within the tetramerization domain of the Tp53 protein (PMID: 20978130). R335H has not been biochemically characterized, but results in increased monomer Tp53 compared to wild-type in cell culture (PMID: 19454241).",498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,1256
TP53 L330H lies within the tetramerization domain of the Tp53 protein (PMID: 20978130). L330H results in decreased Tp53 tetramerization and loss of Tp53 transcriptional activity in cell culture (PMID: 19454241).,499,19454241,Evaluation of transcriptional activity of p53 in individual living mammalian cells.,http://www.ncbi.nlm.nih.gov/pubmed/19454241,498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,1257
TP53 L330R lies within the tetramerization domain of the Tp53 protein (PMID: 20978130). L330R results in decreased Tp53 tetramerization and loss of Tp53 transcriptional activity in cell culture (PMID: 19454241).,498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,499,19454241,Evaluation of transcriptional activity of p53 in individual living mammalian cells.,http://www.ncbi.nlm.nih.gov/pubmed/19454241,1258
"TP53 R337C lies within the tetramerization domain of the Tp53 protein (PMID: 20978130). R337C results decreased tetramerization and loss of Tp53 transcriptional activity, and decreased apoptotic response to irradiation in cell culture (PMID: 19454241, PMID: 9150393).",498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,499,19454241,Evaluation of transcriptional activity of p53 in individual living mammalian cells.,http://www.ncbi.nlm.nih.gov/pubmed/19454241,1259
"AKT1 act mut indicates that this variant results in a gain of function in the AKT1 protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1260
"BRCA1 inact mut indicates that this variant results in a loss of function of the Brca1 protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1261
"BRCA2 inact mut indicates that this variant results in a loss of function of the Brca2 protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1262
"TP53 R337L lies within the tetramerization domain of the Tp53 protein (PMID: 20978130). R337L results in reduced Tp53 tetramerization and transactivation activity in cell culture (PMID: 19454241, PMID: 9766574).",498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,4434,9766574,Characterization of p53 mutants identified in human tumors with a missense mutation in the tetramerization domain.,http://www.ncbi.nlm.nih.gov/pubmed/9766574,499,19454241,Evaluation of transcriptional activity of p53 in individual living mammalian cells.,http://www.ncbi.nlm.nih.gov/pubmed/19454241,1263
TP53 R337P lies within the tetramerization domain of the Tp53 protein (PMID: 20978130). R337P results in decreased Tp53 tetramerization and loss of Tp53 transactivation activity in cell culture (PMID: 19454241).,498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,499,19454241,Evaluation of transcriptional activity of p53 in individual living mammalian cells.,http://www.ncbi.nlm.nih.gov/pubmed/19454241,1264
TP53 F341C lies within the tetramerization domain of the Tp53 protein (PMID: 20978130). F341C results decreased Tp53 transcriptional activity and reduced Tp53 tetramerization in cell culture (PMID: 19454241).,498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,499,19454241,Evaluation of transcriptional activity of p53 in individual living mammalian cells.,http://www.ncbi.nlm.nih.gov/pubmed/19454241,1265
TP53 R342P lies within the tetramerization domain of the Tp53 protein (PMID: 20978130). R342P results in reduced Tp53 tetramerization and loss of Tp53 transactivation activity in cell culture (PMID: 19454241).,498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,499,19454241,Evaluation of transcriptional activity of p53 in individual living mammalian cells.,http://www.ncbi.nlm.nih.gov/pubmed/19454241,1266
TP53 D324A lies within the tetramerization domain of the Tp53 protein (PMID:15510160). D324A demonstrated increased transcription activity and tetramerization ability similar to wild-type Tp53 in yeast (PMID:16007150).,500,16007150,"The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library.",http://www.ncbi.nlm.nih.gov/pubmed/16007150,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,1267
TP53 L344R lies within the tetramerization domain of the Tp53 protein (PMID: 20978130). L344R results in a decreased Tp53 tetramerization and transcriptional activity in cell culture (PMID: 19454241).,498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,499,19454241,Evaluation of transcriptional activity of p53 in individual living mammalian cells.,http://www.ncbi.nlm.nih.gov/pubmed/19454241,1268
TP53 D324Y lies within the tetramerization domain of the Tp53 protein (PMID:15510160). D324Y demonstrated increased Tp53 transcription activity in yeast (PMID:16007150).,500,16007150,"The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library.",http://www.ncbi.nlm.nih.gov/pubmed/16007150,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,1269
TP53 D324H lies within the tetramerization domain of the Tp53 protein (PMID:15510160). D324H demonstrated increased transcription activity and tetramerization ability similar to wild-type Tp53 in yeast (PMID:16007150).,500,16007150,"The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library.",http://www.ncbi.nlm.nih.gov/pubmed/16007150,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,1270
TP53 D324N lies within the tetramerization domain of the Tp53 protein (PMID:15510160). D324N demonstrated increased transcription activity and tetramerization ability similar to wild-type Tp53 in yeast (PMID:16007150).,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,500,16007150,"The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library.",http://www.ncbi.nlm.nih.gov/pubmed/16007150,1271
TP53 L344P lies within the tetramerization domain of the Tp53 protein (PMID: 20978130). L344P results in decreased Tp53 tetramerization and transcriptional activity in cell culture (PMID: 19454241).,499,19454241,Evaluation of transcriptional activity of p53 in individual living mammalian cells.,http://www.ncbi.nlm.nih.gov/pubmed/19454241,498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,1272
"TP53 T329A lies within the tetramerization domain of the Tp53 protein (PMID: 20978130). T329A has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,1273
"HRAS G12X indicates any amino acid change at position 12.  HRAS codon 12 mutations are pathway activating ""hotspot"" mutations.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1274
"HRAS G13X indicates any amino acid change at position 13.  HRAS codon 13 mutations are pathway activating ""hotspot"" mutations.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1275
"HRAS G61X indicates any amino acid change at position 61.  HRAS codon 61 mutations are pathway activating ""hotspot"" mutations.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1276
"TP53 L323R lies within the tetramerization domain of the Tp53 protein (PMID: 20978130). L323R has been identified in sequencing studies (PMID: 10225439), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Nov 2016).",498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,6949,10225439,Mutations of the p53 gene in oral squamous-cell carcinomas from Sudanese dippers of nitrosamine-rich toombak and non-snuff-dippers from the Sudan and Scandinavia.,http://www.ncbi.nlm.nih.gov/pubmed/10225439,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1277
"TP53 P322R does not lie within any known functional domains of the Tp53 protein (PMID: 20978130). P322R has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016). ",498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1278
"TP53 P322Q does not lie within any known functional domains of the Tp53 protein (PMID: 20978130). P322Q has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016). ",498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1279
"TP53 P322S does not lie within any known functional domains of the Tp53 protein (PMID: 20978130). P322S has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016). ",498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1280
"TP53 P322A does not lie within any known functional domains of the Tp53 protein (PMID: 20978130). P322A has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016). ",498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1281
"TP53 K320R lies within the nuclear localization signal of the Tp53 protein (PMID: 11420669). K320R leads to decreased activation of select Tp53 targets and resistance to apoptosis in cell culture (PMID: 14695212, PMID: 15831478).",4405,14695212,Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/14695212,501,11420669,Functional analysis and intracellular localization of p53 modified by SUMO-1.,http://www.ncbi.nlm.nih.gov/pubmed/11420669,2812,15831478,Direct p53 transcriptional repression: in vivo analysis of CCAAT-containing G2/M promoters.,http://www.ncbi.nlm.nih.gov/pubmed/15831478,1282
"TP53 K321R  lies within the HIPK1, CARM1 and HIPK2 interaction region and the bipartite nuclear localization signal motif of the Tp53 protein (UniProt.org). K321R has not been biochemically characterized but demonstrates binding to Daxx to similar level of wild-type Tp53 in yeast (PMID: 15364927). ",295,,,www.uniprot.org,6882,15364927,Negative regulation of p53 functions by Daxx and the involvement of MDM2.,http://www.ncbi.nlm.nih.gov/pubmed/15364927,1283
"TP53 K319R lies within the HIPK1, HIPK2, and CARM1-interacting region and bipartite nuclear localization signal region of the Tp53 protein (UniProt.org). K319R has not been biochemically characterized but demonstrates binding to Daxx to similar level of wild-type Tp53 in yeast (PMID: 15364927). ",295,,,www.uniprot.org,6882,15364927,Negative regulation of p53 functions by Daxx and the involvement of MDM2.,http://www.ncbi.nlm.nih.gov/pubmed/15364927,1284
"TP53 N311S does not lie within any known functional domains of the Tp53 protein (PMID:20978130). N311S has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,1285
"TP53 N310I does not lie within any known functional domains of the Tp53 protein (PMID:20978130). N310I has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,1286
"TP53 N310S does not lie within any known functional domains of the Tp53 protein (PMID:20978130). N310S has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,1287
"TP53 N310H lies within the bipartite nuclear localization signal motif and CARM1 interaction region of the Tp53 protein (UniProt.org). N310H has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1288
"TP53 P309S does not lie within any known functional domains of the Tp53 protein (PMID: 20978130). P309S has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,1289
"TP53 L308R lies within the bipartite nuclear localization signal motif and the CARM1 interaction region of the Tp53 protein (UniProt.org). L308R has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1290
"TP53 A307S lies within the CARM1-interacting region of the Tp53 protein (UniProt.org). A307S has been identified in the scientific literature (PMID: 25220666), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,10068,25220666,"TP53 and PIK3CA gene mutations in adenocarcinoma, squamous cell carcinoma and high-grade intraepithelial neoplasia of the cervix.",http://www.ncbi.nlm.nih.gov/pubmed/25220666,1291
"TP53 A307P lies within the CARM1-interacting region of the Tp53 protein (UniProt.org). A307P has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1292
"TP53 A307T lies within the CARM1-interacting region of the Tp53 protein (UniProt.org). A307T has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1293
FGFR2 rearrangement indicates an unspecified rearrangement of the FGFR2 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1294
FGFR3 rearrangement indicates an unspecified rearrangement of the FGFR3 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1295
PDGFRA rearrange indicates an unspecified rearrangement of the PDGFRA gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1297
KIT rearrangement indicates an unspecified rearrangement of the KIT gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1301
FLT3 rearrangement indicates an unspecified rearrangement of the FLT3 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1302
RET rearrangement indicates an unspecified rearrangement of the RET gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1303
CSF1R rearrange indicates an unspecified rearrangement of the CSF1R gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1304
"TP53 S303G lies within the DNA binding domain of the Tp53 protein (PMID:20978130). S303G has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016). ",498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1308
"TP53 S303R lies within the DNA binding domain of the Tp53 protein (PMID:20978130). S303R has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016). ",498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1309
"TP53 P301R does not lie within any known functional domains of the Tp53 protein (PMID: 20978130). P301R has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016). ",498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1310
"TP53 P301Q does not lie within any known functional domains of the Tp53 protein (PMID:20978130). P301Q has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016). ",498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1311
"TP53 P300R does not lie within any known functional domains of the Tp53 protein (PMID:20978130). P300R has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016). ",498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1312
"TP53 P300H does not lie within any known functional domains of the Tp53 protein (PMID:20978130). P300H has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016). ",498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1313
"TP53 P300A does not lie within any known functional domains of the Tp53 protein (PMID:20978130). P300A has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016). ",498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1314
"TP53 L299R lies within the DNA binding domain of the Tp53 protein (PMID: 20978130). L299R has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,1315
"TP53 E298V lies within the DNA binding domain of the Tp53 protein (PMID: 20978130). E298V has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,1316
"TP53 H297R lies within the DNA binding domain of the Tp53 protein (PMID:20978130). H297R has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,1317
"TP53 H297P lies within the DNA binding domain of the Tp53 protein (PMID:20978130). H297P has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,1318
"TP53 H296Y lies within the DNA binding domain of the Tp53 protein (PMID:20978130). H296Y has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,1319
"TP53 P295L lies within the DNA binding domain of the Tp53 protein (PMID:20978130). P295L has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,1320
"TP53 P295A lies within the DNA binding domain of the Tp53 protein (PMID:20978130). P295A has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,1321
"TP53 E294G lies within the DNA binding domain of the Tp53 protein (PMID: 20978130). E294G has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1322
"TP53 K292Q lies within the DNA binding domain of the Tp53 protein (PMID:20978130). K292Q has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1323
TP53 K291T lies within the DNA binding domain of the Tp53 protein (PMID: 20978130). K291T demonstrates increased ability to induce apoptosis in cultured cells when compared to wild-type Tp53 (PMID: 15781620). ,498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,502,15781620,Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s.,http://www.ncbi.nlm.nih.gov/pubmed/15781620,1324
TP53 K292T lies within the DNA binding domain of the Tp53 protein (PMID: 20978130). K292T demonstrates increased ability to induce apoptosis in cultured cells when compared to wild-type Tp53 (PMID: 15781620). ,498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,502,15781620,Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s.,http://www.ncbi.nlm.nih.gov/pubmed/15781620,1325
TP53 K291I lies within the DNA binding domain of the Tp53 protein (PMID: 20978130). K291I demonstrates increased ability to induce apoptosis in cultured cells when compared to wild-type Tp53 (PMID: 15781620). ,498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,502,15781620,Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s.,http://www.ncbi.nlm.nih.gov/pubmed/15781620,1326
TP53 K291Q lies within the DNA binding domain of the Tp53 protein (PMID: 20978130). K291Q demonstrates increased ability to induce apoptosis in cultured cells when compared to wild-type Tp53 (PMID: 15781620). ,498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,502,15781620,Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s.,http://www.ncbi.nlm.nih.gov/pubmed/15781620,1327
TP53 K291E lies within the DNA binding domain of the Tp53 protein (PMID: 20978130). K291E demonstrates increased ability to induce apoptosis in cultured cells when compared to wild-type Tp53 (PMID: 15781620). ,498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,502,15781620,Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s.,http://www.ncbi.nlm.nih.gov/pubmed/15781620,1328
TP53 R290G lies within the DNA-binding domain of the Tp53 protein (PMID: 20978130). R290G demonstrated increased ability to induce apoptosis in cultured cells when compared to wild-type Tp53 (PMID: 15781620). ,498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,502,15781620,Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s.,http://www.ncbi.nlm.nih.gov/pubmed/15781620,1329
TP53 F212Y lies within the DNA-binding domain of the Tp53 protein (PMID: 20978130). F212Y demonstrates increased ability to induce apoptosis in cultured cells when compared to wild-type Tp53 (PMID: 15781620). ,498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,502,15781620,Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s.,http://www.ncbi.nlm.nih.gov/pubmed/15781620,1330
TP53 S121A lies within the DNA binding domain of the Tp53 protein (PMID:20978130). S121A demonstrates increased ability to induce apoptosis in cultured cells when compared to wild-type Tp53 (PMID:15781620). ,498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,502,15781620,Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s.,http://www.ncbi.nlm.nih.gov/pubmed/15781620,1331
TP53 S121C lies within the DNA binding domain of the Tp53 protein (PMID:20978130). S121C demonstrates increased ability to induce apoptosis in cultured cells when compared to wild-type Tp53 (PMID:15781620). ,498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,502,15781620,Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s.,http://www.ncbi.nlm.nih.gov/pubmed/15781620,1332
TP53 S121F lies within the DNA binding domain of the Tp53 protein (PMID:20978130). S121F demonstrates increased ability to induce apoptosis in cultured cells when compared to wild-type Tp53 (PMID:15781620). ,498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,502,15781620,Lack of correlation between p53-dependent transcriptional activity and the ability to induce apoptosis among 179 mutant p53s.,http://www.ncbi.nlm.nih.gov/pubmed/15781620,1333
"EZH2 L660V (corresponds to L666 in the canonical isoform) lies within a SET domain of the Ezh2 protein (UniProt.org). L660V has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1334
"EZH2 N675K (corresponds to N671 in the canonical isoform) lies within a SET domain of the Ezh2 protein (UniProt.org). N675K has been identified in sequencing studies (PMID: 20601954), but has not been biochemically characterized and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7337,20601954,Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/20601954,295,,,www.uniprot.org,1335
"EZH2 A682G is a “hotspot” mutation in follicular lymphoma (PMID: 24052547) within the SET domain of the Ezh2 protein (UniProt.org) and corresponds to A677G in the canonical sequence (UniProt.org, PMID: 24052547). A682G (A677G) confers a gain of function on Ezh2 to increase H3K27 trimethylation in human B-cell lymphoma cell lines (PMID: 22323599).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,506,22323599,Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27).,http://www.ncbi.nlm.nih.gov/pubmed/22323599,295,,,www.uniprot.org,503,24052547,EZH2 mutations are frequent and represent an early event in follicular lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/24052547,1336
"EZH2 A682T (corresponds to A667 in the canonical isoform) lies within a SET domain of the Ezh2 protein (UniProt.org). A682T has been identified in sequencing studies (PMID: 22190405), but has not been biochemically characterized and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",7050,22190405,Germline mutations in the oncogene EZH2 cause Weaver syndrome and increased human height.,http://www.ncbi.nlm.nih.gov/pubmed/22190405,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1337
"EZH2 A682V (corresponds to A677 in the canonical isoform) lies within a SET domain of the Ezh2 protein (UniProt.org). A682V has been identified in sequencing studies (PMID: 23613835), but has not been biochemically characterized and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7051,23613835,EZH2 mutations are related to low blast percentage in bone marrow and -7/del(7q) in de novo acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23613835,1338
"EZH2 R684C (corresponds to R679 in the canonical isoform) lies within a SET domain of the Ezh2 protein (UniProt.org). R684C has been identified in sequencing studies (PMID: 20601953), but has not been biochemically characterized and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3332,20601953,Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders.,http://www.ncbi.nlm.nih.gov/pubmed/20601953,295,,,www.uniprot.org,1339
"EZH2 R684H (corresponds to R679 in the canonical isoform) lies within a SET domain of the Ezh2 protein (UniProt.org). R684H has been identified in sequencing studies (PMID: 27276561), but has not been biochemically characterized and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",7052,27276561,Genomic Classification and Prognosis in Acute Myeloid Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27276561,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1340
"EZH2 K685fs (corresponds to K683 in the canonical isoform) results in a change in the amino acid sequence of the Ezh2 protein beginning at aa 685 of 751, likely resulting in premature truncation of the functional protein (UniProt.org). K685fs has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1341
"EZH2 R690H (corresponds to R685 in the canonical isoform) lies within a SET domain of the Ezh2 protein (UniProt.org). R690H has been identified in sequencing studies (PMID: 27276561), but has not been biochemically characterized and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",7052,27276561,Genomic Classification and Prognosis in Acute Myeloid Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27276561,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1342
EZH2 R690C (corresponds to R685 in the canonical isoform) lies within a SET domain of the Ezh2 protein (UniProt.org). R690C confers a loss of function to the Ezh2 protein as demonstrated by a loss of downstream H3K27 trimethylation activity (PMID: 20601953).,3332,20601953,Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders.,http://www.ncbi.nlm.nih.gov/pubmed/20601953,295,,,www.uniprot.org,1343
EZH2 A692V is a “hotspot” mutation in follicular lymphoma (PMID: 24052547) within the SET domain of the Ezh2 protein (UniProt.org) and corresponds to A687V in the canonical sequence (UniProt.org). A692V (A687V) confers a gain of function on the Ezh2 protein greatly enhancing methylation of downstream targets (PMID: 22850114).,703,22850114,A687V EZH2 is a gain-of-function mutation found in lymphoma patients.,http://www.ncbi.nlm.nih.gov/pubmed/22850114,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,503,24052547,EZH2 mutations are frequent and represent an early event in follicular lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/24052547,1344
"EZH2 N693T (corresponds to N688 in the canonical isoform) lies within a SET domain of the Ezh2 protein (UniProt.org). N693T has been identified in sequencing studies (PMID: 20724984), but has not been biochemically characterized and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).
",295,,,www.uniprot.org,7053,20724984,Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/20724984,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1345
"EZH2 N693Y (corresponds to N688 in the canonical isoform) lies within a SET domain of the Ezh2 protein (UniProt.org). N693Y has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1346
"EZH2 H694Y (corresponds to H689 in the canonical isoform) lies within a SET domain of the Ezh2 protein (UniProt.org). H694Y has been identified in sequencing studies (PMID: 20724984), but has not been biochemically characterized and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7053,20724984,Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/20724984,1347
"EZH2 H694R (corresponds to H689 in the canonical isoform) lies within a SET domain of the Ezh2 protein (UniProt.org). H694R has been identified in sequencing studies (PMID: 27276561), but has not been biochemically characterized and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7052,27276561,Genomic Classification and Prognosis in Acute Myeloid Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27276561,1348
"EZH2 F728fs (corresponds to F723 in the canonical isoform) results in a change in the amino acid sequence of the Ezh2 protein beginning at aa 728 of 751, likely resulting in premature truncation of the functional protein (UniProt.org). F728fs has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1350
"EZH2 Y731* (Y726* in the canonical isoform) results in a premature truncation of the Ezh2 isoform 2 protein at amino acid 731 of 751 (UniProt.org). Y731* has been identified in sequencing studies (PMID: 22390313), but has not been biochemically characterized and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).
",7341,22390313,Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide.,http://www.ncbi.nlm.nih.gov/pubmed/22390313,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1351
"EZH2 Y733* (Y728* in the canonical isoform) results in a premature truncation of the Ezh2 isoform 2 protein at amino acid 733 of 751 (UniProt.org). Y733* has been identified in sequencing studies (PMID: 21921040), but has not been biochemically characterized and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1352
"EZH2 Y741C (corresponds to Y736C in the canonical isoform) does not lie within any known functional domains of the Ezh2 protein (UniProt.org). Y741C has been identified in sequencing studies (PMID: 22190405), but has not been biochemically characterized and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).
",7050,22190405,Germline mutations in the oncogene EZH2 cause Weaver syndrome and increased human height.,http://www.ncbi.nlm.nih.gov/pubmed/22190405,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1353
"EZH2 V742D (corresponds to V737D of the canonical isoform) does not lie within any known functional domains of the Ezh2 protein (UniProt.org). V742D has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (Pubmed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1354
"EZH2 I744fs (corresponds to I739 in the canonical isoform) results in a change in the amino acid sequence of the Ezh2 protein beginning at aa 744 of 751, likely resulting in premature truncation of the functional protein (UniProt.org). I744fs has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1355
"EZH2 E745K (corresponds to E740 in the canonical isoform) does not lie within any known functional domains of the Ezh2 protein (UniProt.org). E745K has been identified in sequencing studies (PMID: 27276561), but has not been biochemically characterized and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",7052,27276561,Genomic Classification and Prognosis in Acute Myeloid Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27276561,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1356
"EZH2 E745fs (corresponds to E740 in the canonical isoform) results in a change in the amino acid sequence of the Ezh2 protein beginning at aa 745 of 751, likely resulting in premature truncation of the functional protein (UniProt.org). E745fs has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1357
EZH2 A677G lies within the SET domain of the Ezh2 protein (Uniprot.org).  A677G confers a gain of function on Ezh2 to increase H3K27 trimethylation in human B-cell lymphoma cell lines (PMID: 22323599).,506,22323599,Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27).,http://www.ncbi.nlm.nih.gov/pubmed/22323599,295,,,www.uniprot.org,1358
"EZH2 L674V (corresponds to L669 in the canonical isoform) lies within a SET domain of the Ezh2 protein (UniProt.org). L674V has been identified in sequencing studies (PMID: 23613835), but has not been biochemically characterized and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017). ",7051,23613835,EZH2 mutations are related to low blast percentage in bone marrow and -7/del(7q) in de novo acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23613835,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1359
RUNX1 H58N lies within the Runt domain of the Runx1 protein (UniProt.org). H58N results in a loss of binding to Mll but demonstrates transcriptional activity similar to wild-type Runx1 in culture (PMID: 23817177).,5672,23817177,RUNX1 meets MLL: epigenetic regulation of hematopoiesis by two leukemia genes.,http://www.ncbi.nlm.nih.gov/pubmed/23817177,295,,,www.uniprot.org,1360
RUNX1 K83N lies within the DNA binding region of the Runx1 protein (UniProt.org). K83N results in failure to induce senescence-like growth arrest in cell culture compared to wild-type Runx1 (PMID: 19448675). ,507,19448675,"RUNX1 and its fusion oncoprotein derivative, RUNX1-ETO, induce senescence-like growth arrest independently of replicative stress.",http://www.ncbi.nlm.nih.gov/pubmed/19448675,1361
RUNX1 R80C lies within the Runt domain and DNA interaction region of the Runx1 protein (UniProt.org). R80C confers a loss of function to the Runx1 protein as indicated by loss of DNA binding ability and transactivation in culture (PMID: 24098673).,295,,,www.uniprot.org,508,24098673,Functionally deregulated AML1/RUNX1 cooperates with BCR-ABL to induce a blastic phase-like phenotype of chronic myelogenous leukemia in mice.,http://www.ncbi.nlm.nih.gov/pubmed/24098673,1362
RUNX1 S114* results in a premature truncation of the Runx1 protein at amino acid 114 of 453 within the Runt domain (UniProt.org). S114* confers a loss of function to the Runx1 protein as indicated by loss of DNA binding ability in culture (PMID: 10068652).,509,10068652,Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias.,http://www.ncbi.nlm.nih.gov/pubmed/10068652,295,,,www.uniprot.org,1363
RUNX1 R177Q lies within the Runt domain of the Runx1 protein (UniProt.org). R177Q confers a loss of function to the Runx1 protein as indicated by loss of DNA binding ability and transactivation activity in culture (PMID: 10068652).,509,10068652,Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias.,http://www.ncbi.nlm.nih.gov/pubmed/10068652,295,,,www.uniprot.org,1364
RUNX1 R177* results in a premature truncation of the Runx1 protein at amino acid 177 of 453 within the Runt domain (UniProt.org). R177* confers a loss of function to the Runx1 protein as indicated by loss of DNA binding ability in culture (PMID: 10068652).,509,10068652,Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias.,http://www.ncbi.nlm.nih.gov/pubmed/10068652,295,,,www.uniprot.org,1365
"RUNX1 A129E lies within the Runt domain of the Runx1 protein (UniProt.org). A129E has been identified in the scientific literature (PMID: 19357396), but has not been biochemically characterized and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8143,19357396,High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder.,http://www.ncbi.nlm.nih.gov/pubmed/19357396,1366
RUNX1 R174Q lies within the Runt domain and interaction with DNA region of the Runx1 protein (UniProt.org). R174Q confers a loss of function to the Runx1 protein as indicated by loss of DNA binding ability and transactivation activity in culture (PMID: 22318203).,295,,,www.uniprot.org,511,22318203,Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/22318203,1368
"ATM H1380Y is located in the c-Abl binding domain of the Atm protein (PMID: 12969974). H1380Y likely impairs the interaction of Atm with c-Abl, resulting in defective c-Abl activation (PMID: 12969974).",136,12969974,Identification and characterization of polymorphic variations of the ataxia telangiectasia mutated (ATM) gene in childhood Hodgkin disease.,http://www.ncbi.nlm.nih.gov/pubmed/12969974,1369
"ATM dec exp indicates decreased expression of the Atm protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1370
RUNX1 D171G lies within the Runt domain and interaction with DNA region of the Runx1 protein (UniProt.org). D171G confers a loss of function to the Runx1 protein as indicated by loss of DNA binding ability and transactivation activity in culture (PMID: 22318203).,511,22318203,Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/22318203,295,,,www.uniprot.org,1371
"RUNX1 R135G lies within the Runt domain and DNA-interacting region of the Runx1 protein (UniProt.org). R135G has not been characterized, but is predicted to disrupt DNA binding ability of Runx1 protein by structural modeling (PMID: 11276260).",522,11276260,The leukemia-associated AML1 (Runx1)--CBF beta complex functions as a DNA-induced molecular clamp.,http://www.ncbi.nlm.nih.gov/pubmed/11276260,295,,,www.uniprot.org,1372
"RUNX1 G138D lies within the Runt domain and DNA-interacting region of the Runx1 protein (UniProt.org). G138D has not been characterized, but is predicted to disrupt DNA binding ability of Runx1 protein by structural modeling (PMID: 11276260).",522,11276260,The leukemia-associated AML1 (Runx1)--CBF beta complex functions as a DNA-induced molecular clamp.,http://www.ncbi.nlm.nih.gov/pubmed/11276260,295,,,www.uniprot.org,1373
RUNX1 R139G lies within the Runt domain and interaction with DNA region of the Runx1 protein (UniProt.org). R139G confers a loss of function to the Runx1 protein as indicated by loss of DNA binding ability and transactivation activity in culture (PMID: 10068652).,509,10068652,Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias.,http://www.ncbi.nlm.nih.gov/pubmed/10068652,295,,,www.uniprot.org,1374
"RUNX1 V105* results in a premature truncation of the Runx1 protein at amino acid 105 of 453 (UniProt.org). Due to the loss of a portion of the runt homology domain and the loss of the entire transactivation domain, V105* is predicted to lead to a loss of Runx1 protein function (PMID: 25840971).",3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,295,,,www.uniprot.org,1375
"RUNX1 C72fs*111 lies within the Runt domain of the Runx1 protein (UniProt.org). Due to the loss of a portion of the runt homology domain and the loss of the entire transactivation domain, C72fs*111 is predicted to lead to a loss of Runx1 protein function (PMID: 25840971).",3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,295,,,www.uniprot.org,1376
RUNX1 A160T lies within the Runt domain of the Runx1 protein (UniProt.org).  A160T has decreased CBF beta dimerization and C-FMS induction abilities as compared to wild-type Runx1 in culture (PMID: 25840971).,295,,,www.uniprot.org,3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,1377
RUNX1 K83E lies within the Runt domain and interaction with DNA region of the Runx1 protein (UniProt.org). K83E confers a loss of function to the Runx1 protein as indicated by loss of DNA binding ability and transactivation activity in culture (PMID: 11830488).,295,,,www.uniprot.org,523,11830488,In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/11830488,1378
RUNX1 Y260* results in a premature truncation of the Runx1 protein at amino acid 260 of 453 (UniProt.org). Y260* confers a loss of function to the Runx1 protein as indicated by failure to localize in the nucleus and decreased transcriptional activity in culture (PMID: 23817177).,295,,,www.uniprot.org,5672,23817177,RUNX1 meets MLL: epigenetic regulation of hematopoiesis by two leukemia genes.,http://www.ncbi.nlm.nih.gov/pubmed/23817177,1379
"RUNX1 R135fs*177 likely results in a truncation of the 453 aa Runx1 protein at aa 135, followed by 177 nonsense amino acids (UniProt.org). Due to the loss of a portion of the runt homology domain and the loss of the entire transactivation domain, R135fs*177 is predicted to lead to a loss of Runx1 protein function (PMID: 25840971).",295,,,www.uniprot.org,3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,1380
RUNX1 R139* results in a premature truncation of the Runx1 protein at amino acid 139 of 453 (UniProt.org). R139* confers a loss of function to the Runx1 protein as indicated by loss of DNA binding and transcription activity in culture (PMID: 25840971).,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,1381
RUNX1 W79* results in a premature truncation of the Runx1 protein at amino acid 79 of 453 (UniProt.org). W79* confers a loss of function to the Runx1 protein as indicated by loss of DNA binding and transcription activity in culture (PMID: 25840971).,295,,,www.uniprot.org,3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,1382
"TP53 V173L lies within the DNA-binding domain of the Tp53 protein (PMID: 23246812). V173L results in aberrant Tp53 localization and decreased Tp53 target transactivation, and leads to increased cell growth and diminished Tp53 pro-apoptotic function in culture (PMID: 23246812). ",371,23246812,Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.,http://www.ncbi.nlm.nih.gov/pubmed/23246812,1383
ALK G1128A lies within the protein kinase domain of the Alk protein (UniProt.org). G1128A confers a gain of function to the Alk protein as demonstrated by increased downstream signaling in vitro and transformation in cultured cells (PMID: 21838707).,527,21838707,Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.,http://www.ncbi.nlm.nih.gov/pubmed/21838707,295,,,www.uniprot.org,1384
"CDKN2A amp indicates an increased number of copies of the CDKN2A gene. However, the mechanism causing the increase is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1386
"ALK I1171N lies within the protein kinase domain of the Alk protein (UniProt.org). I1171N results in increased ligand-independent Alk phosphorylation, activation of the Stat pathway, and is transforming in cell culture (PMID: 23239810, PMID: 21838707).",1807,23239810,Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/23239810,527,21838707,Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.,http://www.ncbi.nlm.nih.gov/pubmed/21838707,1387
"MET T1010I lies within the juxtamembrane segment of the Met protein and corresponds to T992I in the protein's short isoform (PMID: 14559814, PMID: 20670955). T1010I results in increased colony formation and motility in cultured cells (PMID: 14559814, PMID: 25605252), however, conflicting reports demonstrate an increase (PMID: 25605252) and no effect on Met phosphorylation (PMID: 20670955).",332,14559814,c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.,http://www.ncbi.nlm.nih.gov/pubmed/14559814,2198,20670955,MET receptor sequence variants R970C and T992I lack transforming capacity.,http://www.ncbi.nlm.nih.gov/pubmed/20670955,4815,25605252,Functional consequence of the MET-T1010I polymorphism in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25605252,1388
"KRAS amplification indicates an increased number of copies of the KRAS gene. However, the mechanism causing the increase is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1390
"ALK F1245C lies within the protein kinase domain of the Alk protein (UniProt.org). Alk F1245C results in increased downstream signalling and is transforming in cell culture (PMID: 21838707).
",527,21838707,Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.,http://www.ncbi.nlm.nih.gov/pubmed/21838707,295,,,www.uniprot.org,1391
"ALK R1192P lies within the protein kinase domain of the Alk protein (UniProt.org). R1192P confers a gain of function to the Alk protein as demonstrated by transformed cells and displayed increased downstream signalling, although less robustly than other activating mutants (PMID: 21838707).",295,,,www.uniprot.org,527,21838707,Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.,http://www.ncbi.nlm.nih.gov/pubmed/21838707,1392
"ALK R1275Q lies within the protein kinase domain of the Alk protein (UniProt.org). R1275Q confers a gain of function to the Alk protein as demonstrated by transformation activity in cell culture and increased downstream signalling in in vitro assays (PMID: 21838707).
",295,,,www.uniprot.org,527,21838707,Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684.,http://www.ncbi.nlm.nih.gov/pubmed/21838707,1393
"PDGFRA amplification indicates an increased number of copies of the PDGFRA gene. However, the mechanism causing the increase is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1394
"RET amp indicates an increased number of copies of the RET gene. However, the mechanism causing the increase is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1395
ATM S1455R does not lie within any known functional domains of the Atm protein (UniProt.org). S1455R confers a loss of function to the Atm protein as demonstrated by impaired phosphorylation of p53 and Chek2 in cultured cells (PMID: 12969974).,295,,,www.uniprot.org,136,12969974,Identification and characterization of polymorphic variations of the ataxia telangiectasia mutated (ATM) gene in childhood Hodgkin disease.,http://www.ncbi.nlm.nih.gov/pubmed/12969974,1396
"RUNX1 Q181* results in a premature truncation of the Runx1 protein at amino acid 181 of 453 (UniProt.org). Due to the loss of the transactivation domain, Q181* is predicted to lead to a loss of Runx1 protein function (PMID: 25840971).",3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,295,,,www.uniprot.org,1406
RUNX1 K83Q lies within the Runt domain and interaction with DNA region of the Runx1 protein (Unitprot.org). K83Q is a “hotspot” mutation for blast crisis CML  (PMID: 24098673) and demonstrates DNA binding and transcriptional activity comparable to wild type Runx1 protein (PMID: 24098673).,508,24098673,Functionally deregulated AML1/RUNX1 cooperates with BCR-ABL to induce a blastic phase-like phenotype of chronic myelogenous leukemia in mice.,http://www.ncbi.nlm.nih.gov/pubmed/24098673,295,,,www.uniprot.org,1407
"RUNX1 R178* results in a premature truncation of the Runx1 protein at amino acid 178 of 453 (UniProt.org). Due to the loss of the transactivation domain, R178* is predicted to lead to a loss of Runx1 protein function (PMID: 25840971).",295,,,www.uniprot.org,3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,1408
"RUNX1 Q158* results in a premature truncation of the Runx1 protein at amino acid 158 of 453. Due to the loss of a portion of the runt homology domain and the loss of the entire transactivation domain, Q158* is predicted to lead to a loss of Runx1 protein function (PMID: 25840971).",295,,,www.uniprot.org,3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,1410
"KRAS G13V is a hotspot mutation that lies within a GTP binding region of the Kras protein (UniProt.org). G13V has not been biochemically characterized, however, other G13 mutations result in decreased Kras GTPase activity and activation of downstream signaling (PMID: 26037647, PMID: 20664172), and Ras G13V is predicted to result in decreased GTPase activity by computational modeling (PMID: 25339142), thus, G13V is predicted to result in a loss of Kras protein function.",9844,25339142,Modeling the role of G12V and G13V Ras mutations in the Ras-GAP-catalyzed hydrolysis reaction of guanosine triphosphate.,http://www.ncbi.nlm.nih.gov/pubmed/25339142,295,,,www.uniprot.org,1067,20664172,Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.,http://www.ncbi.nlm.nih.gov/pubmed/20664172,3052,26037647,Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26037647,1411
"KRAS G13A is a hotspot mutation that lies within a GTP binding region of the Kras protein (UniProt.org). G13A has not been biochemically characterized, however, other Ras G13 mutations result in decreased GTPase activity and activation of downstream signaling (PMID: 26037647, PMID: 23455880, PMID: 22589270), thus, G13A is predicted to result in a loss of Kras protein function.",26,23455880,KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23455880,295,,,www.uniprot.org,2097,22589270,A comprehensive survey of Ras mutations in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22589270,3052,26037647,Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26037647,1412
"KRAS G13S is a hotspot mutation that lies within a GTP binding region of the Kras protein (UniProt.org). G13S has not been biochemically characterized, however, other Ras G13 mutations result in decreased GTPase activity and activation of downstream signaling (PMID: 26037647, PMID: 23455880, PMID: 22589270), thus, G13S is predicted to result in a loss of Kras protein function.",26,23455880,KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23455880,295,,,www.uniprot.org,2097,22589270,A comprehensive survey of Ras mutations in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22589270,3052,26037647,Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26037647,1413
"KRAS V14I lies within the GTP nucleotide binding domain (UniProt.org). V14I results in decreased Kras GTPase activity and increased activation of downstream signaling in cell culture (PMID: 19075190, PMID: 20949621).",547,19075190,"High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.",http://www.ncbi.nlm.nih.gov/pubmed/19075190,800,20949621,Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders.,http://www.ncbi.nlm.nih.gov/pubmed/20949621,295,,,www.uniprot.org,1414
"KRAS T74P does not lie within any known functional domains of the Kras protein (UniProt.org). T74P leads to increased Ras-GTP, which may result from disruption of Kras GTPase activity, and is transforming in cell culture (PMID: 19075190).",547,19075190,"High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.",http://www.ncbi.nlm.nih.gov/pubmed/19075190,1415
"KRAS A146T is an exon four mutation, which confers a loss of function to the Kras protein (PMID: 20570890).  A146T decreases Kras GTPase activity, increases phosphorylation of Mek and Erk, and is transforming in cell culture and xenografts (PMID: 19075190, PMID: 20570890).",547,19075190,"High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.",http://www.ncbi.nlm.nih.gov/pubmed/19075190,1805,20617134,Clinical relevance of KRAS in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/20617134,843,20570890,Genomic and biological characterization of exon 4 KRAS mutations in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20570890,1416
"NRAS G60E lies within the nucleotide binding domain of the Nras protein (UniProt.org). G60E results in a loss of Nras GTPase activity and activation of Mek and Erk signaling pathways, and is transforming in cell culture (PMID:19075190).",547,19075190,"High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.",http://www.ncbi.nlm.nih.gov/pubmed/19075190,295,,,www.uniprot.org,1417
"RUNX1 R121* results in a premature truncation of the Runx1 protein at amino acid 121 of 453 (UniProt.org). Due to the loss of a portion of the runt homology domain and the loss of the entire transactivation domain, R121* is predicted to lead to a loss of Runx1 protein function (PMID: 25840971).",3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,295,,,www.uniprot.org,1418
RUNX1 S114P lies within the Runt domain of the Runx1 protein (UniProt.org). S114P demonstrates transactivation activity similar to wild type Runx1 protein in culture (Blood 2009 114:3468).,8614,,High Frequency of C-Terminal Frame-Shift Mutations of RUNX1 Gene in De Novo AML with Partial Tandem Duplication of MLL.,http://www.bloodjournal.org/content/114/22/3468?sso-checked=true,295,,,www.uniprot.org,1419
RUNX1 R135K lies within the Runt domain and DNA interaction region of the Runx1 protein (UniProt.org). R135K results in a loss of Runx1 transcription activity in culture (PMID: 25840971).,3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,295,,,www.uniprot.org,1420
"RUNX1 V425G lies within the Pro/Ser/Thr-rich region of the Runx1 protein (UniProt.org). V425G has been identified in the scientific literature (PMID: 19808697), but has not been biochemically characterized and therefore, its effect on Runx1 protein function is unknown (PubMed, Apr 2017).",549,19808697,AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations.,http://www.ncbi.nlm.nih.gov/pubmed/19808697,295,,,www.uniprot.org,1421
RUNX1 M439L lies within the proline/serine/threonine rich region at the C-terminus of the Runx1 protein (UniProt.org). M439L demonstrates DNA binding and transcription activity similar to wild type Runx1 protein in culture (PMID: 25840971).,3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,295,,,www.uniprot.org,1422
RUNX1 G42R does not lie within any known functional domains of the Runx1 protein (UniProt.org). G42R results in a loss of binding to Mll but demonstrates transcriptional activity similar to wild-type Runx1 in culture (PMID: 23817177).,5672,23817177,RUNX1 meets MLL: epigenetic regulation of hematopoiesis by two leukemia genes.,http://www.ncbi.nlm.nih.gov/pubmed/23817177,295,,,www.uniprot.org,1423
"RUNX1 D317N lies within the KAT6A and KAT6B-interacting regions of the Runx1 protein (UniProt.org). D317N has been identified in the scientific literature (PMID: 19808697), but has not been biochemically characterized and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,549,19808697,AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations.,http://www.ncbi.nlm.nih.gov/pubmed/19808697,1424
"KRAS G13D is a hotspot mutation that lies within a GTP binding region of the Kras protein (UniProt.org). G13D results in increased Kras GTP/GDP exchange and decreased Kras GTPase activity, and leads to increased activation of downstream signaling in cell culture (PMID: 23455880, PMID: 26037647).",26,23455880,KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23455880,295,,,www.uniprot.org,3052,26037647,Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26037647,1425
"RUNX1 R166* results in a premature truncation of the Runx1 protein at amino acid 166 of 453 (UniProt.org). Due to the loss of a portion of the runt homology domain and the loss of the entire transactivation domain, R166* is predicted to lead to a loss of Runx1 protein function (PMID: 25840971).",295,,,www.uniprot.org,3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,1426
"RUNX1 A122fs*123 likely results in a truncation of the Runx1 protein at amino acid 122 of 453 followed by 123 nonsense amino acids within the Runt domain of the Runx1 protein (UniProt.org). Due to the loss of a portion of the runt homology domain and the loss of the entire transactivation domain, A122fs*123 is predicted to lead to a loss of Runx1 protein function (PMID: 25840971).",295,,,www.uniprot.org,3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,1429
"RUNX1 D171N lies within the Runt domain and interaction with DNA region of the Runx1 protein (UniProt.org). D171N is a “hotspot” mutation (PMID: 23471304) that results in loss of DNA binding ability and transactivation activity of the Runx1 protein (PMID: 23471304), and promotes leukemic transformation in culture (PMID: 19850737).",295,,,www.uniprot.org,551,23471304,RUNX1/AML1 mutant collaborates with BMI1 overexpression in the development of human and murine myelodysplastic syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/23471304,552,19850737,AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/19850737,1430
"RUNX1 G143fs*214 likely results in a truncation of the Runx1 protein at amino acid 143 of 453 followed by 214 nonsense amino acids within the Runt domain of the Runx1 protein (UniProt.org) Due to the loss of a portion of the runt homology domain and the loss of the entire transactivation domain, G143fs*214 is predicted to lead to a loss of Runx1 protein function (PMID: 25840971).",295,,,www.uniprot.org,3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,1431
"TP53 P98R lies within the WWOX-interacting region of the Tp53  protein (UniProt.org). P98R has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1446
"TP53 G105D lies within the DNA binding domain of the Tp53 protein (UniProt.org). G105D has been identified in the scientific literature (PMID: 16000567, PMID: 27273737), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",10080,16000567,Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder.,http://www.ncbi.nlm.nih.gov/pubmed/16000567,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,10081,27273737,Hepatocellular carcinoma cell lines retain the genomic and transcriptomic landscapes of primary human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27273737,1447
"TP53 A159G lies within the DNA binding domain of the Tp53 protein (UniProt.org). A159G has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1448
"TP53 N268I lies within the DNA binding domain and the HIPK1, ZNF385A, AXIN1 and E4F1 interaction region of the Tp53 protein (UniProt.org). N268I has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1449
"TP53 T256K lies within the DNA binding domain and the HIPK1, ZNF385A, AXIN1, and E4F1 interaction region of the Tp53 protein (UniProt.org). T256K has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1450
TP53 D7A lies within the interaction with HRMT1L2 and transcription activation region of the Tp53 protein (UniProt.org). D7A confers a loss of function to the Tp53 protein as demonstrated by reduced Pimpt-mediated Tp53 methylation (PMID: 22735455).,295,,,www.uniprot.org,5118,22735455,Protein L-isoaspartyl methyltransferase regulates p53 activity.,http://www.ncbi.nlm.nih.gov/pubmed/22735455,1451
"TP53 V147L lies within the DNA binding domain and HIPK1, ZNF385A, FBXO42, and AXIN1 interacting region of the Tp53 protein (UniProt.org). V147L has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1452
"TP53 P98A lies within the WWOX-interacting region of the Tp53 protein (UniProt.org). P98A results decreased Tp53 transactivation activity and leads to reduced apoptosis relative to wild type Tp53 in cell culture (PMID: 22862161, PMID: 20505364).",4422,20505364,Transactivation by temperature-dependent p53 mutants in yeast and human cells.,http://www.ncbi.nlm.nih.gov/pubmed/20505364,295,,,www.uniprot.org,609,22862161,Roscovitine-induced apoptosis of H1299 cells depends on functional status of p53.,http://www.ncbi.nlm.nih.gov/pubmed/22862161,1453
"TP53 H214Y lies within the DNA binding domain of the Tp53 protein (UniProt.org). H214Y has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1454
TP53 K305N lies within the HIPK1 interaction region and the bipartite nuclear localization signal motif of the Tp53 protein (UniProt.org). K305N results in a loss of nuclear localization of Tp53 but retains the ability to interact with wild-type Tp53 and Mdm2 (PMID: 11127820).,5138,11127820,MDM2-dependent ubiquitination of nuclear and cytoplasmic P53.,http://www.ncbi.nlm.nih.gov/pubmed/11127820,295,,,www.uniprot.org,1455
"TP53 T211I lies within the DNA binding domain and the HIPK1, ZNF385A, FBXO42 and AXIN1 interaction region of the Tp53 protein (UniProt.org). T211I confers temperature-sensitivity to the Tp53 protein with lowest transactivation activity at an elevated temperature (PMID: 22710932).",295,,,www.uniprot.org,554,22710932,Transactivation and reactivation capabilities of temperature-dependent p53 mutants in yeast and human cells.,http://www.ncbi.nlm.nih.gov/pubmed/22710932,1456
"TP53 Y107N lies within the DNA binding domain and WWOX, HIPK1, and ZNF385A interacting region of the Tp53 protein (UniProt.org). Y107N has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1457
"TP53 S9N lies within the interaction with HRMT1L2 and transcription activation region of the Tp53 protein (UniProt.org). S9N has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1458
"TP53 P98L lies within the WWOX-interacting region of the Tp53 protein (UniProt.org). P98L has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1459
TP53 P177T lies within the DNA binding domain of the Tp53 protein (UniProt.org). P177T results in a loss of Tp53 function as indicated by inability to bind DNA or activate transcription in cell culture (PMID:21643018).,295,,,www.uniprot.org,585,21643018,Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.,http://www.ncbi.nlm.nih.gov/pubmed/21643018,1460
"TP53 R267Q lies within the DNA-binding domain of the Tp53 protein (UniProt.org). R267Q has been demonstrated to result in decreased Tp53 transactivation activity in some cell culture assays (PMID: 10435620), while in other assays demonstrates increased activity (PMID: 25584008), and results in decreased ability to suppress growth in cell culture (PMID: 10435620, PMID: 25584008).",295,,,www.uniprot.org,4424,25584008,Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study.,http://www.ncbi.nlm.nih.gov/pubmed/25584008,555,10435620,p53 compound heterozygosity in a severely affected child with Li-Fraumeni syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/10435620,1461
TP53 A161T lies within the DNA-binding domain of the Tp53 protein (PMID: 21232794). A161T results in constitutive activation of Tp53 in cell culture (PMID: 16827139).,295,,,www.uniprot.org,556,21232794,A comprehensive study of TP53 mutations in chronic lymphocytic leukemia: Analysis of 1287 diagnostic and 1148 follow-up CLL samples.,http://www.ncbi.nlm.nih.gov/pubmed/21232794,1462
"TP53 F113Y lies within the DNA binding domain of the Tp53 protein (UniProt.org). F113Y has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1463
"TP53 T102A lies within the DNA-binding domain and WWOX, HIPK1, and ZNF385A-interacting region of the Tp53 protein (UniProt.org). T102A is predicted to confer a loss of function to the Tp53 protein as demonstrated by disruption of the interaction with the apoptotic modulating proteins Puma and Noxa in an in vitro assay (PMID: 22446329).",295,,,www.uniprot.org,4011,22446329,In vitro binding properties of tumor suppressor p53 with PUMA and NOXA.,http://www.ncbi.nlm.nih.gov/pubmed/22446329,1464
"TP53 R213* results in a premature truncation of the Tp53 protein at amino acid 213 of 393 (UniProt.org). Due to the loss of the much of the DNA binding domain, as well as the tetramerization domain and C-terminal basic domain, R213* is predicted to result in a loss of Tp53 protein function (PMID: 20978130). ",498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,295,,,www.uniprot.org,1465
"MAP2K1 K57C does not lie within any known functional domains of the Map2k1 protein (UniProt.org). K57C has not been characterized, however it is predicted to be an activating mutation based on the effect of similar codon 57 missense mutations (PMID: 24463458).",384,24463458,BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.,http://www.ncbi.nlm.nih.gov/pubmed/24463458,295,,,www.uniprot.org,1466
EGFR L747S lies within the protein kinase domain of the Egfr protein (UniProt.org). L747S confers a gain of function to the Egfr protein as indicated by ligand independent proliferation of cultured cells (PMID: 17973572).,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1467
"ALK S1206Y lies within the protein kinase domain of the Alk protein (UniProt.org). S1206Y has not been biochemically characterized, however, has been demonstrated to occur as a secondary drug resistance mutation in the context of ALK rearrangements (PMID: 22277784, PMID: 24675041, PMID: 25727400).",683,22277784,Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/22277784,2525,24675041,The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24675041,2573,25727400,Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.,http://www.ncbi.nlm.nih.gov/pubmed/25727400,295,,,www.uniprot.org,1468
"EGFR P753S lies within the protein kinase domain of the Egfr protein (UniProt.org). P753S is predicted to be an activating, oncogenic mutation based on SIFT analysis (PMID:18006781).",568,18006781,"Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines.",http://www.ncbi.nlm.nih.gov/pubmed/18006781,295,,,www.uniprot.org,1470
"EGFR T751I lies within the protein kinase domain of the Egfr protein (UniProt.org). T751I is predicted to be an activating, oncogenic mutation based on SIFT analysis (PMID:18006781).",568,18006781,"Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines.",http://www.ncbi.nlm.nih.gov/pubmed/18006781,295,,,www.uniprot.org,1471
"SMAD4 A433T lies within the MH2 domain of the Smad4 protein (UniProt.org). A433T has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1472
"PDGFRA R822H lies within the protein kinase domain of the Pdgfra protein (UniProt.org). R822H has been identified in the scientific literature (PMID: 27311873, PMID: 27178821), but has not been biochemically characterized and therefore, its effect on Pdgfra protein function is unknown (PubMed, Aug 2017).",295,,,www.uniprot.org,7791,27311873,"Circumscribed sebaceous neoplasms: a morphological, immunohistochemical and molecular analysis.",http://www.ncbi.nlm.nih.gov/pubmed/27311873,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7993,27178821,"PDGFRA and KIT Mutation Status and Its Association With Clinicopathological Properties, Including DOG1.",http://www.ncbi.nlm.nih.gov/pubmed/27178821,1473
"KDR (VEGFR2) G1308R lies within the cytoplasmic domain of the Kdr (Vegfr2) protein (UniProt.org). G1308R has been identified in sequencing studies (PMID: 25056374), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7205,25056374,Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/25056374,1474
"SMARCB1 R155H lies within the DNA binding region of the Smarcb1 protein (UniProt.org). R155H has not been characterized in the scientific literature and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1475
"RB1 K715E lies within Domain B of the Rb1 protein (UniProt.org). K715E has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1476
"APC W685R lies within ARM repeat 6 of the Apc protein (UniProt.org). W685R has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1477
"DNMT3A R771Q lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (UniProt.org). R771Q has been identified in sequencing studies (PMID: 27276561), but has not been biochemically characterized and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jul 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7052,27276561,Genomic Classification and Prognosis in Acute Myeloid Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27276561,1478
"TP53 V173A lies within the DNA binding domain and the HIPK1, ZNF385A, FBXO42 and AXIN1interacting region of the Tp53 protein (UniProt.org). V173A results in reduced Tp53 transactivation activity in cell culture (PMID: 10617466).",2890,10617466,Pharmacological rescue of mutant p53 conformation and function.,http://www.ncbi.nlm.nih.gov/pubmed/10617466,295,,,www.uniprot.org,1480
"TP53 G154C lies within the DNA binding domain of the Tp53 protein (UniProt.org). G154C has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1481
"SMAD4 D351N lies at a hotspot residue within the MH2 domain of the Smad4 protein (UniProt.org, PMID: 23139211). D351N has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,954,23139211,"SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer.",http://www.ncbi.nlm.nih.gov/pubmed/23139211,295,,,www.uniprot.org,1482
"KDR (VEGFR2) T1152M lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). T1152M has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1483
"KDR (VEGFR2) R275* results in a premature truncation of the Kdr (Vegfr2) protein at amino acid 275 of 1356 (UniProt.org). Due to a loss of multiple functional domains, including the protein kinase domain (UniProt.org), R275* is predicted to lead to a loss of function.",295,,,www.uniprot.org,1484
"GNAQ T96S does not lie within any known functional domains of the Gnaq protein (UniProt.org). T96S has been identified in sequencing studies (PMID: 25855536, PMID: 26343386, PMID: 26286987), but has not been biochemically characterized and therefore, its effect on Gnaq protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7073,26286987,Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination.,http://www.ncbi.nlm.nih.gov/pubmed/26286987,295,,,www.uniprot.org,7139,26343386,Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway.,http://www.ncbi.nlm.nih.gov/pubmed/26343386,7024,25855536,Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets.,http://www.ncbi.nlm.nih.gov/pubmed/25855536,1485
"Notch1 T712P lies within the calcium-binding, EGF-like domain 18 of the Notch1 protein (UniProt.org). T712P has been identified in sequencing studies (PMID: 23700467), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017). ",7981,23700467,Targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/23700467,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1486
"TP53 L344Q lies within the HIPK1, CARM1, and HIPK2-interacting region and oligomerization region of the Tp53 protein (UniProt.org). L344Q has not been characterized in human cells, but results in decreased Tp53 oligomer formation and transcriptional activity in yeast (PMID: 16007150).",500,16007150,"The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library.",http://www.ncbi.nlm.nih.gov/pubmed/16007150,295,,,www.uniprot.org,1487
"TP53 H179D lies within the DNA binding domain of the Tp53 protein (UniProt.org). H179D has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1488
"TP53 K305T lies within the HIPK1 and CARM1 interaction region and the bipartite nuclear localization signal motif of the Tp53 protein (UniProt.org). K305T has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1489
"TP53 E180K lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). E180K confers a loss of function to the Tp53 protein, as indicated by alterations in the the proteolytic processing resulting in weak binding of BCL-xL, as well as decreased activation of downstream targets and reduced apoptosis in cell culture (PMID: 24814347).",2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,2904,24814347,The DNA-binding domain mediates both nuclear and cytosolic functions of p53.,http://www.ncbi.nlm.nih.gov/pubmed/24814347,1490
"TP53 G154S lies within the DNA binding domain of the Tp53 protein (UniProt.org). G154S has been identified in the scientific literature (PMID: 27782820), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,10082,27782820,Comparison between two amplicon-based sequencing panels of different scales in the detection of somatic mutations associated with gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27782820,1491
"TP53 R196G lies within the DNA binding domain and the HIPK1, ZNF385A, FBXO42 and AXIN1 interaction region of the Tp53 protein (UniProt.org). R196G results in decreased transactivation activity of Tp53 in culture (PMID: 22710932).",554,22710932,Transactivation and reactivation capabilities of temperature-dependent p53 mutants in yeast and human cells.,http://www.ncbi.nlm.nih.gov/pubmed/22710932,295,,,www.uniprot.org,1492
"TP53 S99A lies within the interaction with WWOX region of the Tp53  protein (UniProt.org). S99A has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1493
"TP53 A161P lies within the DNA binding domain of the Tp53 protein (UniProt.org). A161P has been identified in the scientific literature (PMID: 27813088), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,10065,27813088,Nutlin-3a selects for cells harbouring TP53 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/27813088,1494
"TP53 K164N lies within the DNA binding domain of the p53 protein (PMID: 15510160). K164N has been identified in the scientific literature (PMID: 16546179), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Aug 2017).",5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,9845,16546179,Understanding mutations and protein stability through tripeptides.,http://www.ncbi.nlm.nih.gov/pubmed/16546179,1495
"TP53 K164M lies within the DNA-binding domain and HIPK1, ZNF385A, FBXO42 and AXIN-interacting region of the Tp53 protein (UniProt.org). K164M confers a loss of function to the Tp53 protein as demonstrated by reduced expression of the Tp53 target gene Cdkn1a (p21Cip1) in human tumor samples (PMID: 8797864).",295,,,www.uniprot.org,2811,8797864,Reduced messenger RNA expression level of p21 CIP1 in human colorectal carcinoma tissues and its association with p53 gene mutation.,http://www.ncbi.nlm.nih.gov/pubmed/8797864,1496
"TP53 T211A lies within the DNA binding domain and the HIPK1, ZNF385A, FBXO42 and AXIN1 interaction region of the Tp53 protein (UniProt.org). T211A has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1497
TP53 E271K lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). E271K is predicted to result in decreased Tp53 stability and reduced Tp53 protein expression by computational modeling (PMID: 21763698).,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,574,21763698,Structural and functional impact of cancer-related missense somatic mutations.,http://www.ncbi.nlm.nih.gov/pubmed/21763698,1498
"TP53 S116C lies within the DNA-binding domain and HIPK1, ZNF385A, FBXO42, and AXIN1-interacting region of the Tp53 protein (UniProt.org). S116C has not been biochemically characterized, but is predicted to destabilize the Tp53 protein by computational mutagenesis (PMID: 15683227).",575,15683227,In the quest for stable rescuing mutants of p53: computational mutagenesis of flexible loop L1.,http://www.ncbi.nlm.nih.gov/pubmed/15683227,295,,,www.uniprot.org,1499
"TP53 S96A lies within the interaction with WWOX region of the Tp53  protein (UniProt.org). S96A has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1500
"TP53 S99P lies within the interaction with WWOX region of the p53  protein (UniProt.org). S99P has not been characterized and therefore, its effect on p53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1501
"TP53 T140S lies within the DNA binding domain and the HIPK1, ZNF385A, FBXO42 and AXIN1 interaction region of the Tp53 protein (UniProt.org). T140S has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Nov 2016).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1502
"TP53 S227P lies within the DNA binding domain and HIPK1, ZNF385A, FBXO42 and AXIN1 interaction region of the Tp53 protein (UniProt.org). S227P has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Nov 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1503
"TP53 D259N lies within the DNA binding domain of the Tp53 protein (UniProt.org). D259N has not been characterized in human cells, but results in altered Tp53 transactivation activity in yeast assays (PMID: 11896595).",295,,,www.uniprot.org,3144,11896595,Tumour p53 mutations exhibit promoter selective dominance over wild type p53.,http://www.ncbi.nlm.nih.gov/pubmed/11896595,1504
"TP53 V203E lies within the DNA binding domain HIPK1, ZNF385A, FBXO42, and AXIN1 interacting region of the Tp53 protein (UniProt.org). V203E has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1505
"TP53 R174G lies within the DNA binding domain and the interaction with HIPK1, ZNF385A, FBXO42 and AXIN1 region of the Tp53 protein (UniProt.org). R174G has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1506
"TP53 M160K lies within the DNA binding domain and the HIPK1, ZNF385A, FBXO42 and AXIN1 interaction region of the Tp53 protein (UniProt.org). M160K has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1507
"TP53 P190L lies within the DNA binding domain of the Tp53 protein (UniProt.org). P190L has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1508
"TP53 K101N lies within the WWOX, HIPK1 and ZNF385A interaction region of the Tp53  protein (UniProt.org). K101N has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1509
"TP53 A161G lies within the DNA binding domain of the Tp53 protein (UniProt.org). A161G has been identified in the scientific literature (PMID: 27813088), but has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,10065,27813088,Nutlin-3a selects for cells harbouring TP53 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/27813088,1510
"TP53 H168Q lies within the DNA binding domain of the Tp53 protein (UniProt.org). H168Q has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1511
"TP53 F212V lies within the DNA binding domain of the Tp53 protein (UniProt.org). F212V has been identified in sequencing studies (PMID: 28769798), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,10069,28769798,Molecular Characterization of Somatic Alterations in Dukes' B and C Colorectal Cancers by Targeted Sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/28769798,1512
"TP53 R267L lies within the DNA binding domain and HIPK1, ZNF385A, AXIN1 and E4F1 interaction region of the Tp53 protein (UniProt.org). R267L has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Nov 2016).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1513
"TP53 Q167L lies within the DNA binding domain of the Tp53 protein (PMID: 21760703). Q167L has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,807,21760703,TP53 status and response to treatment in breast cancers.,http://www.ncbi.nlm.nih.gov/pubmed/21760703,1514
"FBXW7 E192A does not lie within any known functional domains of the Fbxw7 protein (UniProt.org). E192A has been identified in sequencing studies (PMID: 24586741, PMID: 26328274 ), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",9788,26328274,Clinical next-generation sequencing reveals aggressive cancer biology in adolescent and young adult patients.,http://www.ncbi.nlm.nih.gov/pubmed/26328274,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2558,24586741,FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24586741,1516
"EZH2 S556* results in a premature truncation at amino acid 556 of 746. Due to the loss of multiple functional domains, S556* is predicted to result in a loss of Ezh2 protein function (UniProt.org). ",295,,,www.uniprot.org,1517
"TP53 V197L lies within the DNA-binding domain and HIPK1, ZNF385A, FBXO42 and AXIN-interacting region of the Tp53 protein (UniProt.org). V197L results in a temperature-dependent decrease in Tp53 transcriptional activity at 37 degrees, and decreased induction of apoptosis in cultured cells (PMID: 11668476, PMID: 10976406).",584,10976406,[Functional restoration of tumor suppressor p53 alters susceptibility of glioblastoma cells to irradiation--analysis using a cell line containing a temperature-sensitive mutant].,http://www.ncbi.nlm.nih.gov/pubmed/10976406,4441,11668476,Restoration of endogenous wild-type p53 activity in a glioblastoma cell line with intrinsic temperature-sensitive p53 induces growth arrest but not apoptosis.,http://www.ncbi.nlm.nih.gov/pubmed/11668476,295,,,www.uniprot.org,1518
"TP53 G154R lies within the DNA binding domain of the p53 protein (UniProt.org). G154R has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1519
"TP53 H178N lies within the DNA binding domain of the Tp53 protein (UniProt.org). H178N has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1520
"TP53 G154A lies within the DNA binding domain of the Tp53 protein (UniProt.org). G154A has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1521
"TP53 P190A lies within the DNA binding domain of the Tp53 protein (UniProt.org). P190A has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1522
"TP53 N131T lies within the DNA binding domain and the HIPK1, ZNF385A, FBXO42 and AXIN1 interaction region of the Tp53 protein (UniProt.org). N131T has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1523
"TP53 A189D lies within the DNA binding domain of the Tp53 protein (UniProt.org). A189D has been identified in the scientific literature (J Clin Onc 34, no. 15_suppl (May 2016) 6085), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,10067,,Clinical genomic testing of anaplastic thyroid carcinoma (ATC) and need for integration into future prospective clinical trials.,http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.6085,1524
"TP53 V203L lies within the DNA binding domain and HIPK1, ZNF385A, FBXO42, and AXIN1 interacting region of the Tp53 protein (UniProt.org). V203L has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1525
"TP53 N247D lies within the DNA binding domain and the AXIN1, 53BP2 SH3 domain and E4F1 interaction region of the Tp53 protein (UniProt.org). N247D has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1526
"TP53 P177S lies within the DNA binding domain of the Tp53 protein (UniProt.org). P177S  has not been characterized and therefore, its effect on Tp53 protein function is unknown (Pubmed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1527
"TP53 C124G lies within the DNA binding domain of the Tp53 protein (UniProt.org). C124G has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1528
TP53 E258Q lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). E258Q confers a loss of Tp53 DNA binding ability and transcriptional activation in cell culture (PMID: 21643018).,585,21643018,Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.,http://www.ncbi.nlm.nih.gov/pubmed/21643018,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,1529
TP53 R280M lies within the DNA binding domain of the Tp53 protein (UniProt.org). R280M results in decreased Tp53 DNA binding ability and transcriptional activation in cell culture (PMID: 21643018).,585,21643018,Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.,http://www.ncbi.nlm.nih.gov/pubmed/21643018,295,,,www.uniprot.org,1530
TP53 I232S lies within the DNA-binding domain Tp53 protein (PMID: 22713868). I232S results in a loss of Tp53 DNA-binding ability and transcriptional activity in cell culture (PMID: 21643018).,585,21643018,Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.,http://www.ncbi.nlm.nih.gov/pubmed/21643018,295,,,www.uniprot.org,1531
"TP53 P359L lies within the CARM1, HIPK2, and USP7-interacting region of the Tp53 protein (UniProt.org). P359L has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1532
"TP53 H178R lies within the DNA binding domain of the Tp53 protein (UniProt.org). H178R has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1533
"TP53 F341V lies within the HIPK1, CARM1 and HIPK2-interacting, oligomerization region, and nuclear export signal motif of the Tp53 protein (UniProt.org). F341V has not been biochemically characterized in human cells, but results in the inability to form Tp53 tetramers and decreased Tp53 transcriptional activity in yeast assays (PMID: 16007150).",295,,,www.uniprot.org,500,16007150,"The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library.",http://www.ncbi.nlm.nih.gov/pubmed/16007150,1534
"TP53 I50S lies within the HRMT1L2 interaction region and the TADII of the Tp53 protein (UniProt.org). I50S has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1535
"TP53 R333P lies within the HIPK1, CARM1, and HIPK2-interacting and the oligomerization region of the Tp53 protein (UniProt.org). R333P has not been characterized in human cells, but results in a monomer Tp53 protein and loss of Tp53 transcriptional activity in yeast (PMID: 16007150).",295,,,www.uniprot.org,500,16007150,"The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library.",http://www.ncbi.nlm.nih.gov/pubmed/16007150,1536
"TP53 A74T lies within the CCAR2, HRMT1L2, and WWOX-interacting regions of the Tp53 protein (UniProt.org). A74T has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1537
"TP53 S99F lies within the interaction with WWOX region of the Tp53  protein (UniProt.org). S99F has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1538
"TP53 R158C lies within the DNA binding domain of the Tp53 protein (PMID: 21760703).  R158C has been identified in sequencing studies (PMID: 25561229), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Nov 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,807,21760703,TP53 status and response to treatment in breast cancers.,http://www.ncbi.nlm.nih.gov/pubmed/21760703,7010,25561229,Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient selection?,http://www.ncbi.nlm.nih.gov/pubmed/25561229,1539
"TP53 D259G lies within the DNA binding domain of the Tp53 protein (UniProt.org). D259G has been identified in the scientific literature (PMID: 21232794), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,556,21232794,A comprehensive study of TP53 mutations in chronic lymphocytic leukemia: Analysis of 1287 diagnostic and 1148 follow-up CLL samples.,http://www.ncbi.nlm.nih.gov/pubmed/21232794,1540
"TP53 H179P lies within the DNA binding domain of the Tp53 protein (UniProt.org). H179P has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1541
"TP53 G262D lies within the DNA binding domain of the Tp53 protein (UniProt.org). G262D has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1542
"TP53 M237V lies within the DNA binding domain and the HIPK1, ZNF385A and AXIN1 interaction region of the Tp53 protein (UniProt.org). M237V has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1543
"TP53 I251M lies within the DNA binding domain and the HIPK1, ZNF385A, FBXO42 and AXIN1 interaction region of the Tp53 protein (UniProt.org). I251M has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1544
"TP53 T256I lies within the DNA binding domain and HIPK1, ZNF385A, AXIN1 and E4F1 interaction region of the Tp53 protein (UniProt.org). T256I has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1545
TP53 C141S lies within the DNA binding domain of the Tp53 protein (UniProt.org). C141S retains Tp53 transactivation activity in a yeast assay (PMID: 19681600).,610,19681600,Effect of thioredoxin deletion and p53 cysteine replacement on human p53 activity in wild-type and thioredoxin reductase null yeast.,http://www.ncbi.nlm.nih.gov/pubmed/19681600,295,,,www.uniprot.org,1546
"TP53 G108V lies within the DNA binding domain of the Tp53 protein (UniProt.org). G108V has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1547
"ERBB2 (HER2) T798M lies within the gatekeeper position in the ATP binding site of the Erbb2 (HER2) protein. T798M results in activation of the Erbb2 (Her2) protein in cell culture experiments (PMID: 22046346, PMID: 23948973).",624,23948973,Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.,http://www.ncbi.nlm.nih.gov/pubmed/23948973,621,22046346,Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.,http://www.ncbi.nlm.nih.gov/pubmed/22046346,1549
VHL S183L does not lie within any known functional domains of the Vhl protein (UniProt.org). S183L confers a loss of function to the Vhl protein as indicated by impaired ability to regulate Hif1a degradation and function in culture (PMID: 21454469).,626,21454469,Dysregulation of the HIF pathway due to VHL mutation causing severe erythrocytosis and pulmonary arterial hypertension.,http://www.ncbi.nlm.nih.gov/pubmed/21454469,295,,,www.uniprot.org,1551
VHL D126N lies within the CCT complex-binding region of the Vhl protein (UniProt.org). D126N leads to a loss of Vhl function as indicated by impaired regulation of Hif1a in cell culture (PMID: 21454469).,295,,,www.uniprot.org,626,21454469,Dysregulation of the HIF pathway due to VHL mutation causing severe erythrocytosis and pulmonary arterial hypertension.,http://www.ncbi.nlm.nih.gov/pubmed/21454469,1552
"FLT3 D324N lies within the Ig-like C2-type domain of the Flt3 protein (UniProt.org). D324N functions in a manner comparable to wild-type in cultured cells (http://abstracts.hematologylibrary.org/cgi/content/short/104/11/3373).
",627,,The FLT3-D324N Variant Is a Functionally Silent Polymorphism in the FLT3 Gene and May Be Associated with a Higher Risk for AML.,http://abstracts.hematologylibrary.org/cgi/content/short/104/11/3373,1553
"CTNNB1 W383R lies within ARM repeat 6 of the Ctnnb1 protein (UniProt.org). W383R results in increased transcriptional activity as compared to wild-type Ctnnb1 in cultured cells and therefore, is predicted to lead to a gain of Ctnnb1 protein function (PMID: 24735922, PMID: 15579438).",586,15579438,CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15579438,295,,,www.uniprot.org,496,24735922,Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation.,http://www.ncbi.nlm.nih.gov/pubmed/24735922,1554
"TP53 F109L lies within the DNA binding domain of the Tp53 protein (UniProt.org). F109L has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1555
"TP53 F212C lies within the DNA binding domain of the Tp53 protein (UniProt.org). F212C has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1556
"TP53 N288D lies within the DNA-binding domain and HIPK1, ZNF385A, AXIN1 and E4F1-interacting region of the Tp53 protein (UniProt.org). N288D has not been characterized in human cells, but results in decreased Tp53 transcriptional activity in yeast (PMID: 12909720).",295,,,www.uniprot.org,628,12909720,Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity.,http://www.ncbi.nlm.nih.gov/pubmed/12909720,1557
"TP53 F328S lies within the HIPK1, CARM1 and HIPK2-interacting and oligomerization region of the Tp53 protein (UniProt.org). F328S has not been biochemically characterized in human cells, but results in decreased Tp53 transcriptional activity in yeast assays, and is predicted to decrease Tp53 stability in computational models (PMID: 16007150, PMID: 20978130).",295,,,www.uniprot.org,500,16007150,"The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library.",http://www.ncbi.nlm.nih.gov/pubmed/16007150,498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,1558
"TP53 E171V lies within the DNA binding domain of the Tp53 protein (UniProt.org). E171V has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1559
"TP53 T125A lies within the DNA binding domain and the interaction with HIPK1, ZNF385A, FBXO42 and AXIN1 region of the p53 protein (UniProt.org). T125A results in reduced Tp53 DNA binding ability in an in vitro assay, and a gain of function in activation of IGF-II in cell culture (PMID: 16687402, PMID: 10949925).",295,,,www.uniprot.org,629,16687402,Mutational analysis of the p53 core domain L1 loop.,http://www.ncbi.nlm.nih.gov/pubmed/16687402,4440,10949925,Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/10949925,1560
"TP53 K321E lies within the HIPK1, CARM1 and HIPK2 interaction region and the bipartite nuclear localization signal motif of the Tp53 protein (UniProt.org). K321E has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1561
"TP53 P12S lies within the transcription activation region of the Tp53  protein (UniProt.org). P12S has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1562
"TP53 S96P lies within the interaction with WWOX region of the p53  protein (UniProt.org). S96P has not been characterized and therefore, its effect on p53 protein function is unknown (PubMed, Oct 2016).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1563
"TP53 C229R lies within the DNA binding domain of the Tp53 protein (UniProt.org). C229R results in increased Tp53 transactivation activity, but decreased ability to suppress colony formation in cell culture (PMID: 25584008).",4424,25584008,Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study.,http://www.ncbi.nlm.nih.gov/pubmed/25584008,295,,,www.uniprot.org,1564
"TP53 T230P lies within the DNA binding domain and the HIPK1, ZNF385A, FBXO42 and AXIN1-interacting region of the Tp53 protein (UniProt.org). T230P has been identified in the sequencing studies (PMID: 25184754), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,10131,25184754,Unambiguous detection of multiple TP53 gene mutations in AAN-associated urothelial cancer in Belgium using laser capture microdissection.,http://www.ncbi.nlm.nih.gov/pubmed/25184754,1565
"TP53 K139M lies within the DNA binding domain and the HIPK1, ZNF385A, FBXO42 and AXIN1 interaction region of the Tp53 protein (UniProt.org). K139M has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1566
"TP53 E358G lies within the HIPK1, CARM1 and HIPK2-interacting regions of the Tp53 protein (UniProt.org). E358G has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1567
"TP53 H168D lies within the DNA binding domain of the Tp53 protein (UniProt.org). H168D has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1568
"DNMT3A M513I lies within the ADD domain of the Dnmt3a protein (UniProt.org). M513I has not been characterized in the scientific literature and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1569
"TP53 P223R lies within the DNA binding domain of the Tp53 protein (UniProt.org). P223R has not been characterized and therefore, its effect on Tp53 protein function is unknown (Pubmed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1570
"TP53 Q136L lies within the DNA-binding domain and HIPK1, ZNF385A, FBXO42 and AXIN-interacting region of the Tp53 protein (UniProt.org). Q136L has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1571
"TP53 Q100P lies within DNA binding domain of the Tp53 protein (PMID: 21760703). Q100P has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1572
"TP53 L111M lies within the DNA binding domain and the HIPK1 and ZNF385A interaction region of the Tp53 protein (UniProt.org). L111M has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1573
"TP53 K101Q lies within the WWOX, HIPK1 and ZNF385A interaction region of the Tp53 protein (UniProt.org). K101Q has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1574
"TP53 S106T lies within the DNA binding domain and the WWOX, HIPK1 and ZNF385A interaction region of the Tp53 protein (UniProt.org). S106T has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Nov 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1575
"TP53 N131S lies within the DNA binding domain and the HIPK1, ZNF385A, FBXO42 and AXIN1 interaction region of the Tp53 protein (UniProt.org). N131S has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1576
"TP53 N345D lies within the HIPK1, CARM1 and HIPK2-interacting region, oligomerization region, and nuclear export signal motif of the Tp53 protein (UniProt.org). N345D results in impaired tetramerization and is transcriptionally inactive in yeast (PMID: 16007150), but has not been functionally characterized in human cell lines.",295,,,www.uniprot.org,500,16007150,"The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library.",http://www.ncbi.nlm.nih.gov/pubmed/16007150,1577
"TP53 R181C lies within the DNA-binding domain and HIPK1, ZNF385A, FBXO42 and AXIN1-interacting region of the Tp53 protein (UniProt.org). R181C is able to transactivate the Tp53 targets p21, Mdm2, and PIG3, but does not transactivate Bax and IGF-BP3, and leads to decreased induction of apoptosis and is transforming in cell culture (PMID: 10229196).",295,,,www.uniprot.org,4429,10229196,Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions.,http://www.ncbi.nlm.nih.gov/pubmed/10229196,1578
"TP53 G117E lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). G117E has not been biochemically characterized in human cells, but results in decreased Tp53 transcriptional activity in a yeast assay (PMID: 11429700).",2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,4395,11429700,Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay.,http://www.ncbi.nlm.nih.gov/pubmed/11429700,1579
"TP53 S99Y lies within the interaction with WWOX region of the Tp53  protein (UniProt.org). S99Y has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1580
"TP53 S215T lies within the DNA-binding domain and  HIPK1, ZNF385A, FBXO42, and AXIN1-interacting region of the Tp53 protein (UniProt.org). S215T has not been biochemically characterized in human cells, but has been demonstrated to result in increased Tp53 transcriptional activity in yeast (PMID: 11313981).",4436,11313981,"p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay.",http://www.ncbi.nlm.nih.gov/pubmed/11313981,295,,,www.uniprot.org,1581
"TP53 S240R lies within the DNA binding domain and interaction with HIPK1, ZNF385A and AXIN1 region of the p53 protein (UniProt.org). S240R results in decreased activation of the Tp53 targets BAX and p21, and decreased ability to induce apoptosis, but retains growth suppression activity in cell culture (PMID: 12509279, PMID: 10229196).",4437,12509279,A novel p53 mutant retained functional activity in lung carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/12509279,295,,,www.uniprot.org,4429,10229196,Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions.,http://www.ncbi.nlm.nih.gov/pubmed/10229196,1582
"TP53 V147A lies within the DNA binding domain and HIPK1, ZNF385A, FBXO42, and AXIN1 interacting region of the Tp53 protein (UniProt.org). V147A has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1583
"TP53 K164Q lies within the DNA binding domain and the HIPK1, ZNF385A, FBXO42 and AXIN1 interaction region of the Tp53 protein (UniProt.org). K164Q has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1584
"TP53 H297L lies within the DNA binding domain of the Tp53 protein (UniProt.org). H297L  has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1585
"TP53 P223T lies within the DNA binding domain of the Tp53 protein (UniProt.org). P223T has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1586
"RB1 D718N lies within Domain B of the Rb1 protein (UniProt.org). D718N has been identified in the scientific literature (PMID: 12402348), but has not been biochemically characterized and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,630,12402348,Loss of heterozygosity and mutations are the major mechanisms of RB1 gene inactivation in Chinese with sporadic retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/12402348,1587
"NOTCH1 G1659D does not lie within any known functional domains of the Notch1 protein (UniProt.org). G1659D has been identified in the scientific literature (PMID: 19340001, PMID: 22225590), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2634,19340001,"The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.",http://www.ncbi.nlm.nih.gov/pubmed/19340001,295,,,www.uniprot.org,7067,22225590,Impact of complex NOTCH1 mutations on survival in paediatric T-cell leukaemia.,http://www.ncbi.nlm.nih.gov/pubmed/22225590,1588
"NOTCH1 S137L lies within the EGF-like domain 3 of the Notch1 protein (UniProt.org). S137L has been identified in the scientific literature (PMID: 22006338), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",269,22006338,Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22006338,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1590
NOTCH1 R1594Q lies within the heterodimerization domain of the Notch1 protein (PMID: 22006338). R1594Q results in impaired ligand-dependent activation of Notch1 in culture (PMID: 22006338).,269,22006338,Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22006338,1591
"VHL I180V does not lie within any known functional domains of the Vhl protein (UniProt.org). I180V has been identified in sequencing studies (PMID: 23606570), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7430,23606570,Combined mutation of Vhl and Trp53 causes renal cysts and tumours in mice.,http://www.ncbi.nlm.nih.gov/pubmed/23606570,295,,,www.uniprot.org,1592
"ERBB4 G130E lies within the extracellular domain of the Erbb4 protein (UniProt.org). G130E has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1597
"ROS1 P151S lies within the fibronectin type-III domain 1 of the Ros1 protein (UniProt.org). P151S has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1599
"SMO P694fs*82 likely results in a premature truncation of the Smo protein at aa 694 of 787 followed by 82 nonsense amino acids (UniProt.org). P694fs*82 has been identified in sequencing studies (PMID: 25344691), but has not been biochemically characterized and therefore, its effect on Smo protein function is unknown (PubMed, Jan 2017).
",295,,,www.uniprot.org,1689,25344691,RNF43 is frequently mutated in colorectal and endometrial cancers.,http://www.ncbi.nlm.nih.gov/pubmed/25344691,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1600
BRAF G469R lies within the protein kinase domain of the Braf protein (UniProt.org). G469R confers a gain of function to Braf as indicated by constitutive ERK activation in cell culture (PMID: 24920063). ,4372,24920063,Acquired initiating mutations in early hematopoietic cells of CLL patients.,http://www.ncbi.nlm.nih.gov/pubmed/24920063,295,,,www.uniprot.org,1601
"JAK2 M535I does not lie within any known functional domains of the Jak2 protein (UniProt.org). M535I has similar activity as Jak2 wild-type in regards to cultured cell growth, signalling activation, and transformation (PMID: 18755984).",295,,,www.uniprot.org,639,18755984,Activating mutations in human acute megakaryoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/18755984,1602
"JAK3 A573V lies within the protein kinase domain of the Jak3 protein (UniProt.org). A573V results in constitutive phosphorylation of Jak3 and activation of downstream Stat5 and Erk, and is transforming in cultured cells (PMID: 18755984).",295,,,www.uniprot.org,639,18755984,Activating mutations in human acute megakaryoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/18755984,1603
"VHL G106V lies within the CCT complex-interacting region of the Vhl protein (UniProt.org). G106V has not been characterized in the scientific literature and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1604
"VHL S38F lies within tandem repeat 5 of the Vhl protein (UniProt.org). S38F has been identified in sequencing studies (PMID: 15932632), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7440,15932632,Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study.,http://www.ncbi.nlm.nih.gov/pubmed/15932632,1605
"VHL P81S does not lie within any known functional domains of the Vhl protein (UniProt.org). P81S results in a loss of Vhl binding to Tceb1 and failure to regulate Hif1a degradation in culture, and growth advantage in animal tumor models (PMID: 23990666).",640,23990666,"Pleiotropic effects of the trichloroethylene-associated P81S VHL mutation on metabolism, apoptosis, and ATM-mediated DNA damage response.",http://www.ncbi.nlm.nih.gov/pubmed/23990666,295,,,www.uniprot.org,1607
"APC E1286G lies in a region of the Apc protein regulated by ubiquitination (UniProt.org). E1286G has been identified in sequencing studies (PMID: 21720365), but has not been biochemically characterized and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",6943,21720365,Integrated genomic analyses of ovarian carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/21720365,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1610
"MPL T487V lies within the extracellular domain of the Mpl protein (UniProt.org). T487V has not been characterized in the scientific literature and therefore, its effect on Mpl protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1611
"MPL T487A does not lie within any known functional domains of the Mpl protein (UniProt.org). T487A results in activation of Mpl signaling as indicated by increased phosphorylation of Stat5, Erk1/2, and Akt, and is transforming in culture (PMID: 18755984).",639,18755984,Activating mutations in human acute megakaryoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/18755984,295,,,www.uniprot.org,1612
"ABL1 K605del (also reported as K624del in isoform IB) results in the deletion of an amino acid in the nuclear localization signal motif 1 of the Abl1 protein at amino acid 609 (UniProt.org). K605del has not been characterized in the scientific literature and therefore, its effect on Abl1 protein function is unknown (PubMed, Feb 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1614
"KIT D52N lies within the extracellular domain of the Kit protein (PMID: 11377682). D52N has been predicted to confer a gain of function to the Kit protein (PMID: 15167915), however, has not been biochemically characterized and therefore, its effect on Kit protein function is unknown.",285,,,http://www.ncbi.nlm.nih.gov/pubmed,645,11377682,Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy.,http://www.ncbi.nlm.nih.gov/pubmed/11377682,1621
KIT C443Y lies within the extracellular domain of the Kit protein (UniProt.org). C443Y results in constitutive ligand-independent activation of Kit in cell culture (PMID: 19865100).,295,,,www.uniprot.org,646,19865100,Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations.,http://www.ncbi.nlm.nih.gov/pubmed/19865100,1622
"KIT S476I lies within the extracellular domain of the Kit protein (UniProt.org). S476I confers a gain of function to Kit, as indicated by constitutive phosphorylation of Kit in cell culture (PMID: 19865100).",646,19865100,Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations.,http://www.ncbi.nlm.nih.gov/pubmed/19865100,295,,,www.uniprot.org,1623
"KIT Y553C lies within the transmembrane domain of the Kit protein (UniProt.org). Y553C has been identified in sequencing studies (PMID: 23106360), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Dec 2016).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7419,23106360,Spectrum of mutations in gastrointestinal stromal tumor patients - a population-based study from Slovakia.,http://www.ncbi.nlm.nih.gov/pubmed/23106360,1624
"KIT W557G lies within the juxtamembrane domain of the Kit protein (PMID: 16226710). W557G confers a gain of function to Kit, as indicated by constitutive phosphorylation of Kit in cell culture (PMID: 23567324).",647,23567324,Are two better than one? A novel double-mutant KIT in GIST that responds to Imatinib.,http://www.ncbi.nlm.nih.gov/pubmed/23567324,648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,1625
"KIT V559A lies within the juxtamembrane domain of the Kit protein (PMID: 15837988). V559A confers a gain of function to Kit, as indicated by constitutive phosphorylation of Kit and increased MAPK and AKT activation in patient samples and cultured cells (PMID: 15837988, PMID: 19047099).",649,15837988,Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred.,http://www.ncbi.nlm.nih.gov/pubmed/15837988,9825,19047099,Imatinib targeting of KIT-mutant oncoprotein in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/19047099,1626
"KIT V559D lies within the juxtamembrane domain of the Kit protein (PMID: 9438854). V559D confers a gain of function to Kit, as indicated by constitutive Kit phosphorylation, and is transforming in cell culture (PMID: 9438854, PMID: 21689725).",662,21689725,"Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis.",http://www.ncbi.nlm.nih.gov/pubmed/21689725,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,1627
"KIT N505I lies within the Ig-like C2-type domain 5 of the Kit protein (UniProt.org). N505I results in increased Kit autophosphorylation, increased motility, and activation of downstream AKT and ERK, and is transforming in cell culture (PMID: 24317392).",295,,,www.uniprot.org,651,24317392,"A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib.",http://www.ncbi.nlm.nih.gov/pubmed/24317392,1628
"KIT D816V lies within the tyrosine kinase domain region 2 of the Kit protein (PMID: 19865100). D816V confers a gain of function on Kit, leading to activation of STAT5, increased differentiation of cultured cells (PMID: 19865100, PMID: 18390729), and mastocytosis and tumor formation in mice (PMID: 21148330).",652,18390729,"Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens.",http://www.ncbi.nlm.nih.gov/pubmed/18390729,646,19865100,Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations.,http://www.ncbi.nlm.nih.gov/pubmed/19865100,1629
"KIT D816I lies within the tyrosine kinase domain 2 of the Kit protein (PMID: 17555444). D816I confers a gain of function to Kit, as indicated by constitutive phosphorylation of Kit in cell culture (PMID: 19865100).",646,19865100,Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations.,http://www.ncbi.nlm.nih.gov/pubmed/19865100,9818,17555444,Recent advances in the understanding of mastocytosis: the role of KIT mutations.,http://www.ncbi.nlm.nih.gov/pubmed/17555444,1630
"KIT D816H lies within the tyrosine kinase domain region 2 of the Kit protein (PMID: 19164557). D816H confers a gain of function to Kit, leading to STAT3 activation and transformation of cultured cells (PMID:  10362788, PMID:11494148).",654,11494148,STAT3 activation is required for Asp(816) mutant c-Kit induced tumorigenicity.,http://www.ncbi.nlm.nih.gov/pubmed/11494148,655,19164557,KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.,http://www.ncbi.nlm.nih.gov/pubmed/19164557,653,10362788,Activating c-kit gene mutations in human germ cell tumors.,http://www.ncbi.nlm.nih.gov/pubmed/10362788,1632
"KIT D816A lies within the tyrosine kinase domain region 2 of the Kit protein (PMID:15625120).  D816A confers a gain of function to Kit, as indicated by constitutive phosphorylation of Kit and increased Akt phosphorylation in cell culture (PMID: 16188233).",656,15625120,Normal and oncogenic forms of the receptor tyrosine kinase kit.,http://www.ncbi.nlm.nih.gov/pubmed/15625120,1875,16188233,KIT (c-kit oncogene product) pathway is constitutively activated in human testicular germ cell tumors.,http://www.ncbi.nlm.nih.gov/pubmed/16188233,1633
"KIT D816F lies within the tyrosine kinase domain 2 of the Kit protein (PMID: 17555444). D816F confers a gain of function to Kit, as indicated by constitutive phosphorylation of Kit and activation of STAT3, MAPK, and AKT in cultured cells (PMID: 16397263).",657,16397263,"Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.",http://www.ncbi.nlm.nih.gov/pubmed/16397263,9818,17555444,Recent advances in the understanding of mastocytosis: the role of KIT mutations.,http://www.ncbi.nlm.nih.gov/pubmed/17555444,1634
"TP53 negative indicates a lack of the TP53 gene, mRNA, and/or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1635
"KIT D816Y lies within the tyrosine kinase domain 2 of the Kit protein (PMID: 21640708). D816Y confers a gain of function to Kit, as indicated by constitutive phophorylation and activation of the MAPK pathway in cultured cells (PMID: 21640708).",659,21640708,Mechanism of activation of human c-KIT kinase by internal tandem duplications of the juxtamembrane domain and point mutations at aspartic acid 816.,http://www.ncbi.nlm.nih.gov/pubmed/21640708,1636
"KIT D820Y lies within the tyrosine kinase domain 2 of the Kit protein (PMID: 17555444). D820Y confers a gain of function to Kit, as indicated by constitutive phosphorylation of Kit and is transforming in cell culture (PMID: 19035443, PMID: 11984533).",660,11984533,Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene.,http://www.ncbi.nlm.nih.gov/pubmed/11984533,9818,17555444,Recent advances in the understanding of mastocytosis: the role of KIT mutations.,http://www.ncbi.nlm.nih.gov/pubmed/17555444,661,19035443,Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas.,http://www.ncbi.nlm.nih.gov/pubmed/19035443,1638
"KIT N822I lies within the tyrosine kinase domain 2 of the Kit protein (PMID: 17555444). N822I confers a gain of function to Kit, as indicated by constitutive Kit phosphorylation, and is transforming in cell culture (PMID: 21689725).",9818,17555444,Recent advances in the understanding of mastocytosis: the role of KIT mutations.,http://www.ncbi.nlm.nih.gov/pubmed/17555444,662,21689725,"Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis.",http://www.ncbi.nlm.nih.gov/pubmed/21689725,1639
"KIT N822K lies within the activation loop of the Kit protein (PMID: 24205792). N822K confers a gain of function to Kit, leading to ERK1/2 and STAT3 phosphorylation and transformation of cultured cells (PMID: 24205792).",663,24205792,"Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.",http://www.ncbi.nlm.nih.gov/pubmed/24205792,1640
"KIT Y823D lies within the protein kinase domain of the Kit protein (UniProt.org). Y823D confers a gain of function to Kit, as indicated by constitutive phosphorylation of Kit in cultured cells (PMID: 14695343, PMID: 20633291).",666,14695343,KIT mutations are common in testicular seminomas.,http://www.ncbi.nlm.nih.gov/pubmed/14695343,295,,,www.uniprot.org,9827,20633291,Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/20633291,1641
KIT A829P lies within the protein kinase domain of the Kit protein (UniProt.org). A829P confers a gain of function to the Kit protein resulting in increased kinase activity (PMID: 23582185).,295,,,www.uniprot.org,2193,23582185,Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.,http://www.ncbi.nlm.nih.gov/pubmed/23582185,1642
"KIT E839K lies within the tyrosine kinase domain 2 of the Kit protein (PMID: 17555444). E839K leads to a lack Kit protein maturation and confers a dominant loss of function to Kit, as indicated by loss of Kit phosphorylation in cultured cells (PMID: 9990072).",295,,,www.uniprot.org,667,9990072,Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis.,http://www.ncbi.nlm.nih.gov/pubmed/9990072,1643
KIT R796G lies within the protein kinase domain of the Kit protein (UniProt.org). R796G confers a loss of function to Kit in cultured cells (PMID: 20824047).,668,20824047,Mutations in the c-Kit gene disrupt mitogen-activated protein kinase signaling during tumor development in adenoid cystic carcinoma of the salivary glands.,http://www.ncbi.nlm.nih.gov/pubmed/20824047,295,,,www.uniprot.org,1644
KIT H697Y lies within the kinase insertion domain of the Kit protein (PMID: 19861435). H697Y confers a gain of function to the Kit protein and is transforming in cultured cells (PMID: 19861435).,670,19861435,Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.,http://www.ncbi.nlm.nih.gov/pubmed/19861435,1645
"KIT T670S lies within the protein kinase domain of the Kit protein (UniProt.org). T670S has been identified in sequencing studies (PMID: 22980975), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Dec 2016).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1726,22980975,Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/22980975,1646
"KIT T670I is a gatekeeper mutation within the ATP pocket of the Kit protein (PMID: 15236194, PMID: 22355224). T670I confers a gain of function to Kit as indicated by constitutive Kit phosphorylation, is transforming in cultured cells, and is associated with resistance to some Kit inhibitors (PMID: 17699867, PMID: 15236194).",674,22355224,"Study of the role of ""gatekeeper"" mutations V654A and T670I of c-kit kinase in the interaction with inhibitors by means mixed molecular dynamics/docking approach.",http://www.ncbi.nlm.nih.gov/pubmed/22355224,675,15236194,A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient.,http://www.ncbi.nlm.nih.gov/pubmed/15236194,676,17699867,Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.,http://www.ncbi.nlm.nih.gov/pubmed/17699867,1647
"KIT N655K lies within the tyrosine kinase domain 1 of the Kit protein (PMID: 17555444). N655K confers a gain of function to Kit, as indicated by constitutive phosphorylation of Kit in cell culture (PMID: 17489795).",9818,17555444,Recent advances in the understanding of mastocytosis: the role of KIT mutations.,http://www.ncbi.nlm.nih.gov/pubmed/17555444,711,17489795,Characterization of tyrosine kinase I domain c-kit gene mutation Asn655Lys newly found in primary jejunal gastrointestinal stromal tumor.,http://www.ncbi.nlm.nih.gov/pubmed/17489795,1648
"KIT V654A lies within the protein kinase domain of the Kit protein (UniProt.org). V654A increases proliferation of cultured cells, but is not transforming and does not result in constitutive kinase activation, however, has been described as a secondary drug resistance mutation (PMID: 17363509). ",678,17363509,Resistance to c-KIT kinase inhibitors conferred by V654A mutation.,http://www.ncbi.nlm.nih.gov/pubmed/17363509,295,,,www.uniprot.org,1649
"KIT K642E lies within the tyrosine kinase domain 1 of the Kit protein (PMID: 15990278). K642E confers a gain of function to Kit, as indicated by constitutive phosphorylation of Kit and activation of downstream signaling (PMID: 15990278, PMID: 19802003), as well as transformation of cultured cells (PMID: 11073817).",679,11073817,Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/11073817,680,15990278,Differences in signaling pathways and expression level of the phosphoinositide phosphatase SHIP1 between two oncogenic mutants of the receptor tyrosine kinase KIT.,http://www.ncbi.nlm.nih.gov/pubmed/15990278,681,19802003,c-Kit mutants require hypoxia-inducible factor 1alpha to transform melanocytes.,http://www.ncbi.nlm.nih.gov/pubmed/19802003,1650
"KIT Y578C lies within the juxtamembrane domain of the Kit protein (PMID: 16226710). Y578C confers a gain of function to Kit, as indicated by constitutive phosphorylation of Kit in cell culture (PMID: 23567324).",647,23567324,Are two better than one? A novel double-mutant KIT in GIST that responds to Imatinib.,http://www.ncbi.nlm.nih.gov/pubmed/23567324,648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,1651
"VHL F91L does not lie within any known functional domains of the Vhl protein (UniProt.org). F91L has been identified in the scientific literature (PMID: 18836774), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3225,18836774,Computational detection of deleterious SNPs and their effect on sequence and structural level of the VHL gene.,http://www.ncbi.nlm.nih.gov/pubmed/18836774,1654
"ALK T1151dup indicates the insertion of the duplicate amino acid threonine (T)-1151, in the protein kinase domain of the Alk protein (UniProt.org). T1151dup has not been biochemically characterized, however, has been demonstrated to occur as a secondary drug resistance mutation (PMID: 22277784, PMID: 20695522). ",682,20695522,Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/20695522,295,,,www.uniprot.org,683,22277784,Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/22277784,1655
"BRCA1 V340* results in a premature truncation of the Brca1 protein at amino acid 340 of 1863 (UniProt.org). Due to the loss of most major functional domains (UniProt.org), V340* is predicted to result in a loss of function (PMID: 8589721).  ",295,,,www.uniprot.org,684,8589721,Growth retardation and tumour inhibition by BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/8589721,1656
"APC E1309Afs*3 is a missense mutation (E1309A) in conjunction with a likely truncation of the 2843 aa Apc protein at aa 1309, followed by 3 nonsense amino acids. (UniProt.org).  E1309Afs*3 results in a loss of function reducing the ability of Apc to properly regulate beta-catenin (PMID: 10213492, PMID: 17189293).",669,10213492,Dominant negative effect of the APC1309 mutation: a possible explanation for genotype-phenotype correlations in familial adenomatous polyposis.,http://www.ncbi.nlm.nih.gov/pubmed/10213492,1111,17189293,Truncated APC regulates the transcriptional activity of beta-catenin in a cell cycle dependent manner.,http://www.ncbi.nlm.nih.gov/pubmed/17189293,295,,,www.uniprot.org,1657
"CBL E366_K382del (also known as 70Z-Cbl or 70Z del) results in the deletion of 17 amino acids in the Cbl protein from aa 366 to 382. E366_K382del confers a the loss of E3 ubiquitin-protein ligase activity in the CBL protein and displays oncogenic tranformation in cultured cells (PMID: 7925293, PMID: 11239464).",685,7925293,Tumour induction by activated abl involves tyrosine phosphorylation of the product of the cbl oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/7925293,686,11239464,RING finger mutations that abolish c-Cbl-directed polyubiquitination and downregulation of the EGF receptor are insufficient for cell transformation.,http://www.ncbi.nlm.nih.gov/pubmed/11239464,1658
"CDKN2A G23D lies within the first ANK repeat of the Cdkn2a (p16INK4a) protein (UniProt.org). G23D results in a loss of Cdkn2a protein function, evidenced by loss of CDK4 binding, reduced inhibition of pRb phosphorylation, and impaired cell cycle arrest in cultured cells (PMID: 19712690, PMID: 19260062).",687,19260062,"Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients.",http://www.ncbi.nlm.nih.gov/pubmed/19260062,688,19712690,Functional impairment of p16(INK4A) due to CDKN2A p.Gly23Asp missense mutation.,http://www.ncbi.nlm.nih.gov/pubmed/19712690,295,,,www.uniprot.org,1659
"CSF1R L301S lies within the Ig-like C2-type domain 4 of the Csf1r protein (UniProt.org). L301S results in a gain of function in Csf1r, demonstrating constitutive kinase activity, transforming activity in cultured cells (PMID: 2157180), and tumorigenicity in nude mice (PMID: 2974321).",690,2974321,A point mutation in the extracellular domain of the human CSF-1 receptor (c-fms proto-oncogene product) activates its transforming potential.,http://www.ncbi.nlm.nih.gov/pubmed/2974321,689,2157180,Transforming activities of human CSF-1 receptors with different point mutations at codon 301 in their extracellular domains.,http://www.ncbi.nlm.nih.gov/pubmed/2157180,1660
SMO mutant indicates an unspecified mutation in the SMO gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1662
"KIT act mut indicates that this variant results in a gain of function in the Kit protein. However, the specific amino acid change has not been identified. ",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1664
"ATRX M1800fs*12 likely results in a truncation of the 2492 aa Atrx protein at aa 1800, followed by 12 nonsense amino acids (UniProt.org). Due to the loss of the helicase domain, P-box, and glutamine rich region, all required for transcriptional regulation, M1800fs*12 is predicted to result in a loss of function (PMID: 9545503).",694,9545503,"Comparison of the human and murine ATRX gene identifies highly conserved, functionally important domains.",http://www.ncbi.nlm.nih.gov/pubmed/9545503,295,,,www.uniprot.org,1665
"KIT L576P lies within the juxtamembrane domain of the Kit protein (PMID: 17372901). L576P confers a gain of function to Kit, as indicated by constitutive phosphorylation of Kit, and is transforming in cell culture (PMID: 17372901).",695,17372901,L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/17372901,1667
"KIT K509I does not lie within any known functional domains of the Kit protein (UniProt.org). K509I confers a gain of function on Kit, as indicated by constitutive phosphorylation of Kit in cell culture (PMID: 19865100).",295,,,www.uniprot.org,646,19865100,Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations.,http://www.ncbi.nlm.nih.gov/pubmed/19865100,1670
"KIT V560G lies within the juxtamembrane domain of the Kit protein (PMID: 9438854). V560G confers a gain of function to Kit, as indicated by constitutive phosphorylation of Kit in cell culture (PMID: 7691885), and leads to decreased activity of PP2A (PMID: 20551067).",650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,696,7691885,Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.,http://www.ncbi.nlm.nih.gov/pubmed/7691885,697,20551067,Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers.,http://www.ncbi.nlm.nih.gov/pubmed/20551067,1671
"EZH2 over exp indicates an over expression of the EZH2 protein. However, the mechanism causing the over expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1672
ROS1 mutant indicates an unspecified mutation in the ROS1 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1673
"ALK G1202R lies within the protein kinase domain of the Alk protein (UniProt.org). G1202R has not been biochemically characterized, however, has been demonstrated to promote secondary drug resistance in the context of EML4-ALK likely due to interference with drug binding (PMID: 22277784, PMID: 24736079).",2572,24736079,Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.,http://www.ncbi.nlm.nih.gov/pubmed/24736079,295,,,www.uniprot.org,683,22277784,Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/22277784,1678
"APC L1129S lies within a region of the Apc protein responsible for downregulation mediated by ubiquitination (UniProt.org). L1129S has been identified in the scientific literature (PMID: 18166348), but has not been characterized and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",700,18166348,Functional characterization of the novel APC N1026S variant associated with attenuated familial adenomatous polyposis.,http://www.ncbi.nlm.nih.gov/pubmed/18166348,295,,,www.uniprot.org,1683
"APC Q1096R lies within a region of the Apc protein responsible for down-regulation mediated by ubiquitination (UniProt.org). Q1096R has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1685
"GNA11 V344M does not lie within any known functional domains of the Gna11 protein (UniProt.org). V344M has not been characterized and therefore, its effect on Gna11 protein function is unknown (PubMed, Aug 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1686
"KDR (VEGFR2) G1015D lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). G1015D has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017). ",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1687
FGFR2 S373C lies within the extracellular domain of the Fgfr2 protein and corresponds to S372F in the canonical isoform (PMID: 17525745). S373C is predicted to confer a gain of function to the Fgfr2 protein resulting in constitutive dimerization of the receptor (PMID: 17525745).,702,17525745,Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/17525745,1688
EZH2 A687V lies within a SET domain of the Ezh2 protein (UniProt.org). A682V confers a gain of function on the Ezh2 protein greatly enhancing methylation of downstream targets (PMID: 22850114).,295,,,www.uniprot.org,703,22850114,A687V EZH2 is a gain-of-function mutation found in lymphoma patients.,http://www.ncbi.nlm.nih.gov/pubmed/22850114,1689
"ERBB2 (HER2) G776_V777insYVMA results in the insertion of four amino acids in the protein kinase domain of the Erbb2 (Her2) protein between amino acids 776 and 777 (UniProt.org). G776_V777insYVMA results in constitutive phosphorylation of Erbb2 (Her2), activation of downstream signaling, and is transforming in cell culture (PMID: 16843263).",295,,,www.uniprot.org,2004,16843263,HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/16843263,1690
"NOTCH1 R1594_E1595ins12 results in the insertion of 12 amino acids in the heterodimerization domain of the Notch1 protein (PMID: 17646409). R1594_E1595ins12 has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,379,17646409,FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/17646409,1692
"NOTCH1 V2443fs results in a change in the amino acid sequence of the Notch1 protein beginning at aa 2443 of 2555, likely resulting in premature truncation of the functional protein (UniProt.org). V2443fs has not been characterized individually however, cells harboring both V2443fs (reported as V2443fs*34) and L1593P demonstrated constitutive Notch signaling in culture (PMID: 17646409).",295,,,www.uniprot.org,379,17646409,FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/17646409,1693
"NOTCH1 A2441fs results in a change in the amino acid sequence of the Notch1 protein beginning at aa 2441 of 2555, likely resulting in premature truncation of the functional protein (UniProt.org). A2441fs has not been characterized individually however, cells harboring both A2441fs (reported as A2441fs*39) and L1574P demonstrated constitutive Notch signaling in culture (PMID: 17646409).",295,,,www.uniprot.org,379,17646409,FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/17646409,1694
"NOTCH1 P2475fs*4 results in a premature truncation of the Notch1 protein at aa 2475 of 2555, followed by three nonsense amino acids, within the cytoplasmic PEST domain of the Notch1 protein (UniProt.org, PMID: 17646409). P2475fs*4 results in stabilization of the NOTCH intracellular domain and activation of the NOTCH pathway (PMID: 17646409).
",379,17646409,FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/17646409,295,,,www.uniprot.org,1697
"NOTCH1 P2493fs results in a change in the amino acid sequence of the Notch1 protein beginning at aa 2493 of 2555, likely resulting in premature truncation of the functional protein (UniProt.org). P2493fs has not been characterized individually however, cells harboring both P2493fs (reported as P2493fs*100) and L1574P demonstrated constitutive Notch signaling in culture (PMID: 17646409).",379,17646409,FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/17646409,295,,,www.uniprot.org,1698
"NOTCH1 P2514* results in a premature truncation of the Notch1 protein at aa 2514 of 2555 (UniProt.org). P2514* has not been characterized individually however, cells harboring both P2514* and L1600P demonstrated constitutive Notch signaling in culture (PMID: 17646409).",379,17646409,FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/17646409,295,,,www.uniprot.org,1699
"NOTCH1 H2428fs*36 results in a premature truncation of the Notch1 protein at aa 2428 of 2555, followed by 35 nonsense amino acids, within the cytoplasmic PEST domain of the Notch1 protein (UniProt.org, PMID: 17646409). H2428fs*36 results in stabilization of the NOTCH intracellular domain  and activation of the NOTCH pathway (PMID: 17646409).",379,17646409,FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/17646409,295,,,www.uniprot.org,1700
"FLT3 Y599_D600insGLYVDFREYEY results in the insertion of 11 amino acids in the cytoplasmic juxtamembrane region of the Flt3 protein between amino acids 599 and 600 (UniProt.org, PMID: 11756186). Y599_D600insGLYVDFREYEY confers transformation activity in vitro (PMID: 11756186). ",295,,,www.uniprot.org,705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,1702
"NOTCH1 G578_S579insG results in the insertion of a glycine (G) in the 15th EGF-like domain of the Notch1 protein between amino acids 578 and 579 (UniProt.org). G578_S579insG has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1706
"NOTCH1 G691_T692delinsA results in deletion of a glycine (G) and threonine (T) from aa 691 to aa 692 within EGF-like domain 18 of the Notch1 protein, combined with the insertion of an alanine (A) at the same location (UniProt.org). G691_T692delinsA has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1707
"NOTCH1 H562fs*69 likely results in a truncation of the 2555 aa Notch1 protein at aa 562, followed by 69 nonsense amino acids within the EGF-like domain 14 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), H562fs*69  is predicted to lead to a loss of Notch1 protein function. ",295,,,www.uniprot.org,1708
"NOTCH1 T561fs*9 likely result in a premature truncation of the 2555 aa Notch1 protein at aa 561, followed by nine nonsense amino acids in the EGF-like domain 14 (UniProt.org). Due to the loss of the intracellular domain (UniProt.org), T561fs*9  is predicted to lead to a loss of Notch1 protein function. ",295,,,www.uniprot.org,1710
"KIT V559I lies within the juxtamembrane domain of the Kit protein (PMID: 17259998). V559I confers a gain of function to Kit, as indicated by constitutive phosphorylation of Kit and increased phosphorylation of STAT1 and MAPK in cell culture (PMID: 17259998).",712,17259998,Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation.,http://www.ncbi.nlm.nih.gov/pubmed/17259998,1714
"KIT V560D lies within the juxtamembrane domain of the Kit protein (PMID: 19164557). V560D confers a gain of function to Kit, as indicated by constitutive phosphorylation of Kit in cell culture (PMID: 16954519, PMID: 20633291).",655,19164557,KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.,http://www.ncbi.nlm.nih.gov/pubmed/19164557,713,16954519,Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/16954519,9827,20633291,Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/20633291,1715
"KIT V559del results in the deletion of an amino acid in the juxtamembrane domain of the Kit protein at amino acid 559 (PMID: 16226710). V559del confers a gain of function on Kit, resulting in constitutive, ligand independent phosphorylation and activation of the Kit protein (PMID: 15236194, PMID: 22282465).",648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,2056,22282465,KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/22282465,675,15236194,A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient.,http://www.ncbi.nlm.nih.gov/pubmed/15236194,1716
"KIT D579del results in a deletion of an amino acid within the juxtamembrane domain of the Kit protein at 579 (PMID: 9797363). D579del confers a gain of function on Kit, as indicated by constitutive phosphorylation of Kit, transformation of cultured cells and tumor formation in mice (PMID: 9797363).

",714,9797363,A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9797363,1717
"KIT K550_K558del results in the deletion of 9 amino acids in the juxtamembrane domain of the Kit protein from amino acids 550 to 558 (PMID: 15824741). K550_K558del confers a gain of function on Kit, as indicated by constitutive phosphorylation of Kit and transformation of cultured cells (PMID: 9438854).",650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,721,15824741,A mutation-created novel intra-exonic pre-mRNA splice site causes constitutive activation of KIT in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15824741,1718
"KIT P551_V555deI results in the deletion of 5 amino acids in the juxtamembrane domain of the Kit protein from amino acids 551 to 555 (PMID: 9438854). P551_V555del confers a gain of function to Kit, as indicated by constitutive Kit phosphorylation, and is transforming in cell culture (PMID: 9438854).",650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,1721
"KIT W557_K558del results in the deletion of 2 amino acids in the juxtamembrane domain of the Kit protein from amino acids 557 to 558 (PMID: 12918066). W557_K558del results in constitutive activation of Kit and increased Erk phosphorylation, and leads to increased invasiveness and expression of ETV1 in cell culture (PMID: 25239608, PMID: 26936919).",726,12918066,Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/12918066,6397,26936919,KIT Exon 11 Codons 557-558 Deletion Mutation Promotes Liver Metastasis Through the CXCL12/CXCR4 Axis in Gastrointestinal Stromal Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/26936919,3860,25239608,Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.,http://www.ncbi.nlm.nih.gov/pubmed/25239608,1724
"KIT V559_V560del results in the deletion of 2 amino acids in the juxtamembrane domain of the Kit protein from amino acids 559 to 560 (UniProt.org). V559_V560del confers a gain of function to Kit, as indicated by constitutive phosphorylation of Kit, is transforming in cell culture, and promotes tumor formation in mice (PMID: 9797363).",714,9797363,A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9797363,1725
"KIT M552_Y553del results in the deletion of two amino acids in the juxtamembrane domain of the Kit protein from amino acids 552 to 553 (PMID: 15897563). M552_Y553del has not been characterized, however similar Kit exon 11 deletions are activating, thus M552_Y553del is predicted to lead to a gain of Kit protein function (PMID: 9438854, PMID: 15365079).",2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,285,,,http://www.ncbi.nlm.nih.gov/pubmed,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,728,15897563,Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling.,http://www.ncbi.nlm.nih.gov/pubmed/15897563,1726
"KIT Y553_Q556del results in the deletion of 4 amino acids in the juxtamembrane domain of the Kit protein from amino acids 553 to 556 (PMID: 16226710). Y553_Q556del confers a gain of function to Kit, as indicated by Kit phosphorylation and activation of STAT3 and AKT (PMID: 15690055), and increased HMGB1 expression in patient samples (PMID: 12727838).",648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,9830,15690055,Correlation of KIT and platelet-derived growth factor receptor alpha mutations with gene activation and expression profiles in gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15690055,804,12727838,Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation.,http://www.ncbi.nlm.nih.gov/pubmed/12727838,1727
"KIT K550_V559del results in the deletion of 10 amino acids in the juxtamembrane domain of the Kit protein from amino acids 550 to 559 (PMID: 16226710). K550_V559del has not been characterized, however similar Kit exon 11 deletions are activating, thus K550_V559del is predicted to lead to a gain of Kit protein function (PMID: 9438854, PMID: 15365079).",648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,1728
"APC inact mut indicates that this variant results in a loss of function of the Apc protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1749
FGFR3 S249C lies within the linker region between IgD2 and IgD3 of the Fgfr3 protein (PMID: 19381019). S249C confers a gain of function as demonstrated by constitutive ligand-independent cell proliferation (PMID: 19381019).,742,19381019,Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.,http://www.ncbi.nlm.nih.gov/pubmed/19381019,1750
FGFR3 Y375C lies within the transmembrane domain of the Fgfr3 protein (UniProt.org). Y375C confers a gain of function as demonstrated by the transformation of cells in culture (PMID: 19749790).,295,,,www.uniprot.org,373,19749790,Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner.,http://www.ncbi.nlm.nih.gov/pubmed/19749790,1751
FGFR3 R248C lies within the linker region between IgD2 and IgD3 of the Fgfr3 protein.  R248C confers a gain of function as demonstrated by constitutive ligand-independent cell proliferation (PMID: 19381019).,742,19381019,Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.,http://www.ncbi.nlm.nih.gov/pubmed/19381019,1752
"FGFR3 G372C (equivalent to G370C in isoform1) lies within the extracellular domain of the Fgfr3 protein (UniProt.org). G372C confers a gain of function on Fgfr3, as indicated by ligand-independent phosphorylation and dimerization of Fgfr3, and activation of MAPK pathway in cell culture (PMID: 16841094, PMID: 12009017).",746,16841094,Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi.,http://www.ncbi.nlm.nih.gov/pubmed/16841094,295,,,www.uniprot.org,1806,12009017,Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization.,http://www.ncbi.nlm.nih.gov/pubmed/12009017,1753
"TP53 S227F lies within the DNA binding domain and HIPK1, ZNF385A, FBXO42 and AXIN1 interaction region of the Tp53 protein (UniProt.org). S227F has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Nov 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1754
"TP53 Q100R lies within DNA binding domain of the Tp53 protein (PMID: 21760703). Q100R has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,807,21760703,TP53 status and response to treatment in breast cancers.,http://www.ncbi.nlm.nih.gov/pubmed/21760703,1755
"TP53 N200K lies within the DNA binding domain and the HIPK1, ZNF385A, FBXO42 and AXIN1 interaction region of the Tp53 protein (UniProt.org). N200K has not been characterized and therefore, its effect on Tp53 protein function is unknown (Pubmed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1756
"TP53 M160R lies within the DNA binding domain and the HIPK1, ZNF385A, FBXO42 and AXIN1 interaction region of the Tp53 protein (UniProt.org). M160R has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1757
"TP53 G105A lies within the DNA binding domain of the Tp53 protein (UniProt.org). G105A has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1758
"TP53 S33A lies within the interaction with HRMT1L2 and transcription activation region of the Tp53 protein (UniProt.org). S33A has transactivation potential similar to wild type Tp53 but does not transactivate when coupled with S315A and therefore, its effect on Tp53 protein function is unknown (PMID: 19640899).",3986,19640899,The Ste20-like kinase SLK promotes p53 transactivation and apoptosis.,http://www.ncbi.nlm.nih.gov/pubmed/19640899,295,,,www.uniprot.org,1759
"TP53 S240T lies within the DNA binding domain and the HIPK1, ZNF385A and AXIN1 interaction region of the Tp53 protein (UniProt.org). S240T has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Nov 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1760
"TP53 K24I lies within the interaction with HRMT1L2 and transcription activation region of the Tp53 protein (UniProt.org). K24I has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1761
"TP53 R181G lies within the DNA binding domain and the HIPK1, ZNF385A, FBXO42 and AXIN1 interaction region of the Tp53 protein (UniProt.org). R181G has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Nov 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1762
"TP53 P190R lies within the DNA binding domain of the Tp53 protein (UniProt.org). P190R has not been characterized and therefore, its effect on Tp53 protein function is unknown (Pubmed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1763
"TP53 K320E lies within the HIPK1, CARM1 and HIPK2 interaction region of the Tp53 protein (UniProt.org). K320E demonstrates protein expression level similar to wild-type Tp53 in culture (PMID: 21232794).",295,,,www.uniprot.org,556,21232794,A comprehensive study of TP53 mutations in chronic lymphocytic leukemia: Analysis of 1287 diagnostic and 1148 follow-up CLL samples.,http://www.ncbi.nlm.nih.gov/pubmed/21232794,1764
"TP53 N131K lies within the DNA binding domain and the HIPK1, ZNF385A, FBXO42 and AXIN1 interaction region of the Tp53 protein (UniProt.org). N131K has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1765
"TP53 S269R lies within the DNA binding domain and HIPK1, ZNF385A, AXIN1 and E4F1 interaction region of the Tp53 protein (UniProt.org). S269R has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Nov 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1766
"TP53 T253I lies within the DNA binding domain and the HIPK1, ZNF385A and AXIN1 interaction region of the Tp53 protein (UniProt.org). T253I has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1767
"TP53 H193Q lies within the DNA binding domain of the Tp53 protein (UniProt.org). H193Q has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown  (PubMed, Oct 2016).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1768
"FLT3 E598_Y599insGLVQVTGSSDNEYFYVDFREYE results in the insertion of 22 amino acids in the cytoplasmic juxtamembrane region of the Flt3 protein between amino acids E598 and Y599 (UniProt.org, PMID: 11756186). E598_Y599insGLVQVTGSSDNEYFYVDFREYE confers transformation activity in vitro (PMID: 11756186). ",705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,1769
"FLT3 L601_K602insREYEYDL results in the insertion of 7 amino acids in the cytoplasmic juxtamembrane region of the Flt3 protein between amino acids L601 and K602 (UniProt.org, PMID: 11756186). L601_K602insREYEYDL confers transformation activity in vitro (PMID: 11756186). ",705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,1770
"FLT3 L611_E612insCSSDNEYFYVDFREYEYDLKWEFPRENL results in the insertion of 28 amino acids in the cytoplasmic juxtamembrane region of the Flt3 protein between amino acids L611 and E612 (UniProt.org, PMID: 11756186). L611_E612insCSSDNEYFYVDFREYEYDLKWEFPRENL confers transformation activity in vitro (PMID: 11756186). ",705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,1771
"FLT3 E612_F613insGYVDFREYEYDLKWEFRPRENLEF results in the insertion of 24 amino acids in the cytoplasmic juxtamembrane region of the Flt3 protein between amino acids E612 and F613 (UniProt.org, PMID: 11756186). E612_F613insGYVDFREYEYDLKWEFRPRENLEF confers transformation activity in vitro (PMID: 11756186). ",705,11756186,FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.,http://www.ncbi.nlm.nih.gov/pubmed/11756186,1772
"KIT C443S lies within the Ig-like C2-type domain 5 of the Kit protein (UniProt.org). C443S has been identified in sequencing studies (PMID: 25003536), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Sep 2017).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5680,25003536,Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report.,http://www.ncbi.nlm.nih.gov/pubmed/25003536,1773
"ALK amp indicates an increased number of copies of the ALK gene. However, the mechanism causing the increase is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1774
"BRCA2 Q1037* results in a premature truncation of the Brca2 protein at amino acid 1037 of 3418 (UniProt.org). Due to the loss of multiple functional domains, including the DNA binding domain (UniProt.org), Q1037* is predicted to lead to a loss of function. ",295,,,www.uniprot.org,1775
"DNMT3A V636M lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (UniProt.org). V636M has been identified in the scientific literature (PMID: 21993668), but has not been biochemically characterized and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jul 2017). ",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1778
"SMAD4 R361S lies at a hotspot residue within the MH2 domain of the Smad4 protein (UniProt.org). R361S results in a slight reduction in BMP signaling in cell culture, but is not significantly different from wild-type Smad4 (PMID: 22316667).",295,,,www.uniprot.org,3669,22316667,Germline mutations in SMAD4 disrupt bone morphogenetic protein signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22316667,1779
SMAD4 R361H lies at a hotspot residue within the MH2 domain of the Smad4 protein (UniProt.org). R361H is predicted to result in a loss of heterocomplex formation and thus confer a loss of function on Smad4 (PMID: 21763698).,295,,,www.uniprot.org,574,21763698,Structural and functional impact of cancer-related missense somatic mutations.,http://www.ncbi.nlm.nih.gov/pubmed/21763698,1780
"VHL G144A lies within the CCT complex-interacting region of the Vhl protein (UniProt.org). G144A has been identified in sequencing studies (PMID: 9458097), but has not been biochemically characterized and therefore, its effect on VHL protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7424,9458097,Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas.,http://www.ncbi.nlm.nih.gov/pubmed/9458097,1783
"ROS1 positive indicates the presence of the ROS1 gene, mRNA, and/or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1784
"ALK positive indicates the presence of the ALK gene, mRNA, and/or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1785
"VHL P25L lies within the pentameric repeat region of the Vhl protein (UniProt.org).  P25L has been identified in the scientific literature (PMID: 16884327), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",4701,16884327,VHL P25L is not a pathogenic von Hippel-Lindau mutation: a family study.,http://www.ncbi.nlm.nih.gov/pubmed/16884327,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1786
"NOTCH1 R1662W does not lie within any known functional domains of the Notch1 protein (UniProt.org). R1662W has been identified in sequencing studies (PMID: 22225590, PMID: 25406187), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7067,22225590,Impact of complex NOTCH1 mutations on survival in paediatric T-cell leukaemia.,http://www.ncbi.nlm.nih.gov/pubmed/22225590,8136,25406187,Notch1 mutations are drivers of oral tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/25406187,1788
BRAF W531C lies within the protein kinase domain of the Braf protein (UniProt.org). W531I demonstrates activity and transformation ability comparable to wild-type Braf in cultured cells (PMID: 19206169). ,760,19206169,"Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum.",http://www.ncbi.nlm.nih.gov/pubmed/19206169,295,,,www.uniprot.org,1789
"BRAF G469V is a hotspot mutation within the protein kinase domain of the Braf protein (UniProt.org). G469V confers a gain of function to Braf, as indicated by increased activation of downstream MEK and ERK in cell culture (PMID: 27577079).",295,,,www.uniprot.org,7322,27577079,Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.,http://www.ncbi.nlm.nih.gov/pubmed/27577079,1790
BRAF G464E lies within the protein kinase domain of the Braf protein (UniProt.org). G464E confers a gain of function on Braf resulting in increased MEK and ERK activation (PMID: 15035987). ,146,15035987,Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.,http://www.ncbi.nlm.nih.gov/pubmed/15035987,1791
BRAF E275K lies within the phorbol-ester/DAG-type zinc finger region of the Braf protein (UniProt.org). E275K confers a loss of function on the Braf protein as indicated by decreased activation of Mek and Erk in cell culture (PMID: 19206169).,760,19206169,"Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum.",http://www.ncbi.nlm.nih.gov/pubmed/19206169,295,,,www.uniprot.org,1792
IDH1 mutant indicates an unspecified mutation in the IDH1 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1793
"BRAF T241P does not lie within any known functional domains of the Braf protein (UniProt.org). T241P confers a gain of function to Braf protein, however, is only weakly activating of MEK and ERK and does not induce transformation in cell culture (PMID: 19206169).",295,,,www.uniprot.org,760,19206169,"Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum.",http://www.ncbi.nlm.nih.gov/pubmed/19206169,1794
Wild-type FOXL2 indicates that no mutation has been detected within the FOXL2 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1795
"BRCA1 loss indicates loss of the BRCA1 gene, mRNA, and protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1798
"BRCA2 loss indicates loss of the BRCA2 gene, mRNA, and protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1799
"TP53 V272A lies within the DNA binding domain and HIPK1, ZNF385A, AXIN1, and E4F1interacting region of the Tp53 protein (UniProt.org). V272A has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1801
"JAK2 G614fs results in a change in the amino acid sequence of the Jak2 protein beginning at aa 614 of 1132, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of most of protein kinase domain 1 and all of protein kinase domain 2 (UniProt.org, PMID: 16879967), G614fs is predicted to lead to a loss of Jak2 protein function.",295,,,www.uniprot.org,773,16879967,Emerging roles of pseudokinases.,http://www.ncbi.nlm.nih.gov/pubmed/16879967,1802
"JAK2 L609fs results in a change in the amino acid sequence of the Jak2 protein beginning at aa 609 of 1132, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of most of protein kinase domain 1 and all of protein kinase domain 2 (UniProt.org, PMID: 16879967), L609fs is predicted to lead to a loss of Jak2 protein function.",295,,,www.uniprot.org,773,16879967,Emerging roles of pseudokinases.,http://www.ncbi.nlm.nih.gov/pubmed/16879967,1803
"JAK2 L611fs results in a change in the amino acid sequence of the Jak2 protein beginning at aa 611 of 1132, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of most of protein kinase domain 1 and all of protein kinase domain 2 (UniProt.org, PMID: 16879967), L611fs is predicted to lead to a loss of Jak2 protein function.",773,16879967,Emerging roles of pseudokinases.,http://www.ncbi.nlm.nih.gov/pubmed/16879967,295,,,www.uniprot.org,1804
"TP53 K319E lies within the HIPK1, CARM1 and HIPK2 interaction region of the Tp53 protein (UniProt.org). K319E has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1805
"TP53 A189T lies within the DNA binding domain of the Tp53 protein (UniProt.org). A189T has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1806
"JAK2 N612fs results in a change in the amino acid sequence of the Jak2 protein beginning at aa 612 of 1132, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of most of protein kinase domain 1 and all of protein kinase domain 2 (UniProt.org, PMID: 16879967), N612fs is predicted to lead to a loss of Jak2 protein function.",773,16879967,Emerging roles of pseudokinases.,http://www.ncbi.nlm.nih.gov/pubmed/16879967,295,,,www.uniprot.org,1807
"JAK2 Y613fs results in a change in the amino acid sequence of the Jak2 protein beginning at aa 613 of 1132, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of most of protein kinase domain 1 and all of protein kinase domain 2 (UniProt.org, PMID: 16879967), Y613fs is predicted to lead to a loss of Jak2 protein function.",773,16879967,Emerging roles of pseudokinases.,http://www.ncbi.nlm.nih.gov/pubmed/16879967,295,,,www.uniprot.org,1808
"JAK3 P132A lies in the FERM domain of the Jak3 protein (UniProt.org). P132A has transforming activity in immunocompromised mice, although it was not able to sustain BaF3 cells in vitro in the absence of IL-3 (PMID: 21599579).",406,21599579,Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects.,http://www.ncbi.nlm.nih.gov/pubmed/21599579,295,,,www.uniprot.org,1809
"JAK3 S577fs*85 likely results in a truncation of the 1124 aa Jak3 protein at aa 577, followed by 84 nonsense amino acids (UniProt.org). Due to the loss of a significant portion of the protein kinase 1 domain and the entire functional protein kinase 2 domain (UniProt.org, PMID: 12351625), S577fs*85 is predicted to lead to a loss of Jak3 protein function.",295,,,www.uniprot.org,774,12351625,The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction.,http://www.ncbi.nlm.nih.gov/pubmed/12351625,1810
"JAK3 M576fs*86 likely results in a truncation of the 1124 aa Jak3 protein at aa 576, followed by 85 nonsense amino acids (UniProt.org). Due to the loss of a significant portion of the protein kinase 1 domain and the entire functional protein kinase 2 domain (UniProt.org, PMID: 12351625), M576fs*86 is predicted to lead to a loss of Jak3 protein function.",295,,,www.uniprot.org,774,12351625,The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction.,http://www.ncbi.nlm.nih.gov/pubmed/12351625,1811
"JAK3 V579fs*83 likely results in a truncation of the 1124 aa Jak3 protein at aa 579, followed by 82 nonsense amino acids (UniProt.org). Due to the loss of a significant portion of the protein kinase 1 domain and the entire functional protein kinase 2 domain (UniProt.org, PMID: 12351625), V579fs*83 is predicted to lead to a loss of Jak3 protein function.",295,,,www.uniprot.org,774,12351625,The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction.,http://www.ncbi.nlm.nih.gov/pubmed/12351625,1812
"JAK3 E694fs*10 likely results in a truncation of the 1124 aa Jak3 protein at aa 694 , followed by 9 nonsense amino acids (UniProt.org). Due to the loss of a significant portion of the protein kinase 1 domain and the entire functional protein kinase 2 domain (UniProt.org, PMID: 12351625), E694fs*10 is predicted to lead to a loss of function.",295,,,www.uniprot.org,774,12351625,The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction.,http://www.ncbi.nlm.nih.gov/pubmed/12351625,1813
"JAK3 S703fs*53 likely results in a truncation of the 1124 aa Jak3 protein at aa 703, followed by 52 nonsense amino acids (UniProt.org). Due to the loss of a portion of the protein kinase 1 domain and the entire functional protein kinase 2 domain (UniProt.org, PMID: 12351625), S703fs*53 is predicted to lead to a loss of Jak3 protein function.",295,,,www.uniprot.org,774,12351625,The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction.,http://www.ncbi.nlm.nih.gov/pubmed/12351625,1814
"JAK3 F711fs*10 likely results in the truncation of the 1124 aa Jak3 protein at aa 711, followed by 9 nonsense amino acids (UniProt.org). Due to the loss of a portion of the protein kinase 1 domain and the entire functional protein kinase 2 domain (UniProt.org, PMID: 12351625), F711fs*10 is predicted to lead to a loss of Jak3 protein function.",774,12351625,The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction.,http://www.ncbi.nlm.nih.gov/pubmed/12351625,295,,,www.uniprot.org,1815
"TP53 N235Y lies within the DNA binding domain and the HIPK1, ZNF385A, FBXO42 and AXIN1 interaction region of the Tp53 protein (UniProt.org). N235Y has not been characterized and therefore, its effect on Tp53 protein function is unknown (Pubmed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1816
"JAK3 P725fs*9 likely results in a truncation of the 1124 aa Jak3 protein at aa 725, followed by 8 nonsense amino acids (UniProt.org). Due to the loss of a portion of the protein kinase 1 domain and the entire functional protein kinase 2 domain (UniProt.org, PMID: 12351625), P725fs*9 is predicted to lead to a loss of Jak3 protein function.",774,12351625,The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction.,http://www.ncbi.nlm.nih.gov/pubmed/12351625,295,,,www.uniprot.org,1817
"JAK3 A728fs*6 likely results in a truncation of the 1124 aa Jak3 protein at aa 728, followed by 6 nonsense amino acids (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org, PMID: 12351625), A728fs*6 is predicted to lead to a loss of Jak3 protein function.",774,12351625,The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction.,http://www.ncbi.nlm.nih.gov/pubmed/12351625,295,,,www.uniprot.org,1818
"JAK3 I726fs*8 likely results in a truncation of the 1124 aa Jak3 protein at aa 726, followed by 7 nonsense amino acids (UniProt.org). Due to the loss of a portion of the protein kinase 1 domain and the entire functional protein kinase 2 domain (UniProt.org, PMID: 12351625), I726fs*8 is predicted to lead to a loss of Jak3 protein function.",774,12351625,The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction.,http://www.ncbi.nlm.nih.gov/pubmed/12351625,295,,,www.uniprot.org,1819
"JAK3 S727fs*7 likely results in a truncation of the 1124 aa Jak3 protein at aa 727, followed by 6 nonsense amino acids (UniProt.org). Due to the loss of a portion of the protein kinase 1 domain and the entire functional protein kinase 2 domain (UniProt.org, PMID: 12351625), S727fs*7 is predicted to lead to a loss of Jak3 protein function.",774,12351625,The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction.,http://www.ncbi.nlm.nih.gov/pubmed/12351625,295,,,www.uniprot.org,1820
"TP53 F338S lies within the  HIPK1, CARM1 and HIPK2-interacting and the oligomerization region of the Tp53 protein (UniProt.org). F338S has not been biochemically characterized in human cells, but results in decreased Tp53 transcriptional activity in yeast assays (PMID: 16007150).",295,,,www.uniprot.org,500,16007150,"The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library.",http://www.ncbi.nlm.nih.gov/pubmed/16007150,1821
"TP53 V122M lies within the DNA binding domain and HIPK1, ZNF385A, FBXO42, and AXIN1 interacting region of the Tp53 protein (UniProt.org). V122M has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1823
"TP53 E204G lies within the DNA binding domain of the Tp53 protein (UniProt.org). E204G has been identified in the scientific literature (PMID: 22550420), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",7928,22550420,Low Prevalence of TP53 Mutations and MDM2 Amplifications in Pediatric Rhabdomyosarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/22550420,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1824
"TP53 L130I lies within the DNA binding domain and the HIPK1, ZNF385A, FBXO42 and AXIN1 interaction region of the Tp53 protein (UniProt.org). L130I has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1825
"TP53 L137M lies within the DNA binding domain and the interaction with HIPK1, ZNF385A, FBXO42 and AXIN1 region of the Tp53 protein (UniProt.org). L137M has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1826
"TP53 A119P lies within the DNA binding domain of the Tp53 protein (UniProt.org). A119P has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1827
"TP53 E198D lies within the DNA binding domain of the Tp53 protein (UniProt.org). E198D has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1828
"TP53 A276V lies within the DNA binding domain of the Tp53 protein (UniProt.org). A276V has been identified in sequencing studies (PMID: 21232794), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,556,21232794,A comprehensive study of TP53 mutations in chronic lymphocytic leukemia: Analysis of 1287 diagnostic and 1148 follow-up CLL samples.,http://www.ncbi.nlm.nih.gov/pubmed/21232794,1829
TP53 H168N lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). H168N demonstrates DNA binding ability and exonuclease activity comparable to wild-type p53 in cell-free assays (PMID: 19462533). ,295,,,www.uniprot.org,779,19462533,Dissection of the sequence-specific DNA binding and exonuclease activities reveals a superactive yet apoptotically impaired mutant p53 protein.,http://www.ncbi.nlm.nih.gov/pubmed/19462533,1831
"TP53 G112C lies within the DNA binding domain of the Tp53 protein (UniProt.org). G112C has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1832
"TP53 T140I lies within the DNA binding domain and the HIPK1, ZNF385A, FBXO42 and AXIN1 interaction region of the Tp53 protein (UniProt.org). T140I has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Nov 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1833
CDKN2A del indicates a deletion of the CDKN2A gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1834
"CDKN2A loss indicates loss of the CDKN2A gene, mRNA or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1836
"BRCA1 C61G lies within the RING-type domain of the Brca1 protein (UniProt.org). C61G decreases Brca1 heterodimerization and leads to decreased Brca1/Bard1 E3 ubiquitin ligase activity, but may retain some residual Brca1 activity (PMID: 9525870, PMID: 22172724).",2497,22172724,BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.,http://www.ncbi.nlm.nih.gov/pubmed/22172724,799,9525870,The cancer-predisposing mutation C61G disrupts homodimer formation in the NH2-terminal BRCA1 RING finger domain.,http://www.ncbi.nlm.nih.gov/pubmed/9525870,1858
"KRAS F156L does not lie within any known functional domains of the Kras protein (UniProt.org). F156L results in decreased Kras GTPase activity and accumulation of GTP-bound Ras, and leads to increased activation of downstream signaling in cell culture (PMID: 20949621, PMID: 17875937).",830,17875937,Biochemical and functional characterization of germ line KRAS mutations.,http://www.ncbi.nlm.nih.gov/pubmed/17875937,800,20949621,Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders.,http://www.ncbi.nlm.nih.gov/pubmed/20949621,295,,,www.uniprot.org,1859
"HRAS Q61K is a ""hotspot"" mutation within the GTP nucleotide binding region of the Hras protein (UniProt.org). Q61K inhibits GTPase activity of Hras leading to increased activation of downstream signaling (PMID: 19855393).",295,,,www.uniprot.org,801,19855393,Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors.,http://www.ncbi.nlm.nih.gov/pubmed/19855393,1862
"TP53 S127Y lies within the DNA-binding domain of the Tp53 protein (PMID: 21760703). S127Y has been identified in sequencing studies (PMID: 25148578) but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Feb 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,807,21760703,TP53 status and response to treatment in breast cancers.,http://www.ncbi.nlm.nih.gov/pubmed/21760703,7824,25148578,Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/25148578,1871
"TP53 P142L lies within the DNA binding domain of the Tp53 protein (PMID: 21760703).  P142L is unable to transactivate reporter genes in yeast assays (PMID: 17311302), but has not been functionally characterized in human cell lines.",387,17311302,Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.,http://www.ncbi.nlm.nih.gov/pubmed/17311302,285,,,http://www.ncbi.nlm.nih.gov/pubmed,807,21760703,TP53 status and response to treatment in breast cancers.,http://www.ncbi.nlm.nih.gov/pubmed/21760703,1872
"TP53 N235D lies within the DNA binding domain and the HIPK1, ZNF385A, FBXO42 and AXIN1 interaction region of the Tp53 protein (UniProt.org). N235D results in decreased Tp53 transactivation activity and fails to suppress colony formation in cell culture (PMID: 25584008).",295,,,www.uniprot.org,4424,25584008,Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study.,http://www.ncbi.nlm.nih.gov/pubmed/25584008,1882
"TP53 R181S lies within the DNA binding domain and the HIPK1, ZNF385A, FBXO42 and AXIN1 interaction region of the Tp53 protein (UniProt.org). R181S has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Nov 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1883
"TP53 P177A lies within the DNA binding domain of the Tp53 protein (UniProt.org). P177A has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1884
"TP53 A161V lies within the DNA binding domain of the Tp53 protein (UniProt.org). A161V has been identified in the scientific literature (PMID: 11454518), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",7994,11454518,Molecular analysis of CDKN1C and TP53 in sporadic adrenal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/11454518,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1885
"KRAS Q22K does not lie within any known functional domain of the Kras protein (UniProt.org). Q22K decreases Kras GTPase activity, resulting in increased Ras-GTP and transformation of cultured cells (PMID: 11095964, PMID: 20570890).
",843,20570890,Genomic and biological characterization of exon 4 KRAS mutations in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20570890,829,11095964,A novel activating mutation of the K-ras gene in human primary colon adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/11095964,295,,,www.uniprot.org,1890
"KRAS P34R lies within the effector motif of the Kras protein (UniProt.org). P34R results in decreased sensitivity of the Kras protein to GAPs, resulting in accumulation of Ras-GTP and increased MEK and ERK phosphorylation in culture (PMID: 17875937).",830,17875937,Biochemical and functional characterization of germ line KRAS mutations.,http://www.ncbi.nlm.nih.gov/pubmed/17875937,295,,,www.uniprot.org,1892
"KRAS D153V does not lie within any known functional domains of the Kras protein (UniProt.org). D153V does not alter Kras GTPase activity, however, results in increased MEK and ERK phosphorylation (PMID: 17875937), and is predicted to interfere with Kras autoinhibition (PMID: 25941399).",295,,,www.uniprot.org,9842,25941399,Oncogenic and RASopathy-associated K-RAS mutations relieve membrane-dependent occlusion of the effector-binding site.,http://www.ncbi.nlm.nih.gov/pubmed/25941399,830,17875937,Biochemical and functional characterization of germ line KRAS mutations.,http://www.ncbi.nlm.nih.gov/pubmed/17875937,1893
"KRAS T58I lies within the GTP-binding pocket of the Kras protein (PMID: 20617134). T58I results in decreased Kras GTPase activity, increased phosphorylation of Mek and Akt, and is transforming in cell culture (PMID: 16474405).",840,16474405,Germline KRAS mutations cause Noonan syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/16474405,1805,20617134,Clinical relevance of KRAS in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/20617134,1894
"KRAS Q61H is a hotspot mutation, which lies within the GTP binding region of the Kras protein (UniProt.org). Q61H results in decreased GTPase activity in the Kras protein, increased downstream signaling, and transformation of cultured cells (PMID: 20147967).",295,,,www.uniprot.org,841,20147967,Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine.,http://www.ncbi.nlm.nih.gov/pubmed/20147967,1895
"KRAS Q61L is a hotspot mutation, which lies within the GTP binding region of the Kras protein (UniProt.org). Q61L is predicted to confer a loss of function to the Kras protein with reduced GTPase activity and increased downstream pathway activation (PMID: 20147967). ",841,20147967,Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine.,http://www.ncbi.nlm.nih.gov/pubmed/20147967,1896
"KRAS Q61K is a hotspot mutation, which lies within the GTP binding region of the Kras protein (UniProt.org). Q61K is predicted to confer a loss of function to the Kras protein with reduced GTPase activity and increased downstream pathway activation (PMID: 20147967). ",841,20147967,Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine.,http://www.ncbi.nlm.nih.gov/pubmed/20147967,1897
"KRAS Q61R is a hotspot mutation, which lies within the GTP binding region of the Kras protein (UniProt.org). Q61R is predicted to confer a loss of function to the Kras protein with reduced GTPase activity and increased downstream pathway activation (PMID: 20147967). ",841,20147967,Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine.,http://www.ncbi.nlm.nih.gov/pubmed/20147967,1898
"KRAS G60E lies within a GTP binding region of the Kras protein (UniProt.org). G60E has not been characterized in the scientific literature and therefore, its effect on Kras protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1899
"KRAS N116S lies within a GTP binding region of the Kras protein (UniProt.org). N116S results in alteration of Kras GDP–GTP exchange, and lead to increased Ras-GTP and ERK activation in cell culture (PMID: 22302539).",842,22302539,Characterization of a novel KRAS mutation identified in Noonan syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/22302539,295,,,www.uniprot.org,1900
"KRAS K117N is an exon four mutation, which confers a loss of function to the Kras protein (PMID: 20570890). K117N decreases GTPase activity of Kras, resulting in increased Ras-GTP and increased proliferation and transformation of cultured cells (PMID: 20570890).",295,,,www.uniprot.org,843,20570890,Genomic and biological characterization of exon 4 KRAS mutations in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20570890,1901
"KRAS A146V is an exon four mutation, which is predicted to confer a loss of function to the Kras protein. A146V may reduce GTPase activity of Kras, leading to increased downstream pathway activation (PMID: 20570890). 
",843,20570890,Genomic and biological characterization of exon 4 KRAS mutations in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20570890,1902
"KRAS A146P is an exon four mutation, which is predicted to confer a loss of function to the Kras protein. A146P may reduce GTPase activity of Kras, leading to increased downstream pathway activation (PMID: 20570890). ",843,20570890,Genomic and biological characterization of exon 4 KRAS mutations in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20570890,1903
KRAS R164Q does not lie within any known functional domains of the Kras protein (UniProt.org). R164Q activity is similar to wild-type Kras in cultured cells (PMID: 20147967).,841,20147967,Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine.,http://www.ncbi.nlm.nih.gov/pubmed/20147967,1904
"SRC positive indicates the presence of the SRC gene, mRNA, and/or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1908
"STK11 loss indicates loss of the STK11 gene, mRNA or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1922
"VHL negative indicates a lack of the VHL gene, mRNA, and/or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1930
"TP53 N131D lies within the DNA binding domain and the HIPK1, ZNF385A, FBXO42 and AXIN1 interaction region of the Tp53 protein (UniProt.org). N131D has not been characterized and therefore, its effect on Tp53 protein function is unknown (Pubmed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1935
"TP53 R196L lies within the DNA binding domain and the HIPK1, ZNF385A, FBXO42 and AXIN1 interaction region of the Tp53 protein (UniProt.org). R196L has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Nov 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1941
"TP53 C135W lies within the DNA binding domain of the Tp53 protein (UniProt.org). C135W has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1943
"TP53 K320Q lies within the HIPK1, HIPK2 and CARM1-interacting region of the Tp53 protein (UniProt.org). K320Q is able to activate p21, but results in alterations in other Tp53 transcriptional and repressive activities, and leads to resistance to apoptosis in cell culture (PMID: 15831478, PMID: 16717128).",295,,,www.uniprot.org,4404,16717128,Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate.,http://www.ncbi.nlm.nih.gov/pubmed/16717128,2812,15831478,Direct p53 transcriptional repression: in vivo analysis of CCAAT-containing G2/M promoters.,http://www.ncbi.nlm.nih.gov/pubmed/15831478,1945
"TP53 S106N lies within the DNA binding domain and the WWOX, HIPK1 and ZNF385A interaction region of the Tp53 protein (UniProt.org). S106N has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Nov 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1946
"TP53 G112D lies within the DNA binding domain of the Tp53 protein (UniProt.org). G112D has not been characterized in the scientific literature and therefore, its effect onTp53 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1947
"TP53 P151L lies within the DNA binding domain of the Tp53 protein (UniProt.org). P151L has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1948
"TP53 V122E lies within the DNA binding domain and HIPK1, ZNF385A, FBXO42, and AXIN1 interacting region of the Tp53 protein (UniProt.org). V122E has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1949
"TP53 R174M lies within the DNA binding domain and the interaction with HIPK1, ZNF385A, FBXO42 and AXIN1 region of the Tp53 protein (UniProt.org). R174M has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1950
"TP53 S96F lies within the interaction with WWOX region of the Tp53  protein (UniProt.org). S96F has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1951
"TP53 P190T lies within the DNA binding domain of the Tp53 protein (UniProt.org). P190T has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1952
"TP53 T170P lies within the DNA binding domain and the HIPK1, ZNF385A, FBXO42 and AXIN1 interaction region of the Tp53 protein (UniProt.org). T170P has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Nov 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1953
"TP53 L206F lies within the DNA binding domain and the HIPK1, ZNF385A, FBXO42 and AXIN1 interaction region of the Tp53 protein (UniProt.org). L206F has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1954
"TP53 G262R lies within the DNA binding domain of the Tp53 protein (UniProt.org). G262R has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1955
"TP53 K164T lies within the DNA binding domain and the HIPK1, ZNF385A, FBXO42 and AXIN1 interaction region of the Tp53 protein (UniProt.org). K164T has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1956
"TP53 Y103S lies within the DNA binding domain and WWOX, HIPK1, and ZNF385A interacting region of the Tp53 protein (UniProt.org). Y103S has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1957
"TP53 E224K lies within the DNA binding domain of the Tp53 protein (UniProt.org). E224K has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,115,0,,http://www.ncbi.nlm.nih.gov/pubmed,1958
"TP53 D228N lies within the DNA binding domain of the Tp53 protein (UniProt.org). D228N has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1959
"TP53 E171Q lies within the DNA binding domain of the Tp53 protein (UniProt.org). E171Q has been identified in the scientific literature (PMID: 28679771), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9679,28679771,Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Non-amplified Metastatic Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28679771,1960
"TP53 K320T lies within the bipartite nuclear localization signal and HIPK1, CARM1, and HIPK2-interacting region of the Tp53 protein (UniProt.org). K320T results in defective nuclear localization of Tp53 in cell culture (PMID: 23416275, PMID: 22380534), which may result in a loss of Tp53 function.",295,,,www.uniprot.org,3940,23416275,"Modulation of p53 C-terminal acetylation by mdm2, p14ARF, and cytoplasmic SirT2.",http://www.ncbi.nlm.nih.gov/pubmed/23416275,4409,22380534,Direct induction of apoptosis using an optimal mitochondrially targeted p53.,http://www.ncbi.nlm.nih.gov/pubmed/22380534,1961
"TP53 S240I lies within the DNA-binding domain and HIPK1, ZNF385A, and AXIN1-interacting region of the Tp53 protein (UniProt.org). S240I results in reduced Tp53 transactivation activity, but retains growth suppression ability in cell culture (PMID: 10901165).",295,,,www.uniprot.org,3985,10901165,Identification of p53 gene mutations in breast cancers and their effects on transcriptional activation function.,http://www.ncbi.nlm.nih.gov/pubmed/10901165,1962
"TP53 L265V lies within the DNA binding domain and interaction with HIPK1, ZNF385A, AXIN1 and E4F1 region of the Tp53 protein (UniProt.org). L265V has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1963
"SETBP1 V1101I does not lie within any known functional domains of the Setbp1 protein (UniProt.org). V1101I is a common Setbp1 polymorphism, but has not been biochemically characterized and therefore, its effect on Setbp1 protein function is unknown (PMID: 21037274, PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,9828,21037274,Reduced expression by SETBP1 haploinsufficiency causes developmental and expressive language delay indicating a phenotype distinct from Schinzel-Giedion syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/21037274,295,,,www.uniprot.org,1968
"SETBP1 T228fs*8 likely results in a truncation of the 242 aa Setbp1 isoform b protein at aa 228 followed by 8 nonsense amino acids (UniProt.org). T228fs*8 has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, Oct 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1969
"ROS1 S2229C lies within the cytoplasmic domain of the Ros1 protein (UniProt.org). S2229C has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1971
"ROS1 K2228Q lies within the cytoplasmic domain of the Ros1 protein (UniProt.org). K2228Q has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1972
"ROS1 D2213N lies within the cytoplasmic domain of the Ros1 protein (UniProt.org). D2213N has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1973
MYD88 mutant indicates an unspecified mutation in the MYD88 gene. ,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,1974
"MSH6 G39E does not lie within any known functional domains of the Msh6 protein (UniProt.org). G39E has been identificed in sequencing studies (PMID: 26181448), but has not been biochemically characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Aug 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9693,26181448,"Gastric cancers with microsatellite instability sharing clinical features, chemoresistance and germline MSH6 variants.",http://www.ncbi.nlm.nih.gov/pubmed/26181448,1986
"MSH6 F1088fs*2 likely results in a premature truncation of the 1360 aa Msh6 protein at aa 1088 followed by 2 nonsense amino acids  (UniProt.org). Due to the loss of MSH2- and ATP-binding regions (PMID: 12019211), F1088fs*2 is predicted to lead to a loss of Msh6 protein function.",3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,295,,,www.uniprot.org,1987
MSH2 Q130fs*2 likely results in a premature truncation of the 1360 aa Msh6 protein at aa 130 followed by 2 nonsense amino acids (UniProt.org). Due to the loss of all known functional domains Q130fs*2 is predicted to result in a loss of function. ,295,,,www.uniprot.org,1988
"MAP2K1 A76fs*3 likely results in a premature truncation of the 393 aa Map2k1 protein at aa 76 followed by 3 nonsense amino acids (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), A76fs*3 is predicted to result in a loss of Map2k1 function. ",295,,,www.uniprot.org,2023
"SMO D473H lies within the ligand binding pocket of the Smo protein (PMID: 25759020). D473H shows similar activity to wild-type Smo in cell culture, but has been demonstrated to confer resistance to Hedgehog pathway inhibitors (PMID: 19726788). ",2677,25759020,Smoothened variants explain the majority of drug resistance in basal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25759020,885,19726788,Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/19726788,2035
"CDKN2A positive indicates the presence of the CDKN2A gene, mRNA, and/or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,2036
"KRAS loss indicates loss of the KRAS gene, mRNA, and protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,2042
"ALK L1152R lies within the protein kinase domain of the Alk protein (UniProt.org). L1152R has not been biochemically characterized, however, has been demonstrated to occur as a secondary drug resistance mutation in the context of EML4-ALK (PMID: 21791641).",295,,,www.uniprot.org,918,21791641,A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/21791641,2043
"ALK C1156Y lies within the protein kinase domain of the Alk protein (UniProt.org). C1156Y has not been biochemically characterized, however, has been demonstrated to occur as a secondary drug resistance mutation (PMID: 21613408, PMID: 20979473).",912,20979473,EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/20979473,2442,21613408,Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/21613408,2044
"RUNX1 Q308Rfs*259 is a missense mutation (Q308R) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 308, followed by 259 nonsense amino acids (UniProt.org). Q308Rfs*259 has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Mar 2017).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2049
"TP53 E286G lies within the DNA binding domain of the Tp53 protein (PMID: 11902578). E286G has not been characterized in human cells, but does not affect wild-type Tp53 transactivation activity in yeast assays (PMID: 11896595).",3144,11896595,Tumour p53 mutations exhibit promoter selective dominance over wild type p53.,http://www.ncbi.nlm.nih.gov/pubmed/11896595,3142,11902578,Assessing TP53 status in human tumours to evaluate clinical outcome.,http://www.ncbi.nlm.nih.gov/pubmed/11902578,2068
"ROS1 G2032R lies in the protein kinase domain of the Ros1 protein (UniProt.org). G2032R has not been characterized individually however, confers Xalkori (crizotinib) resistance in the context of ROS1 fusions in patients (PMID: 23724914,PMID: 25033171).",901,23724914,Acquired resistance to crizotinib from a mutation in CD74-ROS1.,http://www.ncbi.nlm.nih.gov/pubmed/23724914,902,25033171,P-loop conformation governed crizotinib resistance in G2032R-mutated ROS1 tyrosine kinase: clues from free energy landscape.,http://www.ncbi.nlm.nih.gov/pubmed/25033171,295,,,www.uniprot.org,2069
"RB1 loss indicates loss of the RB1 gene, mRNA, and protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,2070
"JAK2 Y931C lies within the Protein kinase 2 domain of the Jak2 protein (UniProt.org, PMID: 21393331). Y931C results in increased Jak2 kinase activity and confers transforming activity in vitro (PMID: 21393331).",908,21393331,Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/21393331,295,,,www.uniprot.org,2130
"SMAD4 loss indicates the loss of the SMAD4 gene, mRNA or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,2131
"BRCA1 negative indicates a lack of the BRCA1 gene, mRNA, and/or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,2137
"BRCA2 negative indicates a lack of the BRCA2 gene, mRNA, and/or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,2138
"PTEN negative indicates a lack of the PTEN gene, mRNA, or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,2139
"SMARCB1 negative indicates a lack of the SMARCB1 gene, mRNA, or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,2147
"SETBP1 V231L does not lie within any known functional domains of the Setbp1 protein (UniProt.org). V231L has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, Aug 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2150
"SF3B1 R549fs*13 likely results in a truncation of the 1304 aa Sfbp1 protein at aa 549 followed by 13 nonsense amino acids (UniProt.org). SF3B1 R549fs*13 has not been characterized in the scientific literature and therefore, its effect on Sf3bp1 protein function is unknown (PubMed, Jul 2015).  ",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,2153
"SMO P768fs*8 likely results in a truncation of the 787 aa Smo protein at aa 768 followed by 8 nonsense amino acids (UniProt.org). P768fs*8 has not been characterized in the scientific literature and therefore, its effect on Smo protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2155
"PTEN inact mut indicates that this variant results in a loss of function of the PTEN protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,2157
"MET act mut indicates that this variant results in a gain of function in the MET protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,2158
"ROS1 amplification indicates an increased number of copies of the ROS1 gene. However, the mechanism causing the increase is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,2159
"EZH2 Y733Lfs*6 (corresponds to Y728 in the canonical isoform) is a missense mutation (Y733L) in conjunction with a likely truncation of the Ezh2 isoform 2 protein at aa 733 of 751, followed by 6 nonsense amino acids (UniProt.org). Y733Lfs*6 has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2160
"FLT3 A680fs*13 likely results in a truncation of the 993 aa Flt3 protein at aa 680, followed by 13 nonsense amino acids within the protein kinase domain of the Flt3 protein (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), A680fs*13 is predicted to lead to a loss of function.

",295,,,www.uniprot.org,2164
"FLT3 E608fs*26 likely results in a truncation of the 993 aa Flt3 protein at aa 608, followed by 26 nonsense amino acids (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), E608fs*26 is predicted to lead to a loss of function.",295,,,www.uniprot.org,2165
"FLT3 E611fs*23 likely results in a truncation of the 993 aa Flt3 protein at aa 611, followed by 23 nonsense amino acids within the protein kinase domain of the Flt3 protein (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), E611fs*23 is predicted to lead to a loss of function.",295,,,www.uniprot.org,2166
"FLT3 F612fs*22 likely results in a truncation of the 993 aa Flt3 protein at aa 612, followed by 22 nonsense amino acids within the protein kinase domain of the Flt3 protein (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), F612fs*22 is predicted to lead to a loss of function.",295,,,www.uniprot.org,2167
"FLT3 L610fs*24 likely results in a truncation of the 993 aa Flt3 protein at aa 610, followed by 24 nonsense amino acids within the protein kinase domain of the Flt3 protein (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), L610fs*24 is predicted to lead to a loss of function.",295,,,www.uniprot.org,2168
"FLT3 N609fs*25 likely results in a truncation of the 993 aa Flt3 protein at aa 609, followed by 25 nonsense amino acids (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), N609fs*25 is predicted to lead to a loss of function.",295,,,www.uniprot.org,2169
"FLT3 R607fs*27 likely results in a truncation of the 993 aa Flt3 protein at aa 607, followed by 27 nonsense amino acids (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), R607fs*27 is predicted to lead to a loss of function.",295,,,www.uniprot.org,2171
"FLT3 N587fs*24 likely results in a truncation of the 993 aa Flt3 protein at aa 587, followed by 24 nonsense amino acids (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), N587fs*24 is predicted to lead to a loss of function.",295,,,www.uniprot.org,2172
"FLT3 V581* results in a premature truncation of the Flt3 protein at amino acid 581 of 993 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), V581* is predicted to lead to a loss of function.",295,,,www.uniprot.org,2173
"FLT3 V581fs*6 likely results in a truncation of the 993 aa Flt3 protein at aa 581, followed by 6 nonsense amino acids (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), V581fs*6 is predicted to lead to a loss of function.",295,,,www.uniprot.org,2174
"FLT3 V579fs*3 likely results in a truncation of the 993 aa Flt3 protein at aa 579, followed by 3 nonsense amino acids (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), V579fs*3 is predicted to lead to a loss of function.",295,,,www.uniprot.org,2175
"FLT3 K438fs results in a change in the amino acid sequence of the Flt3 protein beginning at aa 438 of 993, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), K438fs is predicted to lead to a loss of function.",295,,,www.uniprot.org,2176
"FLT3 H821fs results in a change in the amino acid sequence of the Flt3 protein beginning at aa 821 of 993, likely resulting in premature truncation of the functional protein (UniProt.org). H821fs has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2177
"FLT3 K826fs results in a change in the amino acid sequence of the Flt3 protein beginning at aa 826 of 993, likely resulting in premature truncation of the functional protein (UniProt.org). K826fs*12 has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2178
"FLT3 L850fs results in a change in the amino acid sequence of the Flt3 protein beginning at aa 850 of 993, likely resulting in premature truncation of the functional protein (UniProt.org). L850fs has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2179
"FLT3 N847fs results in a change in the amino acid sequence of the Flt3 protein beginning at aa 847 of 993, likely resulting in premature truncation of the functional protein (UniProt.org). N847fs has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2180
"FLT3 R849fs results in a change in the amino acid sequence of the Flt3 protein beginning at aa 849 of 993, likely resulting in premature truncation of the functional protein (UniProt.org). R849fs has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2181
"FLT3 V824fs results in a change in the amino acid sequence of the Flt3 protein beginning at aa 824 of 993, likely resulting in premature truncation of the functional protein (UniProt.org). V824fs has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2182
"FLT3 V825* results in a premature truncation of the Flt3 protein at amino acid 825 of 993 within the protein kinase domain of the Flt3 protein (UniProt.org). V825* has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2183
"JAK3 A572V lies within the protein kinase domain 1 of the Jak3 protein (UniProt.org). A572V results in constitutive phosphorylation of Jak3 and activation of downstream Stat5, and leads to cytokine-independent proliferation in cultured cells (PMID: 22705984). ",821,22705984,Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/22705984,295,,,www.uniprot.org,2237
"MPL H620fs results in a change in the amino acid sequence of the Mpl protein at  aa 620 of 635, likely resulting in premature truncation of the functional protein (UniProt.org). H620fs has not been characterized in the scientific literature and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2253
FGFR3 K650E lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). K650E results in constitutive activation of the Fgfr3 protein (PMID: 11055896).,931,11055896,Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype.,http://www.ncbi.nlm.nih.gov/pubmed/11055896,295,,,www.uniprot.org,2260
"FGFR3 K650M lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). K650M has not been characterized, however other K650 mutations result in constitutive activation of the Fgfr3 protein thus K650M is predicted to result in a gain of function (PMID: 11055896).",931,11055896,Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype.,http://www.ncbi.nlm.nih.gov/pubmed/11055896,295,,,www.uniprot.org,2261
FGFR3 K650N lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). K650N results in constitutive activation of the Fgfr3 protein (PMID: 11055896).,931,11055896,Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype.,http://www.ncbi.nlm.nih.gov/pubmed/11055896,295,,,www.uniprot.org,2262
"FGFR3 K650Q lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). K650Q has not been characterized, however other K650 mutations result in constitutive activation of the Fgfr3 protein thus K650Q is predicted to result in a gain of function (PMID: 11055896).",931,11055896,Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype.,http://www.ncbi.nlm.nih.gov/pubmed/11055896,295,,,www.uniprot.org,2263
FGFR3 K650T lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). K650T results in constitutive activation of the Fgfr3 protein (PMID: 11055896).,931,11055896,Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype.,http://www.ncbi.nlm.nih.gov/pubmed/11055896,295,,,www.uniprot.org,2264
"JAK3 R657Q lies within the protein kinase domain 1 of the Jak3 protein (UniProt.org). R657Q confers a gain of function to Jak3, as indicated by phosphorylation of downstream Stat5, and is transforming in cell culture (PMID: 18397343).",295,,,www.uniprot.org,932,18397343,Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/18397343,2267
"JAK3 Q501H does not lie within any known functional domains of the Jak3 protein (UniProt.org). Q501H confers a gain of function to Jak3, as indicated by phosphorylation of downstream Stat5, and is transforming in cell culture (PMID: 18397343).",295,,,www.uniprot.org,932,18397343,Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/18397343,2268
"JAK3 I87T lies within the FERM domain of the Jak3 protein (UniProt.org). I87T confers a gain of function to Jak3, as indicated by constitutive phosphorylation of downstream Stat5, and is transforming in cell culture (PMID: 18397343).",932,18397343,Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/18397343,295,,,www.uniprot.org,2269
JAK3 V674A lies within the protein kinase 1 domain of the Jak3 protein (UniProt.org). V674A confers a gain of function on the Jak3 protein as demonstrated by increased kinase activity and the ability to transform cells in culture (PMID: 16790275).,295,,,www.uniprot.org,933,16790275,Identification of a constitutively active mutant of JAK3 by retroviral expression screening.,http://www.ncbi.nlm.nih.gov/pubmed/16790275,2270
"FLT3 N841I lies within the protein kinase domain of the Flt3 protein (UniProt.org). N841I confers a gain of function with increased receptor phosphorylation, and constitutive activation of STAT5 and ERK signalling pathways (PMID: 15178581). ",935,15178581,Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.,http://www.ncbi.nlm.nih.gov/pubmed/15178581,2272
"JAK3 P84fs results in a change in the amino acid sequence of the Jak3 protein beginning at aa 84 of 1124, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of all known functional domains (UniProt.org, PMID: 12351625), P84fs is predicted to lead to a loss of Jak3 protein function.",295,,,www.uniprot.org,2275
"KIT N320fs results in a change in the amino acid sequence of the Kit protein beginning at aa 320 of 976, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), N320fs is predicted to result in a loss of Kit protein function.",295,,,www.uniprot.org,2276
"EGFR P959fs results in a change in the amino acid sequence of the Egfr protein beginning at aa 959 of 1210, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), P959fs is predicted to result in a loss of function. ",295,,,www.uniprot.org,2280
"ERBB2 (HER2) G1041fs results in a change in the amino acid sequence of the Erbb2 (Her2) protein beginning at aa 1041 of 1255, likely resulting in premature truncation of the functional protein (UniProt.org). G1041fs has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2281
"FBXW7 G670fs*37 likely results in a truncation of the 707 aa Fbxw7 protein at aa 670, followed by 37 nonsense amino acids (UniProt.org). G670fs*37 has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2320
"FBXW7 M83* results in a premature truncation of the Fbxw7 protein at amino acid 83 of 707 (UniProt.org). Due to the loss of all known functional domains, M83* is predicted to lead to a loss of Fbxw7 protein function (UniProt.org).",295,,,www.uniprot.org,2321
"FBXW7 S668fs*39 likely results in a truncation of the 707 aa Fbxw7 protein at aa 668, followed by 39 nonsense amino acids of the Fbxw7 protein (UniProt.org). S668fs*39 has been identified in sequencing studies (PMID: 16824748), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Feb 2017).",295,,,www.uniprot.org,7965,16824748,Mutational analysis of the hCDC4 gene in gastric carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/16824748,285,,,http://www.ncbi.nlm.nih.gov/pubmed,2322
"ATRX R840fs*29 likely results in the truncation of the 2492 Atrx protein at amino acid 840, followed by 28 nonsense residues (UniProt.org). Due to the loss of the helicase domain, P-box, and glutamine rich region, all required for transcriptional regulation, R840fs*29 is predicted to result in a loss of function (PMID: 9545503).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2329
"PTPN11 Q510H lies within the tyrosine-protein phosphatase domain and acts as a substrate binding site (UniProt.org). Q510H has been identified in sequencing studies (PMID: 18925961), but has not been biochemically characterized and therefore, its effect on Ptpn11 protein function is unknown (PubMed, Aug 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7942,18925961,Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes.,http://www.ncbi.nlm.nih.gov/pubmed/18925961,295,,,www.uniprot.org,2335
"RB1 A10fs*21 likely results in the truncation of the 928 aa Rb1 protein at aa 10, followed by 20 nonsense amino acids (UniProt.org). Due to the loss of all known functional domains (UniProt.org), A10fs*21 is predicted to lead to a loss of Rb1 protein function.
",295,,,www.uniprot.org,2337
"RB1 A11fs*20 likely results in the truncation of the 928 aa Rb1 protein at aa 11, followed by 19 nonsense amino acids (UniProt.org). Due to the loss of all known functional domains (UniProt.org), A11fs*20 is predicted to lead to a loss of Rb1 protein function.",295,,,www.uniprot.org,2338
"RET R912L lies within the protein kinase domain of the Ret protein (UniProt.org). R912L has not been characterized and therefore, its effect on Ret protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2339
"ROS1 G514fs*21 likely results in a truncation of the 2347 aa Ros1 protein at aa 514, followed by 20 nonsense amino acids (UniProt.org). Due to the loss of the majority of the extracellular domain and the entire transmembrane and cytoplasmic domains (UniProt.org), G514fs*21 is predicted to lead to a loss of Ros1 protein function.",295,,,www.uniprot.org,2340
"SMAD4 A379T lies in the MH2 domain of the Smad4 protein (UniProt.org). A379T has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2342
"SMAD4 G386D lies in the MH2 domain of the Smad4 protein (UniProt.org). G386D was identified as the underlying genetic defect for a case of juvenile polyposis and hereditary hemorrhagic telangiectasia (PMID: 12116240, PMID: 15031030), likely due to loss of function, and also displayed decreased transcriptional activity on Smad4 (PMID: 20101697, PMID: 26488212).",295,,,www.uniprot.org,951,15031030,A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4).,http://www.ncbi.nlm.nih.gov/pubmed/15031030,4263,26488212,Clinicopathological and genetic differences between low-grade and high-grade colorectal mucinous adenocarcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/26488212,952,20101697,Overlapping spectra of SMAD4 mutations in juvenile polyposis (JP) and JP-HHT syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/20101697,950,12116240,Novel de novo mutation of MADH4/SMAD4 in a patient with juvenile polyposis.,http://www.ncbi.nlm.nih.gov/pubmed/12116240,2369
"ATM R2032K lies within the FAT domain of the Atm protein (UniProt.org). R2032K results in aberrant splicing of ATM mRNA, resulting in skipping of exon 43, which has unknown functional significance (PMID: 9887333).",953,9887333,Characterization of ATM gene mutations in 66 ataxia telangiectasia families.,http://www.ncbi.nlm.nih.gov/pubmed/9887333,2372
"ERBB4 T915S lies within the protein kinase domain of the Erbb4protein (UniProt.org). T915S has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2373
SMAD4 L43V lies in the MH1 domain of the Smad4 protein (UniProt.org). L43V displays reduced Smad4 transactivating activity and loss of DNA binding in cell assays (PMID: 14647410).,295,,,www.uniprot.org,955,14647410,Tumor-derived C-terminal mutations of Smad4 with decreased DNA binding activity and enhanced intramolecular interaction.,http://www.ncbi.nlm.nih.gov/pubmed/14647410,2374
SMAD4 R100T lies in the MH1 domain of the Smad4 protein (UniProt.org). R100T displays reduced Smad4 transactivating activity and loss of DNA binding in cell assays (PMID: 14647410).,295,,,www.uniprot.org,955,14647410,Tumor-derived C-terminal mutations of Smad4 with decreased DNA binding activity and enhanced intramolecular interaction.,http://www.ncbi.nlm.nih.gov/pubmed/14647410,2375
SMAD4 P102L lies in the MH1 domain of the Smad4 protein (UniProt.org). P102L displays reduced Smad4 transactivating activity and loss of DNA binding in cell assays (PMID: 14647410).,295,,,www.uniprot.org,955,14647410,Tumor-derived C-terminal mutations of Smad4 with decreased DNA binding activity and enhanced intramolecular interaction.,http://www.ncbi.nlm.nih.gov/pubmed/14647410,2376
SMAD4 P130S lies in the MH1 domain of the Smad4 protein (UniProt.org). P130S displays reduced Smad4 transactivating activity and DNA binding in cell assays (PMID: 14647410).,295,,,www.uniprot.org,955,14647410,Tumor-derived C-terminal mutations of Smad4 with decreased DNA binding activity and enhanced intramolecular interaction.,http://www.ncbi.nlm.nih.gov/pubmed/14647410,2377
"SMAD4 D351H lies at a hotspot residue in the MH2 domain of the Smad4 protein (UniProt.org, PMID: 23139211). D351H displays reduced Smad4 nuclear localization, transactivating activity, and growth arrest in cell assays (PMID: 14647410).",954,23139211,"SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer.",http://www.ncbi.nlm.nih.gov/pubmed/23139211,295,,,www.uniprot.org,955,14647410,Tumor-derived C-terminal mutations of Smad4 with decreased DNA binding activity and enhanced intramolecular interaction.,http://www.ncbi.nlm.nih.gov/pubmed/14647410,2378
"SMAD4 R361C lies at a hotspot residue within MH2 domain of the Smad4 protein (UniProt.org). R361C displays reduced Smad4 transactivating activity in cell assays (PMID: 14647410, PMID: 26488212). ",295,,,www.uniprot.org,4263,26488212,Clinicopathological and genetic differences between low-grade and high-grade colorectal mucinous adenocarcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/26488212,955,14647410,Tumor-derived C-terminal mutations of Smad4 with decreased DNA binding activity and enhanced intramolecular interaction.,http://www.ncbi.nlm.nih.gov/pubmed/14647410,2379
SMAD4 R497H lies in the MH2 domain of the Smad4 protein (UniProt.org). R497H displays reduced Smad4 transactivating activity and DNA binding in cell assays and acts in a dominant-negative manner (PMID: 14647410).,295,,,www.uniprot.org,955,14647410,Tumor-derived C-terminal mutations of Smad4 with decreased DNA binding activity and enhanced intramolecular interaction.,http://www.ncbi.nlm.nih.gov/pubmed/14647410,2380
SMAD4 K507Q lies in the MH2 domain of the Smad4 protein (UniProt.org). K507Q confers the inability of Smad4 to interact with Smad2 and displays reduced transactivating activity and DNA binding in cell assays (PMID: 14647410).,295,,,www.uniprot.org,955,14647410,Tumor-derived C-terminal mutations of Smad4 with decreased DNA binding activity and enhanced intramolecular interaction.,http://www.ncbi.nlm.nih.gov/pubmed/14647410,2381
SMAD4 R515G lies in the MH2 domain of the Smad4 protein (UniProt.org). R515G confers the inability of Smad4 to interact with Smad2 and displays reduced Smad4 transactivating activity and DNA binding in cell assays (PMID: 14647410).,955,14647410,Tumor-derived C-terminal mutations of Smad4 with decreased DNA binding activity and enhanced intramolecular interaction.,http://www.ncbi.nlm.nih.gov/pubmed/14647410,295,,,www.uniprot.org,2382
"SMAD4 L98F lies within the MH1 domain of the Smad4 protein (UniProt.org). L98F has not been characterized, but is predicted to result in decreased Smad4 protein stability in computational models (PMID: 23139211).",954,23139211,"SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer.",http://www.ncbi.nlm.nih.gov/pubmed/23139211,295,,,www.uniprot.org,2383
"SMAD4 P130Q lies in the MH1 domain of the Smad4 protein (UniProt.org). P130Q has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2384
"SMAD4 K436N lies in the MH2 domain of the Smad4 protein (UniProt.org). K436N has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2385
"SMAD4 W524C lies in the MH2 domain of the Smad4 protein (UniProt.org). W524C has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,2386
RET act mut indicates that this variant results in a gain of function in the Ret protein. However the specific amino acid change has not been identified.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,2410
Wild-type BCOR indicates that no mutation has been detected within the BCOR gene.	,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,2413
DNMT3A Q606* results in a premature truncation  of the Dnmt3a protein at amino acid 606 of 912 (UniProt.org). Q606* is predicted to result in a loss of  Dnmt3a function.,295,,,www.uniprot.org,2414
DNMT3A Y793* results in a premature truncation of the Dnmt3a protein at amino acid 793 of 912 (UniProt.org).  Y793* is predicted to result in a loss of  Dnmt3a function.,295,,,www.uniprot.org,2415
"DNMT3A Q886E lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (UniProt.org.) Q886E has been identified in the scientific literature (PMID: 27276561, PMID: 23251566), but has not been biochemically characterized and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jul 2017).
",7052,27276561,Genomic Classification and Prognosis in Acute Myeloid Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27276561,9256,23251566,High DNA methyltransferase DNMT3B levels: a poor prognostic marker in acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23251566,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2416
"DNMT3A S894R lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (UniProt.org.) S894R has not been characterized in the scientific literature and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jul 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2417
"DNMT3A R899H lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (UniProt.org). R899H has been identified in sequencing studies (PMID: 27276561), but has not been biochemically characterized and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jul 2017).
",295,,,www.uniprot.org,7052,27276561,Genomic Classification and Prognosis in Acute Myeloid Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27276561,285,,,http://www.ncbi.nlm.nih.gov/pubmed,2418
"DNMT3A C911Y lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (Uniprot.org). C911Y has been identified in sequencing studies (PMID: 22722750), but has not been biochemically characterized and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jun 2017).",7326,22722750,Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report.,http://www.ncbi.nlm.nih.gov/pubmed/22722750,295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,2419
"TET2 Q1540K does not lie within any known functional domains of the Tet2 protein (UniProt.org). Q1540K has not been characterized in the scientific literature and therefore, its effect on Tet2 function is unknown (PubMed, Nov 2015). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2420
"TET2 Y1902A lies within the substrate binding region of the Tet2 protein (UniProt.org). Y1902A has not been characterized individually however, results in decreased Tet2 enzymatic activity in conjunction with Y1295A in a cell free assay (PMID: 24315485).  ",295,,,www.uniprot.org,963,24315485,Crystal structure of TET2-DNA complex: insight into TET-mediated 5mC oxidation.,http://www.ncbi.nlm.nih.gov/pubmed/24315485,2421
"TET2 M1293A lies within the DNA interacting region of the Tet2 protein (UniProt.org). M1293A has not been characterized individually however, results in a loss of Tet2 enzymatic activity in conjunction with Y1294A in a cell free assay (PMID: 24315485).",963,24315485,Crystal structure of TET2-DNA complex: insight into TET-mediated 5mC oxidation.,http://www.ncbi.nlm.nih.gov/pubmed/24315485,295,,,www.uniprot.org,2422
"TET2 Y1294A lies within the DNA interacting region of the Tet2 protein (UniProt.org). Y1294A has not been characterized individually however, results in a significant decrease in Tet2 enzymatic activity in conjunction with M1293A in a cell free assay (PMID: 24315485).",963,24315485,Crystal structure of TET2-DNA complex: insight into TET-mediated 5mC oxidation.,http://www.ncbi.nlm.nih.gov/pubmed/24315485,295,,,www.uniprot.org,2423
TET2 N1387A does not lie within any known functional domains of the Tet2 protein (UniProt.org). N1387A results in decreased Tet2 enzymatic activity in a cell free assay (PMID: 24315485).,963,24315485,Crystal structure of TET2-DNA complex: insight into TET-mediated 5mC oxidation.,http://www.ncbi.nlm.nih.gov/pubmed/24315485,295,,,www.uniprot.org,2424
TET2 H1904R lies within the substrate binding region of the Tet2 protein (UniProt.org). H1904R results in decreased Tet2 enzymatic activity in a cell-free assay (PMID: 24315485).,963,24315485,Crystal structure of TET2-DNA complex: insight into TET-mediated 5mC oxidation.,http://www.ncbi.nlm.nih.gov/pubmed/24315485,295,,,www.uniprot.org,2425
"TET2 L1801F does not lie within any known functional domains of the TET2 protein (UniProt.org). L1801F has not been characterized and therefore, its effect on Tet2 protein function is unknown (PubMed, Nov 2015). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2426
"TET2 D1427Y does not lie within any known functional domains of the TET2 protein (UniProt.org). D1427Y has not been characterized and therefore, its effect on Tet2 protein function is unknown (PubMed, Nov 2015). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2427
"TET2 H1380Y lies within a zinc coordination residue of the TET2 protein (UniProt.org). H1380Y has not been characterized and therefore, its effect on Tet2 protein function is unknown (PubMed, Nov 2015). ",963,24315485,Crystal structure of TET2-DNA complex: insight into TET-mediated 5mC oxidation.,http://www.ncbi.nlm.nih.gov/pubmed/24315485,285,,,http://www.ncbi.nlm.nih.gov/pubmed,2428
"TET2 L1322P does not lie within any known functional domains of the TET2 protein (UniProt.org). L1322P has not been characterized and therefore, its effect on Tet2 protein function is unknown (PubMed, Nov 2015). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2429
"TET2 Y1295A lies within the DNA interacting region of the Tet2 protein (UniProt.org). Y1295A has not been characterized individually however, results in a minor decrease in Tet2 enzymatic activity in conjunction with S1290A in a cell free assay (PMID: 24315485).",963,24315485,Crystal structure of TET2-DNA complex: insight into TET-mediated 5mC oxidation.,http://www.ncbi.nlm.nih.gov/pubmed/24315485,295,,,www.uniprot.org,2430
"TET2 S1290A lies within the DNA interacting region of the Tet2 protein (UniProt.org). S1290A has not been characterized individually however, results in minor decrease of Tet2 enzymatic activity in conjunction with Y1295A in a cell free assay (PMID: 24315485).",963,24315485,Crystal structure of TET2-DNA complex: insight into TET-mediated 5mC oxidation.,http://www.ncbi.nlm.nih.gov/pubmed/24315485,295,,,www.uniprot.org,2431
TET2 R1262A does not lie within any known functional domains of the Tet2 protein (UniProt.org). R1262A confers a loss of function to the Tet2 protein resulting in a 2-4 fold decrease in enzymatic activity (PMID: 24315485).,963,24315485,Crystal structure of TET2-DNA complex: insight into TET-mediated 5mC oxidation.,http://www.ncbi.nlm.nih.gov/pubmed/24315485,295,,,www.uniprot.org,2432
"TET2 S1303N lies within the DNA interacting region of the Tet2 protein (UniProt.org). S1303N has not been characterized individually however, results in a loss of Tet2 enzymatic activity in conjunction with K1299E in a cell free assay (PMID: 24315485).",963,24315485,Crystal structure of TET2-DNA complex: insight into TET-mediated 5mC oxidation.,http://www.ncbi.nlm.nih.gov/pubmed/24315485,295,,,www.uniprot.org,2433
"EGFR D761Y lies within the protein kinase domain of the Egfr protein (UniProt.org). D761Y has not been characterized, but has been demonstrated to decrease sensitivity to Egfr tyrosine kinase inhibitors (PMID: 17085664).",295,,,www.uniprot.org,2798,17085664,Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/17085664,2434
"EGFR T854S lies within the protein kinase domain of the Egfr protein (UniProt.org). T854S has been identified in the scientific literature (PMID: 23486275, PMID: 24376513), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017). ",295,,,www.uniprot.org,9198,24376513,Drug resistance missense mutations in cancer are subject to evolutionary constraints.,http://www.ncbi.nlm.nih.gov/pubmed/24376513,9199,23486275,Two rare exon 21 EGFR mutations in patients treated with gefitinib.,http://www.ncbi.nlm.nih.gov/pubmed/23486275,285,,,http://www.ncbi.nlm.nih.gov/pubmed,2435
"EGFR T854A lies within the protein kinase domain of the Egfr protein (UniProt.org). T854A does not alter Egfr phosphorylation, but has been demonstrated to decrease sensitivity to Egfr tyrosine kinase inhibitors in cell culture (PMID: 19010870).",295,,,www.uniprot.org,965,19010870,Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/19010870,2436
TET2 W1291R lies within the DNA interacting region of the Tet2 protein (UniProt.org). W1291R results in a loss of Tet2 enzymatic activity in a cell free assay (PMID: 24315485).,295,,,www.uniprot.org,963,24315485,Crystal structure of TET2-DNA complex: insight into TET-mediated 5mC oxidation.,http://www.ncbi.nlm.nih.gov/pubmed/24315485,2437
"VHL G39D lies within the pentameric repeat region of the Vhl protein (UniProt.org). G39D has been identified in sequencing studies (PMID: 23558940), but has not been biochemically characterized and therefore, its effect on VHL protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7425,23558940,VHL gene alterations in Italian patients with isolated renal cell carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/23558940,295,,,www.uniprot.org,2438
"TET2 S1369* results in a premature truncation of the Tet2 protein at amino acid 1369 of 2002 (UniProt.org). Due to the loss of the substrate binding domain (UniProt.org), S1369* is predicted to result in a loss of function in the Tet2 protein. ",295,,,www.uniprot.org,2439
"TET2 R1359H does not lie within any known functional domains of the Tet2 protein (UniProt.org). R1359H has not been characterized and therefore, its effect on Tet2 protein function is unknown (PubMed, Nov 2015). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2440
"TET2 R1359C does not lie within any known functional domains of the Tet2 protein (UniProt.org). R1359C has not been characterized and therefore, its effect on Tet2 protein function is unknown (PubMed, Nov 2015). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2441
"TET2 G1288S does not lie within any known functional domains of the Tet2 protein (UniProt.org). G1288S has not been characterized and therefore, its effect on Tet2 protein function is unknown (PubMed, Nov 2015). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2442
"TET2 G1275E does not lie within any known functional domains of the Tet2 protein (UniProt.org). G1275E has not been characterized and therefore, its effect on Tet2 protein function is unknown (PubMed, Nov 2015). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2443
"TET2 L1326S does not lie within any known functional domains of the TET2 protein (UniProt.org). L1326S has not been characterized in the scientific literature and therefore, its effect on Tet2 protein function is unknown (PubMed, Nov 2015). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2444
"TET2 H1868D does not lie within any known functional domains of the Tet2 protein (UniProt.org). H1868D has not been characterized and therefore, its effect on Tet2 protein function is unknown (PubMed, Nov 2015). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2445
"TET2 P1889H does not lie within any known functional domains of the TET2 protein (UniProt.org). P1889H has not been characterized and therefore, its effect on Tet2 protein function is unknown (PubMed, Nov 2015). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2446
"CBL Y371H lies within the linker region of the Cbl protein (PMID: 20622007). Y371H results in a loss of Cbl ubiquitin ligase activity, leading to activation of FLT3, AKT, and STAT5, and transformation of cultured cells when co-expressed with FLT3 or KIT (PMID: 23696637, PMID: 20622007). ",3307,20622007,Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism.,http://www.ncbi.nlm.nih.gov/pubmed/20622007,966,23696637,CBL linker region and RING finger mutations lead to enhanced granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling via elevated levels of JAK2 and LYN.,http://www.ncbi.nlm.nih.gov/pubmed/23696637,2447
"TET2 H1219N does not lie within any known functional domains of the TET2 protein (UniProt.org). H1219N has not been characterized and therefore, its effect on Tet2 protein function is unknown (PubMed, Nov 2015). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2448
"CBL Q365_E366insSK lies within the linker region of the Cbl protein (UniProt.org). Q365_E366insSK results in a loss of E3-ligase activity, leading to activation of FLT3, and is transforming when expressed with FLT3 or KIT (PMID: 20622007).",3307,20622007,Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism.,http://www.ncbi.nlm.nih.gov/pubmed/20622007,295,,,www.uniprot.org,2449
Wild-type CDH1 indicates that no mutation has been detected within the CDH1 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,2451
"CDH1 E185V lies within the extracellular Cadherin 1 domain of the Cdh1 protein (UniProt.org). E185V demonstrates normal adhesion function in cell assays, in agreement with predictive modeling (PMID: 22470475).",295,,,www.uniprot.org,967,22470475,E-cadherin destabilization accounts for the pathogenicity of missense mutations in hereditary diffuse gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22470475,2452
"CDH1 S232C lies within the extracellular Cadherin 1 domain of the Cdh1 protein (UniProt.org). S232C demonstrates normal adhesion function in cell assays, in agreement with predictive modeling (PMID: 22470475).",295,,,www.uniprot.org,967,22470475,E-cadherin destabilization accounts for the pathogenicity of missense mutations in hereditary diffuse gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22470475,2453
"CDH1 L583R lies within the extracellular Cadherin 4 domain of the Cdh1 protein (UniProt.org). L583R results in aberrant maturation and decreased stability of Cdh1 protein, and leads to scattered cell distribution, indicating reduction of Cdh1 adhesive function in cell culture (PMID: 22470475).",295,,,www.uniprot.org,967,22470475,E-cadherin destabilization accounts for the pathogenicity of missense mutations in hereditary diffuse gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22470475,2454
Wild-type CEBPA indicates that no mutation has been detected within the CEBPA gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,2456
Wild-type GATA1 indicates that no mutation has been detected within the GATA1 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,2460
Wild-type GATA2 indicates that no mutation has been detected within the GATA2 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,2461
"CDH1 T118R lies within the propeptide region of the Cdh1 protein (UniProt.org). T118R results in reduced affinity of Cdh1 to Egfr and increased Egfr activation, as well as increased phosphorylation of p38 Mapk and Src in cell culture (PMID: 19268661).	",1052,19268661,E-cadherin mutations and cell motility: a genotype-phenotype correlation.,http://www.ncbi.nlm.nih.gov/pubmed/19268661,295,,,www.uniprot.org,2463
"CDH1 G239R lies within the extracellular Cadherin 1 domain of the Cdh1 protein (UniProt.org). G239R results in reduced affinity of Cdh1 to Egfr and increased Egfr activation, as well as increased p38 Mapk and Src phosphorylation, and increased cell migration in culture (PMID: 19268661).",1052,19268661,E-cadherin mutations and cell motility: a genotype-phenotype correlation.,http://www.ncbi.nlm.nih.gov/pubmed/19268661,295,,,www.uniprot.org,2464
"VHL R79G does not lie within any known functional domains of the Vhl protein (UniProt.org). R79G has not been characterized in the scientific literature and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,2466
"VHL N90Y does not lie within any known functional domains of the Vhl protein (UniProt.org). N90Y has been identified in sequencing studies (PMID: 24727139), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,7432,24727139,Unique molecular alteration patterns in von Hippel-Lindau (VHL) gene in a cohort of sporadic renal cell carcinoma patients from Pakistan.,http://www.ncbi.nlm.nih.gov/pubmed/24727139,285,,,http://www.ncbi.nlm.nih.gov/pubmed,2467
NOTCH1 act mut indicates that this variant results in a gain of function in the Notch1 protein. However the specific amino acid change has not been identified.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,2468
KRAS G15X indicates any KRAS missense mutation that results in the replacement of the glycine (G) at amino acid 15 by a different amino acid.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,2471
"FBXW7 E113D does not lie within any known functional domains of the Fbxw7 protein (UniProt.org). E113D has not been characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2472
"FBXW7 W244* results in a premature truncation of the Fbxw7 protein at amino acid 244 of 707 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), W244* is predicted to result in a loss of function.",295,,,www.uniprot.org,2473
"FBXW7 R222* results in a premature truncation of the Fbxw2 protein at amino acid 222 of 707 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), R222* is predicted to result in a loss of function.",295,,,www.uniprot.org,2475
"FBXW7 R278* results in a premature truncation of the Fbxw7 protein at amino acid 278 of 707 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), R278* is predicted to result in a loss of function.",295,,,www.uniprot.org,2476
"FBXW7 S282* results in a premature truncation of the Fbxw7 protein at amino acid 282 of 707 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), S282* is predicted to result in a loss of function.",295,,,www.uniprot.org,2477
"FBXW7 R658* results in a premature truncation of the Fbxw7 protein at amino acid 658 of 707 (UniProt.org). R658* results in decreased Fbxw7 protein level in cell culture, however, did not result in increased tumorigenesis compared to wild-type and therefore, its effect on Fbxw7 protein function is unknown (PMID: 24838835).",295,,,www.uniprot.org,1866,24838835,FBXW7 mutations in melanoma and a new therapeutic paradigm.,http://www.ncbi.nlm.nih.gov/pubmed/24838835,2478
"FBXW7 R505G lies within the WD repeat 4 of the Fbxw7 protein (UniProt.org). R505G has been identified in the scientific literature (PMID: 26155992, PMID: 27852700), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Oct 2017).",7956,26155992,Genetic profiles of cervical tumors by high-throughput sequencing for personalized medical care.,http://www.ncbi.nlm.nih.gov/pubmed/26155992,285,,,http://www.ncbi.nlm.nih.gov/pubmed,8065,27852700,Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/27852700,295,,,www.uniprot.org,2479
"FBXW7 G477S lies within the WD repeat 3 of the Fbxw7 protein (UniProt.org). G477S has been identified in the scientific literature (PMID: 19109228), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",7951,19109228,NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study.,http://www.ncbi.nlm.nih.gov/pubmed/19109228,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2480
"FBXW7 S426L lies within the WD repeat 2 of the Fbxw7 protein (UniProt.org). S426L has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2481
"KIT F522C lies within the transmembrane domain of the Kit protein (PMID: 15070706). F522C confers a gain of function to Kit, as indicated by increased autophosphorylation of Kit in cell culture (PMID: 15070706).",974,15070706,A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.,http://www.ncbi.nlm.nih.gov/pubmed/15070706,2482
KDR mutant indicates an unspecified mutation in the KDR (VEGFR2) gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,2483
"FGFR1 G728fs (corresponds to G697 in the canonical isoform) results in a change int he amino acid sequence of the Fgfr1 protein beginning at aa 728 of 853, likely resulting in premature truncation of the functional protein (UniProt.org). G728fs has not been characterized in the scientific literature and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2488
"GATA1 G340fs*14 likely results in a truncation of the 413 aa Gata1 protein at aa 340, followed by 14 nonsense amino acids (UniProt.org). G340fs*14 has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, Jun 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2491
"GATA2 A164T does not lie within any known functional domains of the Gata2 protein (UniProt.org). A164T has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Jun 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2492
"IDH1 I5fs*13 likely results in a truncation of the 414 aa Idh1 protein at aa 5, followed by 13 nonsense amino acids (UniProt.org). Due to the loss of all known functional domains (UniProt.org), I5fs*13 is predicted to lead to a loss of function.*",295,,,www.uniprot.org,2496
"IDH2 R353fs results in a change in the amino acid sequence of the Idh2 protein beginning at aa 353 of 452, likely resulting in premature truncation of the functional protein (UniProt.org). R353fs has not been characterized in the scientific literature and therefore, its effect on Idh2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2497
"TET2 C1374Y does not lie within any known functional domains of the Tet2 protein (UniProt.org). C1374Y has not been characterized and therefore, its effect on Tet2 protein function is unknown (PubMed, Nov 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2498
"TET2 D1242V does not lie within any known functional domains of the Tet2 protein (UniProt.org). D1242V has not been characterized and therefore, its effect on Tet2 protein function is unknown (PubMed, Nov 2015). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2499
"TET2 Q1389* results in a premature truncation of the Tet2 protein at amino acid 1389 of 2002 (UniProt.org). Due to the loss of the substrate binding domain (UniProt.org), Q1389* is predicted to result in a loss of Tet2 function. ",295,,,www.uniprot.org,2500
TET2 H1881R does not lie within any known functional domains of the Tet2 protein (UniProt.org). H1881R (corresponding to H1802R in the murine counterparts) results in decreased enzymatic activity of Tet2 in culture (PMID: 21057493). ,295,,,www.uniprot.org,987,21057493,Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.,http://www.ncbi.nlm.nih.gov/pubmed/21057493,2501
"TET2 S1870L does not lie within any known functional domains of the TET2 protein (UniProt.org). S1870L has not been characterized and therefore, its effect on Tet2 protein function is unknown (PubMed, Nov 2015). ",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,2502
"TET2 H1380L lies within a zinc coordination residue of the TET2 protein (UniProt.org). H1380L has not been characterized and therefore, its effect on Tet2 protein function is unknown (PubMed, Nov 2015). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,963,24315485,Crystal structure of TET2-DNA complex: insight into TET-mediated 5mC oxidation.,http://www.ncbi.nlm.nih.gov/pubmed/24315485,2503
"TET2 C1378F does not lie within any known functional domains of the Tet2 protein (UniProt.org). C1378F has not been characterized and therefore, its effect on Tet2 protein function is unknown (PubMed, Nov 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2504
"TET2 C1273F does not lie within any known functional domains of the Tet2 protein (UniProt.org). C1273F has not been characterized and therefore, its effect on Tet2 protein function is unknown (PubMed, Nov 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2505
"TET2 C1221Y does not lie within any known functional domains of the Tet2 protein (UniProt.org). C1221Y has not been characterized and therefore, its effect on Tet2 protein function is unknown (PubMed, Nov 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2506
"TET2 S358G does not lie within any known functional domains of the Tet2 protein (UniProt.org). S358G has not been characterized in the scientific literature and therefore, its effect on Tet2 protein function is unknown (PubMed, Nov 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2507
"TET2 V1718L does not lie within any known functional domains of the Tet2 protein (UniProt.org). V1718L has not been characterized and therefore, its effect on Tet2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2508
TET2 C1193W  lies in a cysteine-rich region of the Tet2 protein (PMID: 24697267) and is a metal binding residue (UniProt.org). C1193W results in the loss of Tet2 methylcytosine dioxygenase activity in cell based assays (PMID: 24697267). ,988,24697267,Evaluation of allelic strength of human TET2 mutations and cooperation between Tet2 knockdown and oncogenic Nras mutation.,http://www.ncbi.nlm.nih.gov/pubmed/24697267,2509
TET2 R1261G lies in a cysteine-rich region of the Tet2 protein (PMID: 24697267) and is a 2-oxoglutarate binding site (UniProt.org). R1261G results in the loss of Tet2 methylcytosine dioxygenase activity in cell based assays (PMID: 24697267).,988,24697267,Evaluation of allelic strength of human TET2 mutations and cooperation between Tet2 knockdown and oncogenic Nras mutation.,http://www.ncbi.nlm.nih.gov/pubmed/24697267,2510
TET2 I1873T lies in the catalytic double strand beta helix region of the Tet2 protein (PMID: 24697267). I1873T results in the loss of Tet2 methylcytosine dioxygenase activity in cell based assays (PMID: 24697267). ,988,24697267,Evaluation of allelic strength of human TET2 mutations and cooperation between Tet2 knockdown and oncogenic Nras mutation.,http://www.ncbi.nlm.nih.gov/pubmed/24697267,2511
TET2 H1881Q does not lie within any known functional domains of the Tet2 protein (UniProt.org). H1881Q (corresponding to H1802Q in the murine counterparts) results in decreased enzymatic activity of Tet2 in culture (PMID: 21057493). ,295,,,www.uniprot.org,987,21057493,Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.,http://www.ncbi.nlm.nih.gov/pubmed/21057493,2512
"TET2 R1896S lies in the catalytic double strand beta helix region of the Tet2 protein (PMID: 24697267) and in a binding region of 2-oxoglutarate (UniProt.org). R1896S results in the substantial, but not total loss of Tet2 methylcytosine dioxygenase activity in cell based assays (PMID: 24697267).",988,24697267,Evaluation of allelic strength of human TET2 mutations and cooperation between Tet2 knockdown and oncogenic Nras mutation.,http://www.ncbi.nlm.nih.gov/pubmed/24697267,295,,,www.uniprot.org,2513
"GATA2 G200fs*18 likely results in a truncation of the 480 aa Gata2 protein at aa 200, followed by 18 nonsense amino acids (UniProt.org). Due to the loss of all known functional domains (UniProt.org), G200fs*18 is predicted to lead to a loss of function.",295,,,www.uniprot.org,2520
TET2 W1291_N1296delinsGGSGGS results in a deletion of six amino acids in the DNA interacting region of the Tet2 protein combined with the insertion of six new amino acids in the same location (UniProt.org). W1291_N1296delinsGGSGGS confers a loss of function on the Tet2 protein resulting in a loss of enzymatic activity (PMID: 24315485).,963,24315485,Crystal structure of TET2-DNA complex: insight into TET-mediated 5mC oxidation.,http://www.ncbi.nlm.nih.gov/pubmed/24315485,295,,,www.uniprot.org,2521
"GNAS inact mut indicates that this variant results in a loss of function in the Gnas protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,2523
BRAF E586K lies within the protein kinase domain of the Braf protein (UniProt.org). E586K confers a gain of function on Braf resulting in increased MEK and ERK activation (PMID: 15035987).,295,,,www.uniprot.org,146,15035987,Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.,http://www.ncbi.nlm.nih.gov/pubmed/15035987,2524
"KRAS G12A is a hotspot mutation that lies within a GTP binding region of the Kras protein (UniProt.org). G12A results in decreased Kras GTPase activity and increased activation of downstream signaling in cell culture (PMID: 23455880, PMID: 26037647).",3052,26037647,Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26037647,26,23455880,KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23455880,295,,,www.uniprot.org,2527
"ATM W57* results in a premature truncation of the Atm protein at amino acid 57 of 3056 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), W57* is predicted to result in a loss of Atm protein function.",295,,,www.uniprot.org,2528
"ATM I124V does not lie within any known functional domains of the Atm protein (UniProt.org). I124V has been identified in sequencing studies (PMID: 12673804) but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7873,12673804,ATM gene alterations in childhood acute lymphoblastic leukemias.,http://www.ncbi.nlm.nih.gov/pubmed/12673804,295,,,www.uniprot.org,2529
"ATM A2067D lies within the FAT domain of the Atm protein (UniProt.org). A2067D confers a loss of function to Atm, resulting in reduced Atm protein expression and decreased Atm kinase activity in cell culture (PMID: 25077176).",1004,25077176,"A-TWinnipeg: Pathogenesis of rare ATM missense mutation c.6200C>A with decreased protein expression and downstream signaling, early-onset dystonia, cancer, and life-threatening radiotoxicity.",http://www.ncbi.nlm.nih.gov/pubmed/25077176,295,,,www.uniprot.org,2530
"ATM D2395V lies within the FAT domain of the Atm protein (UniProt.org). D2395V has been identified in sequencing studies (PMID: 22952040) but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).
",7847,22952040,Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/22952040,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2531
"ATM M2405L lies within the FAT domain of the Atm protein (UniProt.org). M2405L has been identified in sequencing studies (PMID: 22952040), but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017).
",7847,22952040,Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/22952040,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2532
"ATM K2756* results in a premature truncation of the Atm protein at amino acid 2756 of 3056 (UniProt.org). Due to the loss of the FATC domain, R2756* is predicted to lead to a loss of Atm protein function (PMID: 16603769).",2669,16603769,The FATC domains of PIKK proteins are functionally equivalent and participate in the Tip60-dependent activation of DNA-PKcs and ATM.,http://www.ncbi.nlm.nih.gov/pubmed/16603769,295,,,www.uniprot.org,2533
"ATM E1072* results in a premature truncation of the Atm protein at amino acid 1072 of 3056 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), E1072* is predicted to result in a loss of Atm protein function.",295,,,www.uniprot.org,2534
ATM V2424G lies within the FAT domain of the Atm protein (UniProt.org). V2424G results in decreased Atm kinase activity in cell culture (PMID: 11830610).,1005,11830610,Dominant negative ATM mutations in breast cancer families.,http://www.ncbi.nlm.nih.gov/pubmed/11830610,2535
"ATM A1309T does not lie within any known functional domains of the Atm protein (UniProt.org). A1309T has been identified in sequencing studies (PMID: 16461462) but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7886,12697903,Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/12697903,295,,,www.uniprot.org,9736,17393301,The spectrum of ATM missense variants and their contribution to contralateral breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17393301,7845,16461462,Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/16461462,2536
"KIT E53K lies within the Ig-like C2-type 1 domain of the Kit protein (UniProt.org). E53K has been identified in sequencing studies (PMID: 17710669), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7398,17710669,Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder.,http://www.ncbi.nlm.nih.gov/pubmed/17710669,295,,,www.uniprot.org,2539
"RB1 positive indicates the presence of the RB1 gene, mRNA, and/or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,2540
"FBXW7 loss indicates loss of the Fbxw7 gene, mRNA or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,2542
"KIT D572A lies within the cytoplasmic domain of the Kit protein (UniProt.org). D572A confers a gain of function on Kit, as indicated by ligand-independent tyrosine phosphorylation in cell culture (PMID: 19865100).",646,19865100,Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations.,http://www.ncbi.nlm.nih.gov/pubmed/19865100,2543
HRAS G13D lies within the GTP nucleotide binding region of the Hras protein (UniProt.org). G13D inhibits GTPase activity of Hras leading to increased activation of downstream signaling in the absence of activation (PMID: 17767136).,1036,17767136,H-Ras mutation modulates the expression of major cell cycle regulatory proteins and disease prognosis in oral carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/17767136,295,,,www.uniprot.org,2544
"RB1 E554* results in a premature truncation of the Rb1 protein in the A domain at amino acid 554 of 928 (UniProt.org). Due to the loss of four major functional domains (UniProt.org), E554* is predicted to lead to a loss of Rb1 protein function. ",295,,,www.uniprot.org,2545
CTNNB1 S37Y lies within the ubiquitination recognition motif of the Ctnnb1 protein and occurs at a Gsk3b phosphorylation site on the Ctnnb1 protein (PMID: 10347231). S37Y confers a gain of function to the Ctnnb1 protein as demonstrated by stabilization and accumulation of the Ctnnb1 protein (PMID: 9065403).,402,9065403,Stabilization of beta-catenin by genetic defects in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/9065403,295,,,www.uniprot.org,2546
"EGFR Y125C lies within the extracellular domain of the Egfr protein (UniProt.org). Y125C has been identified in sequencing studies (PMID: 23788652) but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6164,23788652,Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23788652,2547
"PTEN C211Y lies within the C2 tensin-type domain of the Pten protein (UniProt.org). C211Y has been identified in the scientific literature (PMID: 28027320), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",8044,28027320,Genomic Analysis of Uterine Lavage Fluid Detects Early Endometrial Cancers and Reveals a Prevalent Landscape of Driver Mutations in Women without Histopathologic Evidence of Cancer: A Prospective Cross-Sectional Study.,http://www.ncbi.nlm.nih.gov/pubmed/28027320,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2548
FGFR2 G271E lies within the Ig-like C2-type 3 domain of the Fgfr2 protein (UniProt.org). G271E confers a loss of function to the Fgfr2 protein resulting in impaired receptor processing (PMID: 19147536).,1037,19147536,Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/19147536,295,,,www.uniprot.org,2549
"CDKN2A S56N lies within ANK repeat 2 of the Cdkn2a protein (UniProt.org). S56N has been identified in sequencing studies (PMID: 9414654), but has not been biochemically characterized and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Feb 2017). ",295,,,www.uniprot.org,7793,9414654,p16INK4 gene mutations are relatively frequent in ampullary carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/9414654,285,,,http://www.ncbi.nlm.nih.gov/pubmed,2550
PTEN del indicates a deletion of the PTEN gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,2552
"RET V804M lies within the protein kinase domain of the Ret protein (UniProt.org). V804M confers a gain of function on the Ret protein, resulting in increased kinase activity, cell transformation (PMID: 16469774), and is considered a gatekeeper due to lack of V804M response to some inhibitors, including cabozantinib and vandetanib (PMID: 23811235, PMID: 27712045).",1053,16469774,A novel activating mutation in the RET tyrosine kinase domain mediates neoplastic transformation.,http://www.ncbi.nlm.nih.gov/pubmed/16469774,602,23811235,Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.,http://www.ncbi.nlm.nih.gov/pubmed/23811235,295,,,www.uniprot.org,8444,27712045,Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27712045,2553
"RET V804L lies within the protein kinase domain of the Ret protein (UniProt.org). V804L confers a gain of function on the Ret protein, as indicated by increased kinase activity, cell transformation (PMID: 9242375), and is considered a gatekeeper due to lack of V804L response to some inhibitors, including cabozantinib and vandetanib (PMID: 27712045)",432,9242375,Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain.,http://www.ncbi.nlm.nih.gov/pubmed/9242375,295,,,www.uniprot.org,8444,27712045,Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27712045,2554
"KDR (VEGFR2) R962H lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). R962H has been identified in sequencing studies (PMID: 27077911), but has not been characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",9586,27077911,Molecular Heterogeneity of Ewing Sarcoma as Detected by Ion Torrent Sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/27077911,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2559
"BRAF F595L lies within the protein kinase domain of the Braf protein (UniProt.org). F595L has been demonstrated to increase Braf kinase activity and is transforming in cell culture (PMID: 15035987, PMID: 26582644), and works cooperatively with oncogenic Ras to activate MEK/ERK signaling (PMID: 26582644), however, has also been demonstrated to have low kinase activity in cell culture (PMID: 28783719).",146,15035987,Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.,http://www.ncbi.nlm.nih.gov/pubmed/15035987,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,9695,26582644,Cooperation of BRAF(F595L) and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling.,http://www.ncbi.nlm.nih.gov/pubmed/26582644,2560
"BRAF G596R lies within the protein kinase domain of the Braf protein, within the DFG motif (PMID: 19735675). G596R results in impaired Braf kinase activity and decreased phosphorylation of Mek and MAPK in cell culture (PMID: 19735675, PMID: 28783719).",9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,1060,19735675,Insights into the molecular function of the inactivating mutations of B-Raf involving the DFG motif.,http://www.ncbi.nlm.nih.gov/pubmed/19735675,2561
"TP53 R248W is a hotspot mutation that lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). R248W results in abrogation of Tp53 tumor suppressor activity and a gain-of-function in ATM inactivation, resulting in increased genetic instability and increased tumorigenesis in mouse models (PMID: 17417627).",1106,17417627,p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.,http://www.ncbi.nlm.nih.gov/pubmed/17417627,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,2567
"PIK3CA E545K is a hotspot mutation that lies within the PIK helical domain of the Pik3ca protein (UniProt.org). E545K results in increased phosphorylation of Akt and Mek1/2, growth factor-independent cell survival, and is transforming in culture (PMID: 26627007).",295,,,www.uniprot.org,4255,26627007,Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26627007,2569
"ABL1 K624del results in the deletion of one amino acid of the Abl1 protein at amino acid 624 (corresponding to K605 in canonical isoform) (UniProt.org). K624del has not been characterized in the scientific literature and therefore, its effect on Abl1 protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,2571
"ABL1 V289F lies within the protein kinase domain of the Abl1 protein (UniProt.org). V289F has been identified in the scientific literature (PMID: 23355941), but has not been biochemically characterized and therefore, its effect on Abl1 protein function is unknown (PubMed, Aug 2017). ",295,,,www.uniprot.org,1112,23355941,Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients.,http://www.ncbi.nlm.nih.gov/pubmed/23355941,2572
"APC P1076L lies within a region of the Apc protein responsible for ubiquitination-mediated down-regulation (UniProt.org). P1076L has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2573
"IKZF1 K116fs*2 likely results in a truncation of the 519 aa Ikzf1 protein at aa 116, followed by 2 nonsense amino acids (UniProt.org). Due to the loss of all known DNA binding and zinc-finger domains (UniProt.org), K116fs*2 is predicted to lead to a loss of function.",295,,,www.uniprot.org,2577
"KRAS E76fs*9 likely results in a truncation of the 189 aa Kras protein at aa 76, followed by 9 nonsense amino acids (UniProt.org). Due to the loss of a GTP binding site, E76fs*9 is predicted to lead to a loss of Kras protein function (UniProt.org).",295,,,www.uniprot.org,2579
"DNMT3A R301W lies within the PWWP domain and DNMT1 and DNMT3B-interacting region of the Dnmt3a protein (UniProt.org). R301W has not been characterized in the scientific literature and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2580
"DNMT3A G302del results in the deletion of an amino acid in the PWWP domain and DNMT1 and DNMT3B-interacting region of the Dnmt3a protein at amino acid 302 (UniProt.org). G302del has not been characterized in the scientific literature and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2581
"DNMT3A R320* results in a premature truncation of the Dnmt3a protein at amino acid 320 of 912 (UniProt.org). R320* has been identified in sequencing studies (PMID: 27276561), but has not been biochemically characterized and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jul 2017).
",295,,,www.uniprot.org,7052,27276561,Genomic Classification and Prognosis in Acute Myeloid Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27276561,285,,,http://www.ncbi.nlm.nih.gov/pubmed,2582
"DNMT3A S352N lies within the DNMT1 and DNMT3B-interacting region of the Dnmt3a protein (UniProt.org). S352N has been identified in sequencing studies (PMID: 21993668), but has not been biochemically characterized and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Feb 2016).",295,,,www.uniprot.org,7334,21993668,"Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/21993668,285,,,http://www.ncbi.nlm.nih.gov/pubmed,2583
"DNMT3A Y436* results in a premature truncation of the Dnmt3a protein at amino acid 436 of 912 (UniProt.org). Due to the loss of the SAM-dependent MTase C5-type domain, Y436* is predicted to lead to a loss of Dnmt3a protein function (UniProt.org).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2584
"TET2 A1505T does not lie within any known functional domains of the Tet2 protein (UniProt.org). A1505T has not been characterized and therefore, its effect on Tet2 protein function is unknown (PubMed, Nov 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2586
"FLT3 A680V lies within the N-terminal kinase domain of the Flt3 protein (PMID: 15976757). A680V has not been characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, May 2016).  ",1129,15976757,Specific detection of Flt3 point mutations by highly sensitive real-time polymerase chain reaction in acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/15976757,285,,,http://www.ncbi.nlm.nih.gov/pubmed,2590
"BRAF K601N lies within the protein kinase domain of the Braf protein (UniProt.org). K601N confers a gain of function on Braf, as indicated by increased phosphorylation of MEK and ERK in cell in culture (PMID: 24434212).",295,,,www.uniprot.org,1131,24434212,Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24434212,2591
"BRAF K601I lies within the protein kinase domain of the Braf protein (UniProt.org). K601I has not been biochemically characterized, however, is predicted to confer a gain of function to the Braf protein based on the effects of other mutations at K601 (PMID: 22798288, PMID: 24434212, PMID: 19206169).",3,22798288,BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/22798288,295,,,www.uniprot.org,760,19206169,"Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum.",http://www.ncbi.nlm.nih.gov/pubmed/19206169,1131,24434212,Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24434212,2592
"JAK3 A1090T does not lie within any known functional domains of the Jak3 protein (UniProt.org). A1090T has not been characterized and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2593
"MPL R514K lies within the cytoplasmic domain of the Mpl protein (UniProt.org). MPL R514K has not been characterized in the scientific literature and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2595
"NOTCH1 A1640T lies within the extracellular domain of the Notch1 protein (UniProt.org). A1640T has been identified in sequencing studies (PMID: 22225590), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Jun 2017).",7067,22225590,Impact of complex NOTCH1 mutations on survival in paediatric T-cell leukaemia.,http://www.ncbi.nlm.nih.gov/pubmed/22225590,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2596
"CTNNB1 I35V does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). I35V has been identified in the scientific literature (PMID: 20925459), but has not been biochemically characterized and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Mar 2017).",8365,20925459,"A novel conditionally replicating ""armed"" adenovirus selectively targeting gastrointestinal tumors with aberrant wnt signaling.",http://www.ncbi.nlm.nih.gov/pubmed/20925459,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2597
CTNNB1 G48D does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). G48D is predicted to confer a gain of function to the Ctnnb1 protein as demonstrated by nuclear accumulation of Ctnnb1 (PMID: 11559529).,295,,,www.uniprot.org,1245,11559529,Accumulation of beta-catenin protein and mutations in exon 3 of beta-catenin gene in gastrointestinal carcinoid tumor.,http://www.ncbi.nlm.nih.gov/pubmed/11559529,2598
"ALK fusion indicates a fusion of the ALK gene, but the fusion partner is unknown.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,2602
"ABL1 S991L lies within the F-actin binding region of the Abl1 protein (UniProt.org). S991L has not been characterized and therefore, its effect on Abl1 protein function is unknown (PubMed, Jun 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2605
ALK A1200V lies within the protein kinase domain of the Alk protein (UniProt.org). A1200V has activity comparable to wild-type Alk (PMID: 25517749).,295,,,www.uniprot.org,4535,25517749,ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/25517749,2610
"ALK R1212H lies within the protein kinase domain of the Alk protein (UniProt.org). R1212H has been identified in sequencing studies (PMID: 21499247), but has not been biochemically characterized and therefore, its effect on Alk protein function is unknown (PubMed, Jun 2017).",1333,21499247,Exome sequencing identifies GRIN2A as frequently mutated in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/21499247,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2611
"ALK R311H lies within the MAM 1 domain of the Alk protein (UniProt.org). R311H has been identified in the scientific literature (PMID: 23202128, PMID: 25344691), but has not been biochemically characterized and therefore, its effect on Alk protein function is unknown (PubMed, Oct 2017).",1689,25344691,RNF43 is frequently mutated in colorectal and endometrial cancers.,http://www.ncbi.nlm.nih.gov/pubmed/25344691,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8352,23202128,Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/23202128,2612
"ALK V476A does not lie within any known functional domains of the Alk protein (UniProt.org). V476A has not been characterized in the scientific literature and therefore, its effect on Alk protein function is unknown (PubMed, Jul 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2613
"ABL1 S972L lies in the F-actin-binding region of the Abl1 protein (UniProt.org). S972L has not been characterized in the scientific literature and therefore, its effect on Abl1 protein function is unknown (PubMed, Jun 2017). ",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,2614
"APC A1508V lies within the third of seven 20 amino acid repeats responsible for APC-beta-catenin interaction (PMID: 9196022). A1508V has been identified in sequencing studies (PMID: 20569184), but has not been biochemically characterized and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,1162,9196022,The adenomatous polyposis coli (APC) tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/9196022,7803,20569184,Identification of novel SNPs by next-generation sequencing of the genomic region containing the APC gene in colorectal cancer patients in China.,http://www.ncbi.nlm.nih.gov/pubmed/20569184,2616
"APC A2672T does not lie within any known functional domains of the Apc protein (UniProt.org). A2672T has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2617
"APC A2690T does not lie within any known functional domains of the Apc protein (UniProt.org). A2690T has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2621
"APC D1566N lies within the beta-catenin binding and downregulation region of the Apc protein (PMID: 14672538). D1566N has been identified in sequencing studies (PMID: 22864938), but has not been biochemically characterized and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7809,22864938,"Dietary, lifestyle and clinicopathological factors associated with APC mutations and promoter methylation in colorectal cancers from the EPIC-Norfolk study.",http://www.ncbi.nlm.nih.gov/pubmed/22864938,2622
"APC D1003N lies within a region of the Apc protein responsible for down-regulation mediated by ubiquitination (UniProt.org). D1003N has been identified in sequencing studies (PMID: 25545608), but has not been biochemically characterized and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",7804,25545608,"Target-enriched next-generation sequencing reveals differences between primary and secondary ovarian tumors in formalin-fixed, paraffin-embedded tissue.",http://www.ncbi.nlm.nih.gov/pubmed/25545608,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2623
"APC P1420L does not lie within any known functional domains of the Apc protein (UniProt.org). P1420L has been identified in sequencing studies (PMID: 16906516) but has not been biochemically characterized and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7814,16906516,Phenotype-genotype correlation: challenge of intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses.,http://www.ncbi.nlm.nih.gov/pubmed/16906516,295,,,www.uniprot.org,2624
"APC S940L does not lie within any known functional domains of the Apc protein (UniProt.org). S940L has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2625
"APC R876Q does not lie within any known functional domains of the Apc protein (UniProt.org). R876Q has been identified in sequencing studies (PMID: 22895193) but has not been biochemically characterized and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",295,,,www.uniprot.org,4597,22895193,Recurrent R-spondin fusions in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22895193,285,,,http://www.ncbi.nlm.nih.gov/pubmed,2626
"APC V1472I does not lie within any known functional domains of the Apc protein (UniProt.org). V1472I has been identified in sequencing studies (PMID: 10666372) but has not been biochemically characterized and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",295,,,www.uniprot.org,7798,10666372,APC mutations in sporadic medulloblastomas.,http://www.ncbi.nlm.nih.gov/pubmed/10666372,285,,,http://www.ncbi.nlm.nih.gov/pubmed,2627
"APC R1171H lies within the region of the Apc protein responsible for downregulation mediated by ubiquitination (UniProt.org). R1171H has been identified in sequencing studies (PMID: 1338691) but has not been biochemically characterized and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7816,1338691,Somatic mutation of the APC gene in gastric cancer: frequent mutations in very well differentiated adenocarcinoma and signet-ring cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/1338691,2628
"APC R805Q does not lie within any known functional domains of the Apc protein (UniProt.org). R805Q has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2629
"SMO K575M lies within the C-terminal cytoplasmic tail of the Smo protein (PMID: 16339184). K575M leads to increased expression of the Hedgehog pathway targets PTCH1 and GLI1 in human tumor samples, and is predicted to confer a gain of function to the Smo protein (PMID: 16339184).",1163,16339184,Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/16339184,2632
"BRAF T599R lies within the activation loop in the kinase domain of the Braf protein (PMID: 19206169). T599R confers a gain of function on Braf, as indicated by increased MEK and ERK phosphorylation, and is transforming in cell culture (PMID: 19206169).",760,19206169,"Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum.",http://www.ncbi.nlm.nih.gov/pubmed/19206169,2634
"BRAF K601Q lies within the activation loop in the kinase domain of the Braf protein (PMID: 19206169). K601Q confers a gain of function on Braf, as indicated by increased MEK and ERK phosphorylation, and is transforming in cell culture (PMID: 19206169). ",760,19206169,"Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum.",http://www.ncbi.nlm.nih.gov/pubmed/19206169,2635
"KIT A502_Y503insSA results in the insertion of two amino acids in the Ig-like C2-type 5 domain of the Kit protein between amino acids 502 and 503 (UniProt.org). A502_Y503inSA confers a gain of function on Kit, as indicated by constitutive phosphorylation of Kit in cell culture (PMID: 22324351).",1164,22324351,"Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.",http://www.ncbi.nlm.nih.gov/pubmed/22324351,295,,,www.uniprot.org,2636
"KIT H630Y lies within the protein kinase domain of the Kit protein (UniProt.org). H630Y has been identified in sequencing studies (PMID: 23014346), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7402,23014346,BRAF mutations and KIT aberrations and their clinicopathological correlation in 202 Korean melanomas.,http://www.ncbi.nlm.nih.gov/pubmed/23014346,2638
"KIT R804W lies within the activation loop in the kinase domain of the Kit protein (PMID: 21478825). R804W is predicted to have lower binding affinity for imatinib relative to wild-type Kit protein (PMID: 20140688), but has not been biochemically characterized and therefore, its effect on Kit protein function is unknown (PubMed, May 2017).",9010,20140688,Exploring the cause of drug resistance by the detrimental missense mutations in KIT receptor: computational approach.,http://www.ncbi.nlm.nih.gov/pubmed/20140688,1165,21478825,KIT mutations in ocular melanoma: frequency and anatomic distribution.,http://www.ncbi.nlm.nih.gov/pubmed/21478825,285,,,http://www.ncbi.nlm.nih.gov/pubmed,2639
"KIT T632I lies within the protein kinase domain of the Kit protein (UniProt.org). T632I has been identified in sequencing studies (PMID: 25822088), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Dec 2016).
",7022,25822088,Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.,http://www.ncbi.nlm.nih.gov/pubmed/25822088,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2640
"BRAF G466R (previously reported as G465R) lies within the glycine-rich loop in the protein kinase domain of the Braf protein (PMID: 14681681). G466R results in impaired Braf kinase activity, however, paradoxically activates Erk signaling in cell culture (PMID: 15046639).",1166,15046639,Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis.,http://www.ncbi.nlm.nih.gov/pubmed/15046639,1167,14681681,Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9.,http://www.ncbi.nlm.nih.gov/pubmed/14681681,2641
APC I1307K lies within a regulatory region of the Apc protein mediated by direct ubiquitination (UniProt.org). I1307K has not been biochemically characterized but is associated with increased colorectal cancer risk (PMID: 9724771)and increased chances of APC gene mutations (PMID: 24416237).,295,,,www.uniprot.org,5825,9724771,"The APC variants I1307K and E1317Q are associated with colorectal tumors, but not always with a family history.",http://www.ncbi.nlm.nih.gov/pubmed/9724771,1171,24416237,Colorectal tumors from APC*I1307K carriers principally harbor somatic APC mutations outside the A8 tract.,http://www.ncbi.nlm.nih.gov/pubmed/24416237,2644
"ATM L1675F does not lie within any known functional domains of the Atm protein (UniProt.org). L1675F has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2652
ATM P2699S lies within the ATP-binding pocket of the Atm protein (PMID: 21993670). P2699S is predicted to result in a loss of ATM kinase activity in molecular models (PMID: 21993670).,1173,21993670,ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression.,http://www.ncbi.nlm.nih.gov/pubmed/21993670,2653
"BRCA1 dec exp indicates decreased expression of the Brca1 protein. However, the mechanism causing the decreased expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,2656
"BRAF W619R lies within the protein kinase domain of the Braf protein (UniProt.org). W619R has been identified in sequencing studies (PMID: 16179870), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7114,16179870,Preponderance of the oncogenic V599E and V599K mutations in the B-raf kinase domain is enhanced in melanoma lymph node metastases.,http://www.ncbi.nlm.nih.gov/pubmed/16179870,2662
"ATM P604S does not lie within any known functional domains of the Atm protein (UniProt.org). P604S has been identified in the scientific literature (PMID: 28830922, PMID: 28591191, PMID: 25846456), but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017).
",9879,28830922,Deletion of 11q in neuroblastomas drives sensitivity to PARP inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/28830922,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7878,25846456,Profiling of actionable gene alterations in ovarian cancer by targeted deep sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/25846456,295,,,www.uniprot.org,9880,28591191,Reanalysis of BRCA1/2 negative high risk ovarian cancer patients reveals novel germline risk loci and insights into missing heritability.,http://www.ncbi.nlm.nih.gov/pubmed/28591191,2664
"ATM R2459C lies within the FAT domain of the Atm protein (UniProt.org). R2459C results in lack of ATM expression in the presence of P292R (PMID: 23585524), but has not been characterized individually and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017). ",2653,23585524,ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin.,http://www.ncbi.nlm.nih.gov/pubmed/23585524,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2665
"CTNNB1 A39T does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). A39T has not been biochemically characterized however,  it is predicted to confer a gain of function to Ctnnb1 as demonstrated by nuclear accumulation of Ctnnb1 (PMID: 12474227).",295,,,www.uniprot.org,2347,12474227,Cribriform-morular variant of papillary thyroid carcinoma: a pathological and molecular genetic study with evidence of frequent somatic mutations in exon 3 of the beta-catenin gene.,http://www.ncbi.nlm.nih.gov/pubmed/12474227,2666
"CTNNB1 D32E does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). D32E results in activation of Ctnnb1, as indicated by loss of membranous Ctnnb1 expression, increased nuclear Ctnnb1 expression, and increased TCF-1 and MITF-M expression in tumor samples (PMID: 14633602, PMID: 11950921).",1241,14633602,Alterations of beta-catenin pathway in non-melanoma skin tumors: loss of alpha-ABC nuclear reactivity correlates with the presence of beta-catenin gene mutation.,http://www.ncbi.nlm.nih.gov/pubmed/14633602,1242,11950921,Loss of membranous expression of beta-catenin is associated with tumor progression in cutaneous melanoma and rarely caused by exon 3 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/11950921,2667
"CTNNB1 E55K does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). The functional effect of E55K is conflicting, as E55K has been reported in cases to lead to nuclear accumulation of Ctnnb1 and to have no effect on nuclear accumulation of Ctnnb1 protein (PMID: 10213482). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2668
CTNNB1 E67K does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). E67K confers a gain of function to the Ctnnb1 protein as demonstrated by nuclear accumulation of Ctnnb1 and association with CCND1 overexpression (PMID: 11592102).,4288,11592102,beta-catenin nuclear expression correlates with cyclin D1 overexpression in sporadic desmoid tumours.,http://www.ncbi.nlm.nih.gov/pubmed/11592102,295,,,www.uniprot.org,2669
"CTNNB1 G34E does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). G34E results in resistance of Ctnnb1 to degradation, leading to increased pathway activation (PMID: 18519687).",1243,19293793,An investigation of WNT pathway activation and association with survival in central nervous system primitive neuroectodermal tumours (CNS PNET).,http://www.ncbi.nlm.nih.gov/pubmed/19293793,3661,18519687,"Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene.",http://www.ncbi.nlm.nih.gov/pubmed/18519687,2670
"CTNNB1 G38D lies within the negative regulatory region of the Ctnnb1 protein (PMID: 11559529). G38D does not lead to nuclear Ctnnb1 expression (PMID: 10213482, PMID: 11559529), but its effect on Ctnnb1 protein function is unknown (PubMed, Mar 2017).",1244,10213482,Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/10213482,1245,11559529,Accumulation of beta-catenin protein and mutations in exon 3 of beta-catenin gene in gastrointestinal carcinoid tumor.,http://www.ncbi.nlm.nih.gov/pubmed/11559529,285,,,http://www.ncbi.nlm.nih.gov/pubmed,2671
"CTNNB1 P52H does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). P52H has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2672
"CTNNB1 W66* results in a premature truncation of the Ctnnb1 protein at amino acid 66 of 781 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), W66* is predicted to result in a loss of Ctnnb1 protein function.",295,,,www.uniprot.org,2673
"DNMT3A E664K lies within the SAM-dependent MTase C5-type domain of the Dnmt3A protein (UniProt.org). E664K has been identified in sequencing studies (PMID: 22749068), but has not been biochemically characterized and therefore, its effect on Dnmt3A protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,7328,22749068,Decreased DNA methylation in acute myeloid leukemia patients with DNMT3A mutations and prognostic implications of DNA methylation.,http://www.ncbi.nlm.nih.gov/pubmed/22749068,285,,,http://www.ncbi.nlm.nih.gov/pubmed,2674
"ATM R337H does not lie within any known functional domains of the Atm protein (UniProt.org). R337H has been identified in sequencing studies (PMID: 24997986) but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Feb 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7076,24997986,Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway.,http://www.ncbi.nlm.nih.gov/pubmed/24997986,2676
"ATM R832C does not lie within any known functional domains of the Atm protein (UniProt.org). R832C has been identified in sequencing studies (PMID: 21447618) but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Feb 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7881,21447618,Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries.,http://www.ncbi.nlm.nih.gov/pubmed/21447618,295,,,www.uniprot.org,2680
"ATM S1691R does not lie within any known functional domains of the Atm protein (UniProt.org). S1691R has been identified in the scientific literature (PMID: 16652348) but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Feb 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7889,16652348,The ATM missense mutation p.Ser49Cys (c.146C>G) and the risk of breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16652348,2681
"VHL F76S does not lie within any known functional domains of the Vhl protein (UniProt.org). F76S has been identified in the scientific literature (PMID: 18836774), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",3225,18836774,Computational detection of deleterious SNPs and their effect on sequence and structural level of the VHL gene.,http://www.ncbi.nlm.nih.gov/pubmed/18836774,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2685
"VHL H110Q lies within the CCT complex-interacting region of the Vhl protein (UniProt.org). H110Q has been identified in the scientific literature (PMID: 12781449), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Aug 2017).",1246,12781449,Expression of HIF-1 and ubiquitin in conventional renal cell carcinoma: relationship to mutations of the von Hippel-Lindau tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/12781449,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2687
VHL P154L lies within the CCT complex-binding region of the Vhl protein (UniProt.org). P154L results in a loss of Vhl binding to Tbp-1 and failure to mediate hypoxia-induced Hif1a degradation in culture (PMID: 14556007).,1247,14556007,"Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein.",http://www.ncbi.nlm.nih.gov/pubmed/14556007,295,,,www.uniprot.org,2689
"VHL P192S does not lie within any known functional domains of the Vhl protein (UniProt.org). P192S has been identified in the scientific literature (PMID: 18836774), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).
",295,,,www.uniprot.org,3225,18836774,Computational detection of deleterious SNPs and their effect on sequence and structural level of the VHL gene.,http://www.ncbi.nlm.nih.gov/pubmed/18836774,285,,,http://www.ncbi.nlm.nih.gov/pubmed,2690
"VHL P81T does not lie within any known functional domains of the Vhl protein (UniProt.org). P81T has been identified in sequencing studies (PMID: 21602815), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,7437,21602815,Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel-Lindau gene and hypoxia-inducible factor pathway-related proteins.,http://www.ncbi.nlm.nih.gov/pubmed/21602815,285,,,http://www.ncbi.nlm.nih.gov/pubmed,2691
"TP53 V218del lies in a region of the Tp53 protein that is predicted to be involved in interaction with AXIN1 (UniProt.org). V218del has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2693
"ETV6-NTRK3 is a chromosomal rearrangement that results in the fusion of the Etv6 helix-loop-helix domain to the Ntrk3 protein kinase domain (PMID: 10702799). ETV6-NTRK3 causes ligand-independent dimerization and kinase activity of the fusion protein, is transforming in cultured cells and results in tumor formation in mice (PMID: 10702799). ",1249,10702799,The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells.,http://www.ncbi.nlm.nih.gov/pubmed/10702799,2695
"EZH2 act mut indicates that this variant results in a gain of function in the EZH2 protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,2698
"GATA1 over exp indicates an over expression of the Gata1 protein. However, the mechanism causing the over expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,2700
"TP53 G245S is a hotspot mutation that lies within the DNA binding domain of the Tp53 protein (PMID: 22713868). G245S results in a loss of wild-type Tp53 transcriptional activity, and also confers a gain of function to Tp53, resulting in enhanced Akt signaling and transformation in cell culture (PMID: 20212049, PMID: 23538418).",1298,23538418,Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/23538418,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,1297,20212049,Characterization of functional domains necessary for mutant p53 gain of function.,http://www.ncbi.nlm.nih.gov/pubmed/20212049,2702
"CBL E366K lies within the linker region of the Cbl protein (UniProt.org). E366K has been identified in sequencing studies (PMID: 20678218), but has not been biochemically characterized and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7149,20678218,"Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.",http://www.ncbi.nlm.nih.gov/pubmed/20678218,2708
"CBL V391I lies within the RING finger domain of the Cbl protein (PMID: 20126411). V391I is predicted to result in a loss of function by interfering with the E3 ubiquitin ligase activity of Cbl and displays reduced ubiquitination towards a Cbl target, Egfr (PMID: 20126411, PMID: 26676746).",4519,26676746,Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26676746,1306,20126411,CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.,http://www.ncbi.nlm.nih.gov/pubmed/20126411,2709
"DNMT3A G890D lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (UniProt.org). G890D has been identified in sequencing studies (PMID: 22749068), but has not been biochemically characterized and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7328,22749068,Decreased DNA methylation in acute myeloid leukemia patients with DNMT3A mutations and prognostic implications of DNA methylation.,http://www.ncbi.nlm.nih.gov/pubmed/22749068,2710
"DNMT3A R19W does not lie within any known functional domains of the Dnmt3a protein (UniProt.org). R19W has not been characterized in the scientific literature and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2711
"DNMT3A R478Q does not lie within any known functional domains of the Dnmt3a protein (UniProt.org). R478Q has not been characterized in the scientific literature and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2712
"DNMT3A V716I lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (UniProt.org). V716I has been identified in sequencing studies (PMID: 27288520), but has not been biochemically characterized and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jul 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6946,27288520,Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27288520,2713
"DNMT3A V785M lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (UniProt.org). V785M has been identified in sequencing studies (PMID: 22490330), but has not been biochemically characterized and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jul 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5345,22490330,Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/22490330,2714
"EGFR A864V lies within the protein kinase domain of the Egfr protein (UniProt.org). A864V has been identified in the scientific literature (PMID: 25343854, PMID: 18701186, PMID: 28223509), but not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",7958,18701186,Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/18701186,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7957,25343854,High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25343854,7959,28223509,High-throughput screening of rare metabolically active tumor cells in pleural effusion and peripheral blood of lung cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/28223509,2715
"EGFR E282K lies within the Approximate repeat region of the Egfr protein (UniProt.org). E282K has not been characterized in the scientific literature and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2716
EGFR E746K lies within the protein kinase domain of the Egfr protein (UniProt.org). E746K confers a gain of function to the Egfr protein as demonstrated by increased autophosphorylation and downstream signaling in cell culture (PMID: 24743239).,295,,,www.uniprot.org,3812,24743239,Prediction and prioritization of rare oncogenic mutations in the cancer Kinome using novel features and multiple classifiers.,http://www.ncbi.nlm.nih.gov/pubmed/24743239,2717
"BRCA2 I605fs results in a change in the amino acid sequence of the Brca2 protein beginning at aa 605 of 3418 (UniProt.org). Due to the loss of multiple functional domains (UniProt.org), I605fs is predicted to lead to a loss of Brca2 protein function.",295,,,www.uniprot.org,2720
"BRCA2 L2080* results in a premature truncation of the Brca2 protein at amino acid 2080 of 3418 (UniProt.org). Due to the loss of multiple functional domains, including the DNA binding domain (UniProt.org), L2080* is predicted to lead to a loss Brca2 protein function. ",295,,,www.uniprot.org,2721
"CDKN2A G35E lies within ANK repeat 1 of the Cdkn2a protein (UniProt.org). G35E has been identified in sequencing studies (PMID: 9462707), but has not been biochemically characterized and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Feb 2017).",295,,,www.uniprot.org,7787,9462707,Mutations in the CDKN2A (p16INK4a) gene in microdissected sporadic primary melanomas.,http://www.ncbi.nlm.nih.gov/pubmed/9462707,285,,,http://www.ncbi.nlm.nih.gov/pubmed,2723
"CDKN2A M52I lies within the ANK repeat 2 of the Cdkn2a (p16NK4a) protein (UniProt.org). M52I has been identified in sequencing studies (PMID: 19593635), but has not been biochemically characterized and therefore, its effect on Cdkn2a (p16NK4a) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7163,19593635,Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/19593635,2724
CDKN2A R128W lies within ANK repeat 4 of the Cdkn2a (p16INK4a) protein (UniProt.org). R128W confers a loss of function to the Cdkn2a (p16INK4a) protein as demonstrated by a loss of Sp1 binding (PMID: 24163379). ,295,,,www.uniprot.org,5633,24163379,The cyclin-dependent kinase inhibitor p16INK4a physically interacts with transcription factor Sp1 and cyclin-dependent kinase 4 to transactivate microRNA-141 and microRNA-146b-5p spontaneously and in response to ultraviolet light-induced DNA damage.,http://www.ncbi.nlm.nih.gov/pubmed/24163379,2725
"CDKN2A V51I lies within ANK repeat 2 of the Cdkn2a protein (UniProt.org). V51I has been identified in sequencing studies (PMID: 8640773), but has not been biochemically characterized and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7794,8640773,Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/8640773,2726
"CSF1R P510L lies within the extracellular domain of the Csf1r protein (UniProt.org). P510L has not been characterized in the scientific literature and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2727
"ERBB2 (HER2) G804S lies within the protein kinase domain of the Erbb2 protein (UniProt.org). G804S has not been characterized, but is predicted to activate the kinase activity of Erbb2 (Her2) by structural modeling (PMID: 24817905).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1876,24817905,Structure-functional prediction and analysis of cancer mutation effects in protein kinases.,http://www.ncbi.nlm.nih.gov/pubmed/24817905,2728
"ERBB2 (HER2) W825* results in a premature truncation within the protein kinase domain of the Erbb2 (Her2) protein at amino acid 825 of 1255 (UniProt.org). Due to the disruption of the protein kinase domain (UniProt.org), W825* is predicted to lead to a loss of Erbb2 (Her2) protein function. ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2729
"EGFR R832H lies within the protein kinase domain of the Egfr protein (UniProt.org). R832H has not been characterized in the scientific literature and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2732
"EGFR R748I lies within the protein kinase domain of the Egfr protein (UniProt.org). R748I has not been characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2733
"EGFR P848L lies within the protein kinase domain of the Egfr protein (UniProt.org). P848L is a functionally silent mutation and results in lower autophosphorylation levels compared to activating mutation L858R (PMID: 17877814, PMID: 18573086 ).",9916,18573086,Structure-based view of epidermal growth factor receptor regulation.,http://www.ncbi.nlm.nih.gov/pubmed/18573086,1322,17877814,Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain.,http://www.ncbi.nlm.nih.gov/pubmed/17877814,295,,,www.uniprot.org,2734
"EGFR P699S lies within the region of the Egfr protein that is important for dimerization, phosphorylation, and activation (UniProt.org). P699S has been identified in the scientific literature (PMID: 16870303, PMID: 27027238), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",9193,27027238,Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27027238,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7968,16870303,Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16870303,2735
"EGFR P699L lies within the region of the Egfr protein important for dimerization, phosphorylation, and activation (UniProt.org). P699L has been identified in the scientific literature (PMID: 22722798), but has not been characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",9192,22722798,Rare and novel epidermal growth factor receptor mutations in non-small-cell lung cancer and lack of clinical response to gefitinib in two cases.,http://www.ncbi.nlm.nih.gov/pubmed/22722798,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2736
"EGFR H870Y lies within the protein kinase domain of the Egfr protein (UniProt.org). H870Y has been identified in the scientific literature (PMID: 21070477, PMID: 25862146), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",8184,25862146,PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy.,http://www.ncbi.nlm.nih.gov/pubmed/25862146,8183,21070477,Unique p53 and epidermal growth factor receptor gene mutation status in 46 pulmonary lymphoepithelioma-like carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/21070477,115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2737
"CSF1R T663I lies within the protein kinase domain of the Csf1r protein (UniProt.org). T663I has not been characterized in the scientific literature and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2759
"EGFR H850Y lies within the protein kinase domain of the Egfr protein (UniProt.org). H850Y has been identified in the scientific literature (PMID: 22426987), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8182,22426987,Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/22426987,2760
"EZH2 G159R lies with the region of the Ezh2 protein involved in interaction with DNMT1, DNMT3A, and DNMT3B (UniProt.org). G159R has been identified in sequencing studies (PMID: 24931631), but has not been biochemically characterized and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7336,24931631,The spectrum of somatic mutations in high-risk acute myeloid leukaemia with -7/del(7q).,http://www.ncbi.nlm.nih.gov/pubmed/24931631,2761
"EZH2 G660R (corresponds to G655 in the canonical isoform) lies within the SET domain of the Ezh2 protein (UniProt.org). G660R has been identified in sequencing studies (PMID: 20601953), but has not been biochemically characterized and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3332,20601953,Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders.,http://www.ncbi.nlm.nih.gov/pubmed/20601953,2762
"EZH2 Q62K lies within the region of the Ezh2 protein involved in interaction with DNMT1, DNMT3A and DNMT3B (UniProt.org). Q62K has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2763
"EZH2 R288Q lies within the region of the Ezh2 protein involved in interaction with DNMT1, DNMT3A, and DNMT3B (UniProt.org). Ezh2 has been identified in sequencing studies (PMID: 24478400), but has not been biochemically characterized and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7339,24478400,Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/24478400,2764
"EZH2 W60* results in a premature truncation of the Ezh2 protein at amino acid 60 of 746 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), W60* is predicted to lead to a loss of Ezh2 protein function.",295,,,www.uniprot.org,2765
"ERBB4 E934K lies within the protein kinase domain of the Erbb4 protein (UniProt.org). E934K has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,2766
"EZH2 N152fs*15 likely results in a truncation of the 746 aa Ezh2 protein at aa 152, followed by 15 nonsense amino acids (UniProt.org). Due to the loss of all known functional domains (UniProt.org), N152fs*15 is predicted to result in a loss of function in the Ezh2 protein.",295,,,www.uniprot.org,2767
"FBXW7 G499Vfs*25 is a missense mutation (G499V) in conjunction with a likely truncation of the 707 aa Fbxw7 protein at aa 499, followed by 25 nonsense amino acids (UniProt.org). Due to the loss of several WD domains (UniProt.org), G499Vfs*25 is predicted to lead to a loss of Fbxw7 protein function. ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2768
"FBXW7 G597E lies within the WD repeat 6 of the Fbxw7 protein (UniProt.org). G597E has been identified in sequencing studies (PMID: 23415222), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7846,23415222,Evolution and impact of subclonal mutations in chronic lymphocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23415222,295,,,www.uniprot.org,2769
"FBXW7 H420Y lies within the WD repeat 2 of the Fbxw7 protein (UniProt.org). H420Y is predicted to result in a loss of function, affecting substrate targeting in the Fbxw7 protein (PMID: 18485478).",1372,18485478,FBXW7 mutation in adult T-cell and B-cell acute lymphocytic leukemias.,http://www.ncbi.nlm.nih.gov/pubmed/18485478,295,,,www.uniprot.org,2770
BRAF L505H lies within the protein kinase domain of the Braf protein (UniProt.org). L505H confers a gain of function to the Braf protein resulting in MEK/ERK activation and oncogenic transformation (PMID: 24283590).,295,,,www.uniprot.org,1371,24283590,Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24283590,2771
"FGFR2 W290* results in a premature truncation of the Fgfr2 protein at aa 290 of 821 (UniProt.org). Due to a loss of the protein kinase domain (UniProt.org), W290* is predicted to lead to a loss of function.",295,,,www.uniprot.org,2772
"IDH1 R100* results in a premature truncation of the Idh1 protein at amino acid 100 of 414 (UniProt.org). Due to the loss of all known functional domains, R100* is predicted to lead to a loss of function (PMID: 20962861).",1373,20962861,A nonsense mutation of IDH1 in myelodysplastic syndromes and related disorders.,http://www.ncbi.nlm.nih.gov/pubmed/20962861,295,,,www.uniprot.org,2773
"IDH1 T325M does not lie within any known functional domains of the Idh1 protein (UniProt.org). T325M has not been characterized in the scientific literature and therefore, its effect on Idh1 protein function is unknown (PubMed, Jun 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2774
"GNA11 G208fs*16 likely results in a truncation of the 359 aa Gna11 protein at aa 208, followed by 16 nonsense amino acids (UniProt.org). Due to disruption of the GTPase domain (PMID: 27647839), G208fs*16 is predicted to lead to a loss of GNA11 protein function.",8759,27647839,Disorders of the calcium-sensing receptor and partner proteins: insights into the molecular basis of calcium homeostasis.,http://www.ncbi.nlm.nih.gov/pubmed/27647839,295,,,www.uniprot.org,2775
"GNA11 Y235* results in a truncation of the Gna11 protein at aa 235 of 359 (UniProt.org). Due to disruption of the GTPase domain (PMID: 27647839) , Y235* is predicted to lead to a loss of Gna11 protein function.",8759,27647839,Disorders of the calcium-sensing receptor and partner proteins: insights into the molecular basis of calcium homeostasis.,http://www.ncbi.nlm.nih.gov/pubmed/27647839,295,,,www.uniprot.org,2776
Wild-type IKZF1 indicates that no mutation has been detected within the IKZF1 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,2791
"PIK3CA D1056G lies within the PI3K/PI4K kinase domain of the Pik3ca protein (UniProt.org). D1056G has been identified in the scientific literature (PMID: 17317825), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,8030,17317825,Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17317825,295,,,www.uniprot.org,2806
"PIK3CA D350N lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). D350N has been identified in sequencing studies (PMID: 28002797), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9877,28002797,Targeted exome sequencing reveals distinct pathogenic variants in Iranians with colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28002797,2808
"PIK3CA D520V lies within the PIK helical domain of the Pik3ca protein (UniProt.org). D520V has not been characterized in the scientific literature and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2809
"PIK3CA F550S lies within the PIK helical domain of the Pik3ca protein (UniProt.org). F550S has been identified in sequencing studies (PMID: 17317825), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8030,17317825,Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17317825,2810
"PIK3CA I889M lies within the PI3K/PI4K kinase domain of the Pik3ca protein (UniProt.org). I889M has not been characterized in the scientific literature and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2811
"PIK3CA P298S does not lie within any known functional domains of the Pik3ca protein (UniProt.org). P298S has not been characterized in the scientific literature and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2812
"FGFR1 D166del (corresponds to D133 in the canonical isoform) results in the deletion of one amino acid in the Ig-like C2-type domain 2 of the Fgfr1 protein at amino acid 166 (UniProt.org). D166del has not been characterized in the scientific literature and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Jun 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2821
"TET2 Y867H does not lie within any known functional domains of the Tet2 protein (UniProt.org). Y867H has not been characterized and therefore, its effect on Tet2 protein function is unknown (PubMed, Nov 2015). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2822
"TET2 R1572Q does not lie within any known functional domains of the Tet2 protein (UniProt.org). R1572Q has not been characterized in the scientific literature and therefore, its effect on Tet2 protein function is unknown (PubMed, Nov 2015). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2823
"TET2 P1723S does not lie within any known functional domains of the Tet2 protein (UniProt.org). P1723S has not been characterized and therefore, its effect on Tet2 protein function is unknown (PubMed, Nov 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2824
"TET2 L34F does not lie within any known functional domains of the Tet2 protein (UniProt.org). L34F has not been characterized and therefore, its effect on Tet2 protein function is unknown (PubMed, Aug 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2825
"SMARCB1 P188L lies within repeat 1 and the HIV-1 integrase and MYC-binding regions of the Smarcb1 protein (UniProt.org). P188L has been identified in sequencing studies (PMID: 25769001), but has not been biochemically characterized and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8071,25769001,Mutational dichotomy in desmoplastic malignant melanoma corroborated by multigene panel analysis.,http://www.ncbi.nlm.nih.gov/pubmed/25769001,2827
"SMARCB1 E184D lies within the HIV-1 integrase-binding region of the Smarcb1 protein (UniProt.org). E184D has not been characterized in the scientific literature and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2828
"SMARCB1 E175D lies within the DNA binding region of the Smarcb1 protein (UniProt.org). E175D has not been characterized in the scientific literature and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2829
"PIK3CA D549H lies within the helical domain of the Pik3ca protein (PMID: 21829508). D549H has been identified in the scientific literature (PMID: 21667306, PMID: 22271473, PMID: 25426553), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017).",1461,21829508,PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.,http://www.ncbi.nlm.nih.gov/pubmed/21829508,1756,22271473,PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.,http://www.ncbi.nlm.nih.gov/pubmed/22271473,8059,25426553,Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience.,http://www.ncbi.nlm.nih.gov/pubmed/25426553,8058,21667306,Low frequency of PIK3CA gene mutations in hepatocellular carcinoma in Chinese population.,http://www.ncbi.nlm.nih.gov/pubmed/21667306,2831
"PIK3CA P539S lies within the PIK helical domain of the Pik3ca protein (UniProt.org). P539S has been identified in the scientific literature (PMID: 22292935), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8896,22292935,Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22292935,2832
PIK3CA Q546R lies within the helical domain of the Pik3ca protein (PMID: 24559118). Q546R confers a gain of function to Pik3ca protein as indicated by increased cell survival and transforming ability in cell culture (PMID: 26627007).,4255,26627007,Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26627007,1462,24559118,A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.,http://www.ncbi.nlm.nih.gov/pubmed/24559118,2833
"PTEN A120T lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). A120T has been identified in sequencing studies (PMID: 23633456, PMID: 25424851), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",8033,23633456,PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23633456,9904,25424851,Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.,http://www.ncbi.nlm.nih.gov/pubmed/25424851,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2834
"PTEN D252Y lies within the C2 tensin-type domain of the Pten protein (UniProt.org). D252Y leads to destabilization of the Pten protein in cell culture, resulting in decreased expression and thus, is predicted to result in a loss of Pten protein function (PMID: 17942903).",1463,17942903,In vivo functional analysis of the counterbalance of hyperactive phosphatidylinositol 3-kinase p110 catalytic oncoproteins by the tumor suppressor PTEN.,http://www.ncbi.nlm.nih.gov/pubmed/17942903,295,,,www.uniprot.org,2836
"PTEN G127R lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). G127R is predicted to confer a loss of function on the Pten protein based on behaving similar to Pten loss of function mutation, G129E (PMID: 27147599).",295,,,www.uniprot.org,6273,27147599,Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.,http://www.ncbi.nlm.nih.gov/pubmed/27147599,2837
"PTEN G156R lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). G156R has been identified in sequencing studies (PMID: 11123721), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8048,11123721,Molecular genetics of radiographically defined de novo glioblastoma multiforme.,http://www.ncbi.nlm.nih.gov/pubmed/11123721,2838
"PTEN H61P lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). H61P has been identified in sequencing studies (PMID: 10653004), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8053,10653004,Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas.,http://www.ncbi.nlm.nih.gov/pubmed/10653004,2839
"PTEN M134I lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). M134I has been identified in sequencing studies (PMID: 25527629, PMID: 23674493), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",2323,25527629,Functionally distinct groups of inherited PTEN mutations in autism and tumour syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25527629,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3345,23674493,PI3K pathway dependencies in endometrioid endometrial cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/23674493,2840
"MSH2 T1219I does not lie within any known functional domains of the Msh2 protein (UniProt.org). T1219T results in a loss of Msh2 protein function, as indicated by loss of mismatch induced conformational changes and defective DNA mismatch repair (PMID:   22277660)",295,,,www.uniprot.org,1464,22277660,Biochemical analysis of the human mismatch repair proteins hMutSα MSH2(G674A)-MSH6 and MSH2-MSH6(T1219D).,http://www.ncbi.nlm.nih.gov/pubmed/22277660,2841
"NPM1 over exp indicates an over expression of the Npm1 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,2854
"NPM1 exon12 mutations are found in AML with normal karyotype and predominantly result in a frameshift at the C-terminal, with mutation of either or both T288 and/or T290 and five new terminal residues, VSLRK. As these mutations result in the cytoplasmic location of Npm1 protein, they are also called NPM1c+ or NPMc+ (PMID: 15659725, PMID: 16076867).",1523,16076867,Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.,http://www.ncbi.nlm.nih.gov/pubmed/16076867,1522,15659725,Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.,http://www.ncbi.nlm.nih.gov/pubmed/15659725,2855
"RUNX1 R320Q (corresponds to R293Q in the canonical isoform) lies within the KAT6A-interacting region of the Runx1 protein (UniProt.org). R320Q has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2865
"PDGFRA H570Y lies within the cytoplasmic domain of the Pdgfra protein (UniProt.org). H570Y has not been characterized in the scientific literature and therefore, its effect on Pdgfra protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2869
"PDGFRA P567L lies within the cytoplasmic domain of the Pdgfra protein (UniProt.org). P567L has not been characterized in the scientific literature and therefore, its effect on Pdgfra protein function is unknown (PubMed, Aug 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2870
"KDR (VEGFR2) D717V lies within the Ig-like C2-type 7 domain of the Kdr (Vegfr2) protein (PMID: 19723655). D717V confers a gain of function to the Kdr (Vegfr2) protein, resulting in constitutive tyrosine autophosphorylation (PMID: 19723655).",217,19723655,KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/19723655,2874
"HRAS G15S does not lie within any known functional domains of the Hras protein (UniProt.org). G15S has not been characterized in the scientific literature and therefore, its effect on Hras protein function is unknown (PubMed, Mar 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2902
"IDH2 T146fs*15 likely results in a truncation of the 452 aa Idh2 protein at aa 146, followed by 15 nonsense amino acids (UniProt.org). Due to the loss of sites critical for catalysis (UniProt.org), T146fs*15 is predicted to lead to a loss of Idh2 protein function. ",295,,,www.uniprot.org,2903
JAK2 G571S lies within the protein kinase 1 domain of the Jak2 protein (UniProt.org). G571S lies next to a critical phosphorylation site and thus is predicted to result in constitutive JAK2 kinase activity in a manner similar to mutations at codon 570 (PMID: 19074595).,295,,,www.uniprot.org,1596,19074595,Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias.,http://www.ncbi.nlm.nih.gov/pubmed/19074595,2904
"JAK3 A593T lies within the protein kinase domain 1 of the Jak3 protein (UniProt.org). A593T has been identified in the scientific literature (PMID: 17252020), but has not been biochemically characterized and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8901,17252020,JAK3 mutations occur in acute megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome adults.,http://www.ncbi.nlm.nih.gov/pubmed/17252020,2905
"JAK3 Q39fs*108 likely results in a premature truncation of the 1124 aa Jak3 protein at aa 39, followed by 108 nonsense amino acids (UniProt.org). Due to a loss of all known functional domains (UniProt.org), Q39fs*108 is predicted to lead to a loss of function.",295,,,www.uniprot.org,2906
SETPB1 mutant indicates an unspecified mutation in the SETBP1 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,2908
SETBP1 D868N does not lie within any known functional domains of the Setbp1 protein (UniProt.org). D868N is predicted to result in a gain of function in the Setbp1 protein increasing leukemogenic potential and transforming cultured cells (PMID: 23832012).,1599,23832012,Somatic SETBP1 mutations in myeloid malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/23832012,295,,,www.uniprot.org,2909
SETBP1 I871T does not lie within any known functional domains of the Setbp1 protein (UniProt.org). I871T is predicted to result in a gain of function in the Setbp1 protein increasing leukemogenic potential and transforming cultured cells (PMID: 23832012).,1599,23832012,Somatic SETBP1 mutations in myeloid malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/23832012,295,,,www.uniprot.org,2910
"NOTCH1 A1634V lies within the extracellular domain of the Notch1 protein (UniProt.org). A1634V has been identified in sequencing studies (PMID: 22225590), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7067,22225590,Impact of complex NOTCH1 mutations on survival in paediatric T-cell leukaemia.,http://www.ncbi.nlm.nih.gov/pubmed/22225590,2921
"SRC over exp indicates an over expression of the Src protein. However, the mechanism causing the over expression is not specified. ",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,2936
"ATM P1054R does not lie within any known functional domains of the Atm protein (PMID: 16167060). P1054R has kinase activity equivalent to wild-type Atm in cell culture, but has been predicted to be deleterious in in-silico models (PMID: 17000706, PMID: 18573109).",1708,17000706,Search for low penetrance alleles for colorectal cancer through a scan of 1467 non-synonymous SNPs in 2575 cases and 2707 controls with validation by kin-cohort analysis of 14 704 first-degree relatives.,http://www.ncbi.nlm.nih.gov/pubmed/17000706,1709,18573109,Pathogenic ATM mutations occur rarely in a subset of multiple myeloma patients.,http://www.ncbi.nlm.nih.gov/pubmed/18573109,1707,16167060,"Relation between genetic variants of the ataxia telangiectasia-mutated (ATM) gene, drug resistance, clinical outcome and predisposition to childhood T-lineage acute lymphoblastic leukaemia.",http://www.ncbi.nlm.nih.gov/pubmed/16167060,2938
"EZH2 D146H (corresponds to D154 in the canonical isoform) lies within the DNMT1, DNMT3A and DNMT3B interaction region of the Ezh2 protein (UniProt.org). D146H has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2947
"EZH2 D176H (corresponds to D188 in the canonical isoform) lies within the DNMT1, DNMT3A and DNMT3B interaction region of the Ezh2 protein (UniProt.org). D176H has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2948
"FLT3 act mut indicates that this variant results in a gain of function in the FLT3 protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,2949
"AKT1 S246F lies within the protein kinase domain of the Akt1 protein (UniProt.org). S246F has not been characterized in the scientific literature and therefore, its effect on Akt1 protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2962
"PIK3CA C420R lies within the C2 domain of the Pik3ca protein (PMID: 17376864). C420R confers a gain of function on Pik3ca, as indicated by constitutive phosphorylation of downstream targets Akt and S6, and is transforming in cell culture (PMID: 17376864).",101,17376864,Rare cancer-specific mutations in PIK3CA show gain of function.,http://www.ncbi.nlm.nih.gov/pubmed/17376864,2964
"SMAD4 R445* results in a premature truncation of the Smad4 protein at amino acid 445 of 552 (UniProt.org). R445* has not been characterized however, due to the effects of other truncation mutations downstream of R445, R445* is predicted to lead to a loss of Smad4 protein function (PMID: 11553622, PMID: 22316667).",3668,11553622,Loss of Smad4 function in pancreatic tumors: C-terminal truncation leads to decreased stability.,http://www.ncbi.nlm.nih.gov/pubmed/11553622,295,,,www.uniprot.org,3669,22316667,Germline mutations in SMAD4 disrupt bone morphogenetic protein signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22316667,2965
"HRAS G12S lies within a GTP nucleotide binding region of the Hras protein (UniProt.org). G12S inhibits GTPase activity of Hras leading to increased activation of downstream signaling pathways promoting cell transformation (PMID: 21850009, PMID: 6330729).",1783,21850009,HRAS mutants identified in Costello syndrome patients can induce cellular senescence: possible implications for the pathogenesis of Costello syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/21850009,295,,,www.uniprot.org,1784,6330729,Analysis of the transforming potential of the human H-ras gene by random mutagenesis.,http://www.ncbi.nlm.nih.gov/pubmed/6330729,2966
"HRAS G12V lies within a GTP nucleotide binding region of the Hras protein (UniProt.org). G12V inhibits GTPase activity of Hras leading to increased activation of downstream signaling pathways promoting cell transformation (PMID: 21850009, PMID: 6330729).
",295,,,www.uniprot.org,1783,21850009,HRAS mutants identified in Costello syndrome patients can induce cellular senescence: possible implications for the pathogenesis of Costello syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/21850009,1784,6330729,Analysis of the transforming potential of the human H-ras gene by random mutagenesis.,http://www.ncbi.nlm.nih.gov/pubmed/6330729,2967
"APC V1804D does not lie within any known functional domains of the Apc protein (UniProt.org). V1804D has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2973
"BRCA1 S509G (present in isoform 3) does not lie within any known functional domains of the Brca1 protein (UniProt.org). S509G has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2975
"BRCA1 P824L (corresponds to P871 in the canonical isoform) does not lie within any known functional domains of the Brca1 protein (UniProt.org). P824L has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2976
"BRCA1 E991G (corresponds to E1038 in the canonical isoform) does not lie within any known functional domains of the Brca1 protein (UniProt.org). E991G has been identified in the scientific literature (PMID: 25653542), but has not been biochemically characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8659,25653542,Oncogenic mutation profiling in new lung cancer and mesothelioma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/25653542,2977
"BRCA1 Q309R (corresponds to Q356 in the canonical isoform) does not lie within any known functional domains of the Brca1 protein (UniProt.org). Q309R has been identified in the scientific literature (PMID: 27267837), but has not been biochemically characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,8755,27267837,BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells.,http://www.ncbi.nlm.nih.gov/pubmed/27267837,295,,,www.uniprot.org,2978
"CBL Q882H lies within the UBA domain of the Cbl protein (UniProt.org). Q882H has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2982
MPL V114M lies within the extracellular domain of the Mpl protein (UniProt.org). V114M has been described as non-pathogenic and demonstrates levels of Mpl receptor expression and TPO-dependent proliferation similar to wild-type (PMID: 16219544).,295,,,www.uniprot.org,6520,16219544,Congenital amegakaryocytic thrombocytopenia in three siblings: molecular analysis of atypical clinical presentation.,http://www.ncbi.nlm.nih.gov/pubmed/16219544,2988
"NOTCH1 amplification indicates an increased number of copies of the NOTCH1 gene. However, the mechanism causing the increase is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,2998
"ALK D1529E lies within the cytoplasmic domain of the Alk protein (UniProt.org). D1529E has been identified in sequencing studies (PMID: 26647218), but has not been biochemically characterized and therefore, its effect on Alk protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7258,26647218,Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas.,http://www.ncbi.nlm.nih.gov/pubmed/26647218,2999
"ATM D1853V does not lie within any known functional domains of the Atm protein (UniProt.org). D1853V is a common Atm polymorphism, but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PMID: 15280931, PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7884,15280931,ATM polymorphisms as risk factors for prostate cancer development.,http://www.ncbi.nlm.nih.gov/pubmed/15280931,3000
"BRCA1 Q356R lies within the ZBRK1-binding region of the Brca1 protein (PMID: 11090615). Q356R interferes with binding of Brca1 to Zbrk1, resulting in decreased Brca1-dependent repression activity of Zbrk1, and interferes with repression of ligand-independent ER-alpha transcriptional activation in cell culture (PMID: 11090615, PMID: 11493692).
",1798,11090615,"Sequence-specific transcriptional corepressor function for BRCA1 through a novel zinc finger protein, ZBRK1.",http://www.ncbi.nlm.nih.gov/pubmed/11090615,1799,11493692,BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor.,http://www.ncbi.nlm.nih.gov/pubmed/11493692,3002
"ERBB2 (HER2) P1140A lies within the cytoplasmic domain of isoform 5 of the Erbb2 (Her2) protein and corresponds to P1170A in the canonical sequence (UniProt.org). P1140A (P1170A) is a common polymorphism (PMID: 15743501), but has not been characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3573,15743501,Common ERBB2 polymorphisms and risk of breast cancer in a white British population: a case-control study.,http://www.ncbi.nlm.nih.gov/pubmed/15743501,3003
"IDH1 Y183C does not lie within any known functional domains of the Idh1 protein (UniProt.org). Y183C has not been fully biochemically characterized, but does not result in production of the oncometabolite 2HG, similar to wild-type Idh1, in cell culture (PMID: 23063752).",9221,23063752,Identification of Hedgehog pathway responsive glioblastomas by isocitrate dehydrogenase mutation.,http://www.ncbi.nlm.nih.gov/pubmed/23063752,1800,17406639,Mutation analysis of candidate genes within the 2q33.3 linkage area for familial early-onset generalised osteoarthritis.,http://www.ncbi.nlm.nih.gov/pubmed/17406639,295,,,www.uniprot.org,3009
"TP53 positive indicates the presence of the TP53 gene, mRNA, and/or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,3013
"ABL1 act mut indicates that this variant results in a gain of function in the ABL1 protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,3015
"BRCA1 K1136R (present in isoform 8) does not lie within any known functional domains of the Brca1 protein (UniProt.org). K1136R has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3016
"HRAS inact mut indicates that this variant results in a loss of function of the HRAS protein. However, the specific amino acid change has not been identified. ",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,3047
"CSF1R H362R lies within the extracellular domain of the Csf1r protein (UniProt.org). H362R is predicted to increase Csf1r binding to CSF in a homology-based model, and increases phosphorylation of JNK in cell culture (PMID: 25144241).",295,,,www.uniprot.org,1852,25144241,A functional polymorphism in CSF1R gene is a novel susceptibility marker for lung cancer among never-smoking females.,http://www.ncbi.nlm.nih.gov/pubmed/25144241,3049
"CSF1R V279M lies within the Ig-like C2-type domain 3 of the Csf1r protein (UniProt.org). V279M has been identified in sequencing studies (PMID: 23103869), but has not been biochemically characterized and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",6989,23103869,Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes.,http://www.ncbi.nlm.nih.gov/pubmed/23103869,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3050
"ERBB2 (HER2) I625V lies within the transmembrane domain of isoform 5 of the Erbb2 (Her2) protein and corresponds to I655V in the canonical isoform (UniProt.org). I625V (I655V) as not been characterized, but is predicted to stabilize Erbb2 (Her2) dimerization, resulting in receptor activation and oncogenic transformation (PMID: 18178548, PMID: 12461170)",3378,12461170,A putative molecular-activation switch in the transmembrane domain of erbB2.,http://www.ncbi.nlm.nih.gov/pubmed/12461170,1853,18178548,Spatial structure of the dimeric transmembrane domain of the growth factor receptor ErbB2 presumably corresponding to the receptor active state.,http://www.ncbi.nlm.nih.gov/pubmed/18178548,295,,,www.uniprot.org,3053
"ERBB2 (HER2) I640V lies within the transmembrane domain of isoform 4 of the Erbb2 (Her2) protein and corresponds to I655V in the canonical isoform (UniProt.org). The functional effect of I640V (I655V) is conflicting, as it is predicted to both activate Erbb2 (Her2) (PMID: 18178548) and reduce activation of Erbb2 (Her2) (PMID: 12461170).",3378,12461170,A putative molecular-activation switch in the transmembrane domain of erbB2.,http://www.ncbi.nlm.nih.gov/pubmed/12461170,1853,18178548,Spatial structure of the dimeric transmembrane domain of the growth factor receptor ErbB2 presumably corresponding to the receptor active state.,http://www.ncbi.nlm.nih.gov/pubmed/18178548,3054
"ERBB2 (HER2) I655V lies within the transmembrane domain of the Erbb2 (Her2) protein (PMID: 18178548). I655V has not been characterized, but is predicted to stabilize Erbb2 (Her2) dimerization resulting in receptor activation and oncogenic transformation (PMID: 18178548, PMID: 12461170)",3378,12461170,A putative molecular-activation switch in the transmembrane domain of erbB2.,http://www.ncbi.nlm.nih.gov/pubmed/12461170,1853,18178548,Spatial structure of the dimeric transmembrane domain of the growth factor receptor ErbB2 presumably corresponding to the receptor active state.,http://www.ncbi.nlm.nih.gov/pubmed/18178548,3055
"FGFR1 R416H lies within the juxtamembrane domain of the Fgfr1 protein (PMID: 16507368). R416H has not been characterized and therefore, its effect on Fgfr1 protein function is unknown (PubMed, May 2017).",1855,16507368,Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction.,http://www.ncbi.nlm.nih.gov/pubmed/16507368,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3057
"PDGFRA act mut indicates that this variant results in a gain of function in the PDGFRA protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,3058
"RET positive indicates the presence of the RET gene, mRNA, and/or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,3059
"APC A1492fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1492 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). A1492fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), A1492fs is predicted to reduce the ability of Apc to regulate beta-catenin.",295,,,www.uniprot.org,2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,3060
"APC A1553T does not lie within any known functional domains of the Apc protein (UniProt.org). A1553T has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3061
"ERBB4 W171* results in a premature truncation of the Erbb4 protein at amino acid 171 of 1308 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), W171* is predicted to lead to a loss of Erbb4 function.",295,,,www.uniprot.org,3062
"SMAD4 R189C does not lie within any known functional domains of the Smad4 protein (UniProt.org). R189C has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3063
"APC E128D lies within the coiled coil domain of the Apc protein (UniProt.org). E128D has been identified in sequencing studies (PMID: 24983367), but has not been biochemically characterized and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7176,24983367,Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail.,http://www.ncbi.nlm.nih.gov/pubmed/24983367,3065
"APC E1304L lies within the region of the Apc protein responsible for downregulation mediated by ubiquitination (UniProt.org). E1304L has been identified in the scientific literature (PMID: 24983367), but has not been biochemically characterized and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7176,24983367,Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail.,http://www.ncbi.nlm.nih.gov/pubmed/24983367,3066
"APC E1317Q lies within the region of the Apc protein responsible for downregulation mediated by ubiquitination (UniProt.org). E1317Q has been identified in the scientific literature (PMID: 14578138), but has not been biochemically characterized and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7810,14578138,The APC E1317Q variant in adenomatous polyps and colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14578138,3067
PIK3CA I391M lies within the C2 domain of the Pik3ca protein (UniProt.org). I391M functions in a manner similar to wild-type Pik3ca protein in cultured cells (PMID: 20530683).,1863,20530683,Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations.,http://www.ncbi.nlm.nih.gov/pubmed/20530683,295,,,www.uniprot.org,3068
"PIK3CA N1000D lies within the PI3K/PI4K kinase domain of the Pik3ca protein (UniProt.org). N1000D has not been characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3069
"FBXW7 A503T lies within the WD repeat 4 of the Fbxw7 protein (UniProt.org). A503T has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3070
"FBXW7 V265I does not lie within any known functional domains of the Fbxw7 protein (UniProt.org). V265I has been identified in sequencing studies (PMID: 21282377), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7966,21282377,"FBXW7 influences murine intestinal homeostasis and cancer, targeting Notch, Jun, and DEK for degradation.",http://www.ncbi.nlm.nih.gov/pubmed/21282377,295,,,www.uniprot.org,3071
FBXW7 W486* results in a premature truncation of the Fbxw7 protein at amino acid 486 of 707 (Uniprot.org). W486* results in a loss of function in the Fbxw7 protein and increased tumorigenesis in cultured cells (PMID: 24838835).,295,,,www.uniprot.org,1866,24838835,FBXW7 mutations in melanoma and a new therapeutic paradigm.,http://www.ncbi.nlm.nih.gov/pubmed/24838835,3072
FGFR2 R255Q lies within the extracellular domain of the Fgfr2 protein (UniProt.org). R255Q results in decreased activation of Fgfr2 downstream signaling upon Fgf2 stimulation in culture (PMID: 27323706).,7220,27323706,Ectrodactyly and Lethal Pulmonary Acinar Dysplasia Associated with Homozygous FGFR2 Mutations Identified by Exome Sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/27323706,295,,,www.uniprot.org,3073
FGFR3 G370C lies within the juxtamembrane region of the Fgfr3 protein (PMID: 12009017). G370C confers a gain of function to the Fgfr3 protein resulting in constitutive activation of the mitogen activated protein kinase (MAPK) signaling pathway (PMID: 12009017).,1806,12009017,Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization.,http://www.ncbi.nlm.nih.gov/pubmed/12009017,3074
"FLT3 V819I lies within the protein kinase domain of the Flt3 protein (UniProt.org). V819I has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3075
"NRAS G12D lies within a GTP-binding region of the Nras protein (UniProt.org). G12D results in decreased Nras GTPase activity, leading to activation of downstream signaling and transformation of cultured cells (PMID: 19075190, PMID: 25252692).",295,,,www.uniprot.org,1868,25252692,Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/25252692,547,19075190,"High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.",http://www.ncbi.nlm.nih.gov/pubmed/19075190,3076
"ATM D1963N lies within the FAT domain of the Atm protein (UniProt.org). D1963N has been identified in the scientific literature (PMID: 24983367) but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7176,24983367,Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail.,http://www.ncbi.nlm.nih.gov/pubmed/24983367,3077
"ATM T1756I does not lie within any known functional domains of the Atm protein (UniProt.org). T1756I has been identified in the scientific literature (PMID: 24983367) but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Feb 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7176,24983367,Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail.,http://www.ncbi.nlm.nih.gov/pubmed/24983367,3078
"RET fusion indicates a fusion of the RET gene, but the fusion partner is unknown.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,3079
"ROS1 fusion indicates a fusion of the ROS1 gene, but the fusion partner is unknown.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,3080
"NRAS G60R lies within a GTP-binding region of the Nras protein (UniProt.org). G60R has been identified in sequencing studies (PMID: 25148578, PMID: 19657110), but has not been biochemically characterized and therefore, its effect on Nras protein function is unknown (PubMed, Mar 2017).",8290,19657110,Recurring mutations found by sequencing an acute myeloid leukemia genome.,http://www.ncbi.nlm.nih.gov/pubmed/19657110,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7824,25148578,Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/25148578,3087
"PIK3CA N1044S lies within the PI3K/PI4K kinase domain of the Pik3ca protein (UniProt.org). N1044S has not been characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3088
"NRAS G12S lies within a GTP-binding region of the Nras protein (UniProt.org). G12S is predicted to lead to a loss of Nras function and increased pathway activation, as indicated by increased p-ERK in cell culture (PMID: 17823240).",1872,17823240,Runx1 protects hematopoietic stem/progenitor cells from oncogenic insult.,http://www.ncbi.nlm.nih.gov/pubmed/17823240,3089
"PIK3CA P539R lies within the PIK helical domain of the Pik3ca protein (UniProt.org). P539R increases the stability of the Pik3ca protein, confers a gain of function, as indicated by constitutive phosphorylation of downstream targets Akt and S6, and is transforming in cell culture (PMID: 18951408, PMID: 17376864).",1873,18951408,PIK3CA somatic mutations in breast cancer: Mechanistic insights from Langevin dynamics simulations.,http://www.ncbi.nlm.nih.gov/pubmed/18951408,101,17376864,Rare cancer-specific mutations in PIK3CA show gain of function.,http://www.ncbi.nlm.nih.gov/pubmed/17376864,295,,,www.uniprot.org,3090
"PIK3CA Q546K lies within the PIK helical domain of the Pik3ca protein (UniProt.org, PMID: 17376864). Q546K confers a gain of function to Pik3ca as indicated by constitutive phosphorylation of downstream targets Akt and S6, and is transforming in cell culture (PMID: 17376864).",295,,,www.uniprot.org,101,17376864,Rare cancer-specific mutations in PIK3CA show gain of function.,http://www.ncbi.nlm.nih.gov/pubmed/17376864,3091
"HNF1A P291S lies within the transactivation domain of the Hnf1a protein (PMID: 20132997). P291S has not been characterized and therefore, its effect on Hnf1a protein function is unknown (Pubmed, Mar 2016). ",1874,20132997,Three novel mutations in MODY and its phenotype in three different Czech families.,http://www.ncbi.nlm.nih.gov/pubmed/20132997,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3092
"PIK3CA R115* results in a premature truncation of the Pik3ca protein at amino acid 115 of 1068 (UniProt.org). Due to the loss of multiple functional domains, including the protein kinase domain (UniProt.org), R115* is predicted to lead to a loss of function.",295,,,www.uniprot.org,3093
"PIK3CA S553N lies within the PIK helical domain of the Pik3ca protein (UniProt.org). S553N has been identified in the scientific literature (PMID: 23066039, PMID: 24983367), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Jun 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7388,23066039,PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.,http://www.ncbi.nlm.nih.gov/pubmed/23066039,7176,24983367,Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail.,http://www.ncbi.nlm.nih.gov/pubmed/24983367,3094
"PIK3CA T1025I lies within the PI3K/PI4K protein kinase domain of the Pik3ca protein (UniProt.org). T1025I has been identified in sequencing studies (PMID: 25680416, PMID: 22949056), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7392,22949056,Phosphatidylinositol-3-kinase α catalytic subunit gene somatic mutations in bronchopulmonary neuroendocrine tumours.,http://www.ncbi.nlm.nih.gov/pubmed/22949056,7391,25680416,Driver gene mutations of non-small-cell lung cancer are rare in primary carcinoids of the lung: NGS study by ion Torrent.,http://www.ncbi.nlm.nih.gov/pubmed/25680416,3095
"PIK3CA Y1021F lies within the PI3K/PI4K protein kinase domain of the Pik3ca protein (UniProt.org). Y1021F has been identified in the scientific literature (PMID: 22949056, PMID: 24440717), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017).",8154,24440717,Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24440717,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7392,22949056,Phosphatidylinositol-3-kinase α catalytic subunit gene somatic mutations in bronchopulmonary neuroendocrine tumours.,http://www.ncbi.nlm.nih.gov/pubmed/22949056,3096
"PTEN E256K lies within the C2 tensin-type domain of the Pten protein (UniProt.org). E256K has been identified in sequencing studies (PMID: 20300775), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8046,20300775,PTEN mutation spectrum in breast cancers and breast hyperplasia.,http://www.ncbi.nlm.nih.gov/pubmed/20300775,3097
"PTEN K289Nfs*8 is a missense mutation (K289N) in conjunction with a likely truncation in the C2 tensin-type domain of the 403 aa Pten protein at aa 289, followed by 8 nonsense amino acids (UniProt.org). K289Nfs*8 has not been characterized, however, due to the effects of other deletion downstream of K289 (PMID: 10468583), K289Nfs*8 is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,3098
"PTEN T312I lies within the C2 tensin-type domain of the Pten protein (UniProt.org). T312I has been identified in sequencing studies (PMID: 24983367), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7176,24983367,Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail.,http://www.ncbi.nlm.nih.gov/pubmed/24983367,3099
"KIT I571V lies within the cytoplasmic domain of the Kit protein (UniProt.org). I571V has not been characterized in the scientific literature and therefore, its effect on Kit protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3100
"EGFR G721D lies within the protein kinase domain of the Egfr protein (UniProt.org). G721D has not been biochemically characterized, but is predicted to confer a gain of function on Egfr using computer models (PMID: 24817905).",1876,24817905,Structure-functional prediction and analysis of cancer mutation effects in protein kinases.,http://www.ncbi.nlm.nih.gov/pubmed/24817905,3101
"EGFR R108K lies within the extracellular domain of the Egfr protein (PMID: 17177598). R108K confers a gain of function to Egfr, as indicated by increased autophosphorylation, is transforming in cell culture, and promotes tumor formation in mouse models (PMID: 17177598).",1877,17177598,Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.,http://www.ncbi.nlm.nih.gov/pubmed/17177598,3102
"EGFR S752I lies within the protein kinase domain of the Egfr protein (UniProt.org). S752I has been identified in the scientific literature (PMID: 17409862, PMID: 25411647), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",9195,25411647,Single-Tube Mutation Scanning of The Epidermal Growth Factor Receptor Gene Using Multiplex LATE-PCR and Lights-On/Lights-Off Probes.,http://www.ncbi.nlm.nih.gov/pubmed/25411647,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9194,17409862,Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17409862,3103
"ATM F858L does not lie within any known functional domains of the Atm protein (UniProt.org). F858L has been identified in the scientific literature (PMID: 16832357) but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",7791,27311873,"Circumscribed sebaceous neoplasms: a morphological, immunohistochemical and molecular analysis.",http://www.ncbi.nlm.nih.gov/pubmed/27311873,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7885,16832357,ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles.,http://www.ncbi.nlm.nih.gov/pubmed/16832357,3104
"EGFR A289D lies within the extracellular domain of the Egfr protein (PMID: 22588883). A289D confers a gain of function to Egfr, as indicated by increased Egfr phosphorylation in cell culture (PMID: 22588883).",1887,22588883,Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/22588883,3105
"EGFR A289V lies within the extracellular domain of the Egfr protein (PMID: 17177598). A289V confers a gain of function to Egfr, as indicated by increased ligand-independent Egfr phosphorylation, and is transforming in cell culture (PMID: 17177598).",1877,17177598,Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.,http://www.ncbi.nlm.nih.gov/pubmed/17177598,3106
"EGFR A698T lies within a region of the Egfr protein important for dimerization, phosphorylation, and activation (UniProt.org). A698T has been identified in the scientific literature (PMID: 20371674), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,7943,20371674,Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance.,http://www.ncbi.nlm.nih.gov/pubmed/20371674,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3107
"EGFR A289T lies within the extracellular domain of the Egfr protein (PMID: 17177598). A289T has been identified in the scientific literature (PMID: 17177598, PMID: 26561558), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",5255,26561558,InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/26561558,1877,17177598,Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.,http://www.ncbi.nlm.nih.gov/pubmed/17177598,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3108
"EGFR A702S lies within a region of the Egfr protein important for dimerization, phosphorylation, and activation (UniProt.org). A702S has been identified in the scientific literature (PMID: 26354527), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3109
"EGFR A743T lies within the protein kinase domain of the Egfr protein (UniProt.org). A743T has been identified in the scientific literature (PMID: 18258923, PMID: 24891042), but not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7946,24891042,A comparison of epidermal growth factor receptor mutation testing methods in different tissue types in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24891042,7945,18258923,Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry.,http://www.ncbi.nlm.nih.gov/pubmed/18258923,3110
"EGFR A750P lies within the protein kinase domain of the Egfr protein (UniProt.org). A750P confers a gain of function to Egfr, as indicated by ligand-independent phosphorylation of Egfr in cell culture, and promotes tumor formation in xenograft models (PMID: 19625781).",1889,19625781,"BB, a new EGFR inhibitor, exhibits prominent anti-angiogenesis and antitumor activities.",http://www.ncbi.nlm.nih.gov/pubmed/19625781,3111
"EGFR A767V lies within the protein kinase domain of the Egfr protein (UniProt.org). A767V has been identified in the scientific literature (PMID: 26066407, PMID: 24040454), but not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7953,26066407,Next-generation sequencing for molecular diagnosis of lung adenocarcinoma specimens obtained by fine needle aspiration cytology.,http://www.ncbi.nlm.nih.gov/pubmed/26066407,295,,,www.uniprot.org,7954,24040454,Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/24040454,3112
EGFR A859T lies within the protein kinase domain of the Egfr protein (UniProt.org). A859T did not result in increased Egfr autophosphorylation and was not able to induce phosphorylation of Akt in a cell-based assay (PMID: 17877814).,1322,17877814,Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain.,http://www.ncbi.nlm.nih.gov/pubmed/17877814,295,,,www.uniprot.org,3113
"EGFR A864T lies within the protein kinase domain of the Egfr protein (UniProt.org). A864T confers a gain of function to Egfr, as indicated by ligand-independent Egfr autophosphorylation and activation of Akt and Erk in cell culture (PMID: 19147750).",295,,,www.uniprot.org,1890,19147750,Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/19147750,3114
"APC E1547K does not lie within any known functional domains of the Apc protein (UniProt.org). E1547K has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3115
"APC N1142Y lies within a region of the Apc protein responsible for downregulation mediated by ubiquitination (UniProt.org). N1142Y has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3116
"APC P1453S lies within the beta-catenin binding and downregulation region of the Apc protein (PMID: 14672538). P1453S has been identified in sequencing studies (PMID: 16906516) but has not been biochemically characterized and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",7814,16906516,Phenotype-genotype correlation: challenge of intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses.,http://www.ncbi.nlm.nih.gov/pubmed/16906516,285,,,http://www.ncbi.nlm.nih.gov/pubmed,2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,3117
APC E1397* results in a premature truncation of the Apc protein at amino acid 1397 of 2843 (UniProt.org). E1397* is predicted to confer a loss of function to the Apc protein due to the loss of the highly charged and PDZ domains (UniProt.org).,295,,,www.uniprot.org,3118
APC E1544* results in a premature truncation of the Apc protein at amino acid 1544 of 2843 (UniProt.org). E1544* is predicted to confer a loss of function to the Apc protein due to the loss of the highly charged and PDZ domains (UniProt.org).,295,,,www.uniprot.org,3119
KRAS E31K lies within a GTP nucleotide binding region of the Kras protein (UniProt.org). E31K activity is similar to wild-type Kras (PMID: 20570890).,843,20570890,Genomic and biological characterization of exon 4 KRAS mutations in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20570890,3120
APC Q1127* results in a premature truncation of the Apc protein at amino acid 1127 of 2843 (UniProt.org). Q1127* is predicted to confer a loss of function to the Apc protein due to the loss of the highly charged and PDZ domains (UniProt.org).,295,,,www.uniprot.org,3121
"BRAF A598_T599insV results in the insertion of a valine (V) in the protein kinase domain of the Braf protein between amino acids 598 and 599 (UniProt.org). A598_T599insV results in increased Braf kinase activity, increased downstream Mapk and Mek signaling, and the ability to transform cells in culture (PMID: 16501605).",1892,16501605,Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/16501605,295,,,www.uniprot.org,3123
"AKT1 E49K lies within the PH domain of the Akt1 protein (UniProt.org). E49K results in constitutive activation of Akt1, increased phosphorylation of GSK3-beta, and is transforming in cell culture (PMID: 19802009).",295,,,www.uniprot.org,1893,19802009,AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K.,http://www.ncbi.nlm.nih.gov/pubmed/19802009,3124
AKT1 F35L lies within the PH domain of the Akt1 protein (UniProt.org). F35L results in decreased Akt1 activity but had no effect on cell survival and morphogenesis in culture (PMID: 23134728). ,103,23134728,Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23134728,295,,,www.uniprot.org,3125
"AKT1 G173R lies within the protein kinase domain of the Akt1 protein (UniProt.org). G173R has not been characterized in the scientific literature and therefore, its effect on Akt1 protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3126
BRAF A598V lies within the protein kinase domain of the Braf protein (UniProt.org). A598V results in increased Braf kinase activity and downstream pathway activation (PMID: 19200582).,295,,,www.uniprot.org,1894,19200582,Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/19200582,3127
"AKT1 K179M lies within the protein kinase domain of the Akt1 protein (UniProt.org). K179M results in a loss of function in the Akt1 protein as demonstrated by the lack of kinase activity and the inability to suppress TGF-beta mediated responses (PMID: 7774014, PMID: 9005851, PMID: 16362038). ",295,,,www.uniprot.org,1895,7774014,The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase.,http://www.ncbi.nlm.nih.gov/pubmed/7774014,1896,9005851,Regulation of neuronal survival by the serine-threonine protein kinase Akt.,http://www.ncbi.nlm.nih.gov/pubmed/9005851,1897,16362038,Novel roles of Akt and mTOR in suppressing TGF-beta/ALK5-mediated Smad3 activation.,http://www.ncbi.nlm.nih.gov/pubmed/16362038,3128
"ALK F1174C lies within the protein kinase domain of the Alk protein (UniProt.org). F1174C confers a gain of function to Alk, as indicated by constitutive Alk phosphorylation in cell culture (PMID: 24509625, PMID: 22072639).",295,,,www.uniprot.org,1898,24509625,Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/24509625,1978,22072639,Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22072639,3129
"ALK F1174I lies within the protein kinase domain of the Alk protein (UniProt.org). F1174I results in ligand-independent phosphorylation of the Alk protein, activation of Erk, Stat3 pathways, and is transforming in cell culture (PMID: 23104988). ",295,,,www.uniprot.org,1899,23104988,Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/23104988,3130
"SMAD4 L529fs*17 likely results in a truncation of the 552 aa Smad4 protein at aa 529, followed by 17 nonsense amino acids within the MH2 domain of the Smad4 protein (UniProt.org). L529fs*17 has not been characterized however, due to the effects of other truncation mutations downstream of L529, L529fs*17 is predicted to lead to a loss of Smad4 protein function (PMID: 11553622, PMID: 22316667).",295,,,www.uniprot.org,3668,11553622,Loss of Smad4 function in pancreatic tumors: C-terminal truncation leads to decreased stability.,http://www.ncbi.nlm.nih.gov/pubmed/11553622,3669,22316667,Germline mutations in SMAD4 disrupt bone morphogenetic protein signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22316667,3131
"SMAD4 P356S lies within the MH2 domain of the Smad4 protein (UniProt.org). P356S has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3132
"SMAD4 Q334* results in a premature truncation of the Smad4 protein at amino acid 334 of 552 (UniProt.org). Due to the loss of the C-terminal domain, Q334* is predicted to lead to a loss of Smad4 function (PMID: 9331080).",1900,9331080,Inactivation of Smad4 in gastric carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/9331080,295,,,www.uniprot.org,3133
"BRAF D587A lies within the protein kinase domain of the Braf protein (UniProt.org). D587A has been identified in sequencing studies (PMID: 14500346), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7099,14500346,BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair.,http://www.ncbi.nlm.nih.gov/pubmed/14500346,3134
"BRAF D578E lies within the protein kinase domain of the Braf protein (UniProt.org). D587E has been identified in sequencing studies (PMID: 15935100), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Jun 2017).",7100,15935100,Preponderance of the oncogenic V599E and V599K mutations in B-raf kinase domain is enhanced in melanoma cutaneous/subcutaneous metastases.,http://www.ncbi.nlm.nih.gov/pubmed/15935100,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3135
"BRAF F595S lies within the protein kinase domain of the Braf protein (UniProt.org). F595S has been identified in sequencing studies (PMID: 15331929), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7101,15331929,B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome.,http://www.ncbi.nlm.nih.gov/pubmed/15331929,3136
"BRAF G464R (also reported as G463R) lies within the protein kinase domain of the Braf protein (UniProt.org). G464R results in increased Braf kinase activity, and increased downstream Erk signaling (PMID: 15046639).",1166,15046639,Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis.,http://www.ncbi.nlm.nih.gov/pubmed/15046639,295,,,www.uniprot.org,3137
"BRAF G469S is a hotspot mutation within the protein kinase domain of the Braf protein (UniProt.org). G469S has not been characterized, however other mutations at this codon are activating thus G469S is predicted to result in a gain of function (PMID: 19010912, PMID: 12068308).",295,,,www.uniprot.org,636,19010912,Genetic predictors of MEK dependence in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19010912,637,12068308,Mutations of the BRAF gene in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/12068308,3138
BRAF G596D lies within the protein kinase domain of the Braf protein (UniProt.org). G596D results in decreased Braf kinase activity in cell culture (PMID: 28783719),295,,,www.uniprot.org,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,3139
"BRAF G606E lies within the protein kinase domain of the Braf protein (UniProt.org). G606E has been identified in sequencing studies (PMID: 15331929), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7101,15331929,B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome.,http://www.ncbi.nlm.nih.gov/pubmed/15331929,3140
"BRAF H608R lies within the protein kinase domain of the Braf protein (UniProt.org). H608R has been identified in sequencing studies (PMID: 15331929), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7101,15331929,B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome.,http://www.ncbi.nlm.nih.gov/pubmed/15331929,3141
"BRAF I582M lies within the protein kinase domain of the Braf protein (UniProt.org). I582M has been identified in sequencing studies (PMID: 15331929), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7101,15331929,B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome.,http://www.ncbi.nlm.nih.gov/pubmed/15331929,3142
"BRAF I592M lies within the protein kinase domain of the Braf protein (UniProt.org). I592M has been identified in sequencing studies (PMID: 15331929), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7101,15331929,B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome.,http://www.ncbi.nlm.nih.gov/pubmed/15331929,3143
"BRAF I592V lies within the protein kinase domain of the Braf protein (UniProt.org). I592V has been identified in sequencing studies (PMID: 15331929), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Jun 2017).",7101,15331929,B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome.,http://www.ncbi.nlm.nih.gov/pubmed/15331929,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3144
"FGFR2 fusion indicates a fusion of the FGFR2 gene, but the fusion partner is unknown.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,3145
"APC R1450* results in a premature truncation of the Apc protein at amino acid 1450 of 2843 (UniProt.org). Due to the loss of the highly charged and PDZ-binding domains (UniProt.org), R1450* is predicted to lead to a loss of function.",295,,,www.uniprot.org,3146
"BRAF K601del results in the deletion of an amino acid in the protein kinase domain of the Braf protein at amino acid 601 (UniProt.org). K601del has been identified in sequencing studies (PMID: 19152441), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7105,19152441,High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes.,http://www.ncbi.nlm.nih.gov/pubmed/19152441,295,,,www.uniprot.org,3148
"BRAF L584F lies within the protein kinase domain of the Braf protein (UniProt.org). L584F has been identified in the scientific literature (PMID: 23658559), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Jun 2017).",7106,23658559,Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/23658559,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3150
"APC T1488fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1488 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). T1488fs has not been characterized, however Apc truncations downstream of T1488 are inactivating (PMID: 18199528) thus, T1488fs is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,3151
"BRAF P453T does not lie within any known functional domains of the Braf protein (UniProt.org). P453T has been identified in sequencing studies (PMID: 16404419), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7110,16404419,BRAF mutations and phosphorylation status of mitogen-activated protein kinases in the development of flat and depressed-type colorectal neoplasias.,http://www.ncbi.nlm.nih.gov/pubmed/16404419,295,,,www.uniprot.org,3152
"BRAF R444W does not lie within any known functional domains of the Braf protein (UniProt.org). R444W has been identified in sequencing studies (PMID: 15578519), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Jun 2017).",7111,15578519,BRAF mutations distinguish anorectal from cutaneous melanoma at the molecular level.,http://www.ncbi.nlm.nih.gov/pubmed/15578519,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3153
"BRAF R603* results in a premature truncation within the protein kinase domain of the Braf protein at amino acid 603 of 766 (UniProt.org, PMID: 11032810). Due to the loss of the protein kinase domain (UniProt.org, PMID: 11032810), R603* is predicted to lead to a loss of function.",295,,,www.uniprot.org,1908,11032810,Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601.,http://www.ncbi.nlm.nih.gov/pubmed/11032810,3155
"AKT1 D323H lies within the protein kinase domain of the Akt1 protein (UniProt.org). D323H results in a gain of function of the Akt1 protein as indicated by increased kinase activity, constitutive downstream signaling, transformation of cultured cells, and tumor growth in xenograft models (PMID: 23134728).",103,23134728,Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23134728,295,,,www.uniprot.org,3157
"BRAF S605F lies within the protein kinase domain of the Braf protein (UniProt.org). S605F has been identified in sequencing studies (PMID: 15331929), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7101,15331929,B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome.,http://www.ncbi.nlm.nih.gov/pubmed/15331929,3158
AKT1 I19E lies within the PH domain of the Akt1 protein (UniProt.org). I19E has no effect on kinase activity of the Akt1 protein in cell culture (PMID: 23134728).,103,23134728,Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23134728,295,,,www.uniprot.org,3159
"AKT1 K189N lies within the protein kinase domain of the Akt1 protein (UniProt.org). K189N confers a gain of function to the Akt1 protein as demonstrated by increased kinase activity, constitutive downstream signaling, and transformation in cell culture (PMID: 23134728).",103,23134728,Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23134728,295,,,www.uniprot.org,3160
AKT1 L321A lies within the protein kinase domain of the Akt1 protein (UniProt.org). L321A confers a gain of function to the Akt1 protein as demonstrated by increased kinase activity and promotion of survival in cell culture (PMID: 23134728).,103,23134728,Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23134728,295,,,www.uniprot.org,3161
"BRAF S605G lies within the protein kinase domain of the Braf protein (UniProt.org). S605G has been identified in sequencing studies (PMID: 16773193, PMID: 20635392), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7112,16773193,The oncogenic B-raf V599E mutation occurs more frequently in melanomas at sun-protected body sites.,http://www.ncbi.nlm.nih.gov/pubmed/16773193,3162
"AKT1 L52R lies within the PH domain of the Akt1 protein (UniProt.org). L52R confers a gain of function to the Akt1 protein as demonstrated by increased kinase activity and downstream signaling, and is transforming in cell culture and xenograft models (PMID: 23134728, PMID: 23237847, PMID: 27147599).",6273,27147599,Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.,http://www.ncbi.nlm.nih.gov/pubmed/27147599,103,23134728,Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23134728,295,,,www.uniprot.org,1909,23237847,Functional analysis of non-hotspot AKT1 mutants found in human breast cancers identifies novel driver mutations: implications for personalized medicine.,http://www.ncbi.nlm.nih.gov/pubmed/23237847,3163
AKT1 Q59E lies within the PH domain of the Akt1 protein (UniProt.org). Q59E demonstrated kinase activity comparable to wild-type Akt1 protein in cell culture (PMID: 23134728).,103,23134728,Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23134728,295,,,www.uniprot.org,3164
"AKT1 Q79K lies within the PH domain of the Akt1 protein (UniProt.org). Q79K results in increased Akt1 kinase activity, downstream signaling, and is transforming in cell culture (PMID: 23134728, PMID: 23237847).",1909,23237847,Functional analysis of non-hotspot AKT1 mutants found in human breast cancers identifies novel driver mutations: implications for personalized medicine.,http://www.ncbi.nlm.nih.gov/pubmed/23237847,103,23134728,Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23134728,295,,,www.uniprot.org,3165
AKT1 F55Y lies within the PH domain of the Akt1 protein (UniProt.org). F55Y confers a gain of function to the Akt1 protein as indicated by increased kinase activity and promotion of survival in cell culture (PMID: 23134728).,103,23134728,Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23134728,295,,,www.uniprot.org,3166
AKT1 R200A lies within the protein kinase domain of the Akt1 protein (UniProt.org). R200A demonstrated kinase activity comparable to wild-type Akt1 protein in cell culture (PMID: 23134728).,103,23134728,Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23134728,295,,,www.uniprot.org,3167
AKT1 T195I lies within the protein kinase domain of the Akt1 protein (UniProt.org). T195I confers a gain of function to the Akt1 protein as demonstrated by increased autophosphorylation and promotion of factor-independent cell survival in culture (PMID: 23134728).,103,23134728,Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23134728,295,,,www.uniprot.org,3168
EGFR A871G lies within the protein kinase domain of the Egfr protein (UniProt.org). A871G results in increased Egfr activity in cell culture (PMID: 26146591).,7963,26146591,Proteomic analysis of HEK293 cells expressing non small cell lung carcinoma associated epidermal growth factor receptor variants reveals induction of heat shock response.,http://www.ncbi.nlm.nih.gov/pubmed/26146591,295,,,www.uniprot.org,3169
"EGFR A871T lies within the protein kinase domain of the Egfr protein (UniProt.org). A871T has been identified in the scientific literature (PMID: 25552401, PMID: 25343854, PMID: 16870303), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,7957,25343854,High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25343854,7968,16870303,Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16870303,7967,25552401,Phase I/II study of gefitinib (Iressa(®)) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25552401,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3170
"EGFR C775Y lies within the protein kinase domain of the Egfr protein (UniProt.org). C775Y has been identified in the scientific literature (PMID: 21087480, PMID: 26462025), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,7973,26462025,Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26462025,7972,21087480,Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/21087480,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3171
"BRAF S605N lies within the protein kinase domain of the Braf protein (UniProt.org). S605N has been identified in sequencing studies (PMID: 15331929), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7101,15331929,B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome.,http://www.ncbi.nlm.nih.gov/pubmed/15331929,3172
"BRAF T599I (also reported as T598I) lies within the protein kinase domain of the Braf protein (UniProt.org). T599I results in increased Braf kinase activity, and increased downstream Erk signaling (PMID: 15035987). ",295,,,www.uniprot.org,146,15035987,Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.,http://www.ncbi.nlm.nih.gov/pubmed/15035987,3174
"BRAF T599_V600insT results in the insertion of a threonine (T) in the protein kinase domain of the Braf protein between amino acids 599 and 600 (UniProt.org). T599_V600insT results in increased Braf kinase activity, and increased downstream Erk signaling (PMID: 21190184).",1910,21190184,Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma.,http://www.ncbi.nlm.nih.gov/pubmed/21190184,295,,,www.uniprot.org,3175
"BRAF T599_V600insTT results in the insertion of two threonines (T) in the protein kinase domain of the Braf protein between amino acids 599 and 600 (UniProt.org). T599_V600insTT results in increased Braf kinase activity, and increased downstream Erk signaling (PMID: 21190184).",1910,21190184,Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma.,http://www.ncbi.nlm.nih.gov/pubmed/21190184,295,,,www.uniprot.org,3176
"BRAF V471F lies within the protein kinase domain of the Braf protein (UniProt.org). V471F results in a loss of Braf kinase activity, however, results in dimerization-dependent activation of Erk signaling and is weakly transforming in cultured cells (PMID: 25348715).",1911,25348715,Kinase regulation by hydrophobic spine assembly in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25348715,295,,,www.uniprot.org,3177
"BRAF V600A (previously reported as V599) lies within the activation segment of the kinase domain of the Braf protein (PMID: 15035987). V600A results in phosphorylated Mek protein levels similar to wild-type Braf and therefore, is predicted to have no effect on Braf protein function (PMID: 26744778).",9739,26744778,The yin-yang of kinase activation and unfolding explains the peculiarity of Val600 in the activation segment of BRAF.,http://www.ncbi.nlm.nih.gov/pubmed/26744778,146,15035987,Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.,http://www.ncbi.nlm.nih.gov/pubmed/15035987,3178
"BRAF V600delinsYM results in a deletion of valine (V) at amino acid 600 within the protein kinase domain of the Braf protein, combined with the insertion of a tyrosine (Y) and a methionine (M) at the same site (UniProt.org). V600delinsYM results in increased Braf kinase activity, increased downstream signaling, and the ability to transform cells in culture (PMID: 22752848).",295,,,www.uniprot.org,1912,22752848,"Functional characterization of the novel BRAF complex mutation, BRAF(V600delinsYM) , identified in papillary thyroid carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/22752848,3179
"APC R876* results in a premature truncation of the Apc protein at amino acid 876 of 2843 (UniProt.org). Due to the loss of several known functional domains (UniProt.org, PMID: 17881494), R876* is predicted to lead to a loss of function.",295,,,www.uniprot.org,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,3180
"APC R858* results in a premature truncation of the Apc protein at amino acid 858 of 2843 (UniProt.org). Due to the loss of several known functional domains (UniProt.org, PMID: 17881494), R858* is predicted to lead to a loss of function.",295,,,www.uniprot.org,1921,17881494,Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.,http://www.ncbi.nlm.nih.gov/pubmed/17881494,3181
"BRAF V600L (previously reported as V599) lies within the activation segment of the kinase domain of the Braf protein (PMID: 15035987). V600L has not been characterized, however, other V600 mutations are activating (PMID: 15035987) and therefore, V600L is predicted to result in a gain of Braf protein function. ",146,15035987,Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.,http://www.ncbi.nlm.nih.gov/pubmed/15035987,3182
"BRAF V600Q (previously reported as V599) lies within the activation segment of the kinase domain of the Braf protein (PMID: 15035987). V600Q has not been characterized, however, other V600 mutations are activating (PMID: 15035987) and therefore, V600Q is predicted to result in a gain of Braf protein function. ",146,15035987,Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.,http://www.ncbi.nlm.nih.gov/pubmed/15035987,3183
"BRAF W450* results in a premature truncation the Braf protein at amino acid 450 of 766 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), R450* is predicted to lead to a loss of function.",295,,,www.uniprot.org,3184
"BRAF W604del results in the deletion of an amino acid in the protein kinase domain of the Braf protein at amino acid 604 (UniProt.org). W604del has been identified in sequencing studies (PMID: 15513360), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7113,15513360,Mutational activation of the RAS-RAF-MAPK and the Wnt pathway in small intestinal adenocarcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/15513360,295,,,www.uniprot.org,3185
AKT1 D325A lies within the protein kinase domain of the Akt1 protein (UniProt.org). D325A confers a gain of function to the Akt1 protein as demonstrated by increased kinase activity and promotion of survival in cell culture (PMID: 23134728).,103,23134728,Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23134728,295,,,www.uniprot.org,3187
AKT1 E191A lies within the protein kinase domain of the Akt1 protein (UniProt.org). E191A is predicted to confer a gain of function to the Akt1 protein as demonstrated by increased cell proliferation (PMID: 23134728).,103,23134728,Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23134728,295,,,www.uniprot.org,3188
AKT1 L202F lies within the protein kinase domain of the Akt1 protein (UniProt.org). L202F demonstrated kinase activity comparable to wild-type Akt1 protein in cell culture (PMID: 23134728).,103,23134728,Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23134728,295,,,www.uniprot.org,3189
AKT1 L362R lies within the protein kinase domain of the Akt1 protein (UniProt.org). L362R demonstrated kinase activity comparable to wild-type Akt1 protein in cell culture (PMID: 23134728).,103,23134728,Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23134728,295,,,www.uniprot.org,3190
AKT1 L78T lies within the PH domain of the Akt1 protein (UniProt.org). L78T is predicted to confer a gain of function to the Akt1 protein as indicated by increase cell proliferation in culture (PMID: 23134728).,103,23134728,Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23134728,295,,,www.uniprot.org,3191
AKT1 N53A lies within the PH domain of the Akt1 protein (UniProt.org). N53A is predicted to confer a gain of function to the Akt1 protein as indicated by increased cell proliferation in culture (PMID: 23134728).,103,23134728,Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23134728,295,,,www.uniprot.org,3192
AKT1 Q79E lies within the PH domain of the Akt1 protein (UniProt.org). Q79E is predicted to confer a gain of function to the Akt1 protein as indicated by increased cell proliferation in culture (PMID: 23134728).,103,23134728,Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23134728,295,,,www.uniprot.org,3193
AKT1 R23A lies within the PH domain of the Akt1 protein (UniProt.org). R23A is predicted to confer a gain of function to the Akt1 protein as indicated by increased cell proliferation (PMID: 23134728).,103,23134728,Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23134728,295,,,www.uniprot.org,3194
AKT1 R328A lies within the protein kinase domain of the Akt1 protein (UniProt.org). R328A is predicted to confer a gain of function to the Akt1 protein as indicated by increase cell proliferation in culture (PMID: 23134728).,103,23134728,Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23134728,295,,,www.uniprot.org,3195
AKT1 V270A lies within the protein kinase domain of the Akt1 protein (UniProt.org). V270A is predicted to confer a gain of function to the Akt1 protein as indicated by increase cell proliferation in culture (PMID: 23134728).,103,23134728,Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23134728,295,,,www.uniprot.org,3196
AKT1 V271A lies within the protein kinase domain of the Akt1 protein (UniProt.org). V271A is predicted to confer a gain of function to the Akt1 protein as indicated by increased cell proliferation in culture (PMID: 23134728).,103,23134728,Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23134728,295,,,www.uniprot.org,3197
AKT1 Y18S lies within the PH domain of the Akt1 protein (UniProt.org). Y18S demonstrated kinase activity comparable to wild-type Akt1 protein in cell culture (PMID: 23134728).,103,23134728,Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23134728,295,,,www.uniprot.org,3198
AKT1 W80A lies within the PH domain of the Akt1 protein (UniProt.org). W80A results in increased Akt1 kinase activity and downstream signaling upon growth factor stimulation in cell culture (PMID: 18669636).,1928,18669636,Use of Akt inhibitor and a drug-resistant mutant validates a critical role for protein kinase B/Akt in the insulin-dependent regulation of glucose and system A amino acid uptake.,http://www.ncbi.nlm.nih.gov/pubmed/18669636,295,,,www.uniprot.org,3199
SMO A324T lies within helical domain 3 of the Smo protein (UniProt.org). A324T has activity similar to wild-type Smo in cultured cells (PMID: 17287906).,5529,17287906,Smoothened gene mutations found in digestive cancer have no aberrant Hedgehog signaling activity.,http://www.ncbi.nlm.nih.gov/pubmed/17287906,295,,,www.uniprot.org,3215
"SMO C169G lies within the FZ domain of the Smo protein (UniProt.org). C169G has not been characterized in the scientific literature and therefore, its effect on Smo protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3216
"SMO P634L lies within the cytoplasmic domain of the Smo protein (UniProt.org). P634L has not been characterized in the scientific literature and therefore, its effect on Smo protein function is unknown (PubMed, Jun 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3217
PIK3CA R88Q lies within the PI3K-ABD domain of the Pik3ca protein (UniProt.org). R88Q confers a gain of function to the Pik3ca protein as indicated by increased phosphorylation of downstream targets Akt and S6 (PMID: 18829572). ,295,,,www.uniprot.org,1933,18829572,PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.,http://www.ncbi.nlm.nih.gov/pubmed/18829572,3218
"KIT V530I lies within the transmembrane domain of the Kit protein (PMID: 16081693). V530I confers a gain of function on Kit, as indicated by constitutive phosphorylation of Kit and activation of Akt, MAPK, Stat3, and Stat5 in cell culture (PMID: 16081693).",1934,16081693,"Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate.",http://www.ncbi.nlm.nih.gov/pubmed/16081693,3219
"NRAS Q61R is a ""hotspot"" mutation within a GTP-binding region of the Nras protein (UniProt.org). Q61R results in a loss of Nras GTPase function, leading to activation of downstream pathway signaling (PMID: 18814281).",1935,18814281,Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro.,http://www.ncbi.nlm.nih.gov/pubmed/18814281,3220
NOTCH1 G661S lies within the EGF-like 17 calcium-binding domain of the Notch1 protein (UniProt.org). G661S confers a loss of function to the Notch1 protein resulting in impaired ligand dependent Notch1 activation and reduced Notch1 signaling pathway activation (PMID: 20951801).,295,,,www.uniprot.org,1937,20951801,NOTCH1 missense alleles associated with left ventricular outflow tract defects exhibit impaired receptor processing and defective EMT.,http://www.ncbi.nlm.nih.gov/pubmed/20951801,3229
"TP53 R249S is a hotspot mutation within the DNA-binding domain of the Tp53 protein (PMID: 22713868). R249S results in decreased  DNA binding and transactivation activity of Tp53, and confers context-dependent transforming ability in cell culture (PMID: 20212049, PMID: 20538734).",2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,1936,20538734,Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein.,http://www.ncbi.nlm.nih.gov/pubmed/20538734,1297,20212049,Characterization of functional domains necessary for mutant p53 gain of function.,http://www.ncbi.nlm.nih.gov/pubmed/20212049,3231
"SMO R199W lies within the NH2-terminal region of the Smo protein (PMID: 9581815). R199W has been identified in sequencing studies (PMID: 15656799), but has not been biochemically characterized and therefore, its effect on Smo protein function is unknown (PubMed, Jan 2017).
",1940,9581815,Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system.,http://www.ncbi.nlm.nih.gov/pubmed/9581815,7453,15656799,"Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/15656799,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3233
"RET M918T lies within the kinase domain of the Ret protein (PMID: 17102091). M918T confers a gain of function on Ret, as indicated by ligand-independent autophosphorylation and increased substrate binding, and is transforming in culture (PMID: 17108110). ",1941,17108110,Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B.,http://www.ncbi.nlm.nih.gov/pubmed/17108110,1942,17102091,Molecular implications of RET mutations for pheochromocytoma risk in multiple endocrine neoplasia 2.,http://www.ncbi.nlm.nih.gov/pubmed/17102091,3234
SMO T640A lies within the cytoplasmic domain of the Smo protein (UniProt.org). T640A has activity similar to wild-type Smo in cultured cells (PMID: 17287906).,295,,,www.uniprot.org,5529,17287906,Smoothened gene mutations found in digestive cancer have no aberrant Hedgehog signaling activity.,http://www.ncbi.nlm.nih.gov/pubmed/17287906,3235
SMO V404M lies within a helical transmembrane domain of the Smo protein (UniProt.org). V404M has activity similar to wild-type Smo in cultured cells (PMID: 17287906).,295,,,www.uniprot.org,5529,17287906,Smoothened gene mutations found in digestive cancer have no aberrant Hedgehog signaling activity.,http://www.ncbi.nlm.nih.gov/pubmed/17287906,3236
"EGFR H988P lies within the cytoplasmic domain of the Egfr protein (UniProt.org). H988P has not been characterized, however, computer models have predicted it interferes with Egfr dimerization (PMID: 20049516).",295,,,www.uniprot.org,1943,20049516,Investigating the function of three non-synonymous SNPs in EGFR gene: structural modelling and association with breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20049516,3238
KDR (VEGFR2) V297I lies within the extracellular domain of the Kdr protein (UniProt.org). V297I had no effect on Kdr phosphorylation levels in cell culture (PMID: 21712447).,295,,,www.uniprot.org,20,21712447,Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21712447,3242
"ERBB2 (HER2) P1155A lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). P1155A has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3243
"EGFR D761G lies within the protein kinase domain of the Egfr protein (UniProt.org). D761G has not been characterized in the scientific literature and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3244
"EGFR D761N lies within the protein kinase domain of the Egfr protein (PMID: 19147750). D761N confers a gain of function to Egfr, as indicated by ligand-independent autophosphorylation and increased activation of downstream targets, and is transforming in cell culture (PMID: 19147750).",1890,19147750,Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/19147750,3245
"EGFR W731* results in a premature truncation in the protein kinase domain of the Egfr protein at amino acid 731 of 1210 (UniProt.org). Due to a loss of the protein kinase domain (UniProt.org, PMID: 15623594), W731* is predicted to lead to a loss of function.",1944,15623594,High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.,http://www.ncbi.nlm.nih.gov/pubmed/15623594,295,,,www.uniprot.org,3246
"EGFR D770N lies within the protein kinase domain of the Egfr protein (UniProt.org). D770N has been identified in the scientific literature (PMID: 23371856), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",3320,23371856,"EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.",http://www.ncbi.nlm.nih.gov/pubmed/23371856,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3247
"EGFR V786M lies within the protein kinase domain of the Egfr protein (UniProt.org). V786M has been identified in the scientific literature (PMID: 18379371, PMID: 24406864), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017). ",9202,24406864,High EGFR gene copy number predicts poor outcome in triple-negative breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24406864,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9203,18379371,Long-lasting complete remission with tyrosine kinase inhibitor in bronchioloalveolar carcinoma with a so far unknown EGFR mutation.,http://www.ncbi.nlm.nih.gov/pubmed/18379371,3248
"EGFR V769L lies within the protein kinase domain of the Egfr protein (UniProt.org). V769L has not been biochemically characterized, but is associated with resistance to EGFR inhibitors (PMID: 18588508).",4838,18588508,Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations.,http://www.ncbi.nlm.nih.gov/pubmed/18588508,295,,,www.uniprot.org,3249
"EGFR D770_N771insG results in the insertion of a glycine (G) in the protein kinase domain of the Egfr protein between amino acids 770 and 771 (UniProt.org). D770_N771insG has not been characterized, but can be predicted to result in a gain of function based on the effect of other Egfr exon 20 insertions (PMID: 16187797).",295,,,www.uniprot.org,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,3250
"EGFR V765M lies within the protein kinase domain of the Egfr protein (UniProt.org). V765M has been identified in the scientific literature (PMID: 25343854, PMID: 21070477), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017). ",295,,,www.uniprot.org,7957,25343854,High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25343854,8183,21070477,Unique p53 and epidermal growth factor receptor gene mutation status in 46 pulmonary lymphoepithelioma-like carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/21070477,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3251
"EGFR E709A lies within the cytoplasmic domain of the Egfr protein (UniProt.org). E709A confers a gain of function to Egfr, as indicated by constitutive autophosphorylation and activation of downstream signaling in cell culture (PMID: 19671738).",295,,,www.uniprot.org,1878,19671738,Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations.,http://www.ncbi.nlm.nih.gov/pubmed/19671738,3252
EGFR V742A lies within the protein kinase domain of the Egfr protein (UniProt.org). V742A is an activating mutation resulting in growth factor independent cell proliferation (PMID: 19147750).,295,,,www.uniprot.org,1890,19147750,Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/19147750,3253
"EGFR E709G lies within the cytoplasmic domain of the Egfr protein (UniProt.org). E709G confers a gain of function to Egfr, as indicated by constitutive Egfr phosphorylation in cell culture (PMID: 16205628).",295,,,www.uniprot.org,1945,16205628,Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16205628,3254
"EGFR V738G lies within the protein kinase domain of the Egfr protein (UniProt.org). V738G has not been characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3255
"EGFR E709H lies within the cytoplasmic domain of the Egfr protein (UniProt.org). E709H has been identified in the scientific literature (PMID: 17409929, PMID: 15604253), but not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7977,15604253,Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/15604253,295,,,www.uniprot.org,7976,17409929,PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/17409929,3256
"EGFR T751_I759del results in the deletion of nine amino acids in the protein kinase domain of the Egfr protein from amino acids 751 to 759. T751_I759del has not been characterized, however similar Egfr exon 19 deletions are activating, thus T751_I759del is predicted to lead to a gain of function (PMID: 16373402, PMID: 23387505).",441,23387505,Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/23387505,1804,16373402,Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16373402,295,,,www.uniprot.org,3257
"EGFR S784P lies within the protein kinase domain of the Egfr protein (UniProt.org). S784P has not been characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3258
"EGFR S784F lies within the protein kinase domain of the Egfr protein (UniProt.org). S784F results in constitutive Egfr phosphorylation and activation of downstream signaling, and is transforming in cultured cells (PMID: 19147750).",1890,19147750,Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/19147750,295,,,www.uniprot.org,3259
"EGFR E709K lies within the cytoplasmic domain of the Egfr protein (UniProt.org). E709K confers a gain of function to Egfr, as indicated by increased Egfr phosphorylation in patient samples, and is transforming in cell culture (PMID: 19726454).",1946,19726454,Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/19726454,295,,,www.uniprot.org,3260
"EGFR E709V lies within the cytoplasmic domain of the Egfr protein (UniProt.org). E709V has been identified in the scientific literature (PMID: 18036700, PMID: 22776705, PMID: 23242437), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",7987,22776705,An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting.,http://www.ncbi.nlm.nih.gov/pubmed/22776705,7986,18036700,ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/18036700,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7985,23242437,Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/23242437,295,,,www.uniprot.org,3261
ALK F1174V lies within the protein kinase domain of the Alk protein (UniProt.org). F1174V results in constitutive activation of the Alk protein in cell culture (PMID: 21242967).,1947,21242967,The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking.,http://www.ncbi.nlm.nih.gov/pubmed/21242967,295,,,www.uniprot.org,3262
EGFR H870R lies within the protein kinase domain of the Egfr protein (UniProt.org). H870R results in constitutive phosphorylation of Egfr and activation of downstream signaling in cell culture (PMID: 19671738).,295,,,www.uniprot.org,1878,19671738,Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations.,http://www.ncbi.nlm.nih.gov/pubmed/19671738,3267
"EGFR I821T lies within the protein kinase domain of the Egfr protein (UniProt.org). I821T has been identified in the scientific literature (PMID: 26046796), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,8193,26046796,"Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial.",http://www.ncbi.nlm.nih.gov/pubmed/26046796,295,,,www.uniprot.org,3268
"EGFR H773_V774insNPH results in the insertion of three amino acids in the protein kinase domain of the Egfr protein between amino acids 773 and 774 (UniProt.org). H773_V774insNPH has not been characterized, however other exon 20 insertion mutations are activating, thus H773_V774insNPH is predicted to result in a gain of function (PMID: 24353160).",295,,,www.uniprot.org,440,24353160,"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24353160,3269
"EGFR K745R lies within the protein kinase domain of the Egfr protein (UniProt.org). K745R has been identified in the scientific literature (PMID: 16324836), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8194,16324836,Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/16324836,3270
"EGFR K745_E749del results in the deletion of five amino acids in the protein kinase domain of the Egfr protein from amino acids 745 to 749 (UniProt.org). K745_E749del has not been characterized, however other exon 19 deletion mutations in the Egfr protein are activating, thus K745_E749del is predicted to result in a gain of function (PMID: 16373402, PMID: 16912195, PMID: 23387505).",295,,,www.uniprot.org,21,16912195,"Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib.",http://www.ncbi.nlm.nih.gov/pubmed/16912195,441,23387505,Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/23387505,1804,16373402,Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16373402,3271
"EGFR K754E lies within the protein kinase domain of the Egfr protein (UniProt.org). K754E has been identified in the scientific literature (PMID: 22885469, PMID: 20881644), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",8196,20881644,Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.,http://www.ncbi.nlm.nih.gov/pubmed/20881644,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8195,22885469,Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22885469,3272
"EGFR L703P lies within the region of the Egfr protein important for  dimerization, phosphorylation and activation (UniProt.org). L703P has been identified in the scientific literature (PMID: 21057220), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8088,21057220,Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21057220,3273
"EGFR L730F lies within the protein kinase domain of the Egfr protein (UniProt.org). L730F has been identified in the scientific literature (PMID: 16014883, PMID: 23244191), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",8207,23244191,Epidermal growth factor receptor (EGFR) mutations and expression in squamous cell carcinoma of the esophagus in central Asia.,http://www.ncbi.nlm.nih.gov/pubmed/23244191,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8206,16014883,Erlotinib in lung cancer - molecular and clinical predictors of outcome.,http://www.ncbi.nlm.nih.gov/pubmed/16014883,3274
"EGFR L747P lies within the protein kinase domain of the Egfr protein (UniProt.org). L747P has not been biochemically characterized, but has been identified in patients insensitive to Egfr TKI (PMID: 26339441, PMID: 21531810).",4495,26339441,EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26339441,4496,21531810,"Effectiveness of tyrosine kinase inhibitors on ""uncommon"" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/21531810,295,,,www.uniprot.org,3275
"EGFR L747_E749del results in the deletion of three amino acids in the protein kinase domain of the Egfr protein from amino acids 747 to 749 (UniProt.org). L747_E749del has not been characterized, however other exon 19 deletion mutations in the Egfr protein are activating, thus L747_E749del is predicted to result in a gain of function (PMID: 16373402, PMID: 16912195, PMID: 23387505).",21,16912195,"Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib.",http://www.ncbi.nlm.nih.gov/pubmed/16912195,1804,16373402,Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16373402,441,23387505,Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/23387505,295,,,www.uniprot.org,3276
EGFR L747_T751del results in the deletion of five amino acids in the protein kinase domain of the Egfr protein from amino acids 747 to 751 (UniProt.org). L747_T751del results in increased Egfr kinase activity (PMID: 23387505). ,441,23387505,Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/23387505,295,,,www.uniprot.org,3277
"EGFR L792P lies within the protein kinase domain of the Egfr protein (UniProt.org). L792P has been identified in the scientific literature (PMID: 16014883, PMID: 27895798), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,8206,16014883,Erlotinib in lung cancer - molecular and clinical predictors of outcome.,http://www.ncbi.nlm.nih.gov/pubmed/16014883,295,,,www.uniprot.org,8208,27895798,Exploring the impact of EGFR T790M neighboring SNPs on ARMS-based T790M mutation assay.,http://www.ncbi.nlm.nih.gov/pubmed/27895798,3278
"EGFR L814P lies within the protein kinase domain of the Egfr protein (UniProt.org). L814P has been identified in the scientific literature (PMID: 16870303), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7968,16870303,Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16870303,3279
"EGFR G810D lies within the protein kinase domain of the Egfr protein (UniProt.org). G810D has been identified in the scientific literature (PMID: 17224267, PMID: 26462025, PMID: 26901614), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",7973,26462025,Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26462025,8095,17224267,EGFR mutations and human papillomavirus in squamous cell carcinoma of tongue and tonsil.,http://www.ncbi.nlm.nih.gov/pubmed/17224267,8096,26901614,Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26901614,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3281
EGFR G810S lies within the protein kinase domain of the Egfr protein (UniProt.org). G810S results in increased Egfr kinase activity (PMID: 19147750). ,295,,,www.uniprot.org,1890,19147750,Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/19147750,3282
"EGFR G863D lies within the protein kinase domain of the Egfr protein (UniProt.org). G863D has not been biochemically characterized, but is predicted to result in a gain of Egfr function due to sensitivity to Egfr inhibitors (PMID: 16203769, PMID: 15897572).",295,,,www.uniprot.org,4836,16203769,Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16203769,4837,15897572,Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/15897572,3283
"EGFR G873E lies within the protein kinase domain of the Egfr protein (UniProt.org). G873E has been identified in the scientific literature (PMID: 21030498, PMID: 23800712), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8104,21030498,Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.,http://www.ncbi.nlm.nih.gov/pubmed/21030498,8105,23800712,Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population.,http://www.ncbi.nlm.nih.gov/pubmed/23800712,3284
"EGFR G874S lies within the protein kinase domain of the Egfr protein (UniProt.org). G874S has been identified in the scientific literature (PMID: 18176089, PMID: 25343854, PMID: 26773740), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8106,18176089,Prognostic factors for gefitinib-treated postoperative recurrence in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/18176089,7957,25343854,High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25343854,7970,26773740,Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26773740,3285
EGFR H773L lies within the protein kinase domain of the Egfr protein (UniProt.org). H773L confers a gain of function to the Egfr protein as demonstrated by persistent Egfr signaling in the presence of Egfr TKIs (PMID: 17974985).,295,,,www.uniprot.org,4494,17974985,Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.,http://www.ncbi.nlm.nih.gov/pubmed/17974985,3286
"EGFR H773R lies within the protein kinase domain of the Egfr protein (UniProt.org). H773R has been identified in the scientific literature (PMID: 23584298, PMID: 15623594), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1944,15623594,High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.,http://www.ncbi.nlm.nih.gov/pubmed/15623594,8107,23584298,Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial.,http://www.ncbi.nlm.nih.gov/pubmed/23584298,3287
"EGFR L858M lies within the protein kinase domain of the Egfr protein (UniProt.org). L858M has not been characterized, however other L858 mutations are activating thus L858M is predicted to result in a gain of function (PMID: 16187797).",410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,295,,,www.uniprot.org,3288
EGFR L861R lies within the protein kinase domain of the Egfr protein (UniProt.org). L861R results in increased Egfr autophosphorylation and downstream signaling in cell culture (PMID: 24743239).,295,,,www.uniprot.org,3812,24743239,Prediction and prioritization of rare oncogenic mutations in the cancer Kinome using novel features and multiple classifiers.,http://www.ncbi.nlm.nih.gov/pubmed/24743239,3289
"EGFR P596L lies within the extracellular domain of the Egfr protein (UniProt.org). P596L has been identified in the scientific literature (PMID: 17177598), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1877,17177598,Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.,http://www.ncbi.nlm.nih.gov/pubmed/17177598,3290
"EGFR P733L likes within the protein kinase domain of the Egfr protein (UniProt.org). P733L has been identified in the scientific literature (PMID: 23605641), but has not been biochemically characterized and and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3291
"EGFR P733S lies within the protein kinase domain of the Egfr protein (UniProt.org). P733S has been identified in the scientific literature (PMID: 21949883), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3292
"AKT1 amplification indicates an increased number of copies of the AKT1 gene. However, the mechanism causing the increase is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,3294
"EGFR E734K lies within the protein kinase domain of the Egfr protein (UniProt.org). E734K has been identified in the scientific literature (PMID: 16533793, PMID: 19648884, PMID: 26725423), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",7989,19648884,EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors.,http://www.ncbi.nlm.nih.gov/pubmed/19648884,7988,26725423,Hotspot mutations in polyomavirus positive and negative Merkel cell carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/26725423,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7990,16533793,Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features.,http://www.ncbi.nlm.nih.gov/pubmed/16533793,295,,,www.uniprot.org,3295
"EGFR E746_E749del results in the deletion of four amino acids in the protein kinase domain of the Egfr protein from amino acids 746 to 749 (UniProt.org). E746_E749del has not been characterized, however other exon 19 deletion mutations in the Egfr protein are activating, thus E746_E749del is predicted to result in a gain of function (PMID: 16373402, PMID: 16912195, PMID: 23387505).",21,16912195,"Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib.",http://www.ncbi.nlm.nih.gov/pubmed/16912195,1804,16373402,Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16373402,441,23387505,Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/23387505,295,,,www.uniprot.org,3296
"EGFR E746_S752del results in the deletion of seven amino acids in the protein kinase domain of the Egfr protein from amino acids 746 to 752 (UniProt.org). E746_S752del has not been characterized, however other exon 19 deletion mutations in the Egfr protein are activating, thus E746_S752del is predicted to result in a gain of function (PMID: 16373402, PMID: 16912195, PMID: 23387505).",21,16912195,"Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib.",http://www.ncbi.nlm.nih.gov/pubmed/16912195,441,23387505,Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/23387505,1804,16373402,Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16373402,295,,,www.uniprot.org,3297
"EGFR E746_T751del results in the deletion of six amino acids in the protein kinase domain of the Egfr protein from amino acids 746 to 751 (UniProt.org). E746_T751del has not been characterized, however other exon 19 deletion mutations in the Egfr protein are activating, thus E746_T751del is predicted to result in a gain of function (PMID: 16373402, PMID: 16912195, PMID: 23387505).",295,,,www.uniprot.org,21,16912195,"Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib.",http://www.ncbi.nlm.nih.gov/pubmed/16912195,1804,16373402,Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16373402,441,23387505,Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/23387505,3298
EGFR E868G lies within the protein kinase domain of the Egfr protein (UniProt.org). E868G results in increased Egfr activation in cell culture (PMID: 20942962). ,295,,,www.uniprot.org,1956,20942962,Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma.,http://www.ncbi.nlm.nih.gov/pubmed/20942962,3299
"EGFR F712L lies within the protein kinase domain of the Egfr protein (UniProt.org). F712L has been identified in the scientific literature (PMID: 25529460, PMID: 20512074), but has not been biochemically characterized and therefore, its effect on Egfr function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,8081,20512074,Epidermal growth factor receptor mutation and p53 overexpression during the multistage progression of small adenocarcinoma of the lung.,http://www.ncbi.nlm.nih.gov/pubmed/20512074,295,,,www.uniprot.org,8080,25529460,Assessment of EGFR and KRAS mutation status from FNAs and core-needle biopsies of non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25529460,3300
"EGFR F712S lies within the protein kinase domain of the Egfr protein (UniProt.org). F712S has been identified in the scientific literature (PMID: 22026926, PMID: 27121209), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8083,27121209,Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium).,http://www.ncbi.nlm.nih.gov/pubmed/27121209,8082,22026926,The human epidermal growth factor receptor (EGFR) gene in European patients with advanced colorectal cancer harbors infrequent mutations in its tyrosine kinase domain.,http://www.ncbi.nlm.nih.gov/pubmed/22026926,3301
"EGFR G598V lies within the extracellular domain of the Egfr protein (UniProt.org). G598V results in increased Egfr activity, is transforming in cell culture, and promotes tumor formation in mice (PMID: 17177598).",295,,,www.uniprot.org,1877,17177598,Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.,http://www.ncbi.nlm.nih.gov/pubmed/17177598,3302
"MET Y1003* results in the formation of a stop codon in the juxtamembrane domain of the Met protein, which disrupts several splice enhancer sites (PMID:  25079552). Consequently, Y1003* results in exon skipping deletion of exon 14, increased Met kinase activity, and downstream Akt and Erk signaling (PMID: 25531467, PMID: 16397241).",1974,16397241,Somatic mutations lead to an oncogenic deletion of met in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16397241,1972,25079552,Comprehensive molecular profiling of lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25079552,1975,25531467,Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes.,http://www.ncbi.nlm.nih.gov/pubmed/25531467,3303
MET E168D lies within the Sema domain of the Met protein (UniProt.org). E168D results in an increased affinity of Met for Hgf in an in vitro assay (PMID: 19723643).,295,,,www.uniprot.org,2020,19723643,Ethnic differences and functional analysis of MET mutations in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19723643,3304
"MET A1251T lies within the protein kinase domain of the Met protein (UniProt.org). A1251T has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3305
"ERBB2 (HER2) A751T lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). A751T has not been characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3306
"ERBB2 (HER2) A890V lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). A890V has been identified in sequencing studies (PMID: 22722839), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",1810,22722839,The mutational landscape of lethal castration-resistant prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22722839,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3307
ERBB2 (HER2) C311R lies within the extracellular domain of the Erbb2 (Her2) protein (PMID: 22908275). C311R results in disulfide bond-mediated Erbb2 (Her2) dimerization and is transforming in cell culture (PMID: 22908275).,1979,22908275,Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.,http://www.ncbi.nlm.nih.gov/pubmed/22908275,3308
ERBB2 (HER2) C334S lies within the extracellular domain of the Erbb2 (Her2) protein (PMID: 22908275). C334S results in disulfide bond-mediated Erbb2 (Her2) dimerization and is transforming in cell culture (PMID: 22908275).,1979,22908275,Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.,http://www.ncbi.nlm.nih.gov/pubmed/22908275,3310
"ERBB2 (HER2) C544F lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). C544F has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3311
"ERBB2 (HER2) D769H lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). D769H results in constitutive phosphorylation of Erbb2 (Her2) and activation of downstream signaling, is transforming in cell culture, and promotes tumor formation in xenograft models (PMID: 23220880).",1980,23220880,Activating HER2 mutations in HER2 gene amplification negative breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23220880,295,,,www.uniprot.org,3312
"ERBB2 (HER2) D769Y lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). D769Y results in constitutive phosphorylation of Erbb2 (Her2), increased downstream signaling, and is transforming in cell culture (PMID: 23220880).",295,,,www.uniprot.org,1980,23220880,Activating HER2 mutations in HER2 gene amplification negative breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23220880,3313
"ERBB2 (HER2) E1229* results in a premature truncation of the Erbb2 (Her2) protein at amino acid 1229 of 1255 (UniProt.org). E1229* has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3314
"ERBB2 (HER2) G309A lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). G309A does not result in increased Erbb2 (Her2) phosphorylation, but is transforming in cell culture and promotes tumor formation in xenograft models, and is predicted to enhance Erbb2 (Her2) dimerization (PMID: 23220880).",295,,,www.uniprot.org,1980,23220880,Activating HER2 mutations in HER2 gene amplification negative breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23220880,3315
"KIT A794E lies within the protein kinase domain of the Kit protein (UniProt.org). A794E has not been characterized in the scientific literature and therefore, its effect on Kit protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3316
"MET D1117G lies within the protein kinase domain of the Met protein (UniProt.org). D1117G has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3317
"MET G1144R (also referred to as G1162R) lies within the protein kinase domain of the Met protein (UniProt.org). G1144R has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3318
"MET H1112R lies within the protein kinase domain of the Met protein (UniProt.org). H1112R has not been characterized with respect to Met protein function, however H1112R leads to transformation of cells in culture, thus it is predicted to result in a gain of function (PMID: 9563489).",1990,9563489,Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/9563489,295,,,www.uniprot.org,3319
"MET H1124D lies within the protein kinase domain of the Met protein (UniProt.org). H1124D results in weak activation of Met, leading to increased Met phosphorylation and transformation of cultured cells (PMID: 10327054).",295,,,www.uniprot.org,1991,10327054,Novel mutations of the MET proto-oncogene in papillary renal carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/10327054,3321
"MET N1118Y lies within the protein kinase domain of the Met protein (UniProt.org). N1118Y results in increased Met kinase activity, increased cell proliferation and invasive phenotype in cultured cells (PMID: 12460923).",295,,,www.uniprot.org,1992,12460923,Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion.,http://www.ncbi.nlm.nih.gov/pubmed/12460923,3322
ERBB2 (HER2) D326G lies within the extracellular domain of the Erbb2 (Her2) protein (PMID: 22908275). D326G does not result in increased Erbb2 (Her2) phosphorylation or the ability to transform cells in culture (PMID: 22908275).,1979,22908275,Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.,http://www.ncbi.nlm.nih.gov/pubmed/22908275,3323
ERBB2 (HER2) D845A lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). D845A results in loss of Erbb2 (Her2) phosphorylation and abolishes transformation potential in cell culture (PMID: 22908275).,295,,,www.uniprot.org,1979,22908275,Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.,http://www.ncbi.nlm.nih.gov/pubmed/22908275,3324
ERBB2 (HER2) E321G lies within the extracellular domain of the Erbb2 (Her2) protein (PMID: 22908275). E321G results in disulfide bond-mediated Erbb2 (Her2) dimerization and is transforming in cell culture (PMID: 22908275).,1979,22908275,Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.,http://www.ncbi.nlm.nih.gov/pubmed/22908275,3325
ERBB2 (HER2) G309E lies within the extracellular domain of the Erbb2 (Her2) protein (PMID: 22908275). G309E results in disulfide bond-mediated Erbb2 (Her2) dimerization and is transforming in cell culture (PMID: 22908275).,1979,22908275,Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.,http://www.ncbi.nlm.nih.gov/pubmed/22908275,3326
ERBB2 (HER2) G776S lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). G776S results in increased Erbb2 (Her2) kinase activity and activation of the Mapk pathway (PMID: 18039657).,1996,18039657,Mutational activation of ErbB2 reveals a new protein kinase autoinhibition mechanism.,http://www.ncbi.nlm.nih.gov/pubmed/18039657,295,,,www.uniprot.org,3328
"ERBB2 (HER2) G776V lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). G776V has been identified in the scientific literature (J Clin Oncol 32, 2014 (suppl; abstr e22149)), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,10119,,Identification and validation of actionable mutations in solid tumors.,http://meetinglibrary.asco.org/record/95445/abstract,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3329
"ERBB2 (HER2) G778_S779insG results in the insertion of a glycine (G) in the protein kinase domain of the Erbb2 (Her2) protein between amino acids 778 and 779 (UniProt.org). G778_S779insG has not been characterized, however other exon 20 insertions are activating thus, G778_S779insG is predicted to lead to gain of Erbb2 (Her2) function (PMID: 16843263, PMID: 17311002, PMID: 23220880).",295,,,www.uniprot.org,2004,16843263,HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/16843263,2002,17311002,The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.,http://www.ncbi.nlm.nih.gov/pubmed/17311002,1980,23220880,Activating HER2 mutations in HER2 gene amplification negative breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23220880,3330
ERBB2 (HER2) H878Y lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). H878Y confers a gain of function to the Erbb2 (Her2) protein as demonstrated by increased Erbb2 (Her2) phosphorylation and transformation of cells in cell culture (PMID: 22046346).,621,22046346,Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.,http://www.ncbi.nlm.nih.gov/pubmed/22046346,295,,,www.uniprot.org,3331
"ERBB2 (HER2) I767M lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). I767M results in increased Erbb2 (Her2) kinase activity, sustained Akt phosphorylation, and is transforming in cell culture (PMID: 25994018).",295,,,www.uniprot.org,5833,25994018,Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification.,http://www.ncbi.nlm.nih.gov/pubmed/25994018,3332
ERBB2 (HER2) L49H lies within the extracellular domain of the Erbb2 (Her2) protein (PMID: 22908275). L49H demonstrates phosphorylation level and transformation potential comparable to wild-type Erbb2 (Her2) protein in cell culture (PMID: 22908275).,1979,22908275,Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.,http://www.ncbi.nlm.nih.gov/pubmed/22908275,3333
"FGFR2 amp indicates an increased number of copies of the FGFR2 gene. However, the mechanism causing the increase is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,3334
"ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) indicates the insertion of 4 duplicate amino acids, tyrosine (Y)-772 through alanine (A)-775, in the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). Y772_A775dup results in constitutive phosphorylation of Erbb2 (Her2) and is transforming in cell culture (PMID: 17311002).",295,,,www.uniprot.org,2002,17311002,The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.,http://www.ncbi.nlm.nih.gov/pubmed/17311002,3335
"ERBB2 (HER2) L755M lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). L755M has been identified in sequencing studies (PMID: 22895193), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4597,22895193,Recurrent R-spondin fusions in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22895193,3336
"ERBB2 (HER2) L755P lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). L755P results in increased phosphorylation of Erbb2 (Her2), activation of downstream signaling, and is transforming in cell culture (PMID: 22046346).",621,22046346,Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.,http://www.ncbi.nlm.nih.gov/pubmed/22046346,295,,,www.uniprot.org,3337
"ERBB2 (HER2) L755S lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). L755S results in increased phosphorylation of Erbb2 (Her2), activation of downstream signaling, and is transforming in cell culture (PMID: 22046346).",621,22046346,Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.,http://www.ncbi.nlm.nih.gov/pubmed/22046346,295,,,www.uniprot.org,3338
"ERBB2 (HER2) L755W lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). L755W has been identified in the scientific literature (PMID: 23220880), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",1980,23220880,Activating HER2 mutations in HER2 gene amplification negative breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23220880,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3339
ERBB2 (HER2) N319D lies within the extracellular domain of the Erbb2 (Her2) protein (PMID: 22908275). N319D demonstrates phosphorylation level and transformation potential comparable to wild-type Erbb2 (Her2) protein in cell culture (PMID: 22908275).,295,,,www.uniprot.org,1979,22908275,Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.,http://www.ncbi.nlm.nih.gov/pubmed/22908275,3340
"FLT3 D835Y lies within the protein kinase domain activation loop of the Flt3 protein (UniProt.org, PMID: 11290608). D835Y confers a gain of function to the Flt3 protein resulting in constitutive phosphorylation and transformation of cultured cells (PMID: 11290608).",2011,11290608,Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/11290608,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3341
"FLT3 D835V lies within the protein kinase domain activation loop of the Flt3 protein (UniProt.org, PMID: 11290608). D835V confers a gain of function to the Flt3 protein resulting in constitutive phosphorylation and transformation of cultured cells (PMID: 11290608).",2011,11290608,Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/11290608,295,,,www.uniprot.org,3342
"FLT3 D835H lies within the protein kinase domain activation loop of the Flt3 protein (UniProt.org, PMID: 11290608). D835H confers a gain of function to the Flt3 protein resulting in constitutive phosphorylation and transformation of cultured cells (PMID: 11290608).",2011,11290608,Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/11290608,295,,,www.uniprot.org,3343
"FLT3 D835E lies within the protein kinase domain activation loop of the Flt3 protein (UniProt.org, PMID: 11290608). D835E confers a gain of function to the Flt3 protein resulting in constitutive phosphorylation and transformation of cultured cells (PMID: 11290608).",295,,,www.uniprot.org,2011,11290608,Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/11290608,3345
"FLT3 D835N lies within the protein kinase domain activation loop of the Flt3 protein (UniProt.org, PMID: 11290608). D835N confers a gain of function to the Flt3 protein resulting in constitutive phosphorylation and transformation of cultured cells (PMID: 11290608).",295,,,www.uniprot.org,2011,11290608,Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/11290608,3346
"EGFR V774M lies within the protein kinase domain of the Egfr protein (UniProt.org). V774M has been identified in the scientific literature (PMID: 27123274, PMID: 17409930), but has not been characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",9201,27123274,Distinct epithelial growth factor receptor mutation profile in non-small-cell lung cancer patients from the Xuanwei area of China.,http://www.ncbi.nlm.nih.gov/pubmed/27123274,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9200,17409930,Mutation and polymorphism in the EGFR-TK domain associated with lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17409930,3348
"KIT D572N lies within the cytoplasmic domain of the Kit protein (UniProt.org). D572N has been identified in sequencing studies (PMID: 21478825), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,1165,21478825,KIT mutations in ocular melanoma: frequency and anatomic distribution.,http://www.ncbi.nlm.nih.gov/pubmed/21478825,295,,,www.uniprot.org,3349
"KIT D816E lies within the protein kinase domain of the Kit protein (UniProt.org). D816E has not been characterized, however other D816 mutations are activating, thus D816E is predicted to confer a gain of Kit protein function (PMID: 16397263).",295,,,www.uniprot.org,657,16397263,"Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.",http://www.ncbi.nlm.nih.gov/pubmed/16397263,3350
"KIT D816G lies within the protein kinase domain of the Kit protein (UniProt.org). D816G has not been characterized, however other D816 mutations are activating, thus D816G is predicted to confer a gain of Kit protein function (PMID: 16397263).",295,,,www.uniprot.org,657,16397263,"Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.",http://www.ncbi.nlm.nih.gov/pubmed/16397263,3351
"KIT D820G lies within the protein kinase domain of the Kit protein (UniProt.org). D820G is predicted to confer a gain of function to the Kit protein (PMID: 22937135, PMID: 9029028).",2016,22937135,Prevalence of c-KIT mutations in gonadoblastoma and dysgerminomas of patients with disorders of sex development (DSD) and ovarian dysgerminomas.,http://www.ncbi.nlm.nih.gov/pubmed/22937135,295,,,www.uniprot.org,2017,9029028,A new c-kit mutation in a case of aggressive mast cell disease.,http://www.ncbi.nlm.nih.gov/pubmed/9029028,3354
"KIT D820H lies within the protein kinase domain of the Kit protein (UniProt.org). D820H is predicted to confer a gain of Kit protein function resulting in constitutive activation (PMID: 22937135, PMID: 16741525).",2018,16741525,Detection of c-kit exons 11- and 17-activating mutations in testicular seminomas by high-resolution melting amplicon analysis.,http://www.ncbi.nlm.nih.gov/pubmed/16741525,2016,22937135,Prevalence of c-KIT mutations in gonadoblastoma and dysgerminomas of patients with disorders of sex development (DSD) and ovarian dysgerminomas.,http://www.ncbi.nlm.nih.gov/pubmed/22937135,295,,,www.uniprot.org,3355
MET N375S lies within the extracellular Sema ligand-binding domain of the Met protein (UniProt.org). N375S results in decreased Met binding affinity for Hgf in cell culture (PMID: 19723643).,295,,,www.uniprot.org,2020,19723643,Ethnic differences and functional analysis of MET mutations in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19723643,3356
"MET R1327C lies within the protein kinase domain of the Met protein (UniProt.org). R1327C has not been characterized in the scientific literature and therefore, its effect on protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3357
"MET W911* results in a premature truncation of the Met protein at amino acid 911 of 1390 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), W911* is predicted to lead to a loss of function.",295,,,www.uniprot.org,3358
"MET Y1248C lies within the protein kinase domain of the Met protein and corresponds to Y1230C in the protein’s short isoform (UniProt.org). Y1248C results in increased Met kinase activity, resistance to apoptosis, and is weakly transforming in cell culture (PMID: 19459657, PMID: 10657996).",2021,19459657,Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/19459657,295,,,www.uniprot.org,3359
"MET Y1253D lies within the protein kinase domain of the Met protein and corresponds to Y1235D in the protein’s short isoform (UniProt.org). Y1253D results in increased Met kinase activity (PMID: 16245927, PMIID: 19459657).",295,,,www.uniprot.org,2021,19459657,Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/19459657,2022,16245927,Regulation of the wild-type and Y1235D mutant Met kinase activation.,http://www.ncbi.nlm.nih.gov/pubmed/16245927,3360
"KRAS P34L lies within a GTP-binding region of the Kras protein (UniProt.org). P34L results in decreased Kras GAP sensitivity, leading to accumulation of GTP-bound Kras, but reduces Kras binding affinity for effectors, dampening pathway activation in cell culture (PMID: 20949621).",295,,,www.uniprot.org,800,20949621,Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders.,http://www.ncbi.nlm.nih.gov/pubmed/20949621,3362
"KRAS G60R lies within a GTP-binding region of the Kras protein (UniProt.org). G60R results in decreased Kras GTPase activity, leading to accumulation of GTP-bound Kras, but reduces Kras binding affinity for effectors, dampening pathway activation in cell culture (PMID: 20949621).",800,20949621,Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders.,http://www.ncbi.nlm.nih.gov/pubmed/20949621,295,,,www.uniprot.org,3363
KRAS Q22R does not lie within any known functional domains of the Kras protein (UniProt.org). Q22R results in decreased sensitivity of Kras to GAPs and increased stimulus-dependent activation of downstream signaling in cell culture (PMID: 20949621).,800,20949621,Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders.,http://www.ncbi.nlm.nih.gov/pubmed/20949621,295,,,www.uniprot.org,3364
"KRAS Q22E does not lie within any known functional domains of the Kras protein (UniProt.org). Q22E results in increased rate of Kras GTP/GDP exchange and decreased sensitivity of Kras to GAPs, leading to accumulation of GTP-bound RAS and downstream pathway activation in cell culture (PMID: 20949621).",800,20949621,Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders.,http://www.ncbi.nlm.nih.gov/pubmed/20949621,295,,,www.uniprot.org,3365
KRAS K5N lies at the N-terminus of the Kras protein (PMID: 20949621). K5N results in decreased Kras nucleotide affinity and increased serum-dependent Mapk phosphorylation in cell culture (PMID: 20949621).,800,20949621,Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders.,http://www.ncbi.nlm.nih.gov/pubmed/20949621,3366
"RET S891A lies within the protein kinase domain of the Ret protein (UniProt.org). S891A results in constitutive phosphorylation of Ret and downstream activation of Erk in cell culture (PMID: 17664273).
",589,17664273,Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.,http://www.ncbi.nlm.nih.gov/pubmed/17664273,3377
"RET C634W lies within the extracellular domain of the Ret protein (UniProt.org). C634W results in constitutive phosphorylation of Ret and activation of Erk in cell culture (PMID: 17664273).
",589,17664273,Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.,http://www.ncbi.nlm.nih.gov/pubmed/17664273,3378
"EGFR G719D lies within the P-loop in the kinase domain of the Egfr protein (PMID: 17349580). G719D has not been characterized, but can be predicted to confer a gain of function to Egfr based on the effect of other G719 mutations (PMID: 17349580, PMID: 19680293).",438,17349580,Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.,http://www.ncbi.nlm.nih.gov/pubmed/17349580,2033,19680293,Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/19680293,3383
"KIT Y823C lies within the protein kinase domain of the Kit protein (UniProt.org). Y823C has been identified in sequencing studies (PMID: 27276561), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Dec 2016).
",7052,27276561,Genomic Classification and Prognosis in Acute Myeloid Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27276561,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3386
"KIT Y570_L576del results in the deletion of seven amino acids in the juxtamembrane domain of the Kit protein from amino acids 570 to 576 (PMID: 16226710). Y570_L576del has not been characterized, however similar Kit exon 11 deletions are activating, thus Y570_L576del is predicted to lead to a gain of Kit protein function (PMID: 9438854, PMID: 15365079).",648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,3388
"KIT Y568_T574del results in the deletion of six amino acids in the juxtamembrane domain of the Kit protein from amino acids 568 to 574 (PMID: 16226710). Y568_T574del has not been characterized, however similar Kit exon 11 deletions are activating, thus Y568_T574del is predicted to lead to a gain of Kit protein function (PMID: 9438854, PMID: 15365079).",648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,3390
"KIT Y568D lies within the juxtamembrane domain of the Kit protein (PMID: 23416972). Y568D has been identified in sequencing studies (PMID: 14694524), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Dec 2016).
",2037,23416972,KIT-D816V oncogenic activity is controlled by the juxtamembrane docking site Y568-Y570.,http://www.ncbi.nlm.nih.gov/pubmed/23416972,7420,14694524,Absence of c-kit gene mutations in gastrointestinal stromal tumours from neurofibromatosis type 1 patients.,http://www.ncbi.nlm.nih.gov/pubmed/14694524,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3391
"KIT Y553_W557del results in the deletion of five amino acids in the juxtamembrane domain of the Kit protein from amino acids 553 to 557 (PMID: 16226710). Y553_W557del has not been characterized, however similar Kit exon 11 deletions are activating, thus Y553_W557del is predicted to lead to a gain of function (PMID: 9438854, PMID: 12727838). ",650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,804,12727838,Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation.,http://www.ncbi.nlm.nih.gov/pubmed/12727838,648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,3393
"KIT Y553_K558del results in the deletion of six amino acids in the juxtamembrane domain of the Kit protein from amino acids 553 to 558 (PMID: 16226710). Y553_K558del has not been characterized, however similar Kit exon 11 deletions are activating, thus Y553_K558del is predicted to lead to a gain of function (PMID: 9438854, PMID: 12727838). ",650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,804,12727838,Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation.,http://www.ncbi.nlm.nih.gov/pubmed/12727838,648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,3394
"KIT W557_E561del results in the deletion of five amino acids in the juxtamembrane domain of the Kit protein from amino acids 557 to 561 (PMID: 16226710). W557_E561del has not been characterized, however similar Kit exon 11 deletions are activating, thus W557_E561del is predicted to lead to a gain of function (PMID: 9438854, PMID: 15365079).",650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,3395
"KIT D820V lies within the protein kinase domain of the Kit protein (UniProt.org). D820V is predicted to confer a gain of Kit protein function resulting in constitutive activation (PMID: 11984533, PMID: 14695343).",666,14695343,KIT mutations are common in testicular seminomas.,http://www.ncbi.nlm.nih.gov/pubmed/14695343,660,11984533,Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene.,http://www.ncbi.nlm.nih.gov/pubmed/11984533,3396
"KIT E228* results in a premature truncation of the Kit protein at amino acid 228 of 976 (UniProt.org). Due to a loss of the protein kinase domain (UniProt.org), E228* is predicted to lead to a loss of function.",295,,,www.uniprot.org,3397
"KIT W557_V560del results in the deletion of four amino acids in the juxtamembrane domain of the Kit protein from amino acids 557 to 560 (PMID: 16226710). W557_V560del has not been characterized, however similar Kit exon 11 deletions are activating, thus W557_V560del is predicted to lead to a gain of function (PMID: 9438854, PMID: 9797363).",650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,714,9797363,A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9797363,648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,3398
"KIT E249* results in a premature truncation of the Kit protein at amino acid 249 of 976 (UniProt.org). Due to a loss of the protein kinase domain (UniProt.org), E249* is predicted to lead to a loss of function.",295,,,www.uniprot.org,3399
"KIT E306* results in a premature truncation of the Kit protein at amino acid 306 of 976 (UniProt.org). Due to a loss of the protein kinase domain (UniProt.org), E306* is predicted to lead to a loss of function.",295,,,www.uniprot.org,3400
"KIT W557_V559del results in the deletion of three amino acids in the juxtamembrane domain of the Kit protein from amino acids 557 to 559 (PMID: 16226710). W557_V559del has not been characterized, however similar Kit exon 11 deletions are activating, thus W557_V559del is predicted to lead to a gain of function (PMID: 9438854, PMID: 9797363). ",650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,714,9797363,A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9797363,648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,3401
"KIT E490* results in a premature truncation of the Kit protein at amino acid 490 of 976 (UniProt.org). Due to a loss of the protein kinase domain (UniProt.org), E490* is predicted to lead to a loss of function.
",295,,,www.uniprot.org,3402
"KIT W582* results in a premature truncation of the Kit protein at amino acid 582 of 976 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), W582* is predicted to lead to a loss of function.",295,,,www.uniprot.org,3403
"KIT E554K lies within the cytoplasmic domain of the Kit protein (UniProt.org). E554K has been identified in sequencing studies (PMID: 20861712), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Sep 2017).",7399,20861712,Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size.,http://www.ncbi.nlm.nih.gov/pubmed/20861712,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3404
"KIT W853* results in a premature truncation of the Kit protein at amino acid 853 of 976 (UniProt.org). W853* has been identified in sequencing studies (PMID: 21325067), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Dec 2016).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7411,21325067,Large-scale analysis of KIT aberrations in Chinese patients with melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/21325067,3405
"KIT E554_K558del results in the deletion of five amino acids in the juxtamembrane domain of the Kit protein from amino acids 554 to 558 (PMID: 12879016). E554_K558del has not been characterized, however similar Kit exon 11 deletions are activating, thus E554_K558del is predicted to lead to a gain of Kit protein function (PMID: 9438854, PMID: 15365079).",2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,285,,,http://www.ncbi.nlm.nih.gov/pubmed,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,3406
KIT Y553N lies within the juxtamembrane domain of the Kit protein (PMID: 16226710). Y553N is predicted to stabilize the active conformation of Kit using computer modelling (PMID: 23588081).,648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,2038,23588081,Protein modelling of a novel KIT mutation (N567Y) in the gastrointestinal stromal tumour.,http://www.ncbi.nlm.nih.gov/pubmed/23588081,3407
"KIT E561K lies within the cytoplasmic domain of the Kit protein (UniProt.org). E561K has been identified in sequencing studies (PMID: 16770100), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,7400,16770100,[A case of recurrent GIST successfully treated with low-dose imatinib mesilate].,http://www.ncbi.nlm.nih.gov/pubmed/16770100,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3408
"KIT E562K lies within the cytoplasmic domain of the Kit protein (UniProt.org). E562K has been identified in sequencing studies (PMID: 20861712), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,7399,20861712,Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size.,http://www.ncbi.nlm.nih.gov/pubmed/20861712,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3409
"KIT E695* results in a premature truncation of the Kit protein at amino acid 695 of 976 (UniProt.org). Due to a loss of the protein kinase domain (UniProt.org), E695* is predicted to lead to a loss of function.",295,,,www.uniprot.org,3410
"KIT F584S lies within the cytoplasmic domain of the Kit protein (UniProt.org). F584S has been identified in sequencing studies (PMID: 11376557), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7401,11376557,Mutations in c-kit gene exons 9 and 13 in gastrointestinal stromal tumors among Japanese.,http://www.ncbi.nlm.nih.gov/pubmed/11376557,3411
"KIT G565* results in a premature truncation of the Kit protein at amino acid 565 of 976 (UniProt.org). Due to a loss of the protein kinase domain (UniProt.org), G565* is predicted to lead to a loss of function.",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3412
"KIT G779C lies within the protein kinase domain of the Kit protein (UniProt.org). G779C has not been characterized in the scientific literature and therefore, its effect on Kit protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3413
"KIT G812V lies within the protein kinase domain of the Kit protein (UniProt.org). G812V has not been biochemically characterized, but is predicted to result in a loss of Kit protein function (PMID:         7687267).",3382,7687267,Novel mutations of the KIT (mast/stem cell growth factor receptor) proto-oncogene in human piebaldism.,http://www.ncbi.nlm.nih.gov/pubmed/7687267,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3414
"SMO H692fs results in a change in the amino acid sequence of the Smo protein beginning at aa 692 of 787, likely resulting is a premature truncation of the functional protein (UniProt.org). H692fs has not been characterized and therefore, its effect on Smo protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3415
"KIT K818R lies within the protein kinase domain of the Kit protein (UniProt.org). K818R has been identified in sequencing studies (PMID: 17566038), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Sep 2017).",7407,17566038,Double resistance to imatinib and AMG 706 caused by multiple acquired KIT exon 17 mutations in a gastrointestinal stromal tumour.,http://www.ncbi.nlm.nih.gov/pubmed/17566038,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3417
"KIT L416fs results in a change in the amino acid sequence of the Kit protein beginning at aa 416 of 976, likely resulting is a premature truncation of the protein (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), L416fs is predicted to lead to a loss of function. ",295,,,www.uniprot.org,3418
"KIT L576del results in the deletion of an amino acid in the juxtamembrane domain of the Kit protein at amino acid 576 (PMID: PMID: 9797363). L576del has not been characterized however other Kit exon 11 deletions are activating, thus L576del is predicted to lead to a gain of Kit protein function (PMID: 9438854, PMID: 15365079). ",2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,3419
"KIT L576F lies within the juxtamembrane domain of the Kit protein (PMID: 17372901). L576F has been identified in sequencing studies (PMID: 26971368), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,695,17372901,L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/17372901,7408,26971368,Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26971368,3420
ERBB2 (HER2) T216S lies within the extracellular domain of the Erbb2 (Her2) protein (PMID: 22908275). T216S results in increased Erbb2 (Her2) kinase activity (PMID: 22908275).,1979,22908275,Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.,http://www.ncbi.nlm.nih.gov/pubmed/22908275,3421
ERBB2 (HER2) V750E lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). V750E results in decreased Erbb2 (Her2) kinase activity (PMID: 22908275).,1979,22908275,Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.,http://www.ncbi.nlm.nih.gov/pubmed/22908275,295,,,www.uniprot.org,3422
ERBB2 (HER2) V777A lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). V777A results in decreased Erbb2 (Her2) activity and a decreased ability to transform cells in culture (PMID: 22908275).,295,,,www.uniprot.org,1979,22908275,Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.,http://www.ncbi.nlm.nih.gov/pubmed/22908275,3424
"ERBB2 (HER2) V777L lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). V777L results in increased Erbb2 (Her2) activity, increased downstream Mapk pathway activation, increased ability to transform cells in culture, and increased tumor growth in xenograft models (PMID: 23220880)",295,,,www.uniprot.org,1980,23220880,Activating HER2 mutations in HER2 gene amplification negative breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23220880,3425
"ERBB2 (HER2) V777M lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). V777M has been identified in the scientific literature (PMID: 22761469), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7975,22761469,"Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22761469,3426
"ERBB2 (HER2) V842I lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). V8421 results in increased Erbb2 (Her2) activity, downstream Mapk pathway activation, and the ability to transform cells in culture (PMID: 23220880).",295,,,www.uniprot.org,1980,23220880,Activating HER2 mutations in HER2 gene amplification negative breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23220880,3427
"ERBB2 (HER2) W906* results in a premature truncation of the Erbb2 (Her2) protein within the protein kinase domain of the Erbb2 (Her2) protein at amino acid 906 of 1255 (UniProt.org). Due to the disruption of the Erbb2 (Her2) kinase domain, W906* is predicted to lead to a loss of function. ",295,,,www.uniprot.org,3428
"MET T992I (also referred to as T1010I) does not lie within any known functional domains of the Met protein (UniProt.org). The functional effect of T992I is conflicting, as it has been reported both to have phosphorylation level and transforming capacity similar to wild-type Met protein (PMID: 20670955), and increase Met transforming capability and cell migration in culture (PMID: 14559814).",332,14559814,c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.,http://www.ncbi.nlm.nih.gov/pubmed/14559814,2198,20670955,MET receptor sequence variants R970C and T992I lack transforming capacity.,http://www.ncbi.nlm.nih.gov/pubmed/20670955,295,,,www.uniprot.org,3429
"KIT I563_L576del results in the deletion of fourteen amino acids in the juxtamembrane domain of the Kit protein from amino acids 563 to 576 (PMID: 12879016). I563_L576del has not been characterized, however similar Kit exon 11 deletions are activating, thus I563_L576del is predicted to lead to a gain of Kit protein function (PMID: 9438854, PMID: 15365079).",2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,285,,,http://www.ncbi.nlm.nih.gov/pubmed,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,3430
"KIT I571_L576del results in the deletion of six amino acids in the juxtamembrane domain of the Kit protein from amino acids 571 to 576 (PMID: 12879016). I571_L576del has not been characterized, however similar Kit exon 11 deletions are activating, thus I571_L576del is predicted to lead to a gain of Kit protein function (PMID: 9438854, PMID: 15365079).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,3431
"KIT K558_E562del results in the deletion of five amino acids in the juxtamembrane domain of the Kit protein from amino acids 558 to 562 (PMID: 12879016). K558_E562del has not been characterized, however similar Kit exon 11 deletions are activating, thus K558_E562del is predicted to lead to a gain of function (PMID: 9438854, PMID: 15365079).",2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,3432
"KIT K558_N564del results in the deletion of seven amino acids in the juxtamembrane domain of the Kit protein from amino acids 558 to 564 (PMID: 12879016). K558_N564del has not been characterized, however similar Kit exon 11 deletions are activating, thus K558_N564del is predicted to lead to a gain of function (PMID: 9438854, PMID: 15365079).",2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,3433
"KIT K558_V559del results in the deletion of two amino acids in the juxtamembrane domain of the Kit protein from amino acids 558 to 559 (PMID: 12879016). K558_V559del has not been characterized, however similar Kit exon 11 deletions are activating, thus K558_V559del is predicted to lead to a gain of function (PMID: 9438854, PMID: 15365079).",2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,3434
"KIT K558_V560del results in the deletion of three amino acids in the juxtamembrane domain of the Kit protein from amino acids 558 to 560 (PMID: 12879016). K558_V560del has not been characterized, however similar Kit exon 11 deletions are activating, thus K558_V560del is predicted to lead to a gain of function (PMID: 9438854, PMID: 15365079).",2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,3435
"KIT M552L lies within the juxtamembrane domain of the Kit protein (PMID: 12879016). M552L has been identified in sequencing studies (PMID: 12759497), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7409,12759497,Mutations in exon 11 of the c-kit gene in a myogenic tumor and a neurogenic tumor as well as in gastrointestinal stromal tumors. Utility of c-kit mutation as a prognostic biomarker for gastrointestinal mesenchymal tumor.,http://www.ncbi.nlm.nih.gov/pubmed/12759497,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,3437
"KIT M552_E554del results in the deletion of three amino acids in the juxtamembrane domain of the Kit protein from amino acids 552 to 554 (PMID: 12879016). M552_E554del has not been characterized, however similar Kit exon 11 deletions are activating, thus M552_E554del is predicted to lead to a gain of Kit protein function (PMID: 9438854, PMID: 15365079).",2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,285,,,http://www.ncbi.nlm.nih.gov/pubmed,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,3438
"KIT M552_Q556del results in the deletion of five amino acids in the juxtamembrane domain of the Kit protein from amino acids 552 and 556 (PMID: 12879016) M552_Q556del has not been characterized, however similar Kit exon 11 deletions are activating, thus M552_Q556del is predicted to lead to a gain of function (PMID: 9438854, PMID: 15365079).",2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,3439
"KIT M552_W557del results in the deletion of six amino acids in the juxtamembrane domain of the Kit protein from amino acids 552 and 557 (PMID: 12879016). M552_W557del has not been characterized, however similar Kit exon 11 deletions are activating, thus M552_W557del is predicted to lead to a gain of function (PMID: 9438854, PMID: 15365079).",2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,3440
"KIT N564_L576del results in the deletion of thirteen amino acids in the juxtamembrane domain of the Kit protein from amino acids 564 to 576 (PMID: 12879016). N564_L576del has not been characterized, however similar Kit exon 11 deletions are activating, thus N564_L576del is predicted to lead to a gain of Kit protein function (PMID: 9438854, PMID: 15365079).",650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3441
"KIT N564_Y578del results in the deletion of fifteen amino acids in the juxtamembrane domain of the Kit protein from amino acids 564 to 578 (PMID: 12879016). N564_Y578del has not been characterized, however similar Kit exon 11 deletions are activating, thus N564_Y578del is predicted to lead to a gain of Kit protein function (PMID: 9438854, PMID: 15365079).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,3442
"KIT N566D lies within the juxtamembrane domain of the Kit protein (PMID: 12879016). N566D has been identified in sequencing studies (PMID: 21325067), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,7411,21325067,Large-scale analysis of KIT aberrations in Chinese patients with melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/21325067,3443
"KIT N567K lies within the juxtamembrane domain of the Kit protein (PMID: 12879016). N567K has been identified in sequencing studies (PMID: 15217946), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Sep 2017).",7412,15217946,Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance.,http://www.ncbi.nlm.nih.gov/pubmed/15217946,285,,,http://www.ncbi.nlm.nih.gov/pubmed,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,3444
"KIT Q556_K558del results in the deletion of three amino acids in the juxtamembrane domain of the Kit protein from amino acids 556 to 558 (PMID: 12879016). Q556_K558del has not been characterized, however similar Kit exon 11 deletions are activating, thus Q556_K558del is predicted to lead to a gain of function (PMID: 9438854, PMID: 15365079, PMID: 12918066).",726,12918066,Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/12918066,2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,3445
"KIT N822Y lies within the protein kinase domain of the Kit protein (UniProt.org). N822Y has not been characterized, however other N822 mutations result in constitutive activation of the Kit protein thus N822Y is predicted to result in a gain of function (PMID: 14695343).",666,14695343,KIT mutations are common in testicular seminomas.,http://www.ncbi.nlm.nih.gov/pubmed/14695343,295,,,www.uniprot.org,3446
"KIT P551L lies within the juxtamembrane domain of the Kit protein (PMID: 12879016). P551L has been identified in sequencing studies (PMID: 26956871), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Sep 2017).",7152,26956871,Recurrent neomorphic mutations of MTOR in central nervous system and testicular germ cell tumors may be targeted for therapy.,http://www.ncbi.nlm.nih.gov/pubmed/26956871,285,,,http://www.ncbi.nlm.nih.gov/pubmed,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,3447
"KIT P577S lies within the juxtamembrane domain of the Kit protein (PMID: 12879016). P577S has been identified in sequencing studies (PMID: 21836495), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,7415,21836495,KIT-negative gastrointestinal stromal tumor of the abdominal soft tissue: a clinicopathologic and genetic study of 10 cases.,http://www.ncbi.nlm.nih.gov/pubmed/21836495,3448
"KIT P573L lies within the juxtamembrane domain of the Kit protein (PMID: 12879016). P573L has been identified in sequencing studies (PMID: 21680547), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Sep 2017).",7414,21680547,KIT pathway alterations in mucosal melanomas of the vulva and other sites.,http://www.ncbi.nlm.nih.gov/pubmed/21680547,285,,,http://www.ncbi.nlm.nih.gov/pubmed,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,3449
"KIT P754fs results in a change in the amino acid sequence of the Kit protein beginning at aa 754 of 976 (UniProt.org), likely resulting in premature truncation of the functional protein. Due to the disruption of the protein kinase domain, P754fs is predicted to lead to a loss of Kit protein function (UniProt.org).",295,,,www.uniprot.org,3450
"KIT S197* results in a premature truncation of the Kit protein at amino acid 197 of 976 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), S197* is predicted to lead to a loss of function.",295,,,www.uniprot.org,3451
"KIT S715del results in the deletion of an amino acid within the protein kinase domain of the Kit protein at amino acid 715 (UniProt.org). S715del has been identified in sequencing studies (PMID: 11786393), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Dec 2016).
",7417,11786393,The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors.,http://www.ncbi.nlm.nih.gov/pubmed/11786393,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3452
"KIT T670E lies within the protein kinase domain of the Kit protein (UniProt.org). T670E has been identified in sequencing studies (PMID: 16551858), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Dec 2016).
",7416,16551858,Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.,http://www.ncbi.nlm.nih.gov/pubmed/16551858,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3453
"KIT V555I lies within the juxtamembrane domain of the Kit protein (PMID: 12879016). V555I has been identified in sequencing studies (PMID: 21478825), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Dec 2016).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,1165,21478825,KIT mutations in ocular melanoma: frequency and anatomic distribution.,http://www.ncbi.nlm.nih.gov/pubmed/21478825,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,3454
"KIT V555_E562del results in the deletion of eight amino acids in the juxtamembrane domain of the Kit protein from amino acids 555 to 562 (PMID: 12879016). V555_E562del has not been characterized, however similar Kit exon 11 deletions are activating, thus V555_E562del is predicted to lead to a gain of function (PMID: 9438854, PMID: 15365079).",2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,3455
"KIT V555_I571del results in the deletion of seventeen amino acids in the juxtamembrane domain of the Kit protein from amino acids 555 to 571 (PMID: 12879016). V555_I571del has not been characterized, however similar Kit exon 11 deletions are activating, thus V555_I571del is predicted to lead to a gain of function (PMID: 9438854, PMID: 15365079).",650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,3457
"KIT V555_K558del results in the deletion of four amino acids in the juxtamembrane domain of the Kit protein from amino acids 555 to 558 (PMID: 12879016). V555_K558del has not been characterized, however similar Kit exon 11 deletions are activating, thus V555_K558del is predicted to lead to a gain of Kit protein function (PMID: 9438854, PMID: 15365079).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,3458
KIT V555_P573del results in the deletion of nineteen amino acids in the juxtamembrane domain of the Kit protein from amino acids 555 to 573 (PMID: 12879016). V555_P573del results in phosphorylation of the Kit protein (PMID: 16188233).,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,1875,16188233,KIT (c-kit oncogene product) pathway is constitutively activated in human testicular germ cell tumors.,http://www.ncbi.nlm.nih.gov/pubmed/16188233,3459
"KIT V555_Q556del results in the deletion of two amino acids in the juxtamembrane domain of the Kit protein from amino acids 555 to 556 (PMID: 12879016). V555_Q556del has not been characterized, however similar Kit exon 11 deletions are activating, thus V555_Q556del is predicted to lead to a gain of Kit protein function (PMID: 9438854, PMID: 15365079).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,3460
"KIT V555_V559del results in the deletion of five amino acids in the juxtamembrane domain of the Kit protein from amino acids 55 to 559 (PMID: 12879016). V555_V559del has not been characterized, however similar Kit exon 11 deletions are activating, thus V555_V559del is predicted to lead to a gain of function (PMID: 9438854, PMID: 15365079).",2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,3461
"KIT V555_V560del results in the deletion of six amino acids from the juxtamembrane domain of the Kit protein from amino acids 555 to 560 (PMID: 12879016). V555_V560del has not been characterized, however similar Kit exon 11 deletions are activating, thus KV555_V560del is predicted to lead to a gain of function (PMID: 9438854, PMID: 15365079).",2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,3462
"KIT V556_L576del results in the deletion of twenty-one amino acids in the juxtamembrane domain of the Kit protein (PMID: 12879016). V556_L576 has not been characterized, however similar Kit exon 11 deletions are activating, thus V556_L576del is predicted to lead to a gain of function (PMID: 9438854, PMID: 15365079). ",2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,3463
"KIT V556_V560del results in the deletion of five amino acids in the juxtamembrane domain of the Kit protein from amino acids 556 to 560 (PMID: 12879016). V556_V560del has not been characterized, however similar Kit exon 11 deletions are activating, thus K556_V560del is predicted to lead to a gain of function (PMID: 9438854, PMID: 15365079).",2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,3464
"KIT V559G lies within the juxtamembrane domain of the Kit protein (PMID: 12879016). V559G has not been characterized however other Kit V559 mutations are activating, thus V559G is predicted to result in a gain of function (PMID: 20484085).",2073,20484085,Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/20484085,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,3465
"KIT V559_E561del results in the deletion of three amino acids in the juxtamembrane domain of the Kit protein from amino acids 559 to 561 (PMID: 12879016). V559_E561del has not been characterized, however similar Kit exon 11 deletions are activating, thus V559_E561del is predicted to lead to a gain of function (PMID: 9438854, PMID: 15365079).",2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,3466
"KIT V559_G565del results in the deletion of seven amino acids in the juxtamembrane domain of the Kit protein from amino acids 559 to 565 (PMID: 12879016). V559_G565del has not been characterized, however similar Kit exon 11 deletions are activating, thus V559_G565del is predicted to lead to a gain of function (PMID: 9438854, PMID: 15365079).",2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,3467
ATM mutant indicates an unspecified mutation in the ATM gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,3468
ERBB2 (HER2) M774_A775insAYVM results in the insertion of four amino acids in the protein kinase domain of the Erbb2 (Her2) protein between amino acids 774 and 775 (UniProt.org). M774_A775insAYVM results in constitutive phosphorylation of Erbb2 (Her2) and is transforming in cell culture (PMID: 17311002).,2002,17311002,The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.,http://www.ncbi.nlm.nih.gov/pubmed/17311002,295,,,www.uniprot.org,3470
"ERBB2 (HER2) G778_P780dup (also referred to as P780_Y781insGSP and V777_G778insGSP) indicates the insertion of 3 amino acids, glycine (G)-778 through proline (P)-781, in the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). G778_P780dup results in constitutive activation of Erbb2 (Her2), increased downstream signaling, and is transforming in cell culture (PMID: 23220880).",295,,,www.uniprot.org,1980,23220880,Activating HER2 mutations in HER2 gene amplification negative breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23220880,3472
"ERBB2 (HER2) Q943* results in a premature truncation of the Erbb2 (Her2) protein at amino acid 943 of 1255 (UniProt.org). Q943* has been identified in sequencing studies (PMID: 22980975), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,1726,22980975,Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/22980975,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3473
"ERBB2 (HER2) R432W lies within the extracellular domain of the Erbb2 (Her2) protein (PMID: 22908275). R432W has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,1979,22908275,Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.,http://www.ncbi.nlm.nih.gov/pubmed/22908275,3474
ERBB2 (HER2) R678Q lies within the Kpnb1 and Eea1-interacting region of the Erbb2 (Her2) protein (UniProt.org). R678Q demonstrates phosphorylation level and transformation potential comparable to wild-type Erbb2 (Her2) protein in cell culture and xenograft models (PMID: 23220880).,295,,,www.uniprot.org,1980,23220880,Activating HER2 mutations in HER2 gene amplification negative breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23220880,3475
ERBB2 (HER2) R868W lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). R868W results in decreased Erbb2 (Her2) and Mapk phosphorylation in cell culture (PMID: 28743916).,295,,,www.uniprot.org,10127,28743916,Analysis of somatic mutations across the kinome reveals loss-of-function mutations in multiple cancer types.,http://www.ncbi.nlm.nih.gov/pubmed/28743916,3476
"ERBB2 (HER2) R896C lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). R896C results in constitutive phosphorylation of Erbb2 (Her2), increased downstream signaling, and is transforming in cell culture (PMID: 23220880).",295,,,www.uniprot.org,1980,23220880,Activating HER2 mutations in HER2 gene amplification negative breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23220880,3477
ERBB2 (HER2) S310F lies within the extracellular domain of the Erbb2 (Her2) protein (PMID: 22908275). S310F results in increased phosphorylation of Erbb2 and is transforming in cell culture (PMID: 22908275).,1979,22908275,Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.,http://www.ncbi.nlm.nih.gov/pubmed/22908275,3478
"ERBB2 (HER2) S310Y lies within the extracellular domain of the Erbb2 (Her2) protein (PMID: 22908275). S310Y results in increased transformation potential in cell culture, and is predicted to confer a gain of function to Erbb2 (PMID: 22908275).",1979,22908275,Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.,http://www.ncbi.nlm.nih.gov/pubmed/22908275,3479
"ERBB2 (HER2) S779_P780insVGS results in the insertion of three amino acids in the protein kinase domain of the Erbb2 (Her2) protein between amino acids 779 and 780 (UniProt.org). S779_P780insVGS has not been characterized, however other exon 20 insertions are activating thus, S779_P780insVGS is predicted to lead to gain of Erbb2 (Her2) function (PMID: 16843263, PMID: 17311002, PMID: 23220880).",1980,23220880,Activating HER2 mutations in HER2 gene amplification negative breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23220880,295,,,www.uniprot.org,2004,16843263,HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/16843263,2002,17311002,The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.,http://www.ncbi.nlm.nih.gov/pubmed/17311002,3480
"BRAF fusion indicates a fusion of the BRAF gene, but the fusion partner is unknown.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,3481
"KIT V560E lies within the juxtamembrane domain of the Kit protein (PMID: 12879016). V560E has not been characterized, however other V560 ""hotspot"" mutations are activating, thus V560E is predicted to lead to a gain of function (PMID: 16954519).",713,16954519,Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/16954519,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,3483
KIT V560del results in the deletion of an amino acid in the juxtamembrane domain of the Kit protein at amino acid 560 (PMID: 12879016). V560del confers a gain of function to Kit as indicated by growth factor-independent growth in cell culture (PMID: 19861435).,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,670,19861435,Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.,http://www.ncbi.nlm.nih.gov/pubmed/19861435,3484
"KIT V560_L576del results in the deletion of seventeen amino acids in the juxtamembrane domain of the Kit protein from amino acids 560 to 576 (PMID: 12879016). V560_L576del has not been characterized, however similar Kit exon 11 deletions are activating, thus V560_L576del is predicted to lead to a gain of function (PMID: 9438854, PMID: 15365079).",2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,285,,,http://www.ncbi.nlm.nih.gov/pubmed,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,3485
"APC K716* results in a premature truncation of the Apc protein at amino acid 716 of 2843 (UniProt.org). Due to the loss of multiple functional domains (PMID: 11900252), K716* confers a loss of function likely reducing the ability of Apc to properly regulate beta-catenin (PMID: 7753829). ",2076,11900252,"APC, signal transduction and genetic instability in colorectal cancer.",http://www.ncbi.nlm.nih.gov/pubmed/11900252,2077,7753829,Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene.,http://www.ncbi.nlm.nih.gov/pubmed/7753829,295,,,www.uniprot.org,3486
"EGFR A120P lies within the L1 domain of the Egfr protein (PMID: 19390622). A120P has been identified in the sequencing studies (PMID: 24983367), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",7176,24983367,Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail.,http://www.ncbi.nlm.nih.gov/pubmed/24983367,2078,19390622,Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19390622,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3487
"EGFR D770_N771insN results in the insertion of an asparagine (N) in the protein kinase domain of the Egfr protein between amino acids 770 and 771 (UniProt.org). D770_N771insN D770_N771insN has not been characterized, but can be predicted to result in a gain of function based on the effect of other Egfr exon 20 insertions (PMID: 16187797).",295,,,www.uniprot.org,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,3488
"EGFR G721A lies within the protein kinase domain of the Egfr protein (UniProt.org). G721A has been identified in the scientific literature (PMID: 27121209), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3489
"EGFR G721S lies within the protein kinase domain of the Egfr protein (UniProt.org). G721S has been identified in the scientific literature (PMID: 17192902, PMID: 21057220), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8088,21057220,Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21057220,8087,17192902,The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17192902,3490
EGFR G724S lies within the protein kinase domain of the Egfr protein (UniProt.org). G724S results in constitutive phosphorylation of Egfr and is transforming in cell culture (PMID: 24894453).,295,,,www.uniprot.org,1125,24894453,Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab.,http://www.ncbi.nlm.nih.gov/pubmed/24894453,3491
"EGFR G735S lies within the protein kinase domain of the Egfr protein (UniProt.org). G735S results in ligand-independent Egfr phosphorylation, activation of the Erk signaling pathway, and is transforming in cell culture (PMID: 18193092).",295,,,www.uniprot.org,2079,18193092,Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations.,http://www.ncbi.nlm.nih.gov/pubmed/18193092,3492
"EGFR G779F lies within the protein kinase domain of the Egfr protein (UniProt.org). G779F has been identified in the scientific literature (PMID: 16467085), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8089,16467085,A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening.,http://www.ncbi.nlm.nih.gov/pubmed/16467085,3493
"EGFR P741L lies within the protein kinase domain of the Egfr protein (UniProt.org). P741L has been identified in the scientific literature (PMID: 21771097), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9227,21771097,Low incidence of EGFR and HRAS mutations in cutaneous squamous cell carcinomas of a German cohort.,http://www.ncbi.nlm.nih.gov/pubmed/21771097,3494
"EGFR R776C lies within the protein kinase domain of the Egfr protein (UniProt.org). R776C results in constitutive phosphorylation of Egfr, increased downstream signaling, and is transforming in cell culture (PMID: 19147750).",295,,,www.uniprot.org,1890,19147750,Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/19147750,3495
EGFR R776H lies within the protein kinase domain of the Egfr protein (UniProt.org). R776H results in constitutive phosphorylation of Egfr and activation of Erk and Stat5 in cell culture (PMID: 23358982).,2080,23358982,Activating germline R776H mutation in the epidermal growth factor receptor associated with lung cancer with squamous differentiation.,http://www.ncbi.nlm.nih.gov/pubmed/23358982,295,,,www.uniprot.org,3496
"GNA11 inact mut indicates that this variant results in a loss of function of the Gna11 protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,3497
"GNAQ inact mut indicates that this variant results in a loss of function of the Gnaq protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,3498
"KIT V603D lies within the protein kinase domain of the Kit protein (UniProt.org). V603D has not been characterized in the scientific literature and therefore, its effect on Kit protein function is unknown (PubMed, Dec 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3506
"KIT V643A lies within the protein kinase domain of the Kit protein (UniProt.org). V643A has been identified in sequencing studies (PMID: 19617878), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Dec 2016).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7418,19617878,Identification of c-kit gene mutations in primary adenoid cystic carcinoma of the salivary gland.,http://www.ncbi.nlm.nih.gov/pubmed/19617878,3507
"EGFR S720F lies within the protein kinasedomain of the Egfr protein (UniProt.org). S720F has been identified in the scientific literature (PMID: 23768755), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3509
"EGFR S752P lies within the protein kinase domain of the Egfr protein (UniProt.org). S752P has not been characterized in the scientific literature and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3510
"EGFR S752Y lies within the protein kinase domain of the Egfr protein (UniProt.org). S752Y has not been characterized in the scientific literature and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3511
"EGFR S752_I759del results in the deletion of eight amino acids in the protein kinase domain of the Egfr protein from amino acids 752 to 759 (UniProt.org). S752_I759del results in increased transformation potential in cell culture, and is predicted to confer a gain of function to Egfr (PMID: 16869740).",295,,,www.uniprot.org,2085,16869740,Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/16869740,3512
"EGFR S768I lies within the protein kinase domain of the Egfr protein (UniProt.org). S768I results in constitutive phosphorylation of Egfr, increased downstream signaling, and is transforming in cell culture (PMID: 19147750).",1890,19147750,Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/19147750,295,,,www.uniprot.org,3514
"BRAF G466A lies within the protein kinase domain of the Braf protein (UniProt.org). G466A results in decreased Braf kinase activity, however, leads to increased activation of Erk signaling through CRAF in cell culture (PMID: 15035987, PMID: 28783719).",9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,146,15035987,Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.,http://www.ncbi.nlm.nih.gov/pubmed/15035987,295,,,www.uniprot.org,3515
"BRAF G466E lies within the protein kinase domain of the Braf protein (UniProt.org). G466E results in impaired Braf kinase activity, but paradoxically increases Erk signaling through C-raf activation in cell culture and Xenopus embryos (PMID: 15035987).",146,15035987,Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.,http://www.ncbi.nlm.nih.gov/pubmed/15035987,295,,,www.uniprot.org,3517
BRAF I463S lies within the protein kinase domain of the Braf protein (UniProt.org). I463S results in activation of Braf and increased Erk signaling in cell culture (PMID: 15035987).,146,15035987,Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.,http://www.ncbi.nlm.nih.gov/pubmed/15035987,295,,,www.uniprot.org,3518
"BRAF N581S lies within the protein kinase domain of the Braf protein (UniProt.org). N581S has been demonstrated to result in intermediate Braf kinase activity (PMID: 15035987), as well low Braf kinase activity (PMID: 28783719), and results in Ras-dependent activation of ERK signaling in cell culture (PMID: 28783719).",146,15035987,Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.,http://www.ncbi.nlm.nih.gov/pubmed/15035987,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,295,,,www.uniprot.org,3519
BRAF R462I lies within the protein kinase domain of the Braf protein (UniProt.org). R462I results in activation of Braf and increased Erk signaling in cell culture (PMID: 15035987).,295,,,www.uniprot.org,146,15035987,Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.,http://www.ncbi.nlm.nih.gov/pubmed/15035987,3520
"FGFR3 amp indicates an increased number of copies of the FGFR3 gene. However, the mechanism causing the increase is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,3522
"BRAF P403fs results in a change in the amino acid sequence of the Braf protein beginning at aa 403 of 766, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), P403fs is predicted to lead to a loss of Braf function.",295,,,www.uniprot.org,3524
"NRAS A11T lies within a GTP-binding region of the Nras protein (UniProt.org). A11T has been identified in the scientific literature (PMID: 2183888, PMID: 22261812), but has not been biochemically characterized and therefore, its effect on Nras protein function is unknown (PubMed, Mar 2017).",8288,2183888,The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/2183888,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8289,22261812,Sunitinib therapy for melanoma patients with KIT mutations.,http://www.ncbi.nlm.nih.gov/pubmed/22261812,3528
"NRAS A146T does not lie within any known functional domains of the Nras protein (UniProt.org). A146T results in increased Nras activity and downstream signaling, and is transforming in cell culture, which is predicted to result from increased Nras GDP/GTP exchange rate (PMID: 22389471, PMID: 16969076).",2092,22389471,"Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",http://www.ncbi.nlm.nih.gov/pubmed/22389471,2093,16969076,Recurrent KRAS codon 146 mutations in human colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16969076,295,,,www.uniprot.org,3534
NRAS A18T lies within a GTP-binding region of the Nras protein (UniProt.org). NRAS A18T is predicted to result in increased GTP/GDP cycling and nucleotide affinity comparable to wild-type (PMID: 11406571).,295,,,www.uniprot.org,2095,11406571,A novel N-ras mutation in malignant melanoma is associated with excellent prognosis.,http://www.ncbi.nlm.nih.gov/pubmed/11406571,3541
"NRAS S65C does not lie within any known functional domains of the Nras protein (UniProt.org). S65C confers a gain of function on Nras, as indicated by increased expression of p-MEK and p-ERK in cell culture (PMID: 24798740). ",4644,24798740,"Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/24798740,295,,,www.uniprot.org,3542
"NRAS G12A lies within a GTP-binding region of the Nras protein (UniProt.org). G12A has not been characterized, but can be predicted to result in decreased Nras GTPase activity and increased downstream pathway activation based on the effect of other NRAS codon 12 mutations and G12A mutations in KRAS (PMID: 23092099, PMID: 19075190).",547,19075190,"High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.",http://www.ncbi.nlm.nih.gov/pubmed/19075190,413,23092099,"Involvement of KRAS G12A mutation in the IL-2-independent growth of a human T-LGL leukemia cell line, PLT-2.",http://www.ncbi.nlm.nih.gov/pubmed/23092099,295,,,www.uniprot.org,3543
"NRAS G12C lies within a GTP-binding region of the Nras protein (UniProt.org). G12C has not been characterized, but can be predicted to result in decreased Nras GTPase activity and increased downstream pathway activation based on the effect of other NRAS codon 12 mutations and G12C mutations in KRAS (PMID: 19075190, PMID: 16679305).
",547,19075190,"High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.",http://www.ncbi.nlm.nih.gov/pubmed/19075190,2096,16679305,"K-ras Asp12 mutant neither interacts with Raf, nor signals through Erk and is less tumorigenic than K-ras Val12.",http://www.ncbi.nlm.nih.gov/pubmed/16679305,295,,,www.uniprot.org,3544
"NRAS G12N lies within a GTP-binding region of the Nras protein (UniProt.org). G12N has not been characterized, but can be predicted to result in decreased Nras GTPase activity and increased downstream pathway activation based on the effect of other NRAS codon 12 mutations (PMID: 19075190, PMID: 22589270).",547,19075190,"High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.",http://www.ncbi.nlm.nih.gov/pubmed/19075190,295,,,www.uniprot.org,2097,22589270,A comprehensive survey of Ras mutations in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22589270,3545
"NRAS G12R lies within a GTP-binding region of the Nras protein (UniProt.org). G12R has not been characterized, but can be predicted to result in decreased Nras GTPase activity and increased downstream pathway activation based on the effects of other NRAS codon 12 mutations and G12R in HRAS (PMID: 6092966, PMID: 22589270, PMID: 19075190).
 ",2098,6092966,Biological properties of human c-Ha-ras1 genes mutated at codon 12.,http://www.ncbi.nlm.nih.gov/pubmed/6092966,547,19075190,"High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.",http://www.ncbi.nlm.nih.gov/pubmed/19075190,295,,,www.uniprot.org,2097,22589270,A comprehensive survey of Ras mutations in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22589270,3546
"NRAS G12V lies within a GTP-binding region of the Nras protein (UniProt.org). G12V results in decreased Nras GAP sensitivity, leading to increased Nras pathway activation and is transforming in cell culture (PMID: 21478863, PMID: 19966803).
",2099,21478863,ERK and PDE4 cooperate to induce RAF isoform switching in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/21478863,2100,19966803,A restricted spectrum of NRAS mutations causes Noonan syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/19966803,3547
"NRAS G13D lies within a GTP-binding region of the Nras protein (UniProt.org). G13D results in decreased Nras GTPase activity, leading to activation of Nras downstream pathway signaling in cell culture (PMID: 17517660).",295,,,www.uniprot.org,2101,17517660,NRAS mutation causes a human autoimmune lymphoproliferative syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/17517660,3554
"NRAS G13R lies within a GTP-binding region of the Nras protein (UniProt.org). G13R has not been characterized, but can be predicted to result in decreased Nras GTPase activity and increased downstream pathway activation based on the effect of other RAS codon 13 mutations (PMID: 21993244).
",2102,21993244,RAS oncogenes: weaving a tumorigenic web.,http://www.ncbi.nlm.nih.gov/pubmed/21993244,295,,,www.uniprot.org,3558
"NRAS G13S lies within a GTP-binding region of the Nras protein (UniProt.org). G13S has not been characterized, but can be predicted to result in decreased Nras GTPase activity and increased downstream pathway activation based on the effect of other NRAS codon 13 mutations (PMID: 21993244).
",2102,21993244,RAS oncogenes: weaving a tumorigenic web.,http://www.ncbi.nlm.nih.gov/pubmed/21993244,295,,,www.uniprot.org,3560
"NRAS G13V lies within a GTP-binding region of the Nras protein (UniProt.org). G13V has not been characterized, but can be predicted to result in decreased Nras GTPase activity and increased downstream pathway activation based on the effect of other RAS codon 13 mutations (PMID: 21993244).",2102,21993244,RAS oncogenes: weaving a tumorigenic web.,http://www.ncbi.nlm.nih.gov/pubmed/21993244,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3561
"NRAS G13C lies within a GTP-binding region of the Nras protein (UniProt.org). G13C has not been characterized, but can be predicted to result in decreased Nras GTPase activity and increased downstream pathway activation based on the effect of other RAS codon 13 mutations (PMID: 21993244).",2102,21993244,RAS oncogenes: weaving a tumorigenic web.,http://www.ncbi.nlm.nih.gov/pubmed/21993244,295,,,www.uniprot.org,3564
"NRAS G13A lies within a GTP-binding region of the Nras protein (UniProt.org). G13A has not been characterized, but can be predicted to result decreased Nras GTPase activity and increased downstream pathway activation based on the effect of other RAS codon 13 mutations (PMID: 21993244).",2102,21993244,RAS oncogenes: weaving a tumorigenic web.,http://www.ncbi.nlm.nih.gov/pubmed/21993244,295,,,www.uniprot.org,3565
"KIT W557S lies within the juxtamembrane domain of the Kit protein (PMID: 16226710). W557S has not been characterized, however other W557 mutations are activating, thus W557S is predicted to confer a gain of Kit protein function (PMID: 23567324).",648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,647,23567324,Are two better than one? A novel double-mutant KIT in GIST that responds to Imatinib.,http://www.ncbi.nlm.nih.gov/pubmed/23567324,3566
"NRAS Q61E lies within a GTP-binding region of the Nras protein (UniProt.org). Q61E has not been characterized, but can be predicted to result in decreased Nras GTPase activity and increased downstream pathway activation based on the effect of other NRAS codon 61 mutations (PMID: 18814281, PMID: 21993244).",1935,18814281,Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro.,http://www.ncbi.nlm.nih.gov/pubmed/18814281,2102,21993244,RAS oncogenes: weaving a tumorigenic web.,http://www.ncbi.nlm.nih.gov/pubmed/21993244,3567
"NRAS Q61H lies within a GTP-binding region of the Nras protein (UniProt.org). Q61H results in decreased Nras GTPase activity, leading to increased downstream pathway activation in cell culture (PMID: 23103856).",295,,,www.uniprot.org,2103,23103856,Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling.,http://www.ncbi.nlm.nih.gov/pubmed/23103856,3568
"NRAS Q61L lies within a GTP-binding region of the Nras protein (UniProt.org). Q61L results decreased Nras GTPase activity, leading to increased activation of downstream pathway signaling, and is transforming in cell culture (PMID: 19492075, PMID: 21993244).
",295,,,www.uniprot.org,2104,19492075,Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors.,http://www.ncbi.nlm.nih.gov/pubmed/19492075,2105,18073111,Transformation efficiency of RasQ61 mutants linked to structural features of the switch regions in the presence of Raf.,http://www.ncbi.nlm.nih.gov/pubmed/18073111,2102,21993244,RAS oncogenes: weaving a tumorigenic web.,http://www.ncbi.nlm.nih.gov/pubmed/21993244,3569
"KRAS V14L lies within a GTP-binding region of the Kras protein (UniProt.org). V14L results in decreased Kras GTPase activity, and activation of downstream pathway signaling in cell culture (PMID: 16474405).",295,,,www.uniprot.org,840,16474405,Germline KRAS mutations cause Noonan syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/16474405,3570
KIT W557del results in the deletion of an amino acid in the juxtamembrane domain of the Kit protein at amino acids 557 (PMID: 12918066).  W557del is predicted to alter auto-inhibitory interactions in the Kit protein resulting in a gain of function (PMID: 12918066).,726,12918066,Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/12918066,3571
"KRAS R164* results in a premature truncation of the Kras protein at amino acid 164 of 189 (UniProt.org). R164* has been identified in sequencing studies (PMID: 24200637), but has not been biochemically characterized and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7702,24200637,Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/24200637,3572
"KRAS I36M lies within the switch I domain of the Kras protein (PMID: 17875937). I36M has been identified in sequencing studies (PMID: 27288520), but has not been biochemically characterized and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,830,17875937,Biochemical and functional characterization of germ line KRAS mutations.,http://www.ncbi.nlm.nih.gov/pubmed/17875937,6946,27288520,Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27288520,3573
"KRAS K147N does not lie within any known functional domains of the Kras protein (UniProt.org). K147N has been identified in sequencing studies (PMID: 23619167), but has not been biochemically characterized and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2263,23619167,Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.,http://www.ncbi.nlm.nih.gov/pubmed/23619167,3574
"KRAS K5E does not lie within any known functional domain of the Kras protein (UniProt.org). K5E has been identified as germline mutation in RAS syndromes (PMID: 23123965, PMID: 17704260), but not been biochemically characterized, and therefore its effect on Kras protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,10089,17704260,Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/17704260,5711,23123965,Negative regulation of Shh levels by Kras and Fgfr2 during hair follicle development.,http://www.ncbi.nlm.nih.gov/pubmed/23123965,3575
"KRAS Q61E lies within a GTP-binding region of the Kras protein (UniProt.org). Q61E has not been characterized, but can be predicted to result in decreased Kras GTPase activity based on the effect of other KRAS codon 61 mutations (PMID: 20147967, PMID: 21993244).",841,20147967,Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine.,http://www.ncbi.nlm.nih.gov/pubmed/20147967,2102,21993244,RAS oncogenes: weaving a tumorigenic web.,http://www.ncbi.nlm.nih.gov/pubmed/21993244,295,,,www.uniprot.org,3576
"KRAS Q61P lies within a GTP-binding region of the Kras protein (UniProt.org). Q61P has not been characterized, but can be predicted to result in decreased Kras GTPase activity based on the effect of other KRAS codon 61 mutations (PMID: 20147967, PMID: 21993244).
",841,20147967,Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine.,http://www.ncbi.nlm.nih.gov/pubmed/20147967,2102,21993244,RAS oncogenes: weaving a tumorigenic web.,http://www.ncbi.nlm.nih.gov/pubmed/21993244,295,,,www.uniprot.org,3577
KIT V825A lies within the protein kinase domain of the Kit protein (UniProt.org). V825A confers a gain of function to the Kit protein resulting in transformation of cultured cells (PMID: 24897507). ,2106,24897507,Activating c-KIT mutations confer oncogenic cooperativity and rescue RUNX1/ETO-induced DNA damage and apoptosis in human primary CD34+ hematopoietic progenitors.,http://www.ncbi.nlm.nih.gov/pubmed/24897507,295,,,www.uniprot.org,3578
"KIT V825I lies within the protein kinase domain of the Kit protein (UniProt.org). V825I has been identified in sequencing studies (PMID: 24896186), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Dec 2016).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,1360,24896186,Novel somatic and germline mutations in intracranial germ cell tumours.,http://www.ncbi.nlm.nih.gov/pubmed/24896186,295,,,www.uniprot.org,3579
"FGFR1 E670G lies within the protein kinase domain of the Fgfr1 protein (UniProt.org). E670G has not been characterized and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3580
"FGFR1 G610D lies within the protein kinase domain of the Fgfr1 protein (UniProt.org). G610D has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Jun 2017).",5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3581
"FGFR1 G687V lies within the protein kinase domain of the Fgfr1 protein (UniProt.org). G687V has not been characterized in the scientific literature and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3582
"FGFR1 G70R lies within the Ig-like C2-type domain 1 of the Fgfr1 protein (UniProt.org). G70R has been identified in sequencing studies (PMID: 18948947), but has not been biochemically characterized and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Jun 2017).",6956,18948947,Somatic mutations affect key pathways in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18948947,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3583
"FGFR1 P252S lies within the extracellular domain of the Fgfr1 protein (PMID: 18056464). P252S is predicted to confer a gain of function to the Fgfr1 protein, altering ligand specificity and increasing ligand affinity (PMID: 18056464).",2109,18056464,Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/18056464,3584
FGFR1 P252T lies within the extracellular domain of the Fgfr1 protein (PMID: 18056464). P252T is predicted to confer a gain of function to the Fgfr1 protein by altering ligand specificity and increasing ligand affinity (PMID: 18056464).,2109,18056464,Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/18056464,3585
"FGFR1 Q309* results in a premature truncation of the Fgfr1 protein at amino acid 309 of 822 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), Q309* is predicted to lead to a loss of Fgfr1 protein function.",295,,,www.uniprot.org,3586
"FGFR1 R189H lies within the Ig-like C2-type domain 2 of the Fgfr1 protein (UniProt.org). R189H has not been characterized in the scientific literature and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Jun 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3587
FGFR1 R250W lies within the linker D2–D3 region of the Fgfr1 protein (PMID: 23276709). R250W is predicted to confer a loss of function to the Fgfr1 protein by disrupting ligand binding (PMID: 23276709).,2110,23276709,Comparative functional analysis of two fibroblast growth factor receptor 1 (FGFR1) mutations affecting the same residue (R254W and R254Q) in isolated hypogonadotropic hypogonadism (IHH).,http://www.ncbi.nlm.nih.gov/pubmed/23276709,3588
FGFR1 R250Q lies within the linker D2–D3 region of the Fgfr1 protein (PMID: 23276709). R250Q is predicted to confer a loss of function to the Fgfr1 protein disrupting ligand binding (PMID: 23276709).,2110,23276709,Comparative functional analysis of two fibroblast growth factor receptor 1 (FGFR1) mutations affecting the same residue (R254W and R254Q) in isolated hypogonadotropic hypogonadism (IHH).,http://www.ncbi.nlm.nih.gov/pubmed/23276709,3589
"BRAF V600_K601delinsE results in the deletion of two amino acids formation of a new glutamic acid (E) residue in the protein kinase domain of the Braf protein between amino acids 600 and 601 (UniProt.org, PMID: 22563563). V600_K601delinsE leads to activation of downstream Mek and Erk signaling, and increased colony formation in cultured cells (PMID: 17297294).",2112,17297294,Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17297294,295,,,www.uniprot.org,2113,22563563,Identification of a rare 3 bp BRAF gene deletion in a thyroid nodule by mutant enrichment with 3'-modified oligonucleotides polymerase chain reaction.,http://www.ncbi.nlm.nih.gov/pubmed/22563563,3590
"FGFR1 R507H lies within the protein kinase domain of the Fgfr1 protein and also refers to R505H and R497H in other Fgfr1 isoforms (UniProt.org). R507H has not been characterized in the scientific literature and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3591
"FGFR1 R646L lies within the protein kinase domain of the Fgfr1 protein (UniProt.org). R646L has not been characterized in the scientific literature and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3592
"FGFR1 S125L lies within the extracellular domain of the Fgfr1 protein (UniProt.org). S125L has been identified in the scientific literature (PMID: 15908952, PMID: 25677745), but has not been biochemically characterized and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Jun 2017).",9219,25677745,Rationale for targeting fibroblast growth factor receptor signaling in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25677745,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7208,15908952,A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/15908952,3593
"FGFR1 V102I lies within the Ig-like C2-type domain 1 of the Fgfr1 protein (UniProt.org). V102I has been identified in the scientific literature (PMID: 16764984), but has not been biochemically characterized and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Jun 2017).",7209,16764984,Mutations in fibroblast growth factor receptor 1 cause Kallmann syndrome with a wide spectrum of reproductive phenotypes.,http://www.ncbi.nlm.nih.gov/pubmed/16764984,115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3594
"FGFR1 W684G lies within the protein kinase domain of the Fgfr1 protein (UniProt.org). W684G has not been characterized in the scientific literature and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3595
FGFR2 D101Y lies within the extracellular Ig-like C2-type 1 domain of the Fgfr2 protein (UniProt.org). D101Y results in the transformation of cells in culture (PMID: 18552176). ,252,18552176,Drug-sensitive FGFR2 mutations in endometrial carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18552176,3597
"FGFR2 E596K lies within the protein kinase domain if the Fgfr2 protein (UniProt.org). E596K has not been characterized in the scientific literature and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3598
"FGFR2 E636* results in the premature truncation within the kinase domain of the Fgfr2 at amino acid 636 of 821 (UniProt.org). Due to the disruption of the protein kinase domain, E636* is predicted to lead to a loss of function. ",295,,,www.uniprot.org,3599
"FGFR2 E695K lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). E695K has been identified in sequencing studies (PMID: 24265153), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5840,24265153,The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24265153,3600
"FGFR1 D133E lies within the extracellular domain of the Fgfr1 protein (UniProt.org). D133E has not been characterized and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3601
"FGFR1 E138* results in the premature truncation of the Fgfr1 protein at amino acid 138 of 822 (UniProt.org). Due to the loss of all known functional domains, E138* is predicted to lead to a loss of function.",295,,,www.uniprot.org,3602
"FGFR1 S135F lies within the extracellular domain of the Fgfr1 protein (UniProt.org). S135F has not been characterized in the scientific literature and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3603
"KRAS A11P lies within a GTP binding region of the Kras protein (UniProt.org). A11P has been identified in sequencing studies (PMID: 20592359, PMID: 27705932), but has not been biochemically characterized and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,10045,27705932,KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control.,http://www.ncbi.nlm.nih.gov/pubmed/27705932,7691,20592359,Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/20592359,3604
"KRAS A11V lies within a GTP binding region of the Kras protein (UniProt.org). A11V has been identified in sequencing studies (PMID: 28031051), but has not been biochemically characterized and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7692,28031051,The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28031051,3605
"KRAS A11_G12insGA results in the insertion of two amino acids in the GTP binding domain of the Kras protein between amino acids 11 and 12 (UniProt.org). A11_G12insGA reduces Kras GTPase activity, leads to increased activation of downstream Erk signaling, and promotes transformation in cultured cells (PMID: 24642870).",295,,,www.uniprot.org,2127,24642870,Characterization of rare transforming KRAS mutations in sporadic colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24642870,3606
"KRAS A18D lies within a GTP binding region of the Kras protein (UniProt.org). The functional effect of A18D is conflicting, as A18D has been reported to confer anchorage-independent growth ability on cultured cells (PMID: 19490892), and has also been reported to have no effect on intrinsic GTPase activity or anchorage-independent growth ability on cultured cells (PMID: 25705018).",2128,19490892,Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/19490892,295,,,www.uniprot.org,2129,25705018,"Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines.",http://www.ncbi.nlm.nih.gov/pubmed/25705018,3607
"NRAS Q61P lies within a GTP-binding region of the Nras protein (UniProt.org). Q61P has not been characterized, but can be predicted to result in decreased Nras GTPase activity and increased downstream pathway activation based on the effect of other NRAS codon 61 mutations (PMID: 18814281, PMID: 21993244).",1935,18814281,Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro.,http://www.ncbi.nlm.nih.gov/pubmed/18814281,2102,21993244,RAS oncogenes: weaving a tumorigenic web.,http://www.ncbi.nlm.nih.gov/pubmed/21993244,295,,,www.uniprot.org,3608
"EML4-ALK results from the fusion of EML4 and ALK, resulting in constitutive kinase activity, transformation in cultured cells, and tumor activity in mouse models (PMID: 19064915, PMID: 17625570). ",2130,19064915,A mouse model for EML4-ALK-positive lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19064915,2131,17625570,Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17625570,3610
"FGFR2 K660E lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). K660E results in increased phosphorylation of Fgfr2, activation of downstream signaling, and is transforming in cell culture (PMID: 23786770).",295,,,www.uniprot.org,2132,23786770,Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23786770,3611
"FGFR2 L617F lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). L617F results in enhanced Fgfr2 autophosphorylation and activation of Runx2, but activation of Mapk/Erk similar to wild-type Fgfr2 in cell culture (PMID: 23913723).",2133,23913723,"A novel FGFR2 mutation in tyrosine kinase II domain, L617F, in Crouzon syndrome.",http://www.ncbi.nlm.nih.gov/pubmed/23913723,295,,,www.uniprot.org,3612
"KRAS A59E lies within a GTP binding region of the Kras protein (UniProt.org). A59E has been identified in sequencing studies (PMID: 22931052), but has not been biochemically characterized and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).
",7695,22931052,"Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia.",http://www.ncbi.nlm.nih.gov/pubmed/22931052,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3613
"KRAS A59G lies within the GTP binding domain of the Kras protein (UniProt.org). A59G increases bound GTP to KRAS, activates MAPK and PI3K pathways, and induces tumor formation in in vivo models (PMID: 27147599).
",6273,27147599,Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.,http://www.ncbi.nlm.nih.gov/pubmed/27147599,295,,,www.uniprot.org,3615
KRAS D119N lies within the GTP binding region of the Kras protein (UniProt.org). D119N decreases GTPase activity of Kras leading to increased activation of the downstream Mapk signaling pathway (PMID: 11103938).,2137,11103938,Oncogenic insertional mutations in the P-loop of Ras are overactive in MAP kinase signaling.,http://www.ncbi.nlm.nih.gov/pubmed/11103938,295,,,www.uniprot.org,3616
"KRAS E62K lies adjacent to the Q61 hotspot residue (UniProt.org, PMID: 22589270). E62K may confer a loss of function on the Kras protein as demonstrated by the ability to induce tumor formation in in vivo models (PMID: 27147599).",295,,,www.uniprot.org,6273,27147599,Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.,http://www.ncbi.nlm.nih.gov/pubmed/27147599,2097,22589270,A comprehensive survey of Ras mutations in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22589270,3617
"KRAS E98* results in the premature truncation of the Kras protein at amino acid 98 of 189 (UniProt.org). Due to the the loss of the GTP binding domain (UniProt.org), E98* is predicted to confer loss of function to the Kras protein (PMID: 20570890).",295,,,www.uniprot.org,843,20570890,Genomic and biological characterization of exon 4 KRAS mutations in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20570890,3618
"FGFR2 M538R lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). M538R has not been characterized in the scientific literature and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3624
"FGFR2 N549H lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). N549H confers a gain of function to the Fgfr2 protein as indicated by disengagement of autoinhibitory mechanisms thereby resulting in constitutive activation and downstream pathway activation (PMID: 17525745, PMID: 17803937).",295,,,www.uniprot.org,702,17525745,Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/17525745,1905,17803937,A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases.,http://www.ncbi.nlm.nih.gov/pubmed/17803937,3625
"FGFR2 N550H lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). N550H results in increased Fgfr2 kinase activity, as well as increased Fgfr2 phosphorylation and enhanced cell proliferation in the presence of ligand in culture (PMID: 23908597).",295,,,www.uniprot.org,2138,23908597,"The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/23908597,3626
FGFR2 N550K lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). N550K results in increased Fgfr2 kinase activity and enhanced cell proliferation in the presence of ligand in culture (PMID: 23908597).,2138,23908597,"The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/23908597,295,,,www.uniprot.org,3627
"FGFR2 P253R lies within the region linking Ig-like domains II and III of the Fgfr2 protein (PMID: 11121055). P253R results in loss of ligand specificity, activation of the p38/MAPK pathway in transgenic mouse models, and is transforming in cell culture (PMID: 11121055, PMID: 20175913, PMID: 23786770).",2140,20175913,Activation of p38 MAPK pathway in the skull abnormalities of Apert syndrome Fgfr2(+P253R) mice.,http://www.ncbi.nlm.nih.gov/pubmed/20175913,2132,23786770,Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23786770,2139,11121055,Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/11121055,3628
"FGFR2 S252W lies within the region linking Ig-like domains II and III of the Fgfr2 protein (PMID: 11121055). S252W results in loss of ligand specificity, increased Fgfr2 activation, and is transforming in cell culture (PMID: 11121055, PMID: 18552176).",2139,11121055,Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/11121055,252,18552176,Drug-sensitive FGFR2 mutations in endometrial carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18552176,3629
"FGFR2 P775L lies within the cytoplasmic domain of the Fgfr2 protein (UniProt.org). P775L has not been characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3630
FGFR2 Y376C lies within the extracellular domain of the Fgfr2 protein (PMID: 17525745). Y376C is predicted to confer a gain of function to Fgfr2 via constitutive dimerization through inter-molecular disulfide bonds (PMID: 17525745).,702,17525745,Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/17525745,3631
"FGFR2 E718K lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). E718K has not been characterized in the scientific literature and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3636
"FGFR2 E777K does not lie within any known functional domains of the Fgfr2 protein (UniPort.org). E777K has not been characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3637
"FGFR2 F276C lies within the Ig-like C2-type 3 domain of the Fgfr2 protein (UniPort.org). F276C has been identified in sequencing studies (PMID: 24185509), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,6961,24185509,"Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/24185509,295,,,www.uniprot.org,3638
"FGFR2 G227R lies within the Ig-like C2-type domain 2 of the Fgfr2 protein (UniPort.org). G227R has not been characterized in the scientific literature and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3640
"FGFR2 G583R lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). G583R has not been characterized in the scientific literature and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3641
"FGFR2 G690R lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). G690R has not been characterized in the scientific literature and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3642
"FGFR2 H544Q lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). H544Q has been identified in sequencing studies (PMID: 18948947), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jul 2017).",6956,18948947,Somatic mutations affect key pathways in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18948947,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3643
"FGFR2 I642T lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). I642T has not been characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3644
FGFR2 K310R lies within the Ig-like C2-type 3 domain of the Fgfr2 protein (UniProt.org). K310R is not transforming in cell culture (PMID: 18552176).,252,18552176,Drug-sensitive FGFR2 mutations in endometrial carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18552176,295,,,www.uniprot.org,3645
"FGFR2 P303L lies within the Ig-like C2-type domain 3 of the Fgfr2 protein (UniPort.org). P303L has been identified in the scientific literature (PMID: 19812598), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9357,19812598,Somatic mutation of epidermal growth factor receptor in a small subset of cutaneous squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/19812598,3646
Wild-type EML4 indicates that no mutation has been detected within the EML4 gene. ,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,3651
"TP53 R248Q is a hotspot mutation that lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). R248Q results in decreased wild-type Tp53 transcriptional activity, as well as increased Akt activation and enhanced tumor onset and growth in mouse models (PMID: 23538418).",2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,1298,23538418,Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/23538418,3655
"TP53 V157F lies within the DNA-binding core domain of the Tp53 protein (PMID: 21561095). V157F results in decreased activation and repression of Tp53 targets, and also confers a gain of function to Tp53, resulting in aberrant gene activation in cell culture (PMID: 15077194, PMID: 16778209).",2156,15077194,Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes.,http://www.ncbi.nlm.nih.gov/pubmed/15077194,2157,16778209,"Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells.",http://www.ncbi.nlm.nih.gov/pubmed/16778209,2155,21561095,"Structural effects of the L145Q, V157F, and R282W cancer-associated mutations in the p53 DNA-binding core domain.",http://www.ncbi.nlm.nih.gov/pubmed/21561095,3657
"KRAS G10dup indicates the insertion of the duplicate amino acid, glycine (G)-10, in the GTP binding domain of the Kras protein (UniProt.org). G10dup reduces Kras GTPase activity, leads to increased activation of downstream Erk signaling, and promotes transformation in cultured cells (PMID: 24642870).",2127,24642870,Characterization of rare transforming KRAS mutations in sporadic colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24642870,295,,,www.uniprot.org,3658
"KRAS G12E lies within a mutational “hotspot” in the GTP nucleotide binding domain of the Kras protein (UniProt.org, PMID: 23455880). G12E has not been characterized, however other G12 mutations inhibit Kras GTPase activity and increase downstream signaling, thus G12E is predicted to confer loss of function to the Kras protein (PMID: 23455880).",26,23455880,KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23455880,295,,,www.uniprot.org,3659
"KRAS G12F lies within a mutational “hotspot” in the GTP nucleotide binding domain of the Kras protein (UniProt.org, PMID: 23455880). G12F results in decreased Kras GTPase activity and activation of downstream Mapk signaling (PMID: 11668624)",2159,11668624,Oncogenic levels of mitogen-activated protein kinase (MAPK) signaling of the dinucleotide KRAS2 mutations G12F and GG12-13VC.,http://www.ncbi.nlm.nih.gov/pubmed/11668624,26,23455880,KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23455880,295,,,www.uniprot.org,3660
"FGFR2 Q259* results in a premature truncation of the Fgfr2 protein at amino acid 259 of 821 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), Q259* is predicted to lead to a loss of Fgfr2 function.",295,,,www.uniprot.org,3661
FGFR2 R203C lies within the Ig-like C2-type 2 domain of the Fgfr2 protein (UniProt.org). R203C results in increased phosphorylation of Fgfr2 and activation of Mek signaling in cell culture (PMID: 23527311).,2160,23527311,Activating somatic FGFR2 mutations in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23527311,295,,,www.uniprot.org,3662
"FGFR2 R210Q lies within the Ig-like C2-type domain 2 of the Fgfr2 protein (UniProt.org). R210Q has been identified in sequencing studies (PMID: 26343386), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7139,26343386,Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway.,http://www.ncbi.nlm.nih.gov/pubmed/26343386,3663
"FGFR2 R251* results in a premature truncation of the Fgfr2 protein at amino acid 251 of 821 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), R251* is predicted to lead to a loss of Fgfr2 function.",295,,,www.uniprot.org,3664
FGFR2 R251Q lies within the region linking Ig-like domains II and III of the Fgfr2 protein (PMID: 11121055). R251Q results in loss of ligand binding and diminished Mapk activation upon Fgf2 stimulation in cell culture (PMID: 19147536).,2139,11121055,Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/11121055,1037,19147536,Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/19147536,3665
"FGFR2 R330W lies within the Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). R330W has been identified in sequencing studies (PMID: 22197931), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,429,22197931,Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22197931,3666
"FGFR2 R625Q lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). R625Q has not been characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3667
"FGFR2 R664W lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). R664W results in a 60% decrease in autophosphorylation compared to wild-type in an in vitro kinase assay (PMID: 28151998)  and therefore, is predicted to result in loss of Fgfr2 protein function.",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9358,28151998,Effects of FGFR2 kinase activation loop dynamics on catalytic activity.,http://www.ncbi.nlm.nih.gov/pubmed/28151998,3668
"FGFR2 S372C lies within the extracellular juxtamembrane domain of the Fgfr2 protein (PMID: 17525745). S372C has been identified in the scientific literature (PMID: 8696350), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,702,17525745,Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/17525745,7211,8696350,Fibroblast growth factor receptor 2 mutations in Beare-Stevenson cutis gyrata syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/8696350,3669
"FGFR2 S372F lies within the extracellular juxtamembrane domain of the Fgfr2 protein (PMID: 17525745). S372F has not been characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,702,17525745,Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/17525745,3670
"TP53 R175A is a hotspot mutation that lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). R175A results in a small decrease in Tp53 DNA-binding affinity and transactivation in cell culture (PMID: 10713666, PMID: 17401432).",1939,10713666,Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/10713666,2163,17401432,Structure-function-rescue: the diverse nature of common p53 cancer mutants.,http://www.ncbi.nlm.nih.gov/pubmed/17401432,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,3671
"GNA11 H327R does not lie within any known functional domains of the Gna11 protein (UniProt.org). H327R has not been characterized in the scientific literature and therefore, its effect on Gna11 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3672
"GNA11 K275N lies within the GTPase domain of the Gna11 protein (UniProt.org). K275N has not been characterized in the scientific literature and therefore, its effect on GNA11 protein function is unknown (PubMed, Aug 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3673
"GNA11 L135P does not lie within any known functional domains of the Gna11 protein (UniProt.org). L135P has not been characterized in the scientific literature and therefore, its effect on Gna11 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3674
"GNA11 S268F does not lie within any known functional domains of the Gna11 protein (UniProt.org). S268F has been identified in the scientific literature  (PMID: 26994145), but not been biochemically characterized and therefore, its effect on Gna11 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9847,26994145,MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research.,http://www.ncbi.nlm.nih.gov/pubmed/26994145,3675
"GNAQ D71Y does not lie within any known functional domains of the Gnaq protein (UniProt.org). D71Y has not been characterized in the scientific literature and therefore, its effect on Gnaq protein function is unknown (PubMed, Feb 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3676
"GNAQ E307* results in a premature truncation of the Gnaq protein at amino acid 307 of 359 (UniProt.org). E307* has not been characterized in the scientific literature and therefore, its effect on Gnaq protein function is unknown (PubMed, Feb 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3677
"GNAS Q227E (corresponding to Q870E in isoform XLas-1) lies within the GTP binding domain of the Gnas short isoform 1 (UniProt.org, PMID: 23640210). Q227E is a hotspot mutation, which impairs GTPase function, rendering Gnas and downstream pathways constitutively active (PMID: 23640210).",253,23640210,The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23640210,295,,,www.uniprot.org,3678
"GNAQ K72E does not lie within any known functional domains of the Gnaq protein (UniProt.org). K72E has been identified in sequencing studies (PMID: 22941189), but has not been biochemically characterized and therefore, its effect on Gnaq protein function is unknown (PubMed, Feb 2017).",6959,22941189,Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22941189,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3679
"GNAQ R114* results in a premature truncation of the Gnaq protein at amino acid 114 of 359 (UniProt.org). Due to the loss of the GTPase domain (UniProt.org), R114 is predicted to lead to a loss of Gnaq protein function.",295,,,www.uniprot.org,3680
DNMT3A mutant indicates an unspecified mutation in the DNMT3A gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,3681
ASXL1 mutant indicates an unspecified mutation in the ASXL1 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,3682
"KRAS G12Y lies within a mutational “hotspot” in the GTP nucleotide binding domain of the Kras protein (UniProt.org, PMID: 23455880). G12Y has not been characterized, however other G12 mutations inhibit Kras GTPase activity and increase downstream signaling, thus G12Y is predicted to confer a loss of function to the Kras protein (PMID: 23455880).",26,23455880,KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23455880,295,,,www.uniprot.org,3683
"KRAS G12I lies within a mutational “hotspot” in the GTP nucleotide binding domain of the Kras protein (UniProt.org, PMID: 23455880). G12I has not been characterized, however other G12 mutations inhibit KRas GTPase activity and increase downstream signaling, thus G12I is predicted to confer a loss of function to the Kras protein (PMID: 23455880).",26,23455880,KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23455880,295,,,www.uniprot.org,3685
"KRAS G12W lies within a mutational “hotspot” in the GTP nucleotide binding domain of the Kras protein (UniProt.org, PMID: 23455880). G12W has not been characterized, however other G12 mutations inhibit Kras GTPase activity and increase downstream signaling, thus G12W is predicted to confer a loss of function to the Kras protein (PMID: 23455880).",26,23455880,KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23455880,295,,,www.uniprot.org,3686
"KRAS G12L lies within a mutational “hotspot” in the GTP nucleotide binding domain of the Kras protein (UniProt.org, PMID: 23455880). G12L has not been characterized, however other G12 mutations inhibit Kras GTPase activity and increase downstream signaling, thus G12L is predicted to confer a loss of function to the Kras protein (PMID: 23455880).",26,23455880,KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23455880,295,,,www.uniprot.org,3687
"KRAS D57N lies in a conserved motif within the switch 2 region of the Kras protein (PMID: 15878843). D57N has been identified in sequencing studies (PMID: 23468066), but has not been biochemically characterized and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).
",2172,15878843,Structure of the G60A mutant of Ras: implications for the dominant negative effect.,http://www.ncbi.nlm.nih.gov/pubmed/15878843,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7697,23468066,Increased detection rates of EGFR and KRAS mutations in NSCLC specimens with low tumour cell content by 454 deep sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/23468066,3689
"KRAS V41I lies adjacent to the effector domain of the Kras protein (UniProt). V41I reduces Kras GTPase activity, leads to increased activation of downstream Erk signaling, and promotes transformation of cultured cells (PMID: 16474405, PMID: 19075190).",547,19075190,"High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.",http://www.ncbi.nlm.nih.gov/pubmed/19075190,295,,,www.uniprot.org,840,16474405,Germline KRAS mutations cause Noonan syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/16474405,3690
"KRAS G12dup (also referred to as G12_G13insG) indicates the insertion of the duplicate amino acid, glycine (G)-12, in a GTP binding region of the Kras protein (UniProt.org). G12dup (G12_G13insG) has been identified in the scientific literature (PMID: 24594115, PMID: 16826224), but has not been biochemically characterized and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).",10051,16826224,A novel somatic K-Ras mutation in juvenile myelomonocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/16826224,7699,24594115,KRAS insertions in colorectal cancer: what do we know about unusual KRAS mutations?,http://www.ncbi.nlm.nih.gov/pubmed/24594115,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3691
"KRAS G13R lies within a mutational “hotspot” in the GTP nucleotide binding domain of the Kras protein (UniProt.org, PMID: 23455880). G13R has not been characterized, however other G13 mutations inhibit Kras GTPase activity and increase downstream signaling, thus G13R is predicted to confer a loss of function to the Kras protein (PMID: 23455880).",26,23455880,KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23455880,295,,,www.uniprot.org,3692
"GNAS Q227H (corresponding to Q870H in isoform XLas-1) lies within the GTP conformational domain of the Gnas short isoform 1 (UniProt.org, PMID: 23640210). Q227H is a hotspot mutation, which impairs GTPase function, rendering Gnas and downstream pathways constitutively active (PMID: 23640210).",253,23640210,The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23640210,3693
"GNAS Q227K (corresponding to Q870K in isoform XLas-1) lies within the GTP conformational domain of the Gnas short isoform 1 (UniProt.org, PMID: 23640210). Q227K is a hotspot mutation, which impairs GTPase function, rendering Gnas and downstream pathways constitutively active (PMID: 23640210).",253,23640210,The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23640210,295,,,www.uniprot.org,3694
"GNAQ R166H does not lie within any known functional domains of the Gnaq protein (UniProt.org). R166H has not been characterized in the scientific literature and therefore, its effect on Gnaq protein function is unknown (PubMed, Feb 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3695
"GNAS Q227R (corresponding to Q870R in isoform XLas-1) lies within the GTP conformational domain of the Gnas short isoform 1 (UniProt.org, PMID: 23640210). Q227R is a hotspot mutation, which impairs GTPase function, rendering Gnas and downstream pathways constitutively active (PMID: 23640210).",253,23640210,The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23640210,295,,,www.uniprot.org,3696
"GNA11 R181Q lies within a GTP binding region of the Gna11 protein (UniProt.org). R181Q is predicted to interfere with Gna11 GTPase activity, and results in increased downstream ERK phosphorylation in the presence of calcium, but not constitutive activation of downstream signaling, in cell culture (PMID: 23802516, PMID: 26994139).",295,,,www.uniprot.org,8756,26994139,Allosteric Modulation of the Calcium-sensing Receptor Rectifies Signaling Abnormalities Associated with G-protein α-11 Mutations Causing Hypercalcemic and Hypocalcemic Disorders.,http://www.ncbi.nlm.nih.gov/pubmed/26994139,2173,23802516,Mutations affecting G-protein subunit α11 in hypercalcemia and hypocalcemia.,http://www.ncbi.nlm.nih.gov/pubmed/23802516,3698
"GNAQ R181T lies within the GTP nucleotide binding region of the Gnaq protein (UniProt.org). R181T has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Gnaq protein function is unknown (PubMed, Mar 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,3699
"GNAS R201G (corresponding to R844G in isoform XLas-1) lies within a mutational hotspot in the GTP binding domain of the Gnas short isoform 1 (UniProt.org; PMID: 23640210). R201G impairs GTPase function, rendering Gnas and downstream pathways constitutively active (PMID: 10571700, PMID: 23640210).",253,23640210,The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23640210,295,,,www.uniprot.org,2174,10571700,"A novel GNAS1 mutation, R201G, in McCune-albright syndrome.",http://www.ncbi.nlm.nih.gov/pubmed/10571700,3700
"GNAQ R247L does not lie within any known functional domains of the Gnaq protein (UniProt.org). R247L has been identified in sequencing studies (PMID: 22980975), but has not been biochemically characterized and therefore, its effect on Gnaq protein function is unknown (PubMed, Feb 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1726,22980975,Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/22980975,3701
"GNAS R201H (corresponding to R844H in isoform XLas-1) lies within a hotspot in the GTP binding domain of the Gnas short isoform 1 (UniProt.org; PMID: 23640210). R201H results in a loss of the GTPase activity of Gnas leading to constitutive downstream pathway activation in culture (PMID: 2549426, PMID: 24498230).",2541,24498230,"GNAS mutations identify a set of right-sided, RAS mutant, villous colon cancers.",http://www.ncbi.nlm.nih.gov/pubmed/24498230,253,23640210,The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23640210,295,,,www.uniprot.org,24,2549426,GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours.,http://www.ncbi.nlm.nih.gov/pubmed/2549426,3702
"GNAQ S211L does not lie within any known functional domains of the Gnaq protein (UniProt.org). S211L has been identified in sequencing studies (PMID: 22842228), but has not been biochemically characterized and therefore, its effect on Gnaq protein function is unknown (PubMed, Feb 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7109,22842228,Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22842228,3703
"GNAS R201S (corresponding to R844S in isoform XLas-1) lies within a mutational hotspot in the GTP binding domain of the Gnas short isoform 1 (UniProt.org; PMID: 23640210). R201S impairs GTPase function, rendering Gnas and downstream pathways constitutively active (PMID: 10571700, PMID: 23640210).
",253,23640210,The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23640210,295,,,www.uniprot.org,2174,10571700,"A novel GNAS1 mutation, R201G, in McCune-albright syndrome.",http://www.ncbi.nlm.nih.gov/pubmed/10571700,3704
"GNAQ S268L does not lie within any known functional domains of the Gnaq protein (UniProt.org). S268L has been identified in sequencing stuides (PMID: 24755471), but has not been biochemically characterized and therefore, its effect on Gnaq protein function is unknown (PubMed, Feb 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6962,24755471,Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24755471,3705
"GNAQ T329M does not lie within any known functional domains of the Gnaq protein (UniProt.org). T329M has not been characterized in the scientific literature and therefore, its effect on Gnaq protein function is unknown (PubMed, Feb 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3707
"GNAQ Y101* results in a premature truncation of the Gnaq protein at amino acid 101 of 359 (UniProt.org). Due to the loss of the GTPase domain (UniProt.org), Y101* is predicted to lead to a loss of Gnaq protein function.
",295,,,www.uniprot.org,3708
"FGFR3 V329A lies within the Ig-like C2-type domain 3 of the Fgfr3 protein (UniProt.org). V329A has not been characterized in the scientific literature and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3710
"FGFR3 V700A lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). V700A has not been characterized in the scientific literature and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jul 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3711
"FGFR3 Y373C lies within the extracellular domain of the Fgfr3 protein (UniProt.org). Y373C confers a gain of function to the Fgfr3 protein resulting in constitutive activation, downstream signaling, and transformation of cultured cells (PMID: 11429702).",2175,11429702,"Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.",http://www.ncbi.nlm.nih.gov/pubmed/11429702,295,,,www.uniprot.org,3712
"GNAS R844H does not lie within any known functional domains of the Gnas protein (UniProt.org). R844H confers a loss of function to the Gnas protein as demonstrated by elevated cAMP compared to wild-type Gnas in culture, and localizes to the plasma membrane (PMID: 19423757).",2176,19423757,"Extralarge XL(alpha)s (XXL(alpha)s), a variant of stimulatory G protein alpha-subunit (Gs(alpha)), is a distinct, membrane-anchored GNAS product that can mimic Gs(alpha).",http://www.ncbi.nlm.nih.gov/pubmed/19423757,295,,,www.uniprot.org,3713
"FGFR3 L385M lies within the transmembrane domain of the Fgfr3 protein (UniProt.org). L385M has not been characterized in the scientific literature and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jul 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3715
"FGFR3 L645V lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). L645V has not been characterized in the scientific literature and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jul 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3717
"FGFR3 L794fs results in a change in the amino acid sequence of the Fgfr3 protein beginning at aa 794 of 806, likely resulting in a premature truncation of the functional protein (UniProt.org). L794fs has not been characterized in the scientific literature and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jul 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3719
FGFR3 R200C lies within the Ig-like C2-type 2 domain of the Fgfr3 protein (UniProt.org). R200C confers a gain of function to the Fgfr3 protein resulting in dimerization and constitutive activation (PMID: 16912704).,295,,,www.uniprot.org,2177,16912704,Novel FGFR3 mutations creating cysteine residues in the extracellular domain of the receptor cause achondroplasia or severe forms of hypochondroplasia.,http://www.ncbi.nlm.nih.gov/pubmed/16912704,3721
"FGFR3 R421Q lies within the cytoplasmic domain of the Fgfr3 protein (UniProt.org). R421Q has not been characterized in the scientific literature and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jul 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3722
"FGFR3 R640W lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). R640W has been identified in sequencing studies (PMID: 26517354), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jul 2017).",7216,26517354,Mutational profiling of colorectal cancers with microsatellite instability.,http://www.ncbi.nlm.nih.gov/pubmed/26517354,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3723
"FGFR3 S371C lies within the extracellular domain of the Fgfr3 protein (UniProt.org). S371C confers a gain of function to the Fgfr3 protein resulting in dimerization, constitutive activation, and increased MAPK pathway signaling (PMID: 12009017).",295,,,www.uniprot.org,1806,12009017,Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization.,http://www.ncbi.nlm.nih.gov/pubmed/12009017,3724
"FGFR3 S400fs results in a change in the amino acid sequence of the Fgfr3 protein beginning at aa 400 of 806, likely resulting in a premature truncation of the functional protein (UniProt.org). Due to a loss of the protein kinase domain (UniProt.org), S400fs is predicted to lead to a loss of Fgfr3 protein function.
",295,,,www.uniprot.org,3726
"FGFR2 Y769* results in a premature truncation of the Fgfr2 protein at amino acid 769 of 821 (UniProt.org). Y769* has not been characterized in the scientific literature and therefore, its effect on Fgfr2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3727
"FGFR3 A391E lies within the transmembrane domain of the Fgfr3 protein (UniProt.org). A391E results in increased dimerization and ligand-independent activation of Fgfr3 in cell culture (PMID: 21536014, PMID: 23437153)",2184,23437153,Multiple consequences of a single amino acid pathogenic RTK mutation: the A391E mutation in FGFR3.,http://www.ncbi.nlm.nih.gov/pubmed/23437153,2185,21536014,The A391E mutation enhances FGFR3 activation in the absence of ligand.,http://www.ncbi.nlm.nih.gov/pubmed/21536014,3728
FGFR3 D641N lies within the TK-2 domain of the Fgfr3 protein (PMID: 19287463). D641N results in increased Fgfr3 autophosphorylation and substrate phosphorylation in cell culture (PMID: 26992226).,6316,26992226,Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.,http://www.ncbi.nlm.nih.gov/pubmed/26992226,2186,19287463,FGFR3 and TP53 mutation analysis in inverted urothelial papilloma: incidence and etiological considerations.,http://www.ncbi.nlm.nih.gov/pubmed/19287463,3729
"FGFR3 E456K lies within the cytoplasmic domain of the Fgfr3 protein (UniProt.org). E456K has not been characterized in the scientific literature and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3730
"KRAS G15S lies within a GTP binding region of the Kras protein (UniProt.org). G15S has been identified in sequencing studies (PMID: 24030381), but has not been biochemically characterized and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7701,24030381,Clinical and biological implications of driver mutations in myelodysplastic syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/24030381,3732
"KRAS G138V does not lie within any known functional domains of the Kras protein (UniProt.org). G138V has been identified in sequencing studies (PMID: 22460905), but has not been biochemically characterized and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,10054,22460905,The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.,http://www.ncbi.nlm.nih.gov/pubmed/22460905,3733
"FGFR3 E686K lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). E686K has been identified in the scientific literature (PMID: 19327639), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7214,19327639,Identification of novel fibroblast growth factor receptor 3 gene mutations in actinic cheilitis and squamous cell carcinoma of the lip.,http://www.ncbi.nlm.nih.gov/pubmed/19327639,3734
FGFR3 F384L lies within the transmembrane domain of the Fgfr3 protein (UniProt.org). F384L does not result in activation of Fgfr3 and is not transforming in cell culture (PMID: 11157491).,2189,11157491,Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.,http://www.ncbi.nlm.nih.gov/pubmed/11157491,3735
"FGFR3 G380R lies within the transmembrane domain of the Fgfr3 protein (PMID: 20624921). G380R results in increased ligand-independent phosphorylation of Fgfr3 and enhanced ligand-dependent activation of downstream signaling, but is not transforming in cell culture (PMID: 20624921, PMID: 9136983, PMID: 10611230).",2192,10611230,The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation.,http://www.ncbi.nlm.nih.gov/pubmed/10611230,2191,20624921,"Physical basis behind achondroplasia, the most common form of human dwarfism.",http://www.ncbi.nlm.nih.gov/pubmed/20624921,2114,9136983,Activation of FGF receptors by mutations in the transmembrane domain.,http://www.ncbi.nlm.nih.gov/pubmed/9136983,3736
FGFR3 G637W lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). G637W results in a loss of Fgfr3 kinase activity in cell culture (PMID: 26992226).,6316,26992226,Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.,http://www.ncbi.nlm.nih.gov/pubmed/26992226,295,,,www.uniprot.org,3737
"FGFR3 G697C lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). G697C demonstrates autophosphorylation and substrate phosphorylation similar to wild-type Fgfr3, and is not transforming in cell culture (PMID: 26992226).",6316,26992226,Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.,http://www.ncbi.nlm.nih.gov/pubmed/26992226,295,,,www.uniprot.org,3738
"FGFR3 G710D lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). G710D has not been characterized in the scientific literature and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3739
"HRAS A134T does not lie within any known functional domains of the Hras protein (UniProt.org). A134T has not been characterized in the scientific literature and therefore, its effect on Hras protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3741
"HRAS A59T lies within the GTP binding domain of the Hras protein (UniProt.org). A59T results in decreased Hras GTPase activity and leads to transformation of cultured cells (PMID: 21779495, PMID: 3283542).",2200,21779495,Functional specificity of ras isoforms: so similar but so different.,http://www.ncbi.nlm.nih.gov/pubmed/21779495,2201,3283542,The ras gene family and human carcinogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/3283542,295,,,www.uniprot.org,3742
"HRAS E143K lies within the GTP binding domain of the Hras protein (PIMID: 21779495). E143K has not been characterized in the scientific literature and therefore, its effect on Hras function is unknown (PubMed, Apr 2017).",2200,21779495,Functional specificity of ras isoforms: so similar but so different.,http://www.ncbi.nlm.nih.gov/pubmed/21779495,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3743
"HRAS E62G lies within the GTP binding domain of the Hras protein (PMID: 21779495). E62G has been identified in the scientific literature (PMID: 19628422), but has not been biochemically characterized, and therefore its effect on Hras protein function is unknown (PubMed, Apr 2017).",2200,21779495,Functional specificity of ras isoforms: so similar but so different.,http://www.ncbi.nlm.nih.gov/pubmed/21779495,8603,19628422,Detection of two novel mutations and relatively high incidence of H-RAS mutations in Vietnamese oral cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19628422,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3744
"HRAS G12A lies within the GTP binding domain of the Hras protein (UniProt.org). G12A results in decreased Hras GTPase activity and leads to transformation of cells in culture (PMID: 21779495, PMID: 3283542).",295,,,www.uniprot.org,2200,21779495,Functional specificity of ras isoforms: so similar but so different.,http://www.ncbi.nlm.nih.gov/pubmed/21779495,2201,3283542,The ras gene family and human carcinogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/3283542,3745
"HRAS F82L does not lie within any known functional domains of the Hras protein (UniProt.org). F82L has been identified in the scientific literature (PMID: 25360634), but has not been biochemically characterized and therefore, its effect on Hras protein function is unknown (PubMed, Apr 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,8604,25360634,Cutaneous epithelial tumors induced by vemurafenib involve the MAPK and Pi3KCA pathways but not HPV nor HPyV viral infection.,http://www.ncbi.nlm.nih.gov/pubmed/25360634,3746
"HRAS G12C lies within the GTP binding domain of the Hras protein (UniProt.org). G12C results in decreased Hras GTPase activity and leads to transformation of cells in culture (PMID: 21779495, PMID: 6092966).",295,,,www.uniprot.org,2200,21779495,Functional specificity of ras isoforms: so similar but so different.,http://www.ncbi.nlm.nih.gov/pubmed/21779495,2098,6092966,Biological properties of human c-Ha-ras1 genes mutated at codon 12.,http://www.ncbi.nlm.nih.gov/pubmed/6092966,3747
"HRAS G12D lies within the GTP binding domain of the Hras protein (UniProt.org). G12D results in decreased Hras GTPase activity and leads to transformation of cells in culture (PMID: 21779495, PMID: 6092966).",295,,,www.uniprot.org,2200,21779495,Functional specificity of ras isoforms: so similar but so different.,http://www.ncbi.nlm.nih.gov/pubmed/21779495,2098,6092966,Biological properties of human c-Ha-ras1 genes mutated at codon 12.,http://www.ncbi.nlm.nih.gov/pubmed/6092966,3748
"HRAS G12R lies within the GTP binding domain of the Hras protein (UniProt.org). G12R results in decreased Hras GTPase activity and leads to transformation of cells in culture (PMID: 21779495, PMID: 6092966).",295,,,www.uniprot.org,2200,21779495,Functional specificity of ras isoforms: so similar but so different.,http://www.ncbi.nlm.nih.gov/pubmed/21779495,2098,6092966,Biological properties of human c-Ha-ras1 genes mutated at codon 12.,http://www.ncbi.nlm.nih.gov/pubmed/6092966,3749
"HRAS G13R lies within the GTP binding domain of the Hras protein (UniProt.org). G13R results in decreased Hras GTPase activity and activation of downstream Mapk and Pi3k signaling (PMID: 21779495, PMID: 22683711).",295,,,www.uniprot.org,2202,22683711,Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/22683711,2200,21779495,Functional specificity of ras isoforms: so similar but so different.,http://www.ncbi.nlm.nih.gov/pubmed/21779495,3750
"HRAS G13C lies within the GTP binding domain of the Hras protein (UniProt.org). G13C results in decreased Hras GTPase activity and leads to activation of Erk and Pi3k signaling pathways (PMID:     21850009, PMID: 19035362).",295,,,www.uniprot.org,1783,21850009,HRAS mutants identified in Costello syndrome patients can induce cellular senescence: possible implications for the pathogenesis of Costello syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/21850009,2203,19035362,Oncogenic HRAS mutations cause prolonged PI3K signaling in response to epidermal growth factor in fibroblasts of patients with Costello syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/19035362,3751
"HRAS G13S lies within the GTP-binding domain of the Hras protein (UniProt.org). G13S has not been functionally characterized, but is transforming, and as other codon 13 mutations result in loss of Hras GTPase activity, G13S is predicted to confer a loss of function to Hras (PMID: 6330729, PMID: 21850009).",1783,21850009,HRAS mutants identified in Costello syndrome patients can induce cellular senescence: possible implications for the pathogenesis of Costello syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/21850009,295,,,www.uniprot.org,1784,6330729,Analysis of the transforming potential of the human H-ras gene by random mutagenesis.,http://www.ncbi.nlm.nih.gov/pubmed/6330729,3752
"FGFR3 S679F lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). S679F has not been characterized in the scientific literature and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3753
"HRAS G13I lies within the GTP binding domain of the Hras protein (UniProt.org). G13I has not been characterized, however other codon 13 mutations mutations result in loss of Hras GTPase activity, thus G13I is predicted to confer a loss of function to the Hras protein (PMID: 6330729, PMID: 21850009).",1783,21850009,HRAS mutants identified in Costello syndrome patients can induce cellular senescence: possible implications for the pathogenesis of Costello syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/21850009,295,,,www.uniprot.org,1784,6330729,Analysis of the transforming potential of the human H-ras gene by random mutagenesis.,http://www.ncbi.nlm.nih.gov/pubmed/6330729,3754
"HRAS G13V lies within the GTP binding domain of the Hras protein (UniProt.org). G13V has not been characterized, however other codon 13 mutations result in loss of Hras GTPase activity, thus G13V is predicted to confer a loss of function to the Hras protein (PMID: 6330729, PMID: 21850009).",295,,,www.uniprot.org,1783,21850009,HRAS mutants identified in Costello syndrome patients can induce cellular senescence: possible implications for the pathogenesis of Costello syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/21850009,1784,6330729,Analysis of the transforming potential of the human H-ras gene by random mutagenesis.,http://www.ncbi.nlm.nih.gov/pubmed/6330729,3755
HRAS Q61H lies within the GTP binding domain of the Hras protein (UniProt.org). Q61H results in decreased Hras GTPase activity and leads to transformation of cells in culture (PMID: 3510078). ,2204,3510078,Biological and biochemical properties of human rasH genes mutated at codon 61.,http://www.ncbi.nlm.nih.gov/pubmed/3510078,295,,,www.uniprot.org,3756
HRAS Q61L lies within the GTP binding domain of the Hras protein (UniProt.org). Q61L results in decreased Hras GTPase activity and leads to transformation of cells in culture (PMID: 3510078).,2204,3510078,Biological and biochemical properties of human rasH genes mutated at codon 61.,http://www.ncbi.nlm.nih.gov/pubmed/3510078,295,,,www.uniprot.org,3757
HRAS Q61R lies within the GTP binding domain of the Hras protein (UniProt.org). Q61R results in decreased Hras GTPase activity and leads to transformation of cells in culture (PMID: 3510078). ,2204,3510078,Biological and biochemical properties of human rasH genes mutated at codon 61.,http://www.ncbi.nlm.nih.gov/pubmed/3510078,295,,,www.uniprot.org,3758
"HRAS Q61P lies within the GTP binding domain of the Hras protein (UniProt.org). Q61P confers a loss of function to the Hras protein, resulting in decreased GTPase activity (PMID: 3510078).",2204,3510078,Biological and biochemical properties of human rasH genes mutated at codon 61.,http://www.ncbi.nlm.nih.gov/pubmed/3510078,295,,,www.uniprot.org,3759
HRAS K117N lies within the GTP binding domain of the Hras protein (UniProt.org). K117N results in decreased nucleotide binding affinity and activation of Hras in culture (PMID: 24247240).,295,,,www.uniprot.org,5024,24247240,Differences in the regulation of K-Ras and H-Ras isoforms by monoubiquitination.,http://www.ncbi.nlm.nih.gov/pubmed/24247240,3760
"HRAS R123C does not lie within any known functional domains of the Hras protein (UniProt.org). R123C has not been characterized in the scientific literature and therefore, its effect on Hras protein function is unknown (PubMed, Apr 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3761
"HRAS R123H does not lie within any known functional domains of the Hras protein (UniProt.org). R123H has not been characterized in the scientific literature and therefore, its effect on Hras protein function is unknown (PubMed, Apr 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3762
"HRAS R73C does not lie within any known function domains of the Hras protein (UniProt.org). R73C has been identified in the scientific literature (PMID: 22185227), but has not been biochemically characterized and therefore, its effect on Hras protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8607,22185227,Detection of low prevalence somatic mutations in solid tumors with ultra-deep targeted sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/22185227,3763
"HRAS Y32* results in the premature truncation of the Hras protein at amino acid 32 of 189 (UniProt.org). Due to the loss of the GTP binding domain of Hras (UniProt.org), Y32* is predicted to confer loss of function to the Hras protein. ",295,,,www.uniprot.org,3764
"AKT1 P51L lies within the PH domain of the Akt1 protein (UniProt.org). P51L has been identified in sequencing studies (PMID: 25148578, PMID: 25303977), but has not been biochemically characterized and therefore, its effect on Akt1 protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7006,25303977,Mutational landscape of aggressive cutaneous squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25303977,295,,,www.uniprot.org,7824,25148578,Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/25148578,3765
BRAF K601T lies within the activation segment in the kinase domain of the Braf protein (PMID: 15343278). K601T results in increased Braf kinase activity in cell culture (PMID: 28783719).,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,9694,15343278,Switching on kinases: oncogenic activation of BRAF and the PDGFR family.,http://www.ncbi.nlm.nih.gov/pubmed/15343278,3766
"FGFR2 A264T lies within the Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). A264T has been identified in the scientific literature (PMID: 26645239), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jul 2017).",7210,26645239,Mutational analysis of pulmonary tumours with neuroendocrine features using targeted massive parallel sequencing: a comparison of a neglected tumour group.,http://www.ncbi.nlm.nih.gov/pubmed/26645239,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3767
"FGFR2 A389T lies within the transmembrane domain of the Fgfr2 protein (PMID: 18552176). A389T has not been biochemically characterized, but is not transforming in culture (PMID: 18552176) and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jul 2017). ",252,18552176,Drug-sensitive FGFR2 mutations in endometrial carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18552176,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3768
"FGFR2 D304N lies within the Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). D304N has not been characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3769
"FGFR2 T764fs results in a change in the amino acid sequence of the Fgfr2 protein beginning at aa 764 of 821, likely resulting in premature truncation of the functional protein (UniProt.org). T764fs has not been characterized in the scientific literature and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3772
"FGFR2 W290C lies within the Ig-like C2-type 3 domain of the Fgfr2 protein (UniProt.org). W290C does not result in increased Fgfr2 phosphorylation, but increases both ligand-dependent and ligand-independent dimerization of Fgfr2, is transforming in cell culture, and promotes tumor formation in xenograft models (PMID: 23786770).",295,,,www.uniprot.org,2132,23786770,Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23786770,3773
"FGFR2 Y375C lies within the extracellular juxtamembrane domain of the Fgfr2 protein (PMID: 17525745). Y375C results in constitutive phosphorylation of Fgfr2 in cell culture, activation of Mapk p38 signaling, and abnormal proliferation and differentiation in the skin and skull of transgenic mouse models (PMID: 22585574).",2206,22585574,p38 Inhibition ameliorates skin and skull abnormalities in Fgfr2 Beare-Stevenson mice.,http://www.ncbi.nlm.nih.gov/pubmed/22585574,295,,,www.uniprot.org,3774
PIK3CA A1020V lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). A1020V demonstrates transformation potential and supports cell survival to similar level of wild-type Pik3ca protein in cell culture (PMID: 26627007).,4255,26627007,Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26627007,295,,,www.uniprot.org,3775
"PIK3CA A1035V lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). A1035V has been identified in the scientific literature (PMID: 18193083, PMID: 22498935, PMID: 23665199), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017).",8011,23665199,Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases.,http://www.ncbi.nlm.nih.gov/pubmed/23665199,8010,22498935,"Molecular characterization of endometrial cancer: a correlative study assessing microsatellite instability, MLH1 hypermethylation, DNA mismatch repair protein expression, and PTEN, PIK3CA, KRAS, and BRAF mutation analysis.",http://www.ncbi.nlm.nih.gov/pubmed/22498935,285,,,http://www.ncbi.nlm.nih.gov/pubmed,8009,18193083,Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population.,http://www.ncbi.nlm.nih.gov/pubmed/18193083,295,,,www.uniprot.org,3776
"PIK3CA A1046E lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). A1046E has been identified in the scientific literature (PMID: 18022911, PMID: 22357840, PMID: 22753589), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,8014,22753589,"Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers.",http://www.ncbi.nlm.nih.gov/pubmed/22753589,8013,22357840,Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review.,http://www.ncbi.nlm.nih.gov/pubmed/22357840,8012,18022911,PIK3CA cancer mutations display gender and tissue specificity patterns.,http://www.ncbi.nlm.nih.gov/pubmed/18022911,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3777
"PIK3CA A1046T lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). A1046T has been identified in the scientific literature (PMID: 25150293, PMID: 22357840, PMID: 21239505), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,8016,21239505,KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21239505,8013,22357840,Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review.,http://www.ncbi.nlm.nih.gov/pubmed/22357840,8015,25150293,Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease.,http://www.ncbi.nlm.nih.gov/pubmed/25150293,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3778
"PIK3CA C407W lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). C407W has been identified in the scientific literature (PMID: 20826764, PMID: 25850943), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8023,25850943,Uncovering the genomic heterogeneity of multifocal breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25850943,7456,20826764,Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/20826764,3779
"PIK3CA C901F lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). C901F has been identified in sequencing studies (PMID: 23219661, PMID: 24185509, PMID: 26000489), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,6961,24185509,"Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/24185509,295,,,www.uniprot.org,5982,26000489,Integrative clinical genomics of advanced prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26000489,8025,23219661,"High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/23219661,3780
"PIK3CA D1029H lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). D1029H has been identified in the scientific literature (PMID: 22330809, PMID: 22949056, PMID: 23718828), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7392,22949056,Phosphatidylinositol-3-kinase α catalytic subunit gene somatic mutations in bronchopulmonary neuroendocrine tumours.,http://www.ncbi.nlm.nih.gov/pubmed/22949056,8026,22330809,"PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups.",http://www.ncbi.nlm.nih.gov/pubmed/22330809,8027,23718828,Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV- tumors.,http://www.ncbi.nlm.nih.gov/pubmed/23718828,3781
"PIK3CA D1045N lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). D1045N has been identified in the scientific literature (PMID: 25624430, PMID: 26850916), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8029,26850916,Targeted and exome sequencing identified somatic mutations in hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26850916,8028,25624430,Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25624430,3782
"ABL1 V299L does not lie within any known functional domains of the Abl1 protein (UniProt.org). ABL1 V299L has not been characterized, but has been demonstrated to occur as a secondary resistance mutation in the context of BCR-ABL (PMID: 18242697, PMID: 23086624).",295,,,www.uniprot.org,2209,18242697,Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clones.,http://www.ncbi.nlm.nih.gov/pubmed/18242697,2210,23086624,Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/23086624,3783
"PIK3CA D454Y lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). D454Y has not been characterized in the scientific literature and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3784
"PIK3CA E109del results in the deletion of an amino acid in the region linking PI3K-ABD and PI3K-RBD domains of the Pik3ca protein (UniProt.org). E109del has been identified in sequencing studies (PMID: 25850943, PMID: 24121792), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,6998,24121792,Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation.,http://www.ncbi.nlm.nih.gov/pubmed/24121792,295,,,www.uniprot.org,8023,25850943,Uncovering the genomic heterogeneity of multifocal breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25850943,3785
"PIK3CA E110K does not lie within any known functional domains of the Pik3ca protein (UniProt.org). E110K has been identified in the scientific literature (PMID: 23619167), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2263,23619167,Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.,http://www.ncbi.nlm.nih.gov/pubmed/23619167,295,,,www.uniprot.org,3786
"PIK3CA E418K lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). E418K has been identified in sequencing studies (PMID: 25148578, PMID: 25344691, PMID: 25056374), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017).",7824,25148578,Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/25148578,7205,25056374,Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/25056374,1689,25344691,RNF43 is frequently mutated in colorectal and endometrial cancers.,http://www.ncbi.nlm.nih.gov/pubmed/25344691,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3787
"PIK3CA E453A lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). E453A confers a gain of function to Pik3ca, as indicated by increased Akt phosphorylation in cell culture (PMID: 21266528).",2211,21266528,A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/21266528,295,,,www.uniprot.org,3788
"PIK3CA E453K lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). E453K results in increased phosphorylation of Akt and Mek1/2, enhanced cell survival, and is transforming in cullture (PMID: 26627007).",4255,26627007,Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26627007,295,,,www.uniprot.org,3789
PIK3CA E453Q lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). E453Q confers a gain of function to Pik3ca as indicated by increased lipid kinase activity in cell culture (PMID: 15930273).,295,,,www.uniprot.org,2212,15930273,Functional analysis of PIK3CA gene mutations in human colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/15930273,3790
"PIK3CA E522A lies within the PIK helical domain of the Pik3ca protein (UniProt.org). E522A has not been characterized in the scientific literature and therefore, its effect on Pik3ca protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3791
"PIK3CA E542Q lies within the PIK helical domain of the Pik3ca protein (UniProt.org). E542Q has been identified in the scientific literature (PMID: 25054828), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Mar 2017).",8372,25054828,PIK3CA gene mutations and overexpression: implications for prognostic biomarker and therapeutic target in Chinese esophageal squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25054828,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3792
"KDR amp indicates an increased number of copies of the KDR gene. However, the mechanism causing the increase is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,3793
"TP53 R273C is a hotspot mutation that lies within the DNA binding domain of the Tp53 protein (PMID: 22713868). R273C results in decreased activation of wild-type Tp53 target genes, as well as aberrant activation of gene expression, increased cell proliferation, and increased cell migration in culture (PMID: 23264849, PMID: 23612969).",2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,2225,23264849,Gain-of-Function Activity of Mutant p53 in Lung Cancer through Up-Regulation of Receptor Protein Tyrosine Kinase Axl.,http://www.ncbi.nlm.nih.gov/pubmed/23264849,2224,23612969,A novel p53 mutant found in iatrogenic urothelial cancers is dysfunctional and can be rescued by a second-site global suppressor mutation.,http://www.ncbi.nlm.nih.gov/pubmed/23612969,3795
"TP53 R273L is a hotspot mutation that lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). R273L results in decreased Tp53 transactivation and decreased transcriptional repression of Tp53 targets in cell culture (PMID: 10787423, PMID: 8336941).",2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,2228,10787423,The phosphotyrosyl phosphatase activator gene is a novel p53 target gene.,http://www.ncbi.nlm.nih.gov/pubmed/10787423,2227,8336941,Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences.,http://www.ncbi.nlm.nih.gov/pubmed/8336941,3796
"TP53 R273S is a hotspot mutation that lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). R273S results in decreased activation of Tp53 target genes, as well as increased proliferation and resistance to apoptosis in cell culture (PMID: 23246812).",371,23246812,Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.,http://www.ncbi.nlm.nih.gov/pubmed/23246812,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,3797
"TP53 R248L is a hotspot mutation that lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). R248L results in decreased Tp53 transactivation and repression, and resistance to apoptosis in cell culture (PMID: 8336941, PMID: 20570896, PMID: 18566217).",2227,8336941,Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences.,http://www.ncbi.nlm.nih.gov/pubmed/8336941,2230,20570896,Dysregulation of p53/Sp1 control leads to DNA methyltransferase-1 overexpression in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20570896,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,2229,18566217,Potent synergy of dual antitumor peptides for growth suppression of human glioblastoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/18566217,3798
"PIK3CA G185R does not lie within any known functional domains of the Pik3ca protein (UniProt.org). G185R has not been characterized in the scientific literature and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3799
"PDGFRA G185R lies within the Ig-like C2-type domain 2 of the Pdgfra protein (UniProt.org). G185R has not been characterized in the scientific literature and therefore, its effect on Pdgfra protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3800
"PDGFRA G185W lies within the 	Ig-like C2-type domain 2 of the Pdgfra protein (UniProt.org). G185W has not been characterized in the scientific literature and therefore, its effect on Pdgfra protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3801
"PDGFRA G829E lies within the protein kinase domain of the Pdgfra protein (UniProt.org). G829E has been identified in sequencing studies (PMID: 25303977, PMID: 25148578), but has not been biochemically characterized and therefore, its effect on Pdgfra protein function is unknown (PubMed, Aug 2017).",7824,25148578,Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/25148578,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7006,25303977,Mutational landscape of aggressive cutaneous squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25303977,295,,,www.uniprot.org,3803
"PDGFRA G829R lies within the protein kinase domain of the Pdgfra protein (UniProt.org). G829R results in similar activation to wild-type Pdgfra in a reporter assay, and does not result in cytokine-independent growth in culture (PMID: 23752188).
",476,23752188,PDGFRA alterations in cancer: characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations.,http://www.ncbi.nlm.nih.gov/pubmed/23752188,295,,,www.uniprot.org,3804
"PDGFRA G838V lies within the protein kinase domain of the Pdgfra protein (UniProt.org). G838V has been identified in sequencing studies (PMID: 22980975), but has not been biochemically characterized and therefore, its effect on Pdgfra protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1726,22980975,Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/22980975,3805
PDGFRA G853D lies within the protein kinase domain of the Pdgfra protein (UniProt.org). G853D confers a gain of function to the Pdgfra protein as demonstrated by increased autophosphorylation of Pdgfra (PMID: 24132921).,2242,24132921,Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib.,http://www.ncbi.nlm.nih.gov/pubmed/24132921,295,,,www.uniprot.org,3807
"PDGFRA D842_D846del results in the deletion of five amino acids in the protein kinase domain of the Pdgfra protein from amino acids 842 to 846 (UniProt.org). D842_D846del has been identified in the scientific literature (PMID: 26130666), but has not been biochemically characterized, however, similar PDGFRA exon 18 deletions are activating (PMID: 12522257, PMID: 15928335) and therefore, is predicted to result in a gain of function.",2254,12522257,PDGFRA activating mutations in gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/12522257,7709,26130666,Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/26130666,272,15928335,"PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.",http://www.ncbi.nlm.nih.gov/pubmed/15928335,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3808
"PIK3CA E542V is a hotspot mutation that lies within the PIK helical domain of the Pik3ca protein (UniProt.org). E542V confers a gain of function on Pik3ca, as indicated by increased phosphorylation of Akt and Mek1/2, growth-factor independent cell survival, and is transforming in culture (PMID: 26627007).",295,,,www.uniprot.org,4255,26627007,Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26627007,3809
PIK3CA E545A is a hotspot mutation that lies within the PIK helical domain of the Pik3ca protein (UniProt.org). E545A results in increased phosphorylation of Akt and is transforming in cell culture (PMID: 17376864).,295,,,www.uniprot.org,101,17376864,Rare cancer-specific mutations in PIK3CA show gain of function.,http://www.ncbi.nlm.nih.gov/pubmed/17376864,3810
"PIK3CA E545D lies within the PIK helical domain of the Pik3ca protein (UniProt.org). E545D has not been characterized, however other E545 mutations result in constitutive activation of the Pik3ca protein thus E545D is predicted to result in a gain of function (PMID: 16432179).",295,,,www.uniprot.org,1107,16432179,Cancer-specific mutations in PIK3CA are oncogenic in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/16432179,3811
PIK3CA E545G is a hotspot mutation that lies within the PIK helical domain of the Pik3ca protein (UniProt.org). E545G results in increased phosphorylation of Akt and is transforming in cell culture (PMID: 17376864).,295,,,www.uniprot.org,101,17376864,Rare cancer-specific mutations in PIK3CA show gain of function.,http://www.ncbi.nlm.nih.gov/pubmed/17376864,3812
PIK3CA E545Q is a hotspot mutation that lies within the PIK helical domain of the Pik3ca protein (UniProt.org). E545Q results in growth factor-independent cell survival and is transforming in culture (PMID: 26627007).,295,,,www.uniprot.org,4255,26627007,Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26627007,3813
"PIK3CA E545V lies within the PIK helical domain of the Pik3ca protein (UniProt.org). E545V has not been characterized, however other E545 mutations result in constitutive activation of the Pik3ca protein thus E545V is predicted to result in a gain of function (PMID: 16432179).",1107,16432179,Cancer-specific mutations in PIK3CA are oncogenic in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/16432179,295,,,www.uniprot.org,3814
"PIK3CA E547K lies within the PIK helical domain of the Pik3ca protein (UniProt.org). E547K has been identified in the scientific literature (PMID: 25054828), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Mar 2017).",8372,25054828,PIK3CA gene mutations and overexpression: implications for prognostic biomarker and therapeutic target in Chinese esophageal squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25054828,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3815
"PIK3CA E80K lies within the PI3K-ABD domain of the Pik3ca protein (UniProt.org). E80K has been identified in sequencing studies (PMID: 22722201), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7023,22722201,The landscape of cancer genes and mutational processes in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22722201,3816
"PIK3CA E81K lies within the PI3K-ABD domain of the Pik3ca protein (UniProt.org). E81K results in increased Akt phosphorylation, activation of mTor signaling, and growth advantage in patient-derived dermal fibroblasts in culture (PMID: 25915946).",5094,25915946,Molecular and Functional Characterization of Three Different Postzygotic Mutations in PIK3CA-Related Overgrowth Spectrum (PROS) Patients: Effects on PI3K/AKT/mTOR Signaling and Sensitivity to PIK3 Inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/25915946,295,,,www.uniprot.org,3817
"PIK3CA F1039L lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). F1039L has been identified in sequencing studies (PMID: 22949056), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Mar 2017).",7392,22949056,Phosphatidylinositol-3-kinase α catalytic subunit gene somatic mutations in bronchopulmonary neuroendocrine tumours.,http://www.ncbi.nlm.nih.gov/pubmed/22949056,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3818
"PIK3CA F909L lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). F909L has been identified in the scientific literature (PMID: 24440717), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8154,24440717,Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24440717,3819
"PIK3CA G1049A lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). G1049A has been identified in sequencing studies (PMID: 24062397, PMID: 18022911), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Mar 2017).",8012,18022911,PIK3CA cancer mutations display gender and tissue specificity patterns.,http://www.ncbi.nlm.nih.gov/pubmed/18022911,8374,24062397,Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24062397,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3820
"PIK3CA G1049R lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). G1049R results in increased phosphorylation of Akt and Mek1/2, growth factor-independent cell survival, and is transforming in culture (PMID: 26627007).",4255,26627007,Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26627007,295,,,www.uniprot.org,3821
"PIK3CA G1049S lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). G1049S has been identified in the scientific literature (PMID: 17052259), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",8376,17052259,PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/17052259,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3822
PIK3CA G106_R108del results in the deletion of three amino acids in the region linking the PI3K-ABD and PI3K-RBD domains of the Pik3ca protein from amino acids 106 to 108 (UniProt.org). G106_R108del results in increased phosphorylation of Akt and is transforming in cell culture (PMID: 19394761).,2246,19394761,Oncogenic mutation of PIK3CA in small cell lung carcinoma: a potential therapeutic target pathway for chemotherapy-resistant lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19394761,295,,,www.uniprot.org,3823
"PIK3CA G118D lies within the region linking the PI3K-ABD and PI3K-RBD domains of the Pik3ca protein (UniProt.org). G118D results in enhanced lipid kinase activity in cell culture and increased phosphorylation of Akt in cells derived from Cowden syndrome patients harboring germline mutations (PMID: 22949682, PMID: 23246288).",295,,,www.uniprot.org,2248,22949682,Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA).,http://www.ncbi.nlm.nih.gov/pubmed/22949682,2249,23246288,Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/23246288,3825
"PIK3CA G12D does not lie within any known functional domains of the Pik3ca protein (UniProt.org). G12D has not been characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3826
"PIK3CA G512* results in a premature truncation of the Pik3ca protein at amino acid 512 of 1068 (UniProt.org). Due to the loss of the PI3K/PI4K kinase domain (UniProt.org), G512* is predicted to lead to a loss of Pik3ca function.",295,,,www.uniprot.org,3827
"PIK3CA H1047L is a hotspot mutation that lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). H1047L results in increased phosphorylation of Akt and Mek1/2, growth factor-independent cell survival, and is transforming in culture (PMID: 26627007).",295,,,www.uniprot.org,4255,26627007,Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26627007,3828
"PIK3CA H1047Q lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). H1047Q has not been characterized, however other H1047 mutations result in constitutive activation of the Pik3ca protein thus H1047Q is predicted to result in a gain of function (PMID: 17376864).",295,,,www.uniprot.org,101,17376864,Rare cancer-specific mutations in PIK3CA show gain of function.,http://www.ncbi.nlm.nih.gov/pubmed/17376864,3829
"CTNNB1 act mut indicates that this variant results in a gain of function in the Ctnnb1 protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,3830
"MAP2K1 act mut indicates that this variant results in a gain of function in the Map2k1 protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,3831
"MAP2K1 amp indicates an increased number of copies of the MAP2K1 gene. However, the mechanism causing the increase is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,3832
PDGFRA I843_D846del results in the deletion of four amino acids in the protein kinase domain of the Pdgfra protein from amino acids 843 to 846 (PMID: 15928335). I843_D846del (identical in amino acid sequence to D842_H845del) confers a gain of function as demonstrated by the ligand-independent phosphorylation of Pdgfra (PMID: 12522257).,272,15928335,"PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.",http://www.ncbi.nlm.nih.gov/pubmed/15928335,2254,12522257,PDGFRA activating mutations in gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/12522257,3833
PDGFRA I843del results in the deletion of one amino acid in the protein kinase domain of the Pdgfra protein (UniProt.org). I843del confers a gain of function to the Pdgfra protein as demonstrated by increased ligand-independent phosphorylation of Pdgfra (PMID: 14645423).,2255,14645423,Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.,http://www.ncbi.nlm.nih.gov/pubmed/14645423,295,,,www.uniprot.org,3834
"PDGFRA L819R lies within the protein kinase domain of the Pdgfra protein (UniProt.org). L819R has not been characterized in the scientific literature and therefore, its effect on Pdgfra protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3835
"PDGFRA M844_S847del results in the deletion of four amino acids within the protein kinase domain of the Pdgfra protein from amino acids 844 to 847 (UniProt.org).	M844_S847del has been identified in sequencing studies (PMID: 18547963, PMID: 20470368), but has not been biochemically characterized, however, similar PDGFRA exon 18 deletions are activating (PMID: 12522257, PMID: 15928335) and therefore, is predicted to result in a gain of function.",272,15928335,"PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.",http://www.ncbi.nlm.nih.gov/pubmed/15928335,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7843,18547963,PDGFRalpha gene mutation and protein expression in gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/18547963,2254,12522257,PDGFRA activating mutations in gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/12522257,3837
PDGFRA N659K lies within the protein kinase domain of the Pdgfra protein (UniProt.org). N659K confers a gain of function to the Pdgfra protein as demonstrated by ligand-independent phosphorylation of Pdgfra (PMID: 22745105),2167,22745105,Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/22745105,295,,,www.uniprot.org,3838
"PDGFRA N659Y lies within the protein kinase domain of the Pdgfra protein (UniProt.org). N659Y has not been fully biochemically characterized, but has been associated with decreased response to sorafenib in the context of FIP1L1-PDGFRA in cell culture (PMID: 20972453).",5809,20972453,The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro.,http://www.ncbi.nlm.nih.gov/pubmed/20972453,295,,,www.uniprot.org,3839
PDGFRA P577S lies within the juxtamembrane domain of the Pdgfra protein (PMID: 24132921). P577S confers a gain of function to the Pdgfra protein as demonstrated by increased autophosphorylation of Pdgfra (PMID: 24132921).,2242,24132921,Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib.,http://www.ncbi.nlm.nih.gov/pubmed/24132921,3840
"PDGFRA Y98* results in a premature truncation of the Pdgfra protein at amino acid 98 of 1089 (UniProt.org). Due to the loss of a majority of the ligand-binding and protein kinase domains (UniProt.org), Y98* is predicted to confer a loss of function to the Pdgfra protein.",295,,,www.uniprot.org,3841
"PIK3CA H1047Y is a hotspot mutation that lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). H1047Y results in increased phosphorylation of Akt, activation of downstream signaling, and is transforming in cell culture (PMID: 17376864).",295,,,www.uniprot.org,101,17376864,Rare cancer-specific mutations in PIK3CA show gain of function.,http://www.ncbi.nlm.nih.gov/pubmed/17376864,3842
"PIK3CA H1048R lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). H1048R has not been characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3843
PIK3CA H701P does not lie within any known functional domains of the Pik3ca protein (UniProt.org). H701P demonstrates transformation potential and ability to promote growth factor-independent cell survival to similar levels of wild-type Pik3ca protein in culture (PMID: 26627007).,295,,,www.uniprot.org,4255,26627007,Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26627007,3844
"PIK3CA I112N lies within the region linking the PI3K-ABD and PI3K-RBD domains of the Pik3ca protein (UniProt.org). I112N has been identified in the scientific literature (PMID: 17471559), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8882,17471559,Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/17471559,3845
"PIK3CA K111del results in the deletion of one amino acid in the Pik3ca protein at amino acid 111 (UniProt.org). K111del has not been characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3846
"PIK3CA K111E lies within the region linking the PI3K-ABD and PI3K-RBD domains of the Pik3ca protein (UniProt.org). K111E results in increased lipid kinase activity and phosphorylation of Akt in cell culture (PMID: 22949682, PMID: 17376864).",295,,,www.uniprot.org,2248,22949682,Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA).,http://www.ncbi.nlm.nih.gov/pubmed/22949682,101,17376864,Rare cancer-specific mutations in PIK3CA show gain of function.,http://www.ncbi.nlm.nih.gov/pubmed/17376864,3847
"PIK3CA K111N lies within the region linking the PI3K-ABD and PI3K-RBD domains of the Pik3ca protein (UniProt.org). K111N results in increased phosphorylation of Akt, activation of downstream signaling, and is transforming in cell culture (PMID: 17376864).",295,,,www.uniprot.org,101,17376864,Rare cancer-specific mutations in PIK3CA show gain of function.,http://www.ncbi.nlm.nih.gov/pubmed/17376864,3848
"PIK3CA K111R does not lie within any known functional domains of the Pik3ca protein (UniProt.org). K111R has been identified in the scientific literature (PMID: 24240111), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",4924,24240111,Targeting small cell lung cancer harboring PIK3CA mutation with a selective oral PI3K inhibitor PF-4989216.,http://www.ncbi.nlm.nih.gov/pubmed/24240111,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3849
"PIK3CA L113del results in the deletion of one amino acid in the Pik3ca protein at amino acid 113 (UniProt.org). L113del has not been characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3850
"PIK3CA M1043I lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). M1043I results in increased phosphorylation of Akt, activation of downstream signaling, and is transforming in cell culture (PMID: 17376864).",101,17376864,Rare cancer-specific mutations in PIK3CA show gain of function.,http://www.ncbi.nlm.nih.gov/pubmed/17376864,295,,,www.uniprot.org,3851
"PIK3CA M1043T lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). M1043T has not been characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3852
"PIK3CA M1043V lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). M1043V results in increased phosphorylation of Akt, activation of downstream signaling, and is transforming in cell culture (PMID: 17376864).",101,17376864,Rare cancer-specific mutations in PIK3CA show gain of function.,http://www.ncbi.nlm.nih.gov/pubmed/17376864,295,,,www.uniprot.org,3853
"PIK3CA N1044D lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). N1044D has not been characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3854
PIK3CA N1044K lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). N1044K confers a gain of function to Pik3ca protein as indicated by increased cell survival and transforming ability in cell culture (PMID: 26627007).,4255,26627007,Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26627007,295,,,www.uniprot.org,3855
PIK3CA N1068fs*4 is a frameshift beginning at the Pik3ca stop codon that results in the addition of four additional amino acids to the 1068 aa Pik3ca protein at aa 1068 (UniProt.org). N1068fs*4 results in activation of Akt/mTor signaling and tumorigenesis in transgenic animal models (PMID: 21703185).,2258,21703185,Altered composition of fatty acids exacerbates hepatotumorigenesis during activation of the phosphatidylinositol 3-kinase pathway.,http://www.ncbi.nlm.nih.gov/pubmed/21703185,295,,,www.uniprot.org,3856
"PIK3CA N170S lies within the region linking the PI3K-ABD and PI3K-RBD domains of the Pik3ca protein (UniProt.org). N170S has not been characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3857
"PIK3CA N345K lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). N345K results in increased phosphorylation of Akt, activation of downstream signaling, and is transforming in cell culture (PMID: 17376864).",295,,,www.uniprot.org,101,17376864,Rare cancer-specific mutations in PIK3CA show gain of function.,http://www.ncbi.nlm.nih.gov/pubmed/17376864,3858
"PIK3CA N457K lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). N457K has been identified in the scientific literature (PMID: 19844788), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,8894,19844788,Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19844788,295,,,www.uniprot.org,3859
"PIK3CA P104L lies within the PI3K-ABD domain of the Pik3ca protein (UniProt.org). P104L has been identified in the scientific literature (PMID: 24983367), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7176,24983367,Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail.,http://www.ncbi.nlm.nih.gov/pubmed/24983367,3860
"PIK3CA P421L lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). P421L has not been characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3861
"PDGFRA D842del results in the deletion of an amino acid in the protein kinase domain of the Pdgfra protein at amino acid 842 (UniProt.org). D842del has been identified in the scientific literature (PMID: 26130666), but has not been biochemically characterized and therefore, its effect on Pdgfra protein function is unknown (PubMed, Aug 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7709,26130666,Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/26130666,3862
PDGFRA D842I lies within the protein kinase domain of the Pdgfra protein (UniProt.org). D842I confers a gain of function to the Pdgfra protein as demonstrated by increased ligand-independent phosphorylation of Pdgfra (PMID: 22745105).,2167,22745105,Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/22745105,295,,,www.uniprot.org,3864
PDGFRA D842Y lies within the protein kinase domain of the Pdgfra protein (UniProt.org). D842Y confers a gain of function to the Pdgfra protein as demonstrated by increased ligand-independent phosphorylation of Pdgfra (PMID: 15928335).,272,15928335,"PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.",http://www.ncbi.nlm.nih.gov/pubmed/15928335,295,,,www.uniprot.org,3866
"PDGFRA D842_H845del results in the deletion of four amino acids in the protein kinase domain of the Pdgfra protein from amino acids 842 to 845 (UniProt.org). D842_H845del confers a gain of function to Pdgfra, as indicated by constitutive phosphorylation of Pdgfra in cell culture (PMID: 12522257).",295,,,www.uniprot.org,2254,12522257,PDGFRA activating mutations in gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/12522257,3867
PDGFRA D846Y lies within the protein kinase domain of the Pdgfra protein (UniProt.org). D846Y confers a gain of function to the Pdgfra protein as demonstrated by increased ligand-independent phosphorylation of Pdgfra (PMID: 15928335).,272,15928335,"PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.",http://www.ncbi.nlm.nih.gov/pubmed/15928335,295,,,www.uniprot.org,3868
"PDGFRA E252* results in a premature truncation of the Pdgfra protein at amino acid 252 of 1089 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), E252* is predicted to lead to a loss of Pdgfra protein function.",295,,,www.uniprot.org,3869
"PDGFRA E301* results in a premature truncation of the Pdgfra protein at amino acid 301 of 1089 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), Pdgfra is predicted to lead to a loss of Pdgfra protein function.",295,,,www.uniprot.org,3870
"EGFR L747_P753delinsS results in a deletion of seven amino acids in the protein kinase domain of the Egfr protein from aa 747 to aa 753, combined with the insertion of a serine (S) at the same location (UniProt.org). L747_P753delinsS confers a gain of function resulting in autophosphorylation of the Egfr protein and transformation of cultured cells (PMID: 19147750).",1890,19147750,Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/19147750,295,,,www.uniprot.org,3871
"PDGFRA E887D lies within the protein kinase domain of the Pdgfra protein (UniProt.org). E887D has not been characterized in the scientific literature and therefore, its effect on Pdgfra protein function is unknown (PubMed, Aug 2017).   ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3872
"PDGFRA G185E lies within the Ig-like C2-type domain 2 of the Pdgfra protein (UniProt.org). G185E has been identified in sequencing studies (PMID: 21720365), but has not been biochemically characterized and therefore, its effect on Pdgfra protein function is unknown (PubMed, Aug 2017).",295,,,www.uniprot.org,6943,21720365,Integrated genomic analyses of ovarian carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/21720365,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3873
PIK3CA R115L does not lie within any known functional domains of the Pik3ca protein (UniProt.org). R115L confers a gain of function to the Pik3ca protein as demonstrated by increased cell growth and activation of the PI3K pathway (PMID: 23619167). ,2263,23619167,Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.,http://www.ncbi.nlm.nih.gov/pubmed/23619167,295,,,www.uniprot.org,3874
"PIK3CA R401Q lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). R401Q has not been characterized in the scientific literature and therefore, its effect on Pik3ca protein function is unknown (PubMed, Jun 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3875
"PIK3CA R524M lies within the PIK helical domain of the Pik3ca protein (UniProt.org). R524M has been identified in sequencing studies (PMID: 21225506, PMID: 16822308), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Jun 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7277,16822308,Mutations in PIK3CA are infrequent in neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/16822308,7276,21225506,"EGFR, PIK3CA and PTEN gene status and their protein product expression in neuroblastic tumours.",http://www.ncbi.nlm.nih.gov/pubmed/21225506,3876
"RET W85* results in a premature truncation of the Ret protein at amino acid 85 of 1114 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), W85* is predicted to lead to a loss of Ret protein function. ",295,,,www.uniprot.org,3877
"PDGFRA D842_M844del results in the deletion of three amino acids in the protein kinase domain of the Pdgfra protein from amino acids 842 to 844 (UniProt.org). D842_M844del has been identified in the scientific literature (PMID: 24638008), but has not been biochemically characterized, however, similar PDGFRA exon 18 deletions are activating (PMID: 12522257, PMID: 15928335) and therefore, is predicted to result in a gain of function.",295,,,www.uniprot.org,7711,24638008,In vivo imatinib sensitivity in a patient with GI stromal tumor bearing a PDGFRA deletion DIM842-844.,http://www.ncbi.nlm.nih.gov/pubmed/24638008,3878
"PDGFRA R340Q lies within the Ig-like C2-type domain 4 of the Pdgfra protein (UniProt.org). R340Q has not been characterized in the scientific literature and therefore, its effect on Pdgfra protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3879
"RET V648I lies within the transmembrane domain of the Ret protein (UniProt.org). V648I has not been biochemically characterized, however, it promotes cell proliferation, but is not transforming in culture (PMID: 21810974).",295,,,www.uniprot.org,2264,21810974,In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21810974,3880
"PDGFRA R554_Y555del results in the deletion of two amino acids in the juxtamembrane domain of the Pdgfra protein from amino acids 554 to 555 (PMID: 24132921). R554_Y555del has not been characterized in the scientific literature and therefore, its effect on Pdgfra protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2242,24132921,Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib.,http://www.ncbi.nlm.nih.gov/pubmed/24132921,3881
"RET V637M lies within the transmembrane domain of the Ret protein (UniProt.org). V637M has not been characterized in the scientific literature and therefore, its effect on Ret protein function is unknown (PubMed, Sep 2017).  ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3882
"PDGFRA R558C lies within the juxtamembrane domain of the Pdgfra protein (PMID: 24132921). R558C has been identified in sequencing studies (PMID: 25148578), but has not been biochemically characterized and therefore, its effect on Pdgfra protein function is unknown (PubMed, Aug 2017).
",2242,24132921,Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib.,http://www.ncbi.nlm.nih.gov/pubmed/24132921,7824,25148578,Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/25148578,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3883
"RET S936F lies within the protein kinase domain of the Ret protein (UniProt.org). S936F has not been characterized in the scientific literature and therefore, its effect on Ret protein function is unknown (PubMed, Sep 2017).  ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3884
"PDGFRA R560_S564del results in the deletion of five amino acids in the juxtamembrane domain of the Pdgfra protein from amino acids 560 to 564 (PMID: 24132921). R560_S564del has not been characterized in the scientific literature and therefore, its effect on Pdgfra protein function is unknown (PubMed, Aug 2017).",2242,24132921,Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib.,http://www.ncbi.nlm.nih.gov/pubmed/24132921,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3885
"PDGFRA R841_D842del results in the deletion of two amino acids in the protein kinase domain of the Pdgfra protein from amino acids 841 to 842 (UniProt.org). R841_D842del has been identified in sequencing studies (PMID: 25157968), but has not been biochemically characterized and therefore, its effect on Pdgfra protein function is unknown (PubMed, Aug 2017).
",7996,25157968,Prospective enterprise-level molecular genotyping of a cohort of cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/25157968,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3886
PDGFRA R841K lies within the protein kinase domain of the Pdgfra protein (UniProt.org). R841K confers a gain of function to the Pdgfra protein as demonstrated by increased autophosphorylation of Pdgfra (PMID: 24132921).,2242,24132921,Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib.,http://www.ncbi.nlm.nih.gov/pubmed/24132921,295,,,www.uniprot.org,3887
"PDGFRA R914W lies within the protein kinase domain of the Pdgfra protein (UniProt.org). R914W has not been characterized in the scientific literature and therefore, its effect on Pdgfra protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3888
"PDGFRA S566fs*6 likely results in a truncation of the 1089 aa Pdgfra protein at aa 566, followed by 6 nonsense amino acids within the juxtamembrane domain of the Pdgfra protein (UniProt.org, PMID: 24132921). Due to the loss of the protein kinase domain (UniProt.org), S566fs*6 is predicted to confer a loss of function to the Pdgfra protein.",295,,,www.uniprot.org,2242,24132921,Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib.,http://www.ncbi.nlm.nih.gov/pubmed/24132921,3889
PDGFRA V658A lies within the protein kinase domain of the Pdgfra protein (UniProt.org). V658A confers a gain of function to the Pdgfra protein as demonstrated by increased autophosphorylation of Pdgfra (PMID: 24132921).,295,,,www.uniprot.org,2242,24132921,Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib.,http://www.ncbi.nlm.nih.gov/pubmed/24132921,3890
"PIK3CA R617W lies within the PIK helical domain of the Pik3ca protein (UniProt.org). R617W has not been characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Jun 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3892
"RET S891L lies within the protein kinase domain of the Ret protein (UniProt.org). S891L has not been characterized in the scientific literature and therefore, its effect on Ret protein function is unknown (PubMed, Sep 2017).  ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3893
"PIK3CA R777M does not lie within any known functional domains of the Pik3ca protein (UniProt.org). R777M has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Jun 2017). ",5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3894
"RET R959W lies within the protein kinase domain of the Ret protein (UniProt.org). R959W has not been characterized in the scientific literature and therefore, its effect on Ret protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3895
"RET R873W lies within the protein kinase domain of the Ret protein (UniProt.org). R873W has been identified in sequencing studies (PMID: 22622578), but has not been characterized and therefore, its effect on Ret protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,6955,22622578,Melanoma genome sequencing reveals frequent PREX2 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/22622578,3896
"RET R77L lies within the extracellular domain of the Ret protein (UniProt.org). R77L has been identified in the scientific literature (PMID: 27372520), but has not been characterized and therefore, its effect on Ret protein function is unknown (PubMed, Sep 2017).",9875,27372520,"USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs.",http://www.ncbi.nlm.nih.gov/pubmed/27372520,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3897
"RET R77H lies within the extracellular domain of the Ret protein (UniProt.org). R77H has not been characterized and therefore, its effect on Ret protein function is unknown (PubMed, Sep 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3898
"PIK3CA R818C lies within the PI3K/PI4K protein kinase domain of the Pik3ca protein (UniProt.org). R818C has been identified in sequencing studies (PMID: 25233892), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Jun 2017). ",7231,25233892,Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes.,http://www.ncbi.nlm.nih.gov/pubmed/25233892,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3899
"RET R770Q lies within the protein kinase domain of the Ret protein (UniProt.org). R770Q has been identified in the scientific literature (PMID: 20013610), but has not been characterized and therefore, its effect on Ret protein function is unknown (PubMed, Sep 2017).",9873,20013610,New mutations in the RET protooncogene-L881V - associated with medullary thyroid carcinoma and -R770Q - in a patient with mixed medullar/follicular thyroid tumour.,http://www.ncbi.nlm.nih.gov/pubmed/20013610,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3900
"PIK3CA R992P lies within the PI3K/PI4K protein kinase domain of the Pik3ca protein (UniProt.org). R992P has not been characterized in the scientific literature and therefore, its effect on Pik3ca protein function is unknown (PubMed, Jun 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3901
"RET R57W lies within the extracellular domain of the Ret protein (UniProt.org). R57W has not been characterized in the scientific literature and therefore, its effect on Ret protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3902
"RET A756D lies within the protein kinase domain of the Ret protein (UniProt.org). A756D has not been characterized in the scientific literature and therefore, its effect on Ret protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3903
"RET R418* results in a premature truncation of the Ret protein at amino acid 418 of 1114 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), R418* is predicted to lead to a loss of Ret protein function. ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3904
"PIK3CA S405F lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). S405F has been identified in sequencing studies (PMID: 24695838, PMID: 27738081), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Jun 2017). ",295,,,www.uniprot.org,7387,27738081,Analysis of genes involved in the PI3K/Akt pathway in radiation- and MNU-induced rat mammary carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/27738081,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7385,24695838,Multigene profiling to identify alternative treatment options for glioblastoma: a pilot study.,http://www.ncbi.nlm.nih.gov/pubmed/24695838,3905
"RET P1070S lies within the cytoplasmic domain of the Ret protein (UniProt.org). P1070S has not been characterized in the scientific literature and therefore, its effect on Ret protein function is unknown (PubMed, Aug 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3906
"PIK3CA S773F does not lie within any known functional domains of the Pik3ca protein (UniProt.org). S773F has not been characterized in the scientific literature and therefore, its effect on Pik3ca protein function is unknown (PubMed, Jun 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3907
RET M980T lies within the protein kinase domain of the Ret protein (UniProt.org). M980T confers a loss of function to the Ret protein by reducing autophosphorylation and activation of downstream signaling pathways (PMID: 11438491).,295,,,www.uniprot.org,2266,11438491,Functional analysis of RET with Hirschsprung mutations affecting its kinase domain.,http://www.ncbi.nlm.nih.gov/pubmed/11438491,3908
"PIK3CA T1025A lies within the PI3K/PI4K protein kinase domain of the Pik3ca protein (UniProt.org). T1025A has been identified in sequencing studies (PMID: 18852163, PMID: 16764926), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Jun 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7390,16764926,"Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene.",http://www.ncbi.nlm.nih.gov/pubmed/16764926,295,,,www.uniprot.org,7389,18852163,Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors.,http://www.ncbi.nlm.nih.gov/pubmed/18852163,3909
"RET L923I lies within the protein kinase domain of the Ret protein (UniProt.org). L923I has not been characterized in the scientific literature and therefore, its effect on Ret protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3910
"PIK3CA T1025N lies within the PI3K/PI4K protein kinase domain of the Pik3ca protein (UniProt.org). T1025N has been identified in sequencing studies (PMID: 21266528), but has not been characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Jun 2017). ",2211,21266528,A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/21266528,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3913
"RET A919V lies within the protein kinase domain of the Ret protein (UniProt.org). A919V has not been characterized, but is predicted to result in decreased Ret protein stability in computational models (PMID: 19186126).",2269,19186126,"Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability.",http://www.ncbi.nlm.nih.gov/pubmed/19186126,295,,,www.uniprot.org,3914
"PIK3CA T1025S lies within the PI3K/PI4K domain in the Pik3ca protein (UniProt.org). T1025S confers a gain of function to the Pik3ca protein, which results in constitutive activation of downstream signaling and transformation in cultured cells (PMID: 17376864).",101,17376864,Rare cancer-specific mutations in PIK3CA show gain of function.,http://www.ncbi.nlm.nih.gov/pubmed/17376864,295,,,www.uniprot.org,3915
"RET C618R lies within the cysteine-rich region of the Ret protein (PMID: 9879991). C618R results in constitutive Ret phosphorylation and increased Ret kinase activity, but decreased Ret cell surface expression, and is transforming in cell culture (PMID: 9230192, PMID: 9879991).",2271,9879991,Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines.,http://www.ncbi.nlm.nih.gov/pubmed/9879991,2272,9230192,"Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype.",http://www.ncbi.nlm.nih.gov/pubmed/9230192,3916
"PIK3CA T324I does not lie within any known functional domains of the Pik3ca protein (UniProt.org). T324I has been identified in the scientific literature (PMID: 16778113, PMID: 18343945), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017).",8137,16778113,PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas.,http://www.ncbi.nlm.nih.gov/pubmed/16778113,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8138,18343945,"PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas.",http://www.ncbi.nlm.nih.gov/pubmed/18343945,3917
"PIK3CA T544N lies within the PIK helical domain of the Pik3ca protein (UniProt.org). T544N has been identified in the scientific literature (PMID: 26276776), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017).",8060,26276776,Distinct β-catenin and PIK3CA mutation profiles in endometriosis-associated ovarian endometrioid and clear cell carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/26276776,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3918
"RET C630R lies within the cysteine-rich region of the Ret protein (PMID: 9879991). C630R results in constitutive Ret phosphorylation and increased Ret kinase activity, formation of covalent Ret homodimers, and is transforming in cell culture (PMID: 9879991, PMID: 9230192).",2271,9879991,Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines.,http://www.ncbi.nlm.nih.gov/pubmed/9879991,2272,9230192,"Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype.",http://www.ncbi.nlm.nih.gov/pubmed/9230192,3919
"PIK3CA V344G lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). V344G has been identified in the scientific literature (PMID: 2700708, PMID: 22810696, PMID: 25186949), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017).",7554,25186949,The genomic landscape of pediatric Ewing sarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/25186949,8145,2700708,[Shear strength measurements for the clinical evaluation of bonded ceramic systems].,http://www.ncbi.nlm.nih.gov/pubmed/2700708,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,3920
"PIK3CA V344M lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). V344M has been identified in sequencing studies (PMID: 27302833, PMID: 23917401, PMID: 22653804), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,8024,27302833,Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes.,http://www.ncbi.nlm.nih.gov/pubmed/27302833,7748,22653804,Use of mutation profiles to refine the classification of endometrial carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/22653804,3963,23917401,The integrated landscape of driver genomic alterations in glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/23917401,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3921
"RET C634Y lies within the cysteine-rich region of the Ret protein (PMID: 9230192). C634Y results in formation of covalent Ret homodimers, increased Ret phosphorylation and activation of downstream signaling, resistance to apoptosis, and is transforming in cell culture (PMID: 9230192, PMID: 10919641).",2353,10919641,Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival.,http://www.ncbi.nlm.nih.gov/pubmed/10919641,2272,9230192,"Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype.",http://www.ncbi.nlm.nih.gov/pubmed/9230192,3922
"PIK3CA W552G lies within the PIK helical domain of the Pik3ca protein (UniProt.org). W552G has been identified in the scientific literature (PMID: 16778113), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8137,16778113,PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas.,http://www.ncbi.nlm.nih.gov/pubmed/16778113,3923
RET D631G lies within the extracellular domain of the Ret protein (UniProt.org). D631G does not result in covalent Ret dimerization and is not transforming in cell culture (PMID: 10049754).,5095,10049754,Mechanism of Ret activation by a mutation at aspartic acid 631 identified in sporadic pheochromocytoma.,http://www.ncbi.nlm.nih.gov/pubmed/10049754,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3924
"RET E1006D lies within the protein kinase domain of the Ret protein (UniProt.org). E1006D has not been characterized in the scientific literature and therefore, its effect on Ret protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3925
"PIK3CA Y1021C lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). Y1021C has been identified in sequencing studies (PMID: 25078343, PMID: 27302833), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8153,25078343,"Molecular alterations of PIK3CA in uterine carcinosarcoma, clear cell, and serous tumors.",http://www.ncbi.nlm.nih.gov/pubmed/25078343,8024,27302833,Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes.,http://www.ncbi.nlm.nih.gov/pubmed/27302833,3926
"RET E623K lies within the extracellular domain of the Ret protein (UniProt.org). E623K has been identified in the scientific literature (PMID: 16849421, PMID: 15858153), but has not been characterized and therefore, its effect on Ret protein function is unknown (PubMed, Aug 2017).",9783,16849421,RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors.,http://www.ncbi.nlm.nih.gov/pubmed/16849421,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9784,15858153,Nine novel germline gene variants in the RET proto-oncogene identified in twelve unrelated cases.,http://www.ncbi.nlm.nih.gov/pubmed/15858153,3927
"PIK3CA Y1021H lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). Y1021H has been identified in the scientific literature (PMID: 18084252, PMID: 27302833, PMID: 22610119), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8024,27302833,Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes.,http://www.ncbi.nlm.nih.gov/pubmed/27302833,6289,22610119,"Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.",http://www.ncbi.nlm.nih.gov/pubmed/22610119,8155,18084252,PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters.,http://www.ncbi.nlm.nih.gov/pubmed/18084252,3928
"RET E623_L633del results in the deletion of eleven amino acids in the extracellular domain of the Ret protein from amino acids 623 to 633 (UniProt.org). E623_L633del has not been characterized in the scientific literature and therefore, its effect on Ret protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3929
"PIK3CA Y272* results in a premature truncation of the Pik3ca protein at amino acid 272 of 1068 (UniProt.org). Due to the loss of multiple functional domains in the Pik3ca protein (UniProt.org), Y272* is predicted to lead to a loss of function. ",295,,,www.uniprot.org,3930
"RET L923H lies within the protein kinase domain of the Ret protein (UniProt.org). L923H has not been characterized in the scientific literature and therefore, its effect on Ret protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3931
"RET G736R lies within the protein kinase domain of the Ret protein (UniProt.org). G736R has not been characterized and therefore, its effect on Ret protein function is unknown (PubMed, Aug 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3932
"PDGFRA D836N lies within the protein kinase domain of the Pdgfra protein (UniProt.org). D836N has not been characterized in the scientific literature and therefore, its effect on Pdgfra protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3933
"RET F612_C620del results in the deletion of nine amino acids in the extracellular domain of the Ret protein from amino acids 612 to 620 (UniProt.org). F612_C620del has been identified in sequencing studies (PMID: 25157968), but has not been characterized and therefore, its effect on Ret protein function is unknown (PubMed, Aug 2017).",7996,25157968,Prospective enterprise-level molecular genotyping of a cohort of cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/25157968,115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3934
"RET F329L lies within the extracellular domain of the Ret protein (UniProt.org). F329L has not been characterized in the scientific literature and therefore, its effect on Ret protein function is unknown (PubMed, Aug 2017).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3935
PDGFRA H845Y lies within the tyrosine kinase 2 domain of the Pdgfra protein (PMID: 24132921). H845Y results in increased Pdgfra autophosphorylation and is transforming in cell culture (PMID: 24132921).,2242,24132921,Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib.,http://www.ncbi.nlm.nih.gov/pubmed/24132921,3936
RET E768D lies within the protein kinase domain of the Ret protein (UniProt.org). E768D results in increased Met autophosphorylation and is weakly transforming in cell culture  (PMID: 10445857). ,295,,,www.uniprot.org,2268,10445857,Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/10445857,3937
"RET E921K lies within the protein kinase domain of the Ret protein (UniProt.org). E921K results in a loss of Ret kinase activity in cultured cells (PMID: 11438491).
",295,,,www.uniprot.org,2266,11438491,Functional analysis of RET with Hirschsprung mutations affecting its kinase domain.,http://www.ncbi.nlm.nih.gov/pubmed/11438491,3938
"BRAF W604G lies within the protein kinase domain of the Braf protein (UniProt.org). W604G has been identified in sequencing studies (PMID: 15331929), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7101,15331929,B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome.,http://www.ncbi.nlm.nih.gov/pubmed/15331929,3939
"PIK3CA R108P lies within the p85 domain of the Pik3ca protein (PMID: 15016963). R108P has been identified in sequencing studies (PMID: 15016963), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Jun 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2280,15016963,High frequency of mutations of the PIK3CA gene in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/15016963,3940
"PDGFRA I843_M844del results in the deletion of two amino acids in the protein kinase domain of the Pdgfra protein between amino acids 843 to 844 (UniProt.org). I843_M844del has not been characterized, however, similar PDGFRA exon 18 deletions are activating (PMID: 15928335, PMID: 14645423) and therefore, is predicted to result in a gain of function.",272,15928335,"PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.",http://www.ncbi.nlm.nih.gov/pubmed/15928335,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2255,14645423,Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.,http://www.ncbi.nlm.nih.gov/pubmed/14645423,3941
RET R897Q lies within the protein kinase domain of the Ret protein (UniProt.org). R897Q results in a loss of Ret kinase activity in cultured cells (PMID: 11438491).,295,,,www.uniprot.org,2266,11438491,Functional analysis of RET with Hirschsprung mutations affecting its kinase domain.,http://www.ncbi.nlm.nih.gov/pubmed/11438491,3942
RET F893L lies within the protein kinase domain of the Ret protein (UniProt.org). F893L results in a loss of Ret kinase activity in cultured cells (PMID: 11438491).,2266,11438491,Functional analysis of RET with Hirschsprung mutations affecting its kinase domain.,http://www.ncbi.nlm.nih.gov/pubmed/11438491,295,,,www.uniprot.org,3943
"RET R873Q lies within the protein kinase domain of the Ret protein (UniProt.org). R873Q results in a loss of Ret kinase activity in cultured cells (PMID: 11438491).
",295,,,www.uniprot.org,2266,11438491,Functional analysis of RET with Hirschsprung mutations affecting its kinase domain.,http://www.ncbi.nlm.nih.gov/pubmed/11438491,3944
"RET S765P lies within the protein kinase domain of the Ret protein (UniProt.org). S765P results in a loss of Ret kinase activity in cultured cells (PMID: 11438491).
",2266,11438491,Functional analysis of RET with Hirschsprung mutations affecting its kinase domain.,http://www.ncbi.nlm.nih.gov/pubmed/11438491,295,,,www.uniprot.org,3945
"CTNNB1 D32Y lies within the ubiquitination recognition motif of the Ctnnb1 protein (PMID: 15064718). D32Y confers a gain of function on the Ctnnb1 protein as demonstrated by decreased ubiquitination and increased Ctnnb1-dependent transcription (PMID: 15064718, PMID: 10987273).",2317,10987273,Beta-catenin affects androgen receptor transcriptional activity and ligand specificity.,http://www.ncbi.nlm.nih.gov/pubmed/10987273,408,15064718,Phosphorylation and ubiquitination of oncogenic mutants of beta-catenin containing substitutions at Asp32.,http://www.ncbi.nlm.nih.gov/pubmed/15064718,3956
"CTNNB1 D32G lies within the ubiquitination recognition motif of the Ctnnb1 protein (PMID: 15064718). D32G confers a gain of function on the Ctnnb1 protein as demonstrated by decreased ubiquitination and increased Ctnnb1-dependent transcription (PMID: 15064718, PMID: 22298898).",408,15064718,Phosphorylation and ubiquitination of oncogenic mutants of beta-catenin containing substitutions at Asp32.,http://www.ncbi.nlm.nih.gov/pubmed/15064718,2315,22298898,Activation of β-catenin signaling in androgen receptor-negative prostate cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/22298898,3957
CTNNB1 D32H lies within the ubiquitination recognition motif of the Ctnnb1 protein (PMID: 15064718). D32H is predicted to confer a gain of function on the Ctnnb1 protein as demonstrated by nuclear accumulation of Ctnnb1 (PMID: 17163846). ,408,15064718,Phosphorylation and ubiquitination of oncogenic mutants of beta-catenin containing substitutions at Asp32.,http://www.ncbi.nlm.nih.gov/pubmed/15064718,2287,17163846,Mutations and nuclear accumulation of beta-catenin correlate with intestinal phenotypic expression in human gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17163846,3958
"CTNNB1 A13T does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). A13T has not been biochemically characterized however,  it is predicted to confer a gain of function to Ctnnb1 as demonstrated by nuclear accumulation of Ctnnb1 (PMID: 12067995).",295,,,www.uniprot.org,4287,12067995,beta-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/12067995,3959
"CTNNB1 A20V does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). A20V does not result in nuclear accumulation of the Ctnnb1 protein (PMID: 10213482), and has not been otherwise characterized and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Mar 2017).",1244,10213482,Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/10213482,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3960
"CTNNB1 A21T does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). A21T has not been biochemically characterized however,  it is predicted to confer a gain of function to Ctnnb1 as demonstrated by nuclear accumulation of Ctnnb1 and increased expression of downstream CCND1 (PMID: 12067995, PMID: 11592102).",4287,12067995,beta-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/12067995,4288,11592102,beta-catenin nuclear expression correlates with cyclin D1 overexpression in sporadic desmoid tumours.,http://www.ncbi.nlm.nih.gov/pubmed/11592102,295,,,www.uniprot.org,3961
"CTNNB1 A39G does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). A39G has not been biochemically characterized however,  it is predicted to confer a gain of function to Ctnnb1 as demonstrated by nuclear accumulation of Ctnnb1 (PMID: 12067995)",4287,12067995,beta-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/12067995,295,,,www.uniprot.org,3962
"CTNNB1 A43P does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). A43P has not been biochemically characterized however,  it is predicted to confer a gain of function to Ctnnb1 as demonstrated by nuclear accumulation of Ctnnb1 (PMID: 11148558).",295,,,www.uniprot.org,4289,11148558,Frequent nuclear accumulation of beta-catenin in pituitary adenoma.,http://www.ncbi.nlm.nih.gov/pubmed/11148558,3963
"CTNNB1 A43T does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). A43T has not been biochemically characterized however,  it is predicted to confer a gain of function to Ctnnb1 as demonstrated by nuclear accumulation of Ctnnb1 (PMID: 11148558).",295,,,www.uniprot.org,4289,11148558,Frequent nuclear accumulation of beta-catenin in pituitary adenoma.,http://www.ncbi.nlm.nih.gov/pubmed/11148558,3964
"CTNNB1 A43V does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). A43V does not result in nuclear accumulation of the Ctnnb1 protein (PMID: 10213482), and has not been otherwise characterized and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Mar 2017).",1244,10213482,Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/10213482,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3965
CTNNB1 D32A lies within the ubiquitination recognition motif of the Ctnnb1 protein (PMID: 15064718). D32A confers a gain of function to the Ctnnb1 protein as demonstrated by reduced ubiquitination of the Ctnnb1 protein and transformation of cells in culture (PMID: 15829978). ,408,15064718,Phosphorylation and ubiquitination of oncogenic mutants of beta-catenin containing substitutions at Asp32.,http://www.ncbi.nlm.nih.gov/pubmed/15064718,461,15829978,Functional correlates of mutation of the Asp32 and Gly34 residues of beta-catenin.,http://www.ncbi.nlm.nih.gov/pubmed/15829978,3966
"CTNNB1 D32V lies within the ubiquitination recognition motif of the Ctnnb1 protein (PMID: 15064718). D32V is predicted to confer a gain of function to the Ctnnb1 protein as demonstrated by nuclear accumulation of Ctnnb1 (PMID: 10597262, PMID: 25431235). ",408,15064718,Phosphorylation and ubiquitination of oncogenic mutants of beta-catenin containing substitutions at Asp32.,http://www.ncbi.nlm.nih.gov/pubmed/15064718,2293,25431235,Nuclear expression and gain-of-function β-catenin mutation in glomangiopericytoma (sinonasal-type hemangiopericytoma): insight into pathogenesis and a diagnostic marker.,http://www.ncbi.nlm.nih.gov/pubmed/25431235,2292,10597262,Close correlation between beta-catenin gene alterations and nuclear accumulation of the protein in human hepatocellular carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/10597262,3967
"CTNNB1 D712N does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). D712N has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3968
"CTNNB1 E15K does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). E15K has been identified in the scientific literature (PMID: 20717765), but has not been biochemically characterized and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,8325,20717765,Analysis of β-catenin alterations in colon tumors: a novel exon 3 mutation.,http://www.ncbi.nlm.nih.gov/pubmed/20717765,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3969
"CTNNB1 E396D does not lie within any functional domains of the Ctnnb1 protein (UniProt.org). E396D has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3970
"CTNNB1 E571* results in a premature truncation of the Ctnnb1 protein at amino acid 571 of 781 (UniProt.org). E571* lies within an armadillo repeat domain of Ctnnb1 and, shorter Ctnnb1 truncation mutants result in loss of function thus, E571* is predicted to confer loss of function to the Ctnnb1 protein (PMID: 14612392).",295,,,www.uniprot.org,2294,14612392,Requirement for a nuclear function of beta-catenin in Wnt signaling.,http://www.ncbi.nlm.nih.gov/pubmed/14612392,3971
"CTNNB1 G34R lies within the ubiquitination recognition motif of the Ctnnb1 protein (PMID: 15064718). G34R is predicted to confer a gain of function to the Ctnnb1 protein as demonstrated by nuclear accumulation of Ctnnb1 (PMID: 10597262, PMID: 10671680). ",2295,10671680,Mutational analysis of the CTNNB1 (beta-catenin) gene in human endometrial cancer: frequent mutations at codon 34 that cause nuclear accumulation.,http://www.ncbi.nlm.nih.gov/pubmed/10671680,2292,10597262,Close correlation between beta-catenin gene alterations and nuclear accumulation of the protein in human hepatocellular carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/10597262,408,15064718,Phosphorylation and ubiquitination of oncogenic mutants of beta-catenin containing substitutions at Asp32.,http://www.ncbi.nlm.nih.gov/pubmed/15064718,3972
CTNNB1 G34V lies within the ubiquitination recognition motif of the Ctnnb1 protein (PMID: 15064718). G34V is predicted to confer a gain of function to the Ctnnb1 protein as demonstrated by nuclear accumulation of Ctnnb1 (PMID: 9671767).,2296,9671767,Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/9671767,408,15064718,Phosphorylation and ubiquitination of oncogenic mutants of beta-catenin containing substitutions at Asp32.,http://www.ncbi.nlm.nih.gov/pubmed/15064718,3973
"CTNNB1 G38fs results in a change in the amino acid sequence of the Ctnnb1 protein beginning at aa 38 of 781, likely resulting in a truncation of the functional protein (UniProt.org). Due to the loss of all known functional domains (UniProt.org), G38fs is predicted to lead to a loss of Ctnnb1 protein function.",295,,,www.uniprot.org,3974
"PIK3CA P449L lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). P449L has not been characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3975
"PIK3CA P466S lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). P466S has not been characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3976
PIK3CA Q546E lies within the PIK helical domain of the Pik3ca protein (UniProt.org). Q546E confers a gain of function to Pik3ca protein as indicated by increased cell survival and transforming ability in cell culture (PMID: 26627007).,4255,26627007,Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26627007,295,,,www.uniprot.org,3977
"PIK3CA Q546H lies within the PIK helical domain of the Pik3ca protein (UniProt.org). Q546H has been identified in the scientific literature (PMID: 23370426, PMID: 19148475), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",8898,19148475,Mutation of PIK3CA: possible risk factor for cervical carcinogenesis in older women.,http://www.ncbi.nlm.nih.gov/pubmed/19148475,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8897,23370426,Identification of uncommon PIK3CA mutations in lung cancer by using pyrosequencing.,http://www.ncbi.nlm.nih.gov/pubmed/23370426,3978
"PIK3CA Q546L lies within the PIK helical domain of the Pik3ca protein (UniProt.org). Q546L has been identified in the scientific literature (PMID: 17052259), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8376,17052259,PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/17052259,3979
"PIK3CA Q546P lies within the PIK helical domain of the Pik3ca protein (UniProt.org). Q546P M1043V results in increased phosphorylation of Akt, activation of downstream signaling, and is transforming in cell culture (PMID: 17376864).",101,17376864,Rare cancer-specific mutations in PIK3CA show gain of function.,http://www.ncbi.nlm.nih.gov/pubmed/17376864,295,,,www.uniprot.org,3980
"PIK3CA Q75E lies within the PI3K-ABD domain of the Pik3ca protein (UniProt.org). Q75E has not been characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).	",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3981
"PIK3CA R1023Q lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). R1023Q has not been characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3982
"PIK3CA R108del results in the deletion of one amino acid in the region linking the PI3K-ABD and PI3K-RBD domains of the Pik3ca protein at amino acid 113 (UniProt.org). R108del has been identified in the scientific literature (PMID: 27161972), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Jun 2017).",7228,27161972,Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid.,http://www.ncbi.nlm.nih.gov/pubmed/27161972,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3983
PIK3CA R108H lies within the region linking the PI3K-ABD and PI3K-RBD domains of the Pik3ca protein (UniProt.org). R108H results in increased phosphorylation of Akt and activation of downstream signaling in cell culture (PMID: 18829572).,1933,18829572,PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.,http://www.ncbi.nlm.nih.gov/pubmed/18829572,295,,,www.uniprot.org,3984
CTNNB1 G38P lies adjacent to the ubiquitination recognition motif of the Ctnnb1 protein (PMID: 9233789). G38P is predicted to confer a gain of function to the Ctnnb1 protein as demonstrated by nuclear accumulation of Ctnnb1 (PMID: 17163846).,2287,17163846,Mutations and nuclear accumulation of beta-catenin correlate with intestinal phenotypic expression in human gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17163846,2301,9233789,beta-catenin is a target for the ubiquitin-proteasome pathway.,http://www.ncbi.nlm.nih.gov/pubmed/9233789,3986
"CTNNB1 H36R lies adjacent to the ubiquitination recognition motif of the Ctnnb1 protein (PMID: 9233789). H36R has been identified in the scientific literature (PMID: 18464243, PMID: 17510384), but has not been biochemically characterized and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2301,9233789,beta-catenin is a target for the ubiquitin-proteasome pathway.,http://www.ncbi.nlm.nih.gov/pubmed/9233789,8346,17510384,Extensive methylation is associated with beta-catenin mutations in hepatocellular carcinoma: evidence for two distinct pathways of human hepatocarcinogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/17510384,8345,18464243,Duplication of paternal IGF2 or loss of maternal IGF2 imprinting occurs in half of Wilms tumors with various structural WT1 abnormalities.,http://www.ncbi.nlm.nih.gov/pubmed/18464243,3987
"CTNNB1 H36Y lies adjacent to the ubiquitination recognition motif of the Ctnnb1 protein (PMID: 9233789). H36Y is predicted to confer a gain of function to the Ctnnb1 protein as demonstrated by nuclear accumulation of Ctnnb1 (PMID: 11276007, PMID: 17163846).",2301,9233789,beta-catenin is a target for the ubiquitin-proteasome pathway.,http://www.ncbi.nlm.nih.gov/pubmed/9233789,2302,11276007,Nuclear localization of beta-catenin is an important prognostic factor in hepatoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/11276007,2287,17163846,Mutations and nuclear accumulation of beta-catenin correlate with intestinal phenotypic expression in human gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17163846,3988
PTEN A121E lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). A121E results in a loss of Pten phosphatase activity in yeast (PMID: 21828076).,295,,,www.uniprot.org,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,3989
PTEN A121P lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). A121P results in a loss of Pten phosphatase activity (PMID: 10866302).,2304,10866302,Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.,http://www.ncbi.nlm.nih.gov/pubmed/10866302,295,,,www.uniprot.org,3990
PTEN A126D lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). A126D results in a loss of Pten phosphatase activity in yeast (PMID: 21828076).,295,,,www.uniprot.org,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,3991
"PTEN A126P lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). A126P has been identified in the scientific literature (PMID: 26504226), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4785,26504226,Discovery and functional characterization of a neomorphic PTEN mutation.,http://www.ncbi.nlm.nih.gov/pubmed/26504226,3992
"PTEN A126S lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). A126S results in decreased phosphatase activity of Pten, but is able to inhibit Pi3k activation in yeast (PMID: 21828076).",2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,295,,,www.uniprot.org,3993
"PTEN A126T lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). A126T has been identified in sequencing studies (PMID: 26517354, PMID: 22807394), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",8035,22807394,Molecular alterations in endometrial archived liquid-based cytology.,http://www.ncbi.nlm.nih.gov/pubmed/22807394,7216,26517354,Mutational profiling of colorectal cancers with microsatellite instability.,http://www.ncbi.nlm.nih.gov/pubmed/26517354,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3994
PTEN A126V lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). A126V results in a loss of Pten phosphatase activity in yeast (PMID: 21828076).,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,295,,,www.uniprot.org,3995
PTEN C105F lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). C105F results in a loss of Pten phosphatase activity and is unable to suppress cell proliferation in culture (PMID: 9823298).,295,,,www.uniprot.org,2305,9823298,The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells.,http://www.ncbi.nlm.nih.gov/pubmed/9823298,3996
"PTEN C105G lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). C105G has not been characterized in the scientific literature and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3997
"PTEN C105S lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). C105S has been identified in the scientific literature (PMID: 11916965), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",8036,11916965,Reversible inactivation of the tumor suppressor PTEN by H2O2.,http://www.ncbi.nlm.nih.gov/pubmed/11916965,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3998
"PTEN C105W lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). C105W has been identified in the scientific literature (PMID: 19471547), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",8037,19471547,Pharmacogenomic profiling of the PI3K/PTEN pathway in sporadic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19471547,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3999
"PTEN C105Y lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). C105Y has been identified in the scientific literature (PMID: 15987703), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,8038,15987703,LKB1 interacts with and phosphorylates PTEN: a functional link between two proteins involved in cancer predisposing syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/15987703,295,,,www.uniprot.org,4000
"PTEN C124F lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). C124F has been identified in sequencing studies (PMID: 25344691), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,1689,25344691,RNF43 is frequently mutated in colorectal and endometrial cancers.,http://www.ncbi.nlm.nih.gov/pubmed/25344691,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4001
"PTEN C124fs*10 likely results in a truncation of the 403 aa Pten protein at aa 124, followed by 10 nonsense amino acids within the phosphatase tensin-type domain (UniProt.org). PTEN C124fs*10 has not been characterized, however, other C-terminal deletion mutants downstream of C124 are inactivating (PMID: 10468583), thus C124fs*10 is predicted to lead to a loss of Pten protein function.",295,,,www.uniprot.org,2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,4002
PTEN C124G lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). C124G results in a loss of Pten phosphatase activity and is unable to suppress cell proliferation in culture (PMID: 9823298).,295,,,www.uniprot.org,2305,9823298,The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells.,http://www.ncbi.nlm.nih.gov/pubmed/9823298,4003
"PTEN C124R lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). C124R results in a loss of Pten phosphatase activity and contributes to tumorigenesis in transgenic animal models (PMID: 10866302, PMID: 20194734).",2304,10866302,Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.,http://www.ncbi.nlm.nih.gov/pubmed/10866302,295,,,www.uniprot.org,2306,20194734,Allele-specific tumor spectrum in pten knockin mice.,http://www.ncbi.nlm.nih.gov/pubmed/20194734,4004
PTEN C124S lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). C124S results in a loss of Pten phosphatase activity and is unable to suppress cell proliferation in culture (PMID: 9811831).,2307,9811831,The lipid phosphatase activity of PTEN is critical for its tumor supressor function.,http://www.ncbi.nlm.nih.gov/pubmed/9811831,295,,,www.uniprot.org,4005
"PTEN C136F lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). C136F has been identified in sequencing studies (PMID: 10096247), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8041,10096247,Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations.,http://www.ncbi.nlm.nih.gov/pubmed/10096247,4006
"PTEN C136R lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). C136R results in increased proteasome-mediated degradation of Pten protein, and activation of Akt and Erk signaling in cell culture (PMID: 23475934).",295,,,www.uniprot.org,2308,23475934,Cowden syndrome-related mutations in PTEN associate with enhanced proteasome activity.,http://www.ncbi.nlm.nih.gov/pubmed/23475934,4007
"KDR (VEGFR2) A248G lies within the Ig-like C2-type domain 3 of the Kdr (Vegfr2) protein (UniProt.org). A248G has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4008
"KDR (VEGFR2) A352V lies within the Ig-like C2-type domain 4 of the Kdr (Vegfr2) protein (UniProt.org). A352V has not been characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4009
"KDR (VEGFR2) A467T lies within the Ig-like C2-type domain 5 of the Kdr (Vegfr2) protein (UniProt.org). A467T has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4010
"KDR (VEGFR2) A973S lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). A973S has not been characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4011
"KDR (VEGFR2) C737Y lies within the Ig-like C2-type domain 7 of the Kdr (Vegfr2) protein (UniProt.org). C737Y has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4012
"KDR (VEGFR2) D1174Y lies within the cytoplasmic domain of the Kdr (Vegfr2) protein (UniProt.org). D1174Y has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4013
"KDR (VEGFR2) D1254N lies within the cytoplasmic domain of the Kdr (Vegfr2) protein (UniProt.org). D1254N has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4014
"KDR (VEGFR2) D39Y lies within the extracellular domain of the Kdr (Vegfr2) protein (UniProt.org). D39Y has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4015
"KDR (VEGFR2) D639Y lies within the Ig-like C2-type domain 6 of the Kdr (Vegfr2) protein (UniProt.org). D639Y has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4016
"KDR (VEGFR2) D832Y lies within the cytoplasmic domain of the Kdr (Vegfr2) protein (UniProt.org). D832Y has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4017
"KDR (VEGFR2) D998N lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). D998N has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4018
"KDR (VEGFR2) E1114* results in a premature truncation of the Kdr (Vegfr2) protein at amino acid 1114 of 1356 (UniProt.org). E1114* has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).

",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4019
"KDR (VEGFR2) E1325* results in a premature truncation of the Kdr (Vegfr2) protein at amino acid 1325 of 1356 (UniProt.org). E1325* has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4020
"KDR (VEGFR2) E469K lies within the Ig-like C2-type domain 5 of the Kdr (Vegfr2) protein (UniProt.org). E469K has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4021
"KDR (VEGFR2) E759V  lies within the extracellular domain of the Kdr (Vegfr2) protein (UniProt.org). E759V has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4022
"KDR (VEGFR2) F1115C lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). F1115C has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4023
"KDR (VEGFR2) A345R lies within the Ig-like C2-type domain 4 of the Kdr (Vegfr2) protein (UniProt.org). A345R has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4024
"KDR (VEGFR2) F921C lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). F921C has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4025
"FOXL2 A331V does not lie within any known functional domains of the Foxl2 protein (UniProt.org). A331V has not been characterized and therefore, its effect on Foxl2 protein function is unknown (PubMed, Mar 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4026
CTNNB1 I35T lies within the ubiquitination recognition motif of the Ctnnb1 protein (PMID: 15064718). I35T is predicted to confer a gain of function to the Ctnnb1 protein as demonstrated by nuclear localization of Ctnnb1 (PMID: 15943036). ,2318,15943036,"Expression of beta-catenin, E-cadherin and cyclin D1 in adenoid cystic carcinoma of the salivary gland.",http://www.ncbi.nlm.nih.gov/pubmed/15943036,408,15064718,Phosphorylation and ubiquitination of oncogenic mutants of beta-catenin containing substitutions at Asp32.,http://www.ncbi.nlm.nih.gov/pubmed/15064718,4027
"FOXL2 C134W lies within the DNA binding domain of the Foxl2 protein (UniProt.org). C134W alters Foxl2 transcriptional regulation, resulting in the increased production of the target gene CYP19A1 (aromatase) (PMID: 21188138) and induces proliferation of ovarian granulosa cells (PMID: 28276867).",2319,21188138,Aromatase is a direct target of FOXL2: C134W in granulosa cell tumors via a single highly conserved binding site in the ovarian specific promoter.,http://www.ncbi.nlm.nih.gov/pubmed/21188138,8392,28276867,Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary.,http://www.ncbi.nlm.nih.gov/pubmed/28276867,295,,,www.uniprot.org,4028
"CTNNB1 I140N does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). I140N has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4029
"CTNNB1 K354T lies within the ARM repeat region 5 of the Ctnnb1 protein (UniProt.org). K354T has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4030
"CTNNB1 L405F lies within ARM repeat 7 of the Ctnnb1 protein (UniProt.org). L405F has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4031
"CTNNB1 M553V lies within ARM repeat 10 of the Ctnnb1 protein (UniProt.org). M553V has been identified in sequencing studies (PMID: 22653804), but has not been biochemically characterized and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Mar 2017).",7748,22653804,Use of mutation profiles to refine the classification of endometrial carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/22653804,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4032
"CTNNB1 N415H lies within ARM repeat 7 of the Ctnnb1 protein (UniProt.org). N415H has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4033
"CTNNB1 P16S does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). P16S has been identified in the scientific literature (PMID: 25393105, PMID: 25148578), but has not been biochemically characterized and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Mar 2017).",8347,25393105,Clonal architectures and driver mutations in metastatic melanomas.,http://www.ncbi.nlm.nih.gov/pubmed/25393105,295,,,www.uniprot.org,7824,25148578,Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/25148578,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4034
"CTNNB1 G487fs results in a change in the amino acid sequence of the Ctnnb1 protein beginning at aa 487 of 781, likely resulting in a truncation of the functional protein (UniProt.org). Due to the loss of multiple armadillo repeats (UniProt.org), L487fs is predicted to confer a loss of function to the Ctnnb1 protein.",295,,,www.uniprot.org,4035
"CTNNB1 P44A lies adjacent to the Gsk3b phosphorylation priming site (PMID: 12051714). P44A confers gain of function to the Ctnnb1 protein, as demonstrated by increased Ctnnb1-dependent transcription (PMID: 18282277).",2320,12051714,Characterisation of the phosphorylation of beta-catenin at the GSK-3 priming site Ser45.,http://www.ncbi.nlm.nih.gov/pubmed/12051714,401,18282277,Correlation between beta-catenin mutations and expression of Wnt-signaling target genes in hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18282277,4036
"CTNNB1 P44L lies adjacent to the Gsk3b phosphorylation priming site (PMID: 12051714). P44L has not been biochemically characterized however, nuclear accumulation of Ctnnb1was observed in the presence of a coincident K49E mutation (PMID: 12474227).",2320,12051714,Characterisation of the phosphorylation of beta-catenin at the GSK-3 priming site Ser45.,http://www.ncbi.nlm.nih.gov/pubmed/12051714,2347,12474227,Cribriform-morular variant of papillary thyroid carcinoma: a pathological and molecular genetic study with evidence of frequent somatic mutations in exon 3 of the beta-catenin gene.,http://www.ncbi.nlm.nih.gov/pubmed/12474227,4037
"CTNNB1 P44S lies adjacent to the Gsk3b phosphorylation priming site (PMID: 12051714). P44S has been identified in conjunction with other Ctnnb1 mutations but the functional effect is conflicting, as some samples with P44S result in nuclear accumulation of Ctnnb1 and some samples do not (PMID: 10213482).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2320,12051714,Characterisation of the phosphorylation of beta-catenin at the GSK-3 priming site Ser45.,http://www.ncbi.nlm.nih.gov/pubmed/12051714,4038
"CTNNB1 Q193* results in a premature truncation of the Ctnnb1 protein at amino acid 193 of 781 (UniProt.org). Due to the loss of the majority of armadillo repeat regions (UniProt.org), Q193* is predicted to confer a loss of function to the Ctnnb1 protein (UniProt.org).",295,,,www.uniprot.org,4039
"CTNNB1 Q302H lies within the ARM repeat region 4 of the Ctnnb1 protein (UniProt.org). Q302H has been identified in sequencing studies (PMID: 22895193), but has not been biochemically characterized and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4597,22895193,Recurrent R-spondin fusions in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22895193,4040
"CTNNB1 Q322K lies within the armadillo repeat region 5 of the Ctnnb1 protein (UniProt.org). Q322K has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4041
PIK3CA Q60K lies within the PI3K-ABD domain of the Pik3ca protein (UniProt.org). Q60K demonstrates kinase activity and transformation potential similar to wild-type Pik3ca protein (PMID: 18074223).,295,,,www.uniprot.org,2321,18074223,Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells.,http://www.ncbi.nlm.nih.gov/pubmed/18074223,4042
"PTEN C136W lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). C136W has been identified in sequencing studies (PMID: 24425785), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8042,24425785,Genomic analysis of head and neck squamous cell carcinoma cell lines and human tumors: a rational approach to preclinical model selection.,http://www.ncbi.nlm.nih.gov/pubmed/24425785,4043
PTEN C136Y lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). C136Y results in a loss of Pten phosphatase activity in an in vitro assay (PMID: 10866302).,2304,10866302,Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.,http://www.ncbi.nlm.nih.gov/pubmed/10866302,295,,,www.uniprot.org,4044
"PTEN C250fs*2 likely results in a truncation of the 403 aa Pten protein at aa 250, followed by 2 nonsense amino acids within the C2 tensin-type domain (UniProt.org). C250fs*2 has not been characterized, however, other C-terminal deletion mutants downstream of C250 are inactivating (PMID: 10468583), thus C250fs*2 is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4045
PTEN C71Y lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). C71Y results in a loss of Pten phosphatase activity in an in vitro assay (PMID: 11051241).,2322,11051241,Functional evaluation of p53 and PTEN gene mutations in gliomas.,http://www.ncbi.nlm.nih.gov/pubmed/11051241,295,,,www.uniprot.org,4046
PTEN D107Y lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). D107Y results in a loss of Pten phosphatase activity in an in vitro assay (PMID: 10866302).,2304,10866302,Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.,http://www.ncbi.nlm.nih.gov/pubmed/10866302,295,,,www.uniprot.org,4047
"PTEN D115Y lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). D115Y has not been characterized in the scientific literature and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4048
"PTEN D116fs*18 likely results in a truncation of the 403 aa Pten protein at aa 116, followed by 18 nonsense amino acids within the phosphatase tensin-type domain (UniProt.org). Due to the loss of the C2 tensin-type domain (UniProt.org), D116fs*18 is predicted to lead to a loss of Pten function.",295,,,www.uniprot.org,4049
"PTEN D24G lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). D24G has been identified in sequencing studies (PMID: 21266528, PMID: 25256166), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,2211,21266528,A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/21266528,9906,25256166,Mutational profiling of kinases in glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/25256166,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4050
"PTEN D24V lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). D24V has been identified in sequencing studies (PMID: 25527629, PMID: 24498881), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9907,24498881,A novel deleterious PTEN mutation in a patient with early-onset bilateral breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24498881,2323,25527629,Functionally distinct groups of inherited PTEN mutations in autism and tumour syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25527629,4051
"PTEN D252G lies within the C2 tensin-type domain of the Pten protein (UniProt.org). D252G results in decreased Pten phosphatase activity, but is able to inhibit Pi3k activation in cell culture (PMID: 21828076, PMID: 25527629).",295,,,www.uniprot.org,2323,25527629,Functionally distinct groups of inherited PTEN mutations in autism and tumour syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25527629,4052
"PTEN D331fs*13 likely results in a truncation of the 403 aa Pten protein at aa 331, followed by 13 nonsense amino acids within the phosphatase tensin-type domain (UniProt.org). D331fs*13 has not been characterized, however, other C-terminal deletion mutants downstream of D331 are inactivating (PMID: 10468583), thus D331fs*13 is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4053
"PTEN D331G lies within the C2 tensin-type domain of the Pten protein (UniProt.org). D331G results in decreased Pten protein stability and reduced phosphatase activity, but demonstrates growth inhibition to a similar level of wild-type protein in cell culture (PMID: 11156408, PMID: 10866302).",2304,10866302,Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.,http://www.ncbi.nlm.nih.gov/pubmed/10866302,295,,,www.uniprot.org,2324,11156408,Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/11156408,4054
PTEN D92E lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). D92E results in a loss of Pten phosphatase activity in yeast (PMID: 21828076).,295,,,www.uniprot.org,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,4055
"PTEN E201*results in a premature truncation of the Pten protein at amino acid 201 of 403 (UniProt.org). Due to the loss of C2 tensin-type domain (UniProt.org), E201* is predicted to lead to a loss of Pten function.",295,,,www.uniprot.org,4056
"PTEN E235* results in a premature truncation of the Pten protein at amino acid 235 of 403 (UniProt.org). E235* has not been characterized, however, other C-terminal deletion mutants downstream of E235 are inactivating (PMID: 10468583), thus E235* is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4057
"PTEN E242* results in a premature truncation of the Pten protein at amino acid 242 of 403 (UniProt.org). E242*has not been characterized, however, other C-terminal deletion mutants downstream of E242 are inactivating (PMID: 10468583), thus E242* is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4058
"PTEN E242fs*1 likely results in a truncation of the 403 aa Pten protein at aa 242, followed by 1 nonsense amino acids within the C2 tensin-type domain (UniProt.org). E242fs*1 has not been characterized, however, other C-terminal deletion mutants downstream of E242 are inactivating (PMID: 10468583), thus E242fs*1 is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4059
"PTEN E242fs*15 likely results in a truncation of the 403 aa Pten protein at aa 242, followed by 15 nonsense amino acids within the C2 tensin-type domain (UniProt.org). E242fs*15 has not been characterized, however, other C-terminal deletion mutants downstream of E242 are inactivating (PMID: 10468583), thus E242fs*15 is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4060
"PTEN E284fs results in a change in the amino acid sequence of the Pten protein beginning at aa 284 of 403, likely resulting in premature truncation of the functional protein (UniProt.org). E284fs has not been characterized, however other C-terminal deletion mutants downstream of E284 are inactivating (PMID: 10468583), thus E284fs is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4061
"PTEN E285* results in a premature truncation of the Pten protein at amino acid 285 of 403 (UniProt.org). E285* has not been characterized, however, other C-terminal deletion mutants downstream of E285 are inactivating (PMID: 10468583), thus E285* is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4062
"PTEN E285K lies within the C2 tensin-type domain of the Pten protein (UniProt.org). E285K has not been characterized in the scientific literature and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4063
"PTEN E288* results in a premature truncation of the Pten protein at amino acid 288 of 403 (UniProt.org). E288*has not been characterized, however, other C-terminal deletion mutants downstream of E288 are inactivating (PMID: 10468583), thus E288* is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4064
"PTEN E288fs results in a change in the amino acid sequence of the Pten protein beginning at aa 288 of 403, likely resulting in premature truncation of the functional protein (UniProt.org). E288fs has not been characterized, however, other C-terminal deletion mutants downstream of E288 are inactivating (PMID: 10468583), thus E288fs is predicted to lead to a loss of Pten protein function.",295,,,www.uniprot.org,2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,4065
"PTEN E288fs*3 likely results in a truncation of the 403 aa Pten protein at aa 288, followed by 3 nonsense amino acids within the C2 tensin-type domain (UniProt.org). E288fs*3 has not been characterized, however, other C-terminal deletion mutants downstream of E288 are inactivating (PMID: 10468583), thus E288fs*3 is predicted to lead to a loss of Pten protein function.",295,,,www.uniprot.org,2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,4066
"PTEN E291* results in a premature truncation of the Pten protein at amino acid 291 of 403 (UniProt.org). E291* has not been characterized, however, other C-terminal deletion mutants downstream of E291 are inactivating (PMID: 10468583), thus E291* is predicted to lead to a loss of Pten protein function.",295,,,www.uniprot.org,2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,4067
"PTEN E299* results in a premature truncation of the Pten protein at amino acid 299 of 403 (UniProt.org). E299* has not been characterized, however, other C-terminal deletion mutants downstream of E299 are inactivating (PMID: 10468583), thus E299* is predicted to lead to a loss of Pten protein function.",295,,,www.uniprot.org,2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,4068
"PTEN E7* results in a premature truncation of the Pten protein at amino acid 7 of 403 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), E7* is predicted to lead to a loss of Pten function.",295,,,www.uniprot.org,4069
"PTEN F337fs*6 likely results in a truncation of the 403 aa Pten protein at aa 337, followed by 6 nonsense amino acids within the C2 tensin-type domain (UniProt.org). F337fs*6 has not been characterized, however, other C-terminal deletion mutants downstream of F337 are inactivating (PMID: 10468583), thus F337fs*6 is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4070
"MAP2K1 D190Y lies within the protein kinase domain of the Map2k1 protein (UniProt.org). D190Y has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Mar 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4071
"PTEN F337fs*7 likely results in a truncation of the 403 aa Pten protein at aa 337, followed by 7 nonsense amino acids within the C2 tensin-type domain (UniProt.org). F337fs*7 has not been characterized, however, other C-terminal deletion mutants downstream of F337 are inactivating (PMID: 10468583), thus F337fs*7 is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4072
PTEN F341V lies within the C2 tensin-type domain of the Pten protein (UniProt.org). F341V results in a loss of Pten phosphatase activity in an in vitro assay (PMID: 11051241).,295,,,www.uniprot.org,2322,11051241,Functional evaluation of p53 and PTEN gene mutations in gliomas.,http://www.ncbi.nlm.nih.gov/pubmed/11051241,4073
"MAP2K1 E333A lies within the protein kinase domain of the Map2k1 protein (UniProt.org). E333A has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Mar 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4074
"MAP2K1 G301* results in a premature truncation of the Map2k1 protein at amino acid 301 of 393 (UniProt.org). G301* lies within the RAF1-binding region, however, it has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (UniProt.org, PubMed, Mar 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4075
"MAP2K1 I310L lies within the protein kinase domain of the Map2k1 protein (UniProt.org). I310L has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Apr 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4076
"KDR (VEGFR2) G1145E lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). G1145E has been identified in sequencing studies (PMID: 18948947), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",6956,18948947,Somatic mutations affect key pathways in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18948947,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4077
"FOXL2 E118K lies within the DNA binding domain of the Foxl2 protein (UniProt.org). E118K has not been characterized in the scientific literature and therefore, its effect on Foxl2 protein function is unknown (PubMed, Mar 2015). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4078
"KDR (VEGFR2) G1145R lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). G1145R has been identified in sequencing studies (PMID: 22842228), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",7109,22842228,Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22842228,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4079
"KDR (VEGFR2) G1308* results in a premature truncation of the Kdr (Vegfr2) protein at amino acid 1308 of 1356 (UniProt.org). G1308* has been identified in sequencing studies (PMID: 18948947), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,6956,18948947,Somatic mutations affect key pathways in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18948947,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4081
"FOXL2 E139K lies within the DNA binding domain of the Foxl2 protein (UniProt.org). E139K has not been characterized in the scientific literature and therefore, its effect on Foxl2 protein function is unknown (PubMed, Mar 2015). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4082
"MAP2K1 K57T lies within the negative regulatory region of the Map2k1 protein (PMID: 24241536). K57T has not been biochemically characterized, but has been described as a secondary drug resistance mutation (PMID: 26644315). ",2325,24241536,High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias.,http://www.ncbi.nlm.nih.gov/pubmed/24241536,4531,26644315,Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26644315,4083
"FOXL2 E352K does not lie within any known functional domains of the Foxl2 protein (UniProt.org). E352K has not been characterized and therefore, its effect on Foxl2 protein function is unknown (PubMed, Mar 2015).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4084
MAP2K1 P124L lies within the protein kinase domain of the Map2k1 protein (UniProt.org). P124L results in increased Erk 1/2 phosphorylation in cultured cells and confers resistance to some Mek and Braf inhibitors in melanoma cells (PMID: 19915144).  ,295,,,www.uniprot.org,134,19915144,MEK1 mutations confer resistance to MEK and B-RAF inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/19915144,4085
"MAP2K1 P124Q lies within the protein kinase domain of the Map2k1 protein (UniProt.org). P124Q leads to increased Map2k1 activity, as demonstrated by increased activation of downstream Erk1/2 in cell culture (PMID: 25370473).
",6439,25370473,Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.,http://www.ncbi.nlm.nih.gov/pubmed/25370473,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4086
"FOXL2 E69D lies within the DNA binding domain of the Foxl2 protein (UniProt.org). E69D has not been characterized in the scientific literature and therefore, its effect on Foxl2 protein function is unknown (PubMed, Mar 2015). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4087
"MAP2K1 R349K lies within the protein kinase domain of the Map2k1 protein (UniProt.org). R349K has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Apr 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4088
"FOXL2 E69K lies within the DNA binding domain of the Foxl2 protein (UniProt.org). E69K results in nuclear aggregation of the Foxl2 protein however, its effect on Foxl2 transcriptional regulation has not been fully characterized (PMID: 18372316, PubMed, Mar 2015).",2326,18372316,"Missense mutations in the forkhead domain of FOXL2 lead to subcellular mislocalization, protein aggregation and impaired transactivation.",http://www.ncbi.nlm.nih.gov/pubmed/18372316,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4089
"FOXL2 E69Q lies within the DNA binding domain of the Foxl2 protein (UniProt.org). E69Q has not been characterized in the scientific literature and therefore, its effect on Foxl2 protein function is unknown (PubMed, Mar 2015). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4091
"FOXL2 G121S lies within the DNA binding domain of the Foxl2 protein (UniProt.org). G121S has not been characterized in the scientific literature and therefore, its effect on Foxl2 protein function is unknown (PubMed, Mar 2015). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4092
"KDR (VEGFR2) G394E lies within the Ig-like C2-type domain 4 of the Kdr (Vegfr2) protein (UniProt.org). G394E has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4095
"KDR (VEGFR2) G394R lies within the Ig-like C2-type domain 4 of the Kdr (Vegfr2) protein (UniProt.org). G394R has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4096
"FOXL2 G38S does not lie within any known functional domains of the Foxl2 protein (UniProt.org). G38S has not been characterized in the scientific literature and therefore, its effect on Foxl2 protein function is unknown (PubMed, Mar 2015).
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4097
"FOXL2 G43R does not lie within any known functional domains of the Foxl2 protein (UniProt.org). G43R has not been characterized in the scientific literature and therefore, its effect on Foxl2 protein function is unknown (PubMed, Mar 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4099
"KDR (VEGFR2) G873R lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). G873R has been identified in sequencing studies (PMID: 16959974), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4101
"KDR (VEGFR2) H1026N lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). H1026N has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4102
"KDR (VEGFR2) I1077L lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). I1077L has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4104
"FOXL2 I63fs results in a change in the amino acid sequence of the Foxl2 protein beginning at aa 63 of 376, likely resulting in a premature truncation of the functional protein (UniProt.org). Due to a loss of the DNA binding domain (UniProt.org), I63fs is predicted to result in a loss of Foxl2 protein function. ",295,,,www.uniprot.org,4105
"KDR (VEGFR2) K353N lies within the Ig-like C2-type domain 4 of the Kdr (Vegfr2) protein (UniProt.org). K353N has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4107
"FOXL2 N109S lies within the DNA binding domain of the Foxl2 protein (UniProt.org). N109S has not been characterized in the scientific literature and therefore, its effect on Foxl2 protein function is unknown (PubMed, Mar 2015). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4108
"KDR (VEGFR2) L1049W lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). L1049W has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4110
"FOXL2 P116Q lies within the DNA binding domain of the Foxl2 protein (UniProt.org). P116Q has not been characterized in the scientific literature and therefore, its effect on Foxl2 protein function is unknown (PubMed, Mar 2015).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4111
"KDR (VEGFR2) K366T lies within the Ig-like C2-type 4 domain of the Kdr (Vegfr2) protein (UniProt.org). K366T has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4113
"FOXL2 R146P lies within the DNA binding domain of the Foxl2 protein (UniProt.org). R146P has not been characterized and therefore, its effect on Foxl2 protein function is unknown (PubMed, Mar 2015).
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4114
"KDR (VEGFR2) L1140M lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). L1140M has been identified in sequencing studies (PMID: 18948947), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6956,18948947,Somatic mutations affect key pathways in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18948947,4115
"FOXL2 R147L lies within the DNA binding domain of the Foxl2 protein (UniProt.org). R147L has not been characterized in the scientific literature and therefore, its effect on Foxl2 protein function is unknown (PubMed, Mar 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4117
"FOXL2 T76M lies within the DNA binding domain of the Foxl2 protein (UniProt.org). T76M has not been characterized and therefore, its effect on Foxl2 protein function is unknown (PubMed, Mar 2015).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4118
FOXL2 S58L lies within the DNA binding domain of the Foxl2 protein (UniProt.org). S58L results in Foxl2 protein aggregation and an impaired ability to transactivate target genes (PMID: 18372316).,2326,18372316,"Missense mutations in the forkhead domain of FOXL2 lead to subcellular mislocalization, protein aggregation and impaired transactivation.",http://www.ncbi.nlm.nih.gov/pubmed/18372316,295,,,www.uniprot.org,4120
FOXL2 I63T lies within the DNA binding domain of the Foxl2 protein (UniProt.org). I63T results in Foxl2 protein aggregation and an impaired ability to transactivate target genes (PMID: 18372316).,2326,18372316,"Missense mutations in the forkhead domain of FOXL2 lead to subcellular mislocalization, protein aggregation and impaired transactivation.",http://www.ncbi.nlm.nih.gov/pubmed/18372316,295,,,www.uniprot.org,4122
"FOXL2 A66V lies within the DNA binding domain of the Foxl2 protein (UniProt.org). A66V results in Foxl2 protein aggregation and an impaired ability to transactivate target genes (PMID: 18372316).
",2326,18372316,"Missense mutations in the forkhead domain of FOXL2 lead to subcellular mislocalization, protein aggregation and impaired transactivation.",http://www.ncbi.nlm.nih.gov/pubmed/18372316,295,,,www.uniprot.org,4123
FOXL2 S70I lies within the DNA binding domain of the Foxl2 protein (UniProt.org). S70I results in Foxl2 protein aggregation and an impaired ability to transactivate target genes (PMID: 18372316).,2326,18372316,"Missense mutations in the forkhead domain of FOXL2 lead to subcellular mislocalization, protein aggregation and impaired transactivation.",http://www.ncbi.nlm.nih.gov/pubmed/18372316,295,,,www.uniprot.org,4124
"FOXL2 I80T lies within the DNA binding domain of the Foxl2 protein (UniProt.org). I80T results in Foxl2 protein aggregation and an impaired ability to transactivate target genes (PMID: 18372316).
",2326,18372316,"Missense mutations in the forkhead domain of FOXL2 lead to subcellular mislocalization, protein aggregation and impaired transactivation.",http://www.ncbi.nlm.nih.gov/pubmed/18372316,295,,,www.uniprot.org,4125
FOXL2 I84N lies within the DNA binding domain of the Foxl2 protein (UniProt.org). I84N results in Foxl2 protein aggregation and an impaired ability to transactivate target genes (PMID: 18372316).,2326,18372316,"Missense mutations in the forkhead domain of FOXL2 lead to subcellular mislocalization, protein aggregation and impaired transactivation.",http://www.ncbi.nlm.nih.gov/pubmed/18372316,295,,,www.uniprot.org,4126
"FOXL2 F90S lies within the DNA binding domain of the Foxl2 protein (UniProt.org). F90S results in Foxl2 protein aggregation and an impaired ability to transactivate target genes (PMID: 18372316).
",2326,18372316,"Missense mutations in the forkhead domain of FOXL2 lead to subcellular mislocalization, protein aggregation and impaired transactivation.",http://www.ncbi.nlm.nih.gov/pubmed/18372316,295,,,www.uniprot.org,4127
"FOXL2 W98G lies within the DNA binding domain of the Foxl2 protein (UniProt.org). W98G results in Foxl2 protein aggregation and an impaired ability to transactivate target genes (PMID: 18372316).
",2326,18372316,"Missense mutations in the forkhead domain of FOXL2 lead to subcellular mislocalization, protein aggregation and impaired transactivation.",http://www.ncbi.nlm.nih.gov/pubmed/18372316,295,,,www.uniprot.org,4128
"CTNNB1 Q703H does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). Q703H has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4129
"CTNNB1 R151fs results in a change in the amino acid sequence of the Ctnnb1 protein beginning at aa 151 of 781, likely resulting in a truncation of the functional protein (UniProt.org). Due to the loss of most functional domains (UniProt.org), R151fs is predicted to lead to a loss of Ctnnb1 protein function.",295,,,www.uniprot.org,4130
"CTNNB1 R453L lies within the ARM repeat region 8 of the Ctnnb1 protein (UniProt.org). R453L has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4131
"CTNNB1 R453Q lies within the ARM repeat region 8 of the Ctnnb1 protein (UniProt.org). R453Q has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4132
"CTNNB1 R515Q lies within the ARM repeat region 9 of the Ctnnb1 protein (UniProt.org). R515Q has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,295,,,www.uniprot.org,4133
"CTNNB1 R535* results in a premature truncation of the Ctnnb1 protein at amino acid 535 of 781 (UniProt.org). R535* has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4134
"CTNNB1 R535Q lies within the ARM repeat region 10 of the Ctnnb1 protein (UniProt.org). R535Q has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4135
"CTNNB1 R542H lies within the ARM repeat region 9 of the Ctnnb1 protein (UniProt.org). R542H has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4136
"CTNNB1 R587Q does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). R587Q has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4137
"CTNNB1 R95* results in a premature truncation of the Ctnnb1 protein at amino acid 95 of 781 (UniProt.org). Due to the loss of the majority of armadillo repeat regions (UniProt.org), R95* is predicted to confer a loss of function to the Ctnnb1 protein (UniProt.org).",295,,,www.uniprot.org,4138
"CTNNB1 S23_S33del results in the deletion of eleven amino acids in the ubiquitination recognition motif of the Ctnnb1 protein from amino acids 23 to 33 (PMID: 15064718). S23_S33del has been identified in sequencing studies (PMID: 11309340), but has not been biochemically characterized and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2327,11309340,Frequent deletions and mutations of the beta-catenin gene are associated with overexpression of cyclin D1 and fibronectin and poorly differentiated histology in childhood hepatoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/11309340,408,15064718,Phosphorylation and ubiquitination of oncogenic mutants of beta-catenin containing substitutions at Asp32.,http://www.ncbi.nlm.nih.gov/pubmed/15064718,4139
"CTNNB1 S23G lies within a Gsk3b phosphorylation site of the Ctnnb1 protein (PMID: 12027456). S23G has not been been fully biochemically characterized, but did not increase Ctnnb1 transcriptional activation of cyclinD1 in cell culture (PMID: 12049819).",2328,12027456,Identification of two novel regulated serines in the N terminus of beta-catenin.,http://www.ncbi.nlm.nih.gov/pubmed/12027456,3663,12049819,"Differential expression of Wnt genes, beta-catenin and E-cadherin in human brain tumors.",http://www.ncbi.nlm.nih.gov/pubmed/12049819,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4140
"CTNNB1 S29F lies within a Gsk3b phosphorylation site of the Ctnnb1 protein (PMID: 12027456). S29F has not been fully biochemically characterized, but is not transforming and does not activate Ctnnb1-dependent transcription in cell culture (PMID: 12027456).",2328,12027456,Identification of two novel regulated serines in the N terminus of beta-catenin.,http://www.ncbi.nlm.nih.gov/pubmed/12027456,4141
"CTNNB1 S33C lies within the ubiquitination recognition motif of the Ctnnb1 protein and occurs at a Gsk3b phosphorylation site on the Ctnnb1 protein (PMID: 15064718). S33C confers a gain of function to the Ctnnb1 protein as demonstrated by nuclear accumulation of Ctnnb1 and increased Ctnnb1-driven transcription (PMID: 10076565, PMID: 21881488, PMID: 19582367).",2331,10076565,Mutations of the beta-catenin gene in endometrial carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/10076565,408,15064718,Phosphorylation and ubiquitination of oncogenic mutants of beta-catenin containing substitutions at Asp32.,http://www.ncbi.nlm.nih.gov/pubmed/15064718,2329,21881488,β-catenin (CTNNB1) S33C mutation in ovarian microcystic stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/21881488,2330,19582367,CTNNB1 (beta-catenin) mutation is rare in brain tumours but involved as a sporadic event in a brain metastasis.,http://www.ncbi.nlm.nih.gov/pubmed/19582367,4142
"CTNNB1 S33Y lies within the ubiquitination recognition motif of the Ctnnb1 protein and occurs at a Gsk3b phosphorylation site on the Ctnnb1 protein (PMID: 15064718). S33Y confers a gain of function to the Ctnnb1 protein as demonstrated by nuclear accumulation of Ctnnb1, increased Ctnnb1-driven transcription, and increased proliferation of cells in culture (PMID: 18757411).",408,15064718,Phosphorylation and ubiquitination of oncogenic mutants of beta-catenin containing substitutions at Asp32.,http://www.ncbi.nlm.nih.gov/pubmed/15064718,2332,18757411,Illegitimate WNT pathway activation by beta-catenin mutation or autocrine stimulation in T-cell malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/18757411,4143
"CTNNB1 S33F lies within the ubiquitination recognition motif of the Ctnnb1 protein and occurs at a Gsk3b phosphorylation site on the Ctnnb1 protein (PMID: 15064718). S33F is predicted to confer a gain of function to the Ctnnb1 protein as demonstrated by nuclear accumulation of Ctnnb1 (PMID: 10597262, PMID: 10213482).",2292,10597262,Close correlation between beta-catenin gene alterations and nuclear accumulation of the protein in human hepatocellular carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/10597262,408,15064718,Phosphorylation and ubiquitination of oncogenic mutants of beta-catenin containing substitutions at Asp32.,http://www.ncbi.nlm.nih.gov/pubmed/15064718,1244,10213482,Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/10213482,4144
"S33L lies within the ubiquitination recognition motif of the Ctnnb1 protein and occurs at a Gsk3b phosphorylation site on the Ctnnb1 protein (PMID: 15064718). S33L has not been characterized, however other S33 “hotspot” mutations are activating thus, S33L is predicted to result in a gain of Ctnnb1 function (PMID: 19582367, PMID: 18757411, PMID: 15829978).",408,15064718,Phosphorylation and ubiquitination of oncogenic mutants of beta-catenin containing substitutions at Asp32.,http://www.ncbi.nlm.nih.gov/pubmed/15064718,2332,18757411,Illegitimate WNT pathway activation by beta-catenin mutation or autocrine stimulation in T-cell malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/18757411,461,15829978,Functional correlates of mutation of the Asp32 and Gly34 residues of beta-catenin.,http://www.ncbi.nlm.nih.gov/pubmed/15829978,2330,19582367,CTNNB1 (beta-catenin) mutation is rare in brain tumours but involved as a sporadic event in a brain metastasis.,http://www.ncbi.nlm.nih.gov/pubmed/19582367,4145
CTNNB1 S33N lies within the ubiquitination recognition motif of the Ctnnb1 protein and occurs at a Gsk3b phosphorylation site on the Ctnnb1 protein (PMID: 15064718). S33N is predicted to confer a gain of function to the Ctnnb1 protein as demonstrated by nuclear accumulation of Ctnnb1 (PMID: 11276007).,2302,11276007,Nuclear localization of beta-catenin is an important prognostic factor in hepatoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/11276007,408,15064718,Phosphorylation and ubiquitination of oncogenic mutants of beta-catenin containing substitutions at Asp32.,http://www.ncbi.nlm.nih.gov/pubmed/15064718,4147
CTNNB1 S33P lies within the ubiquitination recognition motif of the Ctnnb1 protein and occurs at a Gsk3b phosphorylation site on the Ctnnb1 protein (PMID: 15064718). S33P is predicted to confer a gain of function to the Ctnnb1 protein as demonstrated by nuclear accumulation of Ctnnb1 (PMID: 11731417). ,2333,11731417,Frequent beta-catenin mutation and cytoplasmic/nuclear accumulation in pancreatic solid-pseudopapillary neoplasm.,http://www.ncbi.nlm.nih.gov/pubmed/11731417,408,15064718,Phosphorylation and ubiquitination of oncogenic mutants of beta-catenin containing substitutions at Asp32.,http://www.ncbi.nlm.nih.gov/pubmed/15064718,4148
"FOXL2 S101R lies within the DNA binding domain of the Foxl2 protein (UniProt.org). S101R results in Foxl2 protein aggregation and an impaired ability to transactivate target genes (PMID: 18372316).
",2326,18372316,"Missense mutations in the forkhead domain of FOXL2 lead to subcellular mislocalization, protein aggregation and impaired transactivation.",http://www.ncbi.nlm.nih.gov/pubmed/18372316,295,,,www.uniprot.org,4153
FOXL2 I102T lies within the DNA binding domain of the Foxl2 protein (UniProt.org). I102T results in Foxl2 protein aggregation and an impaired ability to transactivate target genes (PMID: 18372316).,2326,18372316,"Missense mutations in the forkhead domain of FOXL2 lead to subcellular mislocalization, protein aggregation and impaired transactivation.",http://www.ncbi.nlm.nih.gov/pubmed/18372316,295,,,www.uniprot.org,4154
"FOXL2 L106F lies within the DNA binding domain of the Foxl2 protein (UniProt.org). L106F results in Foxl2 protein aggregation and an impaired ability to transactivate target genes (PMID: 18372316).
",2326,18372316,"Missense mutations in the forkhead domain of FOXL2 lead to subcellular mislocalization, protein aggregation and impaired transactivation.",http://www.ncbi.nlm.nih.gov/pubmed/18372316,295,,,www.uniprot.org,4155
"FOXL2 L106P lies within the DNA binding domain of the Foxl2 protein (UniProt.org). L106P results in Foxl2 protein aggregation and an impaired ability to transactivate target genes (PMID: 18372316).
",2326,18372316,"Missense mutations in the forkhead domain of FOXL2 lead to subcellular mislocalization, protein aggregation and impaired transactivation.",http://www.ncbi.nlm.nih.gov/pubmed/18372316,295,,,www.uniprot.org,4156
"FOXL2 N109K lies within the DNA binding domain of the Foxl2 protein (UniProt.org). N109K impairs the ability of the Foxl2 protein to transactivate target genes (PMID: 18372316).
",2326,18372316,"Missense mutations in the forkhead domain of FOXL2 lead to subcellular mislocalization, protein aggregation and impaired transactivation.",http://www.ncbi.nlm.nih.gov/pubmed/18372316,295,,,www.uniprot.org,4157
"CTNNB1 S37A lies within the ubiquitination recognition motif of the Ctnnb1 protein and occurs at a Gsk3b phosphorylation site on the Ctnnb1 protein (PMID: 10347231). S37A confers a gain of function to the Ctnnb1 protein as demonstrated by decreased ubiquitination and stabilization of Ctnnb1-dependent transcription (PMID: 10347231).
",2336,10347231,The ubiquitin-proteasome pathway and serine kinase activity modulate adenomatous polyposis coli protein-mediated regulation of beta-catenin-lymphocyte enhancer-binding factor signaling.,http://www.ncbi.nlm.nih.gov/pubmed/10347231,4164
"CTNNB1 S37C lies within the ubiquitination recognition motif of the Ctnnb1 protein and occurs at a Gsk3b phosphorylation site on the Ctnnb1 protein (PMID: 10347231). S37C is predicted to confer a gain of function to the Ctnnb1 protein as demonstrated by nuclear accumulation of Ctnnb1 (PMID: 12754743, PMID: 10433945).  ",2336,10347231,The ubiquitin-proteasome pathway and serine kinase activity modulate adenomatous polyposis coli protein-mediated regulation of beta-catenin-lymphocyte enhancer-binding factor signaling.,http://www.ncbi.nlm.nih.gov/pubmed/10347231,2337,12754743,Beta-catenin mutations in pulmonary blastomas: association with morule formation.,http://www.ncbi.nlm.nih.gov/pubmed/12754743,2338,10433945,"beta-catenin expression pattern in stage I and II ovarian carcinomas : relationship with beta-catenin gene mutations, clinicopathological features, and clinical outcome.",http://www.ncbi.nlm.nih.gov/pubmed/10433945,4165
"CTNNB1 S37F lies within the ubiquitination recognition motif of the Ctnnb1 protein and occurs at a Gsk3b phosphorylation site on the Ctnnb1 protein (PMID: 10347231). S37F is predicted to confer a gain of function to the Ctnnb1 protein as demonstrated by nuclear accumulation of Ctnnb1 (PMID: 11196159, PMID: 11943721).  ",2339,11196159,More frequent beta-catenin exon 3 mutations in gallbladder adenomas than in carcinomas indicate different lineages.,http://www.ncbi.nlm.nih.gov/pubmed/11196159,2336,10347231,The ubiquitin-proteasome pathway and serine kinase activity modulate adenomatous polyposis coli protein-mediated regulation of beta-catenin-lymphocyte enhancer-binding factor signaling.,http://www.ncbi.nlm.nih.gov/pubmed/10347231,2340,11943721,Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations.,http://www.ncbi.nlm.nih.gov/pubmed/11943721,4166
"CTNNB1 S37P lies within the ubiquitination recognition motif of the Ctnnb1 protein and occurs at a Gsk3b phosphorylation site on the Ctnnb1 protein (PMID: 10347231). S37P has not been characterized, however other S37 “hotspot” mutations are activating thus, S37P is predicted to result in a gain of Ctnnb1 function (PMID: 9671767, PMID: 10347231).",2336,10347231,The ubiquitin-proteasome pathway and serine kinase activity modulate adenomatous polyposis coli protein-mediated regulation of beta-catenin-lymphocyte enhancer-binding factor signaling.,http://www.ncbi.nlm.nih.gov/pubmed/10347231,2296,9671767,Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/9671767,4167
CTNNB1 S45A lies within a Gsk3b phosphorylation site on the Ctnnb1 protein (UniProt.org). S45A confers a gain of function to the Ctnnb1 protein as demonstrated by stabilization of the Ctnnb1 protein resulting in increased Ctnnb1-dependent transcription (PMID: 19321622).,295,,,www.uniprot.org,2341,19321622,Characterization of the interaction between latency-associated nuclear antigen and glycogen synthase kinase 3beta.,http://www.ncbi.nlm.nih.gov/pubmed/19321622,4168
"S45C lies within a Gsk3b phosphorylation site on the Ctnnb1 protein (UniProt). S45C has not been characterized, however other S45 “hotspot” mutations are activating thus, S45C is predicted to result in a gain of Ctnnb1 function (PMID: 15579438, PMID: 23258168).",586,15579438,CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15579438,295,,,www.uniprot.org,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,4169
CTNNB1 S45F lies within a Gsk3b phosphorylation site on the Ctnnb1 protein (UniProt.org). S45F confers a gain of function to the Ctnnb1 protein as demonstrated by nuclear accumulation of Ctnnb1 and increased Ctnnb1-dependent transcription (PMID: 18282277).,295,,,www.uniprot.org,401,18282277,Correlation between beta-catenin mutations and expression of Wnt-signaling target genes in hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18282277,4170
"CTNNB1 S45Y lies within a Gsk3b phosphorylation site on the Ctnnb1 protein (UniProt.org). S45Y confers a gain of function to the Ctnnb1 protein as demonstrated by stabilization of Ctnnb1 and nuclear accumulation of Ctnnb1 (PMID: 9065403, PMID: 10487827).",402,9065403,Stabilization of beta-catenin by genetic defects in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/9065403,2342,10487827,Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation.,http://www.ncbi.nlm.nih.gov/pubmed/10487827,4171
"CTNNB1 T40I lies adjacent to a Gsk3b phosphorylation site on the Ctnnb1 protein (UniProt.org). The functional effect of T40I is conflicting, as T40I has been associated both with nuclear accumulation of Ctnnb1 and lack of nuclear accumulation of Ctnnb1 (PMID: 10213482, PMID: 17096730).",1244,10213482,Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/10213482,2343,17096730,Gene mutation analysis and immunohistochemical study of beta-catenin in odontogenic tumors.,http://www.ncbi.nlm.nih.gov/pubmed/17096730,295,,,www.uniprot.org,4172
"CTNNB1 T41A lies within a Gsk3b phosphorylation site on the Ctnnb1 protein (UniProt.org). T41A confers a gain of function to the Ctnnb1 protein as demonstrated by nuclear accumulation of Ctnnb1 and increased Ctnnb1-dependent transcription (PMID: 10698519, PMID: 10487827, PMID: 12200448).",2344,10698519,Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas.,http://www.ncbi.nlm.nih.gov/pubmed/10698519,2342,10487827,Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation.,http://www.ncbi.nlm.nih.gov/pubmed/10487827,2345,12200448,Transcriptional activation of interleukin-8 by beta-catenin-Tcf4.,http://www.ncbi.nlm.nih.gov/pubmed/12200448,295,,,www.uniprot.org,4173
"CTNNB1 T41I lies within a Gsk3b phosphorylation site on the Ctnnb1 protein (UniProt.org). T41I has not been biochemically characterized, however, it is predicted to confer a gain of function to Ctnnb1 as demonstrated by nuclear accumulation of Ctnnb1(PMID: 10213482).
",1244,10213482,Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/10213482,295,,,www.uniprot.org,4174
"CTNNB1 T41N lies within a Gsk3b phosphorylation site on the Ctnnb1 protein (UniProt.org). T41N has been identified in sequencing studies (PMID: 27389594), but has not been biochemically characterized and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7305,27389594,Genetic Landscape of Sporadic Unilateral Adrenocortical Adenomas Without PRKACA p.Leu206Arg Mutation.,http://www.ncbi.nlm.nih.gov/pubmed/27389594,295,,,www.uniprot.org,4175
"CTNNB1 T41P lies within a Gsk3b phosphorylation site on the Ctnnb1 protein (UniProt.org). T41P has been identified in sequencing studies (PMID: 22470196), but has not been biochemically characterized and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",7306,22470196,Stratification of Wilms tumor by genetic and epigenetic analysis.,http://www.ncbi.nlm.nih.gov/pubmed/22470196,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4176
"CTNNB1 T41S lies within a Gsk3b phosphorylation site on the Ctnnb1 protein (UniProt.org). T41S has been identified in sequencing studies (PMID: 11329142), but has not been biochemically characterized and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,7307,11329142,Frequent nuclear beta-catenin accumulation and associated mutations in endometrioid-type endometrial and ovarian carcinomas with squamous differentiation.,http://www.ncbi.nlm.nih.gov/pubmed/11329142,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4177
"CTNNB1 T42fs*7 likely results in a truncation of the 781 aa Ctnnb1 protein at aa 42, followed by 7 nonsense amino acids (UniProt.org). Due to the loss of all armadillo domains of Ctnnb1, T42fs*7 is predicted to confer loss of function to the Ctnnb1 protein (UniProt.org). ",295,,,www.uniprot.org,4178
"CTNNB1 T42I does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). T42I has been identified in sequencing studies (PMID: 25012536), but has not been biochemically characterized and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7308,25012536,β-catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25012536,4180
"CTNNB1 T42R does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). T42R has been identified in sequencing studies (PMID: 18715618), but has not been biochemically characterized and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7309,18715618,Correlation between beta-catenin widespread nuclear expression and matrix metalloproteinase-7 overexpression in sporadic desmoid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/18715618,4181
"CTNNB1 V199I lies within ARM repeat region 2 of the Ctnnb1 protein (UniProt.org). V199I has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4182
"CTNNB1 V22_G38del results in the deletion of seventeen amino acids in the ubiquitination recognition motif of the Ctnnb1 protein from amino acids 22 to 38 (PMID: 15064718). V22_G38del has been identified in sequencing studies (PMID: 11282485), but has not been biochemically characterized and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7312,11282485,Frequent beta-catenin aberration in human hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/11282485,408,15064718,Phosphorylation and ubiquitination of oncogenic mutants of beta-catenin containing substitutions at Asp32.,http://www.ncbi.nlm.nih.gov/pubmed/15064718,4183
"CTNNB1 V22_S33del results in the deletion of twelve amino acids in the ubiquitination recognition motif of the Ctnnb1 protein from amino acids 23 to 33 (PMID: 15064718). V22_S33del has been identified in sequencing studies (PMID: 11309340), but has not been biochemically characterized and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2327,11309340,Frequent deletions and mutations of the beta-catenin gene are associated with overexpression of cyclin D1 and fibronectin and poorly differentiated histology in childhood hepatoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/11309340,408,15064718,Phosphorylation and ubiquitination of oncogenic mutants of beta-catenin containing substitutions at Asp32.,http://www.ncbi.nlm.nih.gov/pubmed/15064718,4184
"CTNNB1 V22A lies adjacent to a Gsk3b phosphorylation site on the Ctnnb1 protein (PMID: 12027456). V22A is predicted to confer a gain of function to the Ctnnb1 protein, as demonstrated by nuclear accumulation of Ctnnb1 (PMID: 10213482, PMID: 12474227).",1244,10213482,Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/10213482,2328,12027456,Identification of two novel regulated serines in the N terminus of beta-catenin.,http://www.ncbi.nlm.nih.gov/pubmed/12027456,2347,12474227,Cribriform-morular variant of papillary thyroid carcinoma: a pathological and molecular genetic study with evidence of frequent somatic mutations in exon 3 of the beta-catenin gene.,http://www.ncbi.nlm.nih.gov/pubmed/12474227,4185
"CTNNB1 V22I lies adjacent to a Gsk3b phosphorylation site on the Ctnnb1 protein (PMID: 12027456). V22I has been identified in sequencing studies (PMID: 20696052), but has not been biochemically characterized and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",7311,20696052,Mutations in the WTX-gene are found in some high-grade microsatellite instable (MSI-H) colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/20696052,285,,,http://www.ncbi.nlm.nih.gov/pubmed,2328,12027456,Identification of two novel regulated serines in the N terminus of beta-catenin.,http://www.ncbi.nlm.nih.gov/pubmed/12027456,4186
"CTNNB1 W25* results in a premature truncation of the Ctnnb1 protein at amino acid 25 of 781 (UniProt.org). Due to the loss of all known functional domains of Ctnnb1, W25* is predicted to lead to a loss of function (UniProt.org).",295,,,www.uniprot.org,4187
"CTNNB1 W25_D32del results in the deletion of eight amino acids in the ubiquitination recognition motif of the Ctnnb1 protein from amino acids 25 to 32 (PMID: 15064718). W25_D32del confers a gain of function to the Ctnnb1 protein as demonstrated by nuclear accumulation of Ctnnb1 (PMID: 11309340, PMID: 10698519).",2344,10698519,Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas.,http://www.ncbi.nlm.nih.gov/pubmed/10698519,408,15064718,Phosphorylation and ubiquitination of oncogenic mutants of beta-catenin containing substitutions at Asp32.,http://www.ncbi.nlm.nih.gov/pubmed/15064718,2327,11309340,Frequent deletions and mutations of the beta-catenin gene are associated with overexpression of cyclin D1 and fibronectin and poorly differentiated histology in childhood hepatoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/11309340,4189
"CTNNB1 W25L does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). W25L has been identified in sequencing studies (PMID: 12067995), but has not been biochemically characterized and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",4287,12067995,beta-Catenin mutation is a frequent cause of Wnt pathway activation in gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/12067995,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4190
"CTNNB1 Y30* results in a premature truncation of the Ctnnb1 protein at amino acid 30 of 781 (UniProt.org). Due to the loss of all known functional domains of Ctnnb1, Y30* is predicted to lead to a loss of function (UniProt.org).",295,,,www.uniprot.org,4191
"CTNNB1 Y30fs results in a change in the amino acid sequence of the Ctnnb1 protein beginning at aa 30 of 781, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of all known function domains of the Ctnnb1 protein, Y30fs is predicted to lead to a loss of function (UniProt.org).",295,,,www.uniprot.org,4192
"CTNNB1 Y670* results in a premature truncation of the Ctnnb1 protein at amino acid 670 of 781 (UniProt.org). Y670* does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org), has not been characterized in the scientific literature, and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4193
"CTNNB1 Y30_S33del results in the deletion of four amino acids in the ubiquitination recognition motif of the Ctnnb1 protein from amino acids 30 to 33 (PMID: 15064718). Y30_S33del has been identified in sequencing studies (PMID: 18467159), but has not been biochemically characterized and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",408,15064718,Phosphorylation and ubiquitination of oncogenic mutants of beta-catenin containing substitutions at Asp32.,http://www.ncbi.nlm.nih.gov/pubmed/15064718,7313,18467159,Chromosome instability in human hepatocellular carcinoma depends on p53 status and aflatoxin exposure.,http://www.ncbi.nlm.nih.gov/pubmed/18467159,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4194
"CTNNB1 amplification indicates an increased number of copies of the CTNNB1 gene. However, the mechanism causing the increase is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,4201
"PTEN F90S lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). F90S does not affect Pten phosphatase activity, but decreases its membrane localization in cell culture (PMID: 25448479) and therefore, its effect on Pten protein function is unknown.",2354,25448479,Engineering PTEN function: membrane association and activity.,http://www.ncbi.nlm.nih.gov/pubmed/25448479,295,,,www.uniprot.org,4203
PTEN G127E lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). G127E results in a loss of Pten phosphatase activity in yeast (PMID: 21828076).,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,295,,,www.uniprot.org,4204
"PTEN G129* results in a premature truncation of the Pten protein at amino acid 129 of 403 (UniProt.org). Due to the loss of C2 tensin-type domain (UniProt.org), G129* is predicted to lead to a loss of Pten function.",295,,,www.uniprot.org,4205
"PTEN G129E lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). G129E results in a loss of Pten phosphatase activity and is unable to inhibit cell survival and proliferation in culture (PMID: 9811831, PMID: 9823298).",2307,9811831,The lipid phosphatase activity of PTEN is critical for its tumor supressor function.,http://www.ncbi.nlm.nih.gov/pubmed/9811831,295,,,www.uniprot.org,2305,9823298,The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells.,http://www.ncbi.nlm.nih.gov/pubmed/9823298,4206
PTEN G129R lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). G129R results in a loss of Pten phosphatase activity and is unable to suppress cell proliferation and inhibit cell growth in culture (PMID: 9823298).,2305,9823298,The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells.,http://www.ncbi.nlm.nih.gov/pubmed/9823298,295,,,www.uniprot.org,4207
"PTEN G129V lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). G129V results in a loss of Pten phosphatase activity in yeast and behaves similar to Pten loss of function mutation, G129E (PMID: 21828076, PMID: 27147599).",6273,27147599,Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.,http://www.ncbi.nlm.nih.gov/pubmed/27147599,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,295,,,www.uniprot.org,4208
PTEN G132S lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). G132S is predicted to lead to a loss of Pten function in a computational model (PMID: 19654296).,295,,,www.uniprot.org,2355,19654296,Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations.,http://www.ncbi.nlm.nih.gov/pubmed/19654296,4209
PTEN G165E lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). G165E results in a loss of Pten phosphatase activity in yeast (PMID: 21828076).,295,,,www.uniprot.org,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,4210
PTEN G165R lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). G165R results in a loss of Pten phosphatase activity in an in vitro assay (PMID: 10866302).,295,,,www.uniprot.org,2304,10866302,Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.,http://www.ncbi.nlm.nih.gov/pubmed/10866302,4211
"PTEN G251C lies within the C2 tensin-type domain of the Pten protein (UniProt.org). G251C results in a loss of Pten phosphatase activity and is unable to suppress Akt activation and cell proliferation in culture (PMID: 11156408, PMID: 10866302).",2304,10866302,Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.,http://www.ncbi.nlm.nih.gov/pubmed/10866302,295,,,www.uniprot.org,2324,11156408,Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/11156408,4212
PTEN H123D lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). H123D results in a loss of Pten phosphatase activity in yeast (PMID: 21828076).,295,,,www.uniprot.org,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,4213
PTEN H123Y lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). H123Y results in a loss of Pten phosphatase activity and increases Akt activation and cell survival in culture (PMID: 11448956).,295,,,www.uniprot.org,2356,11448956,The tumor suppressor gene PTEN can regulate cardiac hypertrophy and survival.,http://www.ncbi.nlm.nih.gov/pubmed/11448956,4215
PTEN H61R lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). H61R results in a loss of Pten phosphatase activity in an in vitro assay (PMID: 10866302).,2304,10866302,Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.,http://www.ncbi.nlm.nih.gov/pubmed/10866302,295,,,www.uniprot.org,4216
"PTEN K125E lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). K125E results in a loss of Pten phosphatase activity, decreased p53 transcriptional activity, and increased cell proliferation in culture (PMID: 21828076, PMID: 19457929, PMID: 20926450).",2358,20926450,Naturally occurring germline and tumor-associated mutations within the ATP-binding motifs of PTEN lead to oxidative damage of DNA associated with decreased nuclear p53.,http://www.ncbi.nlm.nih.gov/pubmed/20926450,295,,,www.uniprot.org,2357,19457929,Germline and somatic cancer-associated mutations in the ATP-binding motifs of PTEN influence its subcellular localization and tumor suppressive function.,http://www.ncbi.nlm.nih.gov/pubmed/19457929,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,4217
"PTEN K128N lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). K128N results in decreased Pten phosphatase activity, but is able to inhibit Pi3k activation in yeast (PMID: 21828076).",2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,295,,,www.uniprot.org,4218
"PTEN K13E lies within the polybasic N-terminal motif of the Pten protein (PMID: 14711368). K13E demonstrates phosphatase activity similar to wild-type Pten protein, but fails to translocate into the nucleus, and is unable to inhibit Akt activation and cell proliferation in culture (PMID: 14711368, PMID: 17213812).",2359,14711368,The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif.,http://www.ncbi.nlm.nih.gov/pubmed/14711368,2360,17213812,A short N-terminal sequence of PTEN controls cytoplasmic localization and is required for suppression of cell growth.,http://www.ncbi.nlm.nih.gov/pubmed/17213812,4219
"PTEN L112P lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). L112P results in a loss of Pten phosphatase activity and is unable to suppress Akt activation in cell culture (PMID: 10866302, PMID: 25527629).",2304,10866302,Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.,http://www.ncbi.nlm.nih.gov/pubmed/10866302,2323,25527629,Functionally distinct groups of inherited PTEN mutations in autism and tumour syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25527629,295,,,www.uniprot.org,4220
PTEN L112R lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). L112R results in a loss of Pten phosphatase activity in an in vitro assay (PMID: 10866302).,2304,10866302,Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.,http://www.ncbi.nlm.nih.gov/pubmed/10866302,295,,,www.uniprot.org,4221
"EGFR exon 20 insertions are in-frame insertions within the kinase domain of Egfr (PMID: 17318210). Exon 20 insertions result in increased Egfr kinase activity, and are associated with low sensitivity to Egfr tyrosine kinase inhibitors (PMID: 17318210).",1881,17318210,Epidermal growth factor receptor mutations in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17318210,4232
"ROS1 A1964T lies within the protein kinase domain of the Ros1 protein (UniProt.org). A1964T has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,4237
"ROS1 A2081T lies within the protein kinase domain of the Ros1 protein (UniProt.org). A2081T has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4238
"ROS1 C72R lies within the extracellular domain of the Ros1 protein (UniProt.org). C72R has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4239
"ROS1 D1192V lies within the extracellular domain of the Ros1 protein (UniProt.org). D1192V has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4240
"ROS1 R245I lies within the fibronectin type-III domain 2 of the Ros1 protein (UniProt.org). R245I has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4241
"ROS1 D2247Y lies within the cytoplasmic domain of the Ros1 protein (UniProt.org). D2247Y has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4242
"PTEN V119fs*15 likely results in a truncation of the 533 aa Pten protein at aa 119, followed by 15 nonsense amino acids (UniProt.org). Due to the disruption of the phosphatase-tensin type domain (UniProt.org), V119fs*15 is predicted to lead to a loss of Pten protein function.",295,,,www.uniprot.org,4252
"PTEN V119K lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). V119K has not been characterized in the scientific literature and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4253
PTEN L57W lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). L57W results in a loss of Pten phosphatase activity and is unable to inhibit cell proliferation in culture (PMID: 9356475).,2363,9356475,Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain.,http://www.ncbi.nlm.nih.gov/pubmed/9356475,295,,,www.uniprot.org,4254
"PTEN F56S lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). F56S has not been characterized in the scientific literature and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4255
"PTEN F56V lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). F56V has been identified in sequencing studies (PMID: 18757403, PMID: 11395387), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",7868,11395387,"Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/11395387,7867,18757403,Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation.,http://www.ncbi.nlm.nih.gov/pubmed/18757403,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4256
"PTEN G127V lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). G127V is predicted to confer a loss of function on the Pten protein based on behaving similar to Pten loss of function mutation, G129E (PMID: 27147599).",6273,27147599,Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.,http://www.ncbi.nlm.nih.gov/pubmed/27147599,295,,,www.uniprot.org,4257
"PTEN G132D lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). G132D has been identified in sequencing studies (PMID: 25527629, PMID: 26919320), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,2323,25527629,Functionally distinct groups of inherited PTEN mutations in autism and tumour syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25527629,285,,,http://www.ncbi.nlm.nih.gov/pubmed,9919,26919320,Molecular Diagnostics of Gliomas Using Next Generation Sequencing of a Glioma-Tailored Gene Panel.,http://www.ncbi.nlm.nih.gov/pubmed/26919320,4258
"PTEN G251D lies within the C2 tensin-type domain of the Pten protein (UniProt.org). G251D has not been biochemically characterized, but is associated with decreased Pten protein level and increased phosphorylation of Akt and S6 in patient tumor sample (PMID: 25003235).",295,,,www.uniprot.org,8049,25003235,PTEN mutations and activation of the PI3K/Akt/mTOR signaling pathway in papillary tumors of the pineal region.,http://www.ncbi.nlm.nih.gov/pubmed/25003235,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4259
"PTEN G293fs*14 likely results in a truncation of the 403 aa Pten protein at aa 293, followed by 14 nonsense amino acids within the C2 tensin-type domain (UniProt.org). G293fs*14 has not been characterized, however, other C-terminal deletion mutants downstream of G293 are inactivating (PMID: 10468583), thus G293fs*14 is predicted to lead to a loss of Pten protein function.",295,,,www.uniprot.org,2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,4260
"PTEN H118fs*8 likely results in a truncation of the 403 aa Pten protein at aa 118, followed by 8 nonsense amino acids within the phosphatase tensin-type domain (UniProt.org). Due to the loss of the C2 tensin-type domain (UniProt.org), H118fs*8 is predicted to lead to a loss of Pten function.",295,,,www.uniprot.org,4261
"PTEN H123L lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). H123L has not been characterized in the scientific literature and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4262
"PTEN I122fs*2 likely results in a truncation of the 403 aa Pten protein at aa 122, followed by 2 nonsense amino acids within the phosphatase tensin-type domain (UniProt.org). I122fs*2 has not been characterized, however, other C-terminal deletion mutants downstream of I122 are inactivating (PMID: 10468583), thus I122fs*2 is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4263
"PTEN I122N lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). I122N has been identified in sequencing studies (PMID: 26517354, PMID: 27729313), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7216,26517354,Mutational profiling of colorectal cancers with microsatellite instability.,http://www.ncbi.nlm.nih.gov/pubmed/26517354,4264
"PTEN I135K lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). I135K has been identified in sequencing studies (PMID: 22653804), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7748,22653804,Use of mutation profiles to refine the classification of endometrial carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/22653804,4265
"PTEN I253N lies within the C2 tensin-type domain of the Pten protein (UniProt.org). I253N has been identified in the scientific literature (PMID: 18953432, PMID: 26561558), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,8054,18953432,p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors.,http://www.ncbi.nlm.nih.gov/pubmed/18953432,295,,,www.uniprot.org,5255,26561558,InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/26561558,4266
"PTEN I67T lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). I67T has not been characterized in the scientific literature and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4267
"PTEN K125N lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). K125N results in loss of phosphatase function in cell culture (PMID: 25873899).
",295,,,www.uniprot.org,4458,25873899,A method to control phosphoinositides and to analyze PTEN function in living cells using voltage sensitive phosphatases.,http://www.ncbi.nlm.nih.gov/pubmed/25873899,4268
PTEN K128_R130del results in the deletion of 3 amino acids in the phosphatase tensin-type domain of the Pten protein from amino acids 128 to 130 (UniProt.org). K128_R130del confers a loss of function on the Pten protein as indicated by failure to regulate glucose uptake and to dephosphorylate AKT in cell culture (PMID: 27829222).,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8055,27829222,PTEN dephosphorylates AKT to prevent the expression of GLUT1 on plasmamembrane and to limit glucose consumption in cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/27829222,4269
"PTEN K163fs results in a change in the amino acid sequence of the Pten protein beginning at aa 163 of 403, likely resulting in premature truncation of the functional protein (UniProt.org). K163fs has not been characterized, however, other C-terminal deletion mutants downstream of K163 are inactivating (PMID: 10468583), thus K163fs is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4270
"PTEN K237fs*19 likely results in a truncation of the 403 aa Pten protein at aa 237, followed by 19 nonsense amino acids within the C2 tensin-type domain (UniProt.org). K237fs*19 has not been characterized, however, other C-terminal deletion mutants downstream of K237 are inactivating (PMID: 10468583), thus K237fs*19 is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4271
"PTEN K254fs*42 likely results in a truncation of the 403 aa Pten protein at aa 254, followed by 42 nonsense amino acids within the C2 tensin-type domain (UniProt.org). K254fs*42 has not been characterized, however, other C-terminal deletion mutants downstream of K254 are inactivating (PMID: 10468583), thus K254fs*42 is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4272
"PTEN K260fs*6 likely results in a truncation of the 403 aa Pten protein at aa 260, followed by 6 nonsense amino acids within the C2 tensin-type domain (UniProt.org). K260fs*6 has not been characterized, however, other C-terminal deletion mutants downstream of K260 are inactivating (PMID: 10468583), thus K260fs*6 is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4273
"PTEN K263* results in a premature truncation of the Pten protein at amino acid 263 of 403 (UniProt.org). K263* has not been characterized, however, other C-terminal deletion mutants downstream of K263 are inactivating (PMID: 10468583), thus K263* is predicted to lead to a loss of Pten protein function.",295,,,www.uniprot.org,2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,4274
"PTEN K267fs results in a change in the amino acid sequence of the Pten protein beginning at aa 267 of 403, likely resulting in premature truncation of the functional protein (UniProt.org). K267fs has not been characterized, however, other C-terminal deletion mutants downstream of K267 are inactivating (PMID: 10468583), thus K267fs is predicted to lead to a loss of Pten protein function.",295,,,www.uniprot.org,2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,4275
"PTEN K267fs*9 likely results in a truncation of the 403 aa Pten protein at aa 267, followed by 9 nonsense amino acids within the C2 tensin-type domain (UniProt.org). K267fs*9 has not been characterized, however, other C-terminal deletion mutants downstream of K267 are inactivating (PMID: 10468583), thus K267fs*9 is predicted to lead to a loss of Pten protein function.",295,,,www.uniprot.org,2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,4276
"PTEN K60fs*39 likely results in a truncation of the 403 aa Pten protein at aa 60, followed by 39 nonsense amino acids within the phosphatase tensin-type domain (UniProt.org). Due to the loss of the C2 tensin-type domain (UniProt.org), K60fs*39 is predicted to lead to a loss of Pten function.",295,,,www.uniprot.org,4277
"PTEN K66E lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). K66E has been identified in sequencing studies (PMID: 21103049), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8056,21103049,DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset.,http://www.ncbi.nlm.nih.gov/pubmed/21103049,4278
"PTEN K66N lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). K66N has been identified in sequencing studies (PMID: 23525077), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7021,23525077,Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity.,http://www.ncbi.nlm.nih.gov/pubmed/23525077,4279
"PTEN K6fs*4 likely results in a truncation of the 403 aa Pten protein at aa 6, followed by 4 nonsense amino acids within the phosphatase tensin-type domain (UniProt.org). Due to the loss of all known functional domains (UniProt.org), K6fs*4 is predicted to lead to a loss of Pten function.",295,,,www.uniprot.org,4280
"PTEN L108R lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). L108R has not been fully biochemically characterized, however, cell lines harboring PTEN L108R demonstrate decreased Pten expression and increased Akt phosphorylation (PMID: 10582703).  ",4460,10582703,PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death.,http://www.ncbi.nlm.nih.gov/pubmed/10582703,295,,,www.uniprot.org,4281
"PTEN L108_D109del results in the deletion of 2 amino acids in the phosphatase tensin-type domain of the Pten protein from amino acids 108 to 109 (UniProt.org). L108_D109del has been identified in sequencing studies (PMID: 18757403), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7867,18757403,Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation.,http://www.ncbi.nlm.nih.gov/pubmed/18757403,4282
"PTEN L112V lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). L112V has been identified in the scientific literature (PMID: 10560660, PMID: 18669439), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",8067,10560660,Mutational profile of the PTEN gene in primary human astrocytic tumors and cultivated xenografts.,http://www.ncbi.nlm.nih.gov/pubmed/10560660,285,,,http://www.ncbi.nlm.nih.gov/pubmed,9960,18669439,Multiple tumors in a child with germ-line mutations in TP53 and PTEN.,http://www.ncbi.nlm.nih.gov/pubmed/18669439,295,,,www.uniprot.org,4283
"PTEN L152P lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). L152P has been identified in sequencing studies (PMID: 22941189), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",6959,22941189,Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22941189,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4284
"PTEN L182fs results in a change in the amino acid sequence of the Pten protein beginning at aa 182 of 403, likely resulting in premature truncation of the functional protein (UniProt.org). L182fs has not been characterized, however, other C-terminal deletion mutants downstream of L182 are inactivating (PMID: 10468583), thus L182fs is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4285
"PTEN L265fs results in a change in the amino acid sequence of the Pten protein beginning at aa 265 of 403, likely resulting in premature truncation of the functional protein (UniProt.org). L265fs has not been characterized, however, other C-terminal deletion mutants downstream of L265 are inactivating (PMID: 10468583), thus L265fs is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4286
"PTEN L318fs*2 likely results in a truncation of the 403 aa Pten protein at aa 318, followed by 2 nonsense amino acids within the phosphatase tensin-type domain (UniProt.org). L318fs*2 has not been characterized, however, other C-terminal deletion mutants downstream of L318 are inactivating (PMID: 10468583), thus L318fs*2 is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4287
"PTEN L57fs*6 likely results in a truncation of the 403 aa Pten protein at aa 57, followed by 6 nonsense amino acids within the phosphatase tensin-type domain (UniProt.org). Due to the loss of the C2 tensin-type domain (UniProt.org), L57fs*6 is predicted to lead to a loss of Pten function.",295,,,www.uniprot.org,4288
"PTEN L57S lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). L57S has been identified in sequencing studies (PMID: 11438483), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",8068,11438483,PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis.,http://www.ncbi.nlm.nih.gov/pubmed/11438483,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4289
"PTEN L70H lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). L70H has not been characterized in the scientific literature and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4290
"PTEN M205I lies within the C2 tensin-type domain of the Pten protein (UniProt.org). M205I has been identified in the scientific literature (PMID: 11801303, PMID: 25126449), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,8070,11801303,Detection of new PTEN/MMAC1 mutations in head and neck squamous cell carcinomas with loss of chromosome 10.,http://www.ncbi.nlm.nih.gov/pubmed/11801303,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7017,25126449,The determinants of head and neck cancer: Unmasking the PI3K pathway mutations.,http://www.ncbi.nlm.nih.gov/pubmed/25126449,4291
"PTEN N323fs*2 likely results in a truncation of the 403 aa Pten protein at aa 323, followed by 2 nonsense amino acids within the phosphatase tensin-type domain (UniProt.org). N323fs*2 has not been characterized, however, other C-terminal deletion mutants downstream of N323 are inactivating (PMID: 10468583), thus N323fs*2 is predicted to lead to a loss of Pten protein function.",295,,,www.uniprot.org,2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,4292
"PTEN N323fs*21 likely results in a truncation of the 403 aa Pten protein at aa 323, followed by 21 nonsense amino acids within the phosphatase tensin-type domain (UniProt.org). N323fs*21 has not been characterized, however, other C-terminal deletion mutants downstream of N323 are inactivating (PMID: 10468583), thus N323fs*21 is predicted to lead to a loss of Pten protein function.",295,,,www.uniprot.org,2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,4293
"PTEN N329fs*14 likely results in a truncation of the 403 aa Pten protein at aa 329, followed by 14 nonsense amino acids within the phosphatase tensin-type domain (UniProt.org). N329fs*14 has not been characterized, however, other C-terminal deletion mutants downstream of N329 are inactivating (PMID: 10468583), thus N329fs*14 is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4294
"PTEN N340fs results in a change in the amino acid sequence of the Pten protein beginning at aa 340 of 403, likely resulting in premature truncation of the functional protein (UniProt.org). N340fs has not been characterized, however, other C-terminal deletion mutants downstream of N340 are inactivating (PMID: 10468583), thus N340fs is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4295
"PTEN N48I lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). N48I has been identified in the scientific literature (PMID: 11108659, PMID: 28808038), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,8073,11108659,Inactivation of MMAC1 in bladder transitional-cell carcinoma cell lines and specimens.,http://www.ncbi.nlm.nih.gov/pubmed/11108659,295,,,www.uniprot.org,9961,28808038,The Phosphatidylinositol 3-kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28808038,4296
"PTEN N63fs*10 likely results in a truncation of the 403 aa Pten protein at aa 63, followed by 10 nonsense amino acids within the phosphatase tensin-type domain (UniProt.org). Due to the loss of the C2 tensin-type domain (UniProt.org), N63fs*10 is predicted to lead to a loss of Pten function.",295,,,www.uniprot.org,4297
"PTEN N63fs*36 likely results in a truncation of the 403 aa Pten protein at aa 63, followed by 36 nonsense amino acids within the phosphatase tensin-type domain (UniProt.org). Due to the loss of the C2 tensin-type domain (UniProt.org), N63fs*36 is predicted to lead to a loss of Pten function.",295,,,www.uniprot.org,4298
"PTEN P213S lies within the C2 tensin-type domain of the Pten protein (UniProt.org). P213S has been identified in the scientific literature (PMID: 18953432), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",8054,18953432,p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors.,http://www.ncbi.nlm.nih.gov/pubmed/18953432,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4299
"PTEN P246fs*10 likely results in a truncation of the 403 aa Pten protein at aa 246, followed by 10 nonsense amino acids within the phosphatase tensin-type domain (UniProt.org). P246fs*10 has not been characterized, however, other C-terminal deletion mutants downstream of P246 are inactivating (PMID: 10468583), thus P246fs*10 is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4300
PTEN P246L lies within the C2 tensin-type domain of the Pten protein (UniProt.org). P246L demonstrates inhibition of Pi3k signaling to a similar level of wild-type Pten in yeast (PMID: 17942903).,1463,17942903,In vivo functional analysis of the counterbalance of hyperactive phosphatidylinositol 3-kinase p110 catalytic oncoproteins by the tumor suppressor PTEN.,http://www.ncbi.nlm.nih.gov/pubmed/17942903,295,,,www.uniprot.org,4301
"PTEN P248fs*5 likely results in a truncation of the 403 aa Pten protein at aa 248, followed by 5 nonsense amino acids within the phosphatase tensin-type domain (UniProt.org). P248fs*5 has not been characterized, however, other C-terminal deletion mutants downstream of P248 are inactivating (PMID: 10468583), thus P248fs*5 is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4302
"PTEN P283L lies within the C2 tensin-type domain of the Pten protein (UniProt.org). P283L has not been characterized in the scientific literature and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4303
"PTEN P339S lies within the C2 tensin-type domain of the Pten protein (UniProt.org). P339S has been identified in the scientific literature (PMID: 26645239), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",7210,26645239,Mutational analysis of pulmonary tumours with neuroendocrine features using targeted massive parallel sequencing: a comparison of a neglected tumour group.,http://www.ncbi.nlm.nih.gov/pubmed/26645239,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4304
"PTEN P38H lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). P38H has been identified in the scientific literature (PMID: 23361946), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",8075,23361946,Macrocephaly as a clinical indicator of genetic subtypes in autism.,http://www.ncbi.nlm.nih.gov/pubmed/23361946,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4305
"PTEN P38L lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). P38L has been identified in sequencing studies (PMID: 20544847), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,8076,20544847,Somatic alterations in the melanoma genome: a high-resolution array-based comparative genomic hybridization study.,http://www.ncbi.nlm.nih.gov/pubmed/20544847,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4306
"PTEN P38S lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). P38S has been identified in the scientific literature (PMID: 15195137), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",8078,15195137,BRAF alterations are associated with complex mutational profiles in malignant melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/15195137,295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4307
"PTEN P95Q lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). P95Q has not been characterized in the scientific literature and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4308
"PTEN P96L lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). P96L has been identified in sequencing studies (PMID: 18772396), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",6948,18772396,An integrated genomic analysis of human glioblastoma multiforme.,http://www.ncbi.nlm.nih.gov/pubmed/18772396,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4309
"PTEN P96S lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). P96S has been identified in the scientific literature (PMID: 22653804, PMID: 24468202), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",7748,22653804,Use of mutation profiles to refine the classification of endometrial carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/22653804,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9964,24468202,Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24468202,4310
"PTEN P96T lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). P96T has been identified in sequencing studies (PMID: 24132290), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8079,24132290,Mutational landscape and significance across 12 major cancer types.,http://www.ncbi.nlm.nih.gov/pubmed/24132290,4311
"PTEN Q110* results in a premature truncation of the Pten protein at amino acid 110 of 403 (UniProt.org). Due to the loss of C2 tensin-type domain (UniProt.org), Q110* is predicted to lead to a loss of Pten function.",295,,,www.uniprot.org,4312
"PTEN Q17* results in a premature truncation of the Pten protein at amino acid 17 of 403 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), Q17* is predicted to lead to a loss of Pten function.",295,,,www.uniprot.org,4313
"PTEN Q171* results in a premature truncation of the Pten protein at amino acid 171 of 403 (UniProt.org). Due to the loss of C2 tensin-type domain (UniProt.org), Q171* is predicted to lead to a loss of Pten function.",295,,,www.uniprot.org,4314
"PTEN Q171E lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). Q171E has been identified in sequencing studies (PMID: 25527629, PMID: 25185240), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",9965,25185240,Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25185240,2323,25527629,Functionally distinct groups of inherited PTEN mutations in autism and tumour syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25527629,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4315
PTEN V133I lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). V133I confers a loss of function to the Pten protein as demonstrated by loss of phosphatase activity (PMID: 10866302).,2304,10866302,Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.,http://www.ncbi.nlm.nih.gov/pubmed/10866302,295,,,www.uniprot.org,4316
"PTEN V175A lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). V175A has been identified in the scientific literature (PMID: 27494611), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",8129,27494611,Comprehensive Analysis of the Transcriptional and Mutational Landscape of Follicular and Papillary Thyroid Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27494611,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4317
"PTEN V290fs*1 likely results in a premature truncation of the 403 aa Pten protein at aa 290 followed by one nonsense amino acid (UniProt.org). V290fs*1 has not been characterized, however, other C-terminal deletion mutants downstream of V290 are inactivating (PMID: 10468583), thus Q290fs*1 is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4318
"PTEN V317fs results in a change in the amino acid sequence of the Pten protein beginning at aa 317 of 403, likely resulting in premature truncation of the functional protein (UniProt.org). V317fs has not been characterized, however other C-terminal deletion mutants downstream of V317 are inactivating (PMID: 10468583), thus V317fs is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4319
"PTEN V317fs*3 likely results in a premature truncation of the 403 aa Pten protein at aa 317 followed by 3 nonsense amino acids within the C2 tensin-type domain (UniProt.org). V317fs*3 has not been characterized, however other C-terminal deletion mutants downstream of V317 are inactivating (PMID: 10468583), thus V317fs*3 is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4320
"PTEN V317fs*6 likely results in a premature truncation of the 403 aa Pten protein at aa 317 followed by 6 nonsense amino acids within the C2 tensin-type domain (UniProt.org). V317fs*6 has not been characterized, however other C-terminal deletion mutants downstream of V317 are inactivating (PMID: 10468583), thus V317fs*6 is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4321
"PTEN W111* results in a premature truncation of the Pten protein at amino acid 111 of 533 within the phosphatase tensin-type domain (UniProt.org). Due to the disruption of the phosphatase tensin-type domain and the loss of C2 tensin-type domain (UniProt.org), W111* is predicted to lead to a loss of Pten protein function.",295,,,www.uniprot.org,4322
"PTEN W111R lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). W111R has been identified in the scientific literature (PMID: 11476841), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,8128,11476841,Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/11476841,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4323
"PTEN Y16C lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). Y16C has been reported to retain wild type phoshpatase activity, but does not suppress downstream Akt signaling (PMID: 21536651) and therefore, its effect on Pten protein function is unknown.",2365,21536651,"Mechanistic analysis of a DNA damage-induced, PTEN-dependent size checkpoint in human cells.",http://www.ncbi.nlm.nih.gov/pubmed/21536651,295,,,www.uniprot.org,4324
"PTEN Y16fs*28 likely results in a premature truncation of the Pten protein at amino acid 16 of 403, followed by 28 nonsense amino acids (UniProt.org). Due to the disruption of the phosphatase tensin-type domain and the loss of C2 tensin-type domain (UniProt.org), Y16fs*28 is predicted to lead to a loss of Pten function.",295,,,www.uniprot.org,4325
"PTEN Y174D lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). Y174D has been identified in sequencing studies (PMID: 22842228), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7109,22842228,Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22842228,4326
"PTEN Y177C lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). Y177C has been identified in sequencing studies (PMID: 19644652), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8126,19644652,Different molecular patterns in glioblastoma multiforme subtypes upon recurrence.,http://www.ncbi.nlm.nih.gov/pubmed/19644652,4327
"PTEN Y176del results in the deletion of an amino acid within the phosphatase tensin-type domain of the Pten protein at amino acid 176 (UniProt.org). Y176del has been identified in sequencing studies (PMID: 9619835), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8127,9619835,PTEN mutations in gliomas and glioneuronal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9619835,4328
"PTEN Y27D lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). Y27D has been identified in sequencing studies (PMID: 22722201), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7023,22722201,The landscape of cancer genes and mutational processes in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22722201,4329
"ROS1 R304I lies within the extracellular domain of the Ros1 protein (UniProt.org). R304I has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4330
"ROS1 R360I lies within the extracellular domain of the Ros1 protein (UniProt.org). R360I has been identified in sequencing studies (PMID: 23856246), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6964,23856246,The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.,http://www.ncbi.nlm.nih.gov/pubmed/23856246,4331
"ROS1 R380I lies within the extracellular domain of the Ros1 protein (UniProt.org). R380I has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4332
"ROS1 V1729L lies within the fibronection type-III domain 8 of the Ros1 protein (UniProt.org). V1729L has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4333
"ROS1 V785M lies within the extracellular domain of the Ros1 protein (UniProt.org). V785M has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4334
"ROS1 W1817* results in a premature truncation of the Ros1 protein at amino acid 1817 of 2347 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), W1817* is predicted to lead to a loss of Ros1 protein function.",295,,,www.uniprot.org,4335
"ROS1 W21* results in a premature truncation of the Ros1 protein at amino acid 21 of 2347 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), W21* is predicted to lead to a loss of Ros1 protein function.",295,,,www.uniprot.org,4336
"PTEN Q171K lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). Q171K has been identified in sequencing studies (PMID: 24504440), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",7423,24504440,"Multilayer-omics analysis of renal cell carcinoma, including the whole exome, methylome and transcriptome.",http://www.ncbi.nlm.nih.gov/pubmed/24504440,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4337
"PTEN Q171P lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). Q171P has been identified in sequencing studies (PMID: 9393744), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,8084,9393744,PTEN/MMAC1 mutations and EGFR amplification in glioblastomas.,http://www.ncbi.nlm.nih.gov/pubmed/9393744,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4338
"PTEN Q17del results in the deletion of an amino acid in the phosphatase tensin-type domain of the Pten protein at amino acid 17 (UniProt.org). Q17del has been identified in sequencing studies (PMID: 22588880), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,8117,22588880,Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent.,http://www.ncbi.nlm.nih.gov/pubmed/22588880,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4339
"ROS1 D780Y lies within the extracellular domain of the Ros1 protein (UniProt.org). D780Y has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4340
"KDR (VEGFR2) L1184F lies within the cytoplasmic domain of the Kdr (Vegfr2) protein (UniProt.org). L1184F has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4341
"KDR (VEGFR2) M1016K lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). M1016K has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4342
"ROS1 E1244* results in a premature truncation of the Ros1 protein at amino acid 1244 of 2347 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), E1244* is predicted to result in a loss of Ros1 function.",295,,,www.uniprot.org,4343
"KDR (VEGFR2) P1210L lies within the cytoplasmic domain of the Kdr (Vegfr2) protein (UniProt.org). P1210L has been identified in sequencing studies (PMID: 18948947), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6956,18948947,Somatic mutations affect key pathways in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18948947,4344
"ROS1 E1737* results in a premature truncation of the Ros1 protein at amino acid 1737of 2347 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), E1737* is predicted to result in a loss of Ros1 function.",295,,,www.uniprot.org,4345
"KDR (VEGFR2) P1210S lies within the cytoplasmic domain of the Kdr (Vegfr2) protein (UniProt.org). P1210S has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4346
"ROS1 E1840* results in a premature truncation of the Ros1 protein at amino acid 1840 of 2347 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), E1840* is predicted to result in a loss of Ros1 function.
",295,,,www.uniprot.org,4347
"ROS1 E2131D lies within the cytoplasmic domain of the Ros1 protein (UniProt.org). E2131D has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4348
"KDR (VEGFR2) P1355del results in the deletion of an amino acid in the cytoplasmic domain of the Kdr (Vegfr2) protein at amino acid 1355 (UniProt.org). P1355del has been identified in sequencing studies (PMID: 18948947), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",6956,18948947,Somatic mutations affect key pathways in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18948947,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4349
"KDR (VEGFR2) P421L lies within the Ig-like C2-type domain 5 of the Kdr (Vegfr2) protein (UniProt.org). P421L has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4350
"KDR (VEGFR2) Q37H lies within the extracellular domain of the Kdr (Vegfr2) protein (UniProt.org). Q37H has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4351
"KDR (VEGFR2) R1032* results in a premature truncation of the Kdr (Vegfr2) protein at amino acid 1032 of 1356 (UniProt.org). R1032* has been identified in sequencing studies (PMID: 22895193), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",4597,22895193,Recurrent R-spondin fusions in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22895193,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4352
KDR (VEGFR2) R1032Q lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). R1032Q results in decreased ligand-induced phosphorylation of Krd (Vegfr2) and Mapk in cell culture (PMID: 28743916).,10127,28743916,Analysis of somatic mutations across the kinome reveals loss-of-function mutations in multiple cancer types.,http://www.ncbi.nlm.nih.gov/pubmed/28743916,295,,,www.uniprot.org,4353
"KDR (VEGFR2) R1124K lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). R1124K has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4354
"KDR (VEGFR2) R1150I lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). R1150I has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4355
"KDR (VEGFR2) R164I lies within the Ig-like C2-type domain 2 of the Kdr (Vegfr2) protein (UniProt.org). R164I has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4356
"KDR (VEGFR2) R275L lies within the Ig-like C2-type domain 3 of the Kdr (Vegfr2) protein (UniProt.org). R275L has been identified in sequencing studies (PMID: 16959974), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",6996,16959974,The consensus coding sequences of human breast and colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/16959974,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4357
"KDR (VEGFR2) R944Q lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). R944Q has been identified in sequencing studies (PMID: 26343386), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7139,26343386,Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway.,http://www.ncbi.nlm.nih.gov/pubmed/26343386,4358
"PTEN Q214* results in a premature truncation of the Pten protein at amino acid 214 of 403 within the C2 tensin-type domain (UniProt.org). Q214* has not been characterized, however other C-terminal deletion mutants downstream of Q214 are inactivating (PMID: 10468583), thus Q214* is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4360
"PTEN Q219* results in a premature truncation of the Pten protein at amino acid 214 of 403 within the C2 tensin-type domain (UniProt.org). Q219* has not been characterized, however other C-terminal deletion mutants downstream of Q219 are inactivating (PMID: 10468583), thus Q219* is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4361
PTEN R130* results in a premature truncation of the Pten protein at amino acid 130 of 403 within the phosphatase tensin-type domain (UniProt.org). R130* confers a loss of function to the Pten protein as demonstrated by decreased p53 signaling and increased DNA damage in xenografts (PMID: 24721394).,295,,,www.uniprot.org,2372,24721394,Combined PTEN Mutation and Protein Expression Associate with Overall and Disease-Free Survival of Glioblastoma Patients.,http://www.ncbi.nlm.nih.gov/pubmed/24721394,4362
"PTEN Q399* results in a premature truncation of the Pten protein at amino acid 399 of 403 (UniProt.org). Q399* has not been characterized in the scientific literature and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4363
"PTEN Q245* results in a premature truncation of the Pten protein at amino acid 245 of 403 within the C2 tensin-type domain (UniProt.org). Q245* has not been characterized, however other C-terminal deletion mutants downstream of Q245 are inactivating (PMID: 10468583), thus Q245* is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4364
"PTEN Q261* results in a premature truncation of the Pten protein at amino acid 261 of 403 within the C2 tensin-type domain (UniProt.org). Q261* has not been biochemically characterized, but is associated with decreased Pten protein level and increased phosphorylation of Akt and S6 in patient tumor sample (PMID: 25003235).",8049,25003235,PTEN mutations and activation of the PI3K/Akt/mTOR signaling pathway in papillary tumors of the pineal region.,http://www.ncbi.nlm.nih.gov/pubmed/25003235,295,,,www.uniprot.org,4365
"PTEN Q298* results in a premature truncation of the Pten protein at amino acid 298 of 403 within the C2 tensin-type domain (UniProt.org). Q298* has not been characterized, however other C-terminal deletion mutants downstream of Q298 are inactivating (PMID: 10468583), thus Q298* is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4366
"PTEN R130fs*4 likely results in a premature truncation of the 403 aa Pten protein at aa 130, followed by 4 nonsense amino acids within the phosphatase tensin-type domain (UniProt.org). R130fs*4 has not been characterized, however the R130 hotspot nonsense mutation results in Pten inactivation (PMID: 24721394), thus R130fs*4 is predicted to lead to a loss of Pten protein function.",295,,,www.uniprot.org,2372,24721394,Combined PTEN Mutation and Protein Expression Associate with Overall and Disease-Free Survival of Glioblastoma Patients.,http://www.ncbi.nlm.nih.gov/pubmed/24721394,4367
"PTEN R130G lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). R130G confers a loss of function to the Pten protein as demonstrated by loss of phosphatase activity (PMID: 11051241, PMID: 10866302).",2322,11051241,Functional evaluation of p53 and PTEN gene mutations in gliomas.,http://www.ncbi.nlm.nih.gov/pubmed/11051241,2304,10866302,Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.,http://www.ncbi.nlm.nih.gov/pubmed/10866302,295,,,www.uniprot.org,4368
PTEN R130Q lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). R130Q confers a loss of function to the Pten protein as demonstrated by loss of phosphatase activity (PMID: 10866302).,2304,10866302,Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.,http://www.ncbi.nlm.nih.gov/pubmed/10866302,295,,,www.uniprot.org,4369
PTEN R130L lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). R130L confers a loss of function to the Pten protein as demonstrated by loss of phosphatase activity (PMID: 10866302).,295,,,www.uniprot.org,2304,10866302,Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.,http://www.ncbi.nlm.nih.gov/pubmed/10866302,4371
"ROS1 Y1960H lies within the protein kinase domain of the Ros1 protein (UniProt.org). Y1960H has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4372
"ROS1 E2308K lies within the cytoplasmic domain of the Ros1 protein (UniProt.org). E2308K has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4373
"ROS1 E290* results in a premature truncation of the Ros1 protein at amino acid 290 of 2347 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), E290* is predicted to result in a loss of Ros1 function.
",295,,,www.uniprot.org,4374
"ROS1 E539* results in a premature truncation of the Ros1 protein at amino acid 539 of 2347 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), E539* is predicted to result in a loss of Ros1 function.
",295,,,www.uniprot.org,4376
"ROS1 Y718* results in a premature truncation of the Ros1 protein at amino acid 718 of 2347 (UniProt.org). Due to the loss of multiple functional domains (UniProt.org), Y718* is predicted to lead to a loss of Ros1 protein function.",295,,,www.uniprot.org,4377
"ROS1 E919K lies within the extracellular domain of the Ros1 protein (UniProt.org). E919K has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4378
"ROS1 F250L lies within the Fibronectin type-III domain 2 of the Ros1 protein (UniProt.org). F250L has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4379
"ROS1 F383S lies within the extracellular domain of the Ros1 protein (UniProt.org). F383S has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4380
"ROS1 G1954R lies within the protein kinase domain of the Ros1 protein (UniProt.org). G1954R has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4381
"ROS1 R2205I lies within the protein kinase domain of the Ros1 protein (UniProt.org). R2205I has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4382
"ROS1 G2066C lies within the protein kinase domain of the Ros1 protein (UniProt.org). G2066C has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4383
"ROS1 R2096W lies within the protein kinase domain of the Ros1 protein (UniProt.org). R2096W has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4384
"ROS1 G2148V lies within the protein kinase domain of the Ros1 protein (UniProt.org). G2148V has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4385
"ROS1 R2096Q lies within the protein kinase domain of the Ros1 protein (UniProt.org). R2096Q has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4386
"ROS1 K1163N lies within the extracellular domain of the Ros1 protein (UniProt.org). K1163N has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4387
"ROS1 R2096L lies within the protein kinase domain of the Ros1 protein (UniProt.org). R2096L has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4388
"ROS1 R2078W lies within the protein kinase domain of the Ros1 protein (UniProt.org). R2078W has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4389
"ROS1 K1552T lies within the Fibronectin type-III domain 6 of the Ros1 protein (UniProt.org). K1552T has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4390
"KDR (VEGFR2) R347H lies within the Ig-like C2-type 4 domain of the Kdr (Vegfr2) protein (UniProt.org). R347H has been identified in sequencing studies (PMID: 23263491), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7206,23263491,Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23263491,295,,,www.uniprot.org,4391
"ROS1 R118Q lies within the fibronectin type III domain 1 of the Ros1 protein (UniProt.org). R118Q has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4392
KDR (VEGFR2) S1100F lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). S1100F results in decreased ligand-induced phosphorylation of Krd (Vegfr2) and Mapk in cell culture (PMID: 28743916).,295,,,www.uniprot.org,10127,28743916,Analysis of somatic mutations across the kinome reveals loss-of-function mutations in multiple cancer types.,http://www.ncbi.nlm.nih.gov/pubmed/28743916,4393
"ROS1 Q617H lies within the fibronectin-type III domain 3 of the Ros1 protein (UniProt.org). Q617H has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4394
"KDR (VEGFR2) S1221N lies within the cytoplasmic domain of the Kdr (Vegfr2) protein (UniProt.org). S1221N has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4395
"KDR (VEGFR2) S1231N lies within the cytoplasmic domain of the Kdr (Vegfr2) protein (UniProt.org). S1231N has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4396
"ROS1 Q1889P lies within the cytoplasmic domain of the Ros1 protein (UniProt.org). Q1889P has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4397
"KDR (VEGFR2) S338Y lies within the Ig-like C2-type domain 4 of the Kdr (Vegfr2) protein (UniProt.org). S338Y has been identified in sequencing studies (PMID: 22810696), but has not been characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,295,,,www.uniprot.org,4398
"ROS1 Q1797H lies within the fibronectin type-III domain 9 of the Ros1 protein (UniProt.org). Q1797H has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4399
"KDR (VEGFR2) S35I lies within the extracellular domain of the Kdr (Vegfr2) protein (UniProt.org). S35I has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4400
"ROS1 P2130T lies within the protein kinase domain of the Ros1 protein (UniProt.org). P2130T has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4401
"KDR (VEGFR2) S984T lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). S984T has been identified in sequencing studies (PMID: 18948947), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,6956,18948947,Somatic mutations affect key pathways in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18948947,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4402
"KDR (VEGFR2) T343M lies within the Ig-like C2-type domain 4 of the Kdr (Vegfr2) protein (UniProt.org). T343M has been identified in sequencing studies (PMID: 24145436), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,7207,24145436,Landscape of somatic mutations and clonal evolution in mantle cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/24145436,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4403
"KDR (VEGFR2) V1041M lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). V1041M has been identified in sequencing studies (PMID: 18772396), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6948,18772396,An integrated genomic analysis of human glioblastoma multiforme.,http://www.ncbi.nlm.nih.gov/pubmed/18772396,4404
"KDR (VEGFR2) V476L lies within the Ig-like C2-type domain 5 of the Kdr (Vegfr2) protein (UniProt.org). V476L has been identified in sequencing studies (PMID: 18948947), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6956,18948947,Somatic mutations affect key pathways in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18948947,4405
"KDR (VEGFR2) V655M lies within the Ig-like C2-type domain 6 of the Kdr (Vegfr2) protein (UniProt.org). V655M has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4406
"KDR (VEGFR2) W1096L lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). W1096L has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4407
"KDR (VEGFR2) Y822C lies within the cytoplasmic domain of the Kdr (Vegfr2) protein (UniProt.org). Y822C has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4408
"FGFR1 over exp indicates an over expression of the FGFR1 protein. However, the mechanism causing the over expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,4409
"PTEN R130P lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). R130P has not been characterized, however other R130 ""hotspot"" mutations are inactivating (PMID: 10866302) thus, R130P is predicted to result in a loss of Pten protein function.",2304,10866302,Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.,http://www.ncbi.nlm.nih.gov/pubmed/10866302,295,,,www.uniprot.org,4410
"PTEN R14G lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). R14G has been identified in sequencing studies (PMID: 25527629), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",2323,25527629,Functionally distinct groups of inherited PTEN mutations in autism and tumour syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25527629,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4411
"ROS1 K1887Q lies within the cytoplasmic domain of the Ros1 protein (UniProt.org). K1887Q has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4412
"ROS1 K2099N lies within the protein kinase domain of the Ros1 protein (UniProt.org). K2099N has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4413
"ROS1 E298* results in a premature truncation of the Ros1 protein at amino acid 298 of 2347 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), E298* is predicted to result in a loss of Ros1 function.
",295,,,www.uniprot.org,4414
"ROS1 N1800T lies within the Fibronectin type-III domain 9 of the Ros1 protein (UniProt.org). N1800T has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4415
"ROS1 P1020fs results in a change in the amino acid sequence of the Ros1 protein beginning at aa 1020 of 2347, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), P1020fs is predicted to lead to a loss of Ros1 function.
",295,,,www.uniprot.org,4416
"ROS1 P1020H lies within the Fibronectin type-III domain 4 of the Ros1 protein (UniProt.org). P1020H has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4417
"ROS1 P1020S lies within the Fibronectin type-III domain 4 of the Ros1 protein (UniProt.org). P1020S has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4418
"ROS1 P1440L lies within the extracellular domain of the Ros1 protein (UniProt.org). P1440L has been identified in sequencing studies (PMID: 22842228), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,7109,22842228,Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22842228,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4419
"ROS1 P1440S lies within the extracellular domain of the Ros1 protein (UniProt.org). P1440S has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Aug 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4420
"ROS1 P1539S lies within the Fibronectin type-III domain 6 of the Ros1 protein (UniProt.org). P1539S has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4421
"CTNNB1 R159S lies within the ARM repeat region 1 of the Ctnnb1 protein (UniProt.org). R159S has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4422
"PTEN R159S lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). R159S has been identified in the scientific literature (PMID: 17873882), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8118,17873882,Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/17873882,4423
PTEN R15I lies within the phoshphatase tensin-type domain of the Pten protein (UniProt.org). R15I confers a loss of function to the Pten protein as demonstrated by loss of phosphatase activity (PMID: 9823298).,295,,,www.uniprot.org,2305,9823298,The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells.,http://www.ncbi.nlm.nih.gov/pubmed/9823298,4424
"PTEN R173H lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). The effect of R173H on Pten protein function is conflicting as R173H results in a loss of Pten phosphatase activity in an in vitro assay (PMID: 10866302), but correlates with wild-type Pten phenotype in an in vivo tumor growth assay (PMID: 27147599).",2304,10866302,Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.,http://www.ncbi.nlm.nih.gov/pubmed/10866302,295,,,www.uniprot.org,6273,27147599,Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.,http://www.ncbi.nlm.nih.gov/pubmed/27147599,4425
PTEN R173C lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). R173C confers a loss of function to the Pten protein as demonstrated by loss of phosphatase activity (PMID: 10866302).,2304,10866302,Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.,http://www.ncbi.nlm.nih.gov/pubmed/10866302,295,,,www.uniprot.org,4426
"PTEN R173fs*10 likely results in a premature truncation of the 403 aa Pten protein at aa 173 followed by 10 nonsense amino acids within the phosphatase tensin-type domain (UniProt.org). R173fs*10 has not been characterized, however C-terminal deletion mutants downstream of R173 are inactivating (PMID: 10468583), thus R173fs*10 is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4427
"PTEN R335* results in a premature truncation of the Pten protein at amino acid 335 of 403 within the C2 tensin-type domain (UniProt.org). PTEN R335* has not been characterized, however C-terminal deletion mutants downstream of R335 are inactivating (PMID: 10468583), thus R335* is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4428
"PTEN R47M lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). R47M has not been characterized in the scientific literature and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4429
"PTEN S10N does not lie within any known functional domains of the Pten protein (UniProt.org). S10N demonstrates phosphatase activity comparable to wild-type Pten (PMID: 10468583), however, results in reduced membrane localization of the Pten protein due to impaired binding with membrane lipids, and subsequently, is unable to regulate PIP3 signaling (PMID: 25263454).",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,5905,25263454,A new class of cancer-associated PTEN mutations defined by membrane translocation defects.,http://www.ncbi.nlm.nih.gov/pubmed/25263454,4430
"PTEN S170I lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). S170I has been identified in the scientific literature (PMID: 27135926, PMID: 23066114), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7025,27135926,Landscape of somatic mutations in 560 breast cancer whole-genome sequences.,http://www.ncbi.nlm.nih.gov/pubmed/27135926,9968,23066114,Utility of PTEN protein dosage in predicting for underlying germline PTEN mutations among patients presenting with thyroid cancer and Cowden-like phenotypes.,http://www.ncbi.nlm.nih.gov/pubmed/23066114,295,,,www.uniprot.org,4431
PTEN S170N lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). S170N confers a loss of function to the Pten protein as demonstrated by loss of phosphatase activity (PMID:     10866302).,2304,10866302,Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.,http://www.ncbi.nlm.nih.gov/pubmed/10866302,295,,,www.uniprot.org,4432
"PTEN S59* results in a premature truncation of the Pten protein at amino acid 59 of 403 (UniProt.org). Due to the disruption of the phosphatase tensin-type domain and the loss of the C2 tensin-type domain, S59* is predicted to lead to a loss of Pten protein function (UniProt.org).",295,,,www.uniprot.org,4433
"PTEN S338T lies within the C2 tensin-type domain of the Pten protein (UniProt.org). S338T has been identified in sequencing studies (PMID: 11555573), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,8133,11555573,"PTEN mutation located only outside exons 5, 6, and 7 is an independent predictor of favorable survival in endometrial carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/11555573,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4434
PTEN S170R lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). S170R confers a loss of function to the Pten protein as demonstrated by loss of phosphatase activity (PMID: 10866302).,295,,,www.uniprot.org,2304,10866302,Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.,http://www.ncbi.nlm.nih.gov/pubmed/10866302,4435
"PTEN S287* results in a premature truncation of the Pten protein at aa 287 of 403 within the C2 tensin-type domain (UniProt.org). S287* has not been characterized, however C-terminal deletion mutants downstream of S287 are inactivating (PMID: 10468583), thus S287* is predicted to lead to a loss of Pten protein function.",295,,,www.uniprot.org,2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,4436
"PTEN S294fs*2 likely results in a premature truncation of the 403 aa Pten protein at aa 294 followed by 2 nonsense amino acids within the C2 tensin-type domain (UniProt.org). S294fs*2 has not been characterized, however other C-terminal deletion mutants downstream of S294 are inactivating (PMID: 10468583), thus S294fs*2 is predicted to lead to a loss of Pten protein function.",295,,,www.uniprot.org,2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,4437
PTEN T167A lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). T176A results in decreased Pten activity and reduced ability to rescue growth arrest in yeast (PMID: 21828076).     ,295,,,www.uniprot.org,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,4438
"PTEN T319fs*1 likely results in a premature truncation of the 403 aa Pten protein at aa 319 followed by a nonsense amino acid within the C2 tensin-type domain (UniProt.org). T319fs*1 has not been characterized, however other C-terminal deletion mutants downstream of T319 are inactivating (PMID: 10468583), thus T319fs*1 is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4442
PTEN T319del results in the deletion of an amino acid within the C2 tensin-type domain of the Pten protein at amino acid 319 (UniProt.org). T319del confers a loss of function to the Pten protein as demonstrated by increased protein turnover and decreased phosphatase activity (PMID: 10468583).,2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4443
"PTEN T131fs*3 likely results in a truncation of the 403 aa Pten protein at aa 131, followed by 3 nonsense amino acids (UniProt.org). Due to the disruption of the phosphatase tesin-type domain and the loss of the C2 tensin-type domain (UniProt.org), T131fs*3 is predicted to lead to a loss of Pten protein function. ",295,,,www.uniprot.org,4444
"PTEN T319fs*24 likely results in a premature truncation of the 403 aa Pten protein at aa 319 followed by 24 nonsense amino acids within the C2 tensin-type domain (UniProt.org). PTEN T319fs*24 has not been characterized, however other C-terminal deletion mutants downstream of T319 are inactivating (PMID: 10468583), thus PTEN T319fs*24 is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4445
"PTEN T319fs*6 likely results in a premature truncation of the 403 aa Pten protein at aa 319 followed by 6 nonsense amino acids within the C2 tensin-type domain (UniProt.org). PTEN T319fs*6 has not been characterized, however other C-terminal deletion mutants downstream of T319 are inactivating (PMID: 10468583), thus PTEN T319fs*6 is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4446
"PTEN T321fs*23 likely results in a premature truncation of the 403 aa Pten protein at aa 321 followed by 23 nonsense amino acids within the C2 tensin-type domain (UniProt.org). T321fs*23 has not been characterized, however other C-terminal deletion mutants downstream of T321 are inactivating (PMID: 10468583), thus T321fs*23 is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4447
"PTEN T321fs*3 likely results in a premature truncation of the 403 aa Pten protein at aa 321 followed by 3 nonsense amino acids within the C2 tensin-type domain (UniProt.org). T321fs*23 has not been characterized, however other C-terminal deletion mutants downstream of T321 are inactivating (PMID: 10468583), thus T321fs*23 is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4448
"PTEN T321fs results in a change in the amino acid sequence of the PTEN protein beginning at aa 321 of 403, likely resulting in premature truncation of the functional protein (UniProt.org). T321fs has not been characterized, however other C-terminal deletion mutants downstream of T321 are inactivating (PMID: 10468583), thus T321fs is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4449
"PTEN Y336* results in a premature truncation within the C2 tensin-type domain of the Pten protein at amino acid 336 of 403 (UniProt.org). Y336* has not been characterized, however other C-terminal deletion mutants downstream of Y336 are inactivating (PMID: 10468583), thus Y336* is predicted to lead to a loss of Pten protein function.",295,,,www.uniprot.org,2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,4450
"PTEN Y46C lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). Y46C has been identified in sequencing studies (PMID: 20530683), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",1863,20530683,Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations.,http://www.ncbi.nlm.nih.gov/pubmed/20530683,295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4451
"PTEN Y65* results in a premature truncation of the Pten protein at amino acid 65 of 403 within the phosphatase tensin-type domain (UniProt.org). Due to the disruption of the phosphatase tensin-type domain and the loss of the C2 tensin-type domain (UniProt.org), PTEN Y65* is predicted to lead to a loss of Pten protein function.",295,,,www.uniprot.org,4453
PTEN Y68C lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). Y68C confers a loss of function to the Pten protein as demonstrated by a loss of phosphatase activity (PMID: 10866302).,2304,10866302,Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.,http://www.ncbi.nlm.nih.gov/pubmed/10866302,295,,,www.uniprot.org,4454
PTEN Y68H lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). Y68H confers a loss of function to the Pten protein as demonstrated by a loss of phosphatase activity (PMID: 10866302).,2304,10866302,Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.,http://www.ncbi.nlm.nih.gov/pubmed/10866302,295,,,www.uniprot.org,4455
"PTEN Y68fs*5 likely results in a truncation of the 403 aa Pten protein at aa 68, followed by 5 nonsense amino acids within the phosphatase tensin-type domain (UniProt.org). Due to the loss of the C2 tensin-type domain (UniProt.org), Y68fs*5 is predicted to lead to a loss of Pten function.",295,,,www.uniprot.org,4456
PTEN F347L lies within the C2 tensin-type domain of the Pten protein (UniProt.org). F347L confers a loss of function to the Pten protein as demonstrated by loss of phosphatase activity (PMID: 10866302).,2304,10866302,Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.,http://www.ncbi.nlm.nih.gov/pubmed/10866302,295,,,www.uniprot.org,4457
PTEN G20E lies within the phosphatase tesin-type domain of the Pten protein (UniProt.org). G20E confers a loss of function to the Pten protein as demonstrated by loss of phosphatase activity (PMID: 10866302).,2304,10866302,Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.,http://www.ncbi.nlm.nih.gov/pubmed/10866302,295,,,www.uniprot.org,4460
PTEN H93Y lies within the phosphatase tesin-type domain of the Pten protein (UniProt.org). H93Y confers a loss of function to the Pten protein as demonstrated by loss of phosphatase activity (PMID: 10866302).,2304,10866302,Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.,http://www.ncbi.nlm.nih.gov/pubmed/10866302,295,,,www.uniprot.org,4461
PTEN M134L lies within the phosphatase tesin-type domain of the Pten protein (UniProt.org). M134L confers a loss of function to the Pten protein as demonstrated by loss of phosphatase activity (PMID: 10866302).,2304,10866302,Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.,http://www.ncbi.nlm.nih.gov/pubmed/10866302,295,,,www.uniprot.org,4462
PTEN R173P lies within the phosphatase tesin-type domain of the Pten protein (UniProt.org). R173P confers a loss of function to the Pten protein as demonstrated by loss of phosphatase activity (PMID: 10866302).,2304,10866302,Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.,http://www.ncbi.nlm.nih.gov/pubmed/10866302,295,,,www.uniprot.org,4463
PTEN Y155C lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). Y155C confers a loss of function to the Pten protein as demonstrated by loss of phosphatase activity (PMID: 10866302).,2304,10866302,Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.,http://www.ncbi.nlm.nih.gov/pubmed/10866302,295,,,www.uniprot.org,4464
PTEN Y174N lies within the phosphatase tesin-type domain of the Pten protein (UniProt.org). Y174N confers a loss of function to the Pten protein as demonstrated by loss of phosphatase activity (PMID: 10866302).,2304,10866302,Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.,http://www.ncbi.nlm.nih.gov/pubmed/10866302,295,,,www.uniprot.org,4465
PTEN Y27S lies within the phosphatase tesin-type domain of the Pten protein (UniProt.org). Y27S confers a loss of function to the Pten protein as demonstrated by loss of phosphatase activity (PMID: 10866302).,2304,10866302,Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.,http://www.ncbi.nlm.nih.gov/pubmed/10866302,295,,,www.uniprot.org,4466
PTEN L345Q lies within the C2 tensin-type domain of the Pten protein (UniProt.org). L345Q confers a loss of function to the Pten protein as demonstrated by loss of phosphatase activity (PMID: 10866302).,295,,,www.uniprot.org,2304,10866302,Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.,http://www.ncbi.nlm.nih.gov/pubmed/10866302,4467
PTEN S227F lies within the C2 tensin-type domain of the Pten protein (UniProt.org). S227F confers a loss of function to the Pten protein as demonstrated by loss of phosphatase activity (PMID: 10866302).,295,,,www.uniprot.org,2304,10866302,Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.,http://www.ncbi.nlm.nih.gov/pubmed/10866302,4468
PTEN V343E lies within the C2 tensin-type domain of the Pten protein (UniProt.org). V343E confers a loss of function to the Pten protein as demonstrated by loss of phosphatase activity (PMID: 10866302).,295,,,www.uniprot.org,2304,10866302,Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.,http://www.ncbi.nlm.nih.gov/pubmed/10866302,4469
"APC A1351fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1351 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). A1351fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), A1351fs is predicted to reduce the ability of Apc to regulate beta-catenin.",295,,,www.uniprot.org,2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,4472
"APC A1366V lies within the beta-catenin binding and down-regulation region of the Apc protein (PMID: 14672538). A1366V has been identified in the scientific literature (PMID: 21901162), but has not been biochemically characterized and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,404,21901162,Molecular genetic analysis of 103 sporadic colorectal tumours in Czech patients.,http://www.ncbi.nlm.nih.gov/pubmed/21901162,2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,4473
"APC E1295* results in a premature truncation of the Apc protein at amino acid 1295 of 2843 (UniProt.org). E1295* has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), E1295* is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,4475
"APC E1306* results in a premature truncation of the Apc protein at amino acid 1306 of 2843 (UniProt.org). E1306* has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), E1306* is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,4476
"APC E1306K lies within the mutator cluster region of the Apc protein (PMID: 14672538). E1306K has been identified in sequencing studies (PMID: 27311873), but has not been biochemically characterized and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7791,27311873,"Circumscribed sebaceous neoplasms: a morphological, immunohistochemical and molecular analysis.",http://www.ncbi.nlm.nih.gov/pubmed/27311873,2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,4488
"APC E1309* results in a premature truncation of the Apc protein at amino acid 1309 of 2843 (UniProt.org). E1309* has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), E1309* is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,4489
"APC E1309fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1309 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). E1309fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), E1309fs is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,4490
"APC E1317* results in a premature truncation of the Apc protein at amino acid 1317 of 2843 (UniProt.org). E1317* has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), E1317* is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,4492
"APC E1322* results in a premature truncation of the Apc protein at amino acid 1322 of 2843 (UniProt.org). E1322* has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), E1322* is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,4493
"APC E1345* results in a premature truncation of the Apc protein at amino acid 1345 of 2843 (UniProt.org). E1345* has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), E1345* is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,4494
"APC E1353* results in a premature truncation of the Apc protein at amino acid 1353 of 2843 (UniProt.org). E1353* has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), E1353* is predicted to reduce the ability of Apc to regulate beta-catenin.",295,,,www.uniprot.org,2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,4500
"APC E1374* results in a premature truncation of the Apc protein at amino acid 1374 of 2843 (UniProt.org). E1374* has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), E1374* is predicted to reduce the ability of Apc to regulate beta-catenin.",295,,,www.uniprot.org,2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,4501
"APC E1374K lies within the beta-catenin binding and down-regulation region of the Apc protein (PMID: 14672538). E1374K has been identified in sequencing studies (PMID: 27311873), but has not been biochemically characterized and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,7791,27311873,"Circumscribed sebaceous neoplasms: a morphological, immunohistochemical and molecular analysis.",http://www.ncbi.nlm.nih.gov/pubmed/27311873,4502
"APC E1379* results in a premature truncation of the Apc protein at amino acid 1379 of 2843 (UniProt.org). E1379* has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), E1379* is predicted to reduce the ability of Apc to regulate beta-catenin.",295,,,www.uniprot.org,2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,4503
"APC E1451* results in a premature truncation of the Apc protein at amino acid 1451 of 2843 (UniProt.org). E1451* has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), E1451* is predicted to reduce the ability of Apc to regulate beta-catenin.",295,,,www.uniprot.org,2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,4504
"APC E1461* results in a premature truncation of the Apc protein at amino acid 1461 of 2843 (UniProt.org). E1461* has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), E1461* is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,4505
"APC E1464* results in a premature truncation of the Apc protein at amino acid 1464 of 2843 (UniProt.org). E1464* has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), E1464* is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,4506
"APC E1464fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1464 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). E1464fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), E1464fs is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,4507
"APC E1494fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1494 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). E1494fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), E1494fs is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,4508
"APC E1513* results in a premature truncation of the Apc protein at amino acid 1513 of 2843 (UniProt.org). E1513* has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), E1513* is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,4510
"APC E1547* results in a premature truncation of the Apc protein at amino acid 1547 of 2843 (UniProt.org). E1547* has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), E1547* is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,4511
"APC E1552* results in a premature truncation of the Apc protein at amino acid 1552 of 2843 (UniProt.org). E1552* has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), E1552* is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,4512
"APC E1554* results in a premature truncation of the Apc protein at amino acid 1554 of 2843 (UniProt.org). E1554* has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), E1554* is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,4513
"APC F1491fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1491 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). F1491fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), F1491fs is predicted to reduce the ability of Apc to regulate beta-catenin.",295,,,www.uniprot.org,2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,4515
"APC G1120E lies within the beta-catenin binding region of the Apc protein (PMID: 14672538). G1120E inhibits beta-catenin-mediated transcription at a level similar to wild-type Apc in a yeast assay, but other aspects of Apc function were not evaluated and therefore, its effect on Apc protein function is unknown (PMID: 14633595).",2394,14633595,Reconstructed beta-catenin/TCF4 signaling in yeast applicable to functional evaluation of APC mutations.,http://www.ncbi.nlm.nih.gov/pubmed/14633595,2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,4516
"APC G1312* results in a premature truncation of the Apc protein at amino acid 1312 of 2843 (UniProt.org). G1312* has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), G1312* is predicted to reduce the ability of Apc to regulate beta-catenin.",295,,,www.uniprot.org,2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,4517
"APC G1312fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1312 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). G1312fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), G1312fs is predicted to reduce the ability of Apc to regulate beta-catenin.",295,,,www.uniprot.org,2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,4518
"APC G1357fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1357 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). G1357fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), G1357fs is predicted to reduce the ability of Apc to regulate beta-catenin.",295,,,www.uniprot.org,2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,4519
"APC G1499* results in a premature truncation of the Apc protein at amino acid 1499 of 2843 (UniProt.org). G1499* has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), G1499* is predicted to reduce the ability of Apc to regulate beta-catenin.",295,,,www.uniprot.org,2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,4520
"APC G1499R lies within the beta-catenin binding and down-regulation region of the Apc protein (PMID: 14672538). G1499R has been identified in sequencing studies (PMID: 22848674), but has not been biochemically characterized and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7811,22848674,Comprehensive mutation analysis in colorectal flat adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/22848674,2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,4521
"APC H1375fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1375 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). H1375fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), H1375fs is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,4522
"APC H1490fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1490 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). H1490fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), H1490fs is predicted to reduce the ability of Apc to regulate beta-catenin.",295,,,www.uniprot.org,2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,4523
"APC I1307fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1307 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). I1307fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), I1307fs is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,4525
APC K1454E lies within the beta-catenin binding and down-regulation region of the Apc protein (PMID: 14672538). K1454E suppresses beta-catenin mediated transcription at a level similar to wild-type Apc in a cell culture assay (PMID: 18199528).,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,4532
"APC K1555fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1555 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). K1555fs has not been characterized, however Apc truncation mutants downstream of K1555 are inactivating (PMID: 18199528) thus, K1555fs is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,4534
"APC L1488* results in a premature truncation of the Apc protein at amino acid 1488 of 2843 within the Ctnnb1 binding and down-regulation domain (PMID: 14672538). L1488* has not been characterized, however Apc truncation mutants downstream of L1488 are inactivating (PMID: 18199528) thus, L1488* is predicted to lead to a loss of Apc protein function.",2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,4535
"APC L1488fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1488 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). L1488fs has not been characterized, however Apc truncation mutants downstream of L1488 are inactivating (PMID: 18199528) thus, L1488fs is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,4536
"APC L1489fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1489 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). L1489fs has not been characterized, however Apc truncation mutants downstream of L1489 are inactivating (PMID: 18199528) thus, L1489fs is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,4539
"APC L1564* results in a premature truncation of the Apc protein at amino acid 1564 of 2843 within the Ctnnb1 binding and down-regulation domain (PMID: 14672538). L1564* has not been characterized, however Apc truncation mutants downstream of L1488 are inactivating (PMID: 18199528) thus, L1564* is predicted to lead to a loss of Apc protein function.",2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,4541
"APC L2253I does not lie within any known functional domains of the Apc protein (UniProt.org). L2253I has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4542
"APC L2401P does not lie within any known functional domains of the Apc protein (UniProt.org). L2401P has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4543
"APC L508F lies within ARM repeat 2 of the Apc protein (UniProt.org). L508F has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4544
"APC M1431fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1431 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). M1431fs has not been characterized, however Apc truncation mutants downstream of M1431 are inactivating (PMID: 18199528) thus, M1431fs is predicted to lead to a loss of Apc protein function.",2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,295,,,www.uniprot.org,4545
"APC N1300fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1300 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). N1300fs has not been characterized, however Apc truncation mutants downstream of N1300 are inactivating (PMID: 18199528) thus, N1300fs is predicted to lead to a loss of Apc protein function.",2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,295,,,www.uniprot.org,4546
"APC N1455fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1455 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). N1455fs has not been characterized, however Apc truncation mutants downstream of N1455 are inactivating (PMID: 18199528) thus, N1455fs is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,4548
"APC N869fs results in a change in the amino acid sequence of the Apc protein beginning at aa 869 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). N869fs has not been characterized, however Apc truncation mutants downstream of N869 are inactivating (PMID: 18199528) thus, N869fs is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,4549
"APC P1319fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1319 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). P1319fs has not been characterized, however Apc truncation mutants downstream of P1319 are inactivating (PMID: 18199528) thus, P1319fs is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,4550
"APC P1361fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1361 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). P1361fs has not been characterized, however Apc truncation mutants downstream of P1361 are inactivating (PMID: 18199528) thus, P1361fs is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,4551
"APC P1372fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1372 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). P1372fs has not been characterized, however Apc truncation mutants downstream of P1372 are inactivating (PMID: 18199528) thus, P1372fs is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,4552
"APC P1373fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1373 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). P1373fs has not been characterized, however Apc truncation mutants downstream of P1373 are inactivating (PMID: 18199528) thus, P1373fs is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,4553
"APC P1432H lies within the beta-catenin binding and down-regulation region of the Apc protein (PMID: 14672538). P1432H has been identified in sequencing studies (PMID: 17558858) but has not been biochemically characterized and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",7815,17558858,Analysis of APC/beta-catenin genes mutations and Wnt signalling pathway in desmoid-type fibromatosis.,http://www.ncbi.nlm.nih.gov/pubmed/17558858,285,,,http://www.ncbi.nlm.nih.gov/pubmed,2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,4554
"APC P1440fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1440 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). P1440fs has not been characterized, however Apc truncation mutants downstream of P1440 are inactivating (PMID: 18199528) thus, P1440fs is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,4557
"APC P1443fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1443 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). P1443fs has not been characterized, however Apc truncation mutants downstream of P1443 are inactivating (PMID: 18199528) thus, P1443fs is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,4558
"APC P1453fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1453 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). P1453fs has not been characterized, however Apc truncation mutants downstream of P1453 are inactivating (PMID: 18199528) thus, P1453fs is predicted to lead to a loss of Apc protein function.",2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,295,,,www.uniprot.org,4559
"APC P1458fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1458 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). P1458fs has not been characterized, however Apc truncation mutants downstream of P1458 are inactivating (PMID: 18199528) thus, P1458fs is predicted to lead to a loss of Apc protein function.",2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,295,,,www.uniprot.org,4560
"APC P1497fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1497 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). P1497fs has not been characterized, however Apc truncation mutants downstream of P1497 are inactivating (PMID: 18199528) thus, P1497fs is predicted to lead to a loss of Apc protein function.",2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,295,,,www.uniprot.org,4561
"APC P1613H lies within the beta-catenin binding and down-regulation domain of the Apc protein (PMID: 14672538). P1613H has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4562
"APC Q1096* results in a premature truncation of the Apc protein at amino acid 1096 of 2843 within the Ctnnb1 binding domain (PMID: 14672538). Q1096* has not been characterized, however Apc truncation mutants downstream of Q1069 are inactivating (PMID: 18199528) thus, Q1069* is predicted to lead to a loss of Apc protein function.",2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,4563
"APC Q1291* results in a premature truncation of the Apc protein at amino acid 1291 of 2843 within the mutator cluster region (PMID: 14672538). Q1291* has not been characterized, however Apc truncation mutants downstream of Q1291 are inactivating (PMID: 18199528) thus, Q1291* is predicted to lead to a loss of Apc protein function.",2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,4564
"APC Q1294* results in a premature truncation of the Apc protein at amino acid 1294 of 2843 within the mutator cluster region of the Apc protein (PMID: 14672538). Q1294* has not been characterized, however Apc truncation mutants downstream of Q1294	 are inactivating (PMID: 18199528) thus, Q1294* is predicted to lead to a loss of Apc protein function.",2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,4565
"APC Q1303* results in a premature truncation of the Apc protein at amino acid 1303 of 2843 within the mutator cluster region of the Apc protein (PMID: 14672538). Q1303* has not been characterized, however Apc truncation mutants downstream of Q1303 are inactivating (PMID: 18199528) thus, Q1303* is predicted to lead to a loss of Apc protein function.",2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,4566
"APC Q1338* results in a premature truncation of the Apc protein at amino acid 1338 of 2843 within the mutator cluster region of the Apc protein (PMID: 14672538). Q1338* has not been characterized, however Apc truncation mutants downstream of Q1338	are inactivating (PMID: 18199528) thus, Q1338* is predicted to lead to a loss of Apc protein function.",2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,4567
"APC Q1367* results in a premature truncation of the Apc protein at amino acid 1367 of 2843 within the Ctnnb1 binding and down-regulation domain of the Apc protein (PMID: 14672538). Q1367* has not been characterized, however Apc truncation mutants downstream of Q1367 are inactivating (PMID: 18199528) thus, Q1367* is predicted to lead to a loss of Apc protein function.",2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,4568
"APC Q1378* results in a premature truncation of the Apc protein at amino acid 1378 of 2843 within the Ctnnb1 binding and down-regulation domain of the Apc protein (PMID: 14672538). Q1378* has not been characterized, however Apc truncation mutants downstream of Q1378 are inactivating (PMID: 18199528) thus, Q1378* is predicted to lead to a loss of Apc protein function.",2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,4569
"APC Q1294fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1294 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). Q1294fs has not been characterized, however Apc truncation mutants downstream of Q1294 are inactivating (PMID: 18199528) thus, Q1294fs is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,4570
"APC Q1303fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1303 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). Q1303fs has not been characterized, however Apc truncation mutants downstream of Q1303 are inactivating (PMID: 18199528) thus, Q1303fs is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,4571
"APC I1311fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1311 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). I1311fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), I1311fs is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,4572
"APC I1557fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1557 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). I1557fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), I1557fs is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,4574
"APC I880T does not lie within any known functional domains of the Apc protein (UniProt.org). I880T has been identified in sequencing studies (PMID: 9419979) but has not been biochemically characterized and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",7812,9419979,Drastic genetic instability of tumors and normal tissues in Turcot syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/9419979,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4575
"APC K1308* results in a premature truncation of the Apc protein at amino acid 1308 of 2843 (UniProt.org). K1308* has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), K1308* is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,4576
"APC K1310* results in a premature truncation of the Apc protein at amino acid 1310 of 2843 (UniProt.org). K1310* has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), K1310* is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,4577
"APC K1310fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1310 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). K1310fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), K1310fs is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,4578
"APC K1350* results in a premature truncation of the Apc protein at amino acid 1350 of 2843 (UniProt.org). K1350* has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), K1350* is predicted to reduce the ability of Apc to regulate beta-catenin.",295,,,www.uniprot.org,2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,4579
"APC K1370* results in a premature truncation of the Apc protein at amino acid 1370 of 2843 (UniProt.org). K1370* has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), K1370* is predicted to reduce the ability of Apc to regulate beta-catenin.",295,,,www.uniprot.org,2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,4580
"APC K1449fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1449 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). K1449fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), K1449fs is predicted to reduce the ability of Apc to regulate beta-catenin.",295,,,www.uniprot.org,2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,4581
"APC Q1378fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1378 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). APC Q1378fs has not been characterized, however Apc truncation mutants downstream of Q1378 are inactivating (PMID: 18199528) thus, Q1378fs is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,4582
"APC R1314fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1314 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). APC R1314fs has not been characterized, however Apc truncation mutants downstream of R1314 are inactivating (PMID: 18199528) thus, R1314fs is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,4583
"APC R1348fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1348 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). R1348fs has not been characterized, however Apc truncation mutants downstream of R1348 are inactivating (PMID: 18199528) thus, R1348fs is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,4584
"APC R1435fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1435 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). R1435fs has not been characterized, however Apc truncation mutants downstream of R1435 are inactivating (PMID: 18199528) thus, R1435fs is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,4585
"APC Q1406* results in a premature truncation of the Apc protein at amino acid 1406 of 2843 within the Ctnnb1 binding and down-regulation domain of the Apc protein (PMID: 14672538). Q1406* has not been characterized, however Apc truncation mutants downstream of Q1406 are inactivating (PMID: 18199528) thus, Q1406* is predicted to lead to a loss of Apc protein function.",2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,4586
"APC R1114* results in a premature truncation of the Apc protein at amino acid 1114 of 2843 within the Ctnnb1 binding domain of the Apc protein (PMID: 14672538). R1114* has not been characterized, however Apc truncation mutants downstream of R1114 are inactivating (PMID: 18199528) thus, R1114* is predicted to lead to a loss of Apc protein function.",2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,4587
"APC Q1429* results in a premature truncation of the Apc protein at amino acid 1429 of 2843 within the Ctnnb1 binding and down-regulation domain of the Apc protein (PMID: 14672538). Q1429* has not been characterized, however Apc truncation mutants downstream of Q1429 are inactivating (PMID: 18199528) thus, Q1429* is predicted to lead to a loss of Apc protein function.",2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,4588
"APC Q1444* results in a premature truncation of the Apc protein at amino acid 1444 of 2843 within the Ctnnb1 binding and down-regulation domain of the Apc protein (PMID: 14672538). Q1444* has not been characterized, however Apc truncation mutants downstream of Q1444 are inactivating (PMID: 18199528) thus, Q1444* is predicted to lead to a loss of Apc protein function.",2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,4589
"APC Q1469* results in a premature truncation of the Apc protein at amino acid 1469 of 2843 within the Ctnnb1 binding and down-regulation domain of the Apc protein (PMID: 14672538). Q1469* has not been characterized, however Apc truncation mutants downstream of Q1469 are inactivating (PMID: 18199528) thus, Q1469* is predicted to lead to a loss of Apc protein function.",2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,4590
"APC R1435* results in a premature truncation of the Apc protein at amino acid 1435 of 2843 within the Ctnnb1 binding and down-regulation domain of the Apc protein (PMID: 14672538). R1435* has not been characterized, however Apc truncation mutants downstream of R1435 are inactivating (PMID: 18199528) thus, R1435* is predicted to lead to a loss of Apc protein function.",2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,4591
"APC Q886* results in a premature truncation of the Apc protein at amino acid 886 of 2843 (UniProt.org). Q886* has not been characterized, however Apc truncation mutants downstream of Q886 are inactivating (PMID: 18199528) thus, Q886* is predicted to lead to a loss of Apc protein function.",2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,295,,,www.uniprot.org,4593
"APC S1315* results in a premature truncation of the Apc protein at amino acid 1370 of 2843 (UniProt.org). S1315* has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), S1315* is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,4594
"APC S1315fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1315 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). S1315fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), S1315fs is predicted to reduce the ability of Apc to regulate beta-catenin.",295,,,www.uniprot.org,2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,4595
"APC S1346* results in a premature truncation of the Apc protein at amino acid 1346 of 2843 (UniProt.org). S1346* has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), S1346* is predicted to reduce the ability of Apc to regulate beta-catenin.",295,,,www.uniprot.org,2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,4596
"APC S1355fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1355 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). S1355fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), S1355fs is predicted to reduce the ability of Apc to regulate beta-catenin.",295,,,www.uniprot.org,2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,4600
"APC S1355P lies within the beta-catenin binding and down-regulation region of the Apc protein (PMID: 14672538). S1355P has been identified in sequencing studies (PMID: 17558858) but has not been biochemically characterized and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",7815,17558858,Analysis of APC/beta-catenin genes mutations and Wnt signalling pathway in desmoid-type fibromatosis.,http://www.ncbi.nlm.nih.gov/pubmed/17558858,285,,,http://www.ncbi.nlm.nih.gov/pubmed,2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,4601
"APC S1356* results in a premature truncation of the Apc protein at amino acid 1356 of 2843 (UniProt.org). S1356* has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), S1356* is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,4602
"APC S1356fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1356 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). S1356fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), S1356fs is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,4603
"APC S1364fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1364 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). S1364fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), S1364fs is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,4604
"APC S1436fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1436 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). S1436fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), S1436fs is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,4605
"APC S1465fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1465 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). S1465fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), S1465fs is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,4606
"APC S1495fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1495 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). S1495fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), S1495fs is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,4608
"APC R213* results in a premature truncation of the Apc protein at amino acid 213 of 2843 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), R213* is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,4610
"APC R216* results in a premature truncation of the Apc protein at amino acid 216 of 2843 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), R216* is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,4611
"APC R232* results in a premature truncation of the Apc protein at amino acid 232 of 2843 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), R232* is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,4612
"APC R283* results in a premature truncation of the Apc protein at amino acid 283 of 2843 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), R283* is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,4613
"APC R230C lies within a coiled coil domain of the Apc protein (UniProt.org). R230C has been identified in sequencing studies (PMID: 26343386) but has not been biochemically characterized and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7139,26343386,Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway.,http://www.ncbi.nlm.nih.gov/pubmed/26343386,4614
"APC R2525C does not lie within any known functional domains of the Apc protein (UniProt.org). R2525C has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4615
"APC R374W does not lie within any known functional domains of the Apc protein (UniProt.org). R374W has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4629
"APC R564* results in a premature truncation of the Apc protein at amino acid 564 of 2843 (UniProt.org). Due to the loss of the majority of functional domains (UniProt.org), R564* is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,4630
"APC S1495I lies within the beta-catenin binding and down-regulation domain of the Apc protein (PMID: 14672538). S1495I has been identified in sequencing studies (PMID: 21807601), but has not been biochemically characterized and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,7496,21807601,Analysis of molecular aberrations of Wnt pathway gladiators in colorectal cancer in the Kashmiri population.,http://www.ncbi.nlm.nih.gov/pubmed/21807601,4631
"APC T1301S lies within the mutator cluster region of the Apc protein (PMID: 14672538). T1301S has been identified in sequencing studies (PMID: 8118796) but has not been biochemically characterized and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,7817,8118796,Mutations of the APC gene occur during early stages of gastric adenoma development.,http://www.ncbi.nlm.nih.gov/pubmed/8118796,4632
"APC T1301fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1301 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). T1301fs has not been characterized, however Apc truncation mutants downstream of T1301 are inactivating (PMID: 18199528) thus, T1301fs is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,4634
"APC T1438fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1438 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). T1438fs has not been characterized, however Apc truncation mutants downstream of T1438 are inactivating (PMID: 18199528) thus, T1438fs is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,4636
"APC T1445fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1445 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). T1445fs has not been characterized, however Apc truncation mutants downstream of T1445 are inactivating (PMID: 18199528) thus, T1445fs is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,4638
"APC T1556fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1556 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). T1556fs has not been characterized, however Apc truncation mutants downstream of T1556 are inactivating (PMID: 18199528) thus, T1556fs is predicted to lead to a loss of Apc protein function.",2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,295,,,www.uniprot.org,4639
"APC T1459fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1459 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). T1459fs has not been characterized, however Apc truncation mutants downstream of T1459 are inactivating (PMID: 18199528) thus, T1459fs is predicted to lead to a loss of Apc protein function.",2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,295,,,www.uniprot.org,4642
"APC Y1376fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1376 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). Y1376fs has not been characterized, however Apc truncation mutants downstream of Y1376 are inactivating (PMID: 18199528) thus, Y1376fs is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,4646
"APC Y158H lies within the coiled-coil domain of the Apc protein (UniProt.org). Y158H has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4647
"ERBB2 (HER2) G1000E lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). G1000E has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4649
"ERBB2 (HER2) G1015E lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). G1015E has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4650
"ERBB2 (HER2) G985E lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). G985E has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4651
"ERBB2 (HER2) I624V lies within the transmembrane domain of isoform 5 of the Erbb2 (Her2) protein and corresponds to I654V in the canonical isoform (UniProt.org). I624V (I654V) is predicted to stabilize Erbb2 (Her2) dimerization, resulting in increased autophosphorylation and protein kinase activity (PMID: 15550452).",295,,,www.uniprot.org,2472,15550452,The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk.,http://www.ncbi.nlm.nih.gov/pubmed/15550452,4652
"ERBB2 (HER2) I639V lies within the transmembrane domain of isoform 4 of the Erbb2 (Her2) protein and corresponds to I654V in the canonical isoform (UniProt.org). I639V (I654V) is predicted to stabilize Erbb2 (Her2) dimerization, resulting in increased autophosphorylation and protein kinase activity (PMID: 15550452).",295,,,www.uniprot.org,2472,15550452,The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk.,http://www.ncbi.nlm.nih.gov/pubmed/15550452,4653
"ERBB2 (HER2) I654V lies within the transmembrane domain of the Erbb2 (Her2) protein (UniProt.org). I654V is predicted to stabilize Erbb2 (Her2) dimerization, resulting in increased autophosphorylation and protein kinase activity (PMID: 15550452).",2472,15550452,The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk.,http://www.ncbi.nlm.nih.gov/pubmed/15550452,295,,,www.uniprot.org,4654
"TP53 P33R lies within the transactivation domain of the Tp53 protein (PMID: 22713868). P33R has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,4655
"TP53 G245A is a hotspot mutation that lies within the DNA binding domain of the Tp53 protein (PMID: 22713868). G245A results in decreased Tp53 transactivation of p21, and also confers a gain-of-function to the Tp53 protein as demonstrated by increased tumorigenesis in mouse models through direct transcriptional activation of SLC25A1 (PMID: 24681808, PMID: 20589832).",2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,2640,20589832,Restoration of DNA-binding and growth-suppressive activity of mutant forms of p53 via a PCAF-mediated acetylation pathway.,http://www.ncbi.nlm.nih.gov/pubmed/20589832,2455,24681808,"SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker.",http://www.ncbi.nlm.nih.gov/pubmed/24681808,4656
"TP53 G245C is a hotspot mutation that lies within the DNA binding domain of the Tp53 protein (PMID: 22713868). G245C results in a loss of wild-type Tp53 transactivation activity, and also confers a gain-of-function to Tp53, as demonstrated by increased cell growth and cancer cell metabolism through inhibition of Ampk (PMID: 24857548, PMID: 22170099).",2641,22170099,Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/22170099,2456,24857548,Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation.,http://www.ncbi.nlm.nih.gov/pubmed/24857548,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,4657
"TP53 G245D is a hotspot mutation that lies within the DNA binding domain of the Tp53 protein (PMID: 22713868). G245D results in decreased activation of p21, and also confers a gain-of-function to Tp53 as demonstrated by aberrant interaction with ZBP-89, increased cell viability and decreased apoptosis (PMID: 22214764).",2457,22214764,Interaction between ZBP-89 and p53 mutants and its contribution to effects of HDACi on hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22214764,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,4658
"TP53 G245R is a hotspot mutation that lies within the DNA binding domain of the Tp53 protein (PMID: 22713868). G245R has not been characterized, however other G245 mutations confer a loss of function to the Tp53 protein therefore, G245R is predicted to lead to a loss of Tp53 protein function (PMID: 22214764, PMID: 24857548, PMID: 24651012).",2458,24651012,Mutant p53 in cancer: new functions and therapeutic opportunities.,http://www.ncbi.nlm.nih.gov/pubmed/24651012,2456,24857548,Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation.,http://www.ncbi.nlm.nih.gov/pubmed/24857548,2457,22214764,Interaction between ZBP-89 and p53 mutants and its contribution to effects of HDACi on hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22214764,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,4660
"TP53 G245V is a hotspot mutation that lies within the DNA binding domain of the Tp53 protein (PMID: 22713868). G245V has not been characterized, however other G245 mutations confer a loss of function to the Tp53 protein thus, G245V is predicted to lead to a  loss of Tp53 protein function (PMID: 22214764, PMID: 24857548, PMID: 24651012) .  ",2458,24651012,Mutant p53 in cancer: new functions and therapeutic opportunities.,http://www.ncbi.nlm.nih.gov/pubmed/24651012,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,2456,24857548,Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation.,http://www.ncbi.nlm.nih.gov/pubmed/24857548,2457,22214764,Interaction between ZBP-89 and p53 mutants and its contribution to effects of HDACi on hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22214764,4661
"TP53 R158fs*11 likely results in a premature truncation of the 393 aa Tp53 protein at aa 158, followed by 11 nonsense amino acids (UniProt.org). Due to the disruption of the Tp53 DNA binding domain (UniProt.org), R158fs*11 is predicted to lead to a loss of Tp53 protein function.",295,,,www.uniprot.org,4662
"TP53 R175C is a hotspot mutation that lies within the DNA binding domain of the Tp53 protein (PMID: 22713868). R175C retains wild-type Tp53 function in apoptosis and cell cycle assays (PMID: 9632751, PMID: 24665023).",2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,2459,9632751,Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest.,http://www.ncbi.nlm.nih.gov/pubmed/9632751,4663
"TP53 R248E is a hotspot mutation that lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). R248E has not been characterized, however other R248 hotspot mutations result in a loss of function thus, R248E is predicted to lead to a loss of Tp53 protein function (PMID: 8208536, PMID: 24651012, PMID: 20570896).",2230,20570896,Dysregulation of p53/Sp1 control leads to DNA methyltransferase-1 overexpression in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20570896,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,2487,8208536,Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/8208536,2458,24651012,Mutant p53 in cancer: new functions and therapeutic opportunities.,http://www.ncbi.nlm.nih.gov/pubmed/24651012,4664
TP53 R248P is a hotspot mutation that lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). R248P confers a loss of function to the Tp53 protein as demonstrated by a lack of Tp53 transactivation function in cell culture (PMID: 8062826).,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,2162,8062826,Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation.,http://www.ncbi.nlm.nih.gov/pubmed/8062826,4666
"TP53 R249G is a hotspot mutation that lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). R249G results in decreased activation of Tp53 target genes, as well as increased proliferation and resistance to apoptosis in cell culture (PMID: 23246812).",371,23246812,Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.,http://www.ncbi.nlm.nih.gov/pubmed/23246812,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,4667
"TP53 R249K is a hotspot mutation that lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). R249K has not been characterized, but is predicted to result in a loss of Tp53 function due to the effect of other R249 mutations (PMID: 15037740, PMID: 23246812).",2460,15037740,A global suppressor motif for p53 cancer mutants.,http://www.ncbi.nlm.nih.gov/pubmed/15037740,371,23246812,Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.,http://www.ncbi.nlm.nih.gov/pubmed/23246812,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,4668
TP53 R249M is a hotspot mutation that lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). R249M confers a loss of function to the Tp53 protein as demonstrated by loss of Tp53 transcriptional activation in cultured cells (PMID: 15037740). ,2460,15037740,A global suppressor motif for p53 cancer mutants.,http://www.ncbi.nlm.nih.gov/pubmed/15037740,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,4669
"TP53 R249T is a hotspot mutation that lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). R249T has not been characterized, but is predicted to result in a loss of Tp53 function due to the effect of other R249 mutations and computer models (PMID: 15037740, PMID: 23246812, PMID: 9724739).",2460,15037740,A global suppressor motif for p53 cancer mutants.,http://www.ncbi.nlm.nih.gov/pubmed/15037740,2486,9724739,MEKK1/JNK signaling stabilizes and activates p53.,http://www.ncbi.nlm.nih.gov/pubmed/9724739,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,4670
"TP53 R249W is a hotspot mutation that lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). R249W results in increased proliferation and colony formation in cell culture, and confers a gain of function to Tp53 in the ability to repress TIMP-3 (PMID: 23612969, PMID: 16236433).",2488,16236433,Localization of a mutant p53 response element on the tissue inhibitor of metalloproteinase-3 promoter: mutant p53 activities are distinct from wild-type.,http://www.ncbi.nlm.nih.gov/pubmed/16236433,2224,23612969,A novel p53 mutant found in iatrogenic urothelial cancers is dysfunctional and can be rescued by a second-site global suppressor mutation.,http://www.ncbi.nlm.nih.gov/pubmed/23612969,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,4671
"TP53 R273P is a hotspot mutation that lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). R273P results in decreased activation of the Tp53 target gene p21, and exerts  a dominant-negative effect on wild-type Tp53 protein in cell culture (PMID: 22484423).",2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,2461,22484423,p53 modulates homologous recombination at I-SceI-induced double-strand breaks through cell-cycle regulation.,http://www.ncbi.nlm.nih.gov/pubmed/22484423,4672
"TP53 R273Y is a hotspot mutation that lies within the DNA binding domain of the Tp53 protein (PMID: 22713868). R273Y has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,4673
"TP53 R175G is a hotspot mutation that lies within the DNA binding domain of the Tp53 protein (PMID: 22713868). R175G has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4706
TP53 R175L is a hotspot mutation that lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). R175L results in a decrease in Tp53 transactivation activity and reduced ability to induce apoptosis in cell culture (PMID: 16707427).,2462,16707427,Identification of a novel germ line variant hotspot mutant p53-R175L in pediatric adrenal cortical carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/16707427,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,4707
TP53 R282del results in the deletion of an amino acid in the DNA-binding domain of the Tp53 protein at amino acid 282 (PMID: 22713868). R282del confers a loss of function to the Tp53 protein as demonstrated by loss of Tp53-mediated transcriptional activation in cell culture (PMID: 14690015).,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,2465,14690015,A novel dysfunctional p53 mutation in the human neuroblastoma cell line TGW.,http://www.ncbi.nlm.nih.gov/pubmed/14690015,4741
"TP53 R282fs results in a change in the amino acid sequence of the Tp53 protein beginning at aa 282 of 393, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the oligomerization domain (UniProt.org), R282fs is predicted to lead to a loss of Tp53 protein function.",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4742
"TP53 R282Q is a hotspot mutation that lies within the DNA binding domain of the Tp53 protein (PMID: 22713868). R282Q results in decreased activation of wild-type Tp53 targets, and additionally confers a gain of function to the Tp53 protein as demonstrated by activation of PCNA and MDR-1 in cell culture (PMID: 11920959).",2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,2466,11920959,Complex functions of mutant p53 alleles from human prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/11920959,4743
"TP53 R282W is a hotspot mutation that lies within the DNA binding domain of the Tp53 protein (PMID: 22713868). R282W results in decreased activation of Tp53 targets and inhibits Ampk signaling, leading to invasive growth and altered cell metabolism in culture and promotes tumor development in mouse models (PMID: 24857548).",2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,2456,24857548,Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation.,http://www.ncbi.nlm.nih.gov/pubmed/24857548,4744
"TP53 R282G is a hotspot mutation that lies within the DNA binding domain of the Tp53 protein (PMID: 22713868). R282G has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,4745
"TP53 R282H is a hotspot mutation that lies within the DNA binding domain of the Tp53 protein (PMID: 22713868). R282H has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4746
"TP53 R306* results in a premature truncation of the Tp53 protein at amino acid 306 of 393 within the Tp53 tetramerization domain (PMID: 22713868). Due to the loss of the majority of the tetramerization domain (UniProt.org), R306* is predicted to lead to a loss of Tp53 function.",2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,295,,,www.uniprot.org,4747
"TP53 T211S lies within the DNA binding domain of the Tp53 protein (PMID: 22713868). T211S has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4748
"TP53 V274F lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). V274F results in decreased Tp53 transactivation activity and reduced induction of apoptosis, but retains some context-dependent growth suppression in cell culture (PMID: 12782597). ",2467,12782597,Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells.,http://www.ncbi.nlm.nih.gov/pubmed/12782597,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,4749
TP53 Y234H is a hotspot mutation that lies within the DNA binding domain of the Tp53 protein (PMID: 22713868). Y234H confers a loss of function to the Tp53 protein as demonstrated by lack of Tp53 transactivation function in cell culture (PMID: 10871862). ,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,2468,10871862,Identification of a tumor-derived p53 mutant with novel transactivating selectivity.,http://www.ncbi.nlm.nih.gov/pubmed/10871862,4750
"SMO A338V lies within the heptahelical domain of the Smo protein (PMID: 20207148). A338V has not been characterized in the scientific literature and therefore, its effect on Smo protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2471,20207148,Evaluating Smoothened as a G-protein-coupled receptor for Hedgehog signalling.,http://www.ncbi.nlm.nih.gov/pubmed/20207148,4809
"SMO R628Q lies within the cytoplasmic tail domain of the Smo protein (PMID: 20207148). R628Q has not been characterized in the scientific literature and therefore, its effect on Smo protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2471,20207148,Evaluating Smoothened as a G-protein-coupled receptor for Hedgehog signalling.,http://www.ncbi.nlm.nih.gov/pubmed/20207148,4810
"SMO R726Q lies within the cytoplasmic tail domain of the Smo protein (PMID: 20207148). R726Q has been identified in the scientific literature (PMID: 23349881), but has not been biochemically characterized and therefore, its effect on Smo protein function is unknown (PubMed, Jun 2017).",8899,23349881,Mutations in the hedgehog pathway genes SMO and PTCH1 in human gastric tumors.,http://www.ncbi.nlm.nih.gov/pubmed/23349881,285,,,http://www.ncbi.nlm.nih.gov/pubmed,2471,20207148,Evaluating Smoothened as a G-protein-coupled receptor for Hedgehog signalling.,http://www.ncbi.nlm.nih.gov/pubmed/20207148,4811
"SMO V270I lies within helical domain 2 of the Smo protein (PMID: 20207148). V270I has been identified in sequencing studies (PMID: 26647218), but has not been biochemically characterized and therefore, its effect on Smo protein function is unknown (PubMed, Jan 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2471,20207148,Evaluating Smoothened as a G-protein-coupled receptor for Hedgehog signalling.,http://www.ncbi.nlm.nih.gov/pubmed/20207148,7258,26647218,Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas.,http://www.ncbi.nlm.nih.gov/pubmed/26647218,4812
"TP53 R248G is a hotspot mutation that lies within the DNA binding domain of the Tp53 protein (PMID: 22713868). R248G retains the ability to transactivate the Tp53 target gene PCNA, but also gains the ability to activate transcription of ABCB1 (PMID: 11920959).",2466,11920959,Complex functions of mutant p53 alleles from human prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/11920959,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,4813
"TP53 R123H lies within the DNA binding domain of the Tp53 protein (PMID: 11902578). R123H has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",3142,11902578,Assessing TP53 status in human tumours to evaluate clinical outcome.,http://www.ncbi.nlm.nih.gov/pubmed/11902578,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4891
"ALK T680I lies within the MAM2 domain of the Alk protein (UniProt.org). T680I has been identified in sequencing studies (PMID: 25589003) but has not been biochemically characterized and therefore, its effect on Alk protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,6992,25589003,Sporadic hemangioblastomas are characterized by cryptic VHL inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/25589003,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4899
"SRC act mut indicates that this variant results in a gain of function in the Src protein. However, the specific amino acid change has not been identified. ",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,4903
"ERBB2 (HER2) D769N lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). D769N has been identified in the scientific literature (PMID: 25809292), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7971,25809292,Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25809292,4914
"ERBB2 (HER2) G776C lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). G776C has been identified in the scientific literature (PMID: 22761469), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,7975,22761469,"Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/22761469,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4915
"PIK3CA A1046V lies within the PI3K/PI4K protein kinase domain of the Pik3ca protein (UniProt.org). A1046V has been identified in the scientific literature (PMID: 23107319, PMID: 26796526), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,8021,23107319,A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23107319,8022,26796526,Frequency and clinicopathologic profile of PIK3CA mutant GISTs: molecular genetic study of 529 cases.,http://www.ncbi.nlm.nih.gov/pubmed/26796526,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4916
"PIK3CA C901Y lies within the PI3K/PI4K protein kinase domain of the Pik3ca protein (UniProt.org). C901Y has not been characterized in the scientific literature and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4917
PIK3CA D1029Y lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). D1029Y results in increased phosphorylation of Akt and is transforming in cell culture (PMID: 19394761).,295,,,www.uniprot.org,2246,19394761,Oncogenic mutation of PIK3CA in small cell lung carcinoma: a potential therapeutic target pathway for chemotherapy-resistant lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19394761,4918
"PIK3CA E453G lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). E453G has been identified in sequencing studies (PMID: 26832993), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8370,26832993,"Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression.",http://www.ncbi.nlm.nih.gov/pubmed/26832993,4919
"PIK3CA E81* results in a premature truncation of the Pik3ca protein at amino acid 81 of 1068 (UniProt.org). Due to the loss of PI3K/PI4K kinase domain (UniProt.org), E81* is predicted to lead to a loss of Pik3ca function.",295,,,www.uniprot.org,4920
"NOTCH1 over exp indicates an over expression of the Notch1 protein. However, the mechanism causing the over expression is unspecified.
",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,4934
"PIK3CA E542A lies within the PIK helical domain of the Pik3ca protein (UniProt.org, PMID: 25559818). E542A has been identified in sequencing studies (PMID: 25559818), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Mar 2017).",3375,25559818,PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25559818,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4940
"PIK3CA E542G lies within the PIK helical domain of the Pik3ca protein (UniProt.org). E542G has been identified in the scientific literature (PMID: 17990317), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Mar 2017).",8371,17990317,Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17990317,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4941
"PIK3CA G1049C lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). G1049C has been identified in sequencing studies (PMID: 23266353), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Mar 2017).",8375,23266353,PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy.,http://www.ncbi.nlm.nih.gov/pubmed/23266353,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4943
"PIK3CA G1049D lies within the PI3K/PI4K protein kinase domain of the Pik3ca protein (UniProt.org). G1049D has been identified in sequencing studies (PMID: 24062397), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8374,24062397,Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24062397,4944
"PIK3CA H1047P lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). H1047P has not been characterized, however other H1047 mutations result in constitutive activation of the Pik3ca protein, thus H1047P is predicted to result in a gain of function (PMID: 17376864).",101,17376864,Rare cancer-specific mutations in PIK3CA show gain of function.,http://www.ncbi.nlm.nih.gov/pubmed/17376864,295,,,www.uniprot.org,4959
"PIK3CA H1048L lies within the PI3K/PI4K protein kinase domain of the Pik3ca protein (UniProt.org). H1048L has not been characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4960
"PIK3CA H701R does not lie within any known functional domains of the Pik3ca protein (UniProt.org). H701R has not been characterized in the scientific literature and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4961
"PIK3CA M1040I lies within the PI3K/PI4K protein kinase domain of the Pik3ca protein (UniProt.org). M1040I has been identified in the scientific literature (PMID: 28240010), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,8883,28240010,PIK3CA mutations in HER2-positive Breast Cancer Patients; Frequency and Clinicopathological Perspective in Egyptian Patients,http://www.ncbi.nlm.nih.gov/pubmed/28240010,295,,,www.uniprot.org,4962
"PIK3CA N1044Y lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). N1044Y has not been characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4963
"PIK3CA Q75K lies within the PI3K-ABD domain of the Pik3ca protein (UniProt.org). Q75K has not been characterized in the scientific literature and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4964
"PIK3CA R1023L lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). R1023L has been identified in the scientific literature (PMID: 19844788), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,8894,19844788,Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19844788,295,,,www.uniprot.org,4965
"PIK3CA S405Y lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). S405Y has not been characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4966
"PIK3CA T544I lies within the PIK helical domain of the Pik3ca protein (UniProt.org). T544I has been identified in the scientific literature (PMID: 25073438, PMID: 26276776), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8060,26276776,Distinct β-catenin and PIK3CA mutation profiles in endometriosis-associated ovarian endometrioid and clear cell carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/26276776,8139,25073438,"Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/25073438,4967
PIK3CA V344A lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). V344A demonstrates AKT phosphorylation similar to wild-type Pik3ca protein in cell culture (PMID: 21266528).,2211,21266528,A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/21266528,295,,,www.uniprot.org,4968
"PIK3CA Y1021N lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). Y1021N has been identified in the scientific literature (PMID: 22949056, PMID: 15289301), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7392,22949056,Phosphatidylinositol-3-kinase α catalytic subunit gene somatic mutations in bronchopulmonary neuroendocrine tumours.,http://www.ncbi.nlm.nih.gov/pubmed/22949056,8156,15289301,"Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.",http://www.ncbi.nlm.nih.gov/pubmed/15289301,4969
"BRAF D587G lies within the protein kinase domain of the Braf protein (UniProt.org). D587G has not been characterized in the scientific literature and therefore, its effect on Braf protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4983
"BRAF D594A lies within the protein kinase domain of the Braf protein (UniProt.org). D594A results in a loss of Braf kinase activity, however, activates Mek and Erk through transactivation of CRAF in cell culture and mouse models (PMID: 20141835, PMID: 20978199, PMID: 28783719).",295,,,www.uniprot.org,424,20141835,Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.,http://www.ncbi.nlm.nih.gov/pubmed/20141835,2517,20978199,BRAF inactivation drives aneuploidy by deregulating CRAF.,http://www.ncbi.nlm.nih.gov/pubmed/20978199,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,4984
"BRAF G469L is a hotspot mutation within the protein kinase domain of the Braf protein (UniProt.org). G469L has not been characterized, however other G649 hotspot mutations are activating thus, G469L is predicted to result in a gain of Braf protein function (PMID: 19010912, PMID: 12068308).",637,12068308,Mutations of the BRAF gene in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/12068308,295,,,www.uniprot.org,636,19010912,Genetic predictors of MEK dependence in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19010912,4985
"BRAF G596fs*2 likely results in a truncation of the 766 aa Braf protein at aa 596 followed by 2 nonsense amino acids (UniProt.org). Due to the disruption of the protein kinase domain (UniProt.org), G596fs*2 is predicted to lead to a loss of Braf protein function.",295,,,www.uniprot.org,4986
"BRAF G606A lies within the protein kinase domain of the Braf protein (UniProt.org). G606A has been identified in sequencing studies (PMID: 21825258), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Jun 2017).",7103,21825258,Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.,http://www.ncbi.nlm.nih.gov/pubmed/21825258,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4987
"BRAF G606V lies within the protein kinase domain of the Braf protein (UniProt.org). G606V has been identified in sequencing studies (PMID: 21825258), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Jun 2017).",7103,21825258,Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.,http://www.ncbi.nlm.nih.gov/pubmed/21825258,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4988
"BRAF L597P lies within the protein kinase domain of the Braf protein (UniProt.org). L597P has not been characterized, however other L597 hotspot mutations are activating thus, L597P is predicted to lead to a gain of Braf protein function (PMID: 22798288). ",3,22798288,BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/22798288,295,,,www.uniprot.org,4989
BRAF N581I lies within the protein kinase domain of the Braf protein (UniProt.org). N581I results in low Braf kinase activity and Ras-dependent activation of Erk signaling in cell culture (PMID: 28783719).,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,295,,,www.uniprot.org,4990
"BRAF N581T lies within the protein kinase domain of the Braf protein (UniProt.org). N581T has been identified in sequencing studies (PMID: 22842228), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Jun 2017).",7109,22842228,Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22842228,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4991
"PTEN A121T lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). A121T has been identified in the scientific literature (PMID: 24336570), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",8034,24336570,Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma.,http://www.ncbi.nlm.nih.gov/pubmed/24336570,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4992
"PTEN A126fs*8 likely results in a truncation of the 403 aa Pten protein at aa 126, followed by 8 nonsense amino acids within the phosphatase tensin-type domain (UniProt.org). A126fs*8 has not been characterized, however, other C-terminal deletion mutants downstream of A126 are inactivating (PMID: 10468583), thus A126fs*8 is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4993
"PTEN C124Y lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). C124Y has been identified in sequencing studies (PMID: 12695913), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",8039,12695913,Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in advanced gastric carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/12695913,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4994
"PTEN D107H lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). D107H has not been characterized in the scientific literature and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4995
"PTEN D107N lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). D107N has been identified in the scientific literature (PMID: 19471547, PMID: 26800850), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,8037,19471547,Pharmacogenomic profiling of the PI3K/PTEN pathway in sporadic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19471547,9905,26800850,Prediction of functionally significant single nucleotide polymorphisms [SNPs] in PTEN tumor suppressor gene: An in silico approach.,http://www.ncbi.nlm.nih.gov/pubmed/26800850,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4996
"PTEN D252V lies within the C2 tensin-type domain of the Pten protein (UniProt.org). D252V has been identified in sequencing studies (PMID: 25527629), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2323,25527629,Functionally distinct groups of inherited PTEN mutations in autism and tumour syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25527629,4997
"PTEN E242K lies within the C2 tensin-type domain of the Pten protein (UniProt.org). E242K has been identified in sequencing studies (PMID: 15069681), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8045,15069681,Molecular alterations associated with cyclin D1 overexpression in endometrial cancer.,http://www.ncbi.nlm.nih.gov/pubmed/15069681,4998
"PTEN E256* results in a premature truncation of the Pten protein at amino acid 256 of 403 (UniProt.org). E256* has not been characterized, however, other C-terminal deletion mutants downstream of E256 are inactivating (PMID: 10468583), thus E256* is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,4999
"PTEN E256Q lies within the C2 tensin-type domain of the Pten protein (UniProt.org). E256Q has been identified in sequencing studies (PMID: 23633456), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,8033,23633456,PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23633456,295,,,www.uniprot.org,5000
"PTEN E288K lies within the C2 tensin-type domain of the Pten protein (UniProt.org). E288K has been identified in sequencing studies (PMID: 10955808), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8047,10955808,Somatic mutation of PTEN in vulvar cancer.,http://www.ncbi.nlm.nih.gov/pubmed/10955808,5001
"PTEN E291K lies within the C2 tensin-type domain of the Pten protein (UniProt.org). E291K has been identified in sequencing studies (PMID: 15923161), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",7866,15923161,Association of mismatch repair deficiency with PTEN frameshift mutations in endometrial cancers and the precursors in a Japanese population.,http://www.ncbi.nlm.nih.gov/pubmed/15923161,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5002
"PTEN G132C lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). G132C has not been characterized in the scientific literature and therefore, its effect on Pten protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5003
"PTEN G132V lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). G132V has been identified in sequencing studies (PMID: 10096247), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,8041,10096247,Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations.,http://www.ncbi.nlm.nih.gov/pubmed/10096247,295,,,www.uniprot.org,5004
"PTEN G165* results in a premature truncation of the Pten protein at amino acid 165 of 403 (UniProt.org). G165* has not been characterized, however, other C-terminal deletion mutants downstream of G165 are inactivating (PMID: 10468583), thus G165* is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,5005
PTEN G165V lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). G165V results in a loss of Pten phosphatase activity in yeast (PMID: 21828076).,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,295,,,www.uniprot.org,5006
"PTEN G251A lies within the C2 tensin-type domain of the Pten protein (UniProt.org). G251A has not been characterized in the scientific literature and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5007
"PTEN G251S lies within the C2 tensin-type domain of the Pten protein (UniProt.org). G251S has not been characterized in the scientific literature and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5008
"PTEN G251V lies within the C2 tensin-type domain of the Pten protein (UniProt.org). G251V has been identified in the scientific literature (PMID: 27148581), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",8050,27148581,A common founding clone with TP53 and PTEN mutations gives rise to a concurrent germ cell tumor and acute megakaryoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27148581,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5009
"PTEN G293V lies within the C2 tensin-type domain of the Pten protein (UniProt.org). G293V has been identified in sequencing studies (PMID: 22653804), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",7748,22653804,Use of mutation profiles to refine the classification of endometrial carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/22653804,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5010
"PTEN H61L lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). H61L has been identified in sequencing studies (PMID: 10092130), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,8052,10092130,Analysis of PTEN mutations and deletions in B-cell non-Hodgkin's lymphomas.,http://www.ncbi.nlm.nih.gov/pubmed/10092130,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5011
"PTEN I253T lies within the C2 tensin-type domain of the Pten protein (UniProt.org). I253T has not been characterized in the scientific literature and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5012
"PTEN K125* results in a premature truncation of the Pten protein at amino acid 125 of 403 (UniProt.org). K125* has not been characterized, however, other C-terminal deletion mutants downstream of K125 are inactivating (PMID: 10468583), thus K125* is predicted to lead to a loss of Pten protein function.",295,,,www.uniprot.org,2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,5013
"PTEN K13* results in a premature truncation of the Pten protein at amino acid 13 of 403 (UniProt.org). Due to the loss of the phosphatase tensin-type domain (UniProt.org), K13* is predicted to lead to a loss of Pten function.",295,,,www.uniprot.org,5014
PTEN K13Q lies within the polybasic N-terminal motif of the Pten protein (PMID: 14711368). K13Q results in a loss of Pten phosphatase activity in cultured cells (PMID: 16088943).,2359,14711368,The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif.,http://www.ncbi.nlm.nih.gov/pubmed/14711368,2519,16088943,PTEN enters the nucleus by diffusion.,http://www.ncbi.nlm.nih.gov/pubmed/16088943,5015
"PTEN K322E lies within the C2 tensin-type domain of the Pten protein (UniProt.org). K322E has not been characterized in the scientific literature and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5016
"PTEN K60T lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). K60T has been identified in the scientific literature (PMID: 24647592), but has not been biochemically characterized in the scientific literature and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9958,24647592,"PTEN mutation, loss of heterozygosity, promoter methylation and expression in colorectal carcinoma: two hits on the gene?",http://www.ncbi.nlm.nih.gov/pubmed/24647592,5017
"PTEN K66fs*36 likely results in a truncation of the 403 aa Pten protein at aa 66, followed by 36 nonsense amino acids within the phosphatase tensin-type domain (UniProt.org). Due to the loss of the phosphatase tensin-type domain (UniProt.org), K66fs*36 is predicted to lead to a loss of Pten function.",295,,,www.uniprot.org,5018
"BRAF R462K lies within the protein kinase domain of the Braf protein (UniProt.org). R462K has not been characterized in the scientific literature and therefore, its effect on Braf protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5019
"PTEN K66Q lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). K66Q has been identified in sequencing studies (PMID: 10851265), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,8057,10851265,Expression of PTEN and PTEN pseudogene in endometrial carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/10851265,295,,,www.uniprot.org,5020
PTEN L108P lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). L108P results in a loss of Pten phosphatase activity and is unable to suppress Akt activation in cell culture (PMID: 25527629).,2323,25527629,Functionally distinct groups of inherited PTEN mutations in autism and tumour syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25527629,295,,,www.uniprot.org,5021
"PTEN L112I lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). L112I has not been characterized in the scientific literature and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5022
"PTEN L57fs*42 likely results in a truncation of the 403 aa Pten protein at aa 57, followed by 42 nonsense amino acids within the phosphatase tensin-type domain (UniProt.org). Due to the loss of the phosphatase tensin-type domain (UniProt.org), L57fs*42 is predicted to lead to a loss of Pten function.",295,,,www.uniprot.org,5023
"PTEN N323K lies within the C2 tensin-type domain of the Pten protein (UniProt.org). N323K has been identified in the scientific literature (PMID: 14724591), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",8072,14724591,PTEN mutations are common in sporadic microsatellite stable colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/14724591,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5024
"PTEN N323T lies within the C2 tensin-type domain of the Pten protein (UniProt.org). N323T has not been characterized in the scientific literature and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5025
"PTEN P248H lies within the C2 tensin-type domain of the Pten protein (UniProt.org). P248H has not been characterized in the scientific literature and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5026
"PTEN P248L lies within the C2 tensin-type domain of the Pten protein (UniProt.org). P248L has not been characterized in the scientific literature and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5027
"PTEN Q110K lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). Q110K has not been characterized in the scientific literature and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5028
BRAF T599_V600insDFGLAT results in the insertion of six amino acids in the protein kinase domain of the Braf protein between amino acids 599 and 600 (UniProt.org). T599_V600insDFGLAT results in increased colony formation and downstream Mapk and Erk pathway activation in cultured cells (PMID: 17297294).,295,,,www.uniprot.org,2112,17297294,Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17297294,5029
"PTEN Q298fs*9 likely results in a truncation of the 403 aa Pten protein at aa 298, followed by 9 nonsense amino acids within the C2 tensin-type domain (UniProt.org). Q298fs*9 has not been characterized, however, other C-terminal deletion mutants downstream of Q298 are inactivating (PMID: 10468583), thus Q298fs*9 is predicted to lead to a loss of Pten protein function.",295,,,www.uniprot.org,2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,5030
"PTEN R14fs*10 likely results in a truncation of the 403 aa Pten protein at aa 14 followed by 10 nonsense amino acids within the phosphatase tensin-type domain (UniProt.org). Due to the loss of the phosphatase tensin-type domain (UniProt.org), R14fs*10 is predicted to lead to a loss of Pten function.",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5031
"PTEN R15K lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). R15K confers a loss of function to the Pten protein, as indicated by a loss of phosphatase activity in yeast (PMID: 25875300).
",295,,,www.uniprot.org,4506,25875300,A functional dissection of PTEN N-terminus: implications in PTEN subcellular targeting and tumor suppressor activity.,http://www.ncbi.nlm.nih.gov/pubmed/25875300,5032
"PTEN R335G lies within the C2 tensin-type domain of the Pten protein (UniProt.org). R335G has not been characterized in the scientific literature and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5033
"PTEN S10I lies within the polybasic N-terminal motif of the Pten protein (PMID: 14711368). S10I has been identified in sequencing studies (PMID: 19340001), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2359,14711368,The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif.,http://www.ncbi.nlm.nih.gov/pubmed/14711368,2634,19340001,"The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.",http://www.ncbi.nlm.nih.gov/pubmed/19340001,5034
"PTEN S59L lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). S59L has been identified in sequencing studies (PMID: 19962665), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2679,19962665,Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.,http://www.ncbi.nlm.nih.gov/pubmed/19962665,5035
"PTEN T131A lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). T131A has not been fully biochemically characterized, however, results in decreased Pten phosphatase activity (PMID: 21828076).",2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,295,,,www.uniprot.org,5036
"PTEN T131P lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). T131P has been identified in the scientific literature (PMID: 24630729, PMID: 17504928), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",9971,17504928,Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/17504928,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8132,24630729,Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/24630729,5037
PTEN T167P lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). T167P results in decreased Pten phosphatase activity in cell culture (PMID: 9256433).       ,295,,,www.uniprot.org,4461,9256433,"P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase.",http://www.ncbi.nlm.nih.gov/pubmed/9256433,5038
"BRAF T599_V600insEAT results in the insertion of 3 amino acids in the protein kinase domain of the Braf protein between amino acids 599 and 600 (UniProt.org). T599_V600insEAT has not been characterized, however other insertions between T599 and V600 are activating thus, T599_V600insEAT is predicted to lead to a gain of Braf protein function (PMID: 16501605, PMID: 17297294, PMID: 21190184).",1910,21190184,Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma.,http://www.ncbi.nlm.nih.gov/pubmed/21190184,2112,17297294,Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17297294,1892,16501605,Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/16501605,5039
"PTEN Y16fs*1 likely results in a truncation of the 403 aa Pten protein at aa 16 followed by 1 nonsense amino acid within the phosphatase tensin-type domain (UniProt.org). Due to the loss of the phosphatase tensin-type domain (UniProt.org), Y16fs*1 is predicted to lead to a loss of Pten function.",295,,,www.uniprot.org,5040
"PTEN Y177F lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). Y177F has not been characterized in the scientific literature and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5041
"PTEN Y177S lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). Y177S has been identified in sequencing studies (PMID: 23917401), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",3963,23917401,The integrated landscape of driver genomic alterations in glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/23917401,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5042
"PTEN Y68N lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). Y68N has been identified in the scientific literature (PMID: 24744697), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,8125,24744697,Subcellular targeting and dynamic regulation of PTEN: implications for neuronal cells and neurological disorders.,http://www.ncbi.nlm.nih.gov/pubmed/24744697,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5043
"BRAF T599_V600insETT results in the insertion of 3 amino acids in the protein kinase domain of the Braf protein between amino acids 599 and 600 (UniProt.org). BRAF T599_V600insETT has not been characterized, however other insertions between T599 and V600 are activating thus, T599_V600insETT is predicted to lead to a gain of Braf protein function (PMID: 16501605, PMID: 17297294, PMID: 21190184).",1892,16501605,Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/16501605,1910,21190184,Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma.,http://www.ncbi.nlm.nih.gov/pubmed/21190184,2112,17297294,Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17297294,5044
"BRAF V471I lies within the protein kinase domain of the Braf protein (UniProt.org). V471I has been identified in sequencing studies (PMID: 23103869), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6989,23103869,Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes.,http://www.ncbi.nlm.nih.gov/pubmed/23103869,5045
"BRAF V600fs*11 likely results in a premature truncation of the 766 aa Braf protein at aa 600, followed by 11 nonsense amino acids within the protein kinase domain (UniProt.org). Due to the disruption of the protein kinase domain, V600fs*11 is predicted to lead to a loss of Braf protein function (UniProt.org).",295,,,www.uniprot.org,5046
"BRAF V600G (previously reported as V599) lies within the activation segment of the kinase domain of the Braf protein (PMID: 15035987). V600G results in elevated Mek activity compared to wild-type and therefore, confers a gain of function to the Braf protein (PMID: 15035987). ",295,,,www.uniprot.org,146,15035987,Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.,http://www.ncbi.nlm.nih.gov/pubmed/15035987,5047
"BRAF W604R lies within the protein kinase domain of the Braf protein (UniProt.org). W604R has been identified in sequencing studies (PMID: 21825258, PMID: 23833300), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7103,21825258,Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.,http://www.ncbi.nlm.nih.gov/pubmed/21825258,5855,23833300,"Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/23833300,5048
"ALK F1174S lies within the protein kinase domain of the Alk protein (UniProt.org). F1174S results in ligand-independent activation of the Alk protein, increased Erk phosphorylation, and transformation of cells in culture (PMID: 21059859).",295,,,www.uniprot.org,2520,21059859,Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy.,http://www.ncbi.nlm.nih.gov/pubmed/21059859,5051
"ALK R1275L is a hotspot mutation that lies within protein kinase domain of the Alk protein (UniProt.org, PMID: 18923525, PMID: 21242967). R1275L has been identified in sequencing studies (PMID: 25517749), but has not been biochemically characterized and therefore, its effect on Alk protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,4535,25517749,ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/25517749,1947,21242967,The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking.,http://www.ncbi.nlm.nih.gov/pubmed/21242967,296,18923525,Activating mutations in ALK provide a therapeutic target in neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/18923525,5052
"CTNNB1 G34* results in a premature truncation of the Ctnnb1 protein at amino acid 34 of 781 (UniProt.org). Due to the loss of all known functional domains of Ctnnb1, G34* is predicted to lead to a loss of function (UniProt.org).",295,,,www.uniprot.org,5053
"CTNNB1 G38A does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). G38A has been identified in the scientific literature (PMID: 11520139), but has not been biochemically characterized and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Mar 2017).",8342,11520139,Cytoplasmic/nuclear expression without mutation of exon 3 of the beta-catenin gene is frequent in the development of the neoplasm of the uterine cervix.,http://www.ncbi.nlm.nih.gov/pubmed/11520139,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5054
"CTNNB1 G38V lies adjacent to the ubiquitination recognition motif of the Ctnnb1 protein (PMID: 9233789). G38V has not been characterized in the scientific literature and therefore, its effect in Ctnnb1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2301,9233789,beta-catenin is a target for the ubiquitin-proteasome pathway.,http://www.ncbi.nlm.nih.gov/pubmed/9233789,5055
CTNNB1 I35N lies within the ubiquitination recognition motif of the Ctnnb1 protein (PMID: 15064718). I35N is predicted to confer a gain of function to the Ctnnb1 protein as demonstrated by nuclear localization of Ctnnb1 (PMID: 10487827). ,408,15064718,Phosphorylation and ubiquitination of oncogenic mutants of beta-catenin containing substitutions at Asp32.,http://www.ncbi.nlm.nih.gov/pubmed/15064718,2342,10487827,Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation.,http://www.ncbi.nlm.nih.gov/pubmed/10487827,5056
"CTNNB1 L31M lies adjacent to the ubiquitin recognition motif of the Ctnnb1 protein (PMID: 15064718). L31M has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Mar 2017).",408,15064718,Phosphorylation and ubiquitination of oncogenic mutants of beta-catenin containing substitutions at Asp32.,http://www.ncbi.nlm.nih.gov/pubmed/15064718,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5057
"CTNNB1 P44H lies adjacent to the Gsk3b phosphorylation priming site (PMID: 12051714). P44H has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2320,12051714,Characterisation of the phosphorylation of beta-catenin at the GSK-3 priming site Ser45.,http://www.ncbi.nlm.nih.gov/pubmed/12051714,5058
"CTNNB1 S29Y lies within a Gsk3b phosphorylation site of the Ctnnb1 protein (PMID: 12027456). S29Y has been identified in sequencing studies (PMID: 16356174), but has not been biochemically characterized and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",2328,12027456,Identification of two novel regulated serines in the N terminus of beta-catenin.,http://www.ncbi.nlm.nih.gov/pubmed/12027456,7303,16356174,"Mutations in APC, CTNNB1 and K-ras genes and expression of hMLH1 in sporadic colorectal carcinomas from the Netherlands Cohort Study.",http://www.ncbi.nlm.nih.gov/pubmed/16356174,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5059
"S33T lies within the ubiquitination recognition motif of the Ctnnb1 protein and occurs at a Gsk3b phosphorylation site on the Ctnnb1 protein (PMID: 15064718). S33T has not been characterized, however other S33 hotspot mutations are activating thus, S33T is predicted to result in a gain of Ctnnb1 function (PMID: 19582367, PMID: 18757411, PMID: 15829978).",461,15829978,Functional correlates of mutation of the Asp32 and Gly34 residues of beta-catenin.,http://www.ncbi.nlm.nih.gov/pubmed/15829978,2330,19582367,CTNNB1 (beta-catenin) mutation is rare in brain tumours but involved as a sporadic event in a brain metastasis.,http://www.ncbi.nlm.nih.gov/pubmed/19582367,408,15064718,Phosphorylation and ubiquitination of oncogenic mutants of beta-catenin containing substitutions at Asp32.,http://www.ncbi.nlm.nih.gov/pubmed/15064718,2332,18757411,Illegitimate WNT pathway activation by beta-catenin mutation or autocrine stimulation in T-cell malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/18757411,5061
"ALK G1269A lies within the protein kinase domain of the Alk protein (UniProt.org). G1269A has not been biochemically characterized, but has been demonstrated to occur as a secondary resistance mutation in the context of ALK rearrangement (PMID: 23344087, PMID: 22235099).",295,,,www.uniprot.org,2523,23344087,Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23344087,2524,22235099,Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22235099,5063
"ALK I1171T lies within the protein kinase domain of the Alk protein (UniProt.org). I1171T has not been biochemically characterized, however, another mutation at codon 1171 is predicted to result in a locked active conformation of the Alk protein resulting in Alk inhibitor resistance in the context of multiple ALK fusions and is thus, predicted to confer a gain of function (PMID: 27009859).",295,,,www.uniprot.org,1898,24509625,Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/24509625,5064
"GNA11 Q209* results in a premature truncation of the Gna11 protein at amino acid 209 of 359 (UniProt.org). Due to disruption of the GTPase domain (PMID: 27647839), Q209* is predicted to lead to a loss of Gna11 protein function.",8759,27647839,Disorders of the calcium-sensing receptor and partner proteins: insights into the molecular basis of calcium homeostasis.,http://www.ncbi.nlm.nih.gov/pubmed/27647839,295,,,www.uniprot.org,5065
"CTNNB1 S45fs*2 likely results in a premature truncation of the 781 aa Ctnnb1 protein at aa 45, followed by 2 nonsense amino acids (UniProt.org). Due to the loss of all armadillo domains of Ctnnb1, S45fs*2 is predicted to confer loss of function to the Ctnnb1 protein (UniProt.org).",295,,,www.uniprot.org,5071
CTNNB1 S45T lies within a Gsk3b phosphorylation site on the Ctnnb1 protein (UniProt.org). S45T is predicted to confer a gain of function to the Ctnnb1 protein as demonstrated by nuclear accumulation of Ctnnb1 (PMID: 11443619).,2528,11443619,beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance.,http://www.ncbi.nlm.nih.gov/pubmed/11443619,295,,,www.uniprot.org,5072
"EGFR L747* results in a premature truncation of the Egfr protein at amino acid 747 of 1210 (UniProt.org). Due to the loss of a majority of the protein kinase domain including the C-terminal portion of the ATP binding site (UniProt.org), L747* is predicted to lead to a loss of Egfr protein function. ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5073
"MET H1124Y (corresponds to H1106Y in the canonical isoform) lies within the protein kinase domain of the Met protein (UniProt.org). H1124Y has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5074
"MET N1118D (corresponds to N1100D in the canonical isoform) lies within the protein kinase domain of the Met protein (UniProt.org). N1118D has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5075
"MET R988S (corresponds to R970S in the canonical) lies within the cytoplasmic domain of the Met protein (UniProt.org). R988S has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Feb 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5076
"PDGFRA D842F lies within the protein kinase domain of the Pdgfra protein (UniProt.org). D842F has been identified in the scientific literature (PMID: 18657298), but has not been biochemically characterized and therefore, its effect on Pdgfra protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7712,18657298,A gastrointestinal stromal tumor of the stomach morphologically resembling a neurofibroma: demonstration of a novel platelet-derived growth factor receptor alpha exon 18 mutation.,http://www.ncbi.nlm.nih.gov/pubmed/18657298,5077
"PDGFRA D842H lies within the protein kinase domain of the Pdgfra protein (UniProt.org). D842H demonstrates autophosphorylation, Stat5 activation, and transforming ability similar to wild-type Pdgfra protein in cell culture (PMID: 20972453).",295,,,www.uniprot.org,5809,20972453,The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro.,http://www.ncbi.nlm.nih.gov/pubmed/20972453,5079
"PDGFRA V527A lies within the extracellular domain of the Pdgfra protein (UniProt.org). V527A has not been characterized in the scientific literature and therefore, its effect on Pdgfra protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5080
PDGFRA V561A lies within the cytoplasmic domain of the Pdgfra protein (UniProt.org). V561A results in increased phosphorylation of Pdgfra in cultured cells (PMID: 24132921).,295,,,www.uniprot.org,2242,24132921,Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib.,http://www.ncbi.nlm.nih.gov/pubmed/24132921,5082
"MET V37A lies within the Sema domain of the Met protein (UniProt.org). V37A has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5083
"MET Y1253H (corresponds to Y1235H in the canonical isoform) lies in a phosphorylation site within the protein kinase domain of the Met protein (UniProt.org). Y1253H has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5084
"MET Y1253N (corresponds to Y1235N in the canonical isoform) lies in a phosphorylation site within the protein kinase domain of the Met protein (UniProt.org). Y1253N has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5085
"KIT D820A lies within the protein kinase domain of the Kit protein (UniProt.org). D820A has not been biochemically characterized, but has been demonstrated to occur as a secondary drug resistance mutation in Kit (PMID: 17208434).",3381,17208434,KIT mutations in GIST.,http://www.ncbi.nlm.nih.gov/pubmed/17208434,295,,,www.uniprot.org,5086
"KIT D820E lies within the protein kinase domain of the Kit protein (UniProt.org). D820E is predicted to confer a gain-of-function to Kit, and is associated with secondary drug resistance (PMID: 22937135, PMID: 16294026, PMID: 19861442). ",4325,19861442,Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance.,http://www.ncbi.nlm.nih.gov/pubmed/19861442,2016,22937135,Prevalence of c-KIT mutations in gonadoblastoma and dysgerminomas of patients with disorders of sex development (DSD) and ovarian dysgerminomas.,http://www.ncbi.nlm.nih.gov/pubmed/22937135,295,,,www.uniprot.org,4324,16294026,Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes.,http://www.ncbi.nlm.nih.gov/pubmed/16294026,5087
KIT D820N lies within the protein kinase domain of the Kit protein (UniProt.org). D820N is predicted to lead to activation of Kit based on molecular modeling (PMID: 18628470).,295,,,www.uniprot.org,2529,18628470,Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1.,http://www.ncbi.nlm.nih.gov/pubmed/18628470,5088
"KIT K509R lies within the extracellular domain of the Kit protein (UniProt.org). K509R has not been characterized in the scientific literature and therefore, its effect on Kit protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5089
"KIT K558* results in a premature truncation of the Kit protein at amino acid 558 of 976 (UniProt.org). Due to the loss of protein kinase domain (UniProt.org), K558* is predicted to lead to a loss of Kit function.",295,,,www.uniprot.org,5090
"KIT K558E lies within the juxtamembrane domain of the Kit protein (PMID: 16226710). K558E has been identified in sequencing studies (PMID: 21387320), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Sep 2017).",7403,21387320,Mutational status of KIT and PDGFRA and expression of PDGFRA are not associated with prognosis after curative resection of primary gastrointestinal stromal tumors (GISTs).,http://www.ncbi.nlm.nih.gov/pubmed/21387320,648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5091
"KIT K558N lies within the juxtamembrane domain of the Kit protein (PMID: 16226710). K558N has been identified in sequencing studies (PMID: 21326036), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Sep 2017).",648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,7404,21326036,The activated targets of mTOR signaling pathway are characteristic for PDGFRA mutant and wild-type rather than KIT mutant GISTs.,http://www.ncbi.nlm.nih.gov/pubmed/21326036,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5092
"KIT K558R lies within the juxtamembrane domain of the Kit protein (PMID: 16226710). K558R has been identified in sequencing studies (PMID: 24522528), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7405,24522528,Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia.,http://www.ncbi.nlm.nih.gov/pubmed/24522528,648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,5093
"CTNNB1 V22G lies adjacent to a Gsk3b phosphorylation site on the Ctnnb1 protein (PMID: 12027456). V22G has been identified in sequencing studies (PMID: 20923573), but has not been biochemically characterized and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7310,20923573,Genetic and epigenetic characteristics of human multiple hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/20923573,2328,12027456,Identification of two novel regulated serines in the N terminus of beta-catenin.,http://www.ncbi.nlm.nih.gov/pubmed/12027456,5094
"CTNNB1 T40S lies adjacent to a Gsk3b phosphorylation site on the Ctnnb1 protein (UniProt.org). T40S has been identified in sequencing studies (PMID: 22744289), but has not been biochemically characterized and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7304,22744289,Role of tumor-associated macrophages and angiogenesis in desmoid-type fibromatosis.,http://www.ncbi.nlm.nih.gov/pubmed/22744289,5095
"CTNNB1 T42K does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). T42K has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5096
"CTNNB1 T42_A43insSS results in the insertion of two serines (S) within a phosphorylation cluster required for degradation of the Ctnnb1 protein between amino acids 42 and 43 (PMID: 23169527). T42_A43insSS has been identified in sequencing studies (PMID: 25822088), but has not been biochemically characterized and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2530,23169527,The β-catenin destruction complex.,http://www.ncbi.nlm.nih.gov/pubmed/23169527,7022,25822088,Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.,http://www.ncbi.nlm.nih.gov/pubmed/25822088,5097
"RET C630S lies within the cysteine-rich region of the Ret protein (PMID: 9879991). C630S has not been characterized, however other C630 mutations result in constitutive activity of Ret and are transforming in cell culture and therefore, C630S is predicted to confer a gain of function to the Ret protein (PMID: 9230192).",2272,9230192,"Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype.",http://www.ncbi.nlm.nih.gov/pubmed/9230192,2271,9879991,Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines.,http://www.ncbi.nlm.nih.gov/pubmed/9879991,5098
"RET C630G lies within the cysteine-rich region of the Ret protein (PMID: 9879991). C630G has not been characterized, however other C630 mutations result in constitutive activity of Ret and are transforming in cell culture and therefore, C630G is predicted to confer a gain of function to the Ret protein (PMID: 9230192).",2271,9879991,Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines.,http://www.ncbi.nlm.nih.gov/pubmed/9879991,2272,9230192,"Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype.",http://www.ncbi.nlm.nih.gov/pubmed/9230192,5099
RET E632_L633del results in the deletion of two amino acids in the cysteine-rich region of the Ret protein from amino acids 632 to 633 (PMID: 9879991). E632_L633del confers a gain of function to the Ret protein resulting in activation of Ret and transformation in cell culture (PMID: 9191060). ,2271,9879991,Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines.,http://www.ncbi.nlm.nih.gov/pubmed/9879991,2531,9191060,Somatic in frame deletions not involving juxtamembranous cysteine residues strongly activate the RET proto-oncogene.,http://www.ncbi.nlm.nih.gov/pubmed/9191060,5100
"RET C634G lies within the cysteine-rich region of the Ret protein (PMID: 9879991). C634G has not been characterized, however other C634 mutations result in autophosphorylation of Ret and transformation in cell culture and therefore, C634G is predicted to confer a gain of function to the Ret protein (PMID: 9242375, PMID: 17664273). ",2271,9879991,Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines.,http://www.ncbi.nlm.nih.gov/pubmed/9879991,432,9242375,Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain.,http://www.ncbi.nlm.nih.gov/pubmed/9242375,589,17664273,Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.,http://www.ncbi.nlm.nih.gov/pubmed/17664273,5101
"KRAS A11T lies within a GTP binding region of the Kras protein (UniProt.org). A11T has been identified in sequencing studies (PMID: 27888800), but has not been biochemically characterized and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).",10046,27888800,Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/27888800,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5102
"RET C634S lies within the cysteine-rich region of the Ret protein (PMID: 9879991). C634S confers a gain of function to the Ret protein as demonstrated by constitutive phosphorylation of MAPK and transformation in cultured cells (PMID: 15277225, PMID: 9230192). ",2271,9879991,Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines.,http://www.ncbi.nlm.nih.gov/pubmed/9879991,2272,9230192,"Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype.",http://www.ncbi.nlm.nih.gov/pubmed/9230192,2532,15277225,The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/15277225,5103
"RET C634F lies within the cysteine-rich region of the Ret protein (PMID: 9879991). C634F is predicted to result in significant destabilization and therefore, likely results in a gain of Ret protein function (PMID: 24716929). ",2533,24716929,Characterization of wild-type and mutated RET proto- oncogene associated with familial medullary thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24716929,2271,9879991,Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines.,http://www.ncbi.nlm.nih.gov/pubmed/9879991,5106
"KIT D572Y lies within the cytoplasmic domain of the Kit protein (UniProt.org). D572Y has been identified in sequencing studies (PMID: 10485475), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,7397,10485475,Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/10485475,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5107
"KIT D816N lies within the protein kinase domain of the Kit protein (UniProt.org). D816N has not been characterized, however other D816 mutations are activating, thus D816N is predicted to confer a gain of Kit protein function (PMID: 16397263).",295,,,www.uniprot.org,657,16397263,"Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.",http://www.ncbi.nlm.nih.gov/pubmed/16397263,5108
"EGFR G598A lies within the extracellular domain of the Egfr protein (UniProt.org). G598A has been identified in sequencing studies (PMID: 27322546), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8085,27322546,Functional characterization of somatic mutations in cancer using network-based inference of protein activity.,http://www.ncbi.nlm.nih.gov/pubmed/27322546,5109
"EGFR G719fs*29 likely results in a truncation of the 1210 aa Egfr protein at aa 719, followed by 29 nonsense amino acids (UniProt.org). Due to the loss of the protein kinase domain, G719fs*29 is predicted to lead to a loss of Egfr protein function (UniProt.org). ",295,,,www.uniprot.org,5110
"EGFR G721C lies within the protein kinase domain of the Egfr protein (UniProt.org). G721C has been identified in the scientific literature (PMID: 27875527), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8086,27875527,Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment.,http://www.ncbi.nlm.nih.gov/pubmed/27875527,5111
"EGFR G810A lies within the protein kinase domain of the Egfr protein (UniProt.org). G810A has not been characterized in the scientific literature and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5112
"EGFR H773_V774insPH results in the insertion of two amino acids in the protein kinase domain of the Egfr protein between amino acids 773 and 774 (UniProt.org). H773_V774insPH has not been characterized, however other exon 20 insertion mutations are activating, thus H773_V774insPH is predicted to result in a gain of function (PMID: 24353160).",295,,,www.uniprot.org,440,24353160,"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24353160,5113
"EGFR H773_V774insQ results in the insertion of one amino acid in the protein kinase domain of the Egfr protein between amino acids 773 and 774 (UniProt.org). H773_V774insQ has not been characterized, however other exon 20 insertion mutations are activating, thus H773_V774insQ is predicted to result in a gain of function (PMID: 24353160).",295,,,www.uniprot.org,440,24353160,"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24353160,5114
"HRAS Q61E lies within the GTP binding domain of the Hras protein (UniProt.org). Q61E confers a loss of function to the Hras protein, resulting in decreased GTPase activity (PMID: 3510078).",2204,3510078,Biological and biochemical properties of human rasH genes mutated at codon 61.,http://www.ncbi.nlm.nih.gov/pubmed/3510078,295,,,www.uniprot.org,5115
"NRAS G12P lies within a GTP-binding region of the Nras protein (UniProt.org). G12P demonstrates intrinsic hydrolysis rate similar to wild-type Nras and is not transforming in cell culture (PMID: 6092966, PMID: 8357792).",2098,6092966,Biological properties of human c-Ha-ras1 genes mutated at codon 12.,http://www.ncbi.nlm.nih.gov/pubmed/6092966,295,,,www.uniprot.org,4661,8357792,Three-dimensional structures and properties of a transforming and a nontransforming glycine-12 mutant of p21H-ras.,http://www.ncbi.nlm.nih.gov/pubmed/8357792,5116
"FGFR2 S283F (corresponds to S372 in the canonical isoform) lies within the Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). S283F has not been characterized in the scientific literature and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5117
"KIT K642Q lies within the protein kinase domain of the Kit protein (UniProt.org). K642Q has been identified in sequencing studies (PMID: 26744134), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7406,26744134,Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system.,http://www.ncbi.nlm.nih.gov/pubmed/26744134,295,,,www.uniprot.org,5118
"KIT M537L (corresponds to M541L in the canonical isoform) lies within the juxtamembrane domain of the Kit protein (PMID: 16226710). M537L (M541L) has been demonstrated to increase proliferation in the presence of ligand when compared to wild-type Kit (PMID: 18795925; PMID: 25015329), but is not predicted to be pathogenic (PMID: 16307017, PMID: 21757432).",648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,460,18795925,Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT.,http://www.ncbi.nlm.nih.gov/pubmed/18795925,1795,21757432,"The prevalence of the c-kit exon 10 variant, M541L, in aggressive fibromatosis does not differ from the general population.",http://www.ncbi.nlm.nih.gov/pubmed/21757432,1796,16307017,"The c-kit (CD117) sequence variation M541L, but not N564K, is frequent in the general population, and is not associated with CML in Caucasians.",http://www.ncbi.nlm.nih.gov/pubmed/16307017,462,25015329,"Identification of kit(M541L) somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response.",http://www.ncbi.nlm.nih.gov/pubmed/25015329,5119
"KIT M541V lies within the juxtamembrane domain of the Kit protein (PMID: 16226710). M541V has not been characterized in the scientific literature and therefore, its effect on Kit protein function is unknown (PubMed, Sep 2017).",648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5120
"KIT P551H lies within the juxtamembrane domain of the Kit protein (PMID: 16226710). P551H has not been characterized in the scientific literature and therefore, its effect on Kit protein function is unknown (PubMed, Sep 2017).",648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5121
"KIT Q556_V560del results in the deletion of four amino acids in the juxtamembrane domain of the Kit protein from amino acids 556 to 560 (PMID: 16226710). Q556_V560del has not been characterized, however similar Kit exon 11 deletions are activating, thus Q556_V560del is predicted to lead to a gain of function (PMID: 9438854, PMID: 9797363).",648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,714,9797363,A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9797363,5122
"KIT V559K lies within the juxtamembrane domain of the Kit protein (PMID: 12879016). V559K has not been characterized however, other Kit V559 mutations are activating, thus V559K is predicted to lead to a gain of function (PMID: 20484085).",648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,2073,20484085,Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/20484085,5123
KIT V560A lies within the juxtamembrane domain of the Kit protein (PMID: 16226710). V560A results in increased autophosphorylation of Kit in cultured cells (PMID: 10224103).,648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,2534,10224103,Inhibition of spontaneous receptor phosphorylation by residues in a putative alpha-helix in the KIT intracellular juxtamembrane region.,http://www.ncbi.nlm.nih.gov/pubmed/10224103,5124
"KIT Y823H lies within the protein kinase domain of the Kit protein (UniProt.org). Y823H has been identified in sequencing studies (PMID: 23014346), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Dec 2016).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7402,23014346,BRAF mutations and KIT aberrations and their clinicopathological correlation in 202 Korean melanomas.,http://www.ncbi.nlm.nih.gov/pubmed/23014346,5125
"KIT Y823N lies within the protein kinase domain of the Kit protein (UniProt.org). Y823N has not been characterized, however, similar Kit exon 17 mutations are activating, therefore Y823N is predicted to lead to a gain of function (PMID: 16741525).",295,,,www.uniprot.org,2018,16741525,Detection of c-kit exons 11- and 17-activating mutations in testicular seminomas by high-resolution melting amplicon analysis.,http://www.ncbi.nlm.nih.gov/pubmed/16741525,5126
"NRAS G12Y lies within a GTP-binding region of the Nras protein (UniProt.org). G12Y has not been characterized, but can be predicted to result in decreased Nras GTPase activity and increased downstream pathway activation based on the effect of other NRAS codon 12 mutations (PMID: 19075190).",547,19075190,"High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.",http://www.ncbi.nlm.nih.gov/pubmed/19075190,295,,,www.uniprot.org,5131
"NRAS S65G does not lie within any known functional domains of the Nras protein (UniProt.org). S65G has not been characterized in the scientific literature and therefore, its effect on Nras protein function is unknown (PubMed, Mar 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5138
"EGFR D770_N771insAPW results in the insertion of three amino acids in the protein kinase domain of the Egfr protein between amino acids 770 and 771 (UniProt.org). D770_N771insAPW has not been characterized, but can be predicted to result in a gain of function based on the effect of other Egfr exon 20 insertions (PMID: 24353160).",440,24353160,"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24353160,295,,,www.uniprot.org,5139
"EGFR D770_N771insGD results in the insertion of two amino acids in the protein kinase domain of the Egfr protein between amino acids 770 and 771 (UniProt.org). D770_N771insGD has not been characterized, but can be predicted to result in a gain of function based on the effect of other Egfr exon 20 insertions (PMID: 24353160).",295,,,www.uniprot.org,440,24353160,"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24353160,5140
"EGFR D770_N771insGF results in the insertion of two amino acids in the protein kinase domain of the Egfr protein between amino acids 770 and 771 (UniProt.org). D770_N771insGF has not been characterized, but can be predicted to result in a gain of function based on the effect of other Egfr exon 20 insertions (PMID: 24353160).",295,,,www.uniprot.org,440,24353160,"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24353160,5141
"EGFR D770_N771insGL results in the insertion of two amino acids in the protein kinase domain of the Egfr protein between amino acids 770 and 771 (UniProt.org). D770_N771insGL has not been characterized, but can be predicted to result in a gain of function based on the effect of other Egfr exon 20 insertions (PMID: 24353160).",295,,,www.uniprot.org,440,24353160,"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24353160,5142
"EGFR D770_N771insGT results in the insertion of two amino acids in the protein kinase domain of the Egfr protein between amino acids 770 and 771 (UniProt.org). D770_N771insGT has not been characterized, but can be predicted to result in a gain of function based on the effect of other Egfr exon 20 insertions (PMID: 24353160).",295,,,www.uniprot.org,440,24353160,"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24353160,5143
"EGFR D770_N771insMATP results in the insertion of four amino acids in the protein kinase domain of the Egfr protein between amino acids 770 and 771 (UniProt.org). D770_N771insMATP has not been characterized, but can be predicted to result in a gain of function based on the effect of other Egfr exon 20 insertions (PMID: 24353160).",295,,,www.uniprot.org,440,24353160,"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24353160,5144
"EGFR D770_N771insSVE results in the insertion of three amino acids in the protein kinase domain of the Egfr protein between amino acids 770 and 771 (UniProt.org). D770_N771insSVE has not been characterized, but can be predicted to result in a gain of function based on the effect of other Egfr exon 20 insertions (PMID: 24353160).",295,,,www.uniprot.org,440,24353160,"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24353160,5145
"EGFR D770_N771insY results in the insertion of a tyrosine (Y) in the protein kinase domain of the Egfr protein between amino acids 770 and 771 (UniProt.org). D770_N771insY has not been characterized, but can be predicted to result in a gain of function based on the effect of other Egfr exon 20 insertions (PMID: 24353160).",295,,,www.uniprot.org,440,24353160,"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24353160,5146
"EGFR E709Q lies within the cytoplasmic domain of the Egfr protein (UniProt.org). E709Q has been identified in the scientific literature (PMID: 15897572), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4837,15897572,Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/15897572,5147
EGFR E734Q lies within the protein kinase domain of the Egfr protein (UniProt.org). E734Q results in increased autophosphorylation of Egfr in cultured cells (PMID: 20942962).,295,,,www.uniprot.org,1956,20942962,Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma.,http://www.ncbi.nlm.nih.gov/pubmed/20942962,5148
"EGFR E868V lies within the protein kinase domain of the Egfr protein (UniProt.org). E868V has been identified in the scientific literature (PMID: 18379359), but not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8069,18379359,Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/18379359,5149
"EGFR F712Y lies within the protein kinase domain of the Egfr protein (UniProt.org). F712Y has not been characterized in the scientific literature and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5150
"EGFR L747_S752del results in the deletion of six amino acids in the protein kinase domain of the Egfr protein from amino acids 747 to 752 (UniProt.org). L747_E752del has not been characterized, however other exon 19 deletion mutations in the Egfr protein are activating, thus L747_E749del is predicted to result in a gain of function (PMID: 16373402, PMID: 23387505).",441,23387505,Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/23387505,1804,16373402,Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16373402,295,,,www.uniprot.org,5151
"EGFR T751_E758del results in the deletion of eight amino acids in the protein kinase domain of the Egfr protein from amino acids 751 to 758. T751_I758del has not been characterized, however similar Egfr exon 19 deletions are activating, thus T751_I758del is predicted to lead to a gain of function (PMID: 16373402, PMID: 23387505).",1804,16373402,Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16373402,441,23387505,Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/23387505,295,,,www.uniprot.org,5152
"KRAS A18V lies within a GTP binding region of the Kras protein (UniProt.org). A18V has been identified in sequencing studies (PMID: 24811063), but has not been biochemically characterized and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).",7694,24811063,"Evidence for different expression profiles for c-Met, EGFR, PTEN and the mTOR pathway in low and high grade endometrial carcinomas in a cohort of consecutive women. Occurrence of PIK3CA and K-Ras mutations and microsatellite instability.",http://www.ncbi.nlm.nih.gov/pubmed/24811063,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5153
"KRAS A59S lies within a GTP binding region of the Kras protein (UniProt.org). A59S has been identified in sequencing studies (PMID: 23125007), but has not been biochemically characterized and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7696,23125007,"Survey of KRAS, BRAF and PIK3CA mutational status in 209 consecutive Italian colorectal cancer patients.",http://www.ncbi.nlm.nih.gov/pubmed/23125007,5154
"EGFR A702T lies within a region of the Egfr protein important for dimerization, phosphorylation, and activation (UniProt.org). A702T has been identified in the scientific literature (PMID: 19648884), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5155
"EGFR A871V lies within the protein kinase domain of the Egfr protein (UniProt.org). A871V has been identified in the scientific literature (PMID: 16152581, PMID: 19060236, PMID: 26773740), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,7970,26773740,Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26773740,7969,19060236,Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern.,http://www.ncbi.nlm.nih.gov/pubmed/19060236,6027,16152581,Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16152581,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5156
"FGFR1 S117L (corresponds to S125 in the canonical isoform) lies within the Ig-like C2-type domain 1 of the Fgfr1 protein (UniProt.org). S117L has not been characterized and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5157
"FGFR1 S36L lies within the extracellular Ig-like C2-type domain 1 of the Fgfr1 beta A1 isoform and corresponds to S125L in the canonical Fgfr1 isoform (UniProt.org). S36L has not been characterized in the scientific literature and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5158
"EGFR K745M (also referred to as K721M in the post-translationally processed Egfr protein) lies within the protein kinase domain of the Egfr protein (PMID: 20495563, UniProt.org). K745M results in a loss of Egfr kinase activity in cultured cells (PMID: 21081186). 

",295,,,www.uniprot.org,2543,24023066,EGFR lung cancer mutants get specialized.,http://www.ncbi.nlm.nih.gov/pubmed/24023066,2623,21081186,"The interactome of a PTB domain-containing adapter protein, Odin, revealed by SILAC.",http://www.ncbi.nlm.nih.gov/pubmed/21081186,5159
"GNAS R201L (corresponding to R844L in isoform XLas-1) lies within the GTP binding domain of the Gnas short isoform 1 (UniProt.org). R201L has not been characterized, however other codon 201 hotspot mutations result in a loss of GTP hydrolysis and lead to constitutive pathway activation, thus, R201L is predicted to result in a loss of Gnas protein function (PMID: 20531296, PMID: 24498230).",2541,24498230,"GNAS mutations identify a set of right-sided, RAS mutant, villous colon cancers.",http://www.ncbi.nlm.nih.gov/pubmed/24498230,295,,,www.uniprot.org,2540,20531296,The activating mutation R201C in GNAS promotes intestinal tumourigenesis in Apc(Min/+) mice through activation of Wnt and ERK1/2 MAPK pathways.,http://www.ncbi.nlm.nih.gov/pubmed/20531296,5160
VHL mutant indicates an unspecified mutation in the VHL gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,5161
CDKN2A mutant indicates an unspecified mutation in the CDKN2A gene. ,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,5162
"EGFR V769M lies within the protein kinase domain of the Egfr protein (UniProt.org). V769M has not been characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Aug 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5165
"EGFR V774L lies within the protein kinase domain of the Egfr protein (UniProt.org). V774L has been identified in the scientific literature (PMID: 17626639), but has not been characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8090,17626639,Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/17626639,5166
"KRAS G12_G13insA results in the insertion of an alanine (A) in a GTP binding region of the Kras protein between amino acids 12 and 13 (UniProt.org). G12_G13A has been identified in sequencing studies (PMID: 21680795), but has not been biochemically characterized and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).
",7698,21680795,Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.,http://www.ncbi.nlm.nih.gov/pubmed/21680795,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5167
"EGFR N771_P772insVDN results in the insertion of three amino acids in the protein kinase domain of the Egfr protein between amino acids 771 and 772 (UniProt.org). N771_P772insVDN has not been characterized, but can be predicted to result in a gain of function based on the effect of other Egfr exon 20 insertions (PMID: 24353160).",295,,,www.uniprot.org,440,24353160,"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24353160,5168
"KRAS G12_G13dup (also referred to as G12_G13insAG) indicates the insertion of two duplicate amino acids, glycine (G)-12 through glycine (G)-13, in a GTP binding region of the Kras protein (UniProt.org). G12_G13dup (G12_G13insAG) has been identified in the scientific literature (PMID: 20160721), but has not been biochemically characterized and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).",10050,20160721,KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?,http://www.ncbi.nlm.nih.gov/pubmed/20160721,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5169
"EGFR L858K lies within the protein kinase domain of the Egfr protein (UniProt.org). L858K has not been characterized, however other L858 hotspot mutations are activating, thus L858K is predicted to result in a gain of Egfr protein function (PMID: 15118073, PMID: 16187797).",2544,15118073,Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.,http://www.ncbi.nlm.nih.gov/pubmed/15118073,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,295,,,www.uniprot.org,5170
"EGFR L858Q lies within the protein kinase domain of the Egfr protein (UniProt.org). L858Q does not result in a significant increase in Egfr autophosphorylation, but leads to increased Akt activation in the presence of EGF compared to wild-type EGFR in cell culture (PMID: 24743239).",3812,24743239,Prediction and prioritization of rare oncogenic mutations in the cancer Kinome using novel features and multiple classifiers.,http://www.ncbi.nlm.nih.gov/pubmed/24743239,295,,,www.uniprot.org,5171
"EGFR N771_P772insN results in the insertion of an asparagine (N) in the protein kinase domain of the Egfr protein between amino acids 771 and 772 (UniProt.org). N771_P772insN has not been characterized, but can be predicted to result in a gain of function based on the effect of other Egfr exon 20 insertions (PMID: 24353160).",295,,,www.uniprot.org,440,24353160,"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24353160,5172
"KRAS G12N lies within a mutational hotspot in the GTP nucleotide binding domain of the Kras protein (UniProt.org, PMID: 23455880). G12N has not been characterized, however other G12 mutations inhibit Kras GTPase activity and increase downstream signaling, thus G12N is predicted to confer loss of function to the Kras protein (PMID: 23455880).",26,23455880,KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23455880,295,,,www.uniprot.org,5173
"EGFR N771_P772insRH results in the insertion of two amino acids in the protein kinase domain of the Egfr protein between amino acids 771 and 772 (UniProt.org). N771_P772insRH has not been characterized, but can be predicted to result in a gain of function based on the effect of other Egfr exon 20 insertions (PMID: 24353160).",295,,,www.uniprot.org,440,24353160,"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24353160,5174
"KRAS G12fs results in a change in the amino acid sequence of the Kras protein beginning at aa 12 of 189, likely resulting in premature truncation of the functional protein (UniProt.org). Due the loss of several functional domains (UniProt.org), G12fs is predicted to lead to a loss of Kras function.",295,,,www.uniprot.org,5176
"KRAS G13dup (also referred to as G13_V14insG) indicates the insertion of the duplicate amino acid, glycine (G)-13, in the GTP binding region of the Kras protein (UniProt.org). G13dup (G13_V14insG) has been identified in sequencing studies (PMID: 21704278), but has not been biochemically characterized and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).",7700,21704278,"KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers diagnostic and therapeutic implications.",http://www.ncbi.nlm.nih.gov/pubmed/21704278,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5177
"FGFR2 Y286C (corresponds to Y375 in the canonical isoform) lies within the extracellular domain of the Fgfr2 protein (UniProt.org). Y286C has not been characterized in the scientific literature and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5178
"KRAS G13E lies within a mutational hotspot in the GTP nucleotide binding domain of the Kras protein (UniProt.org, PMID: 23455880). G13E has not been characterized, however other G13 mutations inhibit Kras GTPase activity and increase downstream signaling, thus G13E is predicted to confer a loss of function to the Kras protein (PMID: 23455880).",26,23455880,KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23455880,295,,,www.uniprot.org,5179
"KRAS Q22* results in a premature truncation of the Kras protein at amino acid 22 of 189 (UniProt.org). Due to the loss of several functional domains (UniProt.org), Q22* is predicted to lead to a loss of Kras function.",295,,,www.uniprot.org,5180
"EGFR S752F lies within the protein kinase domain of the Egfr protein (UniProt.org). S752F has not been characterized in the scientific literature and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5181
"EGFR P596R lies within the extracellular domain of the Egfr protein (UniProt.org). P596R has been identified in sequencing studies (PMID: 23917401), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5182
"EGFR R776S lies within the protein kinase domain of the Egfr protein (UniProt.org). R776S has not been characterized in the scientific literature and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5183
"EGFR S720C lies within the protein kinase domain of the Egfr protein (UniProt.org). S720C has been identified in the scientific literature (PMID: 28196074), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",9228,28196074,Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service.,http://www.ncbi.nlm.nih.gov/pubmed/28196074,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5184
"EGFR S720Y lies within the protein kinase domain of the Egfr protein (UniProt.org). S720Y has not been characterized in the scientific literature and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5185
"EGFR V769_D770insERG results in the insertion of three amino acids in the protein kinase domain of the Egfr protein between amino acids 769 and 770 (UniProt.org). V769_D770insERG has not been characterized, but can be predicted to result in a gain of function based on the effect of other Egfr exon 20 insertions (PMID: 24353160).",440,24353160,"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24353160,295,,,www.uniprot.org,5186
"EGFR V769_D770insGSV results in the insertion of three amino acids in the protein kinase domain of the Egfr protein between amino acids 769 and 770 (UniProt.org). V769_D770insGSV has not been characterized, but can be predicted to result in a gain of function based on the effect of other Egfr exon 20 insertions (PMID: 24353160).",295,,,www.uniprot.org,440,24353160,"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24353160,5187
"EGFR V769_D770insGVV results in the insertion of three amino acids in the protein kinase domain of the Egfr protein between amino acids 769 and 770 (UniProt.org). V769_D770insGVV has not been characterized, but can be predicted to result in a gain of function based on the effect of other Egfr exon 20 insertions (PMID: 24353160).",295,,,www.uniprot.org,440,24353160,"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24353160,5188
"EGFR V769_D770insMASVD results in the insertion of five amino acids in the protein kinase domain of the Egfr protein between amino acids 769 and 770 (UniProt.org). V769_D770insMASVD  has not been characterized, but can be predicted to result in a gain of function based on the effect of other Egfr exon 20 insertions (PMID: 24353160).",295,,,www.uniprot.org,440,24353160,"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24353160,5189
"FGFR3 F386L lies within the transmembrane domain of the Fgfr3 protein (UniProt.org). F386L is a common Fgfr3 polymorphism, but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PMID: 19377444, PubMed, Jul 2017).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7215,19377444,FGFR3 mutations in prostate cancer: association with low-grade tumors.,http://www.ncbi.nlm.nih.gov/pubmed/19377444,5192
"FGFR3 G382R lies within the transmembrane domain of the Fgfr3 protein (UniProt.org). G382R results in increased Fgfr3 protein dimerization and constitutive activation (PMID: 16841094), and has also been shown to inhibit receptor internalization (PMID: 17172848).",746,16841094,Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi.,http://www.ncbi.nlm.nih.gov/pubmed/16841094,295,,,www.uniprot.org,2545,17172848,FGFR3 mutations in benign skin tumors.,http://www.ncbi.nlm.nih.gov/pubmed/17172848,5193
"FLT3 amp indicates an increased number of copies of the Flt3 gene. However, the mechanism causing the increase is unspecified.
",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,5195
"FLT3 over exp indicates an over expression of the Flt3 protein. However, the mechanism causing the over expression is unspecified.
",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,5196
"IDH1 act mut indicates that this variant results in a gain of function in the Idh1 protein. However, the specific amino acid change has not been identified.
",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,5200
"IDH1 amp indicates an increased number of copies of the IDH1 gene. However, the mechanism causing the increase is unspecified.
",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,5201
"IDH1 over exp indicates an over expression of the Idh1 protein. However, the mechanism causing the over expression is unspecified.
",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,5202
EGFR S768N lies within the protein kinase domain of the Egfr protein (UniProt.org). S768N does not result in increased Egfr phosphorylation or activation of Akt in cell culture (PMID: 21132006).,295,,,www.uniprot.org,2553,21132006,Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry.,http://www.ncbi.nlm.nih.gov/pubmed/21132006,5204
"EGFR S768T lies within the protein kinase domain of the Egfr protein (UniProt.org). S768T has been identified  in the scientific literature (PMID: 23768755), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5205
"EGFR S784Y lies within the protein kinase domain of the Egfr protein (UniProt.org). S784Y has been identified in the scientific literature (PMID: 17224267, PMID: 22317764), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9196,22317764,Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.,http://www.ncbi.nlm.nih.gov/pubmed/22317764,8095,17224267,EGFR mutations and human papillomavirus in squamous cell carcinoma of tongue and tonsil.,http://www.ncbi.nlm.nih.gov/pubmed/17224267,5206
"EGFR T751fs*4 likely results in a truncation of the 1210 aa Egfr protein at aa 751, followed by 4 nonsense amino acids within the protein kinase domain of the Egfr protein (UniProt.org). Due to the loss of the protein kinase domain, T751fs*4 is predicted to lead to a loss of Egfr protein function (UniProt.org).",295,,,www.uniprot.org,5207
"CTNNB1 S37T lies within the ubiquitination recognition motif of the Ctnnb1 protein and occurs at a Gsk3b phosphorylation site on the Ctnnb1 protein (PMID: 10347231). S37T has not been characterized, however other S37 hotspot mutations are activating thus, S37T is predicted to lead to a gain of Ctnnb1 protein function (PMID: 9065403, PMID: 11196159, PMID: 11943721).",2339,11196159,More frequent beta-catenin exon 3 mutations in gallbladder adenomas than in carcinomas indicate different lineages.,http://www.ncbi.nlm.nih.gov/pubmed/11196159,2336,10347231,The ubiquitin-proteasome pathway and serine kinase activity modulate adenomatous polyposis coli protein-mediated regulation of beta-catenin-lymphocyte enhancer-binding factor signaling.,http://www.ncbi.nlm.nih.gov/pubmed/10347231,2340,11943721,Solid-pseudopapillary tumors of the pancreas are genetically distinct from pancreatic ductal adenocarcinomas and almost always harbor beta-catenin mutations.,http://www.ncbi.nlm.nih.gov/pubmed/11943721,402,9065403,Stabilization of beta-catenin by genetic defects in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/9065403,5208
"IDH2 act mut indicates that this variant results in a gain of function in the Idh2 protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,5209
"IDH2 amp indicates an increased number of copies of the Idh2 gene. However, the mechanism causing the increase is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,5210
"IDH2 over exp indicates an over expression of the Idh2 protein. However, the mechanism causing the over expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,5211
"FGFR2 C293R lies within the helical domain of the Fgfr2 protein isoform 20 and corresponds to C382R in the protein’s canonical isoform (UniProt.org). C293R confers a gain of function to the Fgfr2 protein resulting in constitutive MAPK pathway activation, and is transforming in cultured cells (PMID: 24993163).",1904,24993163,Activating FGFR2-RAS-BRAF mutations in ameloblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/24993163,295,,,www.uniprot.org,5212
"KIT N822H lies within the protein kinase domain of the Kit protein (UniProt.org). N822H has been identified in sequencing studies (PMID: 11719439), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Sep 2017).",7413,11719439,KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/11719439,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5213
"FBXW7 inact mut indicates that this variant results in a loss of function of the FBXW7 protein. However, the specific amino acid change has not been identified. ",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,5214
"FGFR2 N460K lies within the protein kinase domain of the Fgfr2 protein isoform 21 and corresponds to N549K in the protein’s canonical isoform (UniProt.org). N460K confers a gain of function to the Fgfr2 protein, resulting in oncogenic transformation in cell-based studies (PMID: 18552176, PMID: 17803937).",252,18552176,Drug-sensitive FGFR2 mutations in endometrial carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18552176,295,,,www.uniprot.org,1905,17803937,A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases.,http://www.ncbi.nlm.nih.gov/pubmed/17803937,5215
"FGFR3 A391V lies within the transmembrane domain of the Fgfr3 protein (UniProt.org). A391V has been identified in sequencing studies (PMID: 24360661), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jul 2017).",7213,24360661,FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy.,http://www.ncbi.nlm.nih.gov/pubmed/24360661,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5217
FGFR2 N547K lies within the protein domain of the Fgfr2 protein isoform 23 and corresponds to N659K of the canonical Fgfr2IIIc isoform and N660K of the Fgfr2IIIb isoform (UniProt.org). N547K results in increased phosphorylation of Fgfr2 (PMID: 23527311).,2160,23527311,Activating somatic FGFR2 mutations in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23527311,295,,,www.uniprot.org,5218
"FGFR2 P164L (corresponds to P253L of the canonical isoform) lies within the extracellular Ig-like C2-type 2 domain of the Fgfr2 protein isoform 3 (UniProt.org). P164L has not been characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5219
"FGFR2 P164R lies within the extracellular Ig-like C2-type 2 domain of the Fgfr2 protein isoform 3 and corresponds to P253R of the canonical Fgfr2IIIc isoform (UniProt.org). P164R results in loss of ligand specificity and is transforming in cell culture (PMID: 11121055, PMID: 22273505, PMID: 23786770).",295,,,www.uniprot.org,2132,23786770,Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23786770,2139,11121055,Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/11121055,2569,22273505,Mechanisms of FGFR-mediated carcinogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/22273505,5221
"FGFR2 P253L lies within the extracellular Ig-like C2-type domain 2 of the Fgfr2 protein (UniProt.org). P253L leads to Apert syndrome (PMID: 26003532) but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5707,26003532,Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26003532,5222
"BRCA1 A314T lies within the RB-binding region of the Brca1 protein (PMID: 22737296). A314T has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5237
"BRCA1 A622V lies within the Rad50-binding region of the Brca1 protein (PMID: 22737296). A622V has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,5238
"BRCA1 A942V lies within the Rad51-binding region of the Brca1 protein (PMID: 22737296). A942V has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,5240
"BRCA1 C47W lies within the RING domain of the Brca1 protein (PMID: 22737296). C47W has been identified in the scientific literature (PMID: 21990299), but has not been biochemically characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,8656,21990299,"Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.",http://www.ncbi.nlm.nih.gov/pubmed/21990299,2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,5241
"BRCA1 C644W lies within the Rad50-binding region of the Brca1 protein (PMID: 22737296). C644W has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,5242
"BRCA1 D1123Y does not lie within any known functional domains of the Brca1 protein (UniProt.org). D1123Y has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5243
"BRCA1 D435Y lies within the Rad50-binding region of the Brca1 protein (PMID: 22737296). D435Y has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,5244
"BRCA1 D821Y lies within the Rad51-binding region of the Brca1 protein (PMID: 22737296). D821Y has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,5245
"BRCA1 D853N lies within the Rad51-binding region of the Brca1 protein (PMID: 22737296). D853N has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,5246
"BRCA1 E1000Q lies within the Rad51-binding region of the Brca1 protein (PMID: 22737296). E1000Q has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,5247
"BRCA1 E1258D lies within the serine cluster domain of the Brca1 protein (PMID: 22737296). E1258D has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,5248
"BRCA1 E23fs results in a change in the amino acid sequence of the Brca1 protein beginning at aa 23 of 1863, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of most known functional domains (UniProt.org), E23fs is predicted to lead to a loss of Brca1 function.",295,,,www.uniprot.org,5249
"BRCA1 E23fs*17 likely results in a truncation of the 1863 aa Brca1 protein at aa 23, followed by 17 nonsense amino acids (UniProt.org). Due to the loss of most known functional domains (UniProt.org), E23fs*17 is predicted to lead to a loss of Brca1 function.",295,,,www.uniprot.org,5250
"BRCA1 E404D lies within the Rad50-binding region of the Brca1 protein (PMID: 22737296). E404D has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5251
"BRCA1 E453D lies within the Rad50-binding region of the Brca1 protein (PMID: 22737296). E453D has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5252
"BRCA1 E489G lies within the Rad50-binding region of the Brca1 protein (PMID: 22737296). E489G has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5253
"BRCA1 E515Q lies within the Rad50-binding region of the Brca1 protein (PMID: 22737296). E515Q has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,5254
"BRCA1 E515V lies within the Rad50-binding region of the Brca1 protein (PMID: 22737296). E515V has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,5255
"BRCA1 E577* results in a premature truncation of the Brca1 protein at amino acid 577 of 1863 (UniProt.org). E577* has not been characterized, however, other C-terminal deletion mutants downstream of E577 are inactivating (PMID: 16618730), thus E577* is predicted to lead to a loss of Brca1 protein function.",295,,,www.uniprot.org,2575,16618730,Identification of domains of BRCA1 critical for the ubiquitin-dependent inhibition of centrosome function.,http://www.ncbi.nlm.nih.gov/pubmed/16618730,5256
"BRCA1 E673* results in a premature truncation of the Brca1 protein at amino acid 673 of 1863 (UniProt.org). E673* has not been characterized, however, other C-terminal deletion mutants downstream of E673 are inactivating (PMID: 16618730), thus E673* is predicted to lead to a loss of Brca1 protein function.",295,,,www.uniprot.org,2575,16618730,Identification of domains of BRCA1 critical for the ubiquitin-dependent inhibition of centrosome function.,http://www.ncbi.nlm.nih.gov/pubmed/16618730,5257
"BRCA1 E851G lies within the Rad51-binding region of the Brca1 protein (PMID: 22737296). E851G has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,5258
"BRCA1 E907K lies within the Rad51-binding region of the Brca1 protein (PMID: 22737296). E907K has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,5259
"BRCA1 E962A lies within the Rad51-binding region of the Brca1 protein (PMID: 22737296). E962A has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,5260
"BRCA1 F461C lies within the Rad50-binding region of the Brca1 protein (PMID: 22737296). F461C has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,5261
"BRCA1 G1077W does not lie within any known functional domains of the Brca1 protein (UniProt.org). G1077W has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5262
"BRCA1 G1384W lies within the serine cluster domain of the Brca1 protein (PMID: 22737296). G1384W has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,5263
"BRCA1 G275D does not lie within any known functional domains of the Brca1 protein (UniProt.org). G275D has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5264
"BRCA1 H513Y lies within the Rad50-binding region of the Brca1 protein (PMID: 22737296). H513Y has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5265
"BRCA1 H619N lies within the Rad50-binding region of the Brca1 protein (PMID: 22737296). H619N has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5266
"BRCA1 K1109T does not lie within any known functional domains of the Brca1 protein (UniProt.org). K1109T has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5267
"BRCA1 K1207N does not lie within any known functional domains of the Brca1 protein (UniProt.org). K1207N has been identified in the scientific literature (PMID: 14722926), but has not been biochemically characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,8745,14722926,Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast and breast-ovarian cancer families.,http://www.ncbi.nlm.nih.gov/pubmed/14722926,5268
"BRCA1 K1254T does not lie within any known functional domains of the Brca1 protein (UniProt.org). K1254T has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5269
"BRCA1 K339fs results in a change in the amino acid sequence of the Brca1 protein beginning at aa 339 of 1863, likely resulting in premature truncation of the functional protein (UniProt.org). K339fs has not been characterized, however, C-terminal deletion mutants downstream of K339 are inactivating (PMID: 16618730), thus K339fs is predicted to lead to a loss of Brca1 protein function.",295,,,www.uniprot.org,2575,16618730,Identification of domains of BRCA1 critical for the ubiquitin-dependent inhibition of centrosome function.,http://www.ncbi.nlm.nih.gov/pubmed/16618730,5270
"BRCA1 K654fs*47 likely results in a truncation of the 1863 aa Brca1 protein at aa 654, followed by 47 nonsense amino acids (UniProt.org). K654fs*47 has not been characterized, however, other C-terminal deletion mutants downstream of K654 are inactivating (PMID: 16618730), thus K654fs*47 is predicted to lead to a loss of Brca1 protein function.",295,,,www.uniprot.org,2575,16618730,Identification of domains of BRCA1 critical for the ubiquitin-dependent inhibition of centrosome function.,http://www.ncbi.nlm.nih.gov/pubmed/16618730,5271
"BRCA1 K893N lies within the Rad51-binding region of the Brca1 protein (PMID: 22737296). K893N has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,5272
"BRCA1 K991Q lies within the Rad51-binding region of the Brca1 protein (PMID: 22737296). K991Q has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,5273
"BRCA1 K996Q lies within the Rad51-binding region of the Brca1 protein (PMID: 22737296). K996Q has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,5274
"BRCA1 L1570P does not lie within any known functional domains of the Brca1 protein (UniProt.org). L1570P has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5275
"BRCA1 L269V does not lie within any known functional domains of the Brca1 protein (UniProt.org). L269V has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5276
"BRCA1 L30F lies within the RING domain of the Brca1 protein (PMID: 22737296). L30F results in decreased homologous DNA repair in cultured cells compared to wild-type Brca1, however, the functional significance of this decrease is unknown (PMID: 25823446).",2576,25823446,Massively Parallel Functional Analysis of BRCA1 RING Domain Variants.,http://www.ncbi.nlm.nih.gov/pubmed/25823446,2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,5277
"BRCA1 L49M lies within the RING domain of the Brca1 protein (PMID: 22737296). L49M results in decreased homologous DNA repair in cultured cells compared to wild-type Brca1, however, the functional significance of this decrease is unknown (PMID: 25823446).",2576,25823446,Massively Parallel Functional Analysis of BRCA1 RING Domain Variants.,http://www.ncbi.nlm.nih.gov/pubmed/25823446,2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,5278
"BRCA1 L574I lies within the Rad50-binding region of the Brca1 protein (PMID: 22737296). L574I has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,5279
"BRCA1 P832S lies within the Rad51-binding region of the Brca1 protein (PMID: 22737296). P832S has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,5280
"BRCA1 P875S lies within the Rad51-binding region of the Brca1 protein (PMID: 22737296). P875S has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5281
"BRCA1 Q1299L lies within the serine cluster domain of the Brca1 protein (PMID: 22737296). Q1299L has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5282
"BRCA1 Q1756fs results in a change in the amino acid sequence of the Brca1 protein beginning at aa 1756 of 1863, likely resulting in premature truncation of the functional protein (UniProt.org). Q1756fs has not been characterized, however, other BRCT domain deletion mutants downstream of Q1756 are destablizing (PMID: 14534301), thus Q1756fs is predicted to lead to a loss of Brca1 protein function.",2590,14534301,Detection of protein folding defects caused by BRCA1-BRCT truncation and missense mutations.,http://www.ncbi.nlm.nih.gov/pubmed/14534301,295,,,www.uniprot.org,5283
"BRCA1 Q202* results in a premature truncation of the Brca1 protein at amino acid 202 of 1863 (UniProt.org). Q202* has not been characterized, however, other C-terminal deletion mutants downstream of Q202 are inactivating (PMID: 16618730), thus Q202* is predicted to lead to a loss of Brca1 protein function.",295,,,www.uniprot.org,2575,16618730,Identification of domains of BRCA1 critical for the ubiquitin-dependent inhibition of centrosome function.,http://www.ncbi.nlm.nih.gov/pubmed/16618730,5284
"BRCA1 Q94* results in a premature truncation of the Brca1 protein at amino acid 94 of 1863 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), Q94* is predicted to lead to a loss of Brca1 protein function.",295,,,www.uniprot.org,5285
"BRCA1 R1203* results in a premature truncation of the Brca1 protein at amino acid 1203 of 1863 (UniProt.org). R1203* has not been characterized, however, other C-terminal deletion mutants downstream of R1203 are inactivating (PMID: 16618730), thus R1203* is predicted to lead to a loss of Brca1 protein function.",295,,,www.uniprot.org,2575,16618730,Identification of domains of BRCA1 critical for the ubiquitin-dependent inhibition of centrosome function.,http://www.ncbi.nlm.nih.gov/pubmed/16618730,5286
"BRCA1 R1443* results in a premature truncation of the Brca1 protein at amino acid 1443 of 1863 (UniProt.org). R1443* has not been characterized, however, other C-terminal deletion mutants downstream of R1443 are inactivating (PMID: 16618730), thus R1443* is predicted to lead to a loss of Brca1 protein function.",295,,,www.uniprot.org,2575,16618730,Identification of domains of BRCA1 critical for the ubiquitin-dependent inhibition of centrosome function.,http://www.ncbi.nlm.nih.gov/pubmed/16618730,5287
"BRCA1 R1589C does not lie within any known functional domains of the Brca1 protein (UniProt.org). R1589C has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5288
BRCA1 R1699L lies within the BRCT 1 domain of the Brca1 protein (UniProt.org). R1699L demonstrates transcriptional activity similar to wild-type Brca1 protein in cultured cells (PMID: 24845084).,295,,,www.uniprot.org,2578,24845084,Probing structure-function relationships in missense variants in the carboxy-terminal region of BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/24845084,5289
BRCA1 R1699Q lies within the BRCT 1 domain of the Brca1 protein (UniProt.org). R1699Q results in decreased Brca1 transcriptional activity in cultured cells (PMID: 11157798).,2579,11157798,Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families.,http://www.ncbi.nlm.nih.gov/pubmed/11157798,295,,,www.uniprot.org,5290
BRCA1 R1699W lies within the BRCT 1 domain of the Brca1 protein (UniProt.org). R1699W results in decreased in decreased Brca1 transcriptional activity in cultured cells (PMID: 11157798).,2579,11157798,Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families.,http://www.ncbi.nlm.nih.gov/pubmed/11157798,295,,,www.uniprot.org,5291
"BRCA1 R320T lies within the RB-binding region of the Brca1 protein (PMID: 22737296). R320T has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,5292
"BRCA1 R610M lies within the Rad50-binding region of the Brca1 protein (PMID: 22737296). R610M has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,5293
"BRCA1 S1009P lies within the Rad51-binding region of the Brca1 protein (PMID: 22737296). S1009P has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,5294
"BRCA1 S1027I lies within the Rad51-binding region of the Brca1 protein (PMID: 22737296). S1027I has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,5295
"BRCA1 S1211F does not lie within any known functional domains of the Brca1 protein (UniProt.org). S1211F has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5296
"BRCA1 S1503* results in a premature truncation of the Brca1 protein at amino acid 1503 of 1863 (UniProt.org). S1503* has not been characterized, however, other C-terminal deletion mutants downstream of S1503 are inactivating (PMID: 16618730), thus S1503* is predicted to lead to a loss of Brca1 protein function.",2575,16618730,Identification of domains of BRCA1 critical for the ubiquitin-dependent inhibition of centrosome function.,http://www.ncbi.nlm.nih.gov/pubmed/16618730,295,,,www.uniprot.org,5297
"BRCA1 S561Y lies within the Rad50-binding region of the Brca1 protein (PMID: 22737296). S561Y has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, May 2017).",2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5298
"BRCA1 S663N lies within the Rad51-binding region of the Brca1 protein (PMID: 22737296). S663N has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, May 2017).",2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5299
"BRCA1 S784L lies within the Rad51-binding region of the Brca1 protein (PMID: 22737296). S784L has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, May 2017).",2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5300
"BRCA1 V1590A does not lie within any known functional domains of the Brca1 protein (UniProt.org). V1590A has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5301
"BRCA1 V412L lies within the Rad50-binding region of the Brca1 protein (PMID: 22737296). V412L has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,5302
"BRCA1 V525A lies within the Rad50-binding region of the Brca1 protein (PMID: 22737296). V525A has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,5303
"BRCA1 V627I lies within the Rad50-binding region of the Brca1 protein (PMID: 22737296). V627I has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,5304
"BRCA1 V899L lies within the Rad51-binding region of the Brca1 protein (PMID: 22737296). V899L has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,5305
"BRCA1 W321C lies within the Rad50-binding region of the Brca1 protein (PMID: 22737296). W321C has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2574,22737296,Structure-Function Of The Tumor Suppressor BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/22737296,5306
"FBXW7 A481V lies within the WD repeat 3 of the Fbxw7 protein (UniProt.org). A481V has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5311
"FBXW7 D135Y does not lie within any known functional domains of the Fbxw7 protein (UniProt.org). D135Y has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5312
"FBXW7 D480Y lies within the WD repeat 3 of the Fbxw7 protein (UniProt.org). D480Y has been identified in sequencing studies (PMID: 18948947), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",6956,18948947,Somatic mutations affect key pathways in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18948947,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5313
"FBXW7 D520N lies within the WD repeat 4 of the Fbxw7 protein (UniProt.org). D520N has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5314
"FBXW7 D600H lies within the WD repeat 6 of the Fbxw7 protein (UniProt.org). D600H has not been characterized in th scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5315
"FBXW7 D600Y lies within the WD repeat 6 of the Fbxw7 protein (UniProt.org). D600Y has been identified in sequencing studies (PMID: 22895193), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5316
"FBXW7 E248D does not lie within any known functional domains of the Fbxw7 protein (UniProt.org). E248D has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5317
"FBXW7 E117del results in the deletion of an amino acid in the Fbxw7 protein at amino acid 117 (UniProt.org). E117del has been identified in sequencing studies (PMID: 24909261), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1174,24909261,Recurrent somatic mutation in DROSHA induces microRNA profile changes in Wilms tumour.,http://www.ncbi.nlm.nih.gov/pubmed/24909261,5318
"FBXW7 E287V lies within the WD repeat 1 of the Fbxw7 protein (UniProt.org). E287V has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,5319
"FBXW7 E369* results in a premature truncation of the Fbxw7 protein at amino acid 369 of 707 (UniProt.org). Due to the loss of all WD repeat domains (UniProt.org), R369* is predicted to result in a loss of function.",295,,,www.uniprot.org,5320
"FBXW7 G411S lies within the WD repeat 1 of the Fbxw7 protein (UniProt.org). G411S has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5321
"FBXW7 G422C lies within the WD repeat 2 of the Fbxw7 protein (UniProt.org). G422C has been identified in sequencing studies (PMID: 22923510), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7948,22923510,Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.,http://www.ncbi.nlm.nih.gov/pubmed/22923510,5322
"BRCA2 A1981S lies within the BRCA2 repeat 7 of the Brca2 protein (UniProt.org). A1981S has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5323
"BRCA2 A2351T lies within the FANCD2-interacting region of the Brca2 protein (UniProt.org). A2351T has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5324
"BRCA2 A2711T lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). A2711T has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,5325
"BRCA2 A2951V lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). A2951V has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,5326
"BRCA2 C1200fs results in a change in the amino acid sequence of the Brca2 protein beginning at aa 1200 of 3418, likely resulting in premature truncation of the functional protein (UniProt.org). C1200fs has not been characterized, however, due to the effects of other truncations downstream of C1200 (PMID: 12619154, PMID: 15695382), C1200fs is predicted to lead to a loss of Brca2 protein function.",2582,15695382,Functional evaluation and cancer risk assessment of BRCA2 unclassified variants.,http://www.ncbi.nlm.nih.gov/pubmed/15695382,295,,,www.uniprot.org,2580,12619154,"Deletion of Brca2 exon 27 causes hypersensitivity to DNA crosslinks, chromosomal instability, and reduced life span in mice.",http://www.ncbi.nlm.nih.gov/pubmed/12619154,5327
"BRCA2 D1177N does not lie within any known functional domains of the Brca2 protein (UniProt.org). D1177N has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5328
"BRCA2 D1420N does not lie within any known functional domains of the Brca2 protein (UniProt.org). D1420N has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5329
"BRCA2 D2218Y does not lie within any known functional domains of the Brca2 protein (UniProt.org). D2218Y has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5330
"BRCA2 D479Y does not lie within any known functional domains of the Brca2 protein (UniProt.org). D479Y has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5331
"BRCA2 D687H lies within the NPM1-interacting region of the Brca2 protein (UniProt.org). D687H has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5332
"BRCA2 E1285fs results in a change in the amino acid sequence of the Brca2 protein beginning at aa 1285 of 3418, likely resulting in premature truncation of the functional protein (UniProt.org). E1285fs has not been characterized, however, due to the effects of other truncations downstream of E1285 (PMID: 12619154, PMID: 15695382), E1285fs is predicted to lead to a loss of Brca2 protein function.",295,,,www.uniprot.org,2580,12619154,"Deletion of Brca2 exon 27 causes hypersensitivity to DNA crosslinks, chromosomal instability, and reduced life span in mice.",http://www.ncbi.nlm.nih.gov/pubmed/12619154,2582,15695382,Functional evaluation and cancer risk assessment of BRCA2 unclassified variants.,http://www.ncbi.nlm.nih.gov/pubmed/15695382,5333
"BRCA2 E1382D lies within the POLH-interacting region of the Brca2 protein (UniProt.org). E1382D has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5334
"BRCA2 E1441* results in a premature truncation of the Brca2 protein at amino acid 1441 of 3418 (UniProt.org). E1441* has not been characterized, however, due to the effects of other truncations downstream of E1441 (PMID: 12619154, PMID: 15695382), E1441* is predicted to lead to a loss of Brca2 protein function.",295,,,www.uniprot.org,2580,12619154,"Deletion of Brca2 exon 27 causes hypersensitivity to DNA crosslinks, chromosomal instability, and reduced life span in mice.",http://www.ncbi.nlm.nih.gov/pubmed/12619154,2582,15695382,Functional evaluation and cancer risk assessment of BRCA2 unclassified variants.,http://www.ncbi.nlm.nih.gov/pubmed/15695382,5348
"BRCA2 E1879D does not lie within any known functional domains of the Brca2 protein (UniProt.org). E1879D has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5349
"BRCA2 E2020K does not lie within any known functional domains of the Brca2 protein (UniProt.org). E2020K has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5350
"BRCA2 E2229* results in a premature truncation of the Brca2 protein at amino acid 2229 of 3418 (UniProt.org). E2229* has not been characterized, however, due to the effects of other truncations downstream of E2229 (PMID: 12619154, PMID: 9699678), E2229* is predicted to lead to a loss of Brca2 protein function.",295,,,www.uniprot.org,2580,12619154,"Deletion of Brca2 exon 27 causes hypersensitivity to DNA crosslinks, chromosomal instability, and reduced life span in mice.",http://www.ncbi.nlm.nih.gov/pubmed/12619154,2581,9699678,Cells deleted for Brca2 COOH terminus exhibit hypersensitivity to gamma-radiation and premature senescence.,http://www.ncbi.nlm.nih.gov/pubmed/9699678,5352
"BRCA2 E2258K does not lie within any known functional domains of the Brca2 protein (UniProt.org). E2258K has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5353
"BRCA2 E2476* results in a premature truncation of the Brca2 protein at amino acid 2476 of 3418 (UniProt.org). E2476* has not been characterized, however, due to the effects of other truncations downstream of E2476 (PMID: 12619154, PMID: 9699678), E2476* is predicted to lead to a loss of Brca2 protein function.",295,,,www.uniprot.org,2580,12619154,"Deletion of Brca2 exon 27 causes hypersensitivity to DNA crosslinks, chromosomal instability, and reduced life span in mice.",http://www.ncbi.nlm.nih.gov/pubmed/12619154,2581,9699678,Cells deleted for Brca2 COOH terminus exhibit hypersensitivity to gamma-radiation and premature senescence.,http://www.ncbi.nlm.nih.gov/pubmed/9699678,5355
BRCA2 E3342K does not lie within any known functional domains of the Brca2 protein (UniProt.org). E3342K is predicted to be deleterious to Brca2 protein function in computational models (PMID: 18724707). ,295,,,www.uniprot.org,2583,18724707,Computational and structural investigation of deleterious functional SNPs in breast cancer BRCA2 gene.,http://www.ncbi.nlm.nih.gov/pubmed/18724707,5356
"BRCA2 E456D does not lie within any known functional domains of the Brca2 protein (UniProt.org). E456D has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5357
"BRCA2 E49* results in a premature truncation of the Brca2 protein at amino acid 49 of 3418 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), E49* is predicted to lead to a loss of Brca2 protein function.",295,,,www.uniprot.org,5358
"BRCA2 E510* results in a premature truncation of the Brca2 protein at amino acid 510 of 3418 (UniProt.org). E510* has not been characterized, however, due to the effects of other truncations downstream of E510 (PMID: 12619154, PMID: 15695382), E510* is predicted to lead to a loss of Brca2 protein function.",2582,15695382,Functional evaluation and cancer risk assessment of BRCA2 unclassified variants.,http://www.ncbi.nlm.nih.gov/pubmed/15695382,295,,,www.uniprot.org,2580,12619154,"Deletion of Brca2 exon 27 causes hypersensitivity to DNA crosslinks, chromosomal instability, and reduced life span in mice.",http://www.ncbi.nlm.nih.gov/pubmed/12619154,5359
"BRCA2 E897* results in a premature truncation of the Brca2 protein at amino acid 897 of 3418 (UniProt.org). E897* has not been characterized, however, due to the effects of other truncations downstream of E897 (PMID: 12619154, PMID: 15695382), E897* is predicted to lead to a loss of Brca2 protein function.",2582,15695382,Functional evaluation and cancer risk assessment of BRCA2 unclassified variants.,http://www.ncbi.nlm.nih.gov/pubmed/15695382,295,,,www.uniprot.org,2580,12619154,"Deletion of Brca2 exon 27 causes hypersensitivity to DNA crosslinks, chromosomal instability, and reduced life span in mice.",http://www.ncbi.nlm.nih.gov/pubmed/12619154,5360
"BRCA2 F1192C does not lie within any known functional domains of the Brca2 protein (UniProt.org). F1192C has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5361
"BRCA2 F701C lies within the NPM1-interacting region of the Brca2 protein (UniProt.org). F701C has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5362
"BRCA2 G1761V lies within the POLH-interacting region of the Brca2 protein (UniProt.org). G1761V has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5363
"BRCA2 G2584C lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). G2584C has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5364
"BRCA2 H1350N lies within the POLH-interacting region of the Brca2 protein (UniProt.org). H1350N has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5365
"BRCA2 H1752Y lies within the POLH-interacting region of the Brca2 protein (UniProt.org). H1752Y has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5366
"BRCA2 I1017F lies within the BRCA2 repeat 1 of the Brca2 protein (UniProt.org). I1017F has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5367
"BRCA2 I1607S lies within the POLH-interacting region of the Brca2 protein (UniProt.org). I1607S has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5368
"BRCA2 I1772S lies within the POLH-interaction region of the Brca2 protein (UniProt.org). I1772S has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5369
"BRCA2 I332F does not lie within any known functional domains of the Brca2 protein (UniProt.org). I332F has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5370
"BRCA2 K1180R does not lie within any known functional domains of the Brca2 protein (UniProt.org). K1180R has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5371
"BRCA2 K1691fs*15 likely results in a truncation of the 3418 aa Brca2 protein at aa 1691, followed by 15 nonsense amino acids (UniProt.org). K1691fs*15 has not been characterized, however, due to the effects of other truncations downstream of K1691 (PMID: 12619154, PMID: 15695382), K1691fs*15 is predicted to lead to a loss of Brca2 protein function.",2582,15695382,Functional evaluation and cancer risk assessment of BRCA2 unclassified variants.,http://www.ncbi.nlm.nih.gov/pubmed/15695382,295,,,www.uniprot.org,2580,12619154,"Deletion of Brca2 exon 27 causes hypersensitivity to DNA crosslinks, chromosomal instability, and reduced life span in mice.",http://www.ncbi.nlm.nih.gov/pubmed/12619154,5372
"BRCA2 K2017T does not lie within any known functional domains of the Brca2 protein (UniProt.org). K2017T has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5373
"BRCA2 K2206N does not lie within any known functional domains of the Brca2 protein (UniProt.org). K2206N has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5374
"BRCA2 K2316Q does not lie within any known functional domains of the Brca2 protein (UniProt.org). K2316Q has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5375
"BRCA2 K2316R does not lie within any known functional domains of the Brca2 protein (UniProt.org). K2316R has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5376
"BRCA2 K604* results in a premature truncation of the Brca2 protein at amino acid 640 of 3418 (UniProt.org). K604* has not been characterized, however, due to the effects of other truncations downstream of K604 (PMID: 12619154, PMID: 15695382), K604* is predicted to lead to a loss of Brca2 protein function.",2582,15695382,Functional evaluation and cancer risk assessment of BRCA2 unclassified variants.,http://www.ncbi.nlm.nih.gov/pubmed/15695382,295,,,www.uniprot.org,2580,12619154,"Deletion of Brca2 exon 27 causes hypersensitivity to DNA crosslinks, chromosomal instability, and reduced life span in mice.",http://www.ncbi.nlm.nih.gov/pubmed/12619154,5377
"BRCA2 K956T lies within the NPM1-interacting region of the Brca2 protein (UniProt.org). K956T has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5378
"BRCA2 L3180F lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). L3180F has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5379
"BRCA2 L482I does not lie within any known functional domains of the Brca2 protein (UniProt.org). L482I has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5380
"BRCA2 N1642T lies within the POLH-interacting region of the Brca2 protein (UniProt.org). N1642T has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5381
"BRCA2 N1747S lies within the POLH-interacting region of the Brca2 protein (UniProt.org). N1747S has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5382
"BRCA2 P143S does not lie within any known functional domains of the Brca2 protein (UniProt.org). P143S has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5383
"BRCA2 P2352S lies within the FANCD2-interacting region of the Brca2 protein (UniProt.org). P2352S has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5384
"BRCA2 P2734H lies within the SEM1-interacting region of the Brca2 protein (PMID: 12228710). P2734H has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,5385
"BRCA2 P288S does not lie within any known functional domains of the Brca2 protein (UniProt.org). P288S has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5386
BRCA2 P3194Q lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). P3194Q is predicted to disrupt Brca2 binding to Cdk2 in computational models (PMID: 23704879).,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,2584,23704879,Missense variants of uncertain significance (VUS) altering the phosphorylation patterns of BRCA1 and BRCA2.,http://www.ncbi.nlm.nih.gov/pubmed/23704879,5387
"BRCA2 P3324L does not lie within any known functional domains of the Brca2 protein (UniProt.org). P3324L has not been characterized n the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5388
"BRCA2 P365Q does not lie within any known functional domains of the Brca2 protein (UniProt.org). P365Q has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5389
"BRCA2 P606L does not lie within any known functional domains of the Brca2 protein (UniProt.org). P606L has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5390
"BRCA2 P89Q does not lie within any known functional domains of the Brca2 protein (UniProt.org). P89Q has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5391
"BRCA2 P920S lies within the NPM1-interacting region of the Brca2 protein (UniProt.org). P920S has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5392
"BRCA2 Q2539H lies within the FANCD2-interacting region of the Brca2 protein (UniProt.org). Q2539H has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5393
"BRCA2 Q3247H does not lie within any known functional domains of the Brca2 protein (UniProt.org). Q3247H has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5394
"BRCA2 R155I does not lie within any known functional domains of the Brca2 protein (UniProt.org). R155I has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5395
"BRCA2 R2268I does not lie within any known functional domains of the Brca2 protein (UniProt.org). R2268I has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5396
"BRCA2 R2418I lies within the FANCD2-interacting region of the Brca2 protein (UniProt.org). R2418I has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5397
"BRCA2 R2488T lies within the FANCD2-interacting region of the Brca2 protein (UniProt.org). R2488T has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5398
"BRCA2 R2494Q lies within the FANCD2-interacting region of the Brca2 protein (UniProt.org). R2494Q has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5399
"BRCA2 R2645fs*3 likely results in a truncation of the 3418 aa Brca2 protein at aa 2645, followed by 3 nonsense amino acids (UniProt.org). R2645fs*3 has not been characterized, however, due to the effects of other truncations downstream of R2645 (PMID: 12619154, PMID: 9699678), R2645fs*3 is predicted to lead to a loss of Brca2 protein function.",295,,,www.uniprot.org,2580,12619154,"Deletion of Brca2 exon 27 causes hypersensitivity to DNA crosslinks, chromosomal instability, and reduced life span in mice.",http://www.ncbi.nlm.nih.gov/pubmed/12619154,2581,9699678,Cells deleted for Brca2 COOH terminus exhibit hypersensitivity to gamma-radiation and premature senescence.,http://www.ncbi.nlm.nih.gov/pubmed/9699678,5400
"BRCA2 R2784Q lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). R2784Q results in decreased Brca2 function, as indicated by decreased homology directed recombination in cultured cells (PMID: 23108138).",2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,5401
"BRCA2 R2787L lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). R2787L has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,5402
"BRCA2 R2842C does not lie within any known functional domains of the Brca2 protein (UniProt.org). R2842C results in decreased Brca1 activity, as indicated by decreased homology directed recombination in cultured cells (PMID: 23108138).",2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,295,,,www.uniprot.org,5403
"BRCA2 R3384Q does not lie within any known functional domains of the Brca2 protein (UniProt.org). R3384Q has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5404
"BRCA2 S1064* results in a premature truncation of the Brca2 protein at amino acid 1064 of 3418 (UniProt.org). S1064* has not been characterized, however, due to the effects of other truncations downstream of S1064 (PMID: 12619154, PMID: 15695382), S1064* is predicted to lead to a loss of Brca2 protein function.",2582,15695382,Functional evaluation and cancer risk assessment of BRCA2 unclassified variants.,http://www.ncbi.nlm.nih.gov/pubmed/15695382,295,,,www.uniprot.org,2580,12619154,"Deletion of Brca2 exon 27 causes hypersensitivity to DNA crosslinks, chromosomal instability, and reduced life span in mice.",http://www.ncbi.nlm.nih.gov/pubmed/12619154,5405
"BRCA2 S1172L does not lie within any known functional domains of the Brca2 protein (UniProt.org). S1172L has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5406
"BRCA2 S1680Y lies within the POLH-interacting region of the Brca2 protein (UniProt.org). S1680Y has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5407
"BRCA2 S1682G lies within the BRCA2 repeat 5 of the Brca2 protein (UniProt.org). S1682G has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5408
BRCA2 S196I does not lie within any known functional domains of the Brca2 protein (UniProt.org). S196I is predicted to disrupt Brca2 interaction with P/Caf via altering conserved phosphorylation motifs (PMID: 23704879).,2584,23704879,Missense variants of uncertain significance (VUS) altering the phosphorylation patterns of BRCA1 and BRCA2.,http://www.ncbi.nlm.nih.gov/pubmed/23704879,295,,,www.uniprot.org,5409
"BRCA2 S1982fs results in a change in the amino acid sequence of the Brca2 protein beginning at aa 1982 of 3418, likely resulting in premature truncation of the functional protein (UniProt.org). S1982fs has not been characterized, however, due to the effects of other truncations downstream of S1982 (PMID: 12619154, PMID: 15695382), S1982fs is predicted to lead to a loss of Brca2 protein function.",2582,15695382,Functional evaluation and cancer risk assessment of BRCA2 unclassified variants.,http://www.ncbi.nlm.nih.gov/pubmed/15695382,295,,,www.uniprot.org,2580,12619154,"Deletion of Brca2 exon 27 causes hypersensitivity to DNA crosslinks, chromosomal instability, and reduced life span in mice.",http://www.ncbi.nlm.nih.gov/pubmed/12619154,5410
"BRCA2 S1982fs*22 likely results in a truncation of the 3418 aa Brca2 protein at aa 1982, followed by 22 nonsense amino acids (UniProt.org). S1982fs*22 results in decreased cell survival and defective DNA-repair in cultured cells (PMID: 15695382).",2582,15695382,Functional evaluation and cancer risk assessment of BRCA2 unclassified variants.,http://www.ncbi.nlm.nih.gov/pubmed/15695382,295,,,www.uniprot.org,5411
"BRCA2 S2216F does not lie within any known functional domains of the Brca2 protein (UniProt.org). S2216F has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5412
"BRCA2 S2243Y does not lie within any known functional domains of the Brca2 protein (UniProt.org). S2243Y has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5413
"BRCA2 S2704F lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). S2704F has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,5414
"BRCA2 S278N does not lie within any known functional domains of the Brca2 protein (UniProt.org). S278N has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5415
"BRCA2 S3016Y lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). S3016Y has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,5416
"BRCA2 S3239Y does not lie within any known functional domains of the Brca2 protein (UniProt.org). S3239Y has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5417
"BRCA2 S3252F does not lie within any known functional domains of the Brca2 protein (UniProt.org). S3252F has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5418
"BRCA2 S3319Y does not lie within any known functional domains of the Brca2 protein (UniProt.org). S3319Y has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5419
"FBXW7 G423* results in a premature truncation of the Fbxw7 protein at amino acid 423 of 707 within the WD repeat domain (UniProt.org). G423* has not been characterized, however due to the loss of the WD repeat domain (UniProt.org), G423* is predicted to lead to a loss of Fbxw7 function.",295,,,www.uniprot.org,5420
"FBXW7 G423R lies within the WD repeat 2 of the Fbxw7 protein (UniProt.org). G423R has not been biochemically characterized however, G423R does not enhance xenograft tumor growth in animal models (PMID: 24838835).",295,,,www.uniprot.org,1866,24838835,FBXW7 mutations in melanoma and a new therapeutic paradigm.,http://www.ncbi.nlm.nih.gov/pubmed/24838835,5421
"FBXW7 G437E lies within the WD repeat 2 of the Fbxw7 protein (UniProt.org). G437E has been identified in the scientific literature (PMID: 27879972), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7950,27879972,Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810.,http://www.ncbi.nlm.nih.gov/pubmed/27879972,295,,,www.uniprot.org,5422
"FBXW7 G437R lies within the WD repeat 2 of the Fbxw7 protein (UniProt.org). G437R has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,5423
"FBXW7 G517E lies within the WD repeat 4 of the Fbxw7 protein (UniProt.org). G517E has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5424
"FBXW7 G579W lies between the WD 5 and 6 repeats of the Fbxw7 protein (UniProt.org). G579W has been identified in sequencing studies (PMID: 24755471), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",6962,24755471,Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24755471,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5425
"FBXW7 H379R lies within the WD repeat 1 of the Fbxw7 protein (UniProt.org). H379R has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5426
BRCA2 A2466V lies within the FANCD2-interaction region of the Brca2 protein (UniProt.org). A2466V mediates homology-directed DNA repair to the level comparable with wild-type Brca2 in cultured cells (PMID: 23108138).,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,295,,,www.uniprot.org,5439
"BRCA2 D2611G lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). D2611G results in decreased Brca2 activity, as indicated by decreased homology-directed DNA repair in cultured cells (PMID: 23108138).",2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,5440
BRCA2 A2951T lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). A2951T mediates homology-directed DNA repair to the level comparable with wild-type Brca2 in cultured cells (PMID: 23108138).,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,5441
BRCA2 D2665G lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). D2665G mediates homology-directed DNA repair at a level comparable to wild-type Brca2 in cultured cells (PMID: 23108138).,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,5442
BRCA2 D2679G lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). D2679G mediates homology-directed DNA repair at a level comparable to wild-type Brca2 in cultured cells (PMID: 23108138).,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,5443
BRCA2 D2679Y lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). D2679Y mediates homology-directed DNA repair at a level comparable to wild-type Brca2 in cultured cells (PMID: 23108138).,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,5444
"BRCA2 D2723A lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). D2723A results in decreased Brca2 function, as indicated by decreased homology-directed DNA repair in cultured cells (PMID: 23108138).",2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,5445
"BRCA2 D2723G lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). D2723G results in decreased Brca2 function, as indicated by decreased homology-directed DNA repair in cultured cells (PMID: 23108138).",2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,5446
"BRCA2 D2723H lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). D2723H results in decreased homology-directed DNA repair, increased chromosomal instability, and is unable to rescue Brca2-null cell survival in culture (PMID: 23108138, PMID: 15695382).",2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,2582,15695382,Functional evaluation and cancer risk assessment of BRCA2 unclassified variants.,http://www.ncbi.nlm.nih.gov/pubmed/15695382,5447
BRCA2 D2965H lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). D2965H mediates homology-directed DNA repair at a level comparable to wild-type Brca2 in cultured cells (PMID: 23108138).,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,5448
"BRCA2 D3073G lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). D3073G results in decreased Brca2 function, indicated by decreased homology-directed DNA repair in cultured cells (PMID: 23108138).",2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,5449
"BRCA2 D3095E lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). D3095E results in decreased Brca2 function, as indicated by decreased homology-directed DNA repair in cultured cells (PMID: 23108138).",2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,5450
BRCA2 E1382del results in the deletion of one amino acid in the POLH-interaction region of the Brca2 protein at amino acids 1382 (UniProt.org). E1382del results in decreased homology-directed DNA repair and is unable to rescue Brca2-null cell survival in culture (PMID: 15695382).,2582,15695382,Functional evaluation and cancer risk assessment of BRCA2 unclassified variants.,http://www.ncbi.nlm.nih.gov/pubmed/15695382,295,,,www.uniprot.org,5451
BRCA2 E2856A lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). E2856A mediates homology-directed DNA repair at a level comparable with wild-type Brca2 in cultured cells (PMID: 23108138).,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,5452
"BRCA2 E3002D lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). E3002D results in decreased Brca2 function, as indicated by decreased homology-directed DNA repair in cultured cells (PMID: 23108138).",2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,5454
"BRCA2 E3002K lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). E3002K results in decreased homology-directed DNA repair and is unable to rescue Brca2-null cell survival in culture (PMID: 23108138, PMID: 22678057).",2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,2588,22678057,Functional evaluation of BRCA2 variants mapping to the PALB2-binding and C-terminal DNA-binding domains using a mouse ES cell-based assay.,http://www.ncbi.nlm.nih.gov/pubmed/22678057,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,5455
BRCA2 E462G does not lie within any known functional domains of the Brca2 protein (UniProt.org). E462G mediates homology-directed DNA repair and rescues Brca2-null cell survival at levels comparable to wild-type Brca2 in culture (PMID: 15695382).,2582,15695382,Functional evaluation and cancer risk assessment of BRCA2 unclassified variants.,http://www.ncbi.nlm.nih.gov/pubmed/15695382,295,,,www.uniprot.org,5456
"BRCA2 F2406L lies within the FANCD2-interaction region of the Brca2 protein (UniProt.org). F2406L mediates homology-directed DNA repair and rescues Brca2-null cell survival at levels comparable to wild-type Brca2 in culture (PMID: 23108138, PMID: 22678057).",2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,2588,22678057,Functional evaluation of BRCA2 variants mapping to the PALB2-binding and C-terminal DNA-binding domains using a mouse ES cell-based assay.,http://www.ncbi.nlm.nih.gov/pubmed/22678057,295,,,www.uniprot.org,5457
"BRCA2 G2585R lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). G2585R results in decreased Brca2 function, as indicated by decreased homology-directed DNA repair in cultured cells (PMID: 23108138).",2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,5459
"BRCA2 G2609D lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). G2609D results in decreased Brca2 function, as indicated by decreased homology-directed DNA repair in cultured cells (PMID: 23108138).",2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,5460
"BRCA2 G2748D lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). G2748D results in decreased Brca2 function, as indicated by decreased homology-directed DNA repair in cultured cells (PMID: 23108138).",2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,5462
"BRCA2 G2793E lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). G2793E results in decreased Brca2 function, as indicated by decreased homology-directed DNA repair in cultured cells (PMID: 23108138).",2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,5463
"BRCA2 G2793R lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). G2793R results in decreased Brca2 function, as indicated by decreased homology-directed DNA repair in cultured cells (PMID: 23108138).",2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,5464
"BRCA2 G2812E lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). G2812E results in decreased Brca2 function, as indicated by decreased homology-directed DNA repair in cultured cells (PMID: 23108138).",2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,5465
BRCA2 G2813E lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). G2813E mediates homology-directed DNA repair at a level comparable to wild-type Brca2 in cultured cells (PMID: 23108138).,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,5467
BRCA2 G2901D lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). G2901D mediates homology-directed DNA repair at a level comparable to wild-type Brca2 in cultured cells (PMID: 23108138).,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,5468
"BRCA2 G3076E lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). G3076E results in decreased Brca2 function, as indicated by decreased homology-directed DNA repair in cultured cells (PMID: 23108138).",2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,5469
"BRCA2 G3076V lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). G3076V results in decreased Brca2 function, as indicated by decreased homology-directed DNA repair in cultured cells (PMID: 23108138).",2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,5471
BRCA2 H2440R lies within the FANCD2-interaction region of the Brca2 protein (UniProt.org). H2440R mediates homology-directed DNA repair at a level comparable to wild-type Brca2 in cultured cells (PMID: 23108138).,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,295,,,www.uniprot.org,5472
"BRCA2 I2627F lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). I2627F results in decreased Brca2 function, as indicated by decreased homology-directed DNA repair in cultured cells (PMID: 23108138).",2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,5474
BRCA2 K2411T lies within the FANCD2-interaction region of the Brca2 protein (UniProt.org). K2411T mediates homology-directed DNA repair at a level comparable to wild-type Brca2 in cultured cells (PMID: 23108138).,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,295,,,www.uniprot.org,5475
BRCA2 K2729N lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). K2411T mediates homology-directed DNA repair at a level comparable to wild-type Brca2 in cultured cells (PMID: 23108138).,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,5476
BRCA2 K3326* results in a premature truncation of the Brca2 protein at amino acid 3326 of 3418 (UniProt.org). K3326* mediates homology-directed DNA repair and rescues Brca2-null cell survival at levels comparable to wild-type Brca2 in culture (PMID: 15695382).,295,,,www.uniprot.org,2582,15695382,Functional evaluation and cancer risk assessment of BRCA2 unclassified variants.,http://www.ncbi.nlm.nih.gov/pubmed/15695382,5477
"BRCA2 L2510P lies within the FANCD2-interaction region of the Brca2 protein (UniProt.org). L2510P results in decreased Brca2 function, as indicated by decreased homology-directed DNA repair in cultured cells (PMID: 23108138).",295,,,www.uniprot.org,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,5478
"BRCA2 L2647P lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). L2647P results in decreased Brca2 function, as indicated by decreased homology-directed DNA repair in cultured cells (PMID: 23108138).",2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,5479
"BRCA2 L2653P lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). L2653P results in decreased Brca2 function, as indicated by decreased homology-directed DNA repair in cultured cells (PMID: 23108138).",2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,5480
"BRCA2 L2654P lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). L2654P results in decreased Brca2 function, as indicated by decreased homology-directed DNA repair in cultured cells (PMID: 23108138).",2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,5482
"BRCA2 L2688P lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). L2688P results in decreased Brca2 function, as indicated by decreased homology-directed DNA repair in cultured cells (PMID: 23108138).",2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,5483
"BRCA2 L2792P lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). L2792P results in decreased Brca2 function, as indicated by decreased homology-directed DNA repair in cultured cells (PMID: 23108138).",2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,5484
BRCA2 L2865V lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). L2865V mediates homology-directed DNA repair at a level comparable to wild-type Brca2 in cultured cells (PMID: 23108138).,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,5485
BRCA2 M2676T lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). M2676T mediates homology-directed DNA repair at a level comparable to wild-type Brca2 in cultured cells (PMID: 23108138).,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,5486
"BRCA2 N3124I lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). N3124I results in decreased homology-directed DNA repair and is unable to rescue Brca2-null cell survival in culture (PMID: 23108138, PMID: 22678057).",2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,2588,22678057,Functional evaluation of BRCA2 variants mapping to the PALB2-binding and C-terminal DNA-binding domains using a mouse ES cell-based assay.,http://www.ncbi.nlm.nih.gov/pubmed/22678057,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,5488
BRCA2 P2589H lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). P2589H mediates homology-directed DNA repair at a level comparable to wild-type Brca2 in cultured cells (PMID: 23108138).,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,5489
"BRCA2 P2800R lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). P2800R results in decreased Brca2 function, as indicated by decreased homology-directed DNA repair in cultured cells (PMID: 23108138).",2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,5490
"BRCA2 P2800S lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). P2800S results in decreased Brca2 function, as indicated by decreased homology-directed DNA repair in cultured cells (PMID: 23108138).",2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,5492
BRCA2 P3063S lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). P3063S mediates homology-directed DNA repair at a level comparable to wild-type Brca2 in cultured cells (PMID: 23108138).,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,5493
"BRCA2 R2659G lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). R2659G results in decreased Brca2 function, as indicated by decreased homology-directed DNA repair in cultured cells (PMID: 23108138).",2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,5494
"BRCA2 R2659K lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). R2659K results in decreased homology-directed DNA repair, increased chromosomal instability, and is unable to rescue Brca2-null cell survival in culture (PMID: 15695382).",2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,2582,15695382,Functional evaluation and cancer risk assessment of BRCA2 unclassified variants.,http://www.ncbi.nlm.nih.gov/pubmed/15695382,5496
"BRCA2 R2784W lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). R2784W results in decreased Brca2 function, as indicated by decreased homology-directed DNA repair in cultured cells (PMID: 23108138).",2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,5497
BRCA2 R2787H lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). R2787H mediates homology-directed DNA repair at a level comparable to wild-type Brca2 in cultured cells (PMID: 23108138).,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,5499
"BRCA2 R2842L lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). R2842L results in decreased Brca2 activity, as indicated by decreased homology-directed DNA repair in cultured cells (PMID: 23108138).",2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,5500
BRCA2 R2973C lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). R2973C mediates homology-directed DNA repair at a level comparable to wild-type Brca2 in cultured cells (PMID: 23108138).,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,5501
"BRCA2 R3052W lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). R3052W results in decreased Brca2 function, as indicated by decreased homology-directed DNA repair in cultured cells (PMID: 23108138).",2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,5502
BRCA2 S2414L lies within the FANCD2-interaction region of the Brca2 protein (UniProt.org). S2414L mediates homology-directed DNA repair at a level comparable to wild-type Brca2 in cultured cells (PMID: 23108138).,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,295,,,www.uniprot.org,5503
BRCA2 S2807L lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). S2807L mediates homology-directed DNA repair at a level comparable to wild-type Brca2 in cultured cells (PMID: 23108138).,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,5504
BRCA2 S3020C lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). S3020C mediates homology-directed DNA repair at a level comparable to wild-type Brca2 in cultured cells (PMID: 23108138).,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,5505
"FLT3 D835X indicates any Flt3 missense mutation which results in the aspartic acid (D) at amino acid 835 being replaced by a different amino acid. FLT3 D835 mutations are ""hotspot"" mutations resulting in increased Flt3 kinase activity (PMID: 11290608).",2011,11290608,Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/11290608,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,5520
"FBXW7 H382N lies within the WD repeat 1 of the Fbxw7 protein (UniProt.org). H382N has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5521
FBXW7 H460R lies within the WD repeat domain of the Fbxw7 protein (UniProt.org). H460R confers a loss of function to the Fbxw7 protein as demonstrated by over expression of its ubiquitination target protein Ccne1 (PMID: 14507635).,2598,14507635,"BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets.",http://www.ncbi.nlm.nih.gov/pubmed/14507635,295,,,www.uniprot.org,5522
"FBXW7 H460Y lies within the WD repeat 3 of the Fbxw7 protein (UniProt.org). H460Y has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5523
"FBXW7 H500D lies within the WD repeat 4 of the Fbxw7 protein (UniProt.org). H500D has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5524
"NPM1-ALK (NPM-ALK) results from the fusion of NPM1 and ALK and has been identified in lymphomas (PMID: 17488663), resulting in an oncogenic protein with constitutive tyrosine kinase activity (PMID: 8122112, PMID: 9121481).",2599,8122112,"Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.",http://www.ncbi.nlm.nih.gov/pubmed/8122112,2600,9121481,Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/9121481,7593,17488663,Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias.,http://www.ncbi.nlm.nih.gov/pubmed/17488663,5525
"FBXW7 Y602H lies within the WD repeat 6 of the Fbxw7 protein (UniProt.org). Y602H has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5526
"FBXW7 W526R lies within the WD repeat 4 of the Fbxw7 protein (UniProt.org). W526R has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5527
"FBXW7 W526L lies within the WD repeat 4 of the Fbxw7 protein (UniProt.org). W526L has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5528
"FBXW7 W446C lies within the WD repeat 2 of the Fbxw7 protein (UniProt.org). W446C has been identified in sequencing studies (PMID: 23103869), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6989,23103869,Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes.,http://www.ncbi.nlm.nih.gov/pubmed/23103869,5529
"FBXW7 W237* results in a premature truncation of the Fbxw7 protein at amino acid 237 of 707 (UniProt.org). Due to the loss of the WD repeat domain, W237* is predicted to lead to a loss of Fbxw7 protein function (UniProt.org). ",295,,,www.uniprot.org,5530
"FBXW7 V504I lies within the WD repeat 4 of the Fbxw7 protein (UniProt.org). V504I has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5531
"FBXW7 V464E lies within the WD repeat 3 of the Fbxw7 protein (UniProt.org). V464E has been identified in sequencing studies (PMID: 22980975), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1726,22980975,Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/22980975,5532
"FBXW7 V418M lies within the WD repeat 1 of the Fbxw7 protein (UniProt.org). V418M has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5533
"FBXW7 T165fs results in a change in the amino acid sequence of the Fbxw7 protein beginning at aa 165 of 707, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of multiple functional domains, T165fs is predicted to lead to a loss of Fbxw7 protein function (UniProt.org). ",295,,,www.uniprot.org,5534
FBXW7 T15_G16insP results in the insertion of a proline (P) in the Fbxw7 protein between amino acids 15 and 16 (UniProt.org). T15_G16insP results in decreased binding of Fbxw7 to cyclinE1 and aberrant Fbxw7 localization in cell culture (PMID: 17909001).,295,,,www.uniprot.org,2635,17909001,FBXW7/hCDC4 is a general tumor suppressor in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17909001,5535
"CTNNB1 P44_S45del results in the deletion of two amino acids within a phosphorylation site of the Ctnnb1 protein from amino acids 44 to 45 (UniProt.org). CTNNB1 P44_S45del has not been biochemically characterized however,  it is predicted to confer a gain of function to Ctnnb1 as demonstrated by nuclear accumulation of Ctnnb1(PMID: 19863445). ",4350,19863445,Cushing's syndrome in an infant secondary to malignant adrenocortical tumors with somatic mutation of beta-catenin.,http://www.ncbi.nlm.nih.gov/pubmed/19863445,295,,,www.uniprot.org,5537
"MAP2K1 D351G lies within the protein kinase domain of the Map2k1 protein (UniProt.org). D351G has been identified in the scientific literature (PMID: 26582713, PMID: 24755471), but has not been biochemically characterized and therefore, its effect on Map2k1 protein function is unknown (PubMed, Mar 2017). ",6962,24755471,Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24755471,5602,26582713,"Identification of an ""Exceptional Responder"" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.",http://www.ncbi.nlm.nih.gov/pubmed/26582713,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5539
"MAP2K1 H119Y lies within the protein kinase domain of the Map2k1 protein (UniProt.org). H119Y has been identified in the scientific literature (PMID: 26582713, PMID: 24755471), but has not been biochemically characterized and therefore, its effect on Map2k1 protein function is unknown (PubMed, Apr 2017). ",295,,,www.uniprot.org,6962,24755471,Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24755471,5602,26582713,"Identification of an ""Exceptional Responder"" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.",http://www.ncbi.nlm.nih.gov/pubmed/26582713,115,0,,http://www.ncbi.nlm.nih.gov/pubmed,5540
"PIK3CA G914R lies within the PI3K/PI4K protein kinase domain of the Pik3ca protein (UniProt.org). G914R has not been characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5544
"EGFR K721M lies within the protein kinase domain of the post-translationally processed Egfr protein, and corresponds to K745M in the canonical form (PMID: 20495563, UniProt.org). K721M results in a loss of Egfr kinase activity in cultured cells (PMID: 3498122, PMID: 19560417).",2542,3498122,Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor.,http://www.ncbi.nlm.nih.gov/pubmed/3498122,2536,19560417,The juxtamembrane region of the EGF receptor functions as an activation domain.,http://www.ncbi.nlm.nih.gov/pubmed/19560417,2624,20495563,Post-translational modifications in signal integration.,http://www.ncbi.nlm.nih.gov/pubmed/20495563,295,,,www.uniprot.org,5553
"FBXW7 H500R lies within the WD repeat 4 of the Fbxw7 protein (UniProt.org). H500R has been identified in sequencing studies (PMID: 22842228), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",7109,22842228,Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22842228,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5554
"FBXW7 H500Y lies within the WD repeat 4 of the Fbxw7 protein (UniProt.org). H500Y has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5555
"FBXW7 K167T does not lie within any known functional domains of the Fbxw7 protein (UniProt.org). K167T has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5556
"FBXW7 K239Q does not lie within any known functional domains of the Fbxw7 protein (UniProt.org). K239Q has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5557
"FBXW7 K299fs results in a change in the amino acid sequence of the Fbxw7 protein beginning at aa 299 of 707, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the WD repeat domains (UniProt.org), K299fs is predicted to lead to a loss of Fbxw7 protein function.",295,,,www.uniprot.org,5558
"FBXW7 K404E lies within the WD 1 repeat domain of the Fbxw7 protein (UniProt.org). K404E has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5559
"FBXW7 L301P lies within the F-box domain of the Fbxw7 protein (UniProt.org). L301P has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5560
"FBXW7 L320I lies within the F-box domain of the Fbxw7 protein (UniProt.org). L320I has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5561
"FBXW7 P247T does not lie within any known functional domains of the Fbxw7 protein (UniProt.org). P247T has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5562
"FBXW7 P285H lies within the F-box domain of the Fbxw7 protein (UniProt.org). P285H has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5563
"FBXW7 P298L lies within the F-box domain of the Fbxw7 protein (UniProt.org). P298L has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5564
RB1 mutant indicates an unspecified mutation in the RB1 gene. ,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,5565
SMAD4 mutant indicates an unspecified mutation in the SMAD4 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,5566
ABL1 E255K lies within the protein kinase domain of the Abl1 protein (UniProt.org). E255K has been demonstrated to occur as a secondary resistance mutation in the context of BCR-ABL and results in both increased kinase activity and phosphorylation of STAT5 (PMID: 15194504).,2626,15194504,The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase.,http://www.ncbi.nlm.nih.gov/pubmed/15194504,5567
"ABL1 over exp indicates an over expression of the Abl1 protein. However, the mechanism causing the over expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,5568
"PIK3CA R38C lies within the PI3K-ABD domain of the Pik3ca protein (UniProt.org). R38C confers a gain of function to Pik3ca, as indicated by increased phosphorylation of downstream targets Akt, GSK3-beta, FoxO1, FoxO3a, and S6 in cell culture (PMID: 18829572).",1933,18829572,PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.,http://www.ncbi.nlm.nih.gov/pubmed/18829572,5569
"PIK3CA E365K lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). E365K confers a gain of function to Pik3ca, as indicated by increased phosphorylation of downstream targets Akt, GSK3-beta, FoxO1, FoxO3a, and S6 in cell culture (PMID: 18829572, PMID: 21266528).",2211,21266528,A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/21266528,1933,18829572,PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.,http://www.ncbi.nlm.nih.gov/pubmed/18829572,5570
"FBXW7 R14Q does not lie within any known functional domains of the Fbxw7 protein (UniProt.org). R14Q has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,5579
"FBXW7 R179C does not lie within any known functional domains of the Fbxw7 protein (UniProt.org). R179C has been identified in sequencing studies (PMID: 27714650), but has not been biochemically  characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Feb 2017).",9789,27714650,Molecular Profiling of Synchronous Colon Cancers and Anaplastic Thyroid Cancer in a Patient with Lynch Syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/27714650,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5580
"FBXW7 R179H does not lie within any known functional domains of the Fbxw7 protein (UniProt.org). R179H has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5581
"FBXW7 R224* results in a premature truncation of the Fbxw7 protein at amino acid 224 of 707 (UniProt.org). Due to the loss of all functional domains (UniProt.org), R224* is predicted to lead to a loss of Fbxw7 protein function. ",295,,,www.uniprot.org,5582
APC mutant indicates an unspecified mutation in the APC gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,5583
"FBXW7 R224Q does not lie within any known functional domains of the Fbxw7 protein (UniProt.org). R224Q has been identified in sequencing studies (PMID: 22895193), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",4597,22895193,Recurrent R-spondin fusions in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22895193,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5584
"FBXW7 R367* results in a premature truncation of the Fbxw7 protein at amino acid 367 of 707 (UniProt.org). Due to the loss of the WD repeat domain, R367* is predicted to lead to a loss of Fbxw7 protein function (UniProt.org). ",295,,,www.uniprot.org,5585
"FBXW7 R393* results in a premature truncation of the Fbxw7 protein at amino acid 393 of 707 (UniProt.org). Due to the disruption of the WD repeat domain, R393* is predicted to lead to a loss of Fbxw7 protein function (UniProt.org).",295,,,www.uniprot.org,5586
"FBXW7 R465L lies within the WD repeat domain of the Fbxw7 protein (UniProt.org). R465L confers a loss of FBXW7-substrate interaction and impairs substrate degradation by FBXW7, resulting in activation of a Notch-driven reporter (PMID: 19340001).",295,,,www.uniprot.org,2634,19340001,"The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.",http://www.ncbi.nlm.nih.gov/pubmed/19340001,5587
"FBXW7 R465P lies within the WD repeat domain of the Fbxw7 protein (UniProt.org). R465P has not been characterized, however other R465 hotspots inactivate Fbxw7, therefore, R465P is predicted to lead to a loss of function (PMID: 17646409, PMID: 17909001, PMID: 19340001).",295,,,www.uniprot.org,379,17646409,FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/17646409,2635,17909001,FBXW7/hCDC4 is a general tumor suppressor in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17909001,2634,19340001,"The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.",http://www.ncbi.nlm.nih.gov/pubmed/19340001,5588
"FBXW7 R465Y lies within the WD repeat domain of the Fbxw7 protein (UniProt.org). R465Y has not been characterized however other R465 hotspots inactivate Fbxw7 therefore, R465Y is predicted to lead to a loss of function (PMID: 17646409, PMID: 17909001, PMID: 19340001).",295,,,www.uniprot.org,2634,19340001,"The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.",http://www.ncbi.nlm.nih.gov/pubmed/19340001,2635,17909001,FBXW7/hCDC4 is a general tumor suppressor in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17909001,379,17646409,FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/17646409,5589
"FBXW7 R473fs results in a change in the amino acid sequence of the Fbxw7 protein beginning at aa 473 of 707, likely resulting in a premature truncation of the functional protein (UniProt.org). Due to the loss of the majority of the WD repeat domains (UniProt.org), R473fs is predicted to lead to a loss of Fbxw7 protein function.",295,,,www.uniprot.org,5590
"FBXW7 R473fs*25 likely results in a truncation of the 707 aa Fbxw7 protein at aa 473, followed by 25 nonsense amino acids (UniProt.org). Due to the loss of the majority of the WD repeat domains (UniProt.org), R473fs*25 is predicted to lead to a loss of Fbxw7 protein function.",295,,,www.uniprot.org,5591
"FBXW7 R473fs*4 likely results in a truncation of the 707 aa Fbxw7 protein at aa 473, followed by 4 nonsense amino acids (UniProt.org). Due to the loss of the majority of the WD repeat domains (UniProt.org), R473fs*4 is predicted to lead to a loss of Fbxw7 protein function.",295,,,www.uniprot.org,5592
"FBXW7 R479* results in a premature truncation of the Fbxw7 protein at amino acid 479 of 707 (UniProt.org). Due to the disruption of the WD repeat domain, R479* is predicted to lead to a loss of Fbxw7 protein function (UniProt.org).",295,,,www.uniprot.org,5593
"FBXW7 R479G lies within the WD repeat domain of the Fbxw7 protein (UniProt.org). R479G has not been characterized, however other R479 hotspot mutations inactivate Fbxw7 therefore, R479G is predicted to lead to a loss of function (PMID: 17646409, PMID: 17575125, PMID: 22608923).",2637,17575125,The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17575125,295,,,www.uniprot.org,2638,22608923,Negative regulation of the stability and tumor suppressor function of Fbw7 by the Pin1 prolyl isomerase.,http://www.ncbi.nlm.nih.gov/pubmed/22608923,379,17646409,FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/17646409,5594
FBXW7 R479L lies within the WD repeat domain of the Fbxw7 protein (UniProt.org). R479L confers a loss of function to the Fbxw7 protein as demonstrated by increased ubiquitination and decreased stability of the Fbxw7 protein (PMID: 22608923).,2638,22608923,Negative regulation of the stability and tumor suppressor function of Fbw7 by the Pin1 prolyl isomerase.,http://www.ncbi.nlm.nih.gov/pubmed/22608923,5595
"FBXW7 R479H lies within the WD repeat domain of the Fbxw7 protein (UniProt.org). R479H confers a loss of FBXW7-substrate interaction and impairs substrate degradation by FBXW7, resulting in activation of a Notch-driven reporter (PMID: 17575125).",2637,17575125,The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17575125,295,,,www.uniprot.org,5596
"FBXW7 R479P lies within the WD repeat domain of the Fbxw7 protein (UniProt.org). R479P has not been characterized, however other R479 hotspot mutations inactivate Fbxw7 therefore, R479P is predicted to lead to a loss of function (PMID: 17646409, PMID: 17575125, PMID: 22608923).",2637,17575125,The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling.,http://www.ncbi.nlm.nih.gov/pubmed/17575125,295,,,www.uniprot.org,379,17646409,FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/17646409,2638,22608923,Negative regulation of the stability and tumor suppressor function of Fbw7 by the Pin1 prolyl isomerase.,http://www.ncbi.nlm.nih.gov/pubmed/22608923,5597
"FBXW7 R505H lies within the WD 4 repeat domain of the Fbxw7 protein (UniProt.org). R505H has been identified in the scientific literature (PMID: 25617745), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7960,25617745,A pathway-centric survey of somatic mutations in Chinese patients with colorectal carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/25617745,5598
"FBXW7 R505S lies within the WD 4 repeat domain of the Fbxw7 protein (UniProt.org). R505S has been identified in the scientific literature (PMID: 27101000), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Feb 2017).",7961,27101000,Validation and Application of a Custom-Designed Targeted Next-Generation Sequencing Panel for the Diagnostic Mutational Profiling of Solid Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/27101000,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5599
FBXW7 R658Q lies within the WD 7 repeat domain of the Fbxw7 protein (UniProt.org). R658Q is predicted to have activity similar to wild-type Fbxw7 based on comparison and correlation analysis of induced gene expression signatures (PMID: 27147599).,295,,,www.uniprot.org,6273,27147599,Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.,http://www.ncbi.nlm.nih.gov/pubmed/27147599,5600
"FBXW7 R689W does not lie within any known functional domains of the Fbxw7 protein (UniProt.org). R689W has been identified in the scientific literature (PMID: 19245433), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Feb 2017).",7962,19245433,FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/19245433,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5601
"FBXW7 S396N lies within the WD 1 repeat domain of the Fbxw7 protein (UniProt.org). S396N has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5602
"FBXW7 S398F lies within the WD repeat 1 of the Fbxw7 protein (UniProt.org). S398F has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5603
"FBXW7 S476I lies within the WD repeat 3 of the Fbxw7 protein (UniProt.org). S476I has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5604
"FBXW7 S516N lies within the WD repeat 4 of the Fbxw7 protein (UniProt.org). S516N has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5605
"FBXW7 S516R lies within the WD repeat 4 of the Fbxw7 protein (UniProt.org). S516R has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5606
"FBXW7 S546L lies within the WD repeat 5 of the Fbxw7 protein (UniProt.org). S546L has been identified in sequencing studies (PMID: 26000489), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5982,26000489,Integrative clinical genomics of advanced prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26000489,5607
"FBXW7 S558F lies within the WD repeat 5 of the Fbxw7 protein (UniProt.org). S558F has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5608
"FBXW7 S562L lies within the WD repeat 5 of the Fbxw7 protein (UniProt.org). S562L has been identified in sequencing studies (PMID: 22622578), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6955,22622578,Melanoma genome sequencing reveals frequent PREX2 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/22622578,5609
"FBXW7 S601F lies within the WD repeat 6 of the Fbxw7 protein (UniProt.org). S601F has been identified in sequencing studies (PMID: 22622578), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6955,22622578,Melanoma genome sequencing reveals frequent PREX2 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/22622578,5610
ATM A1742P does not lie within any known functional domains of the Atm protein (UniProt.org). A1742P confers a loss of function to the Atm protein as demonstrated by defective kinase activity (PMID: 16014569).,295,,,www.uniprot.org,2639,16014569,Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL.,http://www.ncbi.nlm.nih.gov/pubmed/16014569,5611
"ATM C353fs*5 likely results in a truncation of the 3056 aa Atm protein at aa 353, followed by 5 nonsense amino acids (UniProt.org). Due to the loss of all known functional domains (UniProt.org), C353fs*5 is predicted to lead to a loss of Atm function.",295,,,www.uniprot.org,5612
ATM D1682Y does not lie within any known functional domains of the Atm protein (UniProt.org). D1682Y confers a loss of function to the Atm protein as demonstrated by defective kinase activity (PMID: 16014569).,2639,16014569,Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL.,http://www.ncbi.nlm.nih.gov/pubmed/16014569,295,,,www.uniprot.org,5613
"TP53 G245F is a hotspot mutation that lies within the DNA binding domain of the Tp53 protein (PMID: 22713868). G245F has not been characterized, however other G245 mutations confer a loss of wild-type Tp53 function, thus G245F is predicted to lead to a loss of Tp53 protein function (PMID: 22214764, PMID: 24857548, PMID: 24651012).  ",2456,24857548,Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation.,http://www.ncbi.nlm.nih.gov/pubmed/24857548,2457,22214764,Interaction between ZBP-89 and p53 mutants and its contribution to effects of HDACi on hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22214764,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,2458,24651012,Mutant p53 in cancer: new functions and therapeutic opportunities.,http://www.ncbi.nlm.nih.gov/pubmed/24651012,5615
"TP53 V25F lies within the transactivation domain of the Tp53 protein (PMID: 22713868). V25F has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,5616
"TP53 V118F lies within the DNA binding domain of the Tp53 protein (PMID: 22713868). V118F has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5617
"EGFR K745_A750del results in the deletion of six amino acids in the protein kinase domain of the Egfr protein from amino acids 745 to 750 (UniProt.org). K745_A750del has not been characterized, however other exon 19 deletion mutations in the Egfr protein are activating, thus K745_A750del is predicted to result in a gain of function (PMID: 16373402, PMID: 16912195, PMID: 23387505).",21,16912195,"Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib.",http://www.ncbi.nlm.nih.gov/pubmed/16912195,1804,16373402,Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16373402,441,23387505,Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/23387505,295,,,www.uniprot.org,5618
"FGFR3 A257V lies within the Ig-like C2 type domain 3 of the Fgfr3 protein (UniProt.org). A257V has not been characterized in the scientific literature and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jul 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5623
"ATM D2720H lies within the PI3K/PI4K protein kinase domain of the Atm protein (UniProt.org). D2720H has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5625
"ATM D2720N lies within the PI3K/PI4K protein kinase domain of the Atm protein (UniProt.org). D2720N has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5626
"ATM D2721N lies within the PI3K/PI4K protein kinase domain of the Atm protein (UniProt.org). D2721N has been identified in sequencing studies (PMID: 24069199) but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7848,24069199,Identification and characterization of cancer mutations in Japanese lung adenocarcinoma without sequencing of normal tissue counterparts.,http://www.ncbi.nlm.nih.gov/pubmed/24069199,5627
"TP53 P301fs results in a change in the amino acid sequence of the Tp53 protein beginning at aa 301 of 393, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the oligomerization domain (UniProt.org), P301fs is predicted to lead to a loss of Tp53 protein function.",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5628
"ATM D2721Y lies within the PI3K/PI4K protein kinase domain of the Atm protein (UniProt.org). D2721Y has not been characterized in the scientific litersture and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5629
"ATM D2725G lies within the PI3K/PI4K protein kinase domain of the Atm protein (UniProt.org). D2725G has been identified in sequencing studies (PMID: 24522528) but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7405,24522528,Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia.,http://www.ncbi.nlm.nih.gov/pubmed/24522528,5630
"ATM D2725V lies within the PI3K/PI4K protein kinase domain of the Atm protein (UniProt.org). D2725V has been identified in the scientific literature (PMID: 11756177) but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7870,11756177,ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances.,http://www.ncbi.nlm.nih.gov/pubmed/11756177,295,,,www.uniprot.org,5631
"ATM D2870Y lies within the PI3K/PI4K protein kinase domain of the Atm protein (UniProt.org). D2870Y has been identified in sequencing studies (PMID: 22610119) but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6289,22610119,"Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.",http://www.ncbi.nlm.nih.gov/pubmed/22610119,5632
"FGFR3 Q256R lies within the Ig-like C2-type domain of the Fgfr3 protein (UniProt.org). Q256R has not been characterized in the scientific literature and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jul 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5633
"GNAQ D205N lies within the GTP binding region of the Gnaq protein (UniProt.org). D205N has not been characterized in the scientific literature and therefore, its effect on Gnaq protein function is unknown (PubMed, Mar 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5634
"BRCA2 S3332Y does not lie within any known functional domains of the Brca2 protein (UniProt.org). S3332Y has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5635
"BRCA2 S3396R does not lie within any known functional domains of the Brca2 protein (UniProt.org). S3396R has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5636
"BRCA2 T1067A does not lie within any known functional domains of the Brca2 protein (UniProt.org). T1067A has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5637
BRCA2 T1302del results in the deletion of an amino acid within the BRC repeats of the Brca2 protein at amino acid 1302 (PMID: 15695382). T1302del results in increased chromosomal instability and is unable to rescue Brca2-null cell survival in culture (PMID: 15695382).,295,,,www.uniprot.org,2582,15695382,Functional evaluation and cancer risk assessment of BRCA2 unclassified variants.,http://www.ncbi.nlm.nih.gov/pubmed/15695382,5638
"BRCA2 T1346N lies within the POLH-interacting region of the Brca2 protein (UniProt.org). T1346N has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5639
"BRCA2 T1354A lies within the POLH-interacting region of the Brca2 protein (UniProt.org). T1354A has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5640
"BRCA2 T1785I does not lie within any known functional domains of the Brca2 protein (UniProt.org). T1785I has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5641
"BRCA2 T1887M does not lie within any known functional domains of the Brca2 protein (UniProt.org). T1887M has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5642
"BRCA2 T1915M lies within the BRC repeats of the Brca2 protein (PMID: 21671020). T1915M has been identified in sequencing studies (PMID: 25589003), but has not been biochemically characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, Jan 2017).",6992,25589003,Sporadic hemangioblastomas are characterized by cryptic VHL inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/25589003,285,,,http://www.ncbi.nlm.nih.gov/pubmed,2645,21671020,Effect of the overexpression of BRCA2 unclassified missense variants on spontaneous homologous recombination in human cells.,http://www.ncbi.nlm.nih.gov/pubmed/21671020,5643
BRCA2 T2515I lies within the FANCD2-interaction region of the Brca2 protein (UniProt.org). T2515I results in decreased homology-directed DNA repair and is unable to rescue Brca2-null cell survival in culture (PMID: 15695382).,2582,15695382,Functional evaluation and cancer risk assessment of BRCA2 unclassified variants.,http://www.ncbi.nlm.nih.gov/pubmed/15695382,295,,,www.uniprot.org,5644
"BRCA2 T2722R lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). T2722R results in decreased Brca2 function, as indicated by decreased homology-directed DNA repair in cultured cells (PMID: 23108138).",2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,5645
BRCA2 T3013I lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). T3013I mediates homology-directed DNA repair at a level comparable to wild-type Brca2 in cultured cells (PMID: 23108138).,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,5646
"BRCA2 T3030fs results in a change in the amino acid sequence of the Brca2 protein beginning at aa 3030 of 3418, likely resulting in premature truncation of the functional protein (UniProt.org). T3030fs has not been characterized, however, due to the effects of other truncations downstream of T3030 (PMID: 12619154), T3030fs is predicted to lead to a loss of Brca2 protein function.",295,,,www.uniprot.org,2580,12619154,"Deletion of Brca2 exon 27 causes hypersensitivity to DNA crosslinks, chromosomal instability, and reduced life span in mice.",http://www.ncbi.nlm.nih.gov/pubmed/12619154,5647
"BRCA2 T3033fs*29 likely results in a truncation of the 3418 aa Brca2 protein at aa 3033, followed by 29 nonsense amino acids (UniProt.org). T3033fs*29 has not been characterized, however, due to the effects of other truncations downstream of T3033 (PMID: 12619154), T3033fs*29 is predicted to lead to a loss of Brca2 protein function.",295,,,www.uniprot.org,2580,12619154,"Deletion of Brca2 exon 27 causes hypersensitivity to DNA crosslinks, chromosomal instability, and reduced life span in mice.",http://www.ncbi.nlm.nih.gov/pubmed/12619154,5648
"BRCA2 T3033I lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). T3033I results in decreased Brca2 function, as indicated by decreased homology-directed DNA repair in cultured cells (PMID: 23108138).",2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,5649
"BRCA2 T868I lies within the NPM1-interacting region of the Brca2 protein (UniProt.org). T868I has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5650
"BRCA2 V1078I does not lie within any known functional domains of the Brca2 protein (UniProt.org). V1078I has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5651
"BRCA2 V1810I does not lie within any known functional domains of the Brca2 protein (UniProt.org). V1810I has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5652
BRCA2 V2908G lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). V2908G maintains chromosomal stability and rescues Brca2-null cell survival at a level comparable to wild-type Brca2 in culture (PMID: 15695382).,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,2582,15695382,Functional evaluation and cancer risk assessment of BRCA2 unclassified variants.,http://www.ncbi.nlm.nih.gov/pubmed/15695382,5653
"BRCA2 W2626C lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). W2626C results in decreased Brca2 function, indicated by decreased homology-directed DNA repair in cultured cells (PMID: 23108138).",2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,5654
"BRCA2 Y1569C lies within the POLH-interacting region of the Brca2 protein (UniProt.org). Y1569C has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5655
"BRCA2 Y2660C lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). Y2660C has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,5656
"BRCA2 Y2660D lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). Y2660D results in decreased Brca2 function, as indicated by decreased homology-directed DNA repair in cultured cells (PMID: 23108138).",2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,5657
"BRCA2 Y2726C lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). Y2726C results in decreased Brca2 function, as indicated by decreased homology-directed DNA repair in cultured cells (PMID: 23108138).",2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,5658
"BRCA2 Y2997* results in a premature truncation of the Brca2 protein at amino acid 2997 of 3418 (UniProt.org). Y2997* has not been characterized, however, due to the effects of other truncations downstream of Y2997 (PMID: 12619154), Y2997* is predicted to lead to a loss of Brca2 protein function.",295,,,www.uniprot.org,2580,12619154,"Deletion of Brca2 exon 27 causes hypersensitivity to DNA crosslinks, chromosomal instability, and reduced life span in mice.",http://www.ncbi.nlm.nih.gov/pubmed/12619154,5659
BRCA2 Y3092C lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). Y3092C mediates homology-directed DNA repair at a level comparable to wild-type Brca2 in cultured cells (PMID: 23108138).,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,5660
"BRCA2 Y3092S lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). Y3092S results in decreased Brca2 function, as indicated by decreased homology-directed DNA repair in cultured cells (PMID: 23108138).",2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,5661
BRCA2 Y3098H lies within the DNA-binding domain of the Brca2 protein (PMID: 12228710). Y3098H mediates homology-directed DNA repair at a level comparable to wild-type Brca2 in cultured cells (PMID: 23108138).,2585,23108138,A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity.,http://www.ncbi.nlm.nih.gov/pubmed/23108138,2587,12228710,BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure.,http://www.ncbi.nlm.nih.gov/pubmed/12228710,5662
BRCA2 Y42C does not lie within any known functional domains of the Brca2 protein (UniProt.org). Y42C results in decreased homology-directed DNA repair and is unable to rescue Brca2-null cell survival in culture (PMID: 15695382).,2582,15695382,Functional evaluation and cancer risk assessment of BRCA2 unclassified variants.,http://www.ncbi.nlm.nih.gov/pubmed/15695382,295,,,www.uniprot.org,5663
"ATM D351Y does not lie within any known functional domains of the Atm protein (UniProt.org). D351Y has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5664
"ATM E1304L does not lie within any known functional domains of the Atm protein (UniProt.org). E1304L has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5665
"ATM E1666* results in a premature truncation of the Atm protein at amino acid 1666 of 3056 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), E1666* is predicted to lead to a loss of Atm protein function.",295,,,www.uniprot.org,5666
"ATM E2272* results in a premature truncation of the Atm protein at amino acid E2272 of 3056 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), E2272* is predicted to lead to a loss of Atm protein function.",295,,,www.uniprot.org,5668
"ATM E2904K lies within the PI3K/PI4K protein kinase domain of the Atm protein (UniProt.org). E2904K has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5669
"ATM E390* results in a premature truncation of the Atm protein at amino acid 390 of 3056 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), E390* is predicted to lead to a loss of Atm protein function.",295,,,www.uniprot.org,5671
"ATM E522* results in a premature truncation of the Atm protein at amino acid 522 of 3056 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), E522* is predicted to lead to a loss of Atm protein function.",295,,,www.uniprot.org,5672
"ATM E848Q does not lie within any known functional domains of the Atm protein (UniProt.org). E848Q has been identified in sequencing studies (PMID: 16140923) but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",7178,16140923,Somatic mutations of the protein kinase gene family in human lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16140923,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5673
"ATM E871K does not lie within any known functional domains of the Atm protein (UniProt.org). E871K has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5674
"MET M362T lies within the extracellular Sema ligand-binding domain of the Met protein (UniProt.org). M362T has been identified in the scientific literature (PMID: 27438523), but has not been biochemically characterized and therefore, its effect on protein function is unknown (PubMed, Sep 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7941,27438523,"Tubular, lactating, and ductal adenomas are devoid of MED12 Exon2 mutations, and ductal adenomas show recurrent mutations in GNAS and the PI3K-AKT pathway.",http://www.ncbi.nlm.nih.gov/pubmed/27438523,5675
"ATM F1683V does not lie within any known functional domains of the Atm protein (UniProt.org). F1683V has not been characterized in the scientific literature and therefore, its effect on Atm protein function is  unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5676
"ATM F168L does not lie within any known functional domains of the Atm protein (UniProt.org). F168L has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5677
"ATM F2140V lies within the FAT domain of the Atm protein (UniProt.org). F2140V has been identified in sequencing studies (PMID: 22810696) but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,5679
"ATM F570L does not lie within any known functional domains of the Atm protein (UniProt.org). F570L has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5680
"ATM F2839L lies within the PI3K/PI4K protein kinase domain of the Atm protein (UniProt.org). F2839L has been identified in sequencing studies (PMID: 24951259) but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",1253,24951259,Novel recurrently mutated genes and a prognostic mutation signature in colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24951259,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5681
"ATM G2083* results in a premature truncation of the Atm protein at amino acid 2083 of 3056 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), G2083* is predicted to lead to a loss of Atm protein function.",295,,,www.uniprot.org,5682
"SRC A91V lies within the SH3 domain of the Src protein (UniProt.org). A91V has not been characterized in the scientific literature and therefore, its effect on Src protein function is unknown (PubMed, Jan 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5683
"SRC C501R lies within the protein kinase domain of the Src protein (UniProt.org). C501R has not been characterized in the scientific literature and therefore, its effect on Src protein function is unknown (PubMed, Jan 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5684
"SRC D351N lies within the protein kinase domain of the Src protein (UniProt.org). D351N has not been characterized in the scientific literature and therefore, its effect on Src protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5685
"SRC D389E lies within the protein kinase domain of the Src protein (UniProt.org). D389E has not been characterized in the scientific literature and therefore, its effect on Src protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5686
"SRC D407H lies within the protein kinase domain of the Src protein (UniProt.org). D407H has been identified in sequencing studies (PMID: 21720365), but has not been biochemically characterized and therefore, its effect on Src protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6943,21720365,Integrated genomic analyses of ovarian carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/21720365,5687
"SRC E342K lies within the protein kinase domain of the Src protein (UniProt.org). E342K has not been characterized in the scientific literature and therefore, its effect on Src protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5688
"SRC E527K does not lie within any known functional domains of the Src protein (UniProt.org). E527K results in resistance of Src to phosphorylation and inactivation by CSK, and increased Src kinase activity in cultured cells (PMID: 7592628).",2646,7592628,Characterization of two activated mutants of human pp60c-src that escape c-Src kinase regulation by distinct mechanisms.,http://www.ncbi.nlm.nih.gov/pubmed/7592628,295,,,www.uniprot.org,5689
"SRC G133C lies within the SH3 domain of the Src protein (UniProt.org). G133C has not been characterized in the scientific literature and therefore, its effect on Src protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5690
"SRC G347E lies within the protein kinase domain of the Src protein (UniProt.org). G347E has been identified in sequencing studies (PMID: 23917401), but has not been biochemically characterized and therefore, its effect on Src protein function is unknown (PubMed, Jan 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3963,23917401,The integrated landscape of driver genomic alterations in glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/23917401,5691
"SRC I113F lies within the SH3 domain of the Src protein (UniProt.org). I113F has not been characterized in the scientific literature and therefore, its effect on Src protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5692
"SRC K298E lies within the protein kinase domain of the Src protein (UniProt.org). K298E has not been characterized in the scientific literature and therefore, its effect on Src protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5693
"SRC P136S lies within the SH3 domain of the Src protein (UniProt.org). P136S has been identified in sequencing studies (PMID: 22842228), but has not been biochemically characterized and therefore, its effect on Src protein function is unknown (PubMed, Jan 2017).
",7109,22842228,Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22842228,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5694
"SRC P171Q lies within the SH2 domain of the Src protein (UniProt.org). P171Q has not been characterized in the scientific literature and therefore, its effect on Src protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5695
"SRC P428S lies within the protein kinase domain of the Src protein (UniProt.org). P428S has not been characterized in the scientific literature and therefore, its effect on Src protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5696
"SRC P506L lies within the protein kinase domain of the Src protein (UniProt.org). P506L has been identified in sequencing studies (PMID: 24265154), but has not been biochemically characterized and therefore, its effect on Src protein function is unknown (PubMed, Jan 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,6036,24265154,MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/24265154,295,,,www.uniprot.org,5697
SRC Q531* results in a premature truncation of the Src protein at amino acid 531 of 536 (UniProt.org). Q531* confers a gain of function to the Src protein as demonstrated by increased Src kinase activity as compared to wild-type and transforming ability in culture (PMID: 9988270).,295,,,www.uniprot.org,4544,9988270,Activating SRC mutation in a subset of advanced human colon cancers.,http://www.ncbi.nlm.nih.gov/pubmed/9988270,5698
"SRC R163W lies within the SH2 domain of the Src protein (UniProt.org). R163W has not been characterized in the scientific literature and therefore, its effect on Src protein function is unknown (PubMed, Jan 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5699
"SRC R220S lies within the SH2 domain of the Src protein (UniProt.org). R220S has not been characterized in the scientific literature and therefore, its effect on Src protein function is unknown (PubMed, Jan 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5700
"SRC R483W lies within the protein kinase domain of the Src protein (UniProt.org). R483W has not been characterized in the scientific literature and therefore, its effect on Src protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5701
"SRC S225I lies within the SH2 domain of the Src protein (UniProt.org). S225I has not been characterized in the scientific literature and therefore, its effect on Src protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5702
"SRC S269L does not lie within any known functional domains of the Src protein (UniProt.org). S269L has not been characterized in the scientific literature and therefore, its effect on Src protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5703
"SRC T183M lies within the SH2 domain of the Src protein (UniProt.org). T183M has not been characterized in the scientific literature and therefore, its effect on Src protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5704
"SRC V140M lies within the SH3 domain of the Src protein (UniProt.org). V140M has not been characterized in the scientific literature and therefore, its effect on Src protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5705
"SRC W121R lies within the SH3 domain of the Src protein (UniProt.org). W121R has not been characterized in the scientific literature and therefore, its effect on Src protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5706
"FBXW7 S476R lies within the WD repeat 3 of the Fbxw7 protein (UniProt.org). S476R has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5707
FBXW7 R689Q does not lie within any known functional domains of the Fbxw7 protein (UniProt.org). R689Q is predicted to have activity similar to wild-type Fbxw7 based on comparison and correlation analysis of induced gene expression signatures (PMID: 27147599).,6273,27147599,Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.,http://www.ncbi.nlm.nih.gov/pubmed/27147599,295,,,www.uniprot.org,5708
"ATM G2695A does not lie within any known functional domains of the Atm protein (UniProt.org). G2695A has been identified in sequencing studies (PMID: 23407552) but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7872,23407552,The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/23407552,5752
"ATM G2695C does not lie within any known functional domains of the Atm protein (UniProt.org). G2695C has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5753
"ATM G2891R lies within the PI3K/PI4K protein kinase domain of the Atm protein (UniProt.org). G2891R has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5755
"ATM H2872Q lies within the PI3K/PI4K protein kinase domain of the Atm protein (UniProt.org). H2872Q has been identified in sequencing studies (PMID: 18948947) but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",6956,18948947,Somatic mutations affect key pathways in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18948947,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5756
"ATM H2872R lies within the PI3K/PI4K protein kinase domain of the Atm protein (UniProt.org). H2872R has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5757
ATM I1681V does not lie within any known functional domains of the Atm protein (UniProt.org). I1681V confers a loss of function to the Atm protein as demonstrated by reduced Atm and Tp53 phosphorylation (PMID: 16014569).,2639,16014569,Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL.,http://www.ncbi.nlm.nih.gov/pubmed/16014569,295,,,www.uniprot.org,5758
"IDH1 A134D does not lie within any known functional domains of the Idh1 protein (UniProt.org). A134D results in a loss of isocitrate catalytic activity in the Idh1 protein (PMID: 20702649, PMID: 21996744).",2651,21996744,Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.,http://www.ncbi.nlm.nih.gov/pubmed/21996744,2650,20702649,Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/20702649,295,,,www.uniprot.org,5759
"IDH1 A179D does not lie within any known functional domains of the Idh1 protein (UniProt.org). A179D has not been characterized in the scientific literature and therefore, its effect on Idh1 protein function is unknown (PubMed, Jun 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5760
"IDH1 D299H does not lie within any known functional domains of the Idh1 protein (UniProt.org). D299H has not been characterized in the scientific literature and therefore, its effect on Idh1 protein function is unknown (PubMed, Jun 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5761
"IDH1 D375Y does not lie within any known functional domains of the Idh1 protein (UniProt.org). D375Y has not been characterized in the scientific literature and therefore, its effect on Idh1 protein function is unknown (PubMed, Jun 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5762
"IDH1 E17K does not lie within any known functional domains of the Idh1 protein (UniProt.org). E17K has not been characterized in the scientific literature and therefore, its effect on Idh1 protein function is unknown (PubMed, Jun 2017). ",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5763
"IDH1 G123E does not lie within any known functional domains of the Idh1 protein (UniProt.org). G123E has been identified in sequencing studies (PMID: 20567020), but has not been biochemically characterized and therefore, its effect on Idh1 protein function is unknown (PubMed, Jun 2017).
",295,,,www.uniprot.org,7372,20567020,IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.,http://www.ncbi.nlm.nih.gov/pubmed/20567020,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5764
"IDH1 G123R does not lie within any known functional domains of the Idh1 protein (UniProt.org). G123R has been demonstrated to result in decreased Idh1 catalytic activity in an in vitro assay (PMID: 20171178), but has also been demonstrated to have catalytic activity similar to wild-type Idh1 (PMID: 21996744).",295,,,www.uniprot.org,2651,21996744,Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.,http://www.ncbi.nlm.nih.gov/pubmed/21996744,2652,20171178,Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20171178,5765
"IDH1 G221V does not lie within any known functional domains of the Idh1 protein (UniProt.org). G221V has not been characterized in the scientific literature and therefore, its effect on Idh1 protein function is unknown (PubMed, Jun 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5766
"IDH1 G97D lies within the substrate binding domain of the Idh1 protein (UniProt.org). G97D confers a loss-of-function to use isocitrate as substrate, and a concomitant gain-of-function to convert alpha-ketoglutarate to the onco-metabolite 2HG (R(-)-2-hydroxyglutarate), leading to increased 2HG levels (PMID: 21996744).",295,,,www.uniprot.org,2651,21996744,Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.,http://www.ncbi.nlm.nih.gov/pubmed/21996744,5767
IDH1 H133Q does not lie within any known functional domains of the Idh1 protein (UniProt.org). H133Q has been described as having wild-type Idh1 activity (PMID: 21996744). ,295,,,www.uniprot.org,2651,21996744,Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.,http://www.ncbi.nlm.nih.gov/pubmed/21996744,5768
IDH1 G70D does not lie within any known functional domains of the Idh1 protein (UniProt.org). G70D confers a loss of function to IDH1 as indicated by decreased protein stability in cell culture (PMID: 21996744).,295,,,www.uniprot.org,2651,21996744,Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.,http://www.ncbi.nlm.nih.gov/pubmed/21996744,5769
"SRC W121C lies within the SH3 domain of the Src protein (UniProt.org). W121C has been identified in sequencing studies (PMID: 22980975), but has not been biochemically characterized and therefore, its effect on Src protein function is unknown (PubMed, Jan 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1726,22980975,Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/22980975,5770
"ATM I1849fs results in a change in the amino acid sequence of the Atm protein beginning at aa 1849 of 3056, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of all known functional domains (UniProt.org), I1849fs is predicted to lead to a loss of Atm protein function. ",295,,,www.uniprot.org,5771
"ATM I2888L lies within the PI3K/PI4K protein kinase domain of the Atm protein (UniProt.org). I2888L has been identified in sequencing studies (PMID: 26487540) but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",7874,26487540,BRAF alteration status and the histone H3F3A gene K27M mutation segregate spinal cord astrocytoma histology.,http://www.ncbi.nlm.nih.gov/pubmed/26487540,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5772
"ATM I2888T lies within the PI3K/PI4K protein kinase domain of the Atm protein (UniProt.org). I2888T has been identified in the scientific literature (PMID: 12697903) but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",7875,25115387,Targeted ultra-deep sequencing reveals recurrent and mutually exclusive mutations of cancer genes in blastic plasmacytoid dendritic cell neoplasm.,http://www.ncbi.nlm.nih.gov/pubmed/25115387,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7886,12697903,Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/12697903,5773
"ATM L100W does not lie within any known functional domains of the Atm protein (UniProt.org). L100W has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5774
"ATM L1046R does not lie within any known functional domains of the Atm protein (UniProt.org). L1046R has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5775
"ATM L1408F does not lie within any known functional domains of the Atm protein (UniProt.org). L1408F has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5776
"ATM L1408I does not lie within any known functional domains of the Atm protein (UniProt.org). L1408I has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017).
",5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5777
"ATM L1439I does not lie within any known functional domains of the Atm protein (UniProt.org). L1439I has been identified in sequencing studies (PMID: 24755471), but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017).
",6962,24755471,Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24755471,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5778
"ATM L2077I lies within the FAT domain of the Atm protein (UniProt.org). L2077I has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017).
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,5779
"PIK3CA H47R lies within the PI3K-ABD domain of the Pik3ca protein (UniProt.org). H47R has not been characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5793
"ATM K468fs*18 likely results in a truncation of the 3056 aa Atm protein at aa 468, followed by 18 nonsense amino acids (UniProt.org). Due to the loss of all known functional domains (UniProt.org), K468fs*18 is predicted to lead to a loss of Atm protein function.",295,,,www.uniprot.org,5797
ATM L2427P lies within the FAT domain of the Atm protein (UniProt.org). L2427P confers a loss of function to the Atm protein as demonstrated by a defective Tp53 DNA damage response (PMID: 23585524).,2653,23585524,ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin.,http://www.ncbi.nlm.nih.gov/pubmed/23585524,295,,,www.uniprot.org,5798
"ATM L2561M lies within the FAT domain of the Atm protein (UniProt.org). L2561M has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5799
"ATM L259I does not lie within any known functional domains of the Atm protein (UniProt.org). L259I has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5800
"ATM L2722M lies within the PI3K/PI4K protein kinase domain of the Atm protein (UniProt.org). L2722M has not been characterized in the scientific literature and therefore, its effect on Atm protein function (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5801
"ATM L2780R lies within the PI3K/PI4K protein kinase domain of the Atm protein (UniProt.org). L2780R has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5802
"ATM L2877F lies within the PI3K/PI4K protein kinase domain of the Atm protein (UniProt.org). L2877F has been identified in the scientific literature (PMID: 27206246), but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017).
",7887,27206246,Comparison of intramedullary myeloma and corresponding extramedullary soft tissue plasmacytomas using genetic mutational panel analyses.,http://www.ncbi.nlm.nih.gov/pubmed/27206246,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5803
ATM L2890V lies within the PI3K/PI4K protein kinase domain of the Atm protein (UniProt.org). L2890V confers a loss of function to the Atm protein as demonstrated by a defective Tp53 DNA damage response (PMID: 23585524). ,2653,23585524,ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin.,http://www.ncbi.nlm.nih.gov/pubmed/23585524,295,,,www.uniprot.org,5804
"ATM L822V does not lie within any known functional domains of the Atm protein (UniProt.org). L822V has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5805
"ATM L942I does not lie within any known functional domains of the Atm protein (UniProt.org). L942I has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5806
"EGFR P281T lies within the extracellular domain of the Egfr protein (UniProt.org). P281T has been identified in the scientific literature (PMID: 27034166) , but has not been biochemically characterized and therefore, its effect of Egfr protein function is unknown (PubMed, Jun 2017). ",9191,27034166,Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27034166,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5807
"GNAQ D205fs results in a change in the amino acid sequence of the Gnaq protein beginning at aa 205 of 359, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the GTP binding region (UniProt.org), D205fs is predicted to result in a loss of Gnaq protein function. ",295,,,www.uniprot.org,5808
"KIT L859S lies within the protein kinase domain of the Kit protein (UniProt.org). L859S has not been characterized in the scientific literature and therefore, its effect on Kit protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5809
"SMO I637T lies within the C-terminal cytoplasmic tail of the Smo protein (PMID: 20207148). I637T has not been characterized in the scientific literature and therefore, its effect on Smo protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2471,20207148,Evaluating Smoothened as a G-protein-coupled receptor for Hedgehog signalling.,http://www.ncbi.nlm.nih.gov/pubmed/20207148,5810
"KIT L859F lies within the protein kinase domain of the Kit protein (UniProt.org). L859F has not been characterized in the scientific literature and therefore, its effect on Kit protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5813
TP53 P151H lies within the DNA binding domain of the Tp53 protein (PMID: 22713868). P151H results in decreased transactivation of select Tp53 targets in cell culture (PMID: 22673234).,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,2654,22673234,The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/22673234,5814
"EGFR K757R lies within the protein kinase domain of the Egfr protein (UniProt.org). K757R has been identified in the scientific literature (PMID: 26773740, PMID: 23945384), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",7970,26773740,Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26773740,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8197,23945384,Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23945384,5820
"ATM N2875S lies within the PI3K/PI4K protein kinase domain of the Atm protein (UniProt.org). N2875S has been identified in sequencing studies (PMID: 22895193), but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017).
",4597,22895193,Recurrent R-spondin fusions in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22895193,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5823
ATM N2875K lies within the PI3K/PI4K protein kinase domain of the Atm protein (UniProt.org). N2875K results in kinase dead Atm in the context of ATM D2780A (PMID: 17157789).,1926,17157789,Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17157789,295,,,www.uniprot.org,5824
"ATM N2875T lies within the PI3K/PI4K protein kinase domain of the Atm protein (UniProt.org). N2875T has been identified in sequencing studies (PMID: 22634756), but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017).
",7877,22634756,Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators.,http://www.ncbi.nlm.nih.gov/pubmed/22634756,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5825
"ATM P2353H lies within the FAT domain of the Atm protein (UniProt.org). P2353H has not been characterized in the scientific literature and therefore, its effect Atm protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5826
"ATM P2353T lies within the FAT domain of the Atm protein (UniProt.org). P2353T has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017).
",295,,,www.uniprot.org,5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5827
"ATM P2665T does not lie within any known functional domains of the Atm protein (UniProt.org). P2665T has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5828
"ATM P2842L lies within the PI3K/PI4K protein kinase domain of the Atm protein (UniProt.org). P2842L has been identified in sequencing studies (PMID: 24185509), but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6961,24185509,"Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/24185509,5834
"ATM P631S does not lie within any known functional domains of the Atm protein (UniProt.org). P631S has not been characterized in the scientific literature and therefore, its effects on Atm protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5835
"ATM P80S does not lie within any known functional domains of the Atm protein (UniProt.org). P80S has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5836
"ATM Q1579fs results in a change in the amino acid sequence of the Atm protein beginning at aa 1579 of 3056, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of all known functional domains (UniProt.org), Q1579fs is predicted to lead to a loss of Atm protein function. ",295,,,www.uniprot.org,5837
"ATM Q2442P lies within the FAT domain of the Atm protein (UniProt.org). Q2442P has been identified in sequencing studies (PMID: 22634756), but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017).
",7877,22634756,Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators.,http://www.ncbi.nlm.nih.gov/pubmed/22634756,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5838
"ATM R1150I does not lie within any known functional domains of the Atm protein (UniProt.org). R1150I has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5839
"ATM R1466* results in a premature truncation of the Atm protein at amino acid 1466 of 3056 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), R1466* is predicted to lead to a loss of Atm protein function. ",295,,,www.uniprot.org,5840
"ATM R1730* results in a premature truncation of the Atm protein at amino acid 1730 of 3056 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), R1730* is predicted to lead to a loss of Atm protein function. ",295,,,www.uniprot.org,5841
"ATM R2034* results in a premature truncation of the Atm protein at amino acid 2034 of 3056 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), R2034* is predicted to lead to a loss of Atm protein function. ",295,,,www.uniprot.org,5842
"ATM R23Q does not lie within any known functional domains of the Atm protein (UniProt.org). R23Q has been identified in sequencing studies (PMID: 26214590), but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017).
",295,,,www.uniprot.org,7151,26214590,Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.,http://www.ncbi.nlm.nih.gov/pubmed/26214590,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5843
"ATM R2443Q lies within the FAT domain of the Atm protein (UniProt.org). R2443Q has been identified in sequencing studies (PMID: 27693639, PMID: 27175599), but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7879,27693639,Integrative genomic and functional analysis of human oral squamous cell carcinoma cell lines reveals synergistic effects of FAT1 and CASP8 inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/27693639,9881,27175599,The chronological sequence of somatic mutations in early gastric carcinogenesis inferred from multiregion sequencing of gastric adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/27175599,5844
"ATM R248Q does not lie within any known functional domains of the Atm protein (UniProt.org). R248Q has been identified in sequencing studies (PMID: 24145436), but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7207,24145436,Landscape of somatic mutations and clonal evolution in mantle cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/24145436,5845
"ATM R250* results in a premature truncation of the Atm protein at amino acid 250 of 3056 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), R250* is predicted to lead to a loss of Atm protein function.",295,,,www.uniprot.org,5846
"ATM R2598* results in a premature truncation of the Atm protein at amino acid 2598 of 3056 (UniProt.org). Due to the loss of the protein kinase and FATC domains (UniProt.org), R2598* is predicted to lead to a loss of Atm protein function.",295,,,www.uniprot.org,5847
"ATM R2598Q does not lie within any known functional domains of the Atm protein (UniProt.org). R2598Q has been identified in sequencing studies (PMID: 22810696) but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Feb 2017).
",5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5848
"ATM R2691C does not lie within any known functional domains of the Atm protein (UniProt.org). R2691C has been identified in the scientific literature (PMID: 21993670) but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Feb 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1173,21993670,ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression.,http://www.ncbi.nlm.nih.gov/pubmed/21993670,5878
ATM R2832C lies within the PI3K/PI4K protein kinase domain of the Atm protein (UniProt.org). R2832C confers a loss of function to the Atm protein as demonstrated by reduced Atm protein expression and increased radiosensitivity of cultured cells (PMID: 18634022). ,295,,,www.uniprot.org,2668,18634022,Functional and computational assessment of missense variants in the ataxia-telangiectasia mutated (ATM) gene: mutations with increased cancer risk.,http://www.ncbi.nlm.nih.gov/pubmed/18634022,5879
"ATM R2849* results in a premature truncation of the Atm protein at amino acid 2849 of 3056 (UniProt.org). Due to the loss of the PI3K/PI4K protein kinase and FATC domains (UniProt.org), R2848* is predicted to lead to a loss of Atm protein function.",295,,,www.uniprot.org,5880
"ATM R2993* results in a premature truncation of the Atm protein at amino acid 2993 of 3056 (UniProt.org). Due to the loss of the FATC domain, R2993* is predicted to lead to a loss of Atm protein function (PMID: 16603769).",2669,16603769,The FATC domains of PIKK proteins are functionally equivalent and participate in the Tip60-dependent activation of DNA-PKcs and ATM.,http://www.ncbi.nlm.nih.gov/pubmed/16603769,295,,,www.uniprot.org,5881
ATM R3008C lies within the PI3K/PI4K protein kinase domain of the Atm protein (UniProt.org). R3008C confers a loss of function to the Atm protein as demonstrated by the inability to phosphorylate downstream Atm targets (PMID: 10706620).,295,,,www.uniprot.org,2670,10706620,Mantle cell lymphoma is characterized by inactivation of the ATM gene.,http://www.ncbi.nlm.nih.gov/pubmed/10706620,5882
ATM R3008H lies within the PI3K/PI4K protein kinase domain of the Atm protein (UniProt.org). R3008H confers a loss of function to the Atm protein as demonstrated by a defective Tp53 DNA damage response (PMID: 23585524).,2653,23585524,ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin.,http://www.ncbi.nlm.nih.gov/pubmed/23585524,295,,,www.uniprot.org,5883
"ATM R3047* results in a premature truncation of the Atm protein at amino acid 3047 of 3056 (UniProt.org). Due to the loss of the FATC domain, R3047* is predicted to lead to a loss of Atm protein function (PMID: 16603769).",2669,16603769,The FATC domains of PIKK proteins are functionally equivalent and participate in the Tip60-dependent activation of DNA-PKcs and ATM.,http://www.ncbi.nlm.nih.gov/pubmed/16603769,295,,,www.uniprot.org,5884
"ATM R337C does not lie within any known functional domains of the Atm protein (UniProt.org). R337C has been identified in sequencing studies (PMID: 27334835) but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Feb 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7355,27334835,"Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations.",http://www.ncbi.nlm.nih.gov/pubmed/27334835,5885
"ATM R337S does not lie within any known functional domains of the Atm protein (UniProt.org). R337S confers a loss of function to the Atm protein as demonstrated by reduced phosphorylation of Atm target proteins, Tp53 and Smc1 (PMID: 16014569).",2639,16014569,Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL.,http://www.ncbi.nlm.nih.gov/pubmed/16014569,295,,,www.uniprot.org,5886
"ATM R805* results in a premature truncation of the Atm protein at amino acid 805 of 3056 (UniProt.org). Due to the loss of all known functional domains of the Atm protein (UniProt.org), R805* is predicted to lead to a loss of Atm protein function.",295,,,www.uniprot.org,5887
"ATM S131* results in a premature truncation of the Atm protein at amino acid 131 of 3056 (UniProt.org). Due to the loss of all known functional domains of the Atm protein (UniProt.org), S131* is predicted to lead to a loss of Atm protein function. ",295,,,www.uniprot.org,5888
"ATM S2812Y lies within the PI3K/PI4K protein kinase domain of the Atm protein (UniProt.org). S2812Y has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5889
"ATM S3027I lies within the FATC domain of the Atm protein (UniProt.org). S3027I has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Feb 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5890
"ATM S719* results in a premature truncation of the Atm protein at amino acid 719 of 3056 (UniProt.org). Due to the loss of all known functional domains of the Atm protein (UniProt.org), S719* is predicted to lead to a loss of Atm protein function. ",295,,,www.uniprot.org,5891
"ATM S978A does not lie within any known functional domains of the Atm protein (UniProt.org). S978A has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5892
"ATM T1880R does not lie within any known functional domains of the Atm protein (UniProt.org). T1880R has been identified in sequencing studies (PMID: 25275298) but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Feb 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1586,25275298,The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies.,http://www.ncbi.nlm.nih.gov/pubmed/25275298,5893
"KIT S501_A502insSAY results in an insertion of three amino acids in the Ig-like C2-type 5 domain of the Kit protein between amino acids 501 and 502 (UniProt.org). S501_A502insSAY has not been characterized, however similar insertions in this domain are activating, thus S501_A502insSAY is predicted to lead to a gain of Kit protein function (PMID: 22324351, PMID: 24127596). ",2675,24127596,Structural basis for KIT receptor tyrosine kinase inhibition by antibodies targeting the D4 membrane-proximal region.,http://www.ncbi.nlm.nih.gov/pubmed/24127596,295,,,www.uniprot.org,1164,22324351,"Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.",http://www.ncbi.nlm.nih.gov/pubmed/22324351,5894
"KIT K558_V559insNP results in an insertion of two amino acids in the juxtamembrane domain of the Kit protein between amino acids 558 and 559 (UniProt.org). K558_V559insNP has not been characterized in the scientific literature and therefore, its effect on Kit protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5895
"TP53 L22P lies within the transcription activation region of the Tp53 protein (UniProt.org). L22P has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5896
"KIT Y578_D579del results in the deletion of two amino acids in the juxtamembrane domain of the Kit protein from amino acids 578 to 579 (UniProt.org). Y578_D579del has not been characterized, however similar Kit exon 11 deletions are activating, thus Y578_D579del is predicted to lead to a gain of Kit protein function (PMID: 9438854, PMID: 15365079).",2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,295,,,www.uniprot.org,5897
"SMO V321M lies within helical domain 3 of the Smo protein (UniProt.org). V321M confers a gain of function to the Smo protein as demonstrated by constitutive activation of Hedgehog signaling in cell culture, and has been demonstrated to confer Hh pathway inhibitor resistance (PMID: 25759020).",2677,25759020,Smoothened variants explain the majority of drug resistance in basal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25759020,5900
ATM T2666A does not lie within any known functional domains of the Atm protein (UniProt.org). T2666A confers a loss of function to the Atm protein as demonstrated by an Atm functional assay (PMID: 23585524).,2653,23585524,ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin.,http://www.ncbi.nlm.nih.gov/pubmed/23585524,295,,,www.uniprot.org,5901
"ATM T2934I lies within the PI3K/PI4K protein kinase domain of the Atm protein (UniProt.org). T2934I has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5902
"ATM T2947S (also referred to as T2946S) lies within the PI3K/PI4K protein kinase domain of the Atm protein (UniProt.org). T2947S confers a loss of function to the Atm protein as demonstrated by defective kinase activity (PMID: 16014569).
",2639,16014569,Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL.,http://www.ncbi.nlm.nih.gov/pubmed/16014569,295,,,www.uniprot.org,5903
ATM V1941L lies within the FAT domain of the Atm protein (UniProt.org). V1941L confers a loss of function to the Atm protein as demonstrated by partially defective kinase activity (PMID: 16014569).,2639,16014569,Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL.,http://www.ncbi.nlm.nih.gov/pubmed/16014569,295,,,www.uniprot.org,5904
"ATM V2951F lies within the PI3K/PI4K protein kinase domain of the Atm protein (UniProt.org). V2951F has been identified in sequencing studies (PMID: 22832583) but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Feb 2017).
",7442,22832583,Dissecting the genomic complexity underlying medulloblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22832583,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5905
"ATM V410A does not lie within any known functional domains of the Atm protein (UniProt.org). V410A has been identified in sequencing studies (PMID: 25148578) but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Feb 2017).
",295,,,www.uniprot.org,7824,25148578,Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/25148578,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5906
"ATM W2845C lies within the PI3K/PI4K protein kinase domain of the Atm protein (UniProt.org). W2845C has been identified in sequencing studies (PMID: 25186949) but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Feb 2017).
",295,,,www.uniprot.org,7554,25186949,The genomic landscape of pediatric Ewing sarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/25186949,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5907
"ATM Y2437C lies within the FAT domain of the Atm protein (UniProt.org). Y2437C has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5908
"ATM Y2755C lies within the PI3K/PI4K protein kinase domain of the Atm protein (UniProt.org). Y2755C has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5909
"ATM W3052C lies within the FATC domain of the Atm protein (UniProt.org). W3052C has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5910
"ATM Y2398C lies within the FAT domain of the Atm protein (UniProt.org). Y2398C has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5911
"ATM Y2954C lies within the PI3K/PI4K protein kinase domain of the Atm protein (UniProt.org). Y2954C has been identified in sequencing studies (PMID: 22634756) but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Feb 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7877,22634756,Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators.,http://www.ncbi.nlm.nih.gov/pubmed/22634756,5912
"APC G1339_S1340dup indicates the insertion of 2 duplicate amino acids, glycine (G)-1339 through serine (S)-1340, in the Apc protein (UniProt.org). G1339_S1340dup has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5914
"APC R302* results in a premature truncation of the Apc protein at amino acid 302 of 2843 (UniProt.org). Due to the loss of the WD repeat domain (UniProt.org), R302* is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,5915
"ERBB4 (HER4) act mut indicates that this variant results in a gain of function in the Erbb4 (Her4) protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,5974
"ERBB4 (HER4) amp indicates an increased number of copies of the ERBB4 (HER4) gene. However, the mechanism causing the increase is unspecified.
",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,5975
"ERBB4 over exp indicates an over expression of the Erbb4 protein. However, the mechanism causing the over expression is unspecified.
",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,5976
"RB1 inact mut indicates that this variant results in a loss of function of the Rb1 protein. However, the specific amino acid change has not been identified. ",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,6058
FLT3 A627T lies within the protein kinase domain of the Flt3 protein (UniProt.org). A627T has not been biochemically characterized but has been identified as a drug resistance mutation (PMID:     15374944). ,3767,15374944,Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/15374944,295,,,www.uniprot.org,6069
"FLT3 D750Y lies within the protein kinase domain of the Flt3 protein (UniProt.org). D750Y has been identified in sequencing studies (PMID: 22980975), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1726,22980975,Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/22980975,6070
"FLT3 D835A lies within the protein kinase domain activation loop of the Flt3 protein (UniProt.org, PMID: 11290608). D835A confers a gain of function to the Flt3 protein resulting in constitutive phosphorylation and transformation of cultured cells (PMID: 15256420).",2011,11290608,Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/11290608,2706,15256420,Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518.,http://www.ncbi.nlm.nih.gov/pubmed/15256420,6071
"FLT3 D835del results in the deletion of an amino acid in the protein kinase domain activation loop of the Flt3 protein at amino acid 835 (UniProt.org, PMID: 11290608). D835del confers a gain of function to the Flt3 protein resulting in constitutive phosphorylation and transformation of cultured cells (PMID: 15256420).",2011,11290608,Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/11290608,2706,15256420,Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518.,http://www.ncbi.nlm.nih.gov/pubmed/15256420,6072
FLT3 D839G lies within the protein kinase domain activation loop of the Flt3 protein (UniProt.org). D839G confers a gain of function to the Flt3 protein resulting in constitutive phosphorylation and transformation of cultured cells (PMID: 24608088).,2707,24608088,Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/24608088,295,,,www.uniprot.org,6073
"FLT3 D870E lies within the protein kinase domain of the Flt3 protein (UniProt.org). D870E has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6074
"FLT3 D895Y lies within the protein kinase domain of the Flt3 protein (UniProt.org). D895Y has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6075
"FLT3 E140* results in the premature truncation of the Flt3 protein at amino acid 140 of 933 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), E140* is predicted to lead to a loss of Flt3 protein function. ",295,,,www.uniprot.org,6076
"FLT3 E366* results in the premature truncation of the Flt3 protein at amino acid 366 of 933 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), E366* is predicted to lead to a loss of Flt3 protein function. ",295,,,www.uniprot.org,6077
IDH2 mutant indicates an unspecified mutation in the IDH1 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,6079
"NOTCH1 positive indicates the presence of the NOTCH1 gene, mRNA, and/or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,6099
"ERBB4 A1083V lies within the cytoplasmic domain of the Erbb4 protein (UniProt.org). A1083V has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6193
"ERBB4 A672D lies within the transmembrane domain of the Erbb4 protein (UniProt.org). A672D has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,6194
"ERBB4 A828D lies within the protein kinase domain of the Erbb4 protein (UniProt.org). A828D has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,6195
"ERBB4 A845V lies within the protein kinase domain of the Erbb4 protein (UniProt.org). A845V has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6196
"ERBB4 A888T lies within the protein kinase domain of the Erbb4 protein (UniProt.org). A888T has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6197
"ERBB4 C217R lies within the extracellular domain of the Erbb4 protein (UniProt.org). C217R has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6198
"ERBB4 C293F lies within the extracellular domain of the Erbb4 protein (UniProt.org). C293F has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6199
"ERBB4 C304F lies within the extracellular domain of the Erbb4 protein (UniProt.org). C304F has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6200
"ERBB4 C56Y lies within the extracellular domain of the Erbb4 protein (UniProt.org). C56Y has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6201
"ERBB4 C589F lies within the extracellular domain of the Erbb4 protein (UniProt.org). C589F has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6202
"ERBB4 C589R lies within the extracellular domain of the Erbb4 protein (UniProt.org). C589R has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6203
"ERBB4 C593F lies within the extracellular domain of the Erbb4 protein (UniProt.org). C593F has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6204
"ERBB4 D1104Y lies within the cytoplasmic domain of the Erbb4 protein (UniProt.org). D1104Y has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6205
"ERBB4 D335N lies within the extracellular domain of the Erbb4 protein (UniProt.org). D335N has been identified in sequencing studies (PMID: 24983367), but has not been biochemically characterized and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",7176,24983367,Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail.,http://www.ncbi.nlm.nih.gov/pubmed/24983367,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6206
"ERBB4 D518G lies within the extracellular domain of the Erbb4 protein (UniProt.org). D518G has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6207
"ERBB4 D595V lies within the extracellular domain of the Erbb4 protein (UniProt.org). D595V confers a gain of function to the Erbb4 protein as demonstrated by increased receptor dimerization, transactivation, and Erbb4 phosphorylation (PMID: 26050618).",3637,26050618,Activating ERBB4 mutations in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26050618,295,,,www.uniprot.org,6208
"ERBB4 D931Y lies within the protein kinase domain of the Erbb4 protein (UniProt.org). D931Y confers a gain of function to the Erbb4 protein as demonstrated by increased receptor transactivation, heterdimerization with Erbb2 (Her2), and increased Erbb4 phosphorylation (PMID: 26050618).",3637,26050618,Activating ERBB4 mutations in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26050618,295,,,www.uniprot.org,6209
"ERBB4 D991N lies within the cytoplasmic domain of the Erbb4 protein (UniProt.org). D991N has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,6210
"ERBB4 E1121D lies within the cytoplasmic domain of the Erbb4 protein (UniProt.org). E1121D has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,6211
"ERBB4 E1144* results in a premature truncation of the Erbb4 protein at amino acid 1144 of 1308 (UniProt.org). E1144* has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6212
"ERBB4 E387D lies within the extracellular domain of the Erbb4 protein (UniProt.org). E387D has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6213
"ERBB4 E397A lies within the extracellular domain of the Erbb4 protein (UniProt.org). E397A has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6214
"ERBB4 E560K lies within the extracellular domain of the Erbb4 protein (UniProt.org). E560K has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6215
"ERBB4 E693D lies within the cytoplasmic domain of the Erbb4 protein (UniProt.org). E693D has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6216
"ERBB4 E874* results in a premature truncation of the Erbb4 protein at amino acid 874 of 1308 (UniProt.org). E874* has been identified in sequencing studies (PMID: 22895193), but has not been biochemically characterized and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4597,22895193,Recurrent R-spondin fusions in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22895193,6217
"ERBB4 E928* results in a premature truncation of the Erbb4 protein at amino acid 928 of 1308 (UniProt.org). E928* has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6218
"ERBB4 F1003L lies within the cytoplasmic domain of the Erbb4 protein (UniProt.org). F1003L has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6219
"ERBB4 F1267L lies within the cytoplasmic domain of the Erbb4 protein (UniProt.org). F1267L has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6220
"ERBB4 F252L lies within the extracellular domain of the Erbb4 protein (UniProt.org). F252L has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6221
"ERBB4 G107V lies within the extracellular domain of the Erbb4 protein (UniProt.org). G107V has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6222
"ERBB4 G456E lies within the extracellular domain of the Erbb4 protein (UniProt.org). G456E has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6223
"ERBB4 G516V lies within the extracellular domain of the Erbb4 protein (UniProt.org). G516V has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6224
"ERBB4 G516W lies within the extracellular domain of the Erbb4 protein (UniProt.org). G516W has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6225
"ERBB4 G727D lies within the protein kinase domain of the Erbb4 protein (UniProt.org). G727D has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,6226
"ERBB4 G880R lies within the protein kinase domain of the Erbb4 protein (UniProt.org). G880R has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,6227
"ERBB4 G907E lies within the protein kinase domain of the Erbb4 protein (UniProt.org). G907E has not been characterized and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6228
"ERBB4 G917V lies within the protein kinase domain of the Erbb4 protein (UniProt.org). G917V has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6229
ERBB4 H618P lies within the extracellular domain of the Erbb4 protein (UniProt.org). H618P does not affect Erbb4 protein function in cell culture (PMID: 26050618).,295,,,www.uniprot.org,3637,26050618,Activating ERBB4 mutations in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26050618,6230
"ERBB4 H841Q lies within the protein kinase domain of the Erbb4 protein (UniProt.org). H841Q has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6231
"ERBB4 I161M lies within the extracellular domain of the Erbb4 protein (UniProt.org). I161M has been identified in sequencing studies (PMID: 24755471), but has not been biochemically characterized and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6962,24755471,Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24755471,6232
"ERBB4 I166N lies within the extracellular domain of the Erbb4 protein (UniProt.org). I166N has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6233
"ERBB4 I771T lies within the protein kinase domain of the Erbb4 protein (UniProt.org). I771T has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6234
"ERBB4 I827R lies within the protein kinase domain of the Erbb4 protein (UniProt.org). I827R has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6235
"ERBB4 K1002N lies within the cytoplasmic domain of the Erbb4 protein (UniProt.org). K1002N has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6236
"ERBB4 K1291N lies within the cytoplasmic domain of the Erbb4 protein (UniProt.org). K1291N has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6237
"ERBB4 K751Q lies within the protein kinase domain of the Erbb4 protein (UniProt.org). K751Q has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6238
"ERBB4 K751T lies within the protein kinase domain of the Erbb4 protein (UniProt.org). K751T has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6239
ERBB4 K935I lies within the protein kinase domain of the Erbb4 protein (UniProt.org). K935I confers a gain of function to the Erbb4 protein as demonstrated by increased Erbb4 receptor transactivation and increased cell survival (PMID: 26050618).,3637,26050618,Activating ERBB4 mutations in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26050618,295,,,www.uniprot.org,6240
"ERBB4 L1008V lies within the cytoplasmic domain of the Erbb4 protein (UniProt.org). L1008V has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6241
"ERBB4 L134P lies within the extracellular domain of the Erbb4 protein (UniProt.org). L134P has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,6242
"ERBB4 L155F lies within the extracellular domain of the Erbb4 protein (UniProt.org). L155F has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,6243
"ERBB4 L369I lies within the extracellular domain of the Erbb4 protein (UniProt.org). L369I has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6244
"ERBB4 L420M lies within the extracellular domain of the Erbb4 protein (UniProt.org). L420M has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6245
"ERBB4 L521M lies within the extracellular domain of the Erbb4 protein (UniProt.org). L521M has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6246
"ERBB4 L694V lies within the cytoplasmic domain of the Erbb4 protein (UniProt.org). L694V has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6247
"ERBB4 L864P lies within the protein kinase domain of the Erbb4 protein (UniProt.org). L864P has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6248
"ERBB4 M250I lies within the extracellular domain of the Erbb4 protein (UniProt.org). M250I has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6249
"ERBB4 M882I lies within the protein kinase domain of the Erbb4 protein (UniProt.org). M882I has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,295,,,www.uniprot.org,6250
"ERBB4 N1044D lies within the cytoplasmic domain of the Erbb4 protein (UniProt.org). N1044D has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6251
ERBB4 N181S lies within the extracellular domain of the Erbb4 protein (UniProt.org). N181S confers a gain of function to the Erbb4 protein as demonstrated by the ability to enhance Erbb2 ligand dependent activation in the context of Erbb4-Erbb2 dimerized receptors (PMID: 26050618).,3637,26050618,Activating ERBB4 mutations in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26050618,295,,,www.uniprot.org,6252
"ERBB4 N352S lies within the extracellular domain of the Erbb4 protein (UniProt.org). N352S has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6253
"ERBB4 P386Q lies within the extracellular domain of the Erbb4 protein (UniProt.org). P386Q has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6254
"ERBB4 P594Q lies within the extracellular domain of the Erbb4 protein (UniProt.org). P594Q has been identified in sequencing studies (PMID: 24755471), but has not been biochemically characterized and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",6962,24755471,Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24755471,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6255
"ERBB4 P697S lies within the cytoplasmic domain of the Erbb4 protein (UniProt.org). P697S has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6256
"ERBB4 P920R lies within the protein kinase domain of the Erbb4 protein (UniProt.org). P920R has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6257
"ERBB4 R106C lies within the extracellular domain of the Erbb4 protein (UniProt.org). R106C has been identified in sequencing studies (PMID: 25855536), but has not been biochemically characterized and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,7024,25855536,Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets.,http://www.ncbi.nlm.nih.gov/pubmed/25855536,285,,,http://www.ncbi.nlm.nih.gov/pubmed,6258
"ERBB4 R1139L lies within the cytoplasmic domain of the Erbb4 protein (UniProt.org). R1139L has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,6259
"ERBB4 R168W lies within the extracellular domain of the Erbb4 protein (UniProt.org). R168W has been identified in sequencing studies (PMID: 22895193), but has not been biochemically characterized and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4597,22895193,Recurrent R-spondin fusions in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22895193,6260
"ERBB4 R196C lies within the extracellular domain of the Erbb4 protein (UniProt.org). R196C has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6261
ERBB4 R306S lies within the extracellular domain of the Erbb4 protein (UniProt.org). R306S confers a gain of function to the Erbb4 protein as demonstrated by increased basal phosphorylation of Erbb4 (PMID: 26050618).,295,,,www.uniprot.org,3637,26050618,Activating ERBB4 mutations in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26050618,6262
"ERBB4 R50C lies within the extracellular domain of the Erbb4 protein (UniProt.org). R50C has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6263
"ERBB4 R711C lies within the cytoplasmic domain of the Erbb4 protein (UniProt.org). R711C has been identified in sequencing studies (PMID: 26343386), but has not been biochemically characterized and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7139,26343386,Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway.,http://www.ncbi.nlm.nih.gov/pubmed/26343386,6264
"ERBB4 R711L lies within the cytoplasmic domain of the Erbb4 protein (UniProt.org). R711L has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6265
"ERBB4 R81* results in a premature truncation of the Erbb4 protein at amino acid 81 of 1308 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), R81* is predicted to lead to a loss of Erbb4 function.",295,,,www.uniprot.org,6266
"ERBB4 R842Q lies within the protein kinase domain of the Erbb4 protein (UniProt.org). R842Q has not been characterized and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6267
"ERBB4 R992C lies within the cytoplasmic domain of the Erbb4 protein (UniProt.org). R992C has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6268
"ERBB4 S1043L lies within the cytoplasmic domain of the Erbb4 protein (UniProt.org). S1043L has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6269
"ERBB4 S303Y lies within the extracellular domain of the Erbb4 protein (UniProt.org). S303Y has been identified in sequencing studies (PMID: 16140923), but has not been biochemically characterized and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7178,16140923,Somatic mutations of the protein kinase gene family in human lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16140923,6270
"ERBB4 S341L lies within the extracellular domain of the Erbb4 protein (UniProt.org). S341L has been identified in sequencing studies (PMID: 21499247), but has not been biochemically characterized and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",1333,21499247,Exome sequencing identifies GRIN2A as frequently mutated in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/21499247,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6271
"ERBB4 T1110I lies within the cytoplasmic domain of the Erbb4 protein (UniProt.org). T1110I has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6272
"ERBB4 T140I lies within the extracellular domain of the Erbb4 protein (UniProt.org). T140I has been identified in sequencing studies (PMID: 22586465), but has not been biochemically characterized and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",7179,22586465,Proteome-wide analysis of single-nucleotide variations in the N-glycosylation sequon of human genes.,http://www.ncbi.nlm.nih.gov/pubmed/22586465,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6273
ERBB4 T244R lies within the extracellular domain of the Erbb4 protein (UniProt.org). T244R does not affect Erbb4 activation in cultured cells (PMID: 26050618).,295,,,www.uniprot.org,3637,26050618,Activating ERBB4 mutations in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26050618,6274
ERBB4 V348L lies within the extracellular domain of the Erbb4 protein (UniProt.org). V348L does not result in increased Erbb4 activation in cell culture (PMID: 26050618).,295,,,www.uniprot.org,3637,26050618,Activating ERBB4 mutations in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26050618,6275
"ERBB4 V59D lies within the extracellular domain of the Erbb4 protein (UniProt.org). V59D has been identified in sequencing studies (PMID: 22037554), but has not been biochemically characterized and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6997,22037554,Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22037554,6276
"ERBB4 V732F lies within the protein kinase domain of the Erbb4 protein (UniProt.org). V732F has been identified in sequencing studies (PMID: 22980975), but has not been biochemically characterized and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1726,22980975,Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/22980975,6277
"ERBB4 V903F lies within the protein kinase domain of the Erbb4 protein (UniProt.org). V903F has been identified in sequencing studies (PMID: 22980975), but has not been biochemically characterized and therefore, its effect on Erbb4 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6278
"ERBB4 Y1301C lies within the cytoplasmic domain of the Erbb4 protein (UniProt.org). Y1301C has been identified in sequencing studies (PMID: 22895193), but has not been biochemically characterized and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4597,22895193,Recurrent R-spondin fusions in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22895193,6279
"ERBB4 Y285C lies within the extracellular domain of the Erbb4 protein (UniProt.org). Y285C confers a gain of function to the Erbb4 protein as demonstrated by increased receptor dimerization, transactivation, and Erbb4 phosphorylation (PMID: 26050618).",295,,,www.uniprot.org,3637,26050618,Activating ERBB4 mutations in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26050618,6280
"DH2 R140L lies within the substrate binding of the Idh2 protein (UniProt.org). R140L has been identified in the scientific literature (PMID: 21596855, PMID: 25836588, PMID: 24344212), but has not been biochemically characterized and therefore, its effect on Idh2 protein function is unknown.",9279,25836588,Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/25836588,2751,21596855,The prognostic significance of IDH2 mutations in AML depends on the location of the mutation.,http://www.ncbi.nlm.nih.gov/pubmed/21596855,295,,,www.uniprot.org,9280,24344212,Predicting and communicating the risk of recurrence and death in women with early-stage breast cancer: a systematic review of risk prediction models.,http://www.ncbi.nlm.nih.gov/pubmed/24344212,6286
"IDH2 R140W lies within the substrate binding of the Idh2 protein (UniProt.org). R140W confers a gain of function to the Idh2 protein, as demonstrated by the conversion of alpha-ketoglutarate to 2-HG (2-hydroxyglutarate) in an in vitro assay (PMID: 21647154).",295,,,www.uniprot.org,6287
"IDH2 A370T does not lie within any known functional domains of the Idh2 protein (UniProt.org). A370T has not been characterized in the scientific literature and therefore, its effect on Idh2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6288
"IDH2 A410S does not lie within any known functional domains of the Idh2 protein (UniProt.org). A410S has not been characterized in the scientific literature and therefore, its effect on Idh2 protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,6290
"IDH2 A416fs results in a change in the amino acid sequence of the Idh2 protein beginning at aa 416 of 452, likely resulting in premature truncation of the functional protein (UniProt.org). A416fs has not been characterized in the scientific literature and therefore, its effect on Idh2 protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,6291
"IDH2 D83V does not lie within any known functional domains of the Idh2 protein (UniProt.org). D83V has not been characterized in the scientific literature and therefore, its effect on Idh2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6292
"IDH2 E68K does not lie within any known functional domains of the Idh2 protein (UniProt.org). E68K has not been characterized in the scientific literature and therefore, its effect on Idh2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6293
NOTCH1 A1701P lies within the extracellular domain of the Notch1 protein (UniProt.org). A1701P results in activation of Notch1 signaling as indicated by increased transcription in cell culture (PMID: 16738328).,2752,16738328,Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes.,http://www.ncbi.nlm.nih.gov/pubmed/16738328,295,,,www.uniprot.org,6294
NOTCH1 A1707T lies within the extracellular domain of the Notch1 protein (UniProt.org). A1707T results in increased activation of Notch1 in a reporter assay (PMID: 25104330).,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3550,25104330,Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25104330,6295
"NOTCH1 A2101T lies within the ANK repeat 6 region of the Notch1 protein (UniProt.org). A2101T has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6296
"NOTCH1 A2356V lies within the cytoplasmic domain of the Notch1 protein (UniProt.org). A2356V has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6297
"NOTCH1 A2463fs results in a change in the amino acid sequence of the Notch1 protein beginning at 2463 of 2555, likely resulting in premature truncation of the functional protein (UniProt.org). A2463fs has been identified in sequencing studies (PMID: 19794083), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Jun 2017).",7068,19794083,Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/19794083,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6298
"NOTCH1 A2464fs results in a change in the amino acid sequence of the Notch1 protein beginning at 2464 of 2555, likely resulting in premature truncation of the functional protein (UniProt.org). A2464fs has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6299
"NOTCH1 A465P lies within the EGF-like domain 12 of the Notch1 protein (UniProt.org). A465P has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6300
"NOTCH1 A465T lies within the EGF-like domain 12 of the Notch1 protein (UniProt.org). A465T has been identified in sequencing studies (PMID: 24686850), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Jun 2017).",3551,25234595,Frequent mutations in NOTCH1 ligand-binding regions in Japanese oral squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25234595,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7069,24686850,Genomic and molecular characterization of esophageal squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24686850,6301
"NOTCH1 C1045Y lies within the EGF-like domain 27 of the Notch1 protein (UniProt.org). C1045Y has been identified in sequencing studies (PMID: 22895193), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Jun 2017).",4597,22895193,Recurrent R-spondin fusions in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22895193,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6302
"NOTCH1 C1068Y lies within the EGF-like domain 28 of the Notch1 protein (UniProt.org). C1068Y has been identified in the scientific literature (PMID: 27228302), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Jun 2017).",5947,27228302,Does Notch play a tumor suppressor role across diverse squamous cell carcinomas?,http://www.ncbi.nlm.nih.gov/pubmed/27228302,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6303
"NOTCH1 C1085W lies within the EGF-like domain 28 of the Notch1 protein (UniProt.org). C1085W has been identified in the scientific literature (PMID: 27228302), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Jun 2017).",5947,27228302,Does Notch play a tumor suppressor role across diverse squamous cell carcinomas?,http://www.ncbi.nlm.nih.gov/pubmed/27228302,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6304
"NOTCH1 C1085Y lies within the EGF-like domain 28 of the Notch1 protein (UniProt.org). C1085Y has been identified in the scientific literature (PMID: 27228302), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Jun 2017).",5947,27228302,Does Notch play a tumor suppressor role across diverse squamous cell carcinomas?,http://www.ncbi.nlm.nih.gov/pubmed/27228302,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6305
"NOTCH1 C1094W lies within the EGF-like domain 28 of the Notch1 protein (UniProt.org). C1094W has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,6306
"NOTCH1 C127F lies within the EGF-like domain 3 of the Notch1 protein (UniProt.org). C127F has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,6307
"NOTCH1 C1304Y lies within the EGF-like domain 33 of the Notch1 protein (UniProt.org). C1304Y has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6308
"NOTCH1 C1345Y lies within the EGF-like domain 34 of the Notch1 protein (UniProt.org). C1345Y has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6309
IDH2 G137E lies within the substrate binding domain of the Idh2 protein (UniProt.org). G137E does not confer transforming activity to the Idh2 protein as demonstrated by the lack of tumor formation in animal models (PMID: 27147599).,295,,,www.uniprot.org,6273,27147599,Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.,http://www.ncbi.nlm.nih.gov/pubmed/27147599,6310
"IDH2 G144R does not lie within any known functional domains of the Idh2 protein (UniProt.org). G144R has not been characterized in the scientific literature and therefore, its effect on Idh2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6311
"IDH2 G145fs results in a change in the amino acid sequence of the Idh2 protein beginning at aa 145 of 452, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of sites critical for catalysis, G145fs is predicted to lead to a loss of Idh2 protein function (UniProt.org).",295,,,www.uniprot.org,6312
"IDH2 G171D does not lie within any known functional domains of the Idh2 protein (UniProt.org). G171D has been identified in sequencing studies (PMID: 21356389), but has not been biochemically characterized and therefore, its effect on Idh2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2750,21356389,Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation.,http://www.ncbi.nlm.nih.gov/pubmed/21356389,6313
"IDH2 G190D does not lie within any known functional domains of the Idh2 protein (UniProt.org). G190D has not been characterized in the scientific literature and therefore, its effect on Idh2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6314
"IDH2 G201D does not lie within any known functional domains of the Idh2 protein (UniProt.org). G201D has not been characterized in the scientific literature and therefore, its effect on Idh2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6315
"IDH2 G260W does not lie within any known functional domains of the Idh2 protein (UniProt.org). G260W has not been characterized in the scientific literature and therefore, its effect on Idh2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6316
"IDH2 G421S does not lie within any known functional domains of the Idh2 protein (UniProt.org). G421S has not been characterized in the scientific literature and therefore, its effect on Idh2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6317
"IDH2 H358R does not lie within any known functional domains of the Idh2 protein (UniProt.org). H358R has not been characterized in the scientific literature and therefore, its effect on Idh2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6318
"IDH2 I139F lies within the substrate binding domain and adjacent to the R140 hotspot of the Idh2 protein (UniProt.org, PMID: 21596855). I139F does not confer transforming activity to the Idh2 protein as demonstrated by the lack of tumor formation in animal models (PMID: 27147599).",2751,21596855,The prognostic significance of IDH2 mutations in AML depends on the location of the mutation.,http://www.ncbi.nlm.nih.gov/pubmed/21596855,6273,27147599,Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.,http://www.ncbi.nlm.nih.gov/pubmed/27147599,295,,,www.uniprot.org,6319
"NOTCH1 C1425F lies within the EGF-like domain 36 of the Notch1 protein (UniProt.org). C1425F has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6320
"NOTCH1 C227Y lies within the EGF-like domain 6 of the Notch1 protein (UniProt.org). C227Y has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6321
"NOTCH1 C387Y lies within the EGF-like domain 10 of the Notch1 protein (UniProt.org). C387Y has not been characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,6322
"NOTCH1 C416F lies within the EGF-like domain 11 of the Notch1 protein (UniProt.org). C416F has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,6323
"NOTCH1 C423W lies within the EGF-like domain 11 of the Notch1 protein (UniProt.org). C423W has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6324
"NOTCH1 C429F lies within the EGF-like domain 11 of the Notch1 protein (UniProt.org). C429F has been identified in sequencing studies (PMID: 23856246), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",6964,23856246,The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.,http://www.ncbi.nlm.nih.gov/pubmed/23856246,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6325
"NOTCH1 C429S lies within the EGF-like domain 11 of the Notch1 protein (UniProt.org). C429S has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6326
"NOTCH1 C429Y lies within the EGF-like domain 11 of the Notch1 protein (UniProt.org). C429Y has been identified in sequencing studies (PMID: 26873401), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7161,26873401,Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population.,http://www.ncbi.nlm.nih.gov/pubmed/26873401,6327
"NOTCH1 C440F lies within the EGF-like domain 11 of the Notch1 protein (UniProt.org). C440F has been identified in sequencing studies (PMID: 26873401), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7161,26873401,Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population.,http://www.ncbi.nlm.nih.gov/pubmed/26873401,295,,,www.uniprot.org,6328
"NOTCH1 C440R lies within the EGF-like domain 11 of the Notch1 protein (UniProt.org). C440R has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6329
"NOTCH1 C440S lies within the EGF-like domain 11 of the Notch1 protein (UniProt.org). C440S has been identified in sequencing studies (PMID: 26873401), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7161,26873401,Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population.,http://www.ncbi.nlm.nih.gov/pubmed/26873401,295,,,www.uniprot.org,6330
"NOTCH1 C449Y lies within the EGF-like domain 11 of the Notch1 protein (UniProt.org). C449Y has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6331
"NOTCH1 C456Y lies within the EGF-like domain 12 of the Notch1 protein (UniProt.org). C456Y has been identified in sequencing studies (PMID: 26873401, PMID: 24686850), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",7161,26873401,Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population.,http://www.ncbi.nlm.nih.gov/pubmed/26873401,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7069,24686850,Genomic and molecular characterization of esophageal squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24686850,6332
"NOTCH1 C461Y lies within the EGF-like domain 12 of the Notch1 protein (UniProt.org). C461Y has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6333
"NOTCH1 C467F lies within the EGF-like domain 12 of the Notch1 protein (UniProt.org). C467F has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6334
"NOTCH1 C467Y lies within the EGF-like domain 12 of the Notch1 protein (UniProt.org). C467Y has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6335
"NOTCH1 C478S lies within the EGF-like domain 12 of the Notch1 protein (UniProt.org). C478S has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6336
"NOTCH1 C478Y lies within the EGF-like domain 12 of the Notch1 protein (UniProt.org). C478Y has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6337
"NOTCH1 C532Y lies within the EGF-like domain 14 of the Notch1 protein (UniProt.org). C532Y has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,6338
"NOTCH1 C600S lies within the EGF-like domain 15 of the Notch1 protein (UniProt.org). C600S has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,6339
"NOTCH1 C664R lies within the EGF-like domain 17 of the Notch1 protein (UniProt.org). C664R has been identified in sequencing studies (PMID: 24816253), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,6958,24816253,Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24816253,295,,,www.uniprot.org,6340
"NOTCH1 C682F lies within the EGF-like domain 18 of the Notch1 protein (UniProt.org). C682F has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6341
"NOTCH1 C68Y lies within the EGF-like domain 2 of the Notch1 protein (UniProt.org). C68Y has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6342
"NOTCH1 C74F lies within the EGF-like domain 2 of the Notch1 protein (UniProt.org). C74F has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6343
"NOTCH1 C750S lies within the EGF-like domain 19 of the Notch1 protein (UniProt.org). C750S has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6344
"NOTCH1 C815R lies within the EGF-like domain 21 of the Notch1 protein (UniProt.org). C815R has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6345
"NOTCH1 C833Y lies within the EGF-like domain 22 of the Notch1 protein (UniProt.org). C833Y has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6346
"NOTCH1 C878Y lies within the EGF-like domain 23 of the Notch1 protein (UniProt.org). C878Y has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6347
"NOTCH1 C893S lies within the EGF-like domain 23 of the Notch1 protein (UniProt.org). C893S has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6348
"NOTCH1 C969G lies within the EGF-like domain 25 of the Notch1 protein (UniProt.org). C969G has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6349
"NOTCH1 D469Y lies within the EGF-like domain 12 of the Notch1 protein (UniProt.org). D469Y has been identified in sequencing studies (PMID: 23685749), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",7704,23685749,The mutational landscape of adenoid cystic carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23685749,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6350
"NOTCH1 D573A lies within the EGF-like domain 15 of the Notch1 protein (UniProt.org). D573A has been identified in sequencing studies (PMID: 25275298), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",1586,25275298,The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies.,http://www.ncbi.nlm.nih.gov/pubmed/25275298,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6351
"NOTCH1 D622N lies within the EGF-like domain 16 of the Notch1 protein (UniProt.org). D622N has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6352
"NOTCH1 E450K lies within the EGF-like domain 11 of the Notch1 protein (UniProt.org). E450K has been identified in sequencing studies (PMID: 21798897, PMID: 24292195, PMID: 25303977), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",7160,24292195,Mutational landscape of gingivo-buccal oral squamous cell carcinoma reveals new recurrently-mutated genes and molecular subgroups.,http://www.ncbi.nlm.nih.gov/pubmed/24292195,7349,21798897,Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1.,http://www.ncbi.nlm.nih.gov/pubmed/21798897,7006,25303977,Mutational landscape of aggressive cutaneous squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25303977,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6353
"NOTCH1 E943K lies within the EGF-like domain 24 of the Notch1 protein (UniProt.org). E943K has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,6354
NOTCH1 F1592S lies within the HD domain of the Notch1 protein (UniProt.org). F1592S results in increased cleavage of Notch1 protein and ligand-independent activation of Notch1 signaling in cell culture (PMID: 16738328).,295,,,www.uniprot.org,2752,16738328,Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes.,http://www.ncbi.nlm.nih.gov/pubmed/16738328,6355
"NOTCH1 F357del results in the deletion of an amino acid in the EGF-like domain 9 of the Notch1 protein at amino acid 357 (UniProt.org). F357del has been identified in sequencing studies (PMID: 21798893), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6999,21798893,The mutational landscape of head and neck squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/21798893,6356
"NOTCH1 F357S lies within the EGF-like domain 9 of the Notch1 protein (UniProt.org). F357S has not been characterized in the scientific literature (PMID: 27035284), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8158,27035284,Somatic Mutations and Genetic Variants of NOTCH1 in Head and Neck Squamous Cell Carcinoma Occurrence and Development.,http://www.ncbi.nlm.nih.gov/pubmed/27035284,6357
"NOTCH1 F783S lies within the EGF-like domain 20 of the Notch1 protein (UniProt.org). F783S has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6358
"NOTCH1 G1215C lies within the EGF-like domain 31 of the Notch1 protein (UniProt.org). G1215C has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6359
"NOTCH1 G193A lies within the EGF-like domain 5 of the Notch1 protein (UniProt.org). G193A has been identified in sequencing studies (PMID: 25275298), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1586,25275298,The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies.,http://www.ncbi.nlm.nih.gov/pubmed/25275298,6360
"NOTCH1 G21V lies within the EGF-like domain 1 of the Notch1 protein (UniProt.org). G21V has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6361
"NOTCH1 G326V lies within the EGF-like domain 8 of the Notch1 protein (UniProt.org). G326V has been identified in sequencing studies (PMID: 23856246), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6964,23856246,The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.,http://www.ncbi.nlm.nih.gov/pubmed/23856246,6362
"NOTCH1 G434C lies within the EGF-like domain 11 of the Notch1 protein (UniProt.org). G434C has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6363
"NOTCH1 G481C lies within the EGF-like domain 12 of the Notch1 protein (UniProt.org). G481C has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6364
"NOTCH1 G481R lies within the EGF-like domain 12 of the Notch1 protein (UniProt.org). G481R has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6365
"NOTCH1 G481S lies within the EGF-like domain 12 of the Notch1 protein (UniProt.org). G481S has not been characterized, but is predicted to result in decreased flexibility of Notch1 by structural modeling (PMID: 25234595).",3551,25234595,Frequent mutations in NOTCH1 ligand-binding regions in Japanese oral squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25234595,295,,,www.uniprot.org,6366
"NOTCH1 G481V lies within the EGF-like domain 12 of the Notch1 protein (UniProt.org). G481V has been identified in the scientific literature (PMID: 25406187, PMID: 25839328), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",8136,25406187,Notch1 mutations are drivers of oral tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/25406187,285,,,http://www.ncbi.nlm.nih.gov/pubmed,8164,25839328,Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25839328,295,,,www.uniprot.org,6367
"NOTCH1 G484V lies within the EGF-like domain 12 of the Notch1 protein (UniProt.org). G484V has been identified in the scientific literature (PMID: 23619168, PMID: 21798897), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",7349,21798897,Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1.,http://www.ncbi.nlm.nih.gov/pubmed/21798897,7132,23619168,Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers.,http://www.ncbi.nlm.nih.gov/pubmed/23619168,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6368
"NOTCH1 G653C lies within the EGF-like domain 17 of the Notch1 protein (UniProt.org). G653C has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6369
"NOTCH1 G672W lies within the EGF-like domain 17 of the Notch1 protein (UniProt.org). G672W has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,6370
"NOTCH1 G690V lies within the EGF-like domain 18 of the Notch1 protein (UniProt.org). G690V has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,6371
"NOTCH1 G842W lies within the EGF-like domain 22 of the Notch1 protein (UniProt.org). G842W has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6372
"NOTCH1 G919W lies within the EGF-like domain 24 of the Notch1 protein (UniProt.org). G919W has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6373
"NOTCH1 G936C lies within the EGF-like domain 24 of the Notch1 protein (UniProt.org). G936C has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6374
"NOTCH1 G957W lies within the EGF-like domain 25 of the Notch1 protein (UniProt.org). G957W has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6375
"NOTCH1 G95W lies within the EGF-like domain 2 of the Notch1 protein (UniProt.org). G95W has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6376
"NOTCH1 G977E lies within the EGF-like domain 25 of the Notch1 protein (UniProt.org). G977E has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6377
"NOTCH1 G977W lies within the EGF-like domain 25 of the Notch1 protein (UniProt.org). G977W has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6378
"NOTCH1 I1616N lies within the extracellular domain of the Notch1 protein (UniProt.org). I1616N has been identified in the scientific literature (PMID: 19245433, PMID: 16424867), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8165,16424867,High incidence of Notch-1 mutations in adult patients with T-cell acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/16424867,7962,19245433,FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/19245433,6379
NOTCH1 L1574P lies within the extracellular domain of the Notch1 protein (UniProt.org). L1574P results in activation of Notch1 signaling as indicated by increased transcription in cell culture (PMID: 16614245).,2805,16614245,Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/16614245,295,,,www.uniprot.org,6380
"IDH2 E208* results in a premature truncation of the Idh2 protein at amino acid 208 of 452 (UniProt.org). Due to the loss of sites critical for catalysis, E208* is predicted to lead to a loss of Idh2 protein function (UniProt.org).",295,,,www.uniprot.org,6381
"IDH2 I228L does not lie within any known functional domains of the Idh2 protein (UniProt.org). I228L has not been characterized in the scientific literature and therefore, its effect on Idh2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6382
"IDH2 I441T does not lie within any known functional domains of the Idh2 protein (UniProt.org). I441T has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Idh2 protein function is unknown (PubMed, Jul 2017).
",5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6383
"IDH2 K130del results in the deletion of an amino acid in the Idh2 protein at amino acid 130 (UniProt.org). K130del has not been characterized in the scientific literature and therefore, its effect on Idh2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6384
"IDH2 K133R does not lie within any known functional domains of the Idh2 protein (UniProt.org). K133R has not been characterized in the scientific literature and therefore, its effect on Idh2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6385
"IDH2 K280N does not lie within any known functional domains of the Idh2 protein (UniProt.org). K280N has not been characterized in the scientific literature and therefore, its effect on Idh2 protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,6386
"IDH2 K48N does not lie within any known functional domains of the Idh2 protein (UniProt.org). K48N has been identified in sequencing studies (PMID: 24121792), but has not been biochemically characterized and therefore, its effect on Idh2 protein function is unknown (PubMed, Jul 2017).
",295,,,www.uniprot.org,6998,24121792,Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation.,http://www.ncbi.nlm.nih.gov/pubmed/24121792,285,,,http://www.ncbi.nlm.nih.gov/pubmed,6387
"IDH2 L143M does not lie within any known functional domains of the Idh2 protein (UniProt.org). L143M has not been characterized in the scientific literature and therefore, its effect on Idh2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6388
"IDH2 M248T does not lie within any known functional domains of the Idh2 protein (UniProt.org). M248T has been identified in sequencing studies (PMID: 22895193), but has not been biochemically characterized and therefore, its effect on Idh2 protein function is unknown (PubMed, Jul 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4597,22895193,Recurrent R-spondin fusions in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22895193,6389
"IDH2 P158L does not lie within any known functional domains of the Idh2 protein (UniProt.org). P158L has been identified in sequencing studies (PMID: 25495392), but has not been biochemically characterized and therefore, its effect on Idh2 protein function is unknown (PubMed, Jul 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5216,25495392,IDH2 mutation in gliomas including novel mutation.,http://www.ncbi.nlm.nih.gov/pubmed/25495392,295,,,www.uniprot.org,6390
"IDH2 P158T does not lie within any known functional domains of the Idh2 protein (UniProt.org). P158T has been identified in sequencing studies (PMID: 21356389), but has not been biochemically characterized and therefore, its effect on Idh2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2750,21356389,Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation.,http://www.ncbi.nlm.nih.gov/pubmed/21356389,6391
"IDH2 P162S does not lie within any known functional domains of the Idh2 protein (UniProt.org). P162S has been identified in the scientific literature (PMID: 25495392, PMID: 26068201), but has not been biochemically characterized and therefore, its effect on Idh2 protein function is unknown (PubMed, Jul 2017).",5216,25495392,IDH2 mutation in gliomas including novel mutation.,http://www.ncbi.nlm.nih.gov/pubmed/25495392,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9272,26068201,TCF12 is mutated in anaplastic oligodendroglioma.,http://www.ncbi.nlm.nih.gov/pubmed/26068201,6392
"IDH2 Q322K does not lie within any known functional domains of the Idh2 protein (UniProt.org). Q322K has not been characterized in the scientific literature and therefore, its effect on Idh2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6393
"IDH2 Q359H does not lie within any known functional domains of the Idh2 protein (UniProt.org). Q359H has not been characterized in the scientific literature and therefore, its effect on Idh2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6394
"IDH2 R159H does not lie within any known functional domains of the Idh2 protein (UniProt.org). R159H has not been characterized in the scientific literature and therefore, its effect on Idh2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6395
"SMO F460L lies within the pivot region of transmembrane helix 6 in the Smo protein (PMID: 25759020). F460L confers a gain of function to Smo in cell culture as indicated by ligand-independent activation of Hedgehog signaling, and has been demonstrated to confer resistance to Hedgehog pathway inhibitors (PMID: 25759020).",2677,25759020,Smoothened variants explain the majority of drug resistance in basal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25759020,6396
"SMO L412F lies within the pivot region of transmembrane helix 5 in the Smo protein (PMID: 25759020). L412F confers a gain of function to the Smo protein as indicated by constitutive activation of Hedgehog signaling in cell culture, and has been demonstrated to confer Hh pathway inhibitor resistance (PMID: 25759020).",2677,25759020,Smoothened variants explain the majority of drug resistance in basal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25759020,6397
"SMO D473G lies within the ligand binding pocket of the Smo protein (PMID: 25759020). D473G does not result in activation of Smo, as indicated by the lack of increased basal Hedgehog (Hh) pathway signaling in cell culture, but has been demonstrated to confer resistance to Hh pathway inhibitors (PMID: 25759020). ",2677,25759020,Smoothened variants explain the majority of drug resistance in basal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25759020,6398
"PIK3CA S900I lies within the PI3K/PI4K protein kinase domain of the Pik3ca protein (UniProt.org). S900I has not been characterized in the scientific literature and therefore, its effect on Pik3ca protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,6403
"FGFR3 S402fs results in a change in the amino acid sequence of the Fgfr3 protein beginning at aa 402 of 806, likely resulting in a premature truncation of the functional protein (UniProt.org). Due to a loss of the protein kinase domain (UniProt.org), S402fs is predicted to lead to a loss of Fgfr3 protein function.",295,,,www.uniprot.org,6404
IDH2 R172S lies within the active site of the Idh2 protein (PMID: 19228619). R172S confers a gain of function to the Idh2 protein as demonstrated by accumulation of the onco-metabolite 2HG (R(-)-2-hydroxyglutarate) in cultured cells (PMID: 23264629).,2754,23264629,The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.,http://www.ncbi.nlm.nih.gov/pubmed/23264629,486,19228619,IDH1 and IDH2 mutations in gliomas.,http://www.ncbi.nlm.nih.gov/pubmed/19228619,6405
"IDH2 R172W lies within the active site of the Idh2 protein (PMID: 19228619). R172W has not been characterized, however other R172 hotspot mutations are activating thus, R172 is predicted to result in a gain of Idh2 protein function (PMID: 21326614, PMID: 23264629, PMID: 22309944).",2755,21326614,"2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.",http://www.ncbi.nlm.nih.gov/pubmed/21326614,2754,23264629,The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.,http://www.ncbi.nlm.nih.gov/pubmed/23264629,489,22309944,Glioma derived isocitrate dehydrogenase-2 mutations induced up-regulation of HIF-1α and β-catenin signaling: possible impact on glioma cell metastasis and chemo-resistance.,http://www.ncbi.nlm.nih.gov/pubmed/22309944,486,19228619,IDH1 and IDH2 mutations in gliomas.,http://www.ncbi.nlm.nih.gov/pubmed/19228619,6406
"IDH2 R377C does not lie within any known functional domains of the Idh2 protein (UniProt.org). R377C has been identified in sequencing studies (PMID: 24755471), but has not been biochemically characterized and therefore, its effect on Idh2 protein function is unknown (PubMed, Jul 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6962,24755471,Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24755471,6407
IDH2 T331M does not lie within any known functional domains of the Idh2 protein (UniProt.org). T331M does not confer transforming activity to the Idh2 protein as demonstrated by the lack of tumor formation in animal models (PMID: 27147599).,295,,,www.uniprot.org,6273,27147599,Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.,http://www.ncbi.nlm.nih.gov/pubmed/27147599,6408
"IDH2 W244* results in a premature truncation of the Idh2 protein at amino acid 244 of 452 (UniProt.org). Due to the loss of a site critical for catalysis (UniProt.org), W244* is predicted to lead to a loss of Idh2 protein function.",295,,,www.uniprot.org,6409
"IDH2 W375* results in a premature truncation of the Idh2 protein at amino acid 375 of 452 (UniProt.org). W375* has not been characterized in the scientific literature and therefore, its effect on Idh2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6410
"SMO W281C lies within the ligand binding pocket of the Smo protein (PMID: 25759020). W281C does not result in activation of Smo, as indicated by the lack of increased basal Hedgehog (Hh) pathway signaling in cell culture, but has been demonstrated to confer resistance to Hh pathway inhibitors (PMID: 25759020). ",2677,25759020,Smoothened variants explain the majority of drug resistance in basal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25759020,6427
"SMO H231R lies within the ligand binding pocket of the Smo protein (PMID: 25759020). H231R does not result in activation of Smo, as indicated by the lack of increased basal Hedgehog (Hh) pathway signaling in cell culture, but has been demonstrated to confer resistance to Hh pathway inhibitors (PMID: 25759020). ",2677,25759020,Smoothened variants explain the majority of drug resistance in basal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25759020,6428
"SMO Q477E lies within the ligand binding pocket of the Smo protein (PMID: 25759020). Q477E does not result in activation of Smo, as indicated by the lack of increased basal Hedgehog (Hh) pathway signaling in cell culture, but has been demonstrated to confer resistance to Hh pathway inhibitors (PMID: 25759020). ",2677,25759020,Smoothened variants explain the majority of drug resistance in basal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25759020,6429
ERBB4 mutant indicates an unspecified mutation in the ERBB4 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,6459
"NOTCH1 L1585P lies within the HD domain of the Notch1 protein (UniProt.org). L1585P has been identified in the scientific literature (PMID: 19245433, PMID: 22547598), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",8166,22547598,"Clinical impact of NOTCH1 and/or FBXW7 mutations, FLASH deletion, and TCR status in pediatric T-cell lymphoblastic lymphoma.",http://www.ncbi.nlm.nih.gov/pubmed/22547598,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7962,19245433,FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/19245433,6460
NOTCH1 L1593P lies within the HD domain of the Notch1 protein (UniProt.org). L1593P results in increased cleavage of Notch1 protein and ligand-independent activation of Notch1 signaling in cell culture (PMID: 16738328).,2752,16738328,Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes.,http://www.ncbi.nlm.nih.gov/pubmed/16738328,295,,,www.uniprot.org,6461
NOTCH1 L1600P lies within the HD domain of the Notch1 protein (UniProt.org). L1600P results in increased cleavage of Notch1 protein and ligand-independent activation of Notch1 signaling in cell culture (PMID: 18411416).,2797,18411416,NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL.,http://www.ncbi.nlm.nih.gov/pubmed/18411416,295,,,www.uniprot.org,6462
NOTCH1 L1600Q lies within the HD domain of the Notch1 protein (UniProt.org). L1600Q demonstrates gene expression from Notch1 target genes at levels similar to wild-type Notch1 protein in an in vitro reporter assay (PMID: 27870570).,8167,27870570,"Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/27870570,295,,,www.uniprot.org,6463
NOTCH1 L1678P lies within the HD domain of the Notch1 protein (UniProt.org). L1678P results in increased cleavage of Notch1 protein and ligand-independent activation of Notch1 signaling in cell culture (PMID: 16738328).,2752,16738328,Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes.,http://www.ncbi.nlm.nih.gov/pubmed/16738328,295,,,www.uniprot.org,6464
"FLT3 E366D lies within the extracellular domain of the Flt3 protein (UniProt.org). E366D has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,6483
"FLT3 E415K lies within the extracellular domain of the Flt3 protein (UniProt.org). E415K has been identified in sequencing studies (PMID: 25303977), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7006,25303977,Mutational landscape of aggressive cutaneous squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25303977,295,,,www.uniprot.org,6484
"FLT3 E880K lies within the protein kinase domain of the Flt3 protein (UniProt.org). E880K has been identified in sequencing studies (PMID: 26343386), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7139,26343386,Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway.,http://www.ncbi.nlm.nih.gov/pubmed/26343386,6485
"FLT3 E964A lies within the cytoplasmic domain of the Flt3 protein (UniProt.org). E964A has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6487
"FLT3 F406C lies within the extracellular domain of the Flt3 protein (UniProt.org). F406C has been identified in sequencing studies (PMID: 23856246), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",6964,23856246,The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.,http://www.ncbi.nlm.nih.gov/pubmed/23856246,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6488
"FLT3 F804C lies within the protein kinase domain of the Flt3 protein (UniProt.org). F804C has been identified in sequencing studies (PMID: 22895193), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4597,22895193,Recurrent R-spondin fusions in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22895193,6489
"FLT3 G617E lies within the protein kinase domain of the Flt3 protein (UniProt.org). G617E has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6490
"FLT3 G619V lies within the protein kinase domain of the Flt3 protein (UniProt.org). G619V has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6491
"FLT3 G822R lies within the protein kinase domain of the Flt3 protein (UniProt.org). G822R has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6492
"IDH1 Q277* results in a premature truncation of the Idh1 protein at amino acid 277 of 414 (UniProt.org). Due to the loss of the large domain required for formation of the active site, Q277* is predicted to lead to a loss of Idh1 protein function (PMID: 20513808).",295,,,www.uniprot.org,5710,20513808,Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism.,http://www.ncbi.nlm.nih.gov/pubmed/20513808,6493
FLT3 G831E lies within the protein kinase domain of the Flt3 protein (UniProt.org). G831E results in a loss of Flt3 kinase activity (PMID: 18068628).,2803,18068628,Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.,http://www.ncbi.nlm.nih.gov/pubmed/18068628,295,,,www.uniprot.org,6494
"IDH1 Q320H does not lie within any known functional domains of the Idh1 protein (UniProt.org). Q320H has been identified in sequencing studies (PMID: 24121792), but has not been biochemically characterized and therefore, its effect on Idh1 protein function is unknown (PubMed, Jun 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,6998,24121792,Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation.,http://www.ncbi.nlm.nih.gov/pubmed/24121792,295,,,www.uniprot.org,6496
"IDH1 I113V does not lie within any known functional domains of the Idh1 protein (UniProt.org). I113V has not been characterized in the scientific literature and therefore. its effect on Idh1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6502
IDH1 I130M does not lie within any known functional domains of the Idh1 protein (UniProt.org). I130M has been described as having wild-type Idh1 activity (PMID: 21996744).,295,,,www.uniprot.org,2651,21996744,Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.,http://www.ncbi.nlm.nih.gov/pubmed/21996744,6504
"IDH1 I380F does not lie within any known functional domains of the Idh1 protein (UniProt.org). I380F has been identified in sequencing studies (PMID: 22941189), but has not been biochemically characterized and therefore, its effect on Idh1 protein function is unknown (PubMed, Jun 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6959,22941189,Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22941189,6505
"IDH1 K81N does not lie within any known functional domains of the Idh1 protein (UniProt.org). K81N has not been characterized in the scientific literature and therefore, its effect on Idh1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6506
"IDH1 L359F does not lie within any known functional domains of the Idh1 protein (UniProt.org). L359F has not been characterized in the scientific literature and therefore, its effect on Idh1 protein function is unknown (PubMed, Jun 2017).

",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6507
"IDH1 M182L does not lie within any known functional domains of the Idh1 protein (UniProt.org). M182L has not been characterized in the scientific literature and therefore, its effect on Idh1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6508
NOTCH1 L1596H lies within the HD domain of the Notch1 protein (UniProt.org). L1597H results in increased cleavage of Notch1 protein and ligand-independent activation of Notch1 signaling in cell culture (PMID: 16738328).,2752,16738328,Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes.,http://www.ncbi.nlm.nih.gov/pubmed/16738328,295,,,www.uniprot.org,6509
"NOTCH1 L1980P lies within the ANK 2 domain of the Notch1 protein (UniProt.org). L1980P has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6510
"NOTCH1 L2139F does not lie within any known functional domains of the Notch1 protein (UniProt.org). L2139F has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6511
"NOTCH1 P2415del results in the deletion of an amino acid in the cytoplasmic domain of the Notch1 protein at amino acid 2415 (UniProt.org). P2415del has been identified in sequencing studies (PMID: 25589003, PMID: 25344691, PMID: 22980975), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",1726,22980975,Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/22980975,1689,25344691,RNF43 is frequently mutated in colorectal and endometrial cancers.,http://www.ncbi.nlm.nih.gov/pubmed/25344691,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6992,25589003,Sporadic hemangioblastomas are characterized by cryptic VHL inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/25589003,6512
"NOTCH1 P2462fs*15 likely results in a truncation of the 2555 aa Notch1 protein at aa 2463, followed by 15 nonsense amino acids within the cytoplasmic domain (UniProt.org). P2462fs*15 has not been characterized, however, due to the effects of other PEST domain deletions downstream of P2462 (PMID: 16614245, PMID: 16738328), P2462fs*15 is predicted to lead to activation of Notch1 signaling.",2805,16614245,Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/16614245,2752,16738328,Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes.,http://www.ncbi.nlm.nih.gov/pubmed/16738328,295,,,www.uniprot.org,6513
"NOTCH1 Q2440* results in a premature truncation of the Notch1 protein at amino acid 2440 of 2555 (UniProt.org). Q2440* has not been characterized, however, due to the effects of other PEST domain deletions downstream of Q2440 (PMID: 16614245, PMID: 15472075), Q2440* is predicted to lead to activation of Notch1 signaling.",295,,,www.uniprot.org,2814,15472075,Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/15472075,2805,16614245,Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/16614245,6514
"NOTCH1 Q2459* results in a premature truncation of the Notch1 protein at amino acid 2459 of 2555 (UniProt.org). Q2459* has not been characterized, however, due to the effects of other PEST domain deletions downstream of Q2459 (PMID: 16614245, PMID: 15472075), Q2459* is predicted to lead to activation of Notch1 signaling.",295,,,www.uniprot.org,2805,16614245,Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/16614245,2814,15472075,Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/15472075,6515
"NOTCH1 Q2503* results in a premature truncation of the Notch1 protein at amino acid 2502 of 2555 (UniProt.org). Q2503* has been identified in the scientific literature (PMID: 23295735), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8212,23295735,NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome.,http://www.ncbi.nlm.nih.gov/pubmed/23295735,6516
"NOTCH1 Q442* results in a premature truncation of the Notch1 protein at amino acid 442 of 2555 (UniProt.org). Due to the loss of multiple domains and regions (UniProt.org), Q442* is predicted to lead to a loss of Notch1 function.",295,,,www.uniprot.org,6517
"NOTCH1 R1598P (also referred to as R1599P) lies within the HD domain of the Notch1 protein (UniProt.org). R1598P (also referred to as R1599P) results in a gain of function for Notch1 including increased transcriptional activation of Notch1 target gene expression, increased S2 and S3 cleavage, and increased heterodimer dissociation in the presence of urea (PMID: 16738328).",295,,,www.uniprot.org,2752,16738328,Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes.,http://www.ncbi.nlm.nih.gov/pubmed/16738328,6531
"NOTCH1 R365C lies within the EGF-like domain 9 of the Notch1 protein (UniProt.org). R365C has been identified in the scientific literature (PMID: 25633867, PMID: 21798897, PMID: 22941188), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7166,22941188,Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22941188,295,,,www.uniprot.org,7349,21798897,Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1.,http://www.ncbi.nlm.nih.gov/pubmed/21798897,8213,25633867,"Cleaved NOTCH1 Expression Pattern in Head and Neck Squamous Cell Carcinoma Is Associated with NOTCH1 Mutation, HPV Status, and High-Risk Features.",http://www.ncbi.nlm.nih.gov/pubmed/25633867,6532
"NOTCH1 S2329fs*7 likely results in a truncation of the 2555 aa Notch1 protein at aa 2329, followed by 7 nonsense amino acids within the cytoplasmic domain (UniProt.org). S2329fs*7 has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6534
"NOTCH1 S2467* results in a premature truncation of the Notch1 protein at amino acid 2467 of 2555 (UniProt.org). S2467* has not been characterized, however, due to the effects of other PEST domain deletion downstream of S2467 (PMID: 16614245, PMID: 15472075), S2467* is predicted to lead to activation of Notch1 signaling.",295,,,www.uniprot.org,2805,16614245,Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/16614245,2814,15472075,Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/15472075,6535
"NOTCH1 S2467fs*11 likely results in a truncation of the 2555 aa Notch1 protein at aa 2467, followed by 11 nonsense amino acids within the cytoplasmic domain (UniProt.org). S2467fs*11 has not been characterized, however, due to the effects of other PEST domain deletions downstream of S2467 (PMID: 16614245, PMID: 15472075), S2467fs*11 is predicted to lead to activation of Notch1 signaling.",295,,,www.uniprot.org,2814,15472075,Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/15472075,2805,16614245,Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/16614245,6537
"NOTCH1 S2492* results in a premature truncation of the Notch1 protein at amino acid 2492 of 2555 (UniProt.org). S2492* has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6538
"NOTCH1 T1138P lies within the EGF-like domain 29 of the Notch1 protein (UniProt.org). T1138P has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6539
"NOTCH1 T194P lies within the EGF-like domain 7 of the Notch1 protein (UniProt.org). T194P has been identified in sequencing studies (PMID: 25275298), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,1586,25275298,The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies.,http://www.ncbi.nlm.nih.gov/pubmed/25275298,285,,,http://www.ncbi.nlm.nih.gov/pubmed,6546
"NOTCH1 T311P lies within the EGF-like domain 8 of the Notch1 protein (UniProt.org). T311P has been identified in the scientific literature (Blood 2015 126:4994, PMID: 25275298, PMID: 26648538), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,8254,,Whole-Exome Sequencing in Korean Children with Acute Lymphoblastic Leukemia,http://www.bloodjournal.org/content/126/23/4994?sso-checked=true,8216,26648538,Age-related mutations and chronic myelomonocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/26648538,1586,25275298,The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies.,http://www.ncbi.nlm.nih.gov/pubmed/25275298,285,,,http://www.ncbi.nlm.nih.gov/pubmed,6547
"NOTCH1 T588P lies within the EGF-like domain 15 of the Notch1 protein (UniProt.org). T588P has been identified in sequencing studies (PMID: 25275298), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1586,25275298,The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies.,http://www.ncbi.nlm.nih.gov/pubmed/25275298,6548
"NOTCH1 T767I lies within the EGF-like domain 20 of the Notch1 protein (UniProt.org). T767I has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6549
NOTCH1 V1576E lies within the HD domain of the Notch1 protein (UniProt.org). V1576E results in increased cleavage of Notch1 protein and ligand-independent activation of Notch1 signaling in cell culture (PMID: 16738328).,2752,16738328,Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes.,http://www.ncbi.nlm.nih.gov/pubmed/16738328,295,,,www.uniprot.org,6550
NOTCH1 V1676D lies within the HD domain of the Notch1 protein (UniProt.org). V1676D (also referred to as V1677D) results in increased cleavage of Notch1 protein and ligand-independent activation of Notch1 signaling in cell culture (PMID: 16738328).,2752,16738328,Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes.,http://www.ncbi.nlm.nih.gov/pubmed/16738328,295,,,www.uniprot.org,6551
"NOTCH1 V1721M lies within the HD domain of the Notch1 protein (UniProt.org). V1721M has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6552
"NOTCH1 V2443fs*35 likely results in a truncation of the 2555 aa Notch1 protein at aa 2443, followed by 35 nonsense amino acids within the cytoplasmic domain (UniProt.org). V2443fs*35 has not been characterized, however, due to the effects of other PEST domain deletions downstream of V2443 (PMID: 16614245, PMID: 16738328), P2443fs*35 is predicted to lead to activation of Notch1 signaling.",2752,16738328,Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes.,http://www.ncbi.nlm.nih.gov/pubmed/16738328,295,,,www.uniprot.org,2805,16614245,Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/16614245,6553
"NOTCH1 V2536I lies within the PEST domain of the Notch1 protein (UniProt.org). V2536I has been identified in the scientific literature (PMID: 19631984, PMID: 27127180), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",8218,19631984,T-cell lymphoblastic leukemia in early childhood presents NOTCH1 mutations and MLL rearrangements.,http://www.ncbi.nlm.nih.gov/pubmed/19631984,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8219,27127180,Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis.,http://www.ncbi.nlm.nih.gov/pubmed/27127180,6554
"NOTCH1 W861C lies within the EGF-like domain 22 of the Notch1 protein (UniProt.org). W861C has been identified in sequencing studies (PMID: 22722201), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",7023,22722201,The landscape of cancer genes and mutational processes in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22722201,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6555
"NOTCH1 Y550N lies within the EGF-like domain 14 of the Notch1 protein (UniProt.org). Y550N has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6556
"NOTCH1 Y625D lies within the EGF-like domain 16 of the Notch1 protein (UniProt.org). Y625D has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6557
"MYD88 L265P (corresponds to L252P in the canonical isoform in UniProt.org) lies within the TIR domain of the Myd88 protein (UniProt.org). L265P confers a gain of function to Myd88, resulting in increased NF-kappaB signaling, and promotes cell survival in culture (PMID: 23836557, PMID: 21179087).",2808,23836557,A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.,http://www.ncbi.nlm.nih.gov/pubmed/23836557,2809,21179087,Oncogenically active MYD88 mutations in human lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/21179087,295,,,www.uniprot.org,6656
SMARCB1 E31V does not lie within any known functional domains of the Smarcb1 protein (UniProt.org). E31V has been reported to alter a donor splice site and consequently disrupt Smarcb1 mRNA expression in a family with a history of multiple schwannomas and meningiomas (PMID: 19582488). ,295,,,www.uniprot.org,2813,19582488,Schwannomatosis associated with multiple meningiomas due to a familial SMARCB1 mutation.,http://www.ncbi.nlm.nih.gov/pubmed/19582488,6657
"CDNK2A inact mut indicates that this variant results in a loss of function of the Cdnk2a protein. However, the specific amino acid change has not been identified. ",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,6690
"EGFR exon 19 insertions are in-frame insertions within the kinase domain of Egfr (PMID: 22190593). Exon 19 insertions result in increased Egfr kinase activity, and are associated with sensitivity to Egfr tyrosine kinase inhibitors (PMID: 22190593).",439,22190593,EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22190593,6778
"FLT3 L832F lies within the protein kinase domain of the Flt3 protein (UniProt.org). L832F has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6781
"FLT3 L699F lies within the protein kinase domain of the Flt3 protein (UniProt.org). L699F has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6782
"FLT3 L678M lies within the protein kinase domain of the Flt3 protein (UniProt.org). L678M has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6783
"FLT3 L37S lies within the extracellular domain of the Flt3 protein (UniProt.org). L37S has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6784
"FLT3 K290T lies within the Ig-like C2-type domain of the Flt3 protein (UniProt.org). K290T has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6785
FLT3 I836del results in the deletion of an amino acid in the protein kinase domain activation loop of the Flt3 protein at amino acid 836 (PMID: 12663439). I836del confers a gain of function to the Flt3 protein resulting in constitutive phosphorylation and transformation of cultured cells (PMID: 12663439). ,2863,12663439,Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor.,http://www.ncbi.nlm.nih.gov/pubmed/12663439,6786
"FLT3 G905V lies within the protein kinase domain of the Flt3 protein (UniProt.org). G905V has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,6899
"DNMT3A amp indicates an increased number of copies of the Dnmt3a gene. However, the mechanism causing the increase is unspecified.
",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,6930
"DNMT3A over exp indicates an over expression of the Dnmt3a protein. However, the mechanism causing the over expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,6931
"FLT3 M837P lies within the protein kinase domain of the Flt3 protein (UniProt.org). M837P has been identified in sequencing studies (PMID: 16371029), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7342,16371029,Novel observation of three FLT3 codons mutated in tandem in an elderly acute myeloid leukaemia patient.,http://www.ncbi.nlm.nih.gov/pubmed/16371029,6935
"FLT3 P532S lies within the extracellular domain of the Flt3 protein (UniProt.org). P532S has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6936
"IDH1 N116S does not lie within any known functional domains of the Idh1 protein (UniProt.org). N116S has been identified in sequencing studies (PMID: 21647152), but has not been biochemically characterized and therefore, its effect on Idh1 protein function is unknown (PubMed, Jun 2017).
",7373,21647152,Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups.,http://www.ncbi.nlm.nih.gov/pubmed/21647152,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6937
"FLT3 P733Q lies within the protein kinase domain of the Flt3 protein (UniProt.org). P733Q has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6938
"IDH1 P33S does not lie within any known functional domains of the Idh1 protein (UniProt.org). P33S has not been biochemically characterized, but has an associated gene expression profile that does not correlate to that of Idh1 activating mutations (PMID: 27147599).",6273,27147599,Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.,http://www.ncbi.nlm.nih.gov/pubmed/27147599,295,,,www.uniprot.org,6939
"FLT3 P888S lies within the protein kinase domain of the Flt3 protein (UniProt.org). P888S has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6940
"FLT3 P893L lies within the protein kinase domain of the Flt3 protein (UniProt.org). P893L has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6941
"IDH1 R100Q lies within the substrate binding region of the Idh1 protein (UniProt.org). R100Q confers a gain of function to Idh1, resulting in aberrant production of 2HG in cell culture (PMID: 21996744, PMID: 24529257).",2651,21996744,Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.,http://www.ncbi.nlm.nih.gov/pubmed/21996744,295,,,www.uniprot.org,2894,24529257,D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma.,http://www.ncbi.nlm.nih.gov/pubmed/24529257,6942
"FLT3 P986L lies within the cytoplasmic domain of the Flt3 protein (UniProt.org). P986L has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6943
"FLT3 R174K lies within the extracellular domain of the Flt3 protein (UniProt.org). R174K has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6944
"FLT3 R387Q lies within the extracellular domain of the Flt3 protein (UniProt.org). R387Q has been identified in sequencing studies (PMID: 26689913), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",7346,26689913,Patterns and functional implications of rare germline variants across 12 cancer types.,http://www.ncbi.nlm.nih.gov/pubmed/26689913,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6945
FLT3 R834Q lies within the protein kinase domain of the Flt3 protein (UniProt.org). R834Q confers a gain of function to Flt3 as demonstrated by constitutive phosphorylation and transformation of cultured cells (PMID: 18068628).,295,,,www.uniprot.org,2803,18068628,Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.,http://www.ncbi.nlm.nih.gov/pubmed/18068628,6946
"FLT3 S127F lies within the extracellular domain of the Flt3 protein (UniProt.org). S127F has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,6947
"FLT3 Y842C lies within the protein kinase domain of the Flt3 protein (UniProt.org). Y842C results in constitutive phosphorylation of Flt3, activation of STAT-5 signaling, and is transforming in cell culture (PMID: 15345593).",295,,,www.uniprot.org,2895,15345593,Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).,http://www.ncbi.nlm.nih.gov/pubmed/15345593,6948
"FLT3 Y599_D600insPAPQIMSTSTLISENMNIA results in the insertion of nineteen amino acids in the juxtamembrane domain of the Flt3 protein between amino acids 599 and 600 (UniProt.org). Y599_D600insPAPQIMSTSTLISENMNIA is predicted to lead to activation of Flt3 due to the effects of other Flt3 internal tandem duplication (ITD) mutations (PMID: 12970773, PMID: 9737679, PMID: 11090077).",2896,12970773,FLT3: ITDoes matter in leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/12970773,295,,,www.uniprot.org,2897,9737679,Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product.,http://www.ncbi.nlm.nih.gov/pubmed/9737679,2898,11090077,Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.,http://www.ncbi.nlm.nih.gov/pubmed/11090077,6949
"FLT3 Y599_D600insEYEYEYEY results in the insertion of eight amino acids in the juxtamembrane domain of the Flt3 protein between amino acids 599 and 600 (UniProt.org). Y599_D600insEYEYEYEY is predicted to lead to activation of Flt3 due to the effects of other Flt3 internal tandem duplication (ITD) mutations (PMID: 12970773, PMID: 9737679, PMID: 11090077).",2896,12970773,FLT3: ITDoes matter in leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/12970773,295,,,www.uniprot.org,2897,9737679,Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product.,http://www.ncbi.nlm.nih.gov/pubmed/9737679,2898,11090077,Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.,http://www.ncbi.nlm.nih.gov/pubmed/11090077,6950
"FLT3 Y599F lies within the cytoplasmic domain of the Flt3 protein (UniProt.org). Y599F results in constitutive ligand-dependent phosphorylation of Flt3, but decreased ligand-dependent Erk activation and cell survival in culture due to the loss of Shp2 interaction (PMID: 16684964).",2899,16684964,Identification of Y589 and Y599 in the juxtamembrane domain of Flt3 as ligand-induced autophosphorylation sites involved in binding of Src family kinases and the protein tyrosine phosphatase SHP2.,http://www.ncbi.nlm.nih.gov/pubmed/16684964,295,,,www.uniprot.org,6951
"FLT3 Y572C lies within the cytoplasmic domain of the Flt3 protein (UniProt.org). Y572C results in constitutive phosphorylation of Flt3, activation of Erk, Akt and Stat signaling, and is transforming in cell culture (PMID: 18068628).",2803,18068628,Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.,http://www.ncbi.nlm.nih.gov/pubmed/18068628,295,,,www.uniprot.org,6952
"FLT3 Y457C lies within the extracellular domain of the Flt3 protein (UniProt.org). Y457C has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6953
"FLT3 W603_E604insDREYEYDLKW results in the insertion of ten amino acids in the juxtamembrane domain of the Flt3 protein between amino acids 603 and 604 (UniProt.org). W603_E604insDREYEYDLKW is predicted to lead to activation of Flt3 due to the effects of other Flt3 internal tandem duplication (ITD) mutations (PMID: 12970773, PMID: 9737679, PMID: 11090077).",2896,12970773,FLT3: ITDoes matter in leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/12970773,295,,,www.uniprot.org,2897,9737679,Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product.,http://www.ncbi.nlm.nih.gov/pubmed/9737679,2898,11090077,Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.,http://www.ncbi.nlm.nih.gov/pubmed/11090077,6954
"FLT3 V843A lies within the protein kinase domain of the Flt3 protein (UniProt.org). V843A has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6955
"FLT3 V637I lies within the protein kinase domain of the Flt3 protein (UniProt.org). V637I has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6956
"FLT3 V592A lies within the cytoplasmic domain of the Flt3 protein (UniProt.org). V592A results in constitutive phosphorylation of Flt3, activation of Stat5 signaling, upregulation of Bcl-x(L), and is transforming in cell culture (PMID: 16410449).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2903,16410449,Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML.,http://www.ncbi.nlm.nih.gov/pubmed/16410449,295,,,www.uniprot.org,6957
"FLT3 V557A lies within the transmembrane domain of the Flt3 protein (UniProt.org). V557A has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6958
"TP53 over exp indicates an over expression of the Tp53 protein. However, the mechanism causing the over expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,6987
"VHL inact mut indicates that this variant results in a loss of function of the Vhl protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,6996
FLT3 S451F lies within the extracellular domain of the Flt3 protein (UniProt.org). S541F confers a gain of function to Flt3 as demonstrated by constitutive phosphorylation and transformation of cultured cells (PMID: 18068628).,2803,18068628,Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.,http://www.ncbi.nlm.nih.gov/pubmed/18068628,295,,,www.uniprot.org,7040
"FLT3 S618L lies within the protein kinase domain of the Flt3 protein (UniProt.org). S618L has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7042
"FLT3 S71I lies within the protein kinase domain of the Flt3 protein (UniProt.org). S71I has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7043
"FLT3 S840_N841insGS results in the insertion of two amino acids in the protein kinase domain of the Flt3 protein between amino acids 840 and 841 (UniProt.org). S840_N841insGS confers a gain of function to the Flt3 protein as demonstrated by Flt3 hyperphosphorylation and growth factor independent cell proliferation in culture (PMID: 12384447).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7044
"VHL loss indicates loss of the VHL gene, mRNA and protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,7045
"FLT3 S985fs results in a change in the amino acid sequence of the Flt3 protein beginning at aa 895 of 933, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the disruption of the protein kinase domain (UniProt.org), S985fs is predicted to lead to a loss of Flt3 protein function.",295,,,www.uniprot.org,7046
FLT3 T167A lies within the extracellular domain of the Flt3 protein (UniProt.org). T167A is predicted to have no effect on Flt3 protein function by in silico models and is not transforming in cell culture  (PMID: 18068628).,2803,18068628,Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.,http://www.ncbi.nlm.nih.gov/pubmed/18068628,295,,,www.uniprot.org,7047
"FLT3 V220G lies within the extracellular domain of the Flt3 protein (UniProt.org). V220G has been identified in sequencing studies (PMID: 24755471), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6962,24755471,Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24755471,7048
"FLT3 V592G lies within the protein kinase domain of the Flt3 protein (UniProt.org). V592G confers a gain of function to Flt3 as demonstrated by constitutive phosphorylation and transformation in cultured cells (PMID: 18068628).
",2803,18068628,Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.,http://www.ncbi.nlm.nih.gov/pubmed/18068628,295,,,www.uniprot.org,7066
"IDH1 R109K does not lie within any known functional domains of the Idh1 protein (UniProt.org). R109K has been identified in sequencing studies (PMID: 24532263), but has not been biochemically characterized and therefore, its effect on Idh1 protein function is unknown (PubMed, Jun 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7374,24532263,Analysis of KIAA1549-BRAF fusion gene expression and IDH1/IDH2 mutations in low grade pediatric astrocytomas.,http://www.ncbi.nlm.nih.gov/pubmed/24532263,295,,,www.uniprot.org,7067
"IDH1 R119Q does not lie within any known functional domains of the Idh1 protein (UniProt.org). R119Q has been identified in sequencing studies (PMID: 22610119, PMID: 24376688), but has not been biochemically characterized and therefore, its effect on Idh1 protein function is unknown (PubMed, Jun 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,6289,22610119,"Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.",http://www.ncbi.nlm.nih.gov/pubmed/22610119,9217,24376688,The Frequency and clinical significance of IDH1 mutations in Chinese acute myeloid leukemia patients.,http://www.ncbi.nlm.nih.gov/pubmed/24376688,295,,,www.uniprot.org,7068
"IDH1 R119W does not lie within any known functional domains of the Idh1 protein (UniProt.org). R119W has not been characterized in the scientific literature and therefore, its effect on Idh1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7069
"IDH1 R132V lies within the active site of the Idh1 protein (PMID: 19228619). R132V has not been characterized, however, other R132 hotspot mutations confer a gain-of-function to convert alpha-ketoglutarate to onco-metabolite 2HG (PMID: 19935646, PMID: 28330869), thus, R132V is predicted to confer a gain of Idh1 protein function ",9218,28330869,Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiency.,http://www.ncbi.nlm.nih.gov/pubmed/28330869,486,19228619,IDH1 and IDH2 mutations in gliomas.,http://www.ncbi.nlm.nih.gov/pubmed/19228619,487,19935646,Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.,http://www.ncbi.nlm.nih.gov/pubmed/19935646,7070
"IDH1 R222C does not lie within any known functional domains of the Idh1 protein (UniProt.org). R222C has been identified in sequencing studies (PMID: 24755471), but has not been biochemically characterized and therefore, its effect on Idh1 protein function is unknown (PubMed, Jun 2017).
",6962,24755471,Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24755471,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7071
"IDH1 R314H does not lie within any known functional domains of the Idh1 protein (UniProt.org). R314H has not been characterized in the scientific literature and therefore, its effect on Idh1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7072
"IDH1 R338T does not lie within any known functional domains of the Idh1 protein (UniProt.org). R338T has not been characterized in the scientific literature and therefore, its effect on Idh1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7158
IDH1 R49C does not lie within any known functional domains of the Idh1 protein (UniProt.org). R49C results in decreased accumulation of Idh1 protein in cell culture (PMID: 21996744),295,,,www.uniprot.org,2651,21996744,Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.,http://www.ncbi.nlm.nih.gov/pubmed/21996744,7159
"IDH1 S261L does not lie within any known functional domains of the Idh1 protein (UniProt.org). S261L has been identified in sequencing studies (PMID: 24755471), but has not been biochemically characterized and therefore, its effect on Idh1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6962,24755471,Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24755471,7160
"IDH1 T162A does not lie within any known functional domains of the Idh1 protein (UniProt.org). T162A has not been characterized in the scientific literature and therefore, its effect on Idh1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7161
"IDH1 V276M does not lie within any known functional domains of the Idh1 protein (UniProt.org). V276M has not been characterized in the scientific literature and therefore, its effect on Idh1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7162
"IDH1 W92R does not lie within any known functional domains of the Idh1 protein (UniProt.org). W92R has not been characterized in the scientific literature and therefore, its effect on Idh1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7163
"IDH1 Y235C does not lie within any known functional domains of the Idh1 protein (UniProt.org). Y235C has been identified in sequencing studies (PMID: 24760710), but has not been biochemically characterized and therefore, its effect on Idh1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7377,24760710,Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate.,http://www.ncbi.nlm.nih.gov/pubmed/24760710,295,,,www.uniprot.org,7164
"IDH1 Y285H does not lie within any known functional domains of the Idh1 protein (UniProt.org). Y285H has not been characterized in the scientific literature and therefore, its effect on Idh1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7165
"JAK2 act mut indicates that this variant results in a gain of function in the Jak2 protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,7167
"JAK3 act mut indicates that this variant results in a gain of function in the Jak3 protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,7175
"PDGFRA T674I lies within the protein kinase domain of the Pdgfra protein (UniProt.org). T674I has not been biochemically characterized for functional effects on Pdgfra, but has been demonstrated to occur as a secondary resistance mutation in the context of FIP1L-PDGFRA (PMID: 12660384).",2988,12660384,A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12660384,295,,,www.uniprot.org,7209
"EZH2 A237S lies within the DNMT1, DNMT3A and DNMT3B interaction region of the Ezh2 protein (UniProt.org). A237S has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7325
"EZH2 C530W lies within the CXC domain of the Ezh2 protein (UniProt.org). C530W has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7334
"EZH2 D233Y lies within the DNMT1, DNMT3A and DNMT3B interaction region of the Ezh2 protein (UniProt.org). D233Y has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7338
"EZH2 E162* results in a premature truncation of the Ezh2 protein at amino acid 162 of 746 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), E162* is predicted to lead to a loss of Ezh2 protein function. ",295,,,www.uniprot.org,7344
"EZH2 E246* results in a premature truncation of the Ezh2 protein at amino acid 246 of 746 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), E246* is predicted to lead to a loss of Ezh2 protein function. ",295,,,www.uniprot.org,7348
"EZH2 E396* results in a premature truncation of the Ezh2 protein at amino acid 396 of 746 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), E396* is predicted to lead to a loss of Ezh2 protein function. ",295,,,www.uniprot.org,7353
"EZH2 E59* results in a premature truncation of the Ezh2 protein at amino acid 59 of 746 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), E59* is predicted to lead to a loss of Ezh2 protein function. ",295,,,www.uniprot.org,7355
"EZH2 E169D lies within the DNMT1, DNMT3A and DNMT3B interaction region of the Ezh2 protein (UniProt.org). E169D has been identified in sequencing studies (PMID: 22895193), but has not been biochemically characterized and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",4597,22895193,Recurrent R-spondin fusions in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22895193,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7360
"EZH2 E720K lies within the SET domain of the Ezh2 protein (UniProt.org). E720K has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7381
"EZH2 E740K does not lie within any known functional domains of the Ezh2 protein (UniProt.org). E740K has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7382
"EZH2 E721D lies within the SET domain of the Ezh2 protein (UniProt.org). E721D has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7383
"EZH2 F673C lies within the SET domain of the Ezh2 protein (UniProt.org). F673C has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7384
"EZH2 G5R lies within DNMT1, DNMT3A and DNMT3B interaction region of the Ezh2 protein (UniProt.org). G5R has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7385
"EZH2 K234N lies within the DNMT1, DNMT3A and DNMT3B interaction region of the Ezh2 protein (UniProt.org). K234N has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (PubMed, Dec 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7386
"EZH2 K241Q lies within the DNMT1, DNMT3A and DNMT3B interaction region of the Ezh2 protein (UniProt.org). K241Q has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7387
"EZH2 M662T lies within the SET domain of the Ezh2 protein (UniProt.org). M662T has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7388
"EZH2 P746S does not lie within any known functional domains of the Ezh2 protein (UniProt.org).  P746S has been identified in sequencing studies (PMID: 22817889), but has not been biochemically characterized and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,7789,22817889,A landscape of driver mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22817889,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7394
"EZH2 N423T lies within the CDYL interaction region of the Ezh2 protein (UniProt.org). N423T has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7395
"EZH2 Q540P lies within the CXC domain of the Ezh2 protein (UniProt.org). Q540P has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7396
"EZH2 R18C lies within the DNMT1, DNMT3A and DNMT3B interaction region of the Ezh2 protein (UniProt.org). R18C has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7397
"EZH2 R207Q lies within the DNMT1, DNMT3A and DNMT3B interaction region of the Ezh2 protein (UniProt.org). R207Q has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7398
"EZH2 R213H lies within DNMT1, DNMT3A and DNMT3B interaction region of the Ezh2 protein (UniProt.org). R213H has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7399
"EZH2 R216Q lies within DNMT1, DNMT3A and DNMT3B interaction region of the Ezh2 protein (UniProt.org). R216Q demonstrates H3K27 trimethylation at similar level to wild-type Ezh2 in culture (PMID: 25609585).",295,,,www.uniprot.org,3003,25609585,The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors.,http://www.ncbi.nlm.nih.gov/pubmed/25609585,7400
"EZH2 R34L lies within DNMT1, DNMT3A and DNMT3B interaction region of the Ezh2 protein (UniProt.org). R34L has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7514
"EZH2 R353C lies within the CDYL interaction region of the Ezh2 protein (UniProt.org). R353C has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7515
"EZH2 R355G lies within the CDYL interaction region of the Ezh2 protein (UniProt.org). R355G has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7516
"EZH2 R497Q lies within the CDYL interaction region of the Ezh2 protein (UniProt.org). R497Q has been identified in sequencing studies (PMID: 26812882), but has not been biochemically characterized and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).
",7340,26812882,Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/26812882,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7517
"EZH2 R653I lies within the SET domain of the Ezh2 protein (UniProt.org). R653I has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7518
"EZH2 R679S lies within the SET domain of the Ezh2 protein (UniProt.org). R679S has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7519
"EZH2 S229L lies within the CDYL interaction region of the Ezh2 protein (UniProt.org). S229L has been identified in sequencing studies (PMID: 22842228), but has not been biochemically characterized and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",7109,22842228,Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22842228,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7520
"EZH2 V577A lies within the CXC domain of the Ezh2 protein (UniProt.org). V577A has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7521
"JAK2 A660S lies within the protein kinase domain 1 of the Jak2 protein (UniProt.org). A660S has not been characterized in the scientific literature and therefore, its effect on Jak2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7534
"JAK2 A676V lies within the protein kinase domain 1 of the Jak2 protein (UniProt.org). A676V has not been characterized in the scientific literature and therefore, its effect on Jak2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7535
"JAK2 D319G lies within the FERM domain of the Jak2 protein (UniProt.org). D319G has not been characterized in the scientific literature and therefore, its effect on Jak2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7536
"JAK2 D319N lies within the FERM domain of the Jak2 protein (UniProt.org). D319N has been identified in sequencing studies (PMID: 24755471), but has not been biochemically characterized and therefore, its effect on Jak2 protein function is unknown (PubMed, Jul 2017).",6962,24755471,Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24755471,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7537
"JAK2 D569Y lies within the protein kinase domain 1 of the Jak2 protein (UniProt.org). D569Y has not been characterized in the scientific literature and therefore, its effect on Jak2 protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7538
"JAK2 E1012* results in a premature truncation of the Jak2 protein at amino acid 1021 of 1132 (UniProt.org). E1012* has not been characterized in the scientific literature and therefore, its effect on Jak2 protein function is unknown (PubMed, Dec 2016). ",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7539
"JAK2 E1080* results in a premature truncation of the Jak2 protein at amino acid 1080 of 1132 (UniProt.org). E1080* has not been characterized in the scientific literature and therefore, its effect on Jak2 protein function is unknown (PubMed, Dec 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7540
"JAK2 E10K does not lie within any known functional domains of the Jak2 protein (UniProt.org). E10K has not been characterized in the scientific literature and therefore, its effect on Jak2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7541
"JAK2 E177* results in a premature truncation of the Jak2 protein at amino acid 177 of 1132 (UniProt.org). Due to the loss of the protein kinase domains (UniProt.org), E177* is predicted to lead to a loss of Jak2 function.",295,,,www.uniprot.org,7542
"JAK2 E274*  results in a premature truncation of the Jak2 protein at amino acid 274 of 1132 (UniProt.org). Due to the loss of the protein kinase domains (UniProt.org), E274* is predicted to lead to a loss of Jak2 function.",295,,,www.uniprot.org,7545
"JAK2 E386* results in a premature truncation of the Jak2 protein at amino acid 386 of 1132 (UniProt.org). Due to the loss of the protein kinase domains (UniProt.org), E386* is predicted to lead to a loss of Jak2 function.",295,,,www.uniprot.org,7548
"JAK2 E484K does not lie within any known functional domains of the Jak2 protein (UniProt.org). E484K has not been characterized in the scientific literature and therefore, its effect on Jak2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7551
"JAK2 E818* results in a premature truncation of the Jak2 protein at amino acid 818 of 1132 (UniProt.org). Due to the loss of the protein kinase 2 domain (UniProt.org), E818* is predicted to lead to a loss of Jak2 protein function. ",295,,,www.uniprot.org,7552
"FLT3 F691L lies within the protein kinase domain of the Flt3 protein (PMID: 23430109). F691L has been demonstrated to promote secondary drug resistance in the context of FLT3 internal tandem duplication (FLT3-ITD) mutations (PMID: 23430109, PMID: 19318574).",3028,23430109,Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.,http://www.ncbi.nlm.nih.gov/pubmed/23430109,3029,19318574,FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.,http://www.ncbi.nlm.nih.gov/pubmed/19318574,7560
"FLT3 I836F lies within the protein kinase domain of the Flt3 protein (UniProt.org). I836F has been identified in sequencing studies (PMID: 16371029), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7342,16371029,Novel observation of three FLT3 codons mutated in tandem in an elderly acute myeloid leukaemia patient.,http://www.ncbi.nlm.nih.gov/pubmed/16371029,7561
"FLT3 I836H lies within the protein kinase domain of the Flt3 protein (UniProt.org). I836H has been identified in sequencing studies (PMID: 16912228), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",7343,16912228,Clinical implications of FLT3 mutations in pediatric AML.,http://www.ncbi.nlm.nih.gov/pubmed/16912228,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7562
"FLT3 I836M lies within the protein kinase domain of the Flt3 protein (UniProt.org). I836M has been identified in sequencing studies (PMID: 15390271), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",7344,15390271,Activating FLT3 mutations are rare in children with juvenile myelomonocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/15390271,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7563
"JAK2 E864K lies within the protein kinase 2 domain of the Jak2 protein (UniProt.org). E864K results in increased Jak2 and Stat5 phosphorylation, and has been described as a secondary drug resistance mutation in the context of other Jak2 activating mutations (PMID: 22916261, PMID: 22271575).",3030,22271575,Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/22271575,295,,,www.uniprot.org,3031,22916261,Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/22916261,7567
"JAK2 E890* results in a premature truncation of the Jak2 protein at amino acid 890 of 1132 (UniProt.org). Due to the disruption of the protein kinase 2 domain (UniProt.org), E890* is predicted to lead to a loss of Jak2 protein function. ",295,,,www.uniprot.org,7568
"JAK2 E987D lies within the protein kinase 2 domain of the Jak2 protein (UniProt.org). E987D has not been biochemically characterized, but has been described as a secondary resistance mutation (PMID: 26419724). ",4779,26419724,Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance.,http://www.ncbi.nlm.nih.gov/pubmed/26419724,295,,,www.uniprot.org,7569
"JAK2 F439S lies within the SH2 domain of the Jak2 protein (UniProt.org). F439S has not been characterized in the scientific literature and therefore, its effect on Jak2 protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7570
"JAK2 F560S lies within the protein kinase domain 1 of the Jak2 protein (UniProt.org). F560S has not been characterized in the scientific literature and therefore, its effect on Jak2 protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7571
"ETV6-JAK2 results from the fusion of ETV6 (also referred to as TEL) and JAK2 (PMID: 9736611). ETV6-JAK2 results in growth factor independence, constitutive kinase activity and increased downstream signaling (PMID: 9736611).",3037,9736611,Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes.,http://www.ncbi.nlm.nih.gov/pubmed/9736611,7572
"JAK2 E985K lies within the protein kinase 2 domain of the Jak2 protein (UniProt.org). E985K has not been biochemically characterized for functional effects on Jak2, but has been described as a secondary drug resistance mutation (PMID: 21926964).",295,,,www.uniprot.org,3038,21926964,Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/21926964,7573
"JAK2 G295E lies within the FERM domain of the Jak2 protein (UniProt.org). G295E has not been characterized in the scientific literature and therefore, its effect on Jak2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7574
"JAK2 I540N does not lie within any known functional domains of the Jak2 protein (UniProt.org). I540N has not been characterized in the scientific literature and therefore, its effect on Jak2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7575
"JAK2 K167Q lies within the FERM domain of the Jak2 protein (UniProt.org). K167Q has not been characterized in the scientific literature and therefore, its effect on Jak2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7576
"JAK2 K912T lies within the protein kinase domain 2 of the Jak2 protein (UniProt.org). K912T has not been characterized in the scientific literature and therefore, its effect on Jak2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7577
"JAK2 L1047I lies within the protein kinase domain 2 of the Jak2 protein (UniProt.org). L1047I has not been characterized in the scientific literature and therefore, its effect on Jak2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7578
"JAK2 L393V does not lie within any known functional domains of the Jak2 protein (UniProt.org). L393V has been identified in sequencing studies (PMID: 22762550), but has not been biochemically characterized and therefore, its effect on Jak2 protein function is unknown (PubMed, Jul 2017).",7394,22762550,Lack of JAK2 activating non-synonymous mutations in diffuse large B-cell tumors: JAK2 deregulation still unexplained.,http://www.ncbi.nlm.nih.gov/pubmed/22762550,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7579
"JAK2 L579I lies within the protein kinase domain 1 of the Jak2 protein (UniProt.org). L579I has not been characterized in the scientific literature and therefore, its effect on Jak2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7580
"JAK2 P870L lies within the protein kinase domain 2 of the Jak2 protein (UniProt.org). P870L has not been characterized in the scientific literature and therefore, its effect on Jak2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7581
"JAK2 P870S lies within the protein kinase domain 2 of the Jak2 protein (UniProt.org). P870S has not been characterized in the scientific literature and therefore, its effect on Jak2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7582
JAK2 R683G lies within the protein kinase 1 domain of the Jak2 protein (UniProt.org). R683G results in constitutive activation of the Jak2 protein (PMID: 23748007).,3039,23748007,"The effects of R683S (G) genetic mutations on the JAK2 activity, structure and stability.",http://www.ncbi.nlm.nih.gov/pubmed/23748007,295,,,www.uniprot.org,7583
"JAK2 G935R lies within the protein kinase 2 domain of the Jak2 protein (UniProt.org). G935R results in increased Jak2 and Stat5 phosphorylation, and has been described as a secondary drug resistance mutation in the context of other Jak2 activating mutations (PMID: 22271575, PMID: 22916261).",3030,22271575,Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/22271575,3031,22916261,Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/22916261,295,,,www.uniprot.org,7584
"JAK2 I960V lies within the protein kinase 2 domain of the Jak2 protein (UniProt.org). I960V has not been biochemically characterized for functional effects on Jak2, but has been described as a secondary drug resistance mutation in the context of JAK2 V617F (PMID: 23009939, PMID: 21926964).",3038,21926964,Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/21926964,3040,23009939,Therapy with JAK2 inhibitors for myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23009939,7585
"JAK2 M929I is a gatekeeper mutation that lies within the protein kinase 2 domain of the Jak2 protein (PMID: 22916261, PMID: 23823659). M929I results in increased Jak2 and Stat5 phosphorylation, and has been described as a secondary drug resistance mutation in the context of other Jak2 activating mutations (PMID: 22916261, PMID: 23823659, PMID: 21926964). ",3041,23823659,Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348).,http://www.ncbi.nlm.nih.gov/pubmed/23823659,3038,21926964,Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/21926964,3031,22916261,Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/22916261,7586
"JAK3 C1077F lies within the protein kinase domain 2 of the Jak3 protein (UniProt.org). C1077F has not been characterized in the scientific literature and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7587
"JAK3 D294G lies within the FERM domain of the Jak3 protein (UniProt.org). D294G has not been characterized in the scientific literature and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7588
"JAK3 E552Q lies within the protein kinase domain 1 of the Jak3 protein (UniProt.org). E552Q has not been characterized in the scientific literature and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7589
"JAK3 G1057N lies within the protein kinase domain 2 of the Jak3 protein (UniProt.org). G1057N has not been characterized in the scientific literature and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7590
"JAK3 G538D lies within the protein kinase domain 1 of the Jak3 protein (UniProt.org). G538D has not been characterized in the scientific literature and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7591
"JAK3 G969V lies within the protein kinase domain 2 of the Jak3 protein (UniProt.org). G969V has not been characterized in the scientific literature and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7592
"JAK3 H1118R does not lie within any known functional domains of the Jak3 protein (UniProt.org). H1118R has not been characterized and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7593
"JAK3 I535M lies within the protein kinase domain 1 of the Jak3 protein (UniProt.org). I535M has not been characterized in the scientific literature and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7594
"JAK3 I688L lies within the protein kinase domain 1 of the Jak3 protein (UniProt.org). I688L has not been characterized in the scientific literature and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7595
"JAK3 L1091R lies within the protein kinase domain 2 of the Jak3 protein (UniProt.org). L1091R has not been characterized and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7596
"JAK3 L527P lies within the protein kinase domain 1 of the Jak3 protein (UniProt.org). L527P has not been characterized and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7597
"JAK3 L527R lies within the protein kinase domain 1 of the Jak3 protein (UniProt.org). L527R has not been characterized in the scientific literature and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7598
"JAK3 L679V lies within the protein kinase domain 1 of the Jak3 protein (UniProt.org). L679V has not been characterized in the scientific literature and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7599
"JAK3 M511I does not lie within any known functional domains of the Jak3 protein (UniProt.org). M511I results in increased phosphorylation of Jak3, activation of Stat5 and Erk signaling, enhanced tumor growth in animal models, and is transforming in cell culture (PMID: 25193870).",3042,25193870,"JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/25193870,295,,,www.uniprot.org,7600
"JAK3 M937T lies within the protein kinase domain 2 of the Jak3 protein (UniProt.org). M937T has not been characterized in the scientific literature and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7601
"JAK3 P1086Q lies within the protein kinase domain 2 of the Jak3 protein (UniProt.org). P1086Q has not been characterized in the scientific literature and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7602
"JAK3 P420S lies within the SH2 domain of the Jak3 protein (UniProt.org). P420S has not been characterized in the scientific literature and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7603
"JAK3 Q507L does not lie within any known functional domains of the Jak3 protein (UniProt.org). Q507L has not been characterized and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7604
"JAK3 Q507R does not lie within any known functional domains of the Jak3 protein (UniProt.org). Q507R has not been characterized in the scientific literature and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7605
"JAK3 R1085Q lies within the protein kinase domain 2 of the Jak3 protein (UniProt.org). R1085Q has not been characterized in the scientific literature and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7606
JAK3 R402H lies within the SH2 domain of the Jak3 protein (UniProt.org). R402H results in altered Jak3 subcellular localization and failure to properly localize common gamma chain to the cell membrane in cell culture (PMID: 15143194).,3043,15143194,Jak3-independent trafficking of the common gamma chain receptor subunit: chaperone function of Jaks revisited.,http://www.ncbi.nlm.nih.gov/pubmed/15143194,295,,,www.uniprot.org,7607
"JAK3 R540H lies within the protein kinase domain 1 of the Jak3 protein (UniProt.org). R540H has not been characterized in the scientific literature and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7608
"JAK3 R887C lies within the protein kinase domain 2 of the Jak3 protein (UniProt.org). R887C has not been characterized in the scientific literature and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7609
"JAK3 R944H lies within the protein kinase domain 2 of the Jak3 protein (UniProt.org). R944H has not been characterized and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7610
"JAK3 R948C lies within the protein kinase domain 2 of the Jak3 protein (UniProt.org). R948C has been identified in the scientific literature (PMID: 23619167), but has not been biochemically characterized and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2263,23619167,Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.,http://www.ncbi.nlm.nih.gov/pubmed/23619167,295,,,www.uniprot.org,7611
"JAK3 S1124L lies within the protein kinase domain 2 of the Jak3 protein (UniProt.org). S1124L has not been characterized and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7612
"JAK3 V715A lies within the protein kinase domain 1 of the Jak3 protein (UniProt.org). V715A has not been characterized in the scientific literature and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7613
"JAK3 V718L lies within the protein kinase domain 1 of the Jak3 protein (UniProt.org). V718L has not been characterized in the scientific literature and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7614
"JAK3 W709C lies within the protein kinase domain 1 of the Jak3 protein (UniProt.org). W709C has not been characterized in the scientific literature and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7615
"JAK3 W709L lies within the protein kinase domain 1 of the Jak3 protein (UniProt.org). W709L has not been characterized and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7616
"JAK2 R1063H lies within the protein kinase 2 domain of the Jak2 protein (UniProt.org). R1063H results increased EPO-induced growth, STAT5 phosphorylation and transcriptional activity, and EPO-dependent and independent hematopoietic colony formation in vitro relative to wild-type Jak2 (PMID: 27389715).",295,,,www.uniprot.org,8881,27389715,Cooperation of germ line JAK2 mutations E846D and R1063H in hereditary erythrocytosis with megakaryocytic atypia.,http://www.ncbi.nlm.nih.gov/pubmed/27389715,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7650
"JAK2 N909K lies within the protein kinase 2 domain of the Jak2 protein (UniProt.org). N909K results in increased Jak2, Stat5, Akt and Erk phosphorylation, and has been described as a secondary drug resistance mutation in the context of ETV6-JAK2 (PMID: 22916261).",295,,,www.uniprot.org,3031,22916261,Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/22916261,7651
"JAK2 P1057S lies within the protein kinase 2 domain of the Jak2 protein (UniProt.org). P1057S has not been biochemically characterized for functional effects on Jak2, but has been demonstrated to occur as a secondary drug resistance mutation (PMID: 23670175).",295,,,www.uniprot.org,2981,23670175,Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/23670175,7652
"JAK2 R1127K does not lie within any known functional domains of the Jak2 protein (UniProt.org). R1127K not been biochemically characterized for functional effects on Jak2, but has been demonstrated to occur as a secondary drug resistance mutation (PMID: 22916261).",3031,22916261,Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/22916261,295,,,www.uniprot.org,7653
"JAK2 R215Q lies within the FERM domain of the Jak2 protein (UniProt.org). R215Q has not been characterized and therefore, its effect on Jak2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7654
"JAK2 R426* results in a premature truncation of the Jak2 protein at amino acid 426 of 1132 (UniProt.org). Due to the loss of the protein kinase domains (UniProt.org), R426* is predicted to lead to a loss of Jak2 function.",295,,,www.uniprot.org,7655
"JAK2 R443* results in a premature truncation of the Jak2 protein at amino acid 443 of 1132 (UniProt.org). Due to the loss of the protein kinase domains (UniProt.org), R443* is predicted to lead to a loss of Jak2 function.",295,,,www.uniprot.org,7656
"JAK2 S358* results in a premature truncation of the Jak2 protein at amino acid 358 of 1132 (UniProt.org). Due to the loss of the protein kinase domains (UniProt.org), S358* is predicted to lead to a loss of Jak2 function.",295,,,www.uniprot.org,7657
"JAK2 R487C does not lie within any known functional domains of the Jak2 protein (UniProt.org). R487C has not been characterized in the scientific literature and therefore, its effect on Jak2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7658
"JAK2 R564G lies within the protein kinase domain 1 of the Jak2 protein (UniProt.org). R564G has not been characterized in the scientific literature and therefore, its effect on Jak2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7659
"JAK2 R588I lies within the protein kinase domain 1 of the Jak2 protein (UniProt.org). R588I has not been characterized in the scientific literature and therefore, its effect on Jak2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7660
"JAK2 S126N lies within the FERM domain of the Jak2 protein (UniProt.org). S126N has not been characterized in the scientific literature and therefore, its effect on Jak2 function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7661
"JAK2 S602I lies within the protein kinase domain 1 of the Jak2 protein (UniProt.org). S602I has not been characterized in the scientific literature and therefore, its effect on Jak2 function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7662
"JAK2 S887I lies within the protein kinase domain 2 of the Jak2 protein (UniProt.org). S887I has not been characterized in the scientific literature and therefore, its effect on Jak2 function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7663
"JAK2 V911A lies within the protein kinase domain 2 of the Jak2 protein (UniProt.org). V911A has not been characterized in the scientific literature and therefore, its effect on Jak2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7664
"JAK2 W737L lies within the protein kinase domain 1 of the Jak2 protein (UniProt.org). W737L has not been characterized in the scientific literature and therefore, its effect on Jak2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7665
"JAK2 Y254H lies within the FERM domain of the Jak2 protein (UniProt.org). Y254H has not been characterized in the scientific literature and therefore, its effect on Jak2 protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7666
"JAK2 V881fs results in a change in the amino acid sequence of the Jak2 protein beginning at aa 881 of 1132, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the disruption of the protein kinase 2 domain (UniProt.org), V881fs is predicted to lead to a loss of Jak2 protein function.",295,,,www.uniprot.org,7667
"JAK2 R938L lies within the protein kinase 2 domain of the Jak2 protein (UniProt.org). R938L has not been biochemically characterized for functional effects on Jak2, but has been demonstrated to occur as a secondary drug resistance mutation (PMID: 21926964).",295,,,www.uniprot.org,3038,21926964,Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/21926964,7668
"JAK2 R975G lies within the protein kinase 2 domain of the Jak2 protein (UniProt.org). R975G results in increased Jak2, Stat5, Akt and Erk phosphorylation, and has been described as a secondary drug resistance mutation in the context of ETV6-JAK2 (PMID: 22916261).",3031,22916261,Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/22916261,295,,,www.uniprot.org,7672
"JAK2 V881A lies within the protein kinase 2 domain of the Jak2 protein (UniProt.org). V881A results in increased Jak2, Stat5, Akt and Erk phosphorylation, and has been described as a secondary drug resistance mutation in the context of ETV6-JAK2 (PMID: 22916261).",3031,22916261,Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/22916261,295,,,www.uniprot.org,7673
"JAK2 Y918H lies within the protein kinase 2 domain of the Jak2 protein (UniProt.org). Y918H has not been biochemically characterized for functional effects on Jak2, but has been demonstrated to occur as a secondary drug resistance mutation (PMID: 22916261).",295,,,www.uniprot.org,3031,22916261,Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/22916261,7674
"JAK3 A572T lies within the protein kinase domain 1 of the Jak3 protein (UniProt.org). A572T results in constitutive phosphorylation of Jak3, activation of Stat5 and Erk signaling, and is transforming in cell culture (PMID: 25193870).",3042,25193870,"JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/25193870,295,,,www.uniprot.org,7675
JAK3 C759R lies within the protein kinase domain 1 of the Jak3 protein (UniProt.org). C759R results in a loss of Jak3 kinase activity and fails to mediate IL-2-dependent Stat5 activation in cell culture (PMID: 10629052).,295,,,www.uniprot.org,3053,10629052,Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains.,http://www.ncbi.nlm.nih.gov/pubmed/10629052,7676
JAK3 D949N lies within the protein kinase domain 2 of the Jak3 protein (UniProt.org). D949N demonstrates subcellular localization similar to wild-type Jak3 and promotes common gamma chain membrane expression in cell culture (PMID: 15143194).,3043,15143194,Jak3-independent trafficking of the common gamma chain receptor subunit: chaperone function of Jaks revisited.,http://www.ncbi.nlm.nih.gov/pubmed/15143194,295,,,www.uniprot.org,7677
JAK3 E1106G lies within the protein kinase domain 2 of the Jak3 protein (UniProt.org). E1106G demonstrates phosphorylation of Jak3 similar to wild-type protein and is not transforming in cell culture (PMID: 25193870).,3042,25193870,"JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/25193870,295,,,www.uniprot.org,7678
JAK3 E639K lies within the protein kinase domain 1 of the Jak3 protein (UniProt.org). E639K results in a loss of Jak3 kinase activity and fails to mediate IL-2-dependent Stat5 activation in cell culture (PMID: 10629052).,3053,10629052,Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains.,http://www.ncbi.nlm.nih.gov/pubmed/10629052,295,,,www.uniprot.org,7679
JAK3 K556A lies within the protein kinase domain 1 of the Jak3 protein (UniProt.org). K556A results in altered subcellular localization of Jak3 comparing to wild-type protein in cell culture (PMID: 15143194).,3043,15143194,Jak3-independent trafficking of the common gamma chain receptor subunit: chaperone function of Jaks revisited.,http://www.ncbi.nlm.nih.gov/pubmed/15143194,295,,,www.uniprot.org,7680
JAK3 K855A lies within the protein kinase domain 2 of the Jak3 protein (UniProt.org). K855A results in a loss of Jak3 kinase activity and fails to mediate IL-2-dependent Stat5 activation in cell culture (PMID: 10629052).,295,,,www.uniprot.org,3053,10629052,Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains.,http://www.ncbi.nlm.nih.gov/pubmed/10629052,7681
"JAK3 L857Q lies within the protein kinase domain 2 of the Jak3 protein (UniProt.org). L857Q results in constitutive phosphorylation of Jak3, activation of Stat5 and Erk signaling, hyperplasia in animal models, and is transforming in cell culture (PMID: 25193870).",295,,,www.uniprot.org,3042,25193870,"JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/25193870,7682
JAK3 R272H lies within the FERM domain of the Jak3 protein (UniProt.org). R272H demonstrates phosphorylation of Jak3 similar to wild-type protein and is not transforming in cell culture (PMID: 25193870).,295,,,www.uniprot.org,3042,25193870,"JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/25193870,7683
JAK3 R403H lies within the SH2 domain of the Jak3 protein (UniProt.org). R403H demonstrates phosphorylation of Jak3 similar to wild-type protein and is not transforming in cell culture (PMID: 25193870).,295,,,www.uniprot.org,3042,25193870,"JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/25193870,7684
"JAK3 R657W lies within the protein kinase domain 1 of the Jak3 protein (UniProt.org). R657W has not been biochemically characterized, but is predicted to result in a gain of Jak3 function based on the ability to transform cells in culture (PMID: 25193870).",295,,,www.uniprot.org,3042,25193870,"JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/25193870,7685
"JAK3 V678M lies within the protein kinase domain 1 of the Jak3 protein (UniProt.org). V678M results in constitutive phosphorylation of Jak3, activation of Stat5 and Erk signaling, and is transforming in cell culture (PMID: 25193870).",295,,,www.uniprot.org,3042,25193870,"JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/25193870,7686
JAK3 Y100C lies within the FERM domain of the Jak3 protein (UniProt.org). Y100C results in a loss of gamma c binding and blocks IL-2-dependent Jak3 activation in cell culture (PMID: 10075926). ,295,,,www.uniprot.org,3054,10075926,Autosomal SCID caused by a point mutation in the N-terminus of Jak3: mapping of the Jak3-receptor interaction domain.,http://www.ncbi.nlm.nih.gov/pubmed/10075926,7687
"JAK3 Y980F lies within the protein kinase domain 2 of the Jak3 protein (UniProt.org). Y980F results in impaired Jak3 kinase activity, decreased Stat5 phosphorylation and DNA-binding activity in cell culture (PMID: 9391116).",295,,,www.uniprot.org,3055,9391116,Distinct tyrosine phosphorylation sites in JAK3 kinase domain positively and negatively regulate its enzymatic activity.,http://www.ncbi.nlm.nih.gov/pubmed/9391116,7688
"CDKN2A A102V lies within the ANK repeat 3 of the Cdkn2a protein (UniProt.org). A102V has been identified in the scientific literature (PMID: 9053859), but has not been biochemically characterized and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Feb 2017).",295,,,www.uniprot.org,3063,9053859,Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma.,http://www.ncbi.nlm.nih.gov/pubmed/9053859,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7714
"CDKN2A A20E lies within the ANK repeat 1 of the Cdkn2a protein (UniProt.org). A20E has been identified in sequencing studies (PMID: 8589032), but has not been biochemically characterized and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7773,8589032,Alterations of CDKN2 (p16) in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/8589032,7727
"CDKN2A A127fs results in a change in the amino acid sequence of the Cdkn2a protein beginning at aa 127 of 156, likely resulting in premature truncation of the functional protein (UniProt). A127fs has been identified in sequencing studies (PMID: 9808520), but has not been biochemically characterized and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7772,9808520,p53 and p16/CDKN2 gene mutations in esophageal tumors from a high-incidence area in South Africa.,http://www.ncbi.nlm.nih.gov/pubmed/9808520,7735
CDKN2A A20P lies within the ANK1 domain of the Cdkn2a protein (UniProt.org). A20P confers a loss of function to the Cdkn2a protein as demonstrated by a reduction in Cdk4 inhibitory activity (PMID: 19110720).,3059,19110720,Expression of the p16INK4A/Cdkn2a gene is prevalently downregulated in human pheochromocytoma tumor specimens.,http://www.ncbi.nlm.nih.gov/pubmed/19110720,7738
JAK3 R925S lies within the protein kinase domain 2 of the Jak3 protein (UniProt.org). R925S demonstrates phosphorylation of Jak3 similar to wild-type protein and is not transforming in cell culture (PMID: 25193870).,295,,,www.uniprot.org,3042,25193870,"JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.",http://www.ncbi.nlm.nih.gov/pubmed/25193870,7766
"CDKN2A A21P lies within the ANK repeat 1 of the Cdkn2a (p16INK4a) protein (UniProt.org). A21P has not been characterized in the scientific literature and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7786
"CDKN2A A36G lies within the ANK repeat 1 of the Cdkn2a protein (UniProt.org). A36G has been identified in sequencing studies (PMID: 25275298), but has not been biochemically characterized and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Feb 2017).",1586,25275298,The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies.,http://www.ncbi.nlm.nih.gov/pubmed/25275298,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7787
CDKN2A A36P lies within the ANK1 domain of the Cdkn2a protein (UniProt.org). A36P confers a loss of function to the Cdkn2a protein as demonstrated by the inability to suppress reactive oxygen species formation (PMID: 23190892).,3062,23190892,Familial melanoma-associated mutations in p16 uncouple its tumor-suppressor functions.,http://www.ncbi.nlm.nih.gov/pubmed/23190892,295,,,www.uniprot.org,7788
"CDKN2A A57T lies within the ANK repeat 2 of the Cdkn2a protein (UniProt.org). A57T has been identified in sequencing studies (PMID: 25530832), but has not been biochemically characterized and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7774,25530832,Kinome sequencing reveals RET G691S polymorphism in human neuroendocrine lung cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/25530832,295,,,www.uniprot.org,7789
"CDKN2A A68fs results in a change in the amino acid sequence of the Cdkn2a protein beginning at aa 68 of 156, likely resulting in premature truncation of the functional protein (UniProt.org). A68fs has not been characterized, however, nonsense mutations downstream of A68 are inactivating (PMID: 9053859, PMID: 8668202), thus A68fs is predicted to lead to a loss of Cdkn2a protein function.",295,,,www.uniprot.org,3063,9053859,Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma.,http://www.ncbi.nlm.nih.gov/pubmed/9053859,3108,8668202,Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/8668202,7790
"CDKN2A A68T lies within the ANK2 domain of the Cdkn2a protein (UniProt.org). A68T results in decreased binding of Cdkn2a to Cdk4 and altered subcellular localization of Cdkn2a, but induces cell-cycle arrest similar to wild-type Cdkn2a in culture (PMID: 11518711, PMID: 18990760).",3094,11518711,Mutations in the INK4a/ARF melanoma susceptibility locus functionally impair p14ARF.,http://www.ncbi.nlm.nih.gov/pubmed/11518711,295,,,www.uniprot.org,4247,18990760,Frequent alterations of p16INK4a and p14ARF in oral proliferative verrucous leukoplakia.,http://www.ncbi.nlm.nih.gov/pubmed/18990760,7791
"CDKN2A A73D does not lie within any known functional domains of the Cdkn2a protein (UniProt.org). A73D has been identified in sequencing studies (PMID: 16354195), but has not been biochemically characterized and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Feb 2017).",7775,16354195,Recurrent patterns of dual RB and p53 pathway inactivation in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/16354195,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7792
"CDKN2A A76fs results in a change in the amino acid sequence of the Cdkn2a protein beginning at aa 76 of 156, likely resulting in premature truncation of the functional protein (UniProt.org). A76fs has not been characterized, however, nonsense mutations downstream of A76 are inactivating (PMID: 9053859, PMID: 8668202), thus A76fs is predicted to lead to a loss of Cdkn2a protein function.",3063,9053859,Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma.,http://www.ncbi.nlm.nih.gov/pubmed/9053859,3108,8668202,Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/8668202,295,,,www.uniprot.org,7796
"CDKN2A A80fs results in a change in the amino acid sequence of the Cdkn2a protein beginning at aa 80 of 156, likely resulting in premature truncation of the functional protein (UniProt.org). A80fs has not been characterized, however, nonsense mutations downstream of A80 are inactivating (PMID: 9053859, PMID: 8668202), thus A80fs is predicted to lead to a loss of Cdkn2a protein function.",3063,9053859,Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma.,http://www.ncbi.nlm.nih.gov/pubmed/9053859,295,,,www.uniprot.org,3108,8668202,Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/8668202,7797
"CDKN2A A76T does not lie within any known functional domains of the Cdkn2a protein (UniProt.org). A76T has been identified in sequencing studies (PMID: 26164066), but has not been biochemically characterized and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7776,26164066,Spectrum of gene mutations detected by next generation exome sequencing in brain metastases of lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26164066,7798
"CDKN2A C72* results in a premature truncation of the Cdkn2a protein at amino acid 72 of 156 (UniProt.org). C72* has not been characterized, however, nonsense mutations downstream of C72 are inactivating (PMID: 9053859), thus C72* is predicted to lead to a loss of Cdkn2a protein function.",295,,,www.uniprot.org,3063,9053859,Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma.,http://www.ncbi.nlm.nih.gov/pubmed/9053859,7799
"CDKN2A C72fs results in a change in the amino acid sequence of the Cdkn2a protein beginning at aa 72 of 156, likely resulting in premature truncation of the functional protein (UniProt.org). C72fs has not been characterized, however, nonsense mutations downstream of C72 are inactivating (PMID: 9053859, PMID: 8668202), thus C72fs is predicted to lead to a loss of Cdkn2a protein function. ",3063,9053859,Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma.,http://www.ncbi.nlm.nih.gov/pubmed/9053859,3108,8668202,Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/8668202,295,,,www.uniprot.org,7800
"CDKN2A D108G does not lie within any known functional domains of the Cdkn2a protein (UniProt.org). D108G has been identified in sequencing studies (PMID: 26873401), but has not been biochemically characterized and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7161,26873401,Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population.,http://www.ncbi.nlm.nih.gov/pubmed/26873401,295,,,www.uniprot.org,7801
"CDKN2A D125fs results in a change in the amino acid sequence of the Cdkn2a protein beginning at aa 125 of 156, likely resulting in premature truncation of the functional protein (UniProt.org). D125fs has been identified in sequencing studies (PMID: 8637233), but has not been biochemically characterized and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7784,8637233,Alterations of CDKN2 gene structure in childhood acute lymphoblastic leukemia: mutations of CDKN2 are observed preferentially in T lineage.,http://www.ncbi.nlm.nih.gov/pubmed/8637233,7802
"CDKN2A D14G lies within the ANK repeat 1 of the Cdkn2a protein (UniProt.org). D14G has been identified in sequencing studies (PMID: 26873401), but has not been biochemically characterized and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7161,26873401,Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population.,http://www.ncbi.nlm.nih.gov/pubmed/26873401,295,,,www.uniprot.org,7803
"CDKN2A D14N lies within the ANK repeat 1 of the Cdkn2a protein (UniProt.org). D14N has not been characterized in the scientific literature and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7804
CDKN2A D108H lies within the ANK3 domain of the Cdkn2a protein (UniProt.org). D108H confers a loss of function to the Cdkn2a protein as demonstrated by loss of cell cycle control (PMID: 12606942).,3065,12606942,Detailed computational study of p53 and p16: using evolutionary sequence analysis and disease-associated mutations to predict the functional consequences of allelic variants.,http://www.ncbi.nlm.nih.gov/pubmed/12606942,295,,,www.uniprot.org,7805
CDKN2A D108Y lies within the ANK3 domain of the Cdkn2a protein (UniProt.org). D108Y confers a loss of function to the Cdkn2a protein as demonstrated by loss of cell cycle control (PMID: 12606942).,3065,12606942,Detailed computational study of p53 and p16: using evolutionary sequence analysis and disease-associated mutations to predict the functional consequences of allelic variants.,http://www.ncbi.nlm.nih.gov/pubmed/12606942,295,,,www.uniprot.org,7807
"CDKN2A D108N does not lie within any known functional domains of the Cdkn2a protein (UniProt.org). D108N has been identified in sequencing studies (PMID: 27135926), but has not been biochemically characterized and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Feb 2017).",7025,27135926,Landscape of somatic mutations in 560 breast cancer whole-genome sequences.,http://www.ncbi.nlm.nih.gov/pubmed/27135926,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7808
"CDKN2A D108V does not lie within any known functional domains of the Cdkn2a protein (UniProt.org). D108V has not been characterized in the scientific literature and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7809
CDKN2A D74N lies between the ANK2 and ANK3 domain of the Cdkn2a protein (UniProt.org). D74N confers a loss of function to the Cdkn2a protein as demonstrated by a reduction in Cdk kinase inhibition (PMID: 10491434).,295,,,www.uniprot.org,3067,10491434,Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors.,http://www.ncbi.nlm.nih.gov/pubmed/10491434,7810
FGFR3 N540S lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). N540S results in increased Fgfr3 autophosphorylation in cell culture (PMID: 26992226). ,295,,,www.uniprot.org,6316,26992226,Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.,http://www.ncbi.nlm.nih.gov/pubmed/26992226,7814
"CSF1R positive indicates the presence of the CSF1R gene, mRNA, and/or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,7815
"CSF1R act mut indicates that this variant results in a gain of function in the CSF1R protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,7820
"CDKN2A D74V does not lie within any known functional domains of the Cdkn2a protein (UniProt.org). D74V has been identified in sequencing studies (PMID: 11255261), but has not been biochemically characterized and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Feb 2017).",7785,11255261,Somatic INK4a-ARF locus mutations: a significant mechanism of gene inactivation in squamous cell carcinomas of the head and neck.,http://www.ncbi.nlm.nih.gov/pubmed/11255261,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7821
CDKN2A D84H lies within the ANK3 domain of the Cdkn2a protein (UniProt.org). D84H confers a loss of function to the Cdk2na protein as demonstrated by an inability to bind to Cdk4 and Cdk6 (PMID: 10498896). ,3091,10498896,Functional evaluation of tumour-specific variants of p16INK4a/CDKN2A: correlation with protein structure information.,http://www.ncbi.nlm.nih.gov/pubmed/10498896,295,,,www.uniprot.org,7822
CDKN2A D84N lies within the ANK3 domain of the Cdkn2a protein (UniProt.org). D84N confers a loss of function to the Cdk2na protein as demonstrated by an inability to bind to Cdk4 and Cdk6 (PMID: 10498896).,3091,10498896,Functional evaluation of tumour-specific variants of p16INK4a/CDKN2A: correlation with protein structure information.,http://www.ncbi.nlm.nih.gov/pubmed/10498896,295,,,www.uniprot.org,7823
"CDKN2A D84V lies within the ANK3 domain of the Cdkn2a protein (UniProt.org). D84V confers a loss of function to the Cdk2na protein as demonstrated by an inability to bind to Cdk4 and Cdk6 (PMID: 10498896, PMID: 10491434).",3067,10491434,Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors.,http://www.ncbi.nlm.nih.gov/pubmed/10491434,3091,10498896,Functional evaluation of tumour-specific variants of p16INK4a/CDKN2A: correlation with protein structure information.,http://www.ncbi.nlm.nih.gov/pubmed/10498896,7824
CDKN2A D84Y lies within the ANK3 domain of the Cdkn2a protein (UniProt.org). D84Y confers a loss of function to the Cdk2na protein as demonstrated by an inability to bind to Cdk4 and Cdk6 (PMID: 10498896).,3091,10498896,Functional evaluation of tumour-specific variants of p16INK4a/CDKN2A: correlation with protein structure information.,http://www.ncbi.nlm.nih.gov/pubmed/10498896,295,,,www.uniprot.org,7825
"CDKN2A E119* results in a premature truncation of the Cdkn2a protein at amino acid 119 or 156 (UniProt.org). E119* has not been characterized, however, a nonsense mutation downstream of E119 is inactivating (PMID: 8668202), thus E119* is predicted to lead to a loss of Cdkn2a protein function.",295,,,www.uniprot.org,3108,8668202,Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/8668202,7826
CDKN2A E120* results in a premature truncation of the Cdkn2a protein at amino acid 120 of 156. E120* confers a loss of function to the Cdkn2a protein as demonstrated by a loss of Cdk binding (PMID: 8668202).,3108,8668202,Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/8668202,295,,,www.uniprot.org,7827
"CDKN2A E119K lies within the ANK repeat 4 of the Cdkn2a protein (UniProt.org). E119K has not been characterized in the scientific literature and therefore, its effect on Cdkn2a protein is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7828
"FLT3 F594_R595insSDNEYFYVDF results in the insertion of ten amino acids in the juxtamembrane domain of the Flt3 protein between amino acids 594 and 595 (PMID: 14759363). F594_R595insSDNEYFYVDF is predicted to lead to activation of Flt3 due to the effects of other Flt3 internal tandem duplication (ITD) mutations (PMID: 12970773, PMID: 9737679, PMID: 11090077).",2896,12970773,FLT3: ITDoes matter in leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/12970773,2897,9737679,Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product.,http://www.ncbi.nlm.nih.gov/pubmed/9737679,2898,11090077,Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.,http://www.ncbi.nlm.nih.gov/pubmed/11090077,3093,14759363,The structural basis for autoinhibition of FLT3 by the juxtamembrane domain.,http://www.ncbi.nlm.nih.gov/pubmed/14759363,7829
"CDKN2A E120D lies within the ANK repeat 4 of the Cdkn2a protein (UniProt.org). E120D has not been characterized in the scientific literature and therefore, its effect on Cdkn2a protein is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7830
"FLT3 D600_L601insFREYEYD results in insertion of seven amino acids in the juxtamembrane domain of the Flt3 protein between amino acids 600 and 601 (PMID: 14759363). D600_L601insFREYEYD is predicted to lead to activation of Flt3 due to the effects of other Flt3 internal tandem duplication (ITD) mutations (PMID: 12970773, PMID: 9737679, PMID: 11090077).",2896,12970773,FLT3: ITDoes matter in leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/12970773,2897,9737679,Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product.,http://www.ncbi.nlm.nih.gov/pubmed/9737679,3093,14759363,The structural basis for autoinhibition of FLT3 by the juxtamembrane domain.,http://www.ncbi.nlm.nih.gov/pubmed/14759363,2898,11090077,Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.,http://www.ncbi.nlm.nih.gov/pubmed/11090077,7831
"FLT3 K602_W603insYEYDLK results in the insertion of six amino acids in the juxtamembrane domain of the Flt3 protein between amino acids 602 and 603 (PMID: 14759363). K602_W603insYEYDLK is predicted to lead to activation of Flt3 due to the effects of other Flt3 internal tandem duplication (ITD) mutations (PMID: 12970773, PMID: 9737679, PMID: 11090077).",2896,12970773,FLT3: ITDoes matter in leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/12970773,2897,9737679,Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product.,http://www.ncbi.nlm.nih.gov/pubmed/9737679,3093,14759363,The structural basis for autoinhibition of FLT3 by the juxtamembrane domain.,http://www.ncbi.nlm.nih.gov/pubmed/14759363,2898,11090077,Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.,http://www.ncbi.nlm.nih.gov/pubmed/11090077,7832
CDKN2A E69* results in a premature truncation of the Cdkn2a protein at amino acid 69 of 156 (UniProt.org). E69* confers a loss of function to the Cdkn2a protein as demonstrated by loss of Cdk binding (PMID: 8668202).,295,,,www.uniprot.org,3108,8668202,Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/8668202,7833
"CDKN2A E88* results in a premature truncation of the Cdkn2a protein at amino acid 88 of 156 (UniProt.org). E88* has not been characterized, however, nonsense mutations downstream of E88 are inactivating (PMID: 9053859, PMID: 8668202), thus E88* is predicted to lead to a loss of Cdkn2a protein function.",295,,,www.uniprot.org,3063,9053859,Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma.,http://www.ncbi.nlm.nih.gov/pubmed/9053859,3108,8668202,Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/8668202,7834
CDKN2A E88K lies within the ANK3 domain of the Cdkn2a protein (UniProt.org). E88K confers a loss of function to the Cdkn2a protein as demonstrated by loss of inhibitory binding to Cdk4 and Cdk6 (PMID: 10498896).,3091,10498896,Functional evaluation of tumour-specific variants of p16INK4a/CDKN2A: correlation with protein structure information.,http://www.ncbi.nlm.nih.gov/pubmed/10498896,295,,,www.uniprot.org,7835
"CDKN2A F90fs results in a change in the amino acid sequence of the Cdkn2a protein beginning at aa 90 of 156, likely resulting in premature truncation of the functional protein (UniProt.org). P90fs has not been characterized, however, nonsense mutations downstream of F90 are inactivating (PMID: 9053859, PMID: 8668202), thus F90fs is predicted to lead to a loss of Cdkn2a protein function.",3063,9053859,Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma.,http://www.ncbi.nlm.nih.gov/pubmed/9053859,3108,8668202,Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/8668202,295,,,www.uniprot.org,7836
"CDKN2A G23V lies within the ANK repeat 1 of the Cdk2na protein (UniProt.org). G23V has been identified in the scientific literature (PMID: 27415609), but not been characterized and therefore, its effect on Cdk2na protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7786,27415609,Overview of major molecular alterations during progression from Barrett's esophagus to esophageal adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/27415609,7837
"CDKN2A G67S lies within the ANK repeat 2 of the Cdkn2a protein (UniProt.org). The functional effect of G67S is conflicting, as G67S has been reported to confer a loss of binding to Cdk proteins (PMID: 11518711) and has been reported to have no effect on binding to Cdk proteins (PMID: 20340136).",3094,11518711,Mutations in the INK4a/ARF melanoma susceptibility locus functionally impair p14ARF.,http://www.ncbi.nlm.nih.gov/pubmed/11518711,295,,,www.uniprot.org,3095,20340136,Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.,http://www.ncbi.nlm.nih.gov/pubmed/20340136,7839
"MSH6 loss indicates loss of the MSH6 gene, mRNA or protein. ",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,7852
"CDKN2A H83D lies within the ANK repeat 3 of the Cdkn2a protein (UniProt.org). H83D has been identified in the scientific literature (PMID: 12614625), but has not been biochemically characterized and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Feb 2017).",7796,12614625,Design and characterization of a hyperstable p16INK4a that restores Cdk4 binding activity when combined with oncogenic mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12614625,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7873
"CDKN2A H83Q lies within the ANK repeat 3 of the Cdkn2a protein (UniProt.org). H83Q has been identified in sequencing studies (PMID: 12117769), but has not been biochemically characterized and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Feb 2017).",295,,,www.uniprot.org,7788,12117769,Alterations of the p16(INK4) locus in human malignant mesothelial tumors.,http://www.ncbi.nlm.nih.gov/pubmed/12117769,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7874
"CDKN2A H83R lies within the ANK repeat 3 of the Cdkn2a protein (UniProt.org). H83R has been identified in sequencing studies (PMID: 22817889), but has not been biochemically characterized and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Feb 2017).",295,,,www.uniprot.org,7789,22817889,A landscape of driver mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22817889,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7875
CDKN2A H83Y lies within the ANK3 domain of the Cdkn2a protein (UniProt.org). H83Y confers a loss of function to the Cdk2na protein as demonstrated by loss of cell cycle control (PMID: 10491434).,295,,,www.uniprot.org,3067,10491434,Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors.,http://www.ncbi.nlm.nih.gov/pubmed/10491434,7876
CDKN2A H98P lies within the ANK3 domain of the Cdkn2a protein (UniProt.org). H98P results in decreased inhibition of cell-cycle arrest and cyclin-D1/Cdk4 kinase activity by Cdkn2a in cell culture (PMID: 7777061).,295,,,www.uniprot.org,3676,7777061,Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/7777061,7877
"CDKN2A L130R lies within the ANK repeat 4 of the Cdkn2a protein (UniProt.org). L130R has been identified in sequencing studies (PMID: 25303977), but has not been biochemically characterized and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7006,25303977,Mutational landscape of aggressive cutaneous squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25303977,295,,,www.uniprot.org,7878
"CDKN2A L16fs results in a change in the amino acid sequence of the Cdkn2a protein beginning at aa 16 of 156, likely resulting in premature truncation of the functional protein (UniProt.org). L16fs has not been characterized, however, nonsense mutations downstream of L16 are inactivating (PMID: 9053859, PMID: 8668202), thus, L16fs is predicted to lead to a loss of Cdkn2a protein function.",3108,8668202,Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/8668202,295,,,www.uniprot.org,3063,9053859,Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma.,http://www.ncbi.nlm.nih.gov/pubmed/9053859,7879
CDKN2A L31R lies within the ANK1 domain of the Cdkn2a (p16INK4a) protein (UniProt.org). L31R confers a loss of function to the Cdkn2a protein as demonstrated by the inability to inhibit kinase activity of the Cdk7 complex or the Cdk7 complex (PMID: 11003668).,5632,11003668,Regulation of CDK7-carboxyl-terminal domain kinase activity by the tumor suppressor p16(INK4A) contributes to cell cycle regulation.,http://www.ncbi.nlm.nih.gov/pubmed/11003668,295,,,www.uniprot.org,7880
"CDKN2A L31V lies within the ANK repeat 1 of the Cdkn2a (p16INK4a) protein (UniProt.org). L31V has not been characterized in the scientific literature and therefore, its effect on Cdk2na protein function is unknown (PubMed, Jul 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7881
"CDKN2A L78fs results in a change in the amino acid sequence of the Cdkn2a protein beginning at aa 78 of 156, likely resulting in premature truncation of the functional protein (UniProt.org). L78fs has not been characterized, however, nonsense mutations downstream of L78 are inactivating (PMID: 9053859, PMID: 8668202), thus L78fs is predicted to lead to a loss of Cdkn2a protein function.",295,,,www.uniprot.org,3063,9053859,Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma.,http://www.ncbi.nlm.nih.gov/pubmed/9053859,3108,8668202,Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/8668202,7882
"CDKN2A M52fs results in a change in the amino acid sequence of the Cdkn2a protein beginning at aa 52 of 156, likely resulting in premature truncation of the functional protein (UniProt.org). M52fs has not been characterized, however, nonsense mutations downstream of M52 are inactivating (PMID: 9053859, PMID: 8668202), thus, M52fs is predicted to lead to a loss of Cdkn2a protein function.",3108,8668202,Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/8668202,295,,,www.uniprot.org,3063,9053859,Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma.,http://www.ncbi.nlm.nih.gov/pubmed/9053859,7883
"CDKN2A M52L lies within the ANK repeat 2 of the Cdkn2a (p16INK4a) protein (UniProt.org). M52L has been identified in sequencing studies (PMID: 18948947), but has not been biochemically characterized and therefore, its effect on Cdkn2a (p16INK4a) protein function is unknown (PubMed, Jul 2017).",6956,18948947,Somatic mutations affect key pathways in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18948947,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7884
"CDKN2A M52R lies within the ANK repeat 2 of the Cdkn2a (p16INK4a) protein (UniProt.org). M52R has not been characterized in the scientific literature and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7885
"CDKN2A N42H lies within the ANK repeat 1 of the Cdkn2a (p16INK4a) protein (UniProt.org). N42H has been identified in sequencing studies (PMID: 24436120), but has not been biochemically characterized and therefore, its effect on Cdkn2a (p16INK4a) protein function is unknown (PubMed, Jul 2017).",7164,24436120,Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome.,http://www.ncbi.nlm.nih.gov/pubmed/24436120,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7886
"CDKN2A P113S (in p14ARF) does not lie within any known domains of the Cdkn2a (p14ARF) protein (UniProt.org). P113S has not been characterized in the scientific literature and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7887
"CDKN2A P114H lies within the ANK repeat 4 of the Cdkn2a (p16INK4a) protein (UniProt.org). P114H has been identified in sequencing studies (PMID: 25589618), but has not been biochemically characterized and therefore, its effect on Cdkn2a (p16INK4a) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6963,25589618,Genomic analysis of metastatic cutaneous squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25589618,7888
CDKN2A P114L lies within the ANK4 domain of the Cdkn2a protein (UniProt.org). P114L confers a loss of function to the Cdkn2a protein as demonstrated by inability to suppress Rb phosphorylation and loss of cell cycle control (PMID: 9053859).,3063,9053859,Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma.,http://www.ncbi.nlm.nih.gov/pubmed/9053859,295,,,www.uniprot.org,7889
"CDKN2A P114T lies within the ANK repeat 4 of the Cdkn2a (p16INK4a) protein (UniProt.org). P114T has not been characterized in the scientific literature and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7890
CDKN2A P48L lies within the ANK2 domain of the Cdkn2a protein (UniProt.org). P48L confers a loss of function to the Cdk2na protein as demonstrated by loss of cell cycle control (PMID: 10491434).,295,,,www.uniprot.org,3067,10491434,Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors.,http://www.ncbi.nlm.nih.gov/pubmed/10491434,7892
"CDKN2A P48R lies within the ANK repeat 2 of the Cdkn2a (p16INK4a) protein (UniProt.org). P48R has been identified in sequencing studies (PMID: 25855536), but has not been biochemically characterized and therefore, its effect on Cdkn2a (p16INK4a) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7024,25855536,Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets.,http://www.ncbi.nlm.nih.gov/pubmed/25855536,7893
"CDKN2A P70T lies within the ANK repeat 2 of the Cdkn2a (p16INK4a) protein (UniProt.org). P70T has not been characterized in the scientific literature and therefore, its effect on Cdk2na protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7894
"CDKN2A P81fs results in a change in the amino acid sequence of the Cdkn2a protein beginning at aa 81 of 156, likely resulting in premature truncation of the functional protein (UniProt.org). P81fs has not been characterized, however, nonsense mutations downstream of P81 are inactivating (PMID: 9053859, PMID: 8668202), thus, P81fs is predicted to lead to a loss of Cdkn2a protein function.",3108,8668202,Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/8668202,295,,,www.uniprot.org,3063,9053859,Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma.,http://www.ncbi.nlm.nih.gov/pubmed/9053859,7895
CDKN2A P81L lies within the ANK3 domain of the Cdkn2a protein (UniProt.org). P81L confers a loss of function to the Cdkn2a protein as demonstrated by a reduction in Cdk4 and Cdk6 binding as well as loss of cell cycle control (PMID: 10389768). ,295,,,www.uniprot.org,385,10389768,Functional reassessment of P16 variants using a transfection-based assay.,http://www.ncbi.nlm.nih.gov/pubmed/10389768,7896
"CDKN2A P81S lies within the ANK repeat 3 of the Cdkn2a (p16INK4a) protein (UniProt.org). P81S has been identified in sequencing studies (PMID: 23851445), but has not been biochemically characterized and therefore, its effect on Cdkn2a (p16INK4a) protein function is unknown (PubMed, Jul 2017).",7165,23851445,Mutual exclusivity analysis of genetic and epigenetic drivers in melanoma identifies a link between p14 ARF and RARβ signaling.,http://www.ncbi.nlm.nih.gov/pubmed/23851445,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7897
CDKN2A Q50* results in a premature truncation of the Cdkn2a protein at amino acid 50 of 156 (UniProt.org). Q50* confers a loss of function to the Cdkn2a protein as demonstrated by loss of Cdk binding (PMID: 8668202).,295,,,www.uniprot.org,3108,8668202,Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/8668202,7898
"CDKN2A Q50fs results in a change in the amino acid sequence of the Cdkn2a protein beginning at aa 50 of 156, likely resulting in premature truncation of the functional protein (UniProt.org). Q50fs has not been characterized, however, other nonsense mutations downstream of Q50 are inactivating (PMID: 9053859, PMID: 8668202), thus Q50fs is predicted to lead to a loss of Cdkn2a protein function.",3108,8668202,Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/8668202,295,,,www.uniprot.org,3063,9053859,Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma.,http://www.ncbi.nlm.nih.gov/pubmed/9053859,7899
"CDKN2A Q50H lies within the ANK repeat 2 of the Cdkn2a (p16INK4a) protein (UniProt.org). Q50H has not been characterized in the scientific literature and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7900
"CDKN2A Q50R lies within ANK repeat 2 of the Cdkn2a protein (UniProt.org). Q50R has been identified in sequencing studies (PMID: 10369293), but has not been biochemically characterized and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Feb 2017).",7779,10369293,Establishment and characterization of human laryngeal squamous cell carcinoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/10369293,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7901
"DNMT3A A910V lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (UniProt.org). A910V has been identified in sequencing studies (PMID: 24923295), but has not been biochemically characterized and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7325,24923295,Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis.,http://www.ncbi.nlm.nih.gov/pubmed/24923295,7935
"DNMT3A C497Y lies within the ADD domain of the Dnmt3a protein (UniProt.org). C497Y has been identified in sequencing studies (PMID: 27276561), but has not been biochemically characterized and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jun 2017).",7052,27276561,Genomic Classification and Prognosis in Acute Myeloid Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27276561,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7936
"DNMT3A E477* results in a premature truncation of the Dnmt3a protein at amino acid 477 of 912 (UniProt.org). Due to the loss of the catalytic domain (UniProt.org), E477* is predicted to lead to a loss of Dnmt3a protein function.",295,,,www.uniprot.org,7937
"DNMT3A F414S does not lie within any known functional domains of the Dnmt3a protein (UniProt.org). F414S has been identified in sequencing studies (PMID: 21720365), but has not been biochemically characterized and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,6943,21720365,Integrated genomic analyses of ovarian carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/21720365,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7938
"DNMT3A G590fs results in a change in the amino acid sequence of the Dnmt3a protein beginning at aa 590 of 912, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the catalytic domain (UniProt.org), G590fs is predicted to lead to a loss of Dnmt3a protein function.",295,,,www.uniprot.org,7939
"DNMT3A G685E lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (UniProt.org). G685E has been identified in sequencing studies (PMID: 22842228), but has not been biochemically characterized and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7109,22842228,Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22842228,7940
"DNMT3A I407T does not lie within any known functional domains of the Dnmt3a protein (UniProt.org). I407T has been identified in sequencing studies (PMID: 22642896), but has not been biochemically characterized and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7330,22642896,Detection of high-frequency and novel DNMT3A mutations in acute myeloid leukemia by high-resolution melting curve analysis.,http://www.ncbi.nlm.nih.gov/pubmed/22642896,7941
"DNMT3A L723fs results in a change in the amino acid sequence of the Dnmt3a protein beginning at aa 723 of 912, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the catalytic domain (UniProt.org), L723fs is predicted to lead to a loss of Dnmt3a protein function.",295,,,www.uniprot.org,7942
"DNMT3A L737F lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (UniProt.org). L737F has been identified in sequencing studies (PMID: 21720365), but has not been biochemically characterized and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6943,21720365,Integrated genomic analyses of ovarian carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/21720365,7943
"DNMT3A M880I lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (UniProt.org). M880I has not been characterized in the scientific literature and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7944
"DNMT3A R659H lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (UniProt.org). R659H has been identified in sequencing studies (PMID: 21519343), but has not been biochemically characterized and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jul 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7332,21519343,"DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms.",http://www.ncbi.nlm.nih.gov/pubmed/21519343,7945
"DNMT3A R720C lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (UniProt.org). R720C has been identified in sequencing studies (PMID: 23856246), but has not been biochemically characterized and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6964,23856246,The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.,http://www.ncbi.nlm.nih.gov/pubmed/23856246,7946
"DNMT3A R749C lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (UniProt.org). R749C has been identified in sequencing studies (PMID: 27276561), but has not been biochemically characterized and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jul 2017).",7052,27276561,Genomic Classification and Prognosis in Acute Myeloid Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27276561,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7947
"DNMT3A R882C lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (UniProt.org). R882C has not been biochemically characterized, but is associated with hypomethylation in patient samples and is predicted to result in a loss of Dnmt3a function (PMID: 24656771).",5732,24656771,The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers.,http://www.ncbi.nlm.nih.gov/pubmed/24656771,295,,,www.uniprot.org,7948
"DNMT3A S714C lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (UniProt.org). S714C has been identified in sequencing studies (PMID: 21967546), but has not been biochemically characterized and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jul 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7335,21967546,Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/21967546,7949
"DNMT3A Y533C lies within the ADD domain of the Dnmt3a protein (UniProt.org). Y533C has been identified in sequencing studies (PMID: 27288520, PMID: 28194436), but has not been biochemically characterized and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jul 2017).",6946,27288520,Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27288520,9285,28194436,Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes.,http://www.ncbi.nlm.nih.gov/pubmed/28194436,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7950
"GATA1 A120V does not lie within any known functional domains of the GATA1 protein (UniProt.org). A120V has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, Jun 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7989
"GATA1 A227T lies within the GATA-type 1 zinc finger domain of the Gata1 protein (UniProt.org). A227T has not been characterized and therefore, its effect on Gata1 protein function is unknown (PubMed, Jun 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7990
"GATA1 C279F lies within the GATA-type 2 zinc finger domain of the Gata1 protein (UniProt.org). C279F has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, Jun 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7991
"GATA1 D20V lies within the transcriptional activation domain of the Gata1 protein (PMID: 22556427). D20V has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, Jun 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3109,22556427,N- and C-terminal transactivation domains of GATA1 protein coordinate hematopoietic program.,http://www.ncbi.nlm.nih.gov/pubmed/22556427,7992
"GATA1 D42N lies within the transcriptional activation domain of the Gata1 protein (PMID: 22556427). D42N has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, Jun 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3109,22556427,N- and C-terminal transactivation domains of GATA1 protein coordinate hematopoietic program.,http://www.ncbi.nlm.nih.gov/pubmed/22556427,7993
"GATA1 E114K does not lie within any known functional domains of the GATA1 protein (UniProt.org). E114K has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, Jun 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7994
"GATA1 E13K lies within the transcriptional activation domain of the Gata1 protein (PMID: 22556427). E13K has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, Jun 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3109,22556427,N- and C-terminal transactivation domains of GATA1 protein coordinate hematopoietic program.,http://www.ncbi.nlm.nih.gov/pubmed/22556427,7995
"GATA1 E2fs results in a change in the amino acid sequence of the Gata1 protein beginning at aa 2 of 413, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of all known functional domains (UniProt.org), E2fs is predicted to lead to a loss of Gata1 function.",295,,,www.uniprot.org,7996
"GATA1 E328K does not lie within any known functional domains of the Gata1 protein (UniProt.org). E328K has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, Jun 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7997
"GATA1 F33L lies within the transcriptional activation domain of the Gata1 protein (PMID: 22556427). F33L has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, Jun 2015).",3109,22556427,N- and C-terminal transactivation domains of GATA1 protein coordinate hematopoietic program.,http://www.ncbi.nlm.nih.gov/pubmed/22556427,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7998
"GATA1 G344R does not lie within any known functional domains of the Gata1 protein (UniProt.org). G344R has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, Jun 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7999
"GATA1 G366C does not lie within any known functional domains of the Gata1 protein (UniProt.org). G366C has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, Jun 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8000
"GATA1 G368C does not lie within any known functional domains of the Gata1 protein (UniProt.org). G368C has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, Jun 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8001
"GATA1 G89fs results in a change in the amino acid sequence of the Gata1 protein beginning at aa 89 of 413, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of most known functional domains (UniProt.org), G89fs is predicted to lead to a loss of Gata1 function.",295,,,www.uniprot.org,8002
"GATA1 M1? indicates a disruption of the methionine (M) start codon with an unknown translational affect on the GATA1 protein (PMID: 22556427). M1? has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, Jun 2015).",3109,22556427,N- and C-terminal transactivation domains of GATA1 protein coordinate hematopoietic program.,http://www.ncbi.nlm.nih.gov/pubmed/22556427,285,,,http://www.ncbi.nlm.nih.gov/pubmed,8003
"GATA1 N226D lies within the GATA-type 1 zinc finger domain of the Gata1 protein (UniProt.org). N226D has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, Jun 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8004
"GATA1 P150H does not lie within any known functional domains of the Gata1 protein (UniProt.org). P150H has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, Jun 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8005
"GATA1 P401S does not lie within any known functional domains of the Gata1 protein (UniProt.org). P401S has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, Jun 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8006
"GATA1 P50L lies within the transcriptional activation domain of the Gata1 protein (PMID: 22556427). P50L has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, Jun 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3109,22556427,N- and C-terminal transactivation domains of GATA1 protein coordinate hematopoietic program.,http://www.ncbi.nlm.nih.gov/pubmed/22556427,8007
"GATA1 Q76E lies within the transcriptional activation domain of the Gata1 protein (PMID: 22556427). Q76E has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, Jun 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3109,22556427,N- and C-terminal transactivation domains of GATA1 protein coordinate hematopoietic program.,http://www.ncbi.nlm.nih.gov/pubmed/22556427,8008
"GATA1 Q76H lies within the transcriptional activation domain of the Gata1 protein (PMID: 22556427). Q76H has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, Jun 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3109,22556427,N- and C-terminal transactivation domains of GATA1 protein coordinate hematopoietic program.,http://www.ncbi.nlm.nih.gov/pubmed/22556427,8009
"GATA1 R247C does not lie within any known functional domains of the Gata1 protein (UniProt.org). R247C has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, Jun 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8010
"GATA1 R253Q does not lie within any known functional domains of the Gata1 protein (UniProt.org). R253Q has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, Jun 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8011
"GATA1 R270W lies within the GATA-type 2 zinc finger region of the Gata1 protein (UniProt.org). R270W has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, Jun 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8012
"GATA1 R305* results in a premature truncation of the Gata1 protein at amino acid 305 of 413 (UniProt.org). R305* has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, Jun 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8013
"GATA1 R307C does not lie within any known functional domains of the Gata1 protein (UniProt.org). R307C has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, Jun 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8014
"GATA1 R307H does not lie within any known functional domains of the Gata1 protein (UniProt.org). R307H has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, Jun 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8015
"GATA1 R307L does not lie within any known functional domains of the Gata1 protein (UniProt.org). R307L has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, Jun 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8016
"GATA1 S30* results in a premature truncation of the Gata1 protein at amino acid 30 of 413 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), S30* is predicted to lead to a loss of Gata1 function.",295,,,www.uniprot.org,8017
"GATA1 T54N lies within the transcriptional activation domain of the Gata1 protein (PMID: 22556427). T54N has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, Jun 2015).",3109,22556427,N- and C-terminal transactivation domains of GATA1 protein coordinate hematopoietic program.,http://www.ncbi.nlm.nih.gov/pubmed/22556427,285,,,http://www.ncbi.nlm.nih.gov/pubmed,8018
"GATA2 A198V lies within the negative regulatory domain of the Gata2 protein (PMID: 22786876). A198V has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Jun 2015).",3110,22786876,High GATA2 expression is a poor prognostic marker in pediatric acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/22786876,285,,,http://www.ncbi.nlm.nih.gov/pubmed,8019
"GATA2 A364T lies within the GATA-type 2 zinc finger domain of the Gata2 protein (UniProt.org). A364T has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Jun 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8020
"GATA2 A372T lies within the GATA-type 2 zinc finger domain of the Gata2 protein (UniProt.org). A372T has not been characterized and therefore, its effect on Gata2 protein function is unknown (PubMed, Jun 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8021
"GATA2 G272E does not lie within any known functional domains of the Gata2 protein (UniProt.org). G272E has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Jun 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8022
"GATA2 G272K does not lie within any known functional domains of the Gata2 protein (UniProt.org). G272K has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Jun 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8023
"GATA2 G366R lies within the GATA-type 2 zinc finger domain of the Gata2 protein (UniProt.org). G366R has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Jun 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8024
"GATA2 H471fs results in a change in the amino acid sequence of the Gata1 protein beginning at aa 471 of 480, likely resulting in premature truncation of the functional protein (UniProt.org). H471fs has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Jun 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8025
"GATA2 N371K lies within the GATA-type 2 zinc finger domain of the Gata2 protein (UniProt.org). N371K has not been characterized and therefore, its effect on Gata2 protein function is unknown (PubMed, Jun 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8026
"GATA2 P175L lies within the negative regulatory domain of the Gata2 protein (PMID: 22786876). P175L has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Jun 2015).",3110,22786876,High GATA2 expression is a poor prognostic marker in pediatric acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/22786876,285,,,http://www.ncbi.nlm.nih.gov/pubmed,8027
GATA2 L304H lies within the DNA-binding domain of the Gata2 protein (PMID: 27389056). L304H confers a loss of function to the Gata2 protein as demonstrated by decreased Gata2 transcriptional activity and increased erythroid lineage differentiation in cell culture (PMID: 27389056).,7599,27389056,Exome sequencing identifies highly recurrent somatic GATA2 and CEBPA mutations in acute erythroid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27389056,8028
"GATA2 P385L does not lie within any known functional domains of the Gata2 protein (UniProt.org). P385L has not been characterized and therefore, its effect on Gata2 protein function is unknown (PubMed, Jun 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8029
"GATA2 R230C lies within the negative regulatory domain of the Gata2 protein (PMID: 22786876). R230C has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Jun 2015).",3110,22786876,High GATA2 expression is a poor prognostic marker in pediatric acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/22786876,285,,,http://www.ncbi.nlm.nih.gov/pubmed,8030
"GATA2 R283C does not lie within any known functional domains of the Gata2 protein (UniProt.org). R283C has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Jun 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8031
GATA2 R330* results in a premature truncation of the Gata2 protein at amino acid 330 of 480 (UniProt.org). R330* confers a loss of function to the Gata2 protein as demonstrated by decreased Gata2 transcriptional activity and increased erythroid lineage differentiation in cell culture (PMID: 27389056).,7599,27389056,Exome sequencing identifies highly recurrent somatic GATA2 and CEBPA mutations in acute erythroid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27389056,295,,,www.uniprot.org,8032
"GATA2 R396Q does not lie within any known functional domains of the Gata2 protein (UniProt.org). R396Q has not been characterized and therefore, its effect on Gata2 protein function is unknown (PubMed, Jun 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8033
"GATA2 R398Q does not lie within any known functional domains of the Gata2 protein (UniProt.org). R398Q has not been characterized and therefore, its effect on Gata2 protein function is unknown (PubMed, Jun 2015).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,8034
"GATA2 S251F does not lie within any known functional domains of the Gata2 protein (UniProt.org). S251F has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Jun 2015).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,8035
"GATA2 T354M lies within the GATA-type 2 zinc finger domain of the Gata2 protein (UniProt.org). T354M results in reduced binding of Gata2 to DNA, decreased transcriptional activation, inhibition of cell differentiation and apoptosis in culture (PMID: 21892162). ",3111,21892162,Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/21892162,295,,,www.uniprot.org,8036
"GATA2 T477I does not lie within any known functional domains of the Gata2 protein (UniProt.org). T477I has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Jun 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8037
"GATA2 W10C lies within the transactivation domain of the Gata2 protein (PMID: 22786876). W10C has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Jun 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3110,22786876,High GATA2 expression is a poor prognostic marker in pediatric acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/22786876,8038
"CDKN2A R112P lies within the ANK repeat 4 of the Cdkn2a (p16INK4a) protein (UniProt.org). R112P has been identified in sequencing studies (PMID: 8895759), but has not been biochemically characterized and therefore, its effect on Cdkn2a (p16INK4a) protein function is unknown (PubMed, Jul 2017).",7546,8895759,"Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma.",http://www.ncbi.nlm.nih.gov/pubmed/8895759,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8039
"CDKN2A R124C lies within the ANK repeat 4 of the Cdkn2a (p16INK4a) protein (UniProt.org). R124C has been identified in sequencing studies (PMID: 25303977), but has not been biochemically characterized and therefore, its effect on Cdkn2a (p16INK4a) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7006,25303977,Mutational landscape of aggressive cutaneous squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25303977,8040
CDKN2A R124H lies within the ANK repeat 4 of the Cdkn2a (p16INK4a) protein (UniProt.org). R124H has been reported to have activity similar to wild-type Cdkn2a in in vitro and cell culture assays (PMID: 10491434).,295,,,www.uniprot.org,3067,10491434,Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors.,http://www.ncbi.nlm.nih.gov/pubmed/10491434,8041
"CDKN2A R128fs results in a change in the amino acid sequence of the Cdkn2a (p16INK4a) protein beginning at aa 128 of 156, likely resulting in premature truncation of the functional protein (UniProt.org). R128fs has not been characterized and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8042
"CDKN2A R131C lies within ANK repeat 4 of the Cdkn2a protein (UniProt.org). R131C has been identified in sequencing studies (PMID: 12870051), but has not been biochemically characterized and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7790,12870051,Analysis of p16 gene mutations and deletions in childhood acute lymphoblastic leukemias.,http://www.ncbi.nlm.nih.gov/pubmed/12870051,295,,,www.uniprot.org,8043
CDKN2A R58* results in a premature truncation of the Cdkn2a protein at amino acid 58 or 156 (UniProt.org). R58* confers a loss of function to the Cdkn2a protein as demonstrated by loss of Cdk binding (PMID: 8668202).,3108,8668202,Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/8668202,295,,,www.uniprot.org,8044
"CDKN2A R58fs results in a change in the amino acid sequence of the Cdkn2a protein beginning at 58 of 156, likely resulting in a premature truncation of the functional protein (UniProt.org). R58fs has not been characterized, however, nonsense mutations downstream of R58 are inactivating (PMID: 9053859, PMID: 8668202), thus R58fs is predicted to lead to a loss of Cdkn2a protein function.",3063,9053859,Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma.,http://www.ncbi.nlm.nih.gov/pubmed/9053859,295,,,www.uniprot.org,3108,8668202,Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/8668202,8045
CDKN2A R80* results in a premature truncation of the Cdkn2a protein at amino acid 80 of 156. R80* confers a loss of function to the Cdkn2a protein as demonstrated by loss of Cdk binding (PMID: 8668202).,295,,,www.uniprot.org,3108,8668202,Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/8668202,8046
CDKN2A R87P lies within the ANK3 domain of the Cdkn2a protein (UniProt.org). R87P confers a loss of function to the Cdkn2a protein as demonstrated by a reduction in Cdk4 and Cdk6 binding as well as loss of cell cycle control (PMID: 10491434).,3067,10491434,Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors.,http://www.ncbi.nlm.nih.gov/pubmed/10491434,295,,,www.uniprot.org,8047
"CDKN2A R99P lies within ANK repeat 3 of the Cdkn2a protein (UniProt.org). R99P results in a loss of Cdkn2a cell-cycle regulatory activity, but does not affect the oxidative activity of Cdkn2a in cultured cells (PMID: 23190892).",3062,23190892,Familial melanoma-associated mutations in p16 uncouple its tumor-suppressor functions.,http://www.ncbi.nlm.nih.gov/pubmed/23190892,295,,,www.uniprot.org,8048
"CDKN2A S12* results in a premature truncation of the Cdkn2a protein at amino acid 12 of 156 (UniProt.org). S12* has not been characterized, however, nonsense mutations downstream of S12 are inactivating (PMID: 9053859, PMID: 8668202), thus S12* is predicted to lead to a loss of Cdkn2a protein function.",3108,8668202,Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/8668202,3063,9053859,Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma.,http://www.ncbi.nlm.nih.gov/pubmed/9053859,295,,,www.uniprot.org,8049
"CDKN2A S43I does not lie within any known functional domains of the Cdkn2a protein (UniProt.org). S43I has been identified in sequencing studies (PMID: 14556920), but has not been biochemically characterized and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Feb 2017).",295,,,www.uniprot.org,7792,14556920,Frequent methylation of p16INK4A and p14ARF genes implicated in the evolution of chronic myeloid leukaemia from its chronic to accelerated phase.,http://www.ncbi.nlm.nih.gov/pubmed/14556920,285,,,http://www.ncbi.nlm.nih.gov/pubmed,8050
"CDKN2A R80Q lies within ANK repeat 3 of the Cdkn2a protein (UniProt.org). R80Q has been identified in sequencing studies (PMID: 27311873), but has not been biochemically characterized and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7791,27311873,"Circumscribed sebaceous neoplasms: a morphological, immunohistochemical and molecular analysis.",http://www.ncbi.nlm.nih.gov/pubmed/27311873,8052
"CDKN2A S56fs results in a change in the amino acid sequence of the Cdkn2a protein beginning at 56 of 156, likely resulting in a premature truncation of the functional protein (UniProt.org). S56fs has not been characterized, however, nonsense mutations downstream of S56 are inactivating (PMID: 9053859, PMID: 8668202), thus S56fs is predicted to lead to a loss of Cdkn2a protein function.",3063,9053859,Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma.,http://www.ncbi.nlm.nih.gov/pubmed/9053859,295,,,www.uniprot.org,3108,8668202,Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/8668202,8053
"CDKN2A T72fs results in a change in the amino acid sequence of the Cdkn2a protein beginning at 72 of 156, likely resulting in a premature truncation of the functional protein (UniProt.org). T72fs has not been characterized, however, nonsense mutations downstream of T72 are inactivating (PMID: 9053859, PMID: 8668202), thus T72fs is predicted to lead to a loss of Cdkn2a protein function.",295,,,www.uniprot.org,3063,9053859,Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma.,http://www.ncbi.nlm.nih.gov/pubmed/9053859,3108,8668202,Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/8668202,8054
"CDKN2A T77fs results in a change in the amino acid sequence of the Cdkn2a protein beginning at 77 of 156, likely resulting in a premature truncation of the functional protein (UniProt.org). T77fs has not been characterized, however, nonsense mutations downstream of T77 are inactivating (PMID: 9053859, PMID: 8668202), thus T77fs is predicted to lead to a loss of Cdkn2a protein function.",3108,8668202,Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/8668202,295,,,www.uniprot.org,3063,9053859,Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma.,http://www.ncbi.nlm.nih.gov/pubmed/9053859,8055
"CDKN2A T79fs results in a change in the amino acid sequence of the Cdkn2a protein beginning at 79 of 156, likely resulting in a premature truncation of the functional protein (UniProt.org). T79fs has not been characterized, however, nonsense mutations downstream of T79 are inactivating (PMID: 9053859, PMID: 8668202), thus T79fs is predicted to lead to a loss of Cdkn2a protein function.",3063,9053859,Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma.,http://www.ncbi.nlm.nih.gov/pubmed/9053859,3108,8668202,Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/8668202,295,,,www.uniprot.org,8056
CDKN2A V126D lies within the ANK4 domain of the Cdkn2a protein (UniProt.org). V126D confers a loss of function to the Cdkn2a protein as demonstrated by reduced Cdk binding (PMID: 8668202).,295,,,www.uniprot.org,3108,8668202,Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/8668202,8057
"CDKN2A V82fs results in a change in the amino acid sequence of the Cdkn2a protein beginning at 82 of 156, likely resulting in a premature truncation of the functional protein (UniProt.org). V82fs has not been characterized, however, nonsense mutations downstream of V82 are inactivating (PMID: 9053859, PMID: 8668202), thus V82fs is predicted to lead to a loss of Cdkn2a protein function.",295,,,www.uniprot.org,3063,9053859,Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma.,http://www.ncbi.nlm.nih.gov/pubmed/9053859,3108,8668202,Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/8668202,8058
"CDKN2A V82M lies within ANK repeat 3 of the Cdkn2a protein (UniProt.org). V82M has been identified in sequencing studies (PMID: 27311873), but has not been biochemically characterized and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Feb 2017).",7791,27311873,"Circumscribed sebaceous neoplasms: a morphological, immunohistochemical and molecular analysis.",http://www.ncbi.nlm.nih.gov/pubmed/27311873,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8059
"CDKN2A W110* results in a premature truncation of the Cdkn2a protein at amino acid 110 of 156 (UniProt.org). W110* confers a loss of function to the Cdkn2a protein as demonstrated by loss of Cdk binding and cell cycle control (PMID: 9053859, PMID: 8668202).",295,,,www.uniprot.org,3063,9053859,Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma.,http://www.ncbi.nlm.nih.gov/pubmed/9053859,3108,8668202,Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/8668202,8062
"CDKN2A W110fs results in a change in the amino acid sequence of the Cdkn2a protein beginning at 110 of 156, likely resulting in a premature truncation of the functional protein (UniProt.org). W110fs has not been characterized, however, nonsense mutations downstream of W110 are inactivating (PMID: 8668202), thus W110fs is predicted to lead to a loss of Cdkn2a protein function.",3108,8668202,Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/8668202,295,,,www.uniprot.org,8067
"CDKN2A W15* results in a premature truncation of the Cdkn2a protein at amino acid 15 of 156 (UniProt.org). W15* has not been characterized, however, nonsense mutations downstream of W15 are inactivating (PMID: 9053859, PMID: 8668202), thus W15* is predicted to lead to a loss of Cdkn2a protein function.",295,,,www.uniprot.org,3063,9053859,Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma.,http://www.ncbi.nlm.nih.gov/pubmed/9053859,3108,8668202,Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/8668202,8074
"CDKN2A W15fs results in a change in the amino acid sequence of the Cdkn2a protein beginning at 15 of 156, likely resulting in a premature truncation of the functional protein (UniProt.org). W15fs has not been characterized, however, nonsense mutations downstream of W15 are inactivating (PMID: 9053859, PMID: 8668202), thus W15fs is predicted to lead to a loss of Cdkn2a protein function.",3063,9053859,Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma.,http://www.ncbi.nlm.nih.gov/pubmed/9053859,295,,,www.uniprot.org,3108,8668202,Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/8668202,8077
"CDKN2A Y129* results in a premature truncation of the Cdkn2a protein at amino acid 129 of 156 (UniProt.org). Y129* has been identified in sequencing studies (PMID: 25855536), but has not been biochemically characterized and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7024,25855536,Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets.,http://www.ncbi.nlm.nih.gov/pubmed/25855536,8084
"CDKN2A Y44* results in a premature truncation of the Cdkn2a protein at amino acid 44 of 156 (UniProt.org). Y44* has not been characterized, however, nonsense mutations downstream of Y44 are inactivating (PMID: 9053859, PMID: 8668202), thus Y44* is predicted to lead to a loss of Cdkn2a protein function.",295,,,www.uniprot.org,3063,9053859,Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma.,http://www.ncbi.nlm.nih.gov/pubmed/9053859,3108,8668202,Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/8668202,8094
"CDKN2A Y44fs results in a change in the amino acid sequence of the Cdkn2a protein beginning at 44 of 156, likely resulting in a premature truncation of the functional protein (UniProt.org). Y44fs has not been characterized, however, nonsense mutations downstream of Y44 are inactivating (PMID: 9053859, PMID: 8668202), thus Y44fs is predicted to lead to a loss of Cdkn2a protein function.",3108,8668202,Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/8668202,3063,9053859,Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma.,http://www.ncbi.nlm.nih.gov/pubmed/9053859,295,,,www.uniprot.org,8097
"STK11 inact mut indicates that this variant results in a loss of function of the STK11 protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,8192
"MYD88 A24T does not lie within any known functional domains of the Myd88 protein (UniProt.org). A24T has not been characterized in the scientific literature and therefore, its effect on Myd88 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8327
"MYD88 E104Q lies within the Death domain of the Myd88 protein (UniProt.org). E104Q has not been characterized in the scientific literature and therefore, its effect on Myd88 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8328
"MYD88 F174Y lies within the TIR domain of the Myd88 protein (UniProt.org). F174Y has not been characterized in the scientific literature and therefore, its effect on Myd88 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8329
"MYD88 L289P lies within the TIR domain of the Myd88 protein (UniProt.org). L289P has not been characterized in the scientific literature and therefore, its effect on Myd88 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8330
KDR (VEGFR2) C482R lies within the Ig-like C2-type 5 domain of the Kdr (Vegfr2) protein (UniProt.org). C482R did not have an effect on Kdr (Vegfr2) phosphorylation compared to wild type in culture (PMID: 21712447). ,295,,,www.uniprot.org,20,21712447,Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21712447,8541
"KDR (VEGFR2) L462V lies within the Ig-like C2-type domain 5 of the Kdr (Vegfr2) (UniProt.org). L462V has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017). ",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,8542
"RB1 P515T lies within Domain A of the Rb1 protein (UniProt.org). P515T has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,8622
"RB1 A488V lies within Domain A of the Rb1 protein (UniProt.org). A488V has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8815
RB1 C706F lies within Domain B of the Rb1 protein (UniProt.org). C706F confers a loss of function to the Rb1 protein as demonstrated by loss of Rb1 phosphorylation (PMID: 2168563). ,295,,,www.uniprot.org,3196,2168563,A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding.,http://www.ncbi.nlm.nih.gov/pubmed/2168563,8816
"RB1 E280* results in a premature truncation of the Rb1 protein at amino acid 280 of 928 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), E280* is predicted to lead to a loss of Rb1 protein function.",295,,,www.uniprot.org,8817
"RB1 E413* results in a premature truncation of the Rb1 protein at amino acid 413 of 928 (UniProt.org). Due to the loss of multiple functional domains (UniProt.org), E413* is predicted to lead to a loss of Rb1 protein function.",295,,,www.uniprot.org,8818
"RB1 E440K lies within Domain A of the Rb1 protein (UniProt.org). E440K has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8819
"RB1 E545* results in a premature truncation of the Rb1 protein at amino acid 545 of 928 (UniProt.org). Due to the loss of multiple functional domains (UniProt.org), E545* is predicted to lead to a loss of Rb1 protein function. ",295,,,www.uniprot.org,8820
"RB1 E748* results in a premature truncation of the Rb1 protein at amino acid 748 of 928 (UniProt.org). Due to the loss of the Domain C (UniProt.org), E748* is predicted to lead to a loss of Rb1 protein function. ",295,,,www.uniprot.org,8821
"RB1 K765* results in a premature truncation of the Rb1 protein at amino acid 765 of 928 (UniProt.org). Due to the loss of Domain C (UniProt.org), K765* is predicted to lead to a loss of Rb1 protein function.",295,,,www.uniprot.org,8822
"KRAS L159fs results in a change in the amino acid sequence of the Kras protein beginning at aa 159 of 189, likely resulting in premature truncation of the functional protein (UniProt.org). L159fs has not been characterized in the scientific literature and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8824
"RB1 L199* results in a premature truncation of the Rb1 protein at amino acid 199 of 928 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), L199* is predicted to lead to a loss of Rb1 protein function.",295,,,www.uniprot.org,8891
"RB1 Q217* results in a premature truncation of the Rb1 protein at amino acid 217 of 928 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), Q217* is predicted to lead to a loss of Rb1 protein function.",295,,,www.uniprot.org,8892
"RB1 Q344* results in a premature truncation of the Rb1 protein at amino acid 344 of 928 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), Q344* is predicted to lead to a loss of Rb1 protein function.",295,,,www.uniprot.org,8893
"RB1 K94N does not lie within any known functional domains of the Rb1 protein (UniProt.org). K94N has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,8894
"RB1 Q121H does not lie within any known functional domains of the Rb1 protein (UniProt.org). Q121H has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,8895
"RB1 H483R lies within Domain A of the Rb1 protein (UniProt.org). H483R has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8896
"RB1 G449R lies within Domain A of the Rb1 protein (UniProt.org). G449R has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8897
"RB1 I724N lies within Domain B of the Rb1 protein (UniProt.org). I724N has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8898
"RB1 I752S lies within Domain B of the Rb1 protein (UniProt.org). I752S has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8899
"RB1 K913R lies within Domain C of the Rb1 protein (UniProt.org). K913R has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8900
"RB1 L657P lies within Domain B of the Rb1 protein (UniProt.org). L657P has been identified in the scientific literature (PMID: 10882758), but has not been biochemically characterized and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",3222,10882758,"Two novel germline mutations of the retinoblastoma gene (RB1) that show incomplete penetrance, one splice site and one missense.",http://www.ncbi.nlm.nih.gov/pubmed/10882758,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8901
"RB1 M148T does not lie within any known functional domains of the Rb1 protein (UniProt.org). M148T has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8902
"RB1 M379L lies within Domain A of the Rb1 protein (UniProt.org). M379L has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8903
"RB1 M695V lies within Domain B of the Rb1 protein (UniProt.org). M695V has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8904
"RB1 P374A lies within Domain A of the Rb1 protein (UniProt.org). P374A has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8905
"RB1 Q344fs results in a change in the amino acid sequence of the Rb1 protein beginning at aa 344 of 928, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of all known functional domains (UniProt.org), Q344fs is predicted to lead to a loss of Rb1 protein function.",295,,,www.uniprot.org,8906
"RB1 Q62* results in a premature truncation of the Rb1 protein at amino acid 62 of 928 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), Q62* is predicted to lead to a loss of Rb1 protein function.",295,,,www.uniprot.org,8907
"RB1 Q444H lies within Domain A of the Rb1 protein (UniProt.org). Q444H has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8908
"RB1 Q444L lies within Domain A of the Rb1 protein (UniProt.org). Q444L has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8909
"KRAS A146G does not lie within any known functional domains of the Kras protein (UniProt.org). A146G has been identified in sequencing studies (PMID: 25886136, PMID: 25840541), but has not been biochemically characterized and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,7693,25886136,"A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer.",http://www.ncbi.nlm.nih.gov/pubmed/25886136,285,,,http://www.ncbi.nlm.nih.gov/pubmed,10047,25840541,GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25840541,8910
"FGFR3 over exp indicates an over expression of the Fgfr3 protein. However, the mechanism causing the over expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,8911
"FGFR2 over exp indicates an over expression of the Fgfr2 protein. However, the mechanism causing the over expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,8912
"RB1 L688R lies within Domain B of the Rb1 protein (UniProt.org). L688R has been identified in the scientific literature (PMID: 17960112), but has not been biochemically characterized and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3215,17960112,Ten novel RB1 gene mutations in patients with retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/17960112,8915
"RB1 G449E lies within Domain A of the Rb1 protein (UniProt.org). G449E has been identified in the scientific literature (PMID: 23532519, PMID: 15605413), but has not been biochemically characterized and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",3216,15605413,"Identification of 26 new constitutional RB1 gene mutations in Spanish, Colombian, and Cuban retinoblastoma patients.",http://www.ncbi.nlm.nih.gov/pubmed/15605413,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8558,23532519,Screening of RB1 alterations in Brazilian patients with retinoblastoma and relatives with retinoma: phenotypic and genotypic associations.,http://www.ncbi.nlm.nih.gov/pubmed/23532519,8916
"RB1 Q702K lies within Domain B of the Rb1 protein (UniProt.org). Q702K has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8917
"RB1 R255Q does not lie within any known functional domains of the Rb1 protein (UniProt.org). R255Q has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8919
"RB1 R272I does not lie within any known functional domains of the Rb1 protein (UniProt.org). R272I has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8920
"RB1 R451C lies within Domain A of the Rb1 protein (UniProt.org). R451C has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8921
"RB1 R451H lies within Domain A of the Rb1 protein (UniProt.org). R451H has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8922
"RB1 R556* results in a premature truncation of the Rb1 protein at amino acid 556 of 928 (UniProt.org). Due to the loss of multiple functional domains (UniProt.org), R556* is predicted to lead to a loss of Rb1 protein function.",295,,,www.uniprot.org,8923
"RB1 R552fs results in a change in the amino acid sequence of the Rb1 protein beginning at aa 552 of 928, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of multiple functional domains (UniProt.org), R552fs is predicted to lead to a loss Rb1 protein function. ",295,,,www.uniprot.org,8924
"RB1 R621P lies within the spacer domain of the Rb1 protein (UniProt.org). R621P has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8925
"RB1 R621S lies within the spacer domain of the Rb1 protein (UniProt.org). R621S has been identified in the scientific literature (PMID: 24791139), but has not been biochemically characterized and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,3217,24791139,Screening of RB1 gene mutations in Chinese patients with retinoblastoma and preliminary exploration of genotype-phenotype correlations.,http://www.ncbi.nlm.nih.gov/pubmed/24791139,285,,,http://www.ncbi.nlm.nih.gov/pubmed,8926
"RB1 R698I lies within Domain B of the Rb1 protein (UniProt.org). R698I has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,8927
"RB1 R698W lies within Domain B of the Rb1 protein (UniProt.org). R698W confers a loss of function to the Rb1 protein as demonstrated by decreased apoptotic function, reduced protein stability, and some evidence for transformation ability (PMID: 20594292).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8928
"RB1 R787Q lies within Domain C of the Rb1 protein (UniProt.org). R787Q has been identified in the scientific literature (PMID: 15605413, PMID: 16269091), but has not been biochemically characterized and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,8596,16269091,"RB1 gene mutation up-date, a meta-analysis based on 932 reported mutations available in a searchable database.",http://www.ncbi.nlm.nih.gov/pubmed/16269091,3216,15605413,"Identification of 26 new constitutional RB1 gene mutations in Spanish, Colombian, and Cuban retinoblastoma patients.",http://www.ncbi.nlm.nih.gov/pubmed/15605413,295,,,www.uniprot.org,8929
"RB1 R876C lies within Domain C of the Rb1 protein (UniProt.org). R876C has been identified in the scientific literature (PMID: 19372580), but has not been biochemically characterized and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8598,19372580,Genetic alterations and oncogenic pathways associated with breast cancer subtypes.,http://www.ncbi.nlm.nih.gov/pubmed/19372580,8930
"RB1 S127I does not lie within any known functional domains of the Rb1 protein (UniProt.org). S127I has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8931
"RB1 S612C lies within the spacer domain of the Rb1 protein (UniProt.org). S612C has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8932
"RB1 P515L lies within Domain A of the Rb1 protein (UniProt.org). P515L has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8933
"RB1 S751Y lies within Domain B of the Rb1 protein (UniProt.org). S751Y has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8934
"RB1 S758L lies within Domain B of the Rb1 protein (UniProt.org). S758L has not been characterized in the scientific literature and therefore, its effect on Rb2 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8935
"RB1 V654L lies within Domain B of the Rb1 protein (UniProt.org). V654L has been identified in sequencing studies (PMID: 21615945), but has not been biochemically characterized and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",3221,21615945,Low penetrance of retinoblastoma for p.V654L mutation of the RB1 gene.,http://www.ncbi.nlm.nih.gov/pubmed/21615945,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8936
"RB1 V654M lies within Domain B of the Rb1 protein (UniProt.org). V654M has been identified in sequencing studies (PMID: 22622578), but has not been biochemically characterized and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6955,22622578,Melanoma genome sequencing reveals frequent PREX2 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/22622578,8937
"RB1 W195* results in a premature truncation of the Rb1 protein at amino acid 195 of 928 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), W195* is predicted to lead to a loss of Rb1 protein function.",295,,,www.uniprot.org,8938
"RB1 W563L lies within Domain A of the Rb1 protein (UniProt.org). W563L has been identified in sequencing studies (PMID: 10882758), but has not been biochemically characterized and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017). ",3222,10882758,"Two novel germline mutations of the retinoblastoma gene (RB1) that show incomplete penetrance, one splice site and one missense.",http://www.ncbi.nlm.nih.gov/pubmed/10882758,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8939
"RB1 Y659F lies within Domain B of the Rb1 protein (UniProt.org). Y659F has been identified in sequencing studies (PMID: 23917401), but has not been biochemically characterized and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",3963,23917401,The integrated landscape of driver genomic alterations in glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/23917401,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8940
"RB1 Y728C lies within Domain B of the Rb1 protein (UniProt.org). Y728C has been identified in sequencing studies (PMID: 18772396), but has not been biochemically characterized and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",6948,18772396,An integrated genomic analysis of human glioblastoma multiforme.,http://www.ncbi.nlm.nih.gov/pubmed/18772396,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8941
"RB1 Y756C lies within Domain B of the Rb1 protein (UniProt.org). Y756C has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,8942
"VHL C162F lies within the Elongin BC complex-interacting region of the Vhl protein (UniProt.org). C162F leads to a loss of Vhl function as indicated by failure to bind to Elongin BC complex and inhibition of ubiquitin-dependent proteolysis in cell culture (PMID: 9447969, PMID: 11331612).",3223,9447969,Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2.,http://www.ncbi.nlm.nih.gov/pubmed/9447969,295,,,www.uniprot.org,3224,11331612,von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.,http://www.ncbi.nlm.nih.gov/pubmed/11331612,8952
"VHL C162R lies within the Elongin BC complex-interacting region of the Vhl protein (UniProt.org). C162R has been identified in the scientific literature (PMID: 18836774), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",3225,18836774,Computational detection of deleterious SNPs and their effect on sequence and structural level of the VHL gene.,http://www.ncbi.nlm.nih.gov/pubmed/18836774,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8953
"VHL C162Y lies within the Elongin BC complex-interacting region of the Vhl protein (UniProt.org). C162Y has been identified in sequencing studies (PMID: 23797736), but has not been biochemically characterized and therefore, its effect on VHL protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7248,23797736,Integrated molecular analysis of clear-cell renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23797736,8954
"VHL D121Y lies within the CCT complex-binding region of the Vhl protein (UniProt.org). D121Y has been identified in sequencing studies (PMID: 24504440), but has not been biochemically characterized and therefore, its effect on VHL protein function is unknown (PubMed, Oct 2017).",7423,24504440,"Multilayer-omics analysis of renal cell carcinoma, including the whole exome, methylome and transcriptome.",http://www.ncbi.nlm.nih.gov/pubmed/24504440,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8955
"VHL E173D does not lie within any known functional domains of the Vhl protein (UniProt.org). E173D has not been characterized in the scientific literature and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8956
"VHL E186K does not lie within any known functional domains of the Vhl protein (UniProt.org). E186K has not been characterized in the scientific literature and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8957
"VHL F148fs results in a change in the amino acid sequence of the Vhl protein beginning at aa 148 of 213, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the Elongin BC complex-binding region (UniProt.org), F148fs is predicted to lead to a loss of Vhl protein function.",295,,,www.uniprot.org,8958
"VHL G114C lies within the CCT complex-interacting region of the Vhl protein (UniProt.org). G114C has been identified in the scientific literature (PMID: 18836774), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,3225,18836774,Computational detection of deleterious SNPs and their effect on sequence and structural level of the VHL gene.,http://www.ncbi.nlm.nih.gov/pubmed/18836774,285,,,http://www.ncbi.nlm.nih.gov/pubmed,8959
VHL G114R lies within the CCT complex-interacting region of the Vhl protein (UniProt.org). G114R leads to a loss of Vhl protein function as indicated by failure to bind to Elongin BC complex and TriC in cell culture (PMID: 14636579).,295,,,www.uniprot.org,3226,14636579,Tumorigenic mutations in VHL disrupt folding in vivo by interfering with chaperonin binding.,http://www.ncbi.nlm.nih.gov/pubmed/14636579,8960
"VHL G123W lies within the CCT complex-interacting region of the Vhl protein (UniProt.org). G123W has not been characterized in the scientific literature and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8961
"VHL G127V lies within the CCT complex-interacting region of the Vhl protein (UniProt.org). G127V has been identified in sequencing studies (PMID: 22895193), but has not been biochemically characterized and therefore, its effect on VHL protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4597,22895193,Recurrent R-spondin fusions in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22895193,8962
"VHL G144E lies within the CCT complex-interacting region of the Vhl protein (UniProt.org). G144E has not been characterized in the scientific literature and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8963
"VHL G29D lies within the pentameric repeat region of the Vhl protein (UniProt.org). G29D has been identified in sequencing studies (PMID: 22895193), but has not been biochemically characterized and therefore, its effect on VHL protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4597,22895193,Recurrent R-spondin fusions in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22895193,8964
"VHL G93V does not lie within any known functional domains of the Vhl protein (UniProt.org). G93V has been identified in the scientific literature (Journal of Clinical Oncology 28, no. 15_suppl e15024), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",10071,,"A detailed analysis of von Hippel Lindau (VHL) mutations in sporadic clear cell renal carcinoma (ccRCC), VHL syndrome, and Chuvash polycythaemia.",http://ascopubs.org/doi/abs/10.1200/jco.2010.28.15_suppl.e15024,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8965
"VHL H115N lies within the CCT complex-interacting region of the Vhl protein (UniProt.org). H115N has been identified in sequencing studies (PMID: 24446253), but has not been biochemically characterized and therefore, its effect on VHL protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7426,24446253,VHL and HIF-1α: gene variations and prognosis in early-stage clear cell renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24446253,8966
VHL H115Q lies within the CCT complex-interacting region of the Vhl protein (UniProt.org). H115Q confers a loss of function to the Vhl protein as indicated by decreased binding to Hif-1alpha in cell culture (PMID: 28775317).,10072,28775317,Interaction between von Hippel-Lindau Protein and Fatty Acid Synthase Modulates Hypoxia Target Gene Expression.,http://www.ncbi.nlm.nih.gov/pubmed/28775317,295,,,www.uniprot.org,8967
"VHL H115Y lies within the CCT complex-interacting region of the Vhl protein (UniProt.org). H115Y has been identified in the scientific literature (PMID: 18836774), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",3225,18836774,Computational detection of deleterious SNPs and their effect on sequence and structural level of the VHL gene.,http://www.ncbi.nlm.nih.gov/pubmed/18836774,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8968
"VHL I151F lies within the CCT complex-interacting region of the Vhl protein (UniProt.org). I151F has been identified in sequencing studies (PMID: 10766184), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",7427,10766184,VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation.,http://www.ncbi.nlm.nih.gov/pubmed/10766184,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8969
"VHL I151N lies within the CCT complex-interacting region of the Vhl protein (UniProt.org). I151N has been identified in sequencing studies (PMID: 24335534), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",7428,24335534,Molecular dissection of the VHL gene in solitary capillary hemangioblastoma of the central nervous system.,http://www.ncbi.nlm.nih.gov/pubmed/24335534,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8970
"VHL I151T lies within the CCT complex-interacting region of the Vhl protein (UniProt.org). I151T has been identified in sequencing studies (PMID: 24504440), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",7423,24504440,"Multilayer-omics analysis of renal cell carcinoma, including the whole exome, methylome and transcriptome.",http://www.ncbi.nlm.nih.gov/pubmed/24504440,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8971
"VHL I180N does not lie within any known functional domains of the Vhl protein (UniProt.org). I180N has been identified in sequencing studies (PMID: 25691774), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",7429,25691774,pVHL/HIF-regulated CD70 expression is associated with infiltration of CD27+ lymphocytes and increased serum levels of soluble CD27 in clear cell renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25691774,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8972
"VHL L101P lies within the CCT complex-interacting region of the Vhl protein (UniProt.org). L101P has been identified in sequencing studies (PMID: 19996202), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",7422,19996202,Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/19996202,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8973
"VHL L128H lies within the CCT complex-interacting region of the Vhl protein (UniProt.org). L128H has been identified in sequencing studies (PMID: 22980975), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,1726,22980975,Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/22980975,285,,,http://www.ncbi.nlm.nih.gov/pubmed,8974
"VHL L153P lies within the CCT complex-interacting region of the Vhl protein (UniProt.org). L153P has been identified in sequencing studies (PMID: 24504440), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,7423,24504440,"Multilayer-omics analysis of renal cell carcinoma, including the whole exome, methylome and transcriptome.",http://www.ncbi.nlm.nih.gov/pubmed/24504440,285,,,http://www.ncbi.nlm.nih.gov/pubmed,8975
VHL L158P lies within the CCT complex-interacting region of the Vhl protein (UniProt.org). L158P leads to decreased binding of Vhl to the Elongin BC complex and failure to activate Hif1a ubiquitination in cell culture (PMID: 10973499).,295,,,www.uniprot.org,3227,10973499,Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex.,http://www.ncbi.nlm.nih.gov/pubmed/10973499,8977
"VHL L158V lies within the CCT complex-interacting region of the Vhl protein (UniProt.org). L158V has been identified in the scientific literature (PMID: 27069690), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,10111,27069690,Molecular Characterization of a Novel Germline VHL Mutation by Extensive In Silico Analysis in an Indian Family with Von Hippel-Lindau Disease.,http://www.ncbi.nlm.nih.gov/pubmed/27069690,8978
"VHL L169P does not lie within any known functional domains of the Vhl protein (UniProt.org). L169P has been identified in sequencing studies (PMID: 24727139), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7432,24727139,Unique molecular alteration patterns in von Hippel-Lindau (VHL) gene in a cohort of sporadic renal cell carcinoma patients from Pakistan.,http://www.ncbi.nlm.nih.gov/pubmed/24727139,8979
"VHL L184P does not lie within any known functional domains of the Vhl protein (UniProt.org). L184P confers a loss of function to the Vhl protein, as indicated by decreased binding to Elongin C and Cul2 in culture (PMID: 28775317).",295,,,www.uniprot.org,10072,28775317,Interaction between von Hippel-Lindau Protein and Fatty Acid Synthase Modulates Hypoxia Target Gene Expression.,http://www.ncbi.nlm.nih.gov/pubmed/28775317,8980
"VHL L184R does not lie within any known functional domains of the Vhl protein (UniProt.org). L184R has been identified in sequencing studies (PMID: 23036577), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",7434,23036577,Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23036577,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8981
"VHL L188P does not lie within any known functional domains of the Vhl protein (UniProt.org). L188P  has been identified in the scientific literature (PMID: 18836774), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",3225,18836774,Computational detection of deleterious SNPs and their effect on sequence and structural level of the VHL gene.,http://www.ncbi.nlm.nih.gov/pubmed/18836774,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8982
"VHL L188R does not lie within any known functional domains of the Vhl protein (UniProt.org). L188R has been identified in sequencing studies (PMID: 24504440), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",7423,24504440,"Multilayer-omics analysis of renal cell carcinoma, including the whole exome, methylome and transcriptome.",http://www.ncbi.nlm.nih.gov/pubmed/24504440,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8983
"VHL L201P does not lie within any known functional domains of the Vhl protein (UniProt.org). L201P has been identified in sequencing studies (PMID: 22895193), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",4597,22895193,Recurrent R-spondin fusions in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22895193,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8984
"VHL L89H does not lie within any known functional domains of the Vhl protein (UniProt.org). L89H has been identified in sequencing studies (PMID: 25583177), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7431,25583177,Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.,http://www.ncbi.nlm.nih.gov/pubmed/25583177,8985
"VHL L89P does not lie within any known functional domains of the Vhl protein (UniProt.org). L89P has been identified in the scientific literature (PMID: 18836774), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",3225,18836774,Computational detection of deleterious SNPs and their effect on sequence and structural level of the VHL gene.,http://www.ncbi.nlm.nih.gov/pubmed/18836774,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8986
"VHL N131Y lies within the CCT complex-interacting region of the Vhl protein (UniProt.org). N131Y has been identified in sequencing studies (PMID: 24727139), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",7432,24727139,Unique molecular alteration patterns in von Hippel-Lindau (VHL) gene in a cohort of sporadic renal cell carcinoma patients from Pakistan.,http://www.ncbi.nlm.nih.gov/pubmed/24727139,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8987
"VHL N78D does not lie within any known functional domains of the Vhl protein (UniProt.org). N78D has been identified in the scientific literature (PMID: 23224817), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",10113,23224817,"A novel missense mutation (N78D) in a family with von Hippel-Lindau disease with central nervous system haemangioblastomas, pancreatic and renal cysts.",http://www.ncbi.nlm.nih.gov/pubmed/23224817,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8988
NPM1 mutant indicates an unspecified mutation in the Npm1 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,9007
VHL N78S does not lie within any known functional domains of the Vhl protein (UniProt.org). N78S leads to a loss of Vhl function as indicated by failure to regulate Hif1a ubiquitination in cell culture (PMID: 11331613).,295,,,www.uniprot.org,3234,11331613,Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.,http://www.ncbi.nlm.nih.gov/pubmed/11331613,9008
"VHL N78Y does not lie within any known functional domains of the Vhl protein (UniProt.org). N78Y has been identified in sequencing studies (PMID: 23036577), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7434,23036577,Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23036577,9009
VHL N90I does not lie within any known functional domains of the Vhl protein (UniProt.org). N90I leads to a loss of Vhl function as indicated by failure to regulate Hif1a ubiquitination in cell culture (PMID: 10823831).,3235,10823831,Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.,http://www.ncbi.nlm.nih.gov/pubmed/10823831,295,,,www.uniprot.org,9010
"VHL P86L does not lie within any known functional domains of the Vhl protein (UniProt.org). P86L has been identified in the scientific literature (PMID: 18836774), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3225,18836774,Computational detection of deleterious SNPs and their effect on sequence and structural level of the VHL gene.,http://www.ncbi.nlm.nih.gov/pubmed/18836774,9011
"VHL P95Q does not lie within any known functional domains of the Vhl protein (UniProt.org). P95Q has not been characterized in the scientific literature and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9012
"VHL Q96* results in a premature truncation of the Vhl protein at amino acid 96 of 213 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), Q96* is predicted to lead to a loss of Vhl protein function.",295,,,www.uniprot.org,9013
"VHL R107G lies within the CCT complex-interacting region of the Vhl protein (UniProt.org). R107G has been identified in the scientific literature (PMID: 18836774), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",3225,18836774,Computational detection of deleterious SNPs and their effect on sequence and structural level of the VHL gene.,http://www.ncbi.nlm.nih.gov/pubmed/18836774,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9014
"VHL R107P lies within the CCT complex-interacting region of the Vhl protein (UniProt.org). R107P has been identified in the scientific literature (PMID: 18836774), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",3225,18836774,Computational detection of deleterious SNPs and their effect on sequence and structural level of the VHL gene.,http://www.ncbi.nlm.nih.gov/pubmed/18836774,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9015
"VHL R161* results in a premature truncation of the Vhl protein at amino acid 161 of 213 (UniProt.org). R161* has been identified in sequencing studies (PMID: 26111976), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7438,26111976,Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy.,http://www.ncbi.nlm.nih.gov/pubmed/26111976,295,,,www.uniprot.org,9016
"VHL R161fs results in a change in the amino acid sequence of the Vhl protein beginning at aa 161 of 213, likely resulting in premature truncation of the functional protein (UniProt.org). R161fs has been identified in sequencing studies (PMID: 7881415), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",7439,7881415,Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/7881415,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9017
"VHL R167G does not lie within any known functional domains of the Vhl protein (UniProt.org). R167G has been identified in the scientific literature (PMID: 18836774), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",3225,18836774,Computational detection of deleterious SNPs and their effect on sequence and structural level of the VHL gene.,http://www.ncbi.nlm.nih.gov/pubmed/18836774,295,,,www.uniprot.org,9018
VHL R167Q does not lie within any known functional domains of the Vhl protein (UniProt.org). R167Q leads to a loss of Vhl function as indicated by impaired Enlongin C binding and inhibition of Hif2a expression in cell culture (PMID: 15574766).,3236,15574766,In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations.,http://www.ncbi.nlm.nih.gov/pubmed/15574766,295,,,www.uniprot.org,9019
VHL R167W does not lie within any known functional domains of the Vhl protein (UniProt.org). R167W leads to a loss of Vhl function as indicated by impaired binding to Elongin BC complex and Clu-2 in cell culture (PMID: 9122164).,3237,9122164,"The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins.",http://www.ncbi.nlm.nih.gov/pubmed/9122164,295,,,www.uniprot.org,9020
"VHL R205C does not lie within any known functional domains of the Vhl protein (UniProt.org). R205C has not been characterized in the scientific literature and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9021
"VHL R205H does not lie within any known functional domains of the Vhl protein (UniProt.org). R205H has been identified in sequencing studies (PMID: 22895193), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,4597,22895193,Recurrent R-spondin fusions in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22895193,285,,,http://www.ncbi.nlm.nih.gov/pubmed,9022
VHL R79P does not lie within any known functional domains of the Vhl protein (UniProt.org). R79P is predicted to lead to a loss of Vhl function by computational modeling (PMID: 18836774).,295,,,www.uniprot.org,3225,18836774,Computational detection of deleterious SNPs and their effect on sequence and structural level of the VHL gene.,http://www.ncbi.nlm.nih.gov/pubmed/18836774,9023
VHL R82P does not lie within any known functional domains of the Vhl protein (UniProt.org). R82P leads to a loss of Vhl function as indicated by impaired binding to hVdu1 and inhibition of hVdu1 ubiquitination in cell culture (PMID: 11739384).,295,,,www.uniprot.org,3238,11739384,Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein.,http://www.ncbi.nlm.nih.gov/pubmed/11739384,9025
VHL S111N lies within the CCT complex-interacting region of the Vhl protein (UniProt.org). S111N leads to a loss of Vhl function as indicated by impaired binding to Hif-alpha and inhibition of Hif1a ubiquitination (PMID: 10878807).,295,,,www.uniprot.org,3239,10878807,Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein.,http://www.ncbi.nlm.nih.gov/pubmed/10878807,9026
"VHL S111R lies within the CCT complex-interacting region of the Vhl protein (UniProt.org). S111R leads to a loss of Vhl function as indicated by impaired binding to Hif1a, p300 and Tip60, and failure to transactivate p53 on DNA damage in cell culture (PMID: 22071692).",295,,,www.uniprot.org,3240,22071692,Phosphorylation of von Hippel-Lindau protein by checkpoint kinase 2 regulates p53 transactivation.,http://www.ncbi.nlm.nih.gov/pubmed/22071692,9027
VHL S65W lies within the pentameric repeat region of the Vhl protein (UniProt.org). S65W leads to a loss of Vhl function as indicated by impaired binding to Hif1a and failure to target Hif2a for degradation (PMID: 15611064).,458,15611064,Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1alpha complex.,http://www.ncbi.nlm.nih.gov/pubmed/15611064,295,,,www.uniprot.org,9028
"VHL S68* results in a premature truncation of the Vhl protein at amino acid 68 of 213 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), S68* is predicted to lead to a loss of Vhl protein function.",295,,,www.uniprot.org,9029
"VHL S68fs results in a change in the amino acid sequence of the Vhl protein beginning at aa 68 of 213, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of most known functional domains (UniProt.org), S68fs is predicted to lead to a loss of Vhl protein function.",295,,,www.uniprot.org,9030
VHL S80I does not lie within any known functional domains of the Vhl protein (UniProt.org). S80I is predicted to lead to a loss of Vhl function by computational modeling (PMID: 18836774).,3225,18836774,Computational detection of deleterious SNPs and their effect on sequence and structural level of the VHL gene.,http://www.ncbi.nlm.nih.gov/pubmed/18836774,295,,,www.uniprot.org,9032
VHL S80R does not lie within any known functional domains of the Vhl protein (UniProt.org). S80R is predicted to lead to a loss of Vhl function by computational modeling (PMID: 18836774).,3225,18836774,Computational detection of deleterious SNPs and their effect on sequence and structural level of the VHL gene.,http://www.ncbi.nlm.nih.gov/pubmed/18836774,295,,,www.uniprot.org,9033
"VHL V130D lies within the CCT complex-interacting region of the Vhl protein (UniProt.org). V130D has been identified in sequencing studies (PMID: 25691774), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",7429,25691774,pVHL/HIF-regulated CD70 expression is associated with infiltration of CD27+ lymphocytes and increased serum levels of soluble CD27 in clear cell renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25691774,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9034
VHL V130F lies within the CCT complex-interacting region of the Vhl protein (UniProt.org). V130F is predicted to lead to destabilizing of Vhl by computational modeling (PMID: 19408289).,3243,19408289,Local recurrences and second primary tumors from squamous cell carcinoma of the oral cavity: a retrospective analytic study of 500 patients.,http://www.ncbi.nlm.nih.gov/pubmed/19408289,295,,,www.uniprot.org,9035
"VHL V155M lies within the CCT complex-interacting region of the Vhl protein (UniProt.org). V155M has been identified in sequencing studies (PMID: 24471421), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",7441,24471421,Loss of BRM expression is a frequently observed event in poorly differentiated clear cell renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24471421,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9036
"VHL V165D lies within the Elongin BC complex-interacting region of the Vhl protein (UniProt.org). V165D has been identified in sequencing studies (PMID: 24727139), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",7432,24727139,Unique molecular alteration patterns in von Hippel-Lindau (VHL) gene in a cohort of sporadic renal cell carcinoma patients from Pakistan.,http://www.ncbi.nlm.nih.gov/pubmed/24727139,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9037
"VHL V62fs results in a change in the amino acid sequence of the Vhl protein beginning at aa 62 of 213, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of most known functional domains (UniProt.org), V62fs is predicted to lead to a loss of Vhl protein function.",295,,,www.uniprot.org,9038
"VHL V74D does not lie within any known functional domains of the Vhl protein (UniProt.org). V74D has been identified in sequencing studies (PMID: 24446253), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,7426,24446253,VHL and HIF-1α: gene variations and prognosis in early-stage clear cell renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24446253,285,,,http://www.ncbi.nlm.nih.gov/pubmed,9039
VHL V74G does not lie within any known functional domains of the Vhl protein (UniProt.org). V74G is predicted to lead to a loss of Vhl function by computational modeling (PMID: 18836774).,295,,,www.uniprot.org,3225,18836774,Computational detection of deleterious SNPs and their effect on sequence and structural level of the VHL gene.,http://www.ncbi.nlm.nih.gov/pubmed/18836774,9040
"VHL W88* results in a premature truncation of the Vhl protein at amino acid 88 of 213 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), W88* is predicted to lead to a loss of Vhl protein function.",295,,,www.uniprot.org,9041
"VHL W88L does not lie within any known functional domains of the Vhl protein (UniProt.org). W88L has been identified in sequencing studies (PMID: 24727139), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7432,24727139,Unique molecular alteration patterns in von Hippel-Lindau (VHL) gene in a cohort of sporadic renal cell carcinoma patients from Pakistan.,http://www.ncbi.nlm.nih.gov/pubmed/24727139,9042
"VHL W88R does not lie within any known functional domains of the Vhl protein (UniProt.org). W88R has been identified in sequencing studies (PMID: 23036577), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",7434,23036577,Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23036577,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9043
"VHL Y175* results in a premature truncation of the Vhl protein at amino acid 175 of 213 (UniProt.org). Y175* has been identified in sequencing studies (PMID: 25583177), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",7431,25583177,Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.,http://www.ncbi.nlm.nih.gov/pubmed/25583177,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9044
"PTEN G251_D252del results in the deletion of two amino acids in the C2 tensin-type domain of the Pten protein from amino acids 251 to 252 (UniProt.org). G251_D252del has not been characterized in the scientific literature and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9122
"SMO amp indicates an increased number of copies of the SMO gene. However, the mechanism causing the increase is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,9158
"EGFR H773_V774insAH results in the insertion of two amino acids in the protein kinase domain of the Egfr protein between amino acids 773 and 774, within the drug-binding pocket (UniProt.org, PMID: 23371856). H773_V774insAH has not been characterized, however other Egfr exon 20 insertion mutations are activating, thus H773_V774insAH is predicted to result in a gain of function (PMID: 24353160).",295,,,www.uniprot.org,440,24353160,"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24353160,3320,23371856,"EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.",http://www.ncbi.nlm.nih.gov/pubmed/23371856,9331
"CSF1R A123T lies within the Ig-like C2-type domain 2 of the Csf1r protein (UniProt.org). A123T has been identified in sequencing studies (PMID: 24997986), but has not been biochemically characterized and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",7076,24997986,Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway.,http://www.ncbi.nlm.nih.gov/pubmed/24997986,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9332
"CSF1R A226V lies within the Ig-like C2-type domain 3 of the Csfr1 protein (UniProt.org). A226V has not been characterized in the scientific literature and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9333
"CSF1R A527T lies within the transmembrane domain of the Csf1r protein (UniProt.org). A527T has not been characterized in the scientific literature and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9334
"CSF1R A767V lies within the protein kinase domain of the Csf1r protein (UniProt.org). A767V has not been characterized in the scientific literature and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9335
"CSF1R A781G lies within the protein kinase domain of the Csf1r protein (UniProt.org). A781G has not been characterized in the scientific literature and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9336
"CSF1R A960T lies within the cytoplasmic domain of the Csf1r protein (UniProt.org). A960T has been identified in sequencing studies (PMID: 22941188), but has not been biochemically characterized and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7166,22941188,Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22941188,295,,,www.uniprot.org,9337
"CBL R420Q lies within the RING domain of the Cbl protein (PMID: 17446348). R420Q disrupts Cbl ubiquitin ligase activity, leading to activation of Flt3 signaling, and is transforming in cell culture in the presence of Flt3 (PMID: 17446348).",3300,17446348,Flt3-dependent transformation by inactivating c-Cbl mutations in AML.,http://www.ncbi.nlm.nih.gov/pubmed/17446348,9354
"CBL C379A lies within the RING domain of the Cbl protein (PMID: 20951944). C379A results in disruption of Cbl E3-ubiquitin ligase activity, leading to activation of FLT3 signaling and development of myeloid leukemia in mouse models (PMID: 20951944).",3304,20951944,Myeloid leukemia development in c-Cbl RING finger mutant mice is dependent on FLT3 signaling.,http://www.ncbi.nlm.nih.gov/pubmed/20951944,9355
"CSF1R A96T lies within the Ig-like C2-type domain 1 of the Csf1r protein (UniProt.org). A96T has been identified in sequencing studies (PMID: 22941188), but has not been biochemically characterized and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",7166,22941188,Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22941188,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9356
"CSF1R D837H lies within the protein kinase domain of the Csf1r protein (UniProt.org). D837H has been identified in sequencing studies (PMID: 22980975), but has not been biochemically characterized and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",1726,22980975,Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/22980975,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9357
"CSF1R D837N lies within the protein kinase domain of the Csf1r protein (UniProt.org). D837N has been identified in sequencing studies (PMID: 25151357), but has not been biochemically characterized snd therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9358
"CSF1R E475Q lies within Ig-like C2-type domain 5 of the Csf1r protein (UniProt.org). E475Q has not been characterized in the scientific literature and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,9359
"CSF1R E49K lies within the Ig-like C2-type domain 1 of the Csf1r protein (UniProt.org). E49K has not been characterized in the scientific literature and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,9360
"CSF1R E557D lies within the juxtamembrane domain of the Csf1r protein (UniProt.org). E557D has not been characterized in the scientific literature and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9361
"CSF1R F737L lies within the protein kinase domain of the Csf1r protein (UniProt.org). F737L has been identified in sequencing studies (PMID: 22895193), but has not been biochemically characterized and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4597,22895193,Recurrent R-spondin fusions in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22895193,9362
"CSF1R G340V lies within the Ig-like C2-type domain 4 of the Csf1r protein (UniProt.org). G340V has been identified in sequencing studies (PMID: 22722201), but has not been biochemically characterized and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7023,22722201,The landscape of cancer genes and mutational processes in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22722201,9363
"CSF1R G690S lies within the protein kinase domain of the Csf1r protein (UniProt.org). G690S has not been characterized in the scientific literature and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9364
"CSF1R H345P lies within Ig-like C2-type domain 4 of the Csf1r protein (UniProt.org). H345P has not been characterized in the scientific literature and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9365
"CSF1R H506Q lies within the extracellular domain of the Csf1r protein (UniProt.org). H506Q has not been characterized in the scientific literature and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9366
"CSF1R H506Y lies within the extracellular domain of the Csf1r protein (UniProt.org). H506Y has not been characterized in the scientific literature and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9367
"CSF1R K543M lies within the juxtamembrane domain of the Csf1r protein (UniProt.org). K543M has been identified in sequencing studies (PMID: 22842228), but has not been biochemically characterized and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7109,22842228,Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22842228,9368
"FGFR3 positive indicates the presence of the ESR1 gene, mRNA, and/or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,9369
"CSF1R L303V lies within the Ig-like C2-type domain 4 of the Csf1r protein (UniProt.org). L303V has not been characterized in the scientific literature and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9370
"CSF1R L309P lies within the Ig-like C2-type domain 4 of the Csf1r protein (UniProt.org). L309P has not been characterized in the scientific literature and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9371
"CSF1R N302H lies within the Ig-like C2-type domain 4 of the Csf1r protein (UniProt.org). N302H has not been characterized in the scientific literature and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9372
"CSF1R P104T lies within the Ig-like C2-type domain 1 of the Csf1r protein (UniProt.org). P104T has not been characterized in the scientific literature and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9373
"CSF1R P566L lies within the juxtamembrane domain of the Csf1r protein (UniProt.org). P566L has been identified in sequencing studies (PMID: 27998968), but has not been biochemically characterized and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",8985,27998968,Drug-sensitive FGFR3 mutations in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/27998968,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9374
"CSF1R P56H lies within the Ig-like C2-type domain 2 of the Csf1r protein (UniProt.org). P56H has not been characterized in the scientific literature and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,9375
"CSF1R P56R lies within the Ig-like C2-type domain 1 of the Csf1r protein (UniProt.org). P56R has been identified in sequencing studies (PMID: 21720365), but has not been biochemically characterized and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6943,21720365,Integrated genomic analyses of ovarian carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/21720365,9377
"CSF1R P901S lies within the protein kinase domain of the Csf1r protein (UniProt.org). P901S has been identified in sequencing studies (PMID: 22941188), but has not been biochemically characterized and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7166,22941188,Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22941188,295,,,www.uniprot.org,9378
"CSF1R P966L lies within the cytoplasmic domain of the Csf1r protein (UniProt.org). P966L has not been characterized in the scientific literature and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9379
"CSF1R Q448H lies within the Ig-like C2-type domain 5 of the Csf1r protein (UniProt.org). Q448H has not been characterized in the scientific literature and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9380
"CSF1R R144C lies within the Ig-like C2-type domain 2 of the Csf1r protein (UniProt.org). R144C has not been characterized in the scientific literature and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9381
"CSF1R R144H lies within the Ig-like C2-type domain 2 of the Csf1r protein (UniProt.org). R144H has been identified in sequencing studies (PMID: 22610119), but has not been biochemically characterized and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6289,22610119,"Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.",http://www.ncbi.nlm.nih.gov/pubmed/22610119,9382
"CSF1R R256C lies within Ig-like C2-type domain 3 of the Csf1r protein (UniProt.org). R256C has not been characterized in the scientific literature and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9383
"CSF1R R370C lies within the Ig-like C2-type domain 4 of the Csf1r protein (UniProt.org). R370C has been identified in sequencing studies (PMID: 22842228), but has not been biochemically characterized and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7109,22842228,Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22842228,9384
"CSF1R R370H lies within the Ig-like C2-type domain 4 of the Csf1r protein (UniProt.org). R370H has not been characterized in the scientific literature and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9385
"CSF1R R41Q lies within the Ig-like C2-type domain 2 of the Csf1r protein (UniProt.org). R41Q has not been characterized in the scientific literature and therefore, its effect on R41Q protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9386
"CSF1R R549C lies within the juxtamembrane domain of the Csf1r protein (UniProt.org). R549C has not been characterized in the scientific literature and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9387
"HRAS R73H does not lie within any known function domains of the Hras protein (UniProt.org). R73H has not been characterized in the scientific literature and therefore, its effect on Hras protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9414
"TP53 M237_S241del results in the deletion of five amino acids in the DNA binding domain and the HIPK1, ZNF385A and AXIN1 interaction region of the Tp53 protein (UniProt.org). M237_S241del has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9445
"FGFR1 N546K lies within the protein kinase domain of the Fgfr1 protein (UniProt.org, PMID: 26179511). N546K increases Fgfr1 protein kinase activity and is transforming in cultured cells (PMID: 26179511, PMID: 23817572). ",295,,,www.uniprot.org,1902,23817572,Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.,http://www.ncbi.nlm.nih.gov/pubmed/23817572,3316,26179511,Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/26179511,9479
HRAS K117E lies within the GTP binding domain of the Hras protein (UniProt.org). K117E inhibits GTPase activity of Hras leading to increased activation of downstream signaling pathways promoting cell transformation (PMID: 12569357).  ,3321,12569357,An unusual H-Ras mutant isolated from a human multiple myeloma line leads to transformation and factor-independent cell growth.,http://www.ncbi.nlm.nih.gov/pubmed/12569357,9523
FGFR2 N550S lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). N550S results in increased Fgfr2 kinase activity and enhanced cell proliferation in the presence of ligand in culture (PMID: 23908597).,295,,,www.uniprot.org,2138,23908597,"The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/23908597,9524
FGFR2 N550T lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). N550T results in increased Fgfr2 kinase activity and enhanced cell proliferation in the presence of ligand in culture (PMID: 23908597).,2138,23908597,"The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/23908597,295,,,www.uniprot.org,9525
FGFR2 E566G lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). E566G results in increased Fgfr2 kinase activity and enhanced cell proliferation in the presence of ligand in culture (PMID: 23908597).,295,,,www.uniprot.org,2138,23908597,"The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/23908597,9526
FGFR2 E566G lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). E566A results in increased Fgfr2 kinase activity and enhanced cell proliferation in the presence of ligand in culture (PMID: 23908597).,2138,23908597,"The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/23908597,295,,,www.uniprot.org,9527
FGFR2 K642N (corresponding to K641 in the canonical isoform) lies within the protein kinase domain of the Fgfr2b protein (UniProt.org). K642N results in increased Fgfr2 kinase activity and enhanced cell proliferation in the presence of ligand in culture (PMID: 23908597).,295,,,www.uniprot.org,2138,23908597,"The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/23908597,9528
FGFR2 M536I lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). M536I results in increased Fgfr2 kinase activity and enhanced cell proliferation in the presence of ligand in culture (PMID: 23908597).,2138,23908597,"The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/23908597,295,,,www.uniprot.org,9529
FGFR2 M538I lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). M538I results in increased Fgfr2 kinase activity and enhanced cell proliferation in the presence of ligand in culture (PMID: 23908597).,295,,,www.uniprot.org,2138,23908597,"The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/23908597,9530
FGFR2 I548V lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). I548V results in increased Fgfr2 kinase activity and enhanced cell proliferation in the presence of ligand in culture (PMID: 23908597).,2138,23908597,"The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/23908597,295,,,www.uniprot.org,9531
FGFR2 V565I lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). V565I results in increased Fgfr2 kinase activity and enhanced cell proliferation in the presence of ligand in culture (PMID: 23908597).,295,,,www.uniprot.org,2138,23908597,"The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/23908597,9532
FGFR2 L618M lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). L618M results in increased Fgfr2 kinase activity and enhanced cell proliferation in the presence of ligand in culture (PMID: 23908597).,2138,23908597,"The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/23908597,295,,,www.uniprot.org,9533
"CSF1R R710H lies within the protein kinase domain of the Csf1r protein (UniProt.org). R710H has been identified in sequencing studies (PMID: 22610119), but has not been biochemically characterized and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",6289,22610119,"Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.",http://www.ncbi.nlm.nih.gov/pubmed/22610119,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9534
"CSF1R R753L lies within the protein kinase domain of the Csf1r protein (UniProt.org). R753L has not been characterized in the scientific literature and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,9535
"CSF1R S250F lies within the Ig-like C2-type domain 3 of the Csf1r protein (UniProt.org). S250F has not been characterized in the scientific literature and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,9536
"CSF1R T37M lies within the Ig-like C2-type domain 1 of the Csf1r protein (UniProt.org). T37M has not been characterized in the scientific literature and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017.",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9537
"CSF1R V138D lies within Ig-like C2-type domain 2 of the Csf1r protein (UniProt.org). V138D has not been characterized in the scientific literature and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9538
"CSF1R V325M lies within the Ig-like C2-type domain 4 of the Csf1r protein (UniProt.org). V325M has not been characterized in the scientific literature and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9539
"CSF1R V38M lies within the Ig-like C2-type domain 1 of the Csf1r protein (UniProt.org). V38M has not been characterized in the scientific literature and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9540
"CSF1R V613M lies within the protein kinase domain of the Csf1r protein (UniProt.org). V613M has not been characterized in the scientific literature and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9541
"CSF1R W575* results in a premature truncation of the Csf1r protein at amino acid 575 of 972 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), W575* is predicted to lead to a loss of Csf1r protein function.",295,,,www.uniprot.org,9542
"CSF1R Y360C lies within the Ig-like C2-type domain 4 of the Csf1r protein (UniProt.org). Y360C has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,295,,,www.uniprot.org,9543
"CSF1R Y540S lies within the cytoplasmic domain of the Csf1r protein (UniProt.org). Y540S has been identified in sequencing studies (PMID: 22980975), but has not been biochemically characterized and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1726,22980975,Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/22980975,9544
"CSF1R Y61H lies within the Ig-like C2-type domain 1 of the Csf1r protein (UniProt.org). Y61H has not been characterized in the scientific literature and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9545
"CBL A186V lies within the Cbl-PTB domain of the Cbl protein (UniProt.org). A186V has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9700
"CBL A678D lies within the CD2AP-interacting region of the Cbl protein (UniProt.org). A678D has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9701
"CBL C384R lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). C384R results in a loss of Cbl function as indicated by decreased degradation of Jak2, and increased expression and signaling of Jak2 and Lyn kinase in cell culture (PMID: 23696637).",966,23696637,CBL linker region and RING finger mutations lead to enhanced granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling via elevated levels of JAK2 and LYN.,http://www.ncbi.nlm.nih.gov/pubmed/23696637,295,,,www.uniprot.org,9702
"CBL C384W lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). C384W has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9703
"CBL C401F lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). C401F has not been biochemically characterized, but is predicted to disrupt Cbl stability by computer modeling (PMID: 26676746).",295,,,www.uniprot.org,4519,26676746,Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26676746,9704
"CBL C416S lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). C416S has been identified in sequencing studies (PMID: 22071139), but has not been biochemically characterized and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",7148,22071139,Older patients with normal karyotype acute myeloid leukemia have a higher rate of genomic changes compared to young patients as determined by SNP array analysis.,http://www.ncbi.nlm.nih.gov/pubmed/22071139,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9705
"CBL D459V does not lie within any known functional domains of the Cbl protein (UniProt.org). D459V has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9706
"CBL D460del results in the deletion of one amino acid in the Cbl protein at amino acid 460 (UniProt.org). D460del has been identified in sequencing studies (PMID: 24817963), but has not been biochemically characterized and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9707
"IKZF1 A422V does not lie within any known functional domains of the Ikzf1 protein (UniProt.org). A422V has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, Jul 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9719
"IKZF1 D22N does not lie within any known functional domains of the Ikzf1 protein (UniProt.org). D22N has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, Jul 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9720
"IKZF1 D399G does not lie within any known functional domains of the Ikzf1 protein (UniProt.org). D399G has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, Jul 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9721
"IKZF1 E465K lies within the C2H2-type 5 domain of the Ikzf1 protein (UniProt.org). E465K has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, Jul 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9722
"IKZF1 E513K lies within the C2H2-type 6 domain of the Ikzf1 protein (UniProt.org). E513K has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, Jul 2015).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9723
"IKZF1 G485V does not lie within any known functional domains of the Ikzf1 protein (UniProt.org). G485V has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, Jul 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9724
"IKZF1 G75V does not lie within any known functional domains of the Ikzf1 protein (UniProt.org). G75V has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, Jul 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9725
"IKZF1 G94A does not lie within any known functional domains of the Ikzf1 protein (UniProt.org). G94A has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, Jul 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9726
"IKZF1 L283I does not lie within any known functional domains of the Ikzf1 protein (UniProt.org). L283I has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, Jul 2015).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,9727
"IKZF1 M92I does not lie within any known functional domains of the Ikzf1 protein (UniProt.org). M92I has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, Jul 2015).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,9728
"IKZF1 P19L does not lie within any known functional domains of the Ikzf1 protein (UniProt.org). P19L has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, Jul 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9729
JAK2 E846D does not lie within any known functional domains of the Jak2 protein (UniProt.org). E846D results in prolonged Epo-induced Stat5 activation in an in vitro assay (http://www.bloodjournal.org/content/124/21/4008). ,4778,,JAK2 E846D Germline Mutation Associated with Erythrocytosis Causes Increased and Prolonged Epo-Induced Activation of STAT5,http://www.bloodjournal.org/content/124/21/4008,295,,,www.uniprot.org,9730
"IKZF1 R213* results in a premature truncation of the Ikzf1 protein at amino acid 213 of 519 (UniProt.org). Due to the loss of multiple zinc finger domains (UniProt.org), R213* is predicted to lead to a loss of Ikzf1 protein function. ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9731
"IKZF1 R222C lies within the C2H2-type 4 domain of the Ikzf1 protein (UniProt.org). R222C has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, Jul 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9732
"IKZF1 R260K does not lie within any known functional domains of the Ikzf1 protein (UniProt.org). R260K has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, Jul 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9733
"IKZF1 R433S does not lie within any known functional domains of the Ikzf1 protein (UniProt.org). R433S has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, Jul 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9734
"IKZF1 R511* results in a premature truncation of the Ikzf1 protein at amino acid 511 of 519 (UniProt.org). R511* has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, Jul 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9735
"CBL D501H does not lie within any known functional domains of the Cbl protein (UniProt.org). D501H has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9745
"CBL E143D lies within the Cbl-PTB domain of the Cbl protein (UniProt.org). E143D has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9746
"CBL E276K lies within the Cbl-PTB domain of the Cbl protein (UniProt.org). E276K has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9747
"CBL E886* results in a premature truncation of the Cbl protein at amino acid 886 of 906 (UniProt.org). E886* has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9748
"CBL F418I lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). F418I has been identified in sequencing studies (PMID: 24618614), but has not been biochemically characterized and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",9047,24618614,Desmoplastic melanoma with sarcomatoid dedifferentiation.,http://www.ncbi.nlm.nih.gov/pubmed/24618614,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9749
"CBL F418V lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). F418V has been identified in sequencing studies (PMID: 19620960), but has not been biochemically characterized and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5941,19620960,Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/19620960,9750
"CBL F622C does not lie within any known functional domains of the Cbl protein (UniProt.org). F622C has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9751
"CBL G397V lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). G397V has been identified in sequencing studies (PMID: 23010802), but has not been biochemically characterized and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7150,23010802,Activating CBL mutations are associated with a distinct MDS/MPN phenotype.,http://www.ncbi.nlm.nih.gov/pubmed/23010802,295,,,www.uniprot.org,9752
"CBL G415S lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). G415S has not been biochemically characterized, but is predicted to disrupt Cbl stability by computer modeling (PMID: 26676746).",4519,26676746,Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26676746,295,,,www.uniprot.org,9753
"CBL G868E lies within the UBA domain of the Cbl protein (UniProt.org). G868E has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9754
"CBL H661P lies within the CD2AP-interacting region of the Cbl protein (UniProt.org). H661P has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9755
"CBL I98T lies within the Cbl-PTB domain of the Cbl protein (UniProt.org). I98T has not been biochemically characterized, but is predicted to disrupt Cbl stability by computer modeling (PMID: 26676746).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4519,26676746,Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26676746,9756
"CBL K322T lies within the Cbl-PTB domain of the Cbl protein (UniProt.org). K322T has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9757
"CBL K477M does not lie within any known functional domains of the Cbl protein (UniProt.org). K477M has been identified in sequencing studies (PMID: 22980975), but has not been biochemically characterized and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",1726,22980975,Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/22980975,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9758
"CBL L281H lies within the Cbl-PTB domain of the Cbl protein (UniProt.org). L281H has been identified in sequencing studies (PMID: 22495314), but has not been biochemically characterized and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,7749,22495314,The clonal and mutational evolution spectrum of primary triple-negative breast cancers.,http://www.ncbi.nlm.nih.gov/pubmed/22495314,285,,,http://www.ncbi.nlm.nih.gov/pubmed,9759
"CBL L399P does not lie within any known functional domains of the Cbl protein (UniProt.org). L399P results in a loss of Cbl E3 ubiquitin ligase activity, is transforming in cell culture, and promotes tumor formation in animal models (PMID: 19620960).",295,,,www.uniprot.org,5941,19620960,Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/19620960,9760
"CBL L405P lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). L405P has not been biochemically characterized, but is predicted to disrupt Cbl stability by computer modeling (PMID: 26676746).",4519,26676746,Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26676746,295,,,www.uniprot.org,9761
"CBL L878F lies within the UBA domain of the Cbl protein (UniProt.org). L878F has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9762
"CBL M469I does not lie within any known functional domains of the Cbl protein (UniProt.org). M469I has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9763
"CBL N832I lies within the CD2AP-interacting region of the Cbl protein (UniProt.org). N832I has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9764
"CBL P201S lies within the Cbl-PTB domain of the Cbl protein (UniProt.org). P201S has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9765
"CBL P417H lies within the RING-type zinc finger region of the Cbl protein (UniProt.org). P417H has been identified in sequencing studies (PMID: 23010802), but has not been biochemically characterized and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7150,23010802,Activating CBL mutations are associated with a distinct MDS/MPN phenotype.,http://www.ncbi.nlm.nih.gov/pubmed/23010802,9766
"CBL P417L lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). P417L has been identified in sequencing studies (PMID: 26214590, PMID: 24030381), but has not been biochemically characterized and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",7151,26214590,Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.,http://www.ncbi.nlm.nih.gov/pubmed/26214590,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7701,24030381,Clinical and biological implications of driver mutations in myelodysplastic syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/24030381,9767
CBL P428L does not lie within any known functional domains of the Cbl protein (UniProt.org). P428L displays ubiquitin ligase activity similar to wild-type Cbl towards Egfr in culture (PMID: 26676746),295,,,www.uniprot.org,4519,26676746,Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26676746,9768
"CBL P433Q does not lie within any known functional domains of the Cbl protein (UniProt.org). P433Q has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9769
"CBL P484S does not lie within any known functional domains of the Cbl protein (UniProt.org). P484S has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9770
"CBL P532S does not lie within any known functional domains of the Cbl protein (UniProt.org). P532S has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9771
"CBL P546L does not lie within any known functional domains of the Cbl protein (UniProt.org). P546L has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9772
"CBL P703L lies within the CD2AP-interacting region of the Cbl protein (UniProt.org). P703L has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9773
"CBL Q367R lies within the linker region of the Cbl protein (UniProt.org). Q367R has been identified in sequencing studies (PMID: 24896186), but has not been biochemically characterized and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,1360,24896186,Novel somatic and germline mutations in intracranial germ cell tumours.,http://www.ncbi.nlm.nih.gov/pubmed/24896186,295,,,www.uniprot.org,9774
"CBL R149Q lies within the Cbl-PTB domain of the Cbl protein (UniProt.org). R149Q has been identified in sequencing studies (PMID: 24755471), but has not been biochemically characterized and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,6962,24755471,Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24755471,285,,,http://www.ncbi.nlm.nih.gov/pubmed,9775
"CBL R420* results in a premature truncation of the Cbl protein at amino acid 420 of 906 (UniProt.org). Due to the loss of the UBA domain (UniProt.org), R420* is predicted to lead to a loss of Cbl protein function.",295,,,www.uniprot.org,9776
"CBL R437I does not lie within any known functional domains of the Cbl protein (UniProt.org). R437I has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9777
"CBL R499Q does not lie within any known functional domains of the Cbl protein (UniProt.org). R499Q has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9778
"CBL R559Q does not lie within any known functional domains of the Cbl protein (UniProt.org). R559Q has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9779
"CBL R788Q lies within the CD2AP-interacting region of the Cbl protein (UniProt.org). R788Q has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9780
"CBL R822G lies within the CD2AP-interacting domain of the Cbl protein (UniProt.org). R822G has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9781
"CBL R893L lies within the UBA domain of the Cbl protein (UniProt.org). R893L has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9782
"CBL R96S lies within the Cbl-PTB domain of the Cbl protein (UniProt.org). R96S has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9783
"CBL S217C lies within the Cbl-PTB domain of the Cbl protein (UniProt.org). S217C has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9784
"CBL S217Y lies within the Cbl-PTB domain of the Cbl protein (UniProt.org). S217Y has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9785
"CBL S253F lies within the Cbl-PTB domain of the Cbl protein (UniProt.org). S253F has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9786
"CBL S403F lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). S403F has been identified in sequencing studies (PMID: 24755471), but has not been biochemically characterized and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",6962,24755471,Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24755471,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9787
"CBL S675F lies within the CD2AP-interacting region of the Cbl protein (UniProt.org). S675F has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9788
"CBL T426A lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). T426A has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9789
"CBL W802* results in a premature truncation of the Cbl protein at amino acid 802 of 906 (UniProt.org). Due to the loss of the UBA domain (UniProt.org), W802* is predicted to lead to a loss of Cbl protein function.",295,,,www.uniprot.org,9790
"FGFR2 positive indicates the presence of the FGFR2 gene, mRNA, and/or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,9808
"ROS1 E1990G lies within the protein kinase domain of the Ros1 protein (UniProt.org). E1990G has been described as a secondary resistance mutation in the context of CD74-ROS1 and ROS1 M2128V and therefore, it is predicted to lead to a gain of Ros1 protein function (PMID: 25351743).",3339,25351743,Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25351743,295,,,www.uniprot.org,9822
"ROS1 M2128V lies within the protein kinase domain of the Ros1 protein (UniProt.org). M2128V has described as a secondary resistance mutation in the context of CD74-ROS1 and ROS1 E1990G and therefore, it is predicted to lead to a gain of Ros1 protein function (PMID: 25351743).",295,,,www.uniprot.org,3339,25351743,Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25351743,9823
"PTPN11 act mut indicates that this variant results in a gain of function in the Ptpn11 protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,9824
PTPN11 mutant indicates an unspecified mutation in the PTPN11 gene. ,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,9825
PTPN11 E76K lies within the SH2 domain 1 of the Ptpn11 protein (UniProt.org). E76K confers a gain of function to the Ptpn11 protein as demonstrated by increased activity of protein tyrosine phosphatase and Erk1/2 and the ability to transform cells in culture (PMID: 17942397). ,3365,17942397,Shp2E76K mutant confers cytokine-independent survival of TF-1 myeloid cells by up-regulating Bcl-XL.,http://www.ncbi.nlm.nih.gov/pubmed/17942397,9835
"ALK V1180L lies within the protein kinase domain of the Alk protein (UniProt.org). V1180L has not been biochemically characterized, but has been demonstrated to occur as a secondary resistance mutation in the context of EML4-ALK (PMID: 25228534).",3371,25228534,Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.,http://www.ncbi.nlm.nih.gov/pubmed/25228534,295,,,www.uniprot.org,9838
"ROS1 L1951R lies within the protein kinase domain of the Ros1 protein (UniProt.org). L1951R been described as a secondary resistance mutation in the context of CD74-ROS1 and therefore, it is predicted to lead to a gain of Ros1 protein function (PMID: 25351743).",295,,,www.uniprot.org,3339,25351743,Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25351743,9848
"ROS1 L2026M is a gatekeeper mutation in the protein kinase domain of the Ros1 protein (UniProt.org, PMID: 25351743).  L2060M has been described as a secondary resistance mutation in the context of CD74-ROS1 and therefore, it is predicted to lead to a gain of Ros1 protein function (PMID: 25351743).",295,,,www.uniprot.org,3339,25351743,Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25351743,9849
"ROS1 K2003I lies within the protein kinase domain of the Ros1 protein (UniProt.org). K2003I has been not been biochemically characterized (PubMed, Jul 2016), but retains sensitivity to crizotinib and ceritinib in the context of CD74-ROS1 (PMID: 25351743 ).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3339,25351743,Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25351743,9850
"ROS1 L1982F lies within the protein kinase domain of the Ros1 protein (UniProt.org).  L1982F has been described as a secondary resistance mutation in the context of Ros1 fusions and therefore, it is predicted to lead to a gain of Ros1 protein function (PMID: 25351743, PMID: 24218589).",3476,24218589,Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins.,http://www.ncbi.nlm.nih.gov/pubmed/24218589,295,,,www.uniprot.org,3339,25351743,Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25351743,9889
"FGFR2 S267_D273dup (A266_S267insSTVVGGD) indicates the insertion of 7 duplicate amino acids, serine (S)-267 through aspartic acid (D)-273, in the Ig3 region of the extracellular domain of the Fgfr2 protein (Uniprot.org). S267_D273dup confers a gain of function on Fgfr2 as demonstrated by ligand-independent phosphorylation, dimerization, and oncogenic cell transformation (PMID: 26048680).",295,,,www.uniprot.org,3380,26048680,Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2.,http://www.ncbi.nlm.nih.gov/pubmed/26048680,9979
"FGFR2 W290_I291delinsC results in a deletion of tryptophan (W) at amino acid 290 and isoleucine (I) at amino acid 291 within the Ig3 region of Fgfr2, combined with the insertion of a cysteine (C) at the same site (UniProt.org). W290_I291delinsC confers a gain of function on Fgfr2 as demonstrated by ligand-independent phosphorylation, dimerization, and oncogenic transformation (PMID: 26048680).",3380,26048680,Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2.,http://www.ncbi.nlm.nih.gov/pubmed/26048680,295,,,www.uniprot.org,9980
"FGFR2-TACC3 results from the fusion of FGFR2 and TACC3, resulting in an oncogenic protein as demonstrated by ligand-independent phosphorylation, dimerization, and oncogenic transformation (PMID: 26048680).",3380,26048680,Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2.,http://www.ncbi.nlm.nih.gov/pubmed/26048680,9981
T730S lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). T730S has activity similar to wild-type as demonstrated by equivalent substrate phosphorylation and the lack of oncogenic cell transformation (PMID: 26048680). ,3380,26048680,Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2.,http://www.ncbi.nlm.nih.gov/pubmed/26048680,295,,,www.uniprot.org,9982
V755I lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). V755I has activity similar to wild-type as demonstrated by equivalent substrate phosphorylation and the lack of oncogenic cell transformation (PMID: 26048680). ,295,,,www.uniprot.org,3380,26048680,Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2.,http://www.ncbi.nlm.nih.gov/pubmed/26048680,9983
FGFR2 D530N lies within the protein kinase domain of the FGFR2 protein (PMID: 19147536). D530N confers a loss of function to the FGFR2 protein resulting in a loss of protein kinase activity and reduced downstream MAPK signaling pathway activation (PMID: 19147536).,1037,19147536,Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/19147536,9995
FGFR2 I642V lies within the protein kinase domain of the FGFR2 protein (PMID: 19147536). I642V confers a loss of function to the FGFR2 protein resulting in a loss of protein kinase activity and reduced downstream MAPK signaling pathway activation (PMID: 19147536).,1037,19147536,Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/19147536,9996
FGFR2 A648T lies within the protein kinase domain of the FGFR2 protein (PMID: 19147536). A648T confers a loss of function to the Fgfr2 protein resulting in a loss of protein kinase activity and reduced downstream MAPK signaling pathway activation (PMID: 19147536).,1037,19147536,Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/19147536,9997
FGFR2 G227E lies within the Ig-like C2-type 2 domain of the FGFR2 protein (UniProt.org). G227E confers a loss of function to the FGFR2 protein resulting in impaired receptor processing and trafficking to the cell membrane and a reduced ability to stimulate cell proliferation in response to ligand (PMID: 19147536).,1037,19147536,Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/19147536,295,,,www.uniprot.org,9998
"IDH1 R132X indicates any Idh1 missense mutation that results in the arginine (R) at amino acid 132 being replaced by a different amino acid. IDH1 R132 mutations are ""hotspot"" mutations, which often confer a gain of function to Idh1 (PMID: 19935646, PMID: 28330869).",487,19935646,Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.,http://www.ncbi.nlm.nih.gov/pubmed/19935646,9218,28330869,Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiency.,http://www.ncbi.nlm.nih.gov/pubmed/28330869,10003
"FGFR3-TACC3 results from the fusion of FGFR3 and TACC3, demonstrating constitutive kinase activity, transforming activity in culture and ability to drive tumor growth in xenografts (PMID: 25294908, PMID: 22837387).",3392,25294908,Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25294908,3426,22837387,Transforming fusions of FGFR and TACC genes in human glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22837387,10068
"FGFR2-COL14A1 results from the fusion of FGFR2 and COL14A1 (PMID: 25485619). FGFR2-COL14A1 has been identified in lung cancer (PMID: 25485619), but has not been biochemically characterized and therefore, its effect on protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3678,25485619,A comprehensive transcriptional portrait of human cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/25485619,10069
NOTCH1 C478F lies within the extracellular domain of the Notch1 protein (PMID: 24277854). C478F results in a loss of Notch1 reporter gene activation in cell culture (PMID: 24277854).,3402,24277854,Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974.,http://www.ncbi.nlm.nih.gov/pubmed/24277854,10163
FGFR3 K508M lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). K508M confers a loss of function to the Fgfr3 protein in the context of Fgfr3-Tacc3 as demonstrated by loss of kinase activity (PMID: 22837387).,3426,22837387,Transforming fusions of FGFR and TACC genes in human glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22837387,10473
"FGFR1-TACC1 results from the fusion of FGFR1 and TACC1, demonstrating transforming ability in culture and tumor growth in xenografts (PMID: 22837387).",3426,22837387,Transforming fusions of FGFR and TACC genes in human glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22837387,10474
"CSF1R over exp indicates an over expression of the Csf1r protein. However, the mechanism causing the over expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,10681
"PTEN over exp indicates an over expression of the Pten protein. However, the mechanism causing the over expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,10682
"RET L56M lies within the extracellular domain of the Ret protein (UniProt.org). L56M has not been biochemically characterized, however, it does not affect RET extracellular domain secretion in culture (PMID: 20473317).",6865,20473317,Mammal-restricted elements predispose human RET to folding impairment by HSCR mutations.,http://www.ncbi.nlm.nih.gov/pubmed/20473317,295,,,www.uniprot.org,10684
"APC P1613S does not lie within any known functional domains of the Apc protein (UniProt.org). P1613S has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,10686
"ROS1 V2098I lies within the protein kinase domain of the Ros1 protein (UniProt.org). V2098I has not been biochemically characterized but has been described as a secondary resistance mutation in the context of Ros1 fusions and therefore, it is predicted to lead to a gain of Ros1 protein function (PMID: 24218589).",295,,,www.uniprot.org,3476,24218589,Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins.,http://www.ncbi.nlm.nih.gov/pubmed/24218589,10690
"ROS1 G1971E lies within the protein kinase domain of the Ros1 protein (UniProt.org). G1971E has not been biochemically characterized but has been described as a secondary resistance mutation in the context of Ros1 fusions and therefore, it is predicted to lead to a gain of Ros1 protein function (PMID: 24218589).",295,,,www.uniprot.org,3476,24218589,Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins.,http://www.ncbi.nlm.nih.gov/pubmed/24218589,10691
"ROS1 C2060G lies within the protein kinase domain of the Ros1 protein (UniProt.org). C2060G has not been biochemically characterized but has been described as a secondary resistance mutation in the context of Ros1 fusions and therefore, it is predicted to lead to a gain of Ros1 protein function (PMID: 24218589).",3476,24218589,Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins.,http://www.ncbi.nlm.nih.gov/pubmed/24218589,295,,,www.uniprot.org,10692
"ROS1 L1947R lies within the protein kinase domain of the Ros1 protein (UniProt.org). L1947R has not been biochemically characterized but has been described as a secondary resistance mutation in the context of Ros1 fusions and therefore, it is predicted to lead to a gain of Ros1 protein function (PMID: 24218589).",3476,24218589,Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins.,http://www.ncbi.nlm.nih.gov/pubmed/24218589,295,,,www.uniprot.org,10693
"ROS1 E1935G lies adjacent to the protein kinase domain of the Ros1 protein (UniProt.org). E1935G has not been biochemically characterized but has been described as a secondary resistance mutation in the context of Ros1 fusions and therefore, it is predicted to lead to a gain of Ros1 protein function (PMID: 24218589).",295,,,www.uniprot.org,3476,24218589,Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins.,http://www.ncbi.nlm.nih.gov/pubmed/24218589,10694
"ATM L1420F does not lie within any known functional domains of the Atm protein (UniProt.org). L1420F has been identified in the scientific literature (PMID: 20826828), but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017).
",295,,,www.uniprot.org,4394,20826828,"Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls.",http://www.ncbi.nlm.nih.gov/pubmed/20826828,285,,,http://www.ncbi.nlm.nih.gov/pubmed,10704
MSH6 S144I lies within the PWWP domain of the Msh6 protein (UniProt.org). S144I binds Msh2 and has DNA mismatch repair activity similar to wild-type Msh6 (PMID: 12019211).,295,,,www.uniprot.org,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,10708
"FBXW7 S227A lies within a phosphorylation site in the Fbxw7 protein (UniProt.org). S227A confers a loss of activity on the Fbxw7 protein, as demonstrated by the inability of S227A to induce apoptosis in cell culture (PMID: 21620836).",3529,21620836,PI3K-dependent phosphorylation of Fbw7 modulates substrate degradation and activity.,http://www.ncbi.nlm.nih.gov/pubmed/21620836,295,,,www.uniprot.org,10709
"KIT A502_Y503dup (also referred to as Y503_F504insAY) indicates the insertion of 2 duplicate amino acids, alanine (A)-502 through tyrosine (Y)-503, in the Ig-like C2-type domain 5 of the Kit protein (Uniprot.org). A502_Y503dup results in constitutive phosphorylation of Kit and is transforming in cell culture (PMID: 15790786, PMID: 19865100).",425,15790786,Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.,http://www.ncbi.nlm.nih.gov/pubmed/15790786,646,19865100,Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations.,http://www.ncbi.nlm.nih.gov/pubmed/19865100,295,,,www.uniprot.org,10886
"KIT L813_V824dup indicates the insertion of 12 duplicate amino acids, leucine (L)-813 through valine (V)-824, in the protein kinase domain of the Kit protein (Uniprot.org). L813_V824dup has not been characterized in the scientific literature and therefore, its effect on Kit protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,10887
"KIT V560dup indicates the insertion of the duplicate amino acid, valine (V)-560, in the cytoplasmic domain of the Kit protein (UniProt.org). V560dup has not been characterized in the scientific literature and therefore, its effect on Kit protein function is unknown (PubMed, Dec 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,10888
"MSH6 S1279N does not lie within any known functional domains of the Msh6 protein (UniProt.org). S1279N has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Mar 2017). ",295,,,www.uniprot.org,115,0,,http://www.ncbi.nlm.nih.gov/pubmed,11009
"IDH1 K3N does not lie within any known functional domains of the Idh1 protein (UniProt.org). K3N has not been characterized in the scientific literature and therefore, its effect on Idh1 protein function is unknown (PubMed, Jun 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11011
GATA2 mutant indicates an unspecified mutation in the GATA2 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,11025
ROS1 rearrangement indicates an unspecified rearrangement of the ROS1 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,11042
"SETBP1 G1307V does not lie within any known functional domains of the Setbp1 protein (UniProt.org). G1370V has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, Aug 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11059
"SETBP1 P1130T does not lie within any known functional domains of the Setbp1 protein (UniProt.org). P1130T has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, Aug 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11060
"SRSF2 amplification indicates an increased number of copies of the SRSF2 gene. However, the mechanism causing the increase is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,11069
SMAD4 A226T lies within the linker region of the Smad4 protein (PMID: 22109972). A226T does not result in increased Smad4 transcriptional activation compared to wild-type Smad4 in cell culture (PMID: 22109972).,3577,22109972,A novel human Smad4 mutation is involved in papillary thyroid carcinoma progression.,http://www.ncbi.nlm.nih.gov/pubmed/22109972,11070
"SETBP1 E1466D does not lie within any known functional domains of the Setpb1 protein (UniProt.org). E1466D has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, Aug 2014). ",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,11072
"SMAD4 D537G lies within the MH2 domain of the Smad4 protein (UniProt.org). D537G has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11074
"STK11 Q100* results in a premature truncation of the Stk11 protein at amino acid 100 of 430 (UniProt.org). Due to the loss of the majority of the protein kinase domain, Q100* is predicted to confer a loss of Stk11 protein function. ",295,,,www.uniprot.org,11077
"RET C620R lies within the transmembrane domain of the Ret protein (PMID: 9230192). C620R results in constitutive activation of Ret and is transforming in cell culture, but also results in decreased cell surface expression, potentially resulting in a loss-of-function effect (PMID: 9879991, PMID: 9230192).",2271,9879991,Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines.,http://www.ncbi.nlm.nih.gov/pubmed/9879991,2272,9230192,"Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype.",http://www.ncbi.nlm.nih.gov/pubmed/9230192,11081
"TET2 A855S does not lie within any known functional domains of the Tet2 protein (UniProt.org). A855S has not been characterized in the scientific literature and therefore, its effect on Tet2 protein function is unknown (PubMed, Aug 2015). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11082
"ETV6 A6V does not lie within any known functional domains of the Etv6 protein (UniProt.org). A6V has not been characterized in the scientific literature and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11086
"ETV6 D111N lies within the PNT domain of the Etv6 protein (UniProt.org). D111N has not been characterized in the scientific literature and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,11087
"ETV6 D351H lies within the ETS domain of the Etv6 protein (PMID: 25581430). D351H has not been characterized in the scientific literature and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",3578,25581430,Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.,http://www.ncbi.nlm.nih.gov/pubmed/25581430,285,,,http://www.ncbi.nlm.nih.gov/pubmed,11088
"ETV6 D372N lies within the ETS domain of the Etv6 protein (PMID: 25581430). D372N has been identified in the scientific literature (PMID: 25581430), but has not been biochemically characterized and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3578,25581430,Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.,http://www.ncbi.nlm.nih.gov/pubmed/25581430,11089
"ETV6 D65E lies within the PNT domain of the Etv6 protein (UniProt.org). D65E has not been characterized in the scientific literature and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11090
"ETV6 E392K lies within the ETS domain of the Etv6 protein (PMID: 25581430). E392K has not been characterized in the scientific literature and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",3578,25581430,Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.,http://www.ncbi.nlm.nih.gov/pubmed/25581430,285,,,http://www.ncbi.nlm.nih.gov/pubmed,11091
"ETV6 G375R lies within the ETS domain of the Etv6 protein (PMID: 25581430). G375R has been identified in sequencing studies (PMID: 21720365), but has not been biochemically characterized and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3578,25581430,Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.,http://www.ncbi.nlm.nih.gov/pubmed/25581430,6943,21720365,Integrated genomic analyses of ovarian carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/21720365,11092
"ETV6 H141Y does not lie within any known functional domains of the Etv6 protein (UniProt.org). H141Y has not been characterized in the scientific literature and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11093
"ETV6 I186V does not lie within any known functional domains of the Etv6 protein (UniProt.org). I186V has been identified in sequencing studies (PMID: 22842228), but has not been biochemically characterized and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7109,22842228,Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22842228,11094
"ETV6 I407T lies within the ETS domain of the Etv6 protein (PMID: 25581430). I407T has not been characterized in the scientific literature and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",3578,25581430,Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.,http://www.ncbi.nlm.nih.gov/pubmed/25581430,285,,,http://www.ncbi.nlm.nih.gov/pubmed,11095
"ETV6 K403E lies within the ETS domain of the Etv6 protein (PMID: 25581430). K403E has been identified in sequencing studies (PMID: 23103869), but has not been biochemically characterized and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",6989,23103869,Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes.,http://www.ncbi.nlm.nih.gov/pubmed/23103869,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3578,25581430,Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.,http://www.ncbi.nlm.nih.gov/pubmed/25581430,11096
"ETV6 L117F lies within the PNT domain of the Etv6 protein (UniProt.org). L117F has not been characterized in the scientific literature and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11097
"ETV6 L79S lies within the PNT domain of the Etv6 protein (UniProt.org). L79S has not been characterized in the scientific literature and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11098
"ETV6 N228S does not lie within any known functional domains of the Etv6 protein (UniProt.org). N228S has been identified in sequencing studies (PMID: 22980975, PMID: 21984974), but has not been biochemically characterized and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",7177,21984974,Temporal dissection of tumorigenesis in primary cancers.,http://www.ncbi.nlm.nih.gov/pubmed/21984974,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1726,22980975,Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/22980975,11099
"ETV6 N382D lies within the ETS domain of the Etv6 protein (PMID: 25581430). N382D has not been characterized in the scientific literature and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3578,25581430,Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.,http://www.ncbi.nlm.nih.gov/pubmed/25581430,11100
"ETV6 P194S does not lie within any known functional domains of the Etv6 protein (UniProt.org). P194S has not been characterized in the scientific literature and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11101
ETV6 P214L does not lie within any known functional domains of the Etv6 protein (UniProt.org). P214L results in decreased Etv6 transcriptional repression and delayed megakaryocyte maturation in cell culture (PMID: 25807284).,3579,25807284,"Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/25807284,295,,,www.uniprot.org,11102
"ETV6 P214S lies within the internal linker domain of the Etv6 protein (PMID: 25581430). P214S has not been characterized in the scientific literature and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",3578,25581430,Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.,http://www.ncbi.nlm.nih.gov/pubmed/25581430,285,,,http://www.ncbi.nlm.nih.gov/pubmed,11103
"ETV6 P324Q does not lie within any known functional domains of the Etv6 protein (UniProt.org). P324Q has not been characterized in the scientific literature and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,11104
"ETV6 R14Q does not lie within any known functional domains of the Etv6 protein (UniProt.org). R14Q has not been characterized in the scientific literature and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11105
"ETV6 R181C does not lie within any known functional domains of the Etv6 protein (UniProt.org). R181C has not been characterized in the scientific literature and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11106
"ETV6 R181L does not lie within any known functional domains of the Etv6 protein (UniProt.org). R181L has not been characterized in the scientific literature and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11107
"ETV6 R199Q does not lie within any known functional domains of the Etv6 protein (UniProt.org). R199Q has not been characterized in the scientific literature and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11108
"ETV6 R202W does not lie within any known functional domains of the Etv6 protein (UniProt.org). R202W has been identified in sequencing studies (PMID: 25042771), but has not been biochemically characterized and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7030,25042771,The mutational burdens and evolutionary ages of early gastric cancers are comparable to those of advanced gastric cancers.,http://www.ncbi.nlm.nih.gov/pubmed/25042771,295,,,www.uniprot.org,11109
"ETV6 R217T does not lie within any known functional domains of the Etv6 protein (UniProt.org). R217T has been identified in sequencing studies (PMID: 21798897, PMID: 23619168), but has not been biochemically characterized and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",7132,23619168,Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers.,http://www.ncbi.nlm.nih.gov/pubmed/23619168,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7349,21798897,Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1.,http://www.ncbi.nlm.nih.gov/pubmed/21798897,11110
"ETV6 R259G does not lie within any known functional domains of the Etv6 protein (UniProt.org). R259G has been identified in sequencing studies (PMID: 25581430, PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",3578,25581430,Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.,http://www.ncbi.nlm.nih.gov/pubmed/25581430,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,295,,,www.uniprot.org,11111
"ETV6 R259L does not lie within any known functional domains of the Etv6 protein (UniProt.org). R259L has not been characterized in the scientific literature and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11112
"ETV6 R259Q does not lie within any known functional domains of the Etv6 protein (UniProt.org). R259Q has been identified in sequencing studies (PMID: 25581430, PMID: 22895193, PMID: 24265153), but has not been biochemically characterized and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",4597,22895193,Recurrent R-spondin fusions in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22895193,5840,24265153,The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24265153,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3578,25581430,Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.,http://www.ncbi.nlm.nih.gov/pubmed/25581430,11113
"ETV6 R264C does not lie within any known functional domains of the Etv6 protein (UniProt.org). R264C has been identified in sequencing studies (PMID: 25581430, PMID: 22810696), but has not been characterized and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",3578,25581430,Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.,http://www.ncbi.nlm.nih.gov/pubmed/25581430,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,11114
"ETV6 R309W does not lie within any known functional domains of the Etv6 protein (UniProt.org). R309W has not been characterized in the scientific literature and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11115
"ETV6 R369L lies within the ETS domain of the Etv6 protein (PMID: 25581430). R369L has not been characterized in the scientific literature and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3578,25581430,Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.,http://www.ncbi.nlm.nih.gov/pubmed/25581430,11116
"ETV6 R369W lies within the ETS domain of the Etv6 protein (PMID: 25581430). R369W has been identified in sequencing studies (PMID: 25581430, PMID: 22810696, PMID: 22895193) but has not been biochemically characterized and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",4597,22895193,Recurrent R-spondin fusions in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22895193,5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3578,25581430,Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.,http://www.ncbi.nlm.nih.gov/pubmed/25581430,11117
"ETV6 R378* results in a premature truncation of the Etv6 protein at amino acid 378 of 452 (UniProt.org). R378* has been identified in sequencing studies (PMID: 24345752), but has not been biochemically characterized and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7350,24345752,A targeted mutational landscape of angioimmunoblastic T-cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/24345752,295,,,www.uniprot.org,11118
"ETV6 R378P lies within the ETS domain of the Etv6 protein (PMID: 25581430). R378P has not been characterized in the scientific literature and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",3578,25581430,Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.,http://www.ncbi.nlm.nih.gov/pubmed/25581430,285,,,http://www.ncbi.nlm.nih.gov/pubmed,11119
"ETV6 R386I lies within the ETS domain of the Etv6 protein (PMID: 25581430). R386I has not been characterized in the scientific literature and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",3578,25581430,Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.,http://www.ncbi.nlm.nih.gov/pubmed/25581430,285,,,http://www.ncbi.nlm.nih.gov/pubmed,11120
"ETV6 R396G lies within the ETS domain of the Etv6 protein (PMID: 25581430). R396G has been identified in sequencing studies (PMID: 23856246, PMID: 24755471), but has not been biochemically characterized and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3578,25581430,Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.,http://www.ncbi.nlm.nih.gov/pubmed/25581430,6964,23856246,The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.,http://www.ncbi.nlm.nih.gov/pubmed/23856246,6962,24755471,Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24755471,11121
"ETV6 R396K lies within the ETS domain of the Etv6 protein (PMID: 25581430). R396K has not been characterized in the scientific literature and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",3578,25581430,Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.,http://www.ncbi.nlm.nih.gov/pubmed/25581430,285,,,http://www.ncbi.nlm.nih.gov/pubmed,11123
"ETV6 R399C lies within the ETS domain of the Etv6 protein (PMID: 25581430). R399C results in loss of Etv6 binding to DNA, inhibition of wild-type Etv6 transcriptional repression, and decreased hematopoietic stem cell proliferation in cell culture (PMID: 25581430).",3578,25581430,Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.,http://www.ncbi.nlm.nih.gov/pubmed/25581430,11124
"ETV6 R399H lies within the ETS domain of the Etv6 protein (PMID: 25581430). R399H leads to decreased binding of the Etv6 ETS-domain to DNA, and decreased repression in a reporter assay (Blood Nov 2004, 104 (11) 2055) and therefore, R399H is predicted to result in a loss of Etv6 protein function.",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3578,25581430,Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.,http://www.ncbi.nlm.nih.gov/pubmed/25581430,8005,,R399H Mutated ETS Domain Leads to a Functional ETV6 Double-Knock-Out in Acute Leukemia and Completely Alters the Physiological Function of ETV6,http://www.bloodjournal.org/content/104/11/2055?sso-checked=true,11125
"ETV6 R55C lies within the PNT domain of the Etv6 protein (UniProt.org). R55C has not been characterized in the scientific literature and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11126
"ETV6 S165Y does not lie within any known functional domains of the Etv6 protein (UniProt.org). S165Y has not been characterized in the scientific literature and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11127
"ETV6 S203fs results in a change in the amino acid sequence of the Etv6 protein beginning at aa 203 of 452, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the DNA binding domain, S203fs is predicted to lead to a loss of Etv6 protein function (UniProt.org).",295,,,www.uniprot.org,11128
"ETV6 Y391* results in a premature truncation of the Etv6 protein at amino acid 391 of 452 (UniProt.org). Y391* has been identified in sequencing studies (PMID: 25344691), but has not been biochemically characterized and therefore, its effect on Etv6 protein function is unknown (PubMed, Feb 2017).",1689,25344691,RNF43 is frequently mutated in colorectal and endometrial cancers.,http://www.ncbi.nlm.nih.gov/pubmed/25344691,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11129
"ETV6 Y391fs results in a change in the amino acid sequence of the Etv6 protein beginning at aa 391 of 452, likely resulting in premature truncation of the functional protein (UniProt.org). Y391fs has not been characterized in the scientific literature and therefore, its effect on Etv6 protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11130
"ROS1 R167Q lies within the fibronectin type-III 1 domain of the Ros1 protein (UniProt.org). R167Q has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Sep 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11235
ERBB2 (HER2) N857S lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). N857S results in constitutive phosphorylation of Erbb2 (Her2) and is transforming in cell culture (PMID: 22046346).,295,,,www.uniprot.org,621,22046346,Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.,http://www.ncbi.nlm.nih.gov/pubmed/22046346,11296
ERBB2 (HER2) T862A lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). T862A results in constitutive phosphorylation of Erbb2 (Her2) and is transforming in cell culture (PMID: 22046346).,621,22046346,Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.,http://www.ncbi.nlm.nih.gov/pubmed/22046346,295,,,www.uniprot.org,11297
ERBB2 (HER2) V773A lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). V773A results in constitutive phosphorylation of Erbb2 (Her2) and is transforming in cell culture (PMID: 22046346).,621,22046346,Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.,http://www.ncbi.nlm.nih.gov/pubmed/22046346,295,,,www.uniprot.org,11298
"ROS1 A887V lies within the extracellular domain of the Ros1 protein (UniProt.org). A887V has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,11311
"ROS1 E2265D lies within the cytoplasmic domain of the Ros1 protein (UniProt.org). E2265D has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,11312
"ATM loss indicates loss of the ATM gene, mRNA or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,11332
"ERBB2 (HER2) V659E lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). V659E results in constitutive phosphorylation of Erbb2 (Her2), activation of Src and Akt signaling in cell culture, and increased tumor metastasis in animal models (PMID: 16489002, PMID: 15753384).
",3590,15753384,ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis.,http://www.ncbi.nlm.nih.gov/pubmed/15753384,295,,,www.uniprot.org,3589,16489002,ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/16489002,11334
"EGFR L747_T751delinsP results in the deletion of five amino acids in the protein kinase domain of the Egfr protein from amino acids 747 to 751, combined with the insertion of a proline (P) at the same site (UniProt.org). L747_T751delinsP has not been characterized, however, other exon 19 deletions and deletion insertions in the Egfr protein are activating, thus, L747-T751delinsP is predicted to lead to a gain of function (PMID: 19147750, PMID: 23387505).",441,23387505,Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/23387505,295,,,www.uniprot.org,1890,19147750,Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/19147750,11335
"NPM1 A53S lies within the SENP3-interacting region of the Npm1 protein (UniProt.org). A53S has not been characterized in the scientific literature and therefore, its effect on Npm1 protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,11343
"NPM1 D55N lies within the SENP3-interacting region of the Npm1 protein (UniProt.org). D55N has not been characterized in the scientific literature and therefore, its effect on Npm1 protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,11344
"NPM1 E185K lies within the SENP3-interacting region of the Npm1 protein (UniProt.org). E185K has not been characterized in the scientific literature and therefore, its effect on Npm1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11345
"NPM1 E245Q lies within a region of the Npm1 protein required for nucleolar localization (UniProt.org). E245Q has not been characterized in the scientific literature and therefore, its effect on Npm1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11346
"NPM1 G147D lies within the SENP3-interacting region of the Npm1 protein (UniProt.org). G147D has not been characterized in the scientific literature and therefore, its effect on Npm1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11347
"NPM1 I138V lies within the SENP3-interacting region of the Npm1 protein (UniProt.org). I138V has not been characterized in the scientific literature and therefore, its effect on Npm1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11348
"NPM1 K141R lies within the SENP3-interacting region of the Npm1 protein (UniProt.org). K141R has not been characterized in the scientific literature and therefore, its effect on Npm1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11349
"NPM1 K257E lies within a region of the Npm1 protein required for nucleolar localization (UniProt.org). K257E has not been characterized in the scientific literature and therefore, its effect on Npm1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11350
"NPM1 K273N lies within a region of the Npm1 protein required for nucleolar localization (UniProt.org). K273N has not been characterized in the scientific literature and therefore, its effect on Npm1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11351
"NPM1 L136F lies within the SENP3-interacting region of the Npm1 protein (UniProt.org). L136F has been identified in sequencing studies (PMID: 23917401), but has not been biochemically characterized and therefore, its effect on Npm1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3963,23917401,The integrated landscape of driver genomic alterations in glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/23917401,11352
"NPM1 L294F lies within a region of the Npm1 protein required for nucleolar localization (UniProt.org). L294F has been identified in sequencing studies (PMID: 24121792), but has not been biochemically characterized and therefore, its effect on Npm1 protein function is unknown (PubMed, Oct 2017).",6998,24121792,Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation.,http://www.ncbi.nlm.nih.gov/pubmed/24121792,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11353
"NPM1 M251fs*30 likely results in a truncation of the 294 aa Npm1 protein at aa 251, followed by 30 nonsense amino acids (UniProt.org). NPM1 M251fs*30 has not been characterized in the scientific literature and therefore, its effect on Npm1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11354
"NPM1 N203H does not lie within any known functional domains of the Npm1 protein (UniProt.org). N203H has not been characterized in the scientific literature and therefore, its effect on Npm1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11356
"NPM1 N38D lies within the SENP3-interacting region of the Npm1 protein (UniProt.org). N38D has not been characterized in the scientific literature and therefore, its effect on Npm1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11357
"NPM1 P216S does not lie within any known functional domains of the Npm1 protein (UniProt.org). P216S has not been characterized in the scientific literature and therefore, its effect on Npm1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11358
"NPM1 S106L lies within the SENP3-interacting region of the Npm1 protein (UniProt.org). S106L has not been characterized in the scientific literature and therefore, its effect on Npm1 protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,11359
"NPM1 S207* results in a premature truncation of the Npm1 protein at amino acid 207 of 294 (UniProt.org). S207* has been identified in sequencing studies (PMID: 25151357), but has not been biochemically characterized and therefore, its effect on Npm1 protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,1252,25151357,Genetic landscape of esophageal squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25151357,285,,,http://www.ncbi.nlm.nih.gov/pubmed,11360
"NPM1 V99A lies within the SENP3-interacting region of the Npm1 protein(UniProt.org). V99A has not been characterized in the scientific literature and therefore, its effect on Npm1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11361
"NPM1 V156fs*6 likely results in a truncation of the 294 aa Npm1 protein at aa 156, followed by 6 nonsense amino acids (UniProt.org). Due to the loss of the region required for nucleolar localization, V156fs*6 is predicted to lead to a loss of Npm1 protein function (UniProt.org).",295,,,www.uniprot.org,11362
"NPM1 W288Cfs*12 is a hotspot mutation that results from a 4 bp-duplication causing a frameshift aa 288 of 294, followed by 12 amino acids creating a novel nuclear export sequence (PMID: 16501600, PMID: 15659725). W288Cfs*12 confers a loss of function to the Npm1 protein as demonstrated by mislocalization of the Npm1 protein (PMID: 15659725).",3600,16501600,Cytoplasmic localization of NPM in myeloid leukemias is dictated by gain-of-function mutations that create a functional nuclear export signal.,http://www.ncbi.nlm.nih.gov/pubmed/16501600,1522,15659725,Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.,http://www.ncbi.nlm.nih.gov/pubmed/15659725,11363
"NPM1 K263R lies within a region of the Npm1 protein required for nucleolar localization (UniProt.org). K263R confers a loss of function to the Npm1 protein as demonstrated by loss of sumoylation, loss of Rb1 binding, and reduced E2f1-driven transcriptional activity (PMID: 17535915).",295,,,www.uniprot.org,3599,17535915,"Sumoylation of nucleophosmin/B23 regulates its subcellular localization, mediating cell proliferation and survival.",http://www.ncbi.nlm.nih.gov/pubmed/17535915,11364
"NPM1 W288Lfs*12 is a hotspot mutation that results from a 4 bp-duplication causing a frameshift aa 288 of 294, followed by 12 amino acids creating a novel nuclear export sequence (PMID: 15659725). Other 4-bp duplications at the W288 site confer a mislocalization to the Npm1 protein, therefore, W288Lfs*12 is predicted to lead to a loss of Npm1 protein function (PMID: 15659725, PMID: 16720834).",3600,16501600,Cytoplasmic localization of NPM in myeloid leukemias is dictated by gain-of-function mutations that create a functional nuclear export signal.,http://www.ncbi.nlm.nih.gov/pubmed/16501600,3601,16720834,Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/16720834,1522,15659725,Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.,http://www.ncbi.nlm.nih.gov/pubmed/15659725,11365
"MPL A21V does not lie within any known functional domain of the Mpl protein (UniProt.org). A21V has not been characterized in the scientific literature and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11366
"MPL A286S lies within the extracellular domain of the Mpl protein (UniProt.org). A286S has not been characterized in the scientific literature and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11367
"MPL A506G lies within the transmembrane domain of the Mpl protein (UniProt.org). A506G has not been characterized in the scientific literature and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11368
"MPL A554T lies within the cytoplasmic domain of the Mpl protein (UniProt.org). A554T has not been characterized in the scientific literature and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11369
"MPL E338D lies within the extracellular domain of the Mpl protein (UniProt.org). E338D has not been characterized in the scientific literature and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11370
"MPL G238D lies within the fibronectin type-III domain 1 of the Mpl protein (UniProt.org). G238D has been identified in sequencing studies (PMID: 24755471), but has not been biochemically characterized and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017). ",6962,24755471,Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24755471,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11371
"MPL G282E lies within the extracellular domain of the Mpl protein (UniProt.org). G282E has not been characterized in the scientific literature and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11372
"MPL G429E lies within the fibronectin type-III domain 2 of the Mpl protein (UniProt.org). G429E has not been characterized in the scientific literature and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11374
"MPL G600E lies within the cytoplasmic domain of the Mpl protein (UniProt.org). G600E has not been characterized in the scientific literature and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,11375
"MPL H624D lies within the cytoplasmic domain of the Mpl protein (UniProt.org). H624D has been identified in sequencing studies (PMID: 27276561), but has not been biochemically characterized and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,7052,27276561,Genomic Classification and Prognosis in Acute Myeloid Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27276561,285,,,http://www.ncbi.nlm.nih.gov/pubmed,11376
"MPL L109H lies within the extracellular domain of the Mpl protein (UniProt.org). L109H has not been characterized in the scientific literature and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11377
"MPL L406V lies within the fibronectin type-III domain 2 of the Mpl protein (UniProt.org). L406V has been identified in sequencing studies (PMID: 22675565), but has not been biochemically characterized and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",8321,22675565,High accuracy mutation detection in leukemia on a selected panel of cancer genes.,http://www.ncbi.nlm.nih.gov/pubmed/22675565,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11378
"MPL L48I lies within the extracellular domain of the Mpl protein (UniProt.org). L48I has not been characterized in the scientific literature and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11379
"MPL L498V lies within the transmembrane domain of the Mpl protein (UniProt.org). L498V has not been characterized in the scientific literature and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11380
"MPL L571fs results in a change in the amino acid sequence of the Mpl protein beginning at aa 571 of 635, likely resulting in premature truncation of the functional protein (UniProt.org). L571fs has not been characterized in the scientific literature and therefore, its effect on Mpl protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11381
MPL P106L lies within the extracellular domain of the Mpl protein (UniProt.org). P106L results in constitutive activation of Mpl and ligand-independent growth of cells in culture (PMID: 25538044).,295,,,www.uniprot.org,3602,25538044,The thrombopoietin receptor P106L mutation functionally separates receptor signaling activity from thrombopoietin homeostasis.,http://www.ncbi.nlm.nih.gov/pubmed/25538044,11382
"MPL P159T lies within the extracellular domain of the Mpl protein (UniProt.org). P159T has not been characterized in the scientific literature and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11383
"MPL P195H lies within the fibronectin type-III domain 1 of the Mpl protein (UniProt.org). P195H has been identified in sequencing studies (PMID: 22980975), but has not been biochemically characterized and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1726,22980975,Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/22980975,11384
"MPL P200T lies within the fibronectin type-III domain 1 of the Mpl protein (UniProt.org). P200T has not been characterized in the scientific literature and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11385
"MPL P217S lies within the fibronectin type-III domain 1 of the Mpl protein (UniProt.org). P217S has not been characterized in the scientific literature and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11386
"MPL P347T lies within the extracellular domain of the Mpl protein (UniProt.org). P347T has been identified in sequencing studies (PMID: 22980975), but has not been biochemically characterized and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1726,22980975,Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/22980975,11387
"MPL P551L lies within the cytoplasmic domain of the Mpl protein (UniProt.org). P551L has not been characterized in the scientific literature and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11388
"MPL P551Q lies within the cytoplasmic domain of the Mpl protein (UniProt.org). P551Q has not been characterized in the scientific literature and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11389
"MPL P85S lies within the extracellular domain of the Mpl protein (UniProt.org). P85S has been identified in sequencing studies (PMID: 22895193), but has not been biochemically characterized and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",4597,22895193,Recurrent R-spondin fusions in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22895193,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11390
"MPL R170C lies within the extracellular domain of the Mpl protein (UniProt.org). R170C has not been characterized in the scientific literature and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,11391
"MPL R357Q lies within the extracellular domain of the Mpl protein (UniProt.org). R357Q has not been characterized in the scientific literature and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,11392
"MPL R390C lies within the extracellular domain of the Mpl protein (UniProt.org). R390C has been identified in sequencing studies (PMID: 24755471), but has not been biochemically characterized and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6962,24755471,Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24755471,11393
"MPL R592* results in a premature truncation of the Mpl protein at amino acid 592 of 635 (UniProt.org). R592* has been identified in sequencing studies (PMID: 22980975), but has not been biochemically characterized and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1726,22980975,Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/22980975,11394
"MPL R593I lies within the cytoplasmic domain of the Mpl protein (UniProt.org). R593I has not been characterized in the scientific literature and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11395
"MPL R71W lies within the extracellular domain of the Mpl protein (UniProt.org). R71W has been identified in sequencing studies (PMID: 21798897), but has not been biochemically characterized and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7349,21798897,Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1.,http://www.ncbi.nlm.nih.gov/pubmed/21798897,11396
"MPL R75H lies within the extracellular domain of the Mpl protein (UniProt.org). R75H has not been characterized in the scientific literature and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11397
"MPL R90Q lies within the extracellular domain of the Mpl protein (UniProt.org). R90Q has been identified in sequencing studies (PMID: 26214590), but has not been biochemically characterized and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7151,26214590,Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.,http://www.ncbi.nlm.nih.gov/pubmed/26214590,11398
"MPL S232* results in a premature truncation of the Mpl protein at amino acid 232 of 635 (UniProt.org). Due to the loss of the transmembrane and cytoplasmic domains (UniProt.org), S232* is predicted to lead to a loss of Mpl protein function. ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11399
"MPL S42Y lies within the extracellular domain of the Mpl protein (UniProt.org). S42Y has not been characterized in the scientific literature and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11400
"MPL S550N lies within the cytoplasmic domain of the Mpl protein (UniProt.org). S550N has not been characterized in the scientific literature and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11401
"MPL S557* results in a premature truncation of the Mpl protein at amino acid 557 of 635 (UniProt.org). S557* has not been characterized in the scientific literature and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11402
"MPL S566N lies within the cytoplasmic domain of the Mpl protein (UniProt.org). S566N has not been characterized in the scientific literature and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11403
"MPL T180S lies within the fibronectin type-III domain 1 of the Mpl protein (UniProt.org). T180S has not been characterized in the scientific literature and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11404
"MPL T601A lies within the cytoplasmic domain of the Mpl protein (UniProt.org). T601A has been identified in sequencing studies (PMID: 22941188), but has not been biochemically characterized and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",7166,22941188,Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22941188,115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11405
"MPL V285L lies within the extracellular domain of the Mpl protein (UniProt.org). V285L has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,11406
"MPL V92M lies within the extracellular domain of the Mpl protein (UniProt.org). V92M has not been characterized in the scientific literature and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,11407
"MPL W253R lies within the fibronectin type-III domain 1 of the Mpl protein (UniProt.org). W253R has not been characterized in the scientific literature and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,11408
"MPL W4R lies within the signal peptide of the Mpl protein (UniProt.org). W4R has been identified in sequencing studies (PMID: 25801912), but has not been biochemically characterized and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8324,25801912,Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis.,http://www.ncbi.nlm.nih.gov/pubmed/25801912,11409
"MSH6 A1204P does not lie within any known functional domains of the Msh6 protein (UniProt.org). A1204P has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11458
"MSH6 A175T does not lie within any known functional domains of the Msh6 protein (UniProt.org). A175T has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11478
"MSH6 A339D lies within the MSH2-binding region of the Msh6 protein (PMID: 12019211). A339D has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,11479
"MSH6 A457D lies within the MSH2-binding region of the Msh6 protein (PMID: 12019211). A457D has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,11480
"MSH6 A457V lies within the MSH2-binding region of the Msh6 protein (PMID: 12019211). A457V has been identified in sequencing studies (PMID: 22622578), but has not been biochemically characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Apr 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,6955,22622578,Melanoma genome sequencing reveals frequent PREX2 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/22622578,11481
"MSH6 D197H does not lie within any known functional domains of the Msh6 protein (UniProt.org). D197H has been identified in sequencing studies (PMID: 18948947), but has not been biochemically characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Apr 2017).",6956,18948947,Somatic mutations affect key pathways in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18948947,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11482
"MSH6 D390N lies within the MSH2-binding region of the Msh6 protein (PMID: 12019211). D390N has been identified in sequencing studies (PMID: 10786688), but has not been biochemically characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Apr 2017).
",8550,10786688,HMSH6 alterations in patients with microsatellite instability-low colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/10786688,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,11483
"MSH6 D422G lies within the MSH2-binding region of the Msh6 protein (PMID: 12019211). D422G has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,11484
"MSH6 D667V does not lie within any known functional domains of the Msh6 protein (UniProt.org). D667V has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Aug 2017).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,11485
"MSH6 E1196* results in a premature truncation of the Msh6 protein at amino acid 1196 of 1360 (UniProt.org). E1196* has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11486
"MSH6 E1234* results in a premature truncation of the Msh6 protein at amino acid 1234 of 1360 (UniProt.org). E1234* has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,11487
"MSH6 E1322* results in a premature truncation of the Msh6 protein at amino acid 1322 of 1360 (UniProt.org). E1322* has been identified in sequencing studies (PMID: 24755471), but has not been biochemically characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,6962,24755471,Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24755471,285,,,http://www.ncbi.nlm.nih.gov/pubmed,11488
"MSH6 E224* results in a premature truncation of the Msh6 protein at amino acid 224 of 1360 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), E224* is predicted to lead to a loss of Msh6 protein function.",295,,,www.uniprot.org,11489
"MSH6 E484K lies within the MSH2-binding region of the Msh6 protein (PMID: 12019211). E484K has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,11490
"MSH6 E597Q does not lie within any known functional domains of the Msh6 protein (UniProt.org). E597Q has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11491
"MSH6 E604* results in a premature truncation of the Msh6 protein at amino acid 604 of 1360 (UniProt.org). Due to the loss of MSH2- and ATP-binding regions (PMID: 12019211), E604* is predicted to lead to a loss of Msh6 protein function.",295,,,www.uniprot.org,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,11492
"MSH6 E641* results in a premature truncation of the Msh6 protein at amino acid 641 of 1360 (UniProt.org). Due to the loss of MSH2- and ATP-binding regions (PMID: 12019211), E641* is predicted to lead to a loss of Msh6 protein function.",3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,295,,,www.uniprot.org,11493
"MSH6 E946* results in a premature truncation of the Msh6 protein at amino acid 946 of 1360 (UniProt.org). Due to the loss of MSH2- and ATP-binding regions (PMID: 12019211), E946* is predicted to lead to a loss of Msh6 protein function.",3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,295,,,www.uniprot.org,11494
"MSH6 E956D does not lie within any known functional domains of the Msh6 protein (UniProt.org). E956D has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11495
"MSH6 F689L does not lie within any known functional domains of the Msh6 protein (UniProt.org). F689L has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11496
"MSH6 F689V does not lie within any known functional domains of the Msh6 protein (UniProt.org). F689V has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11497
"MSH6 G1299D does not lie within any known functional domains of the Msh6 protein (UniProt.org). G1299D has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11498
"MSH6 G141D lies within the PWWP domain of the Msh6 protein (UniProt.org). G141D has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11499
"MSH6 G39W does not lie within any known functional domains of the Msh6 protein (UniProt.org). G39W has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11500
"MSH6 G529C lies within the MSH2-binding region of the Msh6 protein (PMID: 12019211). G529C has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,11501
"MSH6 G93E lies within the PWWP domain of the Msh6 protein (UniProt.org). G93E has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11502
"MSH6 I1183K does not lie within any known functional domains of the Msh6 protein (UniProt.org). I1183K has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Aug 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,11503
"MSH6 I1183T does not lie within any known functional domains of the Msh6 protein (UniProt.org). I1183T has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Aug 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,11504
"MSH6 K1013N does not lie within any known functional domains of the Msh6 protein (UniProt.org). K1013N has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11505
"MSH6 K1101N does not lie within any known functional domains of the Msh6 protein (UniProt.org). K1101N has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11506
"MSH6 K125* results in a premature truncation of the Msh6 protein at amino acid 125 of 1360 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), K125* is predicted to lead to a loss of Msh6 protein function.",295,,,www.uniprot.org,11507
"MSH6 K417E lies within the MSH2-binding region of the Msh6 protein (PMID: 12019211). K417E has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,11508
"MSH6 K428T lies within the MSH2-binding region of the Msh6 protein (PMID: 12019211). K428T has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,11509
"MSH6 K692N does not lie within any known functional domains of the Msh6 protein (UniProt.org). K692N has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11510
"MSH6 K99N does not lie within any known functional domains of the Msh6 protein (UniProt.org). K99N has not been characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11511
"MSH6 L373P lies within the MSH2-binding region of the Msh6 protein (PMID: 12019211). L373P has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,11512
"MSH6 L893Q does not lie within any known functional domains of the Msh6 protein (UniProt.org). L893Q has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11513
"MSH6 L979V does not lie within any known functional domains of the Msh6 protein (UniProt.org). L979V has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11514
"MSH6 M1156K does not lie within any known functional domains of the Msh6 protein (UniProt.org). M1156K has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11515
"MSH6 M452V lies within the MSH2-binding region of the Msh6 protein (PMID: 12019211). M452V has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,11516
"MSH6 N897H does not lie within any known functional domains of the Msh6 protein (UniProt.org). N897H has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11517
"MSH6 N960T does not lie within any known functional domains of the Msh6 protein (UniProt.org). N960T has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11518
"MSH6 P1097S does not lie within any known functional domains of the Msh6 protein (UniProt.org). P1097S has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Aug 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,11519
"MSH6 P591Q does not lie within any known functional domains of the Msh6 protein (UniProt.org). P591Q has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Aug 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,11520
"MSH6 P768H does not lie within any known functional domains of the Msh6 protein (UniProt.org). P768H has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11521
"MSH6 P781T does not lie within any known functional domains of the Msh6 protein (UniProt.org). P781T has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11522
"MSH6 R1024W does not lie within any known functional domains of the Msh6 protein (UniProt.org). R1024W has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11523
"MSH6 R1076H does not lie within any known functional domains of the Msh6 protein (UniProt.org). R1076H has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11524
MSH6 R1095H does not lie within any known functional domains of the Msh6 protein (UniProt.org). R1095H demonstrates DNA mismatch repair activity similar to wild-type Msh6 protein in cell culture (PMID: 24040339).,3607,24040339,Functional analysis in mouse embryonic stem cells reveals wild-type activity for three MSH6 variants found in suspected Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/24040339,295,,,www.uniprot.org,11525
"MSH6 R1331Q lies within the MSH2-binding region of the Msh6 protein (PMID: 12019211). R1331Q has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,11526
"MSH6 R178H does not lie within any known functional domains of the Msh6 protein (UniProt.org). R178H has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11527
"MSH6 R482Q lies within the MSH2-binding region of the Msh6 protein (PMID: 12019211). R482Q has not been characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,11528
"MSH6 R577H does not lie within any known functional domains of the Msh6 protein (UniProt.org). R577H has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11529
"MSH6 R644S does not lie within any known functional domains of the Msh6 protein (UniProt.org). R644S has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11530
"MSH6 R761M does not lie within any known functional domains of the Msh6 protein (UniProt.org). R761M has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11531
"MSH6 R772W does not lie within any known functional domains of the Msh6 protein (UniProt.org). R772W has not been biochemically characterized, but is associated with a loss of Msh6 protein expression and increased microsatellite instability in tumor samples (PMID: 14974087).",4613,14974087,Eight novel MSH6 germline mutations in patients with familial and nonfamilial colorectal cancer selected by loss of protein expression in tumor tissue.,http://www.ncbi.nlm.nih.gov/pubmed/14974087,295,,,www.uniprot.org,11532
"MSH6 R959H does not lie within any known functional domains of the Msh6 protein (UniProt.org). R959H has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11533
"MSH6 R961I does not lie within any known functional domains of the Msh6 protein (UniProt.org). R961I has been identified in sequencing studies (PMID: 22895193, PMID: 25233892), but has not been biochemically characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Mar 2017).",7231,25233892,Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes.,http://www.ncbi.nlm.nih.gov/pubmed/25233892,4597,22895193,Recurrent R-spondin fusions in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22895193,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11534
MSH6 R976H lies within the clamp domain of the Msh6 protein (PMID: 18790734). R976H results in decreased Msh6 affinity for ADP and mismatched DNA in cell culture (PMID: 18790734).,3608,18790734,Hereditary cancer-associated missense mutations in hMSH6 uncouple ATP hydrolysis from DNA mismatch binding.,http://www.ncbi.nlm.nih.gov/pubmed/18790734,11535
"MSH6 S1067I does not lie within any known functional domains of the Msh6 protein (UniProt.org). S1067I has been identified in sequencing studies (PMID: 23856246), but has not been biochemically characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,6964,23856246,The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.,http://www.ncbi.nlm.nih.gov/pubmed/23856246,285,,,http://www.ncbi.nlm.nih.gov/pubmed,11536
"MSH6 S1208F lies within the Magnesium-binding region of the Msh6 protein (PMID: 12019211). S1208F has been identified in sequencing studies (PMID: 24628946), but has not been biochemically characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,7882,24628946,Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24628946,11537
"MSH6 S668C does not lie within any known functional domains of the Msh6 protein (UniProt.org). S668C has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11538
"MSH6 S677I does not lie within any known functional domains of the Msh6 protein (UniProt.org). S677I has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11539
"MSH6 T1189I does not lie within any known functional domains of the Msh6 protein (UniProt.org). T1189I has been identified in sequencing studies (PMID: 23856246, PMID: 24755471), but has not been biochemically characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Mar 2017).",6964,23856246,The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.,http://www.ncbi.nlm.nih.gov/pubmed/23856246,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6962,24755471,Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24755471,11540
"MSH6 T1205I does not lie within any known functional domains of the Msh6 protein (UniProt.org). T1205I has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11541
"MSH6 T1238A does not lie within any known functional domains of the Msh6 protein (UniProt.org). T1238A has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11542
"MSH6 T1247S does not lie within any known functional domains of the Msh6 protein (UniProt.org). T1247S has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11543
"MSH6 T750P does not lie within any known functional domains of the Msh6 protein (UniProt.org). T750P has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11544
"MSH6 T757I does not lie within any known functional domains of the Msh6 protein (UniProt.org). T757I has been identified in the scientific literature (PMID: 25078279, PMID: 22622578), but has not been biochemically characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6955,22622578,Melanoma genome sequencing reveals frequent PREX2 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/22622578,8280,25078279,Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.,http://www.ncbi.nlm.nih.gov/pubmed/25078279,11545
"MSH6 V480L lies within the MSH2-binding region of the Msh6 protein (PMID: 12019211). V480L has been identified in the scientific literature (PMID: 12732731), but has not been biochemically characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Mar 2017).",8281,12732731,Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers.,http://www.ncbi.nlm.nih.gov/pubmed/12732731,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,11546
"MSH6 W1047* results in a premature truncation of the Msh6 protein at amino acid 1047 of 1360 (UniProt.org). Due to the loss of MSH2- and ATP-binding regions (PMID: 12019211), W1047* is predicted to lead to a loss of Msh6 protein function.",295,,,www.uniprot.org,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,11547
"MSH6 W912R does not lie within any known functional domains of the Msh6 protein (UniProt.org). W912R has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11548
"MSH6 A1204E does not lie within any known functional domains of the Msh6 protein (UniProt.org). A1204E has been identified in sequencing studies (PMID: 22832583), but has not been biochemically characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Apr 2017).
",7442,22832583,Dissecting the genomic complexity underlying medulloblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22832583,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11549
"EGFR-PPARGC1A results from the fusion of EGFR and PPARGC1A. EGFR-PPARGC1A has not been characterized and therefore, its effect on fusion protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,11612
BRCA2 del indicates a deletion of the BRCA2 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,11620
"ETV6-RUNX1 results from the fusion of ETV6 and RUNX1, which leads to altered transcriptional regulation resulting in preleukemic cells (PMID: 17325341).",3617,17325341,The identification of (ETV6)/RUNX1-regulated genes in lymphopoiesis using histone deacetylase inhibitors in ETV6/RUNX1-positive lymphoid leukemic cells.,http://www.ncbi.nlm.nih.gov/pubmed/17325341,11632
"EGFR L718Q lies within the protein kinase domain of the Egfr protein (UniProt.org). L718Q does not result in transformation of cultured cells, but has been demostrated to confer resistance to third-generation EGFR inhibitors (PMID: 25948633).",3618,25948633,EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/25948633,11633
"EGFR L844V lies within the protein kinase domain of the Egfr protein (UniProt.org). L844V does not result in transformation of cultured cells, but has been demonstrated to confer resistance to third-generation EGFR inhibitors (PMID: 25948633).",295,,,www.uniprot.org,3618,25948633,EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/25948633,11635
"EGFR C797S lies within the ATP-binding pocket in the protein kinase domain of the Egfr protein (PMID: 25964297). C797S has not been biochemically characterized, but has been demonstrated to confer resistance to third-generation EGFR inhibitors (PMID: 25964297, PMID: 25948633).",3620,25964297,The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.,http://www.ncbi.nlm.nih.gov/pubmed/25964297,3618,25948633,EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/25948633,11636
"EGFR Q791R lies with the protein kinase domain of the Egfr protein (UniProt.org). Q791R has not been biochemically characterized, but is associated with resistance to some third generation EGFR inhibitors (PMID: 25948633).",3618,25948633,EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/25948633,11670
"PIK3CA K567R lies within the PIK helical domain of the Pik3ca protein (UniProt.org). K567R has been identified in the scientific literature (PMID: 17314276), but has not been biochemically characterized and therefore, its effect on PIK3CA protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3636,17314276,Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/17314276,11698
"PTEN A72fs*5 likely results in a premature truncation of the 403 aa Pten protein at amino acid 72, followed by 5 nonsense amino acids (UniProt.org). A72fs*5 confers a loss of function to the Pten protein as demonstrated by loss of all known functional domains (UniProt.org) and lack of Pten protein expression in culture (PMID: 21358673).",295,,,www.uniprot.org,3638,21358673,"PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.",http://www.ncbi.nlm.nih.gov/pubmed/21358673,11699
"PIK3CA D549N lies within the PIK helical domain of the Pik3ca protein (UniProt.org). D549N has been identified in the scientific literature (PMID: 26276776, PMID: 24755471, PMID: 16376301), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8061,16376301,Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/16376301,6962,24755471,Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24755471,8060,26276776,Distinct β-catenin and PIK3CA mutation profiles in endometriosis-associated ovarian endometrioid and clear cell carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/26276776,11700
"TP53 R158G lies within the DNA-binding domain of the Tp53 protein (PMID: 21760703). R158G leads to the loss of Tp53 DNA binding activity in an in vitro assay, and interferes with transactivation by wild-type Tp73 in yeast (PMID: 9472631, PMID: 12917626).",4323,9472631,Effects of p53 mutants derived from lung carcinomas on the p53-responsive element (p53RE) of the MDM2 gene.,http://www.ncbi.nlm.nih.gov/pubmed/9472631,807,21760703,TP53 status and response to treatment in breast cancers.,http://www.ncbi.nlm.nih.gov/pubmed/21760703,4423,12917626,Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay.,http://www.ncbi.nlm.nih.gov/pubmed/12917626,11704
CTNNB1 mutant indicates an unspecified mutation in the CTNNB1  gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,11705
"STK11 S19P does not lie within any known functional domains of the Stk11 protein (UniProt.org). S19P has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Dec 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11804
"STK11 L195M lies within the protein kinase domain of the Stk11 protein (UniProt.org). L195M has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Dec 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11805
"STK11 P314H does not lie within any known functional domains of the Stk11 protein (UniProt.org). P314H has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Dec 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11806
"STK11 P179R lies within the protein kinase domain of the Stk11 protein (UniProt.org). P179R has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Dec 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,11807
"STK11 H174Y lies within the protein kinase domain of the Stk11 protein (UniProt.org). H174Y has been identified in sequencing studies (PMID: 24292813), but has not been biochemically characterized and therefore, its effect on Stk11 protein function is unknown (PubMed, Apr 2017).",295,,,www.uniprot.org,8639,24292813,Characterizing the heterogeneity of triple-negative breast cancers using microdissected normal ductal epithelium and RNA-sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/24292813,285,,,http://www.ncbi.nlm.nih.gov/pubmed,11808
"STK11 L183V lies within the protein kinase domain of the Stk11 protein (UniProt.org). L183V has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11809
"STK11 D355N does not lie within the any known functional domains of the Stk11 protein (UniProt.org). D355N has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11810
"STK11 S193F lies within the protein kinase domain of the Stk11 protein (UniProt.org). S193F has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Dec 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11811
"STK11 E199* results in a premature truncation of the Stk11 protein at amino acid 199 of 433 within the protein kinase domain (UniProt.org). Due to the loss of the majority of the protein kinase domain (UniProt.org), E199* is predicted to lead to a loss of Stk11 protein function.",295,,,www.uniprot.org,11817
"STK11 Q137H* results in a premature truncation of the Stk11 protein at amino acid 137 of 433 within the protein kinase domain (UniProt.org). Due to the loss of a majority of the protein kinase domain, Q137* is predicted to lead to a loss of Stk11 protein function.",295,,,www.uniprot.org,11825
STK11 D194Y lies within the protein kinase domain of the Stk11 protein (UniProt.org). D194Y confers a dominant negative loss of function to the Stk11 protein as demonstrated by the ability to suppress Ampk signaling (http://cancerres.aacrjournals.org/content/74/19_Supplement/4159.abstract).,295,,,www.uniprot.org,3649,,Characterization of three recurring STK11/LKB1 mutants in lung adenocarcinoma,http://cancerres.aacrjournals.org/content/74/19_Supplement/4159.abstract,11835
STK11 P281fs*6 likely results in a premature truncation of the Stk11 protein at amino acid 281 of 433 (UniProt.org). STK11 P281fs*6 confers a loss of function to the Stk11 protein as demonstrated by lack of kinase activity (http://cancerres.aacrjournals.org/content/74/19_Supplement/4159.abstract).,295,,,www.uniprot.org,3649,,Characterization of three recurring STK11/LKB1 mutants in lung adenocarcinoma,http://cancerres.aacrjournals.org/content/74/19_Supplement/4159.abstract,11851
"STK11 V236A lies within the protein kinase domain of the Stk11 protein (UniProt.org). V236A has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Dec 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11853
"STK11 D194N lies within the protein kinase domain of the Stk11 protein (UniProt.org). D194N has not been characterized, but is predicted to result in a change of Stk11 binding energy based on computer modeling, thus, possibly resulting in a loss of enzyme function (PMID: 27081308).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8636,27081308,Unraveling the Deleterious Effects of Cancer-Driven STK11 Mutants Through Conformational Sampling Approach.,http://www.ncbi.nlm.nih.gov/pubmed/27081308,11860
"STK11 Q123* results in a premature truncation of the Stk11 protein at amino acid 123 of 433 within the protein kinase domain (UniProt.org). Due to the loss of a majority of the protein kinase domain, Q123* is predicted to lead to a loss of Stk11 protein function.",295,,,www.uniprot.org,11864
"STK11 E70* results in a premature truncation of the Stk11 protein at amino acid 70 of 433 within the protein kinase domain (UniProt.org). Due to the loss of a majority of the protein kinase domain, E70* is predicted to lead to a loss of Stk11 protein function.",295,,,www.uniprot.org,11869
"STK11 Q220* results in a premature truncation of the Stk11 protein at amino acid 220 of 433 within the protein kinase domain (UniProt.org). Q220* has been identified in sequencing studies (PMID: 26087898), but has not been biochemically characterized and therefore, its effect on Stk11 protein function is unknown (PubMed, Dec 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7449,26087898,Exome-level comparison of primary well-differentiated neuroendocrine tumors and their cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/26087898,11874
"STK11 A389T does not lie within any known functional domains of the Stk11 protein (UniProt.org). A389T has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11964
STK11 D176N lies within the protein kinase domain of the Stk11 protein (UniProt.org). D176N confers a loss of function to the Stk11 protein as demonstrated by loss of kinase activity (PMID: 9837816).,457,9837816,"Loss of LKB1 kinase activity in Peutz-Jeghers syndrome, and evidence for allelic and locus heterogeneity.",http://www.ncbi.nlm.nih.gov/pubmed/9837816,295,,,www.uniprot.org,11965
"STK11 D176H lies within the protein kinase domain of the Stk11 protein (UniProt.org). D176H has not been characterized and therefore, its effect on Stk11 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11966
"STK11 D176A lies within the protein kinase domain of the Stk11 protein (UniProt.org). D176A has not been characterized and therefore, its effect on Stk11 protein function is unknown (PubMed, Apr 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,11967
"STK11 D194H lies within the protein kinase domain of the Stk11 protein (UniProt.org). D194H has been identified in the scientific literature (PMID: 21816872), but has not been biochemically characterized and therefore, its effect on Stk11 protein function is unknown (PubMed, Apr 2017).",8635,21816872,LKB1 mutations frequently detected in mucinous bronchioloalveolar carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/21816872,295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,11968
"STK11 D237Y lies within the protein kinase domain of the Stk11 protein (UniProt.org). D237Y has not been characterized and therefore, its effect on Stk11 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11969
"STK11 D350E does not lie within any known functional domains of the Stk11 protein (UniProt.org). D350E has not been characterized and therefore, its effect on Stk11 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11970
"STK11 E120* results in a premature truncation of the Stk11 protein at amino acid 120 of 433 within the protein kinase domain (UniProt.org). Due to the loss of a majority of the protein kinase domain, E120* is predicted to lead to a loss of Stk11 protein function.",295,,,www.uniprot.org,11971
"STK11 D53Tfs*11 is a missense mutation (D53T) in conjunction with a likely truncation of the 433 aa Stk11 protein at aa 53, followed by 11 nonsense amino acids (UniProt.org). Due to the loss of a majority of the protein kinase domain, D53Tfs*11 is predicted to lead to a loss of Stk11 protein function.",295,,,www.uniprot.org,11972
"STK11 G196V lies within the protein kinase domain of the Stk11 protein (UniProt.org). G196V has not been characterized and therefore, its effect on Stk11 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11973
"STK11 G242V lies within the protein kinase domain of the Stk11 protein (UniProt.org). G242V has been identified in the scientific literature (PMID: 11389158), but has not been biochemically characterized and therefore, its effect on Stk11 protein function is unknown (PubMed, Apr 2017).",8637,11389158,Peutz-Jeghers families unlinked to STK11/LKB1 gene mutations are highly predisposed to primitive biliary adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/11389158,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11976
"STK11 G242W lies within the protein kinase domain of the Stk11 protein (UniProt.org). G242W has been identified in the scientific literature (PMID: 11389158), but has not been biochemically characterized and therefore, its effect on Stk11 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8637,11389158,Peutz-Jeghers families unlinked to STK11/LKB1 gene mutations are highly predisposed to primitive biliary adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/11389158,11977
"STK11 G251F lies within the protein kinase domain of the Stk11 protein (UniProt.org). G251F has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11978
"STK11 G251V lies within the protein kinase domain of the Stk11 protein (UniProt.org). G251V has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11979
"STK11 G56V lies within the protein kinase domain of the Stk11 protein (UniProt.org). G56V has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11980
"STK11 G56W lies within the protein kinase domain of the Stk11 protein (UniProt.org). G56W has been identified in sequencing studies (PMID: 25234657), but has not been biochemically characterized and therefore, its effect on Stk11 protein function is unknown (PubMed, Apr 2017).",8638,25234657,Tongue carcinoma infrequently harbor common actionable genetic alterations.,http://www.ncbi.nlm.nih.gov/pubmed/25234657,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11981
"STK11 H168R lies within the protein kinase domain of the Stk11 protein (UniProt.org). H168R has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11982
"STK11 G61Afs*3 is a missense mutation (G61A) in conjunction with a likely truncation of the 433 aa Stk11 protein at aa 61, followed by 3 nonsense amino acids (UniProt.org). Due to the loss of a majority of the protein kinase domain, G61Afs*3 is predicted to lead to a loss of Stk11 protein function.",295,,,www.uniprot.org,11983
"STK11 I177T lies within the protein kinase domain of the Stk11 protein (UniProt.org). I177T has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Apr 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,11984
"STK11 I303N lies within the protein kinase domain of the Stk11 protein (UniProt.org). I303N has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11985
"STK11 I303S lies within the protein kinase domain of the Stk11 protein (UniProt.org). I303S has not been characterized and therefore, its effect on Stk11 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11986
"STK11 K78E lies within the protein kinase domain of the Stk11 protein (UniProt.org). K78E has not been characterized and therefore, its effect on Stk11 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11987
"STK11 L282Afs*3 is a missense mutation (L282A) in conjunction with a likely truncation of the 433 aa Stk11 protein at aa 282, followed by 3 nonsense amino acids (UniProt.org). L282Afs*3 has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown.",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11988
STK11 L285Q lies within the protein kinase domain of the Stk11 protein (UniProt.org). L285Q confers a loss  of function to the Stk11 protein as demonstrated by its inability to activate the downstream kinase Ampk (PMID: 19892943).,295,,,www.uniprot.org,3662,19892943,Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation.,http://www.ncbi.nlm.nih.gov/pubmed/19892943,11989
"STK11 N181I lies within the protein kinase domain of the Stk11 protein (UniProt.org). N181I has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Dec 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11990
"STK11 N181Y lies within the protein kinase domain of the Stk11 protein (UniProt.org). N181Y has been identified in sequencing studies (PMID: 15121768), but has not been biochemically characterized and therefore, its effect on Stk11 protein function is unknown (PubMed, Dec 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7448,15121768,Genotype-phenotype correlations in Peutz-Jeghers syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/15121768,11991
"STK11 P179Q lies within the protein kinase domain of the Stk11 protein (UniProt.org). P179Q has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Dec 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11992
"STK11 P179S lies within the protein kinase domain of the Stk11 protein (UniProt.org). P179S has been identified in sequencing studies (PMID: 22722839), but has not been biochemically characterized and therefore, its effect on Stk11 protein function is unknown (PubMed, Dec 2016).
",1810,22722839,The mutational landscape of lethal castration-resistant prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22722839,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11993
"STK11 P221L lies within the protein kinase domain of the Stk11 protein (UniProt.org). P221L has been identified in sequencing studies (PMID: 22980975), but has not been biochemically characterized and therefore, its effect on Stk11 protein function is unknown (PubMed, Dec 2016).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1726,22980975,Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/22980975,11994
"STK11 P369S does not lie within any known functional domains of the Stk11 protein (UniProt.org). P369S has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Dec 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,11995
"STK11 Q159* results in a premature truncation of the Stk11 protein at amino acid 159 of 433 within the protein kinase domain (UniProt.org). Due to the loss of a majority of the protein kinase domain including the active site (UniProt.org), Q159* is predicted to lead to a loss of Stk11 protein function.",295,,,www.uniprot.org,11996
"STK11 Q170* results in a premature truncation of the Stk11 protein at amino acid 170 of 433 within the protein kinase domain (UniProt.org). Due to the loss of a majority of the protein kinase domain including the active site (UniProt.org), Q170* is predicted to lead to a loss of Stk11 protein function. ",295,,,www.uniprot.org,11997
"STK11 Q37* results in a premature truncation of the Stk11 protein at amino acid 37 of 433 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), Q37* is predicted to lead to a loss of Stk11 protein function.",295,,,www.uniprot.org,11998
"STK11 R304G lies within the protein kinase domain of the Stk11 protein (UniProt.org). R304G has been identified in sequencing studies (PMID: 21532627), but has not been biochemically characterized and therefore, its effect on Stk11 protein function is unknown (PubMed, Dec 2016).
",295,,,www.uniprot.org,7450,21532627,Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21532627,285,,,http://www.ncbi.nlm.nih.gov/pubmed,11999
STK11 S216F lies within the protein kinase domain of the Stk11 protein (UniProt.org). S216F confers a loss of function to the Stk11 protein as demonstrated by its inability to activate the downstream kinase Ampk (PMID: 19892943).,295,,,www.uniprot.org,3662,19892943,Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation.,http://www.ncbi.nlm.nih.gov/pubmed/19892943,12000
STK11 F157S lies within the protein kinase domain of the Stk11 protein (UniProt.org). F157S confers a loss of function to the Stk11 protein as demonstrated by its inability to activate the downstream kinase Ampk (PMID: 19892943).,295,,,www.uniprot.org,3662,19892943,Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation.,http://www.ncbi.nlm.nih.gov/pubmed/19892943,12001
"STK11 W239C lies within the protein kinase domain of the Stk11 protein. W239C has been identified in sequencing studies (PMID: 	22980975), but has not been biochemically characterized and therefore, its effect on Stk11 protein function is unknown (PubMed, Dec 2016).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1726,22980975,Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/22980975,12002
"STK11 Y60* results in a premature truncation of the Stk11 protein at amino acid 60 of 433 within the protein kinase domain (UniProt.org). Due to the loss of a majority of the protein kinase domain including the active site (UniProt.org), Y60* is predicted to lead to a loss of Stk11 protein function.",295,,,www.uniprot.org,12003
STK11 V66M lies within the protein kinase domain of the Stk11 protein (UniProt.org). V66M demonstrates complex formation and kinase activity similar to wild-type Stk11 in cell culture (PMID: 19892943). ,295,,,www.uniprot.org,3662,19892943,Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation.,http://www.ncbi.nlm.nih.gov/pubmed/19892943,12004
STK11 R86G lies within the protein kinase domain of the Stk11 protein (UniProt.org). R86G demonstrates complex formation and kinase activity similar to wild-type Stk11 in cell culture (PMID: 19892943). ,295,,,www.uniprot.org,3662,19892943,Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation.,http://www.ncbi.nlm.nih.gov/pubmed/19892943,12005
STK11 Q123R lies within the protein kinase domain of the Stk11 protein (UniProt.org). Q123R demonstrates complex formation and kinase activity similar to wild-type Stk11 in cell culture (PMID: 19892943).,295,,,www.uniprot.org,3662,19892943,Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation.,http://www.ncbi.nlm.nih.gov/pubmed/19892943,12006
STK11 G163D lies within the protein kinase domain of the Stk11 protein (UniProt.org). G163D confers a loss of function to the Stk11 protein as demonstrated by its inability to activate the downstream kinase Ampk (PMID: 19892943).,295,,,www.uniprot.org,3662,19892943,Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation.,http://www.ncbi.nlm.nih.gov/pubmed/19892943,12007
STK11 Q170P lies within the protein kinase domain of the Stk11 protein (UniProt.org). Q170P confers a loss of function to the Stk11 protein as demonstrated by its inability to activate the downstream kinase Ampk (PMID: 19892943).,295,,,www.uniprot.org,3662,19892943,Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation.,http://www.ncbi.nlm.nih.gov/pubmed/19892943,12008
STK11 G171S lies within the protein kinase domain of the Stk11 protein (UniProt.org). G171S confers a loss of function to the Stk11 protein as demonstrated by reduced activation of the downstream kinase Ampk (PMID: 19892943).,295,,,www.uniprot.org,3662,19892943,Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation.,http://www.ncbi.nlm.nih.gov/pubmed/19892943,12009
STK11 H174R lies within the protein kinase domain of the Stk11 protein (UniProt.org). H174R confers a loss of function to the Stk11 protein as demonstrated by its inability to activate the downstream kinase Ampk (PMID: 19892943).,295,,,www.uniprot.org,3662,19892943,Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation.,http://www.ncbi.nlm.nih.gov/pubmed/19892943,12010
STK11 D176Y lies within the protein kinase domain of the Stk11 protein (UniProt.org). D176Y confers a loss of function to the Stk11 protein as demonstrated by its inability to activate the downstream kinase Ampk (PMID: 19892943).,295,,,www.uniprot.org,3662,19892943,Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation.,http://www.ncbi.nlm.nih.gov/pubmed/19892943,12011
STK11 I177N lies within the protein kinase domain of the Stk11 protein (UniProt.org). I177N confers a loss of function to the Stk11 protein as demonstrated by its inability to activate the downstream kinase Ampk (PMID: 19892943).,3662,19892943,Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation.,http://www.ncbi.nlm.nih.gov/pubmed/19892943,295,,,www.uniprot.org,12012
STK11 N181E lies within the protein kinase domain of the Stk11 protein (UniProt.org). N181E confers a loss of function to the Stk11 protein as demonstrated by its inability to activate the downstream kinase Ampk (PMID: 19892943).,3662,19892943,Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation.,http://www.ncbi.nlm.nih.gov/pubmed/19892943,295,,,www.uniprot.org,12013
STK11 E199K lies within the protein kinase domain of the Stk11 protein (UniProt.org). E199K confers a loss of function to the Stk11 protein as demonstrated by reduced activation of the downstream kinase Ampk (PMID: 19892943).,3662,19892943,Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation.,http://www.ncbi.nlm.nih.gov/pubmed/19892943,295,,,www.uniprot.org,12014
STK11 E199Q lies within the protein kinase domain of the Stk11 protein (UniProt.org). E199Q demonstrates kinase activity similar to wild-type Stk11 in cell culture (PMID: 19892943).,295,,,www.uniprot.org,3662,19892943,Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation.,http://www.ncbi.nlm.nih.gov/pubmed/19892943,12015
STK11 A205T lies within the protein kinase domain of the Stk11 protein (UniProt.org). A205T results in decreased Stk11 kinase activity and loss of growth inhibition in cell culture (PMID: 16407837.,295,,,www.uniprot.org,4832,16407837,A novel mutation of STK11/LKB1 gene leads to the loss of cell growth inhibition in head and neck squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/16407837,12016
STK11 E223V lies within the protein kinase domain of the Stk11 protein (UniProt.org). E223V confers a loss of function to the Stk11 protein as demonstrated by its inability to activate the downstream kinase Ampk (PMID: 19892943).,295,,,www.uniprot.org,3662,19892943,Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation.,http://www.ncbi.nlm.nih.gov/pubmed/19892943,12017
STK11 T230P lies within the protein kinase domain of the Stk11 protein (UniProt.org). T230P demonstrates complex formation and kinase activity similar to wild-type Stk11 in cell culture (PMID: 19892943).,295,,,www.uniprot.org,3662,19892943,Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation.,http://www.ncbi.nlm.nih.gov/pubmed/19892943,12018
STK11 S232P lies within the protein kinase domain of the Stk11 protein (UniProt.org). S232P demonstrates complex formation and kinase activity similar to wild-type Stk11 in cell culture (PMID: 19892943). ,295,,,www.uniprot.org,3662,19892943,Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation.,http://www.ncbi.nlm.nih.gov/pubmed/19892943,12019
STK11 L245R lies within the protein kinase domain of the Stk11 protein (UniProt.org). L245R confers a loss of function to the Stk11 protein as demonstrated by its inability to activate the downstream kinase Ampk (PMID: 19892943).,295,,,www.uniprot.org,3662,19892943,Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation.,http://www.ncbi.nlm.nih.gov/pubmed/19892943,12020
STK11 T250P lies within the protein kinase domain of the Stk11 protein (UniProt.org). T250P confers a loss of function to the Stk11 protein as demonstrated by its inability to activate the downstream kinase Ampk (PMID: 19892943).,295,,,www.uniprot.org,3662,19892943,Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation.,http://www.ncbi.nlm.nih.gov/pubmed/19892943,12021
STK11 Y272H lies within the protein kinase domain of the Stk11 protein (UniProt.org). Y272H confers a loss of function to the Stk11 protein as demonstrated by reduced activation of the downstream kinase Ampk (PMID: 19892943).,295,,,www.uniprot.org,3662,19892943,Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation.,http://www.ncbi.nlm.nih.gov/pubmed/19892943,12022
STK11 D277Y lies within the protein kinase domain of the Stk11 protein (UniProt.org). D277Y confers a loss of function to the Stk11 protein as demonstrated by reduced activation of the downstream kinase Ampk (PMID: 19892943).,295,,,www.uniprot.org,3662,19892943,Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation.,http://www.ncbi.nlm.nih.gov/pubmed/19892943,12023
EZH2 H689A lies within the SET domain of Ezh2 (UniProt.org). H689A is a catalytic-activity dead mutant form of Ezh2 (PMID: 23684459).,295,,,www.uniprot.org,3664,23684459,Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells.,http://www.ncbi.nlm.nih.gov/pubmed/23684459,12048
"EZH2 Y726* results in a premature truncation of the Ezh2 protein at amino acid 726 of 746 (UniProt.org). Y726* has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12140
"EZH2 Y728* results in a premature truncation of the Ezh2 protein at amino acid 728 of 746 (UniProt.org). Y728* has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12141
"EZH2 Y728Lfs*6 is a missense mutation (Y728L) in conjunction with a likely truncation of the Ezh2 isoform 2 protein at aa 728 of 746, followed by 6 nonsense amino acids (UniProt.org). Y728Lfs*6 has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12142
"EZH2 Y736C does not lie within any known functional domains of the Ezh2 protein (UniProt.org). Y736C has not been characterized in the scientific literature and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,12143
"SMAD4 A327V lies within the MH2 domain of the Smad4 protein (UniProt.org). A327V has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12151
SMAD4 A406T lies within the MH2 domain of the Smad4 protein (UniProt.org). A406T is analogous to A354T in SMAD2 and is predicted to impair Smad4 oligomerization and transcriptional activity of the Smad complex (PMID: 23139211).,295,,,www.uniprot.org,954,23139211,"SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer.",http://www.ncbi.nlm.nih.gov/pubmed/23139211,12152
"SMAD4 A457S lies within the MH2 domain of the Smad4 protein (UniProt.org). A457S has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,12175
"SMAD4 A60P lies within the MH1 domain of the Smad4 protein (UniProt.org). A60P has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,12176
"SMAD4 C324R lies within the MH2 domain of the Smad4 protein (UniProt.org). C324R has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12177
"SMAD4 C363Y lies within the MH2 domain of the Smad4 protein (UniProt.org). C363Y has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12179
"SMAD4 C499Y lies within the MH2 domain of the Smad4 protein (UniProt.org). C499Y has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12180
"SMAD4 D351A lies at a hotspot residue within the MH2 domain of the Smad4 protein (UniProt.org, PMID: 23139211). D351A has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,954,23139211,"SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer.",http://www.ncbi.nlm.nih.gov/pubmed/23139211,295,,,www.uniprot.org,12181
"SMAD4 D351G lies at a hotspot residue within the MH2 domain of the Smad4 protein (UniProt.org, PMID: 23139211). D351G has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,954,23139211,"SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer.",http://www.ncbi.nlm.nih.gov/pubmed/23139211,12182
"SMAD4 D351Y lies at a hotspot residue within the MH2 domain of the Smad4 protein (UniProt.org, PMID: 23139211). D351Y has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,954,23139211,"SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer.",http://www.ncbi.nlm.nih.gov/pubmed/23139211,295,,,www.uniprot.org,12183
"SMAD4 D355G lies within the MH2 domain of the Smad4 protein (UniProt.org). D355G has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12184
"SMAD4 D355N lies within the MH2 domain of the Smad4 protein (UniProt.org). D355N has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12185
"SMAD4 D355V lies within the MH2 domain of the Smad4 protein (UniProt.org). D355V has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12186
SMAD4 D493A lies within the MH2 domain of the Smad4 protein (UniProt.org). D493A results in decreased binding of Smad4 to receptor-activated Smads in cell culture (PMID: 15350224).,3670,15350224,Structural basis of heteromeric smad protein assembly in TGF-beta signaling.,http://www.ncbi.nlm.nih.gov/pubmed/15350224,295,,,www.uniprot.org,12187
"SMAD4 D493N lies within the MH2 domain of the Smad4 protein (UniProt.org). D493N has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12188
"SMAD4 D537E lies within the MH2 domain of the Smad4 protein (UniProt.org). D537E results in disruption of Smad4 homo- and hetero-oligomerization and failure to translocate to the nucleus upon TGF-beta stimulation in cell culture (PMID: 9214508, PMID: 11265759).",3672,11265759,Regulation of intracellular dynamics of Smad4 by its leucine-rich nuclear export signal.,http://www.ncbi.nlm.nih.gov/pubmed/11265759,3671,9214508,A structural basis for mutational inactivation of the tumour suppressor Smad4.,http://www.ncbi.nlm.nih.gov/pubmed/9214508,295,,,www.uniprot.org,12189
SMAD4 D537H lies within the MH2 domain of the Smad4 protein (UniProt.org). D537H has no effect on heterodimerization of purified Smad4 and Smad2 proteins (PMID: 11274206).,3673,11274206,Formation of a stable heterodimer between Smad2 and Smad4.,http://www.ncbi.nlm.nih.gov/pubmed/11274206,295,,,www.uniprot.org,12190
"SMAD4 D537V lies within the MH2 domain of the Smad4 protein (UniProt.org). D537V has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,12191
"SMAD4 D537Y lies within the MH2 domain of the Smad4 protein (UniProt.org). D537Y results in a loss of Smad4 protein function as indicated by failure to form a functional transcriptional complex with activated Smad2 and Smad3, and absence of nuclear translocation after TGF-beta stimulation in cell culture (PMID: 14715079).",295,,,www.uniprot.org,3674,14715079,Molecular and functional consequences of Smad4 C-terminal missense mutations in colorectal tumour cells.,http://www.ncbi.nlm.nih.gov/pubmed/14715079,12192
"SMAD4 E108* results in a premature truncation of the Smad4 protein at amino acid 108 of 552 (UniProt.org). E108* has not been characterized however, due to the effects of other truncation mutations downstream of E108, E108* is predicted to lead to a loss of Smad4 protein function (PMID: 11553622, PMID: 22316667).",3668,11553622,Loss of Smad4 function in pancreatic tumors: C-terminal truncation leads to decreased stability.,http://www.ncbi.nlm.nih.gov/pubmed/11553622,295,,,www.uniprot.org,3669,22316667,Germline mutations in SMAD4 disrupt bone morphogenetic protein signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22316667,12193
"SMAD4 E134K lies within the MH1 domain of the Smad4 protein (UniProt.org). E134K has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12194
"SMAD4 E161K does not lie within any known functional domains of the Smad4 protein (UniProt.org). E161K has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12195
"SMAD4 E330G lies within the MH2 domain of the Smad4 protein (UniProt.org). E330G results in a slight reduction in BMP signaling in cell culture, but is not significantly different from wild-type Smad4 (PMID: 22316667).",295,,,www.uniprot.org,3669,22316667,Germline mutations in SMAD4 disrupt bone morphogenetic protein signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22316667,12196
"SMAD4 E330K lies within the MH2 domain of the Smad4 protein (UniProt.org). E330K has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12197
"SMAD4 E337K lies within the MH2 domain of the Smad4 protein (UniProt.org). E337K has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12198
"SMAD4 E417* results in a premature truncation of the Smad4 protein at amino acid 417 of 552 (UniProt.org). E417* has not been characterized however, due to the effects of other truncation mutations downstream of E417, E417* is predicted to lead to a loss of Smad4 protein function (PMID: 11553622, PMID: 22316667).",295,,,www.uniprot.org,3668,11553622,Loss of Smad4 function in pancreatic tumors: C-terminal truncation leads to decreased stability.,http://www.ncbi.nlm.nih.gov/pubmed/11553622,3669,22316667,Germline mutations in SMAD4 disrupt bone morphogenetic protein signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22316667,12199
"SMAD4 E417Sfs*11 is a missense mutation (E417S) in conjunction with a likely truncation of the 552 aa Smad4 protein at aa 417, followed by 11 nonsense amino acids (UniProt.org). E417Sfs*11 has not been characterized however, due to the effects of other truncation mutations downstream of E417, E417Sfs*11 is predicted to lead to a loss of Smad4 protein function (PMID: 11553622, PMID: 22316667).",3668,11553622,Loss of Smad4 function in pancreatic tumors: C-terminal truncation leads to decreased stability.,http://www.ncbi.nlm.nih.gov/pubmed/11553622,295,,,www.uniprot.org,3669,22316667,Germline mutations in SMAD4 disrupt bone morphogenetic protein signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22316667,12200
"SMAD4 E526* results in a premature truncation of the Smad4 protein at amino acid 526 of 552 (UniProt.org). E526* has not been characterized however, due to the effects of other truncation mutants downstream of E526, E526* is predicted to lead to a loss of Smad4 protein function (PMID: 22316667).",3669,22316667,Germline mutations in SMAD4 disrupt bone morphogenetic protein signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22316667,295,,,www.uniprot.org,12201
"SMAD4 E526A lies within the MH2 domain of the Smad4 protein (UniProt.org). E526A has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12202
"SMAD4 E526V lies within the MH2 domain of the Smad4 protein (UniProt.org). E526V has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12203
"SMAD4 E538* results in a premature truncation of the Smad4 protein at amino acid 538 of 552 (UniProt.org). E538* has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12204
"SMAD4 E538K lies within the MH2 domain of the Smad4 protein (UniProt.org). E538K has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12205
"SMAD4 F505Y lies within the MH2 domain of the Smad4 protein (UniProt.org). F505Y has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12206
"SMAD4 G231Afs*10 is a missense mutation (G231A) in conjunction with a likely truncation of the 552 aa Smad4 protein at aa 417, followed by 10 nonsense amino acids (UniProt.org). G231Afs*10 has not been characterized however, due to the effects of other truncation mutations downstream of G231, G231Afs*10  is predicted to lead to a loss of Smad4 protein function (PMID: 11553622, PMID: 22316667).",295,,,www.uniprot.org,3668,11553622,Loss of Smad4 function in pancreatic tumors: C-terminal truncation leads to decreased stability.,http://www.ncbi.nlm.nih.gov/pubmed/11553622,3669,22316667,Germline mutations in SMAD4 disrupt bone morphogenetic protein signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22316667,12207
"SMAD4 G299R does not lie within any known functional domains of the Smad4 protein (UniProt.org). G299R has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,12208
"SMAD4 G352A lies within the MH2 domain of the Smad4 protein (UniProt.org). G352A has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12209
"SMAD4 G386C lies within the MH2 domain of the Smad4 protein (UniProt.org). G386C has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12210
"SMAD4 G386S lies within the MH2 domain of the Smad4 protein (UniProt.org). G386S has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12211
"SMAD4 G386V lies within the MH2 domain of the Smad4 protein (UniProt.org). G386V has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12212
SMAD4 G419V lies within the MH2 domain of the Smad4 protein (UniProt.org). G419V decreases transcriptional activity of Smad4 as demonstrated in a reporter assay (PMID: 26488212).,4263,26488212,Clinicopathological and genetic differences between low-grade and high-grade colorectal mucinous adenocarcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/26488212,295,,,www.uniprot.org,12213
"SMAD4 G510Dfs*27 is a missense mutation (G510D) in conjunction with a likely truncation of the 552 aa Smad4 protein at aa 510, followed by 27 nonsense amino acids (UniProt.org). G510Dfs*27 has not been characterized however, due to the effects of other truncation mutations downstream of G510, G510Dfs*27 is predicted to lead to a loss of Smad4 protein function (PMID: 11553622, PMID: 22316667).",295,,,www.uniprot.org,3668,11553622,Loss of Smad4 function in pancreatic tumors: C-terminal truncation leads to decreased stability.,http://www.ncbi.nlm.nih.gov/pubmed/11553622,3669,22316667,Germline mutations in SMAD4 disrupt bone morphogenetic protein signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22316667,12214
"SMAD4 G510R lies within the MH2 domain of the Smad4 protein (UniProt.org). G510R has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12215
"SMAD4 G65E lies within the MH1 domain of the Smad4 protein (UniProt.org). G65E has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12216
"SMAD4 H132Tfs*15 is a missense mutation (H132T) in conjunction with a likely truncation of the 552 aa Smad4 protein at aa 132, followed by 15 nonsense amino acids (UniProt.org). H132Tfs*15 has not been characterized however, due to the effects of other truncation mutations downstream of H132, H132Tfs*15 is predicted to lead to a loss of Smad4 protein function (PMID: 11553622, PMID: 22316667).",3669,22316667,Germline mutations in SMAD4 disrupt bone morphogenetic protein signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22316667,3668,11553622,Loss of Smad4 function in pancreatic tumors: C-terminal truncation leads to decreased stability.,http://www.ncbi.nlm.nih.gov/pubmed/11553622,295,,,www.uniprot.org,12217
SMAD4 H132Y lies within the MH1 domain of the Smad4 protein (UniProt.org). H132Y results in a loss of Smad4 function as indicated by failure to phosphorylate receptor-activated Smads after TGF-beta stimulation in cell culture (PMID: 25275298).,1586,25275298,The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies.,http://www.ncbi.nlm.nih.gov/pubmed/25275298,295,,,www.uniprot.org,12218
"SMAD4 H382D lies within the MH2 domain of the Smad4 protein (UniProt.org). H382D has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12219
"SMAD4 H382L lies within the MH2 domain of the Smad4 protein (UniProt.org). H382L has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12220
"SMAD4 H541Y lies within the MH2 domain of the Smad4 protein (UniProt.org). H541Y has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12221
"SMAD4 H92Y lies within the MH1 domain of the Smad4 protein (UniProt.org). H92Y has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12222
"SMAD4 I383R lies within the MH2 domain of the Smad4 protein (UniProt.org). I383R has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,12223
"SMAD4 K110Nfs*12 is a missense mutation (K110N) in conjunction with a likely truncation of the 552 aa Smad4 protein at aa 110, followed by 12 nonsense amino acids (UniProt.org). K110Nfs*12  has not been characterized however, due to the effects of other truncation mutations downstream of K110, K110Nfs*12 is predicted to lead to a loss of Smad4 protein function (PMID: 11553622, PMID: 22316667).",3668,11553622,Loss of Smad4 function in pancreatic tumors: C-terminal truncation leads to decreased stability.,http://www.ncbi.nlm.nih.gov/pubmed/11553622,295,,,www.uniprot.org,3669,22316667,Germline mutations in SMAD4 disrupt bone morphogenetic protein signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22316667,12224
"SMAD4 K340N lies within the MH2 domain of the Smad4 protein (UniProt.org). K340N has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12225
"SMAD4 K428T lies within the MH2 domain of the Smad4 protein (UniProt.org). K428T has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12226
"SMAD4 K519N lies within the MH2 domain of the Smad4 protein (UniProt.org). K519N has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12227
"SMAD4 K70T lies within the MH1 domain of the Smad4 protein (UniProt.org). K70T has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12228
"SMAD4 L109Q lies within the MH1 domain of the Smad4 protein (UniProt.org). L109Q has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12229
"SMAD4 L109R lies within the MH1 domain of the Smad4 protein (UniProt.org). L109R has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12230
"SMAD4 L367P lies within the MH2 domain of the Smad4 protein (UniProt.org). L367P has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12231
"SMAD4 L495P lies within the MH2 domain of the Smad4 protein (UniProt.org). L495P has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12232
"SMAD4 L533R lies within the MH2 domain of the Smad4 protein (UniProt.org). L533R has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12233
"SMAD4 L536P lies within the MH2 domain of the Smad4 protein (UniProt.org). L536P has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12234
"SMAD4 L536Q lies within the MH2 domain of the Smad4 protein (UniProt.org). L536Q has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12235
"SMAD4 L540H lies within the MH2 domain of the Smad4 protein (UniProt.org). L540H has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12236
SMAD4 L540R lies within the MH2 domain of the Smad4 protein (UniProt.org). L540R is predicted to confer a loss of function on Smad4 through impaired oligomerization (PMID: 11481457).,4264,11481457,"SMAD4 mutations in colorectal cancer probably occur before chromosomal instability, but after divergence of the microsatellite instability pathway.",http://www.ncbi.nlm.nih.gov/pubmed/11481457,295,,,www.uniprot.org,12237
"SMAD4 L57V lies within the MH1 domain of the Smad4 protein (UniProt.org). L57V has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12238
"SMAD4 P130L lies within the MH1 domain of the Smad4 protein (UniProt.org). P130L has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,12239
"SMAD4 P246R does not lie within any known functional domains of the Smad4 protein (UniProt.org). P246R has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,12240
"SMAD4 P356L lies within the MH2 domain of the Smad4 protein (UniProt.org). P356L has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12241
"SMAD4 P356R lies within the MH2 domain of the Smad4 protein (UniProt.org). P356R has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12242
"SMAD4 P470H lies within the MH2 domain of the Smad4 protein (UniProt.org). P470H has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12243
"SMAD4 P544L lies within the MH2 domain of the Smad4 protein (UniProt.org). P544L has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12244
"STK11 P281Rfs*6 is a missense mutation (P281R) in conjunction with a likely truncation of the 433 aa Stk11 protein at aa 281, followed by 6 nonsense amino acids (UniProt.org). P281Rfs*6 has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Dec 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12245
"SMAD4 P91S lies within the MH1 domain of the Smad4 protein (UniProt.org). P91S has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12247
"SMAD4 Q245* results in a premature truncation of the Smad4 protein at amino acid 245 of 552 (UniProt.org). Q245* has not been characterized however, due to the effects of other truncation mutations downstream of Q245, Q245* is predicted to lead to a loss of Smad4 protein function (PMID: 11553622, PMID: 22316667).",3668,11553622,Loss of Smad4 function in pancreatic tumors: C-terminal truncation leads to decreased stability.,http://www.ncbi.nlm.nih.gov/pubmed/11553622,295,,,www.uniprot.org,3669,22316667,Germline mutations in SMAD4 disrupt bone morphogenetic protein signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22316667,12248
"SMAD4 Q311* results in a premature truncation of the Smad4 protein at amino acid 311 of 552 (UniProt.org). Q311* has not been characterized however, due to the effects of other truncation mutations downstream of Q311, Q311* is predicted to lead to a loss of Smad4 protein function (PMID: 11553622, PMID: 22316667).",3669,22316667,Germline mutations in SMAD4 disrupt bone morphogenetic protein signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22316667,3668,11553622,Loss of Smad4 function in pancreatic tumors: C-terminal truncation leads to decreased stability.,http://www.ncbi.nlm.nih.gov/pubmed/11553622,295,,,www.uniprot.org,12249
"SMAD4 R100W lies within the MH1 domain of the Smad4 protein (UniProt.org). R100W has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12250
"SMAD4 R135* results in a premature truncation of the Smad4 protein at amino acid 135 of 552 (UniProt.org). R135* has not been characterized however, due to the effects of other truncation mutations downstream of R135, R135* is predicted to lead to a loss of Smad4 protein function (PMID: 11553622, PMID: 22316667).",3669,22316667,Germline mutations in SMAD4 disrupt bone morphogenetic protein signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22316667,295,,,www.uniprot.org,3668,11553622,Loss of Smad4 function in pancreatic tumors: C-terminal truncation leads to decreased stability.,http://www.ncbi.nlm.nih.gov/pubmed/11553622,12251
"SMAD4 R361G lies at a hotspot residue within the MH2 domain of the Smad4 protein (UniProt.org). R361G results in a slight reduction in BMP signaling in cell culture, but is not significantly different from wild-type Smad4 (PMID: 22316667).",3669,22316667,Germline mutations in SMAD4 disrupt bone morphogenetic protein signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22316667,295,,,www.uniprot.org,12252
"SMAD4 R361P lies at a hotspot residue within the MH2 domain of the Smad4 protein (UniProt.org). R361P has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12253
"SMAD4 R380K lies within the MH2 domain of the Smad4 protein (UniProt.org). R380K has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12254
"SMAD4 R380S lies within the MH2 domain of the Smad4 protein (UniProt.org). R380S has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,12255
SMAD4 R496H lies within the MH2 domain of the Smad4 protein (UniProt.org). R496H decreases transcriptional activity of Smad4 as demonstrated in a reporter assay (PMID: 26488212).,295,,,www.uniprot.org,4263,26488212,Clinicopathological and genetic differences between low-grade and high-grade colorectal mucinous adenocarcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/26488212,12256
"SMAD4 R531Q lies within the MH2 domain of the Smad4 protein (UniProt.org). R531Q has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12257
"SMAD4 R76K lies within the MH1 domain of the Smad4 protein (UniProt.org). R76K has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12258
"SMAD4 R97H lies within the MH1 domain of the Smad4 protein (UniProt.org). R97H has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12259
"SMAD4 S144* results in a premature truncation of the Smad4 protein at amino acid 144 of 552 (UniProt.org). S144* has not been characterized however, due to the effects of other truncation mutations downstream of S144, S144* is predicted to lead to a loss of Smad4 protein function (PMID: 11553622, PMID: 22316667).",3668,11553622,Loss of Smad4 function in pancreatic tumors: C-terminal truncation leads to decreased stability.,http://www.ncbi.nlm.nih.gov/pubmed/11553622,295,,,www.uniprot.org,3669,22316667,Germline mutations in SMAD4 disrupt bone morphogenetic protein signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22316667,12260
"SMAD4 S178* results in a premature truncation of the Smad4 protein at amino acid 178 of 552 (UniProt.org). S178* has not been characterized however, due to the effects of other truncation mutations downstream of S178, S178* is predicted to lead to a loss of Smad4 protein function (PMID: 11553622, PMID: 22316667).",3668,11553622,Loss of Smad4 function in pancreatic tumors: C-terminal truncation leads to decreased stability.,http://www.ncbi.nlm.nih.gov/pubmed/11553622,295,,,www.uniprot.org,3669,22316667,Germline mutations in SMAD4 disrupt bone morphogenetic protein signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22316667,12261
"SMAD4 S343* results in a premature truncation of the Smad4 protein at amino acid 343 of 552 (UniProt.org). S343* has not been characterized however, due to the effects of other truncation mutations downstream of S343, S343* is predicted to lead to a loss of Smad4 protein function (PMID: 11553622, PMID: 22316667).",295,,,www.uniprot.org,3668,11553622,Loss of Smad4 function in pancreatic tumors: C-terminal truncation leads to decreased stability.,http://www.ncbi.nlm.nih.gov/pubmed/11553622,3669,22316667,Germline mutations in SMAD4 disrupt bone morphogenetic protein signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22316667,12262
"SMAD4 S368C lies within the MH2 domain of the Smad4 protein (UniProt.org). S368C has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12263
"SMAD4 S504R lies within the MH2 domain of the Smad4 protein (UniProt.org). S504R has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12265
"SMAD4 T373R lies within the MH2 domain of the Smad4 protein (UniProt.org). T373R has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12266
"SMAD4 V437D lies within the MH2 domain of the Smad4 protein (UniProt.org). V437D has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12267
"SMAD4 V44G lies within the MH1 domain of the Smad4 protein (UniProt.org). V44G has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12268
"SMAD4 V492F lies within the MH2 domain of the Smad4 protein (UniProt.org). V492F has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12270
"SMAD4 W509* results in a premature truncation of the Smad4 protein at amino acid 509 of 552 (UniProt.org). W509* has not been characterized however, due to the effects of other truncation mutations downstream of W509, W509* is predicted to lead to a loss of Smad4 protein function (PMID: 11553622, PMID: 22316667).",3668,11553622,Loss of Smad4 function in pancreatic tumors: C-terminal truncation leads to decreased stability.,http://www.ncbi.nlm.nih.gov/pubmed/11553622,295,,,www.uniprot.org,3669,22316667,Germline mutations in SMAD4 disrupt bone morphogenetic protein signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22316667,12272
"SMAD4 W509G lies within the MH2 domain of the Smad4 protein (UniProt.org). W509G has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12273
"SMAD4 W524R lies within the MH2 domain of the Smad4 protein (UniProt.org). W524R has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12274
"SMAD4 W524S lies within the MH2 domain of the Smad4 protein (UniProt.org). W524S has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12276
"SMAD4 W99C lies within the MH1 domain of the Smad4 protein (UniProt.org). W99C has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12277
"SMAD4 Y133H lies within the MH1 domain of the Smad4 protein (UniProt.org). Y133H has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12278
"SMAD4 Y133N lies within the MH1 domain of the Smad4 protein (UniProt.org). Y133N has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12279
"SMAD4 Y322* results in a premature truncation of the Smad4 protein at amino acid 322 of 552 (UniProt.org). Y322* has not been characterized however, due to the effects of other truncation mutations downstream of Y322, Y322* is predicted to lead to a loss of Smad4 protein function (PMID: 11553622, PMID: 22316667).",3668,11553622,Loss of Smad4 function in pancreatic tumors: C-terminal truncation leads to decreased stability.,http://www.ncbi.nlm.nih.gov/pubmed/11553622,295,,,www.uniprot.org,3669,22316667,Germline mutations in SMAD4 disrupt bone morphogenetic protein signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22316667,12280
"SMAD4 Y322H does not lie within any known functional domains of the Smad4 protein (UniProt.org). Y322H has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12281
"SMAD4 P203Hfs*38 is a missense mutation (P203H) in conjunction with a likely truncation of the 552 aa Smad4 protein at aa 203, followed by 38 nonsense amino acids (UniProt.org). P203Hfs*38 results in a loss of Smad4 function as indicated by reduced BMP signaling in cell culture (PMID: 22316667).",3669,22316667,Germline mutations in SMAD4 disrupt bone morphogenetic protein signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22316667,295,,,www.uniprot.org,12283
"SMAD4 P346Lfs*38 is a missense mutation (P346L) in conjunction with a likely truncation of the 552 aa Smad4 protein at aa 346, followed by 38 nonsense amino acids (UniProt.org). P346Lfs*38 results in a loss of Smad4 function as indicated by reduced BMP signaling in cell culture (PMID: 22316667).",3669,22316667,Germline mutations in SMAD4 disrupt bone morphogenetic protein signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22316667,295,,,www.uniprot.org,12284
SMAD4 E388* results in a premature truncation of the Smad4 protein at amino acid 388 of 552 (UniProt.org). E388* results in a loss of Smad4 function as indicated by reduced BMP signaling in cell culture (PMID: 22316667).,3669,22316667,Germline mutations in SMAD4 disrupt bone morphogenetic protein signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22316667,295,,,www.uniprot.org,12285
SMAD4 W398* results in a premature truncation of the Smad4 protein at amino acid 398 of 552 (UniProt.org). W398* results in a loss of Smad4 function as indicated by reduced BMP signaling in cell culture (PMID: 22316667).,3669,22316667,Germline mutations in SMAD4 disrupt bone morphogenetic protein signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22316667,295,,,www.uniprot.org,12286
"SMAD4 D415Efs*20 is a missense mutation (D415E) in conjunction with a likely truncation of the 552 aa Smad4 protein at aa 415, followed by 15 nonsense amino acids (UniProt.org). D415Efs*20 results in a loss of Smad4 function as indicated by reduced BMP signaling in cell culture (PMID: 22316667).",295,,,www.uniprot.org,3669,22316667,Germline mutations in SMAD4 disrupt bone morphogenetic protein signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22316667,12287
"SMAD4 Q448fs*37 likely results in a truncation of the 552 aa Smad4 protein at aa 448, followed by 37 nonsense amino acids within the MH2 domain (UniProt.org). Q448fs*37 results in a loss of Smad4 function as indicated by reduced BMP signaling in cell culture (PMID: 22316667).",295,,,www.uniprot.org,3669,22316667,Germline mutations in SMAD4 disrupt bone morphogenetic protein signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22316667,12288
"SMAD4 H530Tfs*7 (c.1588delC, reported as R530Tfs*7) is a missense mutation (H530T) in conjunction with a likely truncation of the 552 aa Smad4 protein at aa 530, followed by 7 nonsense amino acids (UniProt.org, PMID: 18823382). H530Tfs*7 results in a loss of Smad4 function, as indicated by reduced BMP signaling in cell culture (PMID: 22316667).",295,,,www.uniprot.org,9796,18823382,The rate of germline mutations and large deletions of SMAD4 and BMPR1A in juvenile polyposis.,http://www.ncbi.nlm.nih.gov/pubmed/18823382,3669,22316667,Germline mutations in SMAD4 disrupt bone morphogenetic protein signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22316667,12289
"SMAD4 V465M lies within the MH2 domain of the Smad4 protein (UniProt.org). V465M results in a slight reduction in BMP signaling in cell culture, but is not significantly different from wild-type Smad4 (PMID: 22316667).",295,,,www.uniprot.org,3669,22316667,Germline mutations in SMAD4 disrupt bone morphogenetic protein signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22316667,12290
"SMAD4 W509R lies within the MH2 domain of the Smad4 protein (UniProt.org). W509R results in a slight reduction in BMP signaling in cell culture, but is not significantly different from wild-type Smad4 (PMID: 22316667).",295,,,www.uniprot.org,3669,22316667,Germline mutations in SMAD4 disrupt bone morphogenetic protein signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22316667,12291
"SMAD4 A118V lies within the MH1 domain of the Smad4 protein (UniProt.org). A118V has not been characterized and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,12463
"SMAD4 Y353N lies within the MH2 domain of the Smad4 protein (UniProt.org). Y353N has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jan 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,12464
EGFR S492R lies within the extracellular domain of the Egfr protein (UniProt.org). S492R results in increased Egfr phosphorylation and confers resistance to Erbitux (cetuximab) in cell culture (PMID: 26059438).,5718,26059438,Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26059438,295,,,www.uniprot.org,12621
"RET R833C lies within the protein kinase domain of the Ret protein (UniProt.org). R833C results in increased Ret autophosphorylation, tumor formation in animal models, and is transforming in cell culture (PMID: 16469774).",1053,16469774,A novel activating mutation in the RET tyrosine kinase domain mediates neoplastic transformation.,http://www.ncbi.nlm.nih.gov/pubmed/16469774,295,,,www.uniprot.org,12636
"RET A883T lies within the protein kinase domain of the Ret protein (UniProt.org). A883T has not been biochemically characterized, but results in increased cell proliferation and is transforming in cell culture (PMID: 21810974).",2264,21810974,In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21810974,295,,,www.uniprot.org,12638
"RET L790F lies within the protein kinase domain of the Ret protein (UniProt.org). The functional effect of L790F is conflicting, as L790F has been reported to result in ligand-independent activation of Ret (PMID: 15184865), but also to display growth promotion and transforming activity similar to wild-type Ret protein (PMID: 21810974).",295,,,www.uniprot.org,3687,15184865,Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/15184865,2264,21810974,In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21810974,12639
"RET M848T lies within the protein kinase domain of the Ret protein (UniProt.org). M848T has not been biochemically characterized, but results in increased cell proliferation and is transforming in cell culture (PMID: 21810974).",295,,,www.uniprot.org,2264,21810974,In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21810974,12640
"RET M918V lies within the protein kinase domain of the Ret protein (UniProt.org). M918V does not have a statistically significant effect on cell proliferation, but is transforming in cell culture (PMID: 21810974).",295,,,www.uniprot.org,2264,21810974,In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21810974,12641
"RET S904F lies within the protein kinase domain of the Ret protein (UniProt.org). S904F has not been biochemically characterized and does not have a significant effect on cell proliferation, but is transforming in cell culture (PMID: 21810974).",295,,,www.uniprot.org,2264,21810974,In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21810974,12642
"RET T338I lies within the extracellular domain of the Ret protein (UniProt.org). T338I results in increased cell proliferation, but is not transforming in cell culture (PMID: 21810974).",295,,,www.uniprot.org,2264,21810974,In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21810974,12643
RET A883F lies within the protein kinase domain of the Ret protein (UniProt.org). A883F confers a gain of function to the Ret protein as demonstrated by increased Ret kinase activity (PMID: 24561444) and transforming properties in cell culture (PMID: 10445857).,3686,24561444,RET revisited: expanding the oncogenic portfolio.,http://www.ncbi.nlm.nih.gov/pubmed/24561444,2268,10445857,Biological and biochemical properties of Ret with kinase domain mutations identified in multiple endocrine neoplasia type 2B and familial medullary thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/10445857,295,,,www.uniprot.org,12654
"RET D898V lies within the protein kinase domain of the Ret protein (UniProt.org). D898V has been identified in the scientific literature (PMID: 23526464), but has not been characterized and therefore, its effect on Ret protein function is unknown (PubMed, Aug 2017).",295,,,www.uniprot.org,312,23526464,Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23526464,285,,,http://www.ncbi.nlm.nih.gov/pubmed,12655
"SMARCB1 A312T lies within repeat 2 of the Smarcb1 protein (UniProt.org). A312T has been identified in sequencing studies (PMID: 22895193), but has not been biochemically characterized and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4597,22895193,Recurrent R-spondin fusions in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22895193,12662
"SMARCB1 A339V does not lie within any known functional domains of the Smarcb1 protein (UniProt.org). A339V has not been characterized in the scientific literature and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12663
"SMARCB1 D104N lies within the DNA binding region of the Smarcb1 protein (UniProt.org). D104N has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12664
"SMARCB1 D159N does not lie within any known functional domains of the Smarcb1 protein (UniProt.org). D159N has not been characterized in the scientific literature and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12665
"SMARCB1 D202E lies within repeat 1 and the HIV-1 integrase and MYC-binding regions of the Smarcb1 protein (UniProt.org). D202E has not been characterized in the scientific literature and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12666
"SMARCB1 D22G lies within the DNA binding region of the Smarcb1 protein (UniProt.org). D22G has been identified in sequencing studies (PMID: 22842228), but has not been biochemically characterized in the scientific literature and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",7109,22842228,Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22842228,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12667
"SMARCB1 D259N lies within repeat 2 of the Smarcb1 protein (UniProt.org). D259N has not been characterized in the scientific literature and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12668
"SMARCB1 E31K lies within the DNA binding region of the Smarcb1 protein (UniProt.org). E31K has not been characterized in the scientific literature and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12669
"SMARCB1 F279C lies within repeat 2 of the Smarcb1 protein (UniProt.org). F279C has not been characterized in the scientific literature and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12670
"SMARCB1 F307V lies within repeat 2 of the Smarcb1 protein (UniProt.org). F307V has not been characterized in the scientific literature and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,12671
"SMARCB1 G80R lies within the DNA binding region of the Smarcb1 protein (UniProt.org).  G80R has not been characterized in the scientific literature and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,12672
"SMARCB1 H79Q lies within the DNA binding region of the Smarcb1 protein (UniProt.org).  H79Q has not been characterized in the scientific literature and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12673
"SMARCB1 K126N lies within the DNA binding region of the Smarcb1 protein (UniProt.org). K126N has not been characterized in the scientific literature and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12674
"SMARCB1 K363N does not lie within any known functional domains of the Smarcb1 protein (UniProt.org). K363N has not been characterized in the scientific literature and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12675
"SMARCB1 K8N lies within the DNA binding region of the Smarcb1 protein (UniProt.org).  K8N has not been characterized in the scientific literature and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12676
"SMARCB1 L142I lies within the DNA binding region of the Smarcb1 protein (UniProt.org). L142I has not been characterized in the scientific literature and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12677
"SMARCB1 N207S lies within repeat 1 and the HIV-1 integrase and MYC-binding regions of the Smarcb1 protein  (UniProt.org). N207S has not been characterized in the scientific literature and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12678
"SMARCB1 P133T lies within the DNA binding region of the Smarcb1 protein (UniProt.org). P133T has not been characterized in the scientific literature and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12679
"SMARCB1 P230Q lies in repeat 1 and the HIV-1 integrase and MYC-binding regions of the Smarcb1 (UniProt.org). P230Q has not been characterized in the scientific literature and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12680
"SMARCB1 P351S does not lie within any known functional domains of the Smarcb1 protein (UniProt.org). P351S has been identified in sequencing studies (PMID: 21720365), but has not been biochemically characterized in the scientific literature and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",6943,21720365,Integrated genomic analyses of ovarian carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/21720365,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12681
"SMARCB1 K364del results in the deletion of one amino acid of the Smarcb1 protein at amino acid 364 (UniProt.org). K364del has not been characterized and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12682
"SMARCB1 Q18* results in a premature truncation of the Smarcb1 protein at amino acid 18 of 385 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), Q18* is predicted to lead to a loss of Smarcb1 protein function. ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12683
"SMARCB1 Q243* results in a premature truncation of the Smarcb1 protein at amino acid 243 of 385 (UniProt.org). Q243* has been identified in sequencing studies (PMID: 22895193), but has not been biochemically characterized in the scientific literature and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",4597,22895193,Recurrent R-spondin fusions in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22895193,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12684
"SMARCB1 Q368* results in a premature truncation of the Smarcb1 protein at amino acid 368 of 385 (UniProt.org). Q368* has not been characterized in the scientific literature and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12685
"SMARCB1 Q368R does not lie within any known functional domains of the Smarcb1 protein (UniProt.org). Q368R has been identified in sequencing studies (PMID: 21720365), but has not been biochemically characterized and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",6943,21720365,Integrated genomic analyses of ovarian carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/21720365,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12686
"SMARCB1 R190L lies within repeat 1 and the HIV-1 integrase and MYC-binding regions of the Smarcb1 protein (UniProt.org). R190L has not been characterized in the scientific literature and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,12687
"SMARCB1 R201Q lies within repeat 1 of the Smarcb1 protein (UniProt.org). R201Q has been identified in sequencing studies (PMID: 27284491), but has not been biochemically characterized in the scientific literature and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,8178,27284491,Mutation profiles of synchronous colorectal cancers from a patient with Lynch syndrome suggest distinct oncogenic pathways.,http://www.ncbi.nlm.nih.gov/pubmed/27284491,285,,,http://www.ncbi.nlm.nih.gov/pubmed,12688
"SMARCB1 R261C lies within repeat 2 of the Smarcb1 protein (UniProt.org). R261C has not been characterized in the scientific literature and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12689
"SMARCB1 R370S does not lie within any known functional domains of the Smarcb1 protein (UniProt.org). R370S has not been characterized in the scientific literature and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12690
"SMARCB1 R374Q does not lie within any known functional domains of the Smarcb1 protein (UniProt.org). R374Q has been identified in the scientific literature (PMID: 26285240, PMID: 23334667), but has not been biochemically characterized and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",8180,26285240,Cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary.,http://www.ncbi.nlm.nih.gov/pubmed/26285240,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8181,23334667,Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/23334667,12691
"SMARCB1 R374W does not lie within any known functional domains of the Smarcb1 protein (UniProt.org). R374W has been identified in sequencing studies (PMID: 22895193), but has not been biochemically characterized and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4597,22895193,Recurrent R-spondin fusions in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22895193,12692
"SMARCB1 R377C does not lie within any known functional domains of the Smarcb1 protein (UniProt.org). R377C has been identified in sequencing studies (PMID: 24670920), but has not been biochemically characterized in the scientific literature and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,8185,24670920,Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids.,http://www.ncbi.nlm.nih.gov/pubmed/24670920,295,,,www.uniprot.org,12693
"SMARCB1 R377H does not lie within any known functional domains of the Smarcb1 protein (UniProt.org). R377H has been identified in the scientific literature (PMID: 23334667, PMID: 11161377, PMID: 24993163), but has not been biochemically characterized and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",8205,11161377,INI1 mutations in meningiomas at a potential hotspot in exon 9.,http://www.ncbi.nlm.nih.gov/pubmed/11161377,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1904,24993163,Activating FGFR2-RAS-BRAF mutations in ameloblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/24993163,295,,,www.uniprot.org,8181,23334667,Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/23334667,12694
"SMARCB1 R53* results in a premature truncation of the Smarcb1 protein at amino acid 53 of 385 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), R53* is predicted to lead to a loss of Smarcb1 protein function.",295,,,www.uniprot.org,12695
"SMARCB1 R53Q lies within the DNA binding region of the Smarcb1 protein (UniProt.org). R53Q has been identified in the scientific literature (PMID: 28692054), but has not been biochemically characterized and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,10021,28692054,Modeling cancer driver events in vitro using barrier bypass-clonal expansion assays and massively parallel sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/28692054,12696
"SMARCB1 S247C lies within the tandem repeat region of the Smarcb1 protein (UniProt.org). S247C has not been characterized in the scientific literature and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12697
PTPN11 A461T lies within the tyrosine-protein phosphatase domain of the Ptpn11 protein (UniProt.org). A461T results in decreased Ptpn11 activity and inhibition of Erk activation in cell culture (PMID: 16377799).,3690,16377799,"PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects.",http://www.ncbi.nlm.nih.gov/pubmed/16377799,295,,,www.uniprot.org,12699
"SMARCB1 S252I lies within the tandem repeat region of the Smarcb1 protein (UniProt.org). S252I has not been characterized in the scientific literature and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12700
"PTPN11 A72D lies within the SH2 domain 1 of the Ptpn11 protein (UniProt.org). A72D confers a gain of function to the Ptpn11 protein as demonstrated by increased phosphatase activity of Ptpn11 and activation of the MAPK and PI3K signaling pathways (J Clin Oncol 32, 2014 (suppl; abstr e22174)). ",3363,,Protein tyrosine phosphatase non receptor 11 (PTPN11/Shp2) as a driver oncogene and a novel therapeutic target in non-small cell lung cancer (NSCLC),http://meetinglibrary.asco.org/content/147146-156,295,,,www.uniprot.org,12701
"SMARCB1 S274F lies within repeat 2 of the Smarcb1 protein (UniProt.org). S274F has not been characterized in the scientific literature and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12702
"PTPN11 A72S lies within the SH2 domain 1 of the Ptpn11 protein (UniProt.org). A72S results in increased Ptpn11 activity, as indicated by increased substrate dephosphorylation in an in vitro assay (PMID: 16358218).",295,,,www.uniprot.org,3691,16358218,Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease.,http://www.ncbi.nlm.nih.gov/pubmed/16358218,12703
"PTPN11 A72V lies within the SH2 domain 1 of the Ptpn11 protein (UniProt.org). A72V results in increased Ptpn11 activity, as indicated by increased substrate dephosphorylation in an in vitro assay (PMID: 16358218).",295,,,www.uniprot.org,3691,16358218,Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease.,http://www.ncbi.nlm.nih.gov/pubmed/16358218,12704
"SMARCB1 S94L lies within the DNA binding region of the Smarcb1 protein (UniProt.org). S94L has not been characterized in the scientific literature and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12705
"PTPN11 D106Y does not lie within any known functional domains of the Ptpn11 protein (UniProt.org). D106Y has been identified in sequencing studies (PMID: 23856246), but has not been biochemically characterized and therefore, its effect on Ptpn11 protein function is unknown (PubMed, Aug 2017).
",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,6964,23856246,The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.,http://www.ncbi.nlm.nih.gov/pubmed/23856246,295,,,www.uniprot.org,12707
"PTPN11 D146Y lies within the SH2 domain 2 of the Ptpn11 protein (UniProt.org). D146Y has not been characterized in the scientific literature and therefore, its effect on Ptpn11 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12708
"PTPN11 D155Y lies within the SH2 domain 2 of the Ptpn11 protein (UniProt.org). D155Y has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Ptpn11 protein function is unknown (PubMed, Aug 2017).
",5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12709
"SMARCB1 T149K lies does not lie within any known functional domains of the Smarcb1 protein (UniProt.org). T149K has not been characterized in the scientific literature and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12711
"PTPN11 E123D lies within the SH2 domain 2 of the Ptpn11 protein (UniProt.org). E123D has not been characterized in the scientific literature and therefore, its effect on Ptpn11 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12714
"PTPN11 E225D does not lie within any known functional domains of the Ptpn11 protein (UniProt.org). E225D has not been characterized in the scientific literature and therefore, its effect on Ptpn11 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12715
"SMARCB1 T232M lies within the 1st repeat region of the Smarcb1 protein (UniProt.org). T232M has not been characterized in the scientific literature and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12717
"PTPN11 E69D lies within the SH2 domain 1 of the Ptpn11 protein (UniProt.org). E69D has not been characterized in the scientific literature and therefore, its effect on Ptpn11 protein function is unknown (PubMed, Aug 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,12719
PTPN11 E69K lies within the SH2 domain 1 of the Ptpn11 protein (UniProt.org). E69K results in increased Ptpn11 phosphatase activity in an in vitro assay (PMID: 15604238).,295,,,www.uniprot.org,3692,15604238,Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/15604238,12720
"SMARCB1 T381M does not lie within any known functional domains of the Smarcb1 protein (UniProt.org). T381M has not been characterized in the scientific literature and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12721
PTPN11 E76G lies within the SH2 domain 1 of the Ptpn11 protein (UniProt.org). E76G is predicted to confer a gain of function to the Ptpn11 protein resulting in decreased cell adhesion (PMID: 18559669).  ,295,,,www.uniprot.org,4280,18559669,Regulation of RhoA-dependent ROCKII activation by Shp2.,http://www.ncbi.nlm.nih.gov/pubmed/18559669,12722
"PTPN11 F341Y lies within the tyrosine-protein phosphatase domain of the Ptpn11 protein (UniProt.org). F341Y has not been characterized in the scientific literature and therefore, its effect on Ptpn11 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12723
"PTPN11 F71L lies within the SH2 domain 1 of the Ptpn11 protein (UniProt.org). F71L has been identified in the scientific literature (PMID: 17053061) but has not been biochemically characterized and therefore, its effect on Ptpn11 protein function is unknown (PubMed, Mar 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8187,17053061,PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase.,http://www.ncbi.nlm.nih.gov/pubmed/17053061,12724
"PTPN11 G13D lies within the SH2 domain 1 of the Ptpn11 protein (UniProt.org). G13D has not been characterized in the scientific literature and therefore, its effect on Ptpn11 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12725
"PTPN11 G503V lies within the tyrosine-protein phosphatase domain of the Ptpn11 protein (UniProt.org). G503V results in increased phosphatase activity compared to wild-type Ptpn11 (PMID: 15834506), and thus is predicted to confer a gain of function to the Ptpn11 protein.",4292,15834506,Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/15834506,295,,,www.uniprot.org,12728
"SMARCB1 V262I lies within the 2nd repeat region of the Smarcb1 protein (UniProt.org). V262I has not been characterized and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12729
"PTPN11 G60R lies within the SH2 domain 1 of the Ptpn11 protein (UniProt.org). G60R has not been biochemically characterized, however, has been referred to as activating in a lymphoma cell line (PMID: 23957426).",4300,23957426,Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11).,http://www.ncbi.nlm.nih.gov/pubmed/23957426,295,,,www.uniprot.org,12730
"SMARCB1 Y326* results in a premature truncation of the Smarcb1 protein at amino acid 326 of 385 (UniProt.org). Y326* has not been characterized and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12731
"PTPN11 G60V lies within the SH2 domain 1 of the Ptpn11 protein (UniProt.org). G60V has been identified in the scientific literature (PMID: 18701506) but has not been biochemically characterized and therefore, its effect on Ptpn11 protein function is unknown (PubMed, Mar 2017).
",8188,18701506,Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/18701506,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12732
"PTPN11 H114Y lies within the SH2 domain 2 of the Ptpn11 protein (UniProt.org). H114Y has not been characterized in the scientific literature and therefore, its effect on Ptpn11 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12733
"SMARCB1 Y47S does not lie within any known functional domains of the Smarcb1 protein (UniProt.org). Y47S has not been characterized and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Apr 2017). ",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,12735
"PTPN11 I172T lies within the SH2 domain 2 of the Ptpn11 protein (UniProt.org). I172T has not been characterized in the scientific literature and therefore, its effect on Ptpn11 protein function is unknown (PubMed, Aug 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,12736
"PTPN11 I282M lies within the Tyrosine-protein phosphatase domain of the Ptpn11 protein (UniProt.org). I282M has been identified in the scientific literature (PMID: 26817465) but has not been biochemically characterized and therefore, its effect on Ptpn11 protein function is unknown (PubMed, Mar 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8189,26817465,Mutation Spectrum and Phenotypic Features in Noonan Syndrome with PTPN11 Mutations: Definition of Two Novel Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26817465,12737
"PTPN11 I54T lies within the SH2 domain 1 of the Ptpn11 protein (UniProt.org). I54T has been identified in sequencing studies (PMID: 24755471), but has not been biochemically characterized and therefore, its effect on Ptpn11 protein function is unknown (PubMed, Aug 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6962,24755471,Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24755471,12739
"PTPN11 K325T lies within the tyrosine-protein phosphatase domain of the Ptpn11 protein (UniProt.org). K325T has not been characterized in the scientific literature and therefore, its effect on Ptpn11 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12740
"PTPN11 K55N lies within the SH2 domain 1 of the Ptpn11 protein (UniProt.org). K55N has not been characterized in the scientific literature and therefore, its effect on Ptpn11 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12741
"PTPN11 L117F lies within the SH2 domain 2 of the Ptpn11 protein (UniProt.org). L117F has not been characterized in the scientific literature and therefore, its effect on Ptpn11 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12742
"PTPN11 L136H lies within the SH2 domain 2 of the Ptpn11 protein (UniProt.org). L136H has not been characterized in the scientific literature and therefore, its effect on Ptpn11 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12743
"PTPN11 L262F lies within the Tyrosine-protein phosphatase domain of the Ptpn11 protein (UniProt.org). L262F has not been characterized in the scientific literature and therefore, its effect on Ptpn11 protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12744
"PTPN11 M82V lies within the SH2 domain 1 of the Ptpn11 protein (UniProt.org). M82V has not been characterized in the scientific literature and therefore, its effect on Ptpn11 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12745
PTPN11 N308D lies within the Tyrosine-protein phosphatase domain of the Ptpn11 protein (UniProt.org). N308D results in increased Ptpn11 phosphatase activity and enhanced cell proliferation in culture (PMID: 12717436).,295,,,www.uniprot.org,3693,12717436,"Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/12717436,12746
"PTPN11 N339S lies within the tyrosine-protein phosphatase domain of the Ptpn11 protein (UniProt.org). N339S has been identified in sequencing studies (PMID: 21720365), but has not been biochemically characterized and therefore, its effect on Ptpn11 protein function is unknown (PubMed, Aug 2017).",6943,21720365,Integrated genomic analyses of ovarian carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/21720365,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12747
"SMARCB1 T118Pfs*25 is a missense mutation (T118P) in conjunction with a likely truncation of the Smarcb1 protein at aa 118 of 385, followed by 25 nonsense amino acids (UniProt.org). Due to the disruption of the DNA binding region and all other known functional domains (UniProt.org), T118Pfs*25 is predicted to lead to a loss of Smarcb1 protein function.",295,,,www.uniprot.org,12748
"PTPN11 N58S lies within the SH2 domain 1 of the Ptpn11 protein (UniProt.org). N58S has not been biochemically characterized, however, has been characterized as activating in a lung cancer cell line (PMID: 23825065).",4299,23825065,Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/23825065,295,,,www.uniprot.org,12749
"SMARCB1 T72Nfs*4 is a missense mutation (T72N) in conjunction with a likely truncation of the Smarcb1 protein at aa 72 of 385, followed by 4 nonsense amino acids (UniProt.org). Due to the loss of all known functional domains (UniProt.org), T72Nfs*4 is predicted to lead to a loss of Smarcb1 protein function.",295,,,www.uniprot.org,12752
"PTPN11 Q510L lies within the tyrosine-protein phosphatase domain of the Ptpn11 protein (UniProt.org). Q510L has been identified in sequencing studies (PMID: 27359055, PMID: 28822769), but has not been biochemically characterized and therefore, its effect on Ptpn11 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7838,27359055,Mutation profiling of 19 candidate genes in acute myeloid leukemia suggests significance of DNMT3A mutations.,http://www.ncbi.nlm.nih.gov/pubmed/27359055,295,,,www.uniprot.org,9772,28822769,Somatic mutation analysis in melanoma using targeted next generation sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/28822769,12754
"PTPN11 R278K lies within the tyrosine-protein phosphatase domain of the Ptpn11 protein (UniProt.org). R278K has not been characterized in the scientific literature and therefore, its effect on Ptpn11 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12756
"SMARCB1 T72Qfs*13 is a missense mutation (T72Q) in conjunction with a likely truncation of the Smarcb1 protein at aa 72 of 385, followed by 13 nonsense amino acids (UniProt.org). Due to the loss of all known functional domains (UniProt.org), T72Qfs*13 is predicted to lead to a loss of Smarcb1 protein function.",295,,,www.uniprot.org,12757
"PTPN11 R384C lies within the tyrosine-protein phosphatase domain of the Ptpn11 protein (UniProt.org). R384C has not been characterized in the scientific literature and therefore, its effect on Ptpn11 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12758
"PTPN11 R498W lies within the Tyrosine-protein phosphatase domain of the Ptpn11 protein (UniProt.org). R498W is predicted to confer a loss of function to the Ptpn11 protein, demonstrating reduced phosphatase activity when compared to wild-type (PMID: 24891296).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12759
PTPN11 T468M lies within the Tyrosine-protein phosphatase domain of the Ptpn11 protein (UniProt.org). T468M results in reduced Ptpn11 activity and inhibition of Erk activation in cell culture (PMID: 16377799).,3690,16377799,"PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects.",http://www.ncbi.nlm.nih.gov/pubmed/16377799,295,,,www.uniprot.org,12766
"PTPN11 T52S lies within the SH2 domain 1 of the Ptpn11 protein (UniProt.org). T52S has not been characterized in the scientific literature and therefore, its effect on Ptpn11 protein function is unknown (PubMed, Aug 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,12767
"PTPN11 V181I lies within the SH2 domain 2 of the Ptpn11 protein (UniProt.org). V181I has not been characterized in the scientific literature and therefore, its effect on Ptpn11 protein function is unknown (PubMed, Aug 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,12768
"PTPN11 Y279C lies within the Tyrosine-protein phosphatase domain of the Ptpn11 protein (UniProt.org). Y279C results in decreased Ptpn11 activity, reduced Erk activation in cell culture, and aberrant activation of Akt/mTOR, Jnk and Stat3 in animal models (PMID: 16377799, PMID: 21339643).",3690,16377799,"PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects.",http://www.ncbi.nlm.nih.gov/pubmed/16377799,295,,,www.uniprot.org,3694,21339643,Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation.,http://www.ncbi.nlm.nih.gov/pubmed/21339643,12770
"RET Y806C lies within the protein kinase domain of the Ret protein (UniProt.org). Y806C has not been biochemically characterized, but has been demonstrated to occur as a secondary resistance mutation (PMID: 19029224).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8446,19029224,Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474.,http://www.ncbi.nlm.nih.gov/pubmed/19029224,12802
"RET E884K lies within the protein kinase domain of the Ret protein (UniProt.org). E884K has been identified in the scientific literature (PMID: 10622534, PMID: 19029224), but has not been characterized and therefore, its effect on Ret protein function is unknown (PubMed, Aug 2017).",8446,19029224,Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474.,http://www.ncbi.nlm.nih.gov/pubmed/19029224,9786,10622534,Somatic mutations in RET exons 12 and 15 in sporadic medullary thyroid carcinomas: different spectrum of mutations in sporadic type from hereditary type.,http://www.ncbi.nlm.nih.gov/pubmed/10622534,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,12812
"EGFR S768_D770dup indicates the insertion of 3 duplicate amino acids, serine (S)-768 through aspartate (D)-770, in the protein kinase domain of the Egfr protein (UniProt.org). S768_D770dup has not been biochemically characterized, but is predicted to lead to Egfr activation based on the effect of other Egfr exon 20 insertions (PMID: 24353160, PMID: 16187797).",410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,295,,,www.uniprot.org,440,24353160,"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24353160,12854
"EGFR N771_H773dup indicates the insertion of 3 duplicate amino acids, asparagine (N)-771 through histidine (H)-773, in the protein kinase domain of the Egfr protein (UniProt.org). N771_H773dup has not been biochemically characterized, but is predicted to lead to Egfr activation based on the effect of other Egfr exon 20 insertions (PMID: 24353160, PMID: 16187797).",440,24353160,"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24353160,410,16187797,Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.,http://www.ncbi.nlm.nih.gov/pubmed/16187797,295,,,www.uniprot.org,12858
"FGFR3 G384D (corresponds to G382 in the canonical isoform) lies within a pentameric consensus region in the transmembrane domain of the Fgfr3 protein (PMID: 11429702). G384D has variable effects on activation of Fgfr3, and is not transforming in cell culture and therefore, its effect on Fgfr3 protein function is unknown (PMID: 11429702).",2175,11429702,"Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.",http://www.ncbi.nlm.nih.gov/pubmed/11429702,12859
"FGFR3 dec exp indicates decreased expression of the Fgfr3 protein. However, the mechanism causing the decreased expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,12860
"FGFR2 C383R (also referred to as C382 in the canonical isoform) lies within the transmembrane domain of the Fgfr2 protein (UniProt.org). C383R has not been biochemically characterized, however, C382R results in Fgfr2 autophosphorylation and transformation in culture and therefore, C383R is predicted to confer a gain of function (PMID: 9136983). ",295,,,www.uniprot.org,2114,9136983,Activation of FGF receptors by mutations in the transmembrane domain.,http://www.ncbi.nlm.nih.gov/pubmed/9136983,12947
"PIK3CA E545X indicates any Pik3ca missense mutation which results in the glutamic acid (E) at amino acid 545 being replaced by a different amino acid. PIK3CA E545X mutations are ""hotspot"" mutations resulting in increased Pik3ca kinase activity (PMID: 15930273).",2212,15930273,Functional analysis of PIK3CA gene mutations in human colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/15930273,13000
"PIK3CA H1047X indicates any Pik3ca missense mutation which results in the histidine (H) at amino acid 1047 being replaced by a different amino acid. PIK3CA H1047X mutations are ""hotspot"" mutations resulting in increased Pik3ca kinase activity and transformation activity in culture (PMID: 15930273).",2212,15930273,Functional analysis of PIK3CA gene mutations in human colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/15930273,13001
"TP53 T377P lies within the region of the Tp53 protein involved in repression of DNA binding and interaction with CARM1 (UniProt.org). T377P has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13014
"CBL L405R lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). L405R has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13015
"ASXL1 R693* results in a premature truncation of the Asxl1 protein at amino acid 693 of 1541 (UniProt.org). ASXL1 R693* has not been biochemically characterized, however, due to the effects of other ASXL1 truncation mutations that result in the loss of the PHD domain, R693* is predicted to result in a loss of Asxl1 function (PMID: 24216483, PMID: 22897849).",295,,,www.uniprot.org,3732,22897849,ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.,http://www.ncbi.nlm.nih.gov/pubmed/22897849,3733,24216483,Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24216483,13016
"TET2 D1143fs results in a change in the amino acid sequence of the Tet2 protein beginning at aa 1143 of 2002, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the DNA-interacting region and substrate binding region (UniProt.org), D1143fs is predicted to lead to a loss of Tet2 function.",295,,,www.uniprot.org,13017
"TET2 K1171fs results in a change in the amino acid sequence of the Tet2 protein beginning at aa 1171 of 2002, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the DNA-interacting region and substrate binding region (UniProt.org), K1171fs is predicted to lead to a loss of Tet2 function.",295,,,www.uniprot.org,13018
"SRSF2 Y44H lies within the RRM domain of the Srsf2 protein (UniProt.org). Y44H has not been characterized and therefore, its effect on Srsf2 protein function is unknown (PubMed, Oct 2015). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13019
TET2 mutant indicates an unspecified mutation in the TET2 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,13020
"IDH2 H348Q does not lie within any known functional domains of the Idh2 protein (UniProt.org). H348Q has not been characterized in the scientific literature and therefore, its effect on Idh2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13021
CBL mutant indicates an unspecified mutation in the CBL gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,13022
"TP53 R337H lies within the tetramerization domain of the Tp53 protein (PMID: 20978130). R337H results in decreased Tp53 tetramerization and transactivation activity in cell culture (PMID: 19454241), and increased Tp53 nuclear accumulation in patient samples (PMID: 26452166), and has a pH-dependent effect on Tp53 stability with activity similar to wild-type in some assays (PMID: 25584008).",499,19454241,Evaluation of transcriptional activity of p53 in individual living mammalian cells.,http://www.ncbi.nlm.nih.gov/pubmed/19454241,3741,26452166,Occurrence of Neuroblastoma among TP53 p.R337H Carriers.,http://www.ncbi.nlm.nih.gov/pubmed/26452166,4424,25584008,Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study.,http://www.ncbi.nlm.nih.gov/pubmed/25584008,498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,13061
SMARCB1 mutant indicates an unspecified mutation in the SMARCB1 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,13133
"SMARCB1 loss indicates loss of the SMARCB1 gene, mRNA or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,13134
"EGFR E709X indicates any Egfr missense mutation which results in the glutamic acid (E) at amino acid 709 being replaced by a different amino acid. EGFR E709 mutations are considered  ""hotspot"" mutations (PMID: 18372921).",3762,18372921,EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: one-third of doublets occur at five pairs of amino acids.,http://www.ncbi.nlm.nih.gov/pubmed/18372921,13135
"EGFR A750V lies within the protein kinase domain of the Egfr protein (UniProt.org). A750V has not been characterized, but has been described as a secondary resistance mutation to Egfr inhibitors (PubMed, Aug 2016, PMID: 18588508).",295,,,www.uniprot.org,4838,18588508,Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations.,http://www.ncbi.nlm.nih.gov/pubmed/18588508,285,,,http://www.ncbi.nlm.nih.gov/pubmed,13136
"TP53 C135Y lies within the DNA binding domain of the Tp53 protein (UniProt.org). C135Y confers a loss of function to the Tp53 protein as demonstrated by loss of binding to the Drosha complex and inability to induce downstream miRs  and loss of transactivation activity in cell culture (PMID: 19626115, PMID: 8336941).",295,,,www.uniprot.org,3763,19626115,Modulation of microRNA processing by p53.,http://www.ncbi.nlm.nih.gov/pubmed/19626115,2227,8336941,Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences.,http://www.ncbi.nlm.nih.gov/pubmed/8336941,13138
"PTEN dec exp indicates decreased expression of the PTEN protein. However, the mechanism causing the decreased expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,13143
ALK K1062M lies within the protein kinase domain of the Alk protein (UniProt.org). K1062M confers a gain of function to the Alk protein as demonstrated by increased Alk kinase activity and downstream Pi3k-Akt and Mapk pathway activation (PMID: 21596819).,295,,,www.uniprot.org,3790,21596819,Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene.,http://www.ncbi.nlm.nih.gov/pubmed/21596819,13148
ALK G1201E lies within the protein kinase domain of the Alk protein (UniProt.org). G1201E confers a gain of function to the Alk protein as demonstrated by increased Alk kinase activity and downstream Pi3k and Mapk pathway (PMID: 21596819).,3790,21596819,Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene.,http://www.ncbi.nlm.nih.gov/pubmed/21596819,295,,,www.uniprot.org,13150
ALK L1198F lies within the protein kinase domain of the Alk protein (UniProt.org). L1198F confers a gain of function to the Alk protein as demonstrated by increased Alk kinase activity and downstream Pi3k and Mapk pathway activation (PMID: 21596819).,3790,21596819,Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene.,http://www.ncbi.nlm.nih.gov/pubmed/21596819,295,,,www.uniprot.org,13151
"ALK L1122V lies within the protein kinase domain of the Alk protein (UniProt.org). L1122V has not been biochemically characterized, however, has been described as a secondary drug resistance mutation in the context of NPM1-ALK (PMID: 25421750).",295,,,www.uniprot.org,3791,25421750,Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/25421750,13152
"ALK P1139S lies within the protein kinase domain of the Alk protein (UniProt.org). P1139S has not been biochemically characterized, however, has been demonstrated to occur as a secondary drug resistance mutation in the context of NPM1-ALK (PMID: 25421750).",295,,,www.uniprot.org,3791,25421750,Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/25421750,13153
"ALK S1206C lies within the protein kinase domain of the Alk protein (UniProt.org). S1206C has not been biochemically characterized, but has been demonstrated to occur as a secondary drug resistance mutation in the context of NPM1-ALK (PMID: 25421750).",295,,,www.uniprot.org,3791,25421750,Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/25421750,13154
"ALK D1203N lies within the protein kinase domain of the Alk protein (UniProt.org). D1203N has not been biochemically characterized, however, has been demonstrated to occur as a secondary drug resistance mutation in the context of NPM1-ALK and ALK L1196M (PMID: 25421750).",3791,25421750,Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/25421750,295,,,www.uniprot.org,13161
"RET V804G lies within the protein kinase domain of the Ret protein (UniProt.org). V804G has not been characterized, however, V804G in combination with C634R results in both decreased Ret kinase activity and transformation activity compared to C634R alone in cell culture (PMID: 15184865).",3687,15184865,Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/15184865,295,,,www.uniprot.org,13162
"NPM1 amp indicates an increased number of copies of the NMP1 gene. However, the mechanism causing the increase is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,13264
"ALK D1249fs*35 likely results in a truncation of the 1620 aa Alk protein at aa 1249, followed by 35 nonsense amino acids within the protein kinase domain (UniProt.org). Due to the loss of the ATP binding site, D1249fs*35 is predicted to lead to a loss of Alk protein function (UniProt.org).",295,,,www.uniprot.org,13293
"ALK Y1278S is a hotspot mutation that lies within the activation loop of the Alk protein (PMID: 24060861, PMID: 25071110). Y1278S results in constitutive activation of Alk and is transforming in cell culture (PMID: 25517749).",5810,24060861,Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.,http://www.ncbi.nlm.nih.gov/pubmed/24060861,5811,25071110,Emergence of new ALK mutations at relapse of neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/25071110,4535,25517749,ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/25517749,13294
"ATM D126E does not lie within any known functional domains of the Atm protein (UniProt.org). D126E has been identified in sequencing studies (PMID: 24793135), but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7497,24793135,A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24793135,9737,16520463,"Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer.",http://www.ncbi.nlm.nih.gov/pubmed/16520463,13299
"ATM S978C does not lie within any known functional domains of the Atm protein (UniProt.org). S978C has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13300
"FLT3 Y599_D600insSTDNEYFYVDFREYEY results in the insertion of sixteen amino acids in the juxtamembrane domain of the Flt3 protein between amino acids 599 and 600 (UniProt.org). Y599_D600insSTDNEYFYVDFREYEY is predicted to lead to activation of Flt3 due to the effects of other Flt3 internal tandem duplication (ITD) mutations (PMID: 12970773, PMID: 9737679, PMID: 11090077).",2898,11090077,Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.,http://www.ncbi.nlm.nih.gov/pubmed/11090077,2896,12970773,FLT3: ITDoes matter in leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/12970773,295,,,www.uniprot.org,2897,9737679,Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product.,http://www.ncbi.nlm.nih.gov/pubmed/9737679,13306
"APC A1296fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1296 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). A1296fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), A1296fs is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,13307
"APC A1296V lies within the mutator cluster region of the Apc protein (PMID: 14672538). A1296V has been identified in sequencing studies (PMID: 10666372), but has not been biochemically characterized and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,7798,10666372,APC mutations in sporadic medulloblastomas.,http://www.ncbi.nlm.nih.gov/pubmed/10666372,285,,,http://www.ncbi.nlm.nih.gov/pubmed,13308
"APC A1305fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1305 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). A1305fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), A1305fs is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,13309
"APC A1305G lies within the mutator cluster region of the Apc protein (PMID: 14672538). A1305G has been identified in sequencing studies (PMID: 18369740), but has not been biochemically characterized and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,7799,18369740,Somatic APC inactivation mechanisms in sporadic colorectal cancer cases in Hungary.,http://www.ncbi.nlm.nih.gov/pubmed/18369740,285,,,http://www.ncbi.nlm.nih.gov/pubmed,13310
"APC A1316fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1316 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). A1316fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), A1316fs is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,13311
"APC A1325fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1325 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). A1325fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), A1325fs is predicted to reduce the ability of Apc to regulate beta-catenin.",295,,,www.uniprot.org,2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,13312
"APC A1358E lies within the Ctnnb1 binding and down-regulation domain of the Apc protein (PMID: 14672538). A1358E has been identified in sequencing studies (PMID: 10440612), but has not been biochemically characterized and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7800,10440612,Germline and somatic mutations in exon 15 of the APC gene and K-ras mutations in duodenal adenomas in patients with familial adenomatous polyposis.,http://www.ncbi.nlm.nih.gov/pubmed/10440612,2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,13314
"APC A1402fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1402 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). A1402fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), A1402fs is predicted to reduce the ability of Apc to regulate beta-catenin.",295,,,www.uniprot.org,2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,13315
"APC A1446fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1446 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). A1446fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), A1446fs is predicted to reduce the ability of Apc to regulate beta-catenin.",295,,,www.uniprot.org,2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,13317
"APC A1470fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1470 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). A1470fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), A1470fs is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,13319
"APC A1470T lies within the Ctnnb1 binding and down-regulation domain of the Apc protein (PMID: 14672538). A1470T has been identified in sequencing studies (PMID: 8242071), but has not been biochemically characterized and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7801,8242071,Somatic mutations of the APC gene in precancerous lesion of the stomach.,http://www.ncbi.nlm.nih.gov/pubmed/8242071,2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,13320
"APC A1471fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1471 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). A1471fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), A1471fs is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,13321
"APC A1475fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1475 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). A1475fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), A1475fs is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,13322
"APC A1475V lies within the Ctnnb1 binding and down-regulation domain of the Apc protein (PMID: 14672538). A1475V has been identified in sequencing studies (PMID: 18844223), but has not been biochemically characterized and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7802,18844223,Somatic mutations of adenomatous polyposis coli gene and nuclear b-catenin accumulation have prognostic significance in invasive urothelial carcinomas: evidence for Wnt pathway implication.,http://www.ncbi.nlm.nih.gov/pubmed/18844223,13323
"APC C1274fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1274 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). C1274fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), C1274fs is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,13324
"APC C1289fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1289 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). C1289fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), C1289fs is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,13325
"APC C1387* results in a premature truncation of the Apc protein at amino acid 1387 of 2843 (UniProt.org). Due to the loss of the Ctnnb1 binding and down-regulation domain (PMID: 14672538), C1387* is predicted to lead to a loss of Apc protein function.",2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,295,,,www.uniprot.org,13326
"APC C1387fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1387 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). C1387fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), C1387fs is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,13327
"APC C1410* results in a premature truncation of the Apc protein at amino acid 1410 of 2843 (UniProt.org). C1410* has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), C1410* is predicted to reduce the ability of Apc to regulate beta-catenin.",295,,,www.uniprot.org,2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,13328
"APC C1578fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1578 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). C1578fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), C1578fs is predicted to reduce the ability of Apc to regulate beta-catenin.",295,,,www.uniprot.org,2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,13329
"APC D1297A lies within the mutator cluster region of the Apc protein (PMID: 14672538). D1297A has been identified in sequencing studies (PMID: 17257127), but has not been biochemically characterized and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7805,17257127,Phenotypes of invasion in sporadic colorectal carcinomas related to aberrations of the adenomatous polyposis coli (APC ) gene.,http://www.ncbi.nlm.nih.gov/pubmed/17257127,2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,13332
"APC D1297fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1297 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). D1297fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), D1297fs is predicted to reduce the ability of Apc to regulate beta-catenin.",295,,,www.uniprot.org,2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,13333
"APC D1318fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1318 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). D1318fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), D1318fs is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,13335
"APC D1422fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1422 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). D1422fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), D1422fs is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,13337
"APC D1422H lies within the Ctnnb1 binding and down-regulation domain of the Apc protein (PMID: 14672538). D1422H has been identified in sequencing studies (PMID: 8221638), but has not been biochemically characterized and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7806,8221638,Coexistence of somatic and germ-line mutations of APC gene in desmoid tumors from patients with familial adenomatous polyposis.,http://www.ncbi.nlm.nih.gov/pubmed/8221638,13340
"APC D1422N lies within the Ctnnb1 binding and down-regulation domain of the Apc protein (PMID: 14672538). D1422N has been identified in sequencing studies (PMID: 18632876), but has not been biochemically characterized and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",7807,18632876,Adenomatous polyposis coli alteration in digestive endocrine tumours: correlation with nuclear translocation of beta-catenin and chromosomal instability.,http://www.ncbi.nlm.nih.gov/pubmed/18632876,2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,285,,,http://www.ncbi.nlm.nih.gov/pubmed,13341
"APC D1425A lies within the Ctnnb1 binding and down-regulation domain of the Apc protein (PMID: 14672538). D1425A has been identified in sequencing studies (PMID: 8055154), but has not been biochemically characterized and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7808,8055154,Lack of mutations of the adenomatous polyposis coli gene in oesophageal and gastric carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/8055154,13342
"APC D1425fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1425 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). D1425fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), D1425fs is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,13343
"APC D1484fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1484 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). D1484fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), D1484fs is predicted to reduce the ability of Apc to regulate beta-catenin.",295,,,www.uniprot.org,2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,13345
"APC E1577* results in a premature truncation of the Apc protein at amino acid 1577 of 2843 (UniProt.org). E1577* has not been characterized, and therefore, its effect on Apc protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13346
"APC G2303R does not lie within any known functional domains of the Apc protein (UniProt.org). G2303R has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13347
"APC Y1376* results in a premature truncation of the Apc protein at amino acid 1376 of 2843 (UniProt.org). Y1376* has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), Y1376* is predicted to reduce the ability of Apc to regulate beta-catenin.",295,,,www.uniprot.org,2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,13348
"TP53-NTRK1 results from the fusion of the 3’ untranslated region of TP53 to NTRK1 (PMID: 24445538). TP53-NTRK1 has been identified in spitzoid tumors (PMID: 24445538), but has not been biochemically characterized and therefore, its effect on protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3819,24445538,Kinase fusions are frequent in Spitz tumours and spitzoid melanomas.,http://www.ncbi.nlm.nih.gov/pubmed/24445538,13350
"ETV6-ITPR2 results from the fusion of ETV6 and ITPR2 (PMID: 20033038). ETV6-ITPR2 has been identified in breast cancer (PMID: 20033038), but has not been biochemically characterized and therefore, its effect on protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3824,20033038,Complex landscapes of somatic rearrangement in human breast cancer genomes.,http://www.ncbi.nlm.nih.gov/pubmed/20033038,13352
"NPM1 W288fs is a hotspot mutation that results from a 4 bp-insertion causing a frameshift at aa 288 of 294, which can result in a novel nuclear export sequence (PMID: 15659725). Other 4-bp insertions at the W288 site confer a mislocalization to the Npm1 protein, therefore, W288fs is predicted to lead to a loss of Npm1 protein function (PMID: 15659725, PMID: 16720834).",1522,15659725,Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.,http://www.ncbi.nlm.nih.gov/pubmed/15659725,295,,,www.uniprot.org,3601,16720834,Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/16720834,13356
BRAF R506_K507insVLR lies within the protein kinase domain (UniProt.org). R506_K507insVLR confers a gain of function to the Braf protein as demonstrated by stabilization of Braf homodimers and increased downstream Erk signaling (PMID: 23817572).,1902,23817572,Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.,http://www.ncbi.nlm.nih.gov/pubmed/23817572,295,,,www.uniprot.org,13358
"KRAS R73M does not lie within any known functional domains of the Kras protein (UniProt.org). R73M has been identified in sequencing studies (PMID: 23817572), but has not been biochemically characterized and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1902,23817572,Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.,http://www.ncbi.nlm.nih.gov/pubmed/23817572,13362
"ABL1 C330G lies within the protein kinase domain of the Abl1 protein (UniProt.org). C330G has been identified in the scientific literature (PMID: 19373669), but has not been biochemically characterized and therefore, its effect on Abl1 protein function is unknown (PubMed, Feb 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7903,19373669,"Presence of a new BCR-ABL kinase domain mutation, C330G in an imatinib naive patient with chronic myeloid leukemia: very low prevalence of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from eastern India.",http://www.ncbi.nlm.nih.gov/pubmed/19373669,13363
ABL1 D276G lies within the protein kinase domain of the Abl1 protein (UniProt.org). D276G has been demonstrated to occur as a secondary resistance mutation in the context of BCR-ABL and results in increased kinase activity (PMID: 15510211).,3827,15510211,Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib.,http://www.ncbi.nlm.nih.gov/pubmed/15510211,295,,,www.uniprot.org,13364
"ABL1 E255V lies within the protein kinase domain of the Abl1 protein (UniProt.org). E255V has not been biochemically characterized, but has been demonstrated to occur as a secondary drug resistance mutation in the context of BCR-ABL (PMID: 21562040).",3828,21562040,BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.,http://www.ncbi.nlm.nih.gov/pubmed/21562040,295,,,www.uniprot.org,13365
"ABL1 E279K lies within the protein kinase domain of the Abl1 protein (UniProt.org). E279K has not been biochemically characterized, but has been demonstrated to occur as a secondary drug resistance mutation in the context of BCR-ABL (PMID: 21562040).",3828,21562040,BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.,http://www.ncbi.nlm.nih.gov/pubmed/21562040,295,,,www.uniprot.org,13366
"ABL1 E355G lies within the protein kinase domain of the Abl1 protein (UniProt.org). E355G has not been biochemically characterized, but has been demonstrated to occur as a secondary drug resistance mutation in the context of BCR-ABL (PMID: 21562040).",295,,,www.uniprot.org,3828,21562040,BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.,http://www.ncbi.nlm.nih.gov/pubmed/21562040,13367
"ABL1 F311I lies within the protein kinase domain of the Abl1 protein (UniProt.org). F311I has not been biochemically characterized, but has been demonstrated to occur as a secondary drug resistance mutation in the context of BCR-ABL (PMID: 21562040).",295,,,www.uniprot.org,3828,21562040,BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.,http://www.ncbi.nlm.nih.gov/pubmed/21562040,13368
"ABL1 F311L lies within the protein kinase domain of the Abl1 protein (UniProt.org). F311L has not been biochemically characterized, but has been demonstrated to occur as a secondary drug resistance mutation in the context of BCR-ABL (PMID: 21562040).",3828,21562040,BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.,http://www.ncbi.nlm.nih.gov/pubmed/21562040,295,,,www.uniprot.org,13369
"ABL1 F317L lies within the protein kinase domain of the Abl1 protein (UniProt.org). F317L has not been biochemically characterized, but has been demonstrated to occur as a secondary drug resistance mutation in the context of BCR-ABL (PMID: 21562040).",3828,21562040,BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.,http://www.ncbi.nlm.nih.gov/pubmed/21562040,295,,,www.uniprot.org,13370
"ABL1 F359I lies within the protein kinase domain of the Abl1 protein (UniProt.org). F359I has not been biochemically characterized, but has been demonstrated to occur as a secondary drug resistance mutation in the context of BCR-ABL (PMID: 21562040).",295,,,www.uniprot.org,3828,21562040,BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.,http://www.ncbi.nlm.nih.gov/pubmed/21562040,13371
"ABL1 F359V lies within the protein kinase domain of the Abl1 protein (UniProt.org). F359V confers a loss of function to the Abl1 protein as demonstrated by a loss of inhibitor binding, and has also been demonstrated to occur as a secondary drug resistance mutation in the context of BCR-ABL (PMID: 16046538, PMID: 21562040).",5631,16046538,"Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.",http://www.ncbi.nlm.nih.gov/pubmed/16046538,3828,21562040,BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.,http://www.ncbi.nlm.nih.gov/pubmed/21562040,295,,,www.uniprot.org,13373
"ABL1 G250E lies within the protein kinase domain of the Abl1 protein (UniProt.org). G250E has not been biochemically characterized, but has been demonstrated to occur as a secondary drug resistance mutation in the context of BCR-ABL (PMID: 21562040).",3828,21562040,BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.,http://www.ncbi.nlm.nih.gov/pubmed/21562040,295,,,www.uniprot.org,13374
"ABL1 H295_P296insH results in the insertion of one amino acid in the protein kinase domain of the Abl1 protein between amino acids 295 and 296 (UniProt.org). H295_P296insH has been identified in sequencing studies (PMID: 21442193) but has not been biochemically characterized and therefore, its effect on Abl1 protein function is unknown (PubMed, Feb 2017).
",7905,21442193,Imatinib resistance and blast transformation of chronic myeloid leukemia associated with a novel tri-nucleotide insertion mutation of BCR-ABL kinase domain at position K294.,http://www.ncbi.nlm.nih.gov/pubmed/21442193,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13375
ABL1 H396P lies within the protein kinase domain of the Abl1 protein (UniProt.org). H396P is predicted to lead to activation of Abl1 as indicated by the conformation of the crystal structure of the catalytic domain (PMID: 16424036).,295,,,www.uniprot.org,3830,16424036,Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.,http://www.ncbi.nlm.nih.gov/pubmed/16424036,13376
"ABL1 H396R lies within the protein kinase domain of the Abl1 protein (UniProt.org). H396R has not been biochemically characterized, but has been demonstrated to occur as a secondary drug resistance mutation in the context of BCR-ABL (PMID: 21562040).",3828,21562040,BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.,http://www.ncbi.nlm.nih.gov/pubmed/21562040,295,,,www.uniprot.org,13377
"ABL1 I242M lies within the protein kinase domain of the Abl1 protein (UniProt.org). I242M has been identified in sequencing studies (PMID: 20668451), but has not been biochemically characterized and therefore, its effect on Abl1 protein function is unknown (PubMed, Feb 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7380,20668451,Diverse somatic mutation patterns and pathway alterations in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/20668451,13378
"ABL1 L248V lies within the protein kinase domain of the Abl1 protein (UniProt.org). L248V has not been characterized, but has been demonstrated to occur as a secondary resistance mutation in the context of BCR-ABL (PMID: 21562040).",295,,,www.uniprot.org,3828,21562040,BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.,http://www.ncbi.nlm.nih.gov/pubmed/21562040,13379
"ABL1 L384M lies within the protein kinase domain of the Abl1 protein (UniProt.org). L384M has not been characterized, but has been demonstrated to occur as a secondary resistance mutation in the context of BCR-ABL (PMID: 21562040).",295,,,www.uniprot.org,3828,21562040,BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.,http://www.ncbi.nlm.nih.gov/pubmed/21562040,13380
"ABL1 L387M lies within the protein kinase domain of the Abl1 protein (UniProt.org). L387M has not been characterized, but has been demonstrated to occur as a secondary resistance mutation in the context of BCR-ABL (PMID: 21562040).",3828,21562040,BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.,http://www.ncbi.nlm.nih.gov/pubmed/21562040,295,,,www.uniprot.org,13381
"ABL1 M244V lies within the protein kinase domain of the Abl1 protein (UniProt.org). M244V has not been characterized, but has been demonstrated to occur as a secondary resistance mutation in the context of BCR-ABL (PMID: 21562040).",3828,21562040,BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.,http://www.ncbi.nlm.nih.gov/pubmed/21562040,295,,,www.uniprot.org,13382
"ABL1 M351T lies within the protein kinase domain of the Abl1 protein (UniProt.org). M351T results in a loss of inhibitor binding, and has been demonstrated to occur as a secondary resistance mutation in the context of BCR-ABL (PMID: 16046538, PMID: 21562040).",295,,,www.uniprot.org,3828,21562040,BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.,http://www.ncbi.nlm.nih.gov/pubmed/21562040,5631,16046538,"Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.",http://www.ncbi.nlm.nih.gov/pubmed/16046538,13383
"ABL1 M388L lies within the protein kinase domain of the Abl1 protein (UniProt.org). M388L has not been characterized, but has been demonstrated to occur as a secondary resistance mutation in the context of BCR-ABL (PMID: 21562040).",3828,21562040,BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.,http://www.ncbi.nlm.nih.gov/pubmed/21562040,295,,,www.uniprot.org,13385
"ABL1 P980L lies within the F-actin-binding region of the Abl1 protein (UniProt.org). P980L has not been characterized and therefore, its effect on Abl1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13386
"ABL1 Q252H lies within the protein kinase domain of the Abl1 protein (UniProt.org). Q252H results in a loss of inhibitor binding, and has also been demonstrated to occur as a secondary resistance mutation in the context of BCR-ABL (PMID: 16046538, PMID: 21562040).",5631,16046538,"Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.",http://www.ncbi.nlm.nih.gov/pubmed/16046538,295,,,www.uniprot.org,3828,21562040,BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.,http://www.ncbi.nlm.nih.gov/pubmed/21562040,13387
"ABL1 Q346L lies within the protein kinase domain of the Abl1 protein (UniProt.org). Q346L has not been characterized, but has been demonstrated to occur as a secondary resistance mutation in the context of BCR-ABL (PMID: 21562040).",295,,,www.uniprot.org,3828,21562040,BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.,http://www.ncbi.nlm.nih.gov/pubmed/21562040,13388
"ABL1 R362fs*21 likely results in a truncation of the 1130 aa Abl1 protein at aa 362, followed by 21 nonsense amino acids within the protein kinase domain (UniProt.org). Due to the loss of the majority of the protein kinase domain (UniProt.org), R362fs*21 is predicted to lead to a loss of Abl1 protein function.",295,,,www.uniprot.org,13389
"ABL1 S417Y lies within the protein kinase domain of the Abl1 protein (UniProt.org). S417Y has not been characterized, but has been demonstrated to occur as a secondary resistance mutation in the context of BCR-ABL (PMID: 21562040).",3828,21562040,BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.,http://www.ncbi.nlm.nih.gov/pubmed/21562040,295,,,www.uniprot.org,13390
"ABL1 T315L lies within the protein kinase domain of the Abl1 protein (UniProt.org). T315L has not been characterized, but has been demonstrated to occur as a secondary resistance mutation in the context of BCR-ABL (PMID: 21562040).",3828,21562040,BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.,http://www.ncbi.nlm.nih.gov/pubmed/21562040,295,,,www.uniprot.org,13391
ABL1 T315N lies within the protein kinase domain of the Abl1 protein (UniProt.org). T315N is predicted to lead to a loss of Abl1 protein function as indicated by a loss of inhibitor binding (PMID: 16046538).,295,,,www.uniprot.org,5631,16046538,"Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.",http://www.ncbi.nlm.nih.gov/pubmed/16046538,13394
ABL1 Y253F lies within the protein kinase domain of the Abl1 protein (UniProt.org). Y253F has been demonstrated to occur as a secondary resistance mutation in the context of BCR-ABL and results in increased kinase activity and enhanced cell proliferation in culture (PMID: 16880519).,3834,16880519,"Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.",http://www.ncbi.nlm.nih.gov/pubmed/16880519,295,,,www.uniprot.org,13395
"ABL1 Y253H lies within the protein kinase domain of the Abl1 protein (UniProt.org). Y253H is a secondary resistance mutation in the context of BCR-ABL with conflicting functional data, Y253H has been reported to not confer a growth advantage over wild-type Abl1 (PMID: 16482207) and has been reported to proliferate more rapidly than wild-type in competition experiments (PMID: 16880519).",295,,,www.uniprot.org,3834,16880519,"Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.",http://www.ncbi.nlm.nih.gov/pubmed/16880519,3835,16482207,The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib.,http://www.ncbi.nlm.nih.gov/pubmed/16482207,13397
BRAF A598T lies within the protein kinase domain of the Braf protein (UniProt.org). A598T confers a loss of function to the Braf protein as demonstrated by loss of kinase activity (PMID: 22926515).,463,22926515,ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers.,http://www.ncbi.nlm.nih.gov/pubmed/22926515,295,,,www.uniprot.org,13400
"BRAF E611D lies within the protein kinase domain of the Braf protein (UniProt.org). E611D has been identified in sequencing studies (PMID: 15935100), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Jun 2017).",7100,15935100,Preponderance of the oncogenic V599E and V599K mutations in B-raf kinase domain is enhanced in melanoma cutaneous/subcutaneous metastases.,http://www.ncbi.nlm.nih.gov/pubmed/15935100,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13401
"FBXW7 C386W lies within the WD repeat 1 of the Fbxw7 protein (UniProt.org). C386W has been identified in sequencing studies (PMID: 17457043), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",7944,17457043,High copy amplification of the Aurora-A gene is associated with chromosomal instability phenotype in human colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/17457043,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13403
"FBXW7 D440N lies within the WD repeat 2 of the Fbxw7 protein (UniProt.org). D440N has been identified in sequencing studies (PMID: 17909001), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",2635,17909001,FBXW7/hCDC4 is a general tumor suppressor in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17909001,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13404
"FBXW7 G397D lies within the WD repeat 1 of the Fbxw7 protein (UniProt.org). G397D has been identified in the scientific literature (PMID: 16357143), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",7947,16357143,CDC4 mutations occur in a subset of colorectal cancers but are not predicted to cause loss of function and are not associated with chromosomal instability.,http://www.ncbi.nlm.nih.gov/pubmed/16357143,115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13405
"FBXW7 H470P lies within the third WD repeat region of the Fbxw7 protein (UniProt.org). H470P has been identified in sequencing studies (PMID: 18485478), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",1372,18485478,FBXW7 mutation in adult T-cell and B-cell acute lymphocytic leukemias.,http://www.ncbi.nlm.nih.gov/pubmed/18485478,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13406
"FBXW7 I563T lies within the WD repeat 5 of the Fbxw7 protein (UniProt.org). I563T has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,13407
"FBXW7 R226C does not lie within any known functional domains of the Fbxw7 protein (UniProt.org). R226C has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,13408
"FBXW7 R385C lies within the first WD repeat region of the Fbxw7 protein (UniProt.org). R385C has been identified in the scientific literature (PMID: 28086948), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7952,28086948,Is there still a role for cytotoxic chemotherapy after targeted therapy and immunotherapy in metastatic melanoma? A case report and literature review.,http://www.ncbi.nlm.nih.gov/pubmed/28086948,13409
"FBXW7 R425C lies within the WD repeat 2 of the Fbxw7 protein (UniProt.org). R425C has been identified in the scientific literature (PMID: 25623536), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7955,25623536,Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis.,http://www.ncbi.nlm.nih.gov/pubmed/25623536,13410
"FBXW7 T144R does not lie within any known functional domains of the Fbxw7 protein (UniProt.org). T144R has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13411
"DNMT3A Q866* results in a premature truncation of the Dnmt3a protein at amino acid 866 of 912 (UniProt.org). Q866* has not been characterized in the scientific literature and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13413
"FBXW7 V154I does not lie within any known functional domains of the Fbxw7 protein (UniProt.org). V154I has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13417
"GATA2 G237D does not lie within any known functional domains of the Gata2 protein (UniProt.org). G237D has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Oct 2015). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13418
"MET R1354Q (corresponds to R1336Q in the canonical isoform) lies within the protein kinase domain and MUC20 and RANBP9-interacting region of the Met protein (UniProt.org). R1354Q has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13419
"ROS1 E2308* results in a premature truncation of the Ros1 protein at amino acid 2308 of 2347 (UniProt.org). E2308* has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13420
"FBXW7 I435fs*9 likely results in a truncation of the 707 aa Fbxw7 protein at aa 435, followed by 9 nonsense amino acids (UniProt.org). Due to a loss of a majority of the WD repeat domains (UniProt.org), I435fs*9 is predicted to lead to a loss of Fbxw7 protein function.",295,,,www.uniprot.org,13421
"FBXW7 K444fs*32 likely results in a truncation of the 707 aa Fbxw7 protein at aa 444, followed by 32 nonsense amino acids (UniProt.org). Due to a loss of a majority of the WD repeat domains (UniProt.org), K444fs*32 is predicted to lead to a loss of Fbxw7 protein function.",295,,,www.uniprot.org,13422
"BRCA1 D693N does not lie within any known functional domains of the Brca1 protein (UniProt.org). D693N is a common Brca1 polymorphism, but has not been biochemically characterized and therefore, its effect on Brca1 protein function is unknown (PMID: 23674270, PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5422,23674270,BRCA1 polymorphisms and breast cancer epidemiology in the Western New York exposures and breast cancer (WEB) study.,http://www.ncbi.nlm.nih.gov/pubmed/23674270,13430
"BRCA1 R841W does not lie within any known functional domains of the Brca1 protein (UniProt.org). R841W has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13431
BRCA2 I2944F does not lie within any known functional domains of the Brca2 protein (UniProt.org). I2944F demonstrates DNA repair activity and rescue of BRCA null ES cells to similar level of wild-type Brca2 in culture (PMID: 22678057).,2588,22678057,Functional evaluation of BRCA2 variants mapping to the PALB2-binding and C-terminal DNA-binding domains using a mouse ES cell-based assay.,http://www.ncbi.nlm.nih.gov/pubmed/22678057,295,,,www.uniprot.org,13432
"ERBB2 (HER2) R217C lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). R217C has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13435
"ERBB2 (HER2) S974A lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). S974A has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13436
"ERBB4 C803S lies within the protein kinase domain of the Erbb4 protein (UniProt.org). C803S has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,13439
"ERBB4 D609N lies within the extracellular domain of the Erbb4 protein (UniProt.org). D609N has been identified in sequencing studies (PMID: 19718025), but has not been biochemically characterized and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,566,19718025,Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.,http://www.ncbi.nlm.nih.gov/pubmed/19718025,285,,,http://www.ncbi.nlm.nih.gov/pubmed,13440
"ERBB4 G936R lies within the protein kinase domain of the Erbb4 protein (UniProt.org). G936R has not been biochemically characterized, but is predicted to result in increased Erbb4 dimerization affinity leading to a gain of function (PMID: 21701703).",295,,,www.uniprot.org,4632,21701703,Analysis of Somatic Mutations in Cancer: Molecular Mechanisms of Activation in the ErbB Family of Receptor Tyrosine Kinases.,http://www.ncbi.nlm.nih.gov/pubmed/21701703,13441
"ERBB4 H295Q lies within the extracellular domain of the Erbb4 protein (UniProt.org). H295Q has been identified in sequencing studies (PMID: 22722201), but has not been biochemically characterized and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7023,22722201,The landscape of cancer genes and mutational processes in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22722201,13442
"ERBB4 M313I lies within the extracellular domain of the Erbb4 protein (UniProt.org). M313I has been identified in sequencing studies (PMID: 19718025), but has not been biochemically characterized and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,566,19718025,Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.,http://www.ncbi.nlm.nih.gov/pubmed/19718025,13443
"ERBB4 P619L lies within the extracellular domain of the Erbb4 protein (UniProt.org). P619L has been identified in sequencing studies (PMID: 21984974), but has not been biochemically characterized and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7177,21984974,Temporal dissection of tumorigenesis in primary cancers.,http://www.ncbi.nlm.nih.gov/pubmed/21984974,13444
"ERBB4 Y111H lies within the extracellular domain of the Erbb4 protein (UniProt.org). Y111H has been identified in the scientific literature (PMID: 19718025), but has not been biochemically characterized and therefore, its effect on Erbb4 protein function is unknown (PubMed, Mar 2017).",566,19718025,Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.,http://www.ncbi.nlm.nih.gov/pubmed/19718025,115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13445
"DNMT3A P569_A574del results in the deletion of six amino acids in the PRC2/EED-EZH2-interacting region of the Dnmt3a protein from amino acids 569 to 574 (UniProt.org). P569_A574del has not been characterized in the scientific literature and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13446
"PTPN11 D61H lies within the SH2 domain 1 of the Ptpn11 protein (UniProt.org). D61H has been identified in the scientific literature (PMID: 26456833) but has not been biochemically characterized and therefore, its effect on Ptpn11 protein function is unknown (PubMed, Mar 2017).
",8186,26456833,Myeloid Dysregulation in a Human Induced Pluripotent Stem Cell Model of PTPN11-Associated Juvenile Myelomonocytic Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/26456833,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13453
"RET A274G lies within the extracellular domain of the Ret protein (UniProt.org). A274G has not been characterized in the scientific literature and therefore, its effect on Ret protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13454
"RET P273L lies within the extracellular domain of the Ret protein (UniProt.org). P273L has not been characterized in the scientific literature and therefore, its effect on Ret protein function is unknown (PubMed, Aug 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,13455
"RET T278S lies within the extracellular domain of the Ret protein (UniProt.org). T278S has not been characterized in the scientific literature and therefore, its effect on Ret protein function is unknown (PubMed, Sep 2017).  ",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,13456
"ROS1 E341D lies within the extracellular domain of the Ros1 protein (UniProt.org). E341D has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13458
"ROS1 L567V lies within the fibronectin type-III domain 3 of the Ros1 protein (UniProt.org). L567V has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13459
"ROS1 T2195S lies within the protein kinase domain of the Ros1 protein (UniProt.org). T2195S has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13460
"ROS1 T804N lies within the extracellular domain of the Ros1 protein (UniProt.org). T804N has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13461
"SMO H577Q lies within the cytoplasmic domain of the Smo protein (UniProt.org). H577Q has not been characterized in the scientific literature and therefore, its effect on Smo protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13464
"SMO H577R lies within the cytoplasmic domain of the Smo protein (UniProt.org). H577R has not been characterized in the scientific literature and therefore, its effect on Smo protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13465
"SMO Q651K lies within the cytoplasmic domain of the Smo protein (UniProt.org). Q651K has not been characterized in the scientific literature and therefore, its effect on Smo protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13466
"SMO R173H lies within the FZ domain of the Smo domain (UniProt.org). R173H has not been characterized in the scientific literature and therefore, its effect on Smo protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13467
"TET2 G355D does not lie within any known functional domains of the Tet2 protein (UniProt.org). G355D has not been characterized in the scientific literature and therefore, its effect on Tet2 protein function is unknown (PubMed, Jun 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13468
"TET2 H924R does not lie within any known functional domains of the Tet2 protein (UniProt.org). H924R has not been characterized in the scientific literature and therefore, its effect on Tet2 protein function is unknown (PubMed, Nov 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13469
"RUNX1 L56S lies within the Runt domain of the Runx1 protein (UniProt.org). L56S has been identified in the scientific literature (PMID: 23831921), but has not been biochemically characterized and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",8577,23831921,Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/23831921,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13474
"JAK2 R867Q lies within the protein kinase domain 2 of the Jak2 protein (UniProt.org). R867Q results in constitutive activation of STAT3/5, AKT and ERK signaling, and increased proliferation in thrombopoietin receptor-expressing cells in culture (PMID: 24398328).",295,,,www.uniprot.org,3844,24398328,Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/24398328,13483
"JAK3 R943C lies within the protein kinase domain 2 of the Jak3 protein (UniProt.org). R943C has not been characterized in the scientific literature and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13484
"KDR (VEGFR2) A331G lies within the Ig-like C2-type domain 4 of the Kdr (Vegfr2) protein (UniProt.org). A331G has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13486
CEBPA mutant indicates an unspecified mutation in the CEBPA gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,13625
"FLT3 P738R lies within the protein kinase domain of the Flt3 protein (UniProt.org). P738R has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13734
"RB1 I348V does not lie within any known functional domains of the Rb1 protein (UniProt.org). I348V has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13736
"ERBB2 (HER2) A1216D lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). A1216D has been identified in sequencing studies (Cancer Res 2016;76(14 Suppl):Abstract nr 4760), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",10117,,Efficacy of EGFR/HER2 duel-kinase inhibitors in PDX models harboring known and novel HER2-mutations,http://cancerres.aacrjournals.org/content/76/14_Supplement/4760,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13738
"ATM S978P does not lie within any known functional domains of the Atm protein (UniProt.org). S978P has been identified in sequencing studies (PMID: 16631465), but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Jan 2017).",295,,,www.uniprot.org,7498,16631465,ATM alterations in childhood non-Hodgkin lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/16631465,285,,,http://www.ncbi.nlm.nih.gov/pubmed,13744
"GNAS amp indicates an increased number of copies of the GNAS gene. However, the mechanism causing the increase is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,13746
FLT3 V194M lies within the extracellular domain of the Flt3 protein (UniProt.org). V194M is predicted to have no effect on Flt3 protein function by in silico models and is not transforming in cell culture  (PMID: 18068628).,2803,18068628,Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.,http://www.ncbi.nlm.nih.gov/pubmed/18068628,295,,,www.uniprot.org,13831
"FLT3 I836_M837del results in the deletion of two amino acids in the protein kinase domain of the Flt3 protein from amino acids 836 to 837 (UniProt.org). I836_M837del has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13832
"FGFR2 H572Y lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). H572Y has not been characterized in the scientific literature and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13853
"MPL S505N lies within the transmembrane domain of the Mpl protein (UniProt.org). S505N results in activation of Mpl signaling as indicated by constitutive phosphorylation of Mek1/2 and Stat5b, and is transforming in cell culture (PMID: 14764528).",295,,,www.uniprot.org,3902,14764528,"Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin.",http://www.ncbi.nlm.nih.gov/pubmed/14764528,13856
"MPL V501M lies within the transmembrane domain of the Mpl protein (UniProt.org). V501M has been identified in the scientific literature (PMID: 23994117), but has not been biochemically characterized and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8323,23994117,Detection of MPL mutations by a novel allele-specific PCR-based strategy.,http://www.ncbi.nlm.nih.gov/pubmed/23994117,13857
"MSH6 T1085fs results in a change in the amino acid sequence of the Msh6 protein beginning at aa 1085 of 1360, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of MSH2- and ATP-binding regions (PMID: 12019211), T1085fs is predicted to lead to a loss of Msh6 protein function.",3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,295,,,www.uniprot.org,13858
"MYD88 R193Q lies within the TIR domain of the Myd88 protein (UniProt.org). R193Q has not been characterized in the scientific literature and therefore, its effect on Myd88 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13860
"NOTCH1 A2331T lies within the cytoplasmic domain of the Notch1 protein (UniProt.org). A2331T has been identified in sequencing studies (PMID: 18593716), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4433,18593716,NOTCH1 mutations in individuals with left ventricular outflow tract malformations reduce ligand-induced signaling.,http://www.ncbi.nlm.nih.gov/pubmed/18593716,13861
KMT2A rearrangement indicates an unspecified rearrangement of the KMT2A gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,13862
"RET F185L lies within the cadherin domain of the Ret protein (UniProt.org). F185L has not been characterized in the scientific literature and therefore, its effect on Ret protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13863
"RB1 R272* results in a premature truncation of the Rb1 protein at amino acid 272 of 928 (UniProt.org). Due to the loss of all functional domains (UniProt.org), R272* is predicted to lead to a loss of Rb1 protein function. ",295,,,www.uniprot.org,13864
"ATM N1356D does not lie within any known functional domains of the Atm protein (UniProt.org). N1356D has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13870
"BRCA2 V894I lies within the NPM1-interacting region of the Brca2 protein (UniProt.org). V894I has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13873
"CSF1R C224S lies within the Ig-like C2-type domain 3 of the Csf1r protein (UniProt.org). C224S has not been characterized in the scientific literature and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13880
"TP53 R280I lies in a DNA contact site within the DNA-binding domain of the Tp53 protein (PMID: 21056992). R280I has not been biochemically characterized, but due to the effects of other R280 mutations (PMID: 22822097, PMID: 18524770, PMID: 21643018), is predicted to result in a loss of Tp53 function.",585,21643018,Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.,http://www.ncbi.nlm.nih.gov/pubmed/21643018,3916,18524770,Oligomerization of BAK by p53 utilizes conserved residues of the p53 DNA binding domain.,http://www.ncbi.nlm.nih.gov/pubmed/18524770,3914,21056992,Mage-A cancer/testis antigens inhibit p53 function by blocking its interaction with chromatin.,http://www.ncbi.nlm.nih.gov/pubmed/21056992,3915,22822097,The rebel angel: mutant p53 as the driving oncogene in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22822097,13882
BRCA1 del indicates a deletion of the BRCA1 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,13883
"SMO P753L lies within the cytoplasmic domain of the Smo protein (UniProt.org). P753L has not been characterized in the scientific literature and therefore, its effect on Smo protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13900
"VHL P86R does not lie within any known functional domains of the Vhl protein (UniProt.org). P86R has been identified in the scientific literature (PMID: 11257211), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).
",10114,11257211,"Is the P25L a ""real"" VHL mutation?",http://www.ncbi.nlm.nih.gov/pubmed/11257211,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13901
"VHL Q132fs results in a change in the amino acid sequence of the Vhl protein beginning at aa 132 of 213, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the Elongin BC complex-binding region (UniProt.org), Q132fs is predicted to lead to a loss of Vhl function.",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13902
"TET2 I812fs results in a change in the amino acid sequence of the Tet2 protein beginning at aa 812 of 2002, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the catalytic domain (PMID: 25132561), I812fs is predicted to lead to a loss of Tet2 protein function.",295,,,www.uniprot.org,3925,25132561,Connections between TET proteins and aberrant DNA modification in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25132561,13903
ABL1 mutant indicates and unspecified mutation in the ABL1 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,13904
"TET2 L1514H does not lie within any known functional domains of the Tet2 protein (UniProt.org). L1514H has not been characterized in the scientific literature and therefore, its effect on Tet2 protein function is unknown (PubMed, Nov 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13906
"TET2 L360W does not lie within any known functional domains of the Tet2 protein (UniProt.org). L360W has not been characterized in the scientific literature and therefore, its effect on Tet2 protein function is unknown (PubMed, Nov 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13907
"TET2 R2000I does not lie within any known functional domains of the Tet2 protein (UniProt.org). R2000I has not been characterized in the scientific literature and therefore, its effect on Tet2 protein function is unknown (PubMed, Nov 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13908
"VHL C77* results in a premature truncation of the Vhl protein at amino acid 77 of 213 (UniProt.org). Due to the loss of all known functional domains (PMID: 19878677), C77* is predicted to lead to a loss of Vhl protein function.",3927,19878677,Adding structural information to the von Hippel-Lindau (VHL) tumor suppressor interaction network.,http://www.ncbi.nlm.nih.gov/pubmed/19878677,295,,,www.uniprot.org,13909
"VHL L116fs results in a change in the amino acid sequence of the Vhl protein beginning at aa 116 of 213, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the Elongin BC complex-binding region (UniProt.org), L116fs is predicted to lead to a loss of Vhl protein function.",295,,,www.uniprot.org,13910
"VHL N131fs results in a change in the amino acid sequence of the Vhl protein beginning at aa 131 of 213, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the Elongin BC complex-binding region (UniProt.org), N131fs is predicted to lead to a loss of Vhl function.",295,,,www.uniprot.org,13911
"VHL L158fs results in a change in the amino acid sequence of the Vhl protein beginning at aa 158 of 213, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the Elongin BC complex-binding region (UniProt.org), L158fs is predicted to lead to a loss of Vhl protein function.",295,,,www.uniprot.org,13912
"VHL L184fs results in a change in the amino acid sequence of the Vhl protein beginning at aa 184 of 213, likely resulting in premature truncation of the functional protein (UniProt.org). L184fs has been identified in sequencing studies (Cancer Res 2016;76(14 Suppl):Abstract nr 4503), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",10112,,Actionable mutations and mutational burden in renal cell carcinoma,http://cancerres.aacrjournals.org/content/76/14_Supplement/4503,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13913
"VHL R177fs results in a change in the amino acid sequence of the Vhl protein beginning at aa 177 of 213, likely resulting in premature truncation of the functional protein (UniProt.org). R177fs has been identified in sequencing studies (PMID: 22683710), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3409,22683710,BAP1 loss defines a new class of renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22683710,13914
"ALK W501* results in a premature truncation of the Alk protein at amino acid 501 of 1620 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), W501* is predicted to lead to a loss of Alk protein function.",295,,,www.uniprot.org,13926
"ATM F897I does not lie within any known functional domains of the Atm protein (UniProt.org). F897I has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13928
"ATM Q1128R does not lie within any known functional domains of the Atm protein (UniProt.org). Q1128R has been identified in sequencing studies (PMID: 16014569), but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017).
",2639,16014569,Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL.,http://www.ncbi.nlm.nih.gov/pubmed/16014569,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13930
"BRCA1 Q155E does not lie within any known functional domains of the Brca1 protein (UniProt.org). Q155E has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13942
"BRCA1 R1347G does not lie within any known functional domains of the Brca1 protein (UniProt.org). R1347G has been identified in the scientific literature (PMID: 12215251), but has not been biochemically characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",6634,12215251,Characterization of common BRCA1 and BRCA2 variants.,http://www.ncbi.nlm.nih.gov/pubmed/12215251,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13943
"BRCA2 V3365_S3366insVNYI results in the insertion of four amino acids in Brca2 protein between amino acids 3365 and 3366 (UniProt.org). V3365_S3366insVNYI has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13944
"BRCA2 V3365fs results in a change in the amino acid sequence of the Brca2 protein beginning at 3365 of 3418, likely resulting in premature truncation of the functional protein (UniProt.org). V3365fs has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13945
"CBL L467V does not lie within any known functional domains of the Cbl protein (UniProt.org). L467V has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13948
"CSF1R R294Q lies within the extracellular domain of the Csf1r protein (UniProt.org). R294Q has not been characterized and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13956
"ETV6 L201P does not lie within any known functional domains of the Etv6 protein (UniProt.org). L201P has not been characterized in the scientific literature and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,13968
"ETV6 R191W does not lie within any known functional domains of the Etv6 protein (UniProt.org). R191W has not been characterized in the scientific literature and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,13969
"NOTCH1 V1110_S1723del results in the deletion of 614 amino acids in the extracellular domain of the Notch1 protein from amino acids 1110 to 1723 (UniProt.org). V1110_S1723del has not been biochemically characterized, although it is associated with increased copy number of the NOTCH1 gene in patient tumor samples (PMID: 25564152).
",3942,25564152,PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/25564152,295,,,www.uniprot.org,14009
"NOTCH1 T887I lies within the EGF-like domain 23 of the Notch1 protein (UniProt.org). T887I has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14010
"NOTCH1 S2523L lies within the PEST domain of the Notch1 protein (PMID: 25564152). S2523L has not been biochemically characterized, although it is associated with increased copy number of NOTCH1 gene in patient tumor samples (PMID: 25564152). 
",3942,25564152,PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/25564152,295,,,www.uniprot.org,14011
"NOTCH1 S2499_F2554del results in the deletion of 56 amino acids in the cytoplasmic domain of the Notch1 protein from amino acids 2499 to 2554 (UniProt.org). S2499_F2554del has not been biochemically characterized, although it is associated with increased copy number of the NOTCH1 gene in patient tumor samples (PMID: 25564152).
",3942,25564152,PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/25564152,295,,,www.uniprot.org,14012
"NOTCH1 Q2487L lies within the PEST domain of the Notch1 protein (PMID: 25564152). Q2487L has not been biochemically characterized, although it is associated with increased copy number of the NOTCH1 gene in patient tumor samples (PMID: 25564152).
",3942,25564152,PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/25564152,14013
"NOTCH1 P2462fs results in a change in the amino acid sequence of the Notch1 protein beginning at aa 2462 of 2555, likely resulting in premature truncation of the functional protein (UniProt.org). P2462fs has not been biochemically characterized, although it is associated with increased copy number of the NOTCH1 gene in patient tumor samples (PMID: 25564152).
",3942,25564152,PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/25564152,295,,,www.uniprot.org,14014
"NOTCH1 P2438fs results in a change in the amino acid sequence of the Notch1 protein beginning at aa 2438 of 2555, likely resulting in premature truncation of the functional protein (UniProt.org). P2438fs has not been biochemically characterized, although it is associated with increased copy number of the NOTCH1 gene in patient tumor samples (PMID: 25564152).
",295,,,www.uniprot.org,3942,25564152,PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/25564152,14015
"NOTCH1 G1376S lies within the EGF-like domain 35 of the Notch1 protein (UniProt.org). G1376S has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).  
",295,,,www.uniprot.org,3942,25564152,PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/25564152,14016
"NOTCH1 A2441T lies within the PEST domain of the Notch1 protein (PMID: 25564152). A2441T has not been biochemically characterized, although it is associated with increased copy number of the NOTCH1 gene in patient tumor samples (PMID: 25564152).
",3942,25564152,PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/25564152,14017
"NOTCH1 A2256fs results in a change in the amino acid sequence of the Notch1 protein beginning at aa 2256 of 2555, likely resulting in premature truncation of the functional protein (UniProt.org). A2256fs has not been biochemically characterized, although it is associated with increased copy number of the NOTCH1 gene in patient tumor samples (PMID: 25564152).
",295,,,www.uniprot.org,3942,25564152,PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/25564152,14018
"NOTCH1 A2036V lies within the ANK domain 4 of the Notch1 protein (UniProt.org). A2036V has not been characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Jun 2017).  
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14019
"NOTCH1 A1125V lies within the EGF-like domain 29 of the Notch1 protein (UniProt.org). A1125V has not been characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Jun 2017).  
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14020
"NOTCH1 V2249* results in a premature truncation of the Notch1 protein at amino acid 2249 of 2555 (UniProt.org). V2249* has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14022
NOTCH1 mutant indicates and unspecified mutation in the NOTCH1 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,14023
"TP53 dec exp indicates decreased expression of the Tp53 protein. However, the mechanism causing the decreased expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,14024
"KDR (VEGFR2) A1065T lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). A1065T confers a gain of function to the Kdr (Vegfr2) protein, resulting in constitutive tyrosine autophosphorylation (PMID: 19723655).",217,19723655,KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/19723655,295,,,www.uniprot.org,14029
"KDR (VEGFR2) G846D lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). G846D has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14030
"MET T698A lies within the IPT/TIG 2 domain of the Met protein (UniProt.org). T698A has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14035
"MET V136I lies within the Sema domain of the Met protein (UniProt.org). V136I has been identified in the scientific literature (PMID: 18709663), but has not been biochemically characterized and therefore, its effect on Met protein function is unknown (PubMed, Feb 2017).",8007,18709663,Expression and mutational analysis of MET in human solid cancers.,http://www.ncbi.nlm.nih.gov/pubmed/18709663,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14036
"MSH6 E544D does not lie within any known functional domains of the Msh6 protein (UniProt.org). E544D has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14041
"MSH6 V878A lies within the lever domain of the Msh6 protein (PMID: 18790734). The functional effect of V878A is conflicting, as it resulted in decreased Msh6 ATPase activity (PMID: 18790734), but also demonstrated proficient mis-match repair activity (PMID: 22102614).",3608,18790734,Hereditary cancer-associated missense mutations in hMSH6 uncouple ATP hydrolysis from DNA mismatch binding.,http://www.ncbi.nlm.nih.gov/pubmed/18790734,4989,22102614,A rapid and cell-free assay to test the activity of lynch syndrome-associated MSH2 and MSH6 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/22102614,14042
Wild-type CSF3R indicates that no mutation has been detected within the CSF3R gene. ,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,14043
"CALR act mut indicates that this variant results in a gain of function in the Calr protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,14044
"TET2 K67fs results in a change in the amino acid sequence of the Tet2 protein beginning at aa 67 of 2002 (UniProt.org). Due to the loss of the catalytic domain (PMID: 25132561), K67fs is predicted to lead to a loss of Tet2 protein function.",295,,,www.uniprot.org,3925,25132561,Connections between TET proteins and aberrant DNA modification in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25132561,14055
"VHL A149D lies within the CCT complex-binding region of the Vhl protein (UniProt.org). A149D has been identified in sequencing studies (PMID: 19996202), but has not been biochemically characterized and therefore, its effect on VHL protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7422,19996202,Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/19996202,295,,,www.uniprot.org,14056
"FBXW7 T15_G16insTP results in the insertion of two amino acids in the Fbxw7 protein between amino acids 15 and 16 (UniProt.org). T15_G16insTP has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Feb 2107).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,14063
"GATA2 P161A does not lie within any known functional domains of the Gata2 protein (UniProt.org). P161A has been identified in the scientific literature (PMID: 22996659), but has not been biochemically characterized and therefore, its effect on Gata2 protein function is unknown (PubMed, Mar 2017).",8353,22996659,Cis-element mutated in GATA2-dependent immunodeficiency governs hematopoiesis and vascular integrity.,http://www.ncbi.nlm.nih.gov/pubmed/22996659,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14066
"IDH1 G289fs results in a change in the amino acid sequence of the Idh1 protein beginning at 289 of 414, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the large domain required for formation of the active site, S289fs is predicted to lead to a loss of Idh1 protein function (PMID: 20513808).",295,,,www.uniprot.org,5710,20513808,Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism.,http://www.ncbi.nlm.nih.gov/pubmed/20513808,14069
"MYD88 L229S lies within the TIR domain of the Myd88 protein (UniProt.org). L229S has not been characterized and therefore, its effect on Myd88 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14070
"IDH2 T435M does not lie within any known functional domains of the Idh2 protein (UniProt.org). T435M has not been characterized in the scientific literature and therefore, its effect on Idh2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14071
"IKZF1 amp indicates an increased number of copies of the IKZF1 gene. However, the mechanism causing the increase is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,14072
"IKZF1 P19T does not lie within any known functional domains of the Ikzf1 protein (UniProt.org). P19T has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, Nov 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14073
"KIT V399I lies within the Ig-like C2-type domain 4 of the Kit protein (UniProt.org). V399I has been identified in sequencing studies (PMID: 25589003), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Dec 2016).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6992,25589003,Sporadic hemangioblastomas are characterized by cryptic VHL inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/25589003,14077
"MPL P324H lies within the extracellular domain of the Mpl protein (UniProt.org). P324H has not been characterized in the scientific literature and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14082
"NOTCH1 E756K lies within one of the extracellular EGF repeat regions of the Notch1 protein (UniProt.org). E756K has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14088
"PIK3CA R770Q does not lie within any known functional domains of the Pik3ca protein (UniProt.org). R770Q has been identified in the scientific literature (PMID: 24755471, PMID: 26681737), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Jun 2017). ",6962,24755471,Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24755471,7386,26681737,T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genes.,http://www.ncbi.nlm.nih.gov/pubmed/26681737,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14093
"RET T1038A does not lie within any known functional domains of the Ret protein (UniProt.org). T1038A has not been characterized in the scientific literature and therefore, its effect on Ret protein function is unknown (PubMed, Sep 2017).  ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14098
Wild-type CALR indicates that no mutation has been detected within the CALR gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,14099
"STK11 F354L lies within the C-terminal region of the Stk11 protein (PMID: 15800014). F354L does not disrupt Stk11 autophosphorylation or growth suppression by Stk11, but results in decreased AMPK phosphorylation and increased mTOR signaling, and alters cell polarization in culture (PMID: 15800014).",3984,15800014,Functional analysis of Peutz-Jeghers mutations reveals that the LKB1 C-terminal region exerts a crucial role in regulating both the AMPK pathway and the cell polarity.,http://www.ncbi.nlm.nih.gov/pubmed/15800014,14384
"ALK M1478T lies within the cytoplasmic domain of the Alk protein (UniProt.org). M1478T has not been characterized in the scientific literature and therefore, its effect on Alk protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14385
"TET2 S1607L does not lie within any known functional domains of the Tet2 protein (UniProt.org). S1607L has not been characterized in the scientific literature and therefore, its effect on Tet2 protein function is unknown (PubMed, Nov 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14387
"APC R2673G does not lie within any known functional domains of the Apc protein (UniProt.org). R2673G has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14388
"CALR Y128C lies within the N-domain region of the Calr protein (UniProt.org). Y128C has not been characterized in the scientific literature and therefore, its effect on Calr protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14396
"CALR T325I lies within the C-domain region of the Calr protein (UniProt.org). T325I has not been characterized in the scientific literature and therefore, its effect on Calr protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14397
"CALR T173fs results in a change in the amino acid sequence of the Calr protein beginning at aa 173 of 417, likely resulting in a premature truncation of the functional protein (UniProt.org). T173fs has not been characterized in the scientific literature and therefore, its effect on Calr protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14398
"CALR S323F lies within the C-domain region of the Calr protein (UniProt.org). S323F has not been characterized in the scientific literature and therefore, its effect on Calr protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,14399
"CALR S300Y lies within the P-domain region of the Calr protein (UniProt.org). S300Y has not been characterized in the scientific literature and therefore, its effect on Calr protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,14400
"CALR R177W lies within the N-domain region of the Calr protein (UniProt.org). R177W has not been characterized in the scientific literature and therefore, its effect on Calr protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14401
"CALR Q67H lies within the N-domain region of the Calr protein (UniProt.org). Q67H has not been characterized in the scientific literature and therefore, its effect on Calr protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14402
"CALR P410L lies within the C-domain region of the Calr protein (UniProt.org). P410L has not been characterized in the scientific literature and therefore, its effect on Calr protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14403
"CALR P204S lies within the P-domain region of the Calr protein (UniProt.org). P204S has not been characterized in the scientific literature and therefore, its effect on Calr protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14404
"CALR N188D lies within the N-domain region of the Calr protein (UniProt.org). N188D has been identified in sequencing studies (PMID: 22895193), but has not been biochemically characterized and therefore, its effect on Calr protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4597,22895193,Recurrent R-spondin fusions in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22895193,14405
"CALR L51V lies within the N-domain region of the Calr protein (UniProt.org). L51V has not been characterized in the scientific literature and therefore, its effect on Calr protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14406
"CALR K64T lies within the N-domain region of the Calr protein (UniProt.org). K64T has not been characterized in the scientific literature and therefore, its effect on Calr protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14407
"CALR K62R lies within the N-domain region of the Calr protein (UniProt.org). K62R has not been characterized in the scientific literature and therefore, its effect on Calr protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14408
"CALR K414E lies within the C-domain region of the Calr protein (UniProt.org). K414E has not been characterized in the scientific literature and therefore, its effect on Calr protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14409
"CALR G343D lies within the C-domain region of the Calr protein (UniProt.org). G343D has not been characterized in the scientific literature and therefore, its effect on Calr protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14410
"CALR F56L lies within the N-domain region of the Calr protein (UniProt.org). F56L has not been characterized in the scientific literature and therefore, its effect on Calr protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14411
"CALR F132L lies within the N-domain region of the Calr protein (UniProt.org). F132L has not been characterized in the scientific literature and therefore, its effect on Calr protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14412
"CALR E406Q lies within the C-domain region of the Calr protein (UniProt.org). E406Q has not been characterized in the scientific literature and therefore, its effect on Calr protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14413
"CALR E403* results in a premature truncation of the Calr protein at amino acid 403 of 417 (UniProt.org). E403* has been identified in sequencing studies (PMID: 23297126), but has not been biochemically characterized and therefore, its effect on Calr protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7142,23297126,Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/23297126,295,,,www.uniprot.org,14414
"CALR E398_D400del results in the deletion of three amino acids in the C-domain region of the Calr protein from amino acids 398 to 400 (UniProt.org). E398_D400del has been identified in the scientific literature (PMID: 25729726), but has not been biochemically characterized and therefore, its effect on Calr protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,9012,25729726,"Incidence, clinical features, and prognostic impact of CALR exon 9 mutations in essential thrombocythemia and primary myelofibrosis: an experience of a single tertiary hospital in Korea.",http://www.ncbi.nlm.nih.gov/pubmed/25729726,285,,,http://www.ncbi.nlm.nih.gov/pubmed,14415
"CALR E389K lies within the C-domain region of the Calr protein (UniProt.org). E389K has not been characterized in the scientific literature and therefore, its effect on Calr protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,14416
"CALR E389D lies within the C-domain region of the Calr protein (UniProt.org). E389D has not been characterized in the scientific literature and therefore, its effect on Calr protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14417
"CALR E386G lies within the C-domain region of the Calr protein (UniProt.org). E386G has not been characterized in the scientific literature and therefore, its effect on Calr protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14418
"CALR E381Q lies within the C-domain region of the Calr protein (UniProt.org). E381Q has not been characterized in the scientific literature and therefore, its effect on Calr protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14419
"CALR E341G lies within the C-domain region of the Calr protein (UniProt.org). E341G has not been characterized in the scientific literature and therefore, its effect on Calr protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14420
"CALR E298* results in a premature truncation of the Calr protein at amino acid 298 of 417 (UniProt.org). E298* has not been characterized in the scientific literature and therefore, its effect on Calr protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14421
"CALR E240D lies within the 4 X approximate repeat region of the Calr protein (UniProt.org). E240D has not been characterized in the scientific literature and therefore, its effect on Calr protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14422
"CALR E234K lies within the 4 X approximate repeat region of the Calr protein (UniProt.org). E234K has not been characterized in the scientific literature and therefore, its effect on Calr protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14423
"CALR E100Q lies within the N-domain region of the Calr protein (UniProt.org). E100Q has not been characterized in the scientific literature and therefore, its effect on Calr protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14424
"CALR D45Y lies within the N-domain region of the Calr protein (UniProt.org). D45Y has been identified in sequencing studies (PMID: 23856246), but has not been biochemically characterized and therefore, its effect on Calr protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6964,23856246,The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.,http://www.ncbi.nlm.nih.gov/pubmed/23856246,14425
"CALR D415E lies within the C-domain region of the Calr protein (UniProt.org). D415E has not been characterized in the scientific literature and therefore, its effect on Calr protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14426
"CALR D394_K401delinsE results in a deletion of eight amino acids from amino acids 394 to 402 within the C-domain region of the Calr protein, combined with the insertion of a glutamate (E) at the same site (UniProt.org). D394_K401delinsE has not been characterized in the scientific literature and therefore, its effect on Calr protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14427
"CALR D335N lies within the C-domain region of the Calr protein (UniProt.org). D335N has not been characterized in the scientific literature and therefore, its effect on Calr protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14428
"CALR D309Y lies within the C-domain region of the Calr protein (UniProt.org). D309Y has not been characterized in the scientific literature and therefore, its effect on Calr protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14429
"CALR D244G lies within the 4 X approximate repeat region of the Calr protein (UniProt.org). D244G has not been characterized in the scientific literature and therefore, its effect on Calr protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14430
"CSF3R A119T lies within the extracellular Ig-like C2-type domain of the Csf3r protein (UniProt.org). A119T has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14530
"CSF3R A124V lies within the extracellular domain of the Csf3r protein (UniProt.org). A124V has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14531
"CSF3R A208V lies within the extracellular Fibronectin type-III 1 domain of the Csf3r protein (UniProt.org). A208V has been identified in sequencing studies (PMID: 25957691), but has not been biochemically characterized and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7004,25957691,Prospective derivation of a living organoid biobank of colorectal cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/25957691,14532
"CSF3R A383V lies within the extracellular Fibronectin type-III 3 domain of the Csf3r protein (UniProt.org). A383V has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14533
"CSF3R A470T lies within the extracellular Fibronectin type-III 4 domain of the Csf3r protein (UniProt.org). A470T has been identified in sequencing studies (Blood 2014 124:4588), but has not been biochemically characterized and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7167,,In-Frame Exon 9 CALR Deletions Co-Occur with Other Alterations in the JAK-STAT Pathway in Myeloproliferative Neoplasms,http://www.bloodjournal.org/content/124/21/4588?sso-checked=true,14534
"CSF3R A520S lies within the extracellular Fibronectin type-III 4 domain of the Csf3r protein (UniProt.org). A520S has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14536
"CSF3R A593T lies within the extracellular Fibronectin type-III 5 domain of the Csf3r protein (UniProt.org). A593T has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14537
"CSF3R A778V lies within the cytoplasmic domain of the Csf3r protein (UniProt.org). A778V has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14538
"CSF3R A832V lies within the cytoplasmic domain of the Csf3r protein (UniProt.org). A832V has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14539
"CSF3R C52G lies within the extracellular Ig-like C2-type domain of the Csf3r protein (UniProt.org). C52G has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14540
"CSF3R D236G lies within the extracellular Fibronectin type-III 2 domain of the Csf3r protein (UniProt.org). D236G has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14541
"CSF3R D364Y lies within the extracellular Fibronectin type-III 3 domain of the Csf3r protein (UniProt.org). D364Y has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14542
"CSF3R D40N lies within the extracellular Ig-like C2-type domain of the Csf3r protein (UniProt.org). D40N has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14543
"CSF3R D702G lies within the cytoplasmic domain of the Csf3r protein (UniProt.org). D702G has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,14544
"CSF3R E149Q lies within the extracellular Fibronectin type-III 1 domain of the Csf3r protein (UniProt.org). E149Q has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,14545
"CSF3R E254K lies within the extracellular Fibronectin type-III 2 domain of the Csf3r protein (UniProt.org). E254K has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14546
"CSF3R E331* results in a premature truncation of the Csf3r protein at amino acid 331 of 836 (UniProt.org). Due to the loss of the transmembrane and cytoplasmic domains (UniProt.org), E331* is predicted to lead to a loss of Csf3r protein function (PubMed, Nov 2015).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14547
"CSF3R E363D lies within the extracellular Fibronectin type-III 3 domain of the Csf3r protein (UniProt.org). E363D has been identified in sequencing studies (PMID: 21720365), but has not been biochemically characterized and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6943,21720365,Integrated genomic analyses of ovarian carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/21720365,14548
"CSF3R E363V lies within the extracellular Fibronectin type-III 3 domain of the Csf3r protein (UniProt.org). E363V has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14549
"CSF3R E553K lies within the extracellular Fibronectin type-III 5 domain of the Csf3r protein (UniProt.org). E553K has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14550
"CSF3R E700Q lies within the cytoplasmic domain of the Csf3r protein (UniProt.org). E700Q has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14551
"CSF3R F156S lies within the extracellular Fibronectin type-III 1 domain of the Csf3r protein (UniProt.org). F156S has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14552
"CSF3R G147_P148insR results in the insertion of an arginine (R) in the extracellular Fibronectin type-III 1 domain of the Csf3r protein between amino acids 147 and 148 (UniProt.org). G147_P148insR has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14553
"CSF3R G21R lies within the signal peptide of the unprocessed Csf3r protein (UniProt.org). G21R has been identified in sequencing studies (PMID: 22722829), but has not been biochemically characterized and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",7168,22722829,Novel mutations target distinct subgroups of medulloblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22722829,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14554
"CSF3R G415R lies within the extracellular Fibronectin type-III 3 domain of the Csf3r protein (UniProt.org). G451R has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14555
"CSF3R G487W lies within the extracellular Fibronectin type-III 4 domain of the Csf3r protein (UniProt.org). G487W has been identified in sequencing studies (PMID: 23525077), but has not been biochemically characterized and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7021,23525077,Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity.,http://www.ncbi.nlm.nih.gov/pubmed/23525077,14556
"CSF3R G513E lies within the extracellular Fibronectin type-III 4 domain of the Csf3r protein (UniProt.org). G513E has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14557
"CSF3R G539C lies within the extracellular Fibronectin type-III 5 domain of the Csf3r protein (UniProt.org). G539C has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14558
"CSF3R G555R lies within the extracellular Fibronectin type-III 5 domain of the Csf3r protein (UniProt.org). G555R has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14559
"CSF3R G671C lies within the cytoplasmic domain of the Csf3r protein (UniProt.org). G671C has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,14560
"CSF3R G72R lies within the extracellular Ig-like C2-type domain of the Csf3r protein (UniProt.org). G72R has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,14561
"CSF3R G757D lies within the cytoplasmic domain of the Csf3r protein (UniProt.org). G757D has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14562
"CSF3R G81R lies within the extracellular Ig-like C2-type domain of the Csf3r protein (UniProt.org). G81R has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14563
"CSF3R H436Mfs*12 is a missense mutation (H436M) in conjunction with a likely truncation of the 836 aa Csf3r protein at aa 436, followed by 12 nonsense amino acids (UniProt.org). Due to the loss of the transmembrane domain (UniProt.org), H436Mfs*12 is predicted to lead to a loss of Csf3r protein function.",295,,,www.uniprot.org,14564
"CSF3R H588Y lies within the extracellular Fibronectin type-III 5 domain of the Csf3r protein (UniProt.org). H588Y has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14565
"CSF3R I48N lies within the extracellular Ig-like C2-type domain of the Csf3r protein (UniProt.org). I48N has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14566
"CSF3R I494V lies within the extracellular Fibronectin type-III 4 domain of the Csf3r protein (UniProt.org). I494V has been identified in sequencing studies (PMID: 24121792), but has not been biochemically characterized and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,6998,24121792,Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation.,http://www.ncbi.nlm.nih.gov/pubmed/24121792,295,,,www.uniprot.org,14567
"CSF3R I598M lies within the extracellular Fibronectin type-III 5 domain of the Csf3r protein (UniProt.org). I598M has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14568
"CSF3R K180N lies within the extracellular Fibronectin type-III 1 domain of the Csf3r protein (UniProt.org). K180N has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14569
"CSF3R K785E lies within the cytoplasmic domain of the Csf3r protein (UniProt.org). K785E has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14570
"CSF3R L285F lies within the extracellular Fibronectin type-III 2 domain of the Csf3r protein (UniProt.org). L285F has been identified in sequencing studies (PMID: 22895193), but has not been biochemically characterized and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",4597,22895193,Recurrent R-spondin fusions in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22895193,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14571
"CSF3R L55Q lies within the extracellular Ig-like C2-type domain of the Csf3r protein (UniProt.org). L55Q has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14572
"CSF3R L595V lies within the extracellular Fibronectin type-III 5 domain of the Csf3r protein (UniProt.org). L595V has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14573
"CSF3R L62Q lies within the extracellular Ig-like C2-type domain of the Csf3r protein (UniProt.org). L62Q has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14574
"CSF3R L685P lies within the cytoplasmic domain of the Csf3r protein (UniProt.org). L685P has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14575
"CSF3R L768R lies within the cytoplasmic domain of the Csf3r protein (UniProt.org). L768R has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,14576
"CSF3R M133I lies within the extracellular Fibronectin type-III 1 domain of the Csf3r protein (UniProt.org). M133I has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,14577
"CSF3R M199I lies within the extracellular Fibronectin type-III 1 domain of the Csf3r protein (UniProt.org). M199I has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14578
"CSF3R M231V lies within the extracellular Fibronectin type-III repeat domain of the Csf3r protein (PMID: 23656643). M231V has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3951,23656643,Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.,http://www.ncbi.nlm.nih.gov/pubmed/23656643,14579
"CSF3R M601I lies within the extracellular Fibronectin type-III 5 domain of the Csf3r protein (UniProt.org). M601I has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14580
"CSF3R A602S lies within the extracellular Fibronectin type-III 5 domain of the Csf3r protein (UniProt.org). A602S has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14581
"CSF3R N656S lies within the cytoplasmic domain of the Csf3r protein (UniProt.org). N656S has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14582
"CSF3R N713K lies within the cytoplasmic domain of the Csf3r protein (UniProt.org). N713K has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14583
"CSF3R N789S lies within the cytoplasmic domain of the Csf3r protein (UniProt.org). N789S has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14584
"CSF3R P20L lies within the signal peptide of the unprocessed Csf3r protein (UniProt.org). P20L has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14585
"CSF3R P221L lies within the extracellular Fibronectin type-III 1 domain of the Csf3r protein (UniProt.org). P221L has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14586
"CSF3R P34L lies within the extracellular Ig-like C2-type domain of the Csf3r protein (UniProt.org). P34L has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14587
"CSF3R P34S lies within the extracellular Ig-like C2-type domain of the Csf3r protein (UniProt.org). P34S has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14588
"CSF3R P360L lies within the extracellular Fibronectin type-III 3 domain of the Csf3r protein (UniProt.org). P360L has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14589
"CSF3R P467L lies within the extracellular Fibronectin type-III 4 domain of the Csf3r protein (UniProt.org). P467L has not been characterized in the scientific literature and therefore, its effect on the Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14590
"CSF3R P527S lies within the extracellular Fibronectin type-III 4 domain of the Csf3r protein (UniProt.org). P527S has been identified in sequencing studies (PMID: 22842228), but has not been biochemically characterized and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",7109,22842228,Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22842228,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14591
"CSF3R P675S lies within the cytoplasmic domain of the Csf3r protein (UniProt.org). P675S has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,14592
"CSF3R P782L lies within the cytoplasmic domain of the Csf3r protein (UniProt.org). P782L has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,14593
"CSF3R Q110* results in a premature truncation of the Csf3r protein at amino acid 110 of 836 (UniProt.org). Due to the loss of the majority of the protein including the transmembrane domain (UniProt.org), Q110* is predicted to lead to a loss of Csf3r protein function.",295,,,www.uniprot.org,14594
"CSF3R Q168H lies within the extracellular Fibronectin type-III 1 domain of the Csf3r protein (UniProt.org). Q168H has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14595
"CSF3R Q197H lies within the extracellular Fibronectin type-III 1 domain of the Csf3r protein (UniProt.org). Q197H has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14596
"CSF3R Q75* results in a premature truncation of the Csf3r protein at amino acid 75 of 836 (UniProt.org). Due to the loss of the majority of the protein including the transmembrane domain (UniProt.org), Q75* is predicted to lead to a loss of Csf3r protein function.",295,,,www.uniprot.org,14597
"CSF3R Q793* results in a premature truncation of the Csf3r protein at amino acid 793 of 836 (UniProt.org). Q793* has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14598
"CSF3R R118P lies adjacent to the Ig-like C2-type domain of the Csf3r protein (UniProt.org). R118P has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14599
"CSF3R R190H lies within the extracellular Fibronectin type-III 1 domain of the Csf3r protein (UniProt.org). R190H has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,295,,,www.uniprot.org,14600
"CSF3R R233W lies within the extracellular Fibronectin type-III 2 domain of the Csf3r protein (UniProt.org). R233W has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14601
"CSF3R R269C lies within the extracellular Fibronectin type-III 2 domain of the Csf3r protein (UniProt.org). R296C has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14602
"CSF3R R274C lies within the extracellular Fibronectin type-III 2 domain of the Csf3r protein (UniProt.org). R274C has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14604
"CSF3R R367W lies within the extracellular Fibronectin type-III 3 domain of the Csf3r protein (UniProt.org). R367W has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14605
"CSF3R R418H lies within the extracellular Fibronectin type-III 3 domain of the Csf3r protein (UniProt.org). R418H has been identified in sequencing studies (PMID: 23525077), but has not been biochemically characterized and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",7021,23525077,Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity.,http://www.ncbi.nlm.nih.gov/pubmed/23525077,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14607
"CSF3R R428K lies within the extracellular Fibronectin type-III 3 domain of the Csf3r protein (UniProt.org). R428K has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,14608
"CSF3R R484T lies within the extracellular Fibronectin type-III 4 domain of the Csf3r protein (UniProt.org). R484T has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,14609
"CSF3R R583L lies within the extracellular Fibronectin type-III 5 domain of the Csf3r protein (UniProt.org). R583L has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14610
"CSF3R R769C lies within the cytoplasmic domain of the Csf3r protein (UniProt.org). R769C has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14611
"CSF3R S374Y lies within the extracellular Fibronectin type-III 3 domain of the Csf3r protein (UniProt.org). S374Y has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14612
"CSF3R S469Afs*22 is a missense mutation (S469A) in conjunction with a likely truncation of the 836 aa Csf3r protein at aa 469, followed by 22 nonsense amino acids (UniProt.org). Due to the loss of the transmembrane domain (UniProt.org), S469Afs*22 is predicted to lead to a loss of Csf3r protein function.",295,,,www.uniprot.org,14613
"CSF3R S469Qfs*5 is a missense mutation (S469Q) in conjunction with a likely truncation of the 836 aa Csf3r protein at aa 469, followed by 5 nonsense amino acids (UniProt.org). Due to the loss of the transmembrane domain (UniProt.org), S469Qfs*5 is predicted to lead to a loss of Csf3r protein function.",295,,,www.uniprot.org,14614
"CSF3R S473G lies within the Fibronectin type-III 4 domain of the Csf3r protein (UniProt.org). S473G has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14615
"CSF3R S573F lies within the extracellular Fibronectin type-III 5 domain of the Csf3r protein (UniProt.org). S573F has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14616
"CSF3R S581F lies within the extracellular Fibronectin type-III 5 domain of the Csf3r protein (UniProt.org). S581F has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14617
"CSF3R S581P lies within the extracellular Fibronectin type-III 5 domain of the Csf3r protein (UniProt.org). S581P has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14618
"CSF3R S582F lies within the extracellular Fibronectin type-III 5 domain of the Csf3r protein (UniProt.org). S582F has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14619
"CSF3R S594G lies within the extracellular Fibronectin type-III 5 domain of the Csf3r protein (UniProt.org). S594G has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14620
"CSF3R S624L lies within the extracellular domain of the Csf3r protein (UniProt.org). S624L has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14621
"CSF3R S651N lies within the cytoplasmic domain of the Csf3r protein (UniProt.org). S651N has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14622
"CSF3R S669G lies within the cytoplasmic domain of the Csf3r protein (UniProt.org). S669G has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14623
"CSF3R S79F lies within the extracellular Ig-like C2-type domain of the Csf3r protein (UniProt.org). S79F has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,14624
"CSF3R T137I lies within the extracellular Fibronectin type-III 1 domain of the Csf3r protein (UniProt.org). T137I has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,14625
"CSF3R T234I lies within the extracellular Fibronectin type-III 2 domain of the Csf3r protein (UniProt.org). T234I has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14626
"CSF3R T476I lies within the extracellular Fibronectin type-III 4 domain of the Csf3r protein (UniProt.org). T476I has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14627
CSF3R T618I lies within the extracellular domain proximal to the transmembrane domain of the Csf3r protein (PMID: 23656643). T618I confers a gain of function to the Csf3r protein as demonstrated by increased proliferation and increased downstream Jak-Stat signaling in transformed cells in culture (PMID: 23656643).,3951,23656643,Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.,http://www.ncbi.nlm.nih.gov/pubmed/23656643,14628
CSF3R T615A lies within the extracellular domain proximal to the transmembrane domain of the Csf3r protein (PMID: 23656643). T615A confers a gain of function to the Csf3r protein as demonstrated by increased proliferation of transformed cells in culture (PMID: 23656643).,3951,23656643,Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.,http://www.ncbi.nlm.nih.gov/pubmed/23656643,14629
CSF3R Q741* results in a premature truncation of the Csf3r protein at amino acid 741 of 836 (UniProt.org). Q741* confers a loss of function to the Csf3r protein as demonstrated by increased proliferation of transformed cells in culture (PMID: 23656643).,295,,,www.uniprot.org,3951,23656643,Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.,http://www.ncbi.nlm.nih.gov/pubmed/23656643,14630
"CSF3R S783fs results in a change in the amino acid sequence of the Csf3r protein beginning at aa 783 of 836, likely resulting in premature truncation of the functional protein (UniProt.org). S783fs confers a loss of function to the Csf3r protein as demonstrated by increased proliferation and downstream signaling of transformed cells in culture (PMID: 23656643).",295,,,www.uniprot.org,3951,23656643,Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.,http://www.ncbi.nlm.nih.gov/pubmed/23656643,14631
"CSF3R Y752* results in a premature truncation of the Csf3r protein at amino acid 752 of 836 (UniProt.org). Y752* has not been biochemically characterized, but is predicted to result in a loss of Csf3r protein function based on the effects of other truncation mutations (PMID: 23656643).",3951,23656643,Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.,http://www.ncbi.nlm.nih.gov/pubmed/23656643,295,,,www.uniprot.org,14632
"CSF3R D771fs results in a change in the amino acid sequence of the Csf3r protein beginning at aa 771 of 836, likely resulting in premature truncation of the functional protein (UniProt.org). D771fs has not been characterized however, due to the effects of other truncation mutations downstream of D771, D771fs is predicted to lead to a loss of Csf3r protein function (PMID: 23656643).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14633
"CSF3R W791* results in a premature truncation of the Csf3r protein at amino acid 791 of 836 (UniProt.org). W791* has not been characterized and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14634
"CSF3R T690M lies within the cytoplasmic domain of the Csf3r protein (UniProt.org). T690M has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14635
"CSF3R T799S lies within the cytoplasmic domain of the Csf3r protein (UniProt.org). T799S has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14636
"CSF3R V178M lies within the extracellular Fibronectin type-III 1 domain of the Csf3r protein (UniProt.org). V178M has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14637
"CSF3R V812F lies within the cytoplasmic domain of the Csf3r protein (UniProt.org). V812F has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14638
"CSF3R W105R lies within the extracellular Ig-like C2-type domain of the Csf3r protein (UniProt.org). W105R has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14639
"CSF3R W202S lies within the extracellular Fibronectin type-III 1 domain of the Csf3r protein (UniProt.org). W202S has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,14640
"CSF3R W279* results in a premature truncation of the Csf3r protein at amino acid 27 of 836 (UniProt.org). Due to the loss of the transmembrane domain (UniProt.org), W279* is predicted to lead to a loss of Csf3r protein function.",295,,,www.uniprot.org,14641
"CSF3R W356S lies within the extracellular Fibronectin type-III 3 domain of the Csf3r protein (UniProt.org). W356S has been identified in sequencing studies (PMID: 22980975), but has not been biochemically characterized and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1726,22980975,Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/22980975,14642
"CSF3R W547R lies within the extracellular Fibronectin type-III 5 domain of the Csf3r protein (UniProt.org). W547R has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14643
"CSF3R Y121S lies within the extracellular domain of the Csf3r protein (UniProt.org). Y121S has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,14644
"CSF3R Y196H lies within the extracellular Fibronectin type-III 1 domain of the Csf3r protein (UniProt.org). Y196H has been identified in sequencing studies (PMID: 22895193), but has not been biochemically characterized and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4597,22895193,Recurrent R-spondin fusions in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22895193,14645
"CSF3R inact mut indicates that this variant results in a loss of function of the Csf3r protein. However, the specific amino acid change has not been identified. ",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,14646
"FGFR3 fusion indicates a fusion of the FGFR3 gene, but the fusion partner is unknown.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,14647
"CSF3R act mut indicates that this variant results in a gain of function in the Csf3r protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,14648
"FGFR1 fusion indicates a fusion of the FGFR1 gene, but the fusion partner is unknown.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,14653
"KRAS positive indicates the presence of the KRAS gene, mRNA, and/or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,14654
"EGFR E709_T710delinsD results in a deletion of two amino acids in the protein kinase domain of the Egfr protein from aa 709 to aa 710, combined with the insertion of an Aspartic Acid (D) at the same location (UniProt.org). E709_T710delinsD confers a gain of function to Egfr, resulting in phosphorylation of the Egfr protein and transformation of cultured cells (PMID: 26206867).",4031,26206867,EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.,http://www.ncbi.nlm.nih.gov/pubmed/26206867,14675
"FGFR3-BAIAP2L1 results from the fusion of FGFR3 and BAIAP2L1, demonstrating constitutive activation and transformation of cells in culture (PMID: 23175443).",4048,23175443,Oncogenic FGFR3 gene fusions in bladder cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23175443,14778
"RUNX1-RUNX1T1 (also referred to as RUNX1-ETO) results from the fusion of RUNX1 and ETO, demonstrating altered transcriptional regulation and a mutator phenotype (PMID: 22201794, PMID: 26050648).",4077,22201794,RUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/22201794,4078,26050648,The leukemia-associated RUNX1/ETO oncoprotein confers a mutator phenotype.,http://www.ncbi.nlm.nih.gov/pubmed/26050648,15094
"RB1 dec exp indicates decreased expression of the Rb1 protein. However, the mechanism causing the decrease is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,15464
"NOTCH1 S2449fs results in a change in the amino acid sequence of the Notch1 protein beginning at aa 2449 of 2555, likely resulting in premature truncation of the functional protein (UniProt.org). S2449fs has not been characterized, however, due to the effects of other PEST domain deletion downstream of S2449 (PMID: 15472075), S2449fs is predicted to lead to activation of Notch1 signaling.",295,,,www.uniprot.org,2814,15472075,Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/15472075,15663
"PIK3CA C378R lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). C378R results in constitutive activation of Pi3k and Akt signaling, and decreased apoptosis in cell culture (PMID: 17363507).",4169,17363507,Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis.,http://www.ncbi.nlm.nih.gov/pubmed/17363507,295,,,www.uniprot.org,15687
"PIK3CA C407Y lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). C407Y has been identified in sequencing studies (PMID: 27302833), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8024,27302833,Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes.,http://www.ncbi.nlm.nih.gov/pubmed/27302833,15688
"PIK3CA D300Y does not lie within any known functional domains of the Pik3ca protein (UniProt.org). D300Y has not been characterized in the scientific literature and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,15689
PIK3CA D350G lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). D350G results in increased phosphorylation of Akt in cell culture (PMID: 24265155).,4170,24265155,Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.,http://www.ncbi.nlm.nih.gov/pubmed/24265155,295,,,www.uniprot.org,15690
"PIK3CA D926N lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). D926N has not been characterized in the scientific literature and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,15691
"PIK3CA E39K lies within the PI3K-ABD domain of the Pik3ca protein (UniProt.org). E39K has been identified in sequencing studies (PMID: 22653804, PMID: 23917401, PMID: 19349352), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017).",3963,23917401,The integrated landscape of driver genomic alterations in glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/23917401,8062,19349352,Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/19349352,7748,22653804,Use of mutation profiles to refine the classification of endometrial carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/22653804,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,15692
"PIK3CA E453del results in the deletion of one amino acid in the C2 PI3K-type domain of the Pik3ca protein at amino acid 453 (UniProt.org). E453del has been identified in sequencing studies (PMID: 20049837), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Mar 2017).",8369,20049837,Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20049837,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,15693
PIK3CA G364R lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). G364R results in increased phosphorylation of Akt in cell culture (PMID: 21266528).,2211,21266528,A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/21266528,295,,,www.uniprot.org,15694
"PIK3CA H1065L lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). H1065L has been identified in the scientific literature (PMID: 18084252), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,8155,18084252,PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters.,http://www.ncbi.nlm.nih.gov/pubmed/18084252,285,,,http://www.ncbi.nlm.nih.gov/pubmed,15695
"PIK3CA H665Q lies within the PIK helical domain of the Pik3ca protein (UniProt.org). H665Q has not been characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,115,0,,http://www.ncbi.nlm.nih.gov/pubmed,15696
"PIK3CA I406V lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). I406V has not been characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,15697
"PIK3CA L339I lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). L339I has been identified in the scientific literature (PMID: 25078343), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8153,25078343,"Molecular alterations of PIK3CA in uterine carcinosarcoma, clear cell, and serous tumors.",http://www.ncbi.nlm.nih.gov/pubmed/25078343,15698
"PIK3CA P471L lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). P471L has been identified in the scientific literature (PMID: 26479420), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8895,26479420,Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies.,http://www.ncbi.nlm.nih.gov/pubmed/26479420,15699
"PIK3CA R357Q lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). R357Q has been identified in sequencing studies (PMID: 25233892, PMID: 23528559), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7232,23528559,DNA polymerase ε and δ exonuclease domain mutations in endometrial cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23528559,7231,25233892,Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes.,http://www.ncbi.nlm.nih.gov/pubmed/25233892,15700
"PIK3CA R38S lies within the PI3K-ABD domain of the Pik3ca protein (UniProt.org). R38S has not been characterized, but is predicted to affect the enzymatic activity of Pik3ca by structural modeling (PMID: 19305151).",295,,,www.uniprot.org,7233,19305151,PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches.,http://www.ncbi.nlm.nih.gov/pubmed/19305151,15701
"PIK3CA R916C lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). R916C has been identified in sequencing studies (PMID:     24356096), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,15702
PIK3CA R93W lies within the PI3K-ABD domain of the Pik3ca protein (UniProt.org). R93W results in increased phosphorylation of Akt in cell culture (PMID: 21266528).,2211,21266528,A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/21266528,295,,,www.uniprot.org,15703
"PIK3CA V146I does not lie within any known functional domains of the Pik3ca protein (UniProt.org). V146I has been identified in the scientific literature (PMID: 26080840), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017).",8144,26080840,Genome Analysis of Latin American Cervical Cancer: Frequent Activation of the PIK3CA Pathway.,http://www.ncbi.nlm.nih.gov/pubmed/26080840,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,15704
"PIK3CA Y165H does not lie within any known functional domains of the Pik3ca protein (UniProt.org). PIK3CA Y165H has not been characterized in the scientific literature and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,15705
"APC I1918V does not lie within any known functional domains of the Apc protein (UniProt.org). I1918V has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,15876
"APC N1118D does not lie within any known functional domains of the Apc protein (UniProt.org). N1118D has been identified in the scientific literature (PMID: 15122587) but has not been biochemically characterized and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7813,15122587,Definition of candidate low risk APC alleles in a Swedish population.,http://www.ncbi.nlm.nih.gov/pubmed/15122587,15877
"ATM K1964E lies within the FAT domain of the Atm protein (UniProt.org). K1964E has been identified in sequencing studies (PMID: 26675346) but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",7869,26675346,Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26675346,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,15879
"ATM L2307F lies within the FAT domain of the Atm protein (UniProt.org). L2307F has been identified in the scientific literature (PMID: 25625042), but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,6937,25625042,ATM gene mutations in sporadic breast cancer patients from Brazil.,http://www.ncbi.nlm.nih.gov/pubmed/25625042,295,,,www.uniprot.org,15880
"ATM L2332P lies within the FAT domain of the Atm protein (UniProt.org). L2332P has been identified in the scientific literature (PMID: 25625042), but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017).
",6937,25625042,ATM gene mutations in sporadic breast cancer patients from Brazil.,http://www.ncbi.nlm.nih.gov/pubmed/25625042,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,15881
"ATM L2492R lies within the FAT domain of the Atm protein (UniProt.org). L2492R has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,15882
CBL H398Y lies with the RING-type zinc finger domain of the Cbl protein (UniProt.org). H398Y results in a loss of ubiquitin ligase activity and is transforming in culture (PMID: 19387008).,295,,,www.uniprot.org,4186,19387008,Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/19387008,15885
"CBL R420L lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). R420L has not been biochemically characterized, but is predicted to disrupt Cbl stability by computer modeling (PMID: 26676746).",4519,26676746,Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26676746,295,,,www.uniprot.org,15886
"CBL Y455_D456del results in the deletion of two amino acids of the Cbl protein from amino acids 455 to 456 (UniProt.org). Y455_D456del has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,15887
"DNMT3A F751fs results in a change in the amino acid sequence of the Dnmt3a protein beginning at aa 751 of 912, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the SAM-dependent MTase C5-type domain (UniProt.org), F751fs is predicted to lead to a loss of Dnmt3a protein function.",295,,,www.uniprot.org,15891
"DNMT3A Q886* results in a premature truncation of the Dnmt3a protein at amino acid 886 of 912 (UniProt.org). Q886* has not been characterized in the scientific literature and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,15892
"DNMT3A R792S lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (UniProt.org). R792S has not been characterized in the scientific literature and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,15893
"DNMT3A S535_Y536insYDDDGYQS results in the insertion of eight amino acids in the ADD domain of the Dnmt3a protein between amino acids 535 and 536 (UniProt.org). S535_Y536insYDDDGYQS has not been characterized in the scientific literature and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,15894
"DNMT3A V649M lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (UniProt.org). V649M has not been characterized in the scientific literature and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,15895
Wild-type HNF1A indicates that no mutation has been detected within the HNF1A gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,16165
"HNF1A inact mut indicates that this variant results in a loss of function of the Hnf1a protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,16166
"CDH1 inact mut indicates that this variant results in a loss of function of the Cdh1 protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,16194
CDH1 mutant indicates an unspecified mutation in the CDH1 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,16195
"CDH1 over exp indicates an over expression of the Cdh1 protein. However, the mechanism causing the over expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,16205
"HNF1A G292Rfs*25 is a missense mutation (G292R) in conjunction with a likely truncation of the 631 aa Hnf1a protein at aa 292, followed by 25 nonsense amino acids (UniProt.org). Due to the loss of the transactivation domain (PMID: 18003757), G292Rfs*25 is predicted to lead to a loss of Hnf1a protein function.",295,,,www.uniprot.org,4227,18003757,The type and the position of HNF1A mutation modulate age at diagnosis of diabetes in patients with maturity-onset diabetes of the young (MODY)-3.,http://www.ncbi.nlm.nih.gov/pubmed/18003757,16241
"HNF1A N237S lies within the HNF1-type homeobox region of the Hnf1a protein (UniProt.org). N237S has not been characterized and therefore, its effect on Hnf1a protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,16242
"HNF1A P289Afs*28 is a missense mutation (P289A) in conjunction with a likely truncation of the 631 aa Hnf1a protein at aa 289, followed by 28 nonsense amino acids (UniProt.org). Due to the loss of the transactivation domain (PMID: 18003757), P289Afs*28 is predicted to lead to a loss of Hnf1a protein function.",295,,,www.uniprot.org,4227,18003757,The type and the position of HNF1A mutation modulate age at diagnosis of diabetes in patients with maturity-onset diabetes of the young (MODY)-3.,http://www.ncbi.nlm.nih.gov/pubmed/18003757,16243
"HNF1A P291Qfs*51 is a missense mutation (P291Q) in conjunction with a likely truncation of the 631 aa Hnf1a protein at aa 291, followed by 51 nonsense amino acids (UniProt.org). Due to the loss of the transactivation domain (PMID: 18003757), P291Qfs*51 is predicted to lead to a loss of Hnf1a protein function.",4227,18003757,The type and the position of HNF1A mutation modulate age at diagnosis of diabetes in patients with maturity-onset diabetes of the young (MODY)-3.,http://www.ncbi.nlm.nih.gov/pubmed/18003757,295,,,www.uniprot.org,16244
"HNF1A R131W lies within the DNA-interacting region of the Hnf1a protein (UniProt.org). R131W results in aberrant subcellular localization of Hnf1a, impaired DNA binding and decreased transcriptional activity in cell culture (PMID: 12574234).",4228,12574234,Hepatocyte nuclear factor-1 alpha gene mutations and diabetes in Norway.,http://www.ncbi.nlm.nih.gov/pubmed/12574234,295,,,www.uniprot.org,16245
"HNF1A R263G lies within the DNA-interacting region of the Hnf1a protein (UniProt.org). R263G has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,16246
"HNF1A R272S lies within the DNA-interacting region of the Hnf1a protein (UniProt.org). R272S has not been characterized and therefore, its effect on Hnf1a protein function is unknown (PubMed, Jan 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,16247
"SMAD4 dec exp indicates decreased expression of the Smad4 protein. However, the mechanism causing the decreased expression is unspecified.
",3257,,The Novel Inhibitor PLX3397 Effectively Inhibits FLT3-Mutant AML,http://abstracts.hematologylibrary.org/cgi/content/abstract/118/21/3632?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=PLX3397&searchid=1&FIRSTINDEX=0&volume=118&issue=21&resourcetype=HWCIT,16263
"CDH1 R749W lies within the cytoplasmic domain of the Cdh1 protein (UniProt.org). R749W confers  a loss of function as demonstrated by loss of p120 association, decreased protein stability of Cdh1, increased Egfr signaling, increased motility, and an invasive phenotype in culture (PMID: 22850631, PMID: 19268661).",1052,19268661,E-cadherin mutations and cell motility: a genotype-phenotype correlation.,http://www.ncbi.nlm.nih.gov/pubmed/19268661,4243,22850631,The importance of E-cadherin binding partners to evaluate the pathogenicity of E-cadherin missense mutations associated to HDGC.,http://www.ncbi.nlm.nih.gov/pubmed/22850631,295,,,www.uniprot.org,16264
"CDH1 A298T lies within the Cadherin-1 domain of the Cdh1 protein (UniProt.org). A298T confers a loss of function to the Cdh1 protein as demonstrated by reduced interaction with Egfr, increased cell motility, increased Egfr signaling, and increased p38 Mapk signaling in culture (PMID: 19268661).",1052,19268661,E-cadherin mutations and cell motility: a genotype-phenotype correlation.,http://www.ncbi.nlm.nih.gov/pubmed/19268661,295,,,www.uniprot.org,16265
"CDH1 E757K lies within the cytoplasmic domain of the Cdh1 protein (UniProt.org). E757K confers a loss of function to the Cdh1 protein as demonstrated by reduced cell surface expression, reduced interaction with Egfr, increased Egfr signaling, and increased cell motility in culture (PMID: 19268661).",1052,19268661,E-cadherin mutations and cell motility: a genotype-phenotype correlation.,http://www.ncbi.nlm.nih.gov/pubmed/19268661,295,,,www.uniprot.org,16266
"CDH1 L214P lies within the Cadherin-1 domain of the Cdh1 protein (UniProt.org). L214P confers a loss of function to the Cdh1 protein as demonstrated by reduced interaction with Egfr, increased Egfr signaling, increased p38 Mapk signaling, and increased cell motility in culture (PMID: 19268661).",1052,19268661,E-cadherin mutations and cell motility: a genotype-phenotype correlation.,http://www.ncbi.nlm.nih.gov/pubmed/19268661,295,,,www.uniprot.org,16267
"CDH1 P373L lies within the Cadherin-2 domain of the Cdh1 protein (UniProt.org). P373L confers a loss of function to the Cdh1 protein as demonstrated by reduced interaction with Egfr, increased Egfr signaling, increased p38 Mapk signaling, and increased cell motility in culture (PMID: 19268661).",1052,19268661,E-cadherin mutations and cell motility: a genotype-phenotype correlation.,http://www.ncbi.nlm.nih.gov/pubmed/19268661,295,,,www.uniprot.org,16268
"CDH1 T340A lies within the Cadherin-2 domain of the Chd1 protein (UniProt.org). T340A confers a loss of function to the Cdh1 protein as demonstrated by increased Egfr signaling, increased p38 Mapk signaling, and increased in cell motility in culture (PMID: 19268661).",1052,19268661,E-cadherin mutations and cell motility: a genotype-phenotype correlation.,http://www.ncbi.nlm.nih.gov/pubmed/19268661,295,,,www.uniprot.org,16269
"SMAD4 E330A lies lies within the MH2 domain of the Smad4 protein (UniProt.org). E330A impairs Smad4 transcriptional activity upon Tgf-beta stimulation (PMID: 17994767, PMID: 26488212). ",4246,17994767,Novel mutations in Smad proteins that inhibit signaling by the transforming growth factor beta in mammalian cells.,http://www.ncbi.nlm.nih.gov/pubmed/17994767,4263,26488212,Clinicopathological and genetic differences between low-grade and high-grade colorectal mucinous adenocarcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/26488212,295,,,www.uniprot.org,16270
"EGFR dec exp indicates decreased expression of the Egfr protein. However, the mechanism causing the decreased expression is unspecified.
",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,16273
PIK3CA I31M lies within the PI3K-ABD domain of the Pik3ca protein (UniProt.org). I31M demonstrated transformation potential and ability to promote growth factor-independent cell survival to similar levels of wild-type Pik3ca protein in culture (PMID: 26627007).,295,,,www.uniprot.org,4255,26627007,Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26627007,16274
SMAD4 G252* results in a premature truncation of the Smad4 protein at amino acid 252 of 552 (UniProt.org). G252*confers a loss of function on Smad4 as demonstrated by decreased transcriptional activity and increased cell proliferation (PMID: 26488212).,295,,,www.uniprot.org,4263,26488212,Clinicopathological and genetic differences between low-grade and high-grade colorectal mucinous adenocarcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/26488212,16281
ROS1 L2155 lies in the protein kinase domain of the Ros1 protein (UniProt.org). L2155S confers crizotinib resistance in ROS1-rearranged NSCLC cell lines (PMID: 25688157).,4265,25688157,Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25688157,295,,,www.uniprot.org,16282
ROS1 G2101A lies in the protein kinase domain of the Ros1 protein (UniProt.org). G2101A confers crizotinib resistance in cell lines expressing ROS1-rearrangements (PMID: 25688157).,4265,25688157,Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25688157,295,,,www.uniprot.org,16283
"MET N38K lies within the Sema domain of the Met protein (UniProt.org). N38K has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,16291
"FBXW7 mutant indicates and unspecified mutation in the FBXW7 gene.
",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,16293
"TP53 I251S lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). I251S has not been biochemically characterized, but is predicted to result in a loss of Tp53 protein function based on conferring similar sensitivity to mutant Tp53-targeted therapeutics compared to cells with characterized Tp53 mutations in culture (PMID: 26748848).",4309,26748848,A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/26748848,16335
"TP53 I195* results in a premature truncation of the Tp53 protein at amino acid 195 of 393 (UniProt.org). Due to the loss of the DNA binding domain including sites that interact with Mre11 (UniProt.org, PMID: 22713868), I195* is predicted to lead to a loss of Tp53 protein function.",295,,,www.uniprot.org,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,16336
"TP53 Y234C lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). Y234C results in decreased Tp53 transactivation and interferes with wild-type Tp53 function in cell culture, and correlates with protein aggregates in human tumor samples (PMID: 21056685, PMID: 16861262).  ",411,16861262,Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/16861262,4320,21056685,Co-localization of mutant p53 and amyloid-like protein aggregates in breast tumors.,http://www.ncbi.nlm.nih.gov/pubmed/21056685,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,16353
"TP53 Y327L (also referred to as Y326L) lies within the transactivation domain of the Tp53 protein (PMID: 22713868). Y327L has not been biochemically characterized, but is predicted to result in a loss of Tp53 protein function based on conferring similar sensitivity to mutant Tp53-targeted therapeutics compared to cells with characterized Tp53 mutations in culture (PMID: 26748848).",2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,4309,26748848,A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/26748848,16359
"ETV6 L341fs results in a change in the amino acid sequence of the Etv6 protein beginning at aa 341of 452, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the DNA binding domain, L341fs is predicted to lead to a loss of Etv6 protein function (UniProt.org).",295,,,www.uniprot.org,16429
"FGFR1 D165_D166del (corresponds to D132 in the canonical isoform) results in the deletion of two amino acids in the Ig-like C2 type domain 2 of the Fgfr1 protein from amino acids 165 to 166 (UniProt.org). D165_D166del has not been characterized in the scientific literature and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,16430
"PIK3CA N345I lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). N345I confers a gain of function to Pik3ca protein as indicated by increased cell survival, although it is not transforming in culture (PMID: 26627007).",4255,26627007,Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26627007,295,,,www.uniprot.org,16474
"TP53 P151S lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). P151S results in a loss of Tp53 transactivation activity and resistance to anoikis in cell culture, and promotes tumor growth in xenograft models (PMID: 21903770, PMID: 23625637).
",2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,4327,21903770,Disruptive TP53 mutation is associated with aggressive disease characteristics in an orthotopic murine model of oral tongue cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21903770,4328,23625637,Serine substitution of proline at codon 151 of TP53 confers gain of function activity leading to anoikis resistance and tumor progression of head and neck cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/23625637,16518
"TP53 P278L lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). P278L has not been biochemically characterized in human cells, but results in a loss of transactivation activity in yeast assays (PMID: 16861262).",411,16861262,Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/16861262,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,16527
"TP53 P278S lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). P278S results in the loss of Tp53 transactivation of p21, while retaining activation of Axl in cell culture, and promotes tumor growth in xenograft models (PMID: 22989750).",4330,22989750,Allele specific gain-of-function activity of p53 mutants in lung cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/22989750,16533
"TP53 R196* results in a premature truncation of the Tp53 protein at amino acid 196 of 393 (UniProt.org). Due to the loss of several functional domains (UniProt.org), R196* is predicted to lead to a loss of Tp53 protein function.",295,,,www.uniprot.org,16538
"TP53 R283C lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). R283C leads to a reduction in Tp53 transactivation activity, and the corresponding mouse variant (R277C) demonstrates decreased ability to prevent TgfB-induced epithelial-to-mesenchymal transition in culture (PMID: 22710932, PMID: 23018556).",554,22710932,Transactivation and reactivation capabilities of temperature-dependent p53 mutants in yeast and human cells.,http://www.ncbi.nlm.nih.gov/pubmed/22710932,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,4331,23018556,p53 regulates epithelial-mesenchymal transition induced by transforming growth factor β.,http://www.ncbi.nlm.nih.gov/pubmed/23018556,16548
"TP53 R342* results in a premature truncation of the Tp53 protein at amino acid 342 of 393 (UniProt.org). R342* has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,16549
"TP53 S241F lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). S241F results in loss of Tp53 transcriptional activity and prevents formation of the Tp53/Bard1/CstF complex in cell culture (PMID: 16835297, PMID: 19225112, PMID: 21383700).",4332,16835297,Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts.,http://www.ncbi.nlm.nih.gov/pubmed/16835297,4333,19225112,A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53.,http://www.ncbi.nlm.nih.gov/pubmed/19225112,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,4334,21383700,p53 inhibits mRNA 3' processing through its interaction with the CstF/BARD1 complex.,http://www.ncbi.nlm.nih.gov/pubmed/21383700,16552
TP53 V272M lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). V272M results in a loss of Tp53 DNA binding and transactivation ability in cell culture (PMID: 11870884).,4335,11870884,Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1.,http://www.ncbi.nlm.nih.gov/pubmed/11870884,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,16555
"TP53 Y103* results in a premature truncation of the Tp53 protein at amino acid 103 of 393 (UniProt.org). Due to the loss of the majority of the DNA-binding domain as well as several other functional domains (UniProt.org), R103* is predicted to lead to a loss of Tp53 protein function.",295,,,www.uniprot.org,16557
"TP53 Y236F lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). Y236F has not been characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2016).",2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,285,,,http://www.ncbi.nlm.nih.gov/pubmed,16561
"TP53 E285K lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). E285K results in a temperature-dependent decrease in transcriptional activation by Tp53 in cell culture (PMID:   15613472, PMID: 22710932).",4336,15613472,Hsp90 is essential for restoring cellular functions of temperature-sensitive p53 mutant protein but not for stabilization and activation of wild-type p53: implications for cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/15613472,554,22710932,Transactivation and reactivation capabilities of temperature-dependent p53 mutants in yeast and human cells.,http://www.ncbi.nlm.nih.gov/pubmed/22710932,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,16568
"TP53 E198* results in a premature truncation of the Tp53 protein at amino acid 198 of 393 (UniProt.org). Due to the loss of several functional domains (UniProt.org), E198* is predicted to lead to a loss of Tp53 protein function.",295,,,www.uniprot.org,16569
"TP53 F212fs*3 likely results in a truncation of the 393 aa Tp53 protein at aa 212, followed by 3 nonsense amino acids (UniProt.org). Due to the loss of several functional domains (UniProt.org), F212fs*3 is predicted to lead to a loss of Tp53 protein function.",295,,,www.uniprot.org,16570
"ROS1 A87T lies within the extracellular domain of the Ros1 protein (UniProt.org). A87T has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,16572
"KRAS act mut indicates that this variant results in a gain of function in the Kras protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,16577
"NRAS act mut indicates that this variant results in a gain of function in the Nras protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,16578
"HRAS act mut indicates that this variant results in a gain of function in the Hras protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,16579
"MLH1 inact mut indicates that this variant results in a loss of function of the Mlh1 protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,16582
"TP53 E298* results in a premature truncation of the Tp53 protein at amino acid 298 of 393 (UniProt.org). Due to the loss of the tetramerization domain (PMID: 22713868), R298* is predicted to lead to a loss of Tp53 function.",2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,295,,,www.uniprot.org,16585
"TP53 E336* results in a premature truncation of the Tp53 protein at amino acid 336 of 393 (UniProt.org). E336* results in decreased Tp53 transactivation activity and reduced nuclear localization in cell culture (PMID: 9331090, PMID: 16969106).",4338,9331090,Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.,http://www.ncbi.nlm.nih.gov/pubmed/9331090,4339,16969106,Oligomerization of p53 precedes its association with dynein and nuclear accumulation.,http://www.ncbi.nlm.nih.gov/pubmed/16969106,16589
"TP53 H179N lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). H179N results in similar Tp53 exonuclease activity compared to wild-type, but leads to decreased DNA binding in an in vitro assay, and decreased apoptotic response to X-Ray in Drosophila expressing the corresponding variant (H159N) (PMID: 10778859, PMID: 19462533).",779,19462533,Dissection of the sequence-specific DNA binding and exonuclease activities reveals a superactive yet apoptotically impaired mutant p53 protein.,http://www.ncbi.nlm.nih.gov/pubmed/19462533,4340,10778859,Drosophila p53 is a structural and functional homolog of the tumor suppressor p53.,http://www.ncbi.nlm.nih.gov/pubmed/10778859,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,16590
"TP53 H179Q lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). H179Q results in decreased Tp53 transactivation activity and disruption of the G1 checkpoint in cell culture (PMID: 16209708, PMID: 22540896).",2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,4343,16209708,Telomerase expression is sufficient for chromosomal integrity in cells lacking p53 dependent G1 checkpoint function.,http://www.ncbi.nlm.nih.gov/pubmed/16209708,4342,22540896,A prognostic signature of defective p53-dependent G1 checkpoint function in melanoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/22540896,16612
"TP53 H193R lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). H193R has not been biochemically characterized in human cells, but results in decreased Tp53 transactivation ability in yeast assays and is predicted to result in decreased Tp53 stability and protein expression by computational modeling (PMID: 9627118, PMID: 21763698).",4345,9627118,Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay.,http://www.ncbi.nlm.nih.gov/pubmed/9627118,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,574,21763698,Structural and functional impact of cancer-related missense somatic mutations.,http://www.ncbi.nlm.nih.gov/pubmed/21763698,16636
TP53 M237I lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). M237I results in decreased Tp53 transactivation activity in cell culture (PMID: 16492679).,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,4346,16492679,Specific TP53 mutation pattern in radiation-induced sarcomas.,http://www.ncbi.nlm.nih.gov/pubmed/16492679,16637
"CTNNB1 K49E does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). K49E has not been biochemically characterized, however, nuclear accumulation of Ctnnb1was observed in the presence of a coincident P44L mutation (PMID: 12474227).",295,,,www.uniprot.org,2347,12474227,Cribriform-morular variant of papillary thyroid carcinoma: a pathological and molecular genetic study with evidence of frequent somatic mutations in exon 3 of the beta-catenin gene.,http://www.ncbi.nlm.nih.gov/pubmed/12474227,16705
"FLT3 D600_L601insDFREYEYD results in the insertion of eight amino acids in the juxtamembrane domain of the Flt3 protein between amino acids 600 and 601 (UniProt.org). FLT3 D600_L601insDFREYEYD is predicted to lead to activation of Flt3 due to the effects of other Flt3 internal tandem duplication (ITD) mutations (PMID: 12970773, PMID: 9737679, PMID: 11090077).",2898,11090077,Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.,http://www.ncbi.nlm.nih.gov/pubmed/11090077,2896,12970773,FLT3: ITDoes matter in leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/12970773,295,,,www.uniprot.org,2897,9737679,Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product.,http://www.ncbi.nlm.nih.gov/pubmed/9737679,16797
"FLT3 I38V lies within the extracellular domain of the Flt3 protein (UniProt.org). I38V has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,16798
"NOTCH1 E694K lies within the calcium-binding, EGF-like domain 18 of the Notch1 protein (UniProt.org). E694K has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,16806
"NPM1 L287fs results in a premature truncation of the Npm1 protein at amino acid 287 of 294 (UniProt.org). L287fs has not been characterized in the scientific literature and therefore, its effect on Npm1 protein function is unknown (PubMed, Oct 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,16813
"SRC amplification indicates an increased number of copies of the SRC gene. However, the mechanism causing the increase is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,16815
"FGFR1 V561M lies within the protein kinase domain of the Fgfr1 protein (UniProt.org), V561M results in increased Fgfr1 autophosphorylation in cell culture, and has been demonstrated to confer resistance to tyrosine kinase inhibitors (PMID: 25686244, PMID: 15157880).",4375,15157880,Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/15157880,295,,,www.uniprot.org,4376,25686244,Illuminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles' heel of targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/25686244,16855
"MAP2K1 C121S lies within the protein kinase domain of the Map2k1 protein (UniProt.org). C121S results in increased Erk1/2 phosphorylation in culture, but has been demonstrated to confer acquired resistance to Raf and Mek inhibitors (PMID: 21383288, PMID: 24448821).",4380,24448821,Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.,http://www.ncbi.nlm.nih.gov/pubmed/24448821,4378,21383288,Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.,http://www.ncbi.nlm.nih.gov/pubmed/21383288,295,,,www.uniprot.org,16856
"AKT1 D262G lies within the protein kinase domain of the Akt1 protein (UniProt.org). D262G has not been characterized in the scientific literature and therefore, its effect on Akt1 protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,16861
"ABL1 Q1117* results in a premature truncation of the Abl1 protein at amino acid 1117 of 1130 (UniProt.org). Q1117* has not been characterized in the scientific literature and therefore, its effect on Abl1 protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,16902
"ABL1 Q939R lies within the DNA-binding region of the Abl1 protein (UniProt.org). Q939R has not been characterized in the scientific literature and therefore, its effect on Abl1 protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,16903
"ABL1 R239C does not lie within any known functional domains of the Abl1 protein (UniProt.org). R239C has not been characterized in the scientific literature and therefore, its effect on Abl1 protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,16904
"ABL1 R596* (corresponds to R577 in the canonical isoform) results in a premature truncation of the Abl1 protein at amino acid 596 of 1130 (UniProt.org). Due to the loss of the DNA-binding and actin-binding regions (UniProot.org), R596* is predicted to lead to a loss of Abl1 protein function.",295,,,www.uniprot.org,16905
"ALK K894T lies within the extracellular domain of the Alk protein (UniProt.org). K894T has not been characterized in the scientific literature and therefore, its effect on Alk protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,16906
"ALK R1113Q lies within the cytoplasmic domain of the Alk protein (UniProt.org). R1113Q has not been characterized in the scientific literature and therefore, its effect on Alk protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,16907
"APC A1485fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1485 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). T1485fs has not been characterized, however Apc truncation mutants downstream of T1485 are inactivating (PMID: 18199528) thus, A1485fs is predicted to lead to a loss of Apc protein function.",2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,295,,,www.uniprot.org,16908
"APC E1494K lies within the beta-catenin binding and down-regulation region of the Apc protein (PMID: 14672538). E1494K has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,285,,,http://www.ncbi.nlm.nih.gov/pubmed,16909
"APC E658* results in a premature truncation of the Apc protein at amino acid 658 of 2843 (UniProt.org). Due to the loss of the beta-catenin binding and down-regulation region (PMID: 14672538), E658* is predicted to lead to a loss of Apc protein function.",2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,295,,,www.uniprot.org,16910
"APC P1483fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1483 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). P1483fs has not been characterized, however Apc truncation mutants downstream of P1483 are inactivating (PMID: 18199528) thus, P1483fs is predicted to lead to a loss of Apc protein function.",2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,295,,,www.uniprot.org,16911
"APC Q424* results in a premature truncation of the Apc protein at amino acid 424 of 2843 (UniProt.org). Due to the loss of the Armadillo repeat and the beta-catenin binding and down-regulation regions (PMID: 14672538), Q424* is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,16912
"APC R106C does not lie within any known functional domains of the Apc protein (UniProt.org). R106C has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,16913
"APC R405* results in a premature truncation of the Apc protein at amino acid 405 of 2843 (UniProt.org). Due to the loss of the Armadillo repeat and the beta-catenin binding and down-regulation regions (PMID: 14672538), R405* is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,16914
"APC S2497L does not lie within any known functional domains of the Apc protein (UniPRot.org). S2497L has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,16915
"APC T1493fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1493 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). T1493fs has not been characterized, however Apc truncation mutants downstream of T1493 are inactivating (PMID: 18199528) thus, T1493fs is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,16916
"ATM A2622T does not lie within any known functional domains of the Atm protein (UniProt.org). A2622T has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,16923
"ATM G1459R does not lie within any known functional domains of the Atm protein (UniProt.org). G1459R has been identified in sequencing studies (PMID: 26214590) but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",7151,26214590,Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.,http://www.ncbi.nlm.nih.gov/pubmed/26214590,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,16924
"ATM L2995I does not lie within any known functional domains of the Atm protein (UniProt.org). L2995I has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,16925
"ATM R1918T does not lie within any known functional domains of the Atm protein (UniProt.org). R1918T has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,16926
"ATM R2443P lies within the FAT domain of the Atm protein (UniProt.org). R2443P has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,16927
"ATM S49C does not lie within any known functional domains of the Atm protein (UniProt.org). S49C has not been biochemically characterized however, it has been associated with modest increase of breast cancer risk by epidemiological analysis (PMID: 20826828).",295,,,www.uniprot.org,4394,20826828,"Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls.",http://www.ncbi.nlm.nih.gov/pubmed/20826828,16928
"ATM S707P does not lie within any known functional domains of the Atm protein (UniProt.org). S707P has not been biochemically characterized however, it has been associated with modest increase of breast cancer risk by epidemiological analysis (PMID: 20826828).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,16929
MLH1 mutant indicates an unspecified mutation in the MLH1 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,17001
MSH6 mutant indicates an unspecified mutation in the MSH6 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,17003
"BRCA1 I1473T (present in isoform 7) does not lie within any known functional domains of the Brca1 protein (UniProt.org). I1473T has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17012
"BRCA1 T1393A does not lie within any known functional domains of the Brca1 protein (UniProt.org). T1393A has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17013
"BRCA1 K654fs results in a change in the amino acid sequence of the Brca1 protein beginning at aa 654 of 1863, likely resulting in premature truncation of the functional protein (UniProt.org). K654fs has not been characterized, however, C-terminal deletion mutants downstream of K654 are inactivating (PMID: 16618730), thus K654fs is predicted to lead to a loss of Brca1 protein function.",295,,,www.uniprot.org,2575,16618730,Identification of domains of BRCA1 critical for the ubiquitin-dependent inhibition of centrosome function.,http://www.ncbi.nlm.nih.gov/pubmed/16618730,17014
TP53 R158H lies within the DNA binding domain of the Tp53 protein (UniProt.org). R158H results in decrease Tp53 transactivation activity and reduced ability to suppress colony formation in cell culture (PMID: 25584008).,295,,,www.uniprot.org,4424,25584008,Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study.,http://www.ncbi.nlm.nih.gov/pubmed/25584008,17017
"BRCA1 S1040N does not lie within any known functional domains of the Brca1 protein (UniProt.org). S1040N has been identified in sequencing studies (PMID: 24793135), but has not been biochemically characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Jan 2017).
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7497,24793135,A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24793135,17024
"BRAF Q262R lies within the phorbol-ester/DAG-type zinc finger region of the Braf protein (UniProt.org). Q262R has not been characterized in the scientific literature and therefore, its effect on Braf protein function is unknown (PubMed, Jul 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17026
"BRAF V226L lies within the Ras-binding domain of the Braf protein (UniProt.org). V226L has not been characterized in the scientific literature and therefore, its effect on Braf protein is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17027
"CBL R709Q lies within the CD2AP-interacting region of the Cbl protein (UniProt.org). R709Q has been identified in sequencing studies (PMID 27449473), but has not been biochemically characterized and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,7844,27449473,Rapid Molecular Profiling of Myeloproliferative Neoplasms Using Targeted Exon Resequencing of 86 Genes Involved in JAK-STAT Signaling and Epigenetic Regulation.,http://www.ncbi.nlm.nih.gov/pubmed/27449473,285,,,http://www.ncbi.nlm.nih.gov/pubmed,17040
"BRCA2 A1689fs results in a change in the amino acid sequence of the Brca2 protein beginning at 1689 of 3418, likely resulting in premature truncation of the functional protein (UniProt.org). A1689fs has not been characterized, however, due to the effects of other truncations downstream of A1689 (PMID: 12619154, PMID: 15695382), A1689fs is predicted to lead to a loss of Brca2 protein function.",2580,12619154,"Deletion of Brca2 exon 27 causes hypersensitivity to DNA crosslinks, chromosomal instability, and reduced life span in mice.",http://www.ncbi.nlm.nih.gov/pubmed/12619154,295,,,www.uniprot.org,2582,15695382,Functional evaluation and cancer risk assessment of BRCA2 unclassified variants.,http://www.ncbi.nlm.nih.gov/pubmed/15695382,17041
"BRCA2 D1902N does not lie within any known functional domains of the Brca2 protein (UniProt.org). D1902N has been identified in the scientific literature (PMID: 23415752), but has not been biochemically characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8829,23415752,BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.,http://www.ncbi.nlm.nih.gov/pubmed/23415752,17052
"BRCA2 D935N lies within the NPM1-interacting region of the Brca2 protein (UniProt.org). D935N has been identified in the scientific literature (PMID: 23415752), but has not been biochemically characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). ",295,,,www.uniprot.org,8829,23415752,BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.,http://www.ncbi.nlm.nih.gov/pubmed/23415752,285,,,http://www.ncbi.nlm.nih.gov/pubmed,17056
"BRCA2 N1742I lies within the POLH-interacting region of the Brca2 protein (UniProt.org). N1742I has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). ",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,17057
"BRCA2 N588D does not lie within any known functional domains of the Brca2 protein (UniProt.org). N588D has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17058
"BRCA2 Q699H lies within the NPM1-interacting region of the Brca2 protein (UniProt.org). Q699H has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17064
"BRCA2 T1414M lies within the POLH-interacting domain of the Brca2 protein (UniProt.org). T1414M has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17068
"BRCA2 T630I does not lie within any known functional domains of the Brca2 protein (UniProt.org). T630I has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17071
"BRCA2 A2233T does not lie within any known functional domains of the Brca2 protein (UniProt.org). A2233T has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17074
"BRCA2 E350* results in a premature truncation of the Brca2 protein at amino acid 350 of 3418 (UniProt.org). E350* has not been characterized, however, due to the effects of other truncations downstream of E350 (PMID: 12619154, PMID: 15695382), E350* is predicted to lead to a loss of Brca2 protein function.",2582,15695382,Functional evaluation and cancer risk assessment of BRCA2 unclassified variants.,http://www.ncbi.nlm.nih.gov/pubmed/15695382,2580,12619154,"Deletion of Brca2 exon 27 causes hypersensitivity to DNA crosslinks, chromosomal instability, and reduced life span in mice.",http://www.ncbi.nlm.nih.gov/pubmed/12619154,295,,,www.uniprot.org,17078
"CDH1 P30T does not lie within any known functional domains of the Cdh1 protein (UniProt.org). P30T has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Jan 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17079
"CDH1 P537L lies within the Cadherin 4 domain of the Cdh1 protein (UniProt.org). P537L has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Jan 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17080
"CDH1 T399_D400del results in the deletion of two amino acids in the Cadherin 3 domain of the Cdh1 protein (UniProt.org). T399_D400del has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Jan 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17081
"CTNNB1 A702V does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). A702V has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17095
"CTNNB1 G367R lies within the armadillo repeat region of the Ctnnb1 protein (UniProt.org). G367R has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17096
"CTNNB1 A97fs results in a change in the amino acid sequence of the Ctnnb1 protein beginning at aa 97 of 781, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of all known functional domains of the Ctnnb1 protein (UniProt.org), A97fs is predicted to lead to a loss of Ctnnb1 protein function.",295,,,www.uniprot.org,17097
"FGFR2 A315T lies within the Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). A315T  has been identified in the scientific literature (PMID: 17525745), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,702,17525745,Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/17525745,17098
FGFR2 K659E lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). K659E confers a gain of function to the Fgfr2 protein as demonstrated by the ability to induce senescence and cooperate with Myc to induce transformation of cell lines in culture (PMID: 19403560).,4421,19403560,The role of senescence and prosurvival signaling in controlling the oncogenic activity of FGFR2 mutants associated with cancer and birth defects.,http://www.ncbi.nlm.nih.gov/pubmed/19403560,295,,,www.uniprot.org,17099
"FGFR2 R593C lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). R593C has not been characterized in the scientific literature and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17100
"KDR (VEGFR2) S1021L lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). S1021L has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,17153
"KDR (VEGFR2) V159M lies within the Ig-like C2-type domain 2 of the Kdr (Vegfr2) protein (UniProt.org). V159M has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17154
"NPM1 W288fs*12 likely results in a truncation of the 294 aa Npm1 protein at aa 288, followed by 12 nonsense amino acids (UniProt.org). W288fs*12 has not been characterized however, because other truncation mutations at W288 are inactivating (PMID: 15659725), W288fs*12 is predicted to lead to a loss of Npm1 protein function.",295,,,www.uniprot.org,1522,15659725,Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.,http://www.ncbi.nlm.nih.gov/pubmed/15659725,17160
NOTCH1 R1279H lies within the EGF-like domain 33 of the Notch1 protein (UniProt.org). R1279H demonstrates signaling activity similar to wild-type Notch1 protein in cell culture (PMID: 18593716).,295,,,www.uniprot.org,4433,18593716,NOTCH1 mutations in individuals with left ventricular outflow tract malformations reduce ligand-induced signaling.,http://www.ncbi.nlm.nih.gov/pubmed/18593716,17178
"NOTCH1 E848K lies within the EGF-like domain 22 of the Notch1 protein (UniProt.org). E848K has been identified in the scientific literature (PMID: 24277457), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8157,24277457,Common and complex Notch1 mutations in Chinese oral squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24277457,17179
"NOTCH1 D1815fs results in a change in the amino acid sequence of the Notch1 protein beginning at aa 1815 of 2555, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of most of the cytoplasmic domain (UniProt.org), D1815fs is predicted to lead to a loss of Notch1 protein function.",295,,,www.uniprot.org,17180
"NOTCH1 A1436V lies within the extracellular domain of the Notch1 protein (UniProt.org). A1436V has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17181
"MSH6 K1009I lies within the lever domain of the Msh6 protein (PMID: 17531815). K1009I has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Sep 2017).",9962,17531815,Structure of the human MutSalpha DNA lesion recognition complex.,http://www.ncbi.nlm.nih.gov/pubmed/17531815,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17191
"MSH6 A25S does not lie within any known functional domains of the Msh6 protein (UniProt.org). A25S demonstrates proficient mismatch repair activity in an in vitro assay (PMID: 22102614, and was not identified to interfere with Msh6 mismatch repair activity in a functional screen (PMID: 28531214).",4989,22102614,A rapid and cell-free assay to test the activity of lynch syndrome-associated MSH2 and MSH6 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/22102614,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,10020,28531214,Suspected Lynch syndrome associated MSH6 variants: A functional assay to determine their pathogenicity.,http://www.ncbi.nlm.nih.gov/pubmed/28531214,17192
"MPL P248L lies within the Fibronectin type-III domain 1 of the Mpl protein (UniProt.org). P248L has not been characterized in the scientific literature and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17195
"MPL F126fs results in a change in the amino acid sequence of the Mpl protein beginning at aa 126 of 635, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of all known functional domains (UniProt.org), F126fs is predicted to lead to a loss of Mpl protein function.",295,,,www.uniprot.org,17196
"MET M630V lies within the IPT/TIG 1 domain of the Met protein (UniProt.org). M630V has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17197
"PTEN P248fs results in a change in the amino acid sequence of the Pten protein beginning at aa 248 of 403, likely resulting in premature truncation of the functional protein (UniProt.org). P248fs has not been characterized, however, other C-terminal deletion mutants downstream of P248 are inactivating (PMID: 10468583), thus P248fs is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,17204
"RB1 A525G lies within Aomain A of the Rb1 protein (UniProt.org). A525G has been identified in the scientific literature (PMID: 23532519), but has not been biochemically characterized and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,8558,23532519,Screening of RB1 alterations in Brazilian patients with retinoblastoma and relatives with retinoma: phenotypic and genotypic associations.,http://www.ncbi.nlm.nih.gov/pubmed/23532519,285,,,http://www.ncbi.nlm.nih.gov/pubmed,17216
"RB1 L797fs results in a change in the amino acid sequence of the Rb1 protein beginning at aa 797 of 928, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of domain C (UniProt.org), L797fs is predicted to lead to a loss of Rb1 protein function.",295,,,www.uniprot.org,17217
"RET E632K lies within the extracellular domain of the Ret protein (UniProt.org). E632K has been identified in sequencing studies (PMID: 22842228), but has not been biochemically characterized and therefore, its effect on Ret protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7109,22842228,Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22842228,17218
"RET S977R lies within the protein kinase domain of the Ret protein (UniProt.org). S977R has been identified in sequencing studies (PMID: 26168399), but has not been biochemically characterized and therefore, its effect on Ret protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6995,26168399,Comprehensive genomic profiles of small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26168399,17219
"RET V253E lies within the cadherin domain of the Ret protein (UniProt.org). V253E has not been characterized in the scientific literature and therefore, its effect on Ret protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17220
"RET V871I lies within the protein kinase domain of the Ret protein (UniProt.org). V871I has been identified in the scientific literature (PMID: 26034076), but has not been biochemically characterized and therefore, its effect on Ret protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8220,26034076,Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26034076,17221
"FGFR2 S57L lies within the Ig-like C2-type domain 1 of the Fgfr2 protein (UniProt.org). S57L has been identified in sequencing studies (PMID: 11781872), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7212,11781872,Genomic screening of fibroblast growth-factor receptor 2 reveals a wide spectrum of mutations in patients with syndromic craniosynostosis.,http://www.ncbi.nlm.nih.gov/pubmed/11781872,17222
"FGFR2-BICC1 results from the fusion of FGFR2 and BICC1, resulting in the ability to induce oligomerization, Fgfr kinase activity, Mapk signaling and transformation of cells in culture and in animal models (PMID: 23558953, PMID: 24122810).",4387,23558953,Identification of targetable FGFR gene fusions in diverse cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23558953,4202,24122810,Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24122810,17223
"FGFR2-AHCYL1 results from the fusion of FGFR1 and AHCYL1, resulting in the ability to activate MAPK signaling and induce transformation of cells in culture and in animal models (PMID: 24122810).",4202,24122810,Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24122810,17224
"FGFR2-AFF3 results from the fusion of FGFR2 and AFF3 (PMID: 23558953). FGFR2-AFF3 has been identified in breast cancer (PMID: 23558953), but has not been biochemically characterized and therefore, its effect on protein function is unknown (PubMed, Jul 2017).",4387,23558953,Identification of targetable FGFR gene fusions in diverse cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23558953,285,,,http://www.ncbi.nlm.nih.gov/pubmed,17226
"FGFR2-CASP7 results from the fusion of FGFR2 and CASP7 (PMID: 23558953). FGFR2-CASP7 has been identified in breast cancer (PMID: 23558953), but has not been biochemically characterized and therefore, its effect on protein function is unknown (PubMed, Jul 2017).",4387,23558953,Identification of targetable FGFR gene fusions in diverse cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23558953,285,,,http://www.ncbi.nlm.nih.gov/pubmed,17227
"FGFR2-CCDC6 results from the fusion of FGFR2 and CCDC6, resulting in the ability to induce oligomerization, activate Fgfr kinase activity, and induce cell proliferation (PMID: 23558953).",4387,23558953,Identification of targetable FGFR gene fusions in diverse cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23558953,17228
"FGFR2-OFD1 results from the fusion of FGFR2 and OFD1 (PMID: 23558953). FGFR2-OFD1 has been identified in thyroid carcinoma (PMID: 23558953), but has not been biochemically characterized and therefore, its effect on protein function is unknown (PubMed, Jan 2017).",4387,23558953,Identification of targetable FGFR gene fusions in diverse cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23558953,285,,,http://www.ncbi.nlm.nih.gov/pubmed,17229
TP53 C135F lies within the DNA binding region of the Tp53 protein (UniProt.org). C135F confers a loss of function to the Tp53 protein as demonstrated by loss of Tp53 transactivation activity in culture (PMID: 16492679).,4346,16492679,Specific TP53 mutation pattern in radiation-induced sarcomas.,http://www.ncbi.nlm.nih.gov/pubmed/16492679,295,,,www.uniprot.org,17251
"STK11 R333C does not lie within any known functional domains of the Stk11 protein (UniProt.org). R333C has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Dec 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17252
"STK11 K44* results in a premature truncation of the Stk11 protein at amino acid 44 of 433 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), K44* is predicted to lead to a loss of Stk11 protein function.",295,,,www.uniprot.org,17253
"STK11 I248T lies within the protein kinase domain of the Stk11 protein (UniProt.org). I248T has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Dec 2016).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17254
"TP53 C135fs results in a change in the amino acid sequence of the Tp53 protein beginning at aa 135 of 393, likely resulting in premature truncation of the functional protein (UniProt.org). Due to disruption of the DNA binding region and loss of the oligomerization domain (UniProt.org), C135fs is predicted to lead to a loss of Tp53 protein function.",295,,,www.uniprot.org,17255
"STK11 A377P does not lie within any known functional domains of the Stk11 protein (UniProt.org). A377P has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Dec 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17256
TP53 C176F lies within a ZInc binding residue in the DNA-binding region of the Tp53 protein (UniProt.org). C176F confers a loss of function to the Tp53 protein as demonstrated by inability to induce CDKN1A (p21) transcription in cell culture (PMID: 22090360).,295,,,www.uniprot.org,4462,22090360,TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence.,http://www.ncbi.nlm.nih.gov/pubmed/22090360,17257
"SMAD4 A466fs*28 likely results in a truncation of the 552 aa Smad4 protein at aa 466, followed by 28 nonsense amino acids within the MH2 domain (UniProt.org). A466fs*28 has not been characterized however, due to the effects of other truncation mutations downstream of A466, A466fs*28 is predicted to lead to a loss of Smad4 protein function (PMID: 11553622, PMID: 22316667).",3669,22316667,Germline mutations in SMAD4 disrupt bone morphogenetic protein signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22316667,3668,11553622,Loss of Smad4 function in pancreatic tumors: C-terminal truncation leads to decreased stability.,http://www.ncbi.nlm.nih.gov/pubmed/11553622,295,,,www.uniprot.org,17262
"TP53 C242F lies within a Zinc binding residue in the DNA binding region of the Tp53 protein (UniProt.org). The functional effect of C242F is conflicting, as it has been reported to lead to destabilization and loss of transactivation (PMID: 25294809, PMID: 22591662), and also has been reported to demonstrate radiosensitivity similar to wild-type Tp53 (PMID: 19035295).",4463,25294809,Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism.,http://www.ncbi.nlm.nih.gov/pubmed/25294809,4486,22591662,Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.,http://www.ncbi.nlm.nih.gov/pubmed/22591662,295,,,www.uniprot.org,4464,19035295,Variations in sensitivity to ionizing radiation in relation to p53 mutation point.,http://www.ncbi.nlm.nih.gov/pubmed/19035295,17263
"TP53 C242fs*5 results in a premature truncation of the Tp53 protein at aa 242 of 393, followed by 5 nonsense amino acids (UniProt.org). Due to the loss of the oligomerization domain (UniProt.org), C242fs*5 is predicted to lead to a loss of Tp53 protein function.",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,17264
"TP53 C275Y lies within the DNA binding region of the Tp53 protein (UniProt.org). C275Y has been identified in sequencing studies (PMID: 27288520), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Nov 2016).",295,,,www.uniprot.org,6946,27288520,Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27288520,285,,,http://www.ncbi.nlm.nih.gov/pubmed,17265
TP53 F134L lies within the DNA binding region of the Tp53 protein (UniProt.org). F134L confers a loss of function to the Tp53 protein as demonstrated by loss of Tp53-dependent DNA damage response (PMID: 14587098).,295,,,www.uniprot.org,4465,14587098,Elevated levels of prostate-specific antigen (PSA) in prostate cancer cells expressing mutant p53 is associated with tumor metastasis.,http://www.ncbi.nlm.nih.gov/pubmed/14587098,17266
"ROS1 W1694* results in a premature truncation of the Ros1 protein at amino acid 1694 of 2347 (UniProt.org). Due to the loss of the protein kinase domain (UniProt), W1694* is predicted to lead to a loss of Ros1 protein function.",295,,,www.uniprot.org,17271
"ROS1 N1534K lies within the Fibronectin type-III domain 6 of the Ros1 protein (UniProt.org). N1534K has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17272
"ROS1 I537M lies within the extracellular domain of the Ros1 protein (UniProt.org). I537M has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17273
"ROS1 G1915R lies within the cytoplasmic domain of the Ros1 protein (UniProt.org). G1915R has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17274
"ROS1 G1556R lies within the Fibronectin type-III domain 6 of the Ros1 protein (UniProt.org). G1556R has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17275
"ROS1 D2058G lies within the protein kinase domain of the Ros1 protein (UniProt.org). D2058G has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17276
"TP53 G105C lies within the DNA binding region of the Tp53 protein (UniProt.org). G105C has been identified in sequencing studies (PMID: 24236184), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6947,24236184,Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel.,http://www.ncbi.nlm.nih.gov/pubmed/24236184,17299
"TP53 H179R lies within the DNA binding region of the Tp53 protein (UniProt.org). H179R results in a loss of Tp53 protein function as indicated by failure to activate downstream gene transcription and increased survival (PMID: 17361096, PMID: 26585234), and also induces cancer gene signature through activation of Ras signaling (PMID: 22427690).",7588,26585234,"Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival.",http://www.ncbi.nlm.nih.gov/pubmed/26585234,295,,,www.uniprot.org,4474,22427690,Various p53 mutant proteins differently regulate the Ras circuit to induce a cancer-related gene signature.,http://www.ncbi.nlm.nih.gov/pubmed/22427690,9055,17361096,Apaf1 in chronic myelogenous leukemia (CML) progression: reduced Apaf1 expression is correlated with a H179R p53 mutation during clinical blast crisis.,http://www.ncbi.nlm.nih.gov/pubmed/17361096,17301
"TP53 L111P lies within the DNA binding region of the Tp53 protein (UniProt.org). L111P has been identified in sequencing studies (PMID: 18772396), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Nov 2016).",6948,18772396,An integrated genomic analysis of human glioblastoma multiforme.,http://www.ncbi.nlm.nih.gov/pubmed/18772396,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17302
"TP53 P72fs results in a change in the amino acid sequence of the Tp53 protein beginning at aa 72 of 393, likely resulting in premature truncation of the functional protein. Due to the loss of the DNA binding region (UniProt.org), P72fs is predicted to lead to a loss of Tp53 protein function.",295,,,www.uniprot.org,17303
"TP53 S20fs results in a change in the amino acid sequence of the Tp53 protein beginning at aa 20 of 393, likely resulting in premature truncation of the functional protein. Due to the loss of all known functional domains (UniProt.org), S20fs is predicted to lead to a loss of Tp53 protein function.",295,,,www.uniprot.org,17304
"TP53 R280A lies within the DNA binding region of the Tp53 protein (UniProt.org). R280A confers a loss of function to the Tp53 protein as demonstrated by loss of Tp53 DNA binding, impaired oligomerization of the pro-apoptotic protein Bak, and resistance to apoptosis (PMID: 7969167, PMID: 18524770).",3916,18524770,Oligomerization of BAK by p53 utilizes conserved residues of the p53 DNA binding domain.,http://www.ncbi.nlm.nih.gov/pubmed/18524770,5292,7969167,"Distinct residues of human p53 implicated in binding to DNA, simian virus 40 large T antigen, 53BP1, and 53BP2.",http://www.ncbi.nlm.nih.gov/pubmed/7969167,295,,,www.uniprot.org,17305
"TP53 R209fs results in a change in the amino acid sequence of the Tp53 protein beginning at aa 209 of 393, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of several functional domains including the oligomerization domain (UniProt.org), R209fs is predicted to lead to a loss of Tp53 protein function.",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17306
"TP53 R342fs results in a change in the amino acid sequence of the Tp53 protein beginning at aa 342 of 393 (UniProt.org, likely resulting in premature truncation of the functional protein. R342fs has been identified in sequencing studies (PMID: 22237106), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Nov 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5796,22237106,The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.,http://www.ncbi.nlm.nih.gov/pubmed/22237106,17307
"TP53 R280K lies within the DNA binding domain of the Tp53 protein (PMID: 22713868). R280K results in decreased activation of wild-type Tp53 target genes, as well as a gain-of-function in activation of novel targets, and leads to increased survival of human cancer cells (PMID: 18472962, PMID: 24763051).",4536,18472962,Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells.,http://www.ncbi.nlm.nih.gov/pubmed/18472962,4476,24763051,A gain-of-function mutant p53-HSF1 feed forward circuit governs adaptation of cancer cells to proteotoxic stress.,http://www.ncbi.nlm.nih.gov/pubmed/24763051,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,17308
"TP53 R273X indicates a hotspot mutation resulting in an amino acid change at codon 273 of the Tp53 protein, which is predicted to result in a loss of Tp53 protein function.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,17309
"TP53 R175X indicates a hotspot mutation resulting in an amino acid change at codon 175 of the Tp53 protein, which is predicted to result in a loss of Tp53 protein function.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,17310
" TP53 T170M lies within the DNA binding region of the Tp53 protein (UniProt.org). T170M has been identified in sequencing studies (PMID: 25480502), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Nov 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7011,25480502,Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting.,http://www.ncbi.nlm.nih.gov/pubmed/25480502,17311
"TP53 V172F lies within the DNA binding region of the Tp53 protein (UniProt.org). V172F is predicted to result in a loss of Tp53 function, as it demonstrates enhanced interaction with Mdm4 and confers context-dependent alterations in Tp53 stability (PMID: 26876197).  
",295,,,www.uniprot.org,8004,26876197,Heterozygous p53(V172F) mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53.,http://www.ncbi.nlm.nih.gov/pubmed/26876197,285,,,http://www.ncbi.nlm.nih.gov/pubmed,17312
17319
TP53 del indicates a deletion of the TP53 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,17327
ATM del indicates a deletion of the ATM gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,17328
NOTCH1 I1680S lies within the negative regulatory region of the Notch1 protein (PMID: 25104330). I1680S results in increased Notch1 signaling in a Luciferase reporter assay in cell culture (PMID: 25104330).,3550,25104330,Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25104330,17404
NOTCH1 E1567K lies within the negative regulatory region of the Notch1 protein (PMID: 25104330). E1567K demonstrates signaling activity similar to wild-type Notch1 in a Luciferase reporter assay in cell culture (PMID: 25104330).,3550,25104330,Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25104330,17405
NOTCH1 A1552G lies within the negative regulatory region of the Notch1 protein (PMID: 25104330). A1552G results in increased Notch1 signaling in a Luciferase reporter assay in cell culture (PMID: 25104330).,3550,25104330,Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25104330,17406
NOTCH1 A1552V lies within the negative regulatory region of the Notch1 protein (PMID: 25104330). A1552V results in increased Notch1 signaling in a Luciferase reporter assay in cell culture (PMID: 25104330).,3550,25104330,Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25104330,17407
NOTCH1 A1570G lies within the negative regulatory region of the Notch1 protein (PMID: 25104330). A1570G results in increased Notch1 signaling in a Luciferase reporter assay in cell culture (PMID: 25104330).,3550,25104330,Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25104330,17408
NOTCH1 R1627L lies within the negative regulatory region of the Notch1 protein (PMID: 25104330). R1627L results in increased Notch1 signaling in a Luciferase reporter assay in cell culture (PMID: 25104330).,3550,25104330,Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25104330,17409
NOTCH1 V1575A lies within the negative regulatory region of the Notch1 protein (PMID: 25104330). V1575A results in increased Notch1 signaling in a Luciferase reporter assay in cell culture (PMID: 25104330).,3550,25104330,Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25104330,17410
NOTCH1 V1599M lies within the negative regulatory region of the Notch1 protein (PMID: 25104330). V1599M results in increased Notch1 signaling in a Luciferase reporter assay in cell culture (PMID: 25104330).,3550,25104330,Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25104330,17411
NOTCH1 R1683W lies within the negative regulatory region of the Notch1 protein (PMID: 25104330). R1683W results in increased Notch1 signaling in a Luciferase reporter assay in cell culture (PMID: 25104330).,3550,25104330,Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25104330,17412
"NOTCH1 R365H lies within the EGF-like domain 9 of the Notch1 protein (UniProt.org). R365H has been identified in the scientific literature (PMID: 25104330), but has not been characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3550,25104330,Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25104330,17413
NOTCH1 rearrange indicates an unspecified rearrangement of the NOTCH1 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,17414
"DNMT3A E30A does not lie within any known functional domains of the Dnmt3a protein (UniProt.org). E30A has been identified in sequencing studies (PMID: 25886620), but has not been biochemically characterized and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,7327,25886620,Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance.,http://www.ncbi.nlm.nih.gov/pubmed/25886620,285,,,http://www.ncbi.nlm.nih.gov/pubmed,17617
"DNMT3A F731fs results in a change in the amino acid sequence of the Dnmt3a protein beginning at aa 731 of 912, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the catalytic domain (UniProt.org), F731fs is predicted to lead to a loss of Dnmt3a protein function.",295,,,www.uniprot.org,17618
"DNMT3A W409C does not lie within any known functional domains of the Dnmt3a protein (UniProt.org). W409C has not been characterized in the scientific literature and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jul 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17619
"ETV6 D206N does not lie within any known functional domains of the Etv6 protein (UniProt.org). D206N has not been characterized in the scientific literature and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,17634
"ETV6 R127Q does not lie within any known functional domains of the Etv6 protein (UniProt.org). R127Q has not been characterized in the scientific literature and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17645
CBL C381A lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). C381A confers a loss of function to the Cbl protein as demonstrated by lack of Cbl activity in cell culture (PMID: 26676746).,295,,,www.uniprot.org,4519,26676746,Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26676746,17646
CBL C396R lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). C396R confers a loss of function to the Cbl protein as demonstrated by lack of Cbl activity in cell culture (PMID: 26676746).,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17647
CBL G375P lies within a linker region of the Cbl protein (UniProt.org). G375P confers a loss of function to the Cbl protein as demonstrated by reduced Cbl activity (PMID: 26676746).,4519,26676746,Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26676746,295,,,www.uniprot.org,17648
CBL H398Q lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). H398Q confers a loss of function to the Cbl protein as demonstrated by lack of Cbl activity in cell culture (PMID: 26676746).,295,,,www.uniprot.org,4519,26676746,Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26676746,17649
"ETV6 Y346C lies within the ETS DNA binding region of the Etv6 protein (UniProt.org). Y346C has not been characterized in the scientific literature and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017). ",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,17650
CBL L399V lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). L399V results in reduced Cbl activity in cell culture (PMID: 26676746).,4519,26676746,Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26676746,295,,,www.uniprot.org,17651
CBL P395A lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). P395A results in reduced Cbl activity in culture (PMID: 26676746).,4519,26676746,Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26676746,295,,,www.uniprot.org,17652
"ERBB2 (HER2) A386D does not lie within any known functional domains of the Erbb2 (Her2) protein (UniProt.org). A386D has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17653
"ERBB2 (HER2) L841V lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). L841V has been identified in sequencing studies (PMID: 26320869), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, May 2017).",7060,26320869,Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26320869,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17654
"ERBB2 (HER2) S250F does not lie within any known functional domains of the Erbb2 (Her2) protein (UniProt.org). S250F has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17655
"ERBB2 (HER2) T496I does not lie within any known functional domains of the Erbb2 (Her2) protein (UniProt.org). T496I has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17656
"ERBB4 A455T does not lie within any known functional domains of the Erbb4 protein (UniProt.org). A455T has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17662
"ERBB4 R524C does not lie within any known functional domains of the Erbb4 protein (UniProt.org). R524C has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jun 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17663
"ERBB4 T480fs results in a change in the amino acid sequence of the Erbb4 protein beginning at aa 480 of 1308, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of all known functional domains (UniProt.org), T480fs is predicted to lead to a loss of Erbb4 function.",295,,,www.uniprot.org,17664
"CBL H94Y lies within the Cbl-PTB domain of the Cbl protein (UniProt.org). H94Y in combination with S80N displayed activity comparable to wild-type Cbl (PMID: 26676746), however, has not been individually characterized and therefore, its effect on Cbl protein function is unknown.",4519,26676746,Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26676746,295,,,www.uniprot.org,17672
"CBL S80N lies within the Cbl-PTB domain of the Cbl protein (UniProt.org). S80N in combination with H94Y displayed activity comparable to wild-type Cbl in culture (PMID: 26676746), however, has not been individually characterized and therefore, its effect on Cbl protein function is unknown.",295,,,www.uniprot.org,4519,26676746,Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26676746,17673
CBL K382E lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). K382E confers a loss of function to the Cbl protein as demonstrated by lack of Cbl activity in cell culture (PMID: 26676746).,4519,26676746,Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26676746,295,,,www.uniprot.org,17675
CBL M374V lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). M374V demonstrates activity comparable to wild-type Cbl in cell culture (PMID: 26676746).,295,,,www.uniprot.org,4519,26676746,Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26676746,17677
CBL Q249E lies within the Cbl-PTB domain of the Cbl protein (UniProt.org). Q249E confers a gain of function to the Cbl protein as demonstrated by increased Cbl activity compared to wild-type Cbl (PMID: 26676746).,4519,26676746,Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26676746,295,,,www.uniprot.org,17679
CBL V430M does not lie within any known functional domains of the Cbl protein (UniProt.org). V430M demonstrates activity comparable to wild-type Cbl in cell culture (PMID: 26676746).,295,,,www.uniprot.org,4519,26676746,Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26676746,17681
"CBL C381G lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). C381G has not been biochemically characterized, but is predicted to disrupt Cbl stability by computer modeling (PMID: 26676746).",295,,,www.uniprot.org,4519,26676746,Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26676746,17685
"CBL C381R lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). C381R is predicted to disupt Cbl stability in computer models (PMID: 26676746), and results in activation of ELK and c-Jun and decreased Notch1 signaling in cell culture (PMID: 22591685).",4525,22591685,Casitas B-cell lymphoma mutation in childhood T-cell acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/22591685,295,,,www.uniprot.org,17686
"CBL C381Y lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). C381Y has not been biochemically characterized, but is predicted to disrupt Cbl stability by computer modeling (PMID: 26676746).",4519,26676746,Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26676746,295,,,www.uniprot.org,17687
"CBL C384Y lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). C384Y has not been biochemically characterized, but is predicted to disrupt Cbl stability by computer modeling (PMID: 26676746).",4519,26676746,Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26676746,295,,,www.uniprot.org,17688
"CBL C401R lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). C401R has not been biochemically characterized, but is predicted to disrupt Cbl stability by computer modeling (PMID: 26676746).",295,,,www.uniprot.org,4519,26676746,Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26676746,17689
"CBL C401Y lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). C401Y has not been biochemically characterized, but is predicted to disrupt Cbl stability by computer modeling (PMID: 26676746).",295,,,www.uniprot.org,4519,26676746,Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26676746,17690
"CBL C404R lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). C404R has not been biochemically characterized, but is predicted to disrupt Cbl stability by computer modeling (PMID: 26676746).",4519,26676746,Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26676746,295,,,www.uniprot.org,17691
"CBL C404Y lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). C404Y has not been biochemically characterized, but is predicted to disrupt Cbl stability by computer modeling (PMID: 26676746).",4519,26676746,Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26676746,295,,,www.uniprot.org,17692
"CBL C416R lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). C416R has not been biochemically characterized, but is predicted to disrupt Cbl stability by computer modeling (PMID: 26676746).",295,,,www.uniprot.org,4519,26676746,Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26676746,17693
"CBL C416W lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). C416W has not been biochemically characterized, but is predicted to disrupt Cbl stability by computer modeling (PMID: 26676746).",295,,,www.uniprot.org,4519,26676746,Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26676746,17694
"CBL C416Y lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). C4C404Y has not been biochemically characterized, but is predicted to disrupt Cbl stability by computer modeling (PMID: 26676746).",4519,26676746,Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26676746,295,,,www.uniprot.org,17695
"CBL C419R lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). C419R has not been biochemically characterized, but is predicted to disrupt Cbl stability by computer modeling (PMID: 26676746).",4519,26676746,Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26676746,295,,,www.uniprot.org,17696
"CBL G413R lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). C413R has not been biochemically characterized, but is predicted to disrupt Cbl stability by computer modeling (PMID: 26676746).",295,,,www.uniprot.org,4519,26676746,Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26676746,17697
"CBL G415V lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). C415V has not been biochemically characterized, but is predicted to disrupt Cbl stability by computer modeling (PMID: 26676746).",295,,,www.uniprot.org,4519,26676746,Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26676746,17698
"CBL H398P lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). H398P has not been biochemically characterized, but is predicted to disrupt Cbl stability by computer modeling (PMID: 26676746).",4519,26676746,Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26676746,295,,,www.uniprot.org,17699
"CBL H398R lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). H398R has not been biochemically characterized, but is predicted to disrupt Cbl stability by computer modeling (PMID: 26676746). ",4519,26676746,Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26676746,295,,,www.uniprot.org,17700
"CBL M400R lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). M400R has not been biochemically characterized, but is predicted to disrupt Cbl stability by computer modeling (PMID: 26676746).",295,,,www.uniprot.org,4519,26676746,Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26676746,17701
"CBL Y371D lies within the linker region of the Cbl protein (UniProt.org). Y371D disrupts Cbl conformation in in vitro assays, and is transforming in cell culture (PMID: 27609087).",295,,,www.uniprot.org,17702
"HNF1A S247T lies at phosphoserine site within the Hnf1a protein (UniProt.org). S247T has not been characterized and therefore, its effect on Hnf1a protein function is unknown (PubMed, Feb 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17827
IDH1 V294M does not lie within any known functional domains of the Idh1 protein (UniProt.org). V294M has been demonstrated to display activity similar to wild-type Idh1 (PMID: 21996744).,295,,,www.uniprot.org,2651,21996744,Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.,http://www.ncbi.nlm.nih.gov/pubmed/21996744,17829
"STK11 C132F lies within the protein kinase domain of the Stk11 protein (UniProt.org). C132F has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Dec 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17833
"STK11 D358N does not lie within any known functional domains of the Stk11 protein (UniProt.org). D358N has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Dec 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17834
"STK11 D359Y does not lie within any known functional domains of the Stk11 protein (UniProt.org). D359Y has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Dec 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17835
"STK11 E165* results in a premature truncation of the Stk11 protein at amino acid 165 of 433 within the protein kinase domain (UniProt.org). Due to the loss of a majority of the protein kinase domain including the active site (UniProt.org), E165* is predicted to lead to a loss of Stk11 protein function.
",295,,,www.uniprot.org,17836
"STK11 E223* results in a premature truncation of the Stk11 protein at amino acid 223 of 433 within the protein kinase domain (UniProt.org). E223* has been identified in sequencing studies (PMID: 22980975), but has not been biochemically characterized and therefore, its effect on Stk11 protein function is unknown (PubMed, Dec 2016).

",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1726,22980975,Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/22980975,17837
"STK11 E317K does not lie within any known functional domains of the Stk11 protein (UniProt.org). E317K has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Dec 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17838
"STK11 E33* results in a premature truncation of the Stk11 protein at amino acid 33 of 433 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), E33* is predicted to lead to a loss of Stk11 protein function.
",295,,,www.uniprot.org,17839
"STK11 Q364K does not lie within any known functional domains of the Stk11 protein (UniProt.org). Q364K has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Dec 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17840
"STK11 P294L lies within the protein kinase domain of the Stk11 protein (UniProt.org). P294L has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Dec 2016). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,17841
"STK11 P281L lies within the protein kinase domain of the Stk11 protein (UniProt.org). P281L confers a loss of function to the Stk11 protein, as indicated by a loss of kinase activity in an in vitro kinase assay (PMID: 10676634). 
",295,,,www.uniprot.org,4547,10676634,No evidence of Peutz-Jeghers syndrome gene LKB1 involvement in left-sided colorectal carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/10676634,17842
"STK11 K78N lies within the protein kinase domain of the Stk11 protein (UniProt.org). K78N has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Dec 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17843
"STK11 K62Sfs*100 is a missense mutation (K62S) in conjunction with a likely truncation of the 433 aa Stk11 protein at aa 62, followed by 100 nonsense amino acids (UniProt.org). Due to the loss of a majority of the protein kinase domain, K62Sfs*100 is predicted to lead to a loss of Stk11 protein function.
",295,,,www.uniprot.org,17844
"STK11 K62* results in a premature truncation of the Stk11 protein at amino acid 62 of 433 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), K62* is predicted to lead to a loss of Stk11 protein function.
",295,,,www.uniprot.org,17845
"STK11 I111N lies within the protein kinase domain of the Stk11 protein (UniProt.org). I111N has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Dec 2016).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17846
"STK11 G56Tfs*4 is a missense mutation (G56T) in conjunction with a likely truncation of the 433 aa Stk11 protein at aa56, followed by 4 nonsense amino acids (UniProt.org). Due to the loss of a majority of the protein kinase domain, G56Tfs*4 is predicted to lead to a loss of Stk11 protein function.
",295,,,www.uniprot.org,17847
"STK11 E57Sfs*107 is a missense mutation (E57S) in conjunction with a likely truncation of the 433 aa Stk11 protein at aa 57, followed by 107 nonsense amino acids (UniProt.org). Due to the loss of a majority of the protein kinase domain, E57Sfs*107 is predicted to lead to a loss of Stk11 protein function.
",295,,,www.uniprot.org,17848
"STK11 E357K does not lie within any known functional domains of the Stk11 protein (UniProt.org). E357K has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Dec 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17849
"STK11 Q37L does not lie within any known functional domains of the Stk11 protein (UniProt.org). Q37L has been identified in sequencing studies (PMID: 18948947), but has not been biochemically characterized and therefore, its effect on Stk11 protein function is unknown (PubMed, Dec 2016).
",6956,18948947,Somatic mutations affect key pathways in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18948947,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17850
"STK11 R310P does not lie within any known functional domains of the Stk11 protein (UniProt.org). R310P has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Dec 2016). 

",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17851
"STK11 W332* results in a premature truncation of the Stk11 protein at amino acid 332 of 433 (UniProt.org). W332* has been identified in sequencing studies (PMID: 17711506), but has not been biochemically characterized and therefore, its effect on Stk11 protein function is unknown (PubMed, Dec 2016).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7451,17711506,LKB1 gene mutations in Japanese lung cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/17711506,17852
"PTEN positive indicates the presence of the PTEN gene, mRNA, and/or protein. ",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,17854
"SMO S533N lies within helical transmembrane domain 7 of the Smo protein (UniProt.org). S533N (corresponding to S539N in mouse) results in increased Hedgehog (Hh) pathway activation in mouse models and human tumor samples (PMID: 10984056, PMID: 9581815), and has been demonstrated to confer resistance to Hh pathway inhibitors (PMID: 26546616, PMID: 9581815).",1301,10984056,Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine.,http://www.ncbi.nlm.nih.gov/pubmed/10984056,295,,,www.uniprot.org,1940,9581815,Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system.,http://www.ncbi.nlm.nih.gov/pubmed/9581815,4477,26546616,An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.,http://www.ncbi.nlm.nih.gov/pubmed/26546616,17855
NRAS E63K lies adjacent to one of the GTP binding sites (UniProt.org). E63K confers a loss of function to the Nras protein as demonstrated by reduced GTPase activity (PMID: 25870145).,4580,25870145,Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.,http://www.ncbi.nlm.nih.gov/pubmed/25870145,17921
"NRAS amp indicates an increased number of copies of the NRAS gene. However, the mechanism causing the increase is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,17922
"CSF1R P855L lies within the protein kinase domain of the Csf1r protein (UniProt.org). P855L has not been characterized in the scientific literature and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,17984
"CSF1R V315L lies within the Ig-like C2-type domain 4 of the Csf1r protein (UniProt.org). V315L has not been characterized in the scientific literature and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,17985
CSF1R D802V lies within the protein kinase domain of the Csf1r protein (UniProt.org). D802V confers a gain of function as demonstrated by increased stability of the Csf1r protein and ability to transform cells (PMID: 10340379).,295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,17986
"ETV6-ABL1 results from the fusion of ETV6 (also referred to as TEL) and ABL1, demonstrating increased kinase activity and the ability to induce CML-like myeloproliferative disease in mice (PMID: 12036890).",4586,12036890,"The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice.",http://www.ncbi.nlm.nih.gov/pubmed/12036890,17993
"ETV6-ABL2 (also known as TEL-ARG) results from the fusion of ETV6 and ABL2, demonstrating increased proliferation and increased phosphorylation of multiple cellular signaling proteins (PMID: 15005341).",4588,15005341,The TEL/ARG leukemia oncogene promotes viability and hyperresponsiveness to hematopoietic growth factors.,http://www.ncbi.nlm.nih.gov/pubmed/15005341,17995
"ETV6-PDGFRB results from the fusion of ETV6 and PDGFRB, demonstrating the ability to stimulate proliferation and differentiation of progenitor cells (PMID: 22271894). ",4589,22271894,ETV6-PDGFRB and FIP1L1-PDGFRA stimulate human hematopoietic progenitor cell proliferation and differentiation into eosinophils: the role of nuclear factor-κB.,http://www.ncbi.nlm.nih.gov/pubmed/22271894,17996
"ETV6-ACSL6 results from the fusion of ETV6 and ACSL6 (PMID: 16572202). ETV6-ACSL6 has been identified in polycythemia vera (PMID: 16572202) and chronic eosinophilic leukemia (PMID: 27458550), but not been biochemically characterized and therefore, the effect of protein function is unknown (PubMed, Aug 2017).",7586,27458550,"Chronic eosinophilic leukemia, NOS with t(5;12)(q31;p13)/ETV6-ACSL6 gene fusion: a novel variant of myeloid proliferative neoplasm with eosinophilia.",http://www.ncbi.nlm.nih.gov/pubmed/27458550,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4590,16572202,t(5;12)(q23-31;p13) with ETV6-ACSL6 gene fusion in polycythemia vera.,http://www.ncbi.nlm.nih.gov/pubmed/16572202,17997
"HRAS amplification indicates an increased number of copies of the HRAS gene. However, the mechanism causing the increase is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,18162
"MSH6 A297T does not lie within any known functional domains of the Msh6 protein (UniProt.org). A297T has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,18177
"MSH6 A322V does not lie within any known functional domains of the Msh6 protein (UniProt.org).  A322V has been identified in sequencing studies (PMID: 26343386), but has not been biochemically characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,7139,26343386,Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway.,http://www.ncbi.nlm.nih.gov/pubmed/26343386,285,,,http://www.ncbi.nlm.nih.gov/pubmed,18178
"MSH6 C615F lies within the connector domain of the Msh6 protein (PMID: 17531815). C615F has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Sep 2017).",9962,17531815,Structure of the human MutSalpha DNA lesion recognition complex.,http://www.ncbi.nlm.nih.gov/pubmed/17531815,285,,,http://www.ncbi.nlm.nih.gov/pubmed,18179
"MSH6 C88W does not lie within any known functional domains of the Msh6 protein (UniProt.org). C88W has been identified in sequencing studies (PMID: 22941188, PMID: 26168399), but has not been biochemically characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7166,22941188,Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22941188,295,,,www.uniprot.org,6995,26168399,Comprehensive genomic profiles of small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26168399,18180
"MSH6 D358E lies within an Msh2-binding site of the Msh6 protein (PMID: 12019211). D358E has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,18181
"MSH6 D358N lies within an Msh2-binding site of the Msh6 protein (PMID: 12019211). D358N has been identified in sequencing studies (PMID: 23525077), but has not been biochemically characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,7021,23525077,Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity.,http://www.ncbi.nlm.nih.gov/pubmed/23525077,18182
"MSH6 D530Y lies within an Msh2-binding site of the Msh6 protein (PMID: 12019211). D530Y has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,18183
"MSH6 D89E does not lie within any known functional domains of the Msh6 protein (UniProt.org). D89E has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Sep 2017).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,18184
"MSH6 E1214* results in a premature truncation of the Msh6 protein at amino acid 1214 of 1360 (UniProt.org). E1214* has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,18185
"MSH6 E1254del results in the deletion of one amino acid in the ATPase domain of the Msh6 protein at amino acid 1254 (PMID: 17531815). E1254del has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Sep 2017).",9962,17531815,Structure of the human MutSalpha DNA lesion recognition complex.,http://www.ncbi.nlm.nih.gov/pubmed/17531815,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,18186
"MSH6 E286K does not lie within any known functional domains of the Msh6 protein (UniProt.org). E286K has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,18187
"MSH6 E463* results in a premature truncation of the Msh6 protein at amino acid 463 of 1360 (UniProt.org). Due to the loss of MSH2- and ATP-binding regions (PMID: 12019211), E463* is predicted to lead to a loss of Msh6 protein function.",3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,295,,,www.uniprot.org,18188
"MSH6 E619* results in a premature truncation of the Msh6 protein at amino acid 619 of 1360 (UniProt.org). Due to the loss of MSH2- and ATP-binding regions (PMID: 12019211), E619* is predicted to lead to a loss of Msh6 protein function.",3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,295,,,www.uniprot.org,18189
"MSH6 E908* results in a premature truncation of the Msh6 protein at amino acid 908 of 1360 (UniProt.org). Due to the loss of MSH2- and ATP-binding regions (PMID: 12019211), E908* is predicted to lead to a loss of Msh6 protein function.",295,,,www.uniprot.org,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,18190
"MSH6 E993K lies within the clamp domain of the Msh6 protein (PMID: 17531815). E993K has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,18191
"MSH6 G1299C lies within the ATPase domain of the Msh6 protein (PMID: 17531815). G1299C has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Sep 2017).",9962,17531815,Structure of the human MutSalpha DNA lesion recognition complex.,http://www.ncbi.nlm.nih.gov/pubmed/17531815,285,,,http://www.ncbi.nlm.nih.gov/pubmed,18192
"MSH6 G1316R lies within an Msh2-binding site of the Msh6 protein (PMID: 12019211). G1316R has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,18193
"MSH6 G624S lies within the connector domain of the Msh6 protein (PMID: 17531815). G624S has been identified in sequencing studies (PMID: 21097718), but has not been biochemically characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Sep 2017).",9962,17531815,Structure of the human MutSalpha DNA lesion recognition complex.,http://www.ncbi.nlm.nih.gov/pubmed/17531815,8276,21097718,Genetic and structural variation in the gastric cancer kinome revealed through targeted deep sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/21097718,115,0,,http://www.ncbi.nlm.nih.gov/pubmed,18195
"MSH6 I1357N lies within an Msh2-binding site of the Msh6 protein (PMID: 12019211). I1357N has been identified in sequencing studies (PMID: 23525077), but has not been biochemically characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,7021,23525077,Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity.,http://www.ncbi.nlm.nih.gov/pubmed/23525077,18196
"MSH6 I258T does not lie within any known functional domains of the Msh6 protein (UniProt.org). I258T has been identified in sequencing studies (PMID: 18948947), but has not been biochemically characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6956,18948947,Somatic mutations affect key pathways in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18948947,18197
"MSH6 I425T lies within the mismatch binding domain of the Msh6 protein (PMID: 17531815). I425T has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9962,17531815,Structure of the human MutSalpha DNA lesion recognition complex.,http://www.ncbi.nlm.nih.gov/pubmed/17531815,18198
"MSH6 I516Sfs*55 likely results in a truncation of the 1360 aa Msh6 protein at aa 516, followed by 55 nonsense amino acids within the Msh2-binding region (PMID: 12019211). Due to the loss of MSH2- and ATP-binding regions (PMID: 12019211), I516Sfs*55 is predicted to lead to a loss of Msh6 protein function.",3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,18199
"MSH6 I944V lies within the clamp domain of the Msh6 protein (PMID: 17531815). I944V has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,18200
"MSH6 K155R does not lie within any known functional domains of the Msh6 protein (UniProt.org). K155R has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,18201
"MSH6 K185T does not lie within any known functional domains of the Msh6 protein (UniProt.org). K185T has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,295,,,www.uniprot.org,18202
"MSH6 K431T lies within the mismatch binding domain of the Msh6 protein (PMID: 17531815). K431T has been identified in sequencing studies (PMID: 25233892), but has not been biochemically characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Sep 2017).",7231,25233892,Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes.,http://www.ncbi.nlm.nih.gov/pubmed/25233892,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,18203
"MSH6 K646R lies within the connector domain of the Msh6 protein (PMID: 17531815). K646R has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,9962,17531815,Structure of the human MutSalpha DNA lesion recognition complex.,http://www.ncbi.nlm.nih.gov/pubmed/17531815,18204
"MSH6 K885N lies within the lever domain of the Msh6 protein (PMID: 17531815). K885N has been identified in sequencing studies (PMID: 24755471), but has not been biochemically characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Sep 2017).",6962,24755471,Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24755471,285,,,http://www.ncbi.nlm.nih.gov/pubmed,9962,17531815,Structure of the human MutSalpha DNA lesion recognition complex.,http://www.ncbi.nlm.nih.gov/pubmed/17531815,18205
"MSH6 L290* results in a premature truncation of the Msh6 protein at amino acid 290 of 1360 (UniProt.org). Due to the loss of MSH2- and ATP-binding regions (PMID: 12019211), L290* is predicted to lead to a loss of Msh6 protein function.",295,,,www.uniprot.org,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,18206
"MSH6 L423I lies within the mismatch binding domain of the Msh6 protein (PMID: 17531815). L423I has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Sep 2017).",9962,17531815,Structure of the human MutSalpha DNA lesion recognition complex.,http://www.ncbi.nlm.nih.gov/pubmed/17531815,285,,,http://www.ncbi.nlm.nih.gov/pubmed,18207
"MSH6 L681F within the connector domain of the Msh6 protein (PMID: 17531815). L681F has been identified in sequencing studies (PMID: 22980975, PMID: 25344691), but has not been biochemically characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Sep 2017).",1726,22980975,Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/22980975,1689,25344691,RNF43 is frequently mutated in colorectal and endometrial cancers.,http://www.ncbi.nlm.nih.gov/pubmed/25344691,9962,17531815,Structure of the human MutSalpha DNA lesion recognition complex.,http://www.ncbi.nlm.nih.gov/pubmed/17531815,285,,,http://www.ncbi.nlm.nih.gov/pubmed,18208
"MSH6 M868I lies within the lever domain of the Msh6 protein (PMID: 17531815). M868I has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Sep 2017).",9962,17531815,Structure of the human MutSalpha DNA lesion recognition complex.,http://www.ncbi.nlm.nih.gov/pubmed/17531815,285,,,http://www.ncbi.nlm.nih.gov/pubmed,18209
"MSH6 M868T lies within the lever domain of the Msh6 protein (PMID: 17531815). M868T has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Sep 2017).",9962,17531815,Structure of the human MutSalpha DNA lesion recognition complex.,http://www.ncbi.nlm.nih.gov/pubmed/17531815,115,0,,http://www.ncbi.nlm.nih.gov/pubmed,18210
"MSH6 P1077S lies within the ATPase domain of the Msh6 protein (PMID: 17531815). P1077S has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Sep 2017).",9962,17531815,Structure of the human MutSalpha DNA lesion recognition complex.,http://www.ncbi.nlm.nih.gov/pubmed/17531815,285,,,http://www.ncbi.nlm.nih.gov/pubmed,18211
"MSH6 P1082L lies within the ATPase domain of the Msh6 protein (PMID: 17531815). P1082L has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,9962,17531815,Structure of the human MutSalpha DNA lesion recognition complex.,http://www.ncbi.nlm.nih.gov/pubmed/17531815,18212
"MSH6 P1082S lies within the ATPase domain of the Msh6 protein (PMID: 17531815). P1082S has not been biochemically characterized, but is predicted to be non-pathogenic by in silico models and is associated with (PMID: 24100870).",4611,24100870,Molecular and clinical characteristics of MSH6 germline variants detected in colorectal cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/24100870,9962,17531815,Structure of the human MutSalpha DNA lesion recognition complex.,http://www.ncbi.nlm.nih.gov/pubmed/17531815,18214
"MSH6 P233S does not lie within any known functional domains of the Msh6 protein (UniProt.org). P233S has been identified in sequencing studies (PMID: 22980975), but has not been biochemically characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1726,22980975,Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/22980975,18215
"MSH6 Q618* results in a premature truncation of the Msh6 protein at amino acid 618 of 1360 (UniProt.org). Due to the loss of MSH2- and ATP-binding regions (PMID: 12019211), Q618* is predicted to lead to a loss of Msh6 protein function.",3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,295,,,www.uniprot.org,18216
"MSH6 Q698E lies within the connector domain of the Msh6 protein (PMID: 17531815). Q698E has not been characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Sep 2017).",9962,17531815,Structure of the human MutSalpha DNA lesion recognition complex.,http://www.ncbi.nlm.nih.gov/pubmed/17531815,285,,,http://www.ncbi.nlm.nih.gov/pubmed,18217
"MSH6 R1034Q lies within the ATPase domain of the Msh6 protein (PMID: 17531815). R1034Q has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Sep 2017).",9962,17531815,Structure of the human MutSalpha DNA lesion recognition complex.,http://www.ncbi.nlm.nih.gov/pubmed/17531815,285,,,http://www.ncbi.nlm.nih.gov/pubmed,18218
"MSH6 R128H does not lie within any known functional domains of the Msh6 protein (UniProt.org). R128H has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,18219
"MSH6 R1331* results in a premature truncation of the Msh6 protein at amino acid 1331 of 1360 (UniProt.org). R1331* has been identified in the scientific literature (PMID: 26552419), but has not been biochemically characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Mar 2017).",8277,26552419,"Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study.",http://www.ncbi.nlm.nih.gov/pubmed/26552419,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,18220
"MSH6 R1334W lies within the Msh2-binding region of the Msh6 protein (PMID: 12019211). R1334W has been identified in sequencing studies (PMID: 25275298), but has not been biochemically characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Mar 2017).",1586,25275298,The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies.,http://www.ncbi.nlm.nih.gov/pubmed/25275298,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,18221
"MSH6 R240* results in a premature truncation of the Msh6 protein at amino acid 240 of 1360 (UniProt.org). Due to the loss of MSH2- and ATP-binding regions (PMID: 12019211), R240* is predicted to lead to a loss of Msh6 protein function.",295,,,www.uniprot.org,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,18222
"MSH6 R361H lies within the Msh2-binding region of the Msh6 protein (PMID: 12019211). R361H has been identified in the scientific literature (PMID: 26674132, PMID: 25344691), but has not been biochemically characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Mar 2017).",1689,25344691,RNF43 is frequently mutated in colorectal and endometrial cancers.,http://www.ncbi.nlm.nih.gov/pubmed/25344691,7015,26674132,Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinoma: immunotheranostic considerations.,http://www.ncbi.nlm.nih.gov/pubmed/26674132,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,18223
"MSH6 R383G lies within the Msh2-binding region of the Msh6 protein (PMID: 12019211). R383G has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,18224
"MSH6 R495* results in a premature truncation of the Msh6 protein at amino acid 495 of 1360 (UniProt.org). Due to the loss of MSH2- and ATP-binding regions (PMID: 12019211), R495* is predicted to lead to a loss of Msh6 protein function.",3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,295,,,www.uniprot.org,18225
"MSH6 R791C does not lie within any known functional domains of the Msh6 protein (UniProt.org). R791C has been identified in sequencing studies (PMID: 25855536), but has not been biochemically characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,7024,25855536,Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets.,http://www.ncbi.nlm.nih.gov/pubmed/25855536,285,,,http://www.ncbi.nlm.nih.gov/pubmed,18226
"MSH6 R791H does not lie within any known functional domains of the Msh6 protein (UniProt.org). R791H has been identified in sequencing studies (PMID: 25233892), but has not been biochemically characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,7231,25233892,Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes.,http://www.ncbi.nlm.nih.gov/pubmed/25233892,285,,,http://www.ncbi.nlm.nih.gov/pubmed,18227
"MSH6 R922* results in a premature truncation of the Msh6 protein at amino acid 922 of 1360 (UniProt.org). Due to the loss of MSH2- and ATP-binding regions (PMID: 12019211), R922* is predicted to lead to a loss of Msh6 protein function.",3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,295,,,www.uniprot.org,18228
"MSH6 R922Q does not lie within any known functional domains of the Msh6 protein (UniProt.org). R922Q has been identified in sequencing studies (PMID: 22037554, PMID: 25233892), but has not been biochemically characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6997,22037554,Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22037554,7231,25233892,Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes.,http://www.ncbi.nlm.nih.gov/pubmed/25233892,18229
"MSH6 S1028L does not lie within any known functional domains of the Msh6 protein (UniProt.org). S1028L has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,18230
"MSH6 S1049F does not lie within any known functional domains of the Msh6 protein (UniProt.org). S1049F has been identified in sequencing studies (PMID: 20668451), but has not been biochemically characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Mar 2017).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,7380,20668451,Diverse somatic mutation patterns and pathway alterations in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/20668451,295,,,www.uniprot.org,18231
"MSH6 S314I does not lie within any known functional domains of the Msh6 protein (UniProt.org). S314I has been identified in sequencing studies (PMID: 21798897), but has not been biochemically characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7349,21798897,Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1.,http://www.ncbi.nlm.nih.gov/pubmed/21798897,18232
"MSH6 S321* results in a premature truncation of the Msh6 protein at amino acid 321 of 1360 (UniProt.org). Due to the loss of MSH2- and ATP-binding regions (PMID: 12019211), S321* is predicted to lead to a loss of Msh6 protein function.",3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,295,,,www.uniprot.org,18233
"MSH6 S360I lies within the Msh2-binding region of the Msh6 protein (PMID: 12019211). S360I has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,18234
"MSH6 S950I does not lie within any known functional domains of the Msh6 protein (UniProt.org). S950I has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,18236
"MSH6 T1010A does not lie within any known functional domains of the Msh6 protein (UniProt.org). T1010A has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,18237
"MSH6 T269S does not lie within any known functional domains of the Msh6 protein (UniProt.org). T269S has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,18238
"MSH6 V1056M does not lie within any known functional domains of the Msh6 protein (UniProt.org). V1056M has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,18239
"MSH6 V1350A lies within the Msh2-binding region of the Msh6 protein (PMID: 12019211). V1350A has been identified in sequencing studies (PMID: 22037554), but has not been biochemically characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Mar 2017).",6997,22037554,Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22037554,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,18240
"MSH6 V450A lies within the Msh2-binding region of the Msh6 protein (PMID: 12019211). V450A has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,18241
"MSH6 W777* results in a premature truncation of the Msh6 protein at amino acid 777 of 1360 (UniProt.org). Due to the loss of MSH2- and ATP-binding regions (PMID: 12019211), W777* is predicted to lead to a loss of Msh6 protein function.",295,,,www.uniprot.org,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,18242
"MSH6 Y1044* results in a premature truncation of the Msh6 protein at amino acid 1044 of 1360 (UniProt.org). Due to the loss of MSH2- and ATP-binding regions (PMID: 12019211), Y1044* is predicted to lead to a loss of Msh6 protein function.",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,18243
"MSH6 Y397H lies within the Msh2-binding region of the Msh6 protein (PMID: 12019211). Y397H has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,18244
MSH6 G566R lies within the Msh2-binding region of the Msh6 protein (PMID: 12019211). G566R results in deficient ATP binding and decreased Msh6 ATPase activity in in vitro assays (PMID: 18790734).,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,3608,18790734,Hereditary cancer-associated missense mutations in hMSH6 uncouple ATP hydrolysis from DNA mismatch binding.,http://www.ncbi.nlm.nih.gov/pubmed/18790734,18245
MSH6 P1087T does not lie within any known functional domains of the Msh6 protein (UniProt.org). P1087T demonstrates binding to Msh2 and in vitro mismatch repair activity similar to wild-type Msh6 protein (PMID: 12019211).,295,,,www.uniprot.org,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,18246
MSH6 P1087R does not lie within any known functional domains of the Msh6 protein (UniProt.org). P1087R demonstrates binding to Msh2 and in vitro mismatch repair activity similar to wild-type Msh6 protein (PMID: 12019211).,295,,,www.uniprot.org,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,18247
"MSH6 W142* results in a premature truncation of the Msh6 protein at amino acid 1044 of 1360 (UniProt.org). W142* has not been biochemically characterized, but is associated with a loss of Msh6 protein expression and increased microsatellite instability in tumor samples (PMID: 14974087).",295,,,www.uniprot.org,4613,14974087,Eight novel MSH6 germline mutations in patients with familial and nonfamilial colorectal cancer selected by loss of protein expression in tumor tissue.,http://www.ncbi.nlm.nih.gov/pubmed/14974087,18248
"MSH6 Y397fs*3 likely results in a truncation of the 1360 aa Msh6 protein at aa 397, followed by 3 nonsense amino acids within the Msh2-binding region (PMID: 12019211). Y397fs*3 has not been biochemically characterized, but is associated with a loss of Msh6 protein expression and increased microsatellite instability in tumor samples (PMID: 14974087).",3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,4613,14974087,Eight novel MSH6 germline mutations in patients with familial and nonfamilial colorectal cancer selected by loss of protein expression in tumor tissue.,http://www.ncbi.nlm.nih.gov/pubmed/14974087,18249
"MSH6 E544fs*26 likely results in a truncation of the 1360 aa Msh6 protein at aa 544, followed by 26 nonsense amino acids within the Msh2-binding region (PMID: 12019211). E544fs*26 has not been biochemically characterized, but is associated with a loss of Msh6 protein expression and increased microsatellite instability in tumor samples (PMID: 14974087).",3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,4613,14974087,Eight novel MSH6 germline mutations in patients with familial and nonfamilial colorectal cancer selected by loss of protein expression in tumor tissue.,http://www.ncbi.nlm.nih.gov/pubmed/14974087,18250
"MSH6 S702* results in a premature truncation of the Msh6 protein at amino acid 1044 of 1360 (UniProt.org). S702* has not been biochemically characterized, but is associated with a loss of Msh6 protein expression and increased microsatellite instability in tumor samples (PMID: 14974087).",295,,,www.uniprot.org,4613,14974087,Eight novel MSH6 germline mutations in patients with familial and nonfamilial colorectal cancer selected by loss of protein expression in tumor tissue.,http://www.ncbi.nlm.nih.gov/pubmed/14974087,18251
"MSH6 I872fs*10 likely results in a truncation of the 1360 aa Msh6 protein at aa 872, followed by 10 nonsense amino acids (UniProt.org). I872fs*10 has not been biochemically characterized, but is associated with a loss of Msh6 protein expression and increased microsatellite instability in tumor samples (PMID: 14974087).",4613,14974087,Eight novel MSH6 germline mutations in patients with familial and nonfamilial colorectal cancer selected by loss of protein expression in tumor tissue.,http://www.ncbi.nlm.nih.gov/pubmed/14974087,295,,,www.uniprot.org,18252
"MSH6 I1109fs*3 likely results in a truncation of the 1360 aa Msh6 protein at aa 1109, followed by 3 nonsense amino acids (UniProt.org). I1109fs*3 has not been biochemically characterized, but is associated with a loss of Msh6 protein expression and increased microsatellite instability in tumor samples (PMID: 14974087).",4613,14974087,Eight novel MSH6 germline mutations in patients with familial and nonfamilial colorectal cancer selected by loss of protein expression in tumor tissue.,http://www.ncbi.nlm.nih.gov/pubmed/14974087,295,,,www.uniprot.org,18253
"MSH6 D1171fs*5 likely results in a truncation of the 1360 aa Msh6 protein at aa 1171, followed by 5 nonsense amino acids (UniProt.org). D1171fs*5 has not been biochemically characterized, but is associated with a loss of Msh6 protein expression and increased microsatellite instability in tumor samples (PMID: 14974087).",4613,14974087,Eight novel MSH6 germline mutations in patients with familial and nonfamilial colorectal cancer selected by loss of protein expression in tumor tissue.,http://www.ncbi.nlm.nih.gov/pubmed/14974087,295,,,www.uniprot.org,18254
"ERBB2 (HER2) E757A lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). E757A has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,18255
"ERBB2 (HER2) L869R lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). L869R results in increased Erbb2 (Her2) phosphorylation, promotes growth in cell culture, and enhances tumor formation and metastasis in animal models (PMID: 27900369).",8396,27900369,"Genomic profiling of multiple sequentially acquired tumor metastatic sites from an ""exceptional responder"" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response.",http://www.ncbi.nlm.nih.gov/pubmed/27900369,295,,,www.uniprot.org,18256
"ERBB2 (HER2) L755_E757del results in the deletion of three amino acids in the protein kinase domain of the Erbb2 (Her2) protein from amino acids 755 to 757 (UniProt.org). L755_E757del has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,18257
"EGFR L698_S1037dup indicates the tandem duplication of exons 18 through 25 of EGFR, resulting in duplication of the kinase domain, constitutive activation of Egfr and a dramatic increase in colony formation relative to L858R (PMID: 26286086).",4643,26286086,EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.,http://www.ncbi.nlm.nih.gov/pubmed/26286086,18315
"IDH1 Y139D lies within a site of the Idh1 protein critical for catalysis of isocitrate and NAPD to 2-oxoglutarate, CO2 and NAPDH (UniProt.org) . R139D confers a loss of Idh1 wild-type activity and a concomitant gain-of-function ability to convert alpha-ketoglutarate to the onco-metabolite 2HG (R(-)-2-hydroxyglutarate) (PMID: 21996744). ",295,,,www.uniprot.org,2651,21996744,Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.,http://www.ncbi.nlm.nih.gov/pubmed/21996744,18316
IDH1 V71I does not lie within any known functional domains of the Idh1 protein (UniProt.org). V71I has been characterized as having wild-type activity (PMID: 21996744).,295,,,www.uniprot.org,2651,21996744,Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.,http://www.ncbi.nlm.nih.gov/pubmed/21996744,18317
IDH1 I99M does not lie within any known functional domains of the Idh1 protein (UniProt.org). I99M has been characterized as having wild-type activity (PMID: 21996744).,2651,21996744,Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.,http://www.ncbi.nlm.nih.gov/pubmed/21996744,295,,,www.uniprot.org,18318
IDH2 V294M does not lie within any known functional domains of the Idh2 protein (UniProt.org). V294M has been characterized as having wild-type activity (PMID: 21996744).,2651,21996744,Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.,http://www.ncbi.nlm.nih.gov/pubmed/21996744,18319
IDH2 F394I does not lie within any known functional domains of the Idh2 protein (UniProt.org). F394I results decreased cellular accumulation of Idh2 protein (PMID: 21996744).,2651,21996744,Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.,http://www.ncbi.nlm.nih.gov/pubmed/21996744,295,,,www.uniprot.org,18320
IDH2 F394V does not lie within any known functional domains of the Idh2 protein (UniProt.org). F394V results in decreased cellular accumulation of Idh2 protein (PMID: 21996744).,2651,21996744,Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.,http://www.ncbi.nlm.nih.gov/pubmed/21996744,295,,,www.uniprot.org,18321
"IDH2 S301L does not lie within any known functional domains of the Idh2 protein (UniProt.org). S301L has not been characterized in the scientific literature and therefore, its effect on Idh2 protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,18322
"ETV6-MECOM results from fusion of ETV6 and MECOM (also referred to as EVI1) (PMID: 9044825). ETV6-MECOM has been identified in myeloproliferative disorders and acute myeloid leukemia (PMID: 9044825, PMID: 28182364), but has not been biochemically characterized and therefore, its effect on fusion protein function is unknown (PubMed, Aug 2017).",4646,9044825,Fusion of ETV6 to MDS1/EVI1 as a result of t(3;12)(q26;p13) in myeloproliferative disorders.,http://www.ncbi.nlm.nih.gov/pubmed/9044825,285,,,http://www.ncbi.nlm.nih.gov/pubmed,9724,28182364,A Rare Case of ETV6/MECOM Rearrangement in Therapy-Related Acute Myeloid Leukemia with t(3;12) and Monosomy 7.,http://www.ncbi.nlm.nih.gov/pubmed/28182364,18330
"ETV6-FGFR3 results from the fusion of ETV6 (also referred to as TEL) and FGFR3 (PMID: 15514005), demonstrating constitutive kinase activity and the ability to transform cells in culture (PMID: 15514005).",4647,15514005,Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML.,http://www.ncbi.nlm.nih.gov/pubmed/15514005,18331
"ETV6-GOT1 results from the fusion of ETV6 and GOT1 (PMID: 16757412). ETV6-GOT1 has been identified in myelodysplastic syndrome (PMID: 16757412, PMID: 18310541), but has not been biochemically characterized and therefore, its effect on protein function is unknown (PubMed, Aug 2017).",7587,18310541,ETV6/GOT1 fusion in a case of t(10;12)(q24;p13)-positive myelodysplastic syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/18310541,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4648,16757412,Fusion of ETV6 to GOT1 in a case with myelodysplastic syndrome and t(10;12)(q24;p13).,http://www.ncbi.nlm.nih.gov/pubmed/16757412,18332
"ETV6-PDGFRA results from the fusion of ETV6 and PDGFRA (PMID: 17555450). ETV6-PDGFRA is responsive to Pdgfra inhibition and therefore, the fusion is predicted to result in a gain of function (PMID: 17555450). ",4649,17555450,Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia.,http://www.ncbi.nlm.nih.gov/pubmed/17555450,18333
"ETV6-ARNT results from the fusion of ETV6 and ARNT (PMID: 20804916). ETV6-ARNT has been identified in childhood T lymphoblastic leukemia (PMID: 20804916), but has not been biochemically characterized and therefore, its effect on fusion protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,4650,20804916,ETV6-ARNT fusion in a patient with childhood T lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/20804916,18335
"TET2 H1778R does not lie within any known functional domains of the Tet2 protein (UniProt.org). H1778R has not been characterized in the scientific literature and therefore, its effect on Tet2 protein function is unknown (PubMed, Feb 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,18338
"TET2 P29R does not lie within any known functional domains of the Tet2 protein (UniProt.org). P29R has not been characterized and therefore, its effect on Tet2 protein function is unknown (PubMed, Feb 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,18372
"TET2 P363L does not lie within any known functional domains of the Tet2 protein (UniProt.org). P363L has not been characterized and therefore, its effect on Tet2 protein function is unknown (PubMed, Feb 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,18374
"TET2 Q1084P does not lie within any known functional domains of the Tet2 protein (UniProt.org). Q1084P has not been characterized and therefore, its effect on Tet2 protein function is unknown (PubMed, Feb 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,18375
"TET2 M1701I does not lie within any known functional domains of the Tet2 protein (UniProt.org). M1701I has not been characterized and therefore, its effect on Tet2 protein function is unknown (PubMed, Feb 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,18377
"TET2 Q876* results in a premature truncation of the Tet2 protein at amino acid 876 of 2002 (UniProt.org). Due to the loss of the DNA binding and substrate binding regions (UniProt.org), Q876* is predicted to lead to a loss of Tet2 protein function.",295,,,www.uniprot.org,18378
"JAK3 T8M lies within the cytokine/interferon/growth hormone receptor-interacting region of the Jak3 protein (UniProt.org). T8M has not been characterized and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,18379
"JAK3 R40H lies within the FERM domain of the Jak3 protein (UniProt.org). R40H has not been characterized and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,18380
TET2 D1384A lies within an iron binding catalytic residue of the Tet2 protein (UniProt.org). D1384A has not been individually characterized but results in an enzymatically dead protein in conjunction with H1382Y (PMID: 23222540).,4662,23222540,TET2 promotes histone O-GlcNAcylation during gene transcription.,http://www.ncbi.nlm.nih.gov/pubmed/23222540,295,,,www.uniprot.org,18381
TET2 H1382Y lies within an iron binding catalytic residue of the Tet2 protein (UniProt.org). H1382Y has not been individually characterized but results in an enzymatically dead protein in conjunction with D1384A (PMID: 23222540).,4662,23222540,TET2 promotes histone O-GlcNAcylation during gene transcription.,http://www.ncbi.nlm.nih.gov/pubmed/23222540,295,,,www.uniprot.org,18382
TET2 D1384V lies within an iron binding catalytic residue of the Tet2 protein (UniProt.org). D1384V has not been individually characterized but results in an enzymatically dead protein in conjunction with H1382Y (PMID: 24315485).,963,24315485,Crystal structure of TET2-DNA complex: insight into TET-mediated 5mC oxidation.,http://www.ncbi.nlm.nih.gov/pubmed/24315485,295,,,www.uniprot.org,18383
TET2 R1896M does not lie within any known functional domains of the Tet2 protein (UniProt.org). R1896M results in reduced Tet2 enzyme activity (PMID: 24315485).,963,24315485,Crystal structure of TET2-DNA complex: insight into TET-mediated 5mC oxidation.,http://www.ncbi.nlm.nih.gov/pubmed/24315485,295,,,www.uniprot.org,18384
"CSF3R T640N lies within the transmembrane domain of the Csf3r protein (UniProt.org). T640N results in transformation of cells, increased Jak-Stat activation, and tumor growth in mouse models (PMID: 26475333).",4663,26475333,"The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I.",http://www.ncbi.nlm.nih.gov/pubmed/26475333,295,,,www.uniprot.org,18385
"FLT3 E77K lies within the extracellular domain of the Flt3 protein (UniProt.org). E77K has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,18389
"FLT3 I417L lies within the extracellular domain of the Flt3 protein (UniProt.org). I417L has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,18390
"FGFR3 R399C lies within the cytoplasmic domain of the Fgfr3 protein (UniProt.org). R399C has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,18393
"FBXW7 G667fs results in a change in the amino acid sequence of the Fbxw7 protein beginning at aa 667 of 707, likely resulting in premature truncation of the functional protein (UniProt.org). G667fs has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,18394
"FBXW7 R543fs results in a change in the amino acid sequence of the Fbxw7 protein beginning at aa 543 of 707, likely resulting in premature truncation of the functional protein (UniProt.org). R543fs has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,18395
"PDGFRA G79D lies within the Ig-like C2-type domain 1 of the Pdgfra protein (UniProt.org). G79D has been identified in the scientific literature (PMID: 19755855), but has not been biochemically characterized and therefore, its effect on Pdgfra protein function is unknown (PubMed, Aug 2017).",7715,19755855,Amplification of chromosomal segment 4q12 in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19755855,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,18490
TP53 H168R lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). H168R leads to decreased Tp53 transactivation activity in cell culture (PMID: 18996393).,4678,18996393,Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.,http://www.ncbi.nlm.nih.gov/pubmed/18996393,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,18536
"ALK act mut indicates that this variant results in a gain of function in the Alk protein.  However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,18537
"MET Y1235D (also referred to as Y1253D) lies in a phosphorylation site within the protein kinase domain of the Met protein (UniProt.org). Y1235D (Y1253D) results in increased Met kinase activity in in vitro assays (PMID: 16245927, PMID: 19459657).",295,,,www.uniprot.org,2021,19459657,Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/19459657,2022,16245927,Regulation of the wild-type and Y1235D mutant Met kinase activation.,http://www.ncbi.nlm.nih.gov/pubmed/16245927,18692
FLT3 exon 14 ins refers to a series of internal tandem duplications (ITD) typically occurring in exon 14 and within the juxtamembrane domain of the Flt3 protein (PMID: 12970773). Exon 14 ins mutations result in constitutive activation of Flt3 (PMID: 12970773).,2896,12970773,FLT3: ITDoes matter in leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/12970773,18773
"FLT3 D835F lies within the protein kinase domain activation loop of the Flt3 protein (UniProt.org, PMID: 11290608). D835F has not been characterized, however other 835 hotspot mutations are activating (PMID: 11290608) and therefore, D835F is predicted to lead to an increase in Flt3 protein kinase activity. ",295,,,www.uniprot.org,2011,11290608,Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/11290608,18774
FLT3 Y842H lies within the protein kinase domain of the Flt3 protein (UniProt.org). Y842H has not been individually characterized but is associated with acquired resistance in the context of FLT3 ITD (PMID: 25847190).,3027,25847190,"Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.",http://www.ncbi.nlm.nih.gov/pubmed/25847190,295,,,www.uniprot.org,18775
"FLT3 D839H lies within the protein kinase domain of the Flt3 protein (UniProt.org). D839H has not been characterized, but has been demonstrated to occur as a secondary resistance mutation (PMID: 19318574).",295,,,www.uniprot.org,3029,19318574,FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.,http://www.ncbi.nlm.nih.gov/pubmed/19318574,18776
"FLT3 E708G lies within the protein kinase domain of the Flt3 protein (UniProt.org). E708G has been identified in sequencing studies (PMID: 25847190), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",3027,25847190,"Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.",http://www.ncbi.nlm.nih.gov/pubmed/25847190,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,18777
"FLT3 M837G lies within the protein kinase domain of the Flt3 protein (UniProt.org). M837G has not been characterized, but has been demonstrated to confer drug resistance when occurred in tandem with S838R and D839H (PMID: 25847190).",3027,25847190,"Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.",http://www.ncbi.nlm.nih.gov/pubmed/25847190,295,,,www.uniprot.org,18778
"FLT3 N609K lies adjacent to the protein kinase domain of the Flt3 protein (UniProt.org). N609K has been identified in sequencing studies (PMID: 25847190), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3027,25847190,"Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.",http://www.ncbi.nlm.nih.gov/pubmed/25847190,295,,,www.uniprot.org,18779
FLT3 N676K lies within the protein kinase domain of the Flt3 protein (UniProt.org). N676K results in constitutive activation of Flt3 (PMID: 26891877).,4740,26891877,Leukemogenic potency of the novel FLT3-N676K mutant.,http://www.ncbi.nlm.nih.gov/pubmed/26891877,295,,,www.uniprot.org,18780
"FLT3 N676T lies within the protein kinase domain of the Flt3 protein (UniProt.org). N676T has been identified in sequencing studies (PMID: 27276561), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",7052,27276561,Genomic Classification and Prognosis in Acute Myeloid Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27276561,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,18781
"FLT3 N841Y lies within the activation loop of the protein kinase domain of the Flt3 protein (UniProt.org). N841Y has been identified in sequencing studies (PMID: 15625552), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7345,15625552,A novel FLT3 activation loop mutation N841K in acute myeloblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/15625552,295,,,www.uniprot.org,18782
"FLT3 S652G lies within the protein kinase domain of the Flt3 protein (UniProt.org). S652G has been identified in sequencing studies (PMID: 25847190), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3027,25847190,"Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.",http://www.ncbi.nlm.nih.gov/pubmed/25847190,295,,,www.uniprot.org,18783
"FLT3 S838R lies within the protein kinase domain of the Flt3 protein (UniProt.org). S838R has not been characterized, but has been demonstrated to confer drug resistance when occurred in tandem with M837G and D839H (PMID: 25847190).",3027,25847190,"Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.",http://www.ncbi.nlm.nih.gov/pubmed/25847190,295,,,www.uniprot.org,18784
"FLT3 T628I lies within the protein kinase domain of the Flt3 protein (UniProt.org). T628I has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,18785
"FLT3 T820A lies within the protein kinase domain of the Flt3 protein (UniProt.org). T820A has not been characterized, but has been demonstrated to occur as a secondary resistance mutation (PMID: 25847190).
",295,,,www.uniprot.org,3027,25847190,"Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.",http://www.ncbi.nlm.nih.gov/pubmed/25847190,18786
"FLT3 D698N lies within the protein kinase domain of the Flt3 protein (UniProt.org). D698N has not been characterized, but has been demonstrated to occur as a secondary resistance mutation (PMID: 25847190).",295,,,www.uniprot.org,3027,25847190,"Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.",http://www.ncbi.nlm.nih.gov/pubmed/25847190,18914
"FLT3 D835G lies within the activation loop of the protein kinase domain of the Flt3 protein (UniProt.org, PMID: 11290608). D835G has not been characterized, however other 835 hotspot mutations are activating (PMID: 11290608) and therefore, D835G is predicted to lead to an increase in Flt3 protein kinase activity.",295,,,www.uniprot.org,2011,11290608,Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/11290608,18915
"FLT3 D839A lies within the activation loop of the protein kinase domain of the Flt3 protein (UniProt.org). D839A has not been characterized, but has been demonstrated to occur as a secondary resistance mutation (PMID: 25847190).",295,,,www.uniprot.org,3027,25847190,"Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.",http://www.ncbi.nlm.nih.gov/pubmed/25847190,18916
"FLT3 D839N lies within the activation loop of the protein kinase domain of the Flt3 protein (UniProt.org). D839A has not been characterized, but has been demonstrated to occur as a secondary resistance mutation (PMID: 25847190).",3027,25847190,"Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.",http://www.ncbi.nlm.nih.gov/pubmed/25847190,295,,,www.uniprot.org,18919
"FLT3 G846R lies within the activation loop of the protein kinase domain of the Flt3 protein (UniProt.org). G846R has not been characterized but, has been demonstrated to occur as a secondary resistance mutation (PMID: 25847190).",3027,25847190,"Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.",http://www.ncbi.nlm.nih.gov/pubmed/25847190,295,,,www.uniprot.org,18921
"FLT3 M664I lies within the protein kinase domain of the Flt3 protein (UniProt.org). M664I has not been characterized, but has been demonstrated to occur as a secondary drug resistance mutation (PMID: 25847190).",3027,25847190,"Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.",http://www.ncbi.nlm.nih.gov/pubmed/25847190,295,,,www.uniprot.org,18925
"FLT3 N676S lies within the protein kinase domain of the Flt3 protein (UniProt.org). N676S has not been characterized, but has been demonstrated to occur as a secondary resistance mutation (PMID: 25847190).",3027,25847190,"Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.",http://www.ncbi.nlm.nih.gov/pubmed/25847190,295,,,www.uniprot.org,18926
"FLT3 N841K lies within the activation loop of the protein kinase domain of the Flt3 protein (UniProt.org). N841K has not been characterized, but has been demonstrated to occur as a secondary resistance mutation (PMID: 25847190).",3027,25847190,"Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.",http://www.ncbi.nlm.nih.gov/pubmed/25847190,295,,,www.uniprot.org,18927
"FLT3 R845G lies within the activation loop of the protein kinase domain of the Flt3 protein (UniProt.org). R845G has not been characterized, but has been demonstrated to occur as a secondary resistance mutation (PMID: 25847190).",3027,25847190,"Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.",http://www.ncbi.nlm.nih.gov/pubmed/25847190,295,,,www.uniprot.org,18928
"FLT3 Y842S lies within the activation loop of the protein kinase domain of the Flt3 protein (UniProt.org). Y842S has not been characterized, but has been demonstrated to occur as a secondary resistance mutation (PMID: 25847190).",3027,25847190,"Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 ""Gatekeeper"" F691L Mutation with PLX3397.",http://www.ncbi.nlm.nih.gov/pubmed/25847190,295,,,www.uniprot.org,18929
"IKZF1 R143Q does not lie within any known functional domains of the Ikzf1 protein (UniProt.org). R143Q has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,18993
"IKZF1 R51T does not lie within any known functional domains of the Ikzf1 protein (UniProt.org). R51T has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, Mar 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,18994
"IKZF1 G337S does not lie within any known functional domains of the Ikzf1 protein (UniProt.org). G337S has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, Mar 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,18995
"S45N lies within a Gsk3b phosphorylation site on the Ctnnb1 protein (UniProt). S45N has not been characterized, however, other S45 “hotspot” mutations are activating thus, S45N is predicted to result in a gain of Ctnnb1 function (PMID: 15579438, PMID: 23258168).",586,15579438,CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15579438,2251,23258168,WNT signalling pathways as therapeutic targets in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23258168,19001
"IDH1 R100A lies within the substrate binding region of the Idh1 protein (UniProt.org). R100A confers a gain of function to Idh1, resulting in aberrant production of 2HG in cell culture (PMID: 21996744).",295,,,www.uniprot.org,2651,21996744,Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.,http://www.ncbi.nlm.nih.gov/pubmed/21996744,19245
"PTEN A126G lies within the tensin-type phosphatase domain of the Pten protein (UniProt.org). A126G results in a shift of Pten from 3- to 5-phosphatase, activation of Pi3k/Akt signaling, and increased cell proliferation and transformation in culture (PMID: 26504226).",295,,,www.uniprot.org,4785,26504226,Discovery and functional characterization of a neomorphic PTEN mutation.,http://www.ncbi.nlm.nih.gov/pubmed/26504226,19378
"JAK2 C480F does not lie within any known functional domains of the Jak2 protein (UniProt.org). C480F has not been characterized in the scientific literature and therefore, its effect on Jak2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19405
BRAF N486_P490del results in the deletion of five amino acids near the alphaC-helix region of the kinase domain (PMID: 26732095). N486_P490del confers a gain of function to the Braf protein as indicated by activation of the MAPK signaling pathway and increased cell proliferation in culture (PMID: 26732095).,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,19426
BRAF V487_P492delinsA results in a deletion of six amino acids near the alphaC-helix region of the kinase domain of the Braf protein combined with the insertion of one new amino acid in the same location (PMID: 26732095). V487_P492delinsA confers a gain of function to the Braf protein as indicated by increased pathway signaling and cell proliferation in culture (PMID: 26732095).,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,19427
BRAF L485_P490delinY results in a deletion of six amino acids near the alphaC-helix region of the Braf protein kinase domain combined with the insertion of one new amino acid in the same location (PMID: 26732095). L485_P490delinY confers a gain of function to the Braf protein as indicated by activation of the MAPK signaling pathway and increased cell proliferation in culture (PMID: 26732095). ,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,19428
BRAF L485_P490delinsF results in a deletion of six amino acids near the alphaC-helix region of the Braf protein kinase domain combined with the insertion of one new amino acid in the same location (PMID: 26732095). L485_P490delinsF confers a gain of function to the Braf protein as indicated by increased downstream signaling of the MAPK pathway (PMID: 26732095).,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,19429
"BRAF P490_Q494del results in the deletion of five amino acids near the alphaC-helix region of the protein kinase domain in the Braf protein from amino acids 490 to 494 (PMID: 26732095). P490_Q494del has not been characterized, however, is predicted to result in a gain of function due to other characterized BRAF deletions in the same region (PMID: 26732095).",4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,19430
"BRAF T488_P492del results in the deletion of five amino acids near the alphaC-helix region of the protein kinase domain in the Braf protein from amino acids 488 to 492 (PMID: 26732095). T488_P492del has not been characterized, however, is predicted to result in a gain of function due to other characterized BRAF deletions in the same region (PMID: 26732095).",4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,19431
"BRAF T488_Q493delinsK results in the deletion of six amino acids near the alphaC-helix region of the Braf protein kinase domain combined with the insertion of one new amino acid in the same location (PMID: 26732095). T488_Q493delinsK has not been characterized, however, is predicted to result in a gain of function due to other characterized BRAF deletions in the same region (PMID: 26732095).",4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,19432
PIK3CA P449T lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). P449T results in increased Pik3ca kinase activity in culture (PMID: 20530683).,295,,,www.uniprot.org,1863,20530683,Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations.,http://www.ncbi.nlm.nih.gov/pubmed/20530683,19434
TP53 L194F lies within the DNA binding domain of the Tp53 protein (UniProt.org). L194F results in decreased Tp53 transactivation activity and decreased binding to Bcl2 in cell culture (PMID: 16443602).,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19440
KIT exon 11 indicates an unspecified mutation has occurred in exon 11 of the KIT gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,19441
KIT exon 9 indicates an unspecified mutation has occurred in exon 9 of the KIT gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,19442
"TP53 P223L lies within the DNA binding domain of the Tp53 protein (UniProt.org). P223L has been identified in the scientific literature (PMID: 20138958), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,10077,20138958,"Iodine induces apoptosis via regulating MAPKs-related p53, p21, and Bcl-xL in thyroid cancer cells.",http://www.ncbi.nlm.nih.gov/pubmed/20138958,285,,,http://www.ncbi.nlm.nih.gov/pubmed,19443
"SMO D384A lies within the type I binding site of the Smo protein (PMID: 25636740). D384A has not been biochemically characterized, but results in reduced Smo inhibitor binding in culture (PMID: 25636740). ",2240,25636740,MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor.,http://www.ncbi.nlm.nih.gov/pubmed/25636740,19444
"SMO S387A lies within the type I binding site of the Smo protein (PMID: 25636740). S387A has not been characterized and therefore, its effect on Smo protein function is unknown (PubMed, Jun 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2240,25636740,MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor.,http://www.ncbi.nlm.nih.gov/pubmed/25636740,19445
"SMO Y394A lies within the type I binding site of the Smo protein (PMID: 25636740). Y394A has not been biochemically characterized, but results in reduced Smo inhibitor binding in culture (PMID: 25636740).",2240,25636740,MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor.,http://www.ncbi.nlm.nih.gov/pubmed/25636740,19446
"SMO R400A lies within the type I binding site of the Smo protein (PMID: 25636740). R400A has not been biochemically characterized, but results in reduced Smo inhibitor binding in culture (PMID: 25636740).",2240,25636740,MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor.,http://www.ncbi.nlm.nih.gov/pubmed/25636740,19447
"SMO L325F lies within one of the transmembrane domain of the Smo protein (UniProt.org). L325F has not been biochemically characterized, but results in reduced Smo inhibitor binding (PMID: 25636740).",2240,25636740,MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor.,http://www.ncbi.nlm.nih.gov/pubmed/25636740,295,,,www.uniprot.org,19448
"HNF1A A160D does not lie within any known functional domains of the Hnf1a protein (UniProt.org). A160D has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19449
"SMO V329F lies within one of the transmembrane domain of the Smo protein (UniProt.org). V329F has not been biochemically characterized, but results in reduced Smo inhibitor binding in culture (PMID: 25636740).",2240,25636740,MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor.,http://www.ncbi.nlm.nih.gov/pubmed/25636740,295,,,www.uniprot.org,19450
"SMO I408F lies within one of the transmembrane domains of the Smo protein (UniProt.org). I408F has not been characterized and therefore, its effect on Smo protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19451
"HNF1A A161T does not lie within any known functional domains of the Hnf1a protein (UniProt.org). A161T has not been characterized and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19452
"SMO T466F lies within one of the transmembrane domains of the Smo protein (UniProt.org). T466F has not been characterized, but results in reduced Smo inhibitor binding in culture (PMID: 25636740).",2240,25636740,MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor.,http://www.ncbi.nlm.nih.gov/pubmed/25636740,295,,,www.uniprot.org,19453
"SMO E518K lies within an extracellular domain of the Smo protein (UniProt.org). E518K has not been biochemically characterized, but has been described as a resistance mutation (PMID: 23940421).",295,,,www.uniprot.org,4839,23940421,Profile of vismodegib and its potential in the treatment of advanced basal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23940421,19455
"SMO M525G lies within one of the transmembrane domains of the Smo protein (UniProt.org). M525G has not been characterized, but results in reduced Smo inhibitor binding in culture (PMID: 25636740).",2240,25636740,MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor.,http://www.ncbi.nlm.nih.gov/pubmed/25636740,295,,,www.uniprot.org,19456
"HNF1A A326S does not lie within any known functional domains of the Hnf1a protein (UniProt.org). A326S has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19457
"HNF1A A532T does not lie within any known functional domains of the Hnf1a protein (UniProt.org). A532T has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,19458
"HNF1A D135N does not lie within any known functional domains of the Hnf1a protein (UniProt.org). D135N has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,19459
"HNF1A D546G does not lie within any known functional domains of the Hnf1a protein (UniProt.org). D546G has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19460
"HNF1A D75N does not lie within any known functional domains of the Hnf1a protein (UniProt.org). D75N has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19461
"HNF1A D76N does not lie within any known functional domains of the Hnf1a protein (UniProt.org). D76N has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19462
"HNF1A D80G does not lie within any known functional domains of the Hnf1a protein (UniProt.org). D80G has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 

",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19463
"HNF1A E188D does not lie within any known functional domains of the Hnf1a protein (UniProt.org). E188D has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19469
"HNF1A E234K lies within the HNF1-type DNA binding region of the Hnf1a protein (UniProt.org). E234K has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19470
"HNF1A E329Q does not lie within any known functional domains of the Hnf1a protein (UniProt.org). E329Q has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19471
"HNF1A E41K does not lie within any known functional domains of the Hnf1a protein (UniProt.org). E41K has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19472
"HNF1A E56D does not lie within any known functional domains of the Hnf1a protein (UniProt.org). E56D has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19473
"HNF1A E79K does not lie within any known functional domains of the Hnf1a protein (UniProt.org). E79K has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,19474
"HNF1A E95K does not lie within any known functional domains of the Hnf1a protein (UniProt.org). E95K has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,19475
"HNF1A F268I lies within the HNF1-type DNA binding region of the Hnf1a protein (UniProt.org). F268I has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19476
"HNF1A F464S does not lie within any known functional domains of the Hnf1a protein (UniProt.org). F464S has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19477
"HNF1A G138N does not lie within any known functional domains of the Hnf1a protein (UniProt.org). G138N has not been characterized and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19478
"HNF1A G253W lies within the HNF1-type DNA binding region of the Hnf1a protein (UniProt.org). G253W has not been characterized and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 

",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19479
"HNF1A G292E does not lie within any known functional domains of the Hnf1a protein (UniProt.org). G292E has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19480
"HNF1A G355S does not lie within any known functional domains of the Hnf1a protein (UniProt.org). G355S has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19481
"HNF1A G40E does not lie within any known functional domains of the Hnf1a protein (UniProt.org). G40E has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19482
"HNF1A G410E does not lie within any known functional domains of the Hnf1a protein (UniProt.org). G410E has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19483
"HNF1A G410R does not lie within any known functional domains of the Hnf1a protein (UniProt.org). G410R has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19484
"HNF1A G51D does not lie within any known functional domains of the Hnf1a protein (UniProt.org). G51D has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19485
"HNF1A G554R does not lie within any known functional domains of the Hnf1a protein (UniProt.org). G554R has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19486
"HNF1A H126Q does not lie within any known functional domains of the Hnf1a protein (UniProt.org). H126Q has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19487
"HNF1A I27M lies within the dimerization region of the Hnf1a protein (UniProt.org). I27M has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19488
"HNF1A I449M does not lie within any known functional domains of the Hnf1a protein (UniProt.org). I449M has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19489
"HNF1A K120N does not lie within any known functional domains of the Hnf1a protein (UniProt.org). K120N has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,19490
"HNF1A K46N does not lie within any known functional domains of the Hnf1a protein (UniProt.org). K46N has not been characterized and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,19491
"HNF1A L38P does not lie within any known functional domains of the Hnf1a protein (UniProt.org). L38P has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19492
"HNF1A L408I does not lie within any known functional domains of the Hnf1a protein (UniProt.org). L408I has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19493
"HNF1A L530P does not lie within any known functional domains of the Hnf1a protein (UniProt.org). L530P has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19494
"HNF1A L536F does not lie within any known functional domains of the Hnf1a protein (UniProt.org). L536F has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19495
"HNF1A L89P does not lie within any known functional domains of the Hnf1a protein (UniProt.org). L89P has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19496
"HNF1A M154T does not lie within any known functional domains of the Hnf1a protein (UniProt.org). M154T has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19497
"HNF1A M405L does not lie within any known functional domains of the Hnf1a protein (UniProt.org). M405L has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19498
"HNF1A N428K does not lie within any known functional domains of the Hnf1a protein (UniProt.org). N428K has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19499
"HNF1A P153H does not lie within any known functional domains of the Hnf1a protein (UniProt.org). P153H has not been characterized and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19500
"HNF1A P314R does not lie within any known functional domains of the Hnf1a protein (UniProt.org). P314R has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19501
"HNF1A P340L does not lie within any known functional domains of the Hnf1a protein (UniProt.org). P340L has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19502
"HNF1A P347S does not lie within any known functional domains of the Hnf1a protein (UniProt.org). P347S has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19503
"HNF1A P379S does not lie within any known functional domains of the Hnf1a protein (UniProt.org). P379S has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19504
"HNF1A P94H does not lie within any known functional domains of the Hnf1a protein (UniProt.org). P94H has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19505
"HNF1A D192Gfs*2 is a missense mutation (D192G) in conjunction with a likely truncation of the 631 aa Hnf1a protein at aa 192, followed by 2 nonsense amino acids (UniProt.org). Due to the loss of the transactivation domain (PMID: 18003757), D192Gfs*2 is predicted to lead to a loss of Hnf1a protein function.
",295,,,www.uniprot.org,4227,18003757,The type and the position of HNF1A mutation modulate age at diagnosis of diabetes in patients with maturity-onset diabetes of the young (MODY)-3.,http://www.ncbi.nlm.nih.gov/pubmed/18003757,19539
"HNF1A E48Pfs*106 is a missense mutation (E48P) in conjunction with a likely truncation of the 631 aa Hnf1a protein at aa 48, followed by 106 nonsense amino acids (UniProt.org). Due to the loss of the transactivation domain (PMID: 18003757), E48Pfs*106 is predicted to lead to a loss of Hnf1a protein function.
",295,,,www.uniprot.org,4227,18003757,The type and the position of HNF1A mutation modulate age at diagnosis of diabetes in patients with maturity-onset diabetes of the young (MODY)-3.,http://www.ncbi.nlm.nih.gov/pubmed/18003757,19540
"HNF1A K23Rfs*9 is a missense mutation (K23R) in conjunction with a likely truncation of the 631 aa Hnf1a protein at aa 23, followed by 9 nonsense amino acids (UniProt.org). Due to the loss of the transactivation domain (PMID: 18003757), K23Rfs*9 is predicted to lead to a loss of Hnf1a protein function.
",295,,,www.uniprot.org,4227,18003757,The type and the position of HNF1A mutation modulate age at diagnosis of diabetes in patients with maturity-onset diabetes of the young (MODY)-3.,http://www.ncbi.nlm.nih.gov/pubmed/18003757,19541
"CDH1 A102T lies within the extracellular domain of the Cdh1 protein (UniProt.org). A102T has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19559
"CDH1 A299S lies within the Cadherin domain 2 of the Cdh1 protein (UniProt.org). A299S has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19560
"CDH1 A403T lies within the Cadherin domain 3 of the Cdh1 protein (UniProt.org). A403T has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19561
"CDH1 A592T lies within the Cadherin domain 4 of the Cdh1 protein (UniProt.org). A592T has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Jun 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19562
"CDH1 A634V lies within the Cadherin domain 5 of the Cdh1 protein (UniProt.org). A634V has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19563
"CDH1 A691T lies within the Cadherin domain 5 of the Cdh1 protein (UniProt.org). A691T has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19564
"CDH1 A692T lies within the Cadherin domain 5 of the Cdh1 protein (UniProt.org). A692T has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19565
"CDH1 A709V lies within the extracellular domain of the Cdh1 protein (UniProt.org). A709V has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19566
"CDH1 A719V lies within the transmembrane domain of the Cdh1 protein (UniProt.org). A719V has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19567
"CDH1 A735V lies within the cytoplasmic domain of the Cdh1 protein (UniProt.org). A735V has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19568
"CDH1 A817V lies within the catenin-binding region of the Cdh1 protein (UniProt.org). A817V has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19569
"CDH1 A824Gfs*5 is a missense mutation (A824G) in conjunction with a likely truncation of the 882 aa Cdh1 protein at aa 824, followed by 5 nonsense amino acids (UniProt.org). Due to the loss of the majority of the catenin-binding region (UniProt.org), A824Gfs*5 is predicted to lead to a loss of Cdh1 protein function.",295,,,www.uniprot.org,19570
"CDH1 A824V lies within the catenin-binding region of the Cdh1 protein (UniProt.org). A824V has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,19571
"CDH1 D221H lies within the Cadherin domain 1 of the Cdh1 protein (UniProt.org). D221H has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19572
"CDH1 D254N lies within the Cadherin domain 1 of the Cdh1 protein (UniProt.org). D254N has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19573
"CDH1 D254Y lies within the Cadherin domain 1 of the Cdh1 protein (UniProt.org). D254Y has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19574
"CDH1 D257G lies within the Cadherin domain 1 of the Cdh1 protein (UniProt.org). D257G has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19575
"CDH1 D257N lies within the Cadherin domain 1 of the Cdh1 protein (UniProt.org). D257N has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19576
"CDH1 D257V lies within the Cadherin domain 1 of the Cdh1 protein (UniProt.org). D257V has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19577
"CDH1 D288N lies within the Cadherin domain 2 of the Cdh1 protein (UniProt.org). D288N has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19578
"CDH1 D288V lies within the Cadherin domain 2 of the Cdh1 protein (UniProt.org). D288V has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19579
"CDH1 D290G lies within the Cadherin domain 2 of the Cdh1 protein (UniProt.org). D290G has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19580
"CDH1 D291Mfs*3 is a missense mutation (D291M) in conjunction with a likely truncation of the 882 aa Cdh1 protein at aa 291, followed by 3 nonsense amino acids (UniProt.org). Due to the loss of the cytoplasmic domain (UniProt.org), D291Mfs*3 is predicted to lead to a loss of Cdh1 protein function.",295,,,www.uniprot.org,19581
"CDH1 D291N lies within the Cadherin domain 2 of the Cdh1 protein (UniProt.org). D291N has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19582
"CDH1 D313N lies within the Cadherin domain 2 of the Cdh1 protein (UniProt.org). D313N has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19583
"CDH1 D370N lies within the Cadherin domain 2 of the Cdh1 protein (UniProt.org). D370N has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19584
"CDH1 D400A lies within the Cadherin domain 3 of the Cdh1 protein (UniProt.org). D400A has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19585
"CDH1 D400del results in the deletion of one amino acid in the Cadherin domain 3 of the Cdh1 protein at amino acid 400 (UniProt.org). D400del has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,19586
"CDH1 D402H lies within the Cadherin domain 3 of the Cdh1 protein (UniProt.org). D402H has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,19587
"CDH1 D402N lies within the Cadherin domain 3 of the Cdh1 protein (UniProt.org). D402N has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19588
"CDH1 D418N lies within the Cadherin domain 3 of the Cdh1 protein (UniProt.org). D418N has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19589
"CDH1 D433N lies within the Cadherin domain 3 of the Cdh1 protein (UniProt.org). D433N has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19590
"CDH1 D549H lies within the Cadherin domain 4 of the Cdh1 protein (UniProt.org). D549H has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19591
"CDH1 D549Y lies within the Cadherin domain 4 of the Cdh1 protein (UniProt.org). D549Y has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19592
"CDH1 D552N lies within the Cadherin domain 4 of the Cdh1 protein (UniProt.org). D552N has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19593
"CDH1 D587H lies within the Cadherin domain 4 of the Cdh1 protein (UniProt.org). D587H has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19594
"CDH1 D587Y lies within the Cadherin domain 4 of the Cdh1 protein (UniProt.org). D587Y has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19595
"CDH1 D644N lies within the Cadherin domain 5 of the Cdh1 protein (UniProt.org). D644N has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19596
"CDH1 D764Gfs*5 is a missense mutation (D764G) in conjunction with a likely truncation of the 882 aa Cdh1 protein at aa 764, followed by 5 nonsense amino acids (UniProt.org). Due to the loss of the majority of the catenin-binding region (UniProt.org), D764Gfs*5 is predicted to lead to a loss of Cdh1 protein function.",295,,,www.uniprot.org,19597
"CDH1 D858E lies within the catenin-binding region of the Cdh1 protein (UniProt.org). D858E has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19598
"CDH1 E165Q lies within the Cadherin domain 1 of the Cdh1 protein (UniProt.org). E165Q has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19599
"CDH1 E243* results in a premature truncation of the Cdh1 protein at amino acid 243 of 882 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), E243* is predicted to lead to a loss of Cdh1 protein function.",295,,,www.uniprot.org,19600
"CDH1 E243K lies within the Cadherin domain 1 of the Cdh1 protein (UniProt.org). E243K has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19601
"CDH1 E243Q lies within the Cadherin domain 1 of the Cdh1 protein (UniProt.org). E243Q has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,19602
"CDH1 E247K lies within the Cadherin domain 1 of the Cdh1 protein (UniProt.org). E247K has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19604
"CDH1 E261K lies within the Cadherin domain 1 of the Cdh1 protein (UniProt.org). E261K has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19605
"CDH1 E273K lies within the Cadherin domain 2 of the Cdh1 protein (UniProt.org). E273K has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19606
"CDH1 E386K lies within the Cadherin domain 3 of the Cdh1 protein (UniProt.org). E386K has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19607
"CDH1 E445A lies within the Cadherin domain 3 of the Cdh1 protein (UniProt.org). E445A has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19608
"CDH1 E445Q lies within the Cadherin domain 2 of the Cdh1 protein (UniProt.org). E445Q has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19609
"CDH1 E463* results in a premature truncation of the Cdh1 protein at amino acid 463 of 882 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), E463* is predicted to lead to a loss of Cdh1 protein function.",295,,,www.uniprot.org,19610
"CDH1 E490K lies within the Cadherin domain 4 of the Cdh1 protein (UniProt.org). E490K has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19611
"CDH1 E494* results in a premature truncation of the Cdh1 protein at amino acid 494 of 882 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), E494* is predicted to lead to a loss of Cdh1 protein function.",295,,,www.uniprot.org,19612
"CDH1 E497K lies within the Cadherin domain 4 of the Cdh1 protein (UniProt.org). E497K has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19613
"CDH1 E512* results in a premature truncation of the Cdh1 protein at amino acid 512 of 882 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), E512* is predicted to lead to a loss of Cdh1 protein function.",295,,,www.uniprot.org,19615
"CDH1 E551K lies within the Cadherin domain 4 of the Cdh1 protein (UniProt.org). E551K has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19616
"CDH1 E58Q lies within the extracellular domain of the Cdh1 protein (UniProt.org). E58Q has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19617
CDH1 E648* results in a premature truncation of the Cdh1 protein at amino acid 648 of 882 (UniProt.org). E648* is predicted to confer a loss of function to the Cdh1 protein as demonstrated by loss of Cdh1 expression and possible increased cell migration (PMID: 26901067).,5017,26901067,Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26901067,295,,,www.uniprot.org,19618
"CDH1 E841K lies within the catenin-binding region of the Cdh1 protein (UniProt.org). E841K has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,19619
"CDH1 R63* results in a premature truncation of the Cdh1 protein at amino acid 63 of 882 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), R63* is predicted to lead to a loss of Cdh1 function.",295,,,www.uniprot.org,19620
"ERBB2 (HER2) L869Q lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). L869Q has been identified in the scientific literature (PMID: 26487584), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4844,26487584,A clinical case of invasive lobular breast carcinoma with ERBB2 and CDH1 mutations presenting a dramatic response to anti-HER2-directed therapy.,http://www.ncbi.nlm.nih.gov/pubmed/26487584,19621
"CDH1 E852Vfs*8 is a missense mutation (E852V) in conjunction with a likely truncation of the 882 aa Cdh1 protein at aa 852, followed by 8 nonsense amino acids (UniProt.org). E852Vfs*8 has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19622
"CDH1 F205S lies within the Cadherin domain 1 of the Cdh1 protein (UniProt.org). F205S has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19623
"CDH1 F317S lies within the Cadherin domain 2 of the Cdh1 protein (UniProt.org). F317S has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19624
"CDH1 F499Lfs*38 is a missense mutation (F499L) in conjunction with a likely truncation of the 882 aa Cdh1 protein at aa 499, followed by 38 nonsense amino acids (UniProt.org). Due to the loss of the cytoplasmic domain (UniProt.org), F499Lfs*38 is predicted to lead to a loss of Cdh1 protein function.",295,,,www.uniprot.org,19625
"CDH1 F601L lies within the Cadherin domain 5 of the Cdh1 protein (UniProt.org). F601L has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19626
"CDH1 F98L lies within the extracellular domain of the Cdh1 protein (UniProt.org). F98L has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19627
"CDH1 D400V lies within the Cadherin domain 3 of the Cdh1 protein (UniProt.org). D400V has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19628
"CDH1 G169Rfs*5 is a missense mutation (G169R) in conjunction with a likely truncation of the 882 aa Cdh1 protein at aa 169, followed by 5 nonsense amino acids (UniProt.org). Due to the loss of most known functional domains (UniProt.org), G169Rfs*5 is predicted to lead to a loss of Cdh1 protein function.",295,,,www.uniprot.org,19629
"CDH1 G212E lies within the Cadherin domain 1 of the Cdh1 protein (UniProt.org). G212E has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19630
"CDH1 G239W lies within the Cadherin domain 1 of the Cdh1 protein (UniProt.org). G239W has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19631
"CDH1 G278* results in a premature truncation of the Cdh1 protein at amino acid 278 of 882 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), G278* is predicted to lead to a loss of Cdh1 protein function.",295,,,www.uniprot.org,19632
"CDH1 G278R lies within the Cadherin domain 2 of the Cdh1 protein (UniProt.org). G278R has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19633
"CDH1 G278V lies within the Cadherin domain 2 of the Cdh1 protein (UniProt.org). G278V has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19634
"CDH1 G693D lies within the Cadherin domain 5 of the Cdh1 protein (UniProt.org). G693D has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,19635
"CDH1 G759Efs*11 is a missense mutation (G759E) in conjunction with a likely truncation of the 882 aa Cdh1 protein at aa 759, followed by 11 nonsense amino acids (UniProt.org). Due to the loss of the majority of the catenin-binding region (UniProt.org), G759Efs*11 is predicted to lead to a loss of Cdh1 protein function.",295,,,www.uniprot.org,19636
"CDH1 H128Ifs*87 is a missense mutation (H128I) in conjunction with a likely truncation of the 882 aa Cdh1 protein at aa 128, followed by 87 nonsense amino acids (UniProt.org). Due to the loss of most known functional domains (UniProt.org), H128Ifs*87 is predicted to lead to a loss of Cdh1 protein function.",295,,,www.uniprot.org,19637
"CDH1 H92D lies within the extracellular domain of the Cdh1 protein (UniProt.org). H92D has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19638
"CDH1 I192N lies within the Cadherin domain 1 of the Cdh1 protein (UniProt.org). I192N has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19639
"CDH1 I248F lies within the Cadherin domain 1 of the Cdh1 protein (UniProt.org). I248F has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19640
"CDH1 I505Sfs*17 is a missense mutation (I505S) in conjunction with a likely truncation of the 882 aa Cdh1 protein at aa 505, followed by 17 nonsense amino acids (UniProt.org). Due to the loss of the cytoplasmic (UniProt.org), I505Sfs*17 is predicted to lead to a loss of Cdh1 protein function.",295,,,www.uniprot.org,19641
"CDH1 I600T lies within the Cadherin domain 5 of the Cdh1 protein (UniProt.org). I600T has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19642
"CDH1 K113E lies within the extracellular domain of the Cdh1 protein (UniProt.org). K113E has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19643
"CDH1 K440N lies within the Cadherin domain 3 of the Cdh1 protein (UniProt.org). K440N has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19644
"CDH1 K447* results in a premature truncation of the Cdh1 protein at amino acid 447 of 882 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), K447* is predicted to lead to a loss of Cdh1 protein function.",295,,,www.uniprot.org,19645
"CDH1 K557N lies within the Cadherin domain 4 of the Cdh1 protein (UniProt.org). K557N has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19646
"CDH1 K668* results in a premature truncation of the Cdh1 protein at amino acid 668 of 882 (UniProt.org). Due to the loss of most the cytoplasmic domain (UniProt.org), K668* is predicted to lead to a loss of Cdh1 protein function.",295,,,www.uniprot.org,19647
"CDH1 K738R lies within the cytoplasmic domain of the Cdh1 protein (UniProt.org). K738R has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19648
"CDH1 L175P lies within the Cadherin domain 1 of the Cdh1 protein (UniProt.org). L175P has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19649
"CDH1 L214R lies within the Cadherin domain 1 of the Cdh1 protein (UniProt.org). L214R has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,19651
"CDH1 L249V lies within the Cadherin domain 1 of the Cdh1 protein (UniProt.org). L249V has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,19652
"CDH1 L452P lies within the Cadherin domain 3 of the Cdh1 protein (UniProt.org). L452P has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19653
"CDH1 L71F lies within the extracellular domain of the Cdh1 protein (UniProt.org). L71F has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19654
"CDH1 L728* results in a premature truncation of the Cdh1 protein at amino acid 728 of 882 (UniProt.org). Due to the loss of the catenin-binding region (UniProt.org), L728* is predicted to lead to a loss of Cdh1 protein function.",295,,,www.uniprot.org,19655
"CDH1 L731F lies within the catenin-binding region of the Cdh1 protein (UniProt.org). L731F has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19656
"CDH1 L731Ffs*39 is a missense mutation (L731F) in conjunction with a likely truncation of the 882 aa Cdh1 protein at aa 731, followed by 39 nonsense amino acids (UniProt.org). Due to the loss of the catenin-binding region (UniProt.org), L731Ffs*39 is predicted to lead to a loss of Cdh1 protein function.",295,,,www.uniprot.org,19657
"CDH1 L776M lies within the catenin-binding region of the Cdh1 protein (UniProt.org). L776M has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19658
"CDH1 L798V lies within the catenin-binding region of the Cdh1 protein (UniProt.org). L798V has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19659
"CDH1 L845V lies within the catenin-binding region of the Cdh1 protein (UniProt.org). L845V has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19660
"CDH1 M282I lies within the Cadherin domain 2 of the Cdh1 protein (UniProt.org). M282I has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19661
"CDH1 M316V lies within the Cadherin domain 2 of the Cdh1 protein (UniProt.org). M316V has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19662
"CDH1 M656* results in a premature truncation of the Cdh1 protein at amino acid 656 of 882 (UniProt.org). Due to the loss of the cytoplasmic domain (UniProt.org), M656* is predicted to lead to a loss of Cdh1 protein function.",295,,,www.uniprot.org,19663
"CDH1 N256I lies within the Cadherin domain 1 of the Cdh1 protein (UniProt.org). N256I has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19664
"CDH1 N294Kfs*6 is a missense mutation (N294K) in conjunction with a likely truncation of the 882 aa Cdh1 protein at aa 294, followed by 6 nonsense amino acids (UniProt.org). Due to the loss of most known functional domains (UniProt.org), N294Kfs*6 is predicted to lead to a loss of Cdh1 protein function.",295,,,www.uniprot.org,19665
"CDH1 N315S lies within the Cadherin domain 2 of the Cdh1 protein (UniProt.org). N315S has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19666
"CDH1 N387H lies within the Cadherin domain 3 of the Cdh1 protein (UniProt.org). N387H has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,19667
"CDH1 N405S lies within the Cadherin domain 3 of the Cdh1 protein (UniProt.org). N405S has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,19668
"CDH1 N458I lies within the Cadherin domain 3 of the Cdh1 protein (UniProt.org). N458I has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19669
"CDH1 N606I lies within the Cadherin domain 5 of the Cdh1 protein (UniProt.org). N606I has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19670
"CDH1 N666S lies within the Cadherin domain 5 of the Cdh1 protein (UniProt.org). N666S has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19671
"CDH1 N674K lies within the Cadherin domain 5 of the Cdh1 protein (UniProt.org). N674K has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19672
"CDH1 N674Y lies within the Cadherin domain 5 of the Cdh1 protein (UniProt.org). N674Y has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19673
"CDH1 N867S lies within the catenin-binding region of the Cdh1 protein (UniProt.org). N867S has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19674
"CDH1 P125L lies within the extracellular domain of the Cdh1 protein (UniProt.org). P125L has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19675
"CDH1 P159L lies within the Cadherin domain 1 of the Cdh1 protein (UniProt.org). P159L has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19676
"CDH1 P159Lfs*56 is a missense mutation (P159L) in conjunction with a likely truncation of the 882 aa Cdh1 protein at aa 159, followed by 56 nonsense amino acids (UniProt.org). Due to the loss of most known functional domains (UniProt.org), P159Lfs*56 is predicted to lead to a loss of Cdh1 protein function.",295,,,www.uniprot.org,19677
"CDH1 P160Rfs*8 is a missense mutation (P160R) in conjunction with a likely truncation of the 882 aa Cdh1 protein at aa 160, followed by 8 nonsense amino acids (UniProt.org). Due to the loss of most known functional domains (UniProt.org), P160Rfs*8 is predicted to lead to a loss of Cdh1 protein function.",295,,,www.uniprot.org,19678
"CDH1 P201A lies within the Cadherin domain 1 of the Cdh1 protein (UniProt.org). P201A has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19679
"CDH1 P201S lies within the Cadherin domain 1 of the Cdh1 protein (UniProt.org). P201S has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19680
"CDH1 P260H lies within the Cadherin domain 1 of the Cdh1 protein (UniProt.org). P260H has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19681
"CDH1 P277S lies within the Cadherin domain 2 of the Cdh1 protein (UniProt.org). P277S has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19682
"CDH1 P373R lies within the Cadherin domain 2 of the Cdh1 protein (UniProt.org). P373R has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,19683
"CDH1 P429L lies within the Cadherin domain 3 of the Cdh1 protein (UniProt.org). P429L has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,19684
"CDH1 P593S lies within the Cadherin domain 4 of the Cdh1 protein (UniProt.org). P593S has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19685
"CDH1 P607S lies within the Cadherin domain 5 of the Cdh1 protein (UniProt.org). P607S has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19686
"CDH1 P744S lies within the cytoplasmic domain of the Cdh1 protein (UniProt.org). P744S has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19687
"CDH1 P825L lies within the catenin-binding region of the Cdh1 protein (UniProt.org). P825L has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19688
"CDH1 Q195* results in a premature truncation of the Cdh1 protein at amino acid 243 of 882 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), Q195* is predicted to lead to a loss of Cdh1 protein function.",295,,,www.uniprot.org,19689
"CDH1 Q195K lies within the Cadherin domain 1 of the Cdh1 protein (UniProt.org). Q195K has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19690
CDH1 Q23* results in a premature truncation of the Cdh1 protein at amino acid 23 of 882 (UniProt.org). Q23* is predicted to confer a loss of function to the Cdh1 protein as demonstrated by loss of Cdh1 expression and possible increased cell migration (PMID: 26901067).,5017,26901067,Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26901067,295,,,www.uniprot.org,19691
"CDH1 Q255* results in a premature truncation of the Cdh1 protein at amino acid 255 of 882 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), Q255* is predicted to lead to a loss of Cdh1 protein function.",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19692
CDH1 Q346* results in a premature truncation of the Cdh1 protein at amino acid 346 of 882 (UniProt.org). Q346* is predicted to confer a loss of function to the Cdh1 protein as demonstrated by loss of Cdh1 expression and possible increased cell migration (PMID: 26901067).,5017,26901067,Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26901067,295,,,www.uniprot.org,19693
"CDH1 Q383* results in a premature truncation of the Cdh1 protein at amino acid 383 of 882 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), Q383* is predicted to lead to a loss of Cdh1 protein function.",295,,,www.uniprot.org,19694
"CDH1 Q448* results in a premature truncation of the Cdh1 protein at amino acid 448 of 882 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), Q448* is predicted to lead to a loss of Cdh1 protein function.",295,,,www.uniprot.org,19695
"CDH1 Q503* results in a premature truncation of the Cdh1 protein at amino acid 503 of 882 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), Q503* is predicted to lead to a loss of Cdh1 protein function.",295,,,www.uniprot.org,19696
"CDH1 Q511* results in a premature truncation of the Cdh1 protein at amino acid 511 of 882 (UniProt.org). Due to the loss of the cytoplasmic domain (UniProt.org), Q511* is predicted to lead to a loss of Cdh1 protein function.",295,,,www.uniprot.org,19697
"CDH1 Q610L lies within the Cadherin domain 5 of the Cdh1 protein (UniProt.org). Q610L has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19698
"CDH1 Q641* results in a premature truncation of the Cdh1 protein at amino acid 641 of 882 (UniProt.org). Due to the loss of the cytoplasmic domain (UniProt.org), Q641* is predicted to lead to a loss of Cdh1 protein function. ",295,,,www.uniprot.org,19699
"CDH1 R222G lies within the Cadherin domain 1 of the Cdh1 protein (UniProt.org). R222G has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,19700
"CDH1 R222I lies within the Cadherin domain 1 of the Cdh1 protein (UniProt.org). R222I has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19701
"CDH1 R224C lies within the Cadherin domain 1 of the Cdh1 protein (UniProt.org). R224C has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19702
"CDH1 R224H lies within the Cadherin domain 1 of the Cdh1 protein (UniProt.org). R224H has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19703
"CDH1 R335* results in a premature truncation of the Cdh1 protein at amino acid 335 of 882 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), R335* is predicted to lead to a loss of Cdh1 protein function.",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19704
"CDH1 R492I lies within the Cadherin domain 4 of the Cdh1 protein (UniProt.org). R492I has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19705
CDH1 R598* results in a premature truncation of the Cdh1 protein at amino acid 598 of 882 (UniProt.org). R598** is predicted to confer a loss of function to the Cdh1 protein as demonstrated by loss of Cdh1 expression and possible increased cell migration (PMID: 26901067).,5017,26901067,Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26901067,295,,,www.uniprot.org,19706
"CDH1 R63G lies within the extracellular domain of the Cdh1 protein (UniProt.org). R63G has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19707
"CDH1 R65I lies within the extracellular domain of the Cdh1 protein (UniProt.org). R65I has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19708
CDH1 R732Q lies within the Cadherin domain 2 of the Cdh1 protein (UniProt.org). R732Q confers a loss of function on the Cdh1 protein as indicated by reduced cell-cell adhesion and increased invasion in culture (PMID: 15235021).,295,,,www.uniprot.org,4846,15235021,Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria.,http://www.ncbi.nlm.nih.gov/pubmed/15235021,19709
CDH1 W409R lies within the Cadherin domain 3 of the Cdh1 protein (UniProt.org). W409R confers a loss of function on the Cdh1 protein as indicated by reduced cell-cell adhesion and increased invasion in culture (PMID: 15235021). ,295,,,www.uniprot.org,4846,15235021,Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria.,http://www.ncbi.nlm.nih.gov/pubmed/15235021,19710
"CDH1 R74* results in a premature truncation of the Cdh1 protein at amino acid 74 of 882 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), R74* is predicted to lead to a loss of Cdh1 protein function.",295,,,www.uniprot.org,19711
"CDH1 R868C lies within the catenin-binding region of the Cdh1 protein (UniProt.org). R868C has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19712
"CDH1 R90Q lies within the extracellular domain of the Cdh1 protein (UniProt.org). R90Q has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19713
"CDH1 R90W lies within the catenin-binding region of the Cdh1 protein (UniProt.org). R90W has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19714
"CDH1 S133F lies within the extracellular domain of the Cdh1 protein (UniProt.org). S133F has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,19715
"CDH1 S191N lies within the Cadherin domain 1 of the Cdh1 protein (UniProt.org). S191N has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,19716
"CDH1 S36Afs*20 is a missense mutation (S36A) in conjunction with a likely truncation of the 882 aa Cdh1 protein at aa 36, followed by 20 nonsense amino acids (UniProt.org). Due to the loss of all known functional domains (UniProt.org), S36Afs*20 is predicted to lead to a loss of Cdh1 protein function.",295,,,www.uniprot.org,19717
"CDH1 S469Y lies within the Cadherin domain 3 of the Cdh1 protein (UniProt.org). S469Y has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19718
"CDH1 S559N lies within the Cadherin domain 4 of the Cdh1 protein (UniProt.org). S559N has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19719
"HNF1A A239V lies within the HNF1-type DNA binding region of the Hnf1a protein (UniProt.org). A239V has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19720
"HNF1A H143Y lies within the DNA interaction region of the Hnf1a protein (UniProt.org). H143Y has not been characterized and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19721
"HNF1A K273E lies within the HNF1-type DNA binding region of the Hnf1a protein (UniProt.org). K273E has not been characterized and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19722
"HNF1A L254Q lies within the HNF1-type DNA binding region of the Hnf1a protein (UniProt.org). L254Q has not been characterized and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19723
"HNF1A M154I does not lie within any known functional domains of the Hnf1a protein (UniProt.org). M154I has not been characterized and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19724
"HNF1A P475L does not lie within any known functional domains of the Hnf1a protein (UniProt.org). P475L has not been characterized and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19725
"HNF1A P568L does not lie within any known functional domains of the Hnf1a protein (UniProt.org). P568L has not been characterized and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19726
"HNF1A P61L does not lie within any known functional domains of the Hnf1a protein (UniProt.org). P61L has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19727
"HNF1A L377Sfs*7 is a missense mutation (L377S) in conjunction with a likely truncation of the 631 aa Hnf1a protein at aa 377, followed by 7 nonsense amino acids (UniProt.org). Due to the loss of most of the transactivation domain (PMID: 18003757), L377Sfs*7 is predicted to lead to a loss of Hnf1a protein function.
",4227,18003757,The type and the position of HNF1A mutation modulate age at diagnosis of diabetes in patients with maturity-onset diabetes of the young (MODY)-3.,http://www.ncbi.nlm.nih.gov/pubmed/18003757,295,,,www.uniprot.org,19728
"HNF1A L611Afs*38 is a missense mutation (L611A) in conjunction with a likely truncation of the 631 aa Hnf1a protein at aa 611, followed by 38 nonsense amino acids (UniProt.org). L611Afs*38 has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19729
"HNF1A G375Afs*9 is a missense mutation (G375A) in conjunction with a likely truncation of the 631 aa Hnf1a protein at aa 375, followed by 9 nonsense amino acids (UniProt.org). Due to the loss of most of the transactivation domain (PMID: 18003757), G375Afs*9 is predicted to lead to a loss of Hnf1a protein function.
",4227,18003757,The type and the position of HNF1A mutation modulate age at diagnosis of diabetes in patients with maturity-onset diabetes of the young (MODY)-3.,http://www.ncbi.nlm.nih.gov/pubmed/18003757,295,,,www.uniprot.org,19730
"HNF1A Q141R does not lie within any known functional domains of the Hnf1a protein (UniProt.org). Q141R has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,19731
"HNF1A Q28* results in a premature truncation of the Hnf1a protein at amino acid 28 of 631 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), Q28* is predicted to lead to a loss of Hnf1a function.",295,,,www.uniprot.org,19732
"HNF1A Q495* results in a premature truncation of the Hnf1a protein at amino acid 495 of 631 (UniProt.org). Due to the loss of most of the transactivation domain (PMID: 18003757), Q495* is predicted to lead to a loss of Hnf1a protein function.
",295,,,www.uniprot.org,4227,18003757,The type and the position of HNF1A mutation modulate age at diagnosis of diabetes in patients with maturity-onset diabetes of the young (MODY)-3.,http://www.ncbi.nlm.nih.gov/pubmed/18003757,19733
"HNF1A Q561* results in a premature truncation of the Hnf1a protein at amino acid 561 of 631 (UniProt.org). Due to the loss of most of the transactivation domain (PMID: 18003757), Q561* is predicted to lead to a loss of Hnf1a protein function.
",295,,,www.uniprot.org,4227,18003757,The type and the position of HNF1A mutation modulate age at diagnosis of diabetes in patients with maturity-onset diabetes of the young (MODY)-3.,http://www.ncbi.nlm.nih.gov/pubmed/18003757,19734
"HNF1A Q561E does not lie within any known functional domains of the Hnf1a protein (UniProt.org). Q561E has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19735
"HNF1A Q570K does not lie within any known functional domains of the Hnf1a protein (UniProt.org). Q570K has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19736
"HNF1A Q570Pfs*79 is a missense mutation (Q570P) in conjunction with a likely truncation of the 631 aa Hnf1a protein at aa 570, followed by 79 nonsense amino acids (UniProt.org). Q570Pfs*79 has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19737
"HNF1A Q576P does not lie within any known functional domains of the Hnf1a protein (UniProt.org). Q576P has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19738
"HNF1A Q7K does not lie within any known functional domains of the Hnf1a protein (UniProt.org). Q7K has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19739
"HNF1A R114C does not lie within any known functional domains of the Hnf1a protein (UniProt.org). R114C has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19740
"HNF1A R114H does not lie within any known functional domains of the Hnf1a protein (UniProt.org). R114H has not been characterized and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19741
"HNF1A R114L does not lie within any known functional domains of the Hnf1a protein (UniProt.org). R114L has not been characterized and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19742
"HNF1A R131L does not lie within any known functional domains of the Hnf1a protein (UniProt.org). R131L has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19743
"CDH1 T251K lies within the Cadherin domain 1 of the Cdh1 protein (UniProt.org). T251K has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19755
"CDH1 T522I lies within the Cadherin domain 4 of the Cdh1 protein (UniProt.org). T522I has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19756
"CDH1 T560R lies within the Cadherin domain 4 of the Cdh1 protein (UniProt.org). T560R has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19757
"CDH1 V188D lies within the Cadherin domain 1 of the Cdh1 protein (UniProt.org). V188D has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19758
"CDH1 V365I lies within the Cadherin domain 2 of the Cdh1 protein (UniProt.org). V365I has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19759
"CDH1 V365Tfs*26 is a missense mutation (V365T) in conjunction with a likely truncation of the 882 aa Cdh1 protein at aa 365, followed by 26 nonsense amino acids (UniProt.org). Due to the loss of most known functional domains (UniProt.org), V365Tfs*26 is predicted to lead to a loss of Cdh1 protein function.",295,,,www.uniprot.org,19760
"CDH1 V454E lies within the Cadherin domain 3 of the Cdh1 protein (UniProt.org). V454E has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19761
"CDH1 V460L lies within the Cadherin domain 3 of the Cdh1 protein (UniProt.org). V460L has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19762
"CDH1 V475A lies within the Cadherin domain 3 of the Cdh1 protein (UniProt.org). V475A has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,19763
"CDH1 V694I lies within the Cadherin domain 5 of the Cdh1 protein (UniProt.org). V694I has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,19764
"CDH1 V737D lies within the catenin-binding region of the Cdh1 protein (UniProt.org). V737D has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19765
"CDH1 W156C lies within the Cadherin domain 1 of the Cdh1 protein (UniProt.org). W156C has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19766
"CDH1 W409* results in a premature truncation of the Cdh1 protein at amino acid 409 of 882 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), W409* is predicted to lead to a loss of Cdh1 protein function.",295,,,www.uniprot.org,19767
"CDH1 W409L lies within the Cadherin domain 3 of the Cdh1 protein (UniProt.org). W409L has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19768
"CDH1 W532* results in a premature truncation of the Cdh1 protein at amino acid 532 of 882 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), W532* is predicted to lead to a loss of Cdh1 protein function.",295,,,www.uniprot.org,19769
"CDH1 W638* results in a premature truncation of the Cdh1 protein at amino acid 638 of 882 (UniProt.org). Due to the loss of the cytoplasmic domain (UniProt.org), W638* is predicted to lead to a loss of Cdh1 protein function.",295,,,www.uniprot.org,19770
"CDH1 Y101C lies within the extracellular domain of the Cdh1 protein (UniProt.org). Y101C has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19771
"CDH1 Y190C lies within the Cadherin domain 1 of the Cdh1 protein (UniProt.org). Y190C has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19772
"CDH1 Y190H lies within the Cadherin domain 1 of the Cdh1 protein (UniProt.org). Y190H has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19773
"CDH1 Y302N lies within the Cadherin domain 2 of the Cdh1 protein (UniProt.org). Y302N has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19774
"CDH1 Y523* results in a premature truncation of the Cdh1 protein at amino acid 523 of 882 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), Y523* is predicted to lead to a loss of Cdh1 protein function.",295,,,www.uniprot.org,19775
"CDH1 Y754Afs*5 is a missense mutation (Y754A) in conjunction with a likely truncation of the 882 aa Cdh1 protein at aa 754, followed by 5 nonsense amino acids (UniProt.org). Due to the loss of the majority of the catenin-binding region (UniProt.org), Y754Afs*5 is predicted to lead to a loss of Cdh1 protein function.",295,,,www.uniprot.org,19776
"CDH1 Y835* results in a premature truncation of the Cdh1 protein at amino acid 835 of 882 (UniProt.org). Y835* has not been characterized in the scientific literature and therefore, its effect on Cdh1 protein function is unknown (PubMed, Mar 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19777
"PIK3CA dec exp indicates decreased expression of the Pik3ca protein. However, the mechanism causing the decreased expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,19816
"PIK3CA positive indicates the presence of the PIK3CA gene, mRNA and/or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,19817
"HNF1A R171* results in a premature truncation of the Hnf1a protein at amino acid 171 of 631 (UniProt.org). Due to the loss of the transactivation domain (PMID: 18003757), R171* is predicted to lead to a loss of Hnf1a protein function.
",4227,18003757,The type and the position of HNF1A mutation modulate age at diagnosis of diabetes in patients with maturity-onset diabetes of the young (MODY)-3.,http://www.ncbi.nlm.nih.gov/pubmed/18003757,295,,,www.uniprot.org,19820
"HNF1A R200Q lies within the nuclear localization signal of the Hnf1a protein (UniProt.org). R200Q has not been characterized and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19821
"HNF1A R229* results in a premature truncation of the Hnf1a protein at amino acid 229 of 631 (UniProt.org). Due to the loss of the transactivation domain (PMID: 18003757), R229* is predicted to lead to a loss of Hnf1a protein function.
",4227,18003757,The type and the position of HNF1A mutation modulate age at diagnosis of diabetes in patients with maturity-onset diabetes of the young (MODY)-3.,http://www.ncbi.nlm.nih.gov/pubmed/18003757,295,,,www.uniprot.org,19822
"HNF1A R229Q lies within the HNF1-type DNA binding region of the Hnf1a protein (UniProt.org). R229Q has not been characterized and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19823
"HNF1A R131Q does not lie within any known functional domains of the Hnf1a protein (UniProt.org). R131Q has not been characterized and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19824
"HNF1A R168C does not lie within any known functional domains of the Hnf1a protein (UniProt.org). R168C has not been characterized and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19825
"HNF1A R244G lies within the HNF1-type DNA binding region of the Hnf1a protein (UniProt.org). R244G has not been characterized and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19826
"HNF1A R271L lies within the HNF1-type DNA binding region of the Hnf1a protein (UniProt.org). R271L has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,19827
"HNF1A S210T lies within the HNF1-type DNA binding region of the Hnf1a protein (UniProt.org). S210T has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,19828
"HNF1A S352F does not lie within any known functional domains of the Hnf1a protein (UniProt.org). S352F has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19829
"HNF1A S352Pfs*12 is a missense mutation (S352P) in conjunction with a likely truncation of the 631 aa Hnf1a protein at aa 352, followed by 12 nonsense amino acids (UniProt.org). Due to the loss of most of the transactivation domain (PMID: 18003757), S352Pfs*12 is predicted to lead to a loss of Hnf1a protein function.
",295,,,www.uniprot.org,4227,18003757,The type and the position of HNF1A mutation modulate age at diagnosis of diabetes in patients with maturity-onset diabetes of the young (MODY)-3.,http://www.ncbi.nlm.nih.gov/pubmed/18003757,19830
"HNF1A S407L does not lie within any known functional domains of the Hnf1a protein (UniProt.org). S407L has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19831
"HNF1A S445R does not lie within any known functional domains of the Hnf1a protein (UniProt.org). S445R has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19832
"HNF1A S574N does not lie within any known functional domains of the Hnf1a protein (UniProt.org). S574N has not been characterized and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19833
"HNF1A S591Y does not lie within any known functional domains of the Hnf1a protein (UniProt.org). S591Y has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19834
"HNF1A T10M does not lie within any known functional domains of the Hnf1a protein (UniProt.org). T10M has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19835
"HNF1A T137A does not lie within any known functional domains of the Hnf1a protein (UniProt.org). T137A has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19836
"HNF1A T231M does not lie within any known functional domains of the Hnf1a protein (UniProt.org). T231M has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19837
"HNF1A T327I does not lie within any known functional domains of the Hnf1a protein (UniProt.org). T327I has not been characterized and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19838
"HNF1A T354M does not lie within any known functional domains of the Hnf1a protein (UniProt.org). T354M has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19839
"HNF1A T425M does not lie within any known functional domains of the Hnf1a protein (UniProt.org). T425M has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19840
"HNF1A T485I does not lie within any known functional domains of the Hnf1a protein (UniProt.org). T485I has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19841
"HNF1A T539A does not lie within any known functional domains of the Hnf1a protein (UniProt.org). T539A has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19842
"HNF1A T589I does not lie within any known functional domains of the Hnf1a protein (UniProt.org). T589I has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,19843
"HNF1A T589S does not lie within any known functional domains of the Hnf1a protein (UniProt.org). T589S has not been characterized and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,19844
"HNF1A T74M does not lie within any known functional domains of the Hnf1a protein (UniProt.org). T74M has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19845
"HNF1A V264I lies within the HNF1-type DNA binding region of the Hnf1a protein (UniProt.org). V264I has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19852
"HNF1A R271Q lies within the HNF1-type DNA binding region of the Hnf1a protein (UniProt.org). R271Q has not been characterized and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19853
"HNF1A R271W lies within the HNF1-type DNA binding region of the Hnf1a protein (UniProt.org). R271W confers a loss of function on Hnf1a, as indicated by reduced DNA binding and transactivation in cell culture (PMID:21170474).",4195,21170474,Differential effects of HNF-1α mutations associated with familial young-onset diabetes on target gene regulation.,http://www.ncbi.nlm.nih.gov/pubmed/21170474,295,,,www.uniprot.org,19854
"HNF1A V2A does not lie within any known functional domains of the Hnf1a protein (UniProt.org). V2A has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19855
"HNF1A Y286F does not lie within any known functional domains of the Hnf1a protein (UniProt.org). Y286F has not been characterized and therefore, its effect on Hnf1a protein function is unknown (PubMed, Mar 2016). 
",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19856
"PIK3CA over exp indicates an over expression of the Pik3ca protein. However, the mechanism causing the over expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,19873
"SMAD4 del indicates a deletion of the SMAD4 gene.
",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,19976
"SMAD4 inact mut indicates that this variant results in a loss of function of the Smad4 protein. However, the specific amino acid change has not been identified.
",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,19977
FGFR2 E160A lies within the Ig-like C2-type 2 domain of the Fgfr2 protein (UniProt.org). E160A is predicted to disrupt Fgfr2-heparan sulfate interaction and Fgfr dimerization based on structural modeling (PMID: 19147536).,1037,19147536,Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/19147536,295,,,www.uniprot.org,19993
FGFR2 E219K lies within the Ig-like C2-type 2 domain of the Fgfr2 protein (UniProt.org). E219K is predicted to disrupt Fgf- and heparin-induced Fgfr2 dimerization based on structural modeling (PMID: 19147536).,1037,19147536,Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/19147536,295,,,www.uniprot.org,19994
"FGFR2 E475K lies within the cytoplasmic domain of the Fgfr2 protein (UniProt.org). E475K demonstrated slightly increased Fgfr2 kinase activity, but also decreased protein stability and cell proliferation in culture (PMID: 19147536).",1037,19147536,Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/19147536,295,,,www.uniprot.org,19995
"FGFR2 E574K lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). E574K has been identified in the scientific literature (PMID: 19147536), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, May 2017).",1037,19147536,Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/19147536,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19996
"FGFR2 E636K lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). E636K has been identified in the scientific literature (PMID: 19147536), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,1037,19147536,Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/19147536,295,,,www.uniprot.org,19997
"FGFR2 G305R lies within the Ig-like C2-type 3 domain of the Fgfr2 protein (UniProt.org). G305R has been identified in the scientific literature (PMID: 19147536), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, May 2017).",1037,19147536,Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/19147536,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,19998
"FGFR2 G701S lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). G701S has not been characterized however, is predicted to inhibit Fgfr2 kinase activity indirectly by structural modeling (PMID: 19147536).",1037,19147536,Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/19147536,295,,,www.uniprot.org,19999
FGFR2 H213Y lies within the Ig-like C2-type 2 domain of the Fgfr2 protein (UniProt.org). H213Y is predicted to disrupt the interaction of Fgfr2 with heparan sulfate based on structural modeling (PMID: 19147536).,1037,19147536,Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/19147536,295,,,www.uniprot.org,20000
FGFR2 L770V lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). L770V is predicted to decrease phospholipase C-gamma activation by Fgfr2 based on structural modeling (PMID: 19147536).,1037,19147536,Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/19147536,295,,,www.uniprot.org,20001
"FGFR2 M640I lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). M640I has been identified in sequencing studies (PMID: 19147536), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, May 2017).",1037,19147536,Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/19147536,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20002
"FGFR2 P708S lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). P708S has been identified in the scientific literature (PMID: 19147536), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1037,19147536,Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/19147536,20003
FGFR2 R759Q lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). R759Q is predicted to disrupt Fgfr2 kinase activity based on structural modeling (PMID: 19147536).,295,,,www.uniprot.org,1037,19147536,Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/19147536,20004
"FGFR2 S24F lies within the extracellular domain of the Fgfr2 protein (UniProt.org). S24F has been identified in sequencing studies (PMID: 19147536), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,1037,19147536,Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/19147536,295,,,www.uniprot.org,20005
"FGFR2 S688F lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). S688F has been identified in the scientific literature (PMID: 19147536), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, May 2017).",1037,19147536,Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/19147536,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20006
"FGFR2 T370R lies within the cytoplasmic domain of the Fgfr2 protein (UniProt.org). T370R has been identified in sequencing studies (PMID: 19147536), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,1037,19147536,Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/19147536,295,,,www.uniprot.org,20007
FGFR2 V248D lies within the extracellular domain of the Fgfr2 protein (UniProt.org). V248D is predicted to to destabilize the tertiary fold of the Fgfr2 protein based on structural modeling (PMID: 19147536).,1037,19147536,Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/19147536,295,,,www.uniprot.org,20008
"FGFR2 V77M lies within the Ig-like C2-type 1 domain of the Fgfr2 protein (UniProt.org). V77M has been identified in the scientific literature (PMID: 19147536), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,1037,19147536,Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/19147536,295,,,www.uniprot.org,20009
FGFR2 K517R lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). K517R results in decreased Fgfr2 kinase activity and inhibited cell proliferation in culture (PMID: 19147536).,1037,19147536,Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/19147536,295,,,www.uniprot.org,20010
"KMT2A-MLLT3 (also referred to as MLL-AF9) results from the fusion of KMT2A and MLLT3, resulting in a gain of function protein that induces cell proliferation and drives tumorigenesis in culture (PMID: 11607819).",5004,11607819,Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins.,http://www.ncbi.nlm.nih.gov/pubmed/11607819,20044
"KDR (VEGFR) over exp indicates an over expression of the Kdr (Vegfr) protein. However, the mechanism causing the over expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,20070
SRC mutant indicates an unspecified mutation in the SRC gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,20071
"KMT2A-AFF1 (also referred to as MLL-AF4) results in the fusion of KMT2A and AFF1, resulting in repression of CDKN1B transcription, which eventually leads to leukemogenesis (PMID: 20194896, PMID: 16169901). ",5007,20194896,The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4.,http://www.ncbi.nlm.nih.gov/pubmed/20194896,5008,16169901,"The MLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B (p27kip1) expression.",http://www.ncbi.nlm.nih.gov/pubmed/16169901,20094
"KMT2A-MLLT1 (also referred to as MLL-ENL) results from the fusion of KMT2A and MLLT1, resulting in transformation in culture and leukemogenesis in mouse models (PMID: 9250666).",5009,9250666,Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL.,http://www.ncbi.nlm.nih.gov/pubmed/9250666,20100
CDH1 E58* results in a premature truncation of the Cdh1 protein at amino acid 58 of 882 (UniProt.org). E58* is predicted to confer a loss of function to the Cdh1 protein as demonstrated by loss of Cdh1 expression and possible increased cell migration (PMID: 26901067).,5017,26901067,Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26901067,20162
CDH1 E806* results in a premature truncation of the Cdh1 protein at amino acid 806 of 882 (UniProt.org). E806* is predicted to confer a loss of function to the Cdh1 protein as demonstrated by loss of Cdh1 expression and possible increased cell migration (PMID: 26901067).,295,,,www.uniprot.org,5017,26901067,Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26901067,20163
CDH1 Q129* results in a premature truncation of the Cdh1 protein at amino acid 129 of 882 (UniProt.org). Q129* is predicted to confer a loss of function to the Cdh1 protein as demonstrated by loss of Cdh1 expression and possible increased cell migration (PMID: 26901067).,295,,,www.uniprot.org,5017,26901067,Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26901067,20164
ALK I1171S lies within the protein kinase domain of the Alk protein (UniProt.org). I1171S is predicted to result in a locked active conformation of the Alk protein resulting in autophosphorylation and has demonstrated Alk inhibitor resistance in the context of multiple Alk fusions (PMID: 27009859).,295,,,www.uniprot.org,5026,27009859,TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.,http://www.ncbi.nlm.nih.gov/pubmed/27009859,20211
"ALK T1151M lies within the protein kinase domain and inhibitor binding region of the Alk protein (UniProt.org). T1151M has not been biochemically characterized, however, has been demonstrated to occur as a secondary drug resistance mutation in the context of NPM1-ALK (PMID: 27009859).",295,,,www.uniprot.org,5026,27009859,TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.,http://www.ncbi.nlm.nih.gov/pubmed/27009859,20212
"ALK C1156F lies within the protein kinase domain of the Alk protein (UniProt.org). C1156F has not been biochemically characterized, but has been demonstrated to occur as a secondary drug resistance in the context of NPM1-ALK (PMID: 25749034).",295,,,www.uniprot.org,5029,25749034,NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.,http://www.ncbi.nlm.nih.gov/pubmed/25749034,20419
"ALK E1210K lies within the protein kinase domain of the Alk protein (UniProt.org). E1210K has not been biochemically characterized, however, has been demonstrated to occur as a secondary drug resistance mutation in the context of NPM1-ALK and EML4-ALK (PMID: 25749034, PMID: 25914136).",5029,25749034,NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.,http://www.ncbi.nlm.nih.gov/pubmed/25749034,5054,25914136,ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25914136,20424
"ALK G1128S lies within the protein kinase domain of the Alk protein (UniProt.org). G1128S has not been biochemically characterized, however, has been demonstrated to occur as a secondary drug resistance mutation in the context of NPM1-ALK (PMID: 25749034).",5029,25749034,NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.,http://www.ncbi.nlm.nih.gov/pubmed/25749034,295,,,www.uniprot.org,20429
"ALK N1178H lies within the protein kinase domain of the Alk protein (UniProt.org). N1178H has not been biochemically characterized, however, has been demonstrated to occur as a secondary drug resistance mutation in the context of NPM1-ALK (PMID: 25749034).",5029,25749034,NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.,http://www.ncbi.nlm.nih.gov/pubmed/25749034,295,,,www.uniprot.org,20431
"STK11 D194E lies within the protein kinase domain of the Stk11 protein (UniProt.org). D194E has not been biochemically characterized, but is associated with Peutz-Jehgers syndrome and is predicted to result in a loss of Stk11 protein function (PMID: 21189378).",295,,,www.uniprot.org,5063,21189378,mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/21189378,20444
CDH1 E677* results in a premature truncation of the Cdh1 protein at amino acid 677 of 882 (UniProt.org). E677*  is predicted to confer a loss of function to the Cdh1 protein as demonstrated by loss of Cdh1 expression and possible increased cell migration (PMID: 26901067).,5017,26901067,Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26901067,295,,,www.uniprot.org,20445
CDH1 Q647* results in a premature truncation of the Cdh1 protein at amino acid 647 of 882 (UniProt.org). E647* is predicted to confer a loss of function to the Cdh1 protein as demonstrated by loss of Cdh1 expression and possible increased cell migration (PMID: 26901067).,5017,26901067,Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26901067,295,,,www.uniprot.org,20446
CDH1 E35* results in a premature truncation of the Cdh1 protein at amino acid 35 of 882 (UniProt.org). E35* is predicted to confer a loss of function to the Cdh1 protein as demonstrated by loss of Cdh1 expression and possible increased cell migration (PMID: 26901067).,5017,26901067,Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26901067,295,,,www.uniprot.org,20447
CDH1 W4* results in a premature truncation of the Cdh1 protein at amino acid 4 of 882 (UniProt.org). W4* is predicted to confer a loss of function to the Cdh1 protein as demonstrated by loss of Cdh1 expression and possible increased cell migration (PMID: 26901067).,5017,26901067,Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26901067,295,,,www.uniprot.org,20448
"CDH1 S70Pfs*13 is a missense mutation (S70P) in conjunction with a likely truncation of the 882 aa Cdh1 protein at aa 70, followed by 13 nonsense amino acids (UniProt.org). S70Pfs*13 is predicted to confer a loss of function to the Cdh1 protein as demonstrated by loss of Cdh1 expression and possible increased cell migration (PMID: 26901067).",5017,26901067,Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26901067,295,,,www.uniprot.org,20449
"CDH1 C163Afs*52 is a missense mutation (C163A) in conjunction with a likely truncation of the 882 aa Cdh1 protein at aa 163, followed by 52 nonsense amino acids (UniProt.org). C163Afs*52 is predicted to confer a loss of function to the Cdh1 protein as demonstrated by loss of Cdh1 expression and possible increased cell migration (PMID: 26901067).",5017,26901067,Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26901067,295,,,www.uniprot.org,20450
"CDH1 T366Rfs*5 is a missense mutation (T366R) in conjunction with a likely truncation of the 882 aa Cdh1 protein at aa 366, followed by 5 nonsense amino acids (UniProt.org). T366Rfs*5 is predicted to confer a loss of function to the Cdh1 protein as demonstrated by loss of Cdh1 expression and increased cell migration (PMID: 26901067).",295,,,www.uniprot.org,5017,26901067,Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26901067,20451
"CDH1 F462Hfs*16 is a missense mutation (F462H) in conjunction with a likely truncation of the 882 aa Cdh1 protein at aa 462, followed by 16 nonsense amino acids (UniProt.org). F462Hfs*16 is predicted to confer a loss of function to the Cdh1 protein as demonstrated by loss of Cdh1 expression and possible increased cell migration (PMID: 26901067).",295,,,www.uniprot.org,5017,26901067,Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26901067,20452
"CDH1 F730Vfs*18 is a missense mutation (F730V) in conjunction with a likely truncation of the 882 aa Cdh1 protein at aa 730, followed by 18 nonsense amino acids (UniProt.org). F730Vfs*18 is predicted to confer a loss of function to the Cdh1 protein as demonstrated by loss of Cdh1 expression and possible increased cell migration (PMID: 26901067).",295,,,www.uniprot.org,5017,26901067,Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26901067,20453
CDH1 S9* results in a premature truncation of the Cdh1 protein at amino acid 9 of 882 (UniProt.org). S9* is predicted to confer a loss of function to the Cdh1 protein as demonstrated by loss of Cdh1 expression and possible increased cell migration (PMID: 26901067).,295,,,www.uniprot.org,5017,26901067,Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26901067,20454
CDH1 E247* results in a premature truncation of the Cdh1 protein at amino acid 247 of 882 (UniProt.org). E247* is predicted to confer a loss of function to the Cdh1 protein as demonstrated by loss of Cdh1 expression and possible increased cell migration (PMID: 26901067).,295,,,www.uniprot.org,5017,26901067,Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26901067,20455
CDH1 Q351* results in a premature truncation of the Cdh1 protein at amino acid 351 of 882 (UniProt.org). Q351* is predicted to confer a loss of function to the Cdh1 protein as demonstrated by loss of Cdh1 expression and possible increased cell migration (PMID: 26901067).,295,,,www.uniprot.org,5017,26901067,Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26901067,20456
"ALK L1196Q lies within the protein kinase domain of the Alk protein (UniProt.org). L1196Q is a gatekeeper mutation, which confers resistance to crizotinib in cultured cells (PMID: 25749034).",295,,,www.uniprot.org,5029,25749034,NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.,http://www.ncbi.nlm.nih.gov/pubmed/25749034,20476
"ATM positive indicates the presence of the ATM gene, mRNA, and/or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,20483
"ERBB2 (HER2) dec exp indicates decreased expression of the Erbb3 (Her3) protein. However, the mechanism causing the decreased expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,20492
"HNF1A Y218C lies within the HNF1-type DNA binding region of the Hnf1a protein (UniProt.org). Y218C has not been characterized and therefore, its effect on Hnf1a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20550
"HNF1A V133M does not lie within any known functional domains of the Hnf1a protein (UniProt.org). V133M has not been characterized and therefore, its effect on Hnf1a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20551
"STK11 D343N does not lie within any known functional domains of the Stk11 protein (UniProt.org). D343N has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20651
"CALR L367fs*46 likely results in a truncation of the 417 aa Calr protein at aa 367, followed by 46 nonsense amino acids within the C-domain region (UniProt.org). L367fs*46 results in activation of Jak-Stat signaling, is transforming in culture, and drives myeloproliferative neoplasm formation in animal models (PMID: 26951227).",5103,26951227,Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.,http://www.ncbi.nlm.nih.gov/pubmed/26951227,295,,,www.uniprot.org,20785
"KDR (VEGFR2) R961W lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). R961W has been identified in the scientific literature (PMID: 27004155), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",5105,27004155,KDR Mutation as a Novel Predictive Biomarker of Exceptional Response to Regorafenib in Metastatic Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27004155,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20786
ERBB4 D245G lies within the extracellular domain of the Erbb4 protein (UniProt.org). D245G demonstrates phosphorylation levels similar to wild-type Erbb4 and is not transforming in culture (PMID: 26826182).,5106,26826182,Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2.,http://www.ncbi.nlm.nih.gov/pubmed/26826182,20788
FGFR1 A263V lies within the Ig-like C2-type domain 3 of the Fgfr1 protein (UniProt.org). A263V demonstrates phosphorylation levels similar to wild-type Fgfr1 and is not transforming in culture (PMID: 26826182).,295,,,www.uniprot.org,5106,26826182,Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2.,http://www.ncbi.nlm.nih.gov/pubmed/26826182,20789
"JAK2 G831R does not lie within any known functional domains of the Jak2 protein (UniProt.org). G831R has not been biochemically characterized for functional effects on Jak2, but has been demonstrated to occur as a secondary drug resistance mutation (PMID: 22916261).",295,,,www.uniprot.org,3031,22916261,Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor.,http://www.ncbi.nlm.nih.gov/pubmed/22916261,20803
"ETV6-NTRK2 results in the fusion of ETV6 and NTRK2 (PMID: 26939704). ETV6-NTRK2 has not been biochemically characterized, but is sensitive to Trk inhibition (PMID: 26939704, PMID: 26884591), and therefore, is predicted to result in a gain of function.",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5130,26939704,"Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.",http://www.ncbi.nlm.nih.gov/pubmed/26939704,20808
"ETV6-ROS1 results from the fusion of ETV6 and ROS1, resulting in constitutive ROS1 activity in cultured cells (PMID: 26939704).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5130,26939704,"Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.",http://www.ncbi.nlm.nih.gov/pubmed/26939704,20809
"ETV6-ALK results in the fusion of ETV6 and ALK (PMID: 26939704). ETV6-ALK has been biochemically characterized, but is sensitive to Alk inhibition (PMID: 26939704), and therefore, is predicted to result in a gain of function.",5130,26939704,"Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.",http://www.ncbi.nlm.nih.gov/pubmed/26939704,285,,,http://www.ncbi.nlm.nih.gov/pubmed,20820
"RET over exp indicates an over expression of the Ret protein. However, the mechanism causing the over expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,20824
MAP2K1 A106T lies within the protein kinase domain of the Map2k1 protein (UniProt.org). A106T demonstrates phosphorylation of Erk similar to wild-type Map2k1 in cell culture (PMID: 25164765).,5144,25164765,Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions.,http://www.ncbi.nlm.nih.gov/pubmed/25164765,20872
MAP2K1 F53L does not lie within any known functional domains of the Map2k1 protein (UniProt.org). F53L results in activation of Mapk2k1 as indicated by increased Erk phosphorylation in cell culture (PMID: 25164765).,295,,,www.uniprot.org,5144,25164765,Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions.,http://www.ncbi.nlm.nih.gov/pubmed/25164765,20873
"MAP2K1 A132V lies within the protein kinase domain of the Map2k1 protein (UniProt.org). A132V has been identified in sequencing studies (PMID: 22895193, PMID: 25839328), but has not been biochemically characterized and therefore, its effect on Map2k1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8164,25839328,Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25839328,4597,22895193,Recurrent R-spondin fusions in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22895193,20874
"MAP2K1 A158T lies within the protein kinase domain of the Map2k1 protein (UniProt.org). A158T has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20875
"MAP2K1 A347T lies within the protein kinase domain of the Map2k1 protein (UniProt.org). A347T has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Mar 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20876
"MAP2K1 A390T does not lie within any known functional domains of the Map2k1 protein (UniProt.org). A390T has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20877
"MAP2K1 A76T lies within the protein kinase domain of the Map2k1 protein (UniProt.org). A76T has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Mar 2017).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20878
"MAP2K1 D136Y lies within the protein kinase domain of the Map2k1 protein (UniProt.org). D136Y has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20879
"MAP2K1 D336H lies within the protein kinase domain of the Map2k1 protein (UniProt.org). D336H has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20880
"MAP2K1 D351N lies within the protein kinase domain of the Map2k1 protein (UniProt.org). D351N has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20881
"MAP2K1 E102_I103del results in the deletion of two amino acids in the protein kinase domain of the Map2k1 protein from amino acids 102 to 103 (UniProt.org). E102_I103del has been identified in the scientific literature (PMID: 24982505), but has not been biochemically characterized and therefore, its effect on Map2k1 protein function is unknown (PubMed, Mar 2017).",8377,24982505,High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis.,http://www.ncbi.nlm.nih.gov/pubmed/24982505,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20882
MAP2K1 E203K lies within the protein kinase domain of the Map2k1 protein (UniProt.org). E203K results in constitutive phosphorylation of Erk and is transforming in cell culture (PMID: 22197931).,295,,,www.uniprot.org,429,22197931,Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22197931,20883
"MAP2K1 E320A lies within the protein kinase domain of the Map2k1 protein (UniProt.org). E320A has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,20884
"MAP2K1 F129L lies within the protein kinase domain of the Map2k1 protein (UniProt.org). F129L confers a gain of function to the Map2k1 protein as demonstrated by increased kinase activity compared to wild-type, activation of downstream Erk signaling, and increased binding affinity to c-Raf (PMID: 21705440).",295,,,www.uniprot.org,6458,21705440,Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation.,http://www.ncbi.nlm.nih.gov/pubmed/21705440,20885
"MAP2K1 F53_Q58delinsL results in a deletion of six amino acids of the Map2k1 protein from amino acids 53 to 58, combined with the insertion of a leucine (L) at the same site (UniProt.org). F53_Q58delinsL has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20886
"MAP2K1 F53I does not lie within any known functional domains of the Map2k1 protein (UniProt.org). F53I has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20887
"MAP2K1 F53Y does not lie within any known functional domains of the Map2k1 protein (UniProt.org). F53Y has been identified in the scientific literature (PMID: 27325104, PMID: 24265153, PMID: 26343386), but has not been biochemically characterized and therefore, its effect on Map2k1 protein function is unknown (PubMed, Mar 2017).",5840,24265153,The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24265153,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7139,26343386,Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway.,http://www.ncbi.nlm.nih.gov/pubmed/26343386,8379,27325104,Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations.,http://www.ncbi.nlm.nih.gov/pubmed/27325104,20888
"MAP2K1 G128R lies within the protein kinase domain of the Map2k1 protein (UniProt.org). G128R has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Mar 2017).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20889
"MAP2K1 G294E lies within the protein kinase domain of the Map2k1 protein (UniProt.org). G294E has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20890
"MAP2K1 G294R lies within the protein kinase domain of the Map2k1 protein (UniProt.org). G294R has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20891
"MAP2K1 G79V lies within the protein kinase domain of the Map2k1 protein (UniProt.org). G79V has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20892
"MAP2K1 G80S lies within the protein kinase domain of the Map2k1 protein (UniProt.org). G80S has been identified in sequencing studies (PMID: 25344691), but has not been biochemically characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Mar 2017).",1689,25344691,RNF43 is frequently mutated in colorectal and endometrial cancers.,http://www.ncbi.nlm.nih.gov/pubmed/25344691,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20893
"MAP2K1 H119Q lies within the protein kinase domain of the Map2k1 protein (UniProt.org). H119Q has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20894
"MAP2K1 I9Sfs*3 is a missense mutation (I9S) in conjunction with a likely truncation of the 393 aa Map2k1 protein at aa 9, followed by 3 nonsense amino acids (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), I9Sfs*3 is predicted to lead to a loss of Map2k1 protein function.",295,,,www.uniprot.org,20895
"MAP2K1 K35N does not lie within any known functional domains of the Map2k1 protein (UniProt.org). K35N has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20896
"MAP2K1 K4N does not lie within any known functional domains of the Map2k1 protein (UniProt.org). K4N has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20897
"MAP2K1 L177M lies within the protein kinase domain of the Map2k1 protein (UniProt.org). L177M has been identified in the scientific literature (PMID: 25351745), but has not been biochemically characterized and therefore, its effect on Map2k1 protein function is unknown (PubMed, Apr 2017).",8452,25351745,MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.,http://www.ncbi.nlm.nih.gov/pubmed/25351745,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20898
"MAP2K1 L177V lies within the protein kinase domain of the Map2k1 protein (UniProt.org). L177V has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Apr 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,20899
"MAP2K1 L235H lies within the protein kinase domain of the Map2k1 protein (UniProt.org). L235H has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Apr 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,20900
"MAP2K1 L42F does not lie within any known functional domains of the Map2k1 protein (UniProt.org). L42F has been identified in sequencing studies (PMID: 26343386), but has not been biochemically characterized and therefore, its effect on Map2k1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7139,26343386,Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway.,http://www.ncbi.nlm.nih.gov/pubmed/26343386,20901
"MAP2K1 M146I lies within the protein kinase domain of the Map2k1 protein (UniProt.org). M146I has been identified in the scientific literature (PMID: 25351745, PMID: 22980975), but has not been biochemically characterized and therefore, its effect on Map2k1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,8452,25351745,MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.,http://www.ncbi.nlm.nih.gov/pubmed/25351745,295,,,www.uniprot.org,1726,22980975,Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/22980975,20902
"MAP2K1 P193S lies within the protein kinase domain of the Map2k1 protein (UniProt.org). P193S has been identified in sequencing studies (PMID: 25344691), but has not been biochemically characterized and therefore, its effect on Map2k1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1689,25344691,RNF43 is frequently mutated in colorectal and endometrial cancers.,http://www.ncbi.nlm.nih.gov/pubmed/25344691,20903
"MAP2K1 P264S lies within the protein kinase domain of the Map2k1 protein (UniProt.org). P264S has been identified in the scientific literature (PMID: 25351745, PMID: 22622578), but has not been biochemically characterized and therefore, its effect on Map2k1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,8452,25351745,MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.,http://www.ncbi.nlm.nih.gov/pubmed/25351745,295,,,www.uniprot.org,6955,22622578,Melanoma genome sequencing reveals frequent PREX2 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/22622578,20904
"MAP2K1 P323A does not lie within any known functional domains of the Map2k1 protein (UniProt.org). P323A has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20905
"MAP2K1 Q354H lies within the protein kinase domain of the Map2k1 protein (UniProt.org). Q354H has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20906
"MAP2K1 R108Q lies within the protein kinase domain of the Map2k1 protein (UniProt.org). R108Q has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20907
"MAP2K1 R201C lies within the protein kinase domain of the Map2k1 protein (UniProt.org). R201C has been identified in sequencing studies (PMID: 22037554), but has not been biochemically characterized and therefore, its effect on Map2k1 protein function is unknown (PubMed, Apr 2017).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20908
"MAP2K1 R260M lies within the protein kinase domain of the Map2k1 protein (UniProt.org). R260M has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20909
MAP2K1 R47Q does not lie within any known functional domains of the Map2k1 protein (UniProt.org). R47Q results in increased phosphorylation of Erk and is transforming in cell culture (PMID: 22327936).,135,22327936,Oncogenic MAP2K1 mutations in human epithelial tumors.,http://www.ncbi.nlm.nih.gov/pubmed/22327936,295,,,www.uniprot.org,20910
"MAP2K1 R49C does not lie within any known functional domains of the Map2k1 protein (UniProt.org). R49C has been identified in the scientific literature (PMID: 24982505), but has not been biochemically characterized and therefore, its effect on Map2k1 protein function is unknown (PubMed, Apr 2017).",8377,24982505,High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis.,http://www.ncbi.nlm.nih.gov/pubmed/24982505,115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20911
"MAP2K1 R96K lies within the protein kinase domain of the Map2k1 protein (UniProt.org). R96K has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20912
"MAP2K1 S327T lies within the protein kinase domain of the Map2k1 protein (UniProt.org). S327T has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20913
"MAP2K1 S331R lies within the protein kinase domain of the Map2k1 protein (UniProt.org). S331R has been identified in the scientific literature (PMID: 25351745, PMID: 22980975), but has not been biochemically characterized and therefore, its effect on Map2k1 protein function is unknown (PubMed, Apr 2017).",1726,22980975,Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/22980975,8452,25351745,MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.,http://www.ncbi.nlm.nih.gov/pubmed/25351745,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20914
"MAP2K1 S86A lies within the protein kinase domain of the Map2k1 protein (UniProt.org). S86A has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Apr 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,20915
"MAP2K1 V211A lies within the protein kinase domain of the Map2k1 protein (UniProt.org). V211A has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Apr 2017).",295,,,www.uniprot.org,115,0,,http://www.ncbi.nlm.nih.gov/pubmed,20916
"MAP2K1 V224M lies within the protein kinase domain of the Map2k1 protein (UniProt.org). V224M has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Apr 2017)",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20917
"MAP2K1 V258I lies within the protein kinase domain of the Map2k1 protein (UniProt.org). V258I has been identified in sequencing studies (PMID: 22895193), but has not been biochemically characterized and therefore, its effect on Map2k1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4597,22895193,Recurrent R-spondin fusions in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22895193,20918
"MAP2K1 V93F lies within the protein kinase domain of the Map2k1 protein (UniProt.org). V93F has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20919
"MAP2K1 W247* results in a premature truncation of the Map2k1 protein at amino acid 247 of 393 (UniProt.org). W247* has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20920
MAP2K1 Y130C lies within the protein kinase domain of the Map2k1 protein (UniProt.org). Y130C results in a gain of Map2k1 protein function as indicated by increased Erk phosphorylation in cell culture (PMID: 16439621).,295,,,www.uniprot.org,5839,16439621,Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/16439621,20921
"MAP2K1 Y134C lies within the protein kinase domain of the Map2k1 protein (UniProt.org). Y134C has not been characterized and therefore, its effect on Map2k1 protein function is unknown (PubMed, Oct 2016).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20922
TP53 S241Y lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). S241Y results in a loss of Tp53 transactivation activity and decreased ability to suppress colony formation in cell culture (PMID: 25584008).,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,4424,25584008,Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study.,http://www.ncbi.nlm.nih.gov/pubmed/25584008,20923
"TP53 P47S lies within the N-terminal domain of the Tp53 protein (PMID: 15510160). P47S is a common polymorphism in Tp53 with conflicting impact on Tp53 function, demonstrating activity similar to wild-type in one study, and reduced transactivation of Tp53 targets and resistance to apoptosis in another (PMID: 25584008, PMID: 27034505).",5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,7574,27034505,An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model.,http://www.ncbi.nlm.nih.gov/pubmed/27034505,4424,25584008,Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study.,http://www.ncbi.nlm.nih.gov/pubmed/25584008,20924
TP53 P219S lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). P219S results in decreased Tp53 transactivation activity and inability to suppress colony formation in cell culture (PMID: 25584008).,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,4424,25584008,Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study.,http://www.ncbi.nlm.nih.gov/pubmed/25584008,20925
TP53 P152L lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). P152L results in decreased Tp53 transactivation activity and inability to suppress colony formation in cell culture (PMID: 25584008).,4424,25584008,Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study.,http://www.ncbi.nlm.nih.gov/pubmed/25584008,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,20926
TP53 I254T lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). I254T results in decreased Tp53 transactivation activity and reduced ability to suppress colony formation in cell culture (PMID: 25584008).,4424,25584008,Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study.,http://www.ncbi.nlm.nih.gov/pubmed/25584008,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,20927
TP53 H193P lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). H193P results in a loss of Tp53 transactivation activity and inability to suppress colony formation in cell culture (PMID: 25584008).,4424,25584008,Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study.,http://www.ncbi.nlm.nih.gov/pubmed/25584008,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,20928
TP53 G334R lies within the hinge residue of the oligomerization domain of the Tp53 protein (PMID: 16007150). G334R results in increased Tp53 transactivation activity and suppression of colony formation in cell culture (PMID: 25584008).,4424,25584008,Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study.,http://www.ncbi.nlm.nih.gov/pubmed/25584008,500,16007150,"The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library.",http://www.ncbi.nlm.nih.gov/pubmed/16007150,20929
TP53 F134Y lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). F134Y results in decreased Tp53 transactivation activity and reduced ability to suppress colony formation in cell culture (PMID: 25584008). ,4424,25584008,Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study.,http://www.ncbi.nlm.nih.gov/pubmed/25584008,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,20930
TP53 E285V lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). E285V results in a loss of Tp53 transactivation activity in cell culture (PMID: 25584008).,4424,25584008,Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study.,http://www.ncbi.nlm.nih.gov/pubmed/25584008,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,20931
TP53 C275* results in a premature truncation of the Tp53 protein at amino acid 275 of 393 (UniProt.org). C275* results in a loss of Tp53 transactivation activity and inability to suppress colony formation in cell culture (PMID: 25584008).,295,,,www.uniprot.org,4424,25584008,Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study.,http://www.ncbi.nlm.nih.gov/pubmed/25584008,20932
"GNA11 I132V does not lie within any known functional domains of the Gna11 protein (UniProt.org). I132V has not been characterized in the scientific literature and therefore, its effect on Gna11 protein function is unknown (PubMed, Apr 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20933
"GNA11 V164G does not lie within any known functional domains of the Gna11 protein (UniProt.org). V164G has not been characterized in the scientific literature and therefore, its effect on Gna11 protein function is unknown (PubMed, Apr 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20934
"GNA11 V269I does not lie within any known functional domains of the Gna11 protein (UniProt.org). V269I has not been characterized in the scientific literature and therefore, its effect on Gna11 protein function is unknown (PubMed, Apr 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20935
"GNA11 K57Q does not lie within any known functional domains of the Gna11 protein (UniProt.org). K57Q has not been characterized in the scientific literature and therefore, its effect on Gna11 protein function is unknown (PubMed, Apr 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20936
"GNA11 L351P does not lie within any known functional domains of the Gna11 protein (UniProt.org). L351P has not been characterized in the scientific literature and therefore, its effect on Gna11 protein function is unknown (PubMed, Apr 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20937
"GNA11 S268A does not lie within any known functional domains of the Gna11 protein (UniProt.org). S268A has not been characterized in the scientific literature and therefore, its effect on Gna11 protein function is unknown (PubMed, Apr 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20938
"GNA11 M203L does not lie within any known functional domains of the Gna11 protein (UniProt.org). M203L has not been characterized in the scientific literature and therefore, its effect on Gna11 protein function is unknown (PubMed, Apr 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20939
"GNA11 P293S does not lie within any known functional domains of the Gna11 protein (UniProt.org). P293S has not been characterized in the scientific literature and therefore, its effect on Gna11 protein function is unknown (PubMed, Apr 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20940
"GNA11 G66S does not lie within any known functional domains of the Gna11 protein (UniProt.org). G66S has been identified in sequencing studies (PMID: 24755471), but has not been biochemically characterized and therefore, its effect on Gna11 protein function is unknown (PubMed, Apr 2017). 
",6962,24755471,Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24755471,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20941
"GNA11 I56V does not lie within any known functional domains of the Gna11 protein (UniProt.org). I56V has not been characterized in the scientific literature and therefore, its effect on Gna11 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20942
"GNA11 A110G does not lie within any known functional domains of the Gna11 protein (UniProt.org). A110G has not been characterized and therefore, its effect on Gna11 protein function is unknown (PubMed, Apr 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20943
"GNA11 A168T does not lie within any known functional domains of the Gna11 protein (UniProt.org). A168T has not been characterized in the scientific literature and therefore, its effect on Gna11 protein function is unknown (PubMed, Apr 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20944
"GNA11 A342T does not lie within any known functional domains of the Gna11 protein (UniProt.org). A342T has not been characterized in the scientific literature and therefore, its effect on Gna11 protein function is unknown (PubMed, Apr 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20945
"GNA11 D195N does not lie within any known functional domains of the Gna11 protein (UniProt.org). D195N has not been characterized in the scientific literature and therefore, its effect on Gna11 protein function is unknown (PubMed, Apr 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20946
"GNA11 E221Q does not lie within any known functional domains of the Gna11 protein (UniProt.org). E221Q has not been characterized in the scientific literature and therefore, its effect on Gna11 protein function is unknown (PubMed, Apr 2017). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,20947
"GNA11 E245K does not lie within any known functional domains of the Gna11 protein (UniProt.org). E245K has not been characterized in the scientific literature and therefore, its effect on Gna11 protein function is unknown (PubMed, Apr 2017). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,20948
"GNA11 E294A does not lie within any known functional domains of the Gna11 protein (UniProt.org). E294A has not been characterized in the scientific literature and therefore, its effect on Gna11 protein function is unknown (PubMed, Apr 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20949
"GNA11 E4K does not lie within any known functional domains of the Gna11 protein (UniProt.org). E4K has not been characterized in the scientific literature and therefore, its effect on Gna11 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20950
"GNA11 G171S does not lie within any known functional domains of the Gna11 protein (UniProt.org). G171S has not been characterized in the scientific literature and therefore, its effect on Gna11 protein function is unknown (PubMed, Apr 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20951
"GNA11 I56M does not lie within any known functional domains of the Gna11 protein (UniProt.org). I56M has not been characterized in the scientific literature and therefore, its effect on Gna11 protein function is unknown (PubMed, Apr 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20952
"GNA11 P318L does not lie within any known functional domains of the Gna11 protein (UniProt.org). P318L has not been characterized in the scientific literature and therefore, its effect on Gna11 protein function is unknown (PubMed, Apr 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20953
"MET A320V lies within the Sema domain of the Met protein (UniProt.org). A320V has been identified in the scientific literature (PMID: 25589003, PMID: 9140397), but has not been biochemically characterized and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",6992,25589003,Sporadic hemangioblastomas are characterized by cryptic VHL inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/25589003,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,10008,9140397,Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/9140397,20955
"MET A48V lies within the Sema domain of the Met protein (UniProt.org). A48V has been identified in sequencing studies (PMID: 22037554), but has not been biochemically characterized and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6997,22037554,Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22037554,20956
"MET A564T lies within the IPT/TIG domain 1 of the Met protein (UniProt.org). A564T has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20957
"MET C98F lies within the Sema domain of the Met protein (UniProt.org). C98F has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20958
"MET D1180Y lies within the protein kinase domain of the Met protein (UniProt.org). D1180Y has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20959
"MET D414N lies within the Sema domain of the Met protein (UniProt.org). D414N has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20960
"MET D543N lies within the extracellular domain of the Met protein (UniProt.org). D543N has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20961
"MET E1253K lies within the protein kinase domain of the Met protein (UniProt.org). E1253K has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20962
"MET E167K lies within the Sema domain of the Met protein (UniProt.org). E167K has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,20963
"MET E168K lies within the Sema domain of the Met protein (UniProt.org). E168K has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,20964
"MET E221G lies within the Sema domain of the Met protein (UniProt.org). E221G has been identified in sequencing studies (PMID: 21720365), but has not been biochemically characterized and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6943,21720365,Integrated genomic analyses of ovarian carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/21720365,20965
"MET F192L lies within the Sema domain of the Met protein (UniProt.org). F192L has been identified in sequencing studies (PMID: 22895193), but has not been biochemically characterized and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4597,22895193,Recurrent R-spondin fusions in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22895193,20966
"MET F228C lies within the Sema domain of the Met protein (UniProt.org). F228C has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,295,,,www.uniprot.org,20967
"MET F346L lies within the Sema domain of the Met protein (UniProt.org). F346L has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20968
"MET F634L lies within the IPT/TIG domain 1 of the Met protein (UniProt.org). F634L has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20969
"MET F634S lies within the IPT/TIG domain 1 of the Met protein (UniProt.org). F634S has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20970
"MET F63V lies within the Sema domain of the Met protein (UniProt.org). F63V has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20971
"MET G225D lies within the Sema domain of the Met protein (UniProt.org). G225D has been identified in sequencing studies (PMID: 24140581), but has not been biochemically characterized and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",7251,24140581,The genetic landscape of anaplastic astrocytoma.,http://www.ncbi.nlm.nih.gov/pubmed/24140581,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20972
"MET H476Y lies within the Sema domain of the Met protein (UniProt.org). H476Y has been identified in sequencing studies (PMID: 25303977), but has not been biochemically characterized and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7006,25303977,Mutational landscape of aggressive cutaneous squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25303977,295,,,www.uniprot.org,20973
"MET H644N lies within the IPT/TIG domain 1 of the Met protein (UniProt.org). H644N has been identified in sequencing studies (PMID: 22980975), but has not been biochemically characterized and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1726,22980975,Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/22980975,20974
"MET I333L lies within the Sema domain of the Met protein (UniProt.org). I333L has been identified in sequencing studies (PMID: 24755471, PMID: 18186519), but has not been biochemically characterized and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",6962,24755471,Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24755471,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7939,18186519,Rapid identification of somatic mutations in colorectal and breast cancer tissues using mismatch repair detection (MRD).,http://www.ncbi.nlm.nih.gov/pubmed/18186519,20975
"MET I565M lies within the IPT/TIG domain 1 of the Met protein (UniProt.org). I565M has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20976
"MET I638L lies within the IPT/TIG domain 1 of the Met protein (UniProt.org). I638L has been identified in sequencing studies (PMID: 23033341), but has not been biochemically characterized and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,1098,23033341,Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events.,http://www.ncbi.nlm.nih.gov/pubmed/23033341,295,,,www.uniprot.org,20977
"MET I639L lies within the IPT/TIG domain 1 of the Met protein (UniProt.org). I639L has been identified in the scientific literature (PMID: 26536169), but has not been biochemically characterized and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017). ",10014,26536169,Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26536169,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20978
"MET I639V lies within the IPT/TIG domain 1 of the Met protein (UniProt.org). I639V has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017). ",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,20979
"MET K183N lies within the Sema domain of the Met protein (UniProt.org). K183N has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,20980
"MET K2N lies within the extracellular domain of the Met protein (UniProt.org). K2N has been identified in sequencing studies (PMID: 22980975), but has not been biochemically characterized and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1726,22980975,Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/22980975,20981
"MET K303N lies within the Sema domain of the Met protein (UniProt.org). K303N has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20982
"MET K305E lies within the Sema domain of the Met protein (UniProt.org). K305E has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20983
"MET K306N lies within the Sema domain of the Met protein (UniProt.org). K306N has been identified in sequencing studies (PMID: 22722201), but has not been biochemically characterized and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7023,22722201,The landscape of cancer genes and mutational processes in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22722201,20984
"MET L238F lies within the Sema domain of the Met protein (UniProt.org). L238F has been identified in sequencing studies (PMID: 21720365), but has not been biochemically characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6943,21720365,Integrated genomic analyses of ovarian carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/21720365,20985
"MET L238Yfs*25 is a missense mutation (L238Y) in conjunction with a likely truncation of the 1390 aa Met protein at aa 238, followed by 25 nonsense amino acids (UniProt.org). Due to the loss of most known functional domains (UniProt.org), L238Yfs*25 is predicted to lead to a loss of Met protein function.",295,,,www.uniprot.org,20986
"MET L296P lies within the Sema domain of the Met protein (UniProt.org). L296P has been identified in the scientific literature (PMID: 26536169), but has not been biochemically characterized and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,10014,26536169,Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26536169,20987
"MET L342I lies within the Sema domain of the Met protein (UniProt.org). L342I has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20988
"MET L429V lies within the Sema domain of the Met protein (UniProt.org). L429V has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20989
"MET L707V lies within the IPT/TIG domain 2 of the Met protein (UniProt.org). L707V has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20990
"MET L964M lies within the cytoplasmic domain of the Met protein (UniProt.org). L964M has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20991
"MET M118L lies within the Sema domain of the Met protein (UniProt.org). M118L has been identified in the scientific literature (PMID: 26700204), but has not been biochemically characterized and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7940,26700204,Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas.,http://www.ncbi.nlm.nih.gov/pubmed/26700204,295,,,www.uniprot.org,20992
"MET N257T lies within the Sema domain of the Met protein (UniProt.org). N257T has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20993
"MET N315S lies within the Sema domain of the Met protein (UniProt.org). N315S has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20994
"MET N393K lies within the Sema domain of the Met protein (UniProt.org). N393K has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017). ",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,20995
"MET P1060S lies within the cytoplasmic domain of the Met protein (UniProt.org). P1060S has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,20996
"MET P295H lies within the Sema domain of the Met protein (UniProt.org). P295H has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20997
"MET P485L lies within the Sema domain of the Met protein (UniProt.org). P485L has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20998
"MET P712R lies within the IPT/TIG 2 domain of the Met protein (UniProt.org). P712R has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,20999
"MET P742A lies within the IPT/TIG domain 3 of the Met protein (UniProt.org). P742A has been identified in sequencing studies (PMID: 22980975), but has not been biochemically characterized and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1726,22980975,Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/22980975,21000
"MET P742L lies within the IPT/TIG domain 3 of the Met protein (UniProt.org). P742L has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21001
"MET P97L lies within the Sema domain of the Met protein (UniProt.org). P97L has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21002
"MET Q558* results in a premature truncation of the Met protein at amino acid 558 of 1390 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), Q558* is predicted to lead to a loss of Met protein function.",295,,,www.uniprot.org,21003
"MET R1022* results in a premature truncation of the Met protein at amino acid 1022 of 1390 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), R1022* is predicted to lead to a loss of Met protein function.",295,,,www.uniprot.org,21004
"MET R1166Q lies within the protein kinase domain of the Met protein (UniProt.org). R1166Q has been identified in the scientific literature (PMID: 16189274, PMID: 25453846), but has not been biochemically characterized and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",7984,25453846,Gene mutations in small-cell lung cancer (SCLC): results of a panel of 6 genes in a cohort of Italian patients.,http://www.ncbi.nlm.nih.gov/pubmed/25453846,7983,16189274,Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/16189274,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21005
"MET R1170* results in a premature truncation of the Met protein at amino acid 1170 of 1390 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), R1170* is predicted to lead to a loss of Met protein function.",295,,,www.uniprot.org,21006
"MET R21M lies within the extracellular domain of the Met protein (UniProt.org). R21M has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21007
"MET R266S lies within the Sema domain of the Met protein (UniProt.org). R266S has been identified in sequencing studies (PMID: 21720365), but has not been biochemically characterized and therefore, its effect on Met protein function is unknown (PubMed, Feb 2017).",6943,21720365,Integrated genomic analyses of ovarian carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/21720365,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21008
"MET R412C lies within the Sema domain of the Met protein (UniProt.org). R412C has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21009
"MET R412G lies within the Sema domain of the Met protein (UniProt.org). R412G has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21010
"MET R417* results in a premature truncation of the Met protein at amino acid 417 of 1390 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), R417* is predicted to lead to a loss of Met protein function.",295,,,www.uniprot.org,21011
"MET R469Q lies within the Sema domain of the Met protein (UniProt.org). R469Q has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Feb 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21012
"MET R547* results in a premature truncation of the Met protein at amino acid 547 of 1390 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), R547* is predicted to lead to a loss of Met protein function.",295,,,www.uniprot.org,21013
"MET R547Q lies within the extracellular domain of the Met protein (UniProt.org). R547Q has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21014
"MET S135N lies within the Sema domain of the Met protein (UniProt.org). S135N has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21015
"MET S203Y lies within the Sema domain of the Met protein (UniProt.org). S203Y has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Met protein function is unknown (PubMed, Feb 2017).",5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21016
"MET S213L lies within the Sema domain of the Met protein (UniProt.org). S213L has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Met protein function is unknown (PubMed, Feb 2017).",5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21017
"MET S33F lies within the Sema domain of the Met protein (UniProt.org). S33F has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21018
"MET S441C lies within the Sema domain of the Met protein (UniProt.org). S441C has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21019
"MET S525T lies within the extracellular domain of the Met protein (UniProt.org). S525T has been identified in sequencing studies (PMID: 22722839), but has not been biochemically characterized and therefore, its effect on Met protein function is unknown (PubMed, Feb 2017).",1810,22722839,The mutational landscape of lethal castration-resistant prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22722839,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21020
"MET S525Y lies within the extracellular domain of the Met protein (UniProt.org). S525Y has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21021
"MET S717* results in a premature truncation of the Met protein at amino acid 717 of 1390 (UniProt.org). Due to the loss of several functional domains, including the protein kinase domain (UniProt.org), S717* is predicted to lead to a loss of Met protein function.",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21022
"MET T263M lies within the Sema domain of the Met protein (UniProt.org). T263M has been identified in sequencing studies (PMID: 22722193, PMID: 26214590, PMID: 25266736), but has not been biochemically characterized and therefore, its effect on Met protein function is unknown (PubMed, Feb 2017).",7151,26214590,Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.,http://www.ncbi.nlm.nih.gov/pubmed/26214590,8006,22722193,Whole-genome analysis informs breast cancer response to aromatase inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/22722193,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3809,25266736,Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes.,http://www.ncbi.nlm.nih.gov/pubmed/25266736,21023
"MET T474I lies within the Sema domain of the Met protein (UniProt.org). T474I has been identified in sequencing studies (PMID: 22722839), but has not been biochemically characterized and therefore, its effect on Met protein function is unknown (PubMed, Feb 2017).",1810,22722839,The mutational landscape of lethal castration-resistant prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22722839,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21024
"MET T660R lies within the IPT/TIG 2 domain of the Met protein (UniProt.org). T660R has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Feb2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21025
"MET T698S lies within the IPT/TIG 2 domain of the Met protein (UniProt.org). T698S has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21026
"MET T733K lies within the IPT/TIG 2 domain of the Met protein (UniProt.org). T733K has been identified in sequencing studies (PMID: 23917401), but has not been biochemically characterized and therefore, its effect on Met protein function is unknown (PubMed, Feb 2017). ",295,,,www.uniprot.org,3963,23917401,The integrated landscape of driver genomic alterations in glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/23917401,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21027
"MET V378I lies within the Sema domain of the Met protein (UniProt.org). V378I has been identified in the scientific literature (PMID: 26887047), but has not been biochemically characterized and therefore, its effect on Met protein function is unknown (PubMed, Feb 2017).",295,,,www.uniprot.org,8008,26887047,Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26887047,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21028
"MET V427G lies within the Sema domain of the Met protein (UniProt.org). V427G has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21029
"MET V504L lies within the Sema domain of the Met protein (UniProt.org). V504L has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21030
"MET W540* results in a premature truncation of the Met protein at amino acid N540 of 1390 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), W540* is predicted to lead to a loss of Met protein function.",295,,,www.uniprot.org,21031
"MET W540S lies within the extracellular domain of the Met protein (UniProt.org). W540S has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Feb 2017).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21032
"MET Y321H lies within the Sema domain of the Met protein (UniProt.org). Y321H has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21033
"MET Y666C lies within the IPT/TIG 2 domain of the Met protein (UniProt.org). Y666C has been identified in sequencing studies (PMID: 22895193), but has not been biochemically characterized and therefore, its effect on Met protein function is unknown (PubMed, Feb 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4597,22895193,Recurrent R-spondin fusions in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22895193,21034
"GNA11 R114W does not lie within any known functional domains of the Gna11 protein (UniProt.org). R114W has not been characterized in the scientific literature and therefore, its effect on Gna11 protein function is unknown (PubMed, Apr 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21036
"GNA11 R166H does not lie within any known functional domains of the Gna11 protein (UniProt.org). R166H has not been characterized in the scientific literature and therefore, its effect on Gna11 protein function is unknown (PubMed, Apr 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21037
"GNA11 R338C does not lie within any known functional domains of the Gna11 protein (UniProt.org). R338C has not been characterized in the scientific literature and therefore, its effect on Gna11 protein function is unknown (PubMed, Apr 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21038
"GNA11 S130G does not lie within any known functional domains of the Gna11 protein (UniProt.org). S130G has not been characterized in the scientific literature and therefore, its effect on Gna11 protein function is unknown (PubMed, Apr 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21039
"GNA11 S18F does not lie within any known functional domains of the Gna11 protein (UniProt.org). S18F has not been characterized in the scientific literature and therefore, its effect on Gna11 protein function is unknown (PubMed, Apr 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21040
"GNA11 E294* results in a premature truncation of the Gna11 protein at amino acid 294 of 359 (UniProt.org). E294* has not been characterized in the scientific literature and therefore, its effect on GNA11 protein function is unknown (PubMed, Apr 2017).",295,,,www.uniprot.org,21041
"GNA11 G208Afs*16 is a missense mutation (G208A) in conjunction with a likely truncation of the 359 aa Gna11 protein at aa 208, followed by 16 nonsense amino acids (UniProt.org). Due to the disruption of the GTPase domain (PMID: 27647839), G208Afs*16 is predicted to lead to a loss of Gna11 protein function.",8759,27647839,Disorders of the calcium-sensing receptor and partner proteins: insights into the molecular basis of calcium homeostasis.,http://www.ncbi.nlm.nih.gov/pubmed/27647839,295,,,www.uniprot.org,21042
"GNA11 R256Gfs*55 is a missense mutation (R256G) in conjunction with a likely truncation of the 359 aa Gna11 protein at aa 256, followed by 55 nonsense amino acids (UniProt.org). Due to disruption of the GTPase domain (PMID: 27647839), R256Gfs*55 is predicted to lead to a loss of Gna11 protein function.
",295,,,www.uniprot.org,8759,27647839,Disorders of the calcium-sensing receptor and partner proteins: insights into the molecular basis of calcium homeostasis.,http://www.ncbi.nlm.nih.gov/pubmed/27647839,21043
"GNA11 S130Vfs*32 is a missense mutation (S130V) in conjunction with a likely truncation of the 359 aa Gna11 protein at aa 130, followed by 32 nonsense amino acids (UniProt.org).  Due to the loss of the majority of the GTP binding regions (UniProt.org), S130Vfs*32 is predicted to lead to a loss of Gna11 protein function.
",295,,,www.uniprot.org,21044
"GNAQ A302G does not lie within any known functional domains of the Gnaq protein (UniProt.org). A302G has been identified in the scientific literature (PMID: 24755198), but has not been biochemically characterized and therefore, its effect on Gnaq protein function is unknown (PubMed, Apr 2017).",8658,24755198,A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance.,http://www.ncbi.nlm.nih.gov/pubmed/24755198,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21053
"GNAQ D146H does not lie within any known functional domains of the Gnaq protein (UniProt.org). D146H has not been characterized in the scientific literature and therefore, its effect on Gnaq protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21054
"GNAQ D205G lies within the GTP binding region of the Gnaq protein (UniProt.org). D205G has not been characterized in the scientific literature and therefore, its effect on Gnaq protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21055
"GNAQ D290N does not lie within any known functional domains of the Gnaq protein (UniProt.org). D290N has not been characterized in the scientific literature and therefore, its effect on Gnaq protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21056
"GNAQ D315N does not lie within any known functional domains of the Gnaq protein (UniProt.org). D315N has been identified in sequencing studies (PMID: 25589618), but has not been biochemically characterized and therefore, its effect on Gnaq protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6963,25589618,Genomic analysis of metastatic cutaneous squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25589618,21057
"GNAQ D319N does not lie within any known functional domains of the Gnaq protein (UniProt.org). D319N has not been characterized in the scientific literature and therefore, its effect on Gnaq protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21058
"GNAQ E249K does not lie within any known functional domains of the Gnaq protein (UniProt.org). E249K has not been characterized and therefore, its effect on Gnaq protein function is unknown (PubMed, Apr 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21059
"GNAQ G48V does not lie within any known functional domains of the Gnaq protein (UniProt.org). G48V has not been characterized in the scientific literature and therefore, its effect on Gnaq protein function is unknown (PubMed, Apr 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21060
"CDKN2A over exp indicates an over expression of the Cdkn2a protein. However, the mechanism causing the over expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,21061
SMARCB1 del indicates a deletion of the SMARCB1 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,21062
"GNAQ G48* results in a premature truncation of the Gnaq protein at amino acid 48 of 359 (UniProt.org). Due to the loss of the GTP binding region (UniProt.org), G48* is predicted to lead to a loss of Gnaq protein function.",295,,,www.uniprot.org,21064
"GNAQ G64A does not lie within any known functional domains of the Gnaq protein (UniProt.org). G64A has not been characterized and therefore, its effect on Gnaq protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21065
"GNAQ I217L does not lie within any known functional domains of the Gnaq protein (UniProt.org). I217L has not been characterized in the scientific literature and therefore, its effect on Gnaq protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21066
"GNAQ I226V does not lie within any known functional domains of the Gnaq protein (UniProt.org). I226L has not been characterized in the scientific literature and therefore, its effect on Gnaq protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21067
"GNAQ K133N does not lie within any known functional domains of the Gnaq protein (UniProt.org). K133N has not been characterized in the scientific literature and therefore, its effect on Gnaq protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21068
"GNAQ K276E lies within the GTP binding region of the Gnaq protein (UniProt.org). K276E has not been characterized in the scientific literature and therefore, its effect on Gnaq protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21069
"GNAQ K311T does not lie within any known functional domains of the Gnaq protein (UniProt.org). K311T has not been characterized in the scientific literature and therefore, its effect on Gnaq protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21070
"GNAQ K345N does not lie within any known functional domains of the Gnaq protein (UniProt.org). K345N has not been characterized in the scientific literature and therefore, its effect on Gnaq protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21071
"GNAQ L135V does not lie within any known functional domains of the Gnaq protein (UniProt.org). L135V has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Gnaq protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21072
"GNAQ L164F does not lie within any known functional domains of the Gnaq protein (UniProt.org). L164F has not been characterized in the scientific literature and therefore, its effect on Gnaq protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21073
"GNAQ P139R does not lie within any known functional domains of the Gnaq protein (UniProt.org). P139R has not been characterized in the scientific literature and therefore, its effect on Gnaq protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21074
"GNAQ P185S lies within the GTP binding region of the Gnaq protein (UniProt.org). P185S has been identified in sequencing studies (PMID: 24755198), but has not been biochemically characterized and therefore, its effect on Gnaq protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21075
"GNAQ R148* results in a premature truncation of the Gnaq protein at amino acid 148 of 359 (UniProt.org). Due to the loss of the majority of key residues that make up the GTP binding region (UniProt.org), R148* is predicted to lead to a loss of Gnaq protein function.",295,,,www.uniprot.org,21076
"GNAQ R214K does not lie within any known functional domains of the Gnaq protein (UniProt.org). R214K has not been characterized in the scientific literature and therefore, its effect on Gnaq protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21077
"GNAQ D333Afs*39 is a missense mutation (D333A) in conjunction with a likely truncation of the 359 aa Gnaq protein at aa 333, followed by 39 nonsense amino acids (UniProt.org). D333Afs*39 has not been characterized in the scientific literature and therefore, its effect on Gnaq protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21078
"GNAQ R247Q does not lie within any known functional domains of the Gnaq protein (UniProt.org). R247Q has not been characterized in the scientific literature and therefore, its effect on Gnaq protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21079
"GNAQ R300K does not lie within any known functional domains of the Gnaq protein (UniProt.org). R300K has not been characterized in the scientific literature and therefore, its effect on Gnaq protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21080
"GNAQ R338H does not lie within any known functional domains of the Gnaq protein (UniProt.org). R338H has been identified in sequencing studies (PMID: 25790293), but has not been biochemically characterized and therefore, its effect on Gnaq protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7443,25790293,Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia.,http://www.ncbi.nlm.nih.gov/pubmed/25790293,21081
MPL E230G lies within the Fibronectin type-III domain 1 of the Mpl protein (UniProt.org). E230G confers a gain of function to Mpl protein as indicated by ligand-independent activation of Jak-Stat signaling in cell culture (PMID: 26423830).,295,,,www.uniprot.org,5153,26423830,Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26423830,21082
MPL R321W lies within the extracellular domain of the Mpl protein (UniProt.org). R321W confers a gain of function to Mpl protein as indicated by ligand-independent activation of Jak-Stat signaling in cell culture (PMID: 26423830).,295,,,www.uniprot.org,5153,26423830,Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26423830,21083
MPL S204F lies within the Fibronectin type-III domain 1 of the Mpl protein (UniProt.org). S204F confers a gain of function to Mpl protein as indicated by ligand-independent activation of Jak-Stat signaling in cell culture (PMID: 26423830).,5153,26423830,Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26423830,295,,,www.uniprot.org,21084
MPL S204P lies within the Fibronectin type-III domain 1 of the Mpl protein (UniProt.org). S204P confers a gain of function to Mpl protein as indicated by ligand-independent activation of Jak-Stat signaling in cell culture (PMID: 26423830).,295,,,www.uniprot.org,5153,26423830,Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26423830,21085
MPL T119I lies within the extracellular domain of the Mpl protein (UniProt.org). T119I confers a gain of function to Mpl protein as indicated by ligand-independent activation of Jak-Stat signaling in cell culture (PMID: 26423830).,295,,,www.uniprot.org,5153,26423830,Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26423830,21086
MPL V285E lies within the extracellular domain of the Mpl protein (UniProt.org). V285E confers a gain of function to Mpl protein as indicated by ligand-independent activation of Jak-Stat signaling in cell culture (PMID: 26423830).,295,,,www.uniprot.org,5153,26423830,Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26423830,21087
MPL Y591D lies within the Fibronectin type-III domain 1 of the Mpl protein (UniProt.org). Y591D confers a gain of function to Mpl protein as indicated by ligand-independent activation of Jak-Stat signaling and growth advantage in cell culture (PMID: 26423830).,5153,26423830,Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26423830,295,,,www.uniprot.org,21088
MPL W515Y lies within the cytoplasmic domain of the Mpl protein (UniProt.org). W515Y confers a gain of function to Mpl protein as indicated by ligand-independent activation of Jak-Stat signaling in cell culture (PMID: 26437785).,5154,26437785,Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26437785,295,,,www.uniprot.org,21089
MPL W515F lies within the cytoplasmic domain of the Mpl protein (UniProt.org). W515F confers a gain of function to Mpl protein as indicated by ligand-independent activation of Jak-Stat signaling in cell culture (PMID: 26437785).,5154,26437785,Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26437785,295,,,www.uniprot.org,21090
MPL W515M lies within the cytoplasmic domain of the Mpl protein (UniProt.org). W515M confers a gain of function to Mpl protein as indicated by ligand-independent activation of Jak-Stat signaling in cell culture (PMID: 26437785).,295,,,www.uniprot.org,5154,26437785,Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26437785,21091
MPL W515I lies within the cytoplasmic domain of the Mpl protein (UniProt.org). W515I confers a gain of function to Mpl protein as indicated by ligand-independent activation of Jak-Stat signaling in cell culture (PMID: 26437785).,295,,,www.uniprot.org,5154,26437785,Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26437785,21092
MPL W515V lies within the cytoplasmic domain of the Mpl protein (UniProt.org). W515V confers a gain of function to Mpl protein as indicated by ligand-independent activation of Jak-Stat signaling in cell culture (PMID: 26437785). ,295,,,www.uniprot.org,5154,26437785,Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26437785,21093
MPL W515A lies within the cytoplasmic domain of the Mpl protein (UniProt.org). W515A confers a gain of function to Mpl protein as indicated by ligand-independent activation of Jak-Stat signaling in cell culture (PMID: 26437785).,295,,,www.uniprot.org,5154,26437785,Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26437785,21094
MPL W515G lies within the cytoplasmic domain of the Mpl protein (UniProt.org). W515G confers a gain of function to Mpl protein as indicated by ligand-independent activation of Jak-Stat signaling in cell culture (PMID: 26437785).,295,,,www.uniprot.org,5154,26437785,Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26437785,21095
MPL W515D lies within the cytoplasmic domain of the Mpl protein (UniProt.org). W515D confers a gain of function to Mpl protein as indicated by ligand-independent activation of Jak-Stat signaling in cell culture (PMID: 26437785).,295,,,www.uniprot.org,5154,26437785,Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26437785,21096
MPL W515E lies within the cytoplasmic domain of the Mpl protein (UniProt.org). W515E confers a gain of function to Mpl protein as indicated by ligand-independent activation of Jak-Stat signaling in cell culture (PMID: 26437785).,295,,,www.uniprot.org,5154,26437785,Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26437785,21097
MPL W515R lies within the cytoplasmic domain of the Mpl protein (UniProt.org). W515R confers a gain of function to Mpl protein as indicated by ligand-independent activation of Jak-Stat signaling in cell culture (PMID: 26437785).,295,,,www.uniprot.org,5154,26437785,Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26437785,21098
MPL W515H lies within the cytoplasmic domain of the Mpl protein (UniProt.org). W515H confers a gain of function to Mpl protein as indicated by ligand-independent activation of Jak-Stat signaling in cell culture (PMID: 26437785).,5154,26437785,Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26437785,21099
MPL W515S lies within the cytoplasmic domain of the Mpl protein (UniProt.org). W515S confers a gain of function to Mpl protein as indicated by ligand-independent activation of Jak-Stat signaling in cell culture (PMID: 26437785).,5154,26437785,Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26437785,295,,,www.uniprot.org,21100
MPL W515T lies within the cytoplasmic domain of the Mpl protein (UniProt.org). W515T confers a gain of function to Mpl protein as indicated by ligand-independent activation of Jak-Stat signaling in cell culture (PMID: 26437785).,5154,26437785,Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26437785,295,,,www.uniprot.org,21101
MPL W515N lies within the cytoplasmic domain of the Mpl protein (UniProt.org). W515N confers a gain of function to Mpl protein as indicated by ligand-independent activation of Jak-Stat signaling in cell culture (PMID: 26437785). ,5154,26437785,Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26437785,295,,,www.uniprot.org,21102
MPL W515Q lies within the cytoplasmic domain of the Mpl protein (UniProt.org). W515Q confers a gain of function to Mpl protein as indicated by ligand-independent activation of Jak-Stat signaling in cell culture (PMID: 26437785).,5154,26437785,Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26437785,295,,,www.uniprot.org,21103
MPL W515C lies within the cytoplasmic domain of the Mpl protein (UniProt.org). W515C demonstrates activation of Jak-Stat signaling to similar level of wild-type Mpl protein in cell culture (PMID: 26437785).,5154,26437785,Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26437785,295,,,www.uniprot.org,21104
MPL W515P lies within the cytoplasmic domain of the Mpl protein (UniProt.org). W515P demonstrates activation of Jak-Stat signaling to similar level of wild-type Mpl protein in cell culture (PMID: 26437785).,5154,26437785,Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26437785,295,,,www.uniprot.org,21105
MPL W515_P518del results in the deletion of four amino acids in the cytoplasmic domain of the Mpl protein from amino acids 515 to 518 (UniProt.org). W515_P518del confers a gain of function to Mpl protein as indicated by ligand-independent activation of Jak-Stat signaling in cell culture (PMID: 26437785).,5154,26437785,Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26437785,295,,,www.uniprot.org,21106
MPL W515_F517del results in the deletion of three amino acids in the cytoplasmic domain of the Mpl protein from amino acids 515 to 517 (UniProt.org). W515_F517del demonstrates activation of Jak-Stat signaling to similar level of wild-type Mpl protein in cell culture (PMID: 26437785).,295,,,www.uniprot.org,5154,26437785,Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26437785,21107
"JAK2 over exp indicates an over expression of the Jak2 protein. 
However, the mechanism causing the over expression is unspecified.
",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,21108
"MPL over exp indicates an over expression of the Mpl protein. 
However, the mechanism causing the over expression is unspecified.
",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,21109
"MAP2K1 L115P lies within the protein kinase domain of the Map2k1 protein (UniProt.org). L115P confers a gain of function on the kinase activity of the Map2k1 protein, but is associated with decreased binding and resistance to Mek inhibitors (PMID: 12370306, PMID: 19915144, PMID: 26399658).",5157,12370306,Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352.,http://www.ncbi.nlm.nih.gov/pubmed/12370306,8440,26399658,MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road.,http://www.ncbi.nlm.nih.gov/pubmed/26399658,134,19915144,MEK1 mutations confer resistance to MEK and B-RAF inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/19915144,21111
"MAP2K1 I103N lies within the protein kinase domain of the Map2k1 protein (UniProt.org). I103N results in increased Map2k1 autophosphorylation in cell culture, but is associated with resistance to Mek inhibitors (PMID: 12370306, PMID: 19915144).",134,19915144,MEK1 mutations confer resistance to MEK and B-RAF inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/19915144,5157,12370306,Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352.,http://www.ncbi.nlm.nih.gov/pubmed/12370306,21112
"GNAS K338R lies within the Ras-like domain of the Gnas protein (PMID: 25802881). K338R has not been characterized in the scientific literature and therefore, its effect on Gnas protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5159,25802881,A positive genotype-phenotype correlation in a large cohort of patients with Pseudohypoparathyroidism Type Ia and Pseudo-pseudohypoparathyroidism and 33 newly identified mutations in the GNAS gene.,http://www.ncbi.nlm.nih.gov/pubmed/25802881,21113
"GNAS R265H lies within the Ras-like domain of the Gnas protein (PMID: 25802881). R265H has not been characterized in the scientific literature and therefore, its effect on Gnas protein function is unknown (PubMed, Apr 2016).",5159,25802881,A positive genotype-phenotype correlation in a large cohort of patients with Pseudohypoparathyroidism Type Ia and Pseudo-pseudohypoparathyroidism and 33 newly identified mutations in the GNAS gene.,http://www.ncbi.nlm.nih.gov/pubmed/25802881,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21114
"GNAS R317C (corresponding to R960C in isoform XLas-1) lies within the Ras-like domain of the Gnas protein (PMID: 25802881). R317C has not been characterized in the scientific literature and therefore, its effect on Gnas protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5159,25802881,A positive genotype-phenotype correlation in a large cohort of patients with Pseudohypoparathyroidism Type Ia and Pseudo-pseudohypoparathyroidism and 33 newly identified mutations in the GNAS gene.,http://www.ncbi.nlm.nih.gov/pubmed/25802881,21115
"GNAQ R37H does not lie within any known functional domains of the Gnaq protein (UniProt.org). R37H has been identified in sequencing studies (PMID: 24755471), but has not been biochemically characterized and therefore, its effect on Gnaq protein function is unknown (PubMed, Apr 2017).",6962,24755471,Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24755471,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21116
"GNAQ S122F does not lie within any known functional domains of the Gnaq protein (UniProt.org). S122F has not been characterized in the scientific literature and therefore, its effect on Gnaq protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21117
"GNAQ S286F does not lie within any known functional domains of the Gnaq protein (UniProt.org). S286F has not been characterized and therefore, its effect on Gnaq protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21118
"GNAQ S50Wfs*19 is a missense mutation (S50W) in conjunction with a likely truncation of the 359 aa Gnaq protein at aa 50, followed by 19 nonsense amino acids (UniProt.org). Due to the loss of the GTP binding region (UniProt.org), S50Wfs*19 is predicted to lead to a loss of Gnaq protein function.",295,,,www.uniprot.org,21119
"GNAQ T54M does not lie within any known functional domains of the Gnaq protein (UniProt.org). T54M has not been characterized in the scientific literature and therefore, its effect on Gnaq protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21120
"GNAQ V167I does not lie within any known functional domains of the Gnaq protein (UniProt.org). V167I has been identified in sequencing studies (PMID: 23525077), but has not been biochemically characterized and therefore, its effect on Gnaq protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21121
"GNAQ Y325F does not lie within any known functional domains of the Gnaq protein (UniProt.org). Y325F has been identified in sequencing studies (PMID: 21798893), but has not been biochemically characterized and therefore, its effect on Gnaq protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21122
"GNAQ Y356C does not lie within any known functional domains of the Gnaq protein (UniProt.org). Y356C has not been characterized in the scientific literature and therefore, its effect on Gnaq protein function is unknown (PubMed, Apr 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21123
"GNAQ Y80* results in a premature truncation of the Gnaq protein at amino acid 80 of 359 (Uniprot.org). Due to the loss of a majority of the GTP binding region (UniProt.org), Y80* is predicted to lead to a loss of Gnaq protein function.",295,,,www.uniprot.org,21124
MLH1 A111P lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). A111P results in a loss of mismatch repair activity in an in vitro assay (PMID: 20020535).,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,5161,20020535,A cell-free assay for the functional analysis of variants of the mismatch repair protein MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/20020535,21125
"MLH1 A120S lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). A120S has not been characterized in the scientific literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21126
"MLH1 A210T lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). A210T has not been characterized in the scientific literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21128
"MLH1 A410T lies within the EXO1-interacting region of the Mlh1 protein (UniProt.org). A410T has not been characterized in the scientific literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21129
"MLH1 A92T lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). A92T has not been characterized in the scientific literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21130
MLH1 A31C lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). A31C has reduced mismatch repair activity relative to wild type Mlh1 in an in vitro assay (PMID: 20020535).,5161,20020535,A cell-free assay for the functional analysis of variants of the mismatch repair protein MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/20020535,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21131
"MLH1 A589D lies within the C-terminal dimerization domain of the Mlh1 protein (PMID: 22753075). The functional effect of A589D is conflicting, as A589D has been reported to result in a loss of mismatch repair activity (PMID: 20020535) and also have proficient mismatch repair activity (PMID: 16083711) in in vitro assays. ",5161,20020535,A cell-free assay for the functional analysis of variants of the mismatch repair protein MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/20020535,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,5166,16083711,Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/16083711,21132
"MAP2K1 I111P lies within the protein kinase domain of the Map2k1 protein (UniProt.org). I111P results in increased Map2k1 kinase activity in an in vitro assay, and is associated with resistance to inhibitors (PMID: 12370306).",5157,12370306,Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352.,http://www.ncbi.nlm.nih.gov/pubmed/12370306,295,,,www.uniprot.org,21133
"MAP2K1 I111A lies within the protein kinase domain of the Map2k1 protein (UniProt.org). I111A results in increased Map2k1 kinase activity in an in vitro assay, and is associated with resistance to inhibitors (PMID: 12370306).",5157,12370306,Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352.,http://www.ncbi.nlm.nih.gov/pubmed/12370306,295,,,www.uniprot.org,21134
"MAP2K1 I111R lies within the protein kinase domain of the Map2k1 protein (UniProt.org). I111R results in increased Map2k1 kinase activity in an in vitro assay, and is associated with resistance to inhibitors (PMID: 12370306).",5157,12370306,Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352.,http://www.ncbi.nlm.nih.gov/pubmed/12370306,295,,,www.uniprot.org,21135
"MAP2K1 I111N lies within the protein kinase domain of the Map2k1 protein (UniProt.org). I111N results in increased Map2k1 kinase activity in an in vitro assay, and is associated with resistance to inhibitors (PMID: 12370306).",5157,12370306,Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352.,http://www.ncbi.nlm.nih.gov/pubmed/12370306,295,,,www.uniprot.org,21136
"MAP2K1 V211D lies within the protein kinase domain of the Map2k1 protein (UniProt.org). V211D has not been demonstrated to increased basal Mapk21 activity, but is associated with inhibitor resistance in culture (PMID: 19915144).",134,19915144,MEK1 mutations confer resistance to MEK and B-RAF inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/19915144,295,,,www.uniprot.org,21137
"KRAS P110H does not lie within any known functional domains of the Kras protein (UniProt.org). P110H has not been characterized in the scientific literature and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21138
"KRAS P110S does not lie within any known functional domains of the Kras protein (UniProt.org). P110S has not been characterized in the scientific literature and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21139
"KRAS P121H does not lie within any known functional domains of the Kras protein (UniProt.org). P121H has been identified in sequencing studies (PMID: 22328975), but has not been biochemically characterized and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,10092,22328975,Genomic complexity and AKT dependence in serous ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22328975,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21140
"KRAS P140H does not lie within any known functional domains of the Kras protein (UniProt.org). P140H has not been characterized in the scientific literature and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21141
"KRAS R135T does not lie within any known functional domains of the Kras protein (UniProt.org). R135T has not been characterized in the scientific literature and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21142
"KRAS R68M does not lie within any known functional domains of the Kras protein (UniProt.org). R68M has not been characterized in the scientific literature and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21143
"KRAS R68S does not lie within any known functional domains of the Kras protein (UniProt.org). R68S been identified in sequencing studies (PMID: 28356789), but has not been biochemically characterized and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,10093,28356789,"Significance of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer patients receiving Bevacizumab: a single institution experience.",http://www.ncbi.nlm.nih.gov/pubmed/28356789,21144
"KRAS S17T lies within a GTP binding region of the Kras protein (UniProt.org). S17T has not been characterized in the scientific literature and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21145
"KRAS T158A does not lie within any known functional domains of the Kras protein (UniProt.org). T158A has not been characterized in the scientific literature and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21146
"KRAS T20R does not lie within any known functional domains of the Kras protein (UniProt.org). T20R has been identified in the scientific literature (PMID: 24549645), but has not been biochemically characterized and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,10094,24549645,KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24549645,21147
"HRAS G10S lies within the GTP binding region of the Hras protein (UniProt.org). G10S has not been characterized in the scientific literature and therefore, its effect on Hras protein function is unknown (PubMed, Apr 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21152
"HRAS L120V does not lie within any known functional domains of the Hras protein (UniProt.org). L120V has not been characterized in the scientific literature and therefore, its effect on Hras protein function is unknown (PubMed, Apr 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21153
"HRAS L133R does not lie within any known functional domains of the Hras protein (UniProt.org). L133R has not been characterized in the scientific literature and therefore, its effect on Hras protein function is unknown (PubMed, Apr 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21154
"HRAS P174S lies within the hypervariable region of the Hras protein (UniProt.org). P174S has not been characterized in the scientific literature and therefore, its effect on Hras protein function is unknown (PubMed, Apr 2017).
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21155
"HRAS R128L does not lie within any known functional domains of the Hras protein (UniProt.org). R128L has not been characterized in the scientific literature and therefore, its effect on Hras protein function is unknown (PubMed, Apr 2017).
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21156
"HRAS R128W does not lie within any known functional domains of the Hras protein (UniProt.org). R128W has not been characterized in the scientific literature and therefore, its effect on Hras protein function is unknown (PubMed, Apr 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21157
"HRAS V81M does not lie within any known functional domains of the Hras protein (UniProt.org). V81M has been identified in the scientific literature (PMID: 14616967), but has not been biochemically characterized and therefore, its effect on Hras protein function is unknown (PubMed, Apr 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8608,14616967,"Alterations of RAS signalling in Chinese multiple myeloma patients: absent BRAF and rare RAS mutations, but frequent inactivation of RASSF1A by transcriptional silencing or expression of a non-functional variant transcript.",http://www.ncbi.nlm.nih.gov/pubmed/14616967,21158
"HRAS A11D lies within the GTP binding region of the Hras protein (UniProt.org). A11D has not been characterized in the scientific literature and therefore, its effect on Hras protein function is unknown (PubMed, Apr 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21159
"HRAS A11S lies within the GTP binding region of the Hras protein (UniProt.org). A11S has been identified in the scientific literature (PMID: 22683711), but has not been biochemically characterized and therefore, its effect on Hras protein function is unknown (PubMed, Apr 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2202,22683711,Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/22683711,21160
"HRAS A130T does not lie within any known functional domains of the Hras protein (UniProt.org). A130T has not been characterized in the scientific literature and therefore, its effect on Hras protein function is unknown (PubMed, Apr 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21161
"HRAS A134S does not lie within any known functional domains of the Hras protein (UniProt.org). A134S has not been characterized and therefore, its effect on Hras protein function is unknown (PubMed, Aug 2016).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21162
"HRAS A66T does not lie within any known functional domains of the Hras protein (UniProt.org). A66T has not been characterized in the scientific literature and therefore, its effect on Hras protein function is unknown (PubMed, Apr 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21163
"HRAS D33N lies within the effector region of the Hras protein (UniProt.org). D33N has been identified in the scientific literature (PMID: 26718898), but has not been biochemically characterized and therefore, its effect on Hras protein function is unknown (PubMed, Apr 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8602,26718898,"Analysis of somatic mutations in BRAF, CDKN2A/p16 and PI3KCA in patients with medullary thyroid carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/26718898,21164
"HRAS E162G does not lie within any known functional domains of the Hras protein (UniProt.org). E162G has not been characterized in the scientific literature and therefore, its effect on Hras protein function is unknown (PubMed, Apr 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21165
"HRAS E91K does not lie within any known functional domains of the Hras protein (UniProt.org). E91K has not been characterized in the scientific literature and therefore, its effect on Hras protein function is unknown (PubMed, Apr 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21166
"MLH1 C233R lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). C233R has not been characterized and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21167
"MLH1 D41N lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). D41N has not been characterized in the scientific literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21168
"MLH1 D41Y lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). D41Y has not been characterized in the scientific literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21169
"MLH1 D631H lies within the C-terminal dimerization domain of the Mlh1 protein (PMID: 22753075). D631H has not been characterized in the scientific literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21170
"MLH1 D72Y lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). D72Y has not been characterized in the scientific literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21171
"MLH1 E102* results in a premature truncation of the Mlh1 protein at amino acid 102 of 756 (UniProt.org). Due to the loss of all domains known to interact with other DNA repair enzymes (PMID: 22753075), E102* is predicted to lead to a loss of Mlh1 protein function. ",295,,,www.uniprot.org,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21172
MLH1 E102D lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). E102D demonstrates decreased mismatch repair activity in an in vitro assay (PMID: 17510385).,295,,,www.uniprot.org,5174,17510385,Functional analysis of human MLH1 variants using yeast and in vitro mismatch repair assays.,http://www.ncbi.nlm.nih.gov/pubmed/17510385,21173
"HRAS R149Gfs*23 is a missense mutation (R149G) in conjunction with a likely truncation of the 189 aa Hras protein at aa 149, followed by 23 nonsense amino acids (UniProt.org). R149Gfs*23 has not been characterized in the scientific literature and therefore, its effect on Hras protein function is unknown (PubMed, Apr 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21174
"MLH1 E172K lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). E172K has been identified in sequencing studies (PMID: 27998968), but has not been biochemically characterized and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,8985,27998968,Drug-sensitive FGFR3 mutations in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/27998968,21175
"HRAS A59Rfs*32 is a missense mutation (A59R) in conjunction with a likely truncation of the 189 aa Hras protein at aa 59, followed by 32 nonsense amino acids (UniProt.org).  Due to the loss of the GTP binding domain of Hras (UniProt.org), A59Rfs*32 is predicted to confer loss of function to the Hras protein. 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21176
"HRAS E162K does not lie within any known functional domains of the Hras protein (UniProt.org). E162K has been identified in the scientific literature (PMID: 22932669), but has not been biochemically characterized and therefore, its effect on Hras protein function is unknown (PubMed, Apr 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1148,22932669,Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22932669,21177
"HRAS G48R does not lie within any known functional domains of the Hras protein (UniProt.org). H48S results in increased formation of Hras nanoscale signaling complexes on the plasma membrane, increased interaction between membrane-bound RAS and RBD in vitro, and no change in GAP activity, interaction between soluble RAS and RBD in vitro, or Hras localization (PMID: 26274561).",8605,26274561,Specific cancer-associated mutations in the switch III region of Ras increase tumorigenicity by nanocluster augmentation.,http://www.ncbi.nlm.nih.gov/pubmed/26274561,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21178
"NRAS A146V does not lie within any known functional domains of the Nras protein (UniProt.org). A146V has not been characterized and therefore, its effect on Nras protein function is unknown (PubMed, Oct 2016).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21179
"NRAS A66V does not lie within any known functional domains of the Nras protein (UniProt.org). A66V has not been characterized in the scientific literature and therefore, its effect on Nras protein function is unknown (PubMed, Oct 2016).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21180
"NRAS D154G does not lie within any known functional domains of the Nras protein (UniProt.org). D154G has not been characterized and therefore, its effect on Nras protein function is unknown (PubMed, Oct 2016).

",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21181
"NRAS D154H does not lie within any known functional domains of the Nras protein (UniProt.org). D154H has not been characterized in the scientific literature and therefore, its effect on Nras protein function is unknown (PubMed, Oct 2016).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21182
"NRAS D175N lies within the hypervariable region of the Nras protein (UniProt.org). D175N has not been characterized and therefore, its effect on Nras protein function is unknown (PubMed, Oct 2016).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21183
"NRAS E132K does not lie within any known functional domains of the Nras protein (UniProt.org). E132K has not been characterized and therefore, its effect on Nras protein function is unknown (PubMed, Oct 2016).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21184
"NRAS H131R does not lie within any known functional domains of the Nras protein (UniProt.org). H131R has not been characterized and therefore, its effect on Nras protein function is unknown (PubMed, Oct 2016).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21185
"NRAS I24L does not lie within any known functional domains of the Nras protein (UniProt.org). I24L has not been characterized and therefore, its effect on Nras protein function is unknown (PubMed, Oct 2016).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21186
"NRAS P34A lies within the effector region of the Nras protein (UniProt.org). P34A has not been characterized and therefore, its effect on Nras protein function is unknown (PubMed, Oct 2016).
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21187
"MLH1 E199K lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). E199K has not been characterized in the scientific literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21188
"MLH1 E227* results in a premature truncation of the Mlh1 protein at amino acid 227 of 756 (UniProt.org). Due to the loss of all domains known to interact with other DNA repair enzymes (PMID: 22753075), E227* is predicted to lead to a loss of Mlh1 protein function.",295,,,www.uniprot.org,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21189
"MLH1 E313* results in a premature truncation of the Mlh1 protein at amino acid 313 of 756 (UniProt.org). Due to the loss of all domains known to interact with other DNA repair enzymes (PMID: 22753075), E313* is predicted to lead to a loss of Mlh1 protein function.",295,,,www.uniprot.org,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21190
"MLH1 E319K lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). E319K has not been characterized in the scientific literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21191
"MLH1 E34* results in a premature truncation of the Mlh1 protein at amino acid 34 of 756 (UniProt.org). Due to the loss of all known functional domains (PMID: 22753075), E34* is predicted to lead to a loss of Mlh1 protein function.",295,,,www.uniprot.org,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21192
MLH1 E37K lies within an ATP binding region in the ATPase domain of the Mlh21 protein (PMID: 22753075). E37K results in a loss of mismatch repair activity of the Mlh1 protein in an in vitro assay (PMID: 20020535).,5161,20020535,A cell-free assay for the functional analysis of variants of the mismatch repair protein MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/20020535,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21193
"MLH1 E703A lies within the C-terminal dimerization domain of the Mlh1 protein (PMID: 22753075). E703A has not been characterized and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21194
"MLH1 E754Q does not lie within any known functional domains of the Mlh1 protein (PMID: 22753075). E754Q has not been characterized in the scientific literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21195
"MLH1 G101S lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). G101S has been identified in sequencing studies (PMID: 24278394), but has not been biochemically characterized and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",8989,24278394,Integrative analysis of hereditary nonpolyposis colorectal cancer: the contribution of allele-specific expression and other assays to diagnostic algorithms.,http://www.ncbi.nlm.nih.gov/pubmed/24278394,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21196
MLH1 E578G lies within the C-terminal dimerization domain (PMID: 22753075). E578G results in a loss of mismatch repair activity of the Mlh1 protein in an in vitro assay (PMID: 20020535).,5161,20020535,A cell-free assay for the functional analysis of variants of the mismatch repair protein MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/20020535,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21197
"MLH1 G357A does not lie within any known functional domains of the Mlh1 protein (PMID: 22753075). G357A has been identified in sequencing studies (PMID: 22980975), but has not been biochemically characterized and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,285,,,http://www.ncbi.nlm.nih.gov/pubmed,1726,22980975,Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/22980975,21198
"MLH1 G532C lies within the C-terminal dimerization domain of the Mlh1 protein (PMID: 22753075). G532A has not been characterized in the scientific literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21199
MLH1 G67R lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). G67R results in a loss of mismatch repair activity of the Mlh1 protein in an in vitro assay (PMID: 20020535).,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,5161,20020535,A cell-free assay for the functional analysis of variants of the mismatch repair protein MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/20020535,21200
"MLH1 G67W lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). G67W has been identified in the scientific literature (PMID: 9927034, but has not been biochemically characterized and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,8990,9927034,Neurofibromatosis and early onset of cancers in hMLH1-deficient children.,http://www.ncbi.nlm.nih.gov/pubmed/9927034,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21201
"MLH1 H109D lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). H109D has not been characterized in the scientific literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21202
MLH1 H109P lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). H109P results in a loss of mismatch repair activity of the Mlh1 protein in an in vitro assay (PMID: 20020535).,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,5161,20020535,A cell-free assay for the functional analysis of variants of the mismatch repair protein MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/20020535,21203
"MLH1 H315Y lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). H315Y has not been characterized in the scientific literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,115,0,,http://www.ncbi.nlm.nih.gov/pubmed,21204
"MLH1 H543R lies within the C-terminal dimerization domain of the Mlh1 protein (PMID: 22753075). H543R has not been characterized in the scientific literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21205
"MLH1 I190T lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). I190T has not been characterized in the scientific literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21206
"MLH1 I262M lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). I262M has not been characterized in the scientific literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21207
"MLH1 I565M lies within the C-terminal dimerization domain of the Mlh1 protein (PMID: 22753075). I565M has not been characterized in the scientific literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21208
MLH1 I107R lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). I107R results in a loss of mismatch repair activity of the Mlh1 protein in an in vitro assay (PMID: 16083711).,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,5166,16083711,Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/16083711,21209
"MLH1 I630S lies within the C-terminal dimerization domain of the Mlh1 protein (PMID: 22753075). I630S has been identified in sequencing studies (PMID: 22895193), but has not been biochemically characterized and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21210
"MLH1 K118N lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). K118N has been identified in sequencing studies (PMID: 22980975), but has not been biochemically characterized and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,1726,22980975,Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/22980975,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21211
"MLH1 K241N lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). K241N has not been characterized in the scientific literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21212
"MLH1 F530Lfs*5 is a missense mutation (F530L) in conjunction with a likely truncation of the 756 aa Mlh1 protein at aa 530, followed by 5 nonsense amino acids (UniProt.org). Due to the loss of the C-terminal dimerization domain (PMID: 22753075), F530Lfs*5 is predicted to lead to a loss of Mlh1 protein function.",295,,,www.uniprot.org,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21213
"MLH1 K254N lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). K254N has not been characterized in the scientific literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21214
"MLH1 K443Q lies within the Exo1 interaction domain of the Mlh1 protein (PMID: 22753075). K443Q is predicted to be benign by in silico analyses (PMID: 20020535, PMID: 22753075) and has mismatch repair activity similar to wild-type Mlh1 (PMID: 16083711, PMID: 20020535) in in vitro assays.",5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,5161,20020535,A cell-free assay for the functional analysis of variants of the mismatch repair protein MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/20020535,5166,16083711,Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/16083711,21215
"MLH1 K618E lies within the C-terminal dimerization domain of the Mlh1 protein (PMID: 22753075). K618E has not been characterized in the scientific literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21216
"MLH1 K618A lies within the C-terminal dimerization domain of the Mlh1 protein (PMID: 22753075). The functional effect of K618A is conflicting, as K618A has mismatch repair activity similar to wild-type Mlh1 in in vitro assays (PMID: 16083711, PMID: 20020535) but has also been reported to have reduced binding to Pms2 (PMID: 10037723) and to cause reduced cell line viability (PMID: 16982745).",5166,16083711,Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/16083711,5167,10037723,The interaction of the human MutL homologues in hereditary nonpolyposis colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/10037723,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,5161,20020535,A cell-free assay for the functional analysis of variants of the mismatch repair protein MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/20020535,5168,16982745,A human cell-based assay to evaluate the effects of alterations in the MLH1 mismatch repair gene.,http://www.ncbi.nlm.nih.gov/pubmed/16982745,21218
"MLH1 L155P lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). L155P has been identified in sequencing studies (PMID: 24686850), but not been biochemically characterized and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,7069,24686850,Genomic and molecular characterization of esophageal squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24686850,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21219
"MLH1 K618T lies within the C-terminal dimerization domain of the Mlh1 protein (PMID: 22753075). The functional effect of K618T is conflicting, as K618T has been shown to have mismatch repair activity and Pms2 binding similar to wild-type Mlh1 (PMID: 16083711, 22753075), but has also been shown to have significantly reduced binding to Pms2 (PMID: 10037723).",5169,15256438,"Mismatch repair gene PMS2: disease-causing germline mutations are frequent in patients whose tumors stain negative for PMS2 protein, but paralogous genes obscure mutation detection and interpretation.",http://www.ncbi.nlm.nih.gov/pubmed/15256438,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,5166,16083711,Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/16083711,5167,10037723,The interaction of the human MutL homologues in hereditary nonpolyposis colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/10037723,21220
MLH1 A681T lies within the C-terminal dimerization domain of the Mlh1 protein (PMID: 22753075). A681T results in a loss of mismatch repair activity of the Mlh1 protein in an in vitro assay (PMID: 16083711).,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,5166,16083711,Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/16083711,21221
"MLH1 L507* results in a premature truncation of the Mlh1 protein at amino acid 507 of 756 (UniProt.org). Due to the loss of the C-terminal dimerization domain (PMID: 22753075), L507* is predicted to lead to a loss of Mlh1 protein function.",295,,,www.uniprot.org,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21222
MLH1 L155R lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). L155R results in a loss of mismatch repair activity of the Mlh1 protein in an in vitro assay (PMID: 16083711).,5166,16083711,Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/16083711,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21223
"MLH1 L550I lies within the C-terminal dimerization domain of the Mlh1 protein (PMID: 22753075). L550I has not been characterized in the scientific literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21224
"MLH1 L550P lies within the C-terminal dimerization domain of the Mlh1 protein (PMID: 22753075). The functional effect of L550P is conflicting, as L550P has been reported to have active mismatch repair activity (PMID: 16083711) and also have a loss of mismatch repair activity in in vitro assays (PMID: 20020535).",5161,20020535,A cell-free assay for the functional analysis of variants of the mismatch repair protein MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/20020535,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,5166,16083711,Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/16083711,21225
MLH1 L582F lies within the C-terminal dimerization domain of the Mlh1 protein (PMID: 22753075). L582F results in a loss of mismatch repair activity of the Mlh1 protein in an in vitro assay (PMID: 20020535).,5161,20020535,A cell-free assay for the functional analysis of variants of the mismatch repair protein MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/20020535,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21226
"MLH1 L588R lies within the C-terminal dimerization domain of the Mlh1 protein (PMID: 22753075). L588R has not been characterized in the scientific literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21227
"MLH1 L590I lies within the C-terminal dimerization domain of the Mlh1 protein (PMID: 22753075). L590I has not been characterized and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21228
"MLH1 L658I lies within the C-terminal dimerization domain of the Mlh1 protein (PMID: 22753075). L658I has not been characterized in the scientific literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21229
"MLH1 A29S lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). A29S does not alter the expression of Mlh1, has mismatch repair activity comparable to wild-type Mlh1, localizes with Pms2, and is predicted to be non-pathogenic (PMID: 16083711).",5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,5166,16083711,Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/16083711,21230
MLH1 C77R lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). C77R confers a loss of function to the Mlh1 protein as demonstrated by reduced mismatch repair activity in an in vitro assay and reduced localization with Pms2 (PMID: 16083711).,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,5166,16083711,Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/16083711,21231
MLH1 D63E lies within an ATP binding domain within the ATPase domain of the Mlh1 protein (PMID: 22753075). D63E confers a loss of function to the Mlh1 protein as demonstrated by reduced mismatch repair activity in an in vitro assay and reduced localization with Pms2 (PMID: 16083711).,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,5166,16083711,Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/16083711,21232
"MLH1 F80V lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). F80V confers a loss of function on Mlh1, indicated by reduced mismatch repair activity in an in vitro assay (PMID: 16083711).",5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,5166,16083711,Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/16083711,21233
MLH1 K84E lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). K84E confers a loss of function to the Mlh1 protein as demonstrated by reduced mismatch repair activity in an in vitro assay (PMID: 16083711).,5166,16083711,Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/16083711,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21234
"ASXL1 A1312S does not lie within any known functional domains of the Asxl1 protein (UniProt.org). A1312S has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21235
"ASXL1 A1312V does not lie within any known functional domains of the Asxl1 protein (UniProt.org). A1312V has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21236
"ASXL1 A158T does not lie within any known functional domains of the Asxl1 protein (UniProt.org). A158T has not been characterized and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21237
"ASXL1 A158V does not lie within any known functional domains of the Asxl1 protein (UniProt.org). A158V has not been characterized and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21238
"ASXL1 A498S lies within the NCOA1 interacting region of the Asxl1 protein (UniProt.org). A498S has not been characterized and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21239
"ASXL1 A54S lies within the ASXN domain of the Asxl1 protein (PMID: 19609284). A54S has not been characterized and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21240
"ASXL1 A627V lies within the NCOA1 interacting region of the Asxl1 protein (UniProt.org). A627V has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21241
"ASXL1 D1004N does not lie within any known functional domains of the Asxl1 protein (UniProt.org). D1004N has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21242
"ASXL1 D475N lies within the NCOA1 interacting region of the Asxl1 protein (UniProt.org). D475N has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21243
"ASXL1 D521N lies within the NCOA1 interacting region of the Asxl1 protein (UniProt.org). D521N has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21244
"ASXL1 D544N lies within the NCOA1 interacting region of the Asxl1 protein (UniProt.org). D544N has not been characterized and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21245
"ASXL1 D756N does not lie within any known functional domains of the Asxl1 protein (UniProt.org). D756N has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21246
"ASXL1 E1228* results in a premature truncation of the Asxl1 protein at amino acid 1228 of 1541 (UniProt.org). E1228* has not been characterized and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21247
"ASXL1 E537D lies within the NCOA1 interacting region of the Asxl1 protein (UniProt.org). E537D has not been characterized and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21248
"ASXL1 E727K does not lie within any known functional domains of the Asxl1 protein (UniProt.org). E727K has not been characterized and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21249
"ASXL1 E865K does not lie within any known functional domains of the Asxl1 protein (UniProt.org). E865K has not been characterized and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21250
"ASXL1 E997* results in a premature truncation of the Asxl1 protein at amino acid 997 of 1541 (UniProt.org). E997* has not been characterized and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21251
"ASXL1 G1299D does not lie within any known functional domains of the Asxl1 protein (UniProt.org). G1299D has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21252
"ASXL1 G42* results in a premature truncation of the Asxl1 protein at amino acid 42 of 1541 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), G42* is predicted to lead to a loss of Asxl1 protein function.",295,,,www.uniprot.org,21253
"ASXL1 G645Vfs*58 is a missense mutation (G645V) in conjunction with a likely truncation of the 1541 aa Asxl1 protein at aa 645, followed by 58 nonsense amino acids (UniProt.org). G645Vfs*58 has not been characterized, however, due to the effects of other ASXL1 truncation mutations, G645Vfs*58 is predicted to result in a loss of Asxl1 function (PMID: 24216483, PMID: 22897849).",295,,,www.uniprot.org,3732,22897849,ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.,http://www.ncbi.nlm.nih.gov/pubmed/22897849,3733,24216483,Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24216483,21254
"ASXL1 G660D does not lie within any known functional domains of the Asxl1 protein (UniProt.org). G660D has not been characterized and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21255
"ASXL1 G679* results in a premature truncation of the Asxl1 protein at amino acid 679 of 1541 (UniProt.org). G679* has not been characterized and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21256
"ASXL1 G812C does not lie within any known functional domains of the Asxl1 protein (UniProt.org). G812C has not been characterized and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21257
"ASXL1 G967del results in the deletion of one amino acid of the Asxl1 protein at amino acid 967 (UniProt.org). G967del has not been characterized and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21258
"ASXL1 I579S lies within the NCOA1 interacting region of the Asxl1 protein (UniProt.org). I579S has not been characterized and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21259
"ASXL1 K162E does not lie within any known functional domains of the Asxl1 protein (UniProt.org). K162E has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21260
"ASXL1 K163T does not lie within any known functional domains of the Asxl1 protein (UniProt.org). K163T has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21261
"ASXL1 L1325F does not lie within any known functional domains of the Asxl1 protein (UniProt.org). L1325F has not been characterized and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21262
"ASXL1 L145F does not lie within any known functional domains of the Asxl1 protein (UniProt.org). L145F has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21263
"ASXL1 L1467I does not lie within any known functional domains of the Asxl1 protein (UniProt.org). L1467I has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21264
"ASXL1 L56I lies within the ASXN domain of the Asxl1 protein (PMID: 19609284). L56I has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5172,19609284,Mutations of ASXL1 gene in myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/19609284,21265
"ASXL1 P1117L does not lie within any known functional domains of the Asxl1 protein (UniProt.org). P1117L has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21266
"ASXL1 P1360S does not lie within any known functional domains of the Asxl1 protein (UniProt.org). P1360S has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21267
"ASXL1 P1392L does not lie within any known functional domains of the Asxl1 protein (UniProt.org). P1392L has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21268
"ASXL1 P494S lies within the NCOA1 interacting region of the Asxl1 protein (UniProt.org). P494S has not been characterized and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21269
"ASXL1 P567L lies within the NCOA1 interacting region of the Asxl1 protein (UniProt.org). P567L has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21270
"ASXL1 Q1491* results in a premature truncation of the Asxl1 protein at amino acid 1491 of 1541 (UniProt.org). Q1491* has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21271
"ASXL1 Q512* results in a premature truncation of the Asxl1 protein at amino acid 512 of 1541 (UniProt.org). Q512* has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21272
"ASXL1 Q588R lies within the NCOA1 interacting region of the Asxl1 protein (UniProt.org). Q588R has not been characterized and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21273
"ASXL1 Q733* results in a premature truncation of the Asxl1 protein at amino acid 733 of 1541 (UniProt.org). Q733* has not been characterized and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21274
"ASXL1 R1090K does not lie within any known functional domains of the Asxl1 protein (UniProt.org). R1090K has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21275
"ASXL1 R1090T does not lie within any known functional domains of the Asxl1 protein (UniProt.org). R1090T has not been characterized and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21276
"ASXL1 R1247C does not lie within any known functional domains of the Asxl1 protein (UniProt.org). R1247C has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21277
"ASXL1 R1273H does not lie within any known functional domains of the Asxl1 protein (UniProt.org). R1273H has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21278
"ASXL1 R1415* results in a premature truncation of the Asxl1 protein at amino acid 1415 of 1541 (UniProt.org). R1415* has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21279
"ASXL1 R143* results in a premature truncation of the Asxl1 protein at amino acid 143 of 1541 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), R143* is predicted to lead to a loss of Asxl1 protein function.",295,,,www.uniprot.org,21280
"ASXL1 R244H lies within the ASXM domain of the Asxl1 protein (PMID: 19609284). R244H has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21281
"ASXL1 R265H lies within the ASXNM domain of the Asxl1 protein (PMID: 19609284). R265H has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",5172,19609284,Mutations of ASXL1 gene in myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/19609284,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21282
"ASXL1 R302C lies within the ASXM domain of the Asxl1 protein (PMID: 19609284). R302C has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",5172,19609284,Mutations of ASXL1 gene in myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/19609284,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21283
"ASXL1 R419K lies within the NCOA1 interacting region of the Asxl1 protein (UniProt.org). R419K has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016). ",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21284
"ASXL1 R545H lies within the NCOA1 interacting region of the Asxl1 protein (UniProt.org). R545H has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21285
"ASXL1 R545P lies within the NCOA1 interacting region of the Asxl1 protein (UniProt.org). R545P has not been characterized and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21286
"ASXL1 R549H lies within the NCOA1 interacting region of the Asxl1 protein (UniProt.org). R549H has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21287
"ASXL1 R965* results in a premature truncation of the Asxl1 protein at amino acid 965 of 1541 (UniProt.org). R965* has not been characterized and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21288
"ASXL1 S1209N does not lie within any known functional domains of the Asxl1 protein (UniProt.org). S1209N has not been characterized and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21289
"ASXL1 S120N does not lie within any known functional domains of the Asxl1 protein (UniProt.org). S120N has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21290
"ASXL1 S203F does not lie within any known functional domains of the Asxl1 protein (UniProt.org). S203F has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21291
"ASXL1 S441F lies within the NCOA1 interacting region of the Asxl1 protein (UniProt.org). S441F has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21292
"ASXL1 S577* results in a premature truncation of the Asxl1 protein at amino acid 577 of 1541 (UniProt.org). S577* has not been characterized and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21293
"ASXL1 S791F does not lie within any known functional domains of the Asxl1 protein (UniProt.org). S791F has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21294
"ASXL1 V1246D does not lie within any known functional domains of the Asxl1 protein (UniProt.org). V1246D has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21295
"ASXL1 W796C does not lie within any known functional domains of the Asxl1 protein (UniProt.org). W796C has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21296
"ASXL1 Y591* results in a premature truncation of the Asxl1 protein at amino acid 591 of 1541 (UniProt.org). Y591* has not been characterized and therefore, its effect on Asxl1 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21297
"ATRX C1590Y lies within the Helicase ATP-binding domain of the Atrx protein (UniProt.org). C1590Y not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21298
"ATRX C220W lies within the ADD domain of the Atrx protein (UniProt.org). C220W has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21299
"ATRX D1222N lies within the DAXX-interacting region of the Atrx protein (UniProt.org). D1222N has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21300
"ATRX D1247H lies within the DAXX-interacting region of the Atrx protein (UniProt.org). D1247H has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21301
"ATRX D1263E lies within the DAXX-interacting region of the Atrx protein (UniProt.org). D1263E has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21302
"ATRX D1383A does not lie within any known functional domains of the Atrx protein (UniProt.org). D1383A has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21303
"ATRX D1487N does not lie within any known functional domains of the Atrx protein (UniProt.org). D1487N has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21304
"ATRX D1719G lies within the Helicase ATP-binding domain of the Atrx protein (UniProt.org). D1719G has been identified in sequencing studies (PMID: 24148618), but has not been biochemically characterized and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9406,24148618,Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.,http://www.ncbi.nlm.nih.gov/pubmed/24148618,21305
"ATRX D2004Y does not lie within any known functional domains of the Atrx protein (UniProt.org). D2004Y has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21306
"ATRX D2136N lies within the helicase C-terminal domain of the Atrx protein (UniProt.org). D2136N has been identified in sequencing studies (PMID: 12673795), but has not been biochemically characterized and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",9407,12673795,Mutational analysis of the ATRX gene by DGGE: a powerful diagnostic approach for the ATRX syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12673795,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21307
"ATRX D547N does not lie within any known functional domains of the Atrx protein (UniProt.org). D547N has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21308
"ATRX E1365A does not lie within any known functional domains of the Atrx protein (UniProt.org). E1365A has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21309
"ATRX E1446* results in a premature truncation of the Atrx protein at amino acid 1446 of 2492 (UniProt.org). Due to the loss of the Helicase domains (UniProt.org), E1446* is predicted to lead to a loss of Atrx protein function.",295,,,www.uniprot.org,21310
"ATRX E1547* results in a premature truncation of the Atrx protein at amino acid 1547 of 2492 (UniProt.org). Due to the loss of the Helicase domains (UniProt.org), E1547* is predicted to lead to a loss of trx protein function.",295,,,www.uniprot.org,21311
"ATRX E1547G does not lie within any known functional domains of the Atrx protein (UniProt.org). E1547G has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21312
"ATRX E1757Q does not lie within any known functional domains of the Atrx protein (UniProt.org). E1757Q has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21313
"ATRX E2172A lies within the Helicase C-terminal domain of the Atrx protein (UniProt.org). E2172A has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21314
"ATRX E2172G lies within the Helicase C-terminal domain of the Atrx protein (UniProt.org). E2172G has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21315
"ATRX E853D does not lie within any known functional domains of the Atrx protein (UniProt.org). E853D has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21316
"ATRX F1384L does not lie within any known functional domains of the Atrx protein (UniProt.org). F1384L has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21317
"ATRX F1570C does not lie within any known functional domains of the Atrx protein (UniProt.org). F1570C has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21318
"ATRX F2102C lies within the Helicase C-terminal domain of the Atrx protein (UniProt.org). F2102C has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21319
"ATRX F2113Lfs*10 is a missense mutation (F2113L) in conjunction with a likely truncation of the 2492 aa Atrx protein at aa 2113, followed by 10 nonsense amino acids (UniProt.org). F2113Lfs*10 has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21320
"ATRX F2113Sfs*9 is a missense mutation (F2113S) in conjunction with a likely truncation of the 2492 aa Atrx protein at aa 2113, followed by 9 nonsense amino acids (UniProt.org). F2113Sfs*9 has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21321
"ATRX G1567D does not lie within any known functional domains of the Atrx protein (UniProt.org). G1567D has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21322
"ATRX G1589E lies within the Helicase ATP-binding domain of the Atrx protein (UniProt.org). G1589E has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21323
"ATRX G2120E lies within the Helicase C-terminal domain of the Atrx protein (UniProt.org). G2120E has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21324
"ATRX G2169E lies within the Helicase C-terminal domain of the Atrx protein (UniProt.org). G2169E has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21325
"ATRX H406D does not lie within any known functional domains of the Atrx protein (UniProt.org). H406D has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21326
"ATRX I1049* results in a premature truncation of the Atrx protein at amino acid 1049 of 2492 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), I1049* is predicted to lead to a loss of Atrx protein function.",295,,,www.uniprot.org,21327
"ATRX I1049Kfs*69 is a missense mutation (I1049K) in conjunction with a likely truncation of the 2492 aa Atrx protein at aa 1049, followed by 69 nonsense amino acids (UniProt.org). Due to the loss of most known functional domains (UniProt.org), I1049Kfs*69 is predicted to lead to a loss of Atrx protein function.",295,,,www.uniprot.org,21328
"ATRX I1049Nfs*4 is a missense mutation (I1049N) in conjunction with a likely truncation of the 2492 aa Atrx protein at aa 1049, followed by 4 nonsense amino acids (UniProt.org). Due to the loss of most known functional domains (UniProt.org), I1049Nfs*4 is predicted to lead to a loss of Atrx protein function.",295,,,www.uniprot.org,21329
"ATRX I1784S does not lie within any known functional domains of the Atrx protein (UniProt.org). I1784S has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21330
"ATRX I2026T lies within the Helicase C-terminal domain of the Atrx protein (UniProt.org). I2026T has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21331
"ATRX I360Rfs*6 is a missense mutation (I360R) in conjunction with a likely truncation of the 2492 aa Atrx protein at aa 360, followed by 6 nonsense amino acids (UniProt.org). Due to the loss of most known functional domains (UniProt.org), I360Rfs*6 is predicted to lead to a loss of Atrx protein function.",295,,,www.uniprot.org,21332
"ATRX I402N does not lie within any known functional domains of the Atrx protein (UniProt.org). I402N has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21333
"ATRX I528M does not lie within any known functional domains of the Atrx protein (UniProt.org). I528M has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21334
"ATRX K1045* results in a premature truncation of the Atrx protein at amino acid 1045 of 2492 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), K1045* is predicted to lead to a loss of Atrx protein function. ",295,,,www.uniprot.org,21335
"ATRX K1420T does not lie within any known functional domains of the Atrx protein (UniProt.org). K1420T has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21336
"ATRX K1600N lies within the Helicase ATP-binding domain of the Atrx protein (UniProt.org). K1600N has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21337
"ATRX K2019E lies within the MECP2-interacting region of the Atrx protein (UniProt.org). K2019E has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21338
"ATRX K2182R lies within the Helicase C-terminal domain of the Atrx protein (UniProt.org). K2182R has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21339
"ATRX K2272R lies within the MECP2-interacting region of the Atrx protein (UniProt.org). K2272R has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21340
"ATRX K46T does not lie within any known functional domains of the Atrx protein (UniProt.org). K46T has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21341
"ATRX L1592F lies within the Helicase ATP-binding domain of the Atrx protein (UniProt.org). L1592F has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21342
"ATRX L1612P lies within the Helicase ATP-binding domain of the Atrx protein (UniProt.org). L1612P has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21343
"ATRX L1612V lies within the Helicase ATP-binding domain of the Atrx protein (UniProt.org). L1612V has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21344
"ATRX L1879V does not lie within any known functional domains of the Atrx protein (UniProt.org). L1879V has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21345
"ATRX L192S lies within the ADD domain of the Atrx protein (UniProt.org). L192S has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21346
"ATRX L2027P lies within the Helicase C-terminal domain of the Atrx protein (UniProt.org). L2027P has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21347
"ATRX L276V lies within the ADD domain of the Atrx protein (UniProt.org). L276V has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21348
"ATRX L346P does not lie within any known functional domains of the Atrx protein (UniProt.org). L346P has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21349
"ATRX L595F does not lie within any known functional domains of the Atrx protein (UniProt.org). L595F has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21350
"ATRX M1596I lies within the Helicase ATP-binding domain of the Atrx protein (UniProt.org). M1596I has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21351
"ATRX N1753D lies within the Helicase ATP-binding domain of the Atrx protein (UniProt.org). N1753D has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21352
"ATRX N1763I lies within the Helicase ATP-binding domain of the Atrx protein (UniProt.org). N1763I has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21353
"ATRX N1763K lies within the Helicase ATP-binding domain of the Atrx protein (UniProt.org). N1763K has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21354
"ATRX N2125S lies within the Helicase C-terminal domain of the Atrx protein (UniProt.org). N2125S has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21355
"ATRX N247S lies within the ADD domain of the Atrx protein (UniProt.org). N247S has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21356
"ATRX P1228S lies within the DAXX-interacting region of the Atrx protein (UniProt.org). P1228S has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21357
"ATRX P1750R lies within the Helicase ATP-binding domain of the Atrx protein (UniProt.org). P1750R has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21358
"ATRX P1829L does not lie within any known functional domains of the Atrx protein (UniProt.org). P1829L has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21359
"ATRX P1886L does not lie within any known functional domains of the Atrx protein (UniProt.org). P1886L has been identified in sequencing studies (PMID: 25608029), but has not been biochemically characterized and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9408,25608029,Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas.,http://www.ncbi.nlm.nih.gov/pubmed/25608029,21360
"ATRX P449L does not lie within any known functional domains of the Atrx protein (UniProt.org). P449L has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21361
"ATRX P83L does not lie within any known functional domains of the Atrx protein (UniProt.org). P83L has been identified in sequencing studies (PMID: 22842228), but has not been biochemically characterized and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",7109,22842228,Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22842228,115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21362
"ATRX Q1603R lies within the Helicase ATP-binding domain of the Atrx protein (UniProt.org). Q1603R has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21363
"ATRX Q1843H does not lie within any known functional domains of the Atrx protein (UniProt.org). Q1843H has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21364
"ATRX Q539R does not lie within any known functional domains of the Atrx protein (UniProt.org). Q539R has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21365
"ATRX R1302Efs*44 is a missense mutation (R1302E) in conjunction with a likely truncation of the 2492 aa Atrx protein at aa 1302, followed by 44 nonsense amino acids (UniProt.org). Due to the loss of Helicase domains (UniProt.org), R1302Efs*44 is predicted to lead to a loss of Atrx protein function.",295,,,www.uniprot.org,21366
"ATRX R1302Kfs*7 is a missense mutation (R1302K) in conjunction with a likely truncation of the 2492 aa Atrx protein at aa 1302, followed by 7 nonsense amino acids (UniProt.org). Due to the loss of Helicase domains (UniProt.org), R1302Kfs*7 is predicted to lead to a loss of Atrx protein function.",295,,,www.uniprot.org,21367
"ATRX ATRX R1302Lfs*43 is a missense mutation (R1302L) in conjunction with a likely truncation of the 2492 aa Atrx protein at aa 1302, followed by 43 nonsense amino acids (UniProt.org). Due to the loss of Helicase domains (UniProt.org), R1302Lfs*43 is predicted to lead to a loss of Atrx protein function. ",295,,,www.uniprot.org,21368
"ATRX R1302Nfs*6 is a missense mutation (R1302N) in conjunction with a likely truncation of the 2492 aa Atrx protein at aa 1302, followed by 6 nonsense amino acids (UniProt.org). Due to the loss of Helicase domains (UniProt.org), R1302Nfs*6 is predicted to lead to a loss of Atrx protein function. ",295,,,www.uniprot.org,21369
"MLH1 N187Y lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). N187Y has not been characterized and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21370
MLH1 N38K lies within an ATP binding domain within the ATPase domain of the Mlh1 protein (PMID: 22753075). N38K confers a loss of function to the Mlh1 protein as demonstrated by a loss of mismatch repair activity in an in vitro assay (PMID: 20020535).,5161,20020535,A cell-free assay for the functional analysis of variants of the mismatch repair protein MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/20020535,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21371
MLH1 N38H lies within an ATP binding domain within the ATPase domain of the Mlh1 protein (PMID: 22753075). N38H confers a loss of function to the Mlh1 protein as demonstrated by a loss of mismatch repair activity in an in vitro assay (PMID: 20020535).,5161,20020535,A cell-free assay for the functional analysis of variants of the mismatch repair protein MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/20020535,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21372
MLH1 P28L lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). P28L is predicted to lead to loss of Mlh1 function in in silico analyses and results in loss of mismatch repair activity in an in vitro assay (PMID: 22753075),5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21373
MLH1 P403S does not lie within any known functional domains of the Mlh1 protein (PMID: 22753075). P403S is predicted to be benign in multiple in silico analyses (PMID: 22753075) and has mismatch repair activity comparable to Mlh1 wild-type in an in vitro assay (PMID: 20020535).,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,5161,20020535,A cell-free assay for the functional analysis of variants of the mismatch repair protein MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/20020535,21374
"MLH1 P640S lies within the C-terminal dimerization domain of the Mlh1 protein (PMID: 22753075). P640S is predicted to be pathogenic based on in silico analyses (PMID: 25871441), but has not been biochemically characterized and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,285,,,http://www.ncbi.nlm.nih.gov/pubmed,8992,25871441,Evaluation of CADD Scores in Curated Mismatch Repair Gene Variants Yields a Model for Clinical Validation and Prioritization.,http://www.ncbi.nlm.nih.gov/pubmed/25871441,21375
"MLH1 P640L lies within the C-terminal dimerization domain of the Mlh1 protein (PMID: 22753075). P640L is predicted to be pathogenic based on in silico analyses (PMID: 25871441), but has not been biochemically characterized and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,285,,,http://www.ncbi.nlm.nih.gov/pubmed,8992,25871441,Evaluation of CADD Scores in Curated Mismatch Repair Gene Variants Yields a Model for Clinical Validation and Prioritization.,http://www.ncbi.nlm.nih.gov/pubmed/25871441,21376
"MLH1 P648L lies within the C-terminal dimerization domain of the Mlh1 protein (PMID: 22753075). P648L shows decreased binding to Exo1 and PMS2 in some assays (PMID: 22753075), but normal interaction with PMS2 in others (PMID: 16083711), and has functional mismatch repair activity (PMID: 20020535, PMID: 16083711) and thus, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,5166,16083711,Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/16083711,5161,20020535,A cell-free assay for the functional analysis of variants of the mismatch repair protein MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/20020535,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21377
"MLH1 P648S lies within the C-terminal dimerization domain of the Mlh1 protein (PMID: 22753075). P648S has demonstrated mismatch repair activity and PMS2 binding similar to wild-type Mlh1 in in vitro assays (PMID: 20020535, PMID: 16083711, PMID: 15139004), but has also shown decreased PMS2 binding (PMID: 16724012), and thus, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",5166,16083711,Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/16083711,6178,16724012,"Assessing the pathogenicity of MLH1 missense mutations in patients with suspected hereditary nonpolyposis colorectal cancer: correlation with clinical, genetic and functional features.",http://www.ncbi.nlm.nih.gov/pubmed/16724012,8993,15139004,"HNPCC mutation MLH1 P648S makes the functional protein unstable, and homozygosity predisposes to mild neurofibromatosis type 1.",http://www.ncbi.nlm.nih.gov/pubmed/15139004,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,5161,20020535,A cell-free assay for the functional analysis of variants of the mismatch repair protein MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/20020535,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21378
MLH1 P654L lies within the C-terminal dimerization domain of the Mlh1 protein (PMID: 22753075). P654L confers a loss of function to the Mlh1 protein as indicated by its prediction to be pathogenic based on an in silico analysis (PMID: 22753075) and a loss of mismatch repair activity in an in vitro assay (PMID: 20020535).,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,5161,20020535,A cell-free assay for the functional analysis of variants of the mismatch repair protein MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/20020535,21379
"MLH1 P709Q lies within the C-terminal dimerization domain of the Mlh1 protein (PMID: 22753075). P709Q has not been characterized in the scientific literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21380
"MLH1 Q48E lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). Q48E has not been characterized in the scientific literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21381
MLH1 Q60P lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). Q60P results in partial loss of DNA mismatch repair activity in yeast (PMID: 15475387).,6513,15475387,Human MutL homolog (MLH1) function in DNA mismatch repair: a prospective screen for missense mutations in the ATPase domain.,http://www.ncbi.nlm.nih.gov/pubmed/15475387,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21382
"MLH1 R100* results in a premature truncation of the Mlh1 protein at amino acid 100 of 756 within the ATPase domain of the Mlh1 protein (UniProt.org, PMID: 22753075). Due to the loss of the majority of the ATPase domain and loss of the C-terminal dimerization domain (PMID: 22753075), R100* is predicted to lead to a loss of Mlh1 protein function.",295,,,www.uniprot.org,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21383
"MLH1 R217C lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). R217C is predicted to be non-pathogenic based on in silico analyses (PMID: 17510385, PMID: 17192056) and was found to have mismatch repair activity similar to wild-type Mlh1 in a cell based assay (PMID: 11781295).",5174,17510385,Functional analysis of human MLH1 variants using yeast and in vitro mismatch repair assays.,http://www.ncbi.nlm.nih.gov/pubmed/17510385,5175,17192056,"The use of microsatellite instability, immunohistochemistry and other variables in determining the clinical significance of MLH1 and MSH2 unclassified variants in Lynch syndrome.",http://www.ncbi.nlm.nih.gov/pubmed/17192056,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,409,11781295,Functional analysis of hMLH1 variants and HNPCC-related mutations using a human expression system.,http://www.ncbi.nlm.nih.gov/pubmed/11781295,21384
"MLH1 R226* results in a premature truncation of the Mlh1 protein at amino acid 226 of 756 (UniProt.org). Due to the loss of the C-terminal dimerization domain (PMID: 22753075), R226* is predicted to lead to a loss of Mlh1 protein function.",295,,,www.uniprot.org,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21386
MLH1 R265S lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). R265S confers a loss of function to the Mlh1 protein as demonstrated by a loss of mismatch repair activity in an in vitro assay (PMID: 20020535).,5161,20020535,A cell-free assay for the functional analysis of variants of the mismatch repair protein MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/20020535,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21387
MLH1 R265C lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). R265C confers a loss of function to the Mlh1 protein as indicated by its prediction to be pathogenic based on in an in silico analysis (PMID: 22753075) and a loss of mismatch repair activity in an in vitro assay (PMID: 20020535).,5161,20020535,A cell-free assay for the functional analysis of variants of the mismatch repair protein MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/20020535,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21388
"MLH1 R325W lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). R325W has not been characterized in the scientific literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21389
"MLH1 R385C does not lie within any known functional domains of the Mlh1 protein (PMID: 22753075). R385C has been identified in the scientific literature (PMID: 15222003, PMID: 25115387), but has not been biochemically characterized and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",7875,25115387,Targeted ultra-deep sequencing reveals recurrent and mutually exclusive mutations of cancer genes in blastic plasmacytoid dendritic cell neoplasm.,http://www.ncbi.nlm.nih.gov/pubmed/25115387,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,285,,,http://www.ncbi.nlm.nih.gov/pubmed,8996,15222003,"Association of colonic and endometrial carcinomas in Portuguese families with hereditary nonpolyposis colorectal carcinoma significantly increases the probability of detecting a pathogenic mutation in mismatch repair genes, primarily the MSH2 gene.",http://www.ncbi.nlm.nih.gov/pubmed/15222003,21390
"MLH1 R487* results in a premature truncation of the Mlh1 protein at amino acid 487 of 756 (UniProt.org). Due to the loss of the C-terminal dimerization domain (PMID: 22753075), R487* is predicted to lead to a loss of Mlh1 protein function.",5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,295,,,www.uniprot.org,21391
"MLH1 R487L lies within the EXO1-interacting region of the Mlh1 protein (PMID: 22753075). R487L has not been characterized in the scientific literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21392
"ATRX R1371T does not lie within any known functional domains of the Atrx protein (UniProt.org). R1371T has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21394
"ATRX R1417L does not lie within any known functional domains of the Atrx protein (UniProt.org). R1417L has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21395
"ATRX R1426* results in a premature truncation of the Atrx protein at amino acid 1426 of 2492 (UniProt.org). Due to the loss of the helicase domains (UniProt.org), R1426* is predicted to lead to a loss of Atrx protein function.",295,,,www.uniprot.org,21396
"ATRX R1427H does not lie within any known functional domains of the Atrx protein (UniProt.org). R1427H has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21397
"ATRX R1742G lies within the Helicase ATP-binding domain of the Atrx protein (UniProt.org). R1742G has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21398
"ATRX R1742S lies within the Helicase ATP-binding domain of the Atrx protein (UniProt.org). R1742S has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21399
"ATRX R1803C does not lie within any known functional domains of the Atrx protein (UniProt.org). R1803C has not been characterized and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21400
"ATRX R2079* results in a premature truncation of the Atrx protein at amino acid 2079 of 2492 (UniProt.org). R2079* has not been characterized and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21401
"ATRX R2085P lies within the Helicase C-terminal domain of the Atrx protein (UniProt.org). R2085P has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21402
"ATRX R2109I lies within the Helicase C-terminal domain of the Atrx protein (UniProt.org). R2109I has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21403
"ATRX R2111* results in a premature truncation of the Atrx protein at amino acid 2111 of 2492 (UniProt.org). R2111* has been identified in sequencing studies (PMID: 24705251), but has not been biochemically characterized and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7252,24705251,The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma.,http://www.ncbi.nlm.nih.gov/pubmed/24705251,21404
"ATRX R2153C lies within the Helicase C-terminal domain of the Atrx protein (UniProt.org). R2153C has been identified in sequencing studies (PMID: 22869205), but has not been biochemically characterized and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",9411,22869205,"Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.",http://www.ncbi.nlm.nih.gov/pubmed/22869205,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21405
"ATRX R2188Q lies within the Helicase C-terminal domain of the Atrx protein (UniProt.org). R2188Q has been identified in sequencing studies (PMID: 22416102), but has not been biochemically characterized and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9405,22416102,Association of age at diagnosis and genetic mutations in patients with neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22416102,21406
"ATRX R2197C lies within the Helicase C-terminal domain of the Atrx protein (UniProt.org). R2197C has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21407
"ATRX R221K lies within the ADD domain of the Atrx protein (UniProt.org). R221K has been identified in sequencing studies (PMID: 22886134), but has not been biochemically characterized and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",9413,22886134,Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/22886134,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21408
"ATRX R2271Kfs*14 is a missense mutation (R2271K) in conjunction with a likely truncation of the 2492 aa Atrx protein at aa 2271, followed by 14 nonsense amino acids (UniProt.org). R2271Kfs*14 has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21409
"ATRX R246C lies within the ADD domain of the Atrx protein (UniProt.org). R246C has been identified in the scientific literature (PMID: 16955409), but has not been biochemically characterized and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9414,16955409,ATRX syndrome in a girl with a heterozygous mutation in the ATRX Zn finger domain and a totally skewed X-inactivation pattern.,http://www.ncbi.nlm.nih.gov/pubmed/16955409,21410
"ATRX R246H lies within the ADD domain of the Atrx protein (UniProt.org). R246H has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21411
"ATRX R418* results in a premature truncation of the Atrx protein at amino acid 418 of 2492 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), R418* is predicted to lead to a loss of Atrx protein function.",295,,,www.uniprot.org,21412
"ATRX R444Q does not lie within any known functional domains of the Atrx protein (UniProt.org). R444Q has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21413
"ATRX R781* results in a premature truncation of the Atrx protein at amino acid 781 of 2492 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), R781* is predicted to lead to a loss of Atrx protein function.",295,,,www.uniprot.org,21414
"ATRX R78Q does not lie within any known functional domains of the Atrx protein (UniProt.org). R78Q has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21415
"ATRX R808* results in a premature truncation of the Atrx protein at amino acid 808 of 2492 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), R808* is predicted to lead to a loss of Atrx protein function.",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21416
"ATRX R81M does not lie within any known functional domains of the Atrx protein (UniProt.org). R81M has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21417
"ATRX R907* results in a premature truncation of the Atrx protein at amino acid 907 of 2492 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), R907* is predicted to lead to a loss of Atrx protein function.",295,,,www.uniprot.org,21418
"ATRX R907Dfs*63 is a missense mutation (R907D) in conjunction with a likely truncation of the 2492 aa Atrx protein at aa 907, followed by 63 nonsense amino acids (UniProt.org). Due to the loss of most known functional domains (UniProt.org), R907Dfs*63 is predicted to lead to a loss of Atrx protein function.",295,,,www.uniprot.org,21419
"ATRX S1046I does not lie within any known functional domains of the Atrx protein (UniProt.org). S1046I has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21420
"ATRX S1792Y does not lie within any known functional domains of the Atrx protein (UniProt.org). S1792Y has been identified in sequencing studies (PMID: 26692951), but has not been biochemically characterized and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21421
"ATRX S2138F lies within the helicase C-terminal domain of the Atrx protein (UniProt.org). S2138F has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21422
"ATRX S342F does not lie within any known functional domains of the Atrx protein (UniProt.org). S342F has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21423
"ATRX S576L does not lie within any known functional domains of the Atrx protein (UniProt.org). S576L has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21424
"ATRX T899M does not lie within any known functional domains of the Atrx protein (UniProt.org). T899M has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21425
"ATRX V128A does not lie within any known functional domains of the Atrx protein (UniProt.org). V128A has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21426
"ATRX V15G does not lie within any known functional domains of the Atrx protein (UniProt.org). V15G has been identified in sequencing studies (PMID: 22037554), but has not been biochemically characterized and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,6997,22037554,Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22037554,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21427
"ATRX V277A lies within the ADD domain of the Atrx protein (UniProt.org). V277A has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21428
"ATRX W263R lies within the ADD domain of the Atrx protein (UniProt.org). W263R has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21429
"ATRX Y266N lies within the ADD domain of the Atrx protein (UniProt.org). Y266N has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21430
"ATRX Y89F does not lie within any known functional domains of the Atrx protein (UniProt.org). Y89F has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21431
"MLH1 R659* results in a premature truncation of the Mlh1 protein at amino acid 659 of 756 (UniProt.org). R659* has been identified in the scientific literature (PMID: 20167975),  but has not been biochemically characterized and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8997,20167975,R659X mutation in the MLH1 gene in hereditary non-polyposis colorectal cancer(HNPCC) in an Indian extended family.,http://www.ncbi.nlm.nih.gov/pubmed/20167975,21433
MLH1 R659P lies within the C-terminal dimerization domain of the Mlh1 protein (PMID: 22753075). R659P is predicted to be pathogenic based on an in silico analysis of Mlh1 variants (PMID: 22753075) and results in a loss of mismatch repair activity in an in vitro assay (PMID: 20020535).,5161,20020535,A cell-free assay for the functional analysis of variants of the mismatch repair protein MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/20020535,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21434
"MLH1 R725C lies within the C-terminal dimerization domain of the Mlh1 protein (PMID: 22753075). R725C demonstrates binding to PMS2 similar to wild-type Mlh1 in yeast assays (PMID: 22252508), but has not been fully biochemically characterized and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,8998,22252508,Three-dimensional reconstruction of protein networks provides insight into human genetic disease.,http://www.ncbi.nlm.nih.gov/pubmed/22252508,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21435
"MLH1 R725H lies within the C-terminal dimerization domain of the Mlh1 protein (PMID: 22753075). R725H has been identified in the scientific literature (PMID: 25142776), but has not been biochemically characterized and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,8999,25142776,Comprehensive screening for mutations associated with colorectal cancer in unselected cases reveals penetrant and nonpenetrant mutations.,http://www.ncbi.nlm.nih.gov/pubmed/25142776,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21436
"MLH1 R9Q lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). R9Q has not been characterized and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21437
MLH1 R659Q lies within the C-terminal dimerization domain of the Mlh1 protein (PMID: 22753075). R659Q is predicted to be non-pathogenic based on in silico analyses of the Mlh1 protein and has no effect on mismatch repair activity in vitro (PMID: 22753075). ,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21438
"MLH1 R522Gfs*13 is a missense mutation (R522G) in conjunction with a likely truncation of the 756 aa Mlh1 protein at aa 522, followed by 13 nonsense amino acids (UniProt.org). Due to the loss of the C-terminal dimerization domain (PMID: 22753075), F522Gfs*13 is predicted to lead to a loss of Mlh1 protein function.",5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,295,,,www.uniprot.org,21439
"MLH1 S252* results in a premature truncation of the Mlh1 protein at amino acid 252 of 756 (UniProt.org). Due to the loss of the C-terminal dimerization domain (PMID: 22753075), S252* is predicted to lead to a loss of Mlh1 protein function.",5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,295,,,www.uniprot.org,21440
"MLH1 S271F lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). S271F has not been characterized and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21441
"MLH1 S368L does not lie within any known functional domains of the Mlh1 protein (PMID: 22753075). S368L has not been characterized and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21442
"MLH1 S508N lies within the C-terminal dimerization domain of the Mlh1 protein (PMID: 22753075). S508N has been identified in sequencing studies (PMID: 22980975), but has not been biochemically characterized and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",1726,22980975,Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/22980975,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21443
"MLH1 S698L lies within the C-terminal dimerization domain of the Mlh1 protein (PMID: 22753075). S698L has not been characterized in the scientifc literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21444
"NRAS P34L lies within the effector region of the Nras protein (UniProt.org). P34L results in decreased Nras GAP sensitivity and reduced binding to effectors (PMID: 20949621). 
",295,,,www.uniprot.org,800,20949621,Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders.,http://www.ncbi.nlm.nih.gov/pubmed/20949621,21445
"NRAS Q22K does not lie within any known functional domains of the Nras protein (UniProt.org). Q22K has not been characterized and therefore, its effect on Nras protein function is unknown (PubMed, Oct 2016).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21446
"NRAS R164C does not lie within any known functional domains of the Nras protein (UniProt.org). R164C has not been characterized in the scientific literature and therefore, its effect on Nras protein function is unknown (PubMed, Oct 2016).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21447
"NRAS S106L does not lie within any known functional domains of the Nras protein (UniProt.org). S106L has not been characterized in the scientific literature and therefore, its effect on Nras protein function is unknown (PubMed, Oct 2016).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21448
"NRAS T74S does not lie within any known functional domains of the Nras protein (UniProt.org). T74S has not been characterized and therefore, its effect on Nras protein function is unknown (PubMed, Oct 2016).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21449
"NRAS D57A does not lie within any known functional domains of the Nras protein (UniProt.org). D57A has not been characterized in the scientific literature and therefore, its effect on Nras protein function is unknown (PubMed, Oct 2016).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21450
"RB1 negative indicates a lack of the RB1 gene, mRNA, and/or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,21453
"MLH1 S505Vfs*3 is a missense mutation (S505V) in conjunction with a likely truncation of the 756 aa Mlh1 protein at aa 505, followed by 3 nonsense amino acids (UniProt.org). Due to the loss of the C-terminal dimerization domain (PMID: 22753075), S505Vfs*3 is predicted to lead to a loss of Mlh1 protein function.",5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,295,,,www.uniprot.org,21454
"MLH1 S93G lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). S93G is predicted to be non-pathogenic based on in silico analyses and has mismatch repair activity comparable to wild-type Mlh1 (PMID: 16083711, PMID:20020535).",5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,5161,20020535,A cell-free assay for the functional analysis of variants of the mismatch repair protein MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/20020535,5166,16083711,Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/16083711,21455
MLH1 T117M lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). T117M confers a loss of function to the Mlh1 protein as demonstrated by loss of mismatch repair activity in an in vitro assay (PMID: 20020535).,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,5161,20020535,A cell-free assay for the functional analysis of variants of the mismatch repair protein MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/20020535,21456
"MLH1 T347I does not lie within any known functional domains of the Mlh1 protein (PMID: 22753075). T347I has not been characterized in the scientific literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21457
"MLH1 S677Rfs*15 is a missense mutation (S667R) in conjunction with a likely truncation of the 756 aa Mlh1 protein at aa 677, followed by 15 nonsense amino acids (UniProt.org). S677Rfs*15 has not been characterized and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21458
"MLH1 T81I lies wthin the ATPase domain of the Mlh1 protein (PMID: 22753075). T81I has not been characterized in the scientific literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21459
"MLH1 V16L lies within the ATPase domain of the Mlh1 protein (PIMD: 22753075). V16L has not been characterized in the scientific literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21460
"MLH1 V194I lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). V194I has not been characterized in the scientific literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21461
MLH1 S247P lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). S247P confers a loss of function to the Mlh1 protein as demonstrated by reduced mismatch repair activity in an in vitro assay (PMID: 16083711).,5166,16083711,Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/16083711,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21462
"MLH1 V213M lies within the ATPase domain of the Mlh1 protein (PIMD: 22753075). V213M demonstrates functional mismatch repair activity and PMS2 interaction in in vitro assays (PMID: 17510385, PMID: 16083711), and thus, is predicted to have no effect on Mlh1 function.",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5166,16083711,Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/16083711,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,5174,17510385,Functional analysis of human MLH1 variants using yeast and in vitro mismatch repair assays.,http://www.ncbi.nlm.nih.gov/pubmed/17510385,21463
"MLH1 V440M lies within the EXO-interacting region of the Mlh1 protein (UniProt.org). V440M has not been characterized in the scientific literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21464
"MLH1 V4A lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). V4A has not been characterized in the scientific literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21465
"MLH1 V716M lies within the C-terminal dimerization domain of the Mlh1 protein (PMID: 22753075). V716M is predicted to be non-pathogenic based on in silico analyses and has mismatch repair activity comparable to wild-type Mlh1 (PMID: 22753075, PMID: 20020535).",5161,20020535,A cell-free assay for the functional analysis of variants of the mismatch repair protein MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/20020535,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,21466
"MLH1 W714* results in a premature truncation of the Mlh1 protein at amino acid 714 of 756 (UniProt.org). W714* has been identified in sequencing studies (PMID: 22895193), but has not been biochemically characterized and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4597,22895193,Recurrent R-spondin fusions in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22895193,21467
MLH1 Y646C lies within the C-terminal dimerization domain of the Mlh1 protein (PMID: 22753075). Y646C is predicted to be non-pathogenic based on in silico analyses and has mismatch repair activity comparable to wild-type Mlh1 in an in vitro assay (PMID: 16083711).,5160,22753075,Functional characterization of MLH1 missense variants identified in Lynch syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/22753075,5166,16083711,Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1.,http://www.ncbi.nlm.nih.gov/pubmed/16083711,21468
"KDR (VEGFR2) positive indicates the presence of the KDR gene, mRNA, and/or protein. ",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,21469
"ERBB2 (HER2) exon 20 insertions are in-frame insertions within the kinase domain of Erbb2 (Her2) (PMID: 16843263). Exon 20 insertions result in increased Erbb2 (Her2) kinase activity, and are associated with low sensitivity to Egfr tyrosine kinase inhibitors (PMID: 16843263).",2004,16843263,HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/16843263,21472
"VHL over exp indicates an over expression of the Vhl protein. However, the mechanism causing the over expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,21473
"BCOR A828T does not lie within any known functional domains of the Bcor protein (Uniprot.org). A828T has not been characterized in the scientific literature and therefore, its effect on Bcor protein function is unknown (PubMed, Apr 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21474
"BCOR D438N does not lie within any known functional domains of the Bcor protein (UniProt.org). D438N has not been characterized in the scientific literature and therefore, its effect on Bcor protein function is unknown (PubMed, Apr 2016). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21475
"BCOR D438Y does not lie within any known functional domains of the Bcor protein (UniProt.org). D438Y has not been characterized in the scientific literature and therefore, its effect on Bcor protein function is unknown (PubMed, Apr 2016). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21476
"BCOR E1001K does not lie within any known functional domains of the Bcor protein (UniProt.org). E1001K has not been characterized in the scientific literature and therefore, its effect on Bcor protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21477
"BCOR E1076K does not lie within any known functional domains of the Bcor protein (UniProt.org). E1076K has not been characterized in the scientific literature and therefore, its effect on Bcor protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21479
"BCOR F977L does not lie within any known functional domains of the Bcor protein (UniProt.org). F977L has not been characterized in the scientific literature and therefore, its effect on Bcor protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21480
"BCOR G154A does not lie within any known functional domains of the Bcor protein (UniProt.org). G154A has not been characterized in the scientific literature and therefore, its effect on Bcor protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21481
"BCOR G154E does not lie within any known functional domains of the Bcor protein (UniProt.org). G154E has not been characterized in the scientific literature and therefore, its effect on Bcor protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21482
"BCOR G1588V does not lie within any known functional domains of the Bcor protein (UniProt.org). G1588V has not been characterized in the scientific literature and therefore, its effect on Bcor protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21483
"BCOR G549C does not lie within any known functional domains of the Bcor protein (UniProt.org). G549C has not been characterized in the scientific literature and therefore, its effect on Bcor protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21485
"BCOR G549D does not lie within any known functional domains of the Bcor protein (UniProt.org). G549D has not been characterized in the scientific literature and therefore, its effect on Bcor protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21486
"BCOR L1467M lies within the ANK 1 repeat domain of the Bcor protein (UniProt.org). L1467M has not been characterized in the scientific literature and therefore, its effect on Bcor protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21487
"BCOR L325M does not lie within any known functional domains of the Bcor protein (UniProt.org). L325M has not been characterized in the scientific literature and therefore, its effect on Bcor protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21488
"BCOR P1451L does not lie within any known functional domains of the Bcor protein (UniProt.org). P1451L has not been characterized in the scientific literature and therefore, its effect on Bcor protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21489
"BCOR P654T does not lie within any known functional domains of the Bcor protein (UniProt.org). P654T has not been characterized in the scientific literature and therefore, its effect on Bcor protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21490
"BCOR P844S does not lie within any known functional domains of the Bcor protein (UniProt.org). P844S has not been characterized in the scientific literature and therefore, its effect on Bcor protein function is unknown (PubMed, Apr 2016). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21491
"BCOR P921R does not lie within any known functional domains of the Bcor protein (UniProt.org). P921R has not been characterized and therefore, its effect on Bcor protein function is unknown (PubMed, Apr 2016). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21492
"BCOR P921S does not lie within any known functional domains of the Bcor protein (UniProt.org). P921S has not been characterized in the scientific literature and therefore, its effect on Bcor protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21493
"BCOR R1031I does not lie within any known functional domains of the Bcor protein (UniProt.org). R1031I has not been characterized in the scientific literature and therefore, its effect on Bcor protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21494
"BCOR R1131L does not lie within any known functional domains of the Bcor protein (UniProt.org). R1131L has not been characterized in the scientific literature and therefore, its effect on Bcor protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21495
"BCOR R1131Q does not lie within any known functional domains of the Bcor protein (UniProt.org). R1131Q has not been characterized in the scientific literature and therefore, its effect on Bcor protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21496
"BCOR R1131W does not lie within any known functional domains of the Bcor protein (UniProt.org). R1131W has not been characterized in the scientific literature and therefore, its effect on Bcor protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21497
"BCOR R810* results in a premature truncation of the Bcor protein at amino acid 810 of 1755 (UniProt.org). R810* has not been characterized in the scientific literature and therefore, its effect on Bcor protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21498
"BCOR S116L does not lie within any known functional domains of the Bcor protein (UniProt.org). S116L has not been characterized in the scientific literature and therefore, its effect on Bcor protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21499
"BCOR S1271L does not lie within any known functional domains of the Bcor protein (UniProt.org). S1271L has not been characterized in the scientific literature and therefore, its effect on Bcor protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21500
"BCOR S214* results in a premature truncation of the Bcor protein at amino acid 214 of 1755 (UniProt.org).  Due to the loss of all known functional domains (UniProt.org), S214* is predicted to lead to a loss of Bcor function.
",295,,,www.uniprot.org,21501
"BCOR S526L does not lie within any known functional domains of the Bcor protein (UniProt.org). S526L has not been characterized in the scientific literature and therefore, its effect on Bcor protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21502
"BCOR V11I does not lie within any known functional domains of the Bcor protein (UniProt.org). V11I has not been characterized in the scientific literature and therefore, its effect on Bcor protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21503
"JAK2 amp indicates an increased number of copies of the JAK2 gene. However, the mechanism causing the increase is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,21505
MAP2K1 P387S does not lie within any known functional domains of the Map2k1 protein (UniProt.org). P387S confers a gain of function to the Map2k1 protein as demonstrated by constitutive phosphorylation of Mek and Erk  (PMID: 22389471).,2092,22389471,"Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",http://www.ncbi.nlm.nih.gov/pubmed/22389471,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21506
"IDH2 R140X indicates any Idh2 missense mutation that results in the arginine (R) at amino acid 140 being replaced by a different amino acid. R140 variants are hotspot mutations in Idh2, which may confer a gain of function to the Idh2 protein (PMID: 23071358, PMID: 27621679).",2749,23071358,IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.,http://www.ncbi.nlm.nih.gov/pubmed/23071358,9276,27621679,IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives.,http://www.ncbi.nlm.nih.gov/pubmed/27621679,21507
"IDH2 R172X indicates any Idh2 missense mutation which results in the arginine (R) at amino acid 172 being replaced by a different amino acid. IDH2 R172 mutations are ""hotspot"" mutations resulting in increased Idh2 activity (PMID: 25495392).",5216,25495392,IDH2 mutation in gliomas including novel mutation.,http://www.ncbi.nlm.nih.gov/pubmed/25495392,21508
"BCORL1 S1279I does not lie within any known functional domains of the Bcorl1 protein (UniProt.org). S1279I has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21509
"BCORL1 S1563F does not lie within any known functional domains of the Bcorl1 protein (UniProt.org). S1563F has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21510
MAP2K1 K59del results in the deletion of amino acid 59 within the protein kinase domain of the Map2k1 protein (UniProt.org). K59del confers a gain of function the the Map2k1 protein as demonstrated by elevated Mek and Erk phosphorylation (PMID: 22389471).,295,,,www.uniprot.org,2092,22389471,"Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.",http://www.ncbi.nlm.nih.gov/pubmed/22389471,21511
"BCORL1 S1702F does not lie within any known functional domains of the Bcorl1 protein (UniProt.org). S1702F has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21512
"BCORL1 S210L does not lie within any known functional domains of the Bcorl1 protein (UniProt.org). S210L has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21513
"BCORL1 S803Y does not lie within any known functional domains of the Bcorl1 protein (UniProt.org). S803Y has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21514
"BCORL1 T345M does not lie within any known functional domains of the Bcorl1 protein (UniProt.org). T345M has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21515
"BCORL1 T799I does not lie within any known functional domains of the Bcorl1 protein (UniProt.org). T799I has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21516
"BCORL1 V1096I does not lie within any known functional domains of the Bcorl1 protein (UniProt.org). V1096I has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21517
"BCORL1 V1430I does not lie within any known functional domains of the Bcorl1 protein (UniProt.org). V1430I has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21518
"BCORL1 W1468L lies within the ANK 1 repeat domain of the Bcorl1 protein (UniProt.org). W1468L has not been characterized and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21519
"BCORL1 R789L does not lie within any known functional domains of the Bcorl1 protein (UniProt.org). R789L has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21520
"BCORL1 R789H does not lie within any known functional domains of the Bcorl1 protein (UniProt.org). R789H has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21521
"BCORL1 R639S does not lie within any known functional domains of the Bcorl1 protein (UniProt.org). R639S has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21522
"BCORL1 R21C does not lie within any known functional domains of the Bcorl1 protein (UniProt.org). R21C has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21523
"BCORL1 R1658M does not lie within any known functional domains of the Bcorl1 protein (UniProt.org). R1658M has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21524
"BCORL1 R1658K does not lie within any known functional domains of the Bcorl1 protein (UniProt.org). R1658K has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21525
"BCORL1 R1548P lies within the ANK 3 repeat domain of the Bcorl1 protein (UniProt.org). R1548P has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21526
"BCORL1 R1536C lies within the ANK 3 repeat domain of the Bcorl1 protein (UniProt.org). R1536C has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21527
"BCORL1 R1466W lies within the ANK 1 repeat domain of the Bcorl1 protein (UniProt.org). R1466W has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21528
"BCORL1 R1224H does not lie within any known functional domains of the Bcorl1 protein (UniProt.org). R1224H has not been characterized and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21529
"BCORL1 Q1191K does not lie within any known functional domains of the Bcorl1 protein (UniProt.org). Q1191K has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21530
"BCORL1 Q1133R does not lie within any known functional domains of the Bcorl1 protein (UniProt.org). Q1133R has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21531
"BCORL1 P968S does not lie within any known functional domains of the Bcorl1 protein (UniProt.org). P968S has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21532
"BCORL1 P714T does not lie within any known functional domains of the Bcorl1 protein (UniProt.org). P714T has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21533
"BCORL1 P564L does not lie within any known functional domains of the Bcorl1 protein (UniProt.org). P564L has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21534
"BCORL1 P1218S does not lie within any known functional domains of the Bcorl1 protein (UniProt.org). P1218S has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21535
"BCORL1 N1387D does not lie within any known functional domains of the Bcorl1 protein (UniProt.org). N1387D has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21536
"BCORL1 L84R does not lie within any known functional domains of the Bcorl1 protein (UniProt.org). L84R has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21537
"BCORL1 L1605R does not lie within any known functional domains of the Bcorl1 protein (UniProt.org). L1605R has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21538
"BCORL1 L1538F lies within the ANK 3 repeat domain of the Bcorl1 protein (UniProt.org). L1538F has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21539
"BCORL1 L1132I does not lie within any known functional domains of the Bcorl1 protein (UniProt.org). L1132I has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21540
"BCORL1 K1207N does not lie within any known functional domains of the Bcorl1 protein (UniProt.org). K1207N has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21541
"BCORL1 H993Y does not lie within any known functional domains of the Bcorl1 protein (UniProt.org). H993Y has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21542
"BCORL1 E1655D does not lie within any known functional domains of the Bcorl1 protein (UniProt.org). E1655D has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21543
"BCORL1 E1157K does not lie within any known functional domains of the Bcorl1 protein (UniProt.org). E1157K has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21544
"BCORL1 D90Y does not lie within any known functional domains of the Bcorl1 protein (UniProt.org). D90Y has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21545
"BCORL1 D90G does not lie within any known functional domains of the Bcorl1 protein (UniProt.org). D90G has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21546
"BCORL1 D1627N does not lie within any known functional domains of the Bcorl1 protein (UniProt.org). D1627N has not been characterized and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21547
"BCORL1 D1627G does not lie within any known functional domains of the Bcorl1 protein (UniProt.org). D1627G has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21548
"BCORL1 D1569V does not lie within any known functional domains of the Bcorl1 protein (UniProt.org). D1569V has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21549
"BCORL1 D1514Y lies within the ANK 2 repeat domain of the Bcorl1 protein (UniProt.org). D1514Y has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21550
"BCORL1 C1422F does not lie within any known functional domains of the Bcorl1 protein (UniProt.org). C1422F has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21551
"BCORL1 A257S does not lie within any known functional domains of the Bcorl1 protein (UniProt.org). A257S has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21552
"BCORL1 A157T does not lie within any known functional domains of the Bcorl1 protein (UniProt.org). A157T has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21553
"BCORL1 A1525S lies within the ANK 3 repeat domain of the Bcorl1 protein (UniProt.org). A1525S has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21554
"BCORL1 R945* results in a premature truncation of the Bcorl1 protein at amino acid 945 of 1711 (UniProt.org).  Due to the loss of all known functional domains (UnitProt.org), R945* is predicted to lead to a loss of Bcorl1 protein function.
",295,,,www.uniprot.org,21555
"BCORL1 R1090* results in a premature truncation of the Bcorl1 protein at amino acid 1090 of 1711 (UniProt.org).  Due to the loss of all known functional domains (UnitProt.org), R1090* is predicted to lead to a loss of Bcorl1 protein function.
",295,,,www.uniprot.org,21556
"BCORL1 E692* results in a premature truncation of the Bcorl1 protein at amino acid 692 of 1711 (UniProt.org).  Due to the loss of all known functional domains (UnitProt.org), E692* is predicted to lead to a loss of Bcorl1 protein function.
",295,,,www.uniprot.org,21557
"BCORL1 E1685* results in a premature truncation of the Bcorl1 protein at amino acid 1685 of 1711 (UniProt.org).  E1685* has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21558
"BCORL1 C1573Lfs*2 is a missense mutation (C1573L) in conjunction with a likely truncation of the 1711 aa Bcorl1 protein at aa 1573, followed by 2 nonsense amino acids (UniProt.org). C1573Lfs*2 has not been characterized in the scientific literature and therefore, its effect on Bcorl1 protein function is unknown (PubMed, Apr 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21559
"CBLB A215T lies within the EF-hand-like region of the Cblb protein (UniProt.org). A215T has not been characterized in the scientific literature and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21564
"CBLB C224F lies within the EF-hand-like region of the Cblb protein (UniProt.org). C224F has not been characterized in the scientific literature and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21565
"CBLB D221Y lies within the EF-hand-like region of the Cblb protein (UniProt.org). D221Y has not been characterized and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21566
"CBLB D430N does not lie within any known functional domains of the Cblb protein (UniProt.org). D430N has not been characterized in the scientific literature and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21567
"CBLB D448N does not lie within any known functional domains of the Cblb protein (UniProt.org). D448N has not been characterized in the scientific literature and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21568
"CBLB D448Y does not lie within any known functional domains of the Cblb protein (UniProt.org). D448Y has not been characterized and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21569
"CBLB D452N does not lie within any known functional domains of the Cblb protein (UniProt.org). D452N has not been characterized and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21570
"CBLB D759E does not lie within any known functional domains of the Cblb protein (UniProt.org). D759E has not been characterized and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21571
"CBLB E127* results in a premature truncation of the Cblb protein at amino acid 127 of 982 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), E127* is predicted to lead to a loss of Cblb protein function.",295,,,www.uniprot.org,21572
"CBLB E135D lies within the Cbl-PTB domain of the Cblb protein (UniProt.org). E135D has not been characterized in the scientific literature and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21573
"CBLB E358G lies within the linker region of the Cblb protein (UniProt.org). E358G has not been characterized in the scientific literature and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21574
"CBLB F197Y lies within the Cbl-PTB domain of the Cblb protein (UniProt.org). F197Y has not been characterized in the scientific literature and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21575
"CBLB F814C does not lie within any known functional domains of the Cblb protein (UniProt.org). F814C has not been characterized and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21576
"CBLB F814L does not lie within any known functional domains of the Cblb protein (UniProt.org). F814L has not been characterized and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21577
"CBLB G323V lies within the Cbl-PTB domain of the Cblb protein (UniProt.org). G323V has not been characterized and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21578
"CBLB G658A does not lie within any known functional domains of the Cblb protein (UniProt.org). G658A has not been characterized in the scientific literature and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21579
"CBLB H152L lies within the Cbl-PTB domain of the Cblb protein (UniProt.org). H152L has not been characterized in the scientific literature and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21580
"CBLB H257Y lies within the Cbl-PTB domain of the Cblb protein (UniProt.org). H257Y has not been characterized in the scientific literature and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21581
"CBLB I149M lies within the Cbl-PTB domain of the Cblb protein (UniProt.org). I149M has not been characterized in the scientific literature and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21582
"CBLB I619M does not lie within any known functional domains of the Cblb protein (UniProt.org). I619M has not been characterized in the scientific literature and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21583
"CBLB I77V lies within the Cbl-PTB domain of the Cblb protein (UniProt.org). I77V has not been characterized in the scientific literature and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21584
"CBLB K217T lies within the Cbl-PTB domain of the Cblb protein (UniProt.org). K217T has not been characterized in the scientific literature and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21585
"CBLB L23W does not lie within any known functional domains of the Cblb protein (UniProt.org). L23W has not been characterized in the scientific literature and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21586
"CBLB L743P does not lie within any known functional domains of the Cblb protein (UniProt.org). L743P has not been characterized in the scientific literature and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",295,,,www.uniprot.org,115,0,,http://www.ncbi.nlm.nih.gov/pubmed,21587
"CBLB L764V does not lie within any known functional domains of the Cblb protein (UniProt.org). L764V has not been characterized in the scientific literature and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21588
"CBLB P428S does not lie within any known functional domains of the Cblb protein (UniProt.org). P428S has not been characterized in the scientific literature and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21589
"CBLB P674L does not lie within any known functional domains of the Cblb protein (UniProt.org). P674L has not been characterized in the scientific literature and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21590
"CBLB P674S does not lie within any known functional domains of the Cblb protein (UniProt.org). P674S has not been characterized in the scientific literature and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21591
"CBLB P824S does not lie within any known functional domains of the Cblb protein (UniProt.org). P824S has not been characterized and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21592
"CBLB P858T does not lie within any known functional domains of the Cblb protein (UniProt.org). P858T has not been characterized in the scientific literature and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21593
"CBLB Q318E lies within the Cbl-PTB domain of the Cblb protein (UniProt.org). Q318E has not been characterized in the scientific literature and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21594
"NRAS T50I does not lie within any known functional domains of the Nras protein (UniProt.org). T50I confers a gain of function on Nras, as indicated by increased phosphorylation of MEK and ERK in cell culture (PMID: 19966803). 
",295,,,www.uniprot.org,2100,19966803,A restricted spectrum of NRAS mutations causes Noonan syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/19966803,21595
"NRAS Y40* results in a premature truncation of the Nras protein at amino acid 40 of 189 (UniProt.org). Due to the loss of the majority of the functional protein, Y40* is predicted to lead to a loss of Nras protein function (UniProt.org). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21596
"NRAS E162* results in a premature truncation of the Nras protein at amino acid 162 of 189 (UniProt.org). E162* has not been characterized in the scientific literature and therefore, its effect on Nras protein function is unknown (PubMed, Oct 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21597
"KDM6A A1203T lies within the JmjC domain of the Kdm6a protein (UniProt.org). A1203T has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21598
"KDM6A A130D lies within the TPR 2 repeat domain of the Kdm6a protein (UniProt.org). A130D has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21599
"KDM6A A30V lies within the SUPT6H interaction domain of the Kdm6a protein (UniProt.org). A30V has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21600
"KDM6A C1334Y does not lie within any known functional domains of the Kdm6a protein (UniProt.org). C1334Y has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21601
"KDM6A D1216N lies within the JmjC domain of the Kdm6a protein (UniProt.org). D1216N has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21602
"KDM6A D1216Y lies within the JmjC domain of the Kdm6a protein (UniProt.org). D1216Y has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21603
"KDM6A D261H lies within the TPR 5 repeat domain of the Kdm6a protein (UniProt.org). D261H has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21604
"KDM6A D336G lies within the TPR 7 repeat domain of the Kdm6a protein (UniProt.org). D336G has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21605
"KDM6A E1102K lies within the JmjC domain of the Kdm6a protein (UniProt.org). E1102K has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21606
"KDM6A E1316Rfs*17 is a missense mutation (E1316R) in conjunction with a likely truncation of the 1401 aa Kdm6a protein at aa 1316, followed by 17 nonsense amino acids (UniProt.org). E1316Rfs*17 has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21607
"KDM6A E1316Rfs*40 is a missense mutation (E1316R) in conjunction with a likely truncation of the 1401 aa Kdm6a protein at aa 1316, followed by 40 nonsense amino acids (UniProt.org). E1316Rfs*40 has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21608
"KDM6A E315Q lies within the TPR 6 repeat domain of the Kdm6a protein (UniProt.org). E315Q has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21609
"KDM6A F1180L lies within the JmjC domain of the Kdm6a protein (UniProt.org). F1180L has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21610
"KDM6A F1343C does not lie within any known functional domains of the Kdm6a protein (UniProt.org). F1343C has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21611
"KDM6A G1085E lies within the SUPT6H interaction domain of the Kdm6a protein (UniProt.org). G1085E has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21612
"KDM6A G1085R lies within the SUPT6H interaction domain of the Kdm6a protein (UniProt.org). G1085R has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21613
"KDM6A G1140E lies within the JmjC domain of the Kdm6a protein (UniProt.org). G1140E has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21614
"KDM6A G1145D lies within the JmjC domain of the Kdm6a protein (UniProt.org). G1145D has not been characterized and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21615
"KDM6A G1160V lies within the JmjC domain of the Kdm6a protein (UniProt.org). G1160V has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21616
"KDM6A G1223D lies within the JmjC domain of the Kdm6a protein (UniProt.org). G1223D has not been characterized and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21617
"KDM6A G1242R lies within the JmjC domain of the Kdm6a protein (UniProt.org). G1242R has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21618
"KDM6A G1242V lies within the JmjC domain of the Kdm6a protein (UniProt.org). G1242V has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21619
"KDM6A G1321W does not lie within any known functional domains of the Kdm6a protein (UniProt.org). G1321W has not been characterized and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21620
"KDM6A G653S lies within the SUPT6H interaction domain of the Kdm6a protein (UniProt.org). G653S has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21621
"KDM6A H101D lies within the TPR 1 repeat domain of the Kdm6a protein (UniProt.org). H101D has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21622
"KDM6A K987R lies within the SUPT6H interaction domain of the Kdm6a protein (UniProt.org). K987R has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21623
"KDM6A L1119P lies within the JmjC domain of the Kdm6a protein (UniProt.org). L1119P has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21624
"KDM6A L1200F lies within the JmjC domain of the Kdm6a protein (UniProt.org). L1200F has not been characterized and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21625
"KDM6A L1306S does not lie within any known functional domains of the Kdm6a protein (UniProt.org). L1306S has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21626
"KDM6A L1375P does not lie within any known functional domains of the Kdm6a protein (UniProt.org). L1375P has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21627
"KDM6A L416F lies within the SUPT6H interaction domain of the Kdm6a protein (UniProt.org). L416F has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21628
"KDM6A M494I lies within the SUPT6H interaction domain of the Kdm6a protein (UniProt.org). M494I has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21629
"KDM6A N1087D lies within the SUPT6H interaction domain of the Kdm6a protein (UniProt.org). N1087D has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21630
MAP2K1 D65N lies adjacent to the protein kinase domain of the Map2k1 protein (UniProt.org). D65N confers a gain of function to the Map2k1 protein as demonstrated by increased Mek phosphorylation relative to wild-type Map2k1 (PMID: 26566875). ,295,,,www.uniprot.org,5227,26566875,Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26566875,21635
"CBLB R141Q lies within the Cbl-PTB domain of the Cblb protein (UniProt.org). R141Q has not been characterized in the scientific literature and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21636
"CBLB R272Q lies within the Cbl-PTB domain of the Cblb protein (UniProt.org). R272Q has not been characterized and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21637
"CBLB R325G lies within the Cbl-PTB domain of the Cblb protein (UniProt.org). R325G has not been characterized in the scientific literature and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21638
"CBLB R468Q does not lie within any known functional domains of the Cblb protein (UniProt.org). R468Q has not been characterized and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21639
"CBLB R58K lies within the Cbl-PTB domain of the Cblb protein (UniProt.org). R58K has not been characterized in the scientific literature and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21640
"CBLB R670W does not lie within any known functional domains of the Cblb protein (UniProt.org). R670W has not been characterized and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21641
"CBLB R734W does not lie within any known functional domains of the Cblb protein (UniProt.org). R734W has not been characterized in the scientific literature and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21642
"CBLB R782M does not lie within any known functional domains of the Cblb protein (UniProt.org). R782M has not been characterized and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21643
"CBLB R884I does not lie within any known functional domains of the Cblb protein (UniProt.org). R884I has not been characterized and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21644
"CBLB R884K does not lie within any known functional domains of the Cblb protein (UniProt.org). R884K has not been characterized in the scientific literature and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21645
"CBLB R979C does not lie within any known functional domains of the Cblb protein (UniProt.org). R979C has not been characterized in the scientific literature and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21646
"CBLB S147F lies within the Cbl-PTB domain of the Cblb protein (UniProt.org). S147F has not been characterized in the scientific literature and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21647
"CBLB S718F does not lie within any known functional domains of the Cblb protein (UniProt.org). S718F has not been characterized in the scientific literature and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21648
"CBLB T687S does not lie within any known functional domains of the Cblb protein (UniProt.org). T687S has not been characterized in the scientific literature and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21649
"CBLB V654I does not lie within any known functional domains of the Cblb protein (UniProt.org). V654I has not been characterized in the scientific literature and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21650
"CBLB W194C lies within the Cbl-PTB domain of the Cblb protein (UniProt.org). W194C has not been characterized in the scientific literature and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21651
"CBLB W400L does not lie within any known functional domains of the Cblb protein (UniProt.org). W400L has not been characterized in the scientific literature and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21652
"CBLB W400R does not lie within any known functional domains of the Cblb protein (UniProt.org). W400R has not been characterized in the scientific literature and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21653
"CBLB Y665C does not lie within any known functional domains of the Cblb protein (UniProt.org). Y665C has not been characterized in the scientific literature and therefore, its effect on Cblb protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21654
"CBLC A191T lies within the Cbl-PTB domain of the Cblc protein (UniProt.org). A191T has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21655
"CBLC A232Gfs*14 is a missense mutation (A232G) in conjunction with a likely truncation of the 474 aa Cblc protein at aa 232, followed by 14 nonsense amino acids (UniProt.org). A232Gfs*14 has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21656
"CBLC A398V lies within the RET-interacting region of the Cblc protein (UniProt.org). A398V has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21657
"CBLC A64T lies within the Cbl-PTB domain of the Cblc protein (UniProt.org). A64T has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21658
"CBLC A6T does not lie within any known functional domains of the Cblc protein (UniProt.org). A6T has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21659
"CBLC A6V does not lie within any known functional domains of the Cblc protein (UniProt.org). A6V has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21660
"CBLC D318N lies within the Cbl-PTB domain of the Cblc protein (UniProt.org). D318N has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21661
"CBLC E14K lies within the Cbl-PTB domain of the Cblc protein (UniProt.org). E14K has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21662
"CBLC E162K lies within the Cbl-PTB domain of the Cblc protein (UniProt.org). E162K has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21663
"CBLC E186K lies within the Cbl-PTB domain of the Cblc protein (UniProt.org). E186K has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21664
"CBLC E356K lies within the RET-interacting region of the Cblc protein (UniProt.org). E356K has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21665
CBLC E392K lies within the RET-interacting region of the Cblc protein (UniProt.org). E392K supports cell proliferation to similar level of wild-type Cblc protein in culture (PMID: 22315494).,3738,22315494,CBL mutations in myeloproliferative neoplasms are also found in the gene's proline-rich domain and in patients with the V617FJAK2.,http://www.ncbi.nlm.nih.gov/pubmed/22315494,295,,,www.uniprot.org,21666
"CBLC E88D lies within the Cbl-PTB domain of the Cblc protein (UniProt.org). E88D has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21667
"CBLC F111L lies within the Cbl-PTB domain of the Cblc protein (UniProt.org). F111L has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21668
"CBLC F214Sfs*65 is a missense mutation (F214S) in conjunction with a likely truncation of the 474 aa Cblc protein at aa 214, followed by 65 nonsense amino acids (UniProt.org). F214Sfs*65 has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21669
"CBLC G141R lies within the Cbl-PTB domain of the Cblc protein (UniProt.org). G141R has not been characterized and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21670
"CBLC G165R lies within the Cbl-PTB domain of the Cblc protein (UniProt.org). G165R has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21671
"CBLC G259C lies within the Cbl-PTB domain of the Cblc protein (UniProt.org). G259C has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21672
"CBLC G312E lies within the Cbl-PTB domain of the Cblc protein (UniProt.org). G312E has not been characterized and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21673
"CBLC G395D lies within the RET-interacting region of the Cblc protein (UniProt.org). G395D has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21674
"CBLC G467* results in a premature truncation of the Cblc protein at amino acid 467 of 474 (UniProt.org). G467* has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21675
"CBLC G72S lies within the Cbl-PTB domain of the Cblc protein (UniProt.org). G72S has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21676
"CBLC H136L lies within the Cbl-PTB domain of the Cblc protein (UniProt.org). H136L has not been characterized and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21677
"CBLC H235P lies within the Cbl-PTB domain of the Cblc protein (UniProt.org). H235P has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21678
"CBLC H405Y lies within the RET-interacting region of the Cblc protein (UniProt.org). H405Y has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21679
"CBLC I126L lies within the Cbl-PTB domain of the Cblc protein (UniProt.org). I126L has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21680
"MYD88 act mut indicates that this variant results in a gain of function in the Myd88 protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,21681
"CBLC I284Tfs*37 is a missense mutation (I284T) in conjunction with a likely truncation of the 474 aa Cblc protein at aa 284, followed by 37 nonsense amino acids (UniProt.org). I284Tfs*37 has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21682
"CBLC K143N lies within the Cbl-PTB domain of the Cblc protein (UniProt.org). K143N has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21683
"CBLC L178F lies within the Cbl-PTB domain of the Cblc protein (UniProt.org). L178F has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21684
"CBLC L442V lies within the RET-interacting region of the Cblc protein (UniProt.org). L442V has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21685
"CBLC M131I lies within the Cbl-PTB domain of the Cblc protein (UniProt.org). M131I has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21686
"CBLC M148L lies within the Cbl-PTB domain of the Cblc protein (UniProt.org). M148L has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21687
"CBLC M148R lies within the Cbl-PTB domain of the Cblc protein (UniProt.org). M148R has not been characterized and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21688
"CBLC P100S lies within the Cbl-PTB domain of the Cblc protein (UniProt.org). P100S has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21689
"CBLC P310L lies within the Cbl-PTB domain of the Cblc protein (UniProt.org). P310L has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21690
"CBLC P35S lies within the Cbl-PTB domain of the Cblc protein (UniProt.org). P35S has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21691
"CBLC P430L lies within the RET-interacting region of the Cblc protein (UniProt.org). P430L has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21692
"CBLC P434L lies within the RET-interacting region of the Cblc protein (UniProt.org). P434L has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21693
"CBLC P444L lies within the RET-interacting region of the Cblc protein (UniProt.org). P444L has not been characterized and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21694
"CBLC P463A lies within the RET-interacting region of the Cblc protein (UniProt.org). P463A has not been characterized and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21695
"CBLC P473S lies within the RET-interacting region of the Cblc protein (UniProt.org). P473S has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21696
"CBLC Q384K lies within the RET-interacting region of the Cblc protein (UniProt.org). Q384K has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21697
"CBLC Q419Pfs*81  is a missense mutation (Q419P) in conjunction with a likely truncation of the 474 aa Cblc protein at aa 419, followed by 81 nonsense amino acids (UniProt.org). Q419Pfs*81 supports cell proliferation to similar level of wild-type Cblc protein in culture (PMID: 22315494).",3738,22315494,CBL mutations in myeloproliferative neoplasms are also found in the gene's proline-rich domain and in patients with the V617FJAK2.,http://www.ncbi.nlm.nih.gov/pubmed/22315494,295,,,www.uniprot.org,21698
"CBLC R104K lies within the Cbl-PTB domain of the Cblc protein (UniProt.org). R104K has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21699
"CBLC R104N lies within the Cbl-PTB domain of the Cblc protein (UniProt.org). R104N has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21700
"CBLC R119Q lies within the Cbl-PTB domain of the Cblc protein (UniProt.org). R119Q has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21701
"CBLC R167G lies within the Cbl-PTB domain of the Cblc protein (UniProt.org). R167G has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21702
"CBLC R20Q lies within the Cbl-PTB domain of the Cblc protein (UniProt.org). R20Q has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21703
"CBLC R269C lies within the Cbl-PTB domain of the Cblc protein (UniProt.org). R269C has not been characterized and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21704
"CBLC R390H lies within the RET-interacting region of the Cblc protein (UniProt.org). R390H has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21705
"CBLC R56* results in a premature truncation of the Cblc protein at amino acid 56 of 474 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), R56* is predicted to lead to a loss of Cblc protein function.",295,,,www.uniprot.org,21706
"CBLC R63W lies within the Cbl-PTB domain of the Cblc protein (UniProt.org). R63W has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21707
"CBLC S381L lies within the RET-interacting region of the Cblc protein (UniProt.org). S381L has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21708
"CBLC S400Vfs*55 is a missense mutation (S400V) in conjunction with a likely truncation of the 474 aa Cblc protein at aa 400, followed by 55 nonsense amino acids (UniProt.org). S400Vfs*55 has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21709
"CBLC S43L lies within the Cbl-PTB domain of the Cblc protein (UniProt.org). S43L has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21710
"CBLC S76Y lies within the Cbl-PTB domain of the Cblc protein (UniProt.org). S76Y has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21711
"CBLC T197del results in the deletion of one amino acid in the Cbl-PTB domain of the Cblc protein at amino acid 197 (UniProt.org). T197del has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21712
"CBLC T215P lies within the Cbl-PTB domain of the Cblc protein (UniProt.org). T215P has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21713
"CBLC T385I lies within the RET-interacting region of the Cblc protein (UniProt.org). T385I has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21714
"CBLC V213L lies within the Cbl-PTB domain of the Cblc protein (UniProt.org). V213L has not been characterized and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21715
"CBLC V247A lies within the Cbl-PTB domain of the Cblc protein (UniProt.org). V247A has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016). ",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21716
"CBLC V247I lies within the Cbl-PTB domain of the Cblc protein (UniProt.org). V247I has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21717
"CBLC V247L lies within the Cbl-PTB domain of the Cblc protein (UniProt.org). V247L has not been characterized and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21718
"CBLC V361A lies within the RET-interacting region of the Cblc protein (UniProt.org). V361A has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21719
"CBLC W378* results in a premature truncation of the Cblc protein at amino acid 378 of 474 (UniProt.org). W378* has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21720
"CBLC W378C lies within the RET-interacting region of the Cblc protein (UniProt.org). W378C has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21721
"CBLC Y341C lies within the linker region of the Cblc protein (UniProt.org). Y341C has not been characterized in the scientific literature and therefore, its effect on Cblc protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21722
CBLC P435S lies within the RET-interacting region of the Cblc protein (UniProt.org). P435S supports cell proliferation to similar level of wild-type Cblc protein in culture (PMID: 22315494).,3738,22315494,CBL mutations in myeloproliferative neoplasms are also found in the gene's proline-rich domain and in patients with the V617FJAK2.,http://www.ncbi.nlm.nih.gov/pubmed/22315494,295,,,www.uniprot.org,21723
MAP2K1 E120Q lies within the protein kinase domain of the Map2k1 protein (UniProt.org). E120Q confers a gain of function to the Map2k1 protein as demonstrated by increased Mek phosphorylation relative to wild-type Map2k1 (PMID: 26566875).,295,,,www.uniprot.org,5227,26566875,Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26566875,21725
MAP2K1 E144K lies within the protein kinase domain of the Map2k1 protein (UniProt.org). E144K confers a gain of function to the Map2k1 protein as demonstrated by increased Mek and Erk phosphorylation relative to wild-type Map2k1 (PMID: 26566875).,295,,,www.uniprot.org,5227,26566875,Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26566875,21726
"MAP2K1 F68L lies within the protein kinase domain of the Map2k1 protein (UniProt.org). F68L has been identified in the scientific literature (PMID: 26566875), but has not been biochemically characterized and therefore, its effect on Map2k1 protein function is unknown (PubMed, Mar 2017).",5227,26566875,Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26566875,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21727
MAP2K1 L37P lies within the nuclear export region of the Map2k1 protein (PMID: 26566875). L37P confers a gain of function to the Map2k1 protein as demonstrated by increased Mek and Erk phosphorylation relative to wild-type Map2k1 (PMID: 26566875).,5227,26566875,Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26566875,21728
"MAP2K1 S123P lies within the protein kinase domain of the Map2k1 protein (UniProt.org). S123P has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21729
MAP2K1 S123T lies within the protein kinase domain of the Map2k1 protein (UniProt.org). S123T confers a gain of function to the Map2k1 protein as demonstrated by increased Mek and Erk phosphorylation relative to wild-type Map2k1 (PMID: 26566875).,5227,26566875,Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26566875,295,,,www.uniprot.org,21730
MAP2K1 V60M does not lie within any known functional domains of the Map2k1 protein (UniProt.org). V60M confers a gain of function to the Map2k1 protein as demonstrated by increased Mek and Erk phosphorylation relative to wild-type Map2k1 (PMID: 26566875).,295,,,www.uniprot.org,5227,26566875,Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26566875,21731
MAP2K1 T28I lies within the Erk binding domain of the Map2k1 protein (PMID: 26566875). T28I confers a gain of function to the Map2k1 protein as demonstrated by increased Mek phosphorylation relative to wild-type Map2k1 (PMID: 26566875).,5227,26566875,Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26566875,21732
"MAP2K1 E51_Q58del results in the deletion of eight amino acids in the Map2k1 protein from amino acids 51 to 58 (UniProt.org). E51_Q58del has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21733
"MAP2K1 F53_Q58del results in the deletion of six amino acids in the Map2k1 protein from amino acids 53 to 58 (UniProt.org). F53_Q58del has been identified in the scientific literature (PMID: 26566875), but has not been biochemically characterized and therefore, its effect on Map2k1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5227,26566875,Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26566875,21734
MAP2K1 Q58_E62del results in the deletion of five amino acids in the Map2k1 protein from amino acis 58 to 62 (UniProt.org). Q58_E62del confers a gain of function to the Map2k1 protein as demonstrated by increased Mek and Erk phosphorylation relative to wild-type Map2k1 (PMID: 26566875).,295,,,www.uniprot.org,5227,26566875,Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26566875,21735
KRAS C118S lies within one of the GTP binding sites of the Kras protein (UniProt.org). C118S confers a loss of function to the Kras protein as demonstrated by reduced Erk phosphorylation and decreased tumorigenesis in knock-in mice harboring C118S in the murine Kras ortholog (PMID: 25394415).,295,,,www.uniprot.org,5237,25394415,Decreased tumorigenesis in mice with a Kras point mutation at C118.,http://www.ncbi.nlm.nih.gov/pubmed/25394415,21739
"KRAS D33E lies within one of the GTP binding sites of the Kras protein (UniProt.org). D33E increases GTP binding to KRAS, activates MAPK and PI3K pathways, and induces tumor formation in animal models (PMID: 27147599).",295,,,www.uniprot.org,6273,27147599,Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.,http://www.ncbi.nlm.nih.gov/pubmed/27147599,21740
"KRAS D92Y does not lie within any known functional domains of the Kras protein (UniProt.org). D92Y has been identified in sequencing studies (PMID: 12438234), but has not been biochemically characterized and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).",10048,12438234,Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.,http://www.ncbi.nlm.nih.gov/pubmed/12438234,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21741
"PTEN R308C lies within the C2 tensin-type domain of the Pten protein (UniProt.org). R308C has been identified in sequencing studies (PMID: 16344319), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",8134,16344319,High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/16344319,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21742
"PTEN N69D lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). N69D has been identified in the scientific literature (PMID: 26362251, PMID: 26561558), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8074,26362251,A systematic screening to identify de novo mutations causing sporadic early-onset Parkinson's disease.,http://www.ncbi.nlm.nih.gov/pubmed/26362251,5255,26561558,InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/26561558,21743
"EGFR A767T lies within the protein kinase domain of the Egfr protein (UniProt.org). A767T leads to increased EGFR autophosphorylation, and is associated with resistance to gefitinib in culture (PMID: 18497962).",295,,,www.uniprot.org,5252,18497962,Mutations of epidermal growth factor receptor in colon cancer indicate susceptibility or resistance to gefitinib.,http://www.ncbi.nlm.nih.gov/pubmed/18497962,21744
"KRAS E62G does not lie within any known functional domains of the Kras protein (UniProt.org). E62G has been identified in sequencing studies (PMID: 24798001), but has not been biochemically characterized and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,10049,24798001,Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification.,http://www.ncbi.nlm.nih.gov/pubmed/24798001,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21747
"KRAS E63K does not lie within any known functional domains of the Kras protein (UniProt.org). E63K has not been characterized, however this evolutionarily conserved site in all Ras isoforms results in a loss of intrinsic Hras GTPase activity (PMID: 17412879, PMID: 1362901) and therefore, it is predicted to lead to a loss of Kras protein function.",295,,,www.uniprot.org,4580,25870145,Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.,http://www.ncbi.nlm.nih.gov/pubmed/25870145,21748
"KRAS I24N does not lie within any known functional domains of the Kras protein (UniProt.org). I24N has not been characterized with Kras, however, this evolutionarily conserved site in all Ras isoforms results in activation of Nras (UniProt.org, PMID: 21263000) and therefore, it is predicted to lead to a loss of Kras protein function.",295,,,www.uniprot.org,5261,21263000,Noonan syndrome gain-of-function mutations in NRAS cause zebrafish gastrulation defects.,http://www.ncbi.nlm.nih.gov/pubmed/21263000,21749
"KRAS I36L does not lie within any known functional domains of the Kras protein (UniProt.org). I36L has been identified in sequencing studies (PMID: 23525077), but has not been biochemically characterized and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7021,23525077,Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity.,http://www.ncbi.nlm.nih.gov/pubmed/23525077,21750
"KRAS I93F does not lie within any known functional domains of the Kras protein (UniProt.org). I93F has not been characterized in the scientific literature and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21751
"KRAS K176Q lies within the hypervariable region of the Kras protein (UniProt.org). K176Q has not been characterized in the scientific literature and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21752
"KRAS K88* results in a premature truncation of the Kras protein at amino acid 88 of 189 (UniProt.org). Due to the the loss of the GTP binding domain (UniProt.org), K88* is predicted to confer loss of function to the Kras protein (PMID: 20570890).",295,,,www.uniprot.org,843,20570890,Genomic and biological characterization of exon 4 KRAS mutations in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20570890,21753
"KRAS L23R does not lie within any known functional domains of the Kras protein (UniProt.org). L23R has been identified in sequencing studies (PMID: 27416986), but has not been biochemically characterized and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).",10090,27416986,A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program.,http://www.ncbi.nlm.nih.gov/pubmed/27416986,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21754
"KDM6A G1314* results in a premature truncation of the Kdm6a protein at amino acid 1314 of 1401 (UniProt.org). G1314* has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21755
"KRAS V9I does not lie within any known functional domains of the Kras protein (UniProt.org). V9I has been identified in sequencing studies (PMID: 24944587), but has not been biochemically characterized and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).",7472,24944587,Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin.,http://www.ncbi.nlm.nih.gov/pubmed/24944587,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21756
"KDM6A H702Qfs*28 is a missense mutation (H702) in conjunction with a likely truncation of the 1401 aa Kdm6a protein at aa 702, followed by 28 nonsense amino acids (UniProt.org). Due to the loss of the JmjC domain (UniProt.org), H702Qfs*28 is predicted to lead to a loss of Kdm6a function. 
",295,,,www.uniprot.org,21757
"KRAS Y64D lies within the G-domain of the Kras protein (PMID: 26080442). Y64D has been identified in sequencing studies (PMID: 27705932, PMID: 26220040), but has not been biochemically characterized and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5918,26080442,Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway.,http://www.ncbi.nlm.nih.gov/pubmed/26080442,10096,26220040,Impact of PTEN abnormalities on outcome in pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial.,http://www.ncbi.nlm.nih.gov/pubmed/26220040,10045,27705932,KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control.,http://www.ncbi.nlm.nih.gov/pubmed/27705932,21758
"KDM6A K987* results in a premature truncation of the Kdm6a protein at amino acid 987 of 1401 (UniProt.org). Due to the loss of the JmjC domain (UniProt.org), K987* is predicted to lead to a loss of Kdm6a function. 
",295,,,www.uniprot.org,21759
"KDM6A E999* results in a premature truncation of the Kdm6a protein at amino acid 999 of 1401 (UniProt.org). Due to the loss of the JmjC domain (UniProt.org), E999* is predicted to lead to a loss of Kdm6a function. 

",295,,,www.uniprot.org,21760
"KRAS Y64H lies within the G-domain of the Kras protein (PMID: 26080442). Y64H has been identified in sequencing studies (PMID: 23456389), but has not been biochemically characterized and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).",5918,26080442,Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway.,http://www.ncbi.nlm.nih.gov/pubmed/26080442,10097,23456389,Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23456389,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21761
"KDM6A E168* results in a premature truncation of the Kdm6a protein at amino acid 168 of 1401 (UniProt.org). Due to the loss of the JmjC domain (UniProt.org), E168* is predicted to lead to a loss of Kdm6a function. ",295,,,www.uniprot.org,21762
"KDM6A L1098* results in a premature truncation of the Kdm6a protein at amino acid 1098 of 1401 (UniProt.org). Due to the loss of the JmjC domain (UniProt.org), L1098* is predicted to lead to a loss of Kdm6a function. 

",295,,,www.uniprot.org,21763
"KDM6A L187* results in a premature truncation of the Kdm6a protein at amino acid 187 of 1401 (UniProt.org). Due to the loss of the JmjC domain (UniProt.org), L187* is predicted to lead to a loss of Kdm6a function. 

",295,,,www.uniprot.org,21764
"KRAS Y64N lies within the G-domain of the Kras protein (PMID: 26080442). Y64N has been identified in sequencing studies (PMID: 26090869), but has not been biochemically characterized and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5918,26080442,Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway.,http://www.ncbi.nlm.nih.gov/pubmed/26080442,10098,26090869,"Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.",http://www.ncbi.nlm.nih.gov/pubmed/26090869,21765
"KDM6A N1151S lies within the JmjC domain of the Kdm6a protein (UniProt.org). N1151S has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21766
"KDM6A N1158H lies within the JmjC domain of the Kdm6a protein (UniProt.org). N1158H has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21767
"KDM6A N902S lies within the SUPT6H interaction domain of the Kdm6a protein (UniProt.org). N902S has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21768
"ETV6-FLT3 results from the fusion of ETV6 and FLT3, demonstrating the ability to transform cells in culture (PMID: 16761019).",5262,16761019,FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation.,http://www.ncbi.nlm.nih.gov/pubmed/16761019,21769
"KDM6A N906Kfs*5 is a missense mutation (N906K) in conjunction with a likely truncation of the 1401 aa Kdm6a protein at aa 906, followed by 5 nonsense amino acids (UniProt.org). Due to the loss of the JmjC domain (UniProt.org), N906Kfs*5 is predicted to lead to a loss of Kdm6a function. 

",295,,,www.uniprot.org,21770
"KDM6A P110R lies within the TPR 1 repeat domain of the Kdm6a protein (UniProt.org). P110R has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21771
"ETV6-MDS2 results from the fusion of ETV6 and MDS2 (PMID: 12203785). ETV6-MDS2 has been identified in myelodysplastic syndrome (PMID: 12203785), but has not been biochemically characterized and therefore, its effect on fusion protein function is unknown (PubMed, Aug 2017).",5263,12203785,"A novel gene, MDS2, is fused to ETV6/TEL in a t(1;12)(p36.1;p13) in a patient with myelodysplastic syndrome.",http://www.ncbi.nlm.nih.gov/pubmed/12203785,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21772
"KDM6A P110S lies within the TPR 1 repeat domain of the Kdm6a protein (UniProt.org). P110S has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21773
"KDM6A P1269S does not lie within any known functional domains of the Kdm6a protein (UniProt.org). P1269S has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21774
"ETV6-NKAIN2 results from the fusion of ETV6 and NKAIN2. ETV6-NKAIN2 has not been characterized in the scientific literature and therefore, its effect on fusion protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,21775
"KDM6A P405S lies within the SUPT6H interaction domain of the Kdm6a protein (UniProt.org). P405S has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21776
"KDM6A P566L lies within the SUPT6H interaction domain of the Kdm6a protein (UniProt.org). P566L has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21777
"ETV6-PER1 is a cryptic fusion of ETV6 and antisense PER1. ETV6-PER1 has been identified in acute myeloid leukemia and has not been biochemically characterized, however, it does not result in a functional fusion protein, but is hypothesized to knock out Per1 expression (PMID: 12661008).",5264,12661008,A novel cryptic translocation t(12;17)(p13;p12-p13) in a secondary acute myeloid leukemia results in a fusion of the ETV6 gene and the antisense strand of the PER1 gene.,http://www.ncbi.nlm.nih.gov/pubmed/12661008,21778
"KDM6A P877L lies within the SUPT6H interaction domain of the Kdm6a protein (UniProt.org). P877L has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21779
"KDM6A P966R lies within the SUPT6H interaction domain of the Kdm6a protein (UniProt.org). P966R has not been characterized and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21780
"KDM6A Q333K lies within the TPR 7 repeat domain of the Kdm6a protein (UniProt.org). Q333K has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21781
"KDM6A Q398H lies within the SUPT6H interaction domain of the Kdm6a protein (UniProt.org). Q398H has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21782
"KDM6A R1213Q lies within the JmjC domain of the Kdm6a protein (UniProt.org). R1213Q has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21783
"KDM6A R1255W lies within the JmjC domain of the Kdm6a protein (UniProt.org). R1255W has not been characterized and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21784
"ETV6-SYK results from the fusion of ETV6 and SYK (PMID: 22373549). ETV6-SYK has been identified in acute lymphoblastic leukemia (PMID: 22373549), and results in constitutive activation of the fusion protein, and is transforming in cultured cells (PMID: 11159536).",7732,11159536,Constitutive kinase activation of the TEL-Syk fusion gene in myelodysplastic syndrome with t(9;12)(q22;p12).,http://www.ncbi.nlm.nih.gov/pubmed/11159536,5265,22373549,Detection of ETV6 gene rearrangements in adult acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/22373549,21785
"ETV6-NCOA2 results from the fusion of ETV6 and NCOA2 (PMID: 18281529). ETV6-NCOA2 has been identified in acute leukemia (PMID: 18281529), but has not been characterized and therefore, its effect on fusion protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5266,18281529,ETV6-NCOA2: a novel fusion gene in acute leukemia associated with coexpression of T-lymphoid and myeloid markers and frequent NOTCH1 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/18281529,21786
"CEBPA A44P lies within the first transactivation domain of the Cebpa protein (PMID: 11672531). A44P has not been characterized in the scientific literature and therefore, its effect on Cebpa protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5267,11672531,E2F repression by C/EBPalpha is required for adipogenesis and granulopoiesis in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/11672531,21787
"GATA2 A109V does not lie within any known functional domains of the Gata2 protein (UniPort.org). A109V has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21788
"GATA2 A163T does not lie within any known functional domains of the Gata2 protein (UniPort.org). A163T has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21789
"GATA2 A198T does not lie within any known functional domains of the Gata2 protein (UniPort.org). A198T has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21790
"GATA2 A203T does not lie within any known functional domains of the Gata2 protein (UniPort.org). A203T has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21791
"GATA2 A302S lies within the GATA-type 1 Zinc finger region of the Gata2 protein (UniProt.org). A302S has not been characterized and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21792
"GATA2 A341V does not lie within any known functional domains of the Gata2 protein (UniPort.org). A341V has not been characterized and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21793
"GATA2 A37V does not lie within any known functional domains of the Gata2 protein (UniPort.org). A37V has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21794
"GATA2 A411V does not lie within any known functional domains of the Gata2 protein (UniPort.org). A411V has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21795
"GATA2 A430E does not lie within any known functional domains of the Gata2 protein (UniPort.org). A430E has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",295,,,www.uniprot.org,115,0,,http://www.ncbi.nlm.nih.gov/pubmed,21796
"GATA2 A478S does not lie within any known functional domains of the Gata2 protein (UniPort.org). A478S has not been characterized and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21797
"GATA2 A478T does not lie within any known functional domains of the Gata2 protein (UniPort.org). A478T has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21798
"GATA2 E423del results in the deletion of one amino acid in the Gata2 protein at amino acid 423 (UniProt.org). E423del has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21799
"GATA2 F428Sfs*49 is a missense mutation (F428S) in conjunction with a likely truncation of the 480 aa Gata2 protein at aa 428, followed by 49 nonsense amino acids (UniProt.org). F428Sfs*49 has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21800
"GATA2 G150Efs*68 is a missense mutation (G150E) in conjunction with a likely truncation of the 480 aa Gata2 protein at aa 150, followed by 68 nonsense amino acids (UniProt.org). G150Efs*68 has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21801
"GATA2 G167D does not lie within any known functional domains of the Gata2 protein (UniPort.org). G167D has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21802
"GATA2 G167S does not lie within any known functional domains of the Gata2 protein (UniPort.org). G167S has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21803
"GATA2 G200Vfs*18 is a missense mutation (G200V) in conjunction with a likely truncation of the 480 aa Gata2 protein at aa 200, followed by 18 nonsense amino acids (UniProt.org). G200Vfs*18 has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21804
"GATA2 G210S does not lie within any known functional domains of the Gata2 protein (UniPort.org). G210S has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21805
"GATA2 G263E does not lie within any known functional domains of the Gata2 protein (UniPort.org). G263E has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21806
"GATA2 G263R does not lie within any known functional domains of the Gata2 protein (UniPort.org). G263R has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21807
"GATA2 G273R does not lie within any known functional domains of the Gata2 protein (UniPort.org). G273R has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21808
"GATA2 G450R does not lie within any known functional domains of the Gata2 protein (UniPort.org). G450R has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21809
"GATA2 G468S does not lie within any known functional domains of the Gata2 protein (UniPort.org). G468S has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21810
"GATA2 H25Pfs*159 is a missense mutation (H25P) in conjunction with a likely truncation of the 480 aa Gata2 protein at aa 25, followed by 159 nonsense amino acids (UniProt.org). Due to the loss of all known functional domains (UniProt.org), H25Pfs*159 is predicted to lead to a loss of Gata2 protein function.",295,,,www.uniprot.org,21811
"GATA2 H460P does not lie within any known functional domains of the Gata2 protein (UniPort.org). H460P has not been characterized and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21812
"GATA2 H471Tfs*6 is a missense mutation (H471T) in conjunction with a likely truncation of the 480 aa Gata2 protein at aa 471, followed by 6 nonsense amino acids (UniProt.org). H471Tfs*6 has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21813
"GATA2 H51Y does not lie within any known functional domains of the Gata2 protein (UniPort.org). H51Y has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21814
"GATA2 L229R does not lie within any known functional domains of the Gata2 protein (UniPort.org). L229R has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21815
"GATA2 M221L does not lie within any known functional domains of the Gata2 protein (UniPort.org). M221L has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21816
"GATA2 M388T does not lie within any known functional domains of the Gata2 protein (UniPort.org). M388T has not been characterized and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21817
"GATA2 M400L does not lie within any known functional domains of the Gata2 protein (UniPort.org). M400L has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21818
"GATA2 N351Kfs*33 is a missense mutation (N351K) in conjunction with a likely truncation of the 480 aa Gata2 protein at aa 351, followed by 33 nonsense amino acids (UniProt.org). N351Kfs*33 has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21819
"GATA2 N50S does not lie within any known functional domains of the Gata2 protein (UniPort.org). N50S has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21820
"GATA2 P228L does not lie within any known functional domains of the Gata2 protein (UniPort.org). P228L has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21821
"GATA2 P240S does not lie within any known functional domains of the Gata2 protein (UniPort.org). P240S has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21822
"GATA2 P247A does not lie within any known functional domains of the Gata2 protein (UniPort.org). P247A has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21823
"GATA2 P267H does not lie within any known functional domains of the Gata2 protein (UniPort.org). P267H has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21824
"GATA2 P267L does not lie within any known functional domains of the Gata2 protein (UniPort.org). P267L has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21825
"GATA2 P461L does not lie within any known functional domains of the Gata2 protein (UniPort.org). P461L has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21826
"GATA2 P87R does not lie within any known functional domains of the Gata2 protein (UniPort.org). P87R has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016). ",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21827
"GATA2 Q328* results in a premature truncation of the Gata2 protein at amino acid 328 of 480 (UniProt.org). Q328* has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21828
"GATA2 Q328K does not lie within any known functional domains of the Gata2 protein (UniPort.org). Q328K has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21829
"GATA2 R86Afs*33 is a missense mutation (R86A) in conjunction with a likely truncation of the 480 aa Gata2 protein at aa 86, followed by 33 nonsense amino acids (UniProt.org). Due to the loss of all known functional domains (UniProt.org), R86Afs*33 is predicted to lead to a loss of Gata2 protein function.",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21830
"GATA2 S139Cfs*45 is a missense mutation (S139C) in conjunction with a likely truncation of the 480 aa Gata2 protein at aa 139, followed by 45 nonsense amino acids (UniProt.org). S139Cfs*45 has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21831
"GATA2 S261N does not lie within any known functional domains of the Gata2 protein (UniPort.org). S261N has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21832
"GATA2 S277G does not lie within any known functional domains of the Gata2 protein (UniPort.org). S277G has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21833
"GATA2 S462F does not lie within any known functional domains of the Gata2 protein (UniPort.org). S462F has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21834
"GATA2 S464R does not lie within any known functional domains of the Gata2 protein (UniPort.org). S464R has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21835
"GATA2 S466F does not lie within any known functional domains of the Gata2 protein (UniPort.org). S466F has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21836
"GATA2 S54W does not lie within any known functional domains of the Gata2 protein (UniPort.org). S54W has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21837
"GATA2 S92R does not lie within any known functional domains of the Gata2 protein (UniPort.org). S92R has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21838
"GATA2 T238I does not lie within any known functional domains of the Gata2 protein (UniPort.org). T238I has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21839
"GATA2 T356N lies within the GATA-type 2 Zinc finger region of the Gata2 protein (UniProt.org). T356N has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21840
"GATA2 Y213F does not lie within any known functional domains of the Gata2 protein (UniPort.org). Y213F has not been characterized in the scientific literature and therefore, its effect on Gata2 protein function is unknown (PubMed, Apr 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21841
"KRAS V160A does not lie within any known functional domains of the Kras protein (UniProt.org). V160A has been identified in sequencing studies (PMID: 24549645), but has not been biochemically characterized in the scientific literature and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).",10094,24549645,KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24549645,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21842
"CEBPA A44Pfs*63 likely results in a premature truncation of the 358 aa Cebpa protein at aa 44, followed by 63 nonsense amino acids (UniProt.org). A44Pfs*63 has not been characterized, however other frameshifts cause alternate translation and the resulting isoform inhibits Cepba DNA binding (PMID: 11242107), thus A44Pfs*63 is predicted to lead to a loss of Cebpa protein function.",295,,,www.uniprot.org,5275,11242107,"Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/11242107,21843
"CEBPA E59* results in a premature truncation of the Cebpa protein at aminoa acid 59 of 358 (UniProt.org). Due to the loss of the basic leucine zipper DNA binding domain (UniProt.org), E59* is predicted to lead to a loss of protein function.",295,,,www.uniprot.org,21844
"CEBPA A111Rfs*59 likely results in a truncation of the 358 aa Cebpa protein at aa 111, followed by 59 nonsense amino acids (UniProt.org). A111Rfs*59 has not been characterized, however other frameshifts cause alternate translation and the resulting isoform inhibits Cepba DNA binding (PMID: 11242107), thus A111RPfs*59 is predicted to lead to a loss of Cebpa protein function.",295,,,www.uniprot.org,5275,11242107,"Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/11242107,21845
"CEBPA R343Afs*79 likely results in a premature truncation of the 358 aa Cepba protein at aa 343, followed by 79 nonsense amino acids (UniProt.org). R343Afs*79 has been identified in the scientific literature (PMID: 26796102), but has not been biochemically characterized and therefore, its effect on Cebpa protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8111,26796102,Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/26796102,21846
"CEBPA R286Pfs*35 likely results in a premature truncation of the 358 aa Cebpa protein at aa 286, followed by 35 nonsense amino acids (UniProt.org). Due to the loss of the basic leucine zipper DNA binding domain (UniProt.org), R286Pfs*35 is predicted to lead to a loss of Cebpa protein function.",295,,,www.uniprot.org,21847
"CEBPA P23Rfs*137 likely results in a premature truncation of the 358 aa Cepba protein at aa 23, followed by 137 nonsense amino acids (UniProt.org). P23Rfs*137 has not been characterized, however other frameshifts cause alternate translation and the resulting isoform inhibits Cepba DNA binding (PMID: 11242107), thus P23Rfs*137 is predicted to lead to a loss of Cebpa protein function.",295,,,www.uniprot.org,5275,11242107,"Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/11242107,21848
"CEBPA V308dup indicates the insertion of the duplicate amino acid, valine (V)-308 within the basic leucine zipper DNA binding domain of the Cebpa protein (UniProt.org). V308dup has not been characterized in the scientific literature and therefore, its effect on Cebpa protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21849
"CEBPA K304_Q305insL results in the insertion of one amino acid residue (L) in the Cebpa protein between amino acids 304 and 305 (UniProt.org). K304_Q305insL has been identified in the scientific literature (PMID: 22389883, PMID: 27359055, PMID: 22649106), but has not been biochemically characterized and therefore, its effect on Cebpa protein function is unknown (PubMed, Mar 2017).",8093,22649106,GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/22649106,285,,,http://www.ncbi.nlm.nih.gov/pubmed,8092,22389883,Novel mutations in CEBPA in Korean Patients with acute myeloid leukemia with a normal karyotype.,http://www.ncbi.nlm.nih.gov/pubmed/22389883,295,,,www.uniprot.org,7838,27359055,Mutation profiling of 19 candidate genes in acute myeloid leukemia suggests significance of DNMT3A mutations.,http://www.ncbi.nlm.nih.gov/pubmed/27359055,21850
"CEBPA Q305dup indicates the insertion of the duplicate amino acid, valine (V)-308 within the basic leucine zipper DNA binding domain of the Cebpa protein (UniProt.org). Q305dup has not been characterized in the scientific literature and therefore, its effect on Cebpa protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21851
"KDM6A R1322W does not lie within any known functional domains of the Kdm6a protein (UniProt.org). R1322W has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21852
"CEBPA R142Sfs*27 likely results in a premature truncation of the 358 aa Cepba protein at aa 142, followed by 27 nonsense amino acids (UniProt.org). Due to the loss of the basic leucine zipper DNA binding domain (UniProt.org), R142Sfs*27 is predicted to lead to a loss of Cebpa protein function.",295,,,www.uniprot.org,21854
"KDM6A R393Q lies within the SUPT6H interaction domain of the Kdm6a protein (UniProt.org). R393Q has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21855
"KDM6A R519P lies within the SUPT6H interaction domain of the Kdm6a protein (UniProt.org). R519P has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21856
"CEBPA T310_Q311insKQNP results in the insertion of four amino acid residues (KQNP) in the Cebpa protein between amino acids 310 and 311 (UniProt.org). T310_Q311insKQNP has not been characterized in the scientific literature and therefore, its effect on Cebpa protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21857
"CEBPA T310_Q311insW results in the insertion of one amino acid residue (W) in the Cebpa protein between amino acids 310 and 311 (UniProt.org). T310_Q311insW has not been characterized in the scientific literature and therefore, its effect on Cebpa protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21858
"CEBPA P46Lfs*114 likely results in a premature truncation of the 358 aa Cepba protein at aa 46, followed by 114 nonsense amino acids (UniProt.org). P46Lfs*114 has not been characterized, however other frameshifts cause alternate translation and the resulting isoform inhibits Cepba DNA binding (PMID: 11242107), thus P46Lfs*114 is predicted to lead to a loss of Cebpa protein function.",5275,11242107,"Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/11242107,295,,,www.uniprot.org,21859
"CEBPA R300C lies within the bZIP domain of the Cebpa protein (UniProt.org). R300C has not been characterized in the scientific literature and therefore, its effect on Cebpa protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21860
"KDM6A R901M lies within the SUPT6H interaction domain of the Kdm6a protein (UniProt.org). R901M has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21861
"KDM6A R971C lies within the SUPT6H interaction domain of the Kdm6a protein (UniProt.org). R971C has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21862
"CEBPA L317_T318insM results in the insertion of one amino acid residue (M) in the Cebpa protein between amino acids 317 and 318 (UniProt.org). L317_T318insM has been identified in the scientific literature (PMID: 15645492), but has not been biochemically characterized and therefore, its effect on Cebpa protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8094,15645492,Acute myeloid leukemia with deletion 9q within a noncomplex karyotype is associated with CEBPA loss-of-function mutations.,http://www.ncbi.nlm.nih.gov/pubmed/15645492,21863
"KDM6A S1114L lies within the JmjC domain of the Kdm6a protein (UniProt.org). S1114L has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21864
"CEBPA T318_S319insI results in the insertion of one amino acid residue (I) in the Cebpa protein between amino acids 318 and 319 (UniProt.org). T318_S319insI has not been characterized in the scientific literature and therefore, its effect on Cebpa protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21865
"KDM6A S886Y lies within the SUPT6H interaction domain of the Kdm6a protein (UniProt.org). S886Y has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21866
"KDM6A T1002A lies within the SUPT6H interaction domain of the Kdm6a protein (UniProt.org). T1002A has not been characterized and therefore, its effect on Kdm6a protein function is unknown (PubMed, Apr 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21867
"CEBPA T318del results in the deletion of a threonine (T) within the basic leucine zipper DNA binding domain of the Cebpa protein domain (UniProt.org). T318del has not been characterized in the scientific literature and therefore, its effect on Cebpa protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21868
"CEBPA R142Tfs*27 likely results in a premature truncation of the 358 aa Cepba protein at aa 142, followed by 27 nonsense amino acids (UniProt.org). Due to the loss of the basic leucine zipper DNA binding domain (UniProt.org), R142Tfs*27 is predicted to lead to a loss of Cebpa protein function.",295,,,www.uniprot.org,21869
"CEBPA I294K lies within the bZIP domain of the Cebpa protein (UniProt.org). I294K has not been characterized in the scientific literature and therefore, its effect on Cebpa protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21870
"CEBPA E59D lies within the first transactivation domain of the Cepba protein (PMID: 11672531). E59D has not been characterized in the scientific literature and therefore, its effect on Cebpa protein function is unknown (PubMed, Sep 2017).",5267,11672531,E2F repression by C/EBPalpha is required for adipogenesis and granulopoiesis in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/11672531,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21871
"CEBPA E329Q lies within the bZIP domain of the Cebpa protein (UniProt.org). E329Q has not been characterized in the scientific literature and therefore, its effect on Cebpa protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21872
"CEBPA R288_V296delinsL results in the deletion of amino acids 288 to 296 of the Cebpa protein, followed by the insertion of a leucine (L). R288_V296delinsL has not been characterized in the scientific literature and therefore, its effect on Cebpa protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,21873
"CEBPA R306P lies within the bZIP domain of the Cebpa protein (UniProt.org). R306P has been identified in the scientific literature (PMID: 11830484, PMID: 22649106, PMID: 27288520), but has not been biochemically characterized and therefore, its effect on Cebpa protein function is unknown (PubMed, Sep 2017).",6946,27288520,Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27288520,8110,11830484,Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias.,http://www.ncbi.nlm.nih.gov/pubmed/11830484,8093,22649106,GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/22649106,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21874
"CEBPA E347G does not lie within any known functional domains of the Cebpa protein (UniProt.org). E347G has not been characterized in the scientific literature and therefore, its effect on Cebpa protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21875
"ATM negative indicates a lack of the ATM gene, mRAN, or protein. ",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,21876
"ASXL1 inact mut indicates that this variant results in a loss of function of the Asxl1 protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,21877
RUNX1 mutant indicates an unspecified mutation in the RUNX1 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,21880
GATA1 mutant indicates an unspecified mutation in the GATA1 gene. ,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,21890
"CEBPA T337A lies within the bZIP domain of the Cebpa protein (UniProt.org). T337A has not been characterized in the scientific literature and therefore, its effect on Cebpa protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21891
"CEBPA L324P lies within the bZIP domain of the Cebpa protein (UniProt.org). L324P has been identified in sequencing studies (PMID: 27288520), but has not been biochemically characterized and therefore, its effect on Cebpa protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,6946,27288520,Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27288520,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21892
"CEBPA K280N lies within the FOXO1-interacting region of the Cebpa protein (UniProt.org). K280N has not been characterized in the scientific literature and therefore, its effect on Cebpa protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21893
"CEBPA R339W lies within the basic leucine zipper DNA binding domain of the Cebpa protein (UniProt.org). R339W has not been characterized in the scientific literature and therefore, its effect on Cebpa protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21894
"CEBPA D301H lies within the bZIP domain of the Cebpa protein (UniProt.org). D301H has not been characterized in the scientific literature and therefore, its effect on Cebpa protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21895
"CEBPA D301N lies within the bZIP domain of the Cebpa protein (UniProt.org). D301N has been identified in sequencing studies (PMID: 27276561), but has not been biochemically characterized and therefore, its effect on Cebpa protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7052,27276561,Genomic Classification and Prognosis in Acute Myeloid Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27276561,21896
"CEBPA F82S lies within the first transactivation domain of the Cebpa protein (PMID: 11672531). F82S has been identified in sequencing studies (PMID: 26343386) not been biochemically characterized and therefore, its effect on Cebpa protein function is unknown (PubMed, Sep 2017).",5267,11672531,E2F repression by C/EBPalpha is required for adipogenesis and granulopoiesis in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/11672531,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7139,26343386,Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway.,http://www.ncbi.nlm.nih.gov/pubmed/26343386,21897
"CEBPA H195_P196dup indicates the insertion of two duplication amino acids, histidine (H)-195 and proline (P)-196 within a transcriptional activation domain of the Cebpa protein (PMID: 11242107). H195_P196dup is a common Cebpa polymorphism, but has not been biochemically characterized and therefore, its effect on Cebpa protein function is unknown (PMID: 25468431, PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5275,11242107,"Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/11242107,7548,25468431,A clinical grade sequencing-based assay for CEBPA mutation testing: report of a large series of myeloid neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/25468431,21898
"CEBPA K326N lies within the bZIP domain of the Cebpa protein (UniProt.org). K326N has not been characterized in the scientific literature and therefore, its effect on Cebpa protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21899
"CEBPA N293del results in the deletion of asparagine (N) within the basic leucine zipper DNA binding domain of the Cebpa protein domain (UniProt.org). N293del has been identified in the scientific literature (PMID: 18729193, PMID: 14726504), but has not been biochemically characterized and therefore, its effect on Cebpa protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8098,14726504,CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.,http://www.ncbi.nlm.nih.gov/pubmed/14726504,8097,18729193,CCAAT/enhancer binding protein-alpha polymorphisms occur more frequently than mutations in acute myeloid leukemia and exist across all cytogenetic risk groups and leukemia subtypes.,http://www.ncbi.nlm.nih.gov/pubmed/18729193,21900
"CEBPA P197Q lies within a transcriptional activation domain of the Cebpa protein (PMID: 11242107). P197Q has been identified in sequencing studies (PMID: 24997986), but has not been biochemically characterized and therefore, its effect on Cebpa protein function is unknown (PubMed, Sep 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5275,11242107,"Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/11242107,7076,24997986,Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway.,http://www.ncbi.nlm.nih.gov/pubmed/24997986,21901
"CEBPA Q312* results in a premature truncation of the Cebpa protein at amino acid 312 of 358 (UniProt.org). Due to the loss of the leucine zipper region (UniProt.org), Q312* is predicted to lead to a loss of Cebpa protein function. ",295,,,www.uniprot.org,21902
"CEBPA Y67* results in a premature truncation of the Cebpa protein at amino acid 67 of 358 (UniProt.org). Due to the loss of the basic leucine zipper DNA binding domain (UniProt.org), Cebpa is predicted to lead to a loss of Cebpa protein function.",295,,,www.uniprot.org,21903
TP53 L289D lies within the DNA binding region of the Tp53 protein (UniProt.org). L289D confers a loss of function to the Tp53 protein as demonstrated by reduced oligomerization of the pro-apoptotic protein Bak by Tp53 in an in vitro assay (PMID: 18524770).,3916,18524770,Oligomerization of BAK by p53 utilizes conserved residues of the p53 DNA binding domain.,http://www.ncbi.nlm.nih.gov/pubmed/18524770,295,,,www.uniprot.org,21904
"TP53 R282D lies within the DNA binding region of the Tp53 protein (UniProt.org). R282D confers a loss of function to the Tp53 protein as demonstrated by lack of DNA binding ability and impaired oligomerization of the pro-apoptotic protein Bak by Tp53 in an in vitro assay (PMID: 7651437, PMID: 18524770).",3916,18524770,Oligomerization of BAK by p53 utilizes conserved residues of the p53 DNA binding domain.,http://www.ncbi.nlm.nih.gov/pubmed/18524770,5293,7651437,Discrimination of DNA binding sites by mutant p53 proteins.,http://www.ncbi.nlm.nih.gov/pubmed/7651437,295,,,www.uniprot.org,21905
"TP53 R280D lies within the DNA binding region of the Tp53 protein (UniProt.org). R280D confers a loss of function to the Tp53 protein as demonstrated by lack of DNA binding ability and impaired oligomerization of the pro-apoptotic protein Bak by Tp53 in an in vitro assay (PMID: 7651437, PMID: 18524770).",3916,18524770,Oligomerization of BAK by p53 utilizes conserved residues of the p53 DNA binding domain.,http://www.ncbi.nlm.nih.gov/pubmed/18524770,295,,,www.uniprot.org,5293,7651437,Discrimination of DNA binding sites by mutant p53 proteins.,http://www.ncbi.nlm.nih.gov/pubmed/7651437,21906
TP53 E287A lies within the DNA binding region of the Tp53 protein (UniProt.org). E287A confers a loss of function to the Tp53 protein as demonstrated by impaired oligomerization of the pro-apoptotic protein Bak by Tp53 in an in vitro assay (PMID: 18524770).,3916,18524770,Oligomerization of BAK by p53 utilizes conserved residues of the p53 DNA binding domain.,http://www.ncbi.nlm.nih.gov/pubmed/18524770,295,,,www.uniprot.org,21907
TP53 D281A lies within the DNA binding region of the Tp53 protein (UniProt.org). D281A confers a loss of function to the Tp53 protein as demonstrated by impaired oligomerization of the pro-apoptotic protein Bak by Tp53 in an in vitro assay (PMID: 18524770).,295,,,www.uniprot.org,3916,18524770,Oligomerization of BAK by p53 utilizes conserved residues of the p53 DNA binding domain.,http://www.ncbi.nlm.nih.gov/pubmed/18524770,21908
TP53 K120A lies within the DNA binding region of the Tp53 protein (UniProt.org). K120A confers a loss of function to the Tp53 protein as demonstrated by impaired oligomerization of the pro-apoptotic protein Bak by Tp53 in an in vitro assay (PMID: 18524770).,295,,,www.uniprot.org,3916,18524770,Oligomerization of BAK by p53 utilizes conserved residues of the p53 DNA binding domain.,http://www.ncbi.nlm.nih.gov/pubmed/18524770,21909
"TP53 K120E lies within the DNA binding region of the Tp53 protein (UniProt.org). K120E confers a loss of function to the Tp53 protein as demonstrated by impaired oligomerization of the pro-apoptotic protein Bak, reduced apoptotic signaling, and resistance to apoptosis in cell culture (PMID: 18524770).",295,,,www.uniprot.org,3916,18524770,Oligomerization of BAK by p53 utilizes conserved residues of the p53 DNA binding domain.,http://www.ncbi.nlm.nih.gov/pubmed/18524770,21910
TP53 R283A lies within the DNA binding region of the Tp53 protein (UniProt.org). R283A confers a loss of function to the Tp53 protein as demonstrated by impaired oligomerization of the pro-apoptotic protein Bak by Tp53 in an in vitro assay (PMID: 18524770).,295,,,www.uniprot.org,3916,18524770,Oligomerization of BAK by p53 utilizes conserved residues of the p53 DNA binding domain.,http://www.ncbi.nlm.nih.gov/pubmed/18524770,21911
"TP53 T284A lies within the DNA binding region of the Tp53 protein (UniProt.org). T284A does not impair oligomerization of the pro-apoptotic protein Bak (PMID: 18524770), but has not been otherwise characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Nov 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3916,18524770,Oligomerization of BAK by p53 utilizes conserved residues of the p53 DNA binding domain.,http://www.ncbi.nlm.nih.gov/pubmed/18524770,21912
"GATA1 A211V lies within the GATA-type 1 zinc finger domain of the Gata1 protein (UniProt.org). A211V has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21913
"GATA1 A55T lies within the N-terminal transactivation domain of the Gata1 protein (PMID: 15684376). A55T has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5294,15684376,"GATA1 function, a paradigm for transcription factors in hematopoiesis.",http://www.ncbi.nlm.nih.gov/pubmed/15684376,21914
"GATA1 D115N does not lie within any known functional domains of the Gata1 protein (UniProt.org). D115N has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21915
"GATA1 E2K lies within the N-terminal transactivation domain of the Gata1 protein (PMID: 15684376). E2K as not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5294,15684376,"GATA1 function, a paradigm for transcription factors in hematopoiesis.",http://www.ncbi.nlm.nih.gov/pubmed/15684376,21916
"GATA1 E2Vfs*37 is a missense mutation (E2V) in conjunction with a likely truncation of the 413 aa Gata1 protein at aa 2, followed by 37 nonsense amino acids (UniProt.org). Due to the loss of all known functional domains (PMID: 15684376), E2Vfs*37 is predicted to lead to a loss of Gata1 protein function.",295,,,www.uniprot.org,5294,15684376,"GATA1 function, a paradigm for transcription factors in hematopoiesis.",http://www.ncbi.nlm.nih.gov/pubmed/15684376,21917
"GATA1 F172L does not lie within any known functional domains of the Gata1 protein (UniProt.org). F172L has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21918
"GATA1 G340S does not lie within any known functional domains of the Gata1 protein (UniProt.org). G340S has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21919
"GATA1 G366D does not lie within any known functional domains of the Gata1 protein (UniProt.org). G366D has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21920
"GATA1 G90Afs*47 is a missense mutation (G90A) in conjunction with a likely truncation of the 413 aa Gata1 protein at aa 90, followed by 47 nonsense amino acids (UniProt.org). Due to the loss of the zinc finger domains required for Gata1 function (PMID: 15684376), G90Afs*47 is predicted to lead to a loss of Gata1 protein function.",5294,15684376,"GATA1 function, a paradigm for transcription factors in hematopoiesis.",http://www.ncbi.nlm.nih.gov/pubmed/15684376,295,,,www.uniprot.org,21921
"GATA1 K312Q does not lie within any known functional domains of the Gata1 protein (UniProt.org). K312Q has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21922
"GATA1 L321V does not lie within any known functional domains of the Gata1 protein (UniProt.org). L321V has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21923
"GATA1 P159H does not lie within any known functional domains of the Gata1 protein (UniProt.org). P159H has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21924
"GATA1 P166T does not lie within any known functional domains of the Gata1 protein (UniProt.org). P166T has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21925
"GATA1 P358Qfs*74 is a missense mutation (P358Q) in conjunction with a likely truncation of the 413 aa Gata1 protein at aa 358, followed by 74 nonsense amino acids (UniProt.org). P358Qfs*74 has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21926
"GATA1 P401L does not lie within any known functional domains of the Gata1 protein (UniProt.org). P401L has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21927
"GATA1 Q303* results in a premature truncation of the Gata1 protein at amino acid 303 of 413 (UniProt.org). Q303* has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21928
"KDM6A V1205G lies within the JmjC domain of the Kdm6a protein (UniProt.org). V1205G has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, May 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21929
"GATA1 Q76* results in a premature truncation of the Gata1 protein at amino acid 76 of 413 (UniProt.org). Due to the loss of the zinc finger regions (UniProt.org), Q76* is predicted to lead to a loss of Gata1 protein function.",295,,,www.uniprot.org,21930
"KDM6A V1253G lies within the JmjC domain of the Kdm6a protein (UniProt.org). V1253G has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, May 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21931
"KDM6A V1338F does not lie within any known functional domains of the Kdm6a protein (UniProt.org). V1338F has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, May 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21932
"KDM6A V607M lies within the SUPT6H interaction domain of the Kdm6a protein (UniProt.org). V607M has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, May 2016). 
",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21933
"KDM6A V815F lies within the SUPT6H interaction domain of the Kdm6a protein (UniProt.org). V815F has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, May 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21934
"KDM6A W1239G lies within the JmjC domain of the Kdm6a protein (UniProt.org). W1239G has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, May 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21935
"KDM6A Y1173N lies within the JmjC domain of the Kdm6a protein (UniProt.org). Y1173N has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, May 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21936
"KDM6A S295* results in a premature truncation of the Kdm6a protein at amino acid 295 of 1401 (UniProt.org). Due to the loss of the JmjC domain (UniProt.org), S295* is predicted to lead to a loss of Kdm6a function. 

",295,,,www.uniprot.org,21937
"KDM6A S775* results in a premature truncation of the Kdm6a protein at amino acid 775 of 1401 (UniProt.org). Due to the loss of the JmjC domain (UniProt.org), S775* is predicted to lead to a loss of Kdm6a function. 

",295,,,www.uniprot.org,21938
"KDM6A Q1133* results in a premature truncation of the Kdm6a protein at amino acid 1133 of 1401 (UniProt.org). Due to the loss of the JmjC domain (UniProt.org), Q1133* is predicted to lead to a loss of Kdm6a function. 

",295,,,www.uniprot.org,21939
"GATA1 R113C does not lie within any known functional domains of the Gata1 protein (UniProt.org). R113C has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21940
"KDM6A Q117* results in a premature truncation of the Kdm6a protein at amino acid 117 of 1401 (UniProt.org). Due to the loss of the JmjC domain (UniProt.org), Q117* is predicted to lead to a loss of Kdm6a function. 

",295,,,www.uniprot.org,21941
"KDM6A Q1229* results in a premature truncation of the Kdm6a protein at amino acid 1229 of 1401 (UniProt.org). Q1229* has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, May 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21942
"GATA1 R113H does not lie within any known functional domains of the Gata1 protein (UniProt.org). R113H has not been characterized and therefore, its effect on Gata1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21943
"KDM6A Q1377* results in a premature truncation of the Kdm6a protein at amino acid 1377 of 1401 (UniProt.org). Q1377* has not been characterized and therefore, its effect on Kdm6a protein function is unknown (PubMed, May 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21944
"KDM6A Q333* results in a premature truncation of the Kdm6a protein at amino acid 333 of 1401 (UniProt.org). Due to the loss of the JmjC domain (UniProt.org), Q333* is predicted to lead to a loss of Kdm6a function. 
",295,,,www.uniprot.org,21945
"KDM6A Q369* results in a premature truncation of the Kdm6a protein at amino acid 369 of 1401 (UniProt.org). Due to the loss of the JmjC domain (UniProt.org), Q369* is predicted to lead to a loss of Kdm6a function. 
",295,,,www.uniprot.org,21946
"GATA1 R140W does not lie within any known functional domains of the Gata1 protein (UniProt.org). R140W has not been characterized and therefore, its effect on Gata1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21947
"GATA1 R298W does lie within any known functional domains of the Gata1 protein (UniProt.org). R298W has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21948
"KDM6A Q541* results in a premature truncation of the Kdm6a protein at amino acid 541 of 1401 (UniProt.org). Due to the loss of the JmjC domain (UniProt.org), Q541* is predicted to lead to a loss of Kdm6a function. 

",295,,,www.uniprot.org,21949
"GATA1 S116C does lie within any known functional domains of the Gata1 protein (UniProt.org). S116C has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21950
"GATA1 S129R does lie within any known functional domains of the Gata1 protein (UniProt.org). S129R has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21951
"GATA1 S187F does lie within any known functional domains of the Gata1 protein (UniProt.org). S187F has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21952
"GATA1 T130N does lie within any known functional domains of the Gata1 protein (UniProt.org). T130N has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21953
"GATA1 T176I does not lie within any known functional domains of the Gata1 protein (UniProt.org). T176I has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21954
"GATA1 T263M lies within the GATA-type 2 zinc finger region of the Gata1 protein (UniProt.org). T263M has not been characterized and therefore, its effect on Gata1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21955
"GATA1 T266M lies within the GATA-type 2 zinc finger region of the Gata1 protein (UniProt.org). T266M has not been characterized and therefore, its effect on Gata1 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21956
"GATA1 T391M does not lie within any known functional domains of the Gata1 protein (UniProt.org). T391M has not been chracerized and therefore, its effect on Gata1 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21957
"KDM6A Q555* results in a premature truncation of the Kdm6a protein at amino acid 555 of 1401 (UniProt.org). Due to the loss of the JmjC domain (UniProt.org), Q555* is predicted to lead to a loss of Kdm6a function. 
",295,,,www.uniprot.org,21958
"KDM6A W1193* results in a premature truncation of the Kdm6a protein at amino acid 1193 of 1401 (UniProt.org). W1193* has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, May 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21959
"KDM6A W1194* results in a premature truncation of the Kdm6a protein at amino acid 1194 of 1401 (UniProt.org). W1194* has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, May 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21960
"GATA1 V278M lies within the GATA-type 2 zinc finger region of the Gata1 protein (UniProt.org). V278M has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21961
"KDM6A Y1256* results in a premature truncation of the Kdm6a protein at amino acid 1256 of 1401 (UniProt.org). Y1256* has not been characterized and therefore, its effect on Kdm6a protein function is unknown (PubMed, May 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21962
"GATA1 W96R does not lie within any known functional domains of the Gata1 protein (UniProt.org). W96R has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21963
"KDM6A Y1256H lies within the JmjC domain of the Kdm6a protein (UniProt.org). Y1256H has not been characterized in the scientific literature and therefore, its effect on Kdm6a protein function is unknown (PubMed, May 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21964
"KDM6A Y126* results in a premature truncation of the Kdm6a protein at amino acid 126 of 1401 (UniProt.org). Due to the loss of the JmjC domain (UniProt.org), Y126* is predicted to lead to a loss of Kdm6a function. 
",295,,,www.uniprot.org,21965
"KDM6A Y126Tfs*54 is a missense mutation (Y126T) in conjunction with a likely truncation of the 1401 aa Kdm6a protein at aa 126, followed by 54 nonsense amino acids (UniProt.org). Due to the loss of the JmjC domain (UniProt.org), Y126Tfs*54 is predicted to lead to a loss of Kdm6a function. 

",295,,,www.uniprot.org,21966
"IKZF1 A441T does not lie within any known functional domains of the Ikzf1 protein (UniProt.org). A441T has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21967
"IKZF1 A79E does not lie within any known functional domains of the Ikzf1 protein (UniProt.org). A79E has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21968
"KMT2A A2571V does not lie within any known functional domains of the Kmt2a protein (UniProt.org). A2571V has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21969
"IKZF1 A79V does not lie within any known functional domains of the Ikzf1 protein (UniProt.org). A79V has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21970
"KMT2A A3737V lies within the FYR C-terminal domain of the Kmt2a protein (UniProt.org). A3737V has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21971
"KMT2A C1173R lies within the CXXC-type zinc finger domain of the Kmt2a protein (UniProt.org). C1173R has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21972
"KMT2A D2295N does not lie within any known functional domains of the Kmt2a protein (UniProt.org). D2295N has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21973
"IKZF1 C203W lies within the C2H2-type 4 zinc finger region of the Ikzf1 protein (UniProt.org). C203W has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21974
"KMT2A D2384E does not lie within any known functional domains of the Kmt2a protein (UniProt.org). D2384E has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21975
"IKZF1 D28N does not lie within any known functional doamins of the Ikzf1 protein (UniProt.org). D28N has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21976
"KMT2A D3876N lies within the SET domain of the Kmt2a protein (UniProt.org). D3876N has been identified in sequencing studies (PMID: 22895193), but has not been biochemically characterized and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4597,22895193,Recurrent R-spondin fusions in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22895193,21977
"IKZF1 E300K does not lie within any known functional doamins of the Ikzf1 protein (UniProt.org). E300K has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21978
"IKZF1 E401K does not lie within any known functional doamins of the Ikzf1 protein (UniProt.org). E401K has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21979
"IKZF1 E405K does not lie within any known functional doamins of the Ikzf1 protein (UniProt.org). E405K has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21980
"KMT2A D3921Y lies within the SET domain of the Kmt2a protein (UniProt.org). D3921Y has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21981
"IKZF1 G106E does not lie within any known functional doamins of the Ikzf1 protein (UniProt.org). G106E has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21982
"KMT2A D505N does not lie within any known functional domains of the Kmt2a protein (UniProt.org). D505N has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21983
"IKZF1 G190S lies within the C2H2-type 3 zinc finger region of the Ikzf1 protein (UniProt.org). G190S has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21984
"KMT2A E1060D does not lie within any known functional domains of the Kmt2a protein (UniProt.org). E1060D has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).",5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21985
"KMT2A E1984K does not lie within any known functional domains of the Kmt2a protein (UniProt.org). E1984K has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21986
"KMT2A E3448K does not lie within any known functional domains of the Kmt2a protein (UniProt.org). E3448K has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21987
"KMT2A E3938K lies within the SET domain of the Kmt2a protein (UniProt.org). E3938K has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21988
"KMT2A F1458S lies within the PHD-type 1 zinc finger domain of the Kmt2a protein (UniProt.org). F1458S has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,21989
"IKZF1 G43E does not lie within any known functional domains of the Ikzf1 protein (UniProt.org). G43E has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21990
"KMT2A F1481L lies within the PHD-type 1 zinc finger domain of the Kmt2a protein (UniProt.org). F1481L has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21991
"KMT2A G2610D does not lie within any known functional domains of the Kmt2a protein (UniProt.org). G2610D has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21992
"KMT2A G3376D does not lie within any known functional domains of the Kmt2a protein (UniProt.org). G3376D has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).

",5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21993
"KMT2A G3842S lies within the SET domain of the Kmt2a protein (UniProt.org). G3842S has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21994
"KMT2A G3899V lies within the SET domain of the Kmt2a protein (UniProt.org). G3899V has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21995
"KMT2A H3907D lies within the SET domain of the Kmt2a protein (UniProt.org). H3907D has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21996
"KMT2A K1103N does not lie within any known functional domains of the Kmt2a protein (UniProt.org). K1103N has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21997
"KMT2A K1256Q does not lie within any known functional domains of the Kmt2a protein (UniProt.org). K1256Q has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21998
"KMT2A K1321T does not lie within any known functional domains of the Kmt2a protein (UniProt.org). K1321T has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct  2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,21999
"KMT2A K1457N lies within the PHD-type 1 zinc finger domain of the Kmt2a protein (UniProt.org). K1457N has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22000
"KMT2A K2276T does not lie within any known functional domains of the Kmt2a protein (UniProt.org). K2276T has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22001
"KMT2A K246N does not lie within any known functional domains of the Kmt2a protein (UniProt.org). K246N has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22002
"KMT2A K254Q does not lie within any known functional domains of the Kmt2a protein (UniProt.org). K254Q has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22003
"KMT2A L3153V does not lie within any known functional domains of the Kmt2a protein (UniProt.org). L3153V has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22004
"KMT2A M2213V does not lie within any known functional domains of the Kmt2a protein (UniProt.org). M2213V has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22005
"IKZF1 G485D lies adjacent to the C2H2-type 5 zinc finger region of the Ikzf1 protein (UniProt.org). G485D has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22006
"IKZF1 G496C does not lie within any known functional domains of the Ikzf1 protein (UniProt.org). G496C has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22007
"IKZF1 H176L lies within the C2H2-type 3 zinc finger region of the Ikzf1 protein (UniProt.org). H176L has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22008
"IKZF1 H508R does not lie within any known functional domains of the Ikzf1 protein (UniProt.org). H508R has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22009
"IKZF1 L132F lies within the C2H2-type 1 zinc finger region of the Ikzf1 protein (UniProt.org). L132F has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22010
"IKZF1 P233Q does not lie within any known functional domains of the Ikzf1 protein (UniProt.org). P233Q has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22011
"IKZF1 P34S does not lie within any known functional domains of the Ikzf1 protein (UniProt.org). P34S has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22012
"IKZF1 R423H does not lie within any known functional domains of the Ikzf1 protein (UniProt.org). R423H has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22013
"IKZF1 R511P does not lie within any known functional domains of the Ikzf1 protein (UniProt.org). R511P has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22014
RUNX1 A107P lies within the Runt domain of the Runx1 protein (UniProt.org). A107P results in a loss of Runx1 transcriptional activity in culture (PMID: 23817177).,5672,23817177,RUNX1 meets MLL: epigenetic regulation of hematopoiesis by two leukemia genes.,http://www.ncbi.nlm.nih.gov/pubmed/23817177,295,,,www.uniprot.org,22015
"RUNX1 A107V lies within the Runt domain of the Runx1 protein (UniProt.org). A107V has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22016
"RUNX1 A115Gfs*2 is a missense mutation (A115G) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 115, followed by 2 nonsense amino acids (UniProt.org). Due to the loss of a portion of the runt homology domain and the loss of the entire transactivation domain, A115Gfs*2 is predicted to lead to a loss of Runx1 protein function (PMID: 25840971).",3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,295,,,www.uniprot.org,22017
"RUNX1 A122P lies within the Runt domain of the Runx1 protein (UniProt.org). A122P has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22018
"RUNX1 A208T does not lie within any known functional domains of the Runx1 protein (UniProt.org). A208T has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22019
"RUNX1 A217V does not lie within any known functional domains of the Runx1 protein (UniProt.org). A217V has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22020
"RUNX1 A288Rfs*284 is a missense mutation (A288R) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 288, followed by 284 nonsense amino acids (UniProt.org). A288Rfs*284 has not been characterized however, because other truncation mutations downstream of A288 are inactivating (Blood 2009 114 (22):3468), A288Rfs*284 is predicted to lead to a loss of Runx1 protein function.",295,,,www.uniprot.org,6488,,High Frequency of C-Terminal Frame-Shift Mutations of RUNX1 Gene in De Novo AML with Partial Tandem Duplication of MLL,http://www.bloodjournal.org/content/114/22/3468?sso-checked=true,22021
"RUNX1 A288V does not lie within any known functional domains of the Runx1 protein (UniProt.org). A288V has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22022
"RUNX1 A311T lies within the KAT6A-interacting region of the Runx1 protein (UniProt.org). A311T has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22023
"RUNX1 A36V does not lie within any known functional domains of the Runx1 protein (UniProt.org). A36V has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22024
"RUNX1 D133G lies within the Runt domain of the Runx1 protein (UniProt.org). D133G has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22025
"RUNX1 D57N lies within the Runt domain of the Runx1 protein (UniProt.org). D57N has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22026
"RUNX1 D66G lies within the Runt domain of the Runx1 protein (UniProt.org). D66G has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22027
"RUNX1 D96Gfs*11 is a missense mutation (D96G) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 96, followed by 11 nonsense amino acids (UniProt.org). Due to the loss of a portion of the runt homology domain and the loss of the entire transactivation domain, D96Gfs*11 is predicted to lead to a loss of Runx1 protein function (PMID: 25840971).",295,,,www.uniprot.org,3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,22028
"RUNX1 D96Gfs*15 is a missense mutation (D96G) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 96, followed by 15 nonsense amino acids (UniProt.org). Due to the loss of a portion of the runt homology domain and the loss of the entire transactivation domain, D96Gfs*15 is predicted to lead to a loss of Runx1 protein function (PMID: 25840971).",295,,,www.uniprot.org,3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,22029
"RUNX1 D96Mfs*10 is a missense mutation (D96M) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 96, followed by 10 nonsense amino acids (UniProt.org). Due to the loss of a portion of the runt homology domain and the loss of the entire transactivation domain, D96Mfs*10 is predicted to lead to a loss of Runx1 protein function (PMID: 25840971).",3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,295,,,www.uniprot.org,22030
"RUNX1 E116_A120del results in the deletion of five amino acids in the Runt domain of the Runx1 protein from amino acids 116 to 120 (UniProt.org). E116_A120del has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22031
"RUNX1 E27Q does not lie within any known functional domains of the Runx1 protein (UniProt.org). E27Q has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22032
"RUNX1 E289K does not lie within any known functional domains of the Runx1 protein (UniProt.org). E289K has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22033
"RUNX1 F70L lies within the Runt domain of the Runx1 protein (UniProt.org). F70L has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22034
"RUNX1 F89L lies within the Runt domain of the Runx1 protein (UniProt.org). F89L has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22035
"RUNX1 G100D lies within the Runt domain of the Runx1 protein (UniProt.org). G100D has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22036
RUNX1 G108D lies within the Runt domain of the Runx1 protein (UniProt.org). G108D results in a loss of DNA binding and inhibition of Runx1 protein transactivation activity of in cell culture (Blood 2009 114 (22):3468).,295,,,www.uniprot.org,6488,,High Frequency of C-Terminal Frame-Shift Mutations of RUNX1 Gene in De Novo AML with Partial Tandem Duplication of MLL,http://www.bloodjournal.org/content/114/22/3468?sso-checked=true,22037
"RUNX1 G138* results in a premature truncation of the Runx1 protein at amino acid 138 of 453 (UniProt.org). Due to the loss of a portion of the runt homology domain and the loss of the entire transactivation domain, G138* is predicted to lead to a loss of Runx1 protein function (PMID: 25840971).",295,,,www.uniprot.org,3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,22038
"RUNX1 G141R lies within the Runt domain and DNA-interacting region of the Runx1 protein (UniProt.org). G141R has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22039
"RUNX1 G143Efs*7 is a missense mutation (G143E) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 143, followed by 7 nonsense amino acids (UniProt.org). Due to the loss of a portion of the runt homology domain and the loss of the entire transactivation domain, G143Efs*7 is predicted to lead to a loss of Runx1 protein function (PMID: 25840971).",295,,,www.uniprot.org,3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,22040
RUNX1 G172E lies within the Runt domain of the Runx1 protein (UniProt.org). G172E confers a loss of function to Runx1 protein as indicated by failure to rescue hematopoietic differentiation in culture (PMID: 24732596).,5297,24732596,Impaired hematopoietic differentiation of RUNX1-mutated induced pluripotent stem cells derived from FPD/AML patients.,http://www.ncbi.nlm.nih.gov/pubmed/24732596,295,,,www.uniprot.org,22041
"RUNX1 G172R lies within the Runt domain of the Runx1 protein (UniProt.org). G172R has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22042
"RUNX1 G338S lies within the KAT6A-interacting region of the Runx1 protein (UniProt.org). G338S has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22043
"RUNX1 G393Hfs*172 is a missense mutation (G393H) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 393, followed by 172 nonsense amino acids (UniProt.org). G393Hfs*172 has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22044
"RUNX1 G95R lies within the Runt domain of the Runx1 protein (UniProt.org). G95R has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22045
"RUNX1 I166M lies within the Runt domain of the Runx1 protein (UniProt.org). I166M has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22046
"RUNX1 I315Hfs*258 is a missense mutation (I315H) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 315, followed by 258 nonsense amino acids (UniProt.org). I315Hfs*258 has not been characterized however, because other truncation mutations downstream of I315 are inactivating (Blood 2009 114 (22):3468), I315Hfs*258 is predicted to lead to a loss of Runx1 protein function.",6488,,High Frequency of C-Terminal Frame-Shift Mutations of RUNX1 Gene in De Novo AML with Partial Tandem Duplication of MLL,http://www.bloodjournal.org/content/114/22/3468?sso-checked=true,295,,,www.uniprot.org,22047
"RUNX1 K90* results in a premature truncation of the Runx1 protein at amino acid 90 of 453 (UniProt.org). Due to the loss of a portion of the runt homology domain and the loss of the entire transactivation domain, K90* is predicted to lead to a loss of Runx1 protein function (PMID: 25840971).",3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,295,,,www.uniprot.org,22048
"RUNX1 K90N lies within the Runt domain of the Runx1 protein (UniProt.org). K90N has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22049
"RUNX1 L134P lies within the Runt domain of the Runx1 protein (UniProt.org). L134P has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22050
"RUNX1 L134Pfs*52 is a missense mutation (L134P) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 134, followed by 52 nonsense amino acids (UniProt.org). Due to the loss of a portion of the runt homology domain and the loss of the entire transactivation domain, L134Pfs*52 is predicted to lead to a loss of Runx1 protein function (PMID: 25840971).",3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,295,,,www.uniprot.org,22051
"RUNX1 L198* results in a premature truncation of the Runx1 protein at amino acid 198 of 453 (UniProt.org). L198* has not been characterized however, because other truncation mutations downstream of L198 are inactivating (Blood 2009 114 (22):3468), L198* is predicted to lead to a loss of Runx1 protein function.",295,,,www.uniprot.org,6488,,High Frequency of C-Terminal Frame-Shift Mutations of RUNX1 Gene in De Novo AML with Partial Tandem Duplication of MLL,http://www.bloodjournal.org/content/114/22/3468?sso-checked=true,22052
"RUNX1 L261Tfs*24 is a missense mutation (L261T) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 261, followed by 24 nonsense amino acids (UniProt.org). L261Tfs*24 has not been characterized however, because other truncation mutations downstream of L261 are inactivating (Blood 2009 114 (22):3468), L261Tfs*24 is predicted to lead to a loss of Runx1 protein function.",295,,,www.uniprot.org,6488,,High Frequency of C-Terminal Frame-Shift Mutations of RUNX1 Gene in De Novo AML with Partial Tandem Duplication of MLL,http://www.bloodjournal.org/content/114/22/3468?sso-checked=true,22053
"RUNX1 L261V does not lie within any known functional domains of the Runx1 protein (UniProt.org). L261V has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22054
"RUNX1 L290F does not lie within any known functional domains of the Runx1 protein (UniProt.org). L290F has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22055
"RUNX1 M18I does not lie within any known functional domains of the Runx1 protein (UniProt.org). M18I has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22056
"RUNX1 M240I does not lie within any known functional domains of the Runx1 protein (UniProt.org). M240I has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22057
"RUNX1 M341V lies within the KAT6A-interacting region of the Runx1 protein (UniProt.org). M341V has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22058
"RUNX1 N112S lies within the Runt domain of the Runx1 protein (UniProt.org). N112S has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22059
"RUNX1 N69K lies within the Runt domain of the Runx1 protein (UniProt.org). N69K has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22060
"RUNX1 N82S lies within the Runt domain of the Runx1 protein (UniProt.org). N82S has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22061
"RUNX1 P11S does not lie within any known functional domains of the Runx1 protein (UniProt.org). P11S has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22062
"RUNX1 P157L lies within the Runt domain of the Runx1 protein (UniProt.org). P157L has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22063
"RUNX1 P216L does not lie within any known functional domains of the Runx1 protein (UniProt.org). P216L has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22064
"RUNX1 P216T does not lie within any known functional domains of the Runx1 protein (UniProt.org). P216T has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22065
"RUNX1 P220Afs*14 is a missense mutation (P220A) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 220, followed by 14 nonsense amino acids (UniProt.org). P220Afs*14 has not been characterized however, because other truncation mutations downstream of P220 are inactivating (Blood 2009 114 (22):3468), P220Afs*14 is predicted to lead to a loss of Runx1 protein function.",6488,,High Frequency of C-Terminal Frame-Shift Mutations of RUNX1 Gene in De Novo AML with Partial Tandem Duplication of MLL,http://www.bloodjournal.org/content/114/22/3468?sso-checked=true,295,,,www.uniprot.org,22066
"RUNX1 P22L does not lie within any known functional domains of the Runx1 protein (UniProt.org). P22L has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22067
"RUNX1 P267S does not lie within any known functional domains of the Runx1 protein (UniProt.org). P267S has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22068
"RUNX1 P323S lies within the KAT6A-interacting region of the Runx1 protein (UniProt.org). P323S has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22069
"RUNX1 P368L lies within the KAT6A-interacting region of the Runx1 protein (UniProt.org). P368L has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22070
"RUNX1 P76T lies within the Runt domain of the Runx1 protein (UniProt.org). P76T has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22071
"RUNX1 P86L lies within the Runt domain of the Runx1 protein (UniProt.org). P86L has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22072
"RUNX1 P86S lies within the Runt domain of the Runx1 protein (UniProt.org). P86S has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22073
"RUNX1 P98Qfs*8 is a missense mutation (P98Q) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 98, followed by 8 nonsense amino acids (UniProt.org). Due to the loss of a portion of the runt homology domain and the loss of the entire transactivation domain, P98Qfs*8 is predicted to lead to a loss of Runx1 protein function (PMID: 25840971).",295,,,www.uniprot.org,3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,22074
"RUNX1 Q186Rfs*24 is a missense mutation (Q186R) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 186, followed by 24 nonsense amino acids (UniProt.org). Q186Rfs*24 results in a loss of Runx1 transcription activity in culture (PMID: 25840971).",295,,,www.uniprot.org,3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,22075
"RUNX1 Q235* results in a premature truncation of the Runx1 protein at amino acid 235 of 453 (UniProt.org). Q235* has not been characterized however, because other truncation mutations downstream of Q235 are inactivating (Blood 2009 114 (22):3468), Q235* is predicted to lead to a loss of Runx1 protein function.",295,,,www.uniprot.org,6488,,High Frequency of C-Terminal Frame-Shift Mutations of RUNX1 Gene in De Novo AML with Partial Tandem Duplication of MLL,http://www.bloodjournal.org/content/114/22/3468?sso-checked=true,22076
"RUNX1 Q237* results in a premature truncation of the Runx1 protein at amino acid 237 of 453 (UniProt.org). Q237* has not been characterized however, because other truncation mutations downstream of Q237 are inactivating (Blood 2009 114 (22):3468), Q237* is predicted to lead to a loss of Runx1 protein function.",295,,,www.uniprot.org,6488,,High Frequency of C-Terminal Frame-Shift Mutations of RUNX1 Gene in De Novo AML with Partial Tandem Duplication of MLL,http://www.bloodjournal.org/content/114/22/3468?sso-checked=true,22077
"RUNX1 Q239* results in a premature truncation of the Runx1 protein at amino acid 239 of 453 (UniProt.org). Q239* has not been characterized however, because other truncation mutations downstream of Q239 are inactivating (Blood 2009 114 (22):3468), Q239* is predicted to lead to a loss of Runx1 protein function.",295,,,www.uniprot.org,6488,,High Frequency of C-Terminal Frame-Shift Mutations of RUNX1 Gene in De Novo AML with Partial Tandem Duplication of MLL,http://www.bloodjournal.org/content/114/22/3468?sso-checked=true,22078
"RUNX1 Q259Ifs*26 is a missense mutation (Q259I) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 259, followed by 26 nonsense amino acids (UniProt.org). Q259Ifs*26 has not been characterized however, because other truncation mutations downstream of Q259 are inactivating (Blood 2009 114 (22):3468), Q259Ifs*26 is predicted to lead to a loss of Runx1 protein function.",6488,,High Frequency of C-Terminal Frame-Shift Mutations of RUNX1 Gene in De Novo AML with Partial Tandem Duplication of MLL,http://www.bloodjournal.org/content/114/22/3468?sso-checked=true,295,,,www.uniprot.org,22079
"RUNX1 Q308R lies within the KAT6A-interacting region of the Runx1 protein (UniProt.org). Q308R has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22080
"RUNX1 R135S lies within the Runt domain and DNA-interacting region of the Runx1 protein (UniProt.org). R135S has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22081
"RUNX1 R142Kfs*44 is a missense mutation (R142K) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 142, followed by 44 nonsense amino acids (UniProt.org). Due to the loss a portion of the runt homology domain and the loss of the entire transactivation domain, R142Kfs*44 is predicted to lead to a loss of Runx1 protein function (PMID: 25840971).",3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,295,,,www.uniprot.org,22082
"RUNX1 R174* results in a premature truncation of the Runx1 protein at amino acid 174 of 453 (UniProt.org). Due to the loss of a portion of the runt homology domain and the loss of the entire transactivation domain, R174* is predicted to lead to a loss of Runx1 protein function (PMID: 25840971).",3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,295,,,www.uniprot.org,22083
"RUNX1 R174G lies within the Runt domain of the Runx1 protein (UniProt.org). R174G has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22084
"RUNX1 R180Q does not lie within any known functional domains of the Runx1 protein (UniProt.org). R180Q has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22085
"RUNX1 R205L does not lie within any known functional domains of the Runx1 protein (UniProt.org). R205L has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22086
"RUNX1 R205W does not lie within any known functional domains of the Runx1 protein (UniProt.org). R205W has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22087
RUNX1 R293* results in a premature truncation of the Runx1 protein at amino acid 293 of 453 (UniProt.org). R293* results in a loss of Runx1 transcription activity in culture (PMID: 25840971).,295,,,www.uniprot.org,6488,,High Frequency of C-Terminal Frame-Shift Mutations of RUNX1 Gene in De Novo AML with Partial Tandem Duplication of MLL,http://www.bloodjournal.org/content/114/22/3468?sso-checked=true,22088
"RUNX1 R307Afs*266 is a missense mutation (R307A) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 307, followed by 266 nonsense amino acids (UniProt.org). R307Afs*266 has not been characterized however, because other truncation mutations downstream of R307 are inactivating (Blood 2009 114 (22):3468), R307Afs*266 is predicted to lead to a loss of Runx1 protein function.",295,,,www.uniprot.org,6488,,High Frequency of C-Terminal Frame-Shift Mutations of RUNX1 Gene in De Novo AML with Partial Tandem Duplication of MLL,http://www.bloodjournal.org/content/114/22/3468?sso-checked=true,22089
"RUNX1 R307H lies within the KAT6A-interacting region of the Runx1 protein (UniProt.org). R307H has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22090
"RUNX1 R319H lies within the KAT6A-interacting region of the Runx1 protein (UniProt.org). R319H has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22091
"RUNX1 R349Hfs*221 is a missense mutation (R349H) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 349, followed by 221 nonsense amino acids (UniProt.org). R349Hfs*221 has not been characterized however, because other truncation mutations downstream of R349 are inactivating (Blood 2009 114 (22):3468), R349Hfs*221 is predicted to lead to a loss of Runx1 protein function.",295,,,www.uniprot.org,6488,,High Frequency of C-Terminal Frame-Shift Mutations of RUNX1 Gene in De Novo AML with Partial Tandem Duplication of MLL,http://www.bloodjournal.org/content/114/22/3468?sso-checked=true,22092
"RUNX1 R400H lies within the KAT6B and FOXP3-interacting regions of the Runx1 protein (UniProt.org). R400H has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22093
"RUNX1 R80H lies within the Runt domain and DNA-interacting region of the Runx1 protein (UniProt.org). R80H has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22094
"RUNX1 S114L lies within the Runt domain of the Runx1 protein (UniProt.org). S114L results in a loss of CBFbeta dimerization, but demonstrates DNA binding and transcription activity similar to wild type Runx1 in culture (PMID: 25840971).",3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,295,,,www.uniprot.org,22095
"RUNX1 S12L does not lie within any known functional domains of the Runx1 protein (UniProt.org). S12L has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22096
"RUNX1 S140_G141del results in the deletion of two amino acids in the Runt domain of the Runx1 protein from amino acids 140 to 141 (UniProt.org). S140_G141del has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22097
"RUNX1 S191Afs*4 is a missense mutation (S191A) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 191, followed by 4 nonsense amino acids (UniProt.org). Due to the loss of transactivation domain, S191Afs*4 is predicted to lead to a loss of Runx1 protein function (PMID: 25840971).",3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,295,,,www.uniprot.org,22098
"RUNX1 S218T does not lie within any known functional domains of the Runx1 protein (UniProt.org). S218T has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22099
"RUNX1 S249Tfs*322 is a missense mutation (S249T) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 249, followed by 322 nonsense amino acids (UniProt.org). S249Tfs*322 has not been characterized however, because other truncation mutations downstream of S249 are inactivating (Blood 2009 114 (22):3468), S249Tfs*322 is predicted to lead to a loss of Runx1 protein function.",295,,,www.uniprot.org,6488,,High Frequency of C-Terminal Frame-Shift Mutations of RUNX1 Gene in De Novo AML with Partial Tandem Duplication of MLL,http://www.bloodjournal.org/content/114/22/3468?sso-checked=true,22100
"RUNX1 S257Dfs*22 is a missense mutation (S257D) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 257, followed by 22 nonsense amino acids (UniProt.org). S257Dfs*22 has not been characterized however, because other truncation mutations downstream of S257 are inactivating (Blood 2009 114 (22):3468), S257Dfs*22 is predicted to lead to a loss of Runx1 protein function.",295,,,www.uniprot.org,6488,,High Frequency of C-Terminal Frame-Shift Mutations of RUNX1 Gene in De Novo AML with Partial Tandem Duplication of MLL,http://www.bloodjournal.org/content/114/22/3468?sso-checked=true,22101
"RUNX1 S268F does not lie within any known functional domains of the Runx1 protein (UniProt.org). S268F has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22102
"RUNX1 S276L does not lie within any known functional domains of the Runx1 protein (UniProt.org). S276L has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22103
"RUNX1 S287Cfs*285 is a missense mutation (S287C) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 287, followed by 285 nonsense amino acids (UniProt.org). S287Cfs*285 has not been characterized however, because other truncation mutations downstream of S287 are inactivating (Blood 2009 114 (22):3468), S287Cfs*285 is predicted to lead to a loss of Runx1 protein function.",295,,,www.uniprot.org,6488,,High Frequency of C-Terminal Frame-Shift Mutations of RUNX1 Gene in De Novo AML with Partial Tandem Duplication of MLL,http://www.bloodjournal.org/content/114/22/3468?sso-checked=true,22104
"RUNX1 S287F does not lie within any known functional domains of the Runx1 protein (UniProt.org). S287F has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22105
"RUNX1 S291A lies within the KAT6A-interacting region of the Runx1 protein (UniProt.org). S291A has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22106
"RUNX1 S295* results in a premature truncation of the Runx1 protein at amino acid 295 of 453 (UniProt.org). S295* has not been characterized however, because other truncation mutations downstream of S295 are inactivating (Blood 2009 114 (22):3468), S295* is predicted to lead to a loss of Runx1 protein function.",295,,,www.uniprot.org,6488,,High Frequency of C-Terminal Frame-Shift Mutations of RUNX1 Gene in De Novo AML with Partial Tandem Duplication of MLL,http://www.bloodjournal.org/content/114/22/3468?sso-checked=true,22107
"RUNX1 S295Ffs*278 is a missense mutation (S295F) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 295, followed by 278 nonsense amino acids (UniProt.org). S295Ffs*278 has not been characterized however, because other truncation mutations downstream of S295 are inactivating (Blood 2009 114 (22):3468), S295Ffs*278 is predicted to lead to a loss of Runx1 protein function.",295,,,www.uniprot.org,6488,,High Frequency of C-Terminal Frame-Shift Mutations of RUNX1 Gene in De Novo AML with Partial Tandem Duplication of MLL,http://www.bloodjournal.org/content/114/22/3468?sso-checked=true,22108
"RUNX1 S390F lies within the FOXP3 and KAT6B-interacting regions of the Runx1 protein (UniProt.org). S390F has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22109
"RUNX1 S433N does not lie within any known functional domains of the Runx1 protein (UniProt.org). S433N has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22110
"RUNX1 S9* results in a premature truncation of the Runx1 protein at amino acid 9 of 453 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), S9* is predicted to lead to a loss of Runx1 protein function.",295,,,www.uniprot.org,22111
"RUNX1 T121Mfs*6 is a missense mutation (T121M) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 121, followed by 6 nonsense amino acids (UniProt.org). Due to the loss of the proline/serine/threonine rich region at the C-terminus (UniProt.org), T121Mfs*6 is predicted to lead to a loss of Runx1 protein function.",295,,,www.uniprot.org,22112
"RUNX1 T187Pfs*23 is a missense mutation (T187P) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 187, followed by 23 nonsense amino acids (UniProt.org). Due to the loss of the entire transactivation domain, T187Pfs*23 is predicted to lead to a loss of Runx1 protein function (PMID: 25840971).",3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,295,,,www.uniprot.org,22113
"RUNX1 T219Hfs*15 is a missense mutation (T219H) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 219, followed by 15 nonsense amino acids (UniProt.org). T219Hfs*15 results in a loss of Runx1 transcription activity in culture (PMID: 25840971).",3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,295,,,www.uniprot.org,22114
"RUNX1 T219M does not lie within any known functional domains of the Runx1 protein (UniProt.org). T219M has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22115
"RUNX1 T273M does not lie within any known functional domains of the Runx1 protein (UniProt.org). T273M has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22116
"RUNX1 V211A does not lie within any known functional domains of the Runx1 protein (UniProt.org). V211A has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22117
"RUNX1 V269Qfs*13 is a missense mutation (V269Q) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 269, followed by 13 nonsense amino acids (UniProt.org). V269Qfs*13 has not been characterized however, because other truncation mutations downstream of V269 are inactivating (Blood 2009 114 (22):3468), V269Qfs*13 is predicted to lead to a loss of Runx1 protein function.",295,,,www.uniprot.org,6488,,High Frequency of C-Terminal Frame-Shift Mutations of RUNX1 Gene in De Novo AML with Partial Tandem Duplication of MLL,http://www.bloodjournal.org/content/114/22/3468?sso-checked=true,22118
"RUNX1 V91A lies within the Runt domain of the Runx1 protein (UniProt.org). V91A has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22119
"RUNX1 W252* results in a premature truncation of the Runx1 protein at amino acid 252 of 453 (UniProt.org). W252* has not been characterized however, because other truncation mutations downstream of W252 are inactivating (Blood 2009 114 (22):3468), W252* is predicted to lead to a loss of Runx1 protein function.",295,,,www.uniprot.org,6488,,High Frequency of C-Terminal Frame-Shift Mutations of RUNX1 Gene in De Novo AML with Partial Tandem Duplication of MLL,http://www.bloodjournal.org/content/114/22/3468?sso-checked=true,22120
"RUNX1 Y162H lies within the Runt domain of the Runx1 protein (UniProt.org). Y162H has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22121
"CEBPA T337M lies within the bZIP domain of the Cebpa protein (UniProt.org). T337M has been identified in sequencing studies (PMID: 24755471), but has not been biochemically characterized and therefore, its effect on Cebpa protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6962,24755471,Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24755471,22122
"IKZF1 R83* results in a premature truncation of the Ikzf1 protein at amino acid 83 of 519 (UniProt.org). Due to a loss of all known functional domains (UniProt.org), R83* is predicted to lead to a loss of Ikzf1 protein function.",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22123
"IKZF1 R83Q does not lie within any known functional domains of the Ikzf1 protein (UniProt.org). R83Q has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22124
"IKZF1 R97M does not lie within any known functional domains of the Ikzf1 protein (UniProt.org). R97M has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22125
"IKZF1 S393R does not lie within any known functional domains of the Ikzf1 protein (UniProt.org). S393R has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22126
"IKZF1 S427L does not lie within any known functional domains of the Ikzf1 protein (UniProt.org). S427L has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22127
"KMT2A N3084S does not lie within any known functional domains of the Kmt2a protein (UniProt.org). N3084S has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22128
"IKZF1 S88L does not lie within any known functional domains of the Ikzf1 protein (UniProt.org). S88L has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22129
"KMT2A P2148S does not lie within any known functional domains of the Kmt2a protein (UniProt.org). P2148S has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22130
"KMT2A P2846H does not lie within any known functional domains of the Kmt2a protein (UniProt.org). P2846H has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22131
"KMT2A P2928L does not lie within any known functional domains of the Kmt2a protein (UniProt.org). P2928L has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22132
"KMT2A P2946S does not lie within any known functional domains of the Kmt2a protein (UniProt.org). P2946S has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22133
"IKZF1 T333M does not lie within any known functional domains of the Ikzf1 protein (UniProt.org). T333M has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22134
"IKZF1 V53M does not lie within any known functional domains of the Ikzf1 protein (UniProt.org). V53M has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22135
"KMT2A P3095Q does not lie within any known functional domains of the Kmt2a protein (UniProt.org). P3095Q has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22136
"KMT2A P3407L does not lie within any known functional domains of the Kmt2a protein (UniProt.org). P3407L has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Apr 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22137
"KMT2A R1532C lies within the PHD-type 2 zinc finger domain of the Kmt2a protein (UniProt.org). R1532C has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct  2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22138
"KMT2A R1976Q does not lie within any known functional domains of the Kmt2a protein (UniProt.org). R1976Q has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22139
"KMT2A R2093M does not lie within any known functional domains of the Kmt2a protein (UniProt.org). R2093M has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22140
"KMT2A R2160Q does not lie within any known functional domains of the Kmt2a protein (UniProt.org). R2160Q has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22141
"KMT2A R2619C does not lie within any known functional domains of the Kmt2a protein (UniProt.org). R2619C has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22142
"KMT2A R3656W does not lie within any known functional domains of the Kmt2a protein (UniProt.org). R3656W has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22143
"KMT2A R3741Q lies within the FYR C-terminal domain of the Kmt2a protein (UniProt.org). R3741Q has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22144
KMT2A R3864C lies within the SET domain of the Kmt2a protein (UniProt.org). The functional effect of R3864C is conflicting as it demonstrates increased histone methyltransferase activity in the absence but decreased activity in the presence of WRA complex stimulation compared to wild type Kmt2a in in vitro assays (PMID: 28182322).,8546,28182322,Somatic cancer mutations in the MLL1 histone methyltransferase modulate its enzymatic activity and dependence on the WDR5/RBBP5/ASH2L complex.,http://www.ncbi.nlm.nih.gov/pubmed/28182322,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22145
"SETBP1 A1385T lies within the SET binding domain of the Setbp1 protein (PMID: 23222956). A1385T has not been characterized in the scientific litearturea and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22146
"SETBP1 A166T does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). A166T has not been characterized in the scientific litearturea and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22147
"SETBP1 A882V lies within the SKI homologous region (PMID: 23222956). A882V has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22148
"SETBP1 A96V does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). A96V has not been characterized in the scientific litearture and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22149
"SETBP1 D1465N lies within the SET binding domain of the Setbp1 protein (PMID: 23222956). D1465N has not been characterized in the scientific litearture and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22150
"SETBP1 D412Y does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). D412Y has not been characterized in the scientific litearture and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22151
"SETBP1 D76N does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). D76N has not been characterized in the scientific litearture and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22152
"SETBP1 D868Y lies within the SKI homologous region (PMID: 23222956). D868Y has not been characterized and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22153
"MET dec exp indicates decreased expression of the Met protein. However, the mechanism causing the decreased expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,22155
"SETBP1 A1193T does not lie within any known functional domain of the Setbp1 protein (PMID: 23222956). A1193T has not been characterized and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22156
"SETBP1 E1196* results in a premature truncation of the Setbp1 protein at amino acid 1196 of 1596 (UniProt.org). E1196* has not been characterized and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22157
"SETBP1 E366K does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). E366K has not been characterized and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22158
"SETBP1 E481D does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). E481D has not been characterized and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22159
"SETBP1 E520* results in a premature truncation of the Setbp1 protein at amino acid 520 of 1596 (UniProt.org). Due to the loss of all known functional domains (PMID: 23222956), E520* is predicted to lead to a loss of Setbp1 protein function.",295,,,www.uniprot.org,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22160
"SETBP1 E599K does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). E599K has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22161
"SETBP1 E599Q does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). E599Q has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22162
"SETBP1 E858K lies within the SKI homologous region of the Setbp1 protein (PMID: 23222956). E585K has not been characterized and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22163
"SETBP1 G1105S does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). G1105S has not been characterized and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22164
"SETBP1 G1105V does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). G1105V has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22165
"SETBP1 G870S lies within a beta-TrCP1 degradation motif in the SKI homologous region of the Setbp1 protein (PMID: 23222956). G870S confers a gain of function to the Setbp1 protein as demonstrated by increased protein stability, increased cell growth and decreased protein phosphatase activity (PMID: 23222956).",5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22166
"SETBP1 K118N does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). K118N has not been characterized and therefore, its effect on Setbp1 protein function is unkown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22167
"SETBP1 K591N does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). K591N has not been characterized and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22168
"SETBP1 K668T does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). K668T has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22169
"SETBP1 K884N lies within the SKI homologous region of the Setbp1 protein (PMID: 23222956). K884N has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22170
"SETBP1 K939M does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). K939M has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22171
"SETBP1 L1147F does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). L1147F has not been characterized and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22172
"RUNX1 E8Q does not lie within any known functional domains of the Runx1 protein (UniProt.org). E8Q has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22173
"RUNX1 F232Sfs*338 is a missense mutation (F232S) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 232, followed by 338 nonsense amino acids (UniProt.org). F232Sfs*338 has not been characterized however, because other truncation mutations downstream of F232 are inactivating (Blood 2009 114 (22):3468), F232Sfs*338 is predicted to lead to a loss of Runx1 protein function.",295,,,www.uniprot.org,6488,,High Frequency of C-Terminal Frame-Shift Mutations of RUNX1 Gene in De Novo AML with Partial Tandem Duplication of MLL,http://www.bloodjournal.org/content/114/22/3468?sso-checked=true,22174
"BRCA2 dec exp indicates decreased expression of the BRCA2 protein. However, the mechanism causing the decreased expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,22175
ETV6 mutant indicates an unspecified mutation in the ETV6 gene. ,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,22184
SF3B1 mutant indicates an unspecified mutation in the SF3B1 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,22185
"SETBP1 L1381F lies within the SET binding domain of the Setbp1 protein (PMID: 23222956). L1381F has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22186
"SETBP1 P1072H does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). P1072H has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22187
"SETBP1 P1338S lies within the SET binding domain of the Setbp1 protein (PMID: 23222956). P1338S has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22188
"SETBP1 P563S does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). P563S has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22189
"SETBP1 P696L does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). P696L has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22190
"SETBP1 P742L lies within the SKI homologous region of the Setbp1 protein (PMID: 23222956). P742L has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22191
"SETBP1 P983S does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). P983S has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22192
"SETBP1 Q378H does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). Q378H has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22193
"SETBP1 R1008C does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). R1008C has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22194
"SETBP1 R1019H lies within the AT hook domain 2 of the Setbp1 protein (PMID: 23222956). R1019H has not been characterized and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22195
"SETBP1 R1262K does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). R1262K has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22196
"SETBP1 R1262T does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). R1262T has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22197
"SETBP1 R1412W lies within SET binding domain of the Setbp1 protein (PMID: 23222956). R1412W has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22198
"SETBP1 R143C does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). R143C has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22199
"SETBP1 R143H does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). R143H has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22200
"SETBP1 R184K does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). R184K has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22201
"SETBP1 R530Q dose not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). R530Q has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22202
"SETBP1 R531M does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). R531M has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22203
"SETBP1 R544* results in a premature truncation of the Setbp1 protein at amino acid 544 of 1596 (UniProt.org). Due to the loss of all known functional domains (PMID: 23222956), R544* is predicted to lead to a loss of Setbp1 protein function.",295,,,www.uniprot.org,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22204
"SETBP1 R627H does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). R627H has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22205
"SETBP1 R727L lies within the SKI homologous region of the Setbp1 protein (PMID: 23222956). R727L has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22206
"SETBP1 R727Q lies within the SKI homologous region of the Setbp1 protein (PMID: 23222956). R727Q has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22207
"SETBP1 R727W lies within the SKI homologous region of the Setbp1 protein (PMID: 23222956). R727W has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22208
"SETBP1 R942Q does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). R942Q has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22209
"SETBP1 R942W does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). R942W has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22210
"SETBP1 R948C does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). R948C has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22211
"SETBP1 R948H does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). R948H has not been characterized and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22212
"SETBP1 R948S does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). R948S has not been characterized and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22213
"SETBP1 S1099Y does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). S1099Y has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22214
"SETBP1 S1287L does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). S1287L has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22215
"SETBP1 S1337I does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). S1337I has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22216
"SETBP1 S1337T does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). S1337T has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22217
"SETBP1 S23C does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). S23C has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22218
"SETBP1 S606F does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). S606F has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22219
"SETBP1 S65L does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). S65L has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22220
"SETBP1 S830F lies within the SKI homologous region of the Setbp1 protein (PMID: 23222956). S830F has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22221
"SETBP1 S716G lies within the SKI homologous region of the Setbp1 protein (PMID: 23222956). S716G has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22222
"SETBP1 S886L lies within the SKI homologous region of the Setbp1 protein (PMID: 23222956). S886L has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22223
"SETBP1 S944N does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). S994N has not been characterized and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22224
IKZF1 del indicates a deletion of the IKZF1 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,22225
"ETV6 inact mut indicates that this variant results in a loss of function of the Etv6 protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,22227
"SETBP1 T1308M lies within the SET binding domain of the Setbp1 binding protein (PMID: 23222956). T1308M has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22228
"SETBP1 T195M does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). T195M has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22229
"SETBP1 T852M lies within the SKI homologous region of the Setbp1 protein (PMID: 23222956). T852M has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22230
"SETBP1 V355F does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). V355F has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22231
"SETBP1 V355I does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). V355I has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22232
"SETBP1 V996M does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). V996M has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22233
"SETBP1 W222* results in a premature truncation of the Setbp1 protein at amino acid 222 of 1596 (UniProt.org). Due to the loss of all known functional domains of the Setbp1 protein (PMID: 23222956), W222* is predicted to lead to a loss of Setbp1 protein function. ",295,,,www.uniprot.org,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22234
"SETBP1 Y1263* results in a premature truncation of the Setbp1 protein at amino acid 1263 of 1596 (UniProt.org). Y1263* has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unkown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22235
"APC V1352A lies within the beta-catenin binding and down-regulation region of the Apc protein (PMID: 14672538). V1352A has been identified in sequencing studies (PMID: 26530882), but has not been biochemically characterized and therefore, its effect on Apc protein function is unknown (PubMed, Jun 2017).",7059,26530882,Targeted DNA Sequencing Detects Mutations Related to Susceptibility among Familial Non-medullary Thyroid Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26530882,285,,,http://www.ncbi.nlm.nih.gov/pubmed,2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,22238
"ATM C730Y does not lie within any known functional domains of the Atm protein (UniProt.org). C730Y has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22240
"BRCA2 R2108H does not lie within any known functional domains of the Brca2 protein (UniProt.org). R2108H has been described as non-pathogenic and like wild-type Brca2, is not sensitive to DNA damaging agents and has no effect on splicing or homologous recombination (PMID: 22678057).",2588,22678057,Functional evaluation of BRCA2 variants mapping to the PALB2-binding and C-terminal DNA-binding domains using a mouse ES cell-based assay.,http://www.ncbi.nlm.nih.gov/pubmed/22678057,22241
"BRCA2 N289H does not lie within any known functional domains of the Brca2 protein (UniProt.org). N289H is a common Brca2 polymorphism (UniProt.org, PMID: 15744044), but has not been biochemically characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",8957,15744044,Complete allelic analysis of BRCA1 and BRCA2 variants in young Nigerian breast cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/15744044,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22242
"BRCA2 N991D lies within a region of the Brca2 protein that interacts with Npm1 (UniProt.org). N991D is a common Brca2 polymorphism (UniProt.org, PMID: 18024013), but has not been biochemically characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, Nov 2016).",8958,18024013,Common variants of DNA repair genes and malignant melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/18024013,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22243
"BRCA2 E537Q does not lie within any known functional domains of the Brca2 protein (UniProt.org). E537Q has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, Jan 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22244
"JAK3 I688F lies within the protein kinase domain 1 of the Jak3 protein (UniProt.org). I688F has not been characterized and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22253
"KIT N80S lies within the Ig-like C2-type 1 domain of the Kit protein (UniProt.org). N80S has not been characterized and therefore, its effect on Kit protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22254
"MLH1 V384D does not lie within any known functional domains of the Mlh1 protein (UniProt.org). V384D is a common MLH1 polymorphism, but has not been biochemically characterized, however, has been associated with clinical response (PMID: 25823662).",5425,25823662,MLH1 V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients with EGFR L858R-positive lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25823662,295,,,www.uniprot.org,22258
"RET E136K does not lie within any known functional domains of the Ret protein (UniProt.org). E136K has not been characterized in the scientific literature and therefore, its effect on Ret protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22266
"ROS1 D1776H lies within the fibronectin type-III repeat domain of the Ros1 protein (UniProt.org). D1776H has been identified in sequencing studies (PMID: 25589003), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",6992,25589003,Sporadic hemangioblastomas are characterized by cryptic VHL inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/25589003,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22267
"TP53 T155P lies within the DNA-binding core domain of the Tp53 protein (PMID: 21561095). T155P has been identified in the scientific literature (PMID: 22991414, PMID: 24766216, PMID: 20385133), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Feb 2017).
",8000,24766216,Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/24766216,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7902,22991414,Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors.,http://www.ncbi.nlm.nih.gov/pubmed/22991414,8001,20385133,p53 inhibits tumor cell invasion via the degradation of snail protein in hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/20385133,2155,21561095,"Structural effects of the L145Q, V157F, and R282W cancer-associated mutations in the p53 DNA-binding core domain.",http://www.ncbi.nlm.nih.gov/pubmed/21561095,22270
"TP53 S215fs results in a change in the amino acid sequence of the Tp53 protein beginning at aa 215 of 393, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the disruption of the DNA binding domain and the loss of the oligomerization domain (UniProt.org, PMID: 21561095), S215fs is predicted to lead to a loss of Tp53 protein function.",295,,,www.uniprot.org,2155,21561095,"Structural effects of the L145Q, V157F, and R282W cancer-associated mutations in the p53 DNA-binding core domain.",http://www.ncbi.nlm.nih.gov/pubmed/21561095,22271
"ATRX loss indicates loss of the ATRX gene, mRNA or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,22272
BCOR mutant indicates an unspecified mutation in the BCOR gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,22273
"BCORL1 over exp indicates an over expression of the Bcorl1 protein. However, the mechanism causing the over expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,22274
SRSF2 mutant indicates an unspecified mutation in the SRSF2 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,22276
"RAD21 A377G lies within the WAPL and PDS5B interaction region of the Rad21 protein (UniProt.org). A377G has not been characterized and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22277
"RAD21 A595T does not lie within any known functional domains of the Rad21 protein (UniProt.org). A595T has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22278
"RAD21 D116E does not lie within any known functional domains of the Rad21 protein (UniProt.org). D116E has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22279
"RAD21 D118V does not lie within any known functional domains of the Rad21 protein (UniProt.org). D118V has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22280
"RAD21 D123Y does not lie within any known functional domains of the Rad21 protein (UniProt.org). D123Y has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22281
"RAD21 D125H does not lie within any known functional domains of the Rad21 protein (UniProt.org). D125H has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22282
"RAD21 D166N does not lie within any known functional domains of the Rad21 protein (UniProt.org). D166N has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22283
"RAD21 D213E does not lie within any known functional domains of the Rad21 protein (UniProt.org). D213E has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22284
"RAD21 D292H lies within the WAPL and PDS5B interaction region of the Rad21 protein (UniProt.org). D292H has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22285
"RAD21 D333H lies within the WAPL and PDS5B interaction region of the Rad21 protein (UniProt.org). D333H has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22286
"RAD21 D333N lies within the WAPL and PDS5B interaction region of the Rad21 protein (UniProt.org). D333N has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22287
"RAD21 D414E does not lie within any known functional domains of the Rad21 protein (UniProt.org). D414E has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22288
"RAD21 D484G does not lie within any known functional domains of the Rad21 protein (UniProt.org). D484G has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22289
"RAD21 D484H does not lie within any known functional domains of the Rad21 protein (UniProt.org). D484H has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22290
"RAD21 D550Y does not lie within any known functional domains of the Rad21 protein (UniProt.org). D550Y has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22291
"RAD21 D95H does not lie within any known functional domains of the Rad21 protein (UniProt.org). D95H has not been characterized and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22292
"RAD21 E419K does not lie within any known functional domains of the Rad21 protein (UniProt.org). E419K has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22293
"RAD21 E453Dfs*3 is a missense mutation (E453D) in conjunction with a likely truncation of the 631 aa Rad21 protein at aa 453, followed by 3 nonsense amino acids (UniProt.org). E453Dfs*3 has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22294
"RAD21 E495D does not lie within any known functional domains of the Rad21 protein (UniProt.org). E495D has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22295
"RAD21 E508Q does not lie within any known functional domains of the Rad21 protein (UniProt.org). E508Q has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22296
"RAD21 E98Q does not lie within any known functional domains of the Rad21 protein (UniProt.org). E98Q has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22297
"RAD21 F114C does not lie within any known functional domains of the Rad21 protein (UniProt.org). F114C has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22298
"RAD21 F373L lies within the WAPL and PDS5B interaction region of the Rad21 protein (UniProt.org). F373L has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22299
"RAD21 F82I does not lie within any known functional domains of the Rad21 protein (UniProt.org). F82I has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22300
"RAD21 G150V does not lie within any known functional domains of the Rad21 protein (UniProt.org). G150V has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22301
"RAD21 G223* results in a premature truncation of the Rad21 protein at amino acid 223 of 631 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), G223* is predicted to lead to a loss of Rad21 protein function.",295,,,www.uniprot.org,22302
"RAD21 G240S does not lie within any known functional domains of the Rad21 protein (UniProt.org). G240S has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22303
"RAD21 G62E does not lie within any known functional domains of the Rad21 protein (UniProt.org). G62E has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22304
"RAD21 H629Y does not lie within any known functional domains of the Rad21 protein (UniProt.org). H629Y has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22305
"RAD21 I154T does not lie within any known functional domains of the Rad21 protein (UniProt.org). I154T has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22306
"RAD21 I44V does not lie within any known functional domains of the Rad21 protein (UniProt.org). I44V has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22307
"RAD21 K29T does not lie within any known functional domains of the Rad21 protein (UniProt.org). K29T has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22308
"RAD21 K335N lies within the WAPL and PDS5B interaction region of the Rad21 protein (UniProt.org). K335N has not been characterized and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22309
"RAD21 K596E does not lie within any known functional domains of the Rad21 protein (UniProt.org). K596E has not been characterized and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22310
"RAD21 L341R lies within the WAPL and PDS5B interaction region of the Rad21 protein (UniProt.org). L341R has not been characterized and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22311
"RAD21 L564F does not lie within any known functional domains of the Rad21 protein (UniProt.org). L564F has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22312
"RAD21 L567V does not lie within any known functional domains of the Rad21 protein (UniProt.org). L567V has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22313
"RAD21 L582P does not lie within any known functional domains of the Rad21 protein (UniProt.org). L582P has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22314
"RAD21 M362L lies within the WAPL and PDS5B interaction region of the Rad21 protein (UniProt.org). M362L has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22315
"RAD21 P283L does not lie within any known functional domains of the Rad21 protein (UniProt.org). P283L has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22316
"RAD21 P426S does not lie within any known functional domains of the Rad21 protein (UniProt.org). P426S has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22317
"RAD21 P443L does not lie within any known functional domains of the Rad21 protein (UniProt.org). P443L has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22318
"RAD21 P506L does not lie within any known functional domains of the Rad21 protein (UniProt.org). P506L has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22319
"RAD21 P509H does not lie within any known functional domains of the Rad21 protein (UniProt.org). P509H has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22320
"RAD21 P509L does not lie within any known functional domains of the Rad21 protein (UniProt.org). P509L has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22321
"RAD21 Q214K does not lie within any known functional domains of the Rad21 protein (UniProt.org). Q214K has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22322
"RAD21 Q293E lies within the WAPL and PDS5B interaction region of the Rad21 protein (UniProt.org). Q293E has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22323
"RAD21 Q474* results in a premature truncation of the Rad21 protein at amino acid 474 of 631 (UniProt.org). Q474* has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22324
"RAD21 Q551* results in a premature truncation of the Rad21 protein at amino acid 551 of 631 (UniProt.org). Q551* has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22325
"RAD21 R168C does not lie within any known functional domains of the Rad21 protein (UniProt.org). R168C has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22326
"RAD21 R391H lies within the WAPL and PDS5B interaction region of the Rad21 protein (UniProt.org). R391H has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22327
"RAD21 R437H does not lie within any known functional domains of the Rad21 protein (UniProt.org). R437H has not been characterized and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22328
"RAD21 R54Q does not lie within any known functional domains of the Rad21 protein (UniProt.org). R54Q has not been characterized and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22329
"RAD21 R54W does not lie within any known functional domains of the Rad21 protein (UniProt.org). R54W has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22330
"RAD21 R586* results in a premature truncation of the Rad21 protein at amino acid 586 of 631 (UniProt.org). R586* has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22331
"RAD21 R65Q does not lie within any known functional domains of the Rad21 protein (UniProt.org). R65Q has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22332
"RAD21 R90W does not lie within any known functional domains of the Rad21 protein (UniProt.org). R90W has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22333
"RAD21 S200C does not lie within any known functional domains of the Rad21 protein (UniProt.org). S200C has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22334
"RAD21 S374F lies within the WAPL and PDS5B interaction region of the Rad21 protein (UniProt.org). S374F has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22335
"RAD21 T390A lies within the WAPL and PDS5B interaction region of the Rad21 protein (UniProt.org). T390A has not been characterized and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22336
"STAG2 N357fs results in a change in the amino acid sequence of the Stag2 protein beginning at aa 357 of 1231, likely resulting in premature truncation of the functional protein (UniProt.org). N357fs results in a loss of Stag2 protein expression and defective sister chromatid cohesion and is associated with chromosomal instability in cell culture (PMID: 21852505).",5470,21852505,Mutational inactivation of STAG2 causes aneuploidy in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21852505,295,,,www.uniprot.org,22337
"RAD21 V129L does not lie within any known functional domains of the Rad21 protein (UniProt.org). V129L has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22338
"RAD21 V284I does not lie within any known functional domains of the Rad21 protein (UniProt.org). V284I has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22339
"STAG2 S653* results in a premature truncation of the Stag2 protein at amino acid 653 of 1231 (UniProt.org). S653* results in a loss of Stag2 protein expression and defective sister chromatid cohesion, and is associated with chromosomal instability in cell culture (PMID: 21852505).",295,,,www.uniprot.org,5470,21852505,Mutational inactivation of STAG2 causes aneuploidy in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21852505,22340
"RAD21 V32M does not lie within any known functional domains of the Rad21 protein (UniProt.org). V32M has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,115,0,,http://www.ncbi.nlm.nih.gov/pubmed,22341
"STAG2 dec exp indicates decreased expression of the Stag2 protein. However, the mechanism causing the decreased expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,22342
"RAD21 V41M does not lie within any known functional domains of the Rad21 protein (UniProt.org). V41M has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22343
"RAD21 W18C does not lie within any known functional domains of the Rad21 protein (UniProt.org). W18C has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22344
"RAD21 Y617C does not lie within any known functional domains of the Rad21 protein (UniProt.org). Y617C has not been characterized in the scientific literature and therefore, its effect on Rad21 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22345
"SF3B1 A1047S lies within the HEAT repeat 8 region of the Sf3b1 protein (UniProt.org). A1047S has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22346
"SF3B1 A176T does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). A176T has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22347
"SF3B1 A284T lies within the RBM39 interaction region of the Sf3b1 protein (UniProt.org). A284T has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22348
"SF3B1 A601T lies within the HEAT repeat 2 region of the Sf3b1 protein (UniProt.org). A601T has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22349
"SF3B1 A633V lies within the HEAT repeat 3 region of the Sf3b1 protein (UniProt.org). A633V has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22350
"SF3B1 A708V lies within the HEAT repeat 5 region of the Sf3b1 protein (UniProt.org). A708V has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22351
"SF3B1 A713T lies within the HEAT repeat 5 region of the Sf3b1 protein (UniProt.org). A713T has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22352
"SF3B1 A847V lies within the HEAT repeat 7 region of the Sf3b1 protein (UniProt.org). A847V has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22353
"SF3B1 A86T does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). A86T has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22354
"SF3B1 A899S does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). A899S has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22355
"SF3B1 A959V does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). A959V has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22356
"SF3B1 A996S does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). A996S has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22357
"SF3B1 D1015G lies within the HEAT repeat 8 region of the Sf3b1 protein (UniProt.org). D1015G has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22358
"SF3B1 D1175Y lies within the HEAT repeat 11 region of the Sf3b1 protein (UniProt.org). D1175Y has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22359
"SF3B1 D219E lies within the RBM39 interaction region of the Sf3b1 protein (UniProt.org). D219E has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22360
"SF3B1 D255N lies within the RBM39 interaction region of the Sf3b1 protein (UniProt.org). D255N has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22361
"SF3B1 D781E lies within the HEAT repeat 6 region of the Sf3b1 protein (UniProt.org). D781E has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22362
"SF3B1 D894del results in the deletion of one amino acid of the Sf3b1 protein at amino acid 894 (UniProt.org). D894del has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22363
"SF3B1 D894G does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). D894G has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22364
"SF3B1 D894N does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). D894N has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22365
"SF3B1 D907Y does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). D907Y has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22366
"SF3B1 E1029K lies within the HEAT repeat 8 region of the Sf3b1 protein (UniProt.org). E1029K has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22367
"SF3B1 E1221Q does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). E1221Q has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22368
"SF3B1 E17* results in a premature truncation of the Sf3b1 protein at amino acid 17 of 1304 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), E17* is predicted to lead to a loss of Sf3b1 protein function.",295,,,www.uniprot.org,22369
"SF3B1 E490K lies within the PPP1R8 interaction region of the Sf3b1 protein (UniProt.org). E490K has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22370
"SF3B1 E622Q lies within the HEAT repeat 3 region of the Sf3b1 protein (UniProt.org). E622Q has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22371
"SF3B1 E722K does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). E722K has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22372
"SF3B1 E862K lies within the HEAT repeat 7 region of the Sf3b1 protein (UniProt.org). E862K has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22373
"SF3B1 E902K does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). E902K has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22374
"SF3B1 E99G does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). E99G has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22375
"SF3B1 G241* results in a premature truncation of the Sf3b1 protein at amino acid 241 of 1304 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), G241* is predicted to lead to a loss of Sf3b1 protein function.",295,,,www.uniprot.org,22376
"SF3B1 G330* results in a premature truncation of the Sf3b1 protein at amino acid 330 of 1304 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), G330* is predicted to lead to a loss of Sf3b1 protein function.",295,,,www.uniprot.org,22377
"SF3B1 G664D lies within the HEAT repeat 4 region of the Sf3b1 protein (UniProt.org). G664D has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22378
"SF3B1 G740E does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). G740E has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22379
"SF3B1 G740V does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). G740V has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22380
"SF3B1 G742D does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). G742D demonstrates similar effects on erythoid differentiation in cell culture as wild-type Sf3b1 (Cancer Res August 1, 2015 75; 2040).",295,,,www.uniprot.org,5479,,Mutations in SF3B1 lead to aberrant splicing through cryptic 3? splice site selection and impair hematopoietic cell differentiation,http://cancerres.aacrjournals.org/content/75/15_Supplement/2040,22381
"SF3B1 G922D does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). G922D has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22382
"SF3B1 H1256Y does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). H1256Y has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22383
SF3B1 H662Q lies within the HEAT repeat 4 region of the Sf3b1 protein (UniProt.org). H662Q confers a gain of function on Sf3b1 protein as indicated by aberrant mRNA splicing in cell culture (PMID: 26565915).,5480,26565915,Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point.,http://www.ncbi.nlm.nih.gov/pubmed/26565915,295,,,www.uniprot.org,22384
"SF3B1 H662R lies within the HEAT repeat 4 region of the Sf3b1 protein (UniProt.org). H662R has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22385
"SF3B1 I1073M lies within the HEAT repeat 9 region of the Sf3b1 protein (UniProt.org). I1073M has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22386
"SF3B1 I1241M does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). I1241M has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22387
"SF3B1 I1241T does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). I1241T has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22388
"SF3B1 I1268M does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). I1268M has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22389
"SF3B1 I1274F does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). I1274F has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22390
"SF3B1 I665F lies within the HEAT repeat 4 region of the Sf3b1 protein (UniProt.org). I665F has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22391
"SF3B1 K120Q does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). K120Q has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22392
"KMT2A-MLLT10 results from the fusion of KMT2A (MLL) and MLLT10 (AF10), resulting in the transformation of primitive myeloid progenitor cells in mouse models, which eventually leads to leukemogenesis (PMID: 11986236).",5484,11986236,The AF10 leucine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10.,http://www.ncbi.nlm.nih.gov/pubmed/11986236,22393
"SF3B1 K121M does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). K121M has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22394
"SF3B1 K357M lies within the PPP1R8 interaction region of the Sf3b1 protein (UniProt.org). K357M has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22395
"SF3B1 K666E lies within the HEAT repeat 4 region of the Sf3b1 protein (UniProt.org). K666E has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22396
SF3B1 K666N lies within the HEAT repeat 4 region of the Sf3b1 protein (UniProt.org). K666N confers a gain of function on Sf3b1 protein as indicated by aberrant mRNA splicing in cell culture (PMID: 26565915).,295,,,www.uniprot.org,5480,26565915,Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point.,http://www.ncbi.nlm.nih.gov/pubmed/26565915,22397
SF3B1 K666T lies within the HEAT repeat 4 region of the Sf3b1 protein (UniProt.org). K666T confers a gain of function on Sf3b1 protein as indicated by aberrant mRNA splicing in cell culture (PMID: 26842708).,295,,,www.uniprot.org,5325,26842708,Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage.,http://www.ncbi.nlm.nih.gov/pubmed/26842708,22398
"ABL1 E275D lies within the protein kinase domain of the Abl1 protein (UniProt.org). E275D has not been characterized in the scientific literature and therefore, its effect on Abl1 protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22399
"ABL1 E450G lies within the protein kinase domain of the Abl1 protein (UniProt.org). E450G has been identified in sequencing studies (PMID: 20512393), but has not been biochemically characterized and therefore, its effect on Abl1 protein function is unknown (PubMed, Feb 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7904,20512393,Rapid and sensitive allele-specific (AS)-RT-PCR assay for detection of T315I mutation in chronic myeloid leukemia patients treated with tyrosine-kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/20512393,22400
"ABL1 T277I lies within the protein kinase domain of the Abl1 protein (UniProt.org). T277I has been identified in sequencing studies (PMID: 26164066), but has not been biochemically characterized and therefore, its effect on Abl1 protein function is unknown (PubMed, Feb 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7776,26164066,Spectrum of gene mutations detected by next generation exome sequencing in brain metastases of lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/26164066,22401
"ABL1 E507G does not lie within any known functional domains of the Abl1 protein (UniProt.org). E507G has been identified in sequencing studies (PMID: 26603839), but has not been biochemically characterized and therefore, its effect on Abl1 protein function is unknown (PubMed, Feb 2017).
",5509,26603839,Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.,http://www.ncbi.nlm.nih.gov/pubmed/26603839,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22402
"ABL1 P310L lies within the protein kinase domain of the Abl1 protein (UniProt.org). P310L has been identified in sequencing studies (PMID: 26603839), but has not been biochemically characterized and therefore, its effect on Abl1 protein function is unknown (PubMed, Feb 2017).",5509,26603839,Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.,http://www.ncbi.nlm.nih.gov/pubmed/26603839,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22403
"ABL1 G250W lies within the protein kinase domain of the Abl1 protein (UniProt.org). G250W has not been characterized in the scientific literature and therefore, its effect on Abl1 protein function is unknown (PubMed, Feb 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22404
"ABL1 E459K lies within the protein kinase domain of the Abl1 protein (UniProt.org). E459K has not been biochemically characterized, but has been identified as a secondary drug resistance mutation in the context of BCR-ABL (PMID: 19201023).",295,,,www.uniprot.org,5487,19201023,"Structural modeling of V299L and E459K Bcr-Abl mutation, and sequential therapy of tyrosine kinase inhibitors for the compound mutations.",http://www.ncbi.nlm.nih.gov/pubmed/19201023,22405
"MET negative indicates a lack of the MET gene, mRNA, and/or protein. ",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,22406
"SF3B1 K700E lies within the HEAT repeat 1 region of the Sf3b1 protein (UniProt.org). K700E confers a gain of function on Sf3b1 protein as indicated by aberrant mRNA splicing in cell culture and knock-in animal models (PMID: 26565915, PMID: 27818134).",7486,27818134,Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27818134,295,,,www.uniprot.org,5480,26565915,Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point.,http://www.ncbi.nlm.nih.gov/pubmed/26565915,22407
"SF3B1 K700R lies within the HEAT repeat 5 region of the Sf3b1 protein (UniProt.org). K700R promotes erythoid differentiation and demonstrates mRNA splicing pattern similar to wild-type SF3B1 in culture (PMID: 26565915, ASH AEE Dec 2014, Abstract  #4615).",295,,,www.uniprot.org,5480,26565915,Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point.,http://www.ncbi.nlm.nih.gov/pubmed/26565915,5497,,Cancer-Associated Mutations in SF3B1 Exhibit Neomorphic Splicing Activity and Block Erythroid Differentiation,https://ash.confex.com/ash/2014/webprogram/Paper72943.html,22408
"SF3B1 K741E does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). K741E has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22409
"SF3B1 K741N does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). K741N has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22410
"SF3B1 K741Q does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). K741Q has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22411
"SF3B1 K741T does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). K741T has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22412
"SF3B1 K786Q lies within the HEAT repeat 6 region of the Sf3b1 protein (UniProt.org). K786Q has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22413
"SF3B1 L1212M does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). L1212M has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22414
"SF3B1 L1280F does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). L1280F has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22415
"SF3B1 L464F lies within the PPP1R8 interaction region of the Sf3b1 protein (UniProt.org). L464F has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22416
"SF3B1 L544P lies within the HEAT repeat 1 region of the Sf3b1 protein (UniProt.org). L544P has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22417
"SF3B1 L773R lies within the HEAT repeat 6 region of the Sf3b1 protein (UniProt.org). L773R has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22418
"SF3B1 M1195V lies within the HEAT repeat 11 region of the Sf3b1 protein (UniProt.org). M1195V has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22419
"SF3B1 M876L lies within the HEAT repeat 7 region of the Sf3b1 protein (UniProt.org). M876L has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22420
"SF3B1 M962I does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). M962I has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22421
"SF3B1 N185S does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). N185S has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22422
"SF3B1 N626D lies within the HEAT repeat 3 region of the Sf3b1 protein (UniProt.org). N626D has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22423
"SF3B1 N626H lies within the HEAT repeat 3 region of the Sf3b1 protein (UniProt.org). N626H has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22424
"SF3B1 P135S does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). P135S has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22425
"SF3B1 P228S lies within the RBM39 interaction region of the Sf3b1 protein (UniProt.org). P228S has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22426
"SF3B1 P279S lies within the RBM39 interaction region of the Sf3b1 protein (UniProt.org). P279S has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22427
"SF3B1 P370L lies within the PPP1R8 interaction region of the Sf3b1 protein (UniProt.org). P370L has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22428
"SF3B1 P409Q lies within the PPP1R8 interaction region of the Sf3b1 protein (UniProt.org). P409Q has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22429
"SF3B1 P465S lies within the PPP1R8 interaction region of the Sf3b1 protein (UniProt.org). P465S has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22430
"SF3B1 P642L does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). P642L has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22431
"SF3B1 P718L lies within the HEAT repeat 5 region of the Sf3b1 protein (UniProt.org). P718L has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22432
"SF3B1 P812S does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). P812S has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22433
"SF3B1 P930S does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). P930S has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22434
"SF3B1 Q220K lies within the RBM39 interaction region of the Sf3b1 protein (UniProt.org). Q220K has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22435
"SF3B1 Q473E lies within the PPP1R8 interaction region of the Sf3b1 protein (UniProt.org). Q473E has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22436
"SF3B1 Q518R lies within the SF3B14 interaction region of the Sf3b1 protein (UniProt.org). Q518R has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22437
"SF3B1 Q669H lies within the HEAT repeat 4 region of the Sf3b1 protein (UniProt.org). Q669H has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22438
"SF3B1 Q901R does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). Q901R has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22439
"SF3B1 R1041H lies within the HEAT repeat 8 region of the Sf3b1 protein (UniProt.org). R1041H has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22440
"SF3B1 R1245T does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). R1245T has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22441
"SF3B1 R1297C does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). R1297C has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22442
"SF3B1 R1297H does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). R1297H has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22443
"SF3B1 R16* results in a premature truncation of the Sf3b1 protein at amino acid 16 of 1304 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), R16* is predicted to lead to a loss of Sf3b1 protein function.",295,,,www.uniprot.org,22444
"SF3B1 R292K lies within the RBM39 interaction region of the Sf3b1 protein (UniProt.org). R292K has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22445
"SF3B1 R315L lies within the RBM39 interaction region of the Sf3b1 protein (UniProt.org). R315L has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22446
"SF3B1 R318* results in a premature truncation of the Sf3b1 protein at amino acid 318 of 1304 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), R318* is predicted to lead to a loss of Sf3b1 protein function.",295,,,www.uniprot.org,22447
"SF3B1 R334I lies within the RBM39 interaction region of the Sf3b1 protein (UniProt.org). R334I has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22448
"SF3B1 R387Q lies within the PPP1R8 interaction region of the Sf3b1 protein (UniProt.org). R387Q has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22449
"SF3B1 R387W lies within the PPP1R8 interaction region of the Sf3b1 protein (UniProt.org). R387W has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22450
"SF3B1 R397H lies within the PPP1R8 interaction region of the Sf3b1 protein (UniProt.org). R397H has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22451
"SF3B1 R425Q lies within the PPP1R8 interaction region of the Sf3b1 protein (UniProt.org). R425Q has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22452
"SF3B1 R451L lies within the PPP1R8 interaction region of the Sf3b1 protein (UniProt.org). R451L has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22453
"SF3B1 R451Q lies within the PPP1R8 interaction region of the Sf3b1 protein (UniProt.org). R451Q has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22454
"SF3B1 R549C lies within the HEAT repeat 1 region of the Sf3b1 protein (UniProt.org). R549C has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22455
"SF3B1 R568C lies within the HEAT repeat 1 region of the Sf3b1 protein (UniProt.org). R568C has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22456
"SF3B1 R594Q lies within the HEAT repeat 2 region of the Sf3b1 protein (UniProt.org). R594Q has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22457
"SF3B1 R625C lies within the HEAT repeat 1 region of the Sf3b1 protein (UniProt.org). R625C has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22459
"SF3B1 R625G lies within the HEAT repeat 1 region of the Sf3b1 protein (UniProt.org). R625G has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22460
"SF3B1 R625H lies within the HEAT repeat 1 region of the Sf3b1 protein (UniProt.org). R625H has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22461
"SF3B1 R625L lies within the HEAT repeat 1 region of the Sf3b1 protein (UniProt.org). R625L has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22462
"SF3B1 R702W lies within the HEAT repeat 5 region of the Sf3b1 protein (UniProt.org). R702W has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22463
"SF3B1 R736S does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). R736S has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22464
"SF3B1 R828I does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). R828I has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22465
"SF3B1 R831Q does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). R831Q has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22466
"SF3B1 R939H does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). R939H has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22467
"SF3B1 R957Q does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). R957Q has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22468
"SF3B1 S1207L does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). S1207L has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22469
"SF3B1 S259R lies within the RBM39 interaction region of the Sf3b1 protein (UniProt.org). S259R has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22470
"SF3B1 S336* results in a premature truncation of the Sf3b1 protein at amino acid 336 of 1304 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), S336* is predicted to lead to a loss of Sf3b1 protein function.",295,,,www.uniprot.org,22471
"SF3B1 S541P lies within the HEAT repeat 1 region of the Sf3b1 protein (UniProt.org). S541P has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22472
"SF3B1 S657F lies within the HEAT repeat 1 region of the Sf3b1 protein (UniProt.org). S657F has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22473
"SF3B1 S71L does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). S71L has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22474
"SF3B1 S908L does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). S908L has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22475
"SF3B1 S97P does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). S97P has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22476
"SF3B1 T1112A does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). T1112A has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22477
"SF3B1 T1187M lies within the HEAT repeat 11 region of the Sf3b1 protein (UniProt.org). T1187M has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22478
"SF3B1 T267N lies within the RBM39 interaction region of the Sf3b1 protein (UniProt.org). T267N has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22479
SF3B1 T434A lies within the PPP1R8 interaction region of the Sf3b1 protein (UniProt.org). T434A results in a loss of Sf3b1 phosphorylation by Dyrk1a in cell culture (PMID: 16512921). ,295,,,www.uniprot.org,5505,16512921,"The protein kinase DYRK1A phosphorylates the splicing factor SF3b1/SAP155 at Thr434, a novel in vivo phosphorylation site.",http://www.ncbi.nlm.nih.gov/pubmed/16512921,22480
"SF3B1 T520A does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). T520A has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22481
"SF3B1 T663P lies within the HEAT repeat 4 region of the Sf3b1 protein (UniProt.org). T663P has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22482
"SF3B1 T7I does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). T7I has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22483
"SF3B1 T916A does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). T916A has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22484
"SF3B1 V1169I lies within the HEAT repeat 11 region of the Sf3b1 protein (UniProt.org). V1169I has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,115,0,,http://www.ncbi.nlm.nih.gov/pubmed,22485
"SF3B1 V422I lies within the PPP1R8 interaction region of the Sf3b1 protein (UniProt.org). V422I has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22486
"SF3B1 V591E lies within the HEAT repeat 2 region of the Sf3b1 protein (UniProt.org). V591E has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22487
"SF3B1 V701I lies within the HEAT repeat 5 region of the Sf3b1 protein (UniProt.org). V701I has not been characterized literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22488
"SF3B1 W1055L lies within the HEAT repeat 9 region of the Sf3b1 protein (UniProt.org). W1055L has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22489
"SF3B1 W658G lies within the HEAT repeat 4 region of the Sf3b1 protein (UniProt.org). W658G has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22490
"SF3B1 W658L lies within the HEAT repeat 4 region of the Sf3b1 protein (UniProt.org). W658L has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22491
"SF3B1 Y1269F does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). Y1269F has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22492
"SF3B1 Y623S lies within the HEAT repeat 3 region of the Sf3b1 protein (UniProt.org). Y623S has not been characterized in the scientific literature and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22493
"SF3B1 Y752C does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). Y752C has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22494
"SF3B1 Y765C lies within the HEAT repeat 6 region of the Sf3b1 protein (UniProt.org). Y765C has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22495
"SF3B1 Y898H does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). Y898H has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22496
"ABL1 F359C lies within the protein kinase domain of the Abl1 protein (UniProt.org). F359C has not been biochemically characterized, but has been identified as a secondary drug resistance mutation in the context of BCR-ABL (PMID: 19798095).",5510,19798095,Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.,http://www.ncbi.nlm.nih.gov/pubmed/19798095,295,,,www.uniprot.org,22497
"ABL1 E355A lies within the protein kinsase domain of the Abl1 protein (UniProt.org). E355A has not been biochemically characterized, but has been identified as a secondary drug resistance mutation in the context of BCR-ABL (PMID: 24456693).",5511,24456693,"BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.",http://www.ncbi.nlm.nih.gov/pubmed/24456693,295,,,www.uniprot.org,22498
"SMO S387N lies within the drug-binding pocket of the Smo protein (PMID: 25759019). S387N has not been biochemically characterized, but has been demonstrated to confer resistance to Hh pathway inhibitors (PMID: 25759019). ",5520,25759019,Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25759019,22499
"SMO D384N lies within the drug-binding pocket of the Smo protein (PMID: 25759019). D384N has not been biochemically characterized, but has been demonstrated to confer resistance to Hh pathway inhibitors (PMID: 25759019). ",5520,25759019,Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25759019,22500
"SMO N219D lies within the drug-binding pocket of the Smo protein (PMID: 25759019). N219D has not been biochemically characterized, but has been demonstrated to confer resistance to Hh pathway inhibitors (PMID: 25759019). ",5520,25759019,Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25759019,22501
"SMO I408V lies within the drug-binding pocket of the Smo protein (PMID: 25759019). I408V has not been biochemically characterized, but has been demonstrated to confer resistance to Hh pathway inhibitors (PMID: 25759019). ",5520,25759019,Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25759019,22502
"SMO C469Y lies within the drug-binding pocket of the Smo protein (PMID: 25759019). C469Y has not been biochemically characterized, but has been demonstrated to confer resistance to Hh pathway inhibitors (PMID: 25759019). ",5520,25759019,Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25759019,22503
SMO T241M does not lie within any known functional domains of the Smo protein (UniProt.org). T241M results in increased Smo activity and confers resistance to Shh inhibitors in cell culture (PMID: 25759019).,5520,25759019,Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25759019,295,,,www.uniprot.org,22505
SMO A459V does not lie within any known functional domains of the Smo protein (UniProt.org). A459V results in increased Smo activity and confers resistance to Shh inhibitors in cell culture (PMID: 25759019).,5520,25759019,Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25759019,295,,,www.uniprot.org,22506
"PTEN V54fs results in a change in the amino acid sequence of the Braf protein beginning at aa 54 of 403, likely resulting in premature truncation of the functional protein (UniProt.org). V54fs has not been characterized, however, other mutants downstream of V54 are inactivating (PMID: 10468583), thus V54fs is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,22510
"PHF6 F214* results in a premature truncation of the Phf6 protein at amino acid 214 of 365 (UniProt.org). F214* has not been characterized in the scientific literature and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22511
"PHF6 G287V lies within the extended PHD2 domain of the Phf6 protein (UniProt.org). G287V has not been characterized and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22512
"SMC3 A1148V lies within the DA-box region of the Smc3 protein (UniProt.org). A1148V has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22513
"PHF6 N23Kfs*2 likely results in a truncation of the 365 aa Phf6 protein at aa 23, followed by 2 nonsense amino acids (UniProt.org). Due to the loss of all known functional domains, N23Kfs*2 is predicted to result in a loss of Phf6 protein function (UniProt.org).",295,,,www.uniprot.org,22514
"SMC3 A163G does not lie within any known functional domains of the Smc3 protein (UniProt.org). A163G has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22515
"SMC3 A878S lies within the coiled-coil domain of the Smc3 protein (UniProt.org). A878S has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22516
"SMC3 D1208N does not lie within any known functional domains of the Smc3 protein (UniProt.org). D1208N has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22517
"SMC3 D21H does not lie within any known functional domains of the Smc3 protein (UniProt.org). D21H has not been characterized and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22518
"PHF6 C242Y lies within the extended PHD2 domain of the Phf6 protein (UniProt.org). C242Y has not been characterized in the scientific literature and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22519
"SMC3 D21V does not lie within any known functional domains of the Smc3 protein (UniProt.org). D21V has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22520
"SMC3 D265Y lies within the coiled-coil domain of the Smc3 protein (UniProt.org). D265Y has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22521
"STAG2 A300V lies within the SCD domain of the Stag2 protein (UniProt.org). A300V has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22522
"SMC3 D712G lies within the coiled-coil domain of the Smc3 protein (UniProt.org). D712G has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22523
"SMC3 D92N does not lie within any known functional domains of the Smc3 protein (UniProt.org). D92N has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22524
"SMC3 E1204D does not lie within any known functional domains of the Smc3 protein (UniProt.org). E1204D has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22525
"STAG2 A532V does not lie within any known functional domains of the Stag2 protein (UniProt.org). A532V has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22526
"STAG2 A998T does not lie within any known functional domains of the Stag2 protein (UniProt.org). A998T has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22527
"STAG2 A998V does not lie within any known functional domains of the Stag2 protein (UniProt.org). A998V has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22528
"PHF6 E139* results in a premature truncation of the Phf6 protein at amino acid 139 of 365 (UniProt.org). Due to the loss of the extended PHD2 domain, E139* is predicted to result in a loss of Phf6 protein function (UniProt.org). ",295,,,www.uniprot.org,22529
"STAG2 C308R lies within the SCD domain of the Stag2 protein (UniProt.org). C308R has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22530
"STAG2 C869R does not lie within any known functional domains of the Stag2 protein (UniProt.org). C869R has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22531
"STAG2 D1055N does not lie within any known functional domains of the Stag2 protein (UniProt.org). D1055N has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22532
"PHF6 S204I does not lie within any known functional domains of the Phf6 protein (UniProt.org). S204I has not been characterized in the scientific literature and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016). ",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22533
"STAG2 D1197N does not lie within any known functional domains of the Stag2 protein (UniProt.org). D1197N has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,22534
"PHF6 R319L lies within the extended PHD2 domain of the Phf6 protein (UniProt.org). R319L has not been characterized in the scientific literature and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22535
"STAG2 D153N does not lie within any known functional domains of the Stag2 protein (UniProt.org). D153N has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22536
"STAG2 D385Y does not lie within any known functional domains of the Stag2 protein (UniProt.org). D385Y has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,22537
"ABL1 M437I lies within the protein kinase domain of the Abl1 protein (UniProt.org). M437I has not been characterized in the scientific literature and therefore, its effect on Abl1 protein function is unknown (PubMed, Feb 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22538
"ABL1 A287V lies within the protein kinase domain of the Abl1 protein (UniProt.org). A287V has not been characterized in the scientific literature and therefore, its effect on Abl1 protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22539
"ABL1 C475W lies within the protein kinase domain of the Abl1 protein (UniProt.org). C457W has not been characterized in the scientific literature and therefore, its effect on Abl1 protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22540
"ABL1 E282D lies within the protein kinase domain of the Abl1 protein (UniProt.org). E282D has not been characterized in the scientific literature and therefore, its effect on Abl1 protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22542
"ABL1 K262N lies within the protein kinase domain of the Abl1 protein (UniProt.org). K262N has not been characterized in the scientific literature and therefore, its effect on Abl1 protein function is unknown (PubMed, Feb 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22543
"ABL1 M237R does not lie within any known functional domains of the Abl1 protein (UniProt.org). M237R has not been characterized in the scientific literature and therefore, its effect on Abl1 protein function is unknown (PubMed, Feb 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22544
"ABL1 R362T lies within the protein kinase domain of the Abl1 protein (UniProt.org). R362T has been identified in sequencing studies (PMID: 26603839), but has not been biochemically characterized and therefore, its effect on Abl1 protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22546
"ABL1 Y456C lies within the protein kinase domain of the Abl1 protein (UniProt.org). Y456C has been identified in the scientific literature (PMID: 23355941), but has not been biochemically characterized and therefore, its effect on Abl1 protein function is unknown (PubMed, Feb 2017).",1112,23355941,Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients.,http://www.ncbi.nlm.nih.gov/pubmed/23355941,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22547
"ABL1 E279W lies within the protein kinase domain of the Abl1 protein (UniProt.org). E279W has not been characterized in the scientific literature and therefore, its effect on Abl1 protein function is unknown (PubMed, Feb 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22548
"ABL1 E279V lies within the protein kinase domain of the Abl1 protein (UniProt.org). E279V has not been characterized in the scientific literature and therefore, its effect on Abl1 protein function is unknown (PubMed, Feb 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22549
"ABL1 E281K lies within the protein kinase domain of the Abl1 protein (UniProt.org). E281K has not been biochemically characterized, but has been associated with drug resistance in the context of BCR-ABL (PMID: 21193419). ",295,,,www.uniprot.org,5538,21193419,Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis.,http://www.ncbi.nlm.nih.gov/pubmed/21193419,22550
"ABL1 I432M lies within the protein kinase domain of the Abl1 protein (UniProt.org). I432M has not been characterized in the scientific literature and therefore, its effect on Abl1 protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22551
"ABL1 R386M lies within the protein kinase domain of the Abl1 protein (UniProt.org). R386M has been identified in sequencing studies (PMID: 26603839), but has not been biochemically characterized and therefore, its effect on Abl1 protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5509,26603839,Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.,http://www.ncbi.nlm.nih.gov/pubmed/26603839,22552
"ABL1 V379I lies within the protein kinase domain of the Abl1 protein (UniProt.org). V379I has not been characterized, but has been demonstrated to occur as a secondary resistance mutation in the context of BCR-ABL (PMID: 21562040).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22553
"ABL1 M237V does not lie within any known functional domains of the Abl1 protein (UniProt.org). M237V has been identified in sequencing studies (PMID: 26603839), but has not been biochemically characterized and therefore, its effect on Abl1 protein function is unknown (PubMed, Feb 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5509,26603839,Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.,http://www.ncbi.nlm.nih.gov/pubmed/26603839,22554
"SMC3 E161K does not lie within any known functional domains of the Smc3 protein (UniProt.org). E161K has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22555
"SMC3 E204D lies within the coiled-coil domain of the Smc3 protein (UniProt.org). E204D has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22556
"SMC3 E289Q lies within the coiled-coil domain of the Smc3 protein (UniProt.org). E289Q has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22557
"SMC3 E315G lies within the coiled-coil domain of the Smc3 protein (UniProt.org). E315G has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22558
"SMC3 E343V lies within the coiled-coil domain of the Smc3 protein (UniProt.org). E343V has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22559
"SMC3 E468* results in a premature truncation of the Smc3 protein at amino acid 468 of 1217 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), E468* is predicted to lead to a loss of Smc3 protein function. ",295,,,www.uniprot.org,22563
"SMC3 E476K lies within the coiled-coil domain of the Smc3 protein (UniProt.org). E476K has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22565
"SMC3 E52Q does not lie withinany known functional domains of the Smc3 protein (UniProt.org). E52Q has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22566
"SMC3 E834* results in a premature truncation of the Smc3 protein at amino acid 834 of 1217 (UniProt.org). E834* has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22567
"SMC3 E896K lies within the coiled-coil domain of the Smc3 protein (UniProt.org). E896K has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22568
"SMC3 E975K lies within the coiled-coil domain of the Smc3 protein (UniProt.org). E975K has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22569
"SMC3 G1064D does not lie withinany known functional domains of the Smc3 protein (UniProt.org). G1064D has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22570
"SMC3 G662C lies within the flexible hinge region of the Smc3 protein (UniProt.org). G662C has not been characterized and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22571
"SMC3 G782* results in a premature truncation of the Smc3 protein at amino acid 782 of 1217 (UniProt.org). G782* has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22576
"SMC3 G823A lies within the coiled-coil domain of the Smc3 protein (UniProt.org). G823A has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22578
"SMC3 H55Y does not lie withinany known functional domains of the Smc3 protein (UniProt.org). H55Y has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22579
"SMC3 H660Y lies within the flexible hinge region of the Smc3 protein (UniProt.org). H660Y has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22581
"SMC3 H917Y lies within the coiled-coil domain of the Smc3 protein (UniProt.org). H917Y has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22582
"SMC3 I1001V does not lie withinany known functional domains of the Smc3 protein (UniProt.org). I1001V has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22583
"SMC3 I176L does not lie withinany known functional domains of the Smc3 protein (UniProt.org). I176L has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22584
"SMC3 I45V does not lie withinany known functional domains of the Smc3 protein (UniProt.org). I45V has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22585
"SMC3 I824F lies within the coiled-coil domain of the Smc3 protein (UniProt.org). I824F has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22587
"SMC3 K180N lies within the coiled-coil domain of the Smc3 protein (UniProt.org). K180N has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22588
"SMC3 K418E lies within the coiled-coil domain of the Smc3 protein (UniProt.org). K418E has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22589
"SMC3 L124R does not lie within any known functional domains of the Smc3 protein (UniProt.org). L124R has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22591
"SMC3 L203V lies within the coiled-coil domain of the Smc3 protein (UniProt.org). L203V has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22592
"SMC3 L210P lies within the coiled-coil domain of the Smc3 protein (UniProt.org). L210P has not been characterized and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22593
"SMC3 L375I does not lie within any known functional domains of the Smc3 protein (UniProt.org). L375I has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22595
"SMC3 L402del results in the deletion of one amino acid in the coiled-coil domain of the Smc3 protein at amino acid 402 (UniProt.org). L402del has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22597
"SMC3 L420V lies within the coiled-coil domain of the Smc3 protein (UniProt.org). L420V has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22598
"SMC3 L497I lies within the coiled-coil domain of the Smc3 protein (UniProt.org). L497I has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22599
"SMC3 L821I lies within the coiled-coil domain of the Smc3 protein (UniProt.org). L821I has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22601
"SMC3 M1109I does not lie within any known functional domains of the Smc3 protein (UniProt.org). M1109I has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22602
"SMC3 M609V lies within the flexible hinge region of the Smc3 protein (UniProt.org). M609V has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22603
"SMC3 M648V lies within the flexible hinge region of the Smc3 protein (UniProt.org). M648V has not been characterized and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22604
"SMC3 M901V lies within the coiled-coil domain of the Smc3 protein (UniProt.org). M901V as not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22605
"SMC3 M925I does not lie within any known functional domains of the Smc3 protein (UniProt.org). M925I has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22606
"SMC3 Q154H does not lie within any known functional domains of the Smc3 protein (UniProt.org). Q154H has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22608
"SMC3 Q230E lies within the coiled-coil domain of the Smc3 protein (UniProt.org). Q230E has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22609
"SMC3 Q809* results in a premature truncation of the Smc3 protein at amino acid 809 of 1217 (UniProt.org). Q809* has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22610
"SMC3 Q989* results in a premature truncation of the Smc3 protein at amino acid 989 of 1217 (UniProt.org). Q989* has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22612
"SMC3 R132Q does not lie within any known functional domains of the Smc3 protein (UniProt.org). R132Q has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22613
"SMC3 R15I does not lie within any known functional domains of the Smc3 protein (UniProt.org). R15I has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22614
"SMC3 R254* results in a premature truncation of the Smc3 protein at amino acid 254 of 1217 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), R254* is predicted to lead to a loss of Smc3 protein function.",295,,,www.uniprot.org,22615
"SMC3 R381Q does not lie within any known functional domains of the Smc3 protein (UniProt.org). R381Q has not been characterized and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22617
"SMC3 R57H does not lie within any known functional domains of the Smc3 protein (UniProt.org). R57H has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22618
"SMC3 R661P lies within the flexible hinge region of the Smc3 protein (UniProt.org). R661P has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22619
"SMC3 R661W lies within the flexible hinge region of the Smc3 protein (UniProt.org). R661W has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22620
"SMC3 R72C does not lie within any known functional domains of the Smc3 protein (UniProt.org). R72C has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22621
"SMC3 R796I lies within the coiled-coil domain of the Smc3 protein (UniProt.org). R796I has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22622
"SMC3 R818I lies within the coiled-coil domain of the Smc3 protein (UniProt.org). R818I has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22623
"SMC3 R827* results in a premature truncation of the Smc3 protein at amino acid 827 of 1217 (UniProt.org). R827* has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22624
"SMC3 R879Q lies within the coiled-coil domain of the Smc3 protein (UniProt.org). R879Q has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22625
"SMC3 R903C lies within the coiled-coil domain of the Smc3 protein (UniProt.org). R903C has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).v",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22626
"SMC3 R928Q does not lie within any known functional domains of the Smc3 protein (UniProt.org). R928Q has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22627
"SMC3 R944* results in a premature truncation of the Smc3 protein at amino acid 944 of 1217 (UniProt.org). R944* has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22628
"SMC3 R967* results in a premature truncation of the Smc3 protein at amino acid 967 of 1217 (UniProt.org). R967* has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22629
"SMC3 R967Q lies within the coiled-coil domain of the Smc3 protein (UniProt.org). R967Q has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22630
"SMC3 R99* results in a premature truncation of the Smc3 protein at amino acid 99 of 1217 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), R99* is predicted to lead to a loss of Smc3 protein function.",295,,,www.uniprot.org,22631
"SMC3 S131Y does not lie within any known functional domains of the Smc3 protein (UniProt.org). S131Y has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22632
"SMC3 S282* results in a premature truncation of the Smc3 protein at amino acid 282 of 1217 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), S282* is predicted to lead to a loss of Smc3 protein function.",295,,,www.uniprot.org,22633
"SMC3 S731C lies within the coiled-coil domain of the Smc3 protein (UniProt.org). S731C has not been characterized and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22634
"SMC3 S948L does not lie within any known functional domains of the Smc3 protein (UniProt.org). S948L has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22635
"SMC3 S97L does not lie within any known functional domains of the Smc3 protein (UniProt.org). S97L has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22636
"SMC3 T1174I does not lie within any known functional domains of the Smc3 protein (UniProt.org). T1174I has not been characterized and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22637
"SMC3 T548A lies within the flexible hinge region of the Smc3 protein (UniProt.org). T548A has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22638
"SMC3 T570M lies within the flexible hinge region of the Smc3 protein (UniProt.org). T570M has not been characterized and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22639
"SMC3 T586A lies within the flexible hinge region of the Smc3 protein (UniProt.org). T586A has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22640
"SMC3 V682A lies within the coiled-coil domain of the Smc3 protein (UniProt.org). V682A has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22641
"SMC3 V682I lies within the coiled-coil domain of the Smc3 protein (UniProt.org). V682I has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22642
"SMC3 W394C lies within the coiled-coil domain of the Smc3 protein (UniProt.org). W394C has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22643
"SMC3 Y43H does not lie within any known functional domains of the Smc3 protein (UniProt.org). Y43H has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22644
"SMC3 Y43Mfs*69 is a missense mutation (Y43M) in conjunction with a likely truncation of the 1217 aa Smc3 protein at aa 43, followed by 69 nonsense amino acids (UniProt.org). Due to the loss of all known functional domains (UniProt.org), Y43Mfs*69 is predicted to lead to a loss of Smc3 protein function.",295,,,www.uniprot.org,22645
"SMC3 Y668Lfs*3 is a missense mutation (Y668L) in conjunction with a likely truncation of the 1217 aa Smc3 protein at aa 668, followed by 3 nonsense amino acids (UniProt.org). Y668Lfs*3 has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,115,0,,http://www.ncbi.nlm.nih.gov/pubmed,22646
"SMC3 Y669D lies within the coiled-coil domain of the Smc3 protein (UniProt.org). Y669D has not been characterized and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22647
"SMC3 Y979C lies within the coiled-coil domain of the Smc3 protein (UniProt.org). Y979C has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22648
"STAG2 D486N does not lie within any known functional domains of the Stag2 protein (UniProt.org). D486N has not been characterized and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22649
"STAG2 D610G does not lie within any known functional domains of the Stag2 protein (UniProt.org). D610G has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22650
"STAG2 E1107* results in a premature truncation of the Stag2 protein at amino acid 1107 of 1231 (UniProt.org). E1107* has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22651
"STAG2 E134D does not lie within any known functional domains of the Stag2 protein (UniProt.org). E134D has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22652
"STAG2 E251A does not lie within any known functional domains of the Stag2 protein (UniProt.org). E251A has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22653
"STAG2 E276D does not lie within any known functional domains of the Stag2 protein (UniProt.org). E276D has not been characterized and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22654
"STAG2 E606A does not lie within any known functional domains of the Stag2 protein (UniProt.org). E606A has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22655
"STAG2 E675D does not lie within any known functional domains of the Stag2 protein (UniProt.org). E675D has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22656
"STAG2 E721V does not lie within any known functional domains of the Stag2 protein (UniProt.org). E721V has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22657
"STAG2 E727D does not lie within any known functional domains of the Stag2 protein (UniProt.org). E727D has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22658
"STAG2 E950* results in a premature truncation of the Stag2 protein at amino acid 950 of 1231 (UniProt.org). E950* has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22659
"STAG2 H217R does not lie within any known functional domains of the Stag2 protein (UniProt.org). H217R has not been characterized and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22660
"STAG2 H698R does not lie within any known functional domains of the Stag2 protein (UniProt.org). H698R has not been characterized and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22661
"STAG2 H73Y does not lie within any known functional domains of the Stag2 protein (UniProt.org). H73Y has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22662
"STAG2 H832R does not lie within any known functional domains of the Stag2 protein (UniProt.org). H832R has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22663
"STAG2 I201M does not lie within any known functional domains of the Stag2 protein (UniProt.org). I201M has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22664
"STAG2 I829N does not lie within any known functional domains of the Stag2 protein (UniProt.org). I829N has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22665
"STAG2 I855T does not lie within any known functional domains of the Stag2 protein (UniProt.org). I855T has not been characterized and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22666
"STAG2 I910R does not lie within any known functional domains of the Stag2 protein (UniProt.org). I910R has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22667
"STAG2 K887E does not lie within any known functional domains of the Stag2 protein (UniProt.org). K887E has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22668
"STAG2 K901E does not lie withinany known functional domains of the Stag2 protein (UniProt.org). K901E has not been characterized and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22669
"ROS1 D2033N lies within the protein kinase domain of the Ros1 protein (UniProt.org). D2033N has not been individually characterized, but results in a loss of drug binding and drug resistance in the context of CD74-ROS1 (PMID: 26673800).",5546,26673800,A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26673800,22670
"STAG2 K92N does not lie withinany known functional domains of the Stag2 protein (UniProt.org). K92N has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22671
"STAG2 K949N does not lie within any known functional domains of the Stag2 protein (UniProt.org). K949N has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22672
"STAG2 L221M does not lie within any known functional domains of the Stag2 protein (UniProt.org). L221M has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22673
"STAG2 L235Q does not lie within any known functional domains of the Stag2 protein (UniProt.org). L235Q has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22674
"STAG2 L237I does not lie within any known functional domains of the Stag2 protein (UniProt.org). L237I has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22675
"STAG2 L405I does not lie within any known functional domains of the Stag2 protein (UniProt.org). L405I has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22676
"STAG2 L571P does not lie within any known functional domains of the Stag2 protein (UniProt.org). L571P has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22677
"STAG2 L858P does not lie within any known functional domains of the Stag2 protein (UniProt.org). L858P has not been characterized and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22678
"STAG2 L961R does not lie within any known functional domains of the Stag2 protein (UniProt.org). L961R has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22679
"STAG2 L997F does not lie within any known functional domains of the Stag2 protein (UniProt.org). L997F has not been characterized and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22680
"STAG2 M224I does not lie within any known functional domains of the Stag2 protein (UniProt.org). M224I has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22681
"STAG2 N412H does not lie within any known functional domains of the Stag2 protein (UniProt.org). N412H has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22682
"STAG2 P160L does not lie within any known functional domains of the Stag2 protein (UniProt.org). P160L has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22683
"STAG2 P572S does not lie within any known functional domains of the Stag2 protein (UniProt.org). P572S has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22684
"STAG2 P987Q does not lie within any known functional domains of the Stag2 protein (UniProt.org). P987Q has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22685
"STAG2 P987T does not lie within any known functional domains of the Stag2 protein (UniProt.org). P987T has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22686
"STAG2 Q1029* results in a premature truncation of the Stag2 protein at amino acid 1029 of 1231 (UniProt.org). Q1029* has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22687
"STAG2 Q185H does not lie within any known functional domains of the Stag2 protein (UniProt.org). Q185H has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22688
"STAG2 Q278E does not lie within any known functional domains of the Stag2 protein (UniProt.org). Q278E has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22689
"STAG2 Q593* results in a premature truncation of the Stag2 protein at amino acid 593 of 1231 (UniProt.org). Q593* has not been characterized, however, due to the effects of Stag2 truncating mutations downstream of Q593 (PMID: 26871722, PMID: 21852505), Q593* is predicted to lead to a loss of Stag2 protein function.",5470,21852505,Mutational inactivation of STAG2 causes aneuploidy in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21852505,6087,26871722,"Intact Cohesion, Anaphase, and Chromosome Segregation in Human Cells Harboring Tumor-Derived Mutations in STAG2.",http://www.ncbi.nlm.nih.gov/pubmed/26871722,295,,,www.uniprot.org,22690
"STAG2 R1012* results in a premature truncation of the Stag2 protein at amino acid 1012 of 1231 (UniProt.org). R1012* has not been characterized and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22691
"STAG2 R1033* results in a premature truncation of the Stag2 protein at amino acid 1033 of 1231 (UniProt.org). R1033* has not been characterized and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22692
"STAG2 R1045* results in a premature truncation of the Stag2 protein at amino acid 1045 of 1231 (UniProt.org). R1045* has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22693
"STAG2 R1045Q does not lie within any known functional domains of the Stag2 protein (UniProt.org). R1045Q has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22694
"STAG2 R110* results in a premature truncation of the Stag2 protein at amino acid N of 1231 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), R110* is predicted to lead to a loss of Stag2 protein function.",295,,,www.uniprot.org,22695
"STAG2 R137I does not lie within any known functional domains of the Stag2 protein (UniProt.org). R137I has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22696
"STAG2 R184W does not lie within any known functional domains of the Stag2 protein (UniProt.org). R184W has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22697
"STAG2 R213T does not lie within any known functional domains of the Stag2 protein (UniProt.org). R213T has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22698
"STAG2 R216* results in a premature truncation of the Stag2 protein at amino acid 216 of 1231 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), R216* is predicted to lead to a loss of Stag2 protein function.",295,,,www.uniprot.org,22699
"STAG2 R216Q does not lie within any known functional domains of the Stag2 protein (UniProt.org). R216Q has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22700
"STAG2 R252Q does not lie within any known functional domains of the Stag2 protein (UniProt.org). R252Q has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22701
"STAG2 R259* results in a premature truncation of the Stag2 protein at amino acid 259 of 1231 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), R259* is predicted to lead to a loss of Stag2 protein function.",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22702
"STAG2 R298C lies within the SCD domain of the Stag2 protein (UniProt.org). R298C has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22703
"STAG2 R305L lies within the SCD domain of the Stag2 protein (UniProt.org). R305L has not been characterized and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22704
"STAG2 R370G lies within the SCD domain of the Stag2 protein (UniProt.org). R370G has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22705
"STAG2 R370Q lies within the SCD domain of the Stag2 protein (UniProt.org). R370Q has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22706
"STAG2 R370W lies within the SCD domain of the Stag2 protein (UniProt.org). R370W has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22707
"STAG2 R439H does not lie within any known functional domains of the Stag2 protein (UniProt.org). R439H has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22708
"STAG2 R541K does not lie within any known functional domains of the Stag2 protein (UniProt.org). R541K has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016). ",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22709
"STAG2 R560W does not lie within any known functional domains of the Stag2 protein (UniProt.org). R560W has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22710
"STAG2 R604* results in a premature truncation of the Stag2 protein at amino acid 604 of 1231 (UniProt.org). R604* has not been characterized, however, due to the effects of Stag2 truncating mutations downstream of R604 (PMID: 26871722, PMID: 21852505), R604* is predicted to lead to a loss of Stag2 function.",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22711
"STAG2 R614* results in a premature truncation of the Stag2 protein at amino acid 614 of 1231 (UniProt.org). R614* has not been characterized, however, due to the effects of Stag2 truncating mutations downstream of R614 (PMID: 26871722, PMID: 21852505), R614* is predicted to lead to a loss of Stag2 function.",6087,26871722,"Intact Cohesion, Anaphase, and Chromosome Segregation in Human Cells Harboring Tumor-Derived Mutations in STAG2.",http://www.ncbi.nlm.nih.gov/pubmed/26871722,295,,,www.uniprot.org,5470,21852505,Mutational inactivation of STAG2 causes aneuploidy in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21852505,22712
"STAG2 R654I does not lie within any known functional domains of the Stag2 protein (UniProt.org). R654I has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22713
"STAG2 R69Q does not lie within any known functional domains of the Stag2 protein (UniProt.org). R69Q has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22714
"STAG2 R861K does not lie within any known functional domains of the Stag2 protein (UniProt.org). R861K has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22715
"STAG2 R862I does not lie within any known functional domains of the Stag2 protein (UniProt.org). R862I has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22716
"STAG2 R954H does not lie within any known functional domains of the Stag2 protein (UniProt.org). R954H has not been characterized and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22717
"STAG2 S1058* results in a premature truncation of the Stag2 protein at amino acid 1058 of 1231 (UniProt.org). S1058* has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22718
"STAG2 S105L does not lie within any known functional domains of the Stag2 protein (UniProt.org). S105L has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22719
"STAG2 S156G does not lie within any known functional domains of the Stag2 protein (UniProt.org). S156G has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22720
"STAG2 S219G does not lie within any known functional domains of the Stag2 protein (UniProt.org). S219G has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22721
"STAG2 S704L does not lie within any known functional domains of the Stag2 protein (UniProt.org). S704L has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22722
"STAG2 T1027A does not lie within any known functional domains of the Stag2 protein (UniProt.org). T1027A has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22723
"STAG2 T966K does not lie within any known functional domains of the Stag2 protein (UniProt.org). T966K has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22724
"STAG2 V181A does not lie within any known functional domains of the Stag2 protein (UniProt.org). V181A has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22725
"STAG2 V181L does not lie within any known functional domains of the Stag2 protein (UniProt.org). V181L has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,115,0,,http://www.ncbi.nlm.nih.gov/pubmed,22726
"STAG2 V465F does not lie within any known functional domains of the Stag2 protein (UniProt.org). V465F has not been characterized and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22727
"STAG2 V620L does not lie within any known functional domains of the Stag2 protein (UniProt.org). V620L has not been characterized and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22728
"STAG2 V783F does not lie within any known functional domains of the Stag2 protein (UniProt.org). V783F has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22729
"STAG2 W102* results in a premature truncation of the Stag2 protein at amino acid 102 of 1231 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), W102* is predicted to lead to a loss of Stag2 protein function.",295,,,www.uniprot.org,22730
"STAG2 W706G does not lie within any known functional domains of the Stag2 protein (UniProt.org). W706G has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22731
"STAG2 W706L does not lie within any known functional domains of the Stag2 protein (UniProt.org). W706L has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22732
"STAG2 Y414F does not lie within any known functional domains of the Stag2 protein (UniProt.org). Y414F has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22733
"STAG2 Y636* results in a premature truncation of the Stag2 protein at amino acid 636 of 1231 (UniProt.org). Y636* has not been characterized, however, due to the effects of Stag2 truncating mutations downstream of Y636 (PMID: 26871722, PMID: 21852505), Y636* is predicted to lead to a loss of Stag2 protein function.",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5470,21852505,Mutational inactivation of STAG2 causes aneuploidy in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21852505,6087,26871722,"Intact Cohesion, Anaphase, and Chromosome Segregation in Human Cells Harboring Tumor-Derived Mutations in STAG2.",http://www.ncbi.nlm.nih.gov/pubmed/26871722,22734
"SETBP1 T508M does not lie within any known functional domains of the Setbp1 protein (PMID: 23222956). T508M has not been characterized in the scientific literature and therefore, its effect on Setbp1 protein function is unknown (Pubmed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5310,23222956,Recurrent SETBP1 mutations in atypical chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23222956,22735
"CTNNB1 A21_A149del results in the deletion of 129 amino acids of the Ctnnb1 protein from amino acids 21 to 149 (UniProt.org). A21_A149del has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22737
"CTNNB1 A21_A152del results in the deletion of 132 amino acids of the Ctnnb1 protein from amino acids 21 to 152 (UniProt.org). A21_A152del has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22738
"CTNNB1 A43_P45dup indicates the insertion of 3 duplicate amino acids, alanine (A)-43 through proline (P)-45 of the Ctnnb1 protein (UniProt.org). A43_P45dup has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22739
"CTNNB1 A5_A80del results in the deletion of 76 amino acids of the Ctnnb1 protein from amino acids 5 to 80 (UniProt.org). A5_A80del has been identified in sequencing studies (PMID: 16496320), but has not been biochemically characterized and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,7296,16496320,Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC.,http://www.ncbi.nlm.nih.gov/pubmed/16496320,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22740
"CTNNB1 A5_Q143del results in the deletion of 139 amino acids of the Ctnnb1 protein from amino acids 5 to 143 (UniProt.org). A5_Q143del has been identified in sequencing studies (PMID: 10698519), but has not been biochemically characterized and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,2344,10698519,Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas.,http://www.ncbi.nlm.nih.gov/pubmed/10698519,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22741
"CTNNB1 G69A does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). G69A has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22742
"CTNNB1 H24_Y142del results in the deletion of 119 amino acids of the Ctnnb1 protein from amino acids 24 to 142 (UniProt.org). H24_Y142del has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22745
"CTNNB1 H24P does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). H24P has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22746
"CTNNB1 I35_G38del results in the deletion of 4 amino acids of the Ctnnb1 protein from amino acids 35 to 38 (UniProt.org). I35_G38del has been identified in sequencing studies (PMID: 17187432), but has not been biochemically characterized and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7297,17187432,Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.,http://www.ncbi.nlm.nih.gov/pubmed/17187432,22747
"CTNNB1 I35del results in the deletion of one amino acid of the Ctnnb1 protein at amino acid 35 (UniProt.org). I35del has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22748
"CTNNB1 K335T lies within the Arm repeat 5 region of the Ctnnb1 protein (UniProt.org). K335T has been identified in sequencing studies (PMID: 25822088), but has not been biochemically characterized and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7022,25822088,Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.,http://www.ncbi.nlm.nih.gov/pubmed/25822088,295,,,www.uniprot.org,22749
"CTNNB1 L10_N141del results in the deletion of 132 amino acids of the Ctnnb1 protein from amino acids 10 to 141 (UniProt.org). L10_N141del has been identified in sequencing studies (PMID: 12297840), but has not been biochemically characterized and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",7302,12297840,P53 gene and Wnt signaling in benign neoplasms: beta-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia.,http://www.ncbi.nlm.nih.gov/pubmed/12297840,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22750
"CTNNB1 L31_I35del results in the deletion of 5 amino acids of the Ctnnb1 protein from amino acids 31 to 35 (UniProt.org). L31_I35del has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22751
"CTNNB1 M12_D144del results in the deletion of 133 amino acids of the Ctnnb1 protein from amino acids 12 to 144 (UniProt.org). M12_D144del has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22752
"CTNNB1 M8_L132del results in the deletion of 125 amino acids of the Ctnnb1 protein from amino acids 8 to 132 (UniProt.org). M8_L132del has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22753
CTNNB1 N387K lies within the Arm repeats 6 region of the Ctnnb1 protein (UniProt.org). N387K results in increased Ctnnb1 transcriptional activity in cell culture (PMID: 27177928).,5574,27177928,Genotype-phenotype correlation of CTNNB1 mutations reveals different ß-catenin activity associated with liver tumor progression.,http://www.ncbi.nlm.nih.gov/pubmed/27177928,295,,,www.uniprot.org,22754
"CTNNB1 P16_K133del results in the deletion of 118 amino acids of the Ctnnb1 protein from amino acids 16 to 133 (UniProt.org). P16_K133del has been identified in sequencing studies (PMID: 10487827), but has not been biochemically characterized and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",2342,10487827,Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation.,http://www.ncbi.nlm.nih.gov/pubmed/10487827,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22755
"CTNNB1 S47L does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). S47L has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22756
"CTNNB1 T3_A126del results in the deletion of 124 amino acids of the Ctnnb1 protein from amino acids 3 to 126 (UniProt.org). T3_A126del has been identified in sequencing studies (PMID: 16496320), but has not been biochemically characterized and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,7296,16496320,Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC.,http://www.ncbi.nlm.nih.gov/pubmed/16496320,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22757
"CTNNB1 T41_P52del results in the deletion of 12 amino acids of the Ctnnb1 protein from amino acids 41 to 52 (UniProt.org). T41_P52del has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22758
"CTNNB1 V22_A97del results in the deletion of 76 amino acids of the Ctnnb1 protein from amino acids 22 to 97 (UniProt.org). V22_A97del has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22759
"CTNNB1 V22_D145del results in the deletion of 124 amino acids of the Ctnnb1 protein from amino acids 22 to 145 (UniProt.org). V22_D145del has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22760
"CTNNB1 V22_Y64del results in the deletion of 43 amino acids of the Ctnnb1 protein from amino acids 22 to 64 (UniProt.org). V22_Y64del has been identified in sequencing studies (PMID: 25822088), but has not been biochemically characterized and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7022,25822088,Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.,http://www.ncbi.nlm.nih.gov/pubmed/25822088,22761
"CTNNB1 W383K lies within the Arm repeat 6 region of the Ctnnb1 protein (UniProt.org). W383K has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22762
"CBL dec exp indicates decreased expression of the Cbl protein. However, the mechanism causing the decreased expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,22763
U2AF1 mutant indicates an unspecified mutation in the U2AF1 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,22764
CBL del indicates a deletion of the CBL gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,22765
CBLB del indicates a deletion of the CBLB gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,22766
"ATM S99G does not lie within any known functional domains of the Atm protein (UniProt.org). S99G has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Nov 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22768
"EGFR R675Q does not lie within any known functional domains of the Egfr protein (UniProt.org). R675Q has been identified in the scientific literature (PMID: 16278407), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",8064,16278407,Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.,http://www.ncbi.nlm.nih.gov/pubmed/16278407,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22770
"PHF6 R116Q lies within the PHD-type 1 zinc finger of the Phf6 protein (UniProt.org). R116Q has not been characterized in the scientific literature and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22772
"KIT T274M lies within the extracellular domain of the Kit protein (UniProt.org). T274M has not been characterized and therefore, its effect on Kit protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22773
"PHF6 A40V lies within the extended PHD1 domain of the Phf6 protein (UniProt.org). A40V has not been characterized in the scientific literature and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22779
"PHF6 C292S lies within the extended PHD2 domain of the Phf6 protein (UniProt.org). C292S has not been characterized in the scientific literature and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22780
"PHF6 D141N does not lie within any known functional domains of the Phf6 protein (UniProt.org). D141N has not been characterized in the scientific literature and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22781
"PHF6 D262N does not lie within any known functional domains of the Phf6 protein (UniProt.org). D262N has not been characterized in the scientific literature and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22782
"PHF6 D264H does not lie within any known functional domains of the Phf6 protein (UniProt.org). D264H has not been characterized in the scientific literature and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22783
"PHF6 E117D lies within the extended PHD1 domain of the Phf6 protein (UniProt.org). E117D has not been characterized in the scientific literature and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22784
"PHF6 E139K does not lie within any known functional domains of the Phf6 protein (UniProt.org). E139K has not been characterized in the scientific literature and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22785
"PHF6 E189D does not lie within any known functional domains of the Phf6 protein (UniProt.org). E189D has not been characterized in the scientific literature and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22786
"PHF6 E189K does not lie within any known functional domains of the Phf6 protein (UniProt.org). E189K has not been characterized in the scientific literature and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22787
"PHF6 G213V lies within the extended PHD2 domain of the Phf6 protein (UniProt.org). G213V has not been characterized in the scientific literature and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22788
"PHF6 D264* results in a premature truncation of the Phf6 protein at amino acid 264 of 365 (UniProt.org). Due to the loss of the PHD-type 2 zinc finger, D264* is predicted to lead to a loss of Phf6 protein function (UniProt.org).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22789
"PHF6 E68* results in a premature truncation of the Phf6 protein at amino acid 68 of 365 (UniProt.org). Due to the loss of all known functional domains, E68* is predicted to lead to a loss of Phf6 protein function (UniProt.org). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22790
"PHF6 G226E lies within the extended PHD2 domain of the Phf6 protein (UniProt.org). G226E has not been characterized in the scientific literature and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22791
"PHF6 G226R lies within the extended PHD2 domain of the Phf6 protein (UniProt.org). G226R has not been characterized and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22792
"PHF6 G248C lies within the extended PHD2 domain of the Phf6 protein (UniProt.org). G248C has not been characterized in the scientific literature and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22793
"CBLB dec exp indicates decreased expression of the Cblb protein. However, the mechanism causing the decreased expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,22794
"CBLC over exp indicates an over expression of the Cblc protein. However, the mechanism causing the over expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,22795
"CBLC dec exp indicates decreased expression of the Cblc protein. However, the mechanism causing the decreased expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,22796
CALR mutant indicates an unspecified mutation in the CALR gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,22797
"SRSF2 E35Q lies within the RRM domain of the Srsf2 protein (UniProt.org). E35Q has not been characterized in the scientific literature and therefore, its effect on Srsf2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22798
"SRSF2 E69G lies within the RRM domain of the Srsf2 protein (UniProt.org). E69G has not been characterized in the scientific literature and therefore, its effect on Srsf2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22799
"SRSF2 E69K lies within the RRM domain of the Srsf2 protein (UniProt.org). E69K has not been characterized in the scientific literature and therefore, its effect on Srsf2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22800
"SRSF2 G104E does not lie within any known functional domains of the Srsf2 protein (UniProt.org). G104E has not been characterized in the scientific literature and therefore, its effect on Srsf2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22801
"SRSF2 K172_S173del results in the deletion of two amino acids of the Srsf2 protein from amino acids 172 to 173 (UniProt.org). K172_S173del has not been characterized in the scientific literature and therefore, its effect on Srsf2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22802
"SRSF2 K207* results in a premature truncation of the Srsf2 protein at amino acid 207 of 221 (UniProt.org). K207* has not been characterized and therefore, its effect on Srsf2 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22803
"SRSF2 K52N lies within the RRM domain of the Srsf2 protein (UniProt.org). K52N has not been characterized in the scientific literature and therefore, its effect on Srsf2 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22804
"SRSF2 M1? indicates a disruption of the methionine (M) start codon with an unknown translational effect on the Srsf2 protein.  M1? has not been characterized and therefore, its effect on Srsf1 protein function is unknown (PubMed, May 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,22805
"SRSF2 M13I does not lie within any known functional domains of the Srsf2 protein (UniProt.org). M13I has not been characterized in the scientific literature and therefore, its effect on Srsf2 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,115,0,,http://www.ncbi.nlm.nih.gov/pubmed,22806
"SRSF2 P209T does not lie within any known functional domains of the Srsf2 protein (UniProt.org). P209T has not been characterized and therefore, its effect on Srsf2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22807
"SRSF2 P95_R102del results in the deletion of 8 amino acids of the Srsf2 protein from amino acids 95 to 102 (UniProt.org). P95_R102del has not been characterized and therefore, its effect on Srsf2 protein function is unknown (PubMed, May 2016).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22808
"SRSF2 P96Rfs*136 is a missense mutation (P96R) in conjunction with a likely truncation of the 221 aa Srsf2 protein at aa 96, followed by 136 nonsense amino acids (UniProt.org). P96Rfs*136 has not been characterized in the scientific literature and therefore, its effect on Srsf2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22809
"SRSF2 R123W does not lie within any known functional domains of the Srsf2 protein (UniProt.org). R123W has not been characterized in the scientific literature and therefore, its effect on Srsf2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22810
"SRSF2 R129* results in a premature truncation of the Srsf2 protein at amino acid 129 of 221 (UniProt.org). R129* has not been characterized in the scientific literature and therefore, its effect on Srsf2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22811
"SRSF2 R129G does not lie within any known functional domains of the Srsf2 protein (UniProt.org). R129G has not been characterized in the scientific literature and therefore, its effect on Srsf2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22812
"SRSF2 R129L does not lie within any known functional domains of the Srsf2 protein (UniProt.org). R129L has not been characterized in the scientific literature and therefore, its effect on Srsf2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22813
"SRSF2 R152_S159del results in the deletion of 8 amino acids of the Srsf2 protein from amino acids 152 to 159 (UniProt.org). R152_S159del has not been characterized in the scientific literature and therefore, its effect on Srsf2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22814
"SRSF2 R167L does not lie within any known functional domains of the Srsf2 protein (UniProt.org). R167L has not been characterized in the scientific literature and therefore, its effect on Srsf2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22815
"SRSF2 R167Q does not lie within any known functional domains of the Srsf2 protein (UniProt.org). R167Q has not been characterized in the scientific literature and therefore, its effect on Srsf2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22816
"SRSF2 R168K does not lie within any known functional domains of the Srsf2 protein (UniProt.org). R168K has not been characterized in the scientific literature and therefore, its effect on Srsf2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22817
"SRSF2 R205L does not lie within any known functional domains of the Srsf2 protein (UniProt.org). R205L has not been characterized in the scientific literature and therefore, its effect on Srsf2 protein function is unknown (PubMed, May 2016).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22818
"SRSF2 S136C does not lie within any known functional domains of the Srsf2 protein (UniProt.org). S136C has not been characterized in the scientific literature and therefore, its effect on Srsf2 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22819
"SRSF2 S15F lies within the RRM domain of the Srsf2 protein (UniProt.org). S15F has not been characterized in the scientific literature and therefore, its effect on Srsf2 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22820
"SRSF2 S171Y does not lie within any known functional domains of the Srsf2 protein (UniProt.org). S171Y has not been characterized in the scientific literature and therefore, its effect on Srsf2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22821
"SRSF2 S174_S179del results in the deletion of 6 amino acids of the Srsf2 protein from amino acids 174 to 179 (UniProt.org). S174_S179del has not been characterized in the scientific literature and therefore, its effect on Srsf2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22822
"SRSF2 S179C does not lie within any known functional domains of the Srsf2 protein (UniProt.org). S179C has not been characterized in the scientific literature and therefore, its effect on Srsf2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22823
"SRSF2 S187Y does not lie within any known functional domains of the Srsf2 protein (UniProt.org). S187Y has not been characterized in the scientific literature and therefore, its effect on Srsf2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22824
"SRSF2 S220C does not lie within any known functional domains of the Srsf2 protein (UniProt.org). S220C has not been characterized in the scientific literature and therefore, its effect on Srsf2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22825
"SRSF2 T51I lies within the RRM domain of the Srsf2 protein (UniProt.org). T51I has not been characterized in the scientific literature and therefore, its effect on Srsf2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22826
"SRSF2 V195L does not lie within any known functional domains of the Srsf2 protein (UniProt.org). V195L has not been characterized in the scientific literature and therefore, its effect on Srsf2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22827
"SRSF2 Y110C does not lie within any known functional domains of the Srsf2 protein (UniProt.org). Y110C as not been characterized in the scientific literature and therefore, its effect on Srsf2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22828
"SRSF2 Y37C lies within the RRM domain of the Srsf2 protein (UniProt.org). Y37C has not been characterized in the scientific literature and therefore, its effect on Srsf2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22829
"SRSF2 Y92_H100del results in the deletion of 9 amino acids of the Srsf2 protein from amino acids 92 to 100 (UniProt.org). Y92_H100del has not been characterized in the scientific literature and therefore, its effect on Srsf2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22830
"SRSF2 Y92_H99del results in the deletion of 8 amino acids of the Srsf2 protein from amino acids 92 to 99 (UniProt.org). Y92_H99del  has not been characterized in the scientific literature and therefore, its effect on Srsf2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22831
"PHF6 G63C lies within the extended PHD1 domain of the Phf6 protein (UniProt.org). G63C has not been characterized in the scientific literature and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22832
"PHF6 G93C lies within the extended PHD1 domain of the Phf6 protein (UniProt.org). G93C has not been characterized in the scientific literature and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22833
"PHF6 H110Q lies within the extended PHD1 domain of the Phf6 protein (UniProt.org). H110Q has not been characterized in the scientific literature and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22834
"PHF6 H131Q lies within the extended PHD1 domain of the Phf6 protein (UniProt.org). H131Q has not been characterized in the scientific literature and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22835
"PHF6 K132N lies adjacent to the extended PHD1 domain of the Phf6 protein (UniProt.org). K132N has not been characterized in the scientific literature and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22836
"PHF6 K132R lies adjacent to the extended PHD1 domain of the Phf6 protein (UniProt.org). K132R has not been characterized in the scientific literature and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,22837
"PHF6 K164R lies within the nucleolar localization motif of the Phf6 protein (UniProt.org). K164R has not been characterized and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22838
"PHF6 K169T lies within the nucleolar localization motif of the Phf6 protein (UniProt.org). K169T has not been characterized in the scientific literature and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22839
"PHF6 K21N lies within the extended PHD1 domain of the Phf6 protein (UniProt.org). K21N has not been characterized in the scientific literature and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22840
"PHF6 K299N lies within the extended PHD2 domain of the Phf6 protein (UniProt.org). K299N has not been characterized in the scientific literature and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22841
"PHF6 M190I does not lie within any known functional domains of the Phf6 protein (UniProt.org). M190I has not been characterized and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22842
"PHF6 N171I does not lie within any known functional domains of the Phf6 protein (UniProt.org). N171I has not been characterized and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22843
"PHF6 N328Y lies within the extended PHD2 domain of the Phf6 protein (UniProt.org). N328Y has not been characterized in the scientific literature and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22844
"PHF6 Q251K lies within the extended PHD2 domain of the Phf6 protein (UniProt.org). Q251K has not been characterized in the scientific literature and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22845
"PHF6 R196K does not lie within any known functional domains fo the Phf6 protein (UniProt.org). R196K has not been characterized in the scientific literature and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22846
"ZRSR2 A2D does not lie within any known functional domains of the Zrsr2 protein (UniProt.org). A2D has not been characterized in the scientific literature and therefore, its effect on Zrsr2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22847
"ZRSR2 A310T lies within the C3H1-type 2 Zinc finger region of the Zrsr2 protein (UniProt.org). A310T has not been characterized in the scientific literature and therefore, its effect on Zrsr2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22848
"PHF6 R274* results in a premature truncation of the Phf6 protein at amino acid 274 of 365 (UniProt.org). Due to the loss of the PHD-type 2 zinc finger, D274* is predicted to lead to a loss of Phf6 protein function (UniProt.org).",295,,,www.uniprot.org,22849
"ZRSR2 A342S does not lie within any known functional domains of the Zrsr2 protein (UniProt.org). A342S has not been characterized in the scientific literature and therefore, its effect on Zrsr2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22850
"PHF6 R274L lies within the extended PHD2 domain of the Phf6 protein (UniProt.org). R274L has not been characterized in the scientific literature and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22851
"ZRSR2 D220A lies within the RRM domain of the Zrsr2 protein (UniProt.org). D220A has not been characterized in the scientific literature and therefore, its effect on Zrsr2 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22852
"ZRSR2 D432_R435del results in the deletion of 4 amino acids of the Zrsr2 protein from amino acids 432 to 435 (UniProt.org). D432_R435del has not been characterized in the scientific literature and therefore, its effect on Zrsr2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22853
"ZRSR2 E123D does not lie within any known functional domains of the Zrsr2 protein (UniProt.org). E123D has not been characterized in the scientific literature and therefore, its effect on Zrsr2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22854
"ZRSR2 E246K lies within the RRM domain of the Zrsr2 protein (UniProt.org). E246K has not been characterized in the scientific literature and therefore, its effect on Zrsr2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22855
"PHF6 R319* results in a premature truncation of the Phf6 protein at amino acid 319 of 365 (UniProt.org). R319* has not been characterized in the scientific literature and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22856
"ZRSR2 E48K does not lie within any known functional domains of the Zrsr2 protein (UniProt.org). E48K has not been characterized in the scientific literature and therefore, its effect on Zrsr2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22857
"ZRSR2 E93K does not lie within any known functional domains of the Zrsr2 protein (UniProt.org). E93K has not been characterized in the scientific literature and therefore, its effect on Zrsr2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22858
"ZRSR2 G150D does not lie within any known functional domains of the Zrsr2 protein (UniProt.org). G150D has not been characterized in the scientific literature and therefore, its effect on Zrsr2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22859
"PHF6 S2* results in a premature truncation of the Phf6 protein at amino acid 2 of 365 (UniProt.org). Due to the loss of all known functional domains, Phf6 is predicted to lead to a loss of Phf6 protein function (UniProt.org).",295,,,www.uniprot.org,22860
"ZRSR2 G323* results in a premature truncation of the Zrsr2 protein at amino acid 323 of 482 (UniProt.org). G323* has not been characterized in the scientific literature and therefore, its effect on Zrsr2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22861
"ZRSR2 G404R does not lie within any known functional domains of the Zrsr2 protein (UniProt.org). G404R has not been characterized in the scientific literature and therefore, its effect on Zrsr2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22862
"PHF6 S4L does not lie within any known functional domains of the Phf6 protein (UniProt.org). S4L has not been characterized in the scientific literature and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22863
"ZRSR2 G404V does not lie within any known functional domains of the Zrsr2 protein (UniProt.org). G404V has not been characterized in the scientific literature and therefore, its effect on Zrsr2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22864
"ZRSR2 G465D does not lie within any known functional domains of the Zrsr2 protein (UniProt.org). G465D has not been characterized in the scientific literature and therefore, its effect on Zrsr2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22865
"PHF6 S83Y lies within the extended PHD1 domain of the Phf6 protein (UniProt.org). S83Y has not been characterized in the scientific literature and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22866
"PHF6 V298I lies within the extended PHD2 domain of the Phf6 protein (UniProt.org). V298I has not been characterized in the scientific literature and therefore, its effect on Phf6 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22867
"PHF6 M1? indicates a disruption of the methionine (M) start codon with unknown translation effect on the Phf6 protein. Due to the disruption of the translational start site of the native protein, M1? is predicted to lead to a loss of Phf6 protein function. ",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,22868
"ZRSR2 H15N does not lie within any known functional domains of the Zrsr2 protein (UniProt.org). H15N has not been characterized in the scientific literature and therefore, its effect on Zrsr2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22869
"ZRSR2 H402Y does not lie within any known functional domains of the Zrsr2 protein (UniProt.org). H402Y has not been characterized in the scientific literature and therefore, its effect on Zrsr2 protein function is unknown (PubMed, May 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22870
"ZRSR2 P303S lies within the RRM domain of the Zrsr2 protein (UniProt.org). P303S has not been characterized in the scientific literature and therefore, its effect on Zrsr2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22871
"ZRSR2 Q255H lies within the RRM domain of the Zrsr2 protein (UniProt.org). Q255H has not been characterized in the scientific literature and therefore, its effect on Zrsr2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22872
"ZRSR2 Q56H does not lie within any known functional domains of the Zrsr2 protein (UniProt.org). Q56H has not been characterized in the scientific literature and therefore, its effect on Zrsr2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22873
"ZRSR2 Q69E does not lie within any known functional domains of the Zrsr2 protein (UniProt.org). Q69E has not been characterized in the scientific literature and therefore, its effect on Zrsr2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22874
"ZRSR2 R126* results in a premature truncation of the Zrsr2 protein at amino acid 126 of 482 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), R126* is predicted to lead to a loss of Zrsr2 protein function.",295,,,www.uniprot.org,22875
"ZRSR2 R216M lies within the RRM domain of the Zrsr2 protein (UniProt.org). R216M has not been characterized and therefore, its effect on Zrsr2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22876
"ZRSR2 R27Q does not lie within any known functional domains of the Zrsr2 protein (UniProt.org). R27Q has not been characterized in the scientific literature and therefore, its effect on Zrsr2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22877
"ZRSR2 R306M lies within the C3H1-type 2 Zinc finger region of the Zrsr2 protein (UniProt.org). R306M has not been characterized in the scientific literature and therefore, its effect on Zrsr2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22878
"ZRSR2 R352Q does not lie within any known functional domains of the Zrsr2 protein (UniProt.org). R352Q has not been characterized in the scientific literature and therefore, its effect on Zrsr2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22879
"ZRSR2 R397K does not lie within any known functional domains of the Zrsr2 protein (UniProt.org). R397K has not been characterized in the scientific literature and therefore, its effect on Zrsr2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22880
"ZRSR2 R397W does not lie within any known functional domains of the Zrsr2 protein (UniProt.org). R397W has not been characterized in the scientific literature and therefore, its effect on Zrsr2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22881
"ZRSR2 R401C does not lie within any known functional domains of the Zrsr2 protein (UniProt.org). R401C has not been characterized in the scientific literature and therefore, its effect on Zrsr2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22882
"ZRSR2 R437Q does not lie within any known functional domains of the Zrsr2 protein (UniProt.org). R437Q has not been characterized in the scientific literature and therefore, its effect on Zrsr2 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22883
"ZRSR2 R70S does not lie within any known functional domains of the Zrsr2 protein (UniProt.org). R70S has not been characterized in the scientific literature and therefore, its effect on Zrsr2 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22884
"ZRSR2 S276L lies within the RRM domain of the Zrsr2 protein (UniProt.org). S276L has not been characterized in the scientific literature and therefore, its effect on Zrsr2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22885
"ZRSR2 S43* results in a premature truncation of the Zrsr2 protein at amino acid 43 of 482 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), S43* is predicted to lead to a loss of Zrsr2 protein function.",295,,,www.uniprot.org,22886
"ZRSR2 S447_R448del results in the deletion of two amino acids of the Zrsr2 protein from amino acids 447 to 448 (UniProt.org). S447_R448del has not been characterized in the scientific literature and therefore, its effect on Zrsr2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22887
"ZRSR2 V270E lies within the RRM domain of the Zrsr2 protein (UniProt.org). V270E has not been characterized in the scientific literature and therefore, its effect on Zrsr2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22888
"ZRSR2 V304M lies within the RRM domain of the Zrsr2 protein (UniProt.org). V304M has not been characterized and therefore, its effect on Zrsr2 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22889
"ZRSR2 W153* results in a premature truncation of the Zrsr2 protein at amino acid 153 of 482 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), W153* is predicted to lead to a loss of Zrsr2 protein function.",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22890
"FLT3 N676D lies within the protein kinase domain of the Flt3 protein (UniProt.org). N676D has not been characterized, but has been demonstrated to occur as a secondary resistance mutation (PMID: 22875611).",5603,22875611,The N676D and G697R mutations in the kinase domain of FLT3 confer resistance to the inhibitor AC220.,http://www.ncbi.nlm.nih.gov/pubmed/22875611,295,,,www.uniprot.org,22892
"ETV6-CDX2 results from the fusion of ETV6 and CDX2 (PMID: 9920852). ETV6-CDX2 has been identified in acute myeloid leukemia (PMID: 9920852), but has not been fully biochemically characterized, however, over expression of CDX2, but not ETV6-CDX2, resulted in transformation in mice (PMID: 14718672).",5605,9920852,Fusion of ETV6 to the caudal-related homeobox gene CDX2 in acute myeloid leukemia with the t(12;13)(p13;q12).,http://www.ncbi.nlm.nih.gov/pubmed/9920852,5606,14718672,Ectopic expression of the homeobox gene Cdx2 is the transforming event in a mouse model of t(12;13)(p13;q12) acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/14718672,22894
"ETV6-FRK results from the fusion of ETV6 and FRK, demonstrating constitutive Frk phosphorylation and transforming ability in culture (PMID: 15611931).",5607,15611931,"Identification of a SRC-like tyrosine kinase gene, FRK, fused with ETV6 in a patient with acute myelogenous leukemia carrying a t(6;12)(q21;p13) translocation.",http://www.ncbi.nlm.nih.gov/pubmed/15611931,22895
"ETV6-BAZ2A results from the fusion of ETV6 and BAZ2A (PMID: 16643428). ETV6-BAZ2A has been identified in acute lymphoblastic leukemia (PMID: 16643428), but has not been biochemically characterized and therefore, its effect on fusion protein function is unknown (PubMed, Aug 2017).",5608,16643428,Fusion of ETV6 with an intronic sequence of the BAZ2A gene in a paediatric pre-B acute lymphoblastic leukaemia with a cryptic chromosome 12 rearrangement.,http://www.ncbi.nlm.nih.gov/pubmed/16643428,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22896
"ETV6-PTPRR (also referred to as TEL-PTPRR) results from the fusion of ETV6 and PTPRR, demonstrating the ability to lead to Stat activation and growth-factor independent growth in culture (PMID: 16061641).",5609,16061641,Cloning and characterization of the novel chimeric gene TEL/PTPRR in acute myelogenous leukemia with inv(12)(p13q13).,http://www.ncbi.nlm.nih.gov/pubmed/16061641,22897
"ETV6-PRDM16 results from the fusion of ETV6 and PRDM16 (PMID: 22050763). ETV6-PRDM16 has been identified in acute myeloid leukemia and myelodysplastic syndrome, but has not been biochemically characterized, however, has been demonstrated to result in over expression of PRDM16 (PMID: 22050763).",5610,22050763,PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/22050763,22898
"U2AF1 A123V lies within the RRM domain of the U2af1 protein (UniProt.org). A123V has not been characterized in the scientific literature and therefore, its effect on U2af1 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22900
"U2AF1 D14G lies within the C3H1-type zinc finger of the U2af1 protein (UniProt.org). D14G has not been characterized in the scientific literature and therefore, its effect on U2af1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22901
"U2AF1 E184D lies within the RS domain of the U2af1 protein (UniProt.org). E184D has not been characterized and therefore, its effect on U2af1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22902
"U2AF1 G106E lies within the RRM domain of the U2af1 protein (UniProt.org). G106E has not been characterized in the scientific literature and therefore, its effect on U2af1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22903
"U2AF1 G217I lies within the RS domain of the U2af1 protein (UniProt.org). G217I has not been characterized and therefore, its effect on U2af1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22904
U2AF1 I24T lies within the interface between zinc fingers of the U2af1 protein (PMID: 26215567). I24T confers a loss of function to the U2af1 protein as demonstrated by loss of RNA binding affinity (PMID: 26215567).,5630,26215567,A novel 3' splice site recognition by the two zinc fingers in the U2AF small subunit.,http://www.ncbi.nlm.nih.gov/pubmed/26215567,22905
"U2AF1 I24V lies within the interface between zinc fingers of the U2af1 protein (PMID: 26215567). I24V has not been characterized in the scientific literature and therefore, its effect on U2af1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22906
"U2AF1 K191N lies within the RS domain of the U2af1 protein (UniProt.org). K191N has not been characterized in the scientific literature and therefore, its effect on U2af1 protein function is unknown (PubMed, May 2016).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22907
"U2AF1 N38H lies within the RRM domain of the U2af21 (UniProt.org). N38H has not been characterized in the scientific literature and therefore, its effect on U2af1 protein function is unknown (PubMed, May 2016).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22908
"U2AF1 G218dup indicates the insertion of the duplicate amino acid, glycine (G)-218 within the poly-glycine rich region of RS domain of the U2af1 protein (UniProt.org). G218dup has not been characterized in the scientific literature and therefore, its effect on U2af1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22909
"KMT2A E1361* results in a premature truncation of the Kmt2a protein at amino acid 1361 of 3969 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), E1361* is predicted to lead to a loss of Kmt2a protein function.",295,,,www.uniprot.org,22910
"KMT2A E1472* results in a premature truncation of the Kmt2a protein at amino acid 1472 of 3969 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), E1472* is predicted to lead to a loss of Kmt2a protein function.",295,,,www.uniprot.org,22911
"KMT2A R1064* results in a premature truncation of the Kmt2a protein at amino acid 1064 of 3969 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), R1064* is predicted to lead to a loss of Kmt2a protein function.",295,,,www.uniprot.org,22912
"KMT2A R1151* results in a premature truncation of the Kmt2a protein at amino acid 1151 of 3969 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), R1151* is predicted to lead to a loss of Kmt2a protein function.",295,,,www.uniprot.org,22913
"KMT2A R2379* results in a premature truncation of the Kmt2a protein at amino acid 2379 of 3969 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), R2379* is predicted to lead to a loss of Kmt2a protein function.",295,,,www.uniprot.org,22914
"KMT2A R2656* results in a premature truncation of the Kmt2a protein at amino acid 2656 of 3969 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), R2656* is predicted to lead to a loss of Kmt2a protein function.",295,,,www.uniprot.org,22915
"KMT2A R3886* results in a premature truncation of the Kmt2a protein at amino acid 3886 of 3969 (UniProt.org). R3886* has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22916
"KMT2A R3903C lies within the SET domain of the Kmt2a protein (UniProt.org). R3903C has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22917
"KMT2A R3932H lies within the SET domain of the Kmt2a protein (UniProt.org). R3932H has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22918
"KMT2A R3965W lies within the post-SET domain of the Kmt2a protein (UniProt.org). R3965W has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22919
"KMT2A R407* results in a premature truncation of the Kmt2a protein at amino acid 407 of 3969 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), R407* is predicted to lead to a loss of Kmt2a protein function.",295,,,www.uniprot.org,22920
"KMT2A R427W does not lie within any known functional domains of the Kmt2a protein (UniProt.org). R427W has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22921
"KMT2A R652* results in a premature truncation of the Kmt2a protein at amino acid 652 of 3969 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), R652* is predicted to lead to a loss of Kmt2a protein function.",295,,,www.uniprot.org,22922
"KMT2A R736M does not lie within any known functional domains of the Kmt2a protein (UniProt.org). R736M has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22923
"KMT2A R933Q does not lie within any known functional domains of the Kmt2a protein (UniProt.org). R933Q has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22924
"KMT2A S1062Y does not lie within any known functional domains of the Kmt2a protein (UniProt.org). S1062Y has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22925
"KMT2A S1152L does not lie within any known functional domains of the Kmt2a protein (UniProt.org). S1152L has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22926
"KMT2A S1643Y does not lie within any known functional domains of the Kmt2a protein (UniProt.org). S1643Y has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22927
"KMT2A S2690Y does not lie within any known functional domains of the Kmt2a protein (UniProt.org). S2690Y has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22928
"KMT2A S2771Y does not lie within any known functional domains of the Kmt2a protein (UniProt.org). S2771Y has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22929
"KMT2A S2785Y does not lie within any known functional domains of the Kmt2a protein (UniProt.org). S2785Y has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22930
"KMT2A S3120L does not lie within any known functional domains of the Kmt2a protein (UniProt.org). S3120L has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22931
"KMT2A S3377L does not lie within any known functional domains of the Kmt2a protein (UniProt.org). S3377L has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22932
"KMT2A S3576F does not lie within any known functional domains of the Kmt2a protein (UniProt.org). S3576F has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Kmt2a protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,22933
"KMT2A S534L does not lie within any known functional domains of the Kmt2a protein (UniProt.org). S534L has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22934
"KMT2A T3868N lies within the SET domain of the Kmt2a protein (UniProt.org). T3868N has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22935
"KMT2A V2178A does not lie within any known functional domains of the Kmt2a protein (UniProt.org). V2178A has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22936
"KMT2A V2246G does not lie within any known functional domains of the Kmt2a protein (UniProt.org). V2246G has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Jul 2017).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22937
"KMT2A Y3883S lies within the SET domain of the Kmt2a protein (UniProt.org). Y3883S has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22938
"U2AF1 P139L lies within the RRM domain of the U2af1 protein (UniProt.org). P139L has not been characterized and therefore, its effect on U2af1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22940
"U2AF1 Q138* results in a premature truncation of the U2af1 protein at amino acid 138 of 240 (UniProt.org). Q138* has not been characterized in the scientific literature and therefore, its effect on U2af1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22941
U2AF1 Q157P lies within the C3H1-type 2 Zinc finger region of the U2af1 protein (UniProt.org). Q157P results in activation of U2af1 protein as indicated by aberrant splicing in cell culture (PMID: 25267526).,5638,25267526,U2AF1 mutations alter splice site recognition in hematological malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/25267526,22942
U2AF1 Q157R lies within the C3H1-type 2 Zinc finger region of the U2af1 protein (UniProt.org). Q157R results in activation of U2af1 protein as indicated by aberrant splicing in cell culture (PMID: 25267526).,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22943
"U2AF1 R156H lies within the C3H1-type 2 Zinc finger region of the U2af1 protein (UniProt.org). R156H has not been characterized and therefore, its effect on U2af1 protein function is unknown (PubMed, May 2016).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22944
"U2AF1 R182Q lies within the RS domain of the U2af1 protein (UniProt.org). R182Q has not been characterized in the scientific literature and therefore, its effect on U2af1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22945
"U2AF1 R188H lies within the RS domain of the U2af1 protein (UniProt.org). R188H has not been characterized in the scientific literature and therefore, its effect on U2af1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22946
"U2AF1 R190H lies within the RS domain of the U2af1 protein (UniProt.org). R190H has not been characterized in the scientific literature and therefore, its effect on U2af1 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22947
"U2AF1 R194S lies within the RS domain of the U2af1 protein (UniProt.org). R194S has not been characterized in the scientific literature and therefore, its effect on U2af1 protein function is unknown (PubMed, May 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,22948
"U2AF1 R198Q lies within the RS domain of the U2af1 protein (UniProt.org). R198Q has not been characterized in the scientific literature and therefore, its effect on U2af1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22949
"U2AF1 R209H lies within the RS domain of the U2af1 protein (UniProt.org). R209H has not been characterized in the scientific literature and therefore, its effect on U2af1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22950
"U2AF1 R229K lies within the RS domain of the U2af1 protein (UniProt.org). R229K has not been characterized in the scientific literature and therefore, its effect on U2af1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22951
"U2AF1 R234C lies within the RS domain of the U2af1 protein (UniProt.org). R234C has not been characterized and therefore, its effect on U2af1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22952
"U2AF1 R239* results in a premature truncation of the U2af1 protein at amino acid 239 of 240 (UniProt.org). R239* has not been characterized in the scientific literature and therefore, its effect on U2af1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22953
"U2AF1 R28H lies within the C3H1-type 1 Zinc finger region of the U2af1 protein (UniProt.org). R28H has not been characterized in the scientific literature and therefore, its effect on U2af1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22954
"U2AF1 S231L lies within the RS domain of the U2af1 protein (UniProt.org). S231L has not been characterized and therefore, its effect on U2af1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22955
"U2AF1 S34F lies within the C3H1-type 1 Zinc finger region of the U2af1 protein (UniProt.org). S34F results in activation of U2af1 protein as indicated by aberrant splicing in cell culture (PMID: 25267526, PMID: 28436936).",5638,25267526,U2AF1 mutations alter splice site recognition in hematological malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/25267526,9928,28436936,The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/28436936,295,,,www.uniprot.org,22956
U2AF1 S34Y lies within the C3H1-type 1 Zinc finger region of the U2af1 protein (UniProt.org). S34Y results in activation of U2af1 protein as indicated by aberrant splicing in cell culture (PMID: 25267526).,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22957
"U2AF1 T148M does not lie within any known functional domains of the U2af1 protein (UniProt.org). T148M has not been characterized in the scientific literature and therefore, its effect on U2af1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22958
"U2AF1 V115I lies within the RRM domain of the U2af1 protein (UniProt.org). V115I has not been characterized in the scientific literature and therefore, its effect on U2af1 protein function is unknown (PubMed, May 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22959
CSF3R mutant indicates an unspecified mutation in the CSF3R gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,22960
Wild-type RAD21 indicates that no mutation has been detected within the RAD21 gene. ,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,22961
"ATRX inact mut indicates that this variant results in a loss of function of the Atrx protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,22963
"PDGFRA negative indicates a lack of the PDGFRA gene, mRNA, and/or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,22984
EGFR D770_N771insNPG results in the insertion of three amino acids in the protein kinase domain of the Egfr protein between amino acids 770 and 771 (UniProt.org). D770_N771insNPG results in increased Egfr kinase activity and is transforming in culture (PMID: 24353160).,295,,,www.uniprot.org,440,24353160,"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24353160,22986
"ERBB2(HER2) G776_V777insVC results in the insertion of two amino acids in the protein kinase domain of the Erbb2(Her2) protein between amino acids 776 and 777 (UniProt.org). G776_V777insVC has been identified in sequencing studies (PMID: 23610105), but has not been biochemically characterized and therefore, its effect on Erbb2 protein function is unknown (PubMed, Oct 2017).",560,23610105,Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.,http://www.ncbi.nlm.nih.gov/pubmed/23610105,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,22987
"TP53 D259Y lies within the DNA binding domain of the Tp53 protein (UniProt.org). D259Y has been identified in the scientific literature (PMID: 22550420, PMID: 27859003), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Feb 2017).
",7929,27859003,"Targeted next generation sequencing of breast implant-associated anaplastic large cell lymphoma reveals mutations in JAK/STAT signalling pathway genes, TP53 and DNMT3A.",http://www.ncbi.nlm.nih.gov/pubmed/27859003,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7928,22550420,Low Prevalence of TP53 Mutations and MDM2 Amplifications in Pediatric Rhabdomyosarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/22550420,22988
"NRAS R167L lies within the hypervariable region of the Nras protein (UniProt.org). R167L has been identified in the scientific literature (PMID: 26343583), but has not been biochemically characterized and therefore, its effect on Nras protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5709,26343583,Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26343583,22989
"BRAF A665V lies within the protein kinase domain of the Braf protein (UniProt.org). A665V has been identified in the scientific literature (PMID: 26343583), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5709,26343583,Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/26343583,295,,,www.uniprot.org,22990
"BRAF R509H lies within the dimerization interface region of the Braf protein (PMID: 22510884). R509H confers a loss of function to the Braf protein, as demonstrated by decreased Braf dimerization and reduced ability to activate downstream Mek signaling in in vitro assays (PMID: 22510884).",5712,22510884,"Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling.",http://www.ncbi.nlm.nih.gov/pubmed/22510884,22991
EGFR G465E lies within the extracellular domain of the Egfr protein (UniProt.org). G465E results in increased Egfr and Erk phosphorylation and confers resistance to Erbitux (cetuximab) and Vectibix (panitumumab) in cell culture (PMID: 26416732).,5717,26416732,The genomic landscape of response to EGFR blockade in colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26416732,295,,,www.uniprot.org,22994
EGFR G465R lies within the extracellular domain of the Egfr protein (UniProt.org). G465R results in increased Egfr phosphorylation and confers resistance to Erbitux (cetuximab) and Vectibix (panitumumab) in cell culture (PMID: 26059438).,295,,,www.uniprot.org,5718,26059438,Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26059438,22995
EGFR I491M lies within the extracellular domain of the Egfr protein (UniProt.org). I491M results in increased Egfr and Erk phosphorylation and confers resistance to Erbitux (cetuximab) and Vectibix (panitumumab) in cell culture (PMID: 26843189).,295,,,www.uniprot.org,5719,26843189,MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26843189,22996
EGFR K467T lies within the extracellular domain of the Egfr protein (UniProt.org). K467T results in increased Egfr and Erk phosphorylation and confers resistance to Erbitux (cetuximab) in cell culture (PMID: 26843189).,5719,26843189,MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26843189,295,,,www.uniprot.org,22997
EGFR R451C lies within the extracellular domain of the Egfr protein (UniProt.org). R451C results in reduced Egfr affinity for Egf binding in cell culture (PMID: 26843189).,5719,26843189,MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26843189,295,,,www.uniprot.org,22998
EGFR S464L lies within the extracellular domain of the Egfr protein (UniProt.org). S464L results in increased Egfr and Erk phosphorylation and confers resistance to Erbitux (cetuximab) and Vectibix (panitumumab) in cell culture (PMID: 26843189).,295,,,www.uniprot.org,5719,26843189,MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26843189,22999
"ETV6-INO80D results from the fusion of ETV6 and INO80D (PMID: 22237106). ETV6-INO80D has been identified in acute lymphoblastic leukemia (PMID: 22237106), but has not been biochemically characterized and therefore, its effect on fusion protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5796,22237106,The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.,http://www.ncbi.nlm.nih.gov/pubmed/22237106,23005
"ETV6-LYN results from the fusion of ETV6 and LYN, demonstrating constitutive Lyn kinase activity and the ability to phosphorylate Stat5, and is transforming in cell culture (PMID: 21492125).",5797,21492125,Direct activation of STAT5 by ETV6-LYN fusion protein promotes induction of myeloproliferative neoplasm with myelofibrosis.,http://www.ncbi.nlm.nih.gov/pubmed/21492125,23006
"ETV6-RNF217-AS1 (also referred to as ETV6-STL) results from the fusion of ETV6 and RNF217-AS1 (PMID: 25298122). ETV6-RNF217-AS1 has been identified in acute lymphoblastic lymphoma (PMID: 25298122), but has not been biochemically characterized and therefore, its effect on protein function is unknown (PubMed, Sep 2017).",5798,25298122,Identification and characterization of OSTL (RNF217) encoding a RING-IBR-RING protein adjacent to a translocation breakpoint involving ETV6 in childhood ALL.,http://www.ncbi.nlm.nih.gov/pubmed/25298122,285,,,http://www.ncbi.nlm.nih.gov/pubmed,23007
"FGFR3-ELAVL3 results from the fusion of FGFR3 and ELAVL3 (PMID: 25204415). FGFR3-ELAVL3 has been identified in glioma (PMID: 25204415, PMID: 26061751), but has not been biochemically characterized and therefore, its effect on protein function is unknown (PubMed, Mar 2017).",7591,26061751,"Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.",http://www.ncbi.nlm.nih.gov/pubmed/26061751,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5799,25204415,The landscape of kinase fusions in cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25204415,23008
"FGFR2-SHTN1(also referred to as FGFR2-KIAA1598) results from the fusion of FGFR2 and SHTN1(PMID: 25536104). FGFR2-SHTN1 has been identified in cholangiocarinoma (PMID: 25536104), but has not been biochemically characterized and therefore, its effect on protein function is unknown (PubMed, Jul 2017).",5800,25536104,Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.,http://www.ncbi.nlm.nih.gov/pubmed/25536104,285,,,http://www.ncbi.nlm.nih.gov/pubmed,23009
"KIT P577_D579del results in the deletion of two amino acids in the juxtamembrane domain of the Kit protein from amino acids 577 to 579 (UniProt.org). P577_D579del has not been characterized, however, similar Kit exon 11 deletions are activating, thus P577_D579del is predicted to lead to a gain of Kit protein function (PMID: 9438854, PMID: 15365079).",2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,295,,,www.uniprot.org,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,23010
"KIT K550_W557del results in the deletion of 8 amino acids in the juxtamembrane domain of the Kit protein from amino acids 550 to 557 (PMID: 16226710). K550_W557del has not been characterized, however similar Kit exon 11 deletions are activating, thus K550_W557del is predicted to lead to a gain of Kit protein function (PMID: 9438854, PMID: 15365079).",648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,23011
KIT K558delinsNP results in the deletion of one amino acid in the juxtamembrane domain of the Kit protein combined with the insertion of two new amino acids in the same location (UniProt.org). K558delinsNP confers a gain of function as demonstrated by constitutive phosphorylation of the Kit protein (PMID: 11526490). ,295,,,www.uniprot.org,5816,11526490,STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications.,http://www.ncbi.nlm.nih.gov/pubmed/11526490,23013
"KIT V560_Y578del results in the deletion of eighteen amino acids in the juxtamembrane domain of the Kit protein from amino acids 560 to 578 (PMID: 12879016). V560_Y578del has not been characterized, however, similar Kit exon 11 deletions are activating, thus V560_Y578del is predicted to lead to a gain of function (PMID: 9438854, PMID: 15365079).",2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,23014
KIT E490K lies within the 	Ig-like C2-type 5 domain of the Kit protein (UniProt.org). E490K is predicted to activate Kit as indicated by increased Kit expression in tumor tissues harboring KIT E490K (PMID: 22357254).,5818,22357254,Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/22357254,295,,,www.uniprot.org,23015
"KIT T417_D419delinsI results in the deletion of three amino acids in the Ig-like C2-type 5 domain of the Kit protein from amino acids 417 to 419, combined with the insertion of an Isoleucine (I) at the same site (UniProt.org). T417_D419delinsI results in constitutive ligand-independent phosphorylation of Kit in cell culture (PMID: 16015387).",295,,,www.uniprot.org,5820,16015387,Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/16015387,23016
KIT D419del results in the deletion of one amino acid in the Ig-like C2-type 5 domain of the Kit protein at amino acid 419 (UniProt.org). D419del confers a gain of function to the Kit protein as demonstrated by ligand independent tyrosine phosphorylation in cell culture (PMID: 16143141).,295,,,www.uniprot.org,5829,16143141,Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis.,http://www.ncbi.nlm.nih.gov/pubmed/16143141,23017
"KIT T417_Y418delinsH results in the deletion of two amino acids in the Ig-like C2-type 5 domain of the Kit protein from amino acids 417 to 418, combined with the insertion of an Histidine (H) at the same site (UniProt.org). T417_Y418delinsH is predicted to lead to a gain of Kit protein function because other KIT exon 8 deletion mutations are activating (PMID: 16015387).",5820,16015387,Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/16015387,295,,,www.uniprot.org,23018
"KIT T417_D419delinsY results in the deletion of three amino acids in the Ig-like C2-type 5 domain of the Kit protein from amino acids 417 to 419, combined with the insertion of a Tyrosine (Y) at the same site (UniProt.org). T417_D419delinsY is predicted to lead to a gain of Kit protein function because other AML-associated KIT exon 8 deletion mutations are activating (PMID: 16015387).",5820,16015387,Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/16015387,295,,,www.uniprot.org,23019
"KIT Y418_D419delinsS results in the deletion of two amino acids in the Ig-like C2-type 5 domain of the Kit protein from amino acids 418 to 419, combined with the insertion of a Serine (S) at the same site (UniProt.org).  Y418_D419delinsS is predicted to lead to a gain of Kit protein function because other AML-associated KIT exon 8 deletion mutations are activating (PMID: 16015387).",5820,16015387,Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/16015387,295,,,www.uniprot.org,23020
"KIT Y418_D419delinsG results in the deletion of two amino acids in the Ig-like C2-type 5 domain of the Kit protein from amino acids 418 to 419, combined with the insertion of a Glycine (G) at the same site (UniProt.org).  Y418_D419delinsG is predicted to lead to a gain of Kit protein function because other AML-associated KIT exon 8 deletion mutations are activating (PMID: 16015387).",5820,16015387,Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/16015387,295,,,www.uniprot.org,23021
"KIT T417_D419delinsRA results in the deletion of three amino acids in the extracellular domain of the Kit protein from amino acids 417 to 419, combined with the insertion of an Arginine (R) and an Alanine (A) at the same site (UniProt.org). T417_D419delinsRA is predicted to lead to a gain of Kit protein function because other KIT exon 8 deletion mutations are activating (PMID: 16015387).",5820,16015387,Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/16015387,295,,,www.uniprot.org,23022
"KIT W557C lies within the juxtamembrane domain of the Kit protein (PMID: 16226710). W557C has not been characterized, however, other W557 mutations are activating, thus W557C is predicted to confer a gain of Kit protein function (PMID: 23567324).",648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,647,23567324,Are two better than one? A novel double-mutant KIT in GIST that responds to Imatinib.,http://www.ncbi.nlm.nih.gov/pubmed/23567324,23024
"KIT P551_W557delinsL results in the deletion of seven amino acids in the juxtamembrane domain of the Kit protein combined with the insertion of one new amino acid in the same location (PMID: 12879016). P551_W557delinsL has not been characterized, however similar Kit exon 11 deletions are activating, thus P551_W557delinsL is predicted to lead to a gain of function (PMID: 9438854, PMID: 15365079).",2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,23026
"KIT M552_K558del results in the deletion of seven amino acids in the juxtamembrane domain of the Kit protein from amino acids 552 and 558 (PMID: 12879016) M552_K558del has not been characterized, however, similar Kit exon 11 deletions are activating, thus M552_K558del is predicted to lead to a gain of function (PMID: 9438854, PMID: 15365079).",2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,23027
AKT1 E40K lies within the PH domain of the Akt1 protein (UniProt.org). E40K results in increased Akt1 kinase activity and inhibition of apoptosis in cell culture (PMID: 9690513).,295,,,www.uniprot.org,5827,9690513,Akt activation by growth factors is a multiple-step process: the role of the PH domain.,http://www.ncbi.nlm.nih.gov/pubmed/9690513,23028
"KIT D60N lies within the first Ig-like domain of the Kit protein (PMID: 24211109). D60N, confers a gain of function to the Kit protein as demonstrated by increased proliferation, and activation of Jak-Stat signaling, while displaying reduced ligand binding, and a reduction in Akt and Erk signaling in mice (PMID: 24211109).",5828,24211109,Mutation in the first Ig-like domain of Kit leads to JAK2 activation and myeloproliferation in mice.,http://www.ncbi.nlm.nih.gov/pubmed/24211109,23029
"KIT V559C lies within the cytoplasmic domain of the Kit protein (UniProt.org). V559C has been identified in sequencing studies (PMID: 25695690), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Dec 2016).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3725,25695690,Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/25695690,23030
"KIT Y570H lies within the cytoplasmic domain of the Kit protein (UniProt.org). Y570H has not been characterized in the scientific literature and therefore, its effect on Kit protein function is unknown (PubMed, Dec 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23031
"AKT1 W80R lies within the PH domain of the Akt1 protein (UniProt.org). W80R has been identified in sequencing studies (PMID: 24211491), but has not been biochemically characterized and therefore, its effect on Akt1 protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7490,24211491,Colorectal carcinomas with CpG island methylator phenotype 1 frequently contain mutations in chromatin regulators.,http://www.ncbi.nlm.nih.gov/pubmed/24211491,23032
"ATRX A1690D lies within the helicase ATP-binding domain of the Atrx protein (UniProt.org). A1609D has been identified in sequencing studies (PMID: 22416102), but has not been biochemically characterized and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",9405,22416102,Association of age at diagnosis and genetic mutations in patients with neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22416102,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23033
"ATRX D774fs results in a change in the amino acid sequence of the Atrx protein beginning at aa 774 of 2492, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of most known functional domains (UniProt.org), D774fs is predicted to lead to a loss of Atrx protein function.",295,,,www.uniprot.org,23034
"ATRX E1010fs results in a change in the amino acid sequence of the Atrx protein beginning at aa 1010 of 2492, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of most known functional domains (UniProt.org), E1010fs is predicted to lead to a loss of Atrx protein function.",295,,,www.uniprot.org,23035
PTEN A121V lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). A121V demonstrated phosphatase activity similar to wild-type Pten in yeast (PMID: 21828076).,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,295,,,www.uniprot.org,23036
"ATRX E555* results in a premature truncation of the Atrx protein at amino acid 555 of 2492 (UniProt.org). Due to the loss of most known functional domains (UniProt.org), E555* is predicted to lead to a loss of Atrx protein function.",295,,,www.uniprot.org,23037
"ATRX E991fs results in a change in the amino acid sequence of the Atrx protein beginning at aa 991 of 2492, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of most known functional domains (UniProt.org), E991fs is predicted to lead to a loss of Atrx protein function.",295,,,www.uniprot.org,23038
"MAP2K1 R49L does not lie within any known functional domains of the Map2k1 protein (UniProt.org). R49L confers a gain of function to the Map2k1 protein as demonstrated by transforming ability in culture and in vivo, and phosphorylation of Erk1/2 (PMID: 22327936).",135,22327936,Oncogenic MAP2K1 mutations in human epithelial tumors.,http://www.ncbi.nlm.nih.gov/pubmed/22327936,295,,,www.uniprot.org,23039
"ATRX K1001fs results in a change in the amino acid sequence of the Atrx protein beginning at aa 1001 of 2492, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of most known functional domains (UniProt.org), K1001fs is predicted to lead to a loss of Atrx protein function.",295,,,www.uniprot.org,23040
"ATRX K425fs results in a change in the amino acid sequence of the Atrx protein beginning at aa 425 of 2492, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of most known functional domains (UniProt.org), K425fs is predicted to lead to a loss of Atrx protein function.",295,,,www.uniprot.org,23041
"PTEN A34D lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). A34D results in a loss of Pten phosphatase activity in yeast and loss of nuclear Pten localization in cell culture (PMID: 21828076, PMID: 25875300).",4506,25875300,A functional dissection of PTEN N-terminus: implications in PTEN subcellular targeting and tumor suppressor activity.,http://www.ncbi.nlm.nih.gov/pubmed/25875300,295,,,www.uniprot.org,23042
PTEN C124N lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). C124N results in a loss of Pten phosphatase activity in yeast (PMID: 21828076).,295,,,www.uniprot.org,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,23043
PTEN D326N lies within the C2 tensin-type domain of the Pten protein (UniProt.org). D326N results in moderately decreased phosphatase activity of Pten in yeast (PMID: 21828076).,295,,,www.uniprot.org,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,23044
"ATRX L407F does not lie within any known functional domains of the Atrx protein (UniProt.org). L407F has been identified in sequencing studies (PMID: 22416102), but has not been biochemically characterized and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9405,22416102,Association of age at diagnosis and genetic mutations in patients with neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22416102,23045
"ATRX L639fs results in a change in the amino acid sequence of the Atrx protein beginning at aa 639 of 2492, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of most known functional domains (UniProt.org), L639fs is predicted to lead to a loss of Atrx protein function.",295,,,www.uniprot.org,23046
"MAP2K1 F53S does not lie within any known functional domains of the Map2k1 protein (UniProt.org). F53S confers a gain of function to the Map2k1 protein as indicated by Erk phosphorylation greater than that induced by wild-type, but not as active as other constitutively active Map2k1 mutants in culture (PMID: 16439621, PMID: 12370306).",295,,,www.uniprot.org,5839,16439621,Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/16439621,5157,12370306,Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352.,http://www.ncbi.nlm.nih.gov/pubmed/12370306,23047
PTEN D92A lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). D92A results in a loss of Pten phosphatase activity in yeast (PMID: 21828076).,295,,,www.uniprot.org,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,23048
"ATRX R1302fs results in a change in the amino acid sequence of the Atrx protein beginning at aa 1302 of 2492, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of most known functional domains (UniProt.org), R1302fs is predicted to lead to a loss of Atrx protein function.",295,,,www.uniprot.org,23049
PTEN D92G lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). D92G results in a loss of Pten phosphatase activity in yeast (PMID: 21828076).,295,,,www.uniprot.org,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,23050
"MAP2K1 F53V does not lie within any know functional domains of the Map2k1 protein (UniProt.org). F53V has been identified in the scientific literature (PMID: 27511764), but has not been biochemically characterized and therefore, its effect on Map2k1 protein function is unknown (PubMed, Mar 2017). ",8378,27511764,Development of a robust DNA quality and quantity assessment qPCR assay for targeted next-generation sequencing library preparation.,http://www.ncbi.nlm.nih.gov/pubmed/27511764,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23051
PTEN D92H lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). D92H results in a loss of Pten phosphatase activity in yeast (PMID: 21828076).,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,295,,,www.uniprot.org,23052
PTEN D92N lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). D92N demonstrated phosphatase activity similar to wild-type Pten in yeast (PMID: 21828076).,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,295,,,www.uniprot.org,23053
PTEN D92V lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). D92V results in a loss of Pten phosphatase activity in yeast (PMID: 21828076).,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,295,,,www.uniprot.org,23054
PTEN E157G lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). E157G results in moderate decrease of Pten phosphatase activity in yeast (PMID: 21828076).,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,295,,,www.uniprot.org,23055
PTEN F241S lies within the C2 tensin-type domain of the Pten protein (UniProt.org). F241S results in a loss of Pten phosphatase activity in yeast (PMID: 21828076).,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,295,,,www.uniprot.org,23056
PTEN G127N lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). G127N results in a loss of Pten phosphatase activity in yeast (PMID: 21828076).,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,295,,,www.uniprot.org,23057
"ATRX R2164S lies within the helicase C-terminal domain of the Atrx protein (UniProt.org). R2164S has been identified in sequencing studies (PMID: 25743702), but has not been biochemically characterized and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",9412,25743702,Genomic landscape of paediatric adrenocortical tumours.,http://www.ncbi.nlm.nih.gov/pubmed/25743702,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23058
"MAP2K1 F53C does not lie within any known functional domains of the Map2k1 protein (UniProt.org). F53C has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Mar 2017). ",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,23059
PTEN G129A lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). G129A demonstrates phosphatase activity similar to wild-type Pten in yeast (PMID: 21828076).,295,,,www.uniprot.org,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,23060
PTEN G129D lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). G129D results in a loss of Pten phosphatase activity in yeast (PMID: 21828076).,295,,,www.uniprot.org,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,23061
PTEN G36R lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). G36R results in a loss of Pten phosphatase activity in yeast (PMID: 21828076).,295,,,www.uniprot.org,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,23062
PTEN G44D lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). G44D results in a loss of Pten phosphatase activity in yeast (PMID: 21828076).,295,,,www.uniprot.org,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,23063
"MAP2K1 V60E does not lie within any known functional domains of the Map2k1 protein (UniProt.org). V60E has not been biochemically characterized, however, has been described as a drug resistance mutation (PMID: 24265153).",5840,24265153,The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24265153,23064
PTEN H118P lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). H118P results in moderate decrease of Pten phosphatase activity in yeast (PMID: 21828076).,295,,,www.uniprot.org,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,23065
PTEN H123Q lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). H123Q results in a loss of Pten phosphatase activity in yeast (PMID: 21828076).,295,,,www.uniprot.org,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,23066
"CBL A848T lies within the CD2AP-interacting region of the Cbl protein (UniProt.org). A848T has been identified in sequencing studies (PMID: 20126411), but has not been biochemically characterized and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,1306,20126411,CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.,http://www.ncbi.nlm.nih.gov/pubmed/20126411,295,,,www.uniprot.org,23067
PTEN H61D lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). H61D results in a loss of Pten phosphatase activity in yeast (PMID: 21828076).,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,295,,,www.uniprot.org,23068
"PTEN H61K lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). H61K has not been characterized in the scientific literature and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23070
"CBL A848V lies within the CD2AP-interacting region of the Cbl protein (UniProt.org). A848V has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23071
"CBL A850V lies within the CD2AP-interacting region of the Cbl protein (UniProt.org). A850V has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23072
PTEN H93D lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). H93D results in a loss of Pten phosphatase activity in yeast (PMID: 21828076).,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,295,,,www.uniprot.org,23073
"CBL A877V lies within the UBA domain of the Cbl protein (UniProt.org). A877V has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23074
PTEN H93Q lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). H93Q results in a loss of Pten phosphatase activity in yeast (PMID: 21828076).,295,,,www.uniprot.org,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,23075
"CBL A881T lies within the UBA domain of the Cbl protein (UniProt.org). A881T has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,23076
PTEN H93R lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). H93R demonstrates phosphatase activity similar to wild-type Pten in yeast (PMID: 21828076).,295,,,www.uniprot.org,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,23077
PTEN I122L lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). I122L results in a moderate decrease of Pten phosphatase activity in yeast (PMID: 21828076).,295,,,www.uniprot.org,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,23078
PTEN I122S lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). I122S results in a loss of Pten phosphatase activity in yeast (PMID: 21828076).,295,,,www.uniprot.org,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,23079
PTEN I122V lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). I122V demonstrates phosphatase activity similar to wild-type Pten in yeast (PMID: 21828076).,295,,,www.uniprot.org,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,23080
"ALK D1091N does not lie within any known functional domains of the Alk protein (UniProt.org). D1091N was observed to increase ERK activation in the presence of agonist antibodies (PMID: 23104988) and has demonstrated sensitivity to ALK inhibitors (PMID: 26786851, PMID: 28455243), but is unable to transform cultured cells (PMID: 23104988).

",7594,26786851,Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.,http://www.ncbi.nlm.nih.gov/pubmed/26786851,295,,,www.uniprot.org,1899,23104988,Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/23104988,9400,28455243,The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.,http://www.ncbi.nlm.nih.gov/pubmed/28455243,23081
KIT R634W lies within the protein kinase domain of the Kit protein (UniProt.org). R634W confers a gain of function to the Kit protein as demonstrated by constitutive Kit phosphorylation and increased Stat3 and Stat5 phosphorylation in cell culture (PMID: 15790786).,425,15790786,Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.,http://www.ncbi.nlm.nih.gov/pubmed/15790786,295,,,www.uniprot.org,23082
"ALK F1245L lies within the protein kinase domain of the Alk protein (UniProt.org). F1245L has been identified in sequencing studies (PMID: 18923524), but has not been biochemically characterized and therefore, its effect on Alk protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7494,18923524,Oncogenic mutations of ALK kinase in neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/18923524,295,,,www.uniprot.org,23083
"ALK F1245Q lies within the protein kinase domain of the Alk protein (UniProt.org). F1245Q has not been characterized in the scientific literature and therefore, its effect on Alk protein function is unknown (PubMed, Jul 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23084
"KIT I653T lies within the protein kinase domain of the Kit protein (UniProt.org). I653T has not been been characterized and therefore, its effect on Kit protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23085
"KIT S709F lies within the protein kinase domain of the Kit protein (UniProt.org). S709F has been identified in sequencing studies (PMID: 16551858), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Sep 2017).",7416,16551858,Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.,http://www.ncbi.nlm.nih.gov/pubmed/16551858,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23086
"ALK G1269S lies within the protein kinase domain of the Alk protein (UniProt.org). G1269S has not been biochemically characterized, however, has been demonstrated to increase Alk phosphorylation and confer secondary drug resistance in the context of EML4-ALK (PMID: 21948233).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23088
"KIT C809G lies within the protein kinase domain of the Kit protein (UniProt.org). C809G has been identified in sequencing studies (PMID: 18452195), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Sep 2017).",7396,18452195,Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs).,http://www.ncbi.nlm.nih.gov/pubmed/18452195,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23091
"FBXW7 K11R does not lie within any known functional domains of the Fbxw7 protein (UniProt.org). K11R results in the disruption of the NSL1 function of Fbxw7 protein in cell culture (PMID: 20815813). 
",295,,,www.uniprot.org,5971,20815813,Regulation of the tumour suppressor Fbw7α by PKC-dependent phosphorylation and cancer-associated mutations.,http://www.ncbi.nlm.nih.gov/pubmed/20815813,23092
"FBXW7 R479S lies within the WD repeat 3 of the Fbxw7 protein (UniProt.org). R479S has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,23093
"KIT P838L lies within the protein kinase domain of the Kit protein (UniProt.org). P838L has not been characterized in the scientific literature and therefore, its effect on Kit protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23094
"KIT N463S lies within the Ig-like C2-type 5 domain of the Kit protein (UniProt.org). N463S has been identified in sequencing studies (PMID: 26424760), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7410,26424760,Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06).,http://www.ncbi.nlm.nih.gov/pubmed/26424760,23095
"KIT V852I lies within the protein kinase domain of the Kit protein (UniProt.org). V852I has been identified in sequencing studies (PMID: 24293293), but has not been biochemically characterized and therefore, its effect on Kit  protein function is unknown (PubMed, Dec 2016).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7257,24293293,Whole-exome sequencing of pancreatic neoplasms with acinar differentiation.,http://www.ncbi.nlm.nih.gov/pubmed/24293293,23096
"KIT V569_L576del results in the deletion of eight amino acids in the juxtamembrane domain of the Kit protein from amino acids 569 and 576 (PMID: 12879016) V569_L576del has not been characterized, however, similar Kit exon 11 deletions are activating, thus V569_L576del is predicted to lead to a gain of Kit protein function (PMID: 9438854, PMID: 15365079).",2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,23097
"MPL L31R lies within the extracellular domain of the Mpl protein (UniProt.org). L31R has not been characterized in the scientific literature and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23098
BRAF A728V (also referred to as A727V) does not lie within any known functional domains of the Braf protein (UniProt.org). A728V confers a gain of function to the Braf protein as demonstrated by increased Braf and Erk phosphorylation in cell culture (PMID: 15035987).,295,,,www.uniprot.org,146,15035987,Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.,http://www.ncbi.nlm.nih.gov/pubmed/15035987,23099
"MPL R321Q lies within the extracellular domain of the Mpl protein (UniProt.org). R321Q has been identified in sequencing studies (PMID: 23292937), but has not been biochemically characterized and therefore, its effect on Mpl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7259,23292937,Genetic heterogeneity of diffuse large B-cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/23292937,23100
"CBL M487V does not lie within any known functional domains of the Cbl protein (UniProt.org). M487V has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23101
"BRAF D594Y lies within the protein kinase domain of the Braf protein (UniProt.org). D594Y has not been characterized, however, other D594 mutations result in loss of Braf kinase activity and Ras-dependent paradoxical activation of Erk signaling through CRAF (PMID: 18794803, PMID: 20141835, PMID: 28783719), and thus, D594Y is predicted to lead to a loss of Braf protein function.",424,20141835,Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.,http://www.ncbi.nlm.nih.gov/pubmed/20141835,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,7,18794803,CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations.,http://www.ncbi.nlm.nih.gov/pubmed/18794803,295,,,www.uniprot.org,23103
"FLT3 D358V lies within the extracellular domain of the Flt3 protein (UniProt.org). D358V has been identified in sequencing studies (PMID: 21984973), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Apr 2017).",8612,21984973,Multiple gene dysfunctions lead to high cancer-susceptibility: evidences from a whole-exome sequencing study.,http://www.ncbi.nlm.nih.gov/pubmed/21984973,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23106
"BRCA2 E1511G does not lie within any known functional domains of the Brca2 protein (UniProt.org). E1511G has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23107
"BRCA1 E1114fs results in a change in the amino acid sequence of the Brca1 protein beginning at aa 1114 of 1863, likely resulting in premature truncation of the functional protein (UniProt.org). E1114fs has not been characterized, however, other BRCT domain deletion mutants downstream of E1114 are destabilizing (PMID: 14534301), thus E1114fs is predicted to lead to a loss of Brca1 protein function.",295,,,www.uniprot.org,2590,14534301,Detection of protein folding defects caused by BRCA1-BRCT truncation and missense mutations.,http://www.ncbi.nlm.nih.gov/pubmed/14534301,23109
"ASXL1 G643fs results in a change in the amino acid sequence of the Asxl1 protein beginning at aa 643 of 1541, likely resulting in premature truncation of the functional protein (UniProt.org). G643fs has not been characterized, however, due to the effects of other ASXL1 truncation mutations, G643fs is predicted to result in a loss of Asxl1 function (PMID: 24216483, PMID: 22897849).",3732,22897849,ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.,http://www.ncbi.nlm.nih.gov/pubmed/22897849,295,,,www.uniprot.org,3733,24216483,Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24216483,23110
"TP53 C238Y lies within the DNA binding domain of the Tp53 protein (PMID: 22713868). C238Y results in binding to MDM2, phosphorylation, and transactivation of Tp53 target genes similar to wild-type Tp53 in cell culture, and does not significantly alter Tp53 structure in molecular models (PMID: 16818505).",2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,5842,16818505,Functional analysis and molecular modeling show a preserved wild-type activity of p53(C238Y).,http://www.ncbi.nlm.nih.gov/pubmed/16818505,23111
"BRAF E501G lies within the protein kinase domain of the Braf protein (UniProt.org). E501G confers a loss of function to the Braf protein as demonstrated by inability to activate downstream reporter assays, impaired kinase activity and presence in genetic diseases associated with Ras/Raf/Mek dysfunction (PMID: 26065894, PMID: 16474404, PMID: 16439621).",5844,16474404,Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/16474404,295,,,www.uniprot.org,5843,26065894,Mitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant Transformation.,http://www.ncbi.nlm.nih.gov/pubmed/26065894,5839,16439621,Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/16439621,23112
"BRCA2 R2845fs results in a change in the amino acid sequence of the Brca2 protein beginning at aa 2845 of 3418, likely resulting in premature truncation of the functional protein (UniProt.org). R2845fs has not been characterized, however, due to the effects of other truncations downstream of R2845 (PMID: 12619154), R2845fs is predicted to lead to a loss of Brca2 protein function.",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23113
"ROS1 Y382H lies within the extracellular domain of the Ros1 protein (UniProt.org). Y382H has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23117
PTEN I168F lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). I168F demonstrates phosphatase activity similar to wild-type Pten in yeast (PMID: 21828076).,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,295,,,www.uniprot.org,23118
"BRAF E501K lies within the protein kinase domain of the Braf protein (UniProt.org). E501K results in activation of a downstream Elk transcription factor with comparable levels to wild-type Braf and results in a loss of Braf kinase activity in the background of a second BRAF mutation (PMID: 16474404, PMID: 17603482).",5844,16474404,Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/16474404,295,,,www.uniprot.org,494,17603482,Germline gain-of-function mutations in RAF1 cause Noonan syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/17603482,23119
"BRAF F468C (also referred to as F467C using alternate amino acid numbering) lies within the protein kinase domain of the Braf protein (UniProt.org). F468C confers a gain of function to the Braf protein as demonstrated by increased kinase activity, increased downstream Mek/Erk phosphorylation and growth in soft agar (PMID: 15150094).",147,15150094,Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation.,http://www.ncbi.nlm.nih.gov/pubmed/15150094,295,,,www.uniprot.org,23120
"BRAF G596C lies within the protein kinase domain of the Braf protein (UniProt.org). G596C results in decreased Braf kinase activity, however, leads to activation of downstream MEK and ERK in combination with CRAF in cell culture (PMID: 27577079).",7322,27577079,Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.,http://www.ncbi.nlm.nih.gov/pubmed/27577079,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23121
BRAF G469del results in the deletion of an amino acid in the protein kinase domain of the Braf protein at amino acid 469 (UniProt.org). G469del confers a loss of function to the Braf protein as demonstrated by lack of kinase activity in vitro (PMID: 23833300).,5855,23833300,"Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/23833300,295,,,www.uniprot.org,23122
"BRAF G596V lies within the protein kinase domain of the Braf protein (UniProt.org). G596V results in impaired Braf kinase activity, but leads to activation of ERK in zebrafish models (PMID: 19376813).",5856,19376813,Kinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/19376813,295,,,www.uniprot.org,23123
"BRAF K483M (also reported as K482M) lies within an ATP binding site in the protein kinase domain of the Braf protein (UniProt.org). K483M results in a loss of Braf kinase activity, however, has been demonstrated to both activate MEK through CRAF (PMID: 16508002, PMID: 23533272), and lack ability to activate ERK and CRAF in cell culture and in Xenopus (PMID: 15035987).",295,,,www.uniprot.org,2256,23533272,Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas.,http://www.ncbi.nlm.nih.gov/pubmed/23533272,9727,16508002,Regulation and role of Raf-1/B-Raf heterodimerization.,http://www.ncbi.nlm.nih.gov/pubmed/16508002,23124
BRAF K499E lies within the protein kinase domain of the Braf protein (UniProt.org). K499E confers a gain of function to the Braf protein as demonstrated by activation of downstream Elk reporter assays (PMID: 16474404).,295,,,www.uniprot.org,5844,16474404,Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/16474404,23125
BRAF N581D lies within the protein kinase domain of the Braf protein (UniProt.org). N581D results in activation of a downstream Elk transcription factor with comparable levels to wild-type Braf (PMID: 16474404).,295,,,www.uniprot.org,5844,16474404,Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/16474404,23126
"BRAF N581Y lies within the protein kinase domain of the Braf protein (UniProt.org). N581Y has been identified in sequencing studies (PMID: 19474002), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7500,19474002,Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19474002,23128
"APC R640G lies within the ARM 5 repeat region of the Apc protein (UniProt.org). R640G has not been biochemically characterized, however the nucleotide change results in exon 14 skipping and the production of a truncated Apc protein (PMID: 19111562).",5857,19111562,A missense mutation in the APC tumor suppressor gene disrupts an ASF/SF2 splicing enhancer motif and causes pathogenic skipping of exon 14.,http://www.ncbi.nlm.nih.gov/pubmed/19111562,295,,,www.uniprot.org,23129
"BRAF L485_Q494del results in the deletion of ten amino acids in the beta-3/alpha-C helix loop in the protein kinase domain of the Braf protein (PMID: 26732095, UniProt.org). L485_Q494del has not been characterized, however, is predicted to result in a gain of function due to other characterized BRAF deletions in the same region (PMID: 26732095).",4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,23130
"BRAF L485_P490del results in the deletion of six amino acids in the beta-3/alpha-C helix loop in the protein kinase domain of the Braf protein (PMID: 26732095, UniProt.org). L485_P490del confers a gain of function to the Braf protein as demonstrated by its ability to activate downstream Mek to Erk signaling and transform cells in culture (PMID: 26732095).",295,,,www.uniprot.org,4801,26732095,Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.,http://www.ncbi.nlm.nih.gov/pubmed/26732095,23131
"BRAF Q257R lies within the phorbol-ester/DAG-type zinc finger region of the BRAF protein (UniProt.org). Q257R confers a gain of function to the Braf protein as demonstrated by increased kinase activity and activation of downstream Mek signaling in cell cuture, and activation of ELK in reporter assays (PMID: 16474404, PMID: 16439621).",5839,16439621,Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/16439621,295,,,www.uniprot.org,5844,16474404,Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/16474404,23132
"BRAF S467A lies within the protein kinase domain of the Braf protein (UniProt.org). S467A confers a gain of function to the Braf protein as demonstrated by increased kinase activity and activation of downstream Mek signaling (PMID: 23680146, PMID: 16439621).",5858,23680146,RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation.,http://www.ncbi.nlm.nih.gov/pubmed/23680146,5839,16439621,Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/16439621,295,,,www.uniprot.org,23134
"BRAF T529I is a gatekeeper mutation that lies within the protein kinase domain of the Braf protein (PMID: 20538618). T529I has not been characterized, however, has been demonstrated to result in resistance to Raf inhibitors in the context of BRAF V600E (PMID: 20538618).",5859,20538618,Gatekeeper mutations mediate resistance to BRAF-targeted therapies.,http://www.ncbi.nlm.nih.gov/pubmed/20538618,23135
"BRAF T529M is a gatekeeper mutation that lies within the protein kinase domain of the Braf protein (PMID: 20538618). T529M has not been characterized, however, has been demonstrated to result in resistance to Raf inhibitors in the context of BRAF V600E (PMID: 20538618).",5859,20538618,Gatekeeper mutations mediate resistance to BRAF-targeted therapies.,http://www.ncbi.nlm.nih.gov/pubmed/20538618,23136
"BRAF T529N is a gatekeeper mutation that lies within the protein kinase domain of the Braf protein (PMID: 20538618). T529N has not been characterized, however, has been demonstrated to result in resistance to Raf inhibitors in the context of BRAF V600E (PMID: 20538618).",5859,20538618,Gatekeeper mutations mediate resistance to BRAF-targeted therapies.,http://www.ncbi.nlm.nih.gov/pubmed/20538618,23137
"BRAF T599dup indicates the insertion of the duplicate amino acid, tyrosine (T)-600, in the protein kinase domain of the Braf protein (UniProt.org). T599dup confers a gain of function to the Braf protein as demonstrated by increased kinase activity and phosphorylation of downstream Mek and Erk signaling (PMID: 21190184).",1910,21190184,Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma.,http://www.ncbi.nlm.nih.gov/pubmed/21190184,295,,,www.uniprot.org,23138
"FGFR2 K659N (also referred to as K660N from the FGFR2IIIb isoform) lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). K659N confers a gain of function to the Fgfr2 protein as demonstrated by increased autophosphorylation and phosphorylation of downstream targets, Mek and Stat3 (PMID: 23527311). ",295,,,www.uniprot.org,2160,23527311,Activating somatic FGFR2 mutations in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23527311,23140
"FGFR2 E731K lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). E731K confers a gain of function to the Fgfr2 protein as demonstrated by increased phosphorylation of Fgfr2, Erk signaling, and transcriptional activation of Runx2 in culture (PMID: 21928350).",295,,,www.uniprot.org,5867,21928350,"Functional characterization of a novel FGFR2 mutation, E731K, in craniosynostosis.",http://www.ncbi.nlm.nih.gov/pubmed/21928350,23141
JAK2 C618R lies within the first protein kinase domain of the Jak2 potein (UniProt.org). C618R confers a gain of function to the Jak2 protein as demonstrated by increased Jak2 kinase activity in vitro (PMID: 22960131).,295,,,www.uniprot.org,5868,22960131,Amino acid residue E543 in JAK2 C618R is a potential therapeutic target for myeloproliferative disorders caused by JAK2 C618R mutation.,http://www.ncbi.nlm.nih.gov/pubmed/22960131,23142
"JAK2 N542_E543del is an exon 12 deletion that results in the deletion of two amino acids in the kinase domain of the Jak2 protein from amino acids 542 to 543 (PMID: 17267906). N542_E543del confers a gain of function to the Jak2 protein as demonstrated by increased proliferation, Jak2 phosphorylation, and downstream Stat5 phosphorylation (PMID: 17267906).",5869,17267906,JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.,http://www.ncbi.nlm.nih.gov/pubmed/17267906,23143
"JAK2 H538Q lies within the first protein kinase domain of the Jak2 protein (UniProt.org). H538Q has not been individually characterized but leads to increased proliferation, Jak2 phosphorylation, and downstream Stat5 phosphorylation when co-mutated with K539L (PMID: 17267906).",5869,17267906,JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.,http://www.ncbi.nlm.nih.gov/pubmed/17267906,295,,,www.uniprot.org,23144
"JAK2 K539L lies within the first protein kinase domain of the Jak2 protien (UniProt.org). K539L confers a gain of function to the Jak2 protein as demonstrated by increased proliferation, Jak2 phosphoyrlation, and downstream Stat5 phosphorylation (PMID: 17267906).",5869,17267906,JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.,http://www.ncbi.nlm.nih.gov/pubmed/17267906,295,,,www.uniprot.org,23145
"JAK2 F537_K539delinsL results in a deletion of three amino acids from 537 to 539 within the protein kinase domain of the Jak2 protein, combined with the insertion of a leucine (L) (UniProt.org, PMID: 17267906). JAK2 F537_K539delinsL confers a gain of function to the Jak2 protein as demonstrated by increased proliferation, Jak2 phosphorylation, and downstream Stat5 phosphorylation (PMID: 17267906).",5869,17267906,JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.,http://www.ncbi.nlm.nih.gov/pubmed/17267906,295,,,www.uniprot.org,23146
"JAK2 L611V lies within the first protein kinase domain of the Jak2 protein (UniProt.org). L611V results in Jak2, Stat5, and Akt phosphorylation levels comparable to wild-type Jak2, however, the mutation results in constitutive activation of Jak2 when co-mutated with V617F (PMID: 20182460).",5870,20182460,JAK2 mutation and disease phenotype: a double L611V/V617F in cis mutation of JAK2 is associated with isolated erythrocytosis and increased activation of AKT and ERK1/2 rather than STAT5.,http://www.ncbi.nlm.nih.gov/pubmed/20182460,295,,,www.uniprot.org,23147
JAK2 R683K lies within the first protein kinase domain of the Jak2 protein (UniProt.org). R683K confers a gain of function to the Jak2 protein as demonstrated by constitutive Jak2 phosphorylation and cytokine-independent growth (PMID: 18805579).,5871,18805579,Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/18805579,295,,,www.uniprot.org,23148
JAK2 R683S lies within the first protein kinase domain of the Jak2 protein (UniProt.org). R683S confers a gain of function to the Jak2 protein as demonstrated by constitutive Jak2 phosphorylation and increased growth cytokine-independent growth and proliferation (PMID: 18805579).,5871,18805579,Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/18805579,295,,,www.uniprot.org,23149
"JAK2 T875N lies within the second protein kinase domain of the Jak2 protein (UniProt.org). T875N confers a gain of function to the Jak2 protein as demonstrated by increased Jak2 and Stat1, Stat3, and Stat5 phosphorylation (PMID: 19543316).",295,,,www.uniprot.org,5872,19543316,"SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling.",http://www.ncbi.nlm.nih.gov/pubmed/19543316,23150
PTEN K125L lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). K125L results in decreased Pten phosphatase activity in yeast (PMID: 21828076).,295,,,www.uniprot.org,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,23154
PTEN K125M lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). K125M results in decreased Pten phosphatase activity in yeast (PMID: 21828076).,295,,,www.uniprot.org,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,23155
PTEN K128Q lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). K128Q results in a loss of Pten phosphatase activity as indicated by increased Akt phosphorylation in cell culture (PMID: 16829519).,295,,,www.uniprot.org,5883,16829519,PCAF modulates PTEN activity.,http://www.ncbi.nlm.nih.gov/pubmed/16829519,23156
PTEN L181P lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). L181P results in a loss of Pten phosphatase activity in yeast (PMID: 21828076).,295,,,www.uniprot.org,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,23157
PTEN M35R lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). M35R results in a loss of Pten phosphatase activity in yeast (PMID: 21828076).,295,,,www.uniprot.org,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,23158
PTEN N48K lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). N48K results in a loss of Pten phosphatase activity as indicated by increased Akt phosphorylation in cell culture (PMID: 14675182).,295,,,www.uniprot.org,5887,14675182,A novel loss-of-function mutation (N48K) in the PTEN gene in a Spanish patient with Cowden disease.,http://www.ncbi.nlm.nih.gov/pubmed/14675182,23159
PTEN N94I lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). N94I results in decreased Pten phosphatase activity in yeast (PMID: 21828076).,295,,,www.uniprot.org,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,23160
PTEN P169H lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). P169H demonstrates phosphatase activity similar to wild-type Pten in yeast (PMID: 21828076).,295,,,www.uniprot.org,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,23161
PTEN P95L lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). P95L results in a loss of Pten phosphatase activity in yeast (PMID: 21828076).,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,295,,,www.uniprot.org,23162
PTEN P95S lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). P95S results in a loss of Pten phosphatase activity as indicated by increased Akt phosphorylation in cell culture (PMID: 19329485).,5888,19329485,Evidence of ultraviolet type mutations in xeroderma pigmentosum melanomas.,http://www.ncbi.nlm.nih.gov/pubmed/19329485,295,,,www.uniprot.org,23163
PTEN P96Q lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). P96Q results in a loss of Pten phosphatase activity in yeast (PMID: 21828076).,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,295,,,www.uniprot.org,23164
PTEN Q110R lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). Q110R demonstrates inhibition of Akt phosphorylation to similar level of wild-type Pten (PMID: 19329485).,295,,,www.uniprot.org,5888,19329485,Evidence of ultraviolet type mutations in xeroderma pigmentosum melanomas.,http://www.ncbi.nlm.nih.gov/pubmed/19329485,23165
PTEN R130A lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). R130A results in a loss of Pten phosphatase activity in yeast (PMID: 21828076).,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,295,,,www.uniprot.org,23166
PTEN R130K lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). R130K results in a loss of Pten phosphatase activity in yeast (PMID: 21828076).,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,295,,,www.uniprot.org,23167
"MAP2K1 K97M lies within the protein kinase domain of the Map2k1 protein (UniProt.org). K97M is referred to as a kinase dead variant and does not result in phosphorylation of Erk1/2 and therefore, confers a loss of function to the Map2k1 protein (PMID: 15342384).",5889,15342384,Mek1 alters epidermal growth and differentiation.,http://www.ncbi.nlm.nih.gov/pubmed/15342384,295,,,www.uniprot.org,23168
PTEN R161G lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). R161G results in decreased Pten phosphatase activity in yeast (PMID: 21828076).,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,295,,,www.uniprot.org,23169
PTEN R335L lies within the C2 tensin-type domain of the Pten protein (UniProt.org). R335L results in decreased Pten phosphatase activity in yeast (PMID: 21828076).,295,,,www.uniprot.org,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,23170
PTEN T131I lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). T131I results in a loss of Pten phosphatase activity in yeast (PMID: 21828076).,295,,,www.uniprot.org,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,23171
PTEN T131L lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). T131L results in a loss of Pten phosphatase activity in yeast (PMID: 21828076).,295,,,www.uniprot.org,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,23172
PTEN T131S lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). T131S demonstrates phosphatase activity similar to wild-type Pten in yeast (PMID: 21828076).,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23173
PTEN T160I lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). T160I results in a loss of Pten phosphatase activity in yeast (PMID: 21828076).,295,,,www.uniprot.org,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,23174
PTEN V217D lies within the C2 tensin-type domain of the Pten protein (UniProt.org). V217D results in decreased Pten phosphatase activity in yeast (PMID: 21828076).,295,,,www.uniprot.org,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,23175
PTEN V343L lies within the C2 tensin-type domain of the Pten protein (UniProt.org). V343L results in a loss of Pten phosphatase activity in yeast (PMID: 21828076).,295,,,www.uniprot.org,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,23176
PTEN Y68D lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). Y68D results in a loss of Pten phosphatase activity in yeast (PMID: 21828076).,295,,,www.uniprot.org,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,23177
"MAP2K1 L115R lies within the protein kinase domain of the Map2k1 protein (UniProt.org). L115R has not been biochemically characterized, however, has been described as a drug resistance mutation and therefore, is predicted to confer a loss of function to the Map2k1 protein (PMID: 19915144).",134,19915144,MEK1 mutations confer resistance to MEK and B-RAF inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/19915144,295,,,www.uniprot.org,23178
PTEN A39P lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). A39P results in a loss of Pten phosphatase activity as demonstrated by failure to inhibit Akt phosphorylation in cell culture (PMID: 25527629).,2323,25527629,Functionally distinct groups of inherited PTEN mutations in autism and tumour syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25527629,295,,,www.uniprot.org,23179
PTEN D162G lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). D162G demonstrates phosphatase activity similar to wild type Pten in yeast (PMID: 21828076).,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,295,,,www.uniprot.org,23180
PTEN D162H lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). D162H demonstrates protein stability and inhibition of Akt signaling to similar level of wild-type Pten protein in cell culture (PMID: 23840064).,5890,23840064,PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/23840064,295,,,www.uniprot.org,23181
"PTEN D24N lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). D24N results in a loss of Pten phosphatase activity as demonstrated by failure to inhibit Akt phosphorylation, cell proliferation and transformation in cell culture (PMID: 17213812).",2360,17213812,A short N-terminal sequence of PTEN controls cytoplasmic localization and is required for suppression of cell growth.,http://www.ncbi.nlm.nih.gov/pubmed/17213812,295,,,www.uniprot.org,23182
PTEN D24Y lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). D24Y results in a loss of Pten phosphatase activity in yeast and reduced nuclear localization in cell culture (PMID: 25875300).,295,,,www.uniprot.org,4506,25875300,A functional dissection of PTEN N-terminus: implications in PTEN subcellular targeting and tumor suppressor activity.,http://www.ncbi.nlm.nih.gov/pubmed/25875300,23183
PTEN D301N lies within the C2 tensin-type domain of the Pten protein (UniProt.org). D301N demonstrates inhibition of Akt phosphorylation similar to wild-type Pten in cell culture (PMID:19329485).,295,,,www.uniprot.org,5888,19329485,Evidence of ultraviolet type mutations in xeroderma pigmentosum melanomas.,http://www.ncbi.nlm.nih.gov/pubmed/19329485,23184
"KRAS F28L lies within the switch II region of the Kras protein (PMID: 20949621). F28L confers a loss of function to the Kras protein as demonstrated by increased bound GTP due to increased nucleotide exchange and not loss of intrinsic GTPase activity, leading to cellular transformation (PMID: 20949621, PMID: 1894650).",800,20949621,Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders.,http://www.ncbi.nlm.nih.gov/pubmed/20949621,5900,1894650,p21 with a phenylalanine 28----leucine mutation reacts normally with the GTPase activating protein GAP but nevertheless has transforming properties.,http://www.ncbi.nlm.nih.gov/pubmed/1894650,23188
PTEN F154L lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). F154L results in a loss of Pten phosphatase activity as demonstrated by failure to inhibit Akt phosphorylation in cell culture (PMID: 19329485).,295,,,www.uniprot.org,5888,19329485,Evidence of ultraviolet type mutations in xeroderma pigmentosum melanomas.,http://www.ncbi.nlm.nih.gov/pubmed/19329485,23189
PTEN F21A lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). F21A retains Pten phosphatase activity but localizes to the nucleus and fails to inhibit Akt phosphorylation and cell proliferation in culture (PMID: 17213812).,295,,,www.uniprot.org,2360,17213812,A short N-terminal sequence of PTEN controls cytoplasmic localization and is required for suppression of cell growth.,http://www.ncbi.nlm.nih.gov/pubmed/17213812,23190
"PTEN I32del results in the deletion of one amino acid in the phosphatase tensin-type domain of the Pten protein at amino acid 32 (UniProt.org). I32del has been identified in sequencing studies (PMID: 26437033, PMID: 28027320), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",7745,26437033,Genomic landscapes of breast fibroepithelial tumors.,http://www.ncbi.nlm.nih.gov/pubmed/26437033,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8044,28027320,Genomic Analysis of Uterine Lavage Fluid Detects Early Endometrial Cancers and Reveals a Prevalent Landscape of Driver Mutations in Women without Histopathologic Evidence of Cancer: A Prospective Cross-Sectional Study.,http://www.ncbi.nlm.nih.gov/pubmed/28027320,23191
PTEN K128R lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). K128R demonstrates inhibition of Akt phosphorylation to similar level of wild-type Pten in cell culture (PMID: 16829519).,295,,,www.uniprot.org,5883,16829519,PCAF modulates PTEN activity.,http://www.ncbi.nlm.nih.gov/pubmed/16829519,23192
PTEN K128T lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). K128T results in a loss of Pten phosphatase activity in yeast (PMID: 21828076).,295,,,www.uniprot.org,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,23193
PTEN K289E lies within the C2 tensin-type domain of the Pten protein (UniProt.org). K289E results in impaired nuclear import of Pten in cell culture (PMID: 17218261).,295,,,www.uniprot.org,5902,17218261,Ubiquitination regulates PTEN nuclear import and tumor suppression.,http://www.ncbi.nlm.nih.gov/pubmed/17218261,23194
PTEN K342N lies within the C2 tensin-type domain of the Pten protein (UniProt.org). K342N demonstrates phosphatase activity similar to wild-type Pten in an in vitro assay (PMID: 10866302).,2304,10866302,Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.,http://www.ncbi.nlm.nih.gov/pubmed/10866302,295,,,www.uniprot.org,23195
"PTEN K62R lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). K62R results in reduced ATP-binding to Pten, increased cell proliferation and is transforming in culture (PMID: 19457929).",2357,19457929,Germline and somatic cancer-associated mutations in the ATP-binding motifs of PTEN influence its subcellular localization and tumor suppressive function.,http://www.ncbi.nlm.nih.gov/pubmed/19457929,295,,,www.uniprot.org,23196
PTEN L23F lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). L23F results in nuclear accumulation of Pten and failure to inhibit Akt phosphorylation and cell proliferation in culture (PMID: 17213812).,2360,17213812,A short N-terminal sequence of PTEN controls cytoplasmic localization and is required for suppression of cell growth.,http://www.ncbi.nlm.nih.gov/pubmed/17213812,295,,,www.uniprot.org,23197
PTEN L325F lies within the C2 tensin-type domain of the Pten protein (UniProt.org). L325F results in a loss of Pten phosphatase activity as demonstrated by failure to inhibit Akt phosphorylation in cell culture (PMID: 19329485).,295,,,www.uniprot.org,5888,19329485,Evidence of ultraviolet type mutations in xeroderma pigmentosum melanomas.,http://www.ncbi.nlm.nih.gov/pubmed/19329485,23198
PTEN L42R lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). L42R retains Pten phosphatase activity but inhibits its membrane localization and fails to inhibit Akt phosphorylation and cell proliferation in culture (PMID: 25263454).,5905,25263454,A new class of cancer-associated PTEN mutations defined by membrane translocation defects.,http://www.ncbi.nlm.nih.gov/pubmed/25263454,295,,,www.uniprot.org,23199
PTEN M199del results in the deletion of one amino acid in the phosphatase tensin-type domain of the Pten protein at amino acid 199 (UniProt.org). M199del results in a loss of Pten phosphatase activity in an in vitro assay (PMID: 11051241).,2322,11051241,Functional evaluation of p53 and PTEN gene mutations in gliomas.,http://www.ncbi.nlm.nih.gov/pubmed/11051241,295,,,www.uniprot.org,23200
PTEN N276S lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). N276S demonstrates phosphatase activity similar to wild type Pten in yeast (PMID: 21828076).,2303,21828076,A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/21828076,295,,,www.uniprot.org,23201
PTEN S362L lies within the C2 tensin-type domain of the Pten protein (UniProt.org). S362L demonstrates inhibition of Akt phosphorylation similar to wild-type Pten (PMID: 19329485).,295,,,www.uniprot.org,5888,19329485,Evidence of ultraviolet type mutations in xeroderma pigmentosum melanomas.,http://www.ncbi.nlm.nih.gov/pubmed/19329485,23202
PTEN T401I does not lie within any known functional domains of the Pten protein (UniProt.org). T401I demonstrates phosphatase activity similar to wild type Pten in an in vitro assay (PMID: 10866302).,295,,,www.uniprot.org,2304,10866302,Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.,http://www.ncbi.nlm.nih.gov/pubmed/10866302,23203
PTEN V369G does not lie within any known functional domains of the Pten protein (UniProt.org). V369G demonstrates phosphatase activity similar to wild type Pten in an in vitro assay (PMID: 10866302).,295,,,www.uniprot.org,2304,10866302,Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay.,http://www.ncbi.nlm.nih.gov/pubmed/10866302,23204
"PTEN Y65C lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). Y65C results in reduced ATP-binding to Pten, increased cell proliferation and is transforming in culture (PMID: 19457929).",295,,,www.uniprot.org,2357,19457929,Germline and somatic cancer-associated mutations in the ATP-binding motifs of PTEN influence its subcellular localization and tumor suppressive function.,http://www.ncbi.nlm.nih.gov/pubmed/19457929,23205
"PIK3CA C420G lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). C420G results in increased Akt phosphorylation and cell proliferation, and is transforming in cell culture (PMID: 18074223). ",295,,,www.uniprot.org,2321,18074223,Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells.,http://www.ncbi.nlm.nih.gov/pubmed/18074223,23206
PIK3CA E116K does not lie within any known functional domains of the Pik3ca protein (UniProt.org). E116K phosphorylates Akt to similar level of wild-type Pik3ca and is not transforming in culture (PMID: 17376864).,295,,,www.uniprot.org,101,17376864,Rare cancer-specific mutations in PIK3CA show gain of function.,http://www.ncbi.nlm.nih.gov/pubmed/17376864,23207
"PIK3CA E726K does not lie within any known functional domains of the Pik3ca protein (UniProt.org). E726K has been identified in the scientific literature (PMID: 24497998), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8373,24497998,Megalencephaly syndromes: exome pipeline strategies for detecting low-level mosaic mutations.,http://www.ncbi.nlm.nih.gov/pubmed/24497998,23208
PIK3CA G106R does not lie within any known functional domains of the Pik3ca proten (UniProt.org). G106R results in activation of Pik3ca as indicated by increased Akt phosphorylation in cell culture (PMID: 21266528).,2211,21266528,A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/21266528,295,,,www.uniprot.org,23209
PIK3CA G106V does not lie within any known functional domains of the Pik3ca proten (UniProt.org). G106V results in activation of Pik3ca as indicated by increased Akt phosphorylation in cell culture (PMID: 21266528).,2211,21266528,A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/21266528,295,,,www.uniprot.org,23210
"PIK3CA M1043L lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). M1043L has been identified in the scientific literature (PMID: 24533074), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8884,24533074,PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.,http://www.ncbi.nlm.nih.gov/pubmed/24533074,23211
"PIK3CA N345D lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). N345D has not been characterized and therefore its effect on Pik3ca protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23212
"PIK3CA N345H lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). N345H has been identified in the scientific literature (PMID: 25846456), but has not been biochemically characterized and therefore its effect on Pik3ca protein function is unknown (PubMed, May 2017).",7878,25846456,Profiling of actionable gene alterations in ovarian cancer by targeted deep sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/25846456,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23213
"PIK3CA N345S lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). N345S has not been characterized and therefore its effect on Pik3ca protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23214
"PIK3CA N345T lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). N345T has not been characterized and therefore its effect on Pik3ca protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23215
"PIK3CA N345Y lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). N345Y has not been characterized in the scientific literature and therefore its effect on Pik3ca protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23216
PIK3CA P449_L455del results in the deletion of seven amino acids in the C2 PI3K-type domain of the Pik3ca protein from amino acids 449 to 455 (UniProt.org). P449_L455del results in increased Akt phosphorylation in cell culture relative to wild-type Pik3ca in culture (PMID: 21266528).,2211,21266528,A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/21266528,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23217
"PIK3CA R38G lies within the PI3K-ABD domain of the Pik3ca protein (UniProt.org). R38G has been identified in the scientific literature (PMID: 27425854), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7561,27425854,Genomic characterization of recurrent high-grade astroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/27425854,23218
"PIK3CA R38H lies within the PI3K-ABD domain of the Pik3ca protein (UniProt.org). R38H results in moderate increase of Pik3ca kinase activity and Akt phosphorylation, but is not transforming in cell culture (PMID: 15930273).",295,,,www.uniprot.org,2212,15930273,Functional analysis of PIK3CA gene mutations in human colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/15930273,23219
"PIK3CA R93L lies within the PI3K-ABD domain of the Pik3ca protein (UniProt.org). R93L has not been characterized in the scientific literature and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23220
PIK3CA R93Q lies within the PI3K-ABD domain of the Pik3ca protein (UniProt.org). R93Q results in Akt phosphorylation to levels similar to wild-type Pik3ca in cell culture (PMID: 21266528).,295,,,www.uniprot.org,2211,21266528,A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/21266528,23221
"KRAS G60D lies within the switch II region of the Kras protein (PMID: 20617134). G60D has been identified in the scientific literature (PMID: 25303977, PMID: 21632860), but has not been biochemically characterized and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).",1805,20617134,Clinical relevance of KRAS in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/20617134,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7006,25303977,Mutational landscape of aggressive cutaneous squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25303977,10056,21632860,Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21632860,23223
"KRAS K147E does not lie within any known functional domains of the Kras protein (UniProt.org). K147E confers a loss of function to the Kras protein as demonstrated by increased bound GTP due to increased nucleotide exchange and not loss of intrinsic activity, and activation of downstream Erk and Mek signaling (PMID: 23059812).",295,,,www.uniprot.org,5915,23059812,Diverging gain-of-function mechanisms of two novel KRAS mutations associated with Noonan and cardio-facio-cutaneous syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/23059812,23224
"KRAS N116H does not lie within any known functional domains of the Kras protein (UniProt.org). N116H results in increased nucleotide exchange and interferes with drug inhibition of KRAS G12C, and therefore, is predicted to result in a loss of Kras protein function (PMID: 26841430).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23225
"KRAS Q25H does not lie within any known functional domains of the Kras protein (UniProt.org). Q25H has been identified in the scientific literature (PMID: 21375404), but has not been biochemically characterized and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).",5916,21375404,A novel polymorphism in codon 25 of the KRAS gene associated with gallbladder carcinoma patients of the eastern part of India.,http://www.ncbi.nlm.nih.gov/pubmed/21375404,295,,,www.uniprot.org,23226
"KRAS Q61A is a hotspot mutation, which lies within the GTP binding region of the Kras protein (UniProt.org). Q61A is predicted to confer a loss of function to the Kras protein with reduced GTPase activity and increased downstream pathway activation (PMID: 20147967).",841,20147967,Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine.,http://www.ncbi.nlm.nih.gov/pubmed/20147967,295,,,www.uniprot.org,23227
"KRAS Y32S lies within the switch I region of the Kras protein (PMID: 11333268). Y32S is predicted to confer a loss of function to the Kras protein as demonstrated by reduced binding to Sos, which contributes to nucleotide stabilization, however, downstream signaling effects are unknown (PMID: 11333268).",5917,11333268,Structure-based mutagenesis reveals distinct functions for Ras switch 1 and switch 2 in Sos-catalyzed guanine nucleotide exchange.,http://www.ncbi.nlm.nih.gov/pubmed/11333268,23228
"KRAS Y40A lies within the swtich I region of the Kras protein (PMID: 11333268). Y40A is predicted to confer a loss of function to the Kras protein as demonstrated by reduced binding to Sos, which contributes to nucleotide stabilization, however, downstream signaling effects are unknown (PMID: 11333268).",5917,11333268,Structure-based mutagenesis reveals distinct functions for Ras switch 1 and switch 2 in Sos-catalyzed guanine nucleotide exchange.,http://www.ncbi.nlm.nih.gov/pubmed/11333268,23229
"KRAS Y71H lies within the switch II region of the Kras protein (PMID: 23059812). Y71H confers a loss of function to the Kras protein as demonstrated by increased intrinsic GTPase activity, is hypothesized to lead to increased binding to Raf1, and leads to activation of modest, but sustained activation of downstream Mek and EGF-stimulated activation of Erk (PMID: 23059812). ",5915,23059812,Diverging gain-of-function mechanisms of two novel KRAS mutations associated with Noonan and cardio-facio-cutaneous syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/23059812,23230
"KRAS Y64A lies within the G-domain of the Kras protein (PMID: 26080442). Y64A leads to reduced Kras GTPase activity in a KRAS G12C background (PMID: 26841430), however, has not been individually characterized and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).",5919,26841430,Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism.,http://www.ncbi.nlm.nih.gov/pubmed/26841430,5918,26080442,Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway.,http://www.ncbi.nlm.nih.gov/pubmed/26080442,23231
"BCOR-CCNB3 results from the fusion of BCOR and CCNB3, resulting in a unique transcriptional signature consistent with Wnt activation and activation of S-phase in transformed cells (PMID: 22387997).",5920,22387997,A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion.,http://www.ncbi.nlm.nih.gov/pubmed/22387997,23232
"CBL E815D lies within the CD2AP-interacting region of the Cbl protein (UniProt.org). E815D has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23233
"NOTCH1 C456R lies within the calcium-binding EGF-like domain 12 of the Notch1 protein (UniProt.org). C456R has been identified in the sequencing studies (PMID: 21798897), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,7349,21798897,Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1.,http://www.ncbi.nlm.nih.gov/pubmed/21798897,285,,,http://www.ncbi.nlm.nih.gov/pubmed,23234
"CBL E894* results in a premature truncation of the Cbl protein at amino acid 894 of 906 (UniProt.org). E894* has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,23235
"CBL E894G lies within the UBA domain of the Cbl protein (UniProt.org). E894G has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23236
"CBL G816S lies within the CD2AP-interacting region of the Cbl protein (UniProt.org). G816S has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Dec 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23238
"CBL G868V lies within the UBA domain of the Cbl protein (UniProt.org). G868V has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23239
"CBL H903L lies within the CD2AP-interacting region of the Cbl protein (UniProt.org). H903L has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,23240
"CBL L620F lies within a proline-rich region of the Cbl protein (UniProt.org). L620F has been identified in the scientific literature (PMID: 20126411), but has not been biochemically characterized and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1306,20126411,CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.,http://www.ncbi.nlm.nih.gov/pubmed/20126411,23243
"CBL N890fs results in a change in the amino acid sequence of the Cbl protein beginning at aa 890 of 906, likely resulting in premature truncation of the functional protein (UniProt.org). N890fs has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23244
"MAP2K1 H119P lies within the protein kinase domain of the Map2k1 protein (UniProt.org).  H119P has not been biochemically characterized, however, has been described as a drug resistance mutation and therefore, is predicted to confer a loss of function to the Map2k1 protein (PMID: 19915144). ",134,19915144,MEK1 mutations confer resistance to MEK and B-RAF inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/19915144,295,,,www.uniprot.org,23245
"MAP2K1 C121G lies within the protein kinase domain of the Map2k1 protein (UniProt.org). C121G has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Mar 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23246
"MAP2K1 G128V lies within the protein kinase domain of the Map2k1 protein (UniProt.org).  G128V has not been biochemically characterized, however, has been described as a drug resistance mutation and therefore, is predicted to confer a loss of function to the Map2k1 protein (PMID: 24265153).",295,,,www.uniprot.org,5840,24265153,The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/24265153,23247
"CBL P417A lies within the RING-finger domain of the Cbl protein (PMID: 20501843). P417A results in decreased Cbl ubiquitin ligase activity, increased cell survival, and is transforming in cell culture (PMID: 19387008).",5944,20501843,Cbl and human myeloid neoplasms: the Cbl oncogene comes of age.,http://www.ncbi.nlm.nih.gov/pubmed/20501843,4186,19387008,Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/19387008,23248
MAP2K1 I204T lies within the protein kinase domain of the Map2k1 protein (UniProt.org). I204T confers a gain of function to the Map2k1 protein as indicated by transformation activity and increased phosphorylation of Erk1/2 in culture (PMID: 22327936). ,135,22327936,Oncogenic MAP2K1 mutations in human epithelial tumors.,http://www.ncbi.nlm.nih.gov/pubmed/22327936,295,,,www.uniprot.org,23249
"CBL Q367P lies within the linker domain of the Cbl protein (PMID: 19620960). Q367P results in decreased Cbl ubiquitinating activity and increased AKT activation, is transforming in cell culture, and leads to increased tumor growth in mouse models (PMID: 19620960).",5941,19620960,Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/19620960,23250
"CBL Q867* results in a premature truncation of the Cbl protein at amino acid 867 of 906 (UniProt.org). Q867* has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,23251
"MAP2K1 S218D lies within the protein kinase domain of the Map2k1 protein (UniProt.org). S218D confers a gain of function to the Map2k1 protein as indicated by increased Map2k1 activity in the absence of growth factor, cell growth in culture, and tumor formation in mouse models (PMID: 7936666). ",295,,,www.uniprot.org,5942,7936666,Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts.,http://www.ncbi.nlm.nih.gov/pubmed/7936666,23252
"CBL Q875* results in a premature truncation of the Cbl protein at amino acid 875 of 906 (UniProt.org). Q875* has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23253
MAP2K1 P306H lies within the protein kinase domain of the Map2k1 protein (UniProt.org). P306H confers a gain of function to the Map2k1 protein as indicated by increased phosphorylation of Erk1/2 and modest transformation activity in culture (PMID: 22327936).,135,22327936,Oncogenic MAP2K1 mutations in human epithelial tumors.,http://www.ncbi.nlm.nih.gov/pubmed/22327936,295,,,www.uniprot.org,23254
"MAP2K1 N382H does not lie within any known functional domains of the Map2k1 protein (UniProt.org). N382H did not result in Erk phosphorylation in culture and therefore, its effect on Map2k1 protein function is unknown (PMID: 22197931).",429,22197931,Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/22197931,295,,,www.uniprot.org,23255
"CBL R420P lies within the RING-finger domain of the Cbl protein (PMID: 20501843) R420P has not been biochemically characterized, however, other mutations at R420 lead to loss of Cbl ubiquitinating activity in cell culture (PMID: 17446348), and R420P leads to destabilization of Cbl-E2 binding in computer models (PMID: 26676746), and is therefore predicted to lead to a loss of Cbl protein function.",3300,17446348,Flt3-dependent transformation by inactivating c-Cbl mutations in AML.,http://www.ncbi.nlm.nih.gov/pubmed/17446348,4519,26676746,Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26676746,5944,20501843,Cbl and human myeloid neoplasms: the Cbl oncogene comes of age.,http://www.ncbi.nlm.nih.gov/pubmed/20501843,23256
"CBL R822T lies within the CD2AP-interacting region of the Cbl protein (UniProt.org). R822T has been identified in sequencing studies (PMID: 24190505), but has not been biochemically characterized and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,9164,24190505,"Exomic analysis of myxoid liposarcomas, synovial sarcomas, and osteosarcomas.",http://www.ncbi.nlm.nih.gov/pubmed/24190505,295,,,www.uniprot.org,23257
"CBL R830K lies within the CD2AP-interacting region of the Cbl protein (UniProt.org). R830K has been identified in sequencing studies (PMID: 20126411), but has not been biochemically characterized and therefore, its effect on Cbl protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,1306,20126411,CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.,http://www.ncbi.nlm.nih.gov/pubmed/20126411,295,,,www.uniprot.org,23258
"CBL S376F lies within the linker region of the Cbl protein (UniProt.org). S376F leads to decreased Cbl ubiquitin ligase activity, increased cell survival, and is transforming in cell culture (PMID: 19387008).",4186,19387008,Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/19387008,23259
MAP2K1 Q56_V60del results in the deletion of five amino acids in the protein kinase domain of the Map2k1 protein from amino acids 56 to 60 (UniProt.org). Q56_V60del confers a gain of function to the Map2k1 protein as indicated by transformation capabilities and increased phosphorylation of Erk and S6k in culture (PMID: 26324360).,295,,,www.uniprot.org,5860,26324360,Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26324360,23260
"MAP2K1 S222D lies within the protein kinase domain of the Map2k1 protein (UniProt.org). S222D has not been individually characterized, however, when combined with MAP2K1 S218D, the combination results in constitutive activation of Map2k1 in culture (PMID: 7936666).",5942,7936666,Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts.,http://www.ncbi.nlm.nih.gov/pubmed/7936666,295,,,www.uniprot.org,23261
"CBL Y371S lies within the linker domain of the Cbl protein (PMID: 19620960). Y371S results in decreased Cbl ubiquitinating activity and increased AKT activation, is transforming in cell culture, and leads to increased tumor growth in mouse models (PMID: 19620960).",5941,19620960,Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/19620960,23262
"EGFR A755G lies within the protein kinase domain of the Egfr protein (UniProt.org). A755G has been identified in the scientific literature (PMID: 25304185), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",7949,25304185,Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25304185,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23264
"NOTCH1 D1517N lies within the LNR 2 domain of the Notch1 protein (UniProt.org). D1517N has not been biochemically characterized, however, is predicted to disrupt calcium binding and Notch1 folding by structural analysis (PMID: 27228302).",5947,27228302,Does Notch play a tumor suppressor role across diverse squamous cell carcinomas?,http://www.ncbi.nlm.nih.gov/pubmed/27228302,295,,,www.uniprot.org,23265
"NOTCH1 E424K lies within the calcium-binding EGF-like domain 11 of the Notch1 protein (UniProt.org). E424K has not been biochemically characterized, however, is predicted to disrupt ligand binding to Notch1 by structural analysis (PMID: 27228302).",295,,,www.uniprot.org,5947,27228302,Does Notch play a tumor suppressor role across diverse squamous cell carcinomas?,http://www.ncbi.nlm.nih.gov/pubmed/27228302,23266
"EGFR A763V lies within the protein kinase domain of the Egfr protein (UniProt.org). A763V has not been biochemically characterized, but is associated with lack of response to an EGFR kinase inhibitor (PMID: 15897572). ",4837,15897572,Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/15897572,23267
EGFR D855G lies within the protein kinase domain of the Egfr protein (UniProt.org). D855G results in a lack of Egfr kinase activity in cell culture (PMID: 26101090).,295,,,www.uniprot.org,7974,26101090,Mechanistic Insights into R776H Mediated Activation of Epidermal Growth Factor Receptor Kinase.,http://www.ncbi.nlm.nih.gov/pubmed/26101090,23268
"ATM E1978* results in a premature truncation of the Atm protein at amino acid 1978 of 3056 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), E1978* is predicted to lead to a loss of Atm protein function.
",295,,,www.uniprot.org,23269
"HRAS A146T does not lie within any known functional domains of the Hras protein (UniProt.org). A146T results in increased GTP binding to Hras, increased Mek and c-Jun signaling, and cell senescence in culture (PMID: 21850009).",295,,,www.uniprot.org,1783,21850009,HRAS mutants identified in Costello syndrome patients can induce cellular senescence: possible implications for the pathogenesis of Costello syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/21850009,23270
"HRAS A59D lies within the GTP binding domain of the Hras protein (UniProt.org). A59D has not been characterized in the scientific literature and therefore, its effect on Hras protein function is unknown (PubMed, Apr 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23271
"HRAS G12N lies within the GTP binding domain of the Hras protein (UniProt.org). G12N has not been characterized in the scientific literature and therefore, its effect on Hras protein function is unknown (PubMed, Apr 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23272
"HRAS K117R lies within the GTP binding region of the Hras protein (UniProt.org). K117R results in increased GTP binding to Hras, increased Mek and c-Jun signaling, and cell senescence in culture (PMID: 21850009).",1783,21850009,HRAS mutants identified in Costello syndrome patients can induce cellular senescence: possible implications for the pathogenesis of Costello syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/21850009,295,,,www.uniprot.org,23273
"IDH1 R132I lies within the active site of the IDH1 protein (PMID: 19228619). R132I has been identified in sequencing studies (PMID: 19935646), but has not been biochemically characterized, however, other R132 hotspot mutations confer a gain-of-function to convert alpha-ketoglutarate to onco-metabolite 2HG (PMID: 19935646, PMID: 28330869), thus, R132I is predicted to confer a gain of Idh1 protein function.",486,19228619,IDH1 and IDH2 mutations in gliomas.,http://www.ncbi.nlm.nih.gov/pubmed/19228619,7375,24403254,Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1.,http://www.ncbi.nlm.nih.gov/pubmed/24403254,285,,,http://www.ncbi.nlm.nih.gov/pubmed,487,19935646,Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.,http://www.ncbi.nlm.nih.gov/pubmed/19935646,9218,28330869,Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiency.,http://www.ncbi.nlm.nih.gov/pubmed/28330869,23274
"IDH1 R132P lies within the active site of the IDH1 protein (PMID: 19228619). R132P has been identified in sequencing studies (PMID: 22520341), but has not been biochemically characterized, however, other R132 hotspot mutations confer a gain-of-function to convert alpha-ketoglutarate to onco-metabolite 2HG (PMID: 19935646, PMID: 28330869), thus, R132P is predicted to confer a gain of Idh1 protein function.",7376,22520341,Adverse impact of IDH1 and IDH2 mutations in primary AML: experience of the Spanish CETLAM group.,http://www.ncbi.nlm.nih.gov/pubmed/22520341,486,19228619,IDH1 and IDH2 mutations in gliomas.,http://www.ncbi.nlm.nih.gov/pubmed/19228619,9218,28330869,Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiency.,http://www.ncbi.nlm.nih.gov/pubmed/28330869,285,,,http://www.ncbi.nlm.nih.gov/pubmed,487,19935646,Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.,http://www.ncbi.nlm.nih.gov/pubmed/19935646,23275
"IDH2 R140K lies within the substrate binding region of the Idh2 protein (UniProt.org). R140K has not been characterized in the scientific literature and therefore, it effect on Idh2 protein function is unknown (PubMed, Jul 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23276
"IDH2 R140M lies within the substrate binding region of the Idh2 protein (UniProt.org). R140M has not been characterized in the scientific literature and therefore, it effect on Idh2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23277
"IDH2 R140S lies within the substrate binding region of the Idh2 protein (UniProt.org). R140S has not been characterized in the scientific literature and therefore, it effect on Idh2 protein function is unknown (PubMed, Jul 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23278
"EGFR E758G lies within the protein kinase domain of the Egfr protein (UniProt.org). E758G has been identified in the scientific literature (PMID: 16152581), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",6027,16152581,Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16152581,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23279
"EGFR E804G lies within the protein kinase domain of the Egfr protein (UniProt.org). E804G results in constitutive activation of Egfr and increased downstream signaling, increased cell proliferation and invasion, and is transforming in cell culture (PMID: 18193092).",2079,18193092,Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations.,http://www.ncbi.nlm.nih.gov/pubmed/18193092,295,,,www.uniprot.org,23280
"EGFR G796S lies within the protein kinase domain of the Egfr protein (UniProt.org). G796S results in constitutive activation of Egfr and increased downstream signaling, and leads to increased proliferation and invasion and transformation of cultured cells (PMID: 18193092).",2079,18193092,Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations.,http://www.ncbi.nlm.nih.gov/pubmed/18193092,295,,,www.uniprot.org,23281
EGFR E866K lies within the protein kinase domain of the Egfr protein (UniProt.org). E866K results in a loss of Egfr kinase activity and is not transforming in cell culture (PMID: 19147750).,295,,,www.uniprot.org,1890,19147750,Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/19147750,23282
"EGFR E884K lies within the protein kinase domain of the Egfr protein (UniProt.org). E884K results in constitutive phosphorylation of Egfr and increased Stat3 phosphorylation in cell culture, and leads to increased cell proliferation and differential tyrosine kinase inhibitor sensitivity in combination with EGFR L858R (PMID: 19015641).",5950,19015641,Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.,http://www.ncbi.nlm.nih.gov/pubmed/19015641,295,,,www.uniprot.org,23283
"EGFR G779S lies within the protein kinase domain of the Egfr protein (UniProt.org). G779S has been identified in the scientific literature (PMID: 17626639, PMID: 22528563), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8091,22528563,EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22528563,8090,17626639,Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/17626639,23284
"EGFR G857E lies within the protein kinase domain of the Egfr protein (UniProt.org). G857E has been identified in the scientific literature (PMID: 19238633, PMID: 23139256, PMID: 25435280), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,8100,23139256,Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy.,http://www.ncbi.nlm.nih.gov/pubmed/23139256,295,,,www.uniprot.org,8099,19238633,Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.,http://www.ncbi.nlm.nih.gov/pubmed/19238633,5989,25435280,HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25435280,23285
"EGFR G857R lies within the protein kinase domain of the Egfr protein (UniProt.org). G857R has been identified in the scientific literature (PMID: 15863375, PMID: 16857803, PMID: 19190079), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",8103,19190079,"Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas.",http://www.ncbi.nlm.nih.gov/pubmed/19190079,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8102,15863375,Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.,http://www.ncbi.nlm.nih.gov/pubmed/15863375,8101,16857803,Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/16857803,23286
"EGFR G873Q lies within the protein kinase domain of the Egfr protein (UniProt.org). G873Q has not been characterized in the scientific literature and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23287
"EGFR H773Y lies within the protein kinase domain of the Egfr protein (UniProt.org). H773Y has been identified in the scientific literature (PMID: 15753462, PMID: 19536777, PMID: 23139256), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",8109,19536777,Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19536777,8100,23139256,Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy.,http://www.ncbi.nlm.nih.gov/pubmed/23139256,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8108,15753462,Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/15753462,23288
"EGFR H835L lies within the protein kinase domain of the Egfr protein (UniProt.org). H835L has been identified in the scientific literature (PMID: 15329413, PMID: 21422421, PMID: 25130612), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",5952,21422421,Good response to gefitinib in a lung adenocarcinoma harboring a heterozygous complex mutation of L833V and H835L in epidermal growth factor receptor gene.,http://www.ncbi.nlm.nih.gov/pubmed/21422421,8112,25130612,Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations.,http://www.ncbi.nlm.nih.gov/pubmed/25130612,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8113,15329413,"EGF receptor gene mutations are common in lung cancers from ""never smokers"" and are associated with sensitivity of tumors to gefitinib and erlotinib.",http://www.ncbi.nlm.nih.gov/pubmed/15329413,23289
"EGFR L833V lies within the protein kinase domain of the Egfr protein (UniProt.org). L833V has been identified in the scientific literature (PMID: 27131295, PMID: 25130612, PMID: 21422421), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",8112,25130612,Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations.,http://www.ncbi.nlm.nih.gov/pubmed/25130612,5952,21422421,Good response to gefitinib in a lung adenocarcinoma harboring a heterozygous complex mutation of L833V and H835L in epidermal growth factor receptor gene.,http://www.ncbi.nlm.nih.gov/pubmed/21422421,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8209,27131295,A Triple Rare E709K and L833V/H835L EGFR Mutation Responsive to an Irreversible Pan-HER Inhibitor: A Case Report of Lung Adenocarcinoma Treated with Afatinib.,http://www.ncbi.nlm.nih.gov/pubmed/27131295,23290
"EGFR H850D lies within the protein kinase domain of the Egfr protein (UniProt.org). H850D has been identified in the scientific literature (PMID: 19060236, PMID: 18509184), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",8114,18509184,Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.,http://www.ncbi.nlm.nih.gov/pubmed/18509184,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7969,19060236,Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern.,http://www.ncbi.nlm.nih.gov/pubmed/19060236,23291
"EGFR I706T lies within the protein kinase domain of the Egfr protein (UniProt.org). I706T has been identified in the scientific literature (PMID: 17575133, PMID: 25521408), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",8192,25521408,Two cases of non-small-cell lung cancer with rare complex mutation of EGFR exon 18 but different response to targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/25521408,8191,17575133,"Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history.",http://www.ncbi.nlm.nih.gov/pubmed/17575133,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23292
"EGFR I853T lies within the protein kinase domain of the Egfr protein (UniProt.org). I853T results in loss of Egfr kinase activity, including in the presence of Egfr activating mutations, and is not transforming in cell culture (PMID: 19147750).",1890,19147750,Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/19147750,295,,,www.uniprot.org,23293
"NOTCH1 F1292L lies within the EGF-like domain 33 of the Notch1 protein (UniProt.org). F1292L has been identified in the scientific literature (PMID: 25633867), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",8213,25633867,"Cleaved NOTCH1 Expression Pattern in Head and Neck Squamous Cell Carcinoma Is Associated with NOTCH1 Mutation, HPV Status, and High-Risk Features.",http://www.ncbi.nlm.nih.gov/pubmed/25633867,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23294
"EGFR L688P lies within the protein kinase domain of the Egfr protein (UniProt.org). L688P results in loss of Egfr kinase activity and reduces the activity of Egfr activating mutations in the context of complex mutations, and is not transforming in cell culture (PMID: 19147750).",1890,19147750,Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/19147750,295,,,www.uniprot.org,23295
"NOTCH1 G1340A lies within the EGF-like domain 34 of the Notch1 protein (UniProt.org). G1340A has been identified in the scientific literature (PMID: 25633867), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",8213,25633867,"Cleaved NOTCH1 Expression Pattern in Head and Neck Squamous Cell Carcinoma Is Associated with NOTCH1 Mutation, HPV Status, and High-Risk Features.",http://www.ncbi.nlm.nih.gov/pubmed/25633867,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23296
"EGFR V851A lies within the protein kinase domain of the Egfr protein (UniProt.org). V851A results in loss of Egfr kinase activity, including in the presence of Egfr activating mutations, and is not transforming in cell culture (PMID: 19147750).",1890,19147750,Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/19147750,23297
"NOTCH1 G1638V lies within the extracellular domain of the Notch1 protein (UniProt.org). G1638V has been identified in the scientific literature (PMID: 21798897), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,7349,21798897,Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1.,http://www.ncbi.nlm.nih.gov/pubmed/21798897,285,,,http://www.ncbi.nlm.nih.gov/pubmed,23298
"NOTCH1 G310R lies within the calcium-binding EGF-like domain 8 of the Notch1 protein (UniProt.org). G310R has been identified in the scientific literature (PMID: 21798897, PMID: 26873401), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,7349,21798897,Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1.,http://www.ncbi.nlm.nih.gov/pubmed/21798897,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7161,26873401,Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population.,http://www.ncbi.nlm.nih.gov/pubmed/26873401,23299
"NOTCH1 G812W lies within the calcium-binding EGF-like domain 21 of the Notch1 protein (UniProt.org). G812W has been identified in the scientific literature (PMID: 21798897, PMID: 26873401), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7161,26873401,Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population.,http://www.ncbi.nlm.nih.gov/pubmed/26873401,7349,21798897,Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1.,http://www.ncbi.nlm.nih.gov/pubmed/21798897,23300
"NOTCH1 M2011R lies within the ANK domain 3 of the Notch1 protein (UniProt.org). M2011R has been identified in the scientific literature (PMID: 21798897), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7349,21798897,Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1.,http://www.ncbi.nlm.nih.gov/pubmed/21798897,23301
"EGFR N826S lies within the protein kinase domain of the Egfr protein (UniProt.org). N826S results in constitutive Egfr phosphorylation and activation of downstream ERK, Stat5, and AKT, transformation of cultured cells, and is associated with drug resistance (PMID: 19147750).",295,,,www.uniprot.org,1890,19147750,Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/19147750,23302
"NOTCH1 P2514fs results in a change in the amino acid sequence of the Notch1 protein beginning at aa 2514 of 2555, likely resulting in premature truncation of the functional protein (UniProt.org). P2514fs has not been characterized individually however, cells harboring both P2514fs (reported as P2514fs*4) and L1600P demonstrated constitutive Notch signaling in culture (PMID: 17646409).",295,,,www.uniprot.org,379,17646409,FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/17646409,23303
"NOTCH1 P391S lies within the calcium-binding EGF-like domain 10 of the Notch1 protein (UniProt.org). P391S has been identified in the scientific literature (PMID: 21798897), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7349,21798897,Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1.,http://www.ncbi.nlm.nih.gov/pubmed/21798897,23305
"NOTCH1 P422S lies within the calcium-binding EGF-like domain 11 of the Notch1 protein (UniProt.org). P422S has not been biochemically characterized, however, is predicted to disrupt ligand binding to Notch1 by structural analysis (PMID: 27228302).",295,,,www.uniprot.org,5947,27228302,Does Notch play a tumor suppressor role across diverse squamous cell carcinomas?,http://www.ncbi.nlm.nih.gov/pubmed/27228302,23306
"EGFR K806A lies within the protein kinase domain of the Egfr protein (UniProt.org). K806A has been identified in the scientific literature (PMID: 19536777), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",8109,19536777,Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19536777,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23307
"NOTCH1 R1280C lies within the EGF-like domain 33 of the Notch1 protein (UniProt.org). R1280C has been identified in the scientific literature (PMID: 21798897), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",7349,21798897,Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1.,http://www.ncbi.nlm.nih.gov/pubmed/21798897,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23308
"NOTCH1 R1608H lies within the extracellular domain of the Notch1 protein (UniProt.org). R1608H has been identified in the scientific literature (PMID: 22210878), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8302,22210878,Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/22210878,23309
"EGFR K806E lies within the protein kinase domain of the Egfr protein (UniProt.org). K806E has been identified in the scientific literature (PMID: 18676761, PMID: 16870303), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",8199,18676761,Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response.,http://www.ncbi.nlm.nih.gov/pubmed/18676761,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7968,16870303,Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16870303,23310
NOTCH1 R1608S lies within the extracellular domain of the Notch1 protein (UniProt.org). R1608S demonstrates activity similar to wild-type Notch1 in a luciferase reporter assay in culture (PMID: 16738328).,2752,16738328,Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes.,http://www.ncbi.nlm.nih.gov/pubmed/16738328,295,,,www.uniprot.org,23311
"NOTCH1 R1608T lies within the extracellular domain of the Notch1 protein (UniProt.org). R1608T has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23312
"NOTCH1 R1608V lies within the extracellular domain of the Notch1 protein (UniProt.org). R1608V has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23313
"EGFR K860I lies within the protein kinase domain of the Egfr protein (UniProt.org). K860I has been identified in the scientific literature (PMID: 26923333, PMID: 19536777, PMID: 21610522), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,8200,26923333,Screening for major driver oncogene alterations in adenosquamous lung carcinoma using PCR coupled with next-generation and Sanger sequencing methods.,http://www.ncbi.nlm.nih.gov/pubmed/26923333,8109,19536777,Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19536777,285,,,http://www.ncbi.nlm.nih.gov/pubmed,8201,21610522,Detection of epithelial growth factor receptor mutations in cerebrospinal fluid from patients with lung adenocarcinoma suspected of neoplastic meningitis.,http://www.ncbi.nlm.nih.gov/pubmed/21610522,23314
"EGFR L692P lies within the protein kinase domain of the Egfr protein (UniProt.org). L692P has been identified in the scientific literature (PMID: 19238633, PMID: 18000506), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,8202,18000506,'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/18000506,8099,19238633,Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.,http://www.ncbi.nlm.nih.gov/pubmed/19238633,285,,,http://www.ncbi.nlm.nih.gov/pubmed,23315
"EGFR L798H lies within the protein kinase domain of the Egfr protein (UniProt.org). L798H has been identified in the scientific literature (PMID: 16870303), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7968,16870303,Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16870303,23316
"MET D1010I lies within the protein kinase domain of the Met protein (UniProt.org). D1010I has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23317
"EGFR L838V lies within the protein kinase domain of the Egfr protein (UniProt.org). L838V results in constitutive Egfr phosphorylation and activation of downstream ERK, Stat5, and AKT, and transformation of cultured cells (PMID: 19147750).",295,,,www.uniprot.org,1890,19147750,Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/19147750,23318
"MET M1250T lies within the protein kinase domain of the Met protein (UniProt.org). M1250T confers a gain of function to the Met protein as demonstrated by transformation in culture, increased Met kinase activity, and activation of the Ras signaling pathway (PMID: 11571647).",5953,11571647,Differential requirement of the last C-terminal tail of Met receptor for cell transformation and invasiveness.,http://www.ncbi.nlm.nih.gov/pubmed/11571647,295,,,www.uniprot.org,23319
"EGFR L861F lies within the protein kinase domain of the Egfr protein (UniProt.org). L861F has been identified in the scientific literature (PMID: 19536777, PMID: 23945384), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",8109,19536777,Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/19536777,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8197,23945384,Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23945384,23320
"NOTCH1 R353C lies within the calcium-binding EGF-like domain 9 of the Notch1 protein (UniProt.org). R353C has been identified in the scientific literature (PMID: 22006338), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",269,22006338,Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22006338,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23321
"EGFR N700D lies within the cytoplasmic domain of the Egfr protein (UniProt.org). N700D has been identified in the scientific literature (PMID: 20127001, PMID: 15897572), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",9148,20127001,Overexpression of EGFR pathway-related genes in the circulation is highly correlated with EGFR mutations and overexpression in paired cancer tissue from patients with non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20127001,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4837,15897572,Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/15897572,23322
"NOTCH1 R353H lies within the calcium-binding EGF-like domain 9 of the Notch1 protein (UniProt.org). R353H has been identified in the scientific literature (PMID: 21798897), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7349,21798897,Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1.,http://www.ncbi.nlm.nih.gov/pubmed/21798897,23323
"NOTCH1 S935N lies within the EGF-like domain 24 of the Notch1 protein (UniProt.org). S935N has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23324
"NOTCH1 V1605del results in the deletion of one amino acid in the extracellular domain of the Notch1 protein at amino acid 1605 (UniProt.org). V1605del has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23325
"NOTCH1 V1671I lies within the extracellular domain of the Notch1 protein (UniProt.org). V1671I has been identified in the scientific literature (PMID: 19340001), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",2634,19340001,"The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.",http://www.ncbi.nlm.nih.gov/pubmed/19340001,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23326
"NOTCH1 V2039E lies within the ANK domain 4 of the Notch1 protein (UniProt.org). V2039E has been identified in the scientific literature (PMID: 21798897), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",7349,21798897,Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1.,http://www.ncbi.nlm.nih.gov/pubmed/21798897,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23327
"NOTCH1 V2039L lies within the ANK domain 4 of the Notch1 protein (UniProt.org). V2039L has been identified in the scientific literature (PMID: 21798897), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",7349,21798897,Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1.,http://www.ncbi.nlm.nih.gov/pubmed/21798897,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23328
"NOTCH1 Y1619P lies within the extracellular domain of the Notch1 protein (UniProt.org). Y1619P has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23329
"NOTCH1 Y1620G lies within the extracellular domain of the Notch1 protein (UniProt.org). Y1620G has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,23330
EGFR R776G lies within the protein kinase domain of the Egfr protein (UniProt.org). R776G results in increased Egfr autophosphorylation in cultured cells (PMID: 21575252).,295,,,www.uniprot.org,5954,21575252,Germ-line mutations in epidermal growth factor receptor (EGFR) are rare but may contribute to oncogenesis: a novel germ-line mutation in EGFR detected in a patient with lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/21575252,23331
"EGFR R803W lies within the protein kinase domain of the Egfr protein (UniProt.org). R803W has not been characterized and therefore, its effect on Egfr protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23332
EGFR R831H lies within the protein kinase domain of the Egfr protein (UniProt.org). R831H results in increased Egfr phosphorylation in cell culture (PMID: 20942962).,295,,,www.uniprot.org,1956,20942962,Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma.,http://www.ncbi.nlm.nih.gov/pubmed/20942962,23334
"EGFR R841K lies within the protein kinase domain of the Egfr protein (UniProt.org). R841K demonstrates Egfr phosphorylation comparable to wild-type Egfr, does not increase proliferation in the absence in ligand and is not transforming, but leads to a moderate increase in  proliferation in the presence of ligand, and increased activation of Akt, Stat5, and Erk in cell culture (PMID: 18193092).",295,,,www.uniprot.org,2079,18193092,Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations.,http://www.ncbi.nlm.nih.gov/pubmed/18193092,23335
"EGFR S720P lies within the protein kinase domain of the Egfr protein (UniProt.org). S720P has been identified in the scientific literature (PMID: 26773740, PMID: 23468551) but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23336
"EGFR S921R lies within the protein kinase domain of the Egfr protein (UniProt.org). S921R has not been characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23337
"ERBB2 (HER2) E265K lies within the extracellular domain of the Erbb2 protein (UniProt.org). E265K has been identified in sequencing studies (PMID: 24997986), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7076,24997986,Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway.,http://www.ncbi.nlm.nih.gov/pubmed/24997986,23338
"ERBB2 (HER2) G292R lies within the extracellular domain of the Erbb2 protein (UniProt.org). G292R has been identified in sequencing studies (PMID: 24997986), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7076,24997986,Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway.,http://www.ncbi.nlm.nih.gov/pubmed/24997986,23339
"EGFR T263P lies within the extracellular domain of the Egfr protein (PMID: 17177598). T263P leads to increased Egfr phosphorylation and transformation of cultured cells, and results in increased tumor growth in mouse models (PMID: 17177598).",1877,17177598,Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain.,http://www.ncbi.nlm.nih.gov/pubmed/17177598,23340
"ERBB2 (HER2) C630Y lies within the extracellular domain of the Erbb2 protein (UniProt.org). C630Y has been identified in the scientific literature (PMID: 18413839), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",5983,18413839,EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.,http://www.ncbi.nlm.nih.gov/pubmed/18413839,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23341
"ERBB2 (HER2) R678L lies within the region that interacts with KPNB1 and EEA1 (UniProt.org). R678L has not been characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23342
"IDH2 R140G lies within the substrate binding region of the Idh2 protein (UniProt.org). R140G has been identified in sequencing studies (PMID: 27276561), but has not been biochemically characterized and therefore, its effect on Idh2 protein function is unknown (PubMed, Jul 2017).
",7052,27276561,Genomic Classification and Prognosis in Acute Myeloid Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27276561,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23343
"IDH2 R172T lies within the active site of the Idh2 protein (PMID: 19228619). R172T has been identified in sequencing studies (PMID: 23485734, PMID: 22215888), but has not been biochemically characterized and therefore, its effect on Idh2 protein function is unknown (PubMed, Jul 2017).
",7371,23485734,R132C IDH1 mutations are found in spindle cell hemangiomas and not in other vascular tumors or malformations.,http://www.ncbi.nlm.nih.gov/pubmed/23485734,486,19228619,IDH1 and IDH2 mutations in gliomas.,http://www.ncbi.nlm.nih.gov/pubmed/19228619,9284,22215888,IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/22215888,285,,,http://www.ncbi.nlm.nih.gov/pubmed,23344
"ATM N2603S does not lie within any known functional domains of the Atm protein (UniProt.org). N2603S has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23359
"ATM G514D does not lie within any known functional domains of the Atm protein (UniProt.org). G514D has been identified in sequencing studies (PMID: 11443540) but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23360
"ATM C353fs results in a change in the amino acid sequence of the Atm protein beginning at aa 353 of 3056, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of all known functional domains (UniProt.org), C353fs is predicted to lead to a loss of Atm function.",295,,,www.uniprot.org,23361
"ATM L348_M349insYIV results in the insertion of three amino acids in the Atm protein between amino acids 348 and 349 (UniProt.org). L348_M349insYIV has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017). ",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,23362
"APC N1026S does not lie within any known functional domains of the Apc protein (UniProt.org). N1026S confers a loss of function on Apc, as indicated by diminished binding to beta catenin and moderate activation of target genes in cell culture (PMID: 18166348). ",295,,,www.uniprot.org,700,18166348,Functional characterization of the novel APC N1026S variant associated with attenuated familial adenomatous polyposis.,http://www.ncbi.nlm.nih.gov/pubmed/18166348,23366
"RB1 R798Q lies within Domain C of the Rb1 protein (UniProt.org). R798Q has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23368
"RB1 I388S lies within Domain A of the Rb1 protein (UniProt.org). I388S has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23369
"RB1 R798W lies within Domain C of the Rb1 protein (UniProt.org). R798W has been identified in the scientific literature (PMID: 9194486), but has not been biochemically characterized and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8597,9194486,Analysis of the Rb gene and cyclin-dependent kinase 4 inhibitor genes (p16INK4 and p15INK4B) in human ovarian carcinoma cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/9194486,23370
BRCA1 A1669S lies within the BRCT1 domain of the Brca1 protein (UniProt.org). A1669S results in BRCT binding and transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 20516115).,295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23371
"BRCA1 A1708E lies within the BRCT1 domain of the Brca1 protein (UniProt.org). A1708E results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23372
"BRCA1 A1708V lies within the BRCT1 domain of the Brca1 protein (UniProt.org). A1708V results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23373
"BRCA1 A1752P does not lie within any known functional domains of the Brca1 protein (UniProt.org). A1752P results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23374
BRCA1 A1752V does not lie within any known functional domains of the Brca1 protein (UniProt.org). A1752V results in defective Brca1 protein folding and decreased transcription activity in cell culture (PMID: 20516115).,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23375
BRCA1 A1789S lies within the BRCT2 domain of the Brca1 protein (UniProt.org). A1789S results in BRCT binding and transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 20516115).,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23376
BRCA1 A1823T lies within the BRCT2 domain of the Brca1 protein (UniProt.org). A1823T results in BRCT binding and transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 20516115).,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23377
BRCA1 A1830T lies within the BRCT2 domain of the Brca1 protein (UniProt.org). A1830T results in BRCT binding and transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 20516115).,295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23378
"BRCA1 A1843P lies within the BRCT2 domain of the Brca1 protein (UniProt.org). A1843P results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23379
BRCA1 C1697R lies within the BRCT1 domain of the Brca1 protein (UniProt.org). C1697R results in defective Brca1 protein folding and decreased transcription activity in cell culture (PMID: 20516115).,295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23380
BRCA1 C1787S lies within the BRCT1 domain of the Brca1 protein (UniProt.org). C1787S results in BRCT binding and transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 20516115).,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23381
BRCA1 D1692H lies within the BRCT1 domain of the Brca1 protein (UniProt.org). D1692H results in decreased Brca1 transcription activity in cell culture (PMID: 20516115).,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23382
"BRCA1 D1692N lies within the BRCT1 domain of the Brca1 protein (UniProt.org). D1692N results in BRCT binding similar to wild-type Brca1 protein in cell culture (PMID: 20516115), but may introduce a deleterious splice junction effect (PMID: 17305420).",5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,7515,17305420,Functional impact of missense variants in BRCA1 predicted by supervised learning.,http://www.ncbi.nlm.nih.gov/pubmed/17305420,23383
BRCA1 D1692Y lies within the BRCT1 domain of the Brca1 protein (UniProt.org). D1692Y results in defective Brca1 protein folding and decreased transcription activity in cell culture (PMID: 20516115).,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23384
"BRCA1 D1739E does not lie within any known functional domains of the Brca1 protein (UniProt.org). D1739E results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23385
"BRCA1 D1739G does not lie within any known functional domains of the Brca1 protein (UniProt.org). D1739G results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23386
"BRCA1 D1739V does not lie within any known functional domains of the Brca1 protein (UniProt.org). D1739V results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23387
"BRCA1 D1739Y does not lie within any known functional domains of the Brca1 protein (UniProt.org). D1739Y results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23388
BRCA1 D1733G lies within the BRCT1 domain of the Brca1 protein (UniProt.org). D1733G results in BRCT binding and transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 20516115).,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23389
BRCA1 D1778G lies within the BRCT2 domain of the Brca1 protein (UniProt.org). D1778G results in BRCT binding and transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 20516115).,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23390
BRCA1 D1778N lies within the BRCT1 domain of the Brca1 protein (UniProt.org). D1778N results in BRCT binding and transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 20516115).,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23391
BRCA1 D1778Y lies within the BRCT2 domain of the Brca1 protein (UniProt.org). D1778Y results in BRCT binding and transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 20516115).,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23392
BRCA1 D1818G lies within the BRCT2 domain of the Brca1 protein (UniProt.org). D1818G results in BRCT binding and transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 20516115).,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23393
BRCA1 D1851E lies within the BRCT2 domain of the Brca1 protein (UniProt.org). D1851E results in BRCT binding and transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 20516115).,295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23394
BRCA1 E1682K lies within the BRCT1 domain of the Brca1 protein (UniProt.org). E1682K results in BRCT binding and transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 20516115).,295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23395
BRCA1 E1682V lies within the BRCT1 domain of the Brca1 protein (UniProt.org). E1682V results in BRCT binding and transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 20516115).,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23396
BRCA1 E1794D lies within the BRCT2 domain of the Brca1 protein (UniProt.org). E1794D results in BRCT binding and transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 20516115).,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23397
"BRCA1 E1836K lies within the BRCT1 domain of the Brca1 protein (UniProt.org). E1836K may result in defective BRCT binding in cell culture, but its effect on Brca1 transcription activity is unclear (PMID: 20516115, PMID: 21473589).",5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,7503,21473589,Impact of BRCA1 BRCT domain missense substitutions on phosphopeptide recognition.,http://www.ncbi.nlm.nih.gov/pubmed/21473589,23398
ERBB2 (HER2) L755_T759del results in the deletion of five amino acids in the protein kinase domain of the Erbb2 (Her2) protein from amino acids 755 to 759 (UniProt.org). L755_T759del confers a gain of function to the Erbb2 (Her2) protein as demonstrated by increased phosphorylation of Egfr and Erbb3 (Her3) and tumor growth (PMID: 23220880).,1980,23220880,Activating HER2 mutations in HER2 gene amplification negative breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23220880,23399
BRCA1 F1662S lies within the BRCT1 domain of the Brca1 protein (UniProt.org). F1662S results in BRCT binding and transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 20516115).,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23400
BRCA1 G1706A lies within the BRCT1 domain of the Brca1 protein (UniProt.org). G1706A results in BRCT binding and transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 20516115).,295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23401
"BRCA1 G1706E lies within the BRCT1 domain of the Brca1 protein (UniProt.org). G1706E results in defective Brca1 protein folding and BRCT binding, and is predicted to disrupt Brca1 protein function (PMID: 20516115).",295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23402
"BRCA1 G1738E does not lie within any known functional domains of the Brca1 protein (UniProt.org). G1738E results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23403
"BRCA1 G1738R does not lie within any known functional domains of the Brca1 protein (UniProt.org). G1738R results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23404
"BRCA1 G1763V lies within the BRCT2 domain of the Brca1 protein (UniProt.org). G1763V results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23405
BRCA1 G1788D lies within the BRCT1 domain of the Brca1 protein (UniProt.org). G1788D results in decreased Brca1 transcription activity in cell culture (PMID: 17308087).,298,17308087,Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis.,http://www.ncbi.nlm.nih.gov/pubmed/17308087,295,,,www.uniprot.org,23406
"BRCA1 G1788V lies within the BRCT2 domain of the Brca1 protein (UniProt.org). G1788V results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23407
BRCA1 G1803A lies within the BRCT2 domain of the Brca1 protein (UniProt.org). G1803A results in decreased Brca1 transcription activity in cell culture (PMID: 20516115).,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23408
"BRCA1 H1746N does not lie within any known functional domains of the Brca1 protein (UniProt.org). H1746N results in defective Brca1 protein folding and BRCT binding, and moderately decreased transcription activity in cell culture (PMID: 20516115).",5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23409
BRCA1 H1805P lies within the BRCT2 domain of the Brca1 protein (UniProt.org). H1805P results in BRCT binding and transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 20516115).,295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23410
"BRCA1 I1766S lies within the BRCT2 domain of the Brca1 protein (UniProt.org). I1766S results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23411
BRCA1 L1664P lies within the BRCT1 domain of the Brca1 protein (UniProt.org). L1664P demonstrates BRCT binding and transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 20516115).,295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23412
"BRCA1 L1764P lies within the BRCT2 domain of the Brca1 protein (UniProt.org). L1764P results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23413
"BRCA1 L1780P lies within the BRCT2 domain of the Brca1 protein (UniProt.org). L1780P results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23414
"BRCA1 L1844R lies within the BRCT2 domain of the Brca1 protein (UniProt.org). L1844R results in defective Brca1 protein folding and BRCT binding, and moderately decreased transcription activity in cell culture (PMID: 20516115).",5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23415
BRCA1 M1652T lies within the BRCT1 domain of the Brca1 protein (UniProt.org). M1652T demonstrates BRCT binding and transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 20516115).,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23416
BRCA1 M1663K lies within the BRCT1 domain of the Brca1 protein (UniProt.org). M1663K demonstrates BRCT binding and transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 20516115).,295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23417
BRCA1 M1663L lies within the BRCT1 domain of the Brca1 protein (UniProt.org). M1663L demonstrates BRCT binding and transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 20516115).,295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23418
"BRCA1 M1689R lies within the BRCT1 domain of the Brca1 protein (UniProt.org). M1689R results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23419
BRCA1 M1689T lies within the BRCT1 domain of the Brca1 protein (UniProt.org). M1689T results in defective BRCT binding and moderately decreased Brca1 transcription activity in cell culture (PMID: 20516115).,295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23420
BRCA1 M1775E lies within the BRCT1 domain of the Brca1 protein (UniProt.org). M1775E results in decreased binding to core RNA polymerase II in an in vitro assay (PMID: 10725406).,295,,,www.uniprot.org,5975,10725406,BRCA1 interaction with RNA polymerase II reveals a role for hRPB2 and hRPB10alpha in activated transcription.,http://www.ncbi.nlm.nih.gov/pubmed/10725406,23421
BRCA1 M1775K lies within the BRCT1 domain of the Brca1 protein (UniProt.org). M1775K results in defective BRCT binding and decreased Brca1 transcription activity in cell culture (PMID: 20516115).,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23422
BRCA1 M1775R lies within the BRCT2 domain of the Brca1 protein (UniProt.org). M1775R results in defective BRCT binding and decreased Brca1 transcription activity in cell culture (PMID: 20516115).,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23423
"BRCA1 M1775V lies within the BRCT2 domain of the Brca1 protein (UniProt.org). M1775V results in transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 8942979).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7577,8942979,Evidence for a transcriptional activation function of BRCA1 C-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/8942979,295,,,www.uniprot.org,23424
BRCA1 M1783I lies within the BRCT2 domain of the Brca1 protein (UniProt.org). M1783I demonstrates BRCT binding and transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 20516115).,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23425
BRCA1 M1783L lies within the BRCT1 domain of the Brca1 protein (UniProt.org). M1783L demonstrates BRCT binding and transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 20516115).,295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23426
BRCA1 M1783T lies within the BRCT2 domain of the Brca1 protein (UniProt.org). M1783T results in moderate defects in BRCT binding and Brca1 transcription activity in cell culture (PMID: 20516115).,295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23427
BRCA1 N1647K lies within the BRCT1 domain of the Brca1 protein (UniProt.org). N1647K demonstrates BRCT binding and transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 20516115).,295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23428
BRCA1 N1730S lies within the BRCT1 domain of the Brca1 protein (UniProt.org). N1730S demonstrates BRCT binding and transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 20516115).,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23429
BRCA1 N1819S lies within the BRCT2 domain of the Brca1 protein (UniProt.org). N1819S demonstrates BRCT binding and transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 20516115).,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23430
"ERBB2 (HER2) E717K does not lie within any known functional domains of the Erbb2 (Her2) protein (UniProt.org). E717K has not been biochemically characterized, but may confer resistance to Tykerb (lapatinib) (PMID: 18413839).",295,,,www.uniprot.org,5983,18413839,EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.,http://www.ncbi.nlm.nih.gov/pubmed/18413839,23431
"BRCA1 P1749R does not lie within any known functional domains of the Brca1 protein (UniProt.org). P1749R results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23432
"BRCA1 P1771L lies within the BRCT2 domain of the Brca1 protein (UniProt.org). P1771L results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23433
BRCA1 P1771R lies within the BRCT2 domain of the Brca1 protein (UniProt.org). P1771R results in moderate decrease of Brca1 transcription activity in cell culture (PMID: 20516115).,295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23434
"ERBB2 (HER2) G776delinsVC results in a deletion of a glycine (G) at amino acid 776 within the protein kinase domain of the Erbb2 (Her2) protein, combined with the insertion of a valine (V) and a cystine (C) at the same site (UniProt.org). G776delinsVC leads to constitutive activation of Erbb2 (Her2) and increased downstream signaling in cell culture (PMID: 26545934).",5974,26545934,"Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.",http://www.ncbi.nlm.nih.gov/pubmed/26545934,295,,,www.uniprot.org,23435
BRCA1 P1806A lies within the BRCT2 domain of the Brca1 protein (UniProt.org). P1806A demonstrates BRCT binding and transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 20516115).,295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23436
BRCA1 P1856S does not lie within any known functional domains of the Brca1 protein (UniProt.org). P1856S demonstrates BRCT binding and transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 20516115).,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23437
BRCA1 P1859R does not lie within any known functional domains of the Brca1 protein (UniProt.org). P1859R demonstrates BRCT binding and transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 20516115).,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23438
"ERBB2 (HER2) G776delinsLC results in a deletion of a glycine (G) at amino acid 776 within the protein kinase domain of the Erbb2 (Her2) protein, combined with the insertion of a leucine (L) and a cystine (C) at the same site (UniProt.org). G776delinsLC leads to constitutive activation of Erbb2 (Her2) and increased downstream signaling in cell culture (PMID: 26545934).",5974,26545934,"Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.",http://www.ncbi.nlm.nih.gov/pubmed/26545934,295,,,www.uniprot.org,23439
"PTPN11 D61Y lies within the SH2 1 domain of the Ptpn11 protein (UniProt.org). D61Y confers a gain of function to the Ptpn11 protein as demonstrated by increased activity of protein tyrosine phosphatase and increased proliferation in cell culture (PMID: 12717436).

",295,,,www.uniprot.org,3693,12717436,"Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.",http://www.ncbi.nlm.nih.gov/pubmed/12717436,23440
"PTPN11 D61N lies within the SH2 1 domain of the Ptpn11 protein (UniProt.org). D61N confers a gain of function to the Ptpn11 protein as demonstrated by increased activity of protein tyrosine phosphatase and increased ERK2 activation in cell culture (PMID: 15834506).
",4292,15834506,Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/15834506,295,,,www.uniprot.org,23441
"PTPN11 F71I lies within the SH2 1 domain of the Ptpn11 protein (UniProt.org). F71I confers a gain of function to the Ptpn11 protein as demonstrated by increased activity of protein tyrosine phosphatase in cell culture (PMID: 15834506).
",295,,,www.uniprot.org,4292,15834506,Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/15834506,23442
"PTPN11 T73I lies within the SH2 1 domain of the Ptpn11 protein (UniProt.org). T73I confers a gain of function to the Ptpn11 protein as demonstrated by increased activity of protein tyrosine phosphatase in cell culture (PMID: 15834506).
",295,,,www.uniprot.org,4292,15834506,Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/15834506,23443
"PTPN11 E76A lies within the SH2 1 domain of the Ptpn11 protein (UniProt.org). E76A confers a gain of function to the Ptpn11 protein as demonstrated by increased activity of protein tyrosine phosphatase in cell culture (PMID: 15834506).
",4292,15834506,Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/15834506,295,,,www.uniprot.org,23444
PTPN11 D106A does not lie within any known functional domains of the Ptpn11 protein (UniProt.org). D106A results in increased Ptpn11 phosphatase activity in an in vitro phosphatase assay (PMID: 15987685).,6017,15987685,Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes.,http://www.ncbi.nlm.nih.gov/pubmed/15987685,295,,,www.uniprot.org,23445
"PTPN11 I282V lies within the tyrosine-protein phosphatase domain of the Ptpn11 protein (UniProt.org). I282V confers a gain of function to the Ptpn11 protein as demonstrated by increased phosphatase activity in cell culture (PMID: 16358218).
",295,,,www.uniprot.org,3691,16358218,Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease.,http://www.ncbi.nlm.nih.gov/pubmed/16358218,23446
"PTPN11 M504V lies within the tyrosine-protein phosphatase domain of the Ptpn11 protein (UniProt.org). M504V confers a gain of function to the Ptpn11 protein as demonstrated by increased phosphatase activity in cell culture (PMID: 16358218).
",295,,,www.uniprot.org,3691,16358218,Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease.,http://www.ncbi.nlm.nih.gov/pubmed/16358218,23447
"PTPN11 T507K lies within the tyrosine-protein phosphatase domain of the Ptpn11 protein (UniProt.org). T507K confers a gain of function to the Ptpn11 protein as demonstrated by increased activity of protein tyrosine phosphatase and the ability to transform cells in culture (PMID: 18223690). 
",295,,,www.uniprot.org,5976,18223690,Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors.,http://www.ncbi.nlm.nih.gov/pubmed/18223690,23449
"PTPN11 V45L lies within the SH2 1 domain of the Ptpn11 protein (UniProt.org). V45L confers a gain of function to the Ptpn11 protein as demonstrated by increased phosphatase activity in an in vitro phosphatase assay (PMID: 15604238).
",3692,15604238,Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/15604238,295,,,www.uniprot.org,23450
"PTPN11 Y62C lies within the SH2 1 domain of the Ptpn11 protein (UniProt.org). Y62C confers a gain of function to the Ptpn11 protein as demonstrated by increased phosphatase activity in an in vitro phosphatase assay (PMID: 15604238).
",3692,15604238,Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/15604238,295,,,www.uniprot.org,23451
PTPN11 Y63C lies within the SH2 1 domain of the Ptpn11 protein (UniProt.org). Y63C results in increased Ptpn11 phosphatase activity in cell culture (PMID: 22711529).,6016,22711529,Counteracting effects operating on Src homology 2 domain-containing protein-tyrosine phosphatase 2 (SHP2) function drive selection of the recurrent Y62D and Y63C substitutions in Noonan syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/22711529,295,,,www.uniprot.org,23452
PTPN11 Q79R lies within the SH2 1 domain of the Ptpn11 protein (UniProt.org). Q79R confers a gain of function to the Ptpn11 protein as demonstrated by increased activity of protein tyrosine phosphatase and increased proliferation in cell culture (PMID: 16166557).,5977,16166557,Noonan syndrome mutation Q79R in Shp2 increases proliferation of valve primordia mesenchymal cells via extracellular signal-regulated kinase 1/2 signaling.,http://www.ncbi.nlm.nih.gov/pubmed/16166557,295,,,www.uniprot.org,23453
"PTPN11 S502T lies within the tyrosine-protein phosphatase domain of the Ptpn11 protein (UniProt.org). S502T has been identified in the scientific literature (PMID: 12325025) but has not been biochemically characterized and therefore, its effect on Ptpn11 protein function is unknown (PubMed, Mar 2017).
",7839,12325025,PTPN11 mutations in Noonan syndrome type I: detection of recurrent mutations in exons 3 and 13.,http://www.ncbi.nlm.nih.gov/pubmed/12325025,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23454
"FLT3 D7G does not lie within any known functional domains of the Flt3 protein (UniProt.org). D7G has been identified in the scientific literature (PMID: 27350795), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Apr 2017). ",8600,27350795,A novel BCR-ABL1 fusion gene identified by next-generation sequencing in chronic myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27350795,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23455
"FLT3 F590G does not lie within any known functional domains of the Flt3 protein (UniProt.org). F590G confers a gain of function on Flt3, as indicated by increased proliferation and upregulation of antiapoptotic genes in culture cells (PMID: 16410449). ",295,,,www.uniprot.org,2903,16410449,Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML.,http://www.ncbi.nlm.nih.gov/pubmed/16410449,23456
"FLT3 F594L does not lie within any known functional domains of the Flt3 protein (UniProt.org). F594L confers a gain of function on Flt3, as indicated by increased proliferation and upregulation of antiapoptotic genes in culture cells (PMID: 16410449). 
",2903,16410449,Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML.,http://www.ncbi.nlm.nih.gov/pubmed/16410449,295,,,www.uniprot.org,23457
"FLT3 I867S lies within the protein kinase domain of the Flt3 protein (UniProt.org). I867S confers a gain of function on Flt3, as indicated by increased proliferation and activation of STAT5 in cultured cells (PMID: 24608088).",2707,24608088,Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/24608088,295,,,www.uniprot.org,23458
FLT3 M737I lies within the protein kinase domain of the Flt3 protein (UniProt.org). M737I does not result in IL-3 independent growth of cultured cells ((PMID: 18068628). ,295,,,www.uniprot.org,2803,18068628,Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.,http://www.ncbi.nlm.nih.gov/pubmed/18068628,23459
"FLT3 S451E does not lie within any known functional domains of the Flt3 protein (UniProt.org). S451E has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Apr 2017). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,23460
"FLT3 T136N does not lie within any known functional domains of the Flt3 protein (UniProt.org). T136N has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Apr 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23461
"FLT3 V557I lies within the transmembrane domain of the Flt3 protein (PMID: 18068628). V557I has been identified in the scientific literature (PMID: 18068628), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Apr 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2803,18068628,Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.,http://www.ncbi.nlm.nih.gov/pubmed/18068628,23462
"FLT3 V579A does not lie within any known functional domains of the Flt3 protein (UniProt.org). V579A confers a gain of function on Flt3, as indicated by increased proliferation and upregulation of antiapoptotic genes in culture cells (PMID: 16410449). ",295,,,www.uniprot.org,2903,16410449,Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML.,http://www.ncbi.nlm.nih.gov/pubmed/16410449,23463
FLT3 Y364H lies within the extracellular domain of the Flt3 protein (PMID: 18068628). Y364H did not result in IL-3-independent growth of cultured cells (PMID: 18068628). ,2803,18068628,Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.,http://www.ncbi.nlm.nih.gov/pubmed/18068628,23464
"FLT3 Y591D does not lie within any known functional domains of the Flt3 protein (UniProt.org). Y591D confers a gain of function on Flt3, as indicated by increased proliferation and upregulation of antiapoptotic genes in cultured cells (PMID: 16410449). ",2903,16410449,Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML.,http://www.ncbi.nlm.nih.gov/pubmed/16410449,295,,,www.uniprot.org,23465
"FLT3 I836_M837insIRC results in the insertion of three amino acids in the protein kinase domain of the Flt3 protein between amino acids 836 and 837 (UniProt.org). I836_M837insIRC has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Apr 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23466
"EZH2 positive indicates the presence of the EZH2 gene, mRNA, and/or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,23470
"ERBB2 (HER2) E719G does not lie within any known functional domains of the Erbb2 (Her2) protein (UniProt.org). E719G has not been biochemically characterized, but may confer resistance to Tykerb (lapatinib) (PMID: 18413839).",5983,18413839,EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.,http://www.ncbi.nlm.nih.gov/pubmed/18413839,295,,,www.uniprot.org,23471
"ERBB2 (HER2) E719K does not lie within any known functional domains of the Erbb2 (Her2) protein (UniProt.org). E719K has not been biochemically characterized, however, may confer resistance to Tykerb (lapatinib) (PMID: 18413839).",5983,18413839,EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.,http://www.ncbi.nlm.nih.gov/pubmed/18413839,295,,,www.uniprot.org,23472
"ERBB2 (HER2) L726F lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). L726F confers a gain of function to the Erbb2 (Her2) protein as indicated by increased cell proliferation in culture, increased tumor growth in vivo, and localization to the perinuclear cytoplasm (PMID: 25435280).",5989,25435280,HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25435280,295,,,www.uniprot.org,23473
ERBB2 (HER2) G660D lies within the transmembrane domain of the Erbb2 (Her2) protein (UniProt.org). G660D leads to constitutive activation of Erbb2 (Her2) and increased downstream signaling in cell culture (PMID: 26545934).,5974,26545934,"Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.",http://www.ncbi.nlm.nih.gov/pubmed/26545934,295,,,www.uniprot.org,23474
ERBB2 (HER2) T733I lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). T733I is predicted to confer a gain of function to the Erbb2 (Her2) protein as indicated by weak transformation activity (PMID: 18413839).,295,,,www.uniprot.org,5983,18413839,EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.,http://www.ncbi.nlm.nih.gov/pubmed/18413839,23475
"ERBB2 (HER2) K753M lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). K753M has been described as a kinase dead mutation, demonstrating loss of Erbb2 phosphorylation (PMID: 16489002).",3589,16489002,ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/16489002,23476
"ERBB2 (HER2) K753A lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). K753A has been described as a kinase deficient mutation, demonstrating loss of Erbb2 (Her2) protein kinase activity (PMID: 22393464).",295,,,www.uniprot.org,5995,22393464,ErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22393464,23477
"ERBB2 (HER2) S760A lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). S760A did not demonstrate an independent functional effect, however, has been shown to occur with other ERBB2 (HER2) activating mutations, including L755_T759del (PMID: 23220880).",295,,,www.uniprot.org,1980,23220880,Activating HER2 mutations in HER2 gene amplification negative breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23220880,23478
ERBB2 (HER2) D769A lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). D769A is predicted to confer a loss of function to the Erbb2 (Her2) protein as indicated by loss of Erbb2 (Her2) kinase activity (PMID: 23843458).,6001,23843458,Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface.,http://www.ncbi.nlm.nih.gov/pubmed/23843458,295,,,www.uniprot.org,23479
"ALK negative indicates a lack of the ALK gene, mRNA, and/or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,23480
"ERBB2 (HER2) P780L lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). P780L has not been biochemically characterized, but has been demonstrated to confer strong resistance to Tykerb (lapatinib) (PMID: 18413839).",295,,,www.uniprot.org,5983,18413839,EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.,http://www.ncbi.nlm.nih.gov/pubmed/18413839,23481
TP53 exon 8 indicates an unspecified mutation has occurred in exon 8 of the TP53 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,23482
"EGFR F856_G857insYIV results in the insertion of three amino acids in the protein kinase domain of the Egfr protein between amino acids 856 and 857 (UniProt.org). F856_G857insYIV has not been characterized in the scientific literature and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23483
"EGFR I740_P741insIHR results in the insertion of three amino acids in the protein kinase domain of the Egfr protein between amino acids 740 and 741 (UniProt.org). I740_P741insIHR has not been characterized in the scientific literature and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23484
"EGFR L792_M793insHIV results in the insertion of three amino acids in the protein kinase domain of the Egfr protein between amino acids 792 and 793 (UniProt.org). L792_M793insHIV has not been characterized, but can be predicted to result in a gain of function based on the effect of other Egfr exon 20 insertions (PMID: 24353160).",295,,,www.uniprot.org,440,24353160,"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24353160,23485
"EGFR T710del results in the deletion of an amino acid in the protein kinase domain of the Egfr protein at amino acid 710 (UniProt.org). T710del has been identified in the scientific literature (PMID: 17094398), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9197,17094398,Gefitinib efficacy associated with multiple expression of HER family in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/17094398,23488
"CDKN2A A57V lies within the ANK repeat 2 of the Cdkn2a protein (UniProt.org). A57V results in a partial loss of Cdk4 binding but had no effect on cell proliferation and therefore, its functional effect on the Cdkn2a protein is unknown (PMID: 19260062).",295,,,www.uniprot.org,687,19260062,"Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients.",http://www.ncbi.nlm.nih.gov/pubmed/19260062,23509
"CDKN2A A60R lies within the ankryin repeat domain of the Cdkn2a protein (UniProt.org). A60R confers a loss of function to the Cdkn2a protein as demonstrated by loss of Cdk4 and Cdk6 binding, and aberrant proliferation of cells in culture (PMID: 19260062, PMID: 20340136).",3095,20340136,Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.,http://www.ncbi.nlm.nih.gov/pubmed/20340136,295,,,www.uniprot.org,687,19260062,"Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients.",http://www.ncbi.nlm.nih.gov/pubmed/19260062,23510
"CDKN2A A60V lies within the ankryin repeat domain of the Cdkn2a protein (UniProt.org). A60V confers a loss of function to the Cdkn2a protein as demonstrated by loss of Cdk4 binding, and aberrant proliferation of cells in culture (PMID: 19260062).",295,,,www.uniprot.org,687,19260062,"Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients.",http://www.ncbi.nlm.nih.gov/pubmed/19260062,23511
CDKN2A D74Y lies within the ankyrin repeat domain of the Cdkn2a protein (UniProt.org). D74Y confers a loss of function to the Cdkn2a protein as demonstrated by loss of Cdk4 binding (PMID: 19260062).,295,,,www.uniprot.org,687,19260062,"Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients.",http://www.ncbi.nlm.nih.gov/pubmed/19260062,23512
"CDKN2A E69G lies within ANK repeat 2 of the Cdkn2a (p16INK4a) protein (UniProt.org). E69G confers a loss of function to the Cdkn2a (p16INK4a) protein as demonstrated by loss of Cdk4 and Cdk6 binding, and aberrant proliferation of cells in culture (PMID: 19260062, PMID: 20340136).",3095,20340136,Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.,http://www.ncbi.nlm.nih.gov/pubmed/20340136,687,19260062,"Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients.",http://www.ncbi.nlm.nih.gov/pubmed/19260062,23513
BRCA1 Q1785H lies within the BRCT2 domain of the Brca1 protein (UniProt.org). Q1785H demonstrates BRCT binding and transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 20516115).,295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23514
"BRCA1 Q1811R lies within the BRCT2 domain of the Brca1 protein (UniProt.org). Q1811R results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23515
BRCA1 R1726G lies within the BRCT1 domain of the Brca1 protein (UniProt.org). R1726G demonstrates BRCT binding and transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 20516115).,295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23516
"BRCA1 R1751P does not lie within any known functional domains of the Brca1 protein (UniProt.org). R1751P results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23517
BRCA1 R1751Q does not lie within any known functional domains of the Brca1 protein (UniProt.org). R1751Q demonstrates BRCT binding and transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 20516115).,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23518
"MLH1 L749P does not lie within any known functional domains of the Mlh1 protein (UniProt.org). L749P confers a loss of function to the Mlh1 protein as demonstrated by protein loss via immunostaining and inefficient mismatch repair activity (PMID: 14504054, PMID: 20533529).",6018,14504054,Microsatellite instability and mutation analysis among southern Italian patients with colorectal carcinoma: detection of different alterations accounting for MLH1 and MSH2 inactivation in familial cases.,http://www.ncbi.nlm.nih.gov/pubmed/14504054,295,,,www.uniprot.org,6019,20533529,Identification of Lynch syndrome mutations in the MLH1-PMS2 interface that disturb dimerization and mismatch repair.,http://www.ncbi.nlm.nih.gov/pubmed/20533529,23519
"BRCA1 R1753T does not lie within any known functional domains of the Brca1 protein (UniProt.org). R1753T results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23520
"BRCA1 R1835P lies within the BRCT1 domain of the Brca1 protein (UniProt.org). R1835P results in impaired binding to BRCT, but demonstrated transcription activity similar to wild-type Brca1 in cell culture (PMID: 20516115).",5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23521
BRCA1 S1651F lies within the BRCT1 domain of the Brca1 protein (UniProt.org). S1651F demonstrates BRCT binding and transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 20516115).,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23522
BRCA1 S1655F lies within the BRCT1 domain of the Brca1 protein (UniProt.org). S1655F results in defective BRCT binding and decreased Brca1 transcription activity in cell culture (PMID: 20516115).,295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23523
BRCA1 S1715C lies within the BRCT1 domain of the Brca1 protein (UniProt.org). S1715C results in decreased Brca1 transcription activity in cell culture (PMID: 20516115).,295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23524
"BRCA1 S1715N lies within the BRCT1 domain of the Brca1 protein (UniProt.org). S1715N results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23525
"BRCA1 S1715R lies within the BRCT1 domain of the Brca1 protein (UniProt.org). S1715R results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23526
"BRCA1 S1722F lies within the BRCT1 domain of the Brca1 protein (UniProt.org). S1722F results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23527
"BRCA1 S1841R lies within the BRCT2 domain of the Brca1 protein (UniProt.org). S1841R results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115). ",5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23528
"BRCA1 S1841N lies within the BRCT2 domain of the Brca1 protein (UniProt.org). S1841N results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23529
"BRCA1 T1685A lies within the BRCT1 domain of the Brca1 protein (UniProt.org). T1685A results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23530
"BRCA1 T1685I lies within the BRCT1 domain of the Brca1 protein (UniProt.org). T1685I results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23531
"BRCA1 T1691I lies within the BRCT1 domain of the Brca1 protein (UniProt.org). T1691I results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23532
"BRCA1 T1691K lies within the BRCT1 domain of the Brca1 protein (UniProt.org). T1691K results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23533
BRCA1 T1700A lies within the BRCT1 domain of the Brca1 protein (UniProt.org). T1700A results in defective Brca1 binding to BRCT and decreased transcription activity in cell culture (PMID: 20516115). ,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23534
BRCA1 T1720A lies within the BRCT1 domain of the Brca1 protein (UniProt.org). T1720A demonstrates BRCT binding and transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 20516115).,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23535
"BRCA1 V1653M lies within the BRCT1 domain of the Brca1 protein (UniProt.org). V1653M results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23536
BRCA1 V1665M lies within the BRCT1 domain of the Brca1 protein (UniProt.org). V1665M demonstrates BRCT binding and transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 20516115).,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23537
"BRCA1 V1696L lies within the BRCT1 domain of the Brca1 protein (UniProt.org). V1696L results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23538
"BRCA1 V1714A lies within the BRCT1 domain of the Brca1 protein (UniProt.org). V1714A has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, Jan 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,23539
"BRCA1 V1714G lies within the BRCT1 domain of the Brca1 protein (UniProt.org). V1714G results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23540
BRCA1 V1736A lies within the BRCT1 domain of the Brca1 protein (UniProt.org). V1736A results in defective Brca1 protein folding and decreased transcription activity in cell culture (PMID: 20516115).,295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23541
"BRCA1 V1736G lies within the BRCT1 domain of the Brca1 protein (UniProt.org). V1736G results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23542
BRCA1 V1741G does not lie within any known functional domains of the Brca1 protein (UniProt.org). V1741G results in defective Brca1 binding to BRCT and decreased transcription activity in cell culture (PMID: 20516115).,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23543
BRCA1 V1808A lies within the BRCT2 domain of the Brca1 protein (UniProt.org). V1808A demonstrates BRCT binding and transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 20516115).,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23544
BRCA1 V1809A lies within the BRCT2 domain of the Brca1 protein (UniProt.org). V1809A results in moderate decrease of Brca1 binding to BRCT and transcription activity in cell culture (PMID: 20516115).,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23545
"BRCA1 V1809F lies within the BRCT2 domain of the Brca1 protein (UniProt.org). V1809F results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23546
BRCA1 V1810G lies within the BRCT1 domain of the Brca1 protein (UniProt.org). V1810G results in decreased Brca1 transcription activity in cell culture (PMID: 20516115).,295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23547
"BRCA1 V1838E lies within the BRCT2 domain of the Brca1 protein (UniProt.org). V1838E results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23548
"BRCA1 W1718C lies within the BRCT1 domain of the Brca1 protein (UniProt.org). W1718C results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23549
"BRCA1 W1718S lies within the BRCT1 domain of the Brca1 protein (UniProt.org). W1718S results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23550
EGFR T725M lies within the protein kinase domain of the Egfr protein (Uniprot.org). T725M results in increased Egfr autophosphorylation and downstream signaling in cell culture (PMID: 24743239).,295,,,www.uniprot.org,3812,24743239,Prediction and prioritization of rare oncogenic mutations in the cancer Kinome using novel features and multiple classifiers.,http://www.ncbi.nlm.nih.gov/pubmed/24743239,23551
"BRCA1 W1837C lies within the BRCT2 domain of the Brca1 protein (UniProt.org). W1837C results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23552
"BRCA1 W1837G lies within the BRCT2 domain of the Brca1 protein (UniProt.org). W1837G results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23553
"BRCA1 W1837R lies within the BRCT2 domain of the Brca1 protein (UniProt.org). W1837R results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,295,,,www.uniprot.org,23554
"BRCA1 Y1853C lies within the BRCT2 domain of the Brca1 protein (UniProt.org). Y1853C results in defective Brca1 protein folding and BRCT binding, and decreased transcription activity in cell culture (PMID: 20516115).",295,,,www.uniprot.org,5972,20516115,Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.,http://www.ncbi.nlm.nih.gov/pubmed/20516115,23555
BRCA1 A1752G does not lie within any known functional domains of the Brca1 protein (UniProt.org). A1752G results in decreased Brca1 transcription activity in cell culture (PMID: 23842040).,295,,,www.uniprot.org,6020,23842040,Functional analysis of BRCA1 missense variants of uncertain significance in Japanese breast cancer families.,http://www.ncbi.nlm.nih.gov/pubmed/23842040,23556
"EGFR T783A lies within the protein kinase domain of the Egfr protein (UniProt.org). T783A has been identified in the scientific literature (PMID: 15897572), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23557
"EGFR T847I lies within the protein kinase domain of the Egfr protein (Uniprot.org). T847I has been identified in the scientific literature PMID: 24743239), but has not been biochemically characterized and therefore its effect on Egfr protein is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,3812,24743239,Prediction and prioritization of rare oncogenic mutations in the cancer Kinome using novel features and multiple classifiers.,http://www.ncbi.nlm.nih.gov/pubmed/24743239,23558
"BRCA1 A1789T lies within the BRCT2 domain of the Brca1 protein (UniProt.org). A1789T results in dysregulation of expression of genes controlling cell cycle and genome integrity, and is considered pathogenic in cancer (PMID: 22646717).",295,,,www.uniprot.org,6021,22646717,Effects on human transcriptome of mutated BRCA1 BRCT domain: a microarray study.,http://www.ncbi.nlm.nih.gov/pubmed/22646717,23559
"BRCA1 C1767S lies within the BRCT1 domain of the Brca1 protein (UniProt.org). C1767S has not been biochemically characterized, but supports cell growth to similar level of wild-type Brca1 in culture (PMID: 23867111).",6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,295,,,www.uniprot.org,23560
BRCA1 A1843T lies within the BRCT2 domain of the Brca1 protein (UniProt.org). A1843T results in a loss of Brca1 transcription activity in yeast (PMID: 12496477).,6023,12496477,Mutations in the BRCT domain confer temperature sensitivity to BRCA1 in transcription activation.,http://www.ncbi.nlm.nih.gov/pubmed/12496477,295,,,www.uniprot.org,23561
"EGFR V689M lies within the juxtamembrane domain of the Egfr protein (PMID: 21165163). V698M (also referred to as V665M) results in constitutive activation of Egfr and is transforming in cell culture, and leads to increased tumor growth in mouse models (PMID: 19560417, PMID: 21165163).",6024,21165163,EGFR-mutated lung cancer: a paradigm of molecular oncology.,http://www.ncbi.nlm.nih.gov/pubmed/21165163,2536,19560417,The juxtamembrane region of the EGF receptor functions as an activation domain.,http://www.ncbi.nlm.nih.gov/pubmed/19560417,23562
BRCA1 C24R lies within the RING-type zinc finger region of the Brca1 protein (UniProt.org). C24R confers a loss of function on Brca1 protein as indicated by defective homologous recombination and centrosome duplication in cell culture (PMID: 21725363).,6025,21725363,Functional differences among BRCA1 missense mutations in the control of centrosome duplication.,http://www.ncbi.nlm.nih.gov/pubmed/21725363,295,,,www.uniprot.org,23563
"EGFR V765A lies within the protein kinase domain of the Egfr protein (UniProt.org). V765A has been identified in the scientific literature (PMID: 15897572, PMID: 19671843, PMID: 20346742), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",9229,19671843,Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.,http://www.ncbi.nlm.nih.gov/pubmed/19671843,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9230,20346742,Epidermal growth factor receptor mutation and diverse tumors: case report and concise literature review.,http://www.ncbi.nlm.nih.gov/pubmed/20346742,4837,15897572,Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/15897572,23564
BRCA1 M18T does not lie within any known functional domains of the Brca1 protein (UniProt.org). M18T confers a loss of function on Brca1 protein as indicated by defective homologous recombination and centrosome duplication in cell culture (PMID: 21725363).,6025,21725363,Functional differences among BRCA1 missense mutations in the control of centrosome duplication.,http://www.ncbi.nlm.nih.gov/pubmed/21725363,295,,,www.uniprot.org,23565
"EGFR V765L lies within the cytoplasmic domain of the Egfr protein between (UniProt.org). V765L has not been characterized in the scientific literature and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23566
BRCA1 I21V does not lie within any known functional domains of the Brca1 protein (UniProt.org). I21V confers a loss of function on Brca1 protein as indicated by impaired centrosome duplication in cell culture (PMID: 21725363).,6025,21725363,Functional differences among BRCA1 missense mutations in the control of centrosome duplication.,http://www.ncbi.nlm.nih.gov/pubmed/21725363,295,,,www.uniprot.org,23567
BRCA1 C27A lies within the RING-type zinc finger region of the Brca1 protein (UniProt.org). C27A confers a loss of function on Brca1 protein as indicated by defective homologous recombination and centrosome duplication in cell culture (PMID: 21725363).,6025,21725363,Functional differences among BRCA1 missense mutations in the control of centrosome duplication.,http://www.ncbi.nlm.nih.gov/pubmed/21725363,295,,,www.uniprot.org,23568
BRCA1 I31M lies within the RING-type zinc finger region of the Brca1 protein (UniProt.org). I31M confers a loss of function on Brca1 protein as indicated by impaired centrosome duplication in cell culture (PMID: 21725363).,6025,21725363,Functional differences among BRCA1 missense mutations in the control of centrosome duplication.,http://www.ncbi.nlm.nih.gov/pubmed/21725363,295,,,www.uniprot.org,23569
BRCA1 T37R lies within the RING-type zinc finger region of the Brca1 protein (UniProt.org). T37R confers a loss of function on Brca1 protein as indicated by defective homologous recombination in cell culture (PMID: 21725363).,6025,21725363,Functional differences among BRCA1 missense mutations in the control of centrosome duplication.,http://www.ncbi.nlm.nih.gov/pubmed/21725363,295,,,www.uniprot.org,23570
BRCA1 C39Y lies within the RING-type zinc finger region of the Brca1 protein (UniProt.org). C39Y confers a loss of function on Brca1 protein as indicated by defective homologous recombination and centrosome duplication in cell culture (PMID: 21725363).,295,,,www.uniprot.org,6025,21725363,Functional differences among BRCA1 missense mutations in the control of centrosome duplication.,http://www.ncbi.nlm.nih.gov/pubmed/21725363,23571
"EGFR V802I lies within the protein kinase domain of the Egfr protein between (UniProt.org). V802I has not been characterized in the scientific literature and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,23572
BRCA1 H41R lies within the RING-type zinc finger region of the Brca1 protein (UniProt.org). H41R confers a loss of function on Brca1 protein as indicated by defective homologous recombination and centrosome duplication in cell culture (PMID: 21725363).,295,,,www.uniprot.org,6025,21725363,Functional differences among BRCA1 missense mutations in the control of centrosome duplication.,http://www.ncbi.nlm.nih.gov/pubmed/21725363,23573
BRCA1 I42V lies within the RING-type zinc finger region of the Brca1 protein (UniProt.org). I42V confers a loss of function on Brca1 protein as indicated by defective centrosome duplication in cell culture (PMID: 21725363).,295,,,www.uniprot.org,6025,21725363,Functional differences among BRCA1 missense mutations in the control of centrosome duplication.,http://www.ncbi.nlm.nih.gov/pubmed/21725363,23574
BRCA1 C44F lies within the RING-type zinc finger region of the Brca1 protein (UniProt.org). C44F confers a loss of function on Brca1 protein as indicated by defective homologous recombination and centrosome duplication in cell culture (PMID: 21725363).,295,,,www.uniprot.org,6025,21725363,Functional differences among BRCA1 missense mutations in the control of centrosome duplication.,http://www.ncbi.nlm.nih.gov/pubmed/21725363,23575
BRCA1 C47G lies within the RING-type zinc finger region of the Brca1 protein (UniProt.org). C47G confers a loss of function on Brca1 protein as indicated by defective homologous recombination and centrosome duplication in cell culture (PMID: 21725363).,295,,,www.uniprot.org,6025,21725363,Functional differences among BRCA1 missense mutations in the control of centrosome duplication.,http://www.ncbi.nlm.nih.gov/pubmed/21725363,23576
"EGFR V843I lies within the protein kinase domain of the Egfr protein (UniProt.org). V843I leads increased Egfr phosphorylation and activation of Stat5 and Erk in the presence of Egf compared to wild-type Egfr, is transforming in cell culture, and is associated with drug resistance (PMID: 25057940).",6026,25057940,"V843I, a lung cancer predisposing EGFR mutation, is responsible for resistance to EGFR tyrosine kinase inhibitors.",http://www.ncbi.nlm.nih.gov/pubmed/25057940,295,,,www.uniprot.org,23577
BRCA1 L52F lies within the RING-type zinc finger region of the Brca1 protein (UniProt.org). L52F confers a loss of function on Brca1 protein as indicated by impaired centrosome duplication in cell culture (PMID: 21725363).,6025,21725363,Functional differences among BRCA1 missense mutations in the control of centrosome duplication.,http://www.ncbi.nlm.nih.gov/pubmed/21725363,295,,,www.uniprot.org,23578
BRCA1 D67Y does not lie within any known functional domains of the Brca1 protein (UniProt.org). D67Y confers a loss of function on Brca1 protein as indicated by impaired centrosome duplication in cell culture (PMID: 21725363).,6025,21725363,Functional differences among BRCA1 missense mutations in the control of centrosome duplication.,http://www.ncbi.nlm.nih.gov/pubmed/21725363,295,,,www.uniprot.org,23579
BRCA1 R71G does not lie within any known functional domains of the Brca1 protein (UniProt.org). R71G demonstrates homologous recombination and centrosome duplication similar to wild-type Brca1 in cell culture (PMID: 21725363).,6025,21725363,Functional differences among BRCA1 missense mutations in the control of centrosome duplication.,http://www.ncbi.nlm.nih.gov/pubmed/21725363,295,,,www.uniprot.org,23580
"BRCA1 C24Y lies within the RING-type zinc finger region of the Brca1 protein (UniProt.org). C24Y has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23581
"EGFR V851I lies within the protein kinase domain of the Egfr protein (UniProt.org). V851I has not been biochemically characterized, but is associated with resistance to Egfr inhibitors in patients (PMID: 16152581, PMID: 15870435).",295,,,www.uniprot.org,6027,16152581,Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16152581,3268,15870435,Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/15870435,23582
BRCA1 C39R lies within the RING-type zinc finger region of the Brca1 protein (UniProt.org). C39R results in impaired Brca1 binding to E2 and loss of E3 ligase activity in yeast (PMID: 16403807).,6028,16403807,Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility.,http://www.ncbi.nlm.nih.gov/pubmed/16403807,295,,,www.uniprot.org,23583
BRCA1 C39S lies within the RING-type zinc finger region of the Brca1 protein (UniProt.org). C39S results in weakened Brca1 binding to Bard1 in yeast (PMID: 16403807).,6028,16403807,Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility.,http://www.ncbi.nlm.nih.gov/pubmed/16403807,295,,,www.uniprot.org,23584
"BRCA1 C44Y lies within the RING-type zinc finger region of the Brca1 protein (UniProt.org). C44Y has not been biochemically characterized, but is considered deleterious to Brca1 protein function based on a predictive algorithm, suggesting loss of ubiquitin protein ligase E3 (E3) activity (PMID: 19543972).",6030,19543972,Characterization of BRCA1 ring finger variants of uncertain significance.,http://www.ncbi.nlm.nih.gov/pubmed/19543972,295,,,www.uniprot.org,23588
BRCA1 C64G lies within the RING-type zinc finger region of the Brca1 protein (UniProt.org). C64G confers a loss of function on Brca1 protein as indicated by failure to repair DNA double strand break in cell culture (PMID: 10635334).,295,,,www.uniprot.org,6031,10635334,Genetic analysis of BRCA1 function in a defined tumor cell line.,http://www.ncbi.nlm.nih.gov/pubmed/10635334,23589
"BRCA1 E29V lies within the RING-type zinc finger region of the Brca1 protein (UniProt.org). E29V has not been characterized, but is predicted to weaken binding to the E2 ubiquitin conjugative enzyme UbcH5a by structural modeling (PMID: 16403807).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6028,16403807,Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility.,http://www.ncbi.nlm.nih.gov/pubmed/16403807,23591
"BRCA1 E60L does not lie within any known functional domains of the Brca1 protein (UniProt.org). E60L has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23592
"BRCA1 F79S does not lie within any known functional domains of the Brca1 protein (UniProt.org). F79S has not been biochemically characterized, but is predicted to change packing of the Brca1 RING-domain to helical domain by structural modeling (PMID: 16403807).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6028,16403807,Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility.,http://www.ncbi.nlm.nih.gov/pubmed/16403807,23593
"BRCA1 G57R lies within the RING-type zinc finger region of the Brca1 protein (UniProt.org). G57R has not been characterized, but may alter packing with E2 or within RING by structural modeling (PMID: 16403807).",6028,16403807,Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility.,http://www.ncbi.nlm.nih.gov/pubmed/16403807,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23594
"BRCA1 I15T does not lie within any known functional domains of the Brca1 protein (UniProt.org). I15T has not been characterized, but is predicted to prevent interaction with the E2 ubiquitin conjugating enzyme UbcH5a by structural modeling (PMID: 16403807).",6028,16403807,Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility.,http://www.ncbi.nlm.nih.gov/pubmed/16403807,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23595
"BRCA1 S4F does not lie within any known functional domains of the Brca1 protein (UniProt.org). S4F demonstrates variable effects on homologous recombination in cell culture (PMID: 23867111), and therefore its effect on Brca1 protein function is unknown. ",6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,295,,,www.uniprot.org,23600
"BRCA1 D1344H does not lie within any known functional domains of the Brca1 protein (UniProt.org). D1344H has been identified in sequencing studies (PMID: 25416589), but has not been biochemically characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Jan 2017).",7501,25416589,Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25416589,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23602
"BRCA1 D1344N does not lie within any known functional domains of the Brca1 protein (UniProt.org). D1344N has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, Jan 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,23604
"BRCA1 N1309H does not lie within any known functional domains of the Brca1 protein (UniProt.org). N1309H has not been characterized and in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23605
"BRCA1 N1309I does not lie within any known functional domains of the Brca1 protein (UniProt.org). N1309I has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23606
BRCA1 T826K does not lie within any known functional domains of the Brca1 protein (UniProt.org). T826K confers a loss of function on Brca1 protein as indicated by failure to repair DNA double strand break in cell culture (PMID: 10635334).,295,,,www.uniprot.org,6031,10635334,Genetic analysis of BRCA1 function in a defined tumor cell line.,http://www.ncbi.nlm.nih.gov/pubmed/10635334,23607
BRCA1 E33A lies within the RING-type zinc finger region of the Brca1 protein (UniProt.org). E33A confers a loss of function on Brca1 protein as indicated by impaired growth inhibition and nuclear spot formation in yeast (PMID: 21922593).,295,,,www.uniprot.org,6035,21922593,Assessment of human Nter and Cter BRCA1 mutations using growth and localization assays in yeast.,http://www.ncbi.nlm.nih.gov/pubmed/21922593,23608
"BRCA1 M1? indicates a disruption of the methionine (M) start codon with an unknown translational effect on the Brca1 protein. M1? has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, Jun 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,23610
BRCA1 N1819Y lies within the BRCT2 domain of the Brca1 protein (UniProt.org). N1819Y results in colony size similar to wild-type Brca1 in yeast (PMID: 15004537).,295,,,www.uniprot.org,6037,15004537,Functional characterization of BRCA1 sequence variants using a yeast small colony phenotype assay.,http://www.ncbi.nlm.nih.gov/pubmed/15004537,23611
"CDKN2A G101W lies within ANK repeat 3 of the Cdkn2a (p16INK4a) protein (UniProt.org). G101W confers a loss of function to the Cdkn2a (p16INK4a) protein as demonstrated by loss of Cdk4 binding, and aberrant proliferation of cells in culture (PMID: 19260062, PMID: 20340136).",687,19260062,"Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients.",http://www.ncbi.nlm.nih.gov/pubmed/19260062,3095,20340136,Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.,http://www.ncbi.nlm.nih.gov/pubmed/20340136,295,,,www.uniprot.org,23613
"CDKN2A G35A lies within ANK repeat 1 of the Cdkn2a (p16INK4a) protein (UniProt.org). G35A confers a loss of function to the Cdkn2a (p16INK4a) protein, as demonstrated by a partial loss of Cdk4 binding and aberrant proliferation of cells in culture (PMID: 19260062).",687,19260062,"Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients.",http://www.ncbi.nlm.nih.gov/pubmed/19260062,295,,,www.uniprot.org,23614
BRCA1 T1720I lies within the BRCT1 domain of the Brca1 protein (UniProt.org). T1720I results in colony size similar to wild-type Brca1 in yeast (PMID: 15004537).,6037,15004537,Functional characterization of BRCA1 sequence variants using a yeast small colony phenotype assay.,http://www.ncbi.nlm.nih.gov/pubmed/15004537,295,,,www.uniprot.org,23615
"CDKN2A G35R lies within the ANK repeat 1 of the Cdkn2a protein (UniProt.org). G35R has been identified in sequencing studies (PMID: 25787093), but has not been biochemically characterized and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Jul 2017).",7545,25787093,"Prevalence of Germline BAP1, CDKN2A, and CDK4 Mutations in an Australian Population-Based Sample of Cutaneous Melanoma Cases.",http://www.ncbi.nlm.nih.gov/pubmed/25787093,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23616
BRCA1 V1804A lies within the BRCT2 domain of the Brca1 protein (UniProt.org). V1804A results in colony size similar to wild-type Brca1 in yeast (PMID: 15004537). ,6037,15004537,Functional characterization of BRCA1 sequence variants using a yeast small colony phenotype assay.,http://www.ncbi.nlm.nih.gov/pubmed/15004537,295,,,www.uniprot.org,23617
BRCA1 V1804D lies within the BRCT2 domain of the Brca1 protein (UniProt.org). V1804D results in colony size similar to wild-type Brca1 in yeast (PMID: 15004537).,6037,15004537,Functional characterization of BRCA1 sequence variants using a yeast small colony phenotype assay.,http://www.ncbi.nlm.nih.gov/pubmed/15004537,295,,,www.uniprot.org,23618
"CDKN2A G35V lies within the ANK repeat 1 of the Cdkn2a (p16INK4a) protein (UniProt.org). G35V confers a loss of function to the Cdkn2a (p16INK4a) protein as demonstrated by a loss of Cdk4 binding, and aberrant proliferation of cells in culture (PMID: 19260062).",295,,,www.uniprot.org,687,19260062,"Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients.",http://www.ncbi.nlm.nih.gov/pubmed/19260062,23619
"BRCA1 L1854P lies within the BRCT2 domain of the Brca1 protein (UniProt.org). L1854P has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, Jan 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,23620
"CDKN2A G67R lies within ANK repeat 2 of the Cdkn2a (p16INK4a) protein (UniProt.org). G67R confers a loss of function to the Cdkn2a (p16INK4a) protein as demonstrated by a loss of Cdk4 binding, and aberrant proliferation of cells in culture (PMID: 19260062).",295,,,www.uniprot.org,687,19260062,"Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients.",http://www.ncbi.nlm.nih.gov/pubmed/19260062,23621
BRCA1 S1841A lies within the BRCT2 domain of the Brca1 protein (UniProt.org). S1841A results in decreased Brca1 transcription activity in cell culture (PMID: 11016938).,295,,,www.uniprot.org,6038,11016938,A functional comparison of BRCA1 C-terminal domains in transcription activation and chromatin remodeling.,http://www.ncbi.nlm.nih.gov/pubmed/11016938,23622
"CDKN2A D84G lies within ANK repeat 2 of the Cdkn2a (p16INK4a) protein (UniProt.org). D84G confers a loss of function to the Cdkn2a (p16INK4a) protein as demonstrated by a loss of Cdk binding, defective kinase inhibition, and aberrant proliferation of cells in culture (PMID: 10491434).",295,,,www.uniprot.org,3067,10491434,Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors.,http://www.ncbi.nlm.nih.gov/pubmed/10491434,23623
"BRCA1 D1778H lies within the BRCT2 domain of the Brca1 protein (UniProt.org). D1778H has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23624
BRCA1 E1660G lies within the BRCT1 domain of the Brca1 protein (UniProt.org). E1660G results in a loss of Brca1 transcription activity in yeast (PMID: 12496477).,6023,12496477,Mutations in the BRCT domain confer temperature sensitivity to BRCA1 in transcription activation.,http://www.ncbi.nlm.nih.gov/pubmed/12496477,295,,,www.uniprot.org,23625
BRCA1 E1735K lies within the BRCT1 domain of the Brca1 protein (UniProt.org). E1735K demonstrates conflicting effects on Brca1 transcription activity in culture (PMID: 23867111).,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,295,,,www.uniprot.org,23626
BRCA1 F1704S lies within the BRCT1 domain of the Brca1 protein (UniProt.org). F1704S results in a loss of Brca1 transcription activity in yeast (PMID: 15004537).,295,,,www.uniprot.org,6023,12496477,Mutations in the BRCT domain confer temperature sensitivity to BRCA1 in transcription activation.,http://www.ncbi.nlm.nih.gov/pubmed/12496477,23627
BRCA1 F1734L lies within the BRCT1 domain of the Brca1 protein (UniProt.org). F1734L results in a temperature-sensitive loss of Brca1 transcription activity in yeast (PMID: 12496477).,295,,,www.uniprot.org,6023,12496477,Mutations in the BRCT domain confer temperature sensitivity to BRCA1 in transcription activation.,http://www.ncbi.nlm.nih.gov/pubmed/12496477,23628
"BRCA1 F1734S lies within the BRCT1 domain of the Brca1 protein (UniProt.org). F1734S has not been characterized, but is predicted to result in decreased stability of Brca1 and Tp53 binding by computational modeling (PMID: 17161371). ",7502,17161371,"""Similarity trap"" in protein-protein interactions could be carcinogenic: simulations of p53 core domain complexed with 53BP1 and BRCA1 BRCT domains.",http://www.ncbi.nlm.nih.gov/pubmed/17161371,295,,,www.uniprot.org,23629
BRCA1 F1761I lies within the BRCT2 domain of the Brca1 protein (UniProt.org). F1761I results in a loss of Brca1 transcription activity in yeast (PMID: 10811118).,295,,,www.uniprot.org,6039,10811118,Functional assay for BRCA1: mutagenesis of the COOH-terminal region reveals critical residues for transcription activation.,http://www.ncbi.nlm.nih.gov/pubmed/10811118,23630
BRCA1 F1761S lies within the BRCT2 domain of the Brca1 protein (UniProt.org). F1761S results in a loss of Brca1 transcription activity in yeast (PMID: 10811118).,6039,10811118,Functional assay for BRCA1: mutagenesis of the COOH-terminal region reveals critical residues for transcription activation.,http://www.ncbi.nlm.nih.gov/pubmed/10811118,295,,,www.uniprot.org,23631
BRCA1 G1656D lies within the BRCT1 domain of the Brca1 protein (UniProt.org). G1656D demonstrates peptide binding affinity similar to wild-type Brca1 protein (PMID: 21473589).,7503,21473589,Impact of BRCA1 BRCT domain missense substitutions on phosphopeptide recognition.,http://www.ncbi.nlm.nih.gov/pubmed/21473589,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23632
BRCA1 G1743R does not lie within any known functional domains of the Brca1 protein (UniProt.org). G1743R results in a loss of Brca1 transcription activity in yeast (PMID: 12496477).,6023,12496477,Mutations in the BRCT domain confer temperature sensitivity to BRCA1 in transcription activation.,http://www.ncbi.nlm.nih.gov/pubmed/12496477,295,,,www.uniprot.org,23634
BRCA1 H1686Q lies within the BRCT1 domain of the Brca1 protein (UniProt.org). H1686Q results in a temperature-sensitive loss of Brca1 transcription activity (PMID: 12496477).,295,,,www.uniprot.org,6023,12496477,Mutations in the BRCT domain confer temperature sensitivity to BRCA1 in transcription activation.,http://www.ncbi.nlm.nih.gov/pubmed/12496477,23635
BRCA1 I1807S lies within the BRCT2 domain of the Brca1 protein (UniProt.org). I1807S results in a loss of Brca1 transcription activity in yeast (PMID: 12496477).,6023,12496477,Mutations in the BRCT domain confer temperature sensitivity to BRCA1 in transcription activation.,http://www.ncbi.nlm.nih.gov/pubmed/12496477,295,,,www.uniprot.org,23639
"BRCA1 K1702E lies within the BRCT1 domain of the Brca1 protein (UniProt.org). K1702E confers a loss of function on Brca1, indicated by decreased transcription activation in a yeast-based assay (PMID: 10811118).",6039,10811118,Functional assay for BRCA1: mutagenesis of the COOH-terminal region reveals critical residues for transcription activation.,http://www.ncbi.nlm.nih.gov/pubmed/10811118,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23641
BRCA1 L1657P lies within the BRCT1 domain of the Brca1 protein (UniProt.org). L1657P results in a loss of Brca1 transcription activity in yeast (PMID: 12496477).,6023,12496477,Mutations in the BRCT domain confer temperature sensitivity to BRCA1 in transcription activation.,http://www.ncbi.nlm.nih.gov/pubmed/12496477,295,,,www.uniprot.org,23642
BRCA1 L1705P lies within the BRCT1 domain of the Brca1 protein (UniProt.org). L1705P results in a loss of Brca1 transcription activity in yeast (PMID: 10811118).,295,,,www.uniprot.org,6039,10811118,Functional assay for BRCA1: mutagenesis of the COOH-terminal region reveals critical residues for transcription activation.,http://www.ncbi.nlm.nih.gov/pubmed/10811118,23644
BRCA1 M1652K lies within the BRCT1 domain of the Brca1 protein (UniProt.org). M1652K confers a loss of function on Brca1 protein as indicated by failure to inhibit colony size in yeast (PMID: 15004537).,6037,15004537,Functional characterization of BRCA1 sequence variants using a yeast small colony phenotype assay.,http://www.ncbi.nlm.nih.gov/pubmed/15004537,295,,,www.uniprot.org,23646
"BRCA1 P1776S lies within the BRCT2 domain of the Brca1 protein (UniProt.org). P1776S has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23647
"BRCA1 P1812S lies within the BRCT2 domain of the Brca1 protein (UniProt.org). P1812S has been identified in sequencing studies (PMID: 17719744, PMID: 15172985), but has not been biochemically characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7505,15172985,Structure-based assessment of missense mutations in human BRCA1: implications for breast and ovarian cancer predisposition.,http://www.ncbi.nlm.nih.gov/pubmed/15172985,295,,,www.uniprot.org,7507,17719744,Identification and in silico analysis of functional SNPs of the BRCA1 gene.,http://www.ncbi.nlm.nih.gov/pubmed/17719744,23648
BRCA1 P1856T does not lie within any known functional domains of the Brca1 protein (UniProt.org). P1856T results in a loss of Brca1 transcription activity in yeast (PMID: 12496477).,6023,12496477,Mutations in the BRCT domain confer temperature sensitivity to BRCA1 in transcription activation.,http://www.ncbi.nlm.nih.gov/pubmed/12496477,295,,,www.uniprot.org,23649
"SMO dec exp indicates decreased expression of the Smo protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,23655
"CDKN2A H83N lies within ANK repeat 3 of the Cdkn2a (p16INK4a) protein (UniProt.org). H83N confers a loss of function to the Cdkn2a (p16INK4a) protein, as demonstrated by a reduction in the ability to inhibit Cdk4 kinase activity in an in vitro assay (PMID: 9660926).",6055,9660926,Tumor suppressor p16INK4A: determination of solution structure and analyses of its interaction with cyclin-dependent kinase 4.,http://www.ncbi.nlm.nih.gov/pubmed/9660926,295,,,www.uniprot.org,23657
"CDKN2A I49S lies within ANK repeat 2 of the Cdkn2a (p16INK4a) protein (UniProt.org). I49S confers a loss of function to the Cdkn2a (p16INK4a) protein as demonstrated by mislocalization, loss of binding to Cdk4 and Cdk6, and elevated Ki67 indicative of increased proliferation in cell culture (PMID: 20340136). ",3095,20340136,Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.,http://www.ncbi.nlm.nih.gov/pubmed/20340136,295,,,www.uniprot.org,23658
"CDKN2A L16P lies within ANK repeat 1 domain of the Cdkn2a (p16INK4a) protein (UniProt.org). L16P confers a loss of function to the Cdkn2a (p16INK4a) protein as demonstrated by mislocalization, loss of binding to Cdk4 and Cdk6, and elevated Ki67 indicative of increased proliferation in cell culture (PMID: 20340136).",295,,,www.uniprot.org,3095,20340136,Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.,http://www.ncbi.nlm.nih.gov/pubmed/20340136,23659
"CDKN2A L32P lies within ANK repeat 1 of the Cdkn2a (p16INK4a) protein (UniProt.org). L32P confers a loss of function to the Cdkn2a (p16INK4a) protein as demonstrated by mislocalization, loss of binding to Cdk4 and Cdk6, and elevated Ki67 indicative of increased proliferation in cell culture (PMID: 20340136).",295,,,www.uniprot.org,3095,20340136,Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.,http://www.ncbi.nlm.nih.gov/pubmed/20340136,23660
"CDKN2A L97R lies within ANK repeat 3 of the Cdkn2a (p16INK4a) protein (UniProt.org). L97R confers a loss of function to the Cdkn2a (p16INK4a) protein as demonstrated by mislocalization, loss of binding to Cdk4 and Cdk6, and elevated Ki67 indicative of increased proliferation in cell culture (PMID: 19260062, PMID: 20340136).",687,19260062,"Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients.",http://www.ncbi.nlm.nih.gov/pubmed/19260062,3095,20340136,Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.,http://www.ncbi.nlm.nih.gov/pubmed/20340136,295,,,www.uniprot.org,23661
"CDKN2A M53I lies within ANK repeat 2 of the Cdkn2a (p16INK4a) protein (UniProt.org). M53I confers a loss of function to the Cdkn2a (p16INK4a) protein as demonstrated by mislocalization and loss of binding to Cdk4 in cell culture (PMID: 19260062, PMID: 20340136).",687,19260062,"Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients.",http://www.ncbi.nlm.nih.gov/pubmed/19260062,3095,20340136,Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.,http://www.ncbi.nlm.nih.gov/pubmed/20340136,295,,,www.uniprot.org,23662
"CDKN2A N71I lies within ANK repeat 2 of the Cdkn2a (p16INK4a) protein (UniProt.org). N71I confers a loss of function to the Cdkn2a (p16INK4a) protein as demonstrated by mislocalization, loss of binding to Cdk4 and Cdk6, and elevated Ki67 indicative of increased proliferation in cell culture (PMID: 20340136).",295,,,www.uniprot.org,3095,20340136,Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.,http://www.ncbi.nlm.nih.gov/pubmed/20340136,23663
"CDKN2A N71K lies within ANK repeat 2 of the Cdkn2a (p16INK4a) protein (UniProt.org). N71K confers a loss of function to the Cdkn2a (p16INK4a) protein as demonstrated by mislocalization, loss of binding to Cdk4 and Cdk6, and elevated Ki67 indicative of increased proliferation in cell culture (PMID: 20340136).",295,,,www.uniprot.org,3095,20340136,Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.,http://www.ncbi.nlm.nih.gov/pubmed/20340136,23664
"CDKN2A N71S lies within ANK repeat 2 of the Cdkn2a (p16INK4a) protein (UniProt.org). N71S confers a loss of function to the Cdkn2a (p16INK4a) protein as demonstrated by mislocalization, reduced binding to Cdk4 and Cdk6, and a reduced ability to cause cell cycle arrest in cell culture (PMID: 10491434, PMID: 20340136).",3067,10491434,Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors.,http://www.ncbi.nlm.nih.gov/pubmed/10491434,3095,20340136,Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.,http://www.ncbi.nlm.nih.gov/pubmed/20340136,295,,,www.uniprot.org,23665
"CDKN2A P114S lies within ANK repeat 4 of the Cdkn2a (p16INK4a) protein (Uniprot.org). P114S confers a loss of function to the Cdkn2a (p16INK4a) protein as demonstrated by a loss of Cdk4 binding, and aberrant proliferation of cells in culture (PMID: 19260062).",687,19260062,"Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients.",http://www.ncbi.nlm.nih.gov/pubmed/19260062,295,,,www.uniprot.org,23666
MET exon 14 indicates an unspecified mutation has occurred in exon 14 of the MET gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,23670
"NRAS T58I lies within the GTP binding pocket of the Nras protein (UniProt.org). T58I is predicted to confer a loss of function to the Nras protein based on the effects of KRAS T58I, which includes decreased GTPase activity, phosphorylation of of Mek and Akt, and transformation in cell culture (PMID: 16474405).",295,,,www.uniprot.org,840,16474405,Germline KRAS mutations cause Noonan syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/16474405,23671
"BRAF amplification indicates an increased number of copies of the Braf gene. However, the mechanism causing the increase is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,23672
"PTEN Y86fs results in a change in the amino acid sequence of the Pten protein beginning at aa 86 of 403, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the C2 tensin-type domain, Y86fs is predicted to result in a loss of Pten protein function (UniProt.org). ",295,,,www.uniprot.org,23681
ERBB2 (HER2) L866M lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). L866M results in constitutive phosphorylation of Erbb2 (Her2) and increased phosphorylation of Mapk in cell culture (PMID: 26243863).,295,,,www.uniprot.org,6069,26243863,HER2 activating mutations are targets for colorectal cancer treatment.,http://www.ncbi.nlm.nih.gov/pubmed/26243863,23685
CDKN2A P81T lies within the ANK repeat 3 of the Cdkn2a protein (UniProt.org). P81T is predicted to result in a loss of Cdkn2a protein function as demonstrated by its reduced ability to suppress ROS activity and regulate the cell cycle in vitro (PMID: 23190892).,295,,,www.uniprot.org,3062,23190892,Familial melanoma-associated mutations in p16 uncouple its tumor-suppressor functions.,http://www.ncbi.nlm.nih.gov/pubmed/23190892,23686
CDKN2A Q50P lies within ANK repeat 2 of the Cdkn2a (p16INK4a) protein (UniProt.org). Q50P confers a loss of function to the Cdkn2a (p16INK4a) protein as demonstrated by a loss of binding to Cdk4 in a yeast assay (PMID: 14508519).,295,,,www.uniprot.org,6073,14508519,Germline splicing mutations of CDKN2A predispose to melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/14508519,23687
"CDKN2A R112G lies within ANK repeat 4 of the Cdkn2a protein (p16INK4a) (UniProt.org). R112G confers a loss of function to the Cdkn2a (p16INK4a) protein as demonstrated by mislocalization, loss of binding to Cdk4, and elevated Ki67 indicative of increased proliferation in cell culture (PMID: 20340136).",295,,,www.uniprot.org,3095,20340136,Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.,http://www.ncbi.nlm.nih.gov/pubmed/20340136,23688
"CDKN2A R24P lies within ANK repeat 1 of the Cdkn2a (p16INK4a) protein (UniProt.org). R24P confers a loss of function to the Cdkn2a (p16INK4a) protein as demonstrated by mislocalization, loss of binding to Cdk4 and Cdk6, and elevated Ki67 indicative of increased proliferation in cell culture (PMID: 20340136).",3095,20340136,Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.,http://www.ncbi.nlm.nih.gov/pubmed/20340136,295,,,www.uniprot.org,23689
CDKN2A R80L lies within ANK repeat 3 the Cdkn2a (p16INK4a) protein (UniProt.org). R80L confers a loss of function to the Cdkn2a (p16INK4a) protein as demonstrated by a reduction in the ability to induce cell cycle arrest (PMID: 10491434).,295,,,www.uniprot.org,3067,10491434,Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors.,http://www.ncbi.nlm.nih.gov/pubmed/10491434,23690
"CDKN2A R80P lies within ANK repeat 3 of the Cdkn2a protein (UniProt.org). R80P has been identified in the scientific literature (PMID: 21462282), but has not been biochemically characterized and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7547,21462282,Classifying variants of CDKN2A using computational and laboratory studies.,http://www.ncbi.nlm.nih.gov/pubmed/21462282,23691
CDKN2A R87L lies within ANK repeat 3 of the Cdkn2a (p16INK4a) protein (UniProt.org). R87L confers a loss of function to the Cdkn2a (p16INK4a) protein as demonstrated by loss of Cdk6 kinase inhibition and a reduction in the ability to induce cell cycle arrest (PMID: 10491434).,295,,,www.uniprot.org,3067,10491434,Biologic and biochemical analyses of p16(INK4a) mutations from primary tumors.,http://www.ncbi.nlm.nih.gov/pubmed/10491434,23692
"CDKN2A R87W lies within ANK repeat 3 of the Cdkn2a (p16INK4a) protein (UniProt.org). R87W confers a loss of function to the Cdkn2a (p16INK4a) protein as demonstrated by loss of Cdk4 binding, and aberrant proliferation of cells in culture (PMID: 19260062).",687,19260062,"Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients.",http://www.ncbi.nlm.nih.gov/pubmed/19260062,295,,,www.uniprot.org,23693
CDKN2A S56I lies within ANK repeat 2 of the Cdkn2a (p16INK4a) protein (UniProt.org). S56I confers a loss of function to the Cdkn2a (p16INK4a) protein as demonstrated by mislocalization and reduced binding to Cdk4 in cell culture (PMID: 20340136).,3095,20340136,Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.,http://www.ncbi.nlm.nih.gov/pubmed/20340136,23694
"CDKN2A T77P lies within ANK repeat 2 of the Cdkn2a (p16INK4a) protein (UniProt.org). T77P confers a loss of function to the Cdkn2a (p16INK4a) protein as demonstrated by loss of Cdk4 binding, and aberrant proliferation of cells in culture (PMID: 19260062).",687,19260062,"Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients.",http://www.ncbi.nlm.nih.gov/pubmed/19260062,295,,,www.uniprot.org,23695
"NOTCH1 dec exp indicates an decreased expression of the Notch1 protein. However, the mechanism causing the decreased expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,23709
"ALK D1529G lies within the cytoplasmic domain of the Alk protein (UniProt.org). D1529G has not been characterized in the scientific literature and therefore, its effect on Alk protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23710
"MET S812C lies within IPT/TIG domain 3 of the Met protein (UniProt.org). S812C has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23711
"STAG2 T626fs results in a change in the amino acid sequence of the Stag2 protein beginning at aa 626 of 1231, likely resulting in premature truncation of the functional protein (UniProt.org). T626fs has not been characterized, however, due to the effects of Stag2 truncating mutations downstream of T626 (PMID: 26871722, PMID: 21852505), T626fs is predicted to lead to a loss of Stag2 function.",295,,,www.uniprot.org,6087,26871722,"Intact Cohesion, Anaphase, and Chromosome Segregation in Human Cells Harboring Tumor-Derived Mutations in STAG2.",http://www.ncbi.nlm.nih.gov/pubmed/26871722,5470,21852505,Mutational inactivation of STAG2 causes aneuploidy in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21852505,23716
"SF3B1 E622D lies within the HEAT repeat domain of the Sf3b1 protein (UniProt.org). E622D has not been individually characterized, however, a group of SF3B1 mutations, including E622D, was associated with a differentially expressed gene signature compared to wild-type, and thus, E622D is predicted to lead to a gain of Sf3b1 protein function (PMID: 25428262). ",295,,,www.uniprot.org,6088,25428262,Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells.,http://www.ncbi.nlm.nih.gov/pubmed/25428262,23717
"SF3B1 K666R lies within the HEAT repeat domain of the Sf3b1 protein (UniProt.org). K666R has not been individually characterized, however, a group of SF3B1 mutations, including K666R, was associated with a differentially expressed gene signature compared to wild-type, and thus, K666R is predicted to lead to a gain of Sf3b1 protein function (PMID: 25428262). ",295,,,www.uniprot.org,6088,25428262,Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells.,http://www.ncbi.nlm.nih.gov/pubmed/25428262,23718
"SF3B1 H662D lies within the HEAT repeat domain of the Sf3b1 protein (UniProt.org). H662D has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, Jun 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23719
"SF3B1 K666M lies within the HEAT repeat domain of the Sf3b1 protein (UniProt.org). K666M has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, Jun 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23720
"SF3B1 K666Q lies within the HEAT repeat domain of the Sf3b1 protein (UniProt.org). K666Q has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, Jun 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23721
"SF3B1 K700I lies within the HEAT repeat domain of the Sf3b1 protein (UniProt.org). K700I has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, Jun 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23722
"SF3B1 K700N lies within the HEAT repeat domain of the Sf3b1 protein (UniProt.org). K700N has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, Jun 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23723
"SF3B1 R625D lies within the HEAT repeat domain of the Sf3b1 protein (UniProt.org). R625D has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, Jun 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23724
"BRCA1 T1852S lies within the BRCT2 domain of the Brca1 protein (UniProt.org). T1852S has been identified in sequencing studies (PMID: 15172985), but has not been biochemically characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7505,15172985,Structure-based assessment of missense mutations in human BRCA1: implications for breast and ovarian cancer predisposition.,http://www.ncbi.nlm.nih.gov/pubmed/15172985,295,,,www.uniprot.org,23725
BRCA1 V1833E lies within the BRCT2 domain of the Brca1 protein (UniProt.org). V1833E results in a loss of Brca1 transcription activity in yeast (PMID: 10811118).,295,,,www.uniprot.org,6039,10811118,Functional assay for BRCA1: mutagenesis of the COOH-terminal region reveals critical residues for transcription activation.,http://www.ncbi.nlm.nih.gov/pubmed/10811118,23726
BRCA1 Y1703H lies within the BRCT1 domain of the Brca1 protein (UniProt.org). Y1703H results in a loss of Brca1 transcription activity in yeast (PMID: 10811118).,6039,10811118,Functional assay for BRCA1: mutagenesis of the COOH-terminal region reveals critical residues for transcription activation.,http://www.ncbi.nlm.nih.gov/pubmed/10811118,295,,,www.uniprot.org,23727
"BRCA1 T47D lies within the RING-type zinc finger region of the Brca1 protein (UniProt.org). T47D has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23728
BRCA1 H1402Y does not lie within any known functional domains of the Brca1 protein (UniProt.org). H1402Y demonstrates transcription activity similar to wild-type Brca1 in yeast (PMID: 15689452).,6089,15689452,Classification of BRCA1 missense variants of unknown clinical significance.,http://www.ncbi.nlm.nih.gov/pubmed/15689452,295,,,www.uniprot.org,23729
BRCA1 H1421Y does not lie within any known functional domains of the Brca1 protein (UniProt.org). H1421Y demonstrates transcription activity similar to wild-type Brca1 in yeast (PMID: 15689452).,6089,15689452,Classification of BRCA1 missense variants of unknown clinical significance.,http://www.ncbi.nlm.nih.gov/pubmed/15689452,295,,,www.uniprot.org,23730
BRCA1 L1407P does not lie within any known functional domains of the Brca1 protein (UniProt.org). L1407P results in a loss of Brca1 transcription activity in yeast (PMID: 15689452).,295,,,www.uniprot.org,6089,15689452,Classification of BRCA1 missense variants of unknown clinical significance.,http://www.ncbi.nlm.nih.gov/pubmed/15689452,23731
BRCA1 M1628T does not lie within any known functional domains of the Brca1 protein (UniProt.org). M1628T demonstrates transcription activity similar to wild-type Brca1 in yeast (PMID: 15689452).,295,,,www.uniprot.org,6089,15689452,Classification of BRCA1 missense variants of unknown clinical significance.,http://www.ncbi.nlm.nih.gov/pubmed/15689452,23732
BRCA1 M1628V does not lie within any known functional domains of the Brca1 protein (UniProt.org). M1628V results in a loss of Brca1 transcription activity in yeast (PMID: 15689452).,295,,,www.uniprot.org,6089,15689452,Classification of BRCA1 missense variants of unknown clinical significance.,http://www.ncbi.nlm.nih.gov/pubmed/15689452,23733
BRCA1 S1512I does not lie within any known functional domains of the Brca1 protein (UniProt.org). S1512I demonstrates transcription activity similar to wild-type Brca1 in yeast (PMID: 15689452).,295,,,www.uniprot.org,6089,15689452,Classification of BRCA1 missense variants of unknown clinical significance.,http://www.ncbi.nlm.nih.gov/pubmed/15689452,23734
"BRCA1 E1419K does not lie within any known functional domains of the Brca1 protein (UniProt.org). E1419K has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23735
BRCA1 D96N does not lie within any known functional domains of the Brca1 protein (UniProt.org). D96N demonstrates binding to Bard1 and E2 to similar levels of wild-type Brca1 in an in vitro assay (PMID: 16403807).,295,,,www.uniprot.org,6028,16403807,Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility.,http://www.ncbi.nlm.nih.gov/pubmed/16403807,23736
"BRCA1 I26N does not lie within any known functional domains of the Brca1 protein (UniProt.org). I26N has not been characterized, but is predicted to disrupt the interaction with the E2 ubiquitin conjugating enzyme UbcH5a by structural modeling (PMID: 16403807).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6028,16403807,Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility.,http://www.ncbi.nlm.nih.gov/pubmed/16403807,23737
"BRCA1 I31N lies within the RING-type zinc finger region of the Brca1 protein (UniProt.org). I31N has not been characterized, but is predicted to disrupt the RING domain of Brca1 by structural modeling (PMID: 16403807).",6028,16403807,Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility.,http://www.ncbi.nlm.nih.gov/pubmed/16403807,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23738
"BRCA1 I31T lies within the RING-type zinc finger region of the Brca1 protein (UniProt.org). I31T has not been characterized, but is predicted to disrupt the RING domain of Brca1 by structural modeling (PMID: 16403807).",6028,16403807,Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility.,http://www.ncbi.nlm.nih.gov/pubmed/16403807,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23739
"BRCA1 I68K does not lie within any known functional domains of the Brca1 protein (UniProt.org). I68K has not been characterized, but is predicted to disrupt the RING domain of Brca1 by structural modeling (PMID: 16403807).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23740
"BRCA1 I89N does not lie within any known functional domains of the Brca1 protein (UniProt.org). I89N has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23741
BRCA1 I89T does not lie within any known functional domains of the Brca1 protein (UniProt.org). I89T demonstrates binding to Bard1 and E2 to similar levels of wild-type Brca1 in an in vitro assay (PMID: 16403807).,6028,16403807,Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility.,http://www.ncbi.nlm.nih.gov/pubmed/16403807,295,,,www.uniprot.org,23742
BRCA1 I90T does not lie within any known functional domains of the Brca1 protein (UniProt.org). I90T demonstrates binding to Bard1 and E2 to similar levels of wild-type Brca1 in an in vitro assay (PMID: 16403807).,6028,16403807,Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility.,http://www.ncbi.nlm.nih.gov/pubmed/16403807,295,,,www.uniprot.org,23743
BRCA1 K38N lies within the RING-type zinc finger region of the Brca1 protein (UniProt.org). K38N demonstrates binding to Bard1 and E2 to similar levels of wild-type Brca1 in an in vitro assay (PMID: 16403807).,6028,16403807,Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility.,http://www.ncbi.nlm.nih.gov/pubmed/16403807,295,,,www.uniprot.org,23744
BRCA1 K45N lies within the RING-type zinc finger region of the Brca1 protein (UniProt.org). K45N results in a loss of E2 binding and Brca1 ubiquitin ligase activity in an in vitro assay (PMID: 16403807).,6028,16403807,Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility.,http://www.ncbi.nlm.nih.gov/pubmed/16403807,295,,,www.uniprot.org,23745
BRCA1 K45T lies within the RING-type zinc finger region of the Brca1 protein (UniProt.org). K45T results in a loss of E2 binding and Brca1 ubiquitin ligase activity in an in vitro assay (PMID: 16403807).,6028,16403807,Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility.,http://www.ncbi.nlm.nih.gov/pubmed/16403807,295,,,www.uniprot.org,23746
"BRCA1 K50E lies within the RING-type zinc finger region of the Brca1 protein (UniProt.org). K50E has not been characterized, but may disrupt the salt bridge to D59 of UbcH5b and weaken binding to E2 by structural modeling (PMID: 16403807). ",295,,,www.uniprot.org,6028,16403807,Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility.,http://www.ncbi.nlm.nih.gov/pubmed/16403807,285,,,http://www.ncbi.nlm.nih.gov/pubmed,23747
"BRCA1 K50L lies within the RING-type zinc finger region of the Brca1 protein (UniProt.org). K50L has not been characterized, but may disrupt the salt bridge to D59 of UbcH5b and weaken binding to E2 by structural modeling (PMID: 16403807). ",295,,,www.uniprot.org,6028,16403807,Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility.,http://www.ncbi.nlm.nih.gov/pubmed/16403807,285,,,http://www.ncbi.nlm.nih.gov/pubmed,23748
"BRCA1 K56N lies within the RING-type zinc finger region of the Brca1 protein (UniProt.org). K56N has not been characterized, but may disrupt hydrogen bonding to S91 of UbcH5b and weaken binding to E2 by structural modeling (PMID: 16403807).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6028,16403807,Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility.,http://www.ncbi.nlm.nih.gov/pubmed/16403807,23749
"BRCA1 K65M lies within the RING-type zinc finger region of the Brca1 protein (UniProt.org). K65M has not been characterized, but is predicted to disrupt hydrogen bonding or the salt bridge to UbcH5a by structural modeling (PMID: 16403807).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6028,16403807,Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility.,http://www.ncbi.nlm.nih.gov/pubmed/16403807,23750
"BRCA1 L28P lies within the RING-type zinc finger region of the Brca1 protein (UniProt.org). L28P has been identified in sequencing studies (PMID: 18779604) and is predicted to disrupt contact with UbcH5a and prevent folding by structural modeling (PMID: 16403807), but has not been biochemically characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6028,16403807,Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility.,http://www.ncbi.nlm.nih.gov/pubmed/16403807,7506,18779604,Performance of BRCA1/2 mutation prediction models in Asian Americans.,http://www.ncbi.nlm.nih.gov/pubmed/18779604,23751
BRCA1 L63F lies within the RING-type zinc finger region of the Brca1 protein (UniProt.org). L63F results in a loss of E2 binding and Brca1 ubiquitin ligase activity in an in vitro assay (PMID: 16403807). ,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23752
BRCA1 L82P does not lie within any known functional domains of the Brca1 protein (UniProt.org). L82P results in a loss of Brca1 binding to Bard1 in an in vitro assay (PMID: 16403807).,295,,,www.uniprot.org,6028,16403807,Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility.,http://www.ncbi.nlm.nih.gov/pubmed/16403807,23753
BRCA1 M18K does not lie within any known functional domains of the Brca1 protein (UniProt.org). M18K results in a loss of E2 binding and Brca1 ubiquitin ligase activity in an in vitro assay (PMID: 16403807).,6028,16403807,Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility.,http://www.ncbi.nlm.nih.gov/pubmed/16403807,295,,,www.uniprot.org,23754
BRCA1 Q12Y does not lie within any known functional domains of the Brca1 protein (UniProt.org). Q12Y results in a loss of Brca1 binding to Bard1 in an in vitro assay (PMID: 16403807).,6028,16403807,Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility.,http://www.ncbi.nlm.nih.gov/pubmed/16403807,295,,,www.uniprot.org,23755
BRCA1 S4P does not lie within any known functional domains of the Brca1 protein (UniProt.org). S4P demonstrates binding to Bard1 and E2 to similar levels of wild-type Brca1 in an in vitro assay (PMID: 16403807).,6028,16403807,Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility.,http://www.ncbi.nlm.nih.gov/pubmed/16403807,295,,,www.uniprot.org,23756
BRCA1 S59R lies within the RING-type zinc finger region of the Brca1 protein (UniProt.org). S59R results in a loss of Brca1 binding to E2 in an in vitro assay (PMID: 16403807).,6028,16403807,Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility.,http://www.ncbi.nlm.nih.gov/pubmed/16403807,295,,,www.uniprot.org,23757
BRCA1 S72R does not lie within any known functional domains of the Brca1 protein (UniProt.org). S72R results in a loss of E2 binding and Brca1 ubiquitin ligase activity in an in vitro assay (PMID: 16403807).,6028,16403807,Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility.,http://www.ncbi.nlm.nih.gov/pubmed/16403807,295,,,www.uniprot.org,23758
BRCA1 T77M does not lie within any known functional domains of the Brca1 protein (UniProt.org). T77M results in a loss of E2 binding and Brca1 ubiquitin ligase activity in an in vitro assay (PMID: 16403807).,6028,16403807,Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility.,http://www.ncbi.nlm.nih.gov/pubmed/16403807,295,,,www.uniprot.org,23759
BRCA1 P1812A lies within the BRCT2 domain of the Brca1 protein (UniProt.org). P1812A demonstrates transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 17020472).,295,,,www.uniprot.org,6096,17020472,The P1812A and P25T BRCA1 and the 5164del4 BRCA2 mutations: occurrence in high-risk non-Ashkenazi Jews.,http://www.ncbi.nlm.nih.gov/pubmed/17020472,23760
BRCA1 F1695L lies within the BRCT1 domain of the Brca1 protein (UniProt.org). F1695L demonstrates BRCT binding similar to wild-type Brca1 protein in an in vitro assay (PMID: 15133503).,6097,15133503,Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/15133503,295,,,www.uniprot.org,23761
BRCA1 D1546N does not lie within any known functional domains of the Brca1 protein (UniProt.org). D1546N demonstrates transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 17308087).,298,17308087,Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis.,http://www.ncbi.nlm.nih.gov/pubmed/17308087,295,,,www.uniprot.org,23762
BRCA1 E1644G lies within the BRCT1 domain of the Brca1 protein (UniProt.org). E1644G demonstrates transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 17308087).,295,,,www.uniprot.org,298,17308087,Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis.,http://www.ncbi.nlm.nih.gov/pubmed/17308087,23763
BRCA1 L1564P does not lie within any known functional domains of the Brca1 protein (UniProt.org). L1564P results in reduced Brca1 transcription activity in cell culture (PMID: 17308087).,298,17308087,Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis.,http://www.ncbi.nlm.nih.gov/pubmed/17308087,295,,,www.uniprot.org,23764
BRCA1 P1614S does not lie within any known functional domains of the Brca1 protein (UniProt.org). P1614S demonstrates transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 17308087).,298,17308087,Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis.,http://www.ncbi.nlm.nih.gov/pubmed/17308087,295,,,www.uniprot.org,23765
BRCA1 R1443G does not lie within any known functional domains of the Brca1 protein (UniProt.org). R1443G results in reduced Brca1 transcription activity in cell culture (PMID: 17308087).,298,17308087,Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis.,http://www.ncbi.nlm.nih.gov/pubmed/17308087,295,,,www.uniprot.org,23766
BRCA1 V1534M does not lie within any known functional domains of the Brca1 protein (UniProt.org). V1534M demonstrates transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 17308087).,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23767
BRCA1 V11A does not lie within any known functional domains of the Brca1 protein (UniProt.org). V11A inhibited satellite transcripts to similar level of wild-type Brca1 protein in cell culture (PMID: 21901007).,295,,,www.uniprot.org,6098,21901007,BRCA1 tumour suppression occurs via heterochromatin-mediated silencing.,http://www.ncbi.nlm.nih.gov/pubmed/21901007,23768
BRCA1 N550H does not lie within any known functional domains of the Brca1 protein (UniProt.org). N550H results in DNA double strand break repair by non-homologous end joining to similar level of wild-type Brca1 protein in cell culture (PMID: 20737206).,6100,20737206,A recombination-based method to characterize human BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/20737206,295,,,www.uniprot.org,23769
BRCA1 S1164I does not lie within any known functional domains of the Brca1 protein (UniProt.org). S1164I confers a loss of function on Brca1 protein as indicated by loss of growth suppression in yeast  (PMID: 19493677).,295,,,www.uniprot.org,6101,19493677,Characterisation of gene expression profiles of yeast cells expressing BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/19493677,23770
BRCA1 Y179C does not lie within any known functional domains of the Brca1 protein (UniProt.org). Y179C confers a loss of function on Brca1 protein as indicated by defective DNA double strand break repair by non-homologous end joining in cell culture (PMID: 20737206).,295,,,www.uniprot.org,6100,20737206,A recombination-based method to characterize human BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/20737206,23771
BRCA1 K1487R does not lie within any known functional domains of the Brca1 protein (UniProt.org). K1487R results in reduced Brca1 transcription activity in cell culture (PMID: 18992264).,6102,18992264,"Analysis of a set of missense, frameshift, and in-frame deletion variants of BRCA1.",http://www.ncbi.nlm.nih.gov/pubmed/18992264,295,,,www.uniprot.org,23772
BRCA1 M1652I lies within the BRCT1 domain of the Brca1 protein (UniProt.org). M1652I demonstrates transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 18992264).,6102,18992264,"Analysis of a set of missense, frameshift, and in-frame deletion variants of BRCA1.",http://www.ncbi.nlm.nih.gov/pubmed/18992264,295,,,www.uniprot.org,23773
BRCA1 Q1826H lies within the BRCT2 domain of the Brca1 protein (UniProt.org). Q1826H demonstrates transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 18992264).,6102,18992264,"Analysis of a set of missense, frameshift, and in-frame deletion variants of BRCA1.",http://www.ncbi.nlm.nih.gov/pubmed/18992264,295,,,www.uniprot.org,23774
BRCA1 S1613C does not lie within any known functional domains of the Brca1 protein (UniProt.org). S1613C demonstrates transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 18992264).,6102,18992264,"Analysis of a set of missense, frameshift, and in-frame deletion variants of BRCA1.",http://www.ncbi.nlm.nih.gov/pubmed/18992264,295,,,www.uniprot.org,23775
BRCA1 V1833M lies within the BRCT2 domain of the Brca1 protein (UniProt.org). V1833M results in reduced Brca1 transcription activity in cell culture (PMID: 18992264).,6102,18992264,"Analysis of a set of missense, frameshift, and in-frame deletion variants of BRCA1.",http://www.ncbi.nlm.nih.gov/pubmed/18992264,295,,,www.uniprot.org,23776
BRCA1 C47F lies within the RING-type zinc finger region of the Brca1 protein (UniProt.org). C47F confers a loss of function on Brca1 protein as indicated by failure to suppress colony size in yeast (PMID: 21922593).,295,,,www.uniprot.org,6035,21922593,Assessment of human Nter and Cter BRCA1 mutations using growth and localization assays in yeast.,http://www.ncbi.nlm.nih.gov/pubmed/21922593,23785
BRCA1 Y1853* results in a premature truncation of the Brca1 protein at amino acid 1853 of 1863 (UniProt.org). Y1853* results in colony size similar to wild-type Brca1 in yeast (PMID: 21922593).,295,,,www.uniprot.org,6035,21922593,Assessment of human Nter and Cter BRCA1 mutations using growth and localization assays in yeast.,http://www.ncbi.nlm.nih.gov/pubmed/21922593,23786
"BRCA1 E143K does not lie within any known functional domains of the Brca1 protein (UniProt.org). E143K repairs DNA double-strand breaks by homology-directed recombination similar to wild-type Brca1, but with reduced activity by the single-strand annealing pathway in cell culture (PMID: 23161852).",6124,23161852,Analysis of BRCA1 variants in double-strand break repair by homologous recombination and single-strand annealing.,http://www.ncbi.nlm.nih.gov/pubmed/23161852,295,,,www.uniprot.org,23787
"BRCA1 I124V does not lie within any known functional domains of the Brca1 protein (UniProt.org). I124V repairs DNA double-strand breaks by homology-directed recombination similar to wild-type Brca1, but with reduced activity by the single-strand annealing pathway in cell culture (PMID: 23161852).",6124,23161852,Analysis of BRCA1 variants in double-strand break repair by homologous recombination and single-strand annealing.,http://www.ncbi.nlm.nih.gov/pubmed/23161852,295,,,www.uniprot.org,23788
"BRCA1 R170Q does not lie within any known functional domains of the Brca1 protein (UniProt.org). R170Q repairs DNA double-strand breaks by homology-directed recombination similar to wild-type Brca1, but with reduced activity by the single-strand annealing pathway in cell culture (PMID: 23161852).",6124,23161852,Analysis of BRCA1 variants in double-strand break repair by homologous recombination and single-strand annealing.,http://www.ncbi.nlm.nih.gov/pubmed/23161852,295,,,www.uniprot.org,23789
"BRCA1 S153R does not lie within any known functional domains of the Brca1 protein (UniProt.org). S153R repairs DNA double-strand breaks by homology-directed recombination similar to wild-type Brca1, but with reduced activity by the single-strand annealing pathway in cell culture (PMID: 23161852).",6124,23161852,Analysis of BRCA1 variants in double-strand break repair by homologous recombination and single-strand annealing.,http://www.ncbi.nlm.nih.gov/pubmed/23161852,295,,,www.uniprot.org,23790
"BRCA1 V191D does not lie within any known functional domains of the Brca1 protein (UniProt.org). V191D repairs DNA double-strand breaks by homology-directed recombination similar to wild-type Brca1, but with reduced activity by the single-strand annealing pathway in cell culture (PMID: 23161852).",6124,23161852,Analysis of BRCA1 variants in double-strand break repair by homologous recombination and single-strand annealing.,http://www.ncbi.nlm.nih.gov/pubmed/23161852,295,,,www.uniprot.org,23791
BRCA1 E1586G does not lie within any known functional domains of the Brca1 protein (UniProt.org). E1586G demonstrates transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 23613828).,295,,,www.uniprot.org,6125,23613828,Functional and structural analysis of C-terminal BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23613828,23792
BRCA1 G1770V lies within the BRCT2 domain of the Brca1 protein (UniProt.org). G1770V results in a loss of Brca1 transcription activity in cell culture (PMID: 23613828).,6125,23613828,Functional and structural analysis of C-terminal BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23613828,295,,,www.uniprot.org,23793
BRCA1 Q1409L does not lie within any known functional domains of the Brca1 protein (UniProt.org). Q1409L demonstrates transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 23613828).,6125,23613828,Functional and structural analysis of C-terminal BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23613828,295,,,www.uniprot.org,23794
BRCA1 R1589H does not lie within any known functional domains of the Brca1 protein (UniProt.org). R1589H demonstrates transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 23613828).,295,,,www.uniprot.org,6125,23613828,Functional and structural analysis of C-terminal BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23613828,23795
BRCA1 S1473P does not lie within any known functional domains of the Brca1 protein (UniProt.org). S1473P demonstrates transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 23613828).,295,,,www.uniprot.org,6125,23613828,Functional and structural analysis of C-terminal BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23613828,23796
BRCA1 W1718L lies within the BRCT1 domain of the Brca1 protein (UniProt.org). W1718L results in a loss of Brca1 transcription activity in cell culture (PMID: 23613828).,295,,,www.uniprot.org,6125,23613828,Functional and structural analysis of C-terminal BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23613828,23797
BRCA1 Y1703S lies within the BRCT1 domain of the Brca1 protein (UniProt.org). Y1703S results in a loss of Brca1 transcription activity in cell culture (PMID: 23613828).,295,,,www.uniprot.org,6125,23613828,Functional and structural analysis of C-terminal BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23613828,23798
"BRCA1 C360R does not lie within any known functional domains of the Brca1 protein (UniProt.org). C360R has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23799
BRCA1 D245V does not lie within any known functional domains of the Brca1 protein (UniProt.org). D245V restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,295,,,www.uniprot.org,23800
BRCA1 D695N does not lie within any known functional domains of the Brca1 protein (UniProt.org). D695N restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,295,,,www.uniprot.org,23801
BRCA1 E1060A does not lie within any known functional domains of the Brca1 protein (UniProt.org). E1060A restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,295,,,www.uniprot.org,23802
BRCA1 E1214K does not lie within any known functional domains of the Brca1 protein (UniProt.org). E1214K restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,295,,,www.uniprot.org,23803
BRCA1 E1250K does not lie within any known functional domains of the Brca1 protein (UniProt.org). E1250K restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,295,,,www.uniprot.org,23804
BRCA1 E1282V does not lie within any known functional domains of the Brca1 protein (UniProt.org). E1282V restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,295,,,www.uniprot.org,23805
BRCA1 E1346K does not lie within any known functional domains of the Brca1 protein (UniProt.org). E1346K restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,295,,,www.uniprot.org,23806
BRCA1 E362H does not lie within any known functional domains of the Brca1 protein (UniProt.org). E362H restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23807
"BRCA1 H1476Q does not lie within any known functional domains of the Brca1 protein (UniProt.org). H1476Q has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23808
BRCA1 H1686R lies within the BRCT1 domain of the Brca1 protein (UniProt.org). H1686R confers a loss of function on Brca1 protein as indicated by failure to restore proliferation in Brca1-null embryonic stem cells in culture (PMID: 23867111).,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,295,,,www.uniprot.org,23809
BRCA1 H1862L does not lie within any known functional domains of the Brca1 protein (UniProt.org). H1862L restores proliferation of Brca1-null embryonic stem cells to a similar level to wild-type Brca1  in culture (PMID: 23867111).,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,295,,,www.uniprot.org,23810
BRCA1 K1110del results in the deletion of one amino acid of the Brca1 protein at amino acid 1110 (UniProt.org). K1110del restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,295,,,www.uniprot.org,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,23811
BRCA1 K45Q lies within the RING-type zinc finger region of the Brca1 protein (UniProt.org). K45Q restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,295,,,www.uniprot.org,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,23812
BRCA1 L147F does not lie within any known functional domains of the Brca1 protein (UniProt.org). L147F restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,295,,,www.uniprot.org,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,23813
BRCA1 L165P does not lie within any known functional domains of the Brca1 protein (UniProt.org). L165P restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,295,,,www.uniprot.org,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,23814
BRCA1 L246V does not lie within any known functional domains of the Brca1 protein (UniProt.org). L246V restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,295,,,www.uniprot.org,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,23815
"BRCA1 L358R does not lie within any known functional domains of the Brca1 protein (UniProt.org). L358R has been identified in the scientific literature (PMID: 23867111), but has not been biochemically characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Jan 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,295,,,www.uniprot.org,23816
BRCA1 L668F does not lie within any known functional domains of the Brca1 protein (UniProt.org). L668F restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,295,,,www.uniprot.org,23817
BRCA1 M1008I does not lie within any known functional domains of the Brca1 protein (UniProt.org). M1008I restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23818
BRCA1 M1400V does not lie within any known functional domains of the Brca1 protein (UniProt.org). M1400V restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,295,,,www.uniprot.org,23819
BRCA1 M1411T does not lie within any known functional domains of the Brca1 protein (UniProt.org). M1411T restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,295,,,www.uniprot.org,23820
BRCA1 N1236K does not lie within any known functional domains of the Brca1 protein (UniProt.org). N1236K restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111). ,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,295,,,www.uniprot.org,23821
BRCA1 N810Y does not lie within any known functional domains of the Brca1 protein (UniProt.org). N810Y restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,295,,,www.uniprot.org,23822
BRCA1 P142H does not lie within any known functional domains of the Brca1 protein (UniProt.org). P142H restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,295,,,www.uniprot.org,23823
BRCA1 P1812R lies within the BRCT2 domain of the Brca1 protein (UniProt.org). P1812R restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,295,,,www.uniprot.org,23824
BRCA1 P798L does not lie within any known functional domains of the Brca1 protein (UniProt.org). P798L restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,295,,,www.uniprot.org,23825
"BRCA1 R133H does not lie within any known functional domains of the Brca1 protein (UniProt.org). R133H has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23826
BRCA1 R170W does not lie within any known functional domains of the Brca1 protein (UniProt.org). R170W restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,295,,,www.uniprot.org,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,23827
BRCA1 R841Q does not lie within any known functional domains of the Brca1 protein (UniProt.org). R841Q restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,295,,,www.uniprot.org,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,23828
BRCA1 R866C does not lie within any known functional domains of the Brca1 protein (UniProt.org). R866C restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,295,,,www.uniprot.org,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,23829
BRCA1 S1101N does not lie within any known functional domains of the Brca1 protein (UniProt.org). S1101N restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,295,,,www.uniprot.org,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,23830
"BRCA1 S1164G does not lie within any known functional domains of the Brca1 protein (UniProt.org). S1164G has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23831
BRCA1 S1297del results in the deletion of one amino acid of the Brca1 protein at amino acid 1297 (UniProt.org). S1297del restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,295,,,www.uniprot.org,23832
BRCA1 S1448G does not lie within any known functional domains of the Brca1 protein (UniProt.org). S1448G restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,295,,,www.uniprot.org,23833
BRCA1 S1486C does not lie within any known functional domains of the Brca1 protein (UniProt.org). S1486C restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,295,,,www.uniprot.org,23834
"BRCA1 S1512A does not lie within any known functional domains of the Brca1 protein (UniProt.org). S1512A has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23835
BRCA1 S1651P lies within the BRCT1 domain of the Brca1 protein (UniProt.org). S1651P confers a loss of function on Brca1 protein as indicated by failure to restore proliferation in Brca1-null embryonic stem cells in culture (PMID: 23867111).,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,295,,,www.uniprot.org,23836
BRCA1 S186Y does not lie within any known functional domains of the Brca1 protein (UniProt.org). S186Y restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,295,,,www.uniprot.org,23837
BRCA1 S308A does not lie within any known functional domains of the Brca1 protein (UniProt.org). S308A restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,295,,,www.uniprot.org,23838
BRCA1 S988A does not lie within any known functional domains of the Brca1 protein (UniProt.org). S988A restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,295,,,www.uniprot.org,23839
BRCA1 T231M does not lie within any known functional domains of the Brca1 protein (UniProt.org). T231M restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,295,,,www.uniprot.org,23840
BRCA1 V1378I does not lie within any known functional domains of the Brca1 protein (UniProt.org). V1378I restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,295,,,www.uniprot.org,23841
BRCA1 V1688del results in the deletion of one amino acid of the Brca1 protein at amino acid 1688 (UniProt.org). V1688del confers a loss of function on Brca1 protein as indicated by failure to restore proliferation in Brca1-null embryonic stem cells in culture (PMID: 23867111).,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,295,,,www.uniprot.org,23842
BRCA1 V191I does not lie within any known functional domains of the Brca1 protein (UniProt.org). V191I restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,295,,,www.uniprot.org,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,23843
BRCA1 V271L does not lie within any known functional domains of the Brca1 protein (UniProt.org). V271L restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,295,,,www.uniprot.org,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,23844
BRCA1 W1782C lies within the BRCT2 domain of the Brca1 protein (UniProt.org). W1782C restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,295,,,www.uniprot.org,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,23845
BRCA1 Y105C does not lie within any known functional domains of the Brca1 protein (UniProt.org). Y105C restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,295,,,www.uniprot.org,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,23846
BRCA1 Y856H does not lie within any known functional domains of the Brca1 protein (UniProt.org). Y856H restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,295,,,www.uniprot.org,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,23847
BRCA1 R1589P does not lie within any known functional domains of the Brca1 protein (UniProt.org). R1589P restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,295,,,www.uniprot.org,23848
"BRCA1 Q1756C lies within the BRCT2 domain of the Brca1 protein (UniProt.org). Q1756C has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23849
BRCA1 P1637L does not lie within any known functional domains of the Brca1 protein (UniProt.org). P1637L results in colony size similar to wild-type Brca1 in yeast (PMID: 15004537).,295,,,www.uniprot.org,6037,15004537,Functional characterization of BRCA1 sequence variants using a yeast small colony phenotype assay.,http://www.ncbi.nlm.nih.gov/pubmed/15004537,23850
"BRCA1 E1258G does not lie within any known functional domains of the Brca1 protein (UniProt.org). E1258G has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23851
BRCA1 L1267S does not lie within any known functional domains of the Brca1 protein (UniProt.org). L1267S restores proliferation to similar level of wild-type Brca1 in Brca1-null embryonic stem cells in culture (PMID: 23867111).,6022,23867111,A high-throughput functional complementation assay for classification of BRCA1 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/23867111,295,,,www.uniprot.org,23852
"ERBB2 (HER2) D277H lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). D277H results in minor changes in Erbb2 (Her2) activity alone, but enhanced phosphorylation of Erbb2 (Her2), Shc and Erk when in combination with S310F in cell culture (PMID: 24971884).",6134,24971884,Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib.,http://www.ncbi.nlm.nih.gov/pubmed/24971884,295,,,www.uniprot.org,23858
ERBB2 (HER2) S653C lies within the transmembrane domain of the Erbb2 (Her2) protein (UniProt.org). S653C results in constitutive activation of Erbb2 (Her2) and phosphorylation of Shc and Erk in cell culture (PMID: 24971884).,295,,,www.uniprot.org,6134,24971884,Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib.,http://www.ncbi.nlm.nih.gov/pubmed/24971884,23862
ERBB2 D821N lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). D821N is weakly transforming and confers Tykerb (lapatinib)-resistance in cell culture (PMID: 18413839).,295,,,www.uniprot.org,5983,18413839,EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.,http://www.ncbi.nlm.nih.gov/pubmed/18413839,23866
"ERBB2 E812K lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). E812K has not been biochemically characterized, but confers Tykerb (lapatinib)-resistance in cell culture (PMID: 18413839).",5983,18413839,EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.,http://www.ncbi.nlm.nih.gov/pubmed/18413839,295,,,www.uniprot.org,23867
"ERBB2 E971G lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). E971G has been identified in the scientific literature (PMID: 21347793), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7980,21347793,Identification of the coexisting HER2 gene amplification and novel mutations in the HER2 protein-overexpressed mucinous epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21347793,295,,,www.uniprot.org,23868
ERBB2 L726I lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). L726I has not been biochemically characterized but confers Iressa (gefitinib)-resistance in cell culture (PMID: 17638894).,295,,,www.uniprot.org,6138,17638894,Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.,http://www.ncbi.nlm.nih.gov/pubmed/17638894,23869
"SMO E518A lies within an extracellular domain of the Smo protein (UniProt.org). E518A confers a gain of function to the Smo protein as demonsrated by activation of a Smo dependent reporter, and continued signaling in the presence of a Smo inhibitor (PMID: 21123452). ",6139,21123452,Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance.,http://www.ncbi.nlm.nih.gov/pubmed/21123452,295,,,www.uniprot.org,23872
"SMO L221R lies within the extracellular domain of the Smo protein (UniProt.org). L221R has not been biochemically characterized, but has been described as a resistance mutation (PMID: 25759020).",2677,25759020,Smoothened variants explain the majority of drug resistance in basal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25759020,295,,,www.uniprot.org,23873
"SMO Q635E lies within the cytoplasmic domain of the Smo protein (UniProt.org). Q635E has not been biochemically characterized, but has been described as a resistance mutation (PMID: 25759020).",2677,25759020,Smoothened variants explain the majority of drug resistance in basal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25759020,295,,,www.uniprot.org,23874
STK11 K78A lies within the protein kinase domain to the Stk11 protein (UniProt.org). K78A confers a loss of function to the Stk11 protein as demonstrated by lack of kinase activity (PMID: 15800014).,295,,,www.uniprot.org,3984,15800014,Functional analysis of Peutz-Jeghers mutations reveals that the LKB1 C-terminal region exerts a crucial role in regulating both the AMPK pathway and the cell polarity.,http://www.ncbi.nlm.nih.gov/pubmed/15800014,23876
STK11 L67P lies within the protein kinase domain of the Stk11 protein (UniProt.org). L67P confers a loss of function to the Stk11 protein as demonstrated by loss of kinase activity (PMID: 9837816).,295,,,www.uniprot.org,457,9837816,"Loss of LKB1 kinase activity in Peutz-Jeghers syndrome, and evidence for allelic and locus heterogeneity.",http://www.ncbi.nlm.nih.gov/pubmed/9837816,23877
STK11 W308C lies within the protein kinase domain of the Stk11 protein (UniProt.org). W308C confers a loss of function to the Stk11 protein as demonstrated by loss of kinase activity (PMID: 9837816).,295,,,www.uniprot.org,457,9837816,"Loss of LKB1 kinase activity in Peutz-Jeghers syndrome, and evidence for allelic and locus heterogeneity.",http://www.ncbi.nlm.nih.gov/pubmed/9837816,23878
STK11 R304W lies within the protein kinase domain of the Stk11 protein (UniProt.org). R304W confers a loss of function to the Stk11 protein as demonstrated by loss of autophosphoryaltion and the inability to suppress growth in culture (PMID: 12552571).,295,,,www.uniprot.org,6141,12552571,Functional analysis of LKB1/STK11 mutants and two aberrant isoforms found in Peutz-Jeghers Syndrome patients.,http://www.ncbi.nlm.nih.gov/pubmed/12552571,23879
STK11 M136R lies within the protein kinase domain of the Stk11 protein (UniProt.org). M136R confers a loss of function to the Stk11 protein as demonstrated by loss of autophosphorylation (PMID: 14668798).,295,,,www.uniprot.org,6142,14668798,Stability of the Peutz-Jeghers syndrome kinase LKB1 requires its binding to the molecular chaperones Hsp90/Cdc37.,http://www.ncbi.nlm.nih.gov/pubmed/14668798,23880
ERBB2 L785F lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). L785F has not been biochemically characterized but confers Tykerb (lapatinib)-resistance in cell culture (PMID: 18413839).,295,,,www.uniprot.org,5983,18413839,EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.,http://www.ncbi.nlm.nih.gov/pubmed/18413839,23882
ERBB2 L915M lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). L915M has not been biochemically characterized but confers Tykerb (lapatinib)-resistance in cell culture (PMID: 18413839).,5983,18413839,EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.,http://www.ncbi.nlm.nih.gov/pubmed/18413839,295,,,www.uniprot.org,23883
"ERBB2 R784H lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). R784H has been identified in the scientific literature (PMID: 24797764), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7982,24797764,ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24797764,23884
"ERBB2 R970W lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). R970W has been identified in the scientific literature (PMID: 21347793), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",7980,21347793,Identification of the coexisting HER2 gene amplification and novel mutations in the HER2 protein-overexpressed mucinous epithelial ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/21347793,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23885
ERBB2 S1002R lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). S1002R has not been biochemically characterized but confers Tykerb (lapatinib)-resistance in cell culture (PMID: 18413839).,5983,18413839,EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.,http://www.ncbi.nlm.nih.gov/pubmed/18413839,295,,,www.uniprot.org,23886
ERBB2 S783P lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). S783P has not been biochemically characterized but confers Tykerb (lapatinib)-resistance in cell culture (PMID: 18413839).,5983,18413839,EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.,http://www.ncbi.nlm.nih.gov/pubmed/18413839,295,,,www.uniprot.org,23887
"ERBB2 T798I lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). T798I does not result in activation of Erbb2 (Her2) downstream signaling or transformation of cultured cells, but is associated with resistance to Erbb2 (Her2) inhibitors (PMID: 25238247, PMID: PMID: 28274957).",6146,25238247,Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1.,http://www.ncbi.nlm.nih.gov/pubmed/25238247,9156,28274957,An Acquired HER2(T798I) Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28274957,295,,,www.uniprot.org,23888
ERBB2 V839G lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). V839G has not been biochemically characterized but confers Tykerb (lapatinib)-resistance in cell culture (PMID: 18413839).,5983,18413839,EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.,http://www.ncbi.nlm.nih.gov/pubmed/18413839,295,,,www.uniprot.org,23889
"ERBB2 Y1248F lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). Y1248F has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23890
ERBB2 Y803N lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). Y803N has not been characterized but confers Tykerb (lapatinib)-resistance in cell culture (PMID: 18413839).,295,,,www.uniprot.org,5983,18413839,EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.,http://www.ncbi.nlm.nih.gov/pubmed/18413839,23891
"ERBB2 Y835F lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). Y835F results in decreased Erbb2 (Her2) kinase activity, reduced cell proliferation, and is not transforming in culture (PMID: 23220880).",295,,,www.uniprot.org,1980,23220880,Activating HER2 mutations in HER2 gene amplification negative breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23220880,23892
"ERBB4 E317K lies within the extracellular domain of the Erbb4 protein (UniProt.org). E317K results in constitutive phosphorylation of Erbb4, increased cell proliferation and is transforming in cell culture (PMID: 19718025).",295,,,www.uniprot.org,566,19718025,Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.,http://www.ncbi.nlm.nih.gov/pubmed/19718025,23894
"ERBB4 E452K lies within the extracellular domain of the Erbb4 protein (UniProt.org). E452K results in constitutive phosphorylation of Erbb4, increased cell proliferation and is transforming in cell culture (PMID: 19718025).",295,,,www.uniprot.org,566,19718025,Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.,http://www.ncbi.nlm.nih.gov/pubmed/19718025,23895
"ERBB4 E563K lies within the extracellular domain of the Erbb4 protein (UniProt.org). E563K results in constitutive phosphorylation of Erbb4, increased cell proliferation and is transforming in cell culture (PMID: 19718025).",566,19718025,Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.,http://www.ncbi.nlm.nih.gov/pubmed/19718025,295,,,www.uniprot.org,23896
"ERBB4 E836K lies within the protein kinase domain of the Erbb4 protein (UniProt.org). E836K results in constitutive phosphorylation of Erbb4, increased cell proliferation and is transforming in cell culture (PMID: 19718025).",566,19718025,Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.,http://www.ncbi.nlm.nih.gov/pubmed/19718025,295,,,www.uniprot.org,23897
"ERBB4 E872K lies within the protein kinase domain of the Erbb4 protein (UniProt.org). E872K results in constitutive phosphorylation of Erbb4, increased cell proliferation and is transforming in cell culture (PMID: 19718025).",566,19718025,Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.,http://www.ncbi.nlm.nih.gov/pubmed/19718025,295,,,www.uniprot.org,23898
"ERBB4 R544W lies within the cytoplasmic domain of the Erbb4 protein (UniProt.org). R544W results in constitutive phosphorylation of Erbb4, increased cell proliferation and is transforming in cell culture (PMID: 19718025).",566,19718025,Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.,http://www.ncbi.nlm.nih.gov/pubmed/19718025,295,,,www.uniprot.org,23899
"PDGFRA C456_N468del results in the deletion of thirteen amino acids in the Ig-like C2-type domain 5 of the Pdgfra protein from amino acids 456 to 468 (UniProt.org). C456_N468del results in constitutive phosphorylation of Pdgfra, activation of Akt signaling, and increased cell proliferation in culture (PMID: 23970477).",6147,23970477,Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas.,http://www.ncbi.nlm.nih.gov/pubmed/23970477,295,,,www.uniprot.org,23900
"PDGFRA C456_R481del results in the deletion of twenty-six amino acids in the Ig-like C2-type domain 5 of the Pdgfra protein from amino acids 456 to 468 (UniProt.org). C456_R481del results in constitutive phosphorylation of Pdgfra, activation of Akt signaling, and increased cell proliferation in culture (PMID: 23970477).",6147,23970477,Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas.,http://www.ncbi.nlm.nih.gov/pubmed/23970477,295,,,www.uniprot.org,23901
"PDGFRA E311_K312del results in the deletion of two amino acids in the extracellular domain of the Pdgfra protein from amino acids 456 to 468 (UniProt.org). E311_K312del results in constitutive phosphorylation of Pdgfra, activation of Akt signaling, and increased cell proliferation in culture (PMID: 23970477).",6147,23970477,Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas.,http://www.ncbi.nlm.nih.gov/pubmed/23970477,295,,,www.uniprot.org,23902
"PDGFRA V544_L555insAVLVLLVIVIISLI results in the insertion of fourteen amino acids in the transmembrane domain of the Pdgfra protein between amino acids 544 and 545 (UniProt.org). V544_L555insAVLVLLVIVIISLI results in constitutive phosphorylation of Pdgfra, activation of Akt signaling, and increased cell proliferation in culture (PMID: 23970477).",295,,,www.uniprot.org,6147,23970477,Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas.,http://www.ncbi.nlm.nih.gov/pubmed/23970477,23903
"PDGFRA C450_K451insMIEWMI results in the insertion of six amino acids in the Ig-like C2-type domain 5 of the Pdgfra protein between amino acids 450 and 451 (UniProt.org). C450_K451insMIEWMI results in constitutive phosphorylation of Pdgfra, activation of Akt signaling, and increased cell proliferation in culture (PMID: 23970477).",295,,,www.uniprot.org,6147,23970477,Novel oncogenic PDGFRA mutations in pediatric high-grade gliomas.,http://www.ncbi.nlm.nih.gov/pubmed/23970477,23904
"PDGFRA Y375_K455del results in the deletion of eighty-one amino acids in the Ig-like C2-type domain 4 of the Pdgfra protein from amino acids 375 to 455 (UniProt.org). Y375_K455del results in constitutive phosphorylation of Pdgfra, promotes proliferation and transformation in cell culture, and induces tumor growth in animal models (PMID: 12569364).",6150,12569364,A human brain tumor-derived PDGFR-alpha deletion mutant is transforming.,http://www.ncbi.nlm.nih.gov/pubmed/12569364,295,,,www.uniprot.org,23905
PDGFRA N848K lies within the protein kinase domain of the Pdgfra protein (UniProt.org). N848K results in constitutive phosphorylation of Pdgfra in cell culture (PMID: 15928335).,272,15928335,"PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.",http://www.ncbi.nlm.nih.gov/pubmed/15928335,295,,,www.uniprot.org,23906
PDGFRA Y894C lies within the protein kinase domain of the Pdgfra protein (UniProt.org). Y894C results in constitutive phosphorylation of Pdgfra in cell culture (PMID: 15928335).,272,15928335,"PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.",http://www.ncbi.nlm.nih.gov/pubmed/15928335,23907
PDGFRA V561_I562insER results in the insertion of two amino acids in the cytoplasmic domain of the Pdgfra protein between amino acids 561 and 562 (UniProt.org). V561_I562insER results in constitutive phosphorylation of Pdgfra in cell culture (PMID: 15928335).,295,,,www.uniprot.org,272,15928335,"PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.",http://www.ncbi.nlm.nih.gov/pubmed/15928335,23908
"PDGFRA S566_E571delinsR results in a deletion of six amino acids from aa 566 to 571 within the cytoplasmic domain of the Pdgfra protein, combined with the insertion of an arginine (R) at the same site (UniProt.org). S566_E571delinsR results in constitutive phosphorylation of Pdgfra in cell culture (PMID: 15928335).",272,15928335,"PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.",http://www.ncbi.nlm.nih.gov/pubmed/15928335,295,,,www.uniprot.org,23912
"PDGFRA R841_D842delinsKI results in a deletion of two amino acids from aa 841 to 842 within the protein kinase domain of the Pdgfra protein, combined with the insertion of a lysine (K) and an isoleucine (I) at the same site (UniProt.org). R841_D842delinsKI results in constitutive phosphorylation of Pdgfra in cell culture (PMID: 15928335).",272,15928335,"PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.",http://www.ncbi.nlm.nih.gov/pubmed/15928335,295,,,www.uniprot.org,23914
"PDGFRA D842_I843delinsIM results in a deletion of two amino acids from aa 842 to 843 within the protein kinase domain of the Pdgfra protein, combined with the insertion of an isoleucine (I) and a methionine (M) at the same site (UniProt.org). D842_I843delinsIM results in constitutive phosphorylation of Pdgfra in cell culture (PMID: 15928335).",272,15928335,"PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.",http://www.ncbi.nlm.nih.gov/pubmed/15928335,295,,,www.uniprot.org,23915
"PDGFRA H845_N848delinsP results in a deletion of four amino acids from aa 845 to 848 within the protein kinase domain of the Pdgfra protein, combined with the insertion of a proline (P) at the same site (UniProt.org). H845_N848delinsP results in constitutive phosphorylation of Pdgfra in cell culture (PMID: 15928335).",272,15928335,"PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.",http://www.ncbi.nlm.nih.gov/pubmed/15928335,295,,,www.uniprot.org,23917
PDGFRA Y555C lies within the cytoplasmic domain of the Pdgfra protein (UniProt.org). Y555C results in constitutive phosphorylation of Pdgfra in cell culture (PMID: 17087943).,295,,,www.uniprot.org,6151,17087943,Intestinal neurofibromatosis is a subtype of familial GIST and results from a dominant activating mutation in PDGFRA.,http://www.ncbi.nlm.nih.gov/pubmed/17087943,23918
"PDGFRA N659S lies within the protein kinase domain of the Pdgfra protein (UniProt.org). N659S results in constitutive phosphorylation of Pdgfra and Stat5, increased cell proliferation, and is transforming in cell culture (PMID: 21224473).",295,,,www.uniprot.org,418,21224473,Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.,http://www.ncbi.nlm.nih.gov/pubmed/21224473,23924
"PDGFRA R748G lies within the protein kinase domain of the Pdgfra protein (UniProt.org). R748G results in constitutive phosphorylation of Pdgfra and Stat5, is transforming in cell culture, and induces leukemia-like disease in animal models (PMID: 21224473).",295,,,www.uniprot.org,418,21224473,Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.,http://www.ncbi.nlm.nih.gov/pubmed/21224473,23925
"PDGFRA Y849S lies within the protein kinase domain of the Pdgfra protein (UniProt.org). Y849S results in constitutive phosphorylation of Pdgfra and Stat5, increased cell proliferation, and is transforming in cell culture (PMID: 21224473).",295,,,www.uniprot.org,418,21224473,Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.,http://www.ncbi.nlm.nih.gov/pubmed/21224473,23926
"PDGFRA W349C lies within the Ig-like C2-type domain 4 of the Pdgfra protein (UniProt.org). W349C results in defective Pdgfra membrane trafficking, loss of ligand-dependent activation Pdgfra, and is not transforming in cell culture (PMID: 23752188).",295,,,www.uniprot.org,476,23752188,PDGFRA alterations in cancer: characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations.,http://www.ncbi.nlm.nih.gov/pubmed/23752188,23928
"PDGFRA D846_S847insTSD results in the insertion of three amino acids in the protein kinase domain of the Pdgfra protein between amino acids 846 and 847 (UniProt.org). D846_S847insTSD has not been characterized in the scientific literature and therefore, its effect on Pdgfra protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23930
"PDGFRA G429R lies within the Ig-like C2-type domain 5 of the Pdgfra protein (UniProt.org). G429R has been identified in the scientific literature (PMID: 20071345), but has not been biochemically characterized and therefore, its effect on Pdgfra protein function is unknown (PubMed, Aug 2017).",7714,20071345,Dysregulation of the PDGFRA gene causes inflow tract anomalies including TAPVR: integrating evidence from human genetics and model organisms.,http://www.ncbi.nlm.nih.gov/pubmed/20071345,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23933
"PDGFRA W559_R560del results in the deletion of two amino acids in the cytoplasmic domain of the Pdgfra protein from amino acids 559 to 560 (UniProt.org). W559_R560del has been identified in the scientific literature (PMID: 26396737), but has not been biochemically characterized and therefore, its effect on Pdgfra protein function is unknown (PubMed, Aug 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7716,26396737,Response to sunitinib of a gastrointestinal stromal tumor with a rare exon 12 PDGFRA mutation.,http://www.ncbi.nlm.nih.gov/pubmed/26396737,295,,,www.uniprot.org,23934
"PIK3CA A1046_H1047insTSA results in the insertion of three amino acids in the PI3K/PI4K domain of the Pik3ca protein between amino acids 1046 and 1047 (UniProt.org). A1046_H1047insTSA has not been characterized in the scientific literature and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23936
"PIK3CA Q546_E547insQTS results in the insertion of three amino acids in the PIK helical domain of the Pik3ca protein between amino acids 546 and 547 (UniProt.org). Q546_E547insQTS has not been characterized in the scientific literature and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23937
"RET C609Y lies within the extracellular domain of the Ret protein (UniProt.org). C609Y results in constitutive activation of Ret, and results in increased resistance to apoptosis, transformation of cultured cells, and enhanced tumor growth in mouse models (PMID: 16715139, PMID: 9230192).",2267,16715139,Evaluation of potential mechanisms underlying genotype-phenotype correlations in multiple endocrine neoplasia type 2.,http://www.ncbi.nlm.nih.gov/pubmed/16715139,2272,9230192,"Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype.",http://www.ncbi.nlm.nih.gov/pubmed/9230192,295,,,www.uniprot.org,23938
"RET C611Y lies within the extracellular domain of the Ret protein (UniProt.org). C611Y has not been fully biochemically characterized, but is transforming in cell culture (PMID: 9230192), and is predicted to confer a gain of function to the Ret protein.",295,,,www.uniprot.org,2272,9230192,"Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype.",http://www.ncbi.nlm.nih.gov/pubmed/9230192,23939
"RET V915_K916insVHR results in the insertion of three amino acids in the protein kinase domain of the Ret protein between amino acids 915 and 916 (UniProt.org). V915_K916insVHR has not been characterized in the scientific literature and therefore, its effect on Ret protein function is unknown (PubMed, Apr 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,23940
"BCOR-RARA results from the fusion of BCOR and RARA and has been identified in acute promyelocytic leukemia, resulting in the ability to bind the retinoic acid response element and altering RARA-driven transcription (PMID: 20807888).",6157,20807888,BCOR as a novel fusion partner of retinoic acid receptor alpha in a t(X;17)(p11;q12) variant of acute promyelocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/20807888,23943
"MLH1 D737V lies within close proximity to the heterodimerization S1 site of the Mlh1 protein (PMID: 23435383). D737V has not been biochemically characterized, however, has been described as a deleterious mutation as determined by a bioinformatic algorithmic tool (PMID: 18383312, PMID: 23435383).",6167,23435383,Structure of the MutLα C-terminal domain reveals how Mlh1 contributes to Pms1 endonuclease site.,http://www.ncbi.nlm.nih.gov/pubmed/23435383,6166,18383312,Accurate classification of MLH1/MSH2 missense variants with multivariate analysis of protein polymorphisms-mismatch repair (MAPP-MMR).,http://www.ncbi.nlm.nih.gov/pubmed/18383312,23959
"MLH1 Q689R does not lie within any known functional domains of the Mlh1 protein (UniProt.org). Q689R demonstrates functional mismatch repair activity in in vitro assays (PMID: 17510385, PMID: 21404117), and thus, is predicted to have no effect on Mlh1 function.",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5174,17510385,Functional analysis of human MLH1 variants using yeast and in vitro mismatch repair assays.,http://www.ncbi.nlm.nih.gov/pubmed/17510385,8995,21404117,Missense variants in hMLH1 identified in patients from the German HNPCC consortium and functional studies.,http://www.ncbi.nlm.nih.gov/pubmed/21404117,295,,,www.uniprot.org,23960
"MLH1 R659L does not lie within any known functional domains of the Mlh1 protein (UniProt.org). R659L confers a loss of function to the Mlh1 protein as demonstrated by decreased MLH1 gene expression and a reduction in dimerization with Pms2 (PMID: 20533529).
",6019,20533529,Identification of Lynch syndrome mutations in the MLH1-PMS2 interface that disturb dimerization and mismatch repair.,http://www.ncbi.nlm.nih.gov/pubmed/20533529,295,,,www.uniprot.org,23966
MLH1 L622H lies within the interaction with EXO1 region of the Mlh1 protein (UniProt.org). L622H confers a loss of function to the Mlh1 protein as demonstrated by decreased gene expression and defects in protein stability (PMID: 23403630).,295,,,www.uniprot.org,6174,23403630,Expression defect size among unclassified MLH1 variants determines pathogenicity in Lynch syndrome diagnosis.,http://www.ncbi.nlm.nih.gov/pubmed/23403630,23971
"MLH1 M587V lies within EXO1-interacting region of the Mlh1 protein (UniProt.org). M587V has not been characterized in the scientific literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,23972
MLH1 L559R lies within the interaction with EXO1 region of the Mlh1 protein (UniProt.org). L559R confers a loss of function to the Mlh1 protein as demonstrated by decreased protein expression and disruption of the interaction between Mlh1 and Pms2 (PMID: 16724012).,295,,,www.uniprot.org,6178,16724012,"Assessing the pathogenicity of MLH1 missense mutations in patients with suspected hereditary nonpolyposis colorectal cancer: correlation with clinical, genetic and functional features.",http://www.ncbi.nlm.nih.gov/pubmed/16724012,23974
"MLH1 N551T lies within the interaction with EXO1 region of the Mlh1 protein (UniProt.org). N551T results in decreased expression compared to wild-type and has been described as a likely pathogenic mutation, and therefore, is predicted to result in a loss of Mlh1 protein function (PMID: 23403630).",295,,,www.uniprot.org,6174,23403630,Expression defect size among unclassified MLH1 variants determines pathogenicity in Lynch syndrome diagnosis.,http://www.ncbi.nlm.nih.gov/pubmed/23403630,23978
FLT3 I836X indicates any Flt3 missense mutation which results in the isoleucine (I) at amino acid 836 being replaced by a different amino acid.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,23981
MLH1 V506A lies within the interaction with EXO1 region of the Mlh1 protein (UniProt.org). V506A is predicted to confer a loss of function to the Mlh1 protein as demonstrated by reduced binding to Pms2 when compared to wild-type in vitro (PMID: 10037723). ,5167,10037723,The interaction of the human MutL homologues in hereditary nonpolyposis colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/10037723,295,,,www.uniprot.org,23982
MLH1 T82A does not lie within any known functional domains of the Mlh1 protein (UniProt.org). T82A confers a loss of function to the Mlh1 protein as demonstrated by loss of mismatch repair activity in vitro (PMID: 22736432). ,6185,22736432,Comprehensive functional assessment of MLH1 variants of unknown significance.,http://www.ncbi.nlm.nih.gov/pubmed/22736432,295,,,www.uniprot.org,23983
"VHL Q73H does not lie within any known functional domains of the Vhl1 protein (UniProt.org). Q73H has not been characterized in the scientific literature and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,23985
"VHL Q73E does not lie within any known functional domains of the Vhl1 protein (UniProt.org). Q73E has not been characterized in the scientific literature and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,23987
VHL Y98H does not lie within any known functional domains of the Vhl protein (UniProt.org). Y98H confers a loss of function to the Vhl protein as demonstrated by defects in Hif1-alpha ubiquitination (PMID: 11331612).,295,,,www.uniprot.org,3224,11331612,von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.,http://www.ncbi.nlm.nih.gov/pubmed/11331612,23989
VHL Y98N does not lie within any known functional domains of the Vhl protein (UniProt.org). Y98N confers a loss of function to the Vhl protein as demonstrated by failure to completely suppress Glut1 and defects in Hif1-alpha ubiquitination (PMID: 10823831).,3235,10823831,Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.,http://www.ncbi.nlm.nih.gov/pubmed/10823831,295,,,www.uniprot.org,23992
"VHL Y98C does not lie within any known functional domains of the Vhl protein (UniProt.org). Y98C has been identified in the scientific literature (PMID: 22799452), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6187,22799452,Identification of 3 novel VHL germ-line mutations in Danish VHL patients.,http://www.ncbi.nlm.nih.gov/pubmed/22799452,23995
"VHL Y112H lies within the CCT binding complex region of the Vhl protein (UniProt.org). Y112H confers a loss of function to the Vhl protein as demonstrated by decreased stability and impaired regulation of Hif1-alpha activity in culture (PMID: 16261165, PMID: 19030229).",6190,19030229,VHL type 2B mutations retain VBC complex form and function.,http://www.ncbi.nlm.nih.gov/pubmed/19030229,6189,16261165,Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1alpha interactions.,http://www.ncbi.nlm.nih.gov/pubmed/16261165,295,,,www.uniprot.org,24002
"VHL N78T does not lie within any known functional domains of the Vhl protein (UniProt.org). N78T has been identified in the scientific literature (PMID: 22177731, PMID: 25691774), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",8291,22177731,"Needle core biopsies provide ample material for genomic and proteomic studies of kidney cancer: observations on DNA, RNA, protein extractions and VHL mutation detection.",http://www.ncbi.nlm.nih.gov/pubmed/22177731,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7429,25691774,pVHL/HIF-regulated CD70 expression is associated with infiltration of CD27+ lymphocytes and increased serum levels of soluble CD27 in clear cell renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25691774,24012
"NOTCH1 C1154W lies within the EGF-like domain 30 of the Notch1 protein (UniProt.org). C1154W has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24013
"NOTCH1 C1253Y lies within the calcium-binding, EGF-like domain 32 of the Notch1 protein (UniProt.org). C1253Y has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24014
"NOTCH1 G115fs results in a change in the amino acid sequence of the Notch1 protein beginning at aa 115 of 2555, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the cytoplasmic domain (UniProt.org), G115fs is predicted to lead to a loss of Notch1 protein function.",295,,,www.uniprot.org,24015
"NOTCH1 G1195R lies within the calcium-binding, EGF-like domain 31 of the Notch1 protein (UniProt.org). G1195R has been identified in sequencing studies (PMID: 23856246, PMID: 24755471), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",6962,24755471,Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24755471,6964,23856246,The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.,http://www.ncbi.nlm.nih.gov/pubmed/23856246,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24016
"NOTCH1 P915L lies within the EGF-like domain 24 of the Notch1 protein (UniProt.org). P915L has been identified in sequencing studies (PMID: 23856246, PMID: 24755471, PMID: 25344691), but has not been biochemically characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",6962,24755471,Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24755471,1689,25344691,RNF43 is frequently mutated in colorectal and endometrial cancers.,http://www.ncbi.nlm.nih.gov/pubmed/25344691,6964,23856246,The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.,http://www.ncbi.nlm.nih.gov/pubmed/23856246,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24017
"NOTCH1 Q1134R lies within the EGF-like domain 29 of the Notch1 protein (UniProt.org). Q1134R has been identified in the scientific literature (PMID: 24277457), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",8157,24277457,Common and complex Notch1 mutations in Chinese oral squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24277457,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24018
"VHL S80N does not lie within any known functional domains of the Vhl protein (UniProt.org). S80N has been identified in the scientific literature (PMID: 22683710, PMID: 23797736), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,3409,22683710,BAP1 loss defines a new class of renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22683710,7248,23797736,Integrated molecular analysis of clear-cell renal cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/23797736,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24019
"NOTCH1 S2450N lies within the cytoplasmic domain of the Notch1 protein (UniProt.org). S2450N has been identified in sequencing studies (PMID: 24755471), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,6962,24755471,Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24755471,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24020
"NOTCH1 S94C lies within the EGF-like domain 2 of the Notch1 protein (UniProt.org). S94C has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24021
VHL P86H does not lie within any known functional domains of the Vhl protein (UniProt.org). P86H confers a loss of function to the Vhl protein as demonstrated by failure to suppress GLUT1 expression and impaired regulatory activity of Hif1-alpha (PMID: 10535940).,295,,,www.uniprot.org,6191,10535940,Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex.,http://www.ncbi.nlm.nih.gov/pubmed/10535940,24025
"NRAS T58_A59insTDV results in the insertion of three amino acids in the Nras protein between amino acids 58 and 59 (UniProt.org). T58_A59insTDV has not been characterized in the scientific literature and therefore, its effect on Nras protein function is unknown (PubMed, Jul 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24029
"VHL H115R lies within the CCT complex binding region of the Vhl protein (UniProt.org). H115R is predicted to confer a loss of function to the Vhl protein based on computer modeling, demonstrating decreased protein stability and interference with Hif1 binding (PMID: 22105711).",295,,,www.uniprot.org,6192,22105711,Effects of point mutations in pVHL on the binding of HIF-1α.,http://www.ncbi.nlm.nih.gov/pubmed/22105711,24032
"PIK3CA Y56H lies within the PI3K-ABD domain of the Pik3ca protein (UniProt.org). Y56H has not been characterized and therefore, its effect on Pik3ca protein is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24035
VHL W117C lies within the CCT complex binding region of the Vhl protein (UniProt.org). W117C confers a loss of function to the Vhl protein as demonstrated by weak binding with CCT resulting in improper folding of the VHL-elongin BC complex (PMID: 14636579).,295,,,www.uniprot.org,3226,14636579,Tumorigenic mutations in VHL disrupt folding in vivo by interfering with chaperonin binding.,http://www.ncbi.nlm.nih.gov/pubmed/14636579,24037
"ALK P1599S does not lie within any known functional domains of the Alk protein (UniProt.org). P1599S has not been characterized in the scientific literature and therefore, its effect on Alk protein function is unknown (PubMed, Jul 2017). ",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24067
"ALK D94N does not lie within any known functional domains of the Alk protein (UniProt.org). D94N has not been characterized in the scientific literature and therefore, its effect on Alk protein function is unknown (PubMed, Jul 2017). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24068
"ALK P1298S lies within the protein kinase domain of the Alk protein (UniProt.org). P1298S has been identified in sequencing studies (PMID: 24755471), but has not been biochemically characterized and therefore, its effect on Alk protein function is unknown (PubMed, Jul 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6962,24755471,Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24755471,24069
"ALK P36S does not lie within any known functional domains of the Alk protein (UniProt.org). P36S has not been characterized in the scientific literature and therefore, its effect on Alk protein function is unknown (PubMed, Jul 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24070
"ALK R753Q does not lie within any known functional domains of the Alk protein (UniProt.org). R753Q has not been characterized in the scientific literature and therefore, its effect on Alk protein function is unknown (PubMed, Jul 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24071
"ERBB4 R393W lies within the extracellular domain of the Erbb4 protein (UniProt.org). R393W has been identified in the scientific literature (PMID: 24258993), but has not been biochemically characterized and therefore, its effect on Erbb4 protein function is unknown (PubMed, May 2017).",8934,24258993,ERBB4 mutation analysis: emerging molecular target for melanoma treatment.,http://www.ncbi.nlm.nih.gov/pubmed/24258993,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24079
"APC A1446_Q1447insDIA results in the insertion of three amino acids in the Apc protein between amino acids 1446 and 1447 (UniProt.org). A1446_Q1447insDIA has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24088
"APC D1394fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1394 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). D1394fs has not been characterized, however Apc truncation mutants downstream of D1394 are inactivating (PMID: 18199528) thus, D1394fs is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,24089
"APC G471E lies within the ARM 1 repeat domain of the Apc protein (UniProt.org). G471E has been identified in sequencing studies (PMID: 24755471), but has not been biochemically characterized and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6962,24755471,Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24755471,24090
"APC K1462fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1462 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). K1462fs has not been characterized, however Apc truncation mutants downstream of K1462 are inactivating (PMID: 18199528) thus, K1462fs is predicted to lead to a loss of Apc protein function.
",295,,,www.uniprot.org,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,24091
"APC K1817fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1817 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). K1817fs has not been characterized, however Apc truncation mutants downstream of K1817 are inactivating (PMID: 18199528) thus, K1817fs is predicted to lead to a loss of Apc protein function.
",295,,,www.uniprot.org,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,24092
"APC N741fs results in a change in the amino acid sequence of the Apc protein beginning at aa 741 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). N741fs has not been characterized, however Apc truncation mutants downstream of N741 are inactivating (PMID: 18199528) thus, N741fs is predicted to lead to a loss of Apc protein function.
",295,,,www.uniprot.org,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,24093
"APC T518A lies within the ARM 2 repeat domain of the Apc protein (UniProt.org). T518A has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24094
"ATM A1127V does not lie within any known functional domains of the Atm protein (UniProt.org). A1127V has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017). ",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24100
"ATM K3043R lies within the FATC domain of the Atm protein (UniProt.org). K3043R has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24101
"ATM P178S does not lie within any known functional domains of the Atm protein (UniProt.org). P178S has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24102
"ATM Q2762R lies within the PI3K/PI4K domain of the Atm protein (UniProt.org). Q2762R has been identified in sequencing studies (PMID: 24755471), but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017).

",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6962,24755471,Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24755471,24103
"ATM T1350M does not lie within any known functional domains of the Atm protein (UniProt.org). T1350M has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Feb 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24104
"CALR D392_D394del results in the deletion of three amino acids in the C-domain region of the Calr protein from amino acids 392 to 394 (UniProt.org). D392_D394del has not been characterized in the scientific literature and therefore, its effect on Calr protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24112
"CALR S189T lies within the N-domain region of the Calr protein (UniProt.org). S189T has not been characterized in the scientific literature and therefore, its effect on Calr protein function is unknown (PubMed, May 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24113
"CBL L892F lies within the UBA domain of the Cbl protein (UniProt.org). L892F has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Feb 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24114
NRAS Y64D does not lie within any known functional domains of the Nras protein (UniProt.org). Y64D does not confer transforming activity to the Nras protein as demonstrated by the lack of tumor formation in animal models (PMID: 27147599).,6273,27147599,Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.,http://www.ncbi.nlm.nih.gov/pubmed/27147599,24126
IDH1 E190K does not lie within any known functional domains of the Idh1 protein (UniProt.org). E190K does not confer transforming activity to the Idh1 protein as demonstrated by the lack of tumor formation in animal models (PMID: 27147599).,6273,27147599,Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.,http://www.ncbi.nlm.nih.gov/pubmed/27147599,295,,,www.uniprot.org,24127
IDH2 E268D does not lie within any known functional domains of the Idh2 protein (UniProt.org). E268D does not confer transforming activity to the Idh2 protein as demonstrated by the lack of tumor formation in animal models (PMID: 27147599).,6273,27147599,Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.,http://www.ncbi.nlm.nih.gov/pubmed/27147599,295,,,www.uniprot.org,24128
IDH2 A416V does not lie within any known functional domains of the Idh2 protein (UniProt.org). A416V does not confer transforming activity to the Idh2 protein as demonstrated by the lack of tumor formation in animal models (PMID: 27147599).,6273,27147599,Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.,http://www.ncbi.nlm.nih.gov/pubmed/27147599,295,,,www.uniprot.org,24129
IDH2 A47V does not lie within any known functional domains of the Idh2 protein (UniProt.org). A47V does not confer transforming activity to the Idh2 protein as demonstrated by the lack of tumor formation in animal models (PMID: 27147599).,6273,27147599,Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.,http://www.ncbi.nlm.nih.gov/pubmed/27147599,295,,,www.uniprot.org,24130
"PTEN R233Q lies within the C2 tensin-type domain of the Pten protein (UniProt.org). R233Q has not been biochemically characterized, however, is correlated with wild-type Pten phenotype in an in vivo tumor growth assay (PMID: 27147599).",295,,,www.uniprot.org,6273,27147599,Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.,http://www.ncbi.nlm.nih.gov/pubmed/27147599,24131
"PTEN K6N does not lie within any known functional domains of the Pten protein (UniProt.org). K6N has not been biochemically characterized, however, overexpression of K6N correlates with the phenotype induced by wild-type Pten overexpression in an in vivo tumor formation assay (PMID: 27147599).",295,,,www.uniprot.org,6273,27147599,Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.,http://www.ncbi.nlm.nih.gov/pubmed/27147599,24132
FBXW7 I347M does not lie within any known functional domains of the Fbxw7 protein (UniProt.org). I347M is predicted to have activity similar to wild-type Fbxw7 based on comparison and correlation analysis of induced gene expression signatures (PMID: 27147599).,6273,27147599,Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.,http://www.ncbi.nlm.nih.gov/pubmed/27147599,295,,,www.uniprot.org,24133
FBXW7 S462Y lies within the WD 3 repeat domain of the Fbxw7 protein (UniProt.org). S462Y is predicted to have activity similar to wild-type Fbxw7 based on comparison and correlation analysis of induced gene expression signatures (PMID: 27147599).,6273,27147599,Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.,http://www.ncbi.nlm.nih.gov/pubmed/27147599,295,,,www.uniprot.org,24134
"CSF1R A245S lies within the Ig-like C2-type domain 3 of the Csf1r protein (UniProt.org). A245S has been identified in sequencing studies (PMID: 23649896), but has not been biochemically characterized and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9144,23649896,Genetic analysis of inherited leukodystrophies: genotype-phenotype correlations in the CSF1R gene.,http://www.ncbi.nlm.nih.gov/pubmed/23649896,24135
"BRCA2 C3198R does not lie within any known functional domains of the Brca2 protein (UniProt.org). C3198R has been identified in sequencing studies (PMID: 17924331), but has not been biochemically characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, Feb 2017).
",7915,17924331,"A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes.",http://www.ncbi.nlm.nih.gov/pubmed/17924331,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24145
"BRCA2 E2871D does not lie within any known functional domains of the Brca2 protein (UniProt.org). E2871D has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, Feb 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24146
"BRCA2 I2672fs results in a change in the amino acid sequence of the Brca2 protein beginning at aa 2672 of 3418, likely resulting in premature truncation of the functional protein (UniProt.org). I2672fs has not been characterized, however, due to the effects of other truncations downstream of I2672 (PMID: 12619154), I2672fs is predicted to lead to a loss of Brca2 protein function.",295,,,www.uniprot.org,2580,12619154,"Deletion of Brca2 exon 27 causes hypersensitivity to DNA crosslinks, chromosomal instability, and reduced life span in mice.",http://www.ncbi.nlm.nih.gov/pubmed/12619154,24147
"BRCA2 K1453E lies within the BRCA2 repeat 3 of the Brca2 protein (UniProt.org). K1453E has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24148
"BRCA2 K1565N lies within the POLH-interaction region of the Brca2 protein (UniProt.org). K1565N has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24149
"TP53 A276_G279del results in the deletion of four amino acids in the DNA interaction region of the Tp53 protein from amino acids 276 to 279 (UniProt.org). A276_G279del has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24155
"TP53 E171_V172insDDV results in the insertion of three amino acids in the DNA-binding domain of the TP53 protein between amino acids 171 and 172 (PMID: 15510160). E171_V172insDDV has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Feb 2017).",5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24156
"TP53 E224D lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). E224D has been identified in sequencing studies (PMID: 24755471, PMID: 22669068, PMID: 19930417), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Feb 2017).
",6962,24755471,Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24755471,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7931,19930417,Beyond BRCA1 and BRCA2 wild-type breast and/or ovarian cancer families: germline mutations in TP53 and PTEN.,http://www.ncbi.nlm.nih.gov/pubmed/19930417,7930,22669068,p53 expression and mutation analysis of odontogenic cysts with and without dysplasia.,http://www.ncbi.nlm.nih.gov/pubmed/22669068,24157
"TP53 E349fs results in a change in the amino acid sequence of the Tp53 protein beginning at aa 349 of 393, likely resulting in premature truncation of the functional protein (UniProt.org). E349fs has been identified in sequencing studies (PMID: 24140581), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Feb 2017).
",7251,24140581,The genetic landscape of anaplastic astrocytoma.,http://www.ncbi.nlm.nih.gov/pubmed/24140581,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24158
"TP53 G245_M246insAMC results in the insertion of three amino acids in the DNA-binding domain of the Tp53 protein between amino acids 245 and 246 (UniProt.org). G245_M246insAMC has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24159
TP53 S241C lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). S241C results in a loss of Tp53 transactivation activity in a yeast assay (PMID: 20407015).,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,643,20407015,Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20407015,24160
"TP53 S392fs results in a change in the amino acid sequence of the Tp53 protein beginning at aa 392 of 393, likely resulting in premature truncation of the functional protein (UniProt.org). S392fs has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24161
"TP53 T118fs results in a change in the amino acid sequence of the Tp53 protein beginning at aa 118 of 393, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the disruption of the DNA binding domain and the loss of the oligomerization domain (PMID: 21561095), T118Qfs*5 is predicted to lead to a loss of Tp53 protein function.",2155,21561095,"Structural effects of the L145Q, V157F, and R282W cancer-associated mutations in the p53 DNA-binding core domain.",http://www.ncbi.nlm.nih.gov/pubmed/21561095,295,,,www.uniprot.org,24162
"BRCA2 D1420Y lies within the POLH interacting domain of the Brca2 protein (UniProt.org). D1420Y has been identified in the scientific literature (PMID: 12215251) but has not been biochemically characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, Feb 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6634,12215251,Characterization of common BRCA1 and BRCA2 variants.,http://www.ncbi.nlm.nih.gov/pubmed/12215251,24174
"BRCA2 D596H does not lie within any known functional domains of the Brca2 protein (UniProt.org). D596H has been identified in sequencing studies (PMID: 16284991), but has not been biochemically characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, Feb 2017).
",7916,16284991,BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.,http://www.ncbi.nlm.nih.gov/pubmed/16284991,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24175
"VHL D121G lies within the CCT complex-binding region of the Vhl protein (UniProt.org). D121G results in decreased binding to Elongin C, but retains Vhl interaction with CUL2, ROC1, and Elongin B, and HIF regulation in culture (PMID: 19030229, PMID: 11865071).",6190,19030229,VHL type 2B mutations retain VBC complex form and function.,http://www.ncbi.nlm.nih.gov/pubmed/19030229,6295,11865071,Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity.,http://www.ncbi.nlm.nih.gov/pubmed/11865071,295,,,www.uniprot.org,24225
VHL L158Q lies within the Elongin BC complex interaction region of the Vhl protein (UniProt.org). L158Q results in decreased Vhl binding to Elongin C but retains HIF regulation in culture (PMID: 26503325).,295,,,www.uniprot.org,6298,26503325,E2-EPF UCP regulates stability and functions of missense mutant pVHL via ubiquitin mediated proteolysis.,http://www.ncbi.nlm.nih.gov/pubmed/26503325,24229
VHL Q164R lies within the Elongin BC complex interaction region of the Vhl protein (UniProt.org). Q164R results in decreased Vhl binding to Elongin C but retains HIF regulation in culture (PMID: 26503325).,6298,26503325,E2-EPF UCP regulates stability and functions of missense mutant pVHL via ubiquitin mediated proteolysis.,http://www.ncbi.nlm.nih.gov/pubmed/26503325,295,,,www.uniprot.org,24232
VHL V155A lies within the CCT complex interaction region of the Vhl protein (UniProt.org). V155A results in decreased Vhl binding to Elongin C but retains HIF regulation in culture (PMID: 26503325).,6298,26503325,E2-EPF UCP regulates stability and functions of missense mutant pVHL via ubiquitin mediated proteolysis.,http://www.ncbi.nlm.nih.gov/pubmed/26503325,295,,,www.uniprot.org,24233
"VHL R161Q lies within the Elongin BC complex interaction region of the Vhl protein (UniProt.org). R161Q has been identified in the scientific literature (PMID: 17102087, PMID: 14767570, PMID: 23842656), but has not been biochemically characterized and therefore, its effect on Vhl protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8294,23842656,p.N78S and p.R161Q germline mutations of the VHL gene are present in von Hippel-Lindau syndrome in two pedigrees.,http://www.ncbi.nlm.nih.gov/pubmed/23842656,8293,14767570,A variety of phenotype with R161Q germline mutation of the von Hippel-Lindau tumor suppressor gene in Japanese kindred.,http://www.ncbi.nlm.nih.gov/pubmed/14767570,8292,17102087,Germline mutation of von Hippel-Lindau (VHL) gene 695 G>A (R161Q) in a patient with a peculiar phenotype with type 2C VHL syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/17102087,24234
"FGFR2 G183fs results in a change in the amino acid sequence of the Fgfr2 protein beginning at aa 183 of 821, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), G183fs is predicted to lead to a loss of Fgfr2 function.

",295,,,www.uniprot.org,24239
"NOTCH1 D2020H lies within the ANK repeat 6 region of the Notch1 protein (UniProt.org). D2020H has not been biochemically characterized, however, is predicted to disrupt ligand binding to Notch1 by structural analysis (PMID: 27228302).",295,,,www.uniprot.org,5947,27228302,Does Notch play a tumor suppressor role across diverse squamous cell carcinomas?,http://www.ncbi.nlm.nih.gov/pubmed/27228302,24253
"NOTCH1 G1995D lies within the ANK repeat 3 region of the Notch1 protein (UniProt.org). G1995D has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24254
"NOTCH1 Q619L lies within the calcium-binding, EGF-like domian 16 of the Notch1 protein (UniProt.org). Q619L has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24255
"NOTCH1 V2110M lies within the ANK repeat 6 region of the Notch1 protein (UniProt.org).  V2110M has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24256
"PIK3CA D1045V lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). D1045V has not been characterized in the scientific literature and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24261
"PIK3CA Q643H lies within the PIK helical domain of the Pik3ca protein (UniProt.org). Q643H has not been characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24262
GNA11 mutant indicates an unspecified mutation in the GNA11 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,24267
"GNAQ mutant indicates an unspecified mutation in the GNAQ gene.
",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,24268
"MLH1 loss indicates loss of the MLH1 gene, mRNA, and protein.
",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,24272
"FGFR3 P253_I254insHIA results in the insertion of three amino acids in the Ig-like C2-type 3 domain of the Fgfr3 protein between amino acids 253 and 254 (UniProt.org). P253_I254insHIA has not been characterized in the scientific literature and therefore, its effect on Fgfr3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24284
"AKT1 D221N lies within the protein kinase domain of the Akt1 protein (UniProt.org). D221N has been identified in sequencing studies (PMID: 22820256, PMID: 25957691), but has not been biochemically characterized and therefore, its effect on Akt1 protein function is unknown (PubMed, Feb 2017). ",7004,25957691,Prospective derivation of a living organoid biobank of colorectal cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/25957691,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7459,22820256,Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations.,http://www.ncbi.nlm.nih.gov/pubmed/22820256,24287
"AKT1 D44N lies within the PH domain of the Akt1 protein (UniProt.org). D44N has not been characterized in the scientific literature and therefore, its effect on Akt1 protein function is unknown (PubMed, Feb 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24288
"AKT1 E267G lies within the protein kinase domain of the Akt1 protein (UniProt.org). E267G has not been biochemically characterized, but induces tumor development in animal models and therefore, is predicted to confer a gain of function to the Akt1 protein (PMID: 27147599). 
",6273,27147599,Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.,http://www.ncbi.nlm.nih.gov/pubmed/27147599,295,,,www.uniprot.org,24289
"AKT1 R370C lies within the protein kinase domain of the Akt1 protein (UniProt.org). R370C has not been biochemically characterized, but induces tumor development in animal models and therefore, is predicted to result in a gain of function (PMID: 27147599). ",6273,27147599,Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.,http://www.ncbi.nlm.nih.gov/pubmed/27147599,295,,,www.uniprot.org,24290
"AKT1 V201I lies within the protein kinase domain of the Akt1 protein (UniProt.org). V201I has not been characterized in the scientific literature and therefore, its effect on Akt1 protein function is unknown (PubMed, Feb 2017). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24291
"ALK E862D does not lie within any known functional domains of the Alk protein (UniProt.org). E862D has not been characterized in the scientific literature and therefore, its effect on Alk protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24292
"ALK G1269E lies within the protein kinase domain of the Alk protein (UniProt.org). G1269E has not been characterized in the scientific literature and therefore, its effect on Alk protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24293
"ALK G746C does not lie within any known functional domains of the Alk protein (UniProt.org). G746C has not been characterized in the scientific literature and therefore, its effect on Alk protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24294
"ALK G922R does not lie within any known functional domains of the Alk protein (UniProt.org). G922R has not been characterized in the scientific literature and therefore, its effect on Alk protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24295
"ALK P1112Q does not lie within any known functional domains of the Alk protein (UniProt.org). P1112Q has not been characterized in the scientific literature and therefore, its effect on Alk protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24296
"APC A1347T lies within the mutator cluster region of the Apc protein (PMID: 14672538). A1347T has been identified in sequencing studies (PMID: 22622578), but has not been biochemically characterized and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,6955,22622578,Melanoma genome sequencing reveals frequent PREX2 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/22622578,24297
"APC A214V does not lie within any known functional domains of the Apc protein (UniProt.org). A214V has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24298
"APC C1410S does not lie within any known functional domains of the Apc protein (UniProt.org). C1410S has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24299
"APC G1312R does not lie within any known functional domains of the Apc protein (UniProt.org). G1312R has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24300
"APC Q1429R does not lie within any known functional domains of the Apc protein (UniProt.org). Q1429R has been identified in sequencing studies (PMID: 21720365) but has not been biochemically characterized and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",6943,21720365,Integrated genomic analyses of ovarian carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/21720365,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24301
"APC R1158K does not lie within any known functional domains of the Apc protein (UniProt.org). R1158K has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24302
"APC V1452I does not lie within any known functional domains of the Apc protein (UniProt.org). V1452I has been identified in sequencing studies (PMID: 27311873) but has not been biochemically characterized and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",7791,27311873,"Circumscribed sebaceous neoplasms: a morphological, immunohistochemical and molecular analysis.",http://www.ncbi.nlm.nih.gov/pubmed/27311873,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24303
"FGFR1 A268S lies within the Ig-like C2-type domain 3 of the Fgfr1 protein (UniProt.org). A268S has been identified in sequencing studies (PMID: 18056464), but has not been biochemically characterized and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Jan 2017).",2109,18056464,Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/18056464,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24310
"FGFR1 A431S lies within the cytoplasmic domain of the Fgfr1 protein (UniProt.org). A431S has been identified in sequencing studies (PMID: 12738854), but has not been biochemically characterized and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7549,12738854,Mutational analysis of the tyrosine kinome in colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/12738854,24311
"FGFR1 C381R lies within the transmembrane domain of the Fgfr1 protein (UniProt.org). C381R has been identified in sequencing studies (PMID: 19855393), but has not been biochemically characterized and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,801,19855393,Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors.,http://www.ncbi.nlm.nih.gov/pubmed/19855393,24312
"FGFR1 E334Q lies within the Ig-like C2-type domain 3 of the Fgfr1 protein (UniProt.org). E334Q has been identified in sequencing studies (PMID: 25056374), but has not been biochemically characterized and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7205,25056374,Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/25056374,24313
"FGFR1 K598N lies within the protein kinase domain of the Fgfr1 protein (UniProt.org). K598N has been identified in sequencing studies (PMID: 23525077), but has not been biochemically characterized and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Jan 2017).",7021,23525077,Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity.,http://www.ncbi.nlm.nih.gov/pubmed/23525077,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24314
"FGFR1 K655I lies within the protein kinase domain of the Fgfr1 protein (UniProt.org). K655I has been identified in sequencing studies (PMID: 26920151), but has not been biochemically characterized and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7573,26920151,Germline and somatic FGFR1 abnormalities in dysembryoplastic neuroepithelial tumors.,http://www.ncbi.nlm.nih.gov/pubmed/26920151,24315
"FGFR1 K656D lies within the protein kinase domain of the Fgfr1 protein (UniProt.org). K656D has been identified in sequencing studies (PMID: 24750136), but has not been biochemically characterized and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7550,24750136,A comparative analysis of MAPK pathway hallmark alterations in pilocytic astrocytomas: age-related and mutually exclusive. [corrected].,http://www.ncbi.nlm.nih.gov/pubmed/24750136,295,,,www.uniprot.org,24316
"FGFR1 K656M lies within the protein kinase domain of the Fgfr1 protein (UniProt.org). K656M has been identified in sequencing studies (PMID: 24185512), but has not been biochemically characterized and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Jan 2017).",1929,24185512,ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24185512,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24317
"FGFR1 K656N lies within the protein kinase domain of the Fgfr1 protein (UniProt.org). K656N has been identified in sequencing studies (PMID: 24750136), but has not been biochemically characterized and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7550,24750136,A comparative analysis of MAPK pathway hallmark alterations in pilocytic astrocytomas: age-related and mutually exclusive. [corrected].,http://www.ncbi.nlm.nih.gov/pubmed/24750136,295,,,www.uniprot.org,24318
"FGFR1 N330I lies within the Ig-like C2-type domain 3 of the Fgfr1 protein (UniProt.org). N330I has been identified in sequencing studies (PMID: 15625620), but has not been biochemically characterized and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Jan 2017).",7551,15625620,Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation.,http://www.ncbi.nlm.nih.gov/pubmed/15625620,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24319
"FGFR1 P150S does not lie within any known functional domains of the Fgfr1 protein (UniProt.org). P150S has been identified in sequencing studies (PMID: 25042771), but has not been biochemically characterized and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7030,25042771,The mutational burdens and evolutionary ages of early gastric cancers are comparable to those of advanced gastric cancers.,http://www.ncbi.nlm.nih.gov/pubmed/25042771,295,,,www.uniprot.org,24320
"FGFR1 P252R does not lie within any known functional domains of the Fgfr1 protein (UniProt.org). P252R has been identified in sequencing studies (PMID: 23348274), but has not been biochemically characterized and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7552,23348274,FGFR1 and FGFR2 mutations in Pfeiffer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/23348274,24321
"FGFR1 R576W lies within the protein kinase domain of the Fgfr1 protein (UniProt.org). R576W has been identified in sequencing studies (PMID: 16186508), but has not been biochemically characterized and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Jan 2017).",7553,16186508,Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas.,http://www.ncbi.nlm.nih.gov/pubmed/16186508,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24322
"FGFR1 R78H lies within the Ig-like C2-type domain 1 of the Fgfr1 protein (UniProt.org). R78H has been identified in sequencing studies (PMID: 18056464), but has not been biochemically characterized and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Jan 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,2109,18056464,Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/18056464,24323
"FGFR1 S430F lies within the cytoplasmic domain of the Fgfr1 protein (UniProt.org). S430F has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Jan 2017).",295,,,www.uniprot.org,5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24324
"FGFR1 T141R does not lie within any known functional domains of the Fgfr1 protein (UniProt.org). T141R has been identified in sequencing studies (PMID: 23887298), but has not been biochemically characterized and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7555,23887298,Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy.,http://www.ncbi.nlm.nih.gov/pubmed/23887298,24325
"FGFR1 T658P lies within the protein kinase domain of the Fgfr1 protein (UniProt.org). T658P has been identified in sequencing studies (PMID: 23817572), but has not been biochemically characterized and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1902,23817572,Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.,http://www.ncbi.nlm.nih.gov/pubmed/23817572,24326
"FGFR1 V664L lies within the protein kinase domain of the Fgfr1 protein (UniProt.org). V664L has been identified in sequencing studies (PMID: 16140923), but has not been biochemically characterized and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7178,16140923,Somatic mutations of the protein kinase gene family in human lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16140923,24327
"FGFR1 Y374C lies within the extracellular domain of the Fgfr1 protein (UniProt.org). Y374C has not been characterized, but is predicted to affect the protein function of Fgfr1 by structural modeling (PMID: 27896051).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7576,27896051,Screening of mutations affecting protein stability and dynamics of FGFR1-A simulation analysis.,http://www.ncbi.nlm.nih.gov/pubmed/27896051,24328
"FGFR2 A314D lies within the Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). A314D has been identified in sequencing studies (PMID: 18552176), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,252,18552176,Drug-sensitive FGFR2 mutations in endometrial carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18552176,24329
"FGFR2 A315S lies within the Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). A315S has been identified in sequencing studies (PMID: 18552176), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).",252,18552176,Drug-sensitive FGFR2 mutations in endometrial carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18552176,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24330
"FGFR2 A344G lies within the Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). A344G has been identified in sequencing studies (PMID: 7874170), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7579,7874170,Jackson-Weiss and Crouzon syndromes are allelic with mutations in fibroblast growth factor receptor 2.,http://www.ncbi.nlm.nih.gov/pubmed/7874170,24331
"FGFR2 A344P lies within the Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). A344P has been identified in sequencing studies (PMID: 11556600), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7580,11556600,A case of Pfeiffer syndrome type 1 with an A344P mutation in the FGFR2 gene.,http://www.ncbi.nlm.nih.gov/pubmed/11556600,295,,,www.uniprot.org,24332
"FGFR2 A97T lies within the Ig-like C2-type domain 1 of the Fgfr2 protein (UniProt.org). A97T has been identified in sequencing studies (PMID: 18552176), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).
",252,18552176,Drug-sensitive FGFR2 mutations in endometrial carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18552176,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24333
"FGFR2 C278F lies within the Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). C278F results in increased Fgfr2 dimerization and autophosphorylation, however, it also lead to rapid FGFR2 degradation (PMID: 16844695), impaired Erk and TGF-beta signaling, and decreased cell viability in culture (PMID: 20004243).",6307,16844695,"Intracellular retention, degradation, and signaling of glycosylation-deficient FGFR2 and craniosynostosis syndrome-associated FGFR2C278F.",http://www.ncbi.nlm.nih.gov/pubmed/16844695,6306,20004243,A single-point mutation in FGFR2 affects cell cycle and Tgfbeta signalling in osteoblasts.,http://www.ncbi.nlm.nih.gov/pubmed/20004243,295,,,www.uniprot.org,24334
"FGFR2 C342F lies within the Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). C342F has been identified in sequencing studies (PMID: 11781872), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).
",7212,11781872,Genomic screening of fibroblast growth-factor receptor 2 reveals a wide spectrum of mutations in patients with syndromic craniosynostosis.,http://www.ncbi.nlm.nih.gov/pubmed/11781872,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24335
"FGFR2 C342R lies within the Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). C342R has been identified in sequencing studies (PMID: 11781872), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Mar 2017).
",7212,11781872,Genomic screening of fibroblast growth-factor receptor 2 reveals a wide spectrum of mutations in patients with syndromic craniosynostosis.,http://www.ncbi.nlm.nih.gov/pubmed/11781872,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24336
"FGFR2 C342S lies within the Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). C342S has been identified in sequencing studies (PMID: 11781872), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Mar 2017).
",7212,11781872,Genomic screening of fibroblast growth-factor receptor 2 reveals a wide spectrum of mutations in patients with syndromic craniosynostosis.,http://www.ncbi.nlm.nih.gov/pubmed/11781872,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24337
"FGFR2 D138N does not lie within any known functional domains of the Fgfr2 protein (UniProt.org). D138N has been identified in sequencing studies (PMID: 17360555), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).",7556,17360555,Impaired FGF signaling contributes to cleft lip and palate.,http://www.ncbi.nlm.nih.gov/pubmed/17360555,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24338
"FGFR2 D247Y lies within the Ig-like C2-type domain 2 of the Fgfr2 protein (UniProt.org). D247Y has been identified in sequencing studies (PMID: 25035393), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).",295,,,www.uniprot.org,7568,25035393,Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a Pan-FGFR inhibitor in a mouse model of NSCLC.,http://www.ncbi.nlm.nih.gov/pubmed/25035393,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24339
"FGFR2 D283N lies within the Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). D283N has been identified in sequencing studies (PMID: 16140923), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).",295,,,www.uniprot.org,7178,16140923,Somatic mutations of the protein kinase gene family in human lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16140923,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24340
"FLT3 P606L does not lie within any known functional domains of the Flt3 protein (UniProt.org). P606L has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Apr 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24341
"FLT3 V197A does not lie within any known functional domains of the Flt3 protein (UniProt.org). V197A has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Apr 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24342
"ATM A3006T does not lie within any known functional domains of the Atm protein (UniProt.org). A3006T has been identified in sequencing studies (PMID: 23415222) but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7846,23415222,Evolution and impact of subclonal mutations in chronic lymphocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23415222,24343
"ATM C430S does not lie within any known functional domains of the Atm protein (UniProt.org). C430S has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24344
"ATM G2695S does not lie within any known functional domains of the Atm protein (UniProt.org). G2695S has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24345
"ATM H2038Y lies within the FAT domain of the Atm protein (UniProt.org). H2038Y has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24346
"ATM R1466Q does not lie within any known functional domains of the Atm protein (UniProt.org). R1466Q has been identified in sequencing studies (PMID: 22895193), but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,4597,22895193,Recurrent R-spondin fusions in colon cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22895193,24347
"ATRX D1615G lies within the Helicase ATP-binding domain of the Atrx protein (UniProt.org). D1615G has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24348
"ATRX D2352Y does not lie within any known functional domains of the Atrx protein (UniProt.org). D2352Y has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24349
"ATRX E1463K does not lie within any known functional domains of the Atrx protein (UniProt.org). E1463K has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24350
"ATRX K1300R lies within the DAXX interaction region of the Atrx protein (UniProt.org). K1300R has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24351
"ATRX K923N does not lie within any known functional domains of the Atrx protein (UniProt.org). K923N has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24352
"BRCA2 A1170V does not lie within any known functional domains of the Brca2 protein (UniProt.org). A1170V has been identified in the scientific literature (PMID: 18824701), but has not been biochemically characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, Feb 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7910,18824701,Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance.,http://www.ncbi.nlm.nih.gov/pubmed/18824701,295,,,www.uniprot.org,24353
"BRCA2 A2351G lies within the FANCD2 interaction region of the Brca2 protein (UniProt.org). A2351G has been identified in the scientific literature (PMID: 21218378), but has not been biochemically characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, Feb 2017).
",7911,21218378,Detection of BRCA1 and BRCA2 mutations in a selected Hawaii population.,http://www.ncbi.nlm.nih.gov/pubmed/21218378,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24354
"BRCA2 A2717S lies within the SHFM1/DSS1 interaction region of the Brca2 protein (UniProt.org). A2717S has been identified in sequencing studies (PMID: 11802209), but has not been biochemically characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, Feb 2017).
",295,,,www.uniprot.org,7912,11802209,Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population.,http://www.ncbi.nlm.nih.gov/pubmed/11802209,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24355
"BRCA2 A2770T lies within the SHFM1/DSS1 interaction region of the Brca2 protein (UniProt.org). A2770T has been identified in the scientific literature (PMID: 21990165), but has not been biochemically characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, Feb 2017).

",295,,,www.uniprot.org,7914,21990165,Classification of missense substitutions in the BRCA genes: a database dedicated to Ex-UVs.,http://www.ncbi.nlm.nih.gov/pubmed/21990165,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24356
"BRCA2 C1265S does not lie within any known functional domains of the Brca2 protein (UniProt.org). C1265S has been identified in the scientific literature (PMID: 16489001), but has not been biochemically characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, Feb 2017).

",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7913,16489001,Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance.,http://www.ncbi.nlm.nih.gov/pubmed/16489001,24357
"BRCA2 C1365Y lies within the POLH interaction region of the Brca2 protein (UniProt.org). C1365Y has been identified in sequencing studies (PMID: 17924331), but has not been biochemically characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, Feb 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7915,17924331,"A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes.",http://www.ncbi.nlm.nih.gov/pubmed/17924331,295,,,www.uniprot.org,24358
"BRCA2 D1280V does not lie within any known functional domains of the Brca2 protein (UniProt.org). D1280V has been identified in sequencing studies (PMID: 17924331), but has not been biochemically characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, Feb 2017).

",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7915,17924331,"A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes.",http://www.ncbi.nlm.nih.gov/pubmed/17924331,24359
"BRCA2 D1352Y lies within the POLH interaction region of the Brca2 protein (UniProt.org). D1352Y has been identified in the scientific literature (PMID: 21990165), but has not been biochemically characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, Feb 2017).

",7914,21990165,Classification of missense substitutions in the BRCA genes: a database dedicated to Ex-UVs.,http://www.ncbi.nlm.nih.gov/pubmed/21990165,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24360
"BRCA2 D191G does not lie within any known functional domains of the Brca2 protein (UniProt.org). D191G has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, Feb 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24361
"BRCA2 D2312V does not lie within any known functional domains of the Brca2 protein (UniProt.org). D2312V has been identified in the scientific literature (PMID: 25556971) but has not been biochemically characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, Feb 2017).
",7927,25556971,Next-generation sequencing of the BRCA1 and BRCA2 genes for the genetic diagnostics of hereditary breast and/or ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/25556971,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24362
"BRCA2 D3170G does not lie within any known functional domains of the Brca2 protein (UniProt.org). D3170G has been identified in the scientific literature (PMID: 17924331), but has not been biochemically characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, Feb 2017).

",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7915,17924331,"A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes.",http://www.ncbi.nlm.nih.gov/pubmed/17924331,24363
"BRCA2 D806H lies within the NPM1 interaction region of the Brca2 protein (UniProt.org). D806H has been identified in sequencing studies (PMID: 17924331), but has not been biochemically characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, Feb 2017).

",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7915,17924331,"A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes.",http://www.ncbi.nlm.nih.gov/pubmed/17924331,295,,,www.uniprot.org,24364
"BRCA2 F1524V lies within the BRCA2 4 repeat region of the Brca2 protein (UniProt.org). F1524V has been identified in sequencing studies (PMID: 25344691), but has not been biochemically characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, Feb 2017).
",1689,25344691,RNF43 is frequently mutated in colorectal and endometrial cancers.,http://www.ncbi.nlm.nih.gov/pubmed/25344691,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24365
"BRCA2 G1194D does not lie within any known functional domains of the Brca2 protein (UniProt.org). G1194D has been identified in the scientific literature (PMID: 17924331), but has not been biochemically characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, Feb 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7915,17924331,"A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes.",http://www.ncbi.nlm.nih.gov/pubmed/17924331,295,,,www.uniprot.org,24366
"BRCA2 G1771D lies within the POLH interaction region of the Brca2 protein (UniProt.org). G1771D has been identified in the scientific literature (PMID: 18431501), but has not been biochemically characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, Feb 2017).

",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7918,18431501,BRCA1 and BRCA2 germline mutations in Malaysian women with early-onset breast cancer without a family history.,http://www.ncbi.nlm.nih.gov/pubmed/18431501,295,,,www.uniprot.org,24367
"BRCA2 G2274V does not lie within any known functional domains of the Brca2 protein (UniProt.org). G2274V has been identified in the scientific literature (PMID: 16489001), but has not been biochemically characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, Feb 2017).
",7913,16489001,Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance.,http://www.ncbi.nlm.nih.gov/pubmed/16489001,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24368
"BRCA2 G602R does not lie within any known functional domains of the Brca2 protein (UniProt.org). G602R has been identified in the scientific literature (PMID: 21218378), but has not been biochemically characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, Feb 2017).

",7911,21218378,Detection of BRCA1 and BRCA2 mutations in a selected Hawaii population.,http://www.ncbi.nlm.nih.gov/pubmed/21218378,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24369
"ABL1 R332W (corresponding to R351W in isoform IB) lies within the protein kinase domain of the Abl1 protein (UniProt.org). R332W results in increased Abl1 kinase activity, as demonstrated by modest increase in CRKL phosphorylation, and increased cytoplasmic retention of Abl1 in cell culture (PMID: 26758680).",6310,26758680,Somatically mutated ABL1 is an actionable and essential NSCLC survival gene.,http://www.ncbi.nlm.nih.gov/pubmed/26758680,24370
"FGFR2 D336N lies within the Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). D336N has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,24371
"FGFR2 D479N lies within the cytoplasmic domain of the Fgfr2 protein (UniProt.org). D479N has been identified in the scientific literature (PMID: 26003532) but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,5707,26003532,Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26003532,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24372
"FGFR2 D602E lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). D602E has not been characterized in the scientific literature and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24373
"FGFR2 E116K lies within the Ig-like C2-type domain 1 of the Fgfr2 protein (UniProt.org). E116K has not been characterized in the scientific literature and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24374
"FGFR2 E470Q lies within the cytoplasmic domain of the Fgfr2 protein (UniProt.org). E470Q has not been characterized in the scientific literature and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24375
"ABL1 G321L (corresponding to G340L in isoform IB) lies within the protein kinase domain of the Abl1 protein (UniProt.org). G321L does not result in increased phosphorylation of CRKL by Abl1, but leads to increased cytoplasmic Abl1 retention and is associated with increased cell survival in culture, and is predicted to lead to a gain of Abl1 function (PMID: 26758680).",6310,26758680,Somatically mutated ABL1 is an actionable and essential NSCLC survival gene.,http://www.ncbi.nlm.nih.gov/pubmed/26758680,295,,,www.uniprot.org,24376
"FGFR2 F276V lies within the Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). F276V has been identified in sequencing studies (PMID: 24578066), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7569,24578066,Quantification of facial skeletal shape variation in fibroblast growth factor receptor-related craniosynostosis syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/24578066,24377
"FGFR2 G272V lies within the Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). G272V has been identified in the scientific literature (PMID: 20106510), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Mar 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7558,20106510,FGFR2 mutations are rare across histologic subtypes of ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/20106510,295,,,www.uniprot.org,24378
"FGFR2 G302W lies within the Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). G302W has not been characterized in the scientific literature and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24379
"FGFR2 G338R lies within the Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). G338R has been identified in sequencing studies (PMID: 16418739), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7559,16418739,Mutation screening in patients with syndromic craniosynostoses indicates that a limited number of recurrent FGFR2 mutations accounts for severe forms of Pfeiffer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/16418739,24380
"FGFR2 G462E lies within the cytoplasmic domain of the Fgfr2 protein (UniProt.org). G462E has not been characterized in the scientific literature and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24381
"FGFR2 G583V lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). G583V has been identified in sequencing studies (PMID: 22980975), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1726,22980975,Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/22980975,24382
"FGFR2 G583W lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). G583W has been identified in sequencing studies (PMID: 22960745), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).",7663,22960745,Comprehensive genomic characterization of squamous cell lung cancers.,http://www.ncbi.nlm.nih.gov/pubmed/22960745,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24383
"FGFR2 I380V lies within the transmembrane domain of the Fgfr2 protein (UniProt.org). I380V has been identified in sequencing studies (PMID: 18948947), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).
",6956,18948947,Somatic mutations affect key pathways in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18948947,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24384
"FGFR2 I547D lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). I547D has been identified in sequencing studies (PMID: 22383975), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).
",7560,22383975,"FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features.",http://www.ncbi.nlm.nih.gov/pubmed/22383975,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24385
"FGFR2 I547V lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). I547V has been identified in sequencing studies (PMID: 17525745), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).
",702,17525745,Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/17525745,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24386
"FGFR2 I590M lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). I590M has not been identified in the scientific literature and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24387
"FGFR2 K405E lies within the cytoplasmic domain of the Fgfr2 protein (UniProt.org). K405E has been identified in sequencing studies (PMID: 25669975), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).
",295,,,www.uniprot.org,7570,25669975,Comprehensive analysis of targetable oncogenic mutations in chinese cervical cancers.,http://www.ncbi.nlm.nih.gov/pubmed/25669975,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24388
"FGFR2 K420I lies within the cytoplasmic domain of the Fgfr2 protein (UniProt.org).K420I has not been characterized in the scientific literature and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24389
FGFR2 K526E lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). K526E results in increased Fgfr2 autophosphorylation in an in vitro assay (PMID: 17803937).,295,,,www.uniprot.org,1905,17803937,A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases.,http://www.ncbi.nlm.nih.gov/pubmed/17803937,24390
"FGFR2 K641R lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). K641R results in increased Fgfr2 autophosphorylation and activation of Mek1/2, Stat3 signaling in cell culture (PMID: 23527311).",2160,23527311,Activating somatic FGFR2 mutations in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23527311,295,,,www.uniprot.org,24391
"FGFR2 K659M lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). K659M has been identified in sequencing studies (PMID: 28034880), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Mar 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8146,28034880,Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28034880,24392
"FGFR2 L397M lies within the transmembrane domain of the Fgfr2 protein (UniProt.org). L397M has been identified in sequencing studies (PMID: 22383975), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7560,22383975,"FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features.",http://www.ncbi.nlm.nih.gov/pubmed/22383975,24393
"FGFR2 L551I lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). L551I has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,24394
"FGFR2 L772F lies within the cytoplasmic domain of the Fgfr2 protein (UniProt.org). L772F has been identified in the scientific literature (PMID: 26003532) but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5707,26003532,Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26003532,24395
"FGFR2 M186T lies within the Ig-like C2-type domain 2 of the Fgfr2 protein (UniProt.org). M186T has been identified in sequencing studies (PMID: 18056464), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).
",2109,18056464,Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines.,http://www.ncbi.nlm.nih.gov/pubmed/18056464,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24396
FGFR2 M391R lies within the Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). M391R results in increased nucleolar Fgfr2 activity and cell proliferation in culture (PMID: 24908667).,295,,,www.uniprot.org,6311,24908667,Bent bone dysplasia syndrome reveals nucleolar activity for FGFR2 in ribosomal DNA transcription.,http://www.ncbi.nlm.nih.gov/pubmed/24908667,24397
"FGFR2 M537I lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). M537I has not been characterized in the scientific literature and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24398
"FGFR2 M584V lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). M584V has been identified in sequencing studies (PMID: 22960745), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).",7663,22960745,Comprehensive genomic characterization of squamous cell lung cancers.,http://www.ncbi.nlm.nih.gov/pubmed/22960745,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24399
"FGFR2 N211I lies within the Ig-like C2-type domain 2 of the Fgfr2 protein (UniProt.org). N211I has been identified in sequencing studies (PMID: 18552176), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).
",252,18552176,Drug-sensitive FGFR2 mutations in endometrial carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18552176,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24400
"FGFR2 N549D lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). N549D has not been biochemically characterized, but has been demonstrated to confer resistance to Fgfr inhibitors in cell culture (PMID: 28034880).
",8146,28034880,Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28034880,295,,,www.uniprot.org,24401
"FGFR2 P253S does not lie within any known functional domains of the Fgfr2 protein (UniProt.org). P253S has been identified in sequencing studies (PMID: 11781872), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).
",7212,11781872,Genomic screening of fibroblast growth-factor receptor 2 reveals a wide spectrum of mutations in patients with syndromic craniosynostosis.,http://www.ncbi.nlm.nih.gov/pubmed/11781872,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24402
"FGFR2 P256S lies within the Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). P256S has been identified in sequencing studies (PMID: 25669975), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).
",295,,,www.uniprot.org,7570,25669975,Comprehensive analysis of targetable oncogenic mutations in chinese cervical cancers.,http://www.ncbi.nlm.nih.gov/pubmed/25669975,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24403
"FGFR2 P582L lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). P582L has been identified in sequencing studies (PMID: 20838624), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).
",295,,,www.uniprot.org,7662,20838624,Mutational profiling of kinases in human tumours of pancreatic origin identifies candidate cancer genes in ductal and ampulla of vater carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/20838624,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24404
"FGFR2 Q212K lies within the Ig-like C2-type domain 2 of the Fgfr2 protein (UniProt.org). Q212K has been identified in sequencing studies (PMID: 23917401), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3963,23917401,The integrated landscape of driver genomic alterations in glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/23917401,24405
"FGFR2 Q289P lies within the Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). Q289P has been identified in sequencing studies (PMID: 19066959), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7562,19066959,Q289P mutation in the FGFR2 gene: first report in a patient with type 1 Pfeiffer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/19066959,24406
"FGFR2 Q620K lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). Q620K has not been characterized in the scientific literature and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24407
"FGFR2 R203H lies within the Ig-like C2-type domain 2 of the Fgfr2 protein (UniProt.org). R203H has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).
",5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24408
"FGFR2 R625T lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). R625T has been identified in sequencing studies (PMID: 17344846), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1723,17344846,Patterns of somatic mutation in human cancer genomes.,http://www.ncbi.nlm.nih.gov/pubmed/17344846,24409
"FGFR2 S252F does not lie within any known functional domains of the Fgfr2 protein (UniProt.org). S252F has been identified in sequencing studies (PMID: 16418739), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).
",7559,16418739,Mutation screening in patients with syndromic craniosynostoses indicates that a limited number of recurrent FGFR2 mutations accounts for severe forms of Pfeiffer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/16418739,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24410
"FGFR2 S252L does not lie within any known functional domains of the Fgfr2 protein (UniProt.org). S252L has been identified in sequencing studies (PMID: 25669975), but has not been biochemically characterized and therefore, its effect on Ret protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7570,25669975,Comprehensive analysis of targetable oncogenic mutations in chinese cervical cancers.,http://www.ncbi.nlm.nih.gov/pubmed/25669975,24411
"FGFR2 S267P lies within the Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). S267P has been identified in sequencing studies (PMID: 11325814), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7563,11325814,Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/11325814,24412
"FGFR2 S347C lies within the Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). S347C has been identified in sequencing studies (PMID: 12544231), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).
",7564,12544231,FGFR2 mutations among Thai children with Crouzon and Apert syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/12544231,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24413
"FGFR2 S354C lies within the Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). S354C has been identified in sequencing studies (PMID: 8528214), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7565,8528214,Novel FGFR2 mutations in Crouzon and Jackson-Weiss syndromes show allelic heterogeneity and phenotypic variability.,http://www.ncbi.nlm.nih.gov/pubmed/8528214,24414
"FGFR2 S587C lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). S587C has been identified in the scientific literature (PMID: 23000897), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7664,23000897,Comprehensive molecular portraits of human breast tumours.,http://www.ncbi.nlm.nih.gov/pubmed/23000897,24415
FGFR2 T341P lies within the Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). T341P results in increased phosphorylation of Fgfr2 and is transforming in cell culture (PMID: 9539778).,6314,9539778,Activating mutations in the extracellular domain of the fibroblast growth factor receptor 2 function by disruption of the disulfide bond in the third immunoglobulin-like domain.,http://www.ncbi.nlm.nih.gov/pubmed/9539778,295,,,www.uniprot.org,24416
"FGFR2 T786K lies within the cytoplasmic domain of the Fgfr2 protein (UniProt.org). T786K has been identified in sequencing studies (PMID: 22960745), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).",7663,22960745,Comprehensive genomic characterization of squamous cell lung cancers.,http://www.ncbi.nlm.nih.gov/pubmed/22960745,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24417
"FGFR2 V392A lies within the transmembrane domain of the Fgfr2 protein (UniProt.org). V392A has been identified in sequencing studies (PMID: 23619168), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).
",7132,23619168,Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers.,http://www.ncbi.nlm.nih.gov/pubmed/23619168,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24418
"FGFR2 V395D lies within the transmembrane domain of the Fgfr2 protein (UniProt.org). V395D has been identified in sequencing studies (PMID: 22383975), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).
",295,,,www.uniprot.org,7560,22383975,"FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features.",http://www.ncbi.nlm.nih.gov/pubmed/22383975,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24419
"FGFR2 Y281C lies within the Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). Y281C has been identified in sequencing studies (PMID: 11781872), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).
",295,,,www.uniprot.org,7212,11781872,Genomic screening of fibroblast growth-factor receptor 2 reveals a wide spectrum of mutations in patients with syndromic craniosynostosis.,http://www.ncbi.nlm.nih.gov/pubmed/11781872,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24420
"FGFR2 Y340C lies within the Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). Y340C has been identified in sequencing studies (PMID: 16418739), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7559,16418739,Mutation screening in patients with syndromic craniosynostoses indicates that a limited number of recurrent FGFR2 mutations accounts for severe forms of Pfeiffer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/16418739,24421
"FGFR2 Y340H lies within the Ig-like C2-type domain 3 of the Fgfr2 protein (UniProt.org). Y340H has been identified in sequencing studies (PMID: 16418739), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7559,16418739,Mutation screening in patients with syndromic craniosynostoses indicates that a limited number of recurrent FGFR2 mutations accounts for severe forms of Pfeiffer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/16418739,24422
"FGFR2 Y588D lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). Y588D has been identified in sequencing studies (PMID: 25669975), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7570,25669975,Comprehensive analysis of targetable oncogenic mutations in chinese cervical cancers.,http://www.ncbi.nlm.nih.gov/pubmed/25669975,24423
"BRCA2 H1918Y does not lie within any known functional domains of the Brca2 protein (UniProt.org). H1918Y has been identified in the scientific literature (PMID: 17924331), but has not been biochemically characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, Feb 2017).

",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7915,17924331,"A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes.",http://www.ncbi.nlm.nih.gov/pubmed/17924331,24424
"BRCA2 H1966Y does not lie within any known functional domains of the Brca2 protein (UniProt.org). H1966Y has been identified in the scientific literature (PMID: 18824701), but has not been biochemically characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, Feb 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7910,18824701,Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance.,http://www.ncbi.nlm.nih.gov/pubmed/18824701,295,,,www.uniprot.org,24425
"BRCA2 H2074N lies within the BRCA2 8 repeat region of the Brca2 protein (UniProt.org). H2074N has been identified in the scientific literature (PMID: 17924331), but has not been biochemically characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, Feb 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7915,17924331,"A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes.",http://www.ncbi.nlm.nih.gov/pubmed/17924331,24426
"BRCA2 I1349T lies within the POLH interaction region of the Brca2 protein (UniProt.org). I1349T has been identified in the scientific literature (PMID: 17924331), but has not been biochemically characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, Feb 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24427
"BRCA2 I1929V does not lie within any known functional domains of the Brca2 protein (UniProt.org). I1929V has been identified in sequencing studies (PMID: 25802882), but has not been biochemically characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, Feb 2017).
",7919,25802882,Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/25802882,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24428
"BRCA2 I2675V lies within the SEM1-interacting region of the Brca2 protein (UniProt.org). I2675V has been identified in the scientific literature (PMID: 26439132), but has not been biochemically characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",8860,26439132,"BRCA1 and BRCA2 mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer.",http://www.ncbi.nlm.nih.gov/pubmed/26439132,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24429
"BRCA2 K1434I lies within the POLH-interacting region of the Brca2 protein (UniProt.org). K1434I has been identified in the scientific literature (PMID: 27797976), but has not been biochemically characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",8849,27797976,Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27797976,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24430
"BRCA2 K2472T lies within the FANCD2-interacting region of the Brca2 protein (UniProt.org). K2472T has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24431
"BRCA2 K513R does not lie within any known functional domains of the Brca2 protein (UniProt.org). K513R has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24432
"BRCA2 K607T does not lie within any known functional domains of the Brca2 protein (UniProt.org). K607T has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24433
"BRCA2 L1904V does not lie within any known functional domains of the Brca2 protein (UniProt.org). L1904V has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24434
"BRCA2 L209F does not lie within any known functional domains of the Brca2 protein (UniProt.org). L209F has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24435
"BRCA2 L2106P does not lie within any known functional domains of the Brca2 protein (UniProt.org). L2106P has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24436
"BRCA2 L2396F lies within the FANCD2-interacting region of the Brca2 protein (UniProt.org). L2396F has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24437
"BRCA2 L2721H lies within the SEM1-interacting region of the Brca2 protein (UniProt.org). L2721H has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24438
"BRCA2 L929S lies within the NPM1-interacting region of the Brca2 protein (UniProt.org). L929S has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24439
"BRCA2 M784V lies within the NPM1-interacting region of the Brca2 protein (UniProt.org). M784V has been identified in the scientific literature (PMID: 18824701), but has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7910,18824701,Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance.,http://www.ncbi.nlm.nih.gov/pubmed/18824701,24440
"BRCA2 N1102Y does not lie within any known functional domains of the Brca2 protein (UniProt.org). N1102Y has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24441
"BRCA2 N1228D lies within the BRCA2 repeat 2 of the Brca2 protein (UniProt.org). N1228D has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24442
"BRCA2 N2048I does not lie within any known functional domains of the Brca2 protein (UniProt.org). N2048I has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24443
"BRCA2 N2113S does not lie within any known functional domains of the Brca2 protein (UniProt.org). N2113S has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24444
"BRCA2 N2436I lies within the FANCD2-interacting region of the Brca2 protein (UniProt.org). N2436I has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24445
"BRCA2 N2829R lies within the SEM-interacting region of the Brca2 protein (UniProt.org). N2829R has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24446
"BRCA2 N517S does not lie within any known functional domains of the Brca2 protein (UniProt.org). N517S has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24447
"BRCA2 N56T does not lie within any known functional domains of the Brca2 protein (UniProt.org). N56T has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24448
"BRCA2 N987I lies within the NPM1-interacting region of the Brca2 protein (UniProt.org). N987I has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24449
"BRCA2 P168T does not lie within any known functional domains of the Brca2 protein (UniProt.org). P168T has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24450
"BRCA2 P1819S does not lie within any known functional domains of the Brca2 protein (UniProt.org). P1819S has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24451
"BRCA2 P375S does not lie within any known functional domains of the Brca2 protein (UniProt.org). P375S has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24452
"BRCA2 Q1396R lies within the POLH interaction region of the Brca2 protein (UniProt.org). Q1396R has been identified in the scientific literature (PMID: 22034289), but has not been biochemically characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8956,22034289,High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/22034289,24453
"BRCA2 Q2384K lies within the FANCD2-interacting region of the Brca2 protein (UniProt.org). Q2384K has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24454
"BRCA2 Q2858R does not lie within any known functional domains of the Brca2 protein (UniProt.org). Q2858R has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24455
"BRCA2 R1190W does not lie within any known functional domains of the Brca2 protein (UniProt.org). R1190W has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24456
"BRCA2 R174C does not lie within any known functional domains of the Brca2 protein (UniProt.org). R174C has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24457
"BRCA2 R18H lies within the PALB2-interacting region of the Brca2 protein (UniProt.org). R18H has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24458
"BRCA2 R2304C does not lie within any known functional domains of the Brca2 protein (UniProt.org). R2304C has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24459
"BRCA2 R2336P does not lie within any known functional domains of the Brca2 protein (UniProt.org). R2336P has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24460
"BRCA2 R2418G lies within the FANCD2-interacting region of the Brca2 protein (UniProt.org). R2418G has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24461
"BRCA2 R2502C lies within the FANCD2 and SEM1-interacting regions of the Brca2 protein (UniProt.org). R2502C has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24462
"BRCA2 R2502H lies within the FANCD2 and SEM1-interacting regions of the Brca2 protein (UniProt.org). R2502H has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24463
"BRCA2 R2602T lies within the SEM1-interacting region of the Brca2 protein (UniProt.org). R2602T has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24464
"BRCA2 R2842H does not lie within any known functional domains of the Brca2 protein (UniProt.org). R2842H has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24465
"BRCA2 R2888C does not lie within any known functional domains of the Brca2 protein (UniProt.org). R2888C has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24466
"BRCA2 S1424C lies within the POLH-interacting region of the Brca2 protein (UniProt.org). S1424C has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24467
"BRCA2 S142I does not lie within any known functional domains of the Brca2 protein (UniProt.org). S142I has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24468
"BRCA2 S1670A lies within the BRCA2 repeat 5 of the Brca2 protein (UniProt.org). S1670A has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24469
"BRCA2 S1733F lies within the POLH-interacting region of the Brca2 protein (UniProt.org). S1733F has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24470
"BRCA2 S206C does not lie within any known functional domains of the Brca2 protein (UniProt.org). S206C has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24471
"BRCA2 S2483N lies within the SEM1-interacting region of the Brca2 protein (UniProt.org). S2483N has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24472
"BRCA2 S326R does not lie within any known functional domains of the Brca2 protein (UniProt.org). S326R has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24473
"BRCA2 S384F does not lie within any known functional domains of the Brca2 protein (UniProt.org). S384F has been identified in the scientific literature (PMID: 16168123), but has not been biochemically characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8962,16168123,Strong evidence that the common variant S384F in BRCA2 has no pathogenic relevance in hereditary breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16168123,24474
"BRCA2 S869L lies within the NPM1-interacting region of the Brca2 protein (UniProt.org). S869L has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24475
"BRCA2 T1354M lies within the POLH-interacting region of the Brca2 protein (UniProt.org). T1354M has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24476
"BRCA2 T2250A does not lie within any known functional domains of the Brca2 protein (UniProt.org). T2250A has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24477
"BRCA2 T2681R lies within the SEM1-interacting region of the Brca2 protein (UniProt.org). T2681R has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24478
"BRCA2 T3211K does not lie within any known functional domains of the Brca2 protein (UniProt.org). T3211K has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24479
"BRCA2 V1306I does not lie within any known functional domains of the Brca2 protein (UniProt.org). V1306I has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24480
"BRCA2 V159M does not lie within any known functional domains of the Brca2 protein (UniProt.org). V159M has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24481
"BRCA2 V1643A lies within the POLH-interacting region of the Brca2 protein (UniProt.org). V1643A has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24482
"BRCA2 V2969M does not lie within any known functional domains of the Brca2 protein (UniProt.org). V2969M has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24483
"BRCA2 V3079I does not lie within any known functional domains of the Brca2 protein (UniProt.org). V3079I has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24484
"BRCA2 G2063E lies within the BRCA2 8 repeat region of the Brca2 protein (UniProt.org). G2063E has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, Feb 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24485
"BRCA2 K1649I lies within the POLH-interaction region of the Brca2 protein (UniProt.org). K1649I has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24486
"BRCA2 S2307L does not lie within any known functional domains of the Brca2 protein (UniProt.org). S2307L has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24487
"BRCA2 V348L does not lie within any known functional domains of the Brca2 protein (UniProt.org). V348L has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24488
RET D631N lies within the extracellular domain of the Ret protein (UniProt.org). D631N does not result in covalent Ret dimerization and is not transforming in cell culture (PMID: 10049754).,5095,10049754,Mechanism of Ret activation by a mutation at aspartic acid 631 identified in sporadic pheochromocytoma.,http://www.ncbi.nlm.nih.gov/pubmed/10049754,295,,,www.uniprot.org,24489
RET D631A lies within the extracellular domain of the Ret protein (UniProt.org). D631A does not result in covalent Ret dimerization and is not transforming in cell culture (PMID: 10049754).,5095,10049754,Mechanism of Ret activation by a mutation at aspartic acid 631 identified in sporadic pheochromocytoma.,http://www.ncbi.nlm.nih.gov/pubmed/10049754,295,,,www.uniprot.org,24490
RET D631Y lies within the extracellular domain of the Ret protein (UniProt.org). D631Y confers a gain of function on the Ret protein as demonstrated by induction of covalent Ret dimerization and transformation of cultured cells (PMID: 10049754).,295,,,www.uniprot.org,5095,10049754,Mechanism of Ret activation by a mutation at aspartic acid 631 identified in sporadic pheochromocytoma.,http://www.ncbi.nlm.nih.gov/pubmed/10049754,24491
RET C630Y lies within the extracellular domain of the Ret protein (UniProt.org). C630Y may confer a gain of function on the Ret protein as demonstrated by transformation of cultured cells (PMID: 10049754).,5095,10049754,Mechanism of Ret activation by a mutation at aspartic acid 631 identified in sporadic pheochromocytoma.,http://www.ncbi.nlm.nih.gov/pubmed/10049754,295,,,www.uniprot.org,24493
"FGFR3 A341T lies within the Ig-like C2-type domain 3 of the Fgfr3 protein (UniProt.org). A341T has been identified in sequencing studies (PMID: 26003532), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5707,26003532,Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26003532,24494
FGFR3 C228R lies within the Ig-like C2-type domain 2 of the Fgfr3 protein (UniProt.org). C228R results in stabilization of Fgfr3 dimers in culture (PMID: 27596331).,8814,27596331,Pathogenic Cysteine Removal Mutations in FGFR Extracellular Domains Stabilize Receptor Dimers and Perturb the TM Dimer Structure.,http://www.ncbi.nlm.nih.gov/pubmed/27596331,295,,,www.uniprot.org,24495
"FGFR3 D222N lies within the Ig-like C2-type domain 2 of the Fgfr3 protein (UniProt.org). D222N has not been characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24496
FGFR3 D646Y lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). D646Y demonstrates autophosphorylation to similar level of wild-type Fgfr3 in cell culture (PMID: 26992226).,6316,26992226,Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.,http://www.ncbi.nlm.nih.gov/pubmed/26992226,295,,,www.uniprot.org,24497
"FGFR3 E216K lies within the Ig-like C2-type domain 2 of the Fgfr3 protein (UniProt.org). E216K has been identified in sequencing studies (PMID: 26003532), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, May 2017).",5707,26003532,Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26003532,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24498
"FGFR3 E322K lies within the Ig-like C2-type domain 3 of the Fgfr3 protein (UniProt.org). E322K has been identified in sequencing studies (PMID: 26003532), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,5707,26003532,Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26003532,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24499
FGFR3 E466K lies within the cytoplasmic domain of the Fgfr3 protein (UniProt.org). E466K demonstrates Fgfr3 autophosphorylation and substrate phosphorylation similar to wild-type Fgfr3 in cell culture (PMID: 26992226).,295,,,www.uniprot.org,6316,26992226,Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.,http://www.ncbi.nlm.nih.gov/pubmed/26992226,24500
FGFR3 A500T lies within the Ig-like C2-type domain 3 of the Fgfr3 protein (UniProt.org). A500T demonstrates autophosphorylation and substrate phosphorylation similar to wild-type Fgfr3 in cell culture (PMID: 26992226).,295,,,www.uniprot.org,6316,26992226,Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.,http://www.ncbi.nlm.nih.gov/pubmed/26992226,24501
FGFR3 I538F lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). I538F demonstrates autophosphorylation and substrate phosphorylation similar to wild-type Fgfr3 in cell culture (PMID: 26992226).,295,,,www.uniprot.org,6316,26992226,Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.,http://www.ncbi.nlm.nih.gov/pubmed/26992226,24502
FGFR3 I538V lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). I538V results in increased Fgfr3 autophosphorylation in cell culture (PMID: 26992226).,295,,,www.uniprot.org,6316,26992226,Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.,http://www.ncbi.nlm.nih.gov/pubmed/26992226,24503
FGFR3 V555M lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). V555M results in increased Fgfr3 autophosphorylation and substrate phosphorylation in cell culture (PMID: 26992226).,295,,,www.uniprot.org,6316,26992226,Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.,http://www.ncbi.nlm.nih.gov/pubmed/26992226,24504
FGFR3 P572A lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). P572A demonstrates autophosphorylation and substrate phosphorylation similar to wild-type Fgfr3 in cell culture (PMID: 26992226).,295,,,www.uniprot.org,6316,26992226,Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.,http://www.ncbi.nlm.nih.gov/pubmed/26992226,24505
FGFR3 C582F lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). C582F demonstrates autophosphorylation and substrate phosphorylation similar to wild-type Fgfr3 in cell culture (PMID: 26992226).,6316,26992226,Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.,http://www.ncbi.nlm.nih.gov/pubmed/26992226,295,,,www.uniprot.org,24506
FGFR3 D617G lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). D617G results in a loss of Fgfr3 activity in cell culture (PMID: 26992226).,6316,26992226,Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.,http://www.ncbi.nlm.nih.gov/pubmed/26992226,295,,,www.uniprot.org,24507
FGFR3 E627D lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). E627D demonstrates autophosphorylation and substrate phosphorylation similar to wild-type Fgfr3 in cell culture (PMID: 26992226).,6316,26992226,Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.,http://www.ncbi.nlm.nih.gov/pubmed/26992226,295,,,www.uniprot.org,24508
FGFR3 V630M lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). V630M demonstrates autophosphorylation and substrate phosphorylation similar to wild-type Fgfr3 in cell culture (PMID: 26992226).,6316,26992226,Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.,http://www.ncbi.nlm.nih.gov/pubmed/26992226,295,,,www.uniprot.org,24509
FGFR3 D641G lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). D641G results in increased Fgfr3 autophosphorylation and substrate phosphorylation in cell culture (PMID: 26992226).,6316,26992226,Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.,http://www.ncbi.nlm.nih.gov/pubmed/26992226,295,,,www.uniprot.org,24510
FGFR3 H643D lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). H643D demonstrates autophosphorylation and substrate phosphorylation similar to wild-type Fgfr3 in cell culture (PMID: 26992226).,6316,26992226,Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.,http://www.ncbi.nlm.nih.gov/pubmed/26992226,295,,,www.uniprot.org,24511
FGFR3 Y647C lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). Y647C results in increased Fgfr3 autophosphorylation in cell culture (PMID: 26992226).,6316,26992226,Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.,http://www.ncbi.nlm.nih.gov/pubmed/26992226,295,,,www.uniprot.org,24512
FGFR3 N653H lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). N653H demonstrates autophosphorylation and substrate phosphorylation similar to wild-type Fgfr3 in cell culture (PMID: 26992226).,6316,26992226,Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.,http://www.ncbi.nlm.nih.gov/pubmed/26992226,295,,,www.uniprot.org,24513
FGFR3 R669G lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). R669G results in increased Fgfr3 autophosphorylation and substrate phosphorylation in cell culture (PMID: 26992226).,6316,26992226,Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.,http://www.ncbi.nlm.nih.gov/pubmed/26992226,295,,,www.uniprot.org,24514
FGFR3 R669Q lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). R669Q results in increased Fgfr3 autophosphorylation in cell culture (PMID: 26992226).,295,,,www.uniprot.org,6316,26992226,Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.,http://www.ncbi.nlm.nih.gov/pubmed/26992226,24515
FGFR3 V677I lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). V677I demonstrates autophosphorylation and substrate phosphorylation similar to wild-type Fgfr3 in cell culture (PMID: 26992226).,295,,,www.uniprot.org,6316,26992226,Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.,http://www.ncbi.nlm.nih.gov/pubmed/26992226,24516
"FGFR3 G197S lies within the Ig-like C2-type domain 2 of the Fgfr3 protein (UniProt.org). G197S has been identified in sequencing studies (PMID: 17344920), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8815,17344920,Expression and mutation status of candidate kinases in multiple myeloma.,http://www.ncbi.nlm.nih.gov/pubmed/17344920,24517
"FGFR3 G235D lies within the Ig-like C2-type domain 2 of the Fgfr3 protein (UniProt.org). G235D has not been characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24518
"FGFR3 G382D lies within the transmembrane domain of the Fgfr3 protein (UniProt.org). G382D results in constitutive activation of Fgfr3 and downstream signaling, but is not transforming in cell culture (PMID: 11429702).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,2175,11429702,"Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.",http://www.ncbi.nlm.nih.gov/pubmed/11429702,24519
"FGFR3 H349Y lies within the Ig-like C2-type domain 3 of the Fgfr3 protein (UniProt.org). H349Y has been identified in sequencing studies (PMID: 26003532), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5707,26003532,Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26003532,24520
"FGFR3 I376C lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). I376C has been identified in sequencing studies (PMID: 26003532), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5707,26003532,Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26003532,24521
"FGFR3 K413N lies within the cytoplasmic domain of the Fgfr3 protein (UniProt.org). K413N has been identified in the scientific literature (PMID: 25056374), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7205,25056374,Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/25056374,24522
"FGFR3 K715M lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). K715M has been identified in sequencing studies (PMID: 26003532), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5707,26003532,Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26003532,24523
"FGFR3 L794R lies within the cytoplasmic domain of the Fgfr3 protein (UniProt.org). L794R has been identified in sequencing studies (PMID: 26003532), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5707,26003532,Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26003532,24524
"FGFR3 N540K lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). N540K results in increased Fgfr3 autophosphorylation and substrate phosphorylation, and is transforming in cell culture (PMID: 26992226).",6316,26992226,Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use.,http://www.ncbi.nlm.nih.gov/pubmed/26992226,295,,,www.uniprot.org,24525
"FGFR3 N540T lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). N540T has been identified in the scientific literature (PMID: 9452043), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8826,9452043,Asn540Thr substitution in the fibroblast growth factor receptor 3 tyrosine kinase domain causing hypochondroplasia.,http://www.ncbi.nlm.nih.gov/pubmed/9452043,24526
"FGFR3 N540V lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). N540V has not been characterized in the scientific literature and therefore, its effect on Fgfr3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24527
"FGFR3 P283S lies within the Ig-like C2-type domain 3 of the Fgfr3 protein (UniProt.org). P283S has been identified in sequencing studies (PMID: 26003532), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, May 2017).",5707,26003532,Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26003532,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24528
"FGFR3 P795A lies within the cytoplasmic domain of the Fgfr3 protein (UniProt.org). P795A has been identified in sequencing studies (PMID: 26003532), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, May 2017).",5707,26003532,Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26003532,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24529
"FGFR3 Q209H lies within the Ig-like C2-type domain 2 of the Fgfr3 protein (UniProt.org). Q209H has been identified in sequencing studies (PMID: 26003532), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, May 2017).",5707,26003532,Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26003532,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24530
"FGFR3 R248H lies within the extracellular domain of the Fgfr3 protein (UniProt.org). R248H has been identified in the scientific literature (PMID: 24452392), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,8827,24452392,A novel somatic FGFR3 mutation in primary lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24452392,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24531
"FGFR3 R603Q lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). R603Q has been identified in sequencing studies (PMID: 26003532), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,5707,26003532,Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26003532,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24532
"FGFR3 S433C lies within the cytoplasmic domain of the Fgfr3 protein (UniProt.org). S433C has been identified in the scientific literature (PMID: 17344920), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8815,17344920,Expression and mutation status of candidate kinases in multiple myeloma.,http://www.ncbi.nlm.nih.gov/pubmed/17344920,24533
"FGFR3 T79S lies within the Ig-like C2-type domain 1 of the Fgfr3 protein (UniProt.org). T79S has been identified in sequencing studies (PMID: 26003532), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5707,26003532,Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26003532,24534
"FGFR3 V306I lies within the Ig-like C2-type domain 3 of the Fgfr3 protein (UniProt.org). V306I has been identified in the scientific literature (PMID: 23443805), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, May 2017).",77,23443805,Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/23443805,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24535
"FGFR3 Y241C lies within the Ig-like C2-type domain 2 of the Fgfr3 protein (UniProt.org). Y241C has been identified in sequencing studies (PMID: 26003532), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5707,26003532,Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26003532,24536
"FGFR3 Y379C lies within the transmembrane domain of the Fgfr3 protein (UniProt.org). Y379C has been identified in sequencing studies (PMID: 26003532), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,5707,26003532,Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations.,http://www.ncbi.nlm.nih.gov/pubmed/26003532,24537
"SRC T341I lies within the protein kinase domain of the Src protein (UniProt.org). T341I results in increased Src autophosphorylation and substrated phosphorylation, and increased cell survival in culture (PMID: 18794843).",295,,,www.uniprot.org,644,18794843,Activation of tyrosine kinases by mutation of the gatekeeper threonine.,http://www.ncbi.nlm.nih.gov/pubmed/18794843,24557
"BRAF dec exp indicates decreased expression of the Braf protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,24559
"FGFR1 dec exp indicates decreased expression of the Fgfr1 protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,24560
"FGFR2 dec exp indicates decreased expression of the Fgfr2 protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,24562
"BRCA2 A2643G lies within the SHFM1/DSS1 interaction region of the Brca2 protein (UniProt.org). A2643G mediates homology-directed DNA repair to the level comparable with wild-type Brca2 in cultured cells (PMID: 18451181).
",295,,,www.uniprot.org,6338,18451181,Functional assays for classification of BRCA2 variants of uncertain significance.,http://www.ncbi.nlm.nih.gov/pubmed/18451181,24568
"BRCA2 G1529R lies within the BRCA2 4 repeat region of the Brca2 protein (UniProt.org). G1529R has been identified in the scientific literature (PMID: 20104584) but has not been biochemically characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, Feb 2017).

",7933,20104584,Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study.,http://www.ncbi.nlm.nih.gov/pubmed/20104584,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24569
"BRCA2 G173C does not lie within any known functional domains of the Brca2 protein (UniProt.org). G173C has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, Feb 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24570
BRCA2 I2285V does not lie within any known functional domains of the Brca2 protein (UniProt.org). I2285V confers no effect on the Brca2 protein as demonstrated by homology-directed DNA repair and induced RAD51 formation foci similar to Brca2 wild-type levels (PMID: 19795481).,295,,,www.uniprot.org,8859,19795481,Functional redundancy of exon 12 of BRCA2 revealed by a comprehensive analysis of the c.6853A>G (p.I2285V) variant.,http://www.ncbi.nlm.nih.gov/pubmed/19795481,24571
"BRCA2 K1690N lies within the BRCA2 repeat 5 of the Brca2 protein (UniProt.org). K1690N has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24572
"BRCA2 K2950N does not lie within any known functional domains of the Brca2 protein (UniProt.org). K2950N has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24573
"BRCA2 L1019V lies within the BRCA2 1 repeat region of the Brca2 protein (UniProt.org). L1019V mediates homology-directed DNA repair to the level comparable with wild-type Brca2 in cultured cells (PMID: 21671020).
",2645,21671020,Effect of the overexpression of BRCA2 unclassified missense variants on spontaneous homologous recombination in human cells.,http://www.ncbi.nlm.nih.gov/pubmed/21671020,295,,,www.uniprot.org,24574
"BRCA2 N319T does not lie within any known functional domains of the Brca2 protein (UniProt.org). N319T mediates homology-directed DNA repair to the level comparable with wild type Brca2 in cultured cells (PMID: 18451181).
",6338,18451181,Functional assays for classification of BRCA2 variants of uncertain significance.,http://www.ncbi.nlm.nih.gov/pubmed/18451181,295,,,www.uniprot.org,24575
BRCA2 R2520Q lies within the SHFM1/DSS1 interaction region of the Brca2 protein (UniProt.org). R2520Q mediates homology-directed DNA repair to the level comparable with wild type Brca2 in cultured cells (PMID: 18451181).,6338,18451181,Functional assays for classification of BRCA2 variants of uncertain significance.,http://www.ncbi.nlm.nih.gov/pubmed/18451181,295,,,www.uniprot.org,24576
"BRCA2 T3349A does not lie within any known functional domains of the Brca2 protein (UniProt.org). T3349A has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24577
"BRCA2 D438Y does not lie within any known functional domains of the Brca2 protein (UniProt.org). D438Y has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, Feb 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24578
"BRCA2 S2670L lies within the SEM1-interacting region of the Brca2 protein (UniProt.org). S2670L has not been characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24579
"BRCA2 V211I does not lie within any known functional domains of the Brca2 protein (UniProt.org). V211I confers a loss of function on Brca2 as indicated by an alteration in RNA splicing and reduced mRNA maturation (PMID: 19179552).
",295,,,www.uniprot.org,6377,19179552,Two mutations of BRCA2 gene at exon and splicing site in a woman who underwent oncogenetic counseling.,http://www.ncbi.nlm.nih.gov/pubmed/19179552,24580
"BRCA2 C554W does not lie within any known functional domains of the Brca2 protein (UniProt.org). C554W has been identified in sequencing studies (PMID: 17924331), but has not been biochemically characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, Feb 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7915,17924331,"A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes.",http://www.ncbi.nlm.nih.gov/pubmed/17924331,24581
"BRCA2 T582P does not lie within any known functional domains of the Brca2 protein (UniProt.org). T582P confers a loss of function on Brca2 as indicated by reduced interaction with Cep55, Alix, and Tsg101 in cell culture (PMID: 22771033). ",295,,,www.uniprot.org,6378,22771033,BRCA2 localization to the midbody by filamin A regulates cep55 signaling and completion of cytokinesis.,http://www.ncbi.nlm.nih.gov/pubmed/22771033,24582
BRCA2 R2318Q does not lie within any known functional domains of the Brca2 protein (UniProt.org). R2318Q is predicted to lead to a loss of Brca2 protein function as indicated by loss of DNA damage repair activity in cultured cells over expressing a peptide of the Brca2 linker region containing R2318Q (PMID: 21741379).,6407,21741379,A new assay for functional screening of BRCA2 linker region mutations identifies variants that alter chemoresistance to cisplatin.,http://www.ncbi.nlm.nih.gov/pubmed/21741379,295,,,www.uniprot.org,24583
"ATM A1812P does not lie within any known functional domains of the Atm protein (UniProt.org). A1812P has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24584
"ATM A1950T does not lie within any known functional domains of the Atm protein (UniProt.org). A1950T has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24585
"ATM K1410* results in a premature truncation of the Atm protein at amino acid 1410 of 3056 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), K1410* is predicted to lead to a loss of Atm protein function.
",295,,,www.uniprot.org,24586
"ATM L1939V does not lie within any known functional domains of the Atm protein (UniProt.org). L1939V has been identified in sequencing studies (PMID: 20054297), but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017).

",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7433,20054297,Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes.,http://www.ncbi.nlm.nih.gov/pubmed/20054297,295,,,www.uniprot.org,24587
"ATM Q2066L lies within the FAT domain of the Atm protein (UniProt.org). Q2066L has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24588
"ATM R221I does not lie within any known functional domains of the Atm protein (UniProt.org). R221I has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24589
"ATM T2902fs results in a change in the amino acid sequence of the Atm protein beginning at aa 2902 of 3056, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the FATC domain, T2902fs is predicted to lead to a loss of Atm protein function (PMID: 16603769).

",295,,,www.uniprot.org,2669,16603769,The FATC domains of PIKK proteins are functionally equivalent and participate in the Tip60-dependent activation of DNA-PKcs and ATM.,http://www.ncbi.nlm.nih.gov/pubmed/16603769,24590
"ABL1 K596* results in a premature truncation of the Abl1 protein at amino acid 596 of 1130 (UniProt.org). Due to the loss of the DNA-binding and actin-binding regions (UniProt.org), R596* is predicted to lead to a loss of Abl1 protein function.
",295,,,www.uniprot.org,24591
"ABL1 V422I lies within the protein kinase domain of the Abl1 protein (UniProt.org). V422I has not been characterized in the scientific literature and therefore, its effect on Abl1 protein function is unknown (PubMed, Feb 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24592
"ALK G689V does not lie within any known functional domains of the Alk protein (UniProt.org). G689V has not been characterized in the scientific literature and therefore, its effect on Alk protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24596
"EGFR P772_H773insPHA results in the insertion of three amino acids in the protein kinase domain of the Egfr protein between amino acids 772 and 773 (UniProt.org). P772_H773insPHA has not been characterized, but can be predicted to result in a gain of function based on the effect of other Egfr exon 20 insertions (PMID: 24353160).",295,,,www.uniprot.org,440,24353160,"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24353160,24601
FLT3 K868N lies within the protein kinase domain of the Flt3 protein (UniProt.org). K868N results in decreased Flt3 autophosphorylation and reduced Erk activity in cell culture (PMID: 27272783).,6339,27272783,Novel Tumor-specific Mutations in Receptor Tyrosine Kinase Subdomain IX Significantly Reduce Extracellular Signal-regulated Kinase Activity.,http://www.ncbi.nlm.nih.gov/pubmed/27272783,295,,,www.uniprot.org,24603
"CBL Y368C lies within the linker region of the Cbl protein (UniProt.org). Y368C results in a loss of Cbl E3 ubiquitin ligase activity, is transforming in cell culture, and promotes tumor formation in animal models (PMID: 19620960).",295,,,www.uniprot.org,5941,19620960,Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/19620960,24604
"CBL Y371C lies within the linker region of the Cbl protein (UniProt.org). Y371C results in a loss of Cbl E3 ubiquitin ligase activity, is transforming in cell culture, and promotes tumor formation in animal models (PMID: 19620960).",5941,19620960,Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/19620960,295,,,www.uniprot.org,24605
"CBL I383L lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). I383L results in a loss of Cbl E3 ubiquitin ligase activity, is transforming in cell culture, and promotes tumor formation in animal models (PMID: 19620960).",5941,19620960,Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/19620960,295,,,www.uniprot.org,24606
"CBL C384G lies within the linker region of the Cbl protein (UniProt.org). C384G results in a loss of Cbl E3 ubiquitin ligase activity, is transforming in cell culture, and promotes tumor formation in animal models (PMID: 19620960).",5941,19620960,Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/19620960,295,,,www.uniprot.org,24607
"CBL Q367K lies within the linker region of the Cbl protein (UniProt.org). Q367K results in a loss of Cbl E3 ubiquitin ligase activity, is transforming in cell culture, and promotes tumor formation in animal models (PMID: 19620960).",5941,19620960,Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.,http://www.ncbi.nlm.nih.gov/pubmed/19620960,295,,,www.uniprot.org,24608
"CBL C396Y lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). C396Y has not been biochemically characterized, but is predicted to disrupt Cbl stability by computer modeling (PMID: 26676746).",4519,26676746,Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26676746,295,,,www.uniprot.org,24609
"CBL E369_Y371del results in the deletion of three amino acids in the linker region of the Cbl protein from amino acids 369 to 371 (UniProt.org). E369_Y371del has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24610
"CBL Y368_K382del results in the deletion of fifteen amino acids in the linker region of the Cbl protein from amino acids 368 to 382 (UniProt.org). Y368_K382del has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Feb 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24611
"CBL R343* results in a premature truncation of the Cbl protein at amino acid 343 of 906 (UniProt.org). R343* has been identified in sequencing studies (PMID: 24030381), but has not been biochemically characterized and therefore, its effect on Cbl protein function is unknown (PubMed, Feb 2017).",295,,,www.uniprot.org,7701,24030381,Clinical and biological implications of driver mutations in myelodysplastic syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/24030381,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24612
"CBL R420G does not lie within any known functional domains of the Cbl protein (UniProt.org). R420G has been associated with increased cell survival in culture (PMID: 19276253), but has not been fully biochemically characterized and therefore, its effect on Cbl protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7825,19276253,CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes.,http://www.ncbi.nlm.nih.gov/pubmed/19276253,295,,,www.uniprot.org,24613
"JAK3 S989I lies within the protein kinase domain 2 of the Jak3 protein (UniProt.org). S989I has been identified in the scientific literature (PMID: 26415585), but has not been biochemically characterized and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,6342,26415585,Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sézary syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/26415585,295,,,www.uniprot.org,24616
"JAK3 Y1023H lies within the protein kinase domain 2 of the Jak3 protein (UniProt.org). Y1023H has not been characterized and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24617
JAK3 L857P lies within the protein kinase domain 2 of the Jak3 protein (UniProt.org). L857P results in cytokine receptor complex-independent activation of Jak3 and increased cell proliferation in culture (PMID: 26446793).,295,,,www.uniprot.org,6343,26446793,Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.,http://www.ncbi.nlm.nih.gov/pubmed/26446793,24619
JAK3 L857H lies within the protein kinase domain 2 of the Jak3 proteim (UniProt.org). L857H results in cytokine receptor complex-independent activation of Jak3 in cell culture (PMID: 26446793).,295,,,www.uniprot.org,6343,26446793,Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.,http://www.ncbi.nlm.nih.gov/pubmed/26446793,24620
JAK3 Y100A lies within the FERM domain of the Jak3 protein (UniProt.org). Y100A results in a loss of Jak3 kinase activity in cell culture (PMID: 11741532). ,295,,,www.uniprot.org,6344,11741532,Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases.,http://www.ncbi.nlm.nih.gov/pubmed/11741532,24621
JAK3 P906S lies within the protein kinase domain 2 of the Jak3 protein (UniProt.org). P906S results in increased cytokine receptor complex-dependent activation of Jak3 in cell culture (PMID: 26446793).,295,,,www.uniprot.org,6343,26446793,Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.,http://www.ncbi.nlm.nih.gov/pubmed/26446793,24622
JAK3 E958K lies within the protein kinase domain 2 of the Jak3 protein (UniProt.org). E958K results in increased cytokine receptor complex-dependent activation of Jak3 in cell culture (PMID: 26446793).,6343,26446793,Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.,http://www.ncbi.nlm.nih.gov/pubmed/26446793,295,,,www.uniprot.org,24623
JAK3 T848A lies within the protein kinase domain 2 of the Jak3 protein (UniProt.org). T848A results in increased cytokine receptor complex-dependent activation of Jak3 in cell culture (PMID: 26446793).,6343,26446793,Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.,http://www.ncbi.nlm.nih.gov/pubmed/26446793,295,,,www.uniprot.org,24624
"JAK3 Y842D lies within the protein kinase domain 2 of the Jak3 protein (UniProt.org). Y842D has not been characterized and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24625
"APC A928fs results in a change in the amino acid sequence of the Apc protein beginning at aa 928 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). A928fs has not been characterized, however Apc truncation mutants downstream of A928 are inactivating (PMID: 18199528) thus, A928fs is predicted to lead to a loss of Apc protein function.
",2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,295,,,www.uniprot.org,24626
"APC C207* results in a premature truncation of the Apc protein at amino acid 207 of 2843 (UniProt.org). Due to the loss of the beta-catenin binding and down-regulation region (PMID: 14672538), C207* is predicted to lead to a loss of Apc protein function.
",295,,,www.uniprot.org,2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,24627
"APC E190* results in a premature truncation of the Apc protein at amino acid 190 of 2843 (UniProt.org). Due to the loss of the beta-catenin binding and down-regulation region (PMID: 14672538), E190* is predicted to lead to a loss of Apc protein function.
",295,,,www.uniprot.org,2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,24628
BRCA2 E2663V lies within the SHFM1/DSS1 interaction region of the Brca2 protein (UniProt.org). E2663V is predicted to lead to a loss of Brca2 protein function due to aberrant splicing and introduction of a premature stop codon (PMID: 18451181). ,295,,,www.uniprot.org,6338,18451181,Functional assays for classification of BRCA2 variants of uncertain significance.,http://www.ncbi.nlm.nih.gov/pubmed/18451181,24634
BRCA2 N1878K does not lie within any known functional domains of the Brca2 protein (UniProt.org). N1878K mediates homology-directed DNA repair to the level comparable with wild-type Brca2 in cultured cells (PMID: 23328489).,6346,23328489,Effect of the expression of BRCA2 on spontaneous homologous recombination and DNA damage-induced nuclear foci in Saccharomyces cerevisiae.,http://www.ncbi.nlm.nih.gov/pubmed/23328489,295,,,www.uniprot.org,24635
"BRCA2 P655R does not lie within any known functional domains of the Brca2 protein (UniProt.org). P655R has been described as non-pathogenic and like wild-type Brca2, is not sensitive to DNA damaging agents and has no effect on splicing or homologous recombination (PMID: 22678057).",2588,22678057,Functional evaluation of BRCA2 variants mapping to the PALB2-binding and C-terminal DNA-binding domains using a mouse ES cell-based assay.,http://www.ncbi.nlm.nih.gov/pubmed/22678057,295,,,www.uniprot.org,24636
BRCA2 R2336H does not lie within any known functional domains of the Brca2 protein (UniProt.org). R2336H is predicted to lead to a loss of Brca2 protein function due to aberrant splicing and introduction of a premature stop codon (PMID: 21719596). ,295,,,www.uniprot.org,6347,21719596,A comprehensive functional characterization of BRCA2 variants associated with Fanconi anemia using mouse ES cell-based assay.,http://www.ncbi.nlm.nih.gov/pubmed/21719596,24637
"BRCA2 R2659T lies within the SHFM1/DSS1 interaction region of the Brca2 protein (UniProt.org). R2659T is predicted to lead to a loss of Brca2 protein function due to aberrant splicing and introduction of a premature stop codon (PMID: 18451181). 
",6338,18451181,Functional assays for classification of BRCA2 variants of uncertain significance.,http://www.ncbi.nlm.nih.gov/pubmed/18451181,295,,,www.uniprot.org,24638
BRCA2 S196N does not lie within any known functional domains of the Brca2 protein (UniProt.org). S196N is predicted to lead to a loss of Brca2 protein function due to aberrant splicing and introduction of a premature stop codon (PMID: 22962691). ,6348,22962691,Multiple sequence variants of BRCA2 exon 7 alter splicing regulation.,http://www.ncbi.nlm.nih.gov/pubmed/22962691,295,,,www.uniprot.org,24639
BRCA2 R3052Q does not lie within any known functional domains of the Brca2 protein (UniProt.org). R3052Q has no effect on cell viability and does not affect genomic stability in culture (PMID: 18607349).,295,,,www.uniprot.org,6349,18607349,Mouse embryonic stem cell-based functional assay to evaluate mutations in BRCA2.,http://www.ncbi.nlm.nih.gov/pubmed/18607349,24640
"BRCA2 A75P does not lie within any known functional domains of the Brca2 protein (UniProt.org). A75P confers a loss of function on Brca2 as indicated by reduced interaction with Plk1 in culture (PMID: 24835992).
",6350,24835992,BRCA2 coordinates the activities of cell-cycle kinases to promote genome stability.,http://www.ncbi.nlm.nih.gov/pubmed/24835992,295,,,www.uniprot.org,24641
"BRCA1 E515G does not lie within any known functional domains of the Brca1 protein (UniProt.org). E515G has not been characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24642
"CBL V478L does not lie within any known functional domains of the Cbl protein (UniProt.org). V478L has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Feb 2017).  
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24643
"CBL W408L lies within the RING-type zinc finger domain of the Cbl protein (UniProt.org). W408L has not been biochemically characterized, but is predicted to disrupt Cbl stability by computer modeling (PMID: 26676746).",295,,,www.uniprot.org,4519,26676746,Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.,http://www.ncbi.nlm.nih.gov/pubmed/26676746,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24644
"CDH1 D402V lies within the Cadherin 3 domain of the Cdh1 protein (UniProt.org). D402V has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Jul 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24646
"CDH1 E336K lies within the Cadherin 2 domain of the Cdh1 protein (UniProt.org). E336K has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Jul 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24647
"CDH1 T340M lies within the Cadherin 2 domain of the Cdh1 protein (UniProt.org). T340M has not been characterized and therefore, its effect on Cdh1 protein function is unknown (PubMed, Jul 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24648
"CDKN2A G111D lies within the ANK 4 repeat region of the Cdkn2a protein (UniProt.org). G111D has been identified in sequencing studies (PMID: 8747595), but has not been biochemically characterized and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7777,8747595,Infrequent somatic mutations of the p16 and p15 genes in human bladder cancer: p16 mutations occur only in low-grade and superficial bladder cancers.,http://www.ncbi.nlm.nih.gov/pubmed/8747595,24649
"CDKN2A G23fs results in a change in the amino acid sequence of the Cdkn2a protein beginning at aa 23 of 156, likely resulting in premature truncation of the functional protein (UniProt.org). G23fs has not been characterized, however, nonsense mutations downstream of G23 are inactivating (PMID: 9053859, PMID: 8668202), thus G23fs is predicted to lead to a loss of Cdkn2a protein function.",3063,9053859,Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma.,http://www.ncbi.nlm.nih.gov/pubmed/9053859,295,,,www.uniprot.org,3108,8668202,Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/8668202,24650
"DNMT3A G746V lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (UniProt.org). G746V has not been characterized in the scientific literature and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jun 2017). ",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24675
"DNMT3A K721R lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (UniProt.org). K721R has not been characterized and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jun 2017). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24676
"DNMT3A Q485H lies within the ADD domain of the Dnmt3a protein (UniProt.org). Q485H has not been characterized and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jul 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24677
"JAK2 I404N lies within the SH2 domain of the Jak2 protein (UniProt.org). I404N has not been characterized in the scientific literature and therefore, its effect on Jak2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24686
"JAK2 R133Q lies within the FERM domain of the Jak2 protein (UniProt.org). R133Q has not been characterized in the scientific literature and therefore, its effect on Jak2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24687
"JAK2 V563I lies within the protein kinase 1 domain of the Jak2 protein (UniProt.org). V563I has not been characterized in the scientific literature and therefore, its effect on Jak2 protein function is unknown (PubMed, May 2017). 
",115,0,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24688
"JAK2 Y613_G614insTSY results in the insertion of three amino acids in the protein kinase 1 domain of the Jak2 protein between amino acids 613 and 614 (UniProt.org). Y613_G614insTSY has not been characterized in the scientific literature and therefore, its effect on Jak2 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24689
"JAK3 C162Y lies within the FERM domain of the Jak3 protein (UniProt.org). C162Y has not been characterized in the scientific literature and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24690
"KDR (VEGFR2) S26G does not lie within any known functional domains of the Kdr (Vegfr2) protein (UniProt.org). S26G has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017). ",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24691
"KDR (VEGFR2) T139N does not lie within any known functional domains of the Kdr (Vegfr2) protein (UniProt.org). T139N has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24692
"KIT L813_A814insHIV results in the insertion of three amino acids in the protein kinase domain of the Kit protein between amino acids 813 and 814 (UniProt.org). L813_A814insHIV has not been characterized in the scientific literature and therefore, its effect on Kit protein function is unknown (PubMed, May 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24701
"MET E994K does not lie within any known functional domains of the Met protein (UniProt.org). E994K has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24702
"MET L1140F lies within the protein kinase domain of the Met protein (UniProt.org). L1140F has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24703
"MET V237fs results in a change in the amino acid sequence of the Met protein beginning at aa 237 of 1390 likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of most known functional domains (UniProt.org), V237fs is predicted to lead to a loss of Met protein function.
",295,,,www.uniprot.org,24704
"KDR (VEGFR2) Y365H lies within the Ig-like C2-type domain 4 of the Kdr (Vegfr2) protein (UniProt.org). Y365H has not been characterized in the scientific literature and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24705
"NOTCH1 C438S lies within the calcium-binding, EGF-like domain 11 of the Notch1 protein (UniProt.org). C438S has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24707
"NOTCH1 G1258C lies within the calcium-binding, EGF-like domain 32 of the Notch1 protein (UniProt.org). G1258C has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24708
"NOTCH1 P1442fs results in a change in the amino acid sequence of the Notch1 protein beginning at aa 1442 of 2555, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the cytoplasmic domain (UniProt.org), P1442fs is predicted to lead to a loss of Notch1 protein function.",295,,,www.uniprot.org,24709
"NOTCH1 Q1019* results in a premature truncation of the Notch1 protein at amino acid 1019 of 2555 (UniProt.org). Due to the loss of the cytoplasmic domain (UniProt.org), Q1019* is predicted to lead to a loss of Notch1 protein function.",295,,,www.uniprot.org,24710
"NOTCH1 Q1076H lies within the EGF-like domain 28 of the Notch1 protein (UniProt.org). Q1076H has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24711
"NOTCH1 R1784W lies within the cytoplasmic domain of the Notch1 protein (UniProt.org). R1784W has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24712
"NOTCH1 Y1716C lies within the extracellular domain of the Notch1 protein (UniProt.org). Y1716C has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24713
"EGFR L62R lies within the extracellular domain of the Egfr protein (UniProt.org). L62R has been identified in the scientific literature (PMID: 25910966), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8077,25910966,A wide spectrum of EGFR mutations in glioblastoma is detected by a single clinical oncology targeted next-generation sequencing panel.,http://www.ncbi.nlm.nih.gov/pubmed/25910966,24726
"ATRX T1928K does not lie within any known functional domains of the Atrx protein (UniProt.org). T1928K has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24753
"ATRX H2260N lies within the MECP2 interacting region of the Atrx protein (UniProt.org). H2260N has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24754
"ATRX D2326Y does not lie within any known functional domains of the Atrx protein (UniProt.org). D2326Y has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24755
"ATRX D163Y lies within the ADD domain of the Atrx protein (UniProt.org). D163Y has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24756
"ATRX D1058Y does not lie within any known functional domains of the Atrx protein (UniProt.org). D1058Y has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24757
"ATRX A507D does not lie within any known functional domains of the Atrx protein (UniProt.org). A507D has not been characterized in the scientific literature and therefore, its effect on Atrx protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24758
"JAK2 inact mut indicates that this variant results in a loss of function of the Jak2 protein. However, the specific amino acid change has not been identified. ",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,24765
"PTEN D268E lies within the C2 tensin-type domain of the Pten protein (UniProt.org). D268E has not been characterized in the scientific literature and therefore, its effect on Pten protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24797
"PTEN F56fs results in a change in the amino acid sequence of the Pten protein beginning at aa 56 of 403, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of all known functional domains (UniProt.org), F56fs is predicted to lead to a loss of Pten protein function.",295,,,www.uniprot.org,24798
"PTPN11 A72T lies within the SH2 domain 1 of the Ptpn11 protein (UniProt.org). A72T has been identified in the scientific literature (PMID: 16518851) but has not been biochemically characterized and therefore, its effect on Ptpn11 protein function is unknown (PubMed, Mar 2017).
",8190,16518851,Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies.,http://www.ncbi.nlm.nih.gov/pubmed/16518851,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24802
"RB1 F755I lies within the Domain B region of the Rb1 protein (UniProt.org). F755I has been identified in the scientific literature (PMID: 22084214), but has not been biochemically characterized and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8560,22084214,Outcomes of integrating genetics in management of patients with retinoblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/22084214,24807
"RB1 I782M lies within the LIMD1 and E4F1- interacting region of the Rb1 protein (UniProt.org). I782M has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24808
"RB1 L550I lies within the Domain A region of the Rb1 protein (UniProt.org). L550I has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24809
"RB1 Q257R does not lie within any known functional domains of the Rb1 protein (UniProt.org). Q257R has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24810
"RET D631_L633delinsE results in a deletion of three amino acids of the Ret protein from amino acids 631 to 633, combined with the insertion of a glutamic acid (E) at the same site (UniProt.org). D631_L633delinsE has been identified in sequencing studies (PMID: 27082517), but has not been biochemically characterized and therefore, its effect on Ret protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6411,27082517,Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center.,http://www.ncbi.nlm.nih.gov/pubmed/27082517,24811
"ROS1 G365A does not lie within any known functional domains of the Ros1 protein (UniProt.org). G365A has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24818
"ROS1 G666S lies within the fibronectin type-III domain 3 of the Ros1 protein (UniProt.org). G666S has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24819
"ROS1 L2086I lies within the protein kinase domain of the Ros1 protein (UniProt.org). L2086I has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24820
"ROS1 S653F lies within the fibronectin type-III domain 3 of the Ros1 protein (UniProt.org). S653F has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24821
"RUNX1 - MECOM (RUNX1 - EVI1) results from the fusion of RUNX1 and MECOM (EVI1), which leads to altered transcriptional regulation resulting in transformation of hematopoietic cells in culture and development of leukemia in animal models (PMID: 19016745).",6370,19016745,Role of the RUNX1-EVI1 fusion gene in leukemogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/19016745,24822
"RUNX1 P173S lies within the Runt domain of the Runx1 protein (UniProt.org).  P173S has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24823
RUNX1 R166Q lies within the fibronectin type-III domain 1 of the Runx1 protein (UniProt.org). R166Q confers a loss of function on Runx1 protein as indicated by failure to regulate AXIN1 mRNA expression in culture (PMID: 26916619).,295,,,www.uniprot.org,6371,26916619,RUNX1 prevents oestrogen-mediated AXIN1 suppression and β-catenin activation in ER-positive breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26916619,24825
RUNX1 R201Q lies within the fibronectin type-III domain 2 of the Runx1 protein (UniProt.org). R201Q confers a loss of function on the Runx1 protein as indicated by a loss of DNA binding and reduced interaction with CBFbeta in culture (PMID: 23848403).,295,,,www.uniprot.org,6372,23848403,"RUNX1, but not its familial platelet disorder mutants, synergistically activates PF4 gene expression in combination with ETS family proteins.",http://www.ncbi.nlm.nih.gov/pubmed/23848403,24826
"RUNX1 S291fs results in a change in the amino acid sequence of the Runx1 protein beginning at aa 291 of 453, likely resulting in premature truncation of the functional protein (UniProt.org). S291fs confers a loss of function on Runx1 protein as indicated by failure to induce myeloid differentiation in culture (PMID: 23979164).",295,,,www.uniprot.org,6373,23979164,Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells.,http://www.ncbi.nlm.nih.gov/pubmed/23979164,24827
"RUNX1 S70fs results in a change in the amino acid sequence of the Runx1 protein beginning at aa 70 of 453, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of a portion of the runt homology domain and the loss of the entire transactivation domain, S70fs is predicted to lead to a loss of Runx1 function (PMID: 25840971).",295,,,www.uniprot.org,3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,24828
"RUNX1 W279* results in a premature truncation of the Runx1 protein at amino acid 279 of 453 (UniProt.org). W279* has not been characterized however, due to the effect of other truncation mutation downstream of W279 (PMID: 23979164), W279* is predicted to lead to a loss of Runx1 protein function.",6373,23979164,Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells.,http://www.ncbi.nlm.nih.gov/pubmed/23979164,295,,,www.uniprot.org,24829
"KMT2A amplification indicates an increased number of copies of the KMT2A gene. However, the mechanism causing the increase is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,24830
"KRAS R97I does not lie within any known functional domains of the Kras protein (UniProt.org). R97I has not been characterized in the scientific literature and therefore, its effect on Kras protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24831
"MAP2K1 N122D lies within the protein kinase domain of the Map2k1 protein (UniProt.org). N122D has been identified in the scientific literature (PMID: 21383288), but has not been biochemically characterized and therefore, its effect on Map2k1 protein function is unknown (PubMed, Apr 2017).",295,,,www.uniprot.org,4378,21383288,Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.,http://www.ncbi.nlm.nih.gov/pubmed/21383288,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24835
"MPL F517_P518insYIV results in the insertion of three amino acids in the Mpl protein between amino acids 517 and 518 (UniProt.org). F517_P518insYIV has not been characterized in the scientific literature and therefore, its effect on Mpl protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24842
MPL K39N does not lie within any known functional domains of the Mpl protein (UniProt.org). K39N confers a loss of function to the Mpl protein as indicated by decreased protein level (PMID: 15269348).,8320,15269348,Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis.,http://www.ncbi.nlm.nih.gov/pubmed/15269348,295,,,www.uniprot.org,24843
"MSH6 F1088Lfs*5 likely results in a premature truncation of the 1360 aa Msh6 protein at aa 1088 followed by 5 nonsense amino acids  (UniProt.org). Due to the loss of MSH2- and ATP-binding regions (PMID: 12019211), F1088Lfs*5 is predicted to lead to a loss of Msh6 protein function.",3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,295,,,www.uniprot.org,24857
"MSH6 F573fs results in a change in the amino acid sequence of the Msh6 protein beginning at aa 573 of 1360, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of MSH2- and ATP-binding regions (PMID: 12019211), F573fs is predicted to lead to a loss of Msh6 protein function. ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3527,12019211,Functional analysis of MSH6 mutations linked to kindreds with putative hereditary non-polyposis colorectal cancer syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/12019211,295,,,www.uniprot.org,24858
"MSH6 K1358Dfs*2 likely results in a truncation of the 1360 aa Msh6 protein at aa 1358, followed by 2 nonsense amino acids (UniProt.org). K1358Dfs*2 has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24859
"MSH6 R1076C does not lie within any known functional domains of the Msh6 protein (UniProt.org). R1076C has been identified in the scientific literature (PMID: 22250089), but has not been biochemically characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Apr 2017).",8562,22250089,Human MSH6 deficiency is associated with impaired antibody maturation.,http://www.ncbi.nlm.nih.gov/pubmed/22250089,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24860
"MSH6 V509A does not lie within any known functional domains of the Msh6 protein (UniProt.org). V509A has been identified in sequencing studies (PMID: 10675480), but has not been biochemically characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Apr 2017).",8563,10675480,Missense mutation of the hMSH6 and p53 genes in sporadic urothelial transitional cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/10675480,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24861
"RUNX1 Y113* results in a premature truncation of the Runx1 protein at amino acid 113 of 453 (UniProt.org). Due to the loss of a portion of the runt homology domain and the loss of the entire transactivation domain, Y113* is predicted to lead to a loss of Runx1 function (PMID: 25840971).",295,,,www.uniprot.org,3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,24870
"SMC3 Q761H lies within the coiled-coil domain of the Smc3 protein (UniProt.org). Q761H has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, Jul 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24873
"SMC3 T876P lies within the coiled-coil domain of the Smc3 protein (UniProt.org). T876P has not been characterized in the scientific literature and therefore, its effect on Smc3 protein function is unknown (PubMed, Jul 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24874
"SMO R576W does not lie within any known functional domains of the Smo protein (UniProt.org). R576W has not been characterized in the scientific literature and therefore, its effect on Smo protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24875
"SMO T179M lies within the FZ domain of the Smo protein (UniProt.org). T179M has not been characterized in the scientific literature and therefore, its effect on Smo protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24876
"ASXL1 M1161I does not lie within any known functional domains of the Asxl1 protein (UniProt.org). M1161I has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Jul 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24882
"SRC Q256fs results in a change in the amino acid sequence of the Src protein beginning at aa 256 of 536, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of protein kinase domain (UniProt.org), Q256fs is predicted to lead to a loss of Src protein function.",295,,,www.uniprot.org,24888
"TP53 C275F lies within the DNA interaction region of the Tp53 protein (UniProt.org). C275F has been identified in sequencing studies (PMID: 26873401, PMID: 24682512, PMID: 27095739) but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Feb 2017).
",7161,26873401,Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population.,http://www.ncbi.nlm.nih.gov/pubmed/26873401,7926,27095739,Targeted next-generation sequencing detects a high frequency of potentially actionable mutations in metastatic breast cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27095739,7925,24682512,p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).,http://www.ncbi.nlm.nih.gov/pubmed/24682512,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24893
TP53 C275S lies within the DNA interaction region of the Tp53 protein (UniProt.org). C275S confers a loss of function to the Tp53 protein as indicated by decreased DNA binding in cell culture (PMID: 12034820).,7605,12034820,Redox state of tumor suppressor p53 regulates its sequence-specific DNA binding in DNA-damaged cells by cysteine 277.,http://www.ncbi.nlm.nih.gov/pubmed/12034820,295,,,www.uniprot.org,24894
"TP53 I195F lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). I195F has been identified in sequencing studies (PMID: 27276561, PMID: 25534115), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Feb 2017).
",7052,27276561,Genomic Classification and Prognosis in Acute Myeloid Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27276561,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7934,25534115,ASPP2 enhances oxaliplatin (L-OHP)-induced colorectal cancer cell apoptosis in a p53-independent manner by inhibiting cell autophagy.,http://www.ncbi.nlm.nih.gov/pubmed/25534115,24895
"TP53 M246I lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). M246I confers a loss of function on Tp53 protein as indicated by reduced DNA binding, decreased transcription activity, and failure to induce apoptosis in cell culture (PMID: 10777217).",5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,6385,10777217,Tumor-derived mutations within the DNA-binding domain of p53 that phenotypically resemble the deletion of the proline-rich domain.,http://www.ncbi.nlm.nih.gov/pubmed/10777217,24896
TP53 M246R lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). M246R results in a loss of Tp53 binding to SV40 large T-antigen (LTag) and failure to inhibit LTag helicase function in culture (PMID: 16951253).,6386,16951253,Crystal structure of SV40 large T-antigen bound to p53: interplay between a viral oncoprotein and a cellular tumor suppressor.,http://www.ncbi.nlm.nih.gov/pubmed/16951253,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,24897
"TP53 S185R lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). S185R has been identified in sequencing studies (PMID: 26873401, PMID: 11454518, PMID: 15523690), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Feb 2017).
",7995,15523690,DHPLC is superior to SSCP in screening p53 mutations in esophageal cancer tissues.,http://www.ncbi.nlm.nih.gov/pubmed/15523690,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,7994,11454518,Molecular analysis of CDKN1C and TP53 in sporadic adrenal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/11454518,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7161,26873401,Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population.,http://www.ncbi.nlm.nih.gov/pubmed/26873401,24898
TP53 S215I lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). S215I confers a loss of function to the Tp53 protein as demonstrated its inability to transactivate Mdm2 in vitro (PMID: 17325666).,7998,17325666,Xeroderma pigmentosum group C gene expression is predominantly regulated by promoter hypermethylation and contributes to p53 mutation in lung cancers.,http://www.ncbi.nlm.nih.gov/pubmed/17325666,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24899
"U2AF1 G217S does not lie within any known functional domains of the U2af1 protein (UniProt.org). G217S has not been characterized in the scientific literature and therefore, its effect on U2af1 protein function is unknown (PubMed, Jul 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24901
"VHL R161P lies within the Elongin BC complex interaction region of the Vhl protein (UniProt.org). R161P confers a loss of function to the Vhl protein as indicated by loss of binding to the elongin BC complex and destabilization of microtubule in culture (PMID: 10587522, PMID: 20855504).",295,,,www.uniprot.org,6391,20855504,Quantitative image analysis identifies pVHL as a key regulator of microtubule dynamic instability.,http://www.ncbi.nlm.nih.gov/pubmed/20855504,6390,10587522,"Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein.",http://www.ncbi.nlm.nih.gov/pubmed/10587522,24902
VHL R161G lies within the Elongin BC complex interaction region of the Vhl protein (UniProt.org). R161G confers a loss of function to the Vhl protein as indicated by failure to bind to the elongin BC complex in an in vitro assay (PMID: 10587522).,295,,,www.uniprot.org,6390,10587522,"Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein.",http://www.ncbi.nlm.nih.gov/pubmed/10587522,24903
"CDKN2A G45S lies within the ANK repeat 2 of the Cdkn2a protein (UniProt.org). G45S has been identified in sequencing studies (PMID: 9495360), but has not been biochemically characterized and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Feb 2017).",7778,9495360,p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9495360,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24913
"DNMT3A A121S does not lie within any known functional domains of the Dnmt3a protein (UniProt.org). A121S has not been characterized in the scientific literature and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jun 2017).
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24916
"DNMT3A D811Y lies within the SAM-dependent MTase C5-type domain of the Dnmt3a protein (UniProt.org). D811Y has not been characterized in the scientific literature and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24917
"DNMT3A E240* results in a premature truncation of the Dnmt3a protein at amino acid 240 of 912 (UniProt.org). Due to the loss of the catalytic domain (UniProt.org), E240* is predicted to lead to a loss of Dnmt3a protein function.",295,,,www.uniprot.org,24918
"GNAS G432V does not lie within any known functional domains of the Gnas protein (UniProt.org). G432V has not been characterized and therefore, its effect on Gnas protein function is unknown (PubMed, Jul 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24919
"GNAS Y216C does not lie within any known functional domains of the Gnas protein (UniProt.org). Y216C has not been characterized in the scientific literature and therefore, its effect on Gnas protein function is unknown (PubMed, Jul 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24920
"HNF1A T152S does not lie within any known functional domains of the Hnf1a protein (UniProt.org). T152S has not been characterized in the scientific literature and therefore, its effect on Hnf1a protein function is unknown (PubMed, Jul 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24922
"FLT3 A450E does not lie within any known functional domains of the Flt3 protein (UniProt.org). A450E has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Apr 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24926
"FLT3 A914D lies within the protein kinase domain of the Flt3 protein (UniProt.org). A914D has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Apr 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24927
"FLT3 R933L lies within the protein kinase domain of the Flt3 protein (UniProt.org). R933L has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Apr 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24928
"FLT3 C184* results in the premature truncation of the Flt3 protein at amino acid 184 of 933 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), C184* is predicted to lead to a loss of Flt3 protein function. ",295,,,www.uniprot.org,24929
"FLT3 E236* results in the premature truncation of the Flt3 protein at amino acid 236 of 933 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), E236* is predicted to lead to a loss of Flt3 protein function. ",295,,,www.uniprot.org,24930
"STK11 A241P lies within the protein kinase domain of the Stk11 protein (UniProt.org). A241P has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Apr 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24936
"STK11 H107L lies within the protein kinase domain of the Stk11 protein (UniProt.org). H107L has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Apr 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24937
"STK11 H174D lies within the protein kinase domain of the Stk11 protein (UniProt.org). H174D has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Apr 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24938
"STK11 L245F lies within the protein kinase domain of the Stk11 protein (UniProt.org). L245F has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Jul 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24939
"STK11 R297S lies within the protein kinase domain of the Stk11 protein (UniProt.org).R297S has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Jul 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24940
"STK11 Y36D does not lie within any known functional domains of the Stk11 protein (UniProt.org). Y36D has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Jul 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24941
"STK11 C278fs results in a change in the amino acid sequence of the Stk11 protein beginning at aa 278 of 433, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of part of the protein kinase domain (UniProt.org), C278fs is predicted to lead to a loss of Stk11 protein function.
",295,,,www.uniprot.org,24942
"STK11 E138* results in a premature truncation of the Stk11 protein at amino acid 138 of 433 within the protein kinase domain (UniProt.org). Due to the loss of a majority of the protein kinase domain including the active site (UniProt.org), E138* is predicted to lead to a loss of Stk11 protein function.",295,,,www.uniprot.org,24943
"STK11 I35Lfs*127 is a missense mutation (I35L) in conjunction with a likely truncation of the 433 aa Stk11 protein at aa 35, followed by 127 nonsense amino acids (UniProt.org). Due to the loss of a majority of the protein kinase domain, I35Lfs*127 is predicted to lead to a loss of Stk11 protein function.",295,,,www.uniprot.org,24944
"STK11 Q214* results in a premature truncation of the Stk11 protein at amino acid 214 of 433 within the protein kinase domain (UniProt.org). Due to the loss of part of the protein kinase domain (UniProt.org), Q214* is predicted to lead to a loss of Stk11 protein function.
",295,,,www.uniprot.org,24945
"STK11 Q302* results in a premature truncation of the Stk11 protein at amino acid 302 of 433 within the protein kinase domain (UniProt.org). Q302* has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Jul 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24946
"STK11 W308* results in a premature truncation of the Stk11 protein at amino acid 308 of 433 within the protein kinase domain (UniProt.org). W308* has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Jul 2016). 
",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24947
"STK11 V320fs results in a change in the amino acid sequence of the Stk11 protein beginning at aa 320 of 433, likely resulting in premature truncation of the functional protein (UniProt.org). V320fs has not been characterized and therefore, its effect on Stk11 protein function is unknown (PubMed, Jul 2016). ",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24948
"FGFR1 inact mut indicates that this variant results in a loss of function of the Fgfr1 protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,24949
"FGFR2 inact mut indicates that this variant results in a loss of function of the Fgfr2 protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,24950
"FGFR3 inact mut indicates that this variant results in a loss of function of the Fgfr3 protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,24951
"NRAS Q150H does not lie within any known functional domains of the Nras protein (UniProt.org). Q150H has not been characterized in the scientific literature and therefore, its effect on Nras protein function is unknown (PubMed, Aug 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24953
"PDGFRA E951* results in a premature truncation of the Pdgfra protein at amino acid 951 of 1089 (UniProt.org). E951* has not been characterized in the scientific literature and therefore, its effect on Pdgfra protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24954
"PDGFRA G51E lies within the Ig-like C2-type domain 1 of the Pdgfra protein (UniProt.org). G51E has not been characterized in the scientific literature and therefore, its effect on Pdgfra protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24955
"PDGFRA H920Y lies within the protein kinase domain of the Pdgfra protein (UniProt.org). H920Y has not been characterized in the scientific literature and therefore, its effect on Pdgfra protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24956
"PDGFRA T152A lies within the Ig-like C2-type domain 2 of the Pdgfra protein (UniProt.org). T152A has not been characterized in the scientific literature and therefore, its effect on Pdgfra protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24957
"PDGFRA V140L lies within the Ig-like C2-type domain 2 of the Pdgfra protein (UniProt.org). V140L has been identified in the scientific literature (PMID: 20169295), but has not been biochemically characterized and therefore, its effect on Pdgfra protein function is unknown (PubMed, Aug 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7840,20169295,Platelet-derived growth factor receptor alpha gene mutations in vitiligo vulgaris.,http://www.ncbi.nlm.nih.gov/pubmed/20169295,24958
"PIK3CA I910M lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). I910M has not been characterized in the scientific literature and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24959
"EGFR-RAD51 results from the fusion of EGFR and RAD51, demonstrating activation of downstream signaling pathways, MAPK and PI3K, transformation activity in culture, and increased colony formation (PMID: 27102076).",6404,27102076,EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27102076,24967
"EGFR-PURB results from the fusion of EGFR and PURB (PMID: 27102076). EGFR-PURB has been identified in lung adenocarcinoma (PMID: 27102076), but has not been biochemically characterized and therefore, its effect on fusion protein function is unknown (PubMed, Sep 2017).",6404,27102076,EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27102076,24971
"PTEN C218* results in a premature truncation within the C2 tensin-type domain of the Pten protein at amino acid 218 of 403 (UniProt.org). C218* has not been characterized, however other C-terminal deletion mutants downstream of C218 are inactivating (PMID: 10468583), thus C218* is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,24974
"PTEN N292fs results in a change in the amino acid sequence of the Pten protein beginning at aa 292 of 403, likely resulting in premature truncation of the functional protein (UniProt.org). N292fs has not been characterized, however other C-terminal deletion mutants downstream of N292 are inactivating (PMID: 10468583), thus N292fs is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,24975
"ROS1 F923I lies within the extracellular domain of the Ros1 protein (UniProt.org). F923I has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24981
"ROS1 M1805V lies within the fibronectin type-III domain 9 of the Ros1 protein (UniProt.org). M1805V has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24982
"ROS1 S1577Y lies within the fibronectin type-III domain 7 of the Ros1 protein (UniProt.org). S1577Y has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24983
"ROS1 S32I lies within the extracellular domain of the Ros1 protein (UniProt.org). S32I has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24984
"ROS1 V1979E lies within the protein kinase domain of the Ros1 protein (UniProt.org). V1979E has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24985
"RUNX1 L44M does not lie within any known functional domains of the Runx1 protein (UniProt.org). L44M has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24987
"SF3B1 I1004L does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). I1004L has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, Aug 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24989
"SF3B1 G140R does not lie within any known functional domains of the Sf3b1 protein (UniProt.org). G140R has not been characterized and therefore, its effect on Sf3b1 protein function is unknown (PubMed, Aug 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24990
"SF3B1 G83* results in a premature truncation of the Sf3b1 protein at amino acid 83 of 1304 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), G83* is predicted to lead to a loss of Sf3b1 protein function.",295,,,www.uniprot.org,24991
"SMAD4 G80R lies within the MH1 domain of the Smad4 protein (UniProt.org). G80R has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Aug 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24992
"SMARCB1 D169H does not lie within any known functional domains of the Smarcb1 protein (UniProt.org). D169H has not been characterized in the scientific literature and therefore, its effect on Smarcb1 protein function is unknown (PubMed, Sep 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24993
"SMO A250D does not lie within any known functional domains of the Smo protein (UniProt.org). A250D has not been characterized and therefore, its effect on Smo protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24994
"SMO R161L lies within the FZ domain of the Smo protein (UniProt.org). R161L has not been characterized and therefore, its effect on Smo protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,24995
"GNAQ E212_R213insERC results in the insertion of three amino acids in the Gnaq protein between amino acids 212 and 213 (UniProt.org). E212_R213insERC has not been characterized in the scientific literature and therefore, its effect on Gnaq protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,24999
"HRAS G151E does not lie within any known functional domains of the Hras protein (UniProt.org). G151E has not been characterized in the scientific literature and therefore, its effect on Hras protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25000
"HRAS N26S does not lie within any known functional domains of the Hras protein (UniProt.org). N26S has been identified in the scientific literature (PMID: 28229982), but has not been biochemically characterized and therefore, its effect on Hras protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8606,28229982,Circulating-free DNA Mutation Associated with Response of Targeted Therapy in Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28229982,25001
"IDH1 I129_I130insIRC results in the insertion of three amino acids in the Idh1 protein between amino acids 129 and 130 (UniProt.org). I129_I130insIRC has not been characterized in the scientific literature and therefore, its effect on Idh1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25002
"IDH1 M291I does not lie within any known functional domains of the Idh1 protein (UniProt.org). M291I has not been characterized and therefore, its effect on Idh1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25003
"IDH1 V386L does not lie within any known functional domains of the Idh1 protein (UniProt.org). V386L has not been characterized in the scientific literature and therefore, its effect on Idh1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25004
"IDH2 A101P does not lie within any known functional domains of the Idh2 protein (UniProt.org). A101P has not been characterized in the scientific literature and therefore, its effect on Idh2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25005
"ETV6 I406S lies within the ETS domain of the Etv6 protein (PMID: 25581430). I406S has not been characterized in the scientific literature and therefore, its effect on Etv6 protein function is unknown (PubMed, Aug 2017).",3578,25581430,Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.,http://www.ncbi.nlm.nih.gov/pubmed/25581430,285,,,http://www.ncbi.nlm.nih.gov/pubmed,25018
"CSF3R D320N lies within the Fibronectin type-III 2 domain of the Csf3r protein (UniProt.org). D320N has been identified in the scientific literature (PMID: 23774674), but has not been biochemically characterized and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9050,23774674,Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/23774674,25022
"CSF3R D510H lies within the Fibronectin type-III 4 domain of the Csf3r protein (UniProt.org). D510H has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25023
"CSF3R R343W lies within the Fibronectin type-III 3 domain of the Csf3r protein (UniProt.org). R343W has not been characterized and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25024
"CSF3R R440Q lies within the Fibronectin type-III 4 domain of the Csf3r protein (UniProt.org). R440Q has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25025
"BRAF A712T lies within the protein kinase domain of the Braf protein (UniProt.org). A712T has been identified in sequencing studies (PMID: 22653804), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Sep 2017). ",7748,22653804,Use of mutation profiles to refine the classification of endometrial carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/22653804,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25026
"BRAF N20T does not lie within any known functional domains of the Braf protein (UniProt.org). N20T has not been characterized in the scientific literature and therefore, its effect on Braf protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,25027
"BRAF Q257H lies within the phorbol-ester/DAG-type zinc finger region of the Braf protein (UniProt.org). Q257H has been identified in sequencing studies (PMID: 22980975), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Jul 2017). 
",295,,,www.uniprot.org,1726,22980975,Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/22980975,285,,,http://www.ncbi.nlm.nih.gov/pubmed,25028
"BRAF A598_T599insARC results in the insertion of 3 amino acids in the protein kinase domain of the Braf protein between amino acids 598 and 599 (UniProt.org). BRAF A598_T599insARC has not been characterized, however other insertions between A598 and T599 are activating thus, A598_T599insARC is predicted to lead to a gain of Braf protein function (PMID: 16501605). 

",295,,,www.uniprot.org,1892,16501605,Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/16501605,25029
"JAK3 P975L lies within the protein kinase domain 2 of the Jak3 protein (UniProt.org). P975L has not been characterized and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25037
"KDR (VEGFR2) R73M lies within the Ig-like C2-type domain 1 of the Kdr (Vegfr2) protein (UniProt.org). R73M has not been characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25042
"KIT A402S lies within the Ig-like C2-type domain 4 of the Kit protein (UniProt.org). A402S has not been characterized in the scientific literature and therefore, its effect on Kit protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,25043
"KIT G387R lies within the Ig-like C2-type domain 4 of the Kit protein (UniProt.org). G387R has not been characterized in the scientific literature and therefore, its effect on Kit protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,25044
"MAP2K1 G128C lies within the protein kinase domain of the Map2k1 protein (UniProt.org).  G128C has not been characterized in the scientific literature and therefore, its effect on Map2k1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25045
"MET D824Y lies within the IPT/TIG domain 3 of the Met protein (UniProt.org). D824Y has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25047
"MET E25D does not lie within any known functional domains of the Met protein (UniProt.org). E25D has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25048
"MSH6 A64V does not lie within any known functional domains of the Msh6 protein (UniProt.org). A64V has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25050
"MSH6 amplification indicates an increased number of copies of the Msh6 gene. However, the mechanism causing the increase is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,25051
"FGFR2 G384E does not lie within any known functional domains of the Fgfr2 protein (UniProt.org). G384E has not been characterized in the scientific literature and therefore, its effect on Fgfr2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25056
"FGFR2-PPHLN1 results from the fusion of FGFR2 and PPHLN1 (PMID: 25608663), resulting in constitutive activation of the fusion protein and activation of downstream Erk1/2 signaling (PMID: 25608663). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3876,25608663,Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25608663,25057
"FGFR2-MGEA5 results from the fusion of FGFR2 and MGEA5 (PMID: 24550739). FGFR2-MGEA5 has been identified in intrahepatic cholangiocarcinoma (PMID: 24550739), but has not been biochemically characterized and therefore, its effect on protein function is unknown (PubMed, Jan 2017).",6412,24550739,"Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/24550739,285,,,http://www.ncbi.nlm.nih.gov/pubmed,25058
"FGFR2-CCAR2 (also referred to as FGFR2-KIAA1967) results from the fusion of FGFR2 and CCAR2 (PMID: 23558953). FGFR2-CCAR2 has been identified in lung cancer (PMID: 27245147, PMID: 23558953), but has not been biochemically characterized and therefore, its effect on fusion protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,5785,27245147,"FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).",http://www.ncbi.nlm.nih.gov/pubmed/27245147,4387,23558953,Identification of targetable FGFR gene fusions in diverse cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23558953,25059
"FGFR2-FAM76A results from the fusion of FGFR2 and FAM76A, which leads to increased proliferation and transformation in cell culture (PMID: 24563622).",6413,24563622,Personalized ovarian cancer disease surveillance and detection of candidate therapeutic drug target in circulating tumor DNA.,http://www.ncbi.nlm.nih.gov/pubmed/24563622,25060
"FGFR2-CIT results from the fusion of FGFR2 and CIT (PMID: 23558953). FGFR2-CIT has been identified in lung adenocarcinoma (PMID: 23558953), but has not been biochemically characterized and therefore, its effect on protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,4387,23558953,Identification of targetable FGFR gene fusions in diverse cancers.,http://www.ncbi.nlm.nih.gov/pubmed/23558953,25061
"FGFR1 R285L lies within the Ig-like C2-type domain 3 of the Fgfr1 protein (UniProt.org). R285L has not been characterized in the scientific literature and therefore, its effect on Fgfr1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25062
"FGFR1 K223I lies within the Ig-like C2-type domain 2 of the Fgfr1 protein (UniProt.org). K223I has not been characterized in the scientific literature and therefore, its effect on Fgfr1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25063
"FBXW7 D550Mfs*6 is a missense mutation (D550M) in conjunction with a likely truncation of the 707 aa Fbxw7 protein at aa 550, followed by 6 nonsense amino acids (UniProt.org). D550Mfs*6 has not been characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25065
"ERBB4 A877S lies within the protein kinase domain of the Erbb4 protein (UniProt.org). A877S has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25070
"ERBB4 K812N lies within the protein kinase domain of the Erbb4 protein (UniProt.org). K812N has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25071
"ERBB4 P224L lies within the extracellular domain of the Erbb4 protein (UniProt.org). P224L has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25072
"ERBB4 Q44E lies within the extracellular domain of the Erbb4 protein (UniProt.org). Q44E has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25073
"ERBB4 R525S lies within the extracellular domain of the Erbb4 protein (UniProt.org). R525S has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25074
"ERBB4 S479I lies within the extracellular domain of the Erbb4 protein (UniProt.org). S479I has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,25075
"ERBB4 V421L lies within the extracellular domain of the Erbb4 protein (UniProt.org). V421L has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,25076
"ERBB4 W823C lies within the protein kinase domain of the Erbb4 protein (UniProt.org). W823C has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25077
"CSF1R A273S lies within the Ig-like C2-type domain 3 of the Csf1r protein (UniProt.org). A273S has not been characterized in the scientific literature and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25078
"CTNNB1 D162E lies within the ARM 1 repeat region of the Ctnnb1 protein (UniProt.org). D162E has been identified in sequencing studies (PMID: 22810696), but has not been biochemically characterized and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Mar 2017).",5152,22810696,Comprehensive molecular characterization of human colon and rectal cancer.,http://www.ncbi.nlm.nih.gov/pubmed/22810696,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25084
"CTNNB1 S73P does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). S73P has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Mar 2017).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25085
"CTNNB1 S45_L46insTSS results in the insertion of three amino acids in the Ctnnb1 protein between amino acids 45 and 46 (UniProt.org). S45_L46insTSS has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25086
"CTNNB1 T257I lies within the ARM 3 repeat region of the Ctnnb1 protein (UniProt.org). T257I has been identified in the scientific literature (PMID: 25859559, PMID: 27334835, PMID: 26822237), but has not been biochemically characterized and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Mar 2017).
",8348,25859559,Clinical next generation sequencing of pediatric-type malignancies in adult patients identifies novel somatic aberrations.,http://www.ncbi.nlm.nih.gov/pubmed/25859559,7355,27334835,"Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations.",http://www.ncbi.nlm.nih.gov/pubmed/27334835,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8349,26822237,Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors.,http://www.ncbi.nlm.nih.gov/pubmed/26822237,25087
CTNNB1 W25_H36del results in the deletion of twelve amino acids in the Ctnnb1 protein from amino acids 25 to 36 (UniProt.org). W25_H36del is predicted to confer a gain of function to the Ctnnb1 protein as demonstrated by nuclear accumulation of Ctnnb1 (PMID: 17011185).,8350,17011185,Mutational analysis of beta-catenin and the RAS-RAF signalling pathway in early flat-type colorectal tumours.,http://www.ncbi.nlm.nih.gov/pubmed/17011185,295,,,www.uniprot.org,25088
"ERBB2 (HER2) V308M lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). V308M has not been characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25089
"ERBB2 (HER2) T182I lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). T182I has not been characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25090
"ERBB2 R897Q lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). R897Q has been identified in sequencing studies (PMID: 23700467), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,7981,23700467,Targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/23700467,285,,,http://www.ncbi.nlm.nih.gov/pubmed,25091
"ERBB2 (HER2) R545* results in a premature truncation of the Erbb2 (Her2) protein at amino acid 545 of 1255 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), R545* is predicted to lead to a loss of Erbb2 (Her2) protein function.",295,,,www.uniprot.org,25092
"ERBB2 P230L lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). P230L has been identified in sequencing studies (PMID: 24755471), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6962,24755471,Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24755471,25093
"ERBB2 (HER2) P1207A lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). P1207A has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25094
"ERBB2 (HER2) A775_G776insYVMA results in the insertion of four amino acids in the protein kinase domain of the Erbb2 (Her2) protein between amino acids 775 and 776 (UniProt.org). A775_G776insYVMA results in the same amino acid change as M774_A775insAYVM, which leads to constitutive phosphorylation of Erbb2 (Her2) and is transforming in cell culture (PMID: 17311002).",295,,,www.uniprot.org,2002,17311002,The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.,http://www.ncbi.nlm.nih.gov/pubmed/17311002,25095
"KMT2A-EP300 results from the fusion of KMT2A and EP300 (PMID: 20980053). KMT2A-EP300 has been identified in acute myeloid leukemia (PMID: 20980053), but not been biochemically characterized and therefore, its effect on protein function is unknown (PubMed, Jul 2017).",6424,20980053,Novel variant form of t(11;22)(q23;q13)/MLL-EP300 fusion transcript in the evolution of an acute myeloid leukemia with myelodysplasia-related changes.,http://www.ncbi.nlm.nih.gov/pubmed/20980053,285,,,http://www.ncbi.nlm.nih.gov/pubmed,25102
"FGFR2 R165W lies within the Ig-like C2-type domain 2 of the Fgfr2 protein (UniProt.org). R165W has not been characterized in the scientific literature and therefore, its effect on Fgfr2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25103
"FOXL2 amplification indicates an increased number of copies of the FOXL2 gene. However, the mechanism causing the increase is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,25106
"GATA1 Y98* results in a premature truncation of the Gata1 protein at amino acid 98 of 413 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), Y98* is predicted to lead to a loss of Gata1 protein function.",295,,,www.uniprot.org,25108
"BCOR A1388S does not lie within any known functional domains of the Bcor protein (UniProt.org). A1388S has not been characterized in the scientific literature and therefore, its effect on Bcor protein function is unknown (PubMed, Aug 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25111
"BCOR A172fs results in a change in the amino acid sequence of the Bcor protein beginning at aa 172 of 1755, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of all known functional domains (UniProt.org), A172fs is predicted to lead to a loss of Bcor protein function.",295,,,www.uniprot.org,25112
"BCOR D1279Y does not lie within any known functional domains of the Bcor protein (UniProt.org). D1279Y has not been characterized and therefore, its effect on Bcor protein function is unknown (PubMed, Aug 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25113
"BCOR E1386Q does not lie within any known functional domains of the Bcor protein (UniProt.org). E1386Q has not been characterized in the scientific literature and therefore, its effect on Bcor protein function is unknown (PubMed, Aug 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25114
"BCOR K219E does not lie within any known functional domains of the Bcor protein (UniProt.org). K219E has not been characterized in the scientific literature and therefore, its effect on Bcor protein function is unknown (PubMed, Aug 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25115
"BCOR L1456P does not lie within any known functional domains of the Bcor protein (UniProt.org). L1456P has not been characterized in the scientific literature and therefore, its effect on Bcor protein function is unknown (PubMed, Aug 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25116
"BCOR N1459S does not lie within any known functional domains of the Bcor protein (UniProt.org). N1459S has not been characterized in the scientific literature and therefore, its effect on Bcor protein function is unknown (PubMed, Aug 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25117
"BCOR R266M does not lie within any known functional domains of the Bcor protein (UniProt.org). R266M has not been characterized in the scientific literature and therefore, its effect on Bcor protein function is unknown (PubMed, Aug 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25118
"BCOR W509C lies within the Bcl6 interaction region of the Bcor protein (UniProt.org). W509C has not been characterized in the scientific literature and therefore, its effect on Bcor protein function is unknown (PubMed, Aug 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25119
"CTNNB1 G34A lies within the ubiquitination recognition motif of the Ctnnb1 protein (PMID: 15064718). G34A confers a gain of function to the Ctnnb1 protein as demonstrated by reduced ubiquitination of the Ctnnb1 protein and transformation of cells in culture (PMID: 15829978). 
",408,15064718,Phosphorylation and ubiquitination of oncogenic mutants of beta-catenin containing substitutions at Asp32.,http://www.ncbi.nlm.nih.gov/pubmed/15064718,461,15829978,Functional correlates of mutation of the Asp32 and Gly34 residues of beta-catenin.,http://www.ncbi.nlm.nih.gov/pubmed/15829978,25121
"KDR (VEGFR2) T771R lies within the transmembrane domain of the Kdr (Vegfr2) protein (UniProt.org). T771R has been identified in the scientific literature (PMID: 19723655), but has not been characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Jul 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,217,19723655,KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/19723655,25125
"EGFR D1014V lies within the cytoplasmic domain of the Egfr protein (UniProt.org). D1014V has not been characterized in the scientific literature and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25127
"EGFR F254I lies within the extracellular domain of the Egfr protein (UniProt.org). F254I has been identified in the scientific literature (PMID: 25910966), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8077,25910966,A wide spectrum of EGFR mutations in glioblastoma is detected by a single clinical oncology targeted next-generation sequencing panel.,http://www.ncbi.nlm.nih.gov/pubmed/25910966,25128
"EGFR G573* results in a premature truncation of the Egfr protein at amino acid 573 of 1210 (UniProt.org). Due to a loss of the protein kinase domain (UniProt.org), G573* is predicted to lead to a loss of Egfr function.
",295,,,www.uniprot.org,25129
"EGFR L90F lies within the extracellular domain of the Egfr protein (UniProt.org). L90F has not been characterized in the scientific literature and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25130
"EGFR P622S lies within the extracellular domain of the Egfr protein (UniProt.org). P622S has not been characterized in the scientific literature and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25131
EGFR I941R lies within the protein kinase domain of the Egfr protein (UniProt.org). I941R confers a loss of function on the Egffr protein as indicated by disruption of dimerization in culture (PMID: 24063894).,1846,24063894,Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization.,http://www.ncbi.nlm.nih.gov/pubmed/24063894,295,,,www.uniprot.org,25145
EGFR L704N lies within the cytoplasmic domain of the Egfr protein (UniProt.org). L704N confers a loss of function on the Egffr protein as indicated by disruption of dimerization in culture (PMID: 24063894).,1846,24063894,Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization.,http://www.ncbi.nlm.nih.gov/pubmed/24063894,295,,,www.uniprot.org,25146
VHL del indicates a deletion of the VHL gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,25151
"ATM	V60F does not lie within any known functional domains of the Atm protein (UniProt.org). V60F has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25153
"APC D1083E lies within a region of the Apc protein mediating direct ubiquitination (UniProt.org). D1083E has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,25155
ATRX K1650N lies within the helicase ATP-binding domain of the Atrx protein (UniProt.org). K1650N results in reduced ATPase activity of Atrx and impaired DNA translocation in cell culture (PMID: 21505078).,6465,21505078,Functional significance of mutations in the Snf2 domain of ATRX.,http://www.ncbi.nlm.nih.gov/pubmed/21505078,295,,,www.uniprot.org,25158
"TP53 V272L lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). V272L has not been biochemically characterized in human cells, but demonstrates transcription activity similar to wild-type Tp53 in yeast (PMID: 20407015).",643,20407015,Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20407015,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,25159
"ERBB4 E57V lies within the extracellular domain of the Erbb4 protein (UniProt.org). E57V has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25160
"MLH1 Q391R does not lie within any known functional domains of the Mlh1 protein (UniProt.org). Q391R has not been characterized in the scientific literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25161
"ABL1 E1085K lies within the F-actin-binding region of the Abl1 protein (UniProt.org). E1085K has not been characterized in the scientific literature and therefore, its effect on Abl1 protein function is unknown (PubMed, Feb 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25164
"APC E763* results in a premature truncation of the Apc protein at amino acid 763 of 2843 (UniProt.org). E763* has not been characterized, however, Apc truncation mutants downstream of E763 are inactivating (PMID: 18199528) thus, E763* is predicted to lead to a loss of Apc protein function.
",295,,,www.uniprot.org,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,25165
"APC F1354fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1354 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). F1354fs has not been characterized, however, Apc truncation mutants downstream of F1354 are inactivating (PMID: 18199528) thus, F1354fs is predicted to lead to a loss of Apc protein function.
",295,,,www.uniprot.org,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,25166
"APC I606fs results in a change in the amino acid sequence of the Apc protein beginning at aa 606 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). I606fs has not been characterized, however, Apc truncation mutants downstream of I606 are inactivating (PMID: 18199528) thus, I606fs is predicted to lead to a loss of Apc protein function.
",2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,295,,,www.uniprot.org,25167
"APC Q1067* results in a premature truncation of the Apc protein at amino acid 1067 of 2843 (UniProt.org). Q1067* has not been characterized, however, Apc truncation mutants downstream of Q1067 are inactivating (PMID: 18199528) thus, Q1067* is predicted to lead to a loss of Apc protein function.
",2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,295,,,www.uniprot.org,25168
"APC R554* results in a premature truncation of the Apc protein at amino acid 554 of 2843 (UniProt.org). R554* has not been characterized, however, Apc truncation mutants downstream of R554 are inactivating (PMID: 18199528) thus, R554* is predicted to lead to a loss of Apc protein function.
",2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,295,,,www.uniprot.org,25169
"APC S1400* results in a premature truncation of the Apc protein at amino acid 1400 of 2843 (UniProt.org). S1400* has not been characterized, however, Apc truncation mutants downstream of S1400 are inactivating (PMID: 18199528) thus, S1400* is predicted to lead to a loss of Apc protein function.
",2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,295,,,www.uniprot.org,25170
"APC T683P lies within the ARM5 repeat region of the Apc protein (UniProt.org). T683P has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,25171
"APC V1377fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1377 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). V1377fs has not been characterized, however, Apc truncation mutants downstream of V1377 are inactivating (PMID: 18199528) thus, V1377fs is predicted to lead to a loss of Apc protein function.
",295,,,www.uniprot.org,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,25172
"ASXL1 M29V does not lie within any known functional domains of the Asxl1 protein (UniProt.org). M29V has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Aug 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25181
"ASXL1 S723F does not lie within any known functional domains of the Asxl1 protein (UniProt.org). S723F has not been characterized in the scientific literature and therefore, its effect on Asxl1 protein function is unknown (PubMed, Aug 2016).
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25182
"ATM L991S does not lie within any known functional domains of the Atm protein (UniProt.org). L991S has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25183
"BCOR R1164* results in a premature truncation of the Bcor protein at amino acid 1164 of 1755 (UniProt.org). R1164* has not been characterized and therefore, its effect on Bcor protein function is unknown (PubMed, Aug 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25186
"CDKN2A V82E lies within the ANK repeat 3 of the Cdkn2a protein (UniProt.org). V82E has been identified in the scientific literature (PMID: 27245685), but has not been biochemically characterized and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Feb 2017). ",295,,,www.uniprot.org,6474,27245685,Development and clinical application of an integrative genomic approach to personalized cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/27245685,285,,,http://www.ncbi.nlm.nih.gov/pubmed,25188
"EGFR D587H does not lie within any known functional domains of the Egfr protein (UniProt.org). D587H results in increased Egfr autophosphorylation in cell culture (PMID: 27245685).
",6474,27245685,Development and clinical application of an integrative genomic approach to personalized cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/27245685,295,,,www.uniprot.org,25192
"ERBB4 A1130S lies within the cytoplasmic domain of the Erbb4 protein (UniProt.org). A1130S has been identified in sequencing studies (PMID: 27245685), but has not been biochemically characterized and therefore, its effect on Erbb4 protein function is unknown (PubMed, May 2017).",6474,27245685,Development and clinical application of an integrative genomic approach to personalized cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/27245685,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25194
"FBXW7 Q47* results in a premature truncation of the Fbxw7 protein at amino acid 47 of 707 (UniProt.org). Due to the loss of all known functional domains, Q47* is predicted to lead to a loss of Fbxw7 protein function (UniProt.org).",295,,,www.uniprot.org,25196
"FGFR2 L236V lies within the Ig-like C2-type 2 domain of the Fgfr2 protein (UniProt.org). L236V has not been characterized in the scientific literature and therefore, its effect on Fgfr2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25197
"GATA1 P357S does not lie within any known functional domains of the Gata1 protein (UniProt.org). P357S has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, Aug 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25200
"GATA1 R216Q lies within the GATA-type 1 zinc finger domain of the Gata1 protein (UniProt.org). R216Q results in minor changes in DNA dissociation rate and gene expression regulation, but is able to support erythroid maturation to similar level of wild-type Gata1 in culture (PMID: 12200364).",6527,12200364,X-linked thrombocytopenia with thalassemia from a mutation in the amino finger of GATA-1 affecting DNA binding rather than FOG-1 interaction.,http://www.ncbi.nlm.nih.gov/pubmed/12200364,295,,,www.uniprot.org,25201
"FLT3 E598_Y599insDVDFREYE results in the insertion of eight amino acids in the Flt3 protein between amino acids 598 and 599 (UniProt.org). E598_Y599insDVDFREYE is predicted to lead to activation of Flt3 due to the effects of other Flt3 internal tandem duplication (ITD) mutations (PMID: 12970773, PMID: 9737679, PMID: 11090077).",2897,9737679,Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product.,http://www.ncbi.nlm.nih.gov/pubmed/9737679,2898,11090077,Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.,http://www.ncbi.nlm.nih.gov/pubmed/11090077,2896,12970773,FLT3: ITDoes matter in leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/12970773,295,,,www.uniprot.org,25202
"HRAS D47E does not lie within any known functional domains of the Hras protein (UniProt.org). D47E has not been characterized in the scientific literature and therefore, its effect on Hras protein function is unknown (PubMed, Apr 2017). ",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,25203
"IKZF1 P103T does not lie within any known functional domains of the Ikzf1 protein (UniProt.org). P103T has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, Aug 2016).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,25204
"IKZF1 S384fs results in a change in the amino acid sequence of the Ikzf1 protein beginning at aa 384 of 519, likely resulting in premature truncation of the functional protein (UniProt.org). S384fs has not been characterized in the scientific literature and therefore, its effect on Ikzf1 protein function is unknown (PubMed, Aug 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25205
"TP53 F270I lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). F270I has been identified in sequencing studies (PMID: 27245685), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Feb 2017).
",6474,27245685,Development and clinical application of an integrative genomic approach to personalized cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/27245685,285,,,http://www.ncbi.nlm.nih.gov/pubmed,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,25208
"TP53 P278A lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). P278A has not been characterized in human cells, but demonstrates transcription activity similar to wild type Tp53 in yeast (PMID: 20407015).",643,20407015,Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20407015,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,25209
"TP53 P98S lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). P98S has been identified in the scientific literature (PMID: 27311873, PMID: 20404912, PMID: 18818522), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Feb 2017).
",7936,20404912,"Inhibition of the proprotein convertases represses the invasiveness of human primary melanoma cells with altered p53, CDKN2A and N-Ras genes.",http://www.ncbi.nlm.nih.gov/pubmed/20404912,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7791,27311873,"Circumscribed sebaceous neoplasms: a morphological, immunohistochemical and molecular analysis.",http://www.ncbi.nlm.nih.gov/pubmed/27311873,7937,18818522,Mutant p53 protein localized in the cytoplasm inhibits autophagy.,http://www.ncbi.nlm.nih.gov/pubmed/18818522,25210
"TP53 R110P lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). R110P confers a loss of function on the Tp53 protein as indicated by increased aggregation and destablization of Tp53, Tp63, and Tp73, and increased expression of antiapoptotic protein in culture (PMID: 21445056).",5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,6479,21445056,Gain of function of mutant p53 by coaggregation with multiple tumor suppressors.,http://www.ncbi.nlm.nih.gov/pubmed/21445056,25211
"TP53 R213fs results in a change in the amino acid sequence of the Tp53 protein beginning at aa 213 of 393, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the disruption of the DNA binding domain and the loss of the oligomerization domain (PMID: 21561095), R213fs is predicted to lead to a loss of Tp53 protein function.",295,,,www.uniprot.org,2155,21561095,"Structural effects of the L145Q, V157F, and R282W cancer-associated mutations in the p53 DNA-binding core domain.",http://www.ncbi.nlm.nih.gov/pubmed/21561095,25212
"TP53 S366Y lies within the C-terminal regulatory domain of the Tp53 protein (UniProt.org). S366Y has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25213
"STAG2 C527F does not lie within any known functional domains of the Stag2 protein (UniProt.org). C527F has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, Aug 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25215
"STAG2 I522F does not lie within any known functional domains of the Stag2 protein (UniProt.org). I522F has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, Aug 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25216
"STAG2 L526F does not lie within any known functional domains of the Stag2 protein (UniProt.org). L526F has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, Aug 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25217
"RUNX1 E422K does not lie within any known functional domains of the Runx1 protein (UniProt.org). E422K has not been characterized in the scientific literature and therefore, its effect on Runx1 protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,25219
"RB1 A496V lies within Domain A of the Rb1 protein (UniProt.org). A496V has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,25220
"RB1 S463fs results in a change in the amino acid sequence of the Rb1 protein beginning at aa 463 of 928, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of all known functional domains (UniProt.org), S463fs is predicted to lead to a loss of Rb1 protein function.",295,,,www.uniprot.org,25221
"NOTCH1 P1386T lies within the extracellular domain of the Notch1 protein (UniProt.org). P1386T has been identified in sequencing studies (PMID: 27245685), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",6474,27245685,Development and clinical application of an integrative genomic approach to personalized cancer therapy.,http://www.ncbi.nlm.nih.gov/pubmed/27245685,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25227
"RET M1009T lies within the protein kinase domain of the Ret protein (UniProt.org). M1009T has not been characterized in the scientific literature and therefore, its effect on Ret protein function is unknown (PubMed, Apr 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25233
"MSH6 G1072C does not lie within any known functional domains of the Msh6 protein (UniProt.org). G1072C has not been characterized in the scientific literature and therefore, its effect on Msh6 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25234
"KMT2A G606E does not lie within any known functional domains of the Kmt2a protein (UniProt.org). G606E has not been characterized in the scientific literature and therefore, its effect on Kmt2a protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25240
"JAK3 D863E lies within the protein kinase domain 2 of the Jak3 protein (UniProt.org). D863E has not been characterized in the scientific literature and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25241
"JAK3 E717K lies within the protein kinase domain 1 of the Jak3 protein (UniProt.org). E717K has not been characterized in the scientific literature and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25242
"JAK3 F569Y lies within the protein kinase domain 1 of the Jak3 protein (UniProt.org). F569Y has not been characterized in the scientific literature and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25243
"JAK3 H583N lies within the protein kinase domain 1 of the Jak3 protein (UniProt.org). H583N has not been characterized in the scientific literature and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25244
"JAK3 W716* results in a premature truncation of the Jak3 protein at amino acid 716 of 1124 (UniProt.org). Due to the loss of most protein kinase domains (UniProt.org), W716* is predicted to lead to a loss of Jak3 protein function.",295,,,www.uniprot.org,25245
"FLT3 P54L lies within the extracellular domain of the Flt3 protein (UniProt.org). P54L has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Apr 2017). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25246
"MLH1 A120S does not lie within any known functional domains of the Mlh1 protein (UniProt.org). A120S has not been characterized and therefore, its effect on Mlh1 protein function is unknown (PubMed, Aug 2016). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25248
"MLH1 A210T does not lie within any known functional domains of the Mlh1 protein (UniProt.org). A210T has not been characterized in the scientific literature and therefore, its effect on Mlh1 protein function is unknown (PubMed, Aug 2016). 
",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25249
STAG2 D193N does not lie within any known functional domains of the Stag2 protein (UniProt.org). D193N confers a loss of function to the Stag2 protein as indicated by decreased binding to Rad21 and Smc1a in culture (PMID: 27500726).,295,,,www.uniprot.org,6497,27500726,Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/27500726,25251
"EGFR T34_A289del results in the deletion of 256 amino acids in the extracellular domain of the Egfr protein from amino acids 34 to 289 (UniProt.org). results in ligand independent constitutive phosphorylation of Egfr, increased proliferation and invasion of cells in culture (PMID: 27216155).",295,,,www.uniprot.org,6503,27216155,"A Novel EGFR Extracellular Domain Mutant, EGFRΔ768, Possesses Distinct Biological and Biochemical Properties in Neuroblastoma.",http://www.ncbi.nlm.nih.gov/pubmed/27216155,25254
"EZH2 Y111D lies within the D1 domain of the Ezh2 protein (PMID: 26360609). Y111D has not been characterized biochemically however, it has been demonstrated as a secondary mutation confers resistance to Ezh2 inhibitors (PMID: 26360609).",6504,26360609,Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/26360609,25255
"EZH2 Y111N lies within the D1 domain of the Ezh2 protein (PMID: 26360609). Y111N has not been characterized biochemically however, it has been demonstrated as a secondary mutation confers resistance to Ezh2 inhibitors (PMID: 26360609).",6504,26360609,Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/26360609,25256
"EZH2 I109K lies within the D1 domain of the Ezh2 protein (PMID: 26360609). I109K has not been characterized biochemically however, it has been demonstrated as a secondary mutation confers resistance to Ezh2 inhibitors (PMID: 26360609).",6504,26360609,Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/26360609,25257
"SMARCB1 inact mut indicates that this variant results in a loss of function of the Smarcb1 protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,25258
"EGFR negative indicates a lack of the EGFR gene, mRNA, and/or protein. ",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,25259
"SRC T341M lies within the protein kinase domain of the Src protein (UniProt.org). T341M results in increased Src autophosphorylation and substrated phosphorylation, increased cell survival in culture (PMID: 18794843), and acquired resistance to dasatinib (PMID: 27222538).",6508,27222538,The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27222538,295,,,www.uniprot.org,644,18794843,Activation of tyrosine kinases by mutation of the gatekeeper threonine.,http://www.ncbi.nlm.nih.gov/pubmed/18794843,25261
"BRAF L485Y lies within the protein kinase domain of the Braf protein (UniProt.org). L485Y has not been biochemically characterized, but has been demonstrated to confer Raf inhibitor resistance to  in cell culture (PMID: 19276360).",6516,19276360,Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.,http://www.ncbi.nlm.nih.gov/pubmed/19276360,295,,,www.uniprot.org,25271
ERBB4 G1109C lies within the cytoplasmic domain of the Erbb4 protein (UniProt.org). G1109C confers a gain of function to the Erbb4 protein as demonstrated by increased phosphorylation of Erbb4 compared to wild-type and the ability to transform cells (PMID: 27207775). ,6519,27207775,Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.,http://www.ncbi.nlm.nih.gov/pubmed/27207775,25272
"RB1 K319Nfs*13 is a missense mutation (K319N) in conjunction with a likely truncation of the 928 aa Rb1 protein at aa 319, followed by 13 nonsense amino acids (UniProt.org). Due to the loss of all known functional domains (UniProt.org), K319Nfs*13 is predicted to lead to a loss of Rb1 function.",295,,,www.uniprot.org,25273
"RB1 W681* results in a premature truncation of the Rb1 protein at amino acid 681 of 928 (UniProt.org). Due to the loss of multiple functional domains (UniProt.org), W681* is predicted to lead to a loss of Rb1 protein function.",295,,,www.uniprot.org,25274
"RB1 V375F lies within Domain A of the Rb1 protein (UniProt.org). V375F has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25275
"RB1 L523fs results in a change in the amino acid sequence of the Rb1 protein beginning at aa 523 of 928, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of multiple functional domains (UniProt.org), L523fs is predicted to lead to a loss Rb1 protein function.",295,,,www.uniprot.org,25276
"RB1 R320L does not lie within any known functional domains of the Rb1 protein (UniProt.org). R320L has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25277
"CSF3R E501K lies within the fibronectin type-III domain 4 of the Csf3r protein (UniProt.org). E501K has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,25284
"CSF1R E920D lies within the cytoplasmic domain of the Csf1r protein (UniProt.org). E920D has not been characterized in the scientific literature and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25286
"RET L517V lies within the extracellular domain of the Ret protein (UniProt.org). L517V has not been characterized in the scientific literature and therefore, its effect on Ret protein function is unknown (PubMed, Apr 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25288
"TP53 W53* results in a premature truncation of the Tp53 protein at amino acid 53 of 393 (UniProt.org). Due to the loss of the DNA-binding domain as well as several other functional domains (UniProt.org), W53* is predicted to lead to a loss of Tp53 protein function. ",295,,,www.uniprot.org,25289
"IDH2 D76fs result in a change in the amino acid sequence of the Idh2 protein beginning at aa 76 of 452, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the substrate binding region and sites critical for catalysis (UniProt.org), D76fs is predicted to lead to a loss of Idh2 protein function.",295,,,www.uniprot.org,25290
BRCA2 S2695L lies within the SHFM1/DSS1 interaction region of the Brca2 protein (UniProt.org). S2695L demonstrates DNA repair activity and rescue of lethality of Brca-null embryonic stem cells to a similar level to wild-type Brca2 in culture (PMID: 22678057).,295,,,www.uniprot.org,2588,22678057,Functional evaluation of BRCA2 variants mapping to the PALB2-binding and C-terminal DNA-binding domains using a mouse ES cell-based assay.,http://www.ncbi.nlm.nih.gov/pubmed/22678057,25291
"FGFR1 positive indicates the presence of the FGFR1 gene, mRNA, and/or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,25292
"TP53 V173M lies within the DNA binding domain and the HIPK1, ZNF385A, FBXO42 and AXIN1interacting region of the Tp53 protein (UniProt.org). V173M results in reduced Tp53 transactivation activity in cell culture (PMID: 15037740).",2460,15037740,A global suppressor motif for p53 cancer mutants.,http://www.ncbi.nlm.nih.gov/pubmed/15037740,25293
"TP53 C141R lies within the DNA binding domain of the Tp53 protein (UniProt.org). C141R has been identified in the scientific literature (PMID: 21483000), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,10075,21483000,Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.,http://www.ncbi.nlm.nih.gov/pubmed/21483000,25296
"SMO over exp indicates an over expression of the Ptch1 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,25297
"CTNNB1 over exp indicates an over expression of the Ctnnb1 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,25300
"JAK2 D894G lies within the protein kinase 2 domain of the Jak2 protein (UniProt.org). D894G has not been characterized and therefore, its effect on Jak2 protein function is unknown (PubMed, May 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25314
"PTEN Y27fs*1 likely results in a truncation of the 403 aa Pten protein at aa 27, followed by 1 nonsense amino acids within the 	phosphatase tensin-type domain (UniProt.org). Due to the loss of most known functional domains (UniProt.org), Y27fs*1 is predicted to lead to a loss of Pten protein function.",295,,,www.uniprot.org,25327
"PTEN R55fs*1 likely results in a truncation of the 403 aa Pten protein at aa 55, followed by 1 nonsense amino acids within the 	phosphatase tensin-type domain (UniProt.org). Due to the loss of most known functional domains (UniProt.org), R55fs*1 is predicted to lead to a loss of Pten protein function.",295,,,www.uniprot.org,25328
"JAK2 fusion indicates a fusion of the JAK2 gene, but the fusion partner is unknown.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,25332
"RB1 E843* results in a premature truncation of the Rb1 protein within its C domain at amino acid 843 of 928 (UniProt.org). E843* has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25335
"AKT1 I19L lies within the PH domain of the Akt1 protein (UniProt.org). I19L has been identified in the scientific literature (PMID: 27601661), but has not been biochemically characterized and therefore, its effect on Akt1 protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,8351,27601661,Whole-exome sequencing identifies recurrent AKT1 mutations in sclerosing hemangioma of lung.,http://www.ncbi.nlm.nih.gov/pubmed/27601661,285,,,http://www.ncbi.nlm.nih.gov/pubmed,25337
"AKT1 N53H lies within the PH domain of the Akt1 protein (UniProt.org). N53H has been identified in the scientific literature (PMID: 27601661), but has not been biochemically characterized and therefore, its effect on Akt1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8351,27601661,Whole-exome sequencing identifies recurrent AKT1 mutations in sclerosing hemangioma of lung.,http://www.ncbi.nlm.nih.gov/pubmed/27601661,25338
"CTNNB1 G38C does not lie within any known functional domains of the Ctnnb1 protein (UniProt.org). G38C has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25339
"BRCA2 V2728I lies within the SEM1-interacting region of the Brca2 protein (UniProt.org). V2728I has not been biochemically characterized, but is predicted to be non-deleterious based on epidemiological data (PMID: 12215251).",6634,12215251,Characterization of common BRCA1 and BRCA2 variants.,http://www.ncbi.nlm.nih.gov/pubmed/12215251,295,,,www.uniprot.org,25342
"CDKN2A C72S lies within the ANK repeat 2 of the Cdkn2a protein (UniProt.org). C72S has not been characterized and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25343
"FBXW7 S668fs results in a change in the amino acid sequence of the Fbxw7 protein beginning at aa 668 of 707, likely resulting in premature truncation of the functional protein (UniProt.org). S668fs has not been characterized in the scientific literature and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Sep 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25347
"IDH1 I112V does not lie within any known functional domains of the Idh1 protein (UniProt.org). I112V has not been characterized in the scientific literature and therefore, its effect on Idh1 protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25349
"KIT E561fs results in a change in the amino acid sequence of the Kit protein beginning at aa 561 of 976, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), E561fs is predicted to lead to a loss of Kit protein function.",295,,,www.uniprot.org,25351
"KIT G510C lies within the extracellular domain of the Kit protein (UniProt.org). G510C has not been characterized in the scientific literature and therefore, its effect on Kit protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,25352
"KIT V532I lies within the transmembrane domain of the Kit protein (UniProt.org). V532I has been identified in the scientific literature (PMID: 25894969), but has not been biochemically characterized and therefore, its effect on Kit protein function is unknown (PubMed, May 2017).",295,,,www.uniprot.org,9001,25894969,Dissecting Genomic Aberrations in Myeloproliferative Neoplasms by Multiplex-PCR and Next Generation Sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/25894969,285,,,http://www.ncbi.nlm.nih.gov/pubmed,25353
"KIT V559fs results in a change in the amino acid sequence of the Kit protein beginning at aa 559 of 976, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), V559fs is predicted to lead to a loss of Kit protein function.",295,,,www.uniprot.org,25354
"TP53 A159fs results in a change in the amino acid sequence of the Tp53 protein beginning at aa 159 of 393, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the disruption of the DNA binding domain and the loss of the oligomerization domain (PMID: 21561095), A159fs is predicted to lead to a loss of Tp53 protein function.",295,,,www.uniprot.org,2155,21561095,"Structural effects of the L145Q, V157F, and R282W cancer-associated mutations in the p53 DNA-binding core domain.",http://www.ncbi.nlm.nih.gov/pubmed/21561095,25360
"TP53 G244C lies within the DNA binding domain of the Tp53 protein (PMID: 15510160). G244C has been identified in the scientific literature (PMID: 11307149), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,10076,11307149,"Determination of microsatellite instability, p53 and K-RAS mutations in hepatic metastases from patients with colorectal cancer: relationship with response to 5-fluorouracil and survival.",http://www.ncbi.nlm.nih.gov/pubmed/11307149,285,,,http://www.ncbi.nlm.nih.gov/pubmed,25361
"FGFR3 G805fs (corresponding to G803fs in canonical isoform) results in a change in the amino acid sequence of the Fgfr3 protein beginning at aa 805 of 808, likely resulting in premature truncation of the functional protein (UniProt.org). G805fs has not been characterized in the scientific literature and therefore, its effect on Fgfr3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25362
"BRCA2 E919K lies within the NPM1-interacting region of the Brca2 protein (UniProt.org). E919K has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25363
"TP53 M44fs results in a change in the amino acid sequence of the Tp53 protein beginning at aa 44 of 393, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the DNA-binding domain as well as several other functional domains (UniProt.org), M44fs is predicted to lead to a loss of Tp53 protein function. ",295,,,www.uniprot.org,25365
"TET2 S1039L does not lie within any known functional domains of the Tet2 protein (UniProt.org). S1039L has not been characterized and therefore, its effect on Tet2 protein function is unknown (PubMed, Sep 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25367
"STK11 amplification indicates an increased number of copies of the STK11 gene. However, the mechanism causing the increase is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,25368
"ROS1 E1902K lies within the cytoplasmic domain of the Ros1 protein (UniProt.org). E1902K has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,25369
"RET T278N lies within the extracellular domain of the Ret protein (UniProt.org). T278N has been identified in sequencing studies (PMID: 24845513), but has not been biochemically characterized and therefore, its effect on Ret protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,8611,24845513,The rare intracellular RET mutation p.S891A in a Chinese Han family with familial medullary thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24845513,295,,,www.uniprot.org,25373
"FGFR3 G65R lies within the Ig-like C2-type domain 1 of the Fgfr3 protein (UniProt.org). G65R has not been characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25382
"GNA11 amplification indicates an increased number of copies of the GNA11 gene. However, the mechanism causing the increase is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,25384
"FGFR3 T452M lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). T452M has not been characterized in the scientific literature and therefore, its effect on Fgfr3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25386
"ASXL1 amplification indicates an increased number of copies of the ASXL1 gene. However, the mechanism causing the increase is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,25387
"BRCA2 G2508S lies within the FANCD2-interacting region of the Brca2 protein (UniProt.org). G2508S has been identified in the scientific literature (PMID: 28283652), but has not been biochemically characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8856,28283652,BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28283652,25394
"APC G471* results in a premature truncation of the Apc protein at amino acid 471 of 2843 (UniProt.org). Due to the loss of the Armadillo repeat and the beta-catenin binding and down-regulation regions (PMID: 14672538), G471* is predicted to lead to a loss of Apc protein function.",2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,295,,,www.uniprot.org,25396
"APC E129Q lies within a coiled-coil domain of the Apc protein (UniProt.org) E129Q has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25398
"JAK2 Y62C lies within the FERM domain of the Jak2 protein (UniProt.org). Y62C has not been characterized in the scientific literature and therefore, its effect on Jak2 protein function is unknown (PubMed, May 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25399
"AKT1 positive indicates the presence of the AKT1 gene, mRNA, and/or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,25401
FGFR2 K660N lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). K660E results in increased phosphorylation of Fgfr2 and activation of downstream signaling (PMID: 23527311).,295,,,www.uniprot.org,2160,23527311,Activating somatic FGFR2 mutations in breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23527311,25402
"ATM N914S does not lie within any known functional domains of the Atm protein (UniProt.org). N914S has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25410
"BRCA2 T1673P lies within the Brca2 repeat 5 of the Brca2 protein (UniProt.org). T1673P has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25411
KRAS K117X indicates any KRAS missense mutation that results in replacement of the lysine (K) at amino acid 117 by a different amino acid.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,25419
KRAS A146X indicates any KRAS missense mutation that results in the replacement of the alanine (A) at amino acid 146 by a different amino acid.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,25420
NRAS A146X indicates any NRAS missense mutation which results in the alanine (A) at amino acid 146 being replaced by a different amino acid.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,25421
"EGFR F795L lies within the protein kinase domain of the Egfr protein (UniProt.org). F795L has not been characterized in the scientific literature and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25424
EGFR del indicates a deletion of the EGFR gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,25425
"EGFR-SEPT14 results from the fusion of EGFR and SEPT14, demonstrating increased cell proliferation, self-renewal, migration, and activated STAT3 signaling in cell culture (PMID: 23917401).",3963,23917401,The integrated landscape of driver genomic alterations in glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/23917401,25432
KIT D816X indicates any Kit missense mutation which results in the aspartic acid (D) at amino acid 816 being replaced by a different amino acid. KIT D816 mutations are associated with resistance to Kit inhibitors (PMID: 17065430).,6687,17065430,Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/17065430,25433
TP53 V216M lies within the DNA binding domain of the Tp53 protein (UniProt.org). V216M results in phenotype resembling Tp53 inactivation in yeast (PMID: 21232794).,295,,,www.uniprot.org,556,21232794,A comprehensive study of TP53 mutations in chronic lymphocytic leukemia: Analysis of 1287 diagnostic and 1148 follow-up CLL samples.,http://www.ncbi.nlm.nih.gov/pubmed/21232794,25434
"TP53 R335fs results in a change in the amino acid sequence of the Tp53 protein beginning at aa 335 of 393, likely resulting in premature truncation of the functional protein (UniProt.org). R335fs has been identified in the scientific literature (PMID: 26272063), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,6689,26272063,MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26272063,295,,,www.uniprot.org,25435
"TP53 R273* results in a premature truncation of the Tp53 protein at amino acid 273 of 393 (UniProt.org). Due to the loss of the tetramerization domain (PMID: 22713868), R273* is predicted to lead to a loss of Tp53 function.",2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,295,,,www.uniprot.org,25436
"KIT P551_V555delinsTL results in a deletion of five amino acids within the juxtamembrane domain of the Kit protein, combined with the insertion of a threonine (T) and a leucine (L) at the same site (PMID: 12879016). P551_V555delinsTL has not been characterized, but is predicted to lead to a gain of function based on the effect of similar Kit exon 11 deletions (PMID: 9438854, PMID: 15365079).",2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,25437
"KIT V559_V560delinsS results in a deletion of two amino acids within the juxtamembrane domain of the Kit protein, combined with the insertion of a serine (S) at the same site (PMID: 12879016). V559_V560delinsS has not been characterized, but is predicted to lead to a gain of function based on the effect of similar Kit exon 11 deletions (PMID: 9438854, PMID: 15365079).",2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,25438
"ALK G1202del results in the deletion of an amino acid in the protein kinase domain of the Alk protein at amino acid 1202 (UniProt.org). G1202del has not been biochemically characterized, but has been demonstrated to occur as a secondary drug resistance mutation in the context of EML4-ALK (PMID: 27432227).
",295,,,www.uniprot.org,6706,27432227,Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27432227,25439
"TP53 T118Qfs*5 is a missense mutation (T118Q) in conjunction with a likely truncation of the 393 aa Tp53 protein at aa 118, followed by 5 nonsense amino acids (UniProt.org). Due to the disruption of the DNA binding domain and the loss of the oligomerization domain (PMID: 21561095), T118Qfs*5 is predicted to lead to a loss of Tp53 protein function.",295,,,www.uniprot.org,2155,21561095,"Structural effects of the L145Q, V157F, and R282W cancer-associated mutations in the p53 DNA-binding core domain.",http://www.ncbi.nlm.nih.gov/pubmed/21561095,25441
"BRCA1 E23Vfs*17 (also referred to as BRCA1 185delAG) is a missense mutation (E23V) in conjunction with a likely truncation of the 1863 aa Brca1 protein at aa 23, followed by 17 nonsense amino acids (UniProt.org). E23Vfs*17 confers a loss of function to Brca1 protein as indicated by embryonic lethality in homozygous and tumorigenesis in heterozygous transgenic mouse models (PMID: 27454287).",6707,27454287,BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/27454287,295,,,www.uniprot.org,25442
"BRCA1 L1795Pfs*3 (also referred to as BRCA1 5382insC) is a missense mutation (L1795P) in conjunction with a likely truncation of the 1863 aa Brca1 protein at aa 1795, followed by 3 nonsense amino acids (UniProt.org). L1795Pfs*3 confers a loss of function to Brca1 protein as indicated by embryonic lethality in homozygous and tumorigenesis in heterozygous transgenic mouse models (PMID: 27454287).",6707,27454287,BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.,http://www.ncbi.nlm.nih.gov/pubmed/27454287,295,,,www.uniprot.org,25443
"ASXL1 G685R does not lie within any known functional domains of the Asxl1 protein (UniProt.org). G685R has not been characterized and therefore, its effect on Asxl1 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25444
"ASXL1 E1102D does not lie within any known functional domains of the Asxl1 protein (UniProt.org). E1102D has not been characterized and therefore, its effect on Asxl1 protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25445
"PTPN11 dec exp indicates decreased expression of the Ptpn11 protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,25448
MET del exon14 is a Met splice variant caused by a mutation resulting in the deletion of exon 14 (PMID: 16397241). Del exon14 results in both increased Met protein stability and ligand-dependent downstream signaling (PMID: 25971938).,1974,16397241,Somatic mutations lead to an oncogenic deletion of met in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16397241,6712,25971938,Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/25971938,25454
"RET G810A lies within the protein kinase domain of the Ret protein (UniProt.org). G810A has not been biochemically characterized, but has been demonstrated to confer resistance to Caprelsa (vandetanib) in the context of KIF5B-RET in cell culture (PMID: 27496134).",6717,27496134,Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/27496134,295,,,www.uniprot.org,25455
"ERBB2 (HER2) K753E lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). K753E has not been biochemically characterized, however, has demonstrated resistance to some Erbb2 (Her2) inhibitors (PMID: 27697991).",6720,27697991,Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27697991,295,,,www.uniprot.org,25456
"ALK L868Q lies within the extracellular domain of the Alk protein (UniProt.org). L868Q has not been characterized in the scientific literature and therefore, its effect on Alk protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25462
"ERBB2 (HER2) L768S lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). L768S confers a gain of function to the Erbb2 (Her2) protein as demonstrated by increased tyrosine kinase activity and phosphorylation compared to wild-type, and abnormal cellular morphology in culture (PMID: 27697991).",295,,,www.uniprot.org,6720,27697991,Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27697991,25466
"ERBB2 (HER2) V773L lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). V773L confers a gain of function to the Erbb2 (Her2) protein as demonstrated by increased tyrosine kinase activity and phosphorylation compared to wild-type, and abnormal cellular morphology in culture (PMID: 27697991).",295,,,www.uniprot.org,6720,27697991,Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27697991,25467
"ERBB2 (HER2) R647K lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). R647K confers no effect to the Erbb2 (Her2) protein, resulting in kinase activity, phosphorylation, and cell morphology in culture similar to wild-type (PMID: 27697991).",295,,,www.uniprot.org,6720,27697991,Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27697991,25468
"ERBB2 (HER2) K676R lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). K676R confers no effect to the Erbb2 (Her2) protein, resulting in kinase activity, phosphorylation, and cell morphology in culture similar to wild-type (PMID: 27697991).",295,,,www.uniprot.org,6720,27697991,Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27697991,25469
"ERBB2 (HER2) Q680R lies within the cytoplasmic domain of the Erbb2 (Her2) protein (UniProt.org). Q680R confers no effect to the Erbb2 (Her2) protein, resulting in kinase activity, phosphorylation, and cell morphology in culture similar to wild-type (PMID: 27697991).",295,,,www.uniprot.org,6720,27697991,Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27697991,25470
"PTEN L70fs*7 likely results in a truncation of the 403 aa Pten protein at aa 70, followed by 7 nonsense amino acids (UniProt.org). L70fs*7 has not been characterized, however other C-terminal deletion mutants downstream of L70 are inactivating (PMID: 10468583), thus L70fs*7 is predicted to lead to a loss of Pten protein function.",295,,,www.uniprot.org,2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,25483
"PTEN E307K lies within the C2 tensin-type domain of the Pten protein (UniProt.org). E307K results in similar enzymatic activity to wild-type Pten, but leads to increased polyubiquitination and membrane localization and decreased nuclear localization of Pten in cell culture (PMID: 22103913).",6762,22103913,Characterization of a novel PTEN mutation in MDA-MB-453 breast carcinoma cell line.,http://www.ncbi.nlm.nih.gov/pubmed/22103913,295,,,www.uniprot.org,25487
"AKT1 over exp indicates an over expression of the Akt1 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,25507
"PIK3CA L866F lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). L866F has not been characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Oct 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25530
"JAK2 R564L lies within the protein kinase domain 1 of the Jak2 protein (UniProt.org). R564L has not been biochemically characterized, but is predicted to disrupt the Jak2 kinase domain conformation by structural simulation (PMID: 19744331).",6794,19744331,Structural effects of clinically observed mutations in JAK2 exons 13-15: comparison with V617F and exon 12 mutations.,http://www.ncbi.nlm.nih.gov/pubmed/19744331,295,,,www.uniprot.org,25535
"JAK2 E543_D544del results in the deletion of two amino acids of the Jak2 protein from amino acids 543 to 544 (UniProt.org). E543_D544del has been identified in the scientific literature (PMID: 27410038, PMID: 26361084, PMID: 17984312), but has not been biochemically characterized and therefore, its effect on Jak2 protein function is unknown (PubMed, May 2017).",8877,17984312,Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders.,http://www.ncbi.nlm.nih.gov/pubmed/17984312,8876,26361084,Detection of mutations in JAK2 exons 12-15 by Sanger sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/26361084,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8875,27410038,Detection of JAK2 Exon 12 Mutations in JAK2 V617F-Negative Polycythemia Vera Patients by Cloning Technique.,http://www.ncbi.nlm.nih.gov/pubmed/27410038,25536
"JAK2 H538_K539delinsL results in a deletion of two amino acids from amino acids 538 to 539 of the Jak2 protein, combined with the insertion of a leucine (L) at the same site (UniProt.org). H538_K539delinsL has been identified in the scientific literature (PMID: 27410038), but has not been biochemically characterized and therefore, its effect on Jak2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,8875,27410038,Detection of JAK2 Exon 12 Mutations in JAK2 V617F-Negative Polycythemia Vera Patients by Cloning Technique.,http://www.ncbi.nlm.nih.gov/pubmed/27410038,295,,,www.uniprot.org,25537
"JAK2 H538_K539delinsQL results in a deletion of two amino acids from amino acids 538 to 539 of the Jak2 protein, combined with the insertion of a glutamine (Q) and a leucine (L) at the same site (UniProt.org). H538_K539delinsQL results in Jak2 autophosphorylation, increased Erk phosphorylation and cell proliferation in culture (PMID: 17267906).",295,,,www.uniprot.org,5869,17267906,JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.,http://www.ncbi.nlm.nih.gov/pubmed/17267906,25538
"JAK2 I540_E543delinsMK results in a deletion of four amino acids from amino acids 540 to 543 of the Jak2 protein, combined with the insertion of a methionine (M) and a lysine (K) at the same site (UniProt.org). I540_E543delinsMK has not been characterized and therefore, its effect on Jak2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25539
"JAK2 R541_E543delinsK results in a deletion of three amino acids from amino acids 541 to 543 of the Jak2 protein, combined with the insertion of a lysine (K) at the same site (UniProt.org). R541_E543delinsK has been identified in the scientific literature (PMID: 26361084), but has not been biochemically characterized and therefore, its effect on Jak2 protein function is unknown (PubMed, May 2017).",8876,26361084,Detection of mutations in JAK2 exons 12-15 by Sanger sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/26361084,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25540
JAK3 P132T lies within the FERM domain of the Jak3 protein (UniProt.org). P132T results in Jak3 autophosphorylation and increased cell proliferation in culture (PMID: 16843266).,6795,16843266,Activating alleles of JAK3 in acute megakaryoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/16843266,295,,,www.uniprot.org,25541
"JAK3 V715I lies within the protein kinase 1 domain of the Jak3 protein (UniProt.org). V715I has been identified in the scientific literature (PMID: 18559588), but has not been biochemically characterized and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",6957,18559588,Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers.,http://www.ncbi.nlm.nih.gov/pubmed/18559588,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25542
"KIT K550_E554del results in the deletion of 5 amino acids in the juxtamembrane domain of the Kit protein from amino acids 550 to 554 (PMID: 16226710). K550_E554del has not been characterized, however similar Kit exon 11 deletions are activating, thus K550_E554del is predicted to lead to a gain of Kit protein function (PMID: 9438854, PMID: 15365079).",648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,25543
"KIT K550_V555delinsI results in the deletion of 6 amino acids in the juxtamembrane domain of the Kit protein from amino acids 550 to 555, combined with the insertion of an isoleucine (L) at the same site (PMID: 16226710). K550_V555delinsI has not been characterized, but is predicted to lead to activation of Kit based on effects of similar Kit exon 11 deletions (PMID: 9438854, PMID: 15365079).",648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,25544
"KIT M552_D572del results in the deletion of 21 amino acids in the juxtamembrane domain of the Kit protein from amino acids 552 to 572 (PMID: 16226710). M552_D572del has not been characterized, however similar Kit exon 11 deletions are activating, thus M552_D572del is predicted to lead to a gain of Kit protein function (PMID: 9438854, PMID: 15365079).",650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,25545
"KIT M552_E554delinsK results in the deletion of 3 amino acids in the juxtamembrane domain of the Kit protein from amino acids 552 to 554, combined with the insertion of a lysine (K) at the same site (PMID: 16226710). M552_E554delinsK has not been characterized, but is predicted to lead to Kit activation based on effects of similar mutations (PMID: 9438854, PMID: 15365079).",650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,25546
"KIT M552_V555del results in the deletion of 4 amino acids in the juxtamembrane domain of the Kit protein from amino acids 552 to 555 (PMID: 16226710). M552_V555del has not been characterized, however similar Kit exon 11 deletions are activating, thus M552_V555del is predicted to lead to a gain of Kit protein function (PMID: 9438854, PMID: 15365079).",650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,25547
"KIT M552_V559delinsI results in the deletion of 8 amino acids in the juxtamembrane domain of the Kit protein from amino acids 552 to 559, combined with the insertion of an isoleucine (I) at the same site (PMID: 16226710). M552_V559delinsI has not been characterized, but is predicted to activate Kit based on effects of similar mutations (PMID: 9438854, PMID: 15365079).",650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,25548
"KIT P551_E554del results in the deletion of 4 amino acids in the juxtamembrane domain of the Kit protein from amino acids 551 to 554 (PMID: 16226710). P551_E554del has not been characterized, however similar Kit exon 11 deletions are activating, thus P551_E554del is predicted to lead to a gain of Kit protein function (PMID: 9438854, PMID: 15365079).",2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,25549
"KIT P551_M552delinsL results in the deletion of 2 amino acids in the juxtamembrane domain of the Kit protein from amino acids 551 to 552, combined with the insertion of a leucine (L) at the same site (PMID: 16226710). P551_M552delinsL has not been characterized, but is predicted to activate Kit based on effects of similar mutations (PMID: 9438854, PMID: 15365079).",2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,25550
"KIT P551_Q556del results in the deletion of 6 amino acids in the juxtamembrane domain of the Kit protein from amino acids 551 to 556 (PMID: 16226710). P551_Q556del has not been characterized, however similar Kit exon 11 deletions are activating, thus P551_Q556del is predicted to lead to a gain of Kit protein function (PMID: 9438854, PMID: 15365079).",2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,25551
"KIT D579_H580insIDPTQLPYD results in the insertion of nine amino acids in the juxtamembrane domain of the Kit protein between amino acids 579 and 580 (PMID: 16226710). D579_H580insIDPTQLPYD has not been characterized and therefore, its effect on Kit protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,25552
"KIT E554_D572delinsA results in the deletion of 19 amino acids in the juxtamembrane domain of the Kit protein from amino acids 554 to 572, combined with the insertion of an alanine (A) at the same site (PMID: 16226710). E554_D572delinsA has not been characterized, but is predicted to activate Kit basing on effects of similar mutations (PMID: 9438854, PMID: 15365079).",2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,25553
"KIT E583_F584insPYDHKWE results in the insertion of seven amino acids in the juxtamembrane domain of the Kit protein between amino acids 583 and 584 (PMID: 16226710). E583_F584insPYDHKWE has not been characterized and therefore, its effect on Kit protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,25554
"KIT H580_K581insPYDH results in the insertion of four amino acids in the juxtamembrane domain of the Kit protein between amino acids 580 and 581 (PMID: 16226710). H580_K581insPYDH has not been characterized and therefore, its effect on Kit protein function is unknown (PubMed, May 2017).",648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,285,,,http://www.ncbi.nlm.nih.gov/pubmed,25555
"KIT K558_D572del results in the deletion of 15 amino acids in the juxtamembrane domain of the Kit protein from amino acids 558 to 572 (PMID: 16226710). K558_D572del has not been characterized, however similar Kit exon 11 deletions are activating, thus K558_D572del is predicted to lead to a gain of Kit protein function (PMID: 9438854, PMID: 15365079).",648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,25556
"KIT K558_Y570delinsN results in the deletion of 13 amino acids in the juxtamembrane domain of the Kit protein from amino acids 558 to 570, combined with the insertion of an asparagine (N) at the same site (PMID: 16226710). K558_Y570delinsN has not been characterized, but is predicted to activate Kit basing on effects of similar mutations (PMID: 9438854, PMID: 15365079).",648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,25557
"KIT K558_Y570delinsR results in the deletion of 13 amino acids in the juxtamembrane domain of the Kit protein from amino acids 558 to 570, combined with the insertion of an arginine (R) at the same site (PMID: 16226710). K558_Y570delinsR has not been characterized, but is predicted to activate Kit basing on effects of similar mutations (PMID: 9438854, PMID: 15365079).",648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,25558
"KIT K558_Y570delinsNP results in the deletion of 13 amino acids in the juxtamembrane domain of the Kit protein from amino acids 558 to 570, combined with the insertion of an asparagine (N) and a proline (P) at the same site (PMID: 16226710). K558_Y570delinsNP has not been characterized, but is predicted to activate Kit basing on effects of similar mutations (PMID: 9438854, PMID: 15365079).",648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,25559
"KIT K558Q lies within the juxtamembrane domain of the Kit protein (PMID: 16226710). K558Q has been identified in the scientific literature (PMID: 19333543), but has not been biochemically characterized and therefore, its effect on Kit protein function is unknown (PubMed, May 2017).",648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,9011,19333543,Interstitial cells of Cajal do not harbor c-kit or PDGFRA gene mutations in patients with sporadic gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/19333543,285,,,http://www.ncbi.nlm.nih.gov/pubmed,25560
"KIT K581_W582insDPTQLPYDH results in the insertion of nine amino acids in the juxtamembrane domain of the Kit protein between amino acids 581 and 582 (PMID: 16226710). K581_W582insDPTQLPYDH has not been characterized and therefore, its effect on Kit protein function is unknown (PubMed, May 2017).",648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,285,,,http://www.ncbi.nlm.nih.gov/pubmed,25561
"KIT N567_P573del results in the deletion of 7 amino acids in the juxtamembrane domain of the Kit protein from amino acids 567 to 573 (PMID: 16226710). N567_P573del has not been characterized, however similar Kit exon 11 deletions are activating, thus N567_P573del is predicted to lead to a gain of Kit protein function (PMID: 9438854, PMID: 15365079).",650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,25562
"KIT P585_R586insLPYDHKWEFP results in the insertion of ten amino acids in the juxtamembrane domain of the Kit protein between amino acids 585 and 586 (PMID: 16226710). P585_R586insLPYDHKWEFP has not been characterized and therefore, its effect on Kit protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,25563
"KIT Q556_V559del results in the deletion of 4 amino acids in the juxtamembrane domain of the Kit protein from amino acids 556 to 559 (PMID: 16226710). Q556_V559del has not been characterized, however similar Kit exon 11 deletions are activating, thus Q556_V559del is predicted to lead to a gain of Kit protein function (PMID: 9438854, PMID: 15365079).",650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,25564
"KIT Q556_V559delinsH results in the deletion of 4 amino acids in the juxtamembrane domain of the Kit protein from amino acids 556 to 559, combined with the insertion of a histidine (H) at the same site (PMID: 16226710). Q556_V559delinsH has not been characterized, but is predicted to activate Kit basing on effects of similar mutations (PMID: 9438854, PMID: 15365079).",2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,25565
"KIT Q556_W557del results in the deletion of 2 amino acids in the juxtamembrane domain of the Kit protein from amino acids 556 to 557 (PMID: 16226710). Q556_W557del has not been characterized, however similar Kit exon 11 deletions are activating, thus Q556_W557del is predicted to lead to a gain of Kit protein function (PMID: 9438854, PMID: 15365079).",2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,25566
"KIT V559_T574del results in the deletion of 16 amino acids in the juxtamembrane domain of the Kit protein from amino acids 559 to 574 (PMID: 16226710). V559_T574del has not been characterized, however similar Kit exon 11 deletions are activating, thus V559_T574del is predicted to lead to a gain of Kit protein function (PMID: 9438854, PMID: 15365079).",2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,25567
"KIT W557_K558delinsC results in the deletion of 2 amino acids in the juxtamembrane domain of the Kit protein from amino acids 557 to 558, combined with the insertion of a cystine (C) at the same site (PMID: 16226710). W557_K558delinsC has not been characterized, but is predicted to activate Kit basing on effects of similar mutations (PMID: 9438854, PMID: 15365079).",2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,25568
"KIT W557_K558delinsE results in the deletion of 2 amino acids in the juxtamembrane domain of the Kit protein from amino acids 557 to 558, combined with the insertion of a glutamic acid (E) at the same site (PMID: 16226710). W557_K558delinsE has not been characterized, but is predicted to activate Kit basing on effects of similar mutations (PMID: 9438854, PMID: 15365079).",2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,25569
"KIT KIT W557_K558delinsF results in the deletion of 2 amino acids in the juxtamembrane domain of the Kit protein from amino acids 557 to 558, combined with the insertion of a phenylalanine (F) at the same site (PMID: 16226710). KIT W557_K558delinsF has not been characterized, but is predicted to activate Kit basing on effects of similar mutations (PMID: 9438854, PMID: 15365079).",2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,25570
"KIT W557F lies within the juxtamembrane domain of the Kit protein (PMID: 16226710). W557F has been identified in the scientific literature (PMID: 19585585), but has not been biochemically characterized and therefore, its effect on Kit protein function is unknown (PubMed, May 2017).",7842,19585585,High density DNA array analysis reveals distinct genomic profiles in a subset of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/19585585,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25571
"KIT Y553_E561delinsLK results in the deletion of 9 amino acids in the juxtamembrane domain of the Kit protein from amino acids 553 to 561, combined with the insertion of a leucine (L) and a lysine (K) at the same site (PMID: 16226710). Y553_E561delinsLK has not been characterized, but is predicted to activate Kit basing on effects of similar mutations (PMID: 9438854, PMID: 15365079).",648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,25572
RET R813Q lies within the protein kinase domain of the Ret protein (UniProt.org). R813Q results in a loss of Ret protein fuction as indicated by reduced GDNF-dependent Mapk activation in culture (PMID: 22729463).,6809,22729463,"Traditional and targeted exome sequencing reveals common, rare and novel functional deleterious variants in RET-signaling complex in a cohort of living US patients with urinary tract malformations.",http://www.ncbi.nlm.nih.gov/pubmed/22729463,295,,,www.uniprot.org,25584
"ALK M1166R lies within the protein kinase domain of the Alk protein (UniProt.org). M1166R confers a gain of function to Alk protein, as indicated by ligand-independent activation of the Alk protein and increased Erk and Stat3 phosphorylation in cell culture (PMID: 23104988).
",295,,,www.uniprot.org,1899,23104988,Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/23104988,25585
"ALK F1245I lies within the protein kinase domain of the Alk protein (UniProt.org). F1245I has not been characterized and therefore, its effect on Alk protein function is unknown (PubMed, Jun 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25586
"ALK I1250T lies within the protein kinase domain of the Alk protein (UniProt.org). I1250T confers a loss of function on Alk, indicated by loss of kinase activity and loss of the ability to activate downstream signaling pathways in cell culture (PMID: 21804922).",295,,,www.uniprot.org,6810,21804922,The neuroblastoma ALK(I1250T) mutation is a kinase-dead RTK in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/21804922,25587
BRAF L485F lies within the protein kinase domain of the Braf protein (UniProt.org). L485F confers a gain of function to the Braf protein as demonstrated by increased kinase activity and activation of downstream Mek signaling and Erk reporter assays (PMID: 16439621).,5839,16439621,Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/16439621,295,,,www.uniprot.org,25588
"KIT G51D lies within the Ig-like C2-type 1 domain of the Kit protein (UniProt.org). G51D has not been characterized in the scientific literature and therefore, its effect on Kit protein function is unknown (PubMed, May 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25594
"CSF1R L301F lies within the Ig-like C2-type domain 4 of the Csf1r protein (UniProt.org). L301F has not been characterized in the scientific literature and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25595
"CSF1R Y969* results in a premature truncation of the Csf1r protein at amino acid 969 of 972 (UniProt.org). Y969* has not been characterized and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25596
"CSF1R Y969C lies within the cytoplasmic domain of the Csf1r protein (UniProt.org). Y969C has been identified in the scientific literature (PMID: 2406720), but has not been biochemically characterized and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9150,2406720,"FMS mutations in myelodysplastic, leukemic, and normal subjects.",http://www.ncbi.nlm.nih.gov/pubmed/2406720,25597
"CSF1R Y969F lies within the cytoplasmic domain of the Csf1r protein (UniProt.org). Y969F has not been biochemically characterized, but results in increased transforming ability compared to wild-type Csf1r protein in cell culture (PMID: 18971950).",397,18971950,Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1.,http://www.ncbi.nlm.nih.gov/pubmed/18971950,295,,,www.uniprot.org,25598
"CSF1R Y969H lies within the cytoplasmic domain of the Csf1r protein (UniProt.org). Y969H has been identified in the scientific literature (PMID: 2406720), but has not been biochemically characterized and therefore, its effect on Csf1r protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9150,2406720,"FMS mutations in myelodysplastic, leukemic, and normal subjects.",http://www.ncbi.nlm.nih.gov/pubmed/2406720,25599
"EGFR E746_T751delinsVA results in a deletion of 6 amino acids in the protein kinase domain of the Egfr protein from amino acids 746 to 751, combined with the insertion of a valine (V) and an alanine (A) at the same site (UniProt.org). E746_T751delinsVA has not been biochemically characterized, however, other exon 19 deletions and deletion insertions in Egfr are activating, thus, L747-T751delinsP is predicted to lead to a gain of function (PMID: 19147750, PMID: 23387505).",441,23387505,Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/23387505,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1890,19147750,Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.,http://www.ncbi.nlm.nih.gov/pubmed/19147750,25600
"EGFR G696E lies within the cytoplasmic domain of the Egfr protein (UniProt.org). G696E has been identified in the scientific literature (PMID: 28229982), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8606,28229982,Circulating-free DNA Mutation Associated with Response of Targeted Therapy in Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28229982,25601
"EGFR Q701* results in a premature truncation of the Egfr protein at amino acid 701 of 1210 (UniProt.org). Due to teh loss of the protein kinase domain (UniProt.org), Q701* is predicted to lead to a loss of Egfr protein function.",295,,,www.uniprot.org,25602
"ERBB2 (HER2) P780_Y781insGSP (also referred to as G778_P780dup) results in the insertion of three amino acids in the protein kinase domain of the Erbb2 (Her2) protein between amino acids 780 and 781 (UniProt.org). P780_Y781insGSP results in constitutive activation of Erbb2 (Her2), increased downstream signaling, and is transforming in cell culture (PMID: 23220880, PMID: 28363995).",1980,23220880,Activating HER2 mutations in HER2 gene amplification negative breast cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23220880,8567,28363995,Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/28363995,295,,,www.uniprot.org,25606
"FGFR2 C342Y lies within the Ig-like C2-type 3 domain of the Fgfr2 protein (UniProt.org). C342Y results in activation of Fgfr2 signaling as indicated by decreased differentiation and increased apoptosis in osteoblasts in culture and in transgenic animal models (PMID: 10851026, PMID: 15316116).",295,,,www.uniprot.org,6834,15316116,A gain-of-function mutation of Fgfr2c demonstrates the roles of this receptor variant in osteogenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15316116,6833,10851026,Signaling by fibroblast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR2)-activating mutations blocks mineralization and induces apoptosis in osteoblasts.,http://www.ncbi.nlm.nih.gov/pubmed/10851026,25608
FGFR2 E565A lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). E565A results in increased Fgfr2 autophosphorylation and substrate phosphorylation in in vitro kinase assays (PMID: 17803937).,295,,,www.uniprot.org,1905,17803937,A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases.,http://www.ncbi.nlm.nih.gov/pubmed/17803937,25609
FGFR2 E565G lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). E565G results in increased Fgfr2 autophosphorylation and substrate phosphorylation in in vitro kinase assays (PMID: 17803937).,295,,,www.uniprot.org,1905,17803937,A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases.,http://www.ncbi.nlm.nih.gov/pubmed/17803937,25610
FGFR2 K525E lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). K525E results in increased Fgfr2 autophosphorylation and substrate phosphorylation in in vitro kinase assays (PMID: 17803937).,295,,,www.uniprot.org,1905,17803937,A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases.,http://www.ncbi.nlm.nih.gov/pubmed/17803937,25611
FGFR2 N549T lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). N549T results in increased Fgfr2 autophosphorylation and substrate phosphorylation in in vitro kinase assays (PMID: 17803937).,295,,,www.uniprot.org,1905,17803937,A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases.,http://www.ncbi.nlm.nih.gov/pubmed/17803937,25612
FGFR2 G663E lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). G663E results in increased Fgfr2 autophosphorylation and substrate phosphorylation in in vitro kinase assays (PMID: 17803937).,295,,,www.uniprot.org,1905,17803937,A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases.,http://www.ncbi.nlm.nih.gov/pubmed/17803937,25613
FGFR2 R678G lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). R678G results in increased Fgfr2 autophosphorylation and substrate phosphorylation in in vitro kinase assays (PMID: 17803937).,295,,,www.uniprot.org,1905,17803937,A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases.,http://www.ncbi.nlm.nih.gov/pubmed/17803937,25614
"MET Y1230H lies within the protein kinase domain of the Met protein (UniProt.org). Y1230H results in constitutive Met autophosphorylation and increased substrate phosphorylation, and is transforming in cell culture (PMID: 9826708).",295,,,www.uniprot.org,6847,9826708,Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth.,http://www.ncbi.nlm.nih.gov/pubmed/9826708,25626
"MET Y1230C lies within the protein kinase domain of the Met protein (UniProt.org). Y1230C results in constitutive Met autophosphorylation and increased substrate phosphorylation, and is transforming in cell culture (PMID: 9826708).",295,,,www.uniprot.org,6847,9826708,Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth.,http://www.ncbi.nlm.nih.gov/pubmed/9826708,25627
"MET D1228N lies within the protein kinase domain of the Met protein (UniProt.org). D1228N results in constitutive Met autophosphorylation and increased substrate phosphorylation, and is transforming in cell culture (PMID: 9826708).",295,,,www.uniprot.org,6847,9826708,Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth.,http://www.ncbi.nlm.nih.gov/pubmed/9826708,25628
"MET D1228H lies within the protein kinase domain of the Met protein (UniProt.org). D1228H results in constitutive Met autophosphorylation and increased substrate phosphorylation, and is transforming in cell culture (PMID: 9826708).",295,,,www.uniprot.org,6847,9826708,Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth.,http://www.ncbi.nlm.nih.gov/pubmed/9826708,25629
"MET V1220I lies within the protein kinase domain of the Met protein (UniProt.org). V1220I results in constitutive Met autophosphorylation, but demonstrates substrate phosphorylation and transforming activity similar to wild-type Met in cell culture (PMID: 9826708).",295,,,www.uniprot.org,6847,9826708,Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth.,http://www.ncbi.nlm.nih.gov/pubmed/9826708,25630
MET L1195V lies within the protein kinase domain of the Met protein (UniProt.org). L1195V results in increased substrate phosphorylation and is transforming in cell culture (PMID: 9826708).,295,,,www.uniprot.org,6847,9826708,Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth.,http://www.ncbi.nlm.nih.gov/pubmed/9826708,25631
MET V1188L lies within the protein kinase domain of the Met protein (UniProt.org). V1188L demonstrates substrate phosphorylation and transforming activity similar to wild-type Met in cell culture (PMID: 9826708).,6847,9826708,Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth.,http://www.ncbi.nlm.nih.gov/pubmed/9826708,295,,,www.uniprot.org,25632
"MET M1131T lies within the protein kinase domain of the Met protein (UniProt.org). M1131T results in constitutive Met autophosphorylation, but demonstrates substrate phosphorylation and transforming activity similar to wild-type Met in cell culture (PMID: 9826708).",6847,9826708,Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth.,http://www.ncbi.nlm.nih.gov/pubmed/9826708,295,,,www.uniprot.org,25633
"MET D1246H lies within the protein kinase domain of the Met protein (UniProt.org). D1246H results in constitutive Met autophosphorylation, is transforming in cell culture, and promotes tumor formation in animal models (PMID: 9326629).",295,,,www.uniprot.org,2199,9326629,Activating mutations for the met tyrosine kinase receptor in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/9326629,25634
"MET M1149T lies within the protein kinase domain of the Met protein (UniProt.org). M1149T results in constitutive Met autophosphorylation and promotes tumor formation in animal models, but is not transforming in cell culture (PMID: 9326629).",2199,9326629,Activating mutations for the met tyrosine kinase receptor in human cancer.,http://www.ncbi.nlm.nih.gov/pubmed/9326629,295,,,www.uniprot.org,25635
PDGFRA Y849C lies within the protein kinase domain of the Pdgfra protein (UniProt.org). Y849C results in constitutive phosphorylation of Pdgfra in cell culture (PMID: 15928335).,295,,,www.uniprot.org,272,15928335,"PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.",http://www.ncbi.nlm.nih.gov/pubmed/15928335,25658
SRC E378G lies within the protein kinase domain of the Src protein (UniProt.org). E378G results in constitutive activation of Src and is transforming in culture (PMID: 2424022).,295,,,www.uniprot.org,6872,2424022,Activation of the transforming potential of p60c-src by a single amino acid change.,http://www.ncbi.nlm.nih.gov/pubmed/2424022,25664
"SRC Y530* results in a premature truncation of the Src protein at amino acid 530 of 536 (UniProt.org). Y530* results in constitutive activation of Src, is transforming in culture, and promotes tumorigenesis and metastasis in animal models (PMID: 9988270).",4544,9988270,Activating SRC mutation in a subset of advanced human colon cancers.,http://www.ncbi.nlm.nih.gov/pubmed/9988270,295,,,www.uniprot.org,25665
"RET C618Y lies within the cysteine-rich region of the Ret protein (PMID: 9879991). C618Y has been identified in the scientific literature (PMID:     18062802, PMID: 25628771, PMID: 23849459), but has not been characterized and therefore, its effect on Ret protein function is unknown (PubMed, Aug 2017).",9781,25628771,Molecular diagnosis and comprehensive treatment of multiple endocrine neoplasia type 2 in Southeastern Chinese.,http://www.ncbi.nlm.nih.gov/pubmed/25628771,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8470,18062802,Familial prevalence and age of RET germline mutations: implications for screening.,http://www.ncbi.nlm.nih.gov/pubmed/18062802,9782,23849459,Prophylactic thyroidectomy for MEN 2-related medullary thyroid carcinoma based on predictive testing for RET proto-oncogene mutation and basal serum calcitonin in China.,http://www.ncbi.nlm.nih.gov/pubmed/23849459,25669
RET C620Y lies within the extracellular domain of the Ret protein (UniProt.org). C620Y results in increased Ret kinase activity and is transforming in cell culture (PMID: 9012462).,6877,9012462,The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype.,http://www.ncbi.nlm.nih.gov/pubmed/9012462,295,,,www.uniprot.org,25670
RET C634_R635insHELC results in the insertion of four amino acids in the extracellular domain of the Ret protein between amino acids 634 and 635 (UniProt.org). C634_R635insHELC results in ligand independent dimerization and constitutive activation of Ret in culture (PMID: 10918602).,6879,10918602,A novel type of mutation in the cysteine rich domain of the RET receptor causes ligand independent activation.,http://www.ncbi.nlm.nih.gov/pubmed/10918602,295,,,www.uniprot.org,25671
RET L633_C634insCRT results in the insertion of three amino acids in the extracellular domain of the Ret protein between amino acids 634 and 635 (UniProt.org). L633_C634insCRT results in ligand independent dimerization and constitutive activation of Ret in culture (PMID: 10918602).,295,,,www.uniprot.org,6879,10918602,A novel type of mutation in the cysteine rich domain of the RET receptor causes ligand independent activation.,http://www.ncbi.nlm.nih.gov/pubmed/10918602,25672
"RET E632_T636delinsSS results in the deletion of 5 amino acids in the Ret protein from amino acids 632 to 636, combined with the insertion of two serines (S) at the same site (UniProt.org). E632_T636delinsSS has been identified in the scientific literature (PMID: 9160884), but has not been characterized and therefore, its effect on Ret protein function is unknown (PubMed, Aug 2017).",295,,,www.uniprot.org,9785,9160884,A complex nine base pair deletion in RET exon 11 common in sporadic medullary thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/9160884,285,,,http://www.ncbi.nlm.nih.gov/pubmed,25673
RET Y606C lies within the extracellular domain of the Ret protein (UniProt.org). Y606C results in ligand independent dimeriation and constitutive activation of Ret in culture (PMID: 18248647).,6881,18248647,The Y606C RET mutation causes a receptor gain of function.,http://www.ncbi.nlm.nih.gov/pubmed/18248647,295,,,www.uniprot.org,25674
"PDGFRA S556_E571delinsR results in a deletion of 16 amino acids within the cytoplasmic domain of the Pdgfra protein, combined with the insertion of an arginine (R) at the same site (UniProt.org). S556_E571delinsR results in constitutive phosphorylation of Pdgfra in cell culture (PMID: 15928335).",272,15928335,"PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.",http://www.ncbi.nlm.nih.gov/pubmed/15928335,295,,,www.uniprot.org,25675
"FGFR3 D788N lies within the cytoplasmic domain of the Fgfr3 protein (UniProt.org). D788N has not been biochemically characterized, but results in increased proliferation under some cell culture conditions (PMID: 27053219), and is predicted to result in a gain of Fgfr3 protein function.",6884,27053219,Evaluation of FGFR3 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/27053219,295,,,www.uniprot.org,25676
"FGFR3 S131L lies within the extracellular domain of the Fgfr3 protein (UniProt.org). S131L has not been biochemically characterized, but results in increased proliferation under some cell culture conditions (PMID: 27053219), and is predicted to result in a gain of Fgfr3 protein function.",6884,27053219,Evaluation of FGFR3 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/27053219,295,,,www.uniprot.org,25677
"FGFR3 D764N lies within the cytoplasmic domain of the Fgfr3 protein (UniProt.org). D764N has not been biochemically characterized, but results in increased proliferation under some cell culture conditions (PMID: 27053219), and is predicted to result in a gain of Fgfr3 protein function.",6884,27053219,Evaluation of FGFR3 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/27053219,295,,,www.uniprot.org,25678
"VHL V155fs results in a change in the amino acid sequence of the Vhl protein beginning at aa 155 of 213, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the Elongin BC complex-binding region (UniProt.org), V155fs is predicted to lead to a loss of Vhl function.",295,,,www.uniprot.org,25684
"APC Q1131* results in a premature truncation of the Apc protein at amino acid 1131 of 2843 within the beta-catenin binding region of the Apc protein (PMID: 14672538). Q1131* has not been characterized, however Apc truncation mutants downstream of Q1131 are inactivating (PMID: 18199528) thus, Q1131* is predicted to lead to a loss of Apc protein function.",2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,25693
"APC G1416* results in a premature truncation of the Apc protein at amino acid 1416 of 2843 within the mutator cluster region of the Apc protein (PMID: 14672538). G1416* has not been characterized, however Apc truncation mutants downstream of G1416 are inactivating (PMID: 18199528) thus, G1416* is predicted to lead to a loss of Apc protein function.",2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,25694
"APC E853* results in a premature truncation of the Apc protein at amino acid 853 of 2843 within the mutator cluster region of the Apc protein (PMID: 14672538). E853* has not been characterized, however Apc truncation mutants downstream of E853 are inactivating (PMID: 18199528) thus, E853* is predicted to lead to a loss of Apc protein function.",2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,25695
"APC K1555* results in a premature truncation of the Apc protein at amino acid 1555 of 2843 within the mutator cluster region of the Apc protein (PMID: 14672538). K1555* has not been characterized, however Apc truncation mutants downstream of K1555 are inactivating (PMID: 18199528) thus, K1555* is predicted to lead to a loss of Apc protein function.",2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,25696
"ALK T429I lies within the extracellular domain of the Alk protein (UniProt.org). T429I has not been characterized in the scientific literature and therefore, its effect on Alk protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25718
"ATM F582L does not lie within any known functional domains of the Atm protein (UniProt.org). F582L has been identified in the scientific literature (PMID: 16574953, PMID: 25625042), but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017).",6936,16574953,Variants in the ATM-BRCA2-CHEK2 axis predispose to chronic lymphocytic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/16574953,285,,,http://www.ncbi.nlm.nih.gov/pubmed,6937,25625042,ATM gene mutations in sporadic breast cancer patients from Brazil.,http://www.ncbi.nlm.nih.gov/pubmed/25625042,295,,,www.uniprot.org,25719
"PTEN K60N lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). K60N has not been characterized in the scientific literature and therefore, its effect on Pten protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25724
"ALK A1266D lies within the protein kinase domain of the Alk protein (UniProt.org). A1266D has not been characterized in the scientific literature and therefore, its effect on Alk protein function is unknown (PubMed, Jun 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25732
FLT3 F691I lies within the protein kinase domain of the Flt3 protein (PMID: 23430109). F691I has been demonstrated to promote secondary drug resistance in the context of FLT3 internal tandem duplication (FLT3-ITD) mutations (PMID: 23392356).,7054,23392356,The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.,http://www.ncbi.nlm.nih.gov/pubmed/23392356,3028,23430109,Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.,http://www.ncbi.nlm.nih.gov/pubmed/23430109,25747
"ALK S1206F lies within the protein kinase domain of the Alk protein (UniProt.org). S1206F has been identified in the scientific literature (PMID: 27565908), but has not been biochemically characterized and therefore, its effect on Alk protein function is unknown (PubMed, Jun 2017).",7055,27565908,De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27565908,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25748
"ALK L1152P lies within the protein kinase domain of the Alk protein (UniProt.org). L1152P has not been biochemically characterized, however, has been demonstrated to confer drug resistance in culture (PMID: 24675041).",2525,24675041,The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/24675041,295,,,www.uniprot.org,25749
"FLT3 A848P lies within the protein kinase domain of the Flt3 protein (UniProt.org). A848P has been identified in the scientific literature (PMID: 20520641), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7056,20520641,Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib.,http://www.ncbi.nlm.nih.gov/pubmed/20520641,25750
"FBXW7 G437V lies within the WD repeat 3 of the Fbxw7 protein (UniProt.org). G437V has been identified in sequencing studies (PMID: 23263491), but has not been biochemically characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,25753
"PDGFRA H687Y lies within the tyrosine kinase domain of the Pdgfra protein (PMID: 21364689). H687Y has not been biochemically characterized, but has been identified as a secondary mutation and is potentially associated with drug resistance (PMID: 18488160).",7082,18488160,Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/18488160,7081,21364689,Targeted therapy in GIST: in silico modeling for prediction of resistance.,http://www.ncbi.nlm.nih.gov/pubmed/21364689,25756
"APC Q1429fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1429 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). Q1429fs has not been characterized, however Apc truncation mutants downstream of Q1429 are inactivating (PMID: 18199528) thus, Q1429fs is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,25757
"PIK3CA R88L lies within the PI3K-ABD domain of the Pik3ca protein (UniProt.org). R88L has been identified in the scientific literature (PMID: 27672108), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7122,27672108,"First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.",http://www.ncbi.nlm.nih.gov/pubmed/27672108,25759
"PIK3CA T1025K lies within the PI3K/PI4K protein kinase domain of the Pik3ca protein (UniProt.org). T1025K has been identified in the scientific literature (PMID: 27672108), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7122,27672108,"First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.",http://www.ncbi.nlm.nih.gov/pubmed/27672108,25760
"TP53 N239I lies within the DNA binding domain of the Tp53 protein (UniProt.org). N239I has been identified in sequencing studies (PMID: 22493262), but has not been biochemically characterized and therefore, its effect on Tp53 protein is unknown (PubMed, Dec 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7191,22493262,Aristolochic acid-associated urothelial cancer in Taiwan.,http://www.ncbi.nlm.nih.gov/pubmed/22493262,25770
"CDH1 V660fs results in a change in the amino acid sequence of the Cdh1 protein beginning at aa 660 of 882, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the catenin-binding region (UniProt.org), V660fs is predicted to lead to a loss of Cdh1 protein function.",295,,,www.uniprot.org,25777
BRCA1 M1673I (corresponding to M1652I in the canonical isoform) lies within the BRCT1 domain of the Brca1 protein (UniProt.org). M1673I (M1652I) demonstrates transcription activity similar to wild-type Brca1 protein in cell culture (PMID: 18992264).,6102,18992264,"Analysis of a set of missense, frameshift, and in-frame deletion variants of BRCA1.",http://www.ncbi.nlm.nih.gov/pubmed/18992264,295,,,www.uniprot.org,25778
"TET2 P174H does not lie within any known functional domains of the Tet2 protein (UniProt.org). A756V has been identified in sequencing studies (PMID: 19420352), but has not been biochemically characterized and therefore, its effect on Ret protein function is unknown (PubMed, Dec 2016).",7239,19420352,"Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.",http://www.ncbi.nlm.nih.gov/pubmed/19420352,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25782
PIK3CA G363A lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). G363A confers a gain of function to the Pik3ca protein as demonstrated by increased PI3K pathway signaling and moderate growth in culture (PMID: 23619167).,295,,,www.uniprot.org,2263,23619167,Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.,http://www.ncbi.nlm.nih.gov/pubmed/23619167,25785
PIK3CA C971R lies within the PI3K/PI4K kinase domain of the Pik3ca protein (UniProt.org). C971R confers a gain of function to the Pik3ca protein as demonstrated by increased PI3K pathway signaling and moderate growth in culture (PMID: 23619167).,2263,23619167,Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.,http://www.ncbi.nlm.nih.gov/pubmed/23619167,295,,,www.uniprot.org,25786
MET D1228V lies within the protein kinase domain of the Met protein (UniProt.org). D1228V has been described as a secondary drug resistance mutation due to its inability to bind some Met inhibitors (PMID: 27694386). ,295,,,www.uniprot.org,7247,27694386,Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27694386,25787
"STK11 D237N lies within the protein kinase domain of the Stk11 protein (UniProt.org). D237N has not been characterized in the scientific literature and therefore, its effect on Stk11 protein function is unknown (PubMed, Dec 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25788
"BCOR D284N does not lie within any known functional domains of the Bcor protein (UniProt.org). D284N has not been characterized in the scientific literature and therefore, its effect on Bcor protein function is unknown (PubMed, Dec 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25789
"ALK S1053F lies within the helical domain of the Alk protein (UniProt.org). S1053F has not been characterized in the scientific literature and therefore, its effect on Alk protein function is unknown (PubMed, Jun 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25792
"BRAF A598S lies within the protein kinase domain of the Braf protein (UniProt.org). A598S has not been characterized in the scientific literature and therefore, its effect on Braf protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25796
"TP53 E339* results in a premature truncation of the Tp53 protein at amino acid 339 of 393 (UniProt.org). E339* has been identified in sequencing studies (PMID: 24140581, PMID: 24705251, PMID: 24997986), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Dec 2016).",7076,24997986,Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway.,http://www.ncbi.nlm.nih.gov/pubmed/24997986,7252,24705251,The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma.,http://www.ncbi.nlm.nih.gov/pubmed/24705251,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7251,24140581,The genetic landscape of anaplastic astrocytoma.,http://www.ncbi.nlm.nih.gov/pubmed/24140581,25797
"EZH2 N322S (corresponds to N317S in the canonical isoform) lies within the DNMT1, DNMT3A and DNMT3B interaction region of the Ezh2 protein (UniProt.org). N322S (N317S) has been identified in the scientific literature (PMID: 20601953, PMID: 21921040), but has not been biochemically characterized and therefore, its effect on Ezh2 protein function is unknown (PubMed, Jun 2017). ",7253,21921040,EZH2 mutational status predicts poor survival in myelofibrosis.,http://www.ncbi.nlm.nih.gov/pubmed/21921040,285,,,http://www.ncbi.nlm.nih.gov/pubmed,3332,20601953,Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders.,http://www.ncbi.nlm.nih.gov/pubmed/20601953,295,,,www.uniprot.org,25798
"ATM over exp indicates an over expression of the Atm protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,25800
"CTNNB1 K354Q lies within the ARM repeat region 5 of the Ctnnb1 protein (UniProt.org). K354Q has not been characterized in the scientific literature and therefore, its effect on Ctnnb1 protein function is unknown (PubMed, Jun 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,25801
"FGFR1 M487I (corresponds to M456 in the canonical isoform) lies within the protein kinase domain of the Fgfr1 protein (UniProt.org). M487I has not been characterized in the scientific literature and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Jun 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25803
"PIK3CA C407F lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). C407F has not been characterized in the scientific literature and therefore, its effect on Pik3ca protein function is unknown (PubMed, Jun 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25805
"TP53 N30fs*14 results in a premature truncation of the Tp53 protein at aa 30 of 393, followed by 14 nonsense amino acids (UniProt.org). Due to the loss of the DNA-binding domain as well as several other functional domains (UniProt.org), N30fs*14 is predicted to lead to a loss of Tp53 protein function. ",295,,,www.uniprot.org,25809
"KIT K558_G565delinsR results in the deletion of 9 amino acids in the juxtamembrane domain of the Kit protein from amino acids 558 to 565, combined with the insertion of an arginine (R) at the same site (PMID: 16226710). K558_G565delinsR has not been characterized, but is predicted to activate Kit basing on effects of similar mutations (PMID: 9438854, PMID: 15365079).",648,16226710,Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/16226710,2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,25813
"KIT P577del results in the deletion of one amino acid in the juxtamembrane domain of the Kit protein at amino acid 577 (PMID: 12879016). P577del has not been characterized, however, other Kit exon 11 deletions are activating, thus, P577del is predicted to lead to a gain of Kit protein function (PMID: 9438854, PMID: 15365079). ",2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,650,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/9438854,2055,12879016,Signal transduction by several KIT juxtamembrane domain mutations.,http://www.ncbi.nlm.nih.gov/pubmed/12879016,25814
"KIT W557Lfs*5 is a missense mutation (W557L) in conjunction with a likely truncation of the 976 aa Kit protein, followed by 5 nonsense amino acids (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), W557Lfs*5 is predicted to result in a loss of Kit protein function. ",295,,,www.uniprot.org,25815
"TP53-KPNA3 results from the fusion of TP53 and KPNA3. TP53-KPNA3 has been identified in osteosarcoma (PMID: 27626065), but has not been biochemically characterized and therefore, its effect on protein function is unknown (PubMed, Dec 2016).",7348,27626065,A novel TP53-KPNA3 translocation defines a de novo treatment-resistant clone in osteosarcoma.,http://www.ncbi.nlm.nih.gov/pubmed/27626065,285,,,http://www.ncbi.nlm.nih.gov/pubmed,25829
"ROS1 S1986Y lies within the protein kinase domain of the Ros1 protein (UniProt.org). S1986Y has not been biochemically characterized, however, has been demonstrated to occur as a secondary drug resistance mutation in the context of ROS1 fusions (PMID: 27401242). ",7357,27401242,Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27401242,25835
"ROS1 S1986F lies within the protein kinase domain of the Ros1 protein (UniProt.org). S1986F has not been biochemically characterized, however, has been demonstrated to occur as a secondary drug resistance mutation in the context of ROS1 fusions (PMID: 27401242). ",7357,27401242,Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/27401242,25836
"CSF3R E405K lies within the extracellular Fibronectin type-III 3 domain of the Csf3r protein (UniProt.org). E405K has not been characterized in the scientific literature and therefore, its effect on Csf3r protein function is unknown (PubMed, Dec 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,25837
"CBL V813I lies within the CD2AP-interacting region of the Cbl protein (UniProt.org). V813I has not been characterized in the scientific literature and therefore, its effect on Cbl protein function is unknown (PubMed, Dec 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,25839
TP53 C238F lies within the DNA binding domain of the Tp53 protein (PMID: 22713868). C238F may confer a loss of function on the Tp53 protein as indicated by loss of transactivation activity (PMID: 20407015).,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,643,20407015,Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20407015,25840
"ROS1 V768L lies within the extracellular domain of the Ros1 protein (UniProt.org). V768L has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Dec 2016).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25841
"KIT K41E does not lie within any known functional domains of the Kit protein (UniProt.org). K41E has not been characterized and therefore, its effect on Kit protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25845
"ATM W412* results in a premature truncation of the Atm protein at amino acid 412 of 3056 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), W412* is predicted to lead to a loss of Atm protein function.",295,,,www.uniprot.org,25846
KIT exon 13 indicates an unspecified mutation has occurred in exon 13 of the KIT gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,25859
"PIK3CA P447_L455del results in the deletion of nine amino acids in the C2 PI3K-type domain of the Pik3ca protein from amino acids 447 to 455 (UniProt.org). P447_L455del results in increased Akt phosphorylation and therefore, confers a gain of function to the Pik3ca protein (PMID: 21266528).",2211,21266528,A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/21266528,25860
"PIK3CA I273V lies within the PI3K-RBD domain of the Pik3ca protein (UniProt.org). I273V has been identified in the scientific literature (PMID: 27126994), but has not been characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017).",7484,27126994,"A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.",http://www.ncbi.nlm.nih.gov/pubmed/27126994,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25861
"PIK3CA D939G lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). D939G has been identified in the scientific literature (PMID: 27738081, PMID: 27126994), but has not been characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017).",7484,27126994,"A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.",http://www.ncbi.nlm.nih.gov/pubmed/27126994,7387,27738081,Analysis of genes involved in the PI3K/Akt pathway in radiation- and MNU-induced rat mammary carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/27738081,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25862
"PIK3CA E78K lies within the PI3K-ABD domain of the Pik3ca protein (UniProt.org). E78K has been identified in the scientific literature (PMID: 27126994), but has not been characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017).",7484,27126994,"A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.",http://www.ncbi.nlm.nih.gov/pubmed/27126994,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25863
"TP53 C277F lies within the DNA binding domain of the Tp53 protein (UniProt.org). C277F results in decreased DNA binding, reduced activation of Tp53 target genes, and reduced growth suppression activity in cultured cells (PMID: 12034820, PMID: 19850740, PMID: 18524770).",7588,26585234,"Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival.",http://www.ncbi.nlm.nih.gov/pubmed/26585234,295,,,www.uniprot.org,7606,19850740,"Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage.",http://www.ncbi.nlm.nih.gov/pubmed/19850740,7605,12034820,Redox state of tumor suppressor p53 regulates its sequence-specific DNA binding in DNA-damaged cells by cysteine 277.,http://www.ncbi.nlm.nih.gov/pubmed/12034820,3916,18524770,Oligomerization of BAK by p53 utilizes conserved residues of the p53 DNA binding domain.,http://www.ncbi.nlm.nih.gov/pubmed/18524770,25931
"KIT T22A does not lie within any known functional domains of the Kit protein (UniProt.org). T22A has been identified in sequencing studies (PMID: 21720365), but has not been biochemically characterized and therefore, its effect on Kit protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6943,21720365,Integrated genomic analyses of ovarian carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/21720365,25934
PDGFRA D842X indicates indicates any amino acid change at codon 842 of the Pdgfra protein.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,25943
KIT exon 17 indicates an unspecified mutation has occurred in exon 17 of the KIT gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,25944
"ERBB4 I658F does not lie within any known functional domains of the Erbb4 protein (UniProt.org). I658F has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Jan 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,25945
"ALK V163L does not lie within any known functional domains of the Alk protein (UniProt.org). V163L has not been characterized in the scientific literature and therefore, its effect on Alk protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25948
"BRCA1 Q1756* results in a premature truncation of the Brca1 protein at amino acid 1756 of 1863 (UniProt.org). Q1756* has not been characterized, however, other BRCT domain deletion mutants downstream of Q1756 are destablizing (PMID: 14534301), thus Q1756* is predicted to lead to a loss of Brca1 protein function.",295,,,www.uniprot.org,2590,14534301,Detection of protein folding defects caused by BRCA1-BRCT truncation and missense mutations.,http://www.ncbi.nlm.nih.gov/pubmed/14534301,25949
GATA2 L321P lies within the DNA-binding domain of the Gata2 protein (PMID: 27389056). L321P confers a loss of function to the Gata2 protein as demonstrated by decreased Gata2 transcriptional activity and increased erythroid lineage differentiation in cell culture (PMID: 27389056).,7599,27389056,Exome sequencing identifies highly recurrent somatic GATA2 and CEBPA mutations in acute erythroid leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/27389056,25951
"PTEN E284* results in a premature truncation of the Pten protein at amino acid 284 of 403 (UniProt.org). E284* has not been characterized, however, other C-terminal deletion mutants downstream of E284 are inactivating (PMID: 10468583), thus, E284* is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,25952
"STK11 dec exp indicates decreased expression of the Stk11 protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,25957
"STK11 K48fs*3 likely results in a premature truncation of the Stk11 protein at amino acid 48 of 433, followed by 3 nonsense amino acids (UniProt.org). K48fs*3 has been identified in the literature (PMID: 27821489), but has not been biochemically characterized, however, due to the loss of the protein kinase domain (UniProt.org), K48fs*3 is predicted to lead to a loss of Stk11 protein function.",7607,27821489,A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/27821489,295,,,www.uniprot.org,25958
"TP53 L111Q lies within the DNA binding domain of the Tp53 protein (UniProt.org). L111Q has been identified in the scientific literature (PMID: 27179933), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Jan 2017). ",7621,27179933,Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27179933,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25959
"TP53 Y163H lies within the DNA binding domain of the Tp53 protein (UniProt.org). Y163H has been identified in the scientific literature (PMID: 27179933, PMID: 17764544), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Jan 2017). ",295,,,www.uniprot.org,7621,27179933,Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/27179933,285,,,http://www.ncbi.nlm.nih.gov/pubmed,7622,17764544,High resolution melting for mutation scanning of TP53 exons 5-8.,http://www.ncbi.nlm.nih.gov/pubmed/17764544,25960
TP53 P278R lies within the DNA binding domain of the Tp53 protein (UniProt.org). P278R is predicted to result in a loss of Tp53 protein function as indicated by the inability of corresponding mouse P275R to induce Tp53 target gene expression of p21 and Noxa (PMID: 20195489).,295,,,www.uniprot.org,7623,20195489,Activation of p73 and induction of Noxa by DNA damage requires NF-kappa B.,http://www.ncbi.nlm.nih.gov/pubmed/20195489,25961
"CBL A757T lies within the CD2AP-interacting region of the Cbl protein (UniProt.org). A757T has been identified in sequencing studies (PMID: 24728327), but has not been biochemically characterized and therefore, its effect on Cbl protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7625,24728327,"Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing.",http://www.ncbi.nlm.nih.gov/pubmed/24728327,25962
"SMO P641A lies within the C-terminal cytoplasmic tail of the Smo protein (PMID: 20207148). P641A has been identified in sequencing studies (PMID: 24728327), but has not been biochemically characterized and therefore, its effect on Smo protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7625,24728327,"Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing.",http://www.ncbi.nlm.nih.gov/pubmed/24728327,2471,20207148,Evaluating Smoothened as a G-protein-coupled receptor for Hedgehog signalling.,http://www.ncbi.nlm.nih.gov/pubmed/20207148,25968
"TP53 C242fs results in a change in the amino acid sequence of the Tp53 protein beginning at aa 242 of 393, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the oligomerization domain (UniProt.org), C242fs is predicted to lead to a loss of Tp53 protein function.",295,,,www.uniprot.org,25970
"SMO R762H lies within the C-terminal cytoplasmic tail of the Smo protein (PMID: 20207148). R762H has not been characterized in the scientific literature and therefore, its effect on Smo protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,2471,20207148,Evaluating Smoothened as a G-protein-coupled receptor for Hedgehog signalling.,http://www.ncbi.nlm.nih.gov/pubmed/20207148,25972
"JAK3 R953* results in a premature truncation of the Jak3 protein at amino acid 953 of 1123 (UniProt.org). R953* has not been characterized in the scientific literature and therefore, its effect on Jak3 protein function is unknown (PubMed, Jan 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,25975
"MPL R102P lies within the Tpo-binding domain of the Mpl protein (PMID: 18422784). R102P is predicted to confer a loss of function to the Mpl protein as indicated by decreased Mpl downstream STAT and PI3K/Akt signaling when compared to wild-type (PMID: 18422784, PMID: 25538044).",7627,18422784,Functional analysis of single amino-acid mutations in the thrombopoietin-receptor Mpl underlying congenital amegakaryocytic thrombocytopenia.,http://www.ncbi.nlm.nih.gov/pubmed/18422784,3602,25538044,The thrombopoietin receptor P106L mutation functionally separates receptor signaling activity from thrombopoietin homeostasis.,http://www.ncbi.nlm.nih.gov/pubmed/25538044,25976
"TP53 L194R lies within the DNA binding domain of the Tp53 protein (UniProt.org). L194R results in decreased wild-type Tp53 transactivation activity and loss of growth suppression activity, and also confers a gain of function to Tp53 resulting in aberrant activation of ASNS and hTERT in culture (PMID: 12509279, PMID: 15077194).",295,,,www.uniprot.org,4437,12509279,A novel p53 mutant retained functional activity in lung carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/12509279,2156,15077194,Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes.,http://www.ncbi.nlm.nih.gov/pubmed/15077194,25977
"MSH6 K1358fs results in a change in the amino acid sequence of the Msh6 protein beginning at aa 1358 of 1360, likely resulting in premature truncation of the functional protein (UniProt.org). K1358fs has been identified in the scientific literature (PMID: 26436112), but has not been biochemically characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Sep 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3793,26436112,Multigene panel analysis identified germline mutations of DNA repair genes in breast and ovarian cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26436112,25986
"ROS1 act mut indicates that this variant results in a gain of function in the Ros1 protein. However, the specific amino acid change has not been identified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,25997
"CSF3R E808K lies within the cytoplasmic domain of the Csf3r protein (UniProt.org). E808K (also referred to as E785K) results in decreased colony formation compared to wild-type CSF3R in cultured cells, however, does not alter activation of ERK2, MAPK, JNK, or STAT5, or cell differentiation (PMID: 15644419), and therefore its effect on Csf3r protein function is unknown.",295,,,www.uniprot.org,7713,15644419,A functional single-nucleotide polymorphism of the G-CSF receptor gene predisposes individuals to high-risk myelodysplastic syndrome.,http://www.ncbi.nlm.nih.gov/pubmed/15644419,26001
"EGFR R252C lies within the extracellular domain of the Egfr protein (UniProt.org). R252C has been identified in sequencing studies (PMID: 23917401), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,3963,23917401,The integrated landscape of driver genomic alterations in glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/23917401,26003
"EGFR K754H lies within the protein kinase domain of the Egfr protein (UniProt.org). K754H has not been characterized in the scientific literature and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26004
"EGFR T448S lies within the extracellular domain of the Egfr protein (UniProt.org). T448S has not been characterized in the scientific literature and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26005
"EGFR R1052I lies within the cytoplasmic domain of the Egfr protein (UniProt.org). R1052I has not been characterized in the scientific literature and therefore, its effect on Egfr protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26006
MAP2K1 G128D lies within the protein kinase domain of the Map2k1 protein (UniProt.org). G128D confers a gain of function to the Map2k1 protein as indicated by increased phosphorylation of downstream targets (PMID: 28115009). ,295,,,www.uniprot.org,7720,28115009,3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets.,http://www.ncbi.nlm.nih.gov/pubmed/28115009,26008
"EGFR L792F lies within the protein kinase domain of the Egfr protein (UniProt.org). L792F has not been biochemically characterized, but is associated with secondary resistance to some EGFR inhibitors (PMID: 27913578).",295,,,www.uniprot.org,7760,27913578,"Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.",http://www.ncbi.nlm.nih.gov/pubmed/27913578,26020
"ALK V1413G lies within the cytoplasmic domain of the Alk protein (UniProt.org). V1413G has not been characterized in the scientific literature and therefore, its effect on Alk protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26028
"ATM R1730Q does not lie within any known functional domains of the Atm protein (UniProt.org). R1730Q has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26029
"BRCA2 T3195A does not lie within any known functional domains of the Brca2 protein (UniProt.org). T3195A has been identified in sequencing studies (PMID: 16905680), but has not been biochemically characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7762,16905680,"Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer.",http://www.ncbi.nlm.nih.gov/pubmed/16905680,26030
"ALK E1303K lies within the protein kinase domain of the Alk protein (UniProt.org). E1303K has not been characterized in the scientific literature and therefore, its effect on Alk protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26032
"ALK E717K lies within the extracellular domain of the Alk protein (UniProt.org). E717K has not been characterized in the scientific literature and therefore, its effect on Alk protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26033
"DNMT3A A376T lies within the DNMT1 and DNMT3B-interacting region of the Dnmt3a protein (UniProt.org). A376T has not been characterized in the scientific literature and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26035
"ERBB2 (HER2) P197S lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). P197S has been identified in sequencing studies (PMID: 25589618), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,6963,25589618,Genomic analysis of metastatic cutaneous squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25589618,26046
"FBXW7 Q275* results in a premature truncation of the Fbxw7 protein at amino acid 275 of 707 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), FBXW7 Q275* is predicted to lead to a loss of Fbxw7 function.",295,,,www.uniprot.org,26048
"JAK3 P396L lies within the SH2 domain of the Jak3 protein (UniProt.org). P396L has not been characterized in the scientific literature and therefore, its effect on Jak3 protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26051
"EGFR A613T lies within the extracellular domain of the Egfr protein (UniProt.org). A613T has not been characterized in the scientific literature and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26055
"FLT3 G282R lies within the Ig-like C2-type domain of the Flt3 protein (UniProt.org). G282R has not been characterized in the scientific literature and therefore, its effect on Flt3 protein function is unknown (PubMed, Feb 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26060
"RB1 Q257* results in a premature truncation of the Rb1 protein at amino acid 257 of 928 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), Q257* is predicted to lead to a loss of Pten protein function.",295,,,www.uniprot.org,26061
"PTEN K260* results in a premature truncation of the Pten protein at amino acid 260 of 403 (UniProt.org). K260* has not been characterized, however other C-terminal deletion mutants downstream of K260 are inactivating (PMID: 10468583), thus K260* is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,26064
"MET Y1003fs results in a change in the amino acid sequence of the Met protein beginning at aa 1003 of 1390, likely resulting in premature truncation of the functional protein (UniProt.org). Y1003fs has not been characterized, however, Y1003* results in exon 14 skipping and Met activation (PMID: 25531467, PMID: 16397241) and therefore, Y1003fs is predicted to result in a gain of function.",1974,16397241,Somatic mutations lead to an oncogenic deletion of met in lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/16397241,1975,25531467,Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes.,http://www.ncbi.nlm.nih.gov/pubmed/25531467,295,,,www.uniprot.org,26065
"EZH2 G648E (corresponds to G644 in the canonical isoform) lies within the SET domain of the Ezh2 protein (UniProt.org). G648E has been identified in sequencing studies (PMID: 22377896), but has not been biochemically characterized and therefore, its effect on Ezh2 protein function is unknown (PubMed, Feb 2017). ",295,,,www.uniprot.org,7818,22377896,Sequencing histone-modifying enzymes identifies UTX mutations in acute lymphoblastic leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/22377896,285,,,http://www.ncbi.nlm.nih.gov/pubmed,26072
"ETV6-FGFR1 results from the fusion of ETV6 (also referred to as TEL) and FGFR1 (PMID: 21764904), and demonstrates transforming ability in cell culture (PMID: 20338520).",7896,21764904,"Potent, selective inhibitors of fibroblast growth factor receptor define fibroblast growth factor dependence in preclinical cancer models.",http://www.ncbi.nlm.nih.gov/pubmed/21764904,2410,20338520,A structure-guided approach to creating covalent FGFR inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/20338520,26074
"ETV6-FGFR4 results from the fusion of ETV6 (also referred to as TEL) and FGFR4 (PMID: 24124571), and demonstrates constitutive kinase activity and the ability to transform cells in culture (PMID: 24124571).",88,24124571,Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).,http://www.ncbi.nlm.nih.gov/pubmed/24124571,26076
MET Y1230D (also referred to as MET Y1248D) lies within the protein kinase domain of the Met protein (UniProt.org). Y1230D (Y1248D) results in constitutive Met phosphorylation and is transforming in cell culture (PMID: 10327054).,295,,,www.uniprot.org,1991,10327054,Novel mutations of the MET proto-oncogene in papillary renal carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/10327054,26084
"MET D1228A lies within the protein kinase domain of the Met protein (UniProt.org). D1228A has not been biochemically characterized, but is associated with resistance to some Met inhibitors in the context of TPR-MET (PMID: 21697284).",8018,21697284,A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/21697284,295,,,www.uniprot.org,26085
"MET V1155L lies within the protein kinase domain of the Met protein (UniProt.org). V1155L has not been biochemically characterized, but is associated with resistance to some Met inhibitors in the context of TPR-MET (PMID: 21697284).",8018,21697284,A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/21697284,295,,,www.uniprot.org,26086
"MET F1200I lies within the protein kinase domain of the Met protein (UniProt.org). F1200I results in increased Met phosphorylation in the context of TPR-MET in an in vitro assay, and is also associated with resistance to some Met inhibitors in the context of TPR-MET (PMID: 21697284).",8018,21697284,A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/21697284,295,,,www.uniprot.org,26087
"ABL1 E327* (corresponds to E308 in the canonical isoform) results in a premature truncation of the Abl1 protein at amino acid 327 of 1149 (UniProt.org). Due the loss of multiple functional domains including the DNA-binding domain (UniProt.org), E327* is predicted to result in a loss of Abl1 protein function.",295,,,www.uniprot.org,26096
"ABL1 K1080I (corresponds to K1061 in the canonical isoform) lies within the F-actin binding region of the Abl1 protein (UniProt.org). K1080I has not been characterized in the scientific literature and therefore, its effect on Abl1 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26098
"SRC P171R lies within the SH2 domain of the Src protein (UniProt.org). P171R has not been characterized in the scientific literature and therefore, its effect on Src protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26109
"IDH2 E226K does not lie within any known functional domains of the Idh2 protein (UniProt.org). E226K has been identified in sequencing studies (PMID: 24030381), but has not been biochemically characterized and therefore, its effect on Idh2 protein function is unknown (PubMed, Mar 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7701,24030381,Clinical and biological implications of driver mutations in myelodysplastic syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/24030381,26110
"ATM S333F does not lie within any known functional domains of the Atm protein (UniProt.org). S333F has been identified in the scientific literature (PMID: 16914028, PMID: 12673804), but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Mar 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,8121,16914028,ATM variants and cancer risk in breast cancer patients from Southern Finland.,http://www.ncbi.nlm.nih.gov/pubmed/16914028,7873,12673804,ATM gene alterations in childhood acute lymphoblastic leukemias.,http://www.ncbi.nlm.nih.gov/pubmed/12673804,26112
"VHL C162W lies within the Elongin BC complex-interaction region of the Vhl protein (UniProt.org). C162W confers a loss of function to the Vhl protein, as indicated by failure to induce protein ubiquitination in culture (PMID: 17350623).",295,,,www.uniprot.org,8122,17350623,PKCzetaII is a target for degradation through the tumour suppressor protein pVHL.,http://www.ncbi.nlm.nih.gov/pubmed/17350623,26114
"ERBB2 (HER2) L755A lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). L755A has been identified in the scientific literature (PMID: 28167203), but has not been biochemically characterized and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8141,28167203,ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.,http://www.ncbi.nlm.nih.gov/pubmed/28167203,26122
"ERBB2 (HER2) A775_G776insSVMA results in the insertion of four amino acids in the protein kinase domain of the Erbb2 (Her2) protein between amino acids 775 and 776 (UniProt.org). A775_G776insSVMA has not been characterized however, because similar exon 20 insertion mutations are activating (PMID: 17311002), A775_G776insSVMA is predicted to lead to activation of Erbb2 (Her2).",295,,,www.uniprot.org,2002,17311002,The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.,http://www.ncbi.nlm.nih.gov/pubmed/17311002,26123
"PIK3CA R425L lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). E418K has been identified in the scientific literature (PMID: 28167203), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8141,28167203,ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.,http://www.ncbi.nlm.nih.gov/pubmed/28167203,26124
"FGFR2-ZMYM4 results from the fusion of FGFR2 and ZMYM4 (PMID: 28034880). FGFR2-ZMYM4 has not been characterized and therefore, its effect on fusion protein function is unknown (PubMed, Mar 2017).",8146,28034880,Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28034880,26126
"FGFR2-OPTN results from the fusion of FGFR2 and OPTN (PMID: 28034880). FGFR2-OPTN has not been characterized and therefore, its effect on fusion protein function is unknown (PubMed, Mar 2017).",8146,28034880,Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28034880,26127
"FGFR3 L608V lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). L608V has not been biochemically characterized, but has been demonstrated to confer resistance to Fgfr inhibitors in cell culture (PMID: 28034880).",295,,,www.uniprot.org,8146,28034880,Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28034880,26128
"FGFR3 V555L lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). V555L has not been biochemically characterized, but has been demonstrated to confer resistance to Fgfr inhibitors in cell culture (PMID: 28034880).",8146,28034880,Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28034880,295,,,www.uniprot.org,26129
FGFR2 V564F lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). V564F results in increased Fgfr2 kinase activity in cell culture (PMID: 25169980).,4388,25169980,"The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.",http://www.ncbi.nlm.nih.gov/pubmed/25169980,295,,,www.uniprot.org,26130
FGFR2 V564I lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). V564I results in increased Fgfr2 kinase activity in cell culture (PMID: 25169980).,295,,,www.uniprot.org,4388,25169980,"The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.",http://www.ncbi.nlm.nih.gov/pubmed/25169980,26131
FGFR2 V564L lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). V564L results in increased Fgfr2 kinase activity in cell culture (PMID: 25169980).,295,,,www.uniprot.org,4388,25169980,"The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.",http://www.ncbi.nlm.nih.gov/pubmed/25169980,26132
"FGFR2 V564M lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). V564M has not been biochemically characterized, but has been demonstrated to confer resistance to Fgfr inhibitors in cell culture (PMID: 28034880).",8146,28034880,Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28034880,295,,,www.uniprot.org,26133
"FGFR2 V564T lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). V564T demonstrates activation rate similar to wild-type Fgfr2, and confers resistance to Fgfr inhibitor in culture (PMID: 21454610).",8150,21454610,A novel mode of protein kinase inhibition exploiting hydrophobic motifs of autoinhibited kinases: discovery of ATP-independent inhibitors of fibroblast growth factor receptor.,http://www.ncbi.nlm.nih.gov/pubmed/21454610,295,,,www.uniprot.org,26134
"FGFR2 L617V lies within the protein kinase domain of the Fgfr2 protein (UniProt.org). L617V has not been biochemically characterized, but has been demonstrated to confer resistance to Fgfr inhibitors in cell culture (PMID: 28034880).",8146,28034880,Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28034880,295,,,www.uniprot.org,26135
"KDM6A loss indicates loss of the KDM6A gene, mRNA, and protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,26142
EGFR exon 20 indicates an unspecified mutation has occurred in exon 20 of the EGFR gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,26148
"PIK3CA H1047K lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). H1047K has not been characterized, however, other H1047 mutations result in constitutive activation of the Pik3ca protein, thus, H1047K is predicted to result in a gain of function (PMID: 17376864).",295,,,www.uniprot.org,101,17376864,Rare cancer-specific mutations in PIK3CA show gain of function.,http://www.ncbi.nlm.nih.gov/pubmed/17376864,26154
MAP2K1 E44G does not lie within any known functional domains of the Map2k1 protein (UniProt.org). E44G does not result in constitutive and ligand-independent activation of Map2k1 or activation of Erk at levels different than wild-type Map2k1 (PMID: 28166211).,8279,28166211,Divergent effects of intrinsically active MEK variants on developmental Ras signaling.,http://www.ncbi.nlm.nih.gov/pubmed/28166211,295,,,www.uniprot.org,26155
"KMT2A-GAS7 results in the fusion of KMT2A to GAS7, and leads to activation of downstream targets and transformation of cells in culture, and induces leukemia in mouse models  (PMID: 26766589, PMID: 12620410).",8306,12620410,MLL-GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice.,http://www.ncbi.nlm.nih.gov/pubmed/12620410,8304,26766589,Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia.,http://www.ncbi.nlm.nih.gov/pubmed/26766589,26167
"MYD88 over exp indicates an over expression of the Myd88 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,26171
"APC E1554fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1554 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). E1554fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), E1554fs is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,26178
"TP53 S227fs results in a change in the amino acid sequence of the Tp53 protein beginning at aa 227 of 393, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the oligomerization domain (UniProt.org), S227fs is predicted to lead to a loss of Tp53 protein function.",295,,,www.uniprot.org,26181
"MET fusion indicates a fusion of the MET gene, but the fusion partner is unknown.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,26183
MSH6 H1248D lies within the ATPase domain of the Msh6 protein (PMID: 18790734). H1248D results in decreased Msh6 ATPase activity and reduced affinity for mismatch DNA in in vitro assays (PMID: 18790734).,3608,18790734,Hereditary cancer-associated missense mutations in hMSH6 uncouple ATP hydrolysis from DNA mismatch binding.,http://www.ncbi.nlm.nih.gov/pubmed/18790734,26184
MSH6 D803G lies within the lever domain of the Msh6 protein (PMID: 18790734). D803G results in reduced affinity for ATP and decreased Msh6 ATPase activity in in vitro assays (PMID: 18790734).,3608,18790734,Hereditary cancer-associated missense mutations in hMSH6 uncouple ATP hydrolysis from DNA mismatch binding.,http://www.ncbi.nlm.nih.gov/pubmed/18790734,26185
MSH6 S285I lies within the mismatch binding domain of the Msh6 protein (PMID: 18790734). S285I demonstrates mismatch stimulated ATPase activity similar to wild-type Msh6 protein in an in vitro ATPase assay (PMID: 18790734).,3608,18790734,Hereditary cancer-associated missense mutations in hMSH6 uncouple ATP hydrolysis from DNA mismatch binding.,http://www.ncbi.nlm.nih.gov/pubmed/18790734,26186
"CDKN2A negative indicates a lack of the CDKN2A gene, mRNA, and/or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,26190
"PTEN V275* results in a premature truncation of the Pten protein at amino acid 275 of 403 (UniProt.org). V275* has not been characterized, however, other C-terminal deletion mutants downstream of V275 are inactivating (PMID: 10468583), thus, V275* is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,26192
KRAS exon 2 indicates an unspecified mutation has occurred in exon 2 of the KRAS gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,26193
KRAS exon 3 indicates an unspecified mutation has occurred in exon 3 of the KRAS gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,26194
KRAS exon 4 indicates an unspecified mutation has occurred in exon 4 of the KRAS gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,26195
NRAS exon 2 indicates an unspecified mutation has occurred in exon 2 of the NRAS gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,26196
NRAS exon 3 indicates an unspecified mutation has occurred in exon 3 of the NRAS gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,26197
NRAS exon 4 indicates an unspecified mutation has occurred in exon 4 of the NRAS gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,26198
"BRCA2 S2616C lies within the SEM1-interacting region of the Brca2 protein (UniProt.org). S2616C has not been characterized in the scientific literature and therefore, its effect on Brca2 protein function is unknown (PubMed, Mar 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26213
"CDKN2A A102fs results in a change in the amino acid sequence of the Cdkn2a protein beginning at aa 102 of 156, likely resulting in premature truncation of the functional protein (UniProt). A102fs has not been characterized, however, nonsense mutations downstream of A102 are inactivating (PMID: 9053859, PMID: 8668202), thus A102fs is predicted to lead to a loss of Cdkn2a protein function.",3108,8668202,Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/8668202,3063,9053859,Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma.,http://www.ncbi.nlm.nih.gov/pubmed/9053859,295,,,www.uniprot.org,26214
"RET R67H lies within the extracellular domain of the Ret protein (UniProt.org). R67H has been identified in the scientific literature (PMID: 21655256), but has not been biochemically characterized and therefore, its effect on Ret protein function is unknown (PubMed, Mar 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26219
"ROS1 N2240K lies within the cytoplasmic domain of the Ros1 protein (UniProt.org). N2240K has not been identified in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Mar 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26221
"TP53 R158P lies within the DNA binding domain of the Tp53 protein (PMID: 21760703). R158P results in decreased Tp53 transactivation activity in yeast (PMID: 16861262), but has not been characterized in human cells.",807,21760703,TP53 status and response to treatment in breast cancers.,http://www.ncbi.nlm.nih.gov/pubmed/21760703,411,16861262,Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers.,http://www.ncbi.nlm.nih.gov/pubmed/16861262,26223
"NOTCH1 G1088S lies within EGF-like domain 28 of the Notch1 protein (UniProt.org). G1088S has been identified in sequencing studies (PMID: 23407552), but has not been biochemically characterized and therefore, its effect on Notch1 protein function is unknown (PubMed, Mar 2017).",295,,,www.uniprot.org,7872,23407552,The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/23407552,285,,,http://www.ncbi.nlm.nih.gov/pubmed,26232
"RB1 R254K does not lie within any known functional domains of the Rb1 protein (UniProt.org). R254K has not been characterized in the scientific literature and therefore, its effect on Rb1 protein function is unknown (PubMed, Oct 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26233
"ALK A1047T does not lie within any known functional domains of the Alk protein (UniProt.org). A1047T has not been characterized in the scientific literature and therefore, its effect on Alk protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26238
"APC D1058G lies within a region of the Apc protein responsible for down-regulation mediated by ubiquitination (UniProt.org). D1058G has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26239
"NOTCH1 N459S lies within the EGF-like domain 12 of the Notch1 protein (UniProt.org). N459S has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26242
"NOTCH1 E294V does not lie within any known functional domains of the Notch1 protein (UniProt.org). E294V has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26243
"RET V292M lies within the cadherin-like domain 3 of the Ret protein (PMID: 20039896). V292M may confer a gain of function to the Ret protein as evidenced by increased tyrosine autophosphorylation, phosphorylation of Mapk, Mek, and Shc proteins, cell proliferation, but has low transforming activity in vitro (PMID: 20039896).",8391,20039896,A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with phaeochromocytoma and medullary thyroid carcinoma: functional characterization.,http://www.ncbi.nlm.nih.gov/pubmed/20039896,26245
"GNAS M162V does not lie within any known functional domains of the Gnas protein (UniProt.org). M162V has not been characterized in the scientific literature and therefore, its effect on Gnas protein function is unknown (PubMed, Apr 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,26247
"ABL1 P918S lies within the DNA-binding region of the Abl1 protein (UniProt.org). P918S has been identified in the scientific literature (PMID: 27900369), but has not been biochemically characterized and therefore, its effect on Abl1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,8396,27900369,"Genomic profiling of multiple sequentially acquired tumor metastatic sites from an ""exceptional responder"" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response.",http://www.ncbi.nlm.nih.gov/pubmed/27900369,295,,,www.uniprot.org,26252
"DNMT3A P59L does not lie within any known functional domains of the Dnmt3a protein (UniProt.org). P59L has been identified in the scientific literature (PMID: 27900369), but has not been biochemically characterized and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Apr 2017).",8396,27900369,"Genomic profiling of multiple sequentially acquired tumor metastatic sites from an ""exceptional responder"" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response.",http://www.ncbi.nlm.nih.gov/pubmed/27900369,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26253
"ROS1 S1581F lies within the fibronectin type-III repeat domain of the Ros1 protein (UniProt.org). S1581F has been identified in the scientific literature (PMID: 27900369), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2017).",8396,27900369,"Genomic profiling of multiple sequentially acquired tumor metastatic sites from an ""exceptional responder"" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response.",http://www.ncbi.nlm.nih.gov/pubmed/27900369,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26255
"ROS1 N790S lies within the extracellular domain of the Ros1 protein (UniProt.org). N790S has been identified in the scientific literature (PMID: 27900369), but has not been biochemically characterized and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2017).",8396,27900369,"Genomic profiling of multiple sequentially acquired tumor metastatic sites from an ""exceptional responder"" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response.",http://www.ncbi.nlm.nih.gov/pubmed/27900369,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26256
"APC E1284K lies within a region of the Apc protein responsible for down-regulation mediated by ubiquitination (UniProt.org). E1284K has been identified in the scientific literature (PMID: 28352668, PMID: 15072829), but has not been biochemically characterized and therefore, its effect on Apc protein function is unknown (PubMed, Apr 2017).",8434,28352668,Genomic profiling reveals mutational landscape in parathyroid carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/28352668,285,,,http://www.ncbi.nlm.nih.gov/pubmed,8435,15072829,APC mutations are infrequent but present in human lung cancer.,http://www.ncbi.nlm.nih.gov/pubmed/15072829,295,,,www.uniprot.org,26260
"NOTCH1 Q439* results in a premature truncation of the Notch1 protein at amino acid 439 of 2555 (UniProt.org). Due to the loss multiple domains and regions (UniProt.org), Q439* is predicted to lead to a loss of Notch1 function.",295,,,www.uniprot.org,26263
"MAP2K1 L115A lies within the protein kinase domain of the Map2k1 protein (UniProt.org). L115A confers a gain of function on the kinase activity of the Map2k1 protein, but is associated with decreased binding and partial response to Mek inhibitors (PMID: 12370306).",5157,12370306,Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352.,http://www.ncbi.nlm.nih.gov/pubmed/12370306,26265
"ATM V2119fs*8 likely results in a truncation of the 3056 aa Atm protein at aa 2119, followed by 8 nonsense amino acids in the FAT domain (UniProt.org). Due to the loss of the PI3K/PI4K and FATC domains (UniProt.org), V2119fs*8 is predicted to lead to a loss of Atm protein function.",295,,,www.uniprot.org,26269
"RET E505_G506del results in the deletion of 2 amino acids in the protein kinase domain of the Ret protein from amino acids 505 to 506 (UniProt.org). E505_G506del confers a gain of function to the Ret protein as evidenced by increased Mapk pathway activation, phosphorylation of Ret, Akt, and Erk, and increased colony formation (PMID: 26765577).",295,,,www.uniprot.org,8468,26765577,"A 6-Base Pair in Frame Germline Deletion in Exon 7 Of RET Leads to Increased RET Phosphorylation, ERK Activation, and MEN2A.",http://www.ncbi.nlm.nih.gov/pubmed/26765577,26270
"RET C609G lies within the extracellular domain of the Ret protein (UniProt.org). C609G has been identified in the scientific literature (PMID: 8626834, PMID: 18062802), but has not been biochemically characterized and therefore, its effect on Ret protein function is unknown (PubMed, Apr 2017).",8470,18062802,Familial prevalence and age of RET germline mutations: implications for screening.,http://www.ncbi.nlm.nih.gov/pubmed/18062802,8469,8626834,Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. German Medullary Thyroid Carcinoma Study Group.,http://www.ncbi.nlm.nih.gov/pubmed/8626834,295,,,www.uniprot.org,26271
"ALK V66G does not lie within any known functional domains of the Alk protein (UniProt.org). V66G has not been characterized in the scientific literature and therefore, its effect on Alk protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,26277
"APC R1835T lies within the beta-catenin binding and down-regulation region of the Apc protein (PMID: 14672538). R1835T has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Apr 2017).",2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,285,,,http://www.ncbi.nlm.nih.gov/pubmed,26278
"TP53 Y205C lies within the DNA binding domain of the Tp53 protein (UniProt.org). Y205C results in a loss of Tp53 transactivation activity in cultured cells (PMID: 15037740, PMID: 22710932).",2460,15037740,A global suppressor motif for p53 cancer mutants.,http://www.ncbi.nlm.nih.gov/pubmed/15037740,554,22710932,Transactivation and reactivation capabilities of temperature-dependent p53 mutants in yeast and human cells.,http://www.ncbi.nlm.nih.gov/pubmed/22710932,26289
"RET C515S lies within the extracellular domain of the Ret protein (UniProt.org). C515S results in increased cell proliferation, Ret autophosphorylation in vitro and in vivo, and ligand-independent Ret homodimer formation (PMID: 18631007).",8475,18631007,A new germline point mutation in Ret exon 8 (cys515ser) in a family with medullary thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/18631007,295,,,www.uniprot.org,26290
RET C609S lies within the extracellular domain of the Ret protein (UniProt.org). C609S results in ligand-independent Ret autophosphorylation in culture (PMID: 16343103).,8476,16343103,Multiple endocrine neoplasia 2A due to a unique C609S RET mutation presents with pheochromocytoma and reduced penetrance of medullary thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/16343103,295,,,www.uniprot.org,26291
"RET C609F lies within the extracellular domain of the Ret protein (UniProt.org). C609F has been identified in the scientific literature (PMID: 9068588, PMID: 24699901), but has not been biochemically characterized and therefore, its effect on Ret protein function is unknown (PubMed, Apr 2017).",8478,24699901,RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24699901,8477,9068588,"Rapid, nonradioactive screening for mutations in exons 10, 11, and 16 of the RET protooncogene associated with inherited medullary thyroid carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/9068588,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26292
"RET C611S lies within the extracellular domain of the Ret protein (UniProt.org). C611S has been identified in the scientific literature (PMID: 12734540, PMID: 25242331), but has not been biochemically characterized and therefore, its effect on Ret protein function is unknown (PubMed, Apr 2017).",295,,,www.uniprot.org,8480,25242331,RET recognition of GDNF-GFRα1 ligand by a composite binding site promotes membrane-proximal self-association.,http://www.ncbi.nlm.nih.gov/pubmed/25242331,8479,12734540,Cys611Ser mutation in RET proto-oncogene in a kindred with medullary thyroid carcinoma and Hirschsprung's disease.,http://www.ncbi.nlm.nih.gov/pubmed/12734540,285,,,http://www.ncbi.nlm.nih.gov/pubmed,26293
"RET C611R lies within the extracellular domain of the Ret protein (UniProt.org). C611R has been identified in the scientific literature (PMID: 21422198, PMID: 23744765, PMID: 25163725), but has not been biochemically characterized and therefore, its effect on Ret protein function is unknown (PubMed, Apr 2017).",295,,,www.uniprot.org,8481,21422198,Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification.,http://www.ncbi.nlm.nih.gov/pubmed/21422198,8483,25163725,mTOR activation in medullary thyroid carcinoma with RAS mutation.,http://www.ncbi.nlm.nih.gov/pubmed/25163725,8482,23744765,Thyroid cancer and co-occurring RET mutations in Hirschsprung disease.,http://www.ncbi.nlm.nih.gov/pubmed/23744765,285,,,http://www.ncbi.nlm.nih.gov/pubmed,26294
"RET C611G lies within the extracellular domain of the Ret protein (UniProt.org). C611G has been identified in the scientific literature (PMID: 9677065), but has not been biochemically characterized and therefore, its effect on Ret protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8484,9677065,Novel point mutation in exon 10 of the RET proto-oncogene in a family with medullary thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/9677065,26295
"RET C611F lies within the extracellular domain of the Ret protein (UniProt.org). C611F has been identified in the scientific literature (PMID: 11331212, PMID: 9950371), but has not been biochemically characterized and therefore, its effect on Ret protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8486,9950371,High prevalence of the C634Y mutation in the RET proto-oncogene in MEN 2A families in Spain.,http://www.ncbi.nlm.nih.gov/pubmed/9950371,8485,11331212,Presentation of a kindred with familial medullary thyroid carcinoma and Cys611Phe mutation of the RET proto-oncogene demonstrating low grade malignancy.,http://www.ncbi.nlm.nih.gov/pubmed/11331212,26296
"RET C611W lies within the extracellular domain of the Ret protein (UniProt.org). C611W has been identified in the scientific literature (PMID: 27809725), but has not been biochemically characterized and therefore, its effect on Ret protein function is unknown (PubMed, Apr 2017).",8487,27809725,Distribution of RET Mutations in Multiple Endocrine Neoplasia 2 in Denmark 1994-2014: A Nationwide Study.,http://www.ncbi.nlm.nih.gov/pubmed/27809725,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26297
"RET C618S lies within the extracellular domain of the Ret protein (UniProt.org). C618S has been identified in the scientific literature (PMID: 22199277, PMID: 21422198), but has not been biochemically characterized and therefore, its effect on Ret protein function is unknown (PubMed, Apr 2017).",8481,21422198,Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification.,http://www.ncbi.nlm.nih.gov/pubmed/21422198,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8488,22199277,"Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/22199277,26298
"RET C618W lies within the extracellular domain of the Ret protein (UniProt.org). C618W has been identified in the scientific literature (PMID: 17384210, PMID: 14718397), but has not been biochemically characterized and therefore, its effect on Ret protein function is unknown (PubMed, Apr 2017).",8490,14718397,Pyrosequencing technology as a method for the diagnosis of multiple endocrine neoplasia type 2.,http://www.ncbi.nlm.nih.gov/pubmed/14718397,285,,,http://www.ncbi.nlm.nih.gov/pubmed,8489,17384210,"RET proto-oncogene genotyping using unlabeled probes, the masking technique, and amplicon high-resolution melting analysis.",http://www.ncbi.nlm.nih.gov/pubmed/17384210,295,,,www.uniprot.org,26299
"RET C620S lies within the extracellular domain of the Ret protein (UniProt.org). C620S has been identified in the scientific literature (PMID: 22199277, PMID: 19401695), but has not been biochemically characterized and therefore, its effect on Ret protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8488,22199277,"Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/22199277,8491,19401695,Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/19401695,26300
"RET C620G lies within the extracellular domain of the Ret protein (UniProt.org). C620G has been identified in the scientific literature (PMID: 9223675, PMID: 22584707, Endocrine Abstracts 2014 34 P189), but has not been biochemically characterized and therefore, its effect on Ret protein function is unknown (PubMed, Apr 2017).",8493,9223675,Novel germline RET proto-oncogene mutations associated with medullary thyroid carcinoma (MTC): mutation analysis in Japanese patients with MTC.,http://www.ncbi.nlm.nih.gov/pubmed/9223675,8492,,"Multiple endocrine neoplasia type 2A in a large family with a C620G mutation of the RET proto-oncogene: diagnostic, treatment, and ethical challenges",http://www.endocrine-abstracts.org/ea/0034/ea0034p189.htm,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8494,22584707,"RET haplotype, not linked to the C620R activating mutation, associated with Hirschsprung disease in a novel MEN2 family.",http://www.ncbi.nlm.nih.gov/pubmed/22584707,26301
"RET C620F lies within the extracellular domain of the Ret protein (UniProt.org). C620F has been identified in the scientific literature (PMID: 21765987, PMID: 25694125, PMID: 16705552), but has not been biochemically characterized and therefore, its effect on Ret protein function is unknown (PubMed, Apr 2017).",8553,25694125,Skewed mutational spectrum of RET proto-oncogene Exon10 in Iranian patients with medullary thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25694125,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8552,21765987,"Predominant RET Germline Mutations in Exons 10, 11, and 16 in Iranian Patients with Hereditary Medullary Thyroid Carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/21765987,8554,16705552,Double germline mutations in the RET Proto-oncogene in MEN 2A and MEN 2B kindreds.,http://www.ncbi.nlm.nih.gov/pubmed/16705552,26302
"RET C620W lies within the extracellular domain of the Ret protein (UniProt.org). C620W has been identified in the scientific literature (PMID: 9068588, PMID: 25163725), but has not been biochemically characterized and therefore, its effect on Ret protein function is unknown (PubMed, Apr 2017).",8483,25163725,mTOR activation in medullary thyroid carcinoma with RAS mutation.,http://www.ncbi.nlm.nih.gov/pubmed/25163725,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8477,9068588,"Rapid, nonradioactive screening for mutations in exons 10, 11, and 16 of the RET protooncogene associated with inherited medullary thyroid carcinoma.",http://www.ncbi.nlm.nih.gov/pubmed/9068588,26303
"RET C630F lies within the cysteine-rich region of the Ret protein (PMID: 9879991). C630F has not been characterized, however other C630 mutations result in constitutive activity of Ret and are transforming in cell culture and therefore, C630F is predicted to confer a gain of function to the Ret protein (PMID: 9230192).",2271,9879991,Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines.,http://www.ncbi.nlm.nih.gov/pubmed/9879991,2272,9230192,"Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype.",http://www.ncbi.nlm.nih.gov/pubmed/9230192,26304
"RET C634L lies within the cysteine-rich region of the Ret protein (PMID: 9879991). C634L has not been characterized, however other C634 mutations result in autophosphorylation of Ret and transformation in cell culture and therefore, C634L is predicted to confer a gain of function to the Ret protein (PMID: 9242375, PMID: 17664273).",2271,9879991,Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmic cysteines.,http://www.ncbi.nlm.nih.gov/pubmed/9879991,432,9242375,Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain.,http://www.ncbi.nlm.nih.gov/pubmed/9242375,589,17664273,Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.,http://www.ncbi.nlm.nih.gov/pubmed/17664273,26305
"RET K666E lies within the cytoplasmic domain of the Ret protein (UniProt.org). K666E confers a gain of function to the Ret protein as demonstrated by anchorage-independent growth, the ability to transform cells in culture, and increased Erk phosphorylation (PMID: 21690267).",295,,,www.uniprot.org,8496,21690267,Functional characterization of the MTC-associated germline RET-K666E mutation: evidence of oncogenic potential enhanced by the G691S polymorphism.,http://www.ncbi.nlm.nih.gov/pubmed/21690267,26306
"RET Q781R lies within the protein kinase domain of the Ret protein (UniProt.org). Q781R has been identified in the scientific literature (PMID: 21422198), but has not been biochemically characterized and therefore, its effect on Ret protein function is unknown (PubMed, Apr 2017).",8481,21422198,Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification.,http://www.ncbi.nlm.nih.gov/pubmed/21422198,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26307
"RET R912P lies within the protein kinase domain of the Ret protein (UniProt.org). R912P has been identified in the scientific literature (PMID: 15240641), but has not been biochemically characterized and therefore, its effect on Ret protein function is unknown (PubMed, Apr 2017).",8497,15240641,A novel point mutation of the RET protooncogene involving the second intracellular tyrosine kinase domain in a family with medullary thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/15240641,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26308
RET E805K lies within the protein kinase domain of the Ret protein (UniProt.org). E805K is predicted to confer a gain of function to the Ret protein based on increased ability to transform cells in culture (PMID: 17047083).,295,,,www.uniprot.org,8498,17047083,RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B.,http://www.ncbi.nlm.nih.gov/pubmed/17047083,26309
"RET S904C lies within the protein kinase domain of the Ret protein (UniProt.org). S904C has been identified in the scientific literature (PMID: 11788682, PMID: 19169500), but has not been biochemically characterized and therefore, its effect on Ret protein function is unknown (PubMed, Apr 2017).",295,,,www.uniprot.org,8500,19169500,Early diagnosis of multiple endocrine neoplasia type 2B: a challenge for physicians.,http://www.ncbi.nlm.nih.gov/pubmed/19169500,8499,11788682,Atypical MEN type 2B associated with two germline RET mutations on the same allele not involving codon 918.,http://www.ncbi.nlm.nih.gov/pubmed/11788682,285,,,http://www.ncbi.nlm.nih.gov/pubmed,26310
"RET Y806E lies within the protein kinase domain of the Ret protein (UniProt.org). Y806E has not been biochemically characterized, but has been demonstrated to occur as a secondary drug resistance mutation in the context of other RET activating mutations (PMID: 19029224).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,8446,19029224,Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474.,http://www.ncbi.nlm.nih.gov/pubmed/19029224,295,,,www.uniprot.org,26311
"RET Y806F lies within the protein kinase domain of the Ret protein (UniProt.org). Y806F has been identified in the scientific literature (PMID: 19029224), but has not been biochemically characterized and therefore, its effect on Ret protein function is unknown (PubMed, Apr 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8446,19029224,Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474.,http://www.ncbi.nlm.nih.gov/pubmed/19029224,26312
KMT2A R3841W lies within the SET domain of the Kmt2a protein (UniProt.org). The functional effect of R3841W is conflicting as it demonstrates increased histone methyltransferase activity in the absence but decreased activity in the presence of WRA complex stimulation compared to wild type Kmt2a in in vitro assays (PMID: 28182322).,295,,,www.uniprot.org,8546,28182322,Somatic cancer mutations in the MLL1 histone methyltransferase modulate its enzymatic activity and dependence on the WDR5/RBBP5/ASH2L complex.,http://www.ncbi.nlm.nih.gov/pubmed/28182322,26317
KMT2A R3903H lies within the SET domain of the Kmt2a protein (UniProt.org). R3903H results in a loss of Kmt2a histone methyltransferase activity in in vitro assays (PMID: 28182322).,8546,28182322,Somatic cancer mutations in the MLL1 histone methyltransferase modulate its enzymatic activity and dependence on the WDR5/RBBP5/ASH2L complex.,http://www.ncbi.nlm.nih.gov/pubmed/28182322,295,,,www.uniprot.org,26318
KMT2A S3865F lies within the SET domain of the Kmt2a protein (UniProt.org). S3865F results in decreased Kmt2a histone methyltransferase alone or in complex with WRA complex in in vitro assays (PMID: 28182322).,8546,28182322,Somatic cancer mutations in the MLL1 histone methyltransferase modulate its enzymatic activity and dependence on the WDR5/RBBP5/ASH2L complex.,http://www.ncbi.nlm.nih.gov/pubmed/28182322,295,,,www.uniprot.org,26319
"RET C618G lies within the extracellular domain of the Ret protein (UniProt.org). C618G has been identified in the scientific literature (PMID: 27207748, PMID: 18062802, PMID: 18063059), but has not been biochemically characterized and therefore, its effect on Ret protein function is unknown (PubMed, Apr 2017).",8556,18063059,Pheochromocytoma penetrance varies by RET mutation in MEN 2A.,http://www.ncbi.nlm.nih.gov/pubmed/18063059,8470,18062802,Familial prevalence and age of RET germline mutations: implications for screening.,http://www.ncbi.nlm.nih.gov/pubmed/18062802,285,,,http://www.ncbi.nlm.nih.gov/pubmed,8555,27207748,Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/27207748,295,,,www.uniprot.org,26320
"RET E616Q lies within the extracellular domain of the Ret protein (UniProt.org). E616Q results in a gain of function of the Ret protein including increased Ret autophosphorylation and increased transcriptional activity from a serum response element-driven luciferase reporter assay in cell culture during serum starvation, serum supplementation, and GDNF treatment (PMID: 27704398).",295,,,www.uniprot.org,8557,27704398,The RET E616Q Variant is a Gain of Function Mutation Present in a Family with Features of Multiple Endocrine Neoplasia 2A.,http://www.ncbi.nlm.nih.gov/pubmed/27704398,26321
"ALK F1245V lies within the protein kinase domain of the Alk protein (UniProt.org). F1245V has been identified in the scientific literature (PMID: 28183697), but has not been biochemically characterized and therefore, its effect on Alk protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8566,28183697,"Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).",http://www.ncbi.nlm.nih.gov/pubmed/28183697,26322
"EGFR D770delinsGY is an exon 20 mutation that results in a deletion of aspartic acid (D) at amino acid 770 within the protein kinase domain of the Egfr protein, combined with the insertion of a glycine (G) and a tyrosine (Y) at the same site (UniProt.org). D770delinsGY results in transformation of cultured cells, and is associated with resistance to some Egfr inhibitors (PMID: 28363995).",8567,28363995,Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/28363995,295,,,www.uniprot.org,26323
"EGFR Y764_V765insHH is an exon 20 mutation that results in the insertion 2 histidines (H) in the protein kinase domain of the Egfr protein between amino acids 764 and 765 (UniProt.org). Y764_V765insHH results in transformation of cultured cells, and is associated with resistance Egfr inhibitor resistance (PMID: 28363995).",8567,28363995,Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/28363995,295,,,www.uniprot.org,26324
"ERBB2 (HER2) M774delinsWLV results in a deletion of methionine (M) at amino acid 774 within the protein kinase domain of the Erbb2 (Her2) protein, combined with the insertion of a tryptophan (W), lysine (L), and a valine (V) at the same site (UniProt.org). M774delinsWLV results in activation of Erbb2 (Her2) and transformation of cultured cells (PMID: 28363995).",295,,,www.uniprot.org,8567,28363995,Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/28363995,26325
"ERBB2 (HER2) G778_S779insCPG results in the insertion of three amino acids in the protein kinase domain of the Erbb2 (Her2) protein between amino acids 778 and 779 (UniProt.org). G778_S779insCPG is transforming in culture (PMID: 28363995), and based on the effects of other ERBB2 (HER2) exon 20 insertions (PMID: 16843263, PMID: 17311002), is predicted to result in a gain of Erbb2 (Her2) function.",295,,,www.uniprot.org,2004,16843263,HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/16843263,8567,28363995,Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/28363995,2002,17311002,The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.,http://www.ncbi.nlm.nih.gov/pubmed/17311002,26326
"EGFR A767_V769dup (also called V769_D770insASV) is a exon 20 mutation that indicates the insertion of 3 duplicate amino acids, alanine (A)-767 through valine (V)-769, in the protein kinase domain of the Egfr protein (UniProt.org). A767_V769dup results in constitutive Egfr phosphorylation, downstream signaling activation, and transformation of cultured cells (PMID: 24353160, PMID: 28363995).",295,,,www.uniprot.org,440,24353160,"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24353160,8567,28363995,Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/28363995,26327
"ERBB2 (HER2) C805S lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). C805S has not been biochemically characterized, however, is associated with resistance to Erbb2 (Her2) targeted drugs (PMID: 28363995).",8567,28363995,Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.,http://www.ncbi.nlm.nih.gov/pubmed/28363995,26329
"EGFR P772_H773insPNP is an exon 20 mutation that results in the insertion of three amino acids in the protein kinase domain of the Egfr protein between amino acids 772 and 773 (UniProt.org). P772_H773insPNP has not been biochemically characterized, but based on the effect of other Egfr exon 20 insertions (PMID: 24353160), is predicted to result in a gain of Egfr function.",295,,,www.uniprot.org,440,24353160,"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",http://www.ncbi.nlm.nih.gov/pubmed/24353160,26330
RUNX1 L29S does not lie within any known functional domains of the Runx1 protein (UniProt.org). L29S results in a loss of binding to Mll but demonstrates transcriptional activity similar to wild-type Runx1 in culture (PMID: 23817177).,295,,,www.uniprot.org,5672,23817177,RUNX1 meets MLL: epigenetic regulation of hematopoiesis by two leukemia genes.,http://www.ncbi.nlm.nih.gov/pubmed/23817177,26331
RUNX1 A33V does not lie within any known functional domains of the Runx1 protein (UniProt.org). A33V results in a loss of binding to Mll but demonstrates transcriptional activity similar to wild-type Runx1 in culture (PMID: 23817177).,295,,,www.uniprot.org,5672,23817177,RUNX1 meets MLL: epigenetic regulation of hematopoiesis by two leukemia genes.,http://www.ncbi.nlm.nih.gov/pubmed/23817177,26332
RUNX1 R49H does not lie within any known functional domains of the Runx1 protein (UniProt.org). R49H results in a loss of binding to Mll but demonstrates transcriptional activity similar to wild-type Runx1 in culture (PMID: 23817177).,295,,,www.uniprot.org,5672,23817177,RUNX1 meets MLL: epigenetic regulation of hematopoiesis by two leukemia genes.,http://www.ncbi.nlm.nih.gov/pubmed/23817177,26333
RUNX1 R49S does not lie within any known functional domains of the Runx1 protein (UniProt.org). R49S results in a loss of binding to Mll but demonstrates transcriptional activity similar to wild-type Runx1 in culture (PMID: 23817177).,295,,,www.uniprot.org,5672,23817177,RUNX1 meets MLL: epigenetic regulation of hematopoiesis by two leukemia genes.,http://www.ncbi.nlm.nih.gov/pubmed/23817177,26334
RUNX1 S67I lies within the Runt domain of the Runx1 protein (UniProt.org). S67I results in a loss of Runx1 binding to Mll and decreased transcriptional activity in culture (PMID: 23817177).,295,,,www.uniprot.org,5672,23817177,RUNX1 meets MLL: epigenetic regulation of hematopoiesis by two leukemia genes.,http://www.ncbi.nlm.nih.gov/pubmed/23817177,26335
RUNX1 S67R lies within the Runt domain of the Runx1 protein (UniProt.org). S67R results in a loss of Runx1 binding to Mll and decreased transcriptional activity in culture (PMID: 23817177).,5672,23817177,RUNX1 meets MLL: epigenetic regulation of hematopoiesis by two leukemia genes.,http://www.ncbi.nlm.nih.gov/pubmed/23817177,295,,,www.uniprot.org,26336
RUNX1 W79C lies within the Runx domain of the Runx1 protein (UniProt.org). W79C results in a loss of Runx1 transcriptional activity in culture (PMID: 23817177).,5672,23817177,RUNX1 meets MLL: epigenetic regulation of hematopoiesis by two leukemia genes.,http://www.ncbi.nlm.nih.gov/pubmed/23817177,295,,,www.uniprot.org,26337
RUNX1 L117P lies within the Runt domain of the Runx1 protein (UniProt.org). L117P confers a loss of function to the Runx1 protein as indicated by decreased DNA binding and loss of transcriptional activity in culture (PMID: 23817177).,5672,23817177,RUNX1 meets MLL: epigenetic regulation of hematopoiesis by two leukemia genes.,http://www.ncbi.nlm.nih.gov/pubmed/23817177,295,,,www.uniprot.org,26338
RUNX1 T149A lies within the Runt domain of the Runx1 protein (UniProt.org). T149A demonstrates DNA binding and transcription activity similar to wild type Runx1 protein in culture (PMID: 23817177).,5672,23817177,RUNX1 meets MLL: epigenetic regulation of hematopoiesis by two leukemia genes.,http://www.ncbi.nlm.nih.gov/pubmed/23817177,295,,,www.uniprot.org,26339
RUNX1 I150T lies within the Runt domain of the Runx1 protein (UniProt.org). I150T results in a loss of Runx1 transcriptional activity in culture (PMID: 23817177).,5672,23817177,RUNX1 meets MLL: epigenetic regulation of hematopoiesis by two leukemia genes.,http://www.ncbi.nlm.nih.gov/pubmed/23817177,295,,,www.uniprot.org,26340
RUNX1 P156A lies within the Runt domain of the Runx1 protein (UniProt.org). P156A results in a loss of Runx1 transcriptional activity in culture (PMID: 23817177).,295,,,www.uniprot.org,5672,23817177,RUNX1 meets MLL: epigenetic regulation of hematopoiesis by two leukemia genes.,http://www.ncbi.nlm.nih.gov/pubmed/23817177,26341
RUNX1 Q158H lies within the Runt domain of the Runx1 protein (UniProt.org). Q158H results in a loss of beta-subunit interaction and decreased Runx1 transcriptional activity in culture (PMID: 23817177).,295,,,www.uniprot.org,5672,23817177,RUNX1 meets MLL: epigenetic regulation of hematopoiesis by two leukemia genes.,http://www.ncbi.nlm.nih.gov/pubmed/23817177,26342
RUNX1 I166T lies within the Runt domain of the Runx1 protein (UniProt.org). I166T results in decreased Runx1 transcriptional activity in culture (PMID: 23817177).,295,,,www.uniprot.org,5672,23817177,RUNX1 meets MLL: epigenetic regulation of hematopoiesis by two leukemia genes.,http://www.ncbi.nlm.nih.gov/pubmed/23817177,26343
"STK11 K48fs results in a change in the amino acid sequence of the Stk11 protein beginning at aa 48 of 433, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), K48fs is predicted to lead to a loss of Stk11 protein function. ",295,,,www.uniprot.org,26344
RUNX1 E196G lies within the proline/serine/threonine rich region at the C-terminus of the Runx1 protein (UniProt.org). E196G demonstrates DNA binding and transcriptional activity similar to wild type Runx1 protein in culture (PMID: 23817177).,295,,,www.uniprot.org,5672,23817177,RUNX1 meets MLL: epigenetic regulation of hematopoiesis by two leukemia genes.,http://www.ncbi.nlm.nih.gov/pubmed/23817177,26345
"STK11 E57fs results in a change in the amino acid sequence of the Stk11 protein beginning at aa 57 of 433, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), E57fs is predicted to lead to a loss of Stk11 protein function.",295,,,www.uniprot.org,26346
RUNX1 R223H lies within the proline/serine/threonine rich region at the C-terminus of the Runx1 protein (UniProt.org). R223H demonstrates DNA binding and transcriptional activity similar to wild type Runx1 protein in culture (PMID: 23817177).,295,,,www.uniprot.org,5672,23817177,RUNX1 meets MLL: epigenetic regulation of hematopoiesis by two leukemia genes.,http://www.ncbi.nlm.nih.gov/pubmed/23817177,26347
RUNX1 E61* results in a premature truncation of the Runx1 protein at amino acid 61 of 453 (UniProt.org). E61* confers a loss of function to the Runx1 protein as indicated by loss of DNA binding and transcription activity in culture (PMID: 25840971).,295,,,www.uniprot.org,3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,26348
"RUNX1 L62Pfs*49 is a missense mutation (L62P) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 62, followed by 49 nonsense amino acids (UniProt.org). L62Pfs*49 confers a loss of function to the Runx1 protein as indicated by loss of DNA binding and transcription activity in culture (PMID: 25840971).",295,,,www.uniprot.org,3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,26349
"RUNX1 L71Sfs*24 is a missense mutation (L71S) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 71, followed by 24 nonsense amino acids (UniProt.org). L71Sfs*24 confers a loss of function to the Runx1 protein as indicated by loss of DNA binding and transcription activity in culture (PMID: 25840971).",295,,,www.uniprot.org,3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,26350
"RUNX1 I87Afs*25 is a missense mutation (I87A) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 87, followed by 25 nonsense amino acids (UniProt.org). I87Afs*25 confers a loss of function to the Runx1 protein as indicated by loss of DNA binding and transcription activity in culture (PMID: 25840971).",3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,295,,,www.uniprot.org,26351
"RUNX1 T101Rfs*11 is a missense mutation (T101R) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 101, followed by 11 nonsense amino acids (UniProt.org). T101Rfs*11
confers a loss of function to the Runx1 protein as indicated by loss of DNA binding and transcription activity in culture (PMID: 25840971).",3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,295,,,www.uniprot.org,26352
"RUNX1 V105Gfs*12 is a missense mutation (V105G) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 105, followed by 12 nonsense amino acids (UniProt.org). V105Gfs*12
confers a loss of function to the Runx1 protein as indicated by loss of DNA binding and transcription activity in culture (PMID: 25840971).",3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,295,,,www.uniprot.org,26353
"RUNX1 I150Hfs*36 is a missense mutation (I150H) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 150, followed by 36 nonsense amino acids (UniProt.org). I150Hfs*36
confers a loss of function to the Runx1 protein as indicated by loss of DNA binding and transcription activity in culture (PMID: 25840971).",3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,295,,,www.uniprot.org,26354
"RUNX1 S195Pfs*15 is a missense mutation (S195P) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 195, followed by 15 nonsense amino acids (UniProt.org). S195Pfs*15
confers a loss of function to the Runx1 protein as indicated by loss of DNA binding and transcription activity in culture (PMID: 25840971).",3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,295,,,www.uniprot.org,26355
RUNX1 C72W lies within the Runt domain of the Runx1 protein (UniProt.org). C72W results in a loss of CBFbeta dimerization but demonstrates DNA binding and transcription activity similar to wild type Runx1 protein in culture (PMID: 25840971).,3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,295,,,www.uniprot.org,26356
RUNX1 H78E lies within the Runt domain of the Runx1 protein (UniProt.org). H78E results in a  loss of Runx1 transcription activity in culture (PMID: 25840971).,295,,,www.uniprot.org,3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,26357
"APC S811* results in a premature truncation of the Apc protein at amino acid 811 of 2843 (UniProt.org). S811* results in loss of the 20-amino acid repeats of Apc involved in degradation of Beta-catenin and leads to TCF/LEF activity in culture (PMID: 28179481), and thus is predicted to result in a loss of Apc function.",295,,,www.uniprot.org,8618,28179481,APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28179481,26358
"APC S1278* results in a premature truncation of the Apc protein at amino acid 1278 of 2843 (UniProt.org). Due to the loss of the 20-amino acid repeats involved in Beta-catenin degradation (PMID: 28179481), S1278* is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,8618,28179481,APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28179481,26359
RUNX1 W79R lies within the Runt domain of the Runx1 protein (UniProt.org). W79R results in a loss of Runx1 transcription activity in culture (PMID: 25840971).,295,,,www.uniprot.org,3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,26360
RUNX1 N109K lies within the Runt domain of the Runx1 protein (UniProt.org). N109K confers a loss of function to the Runx1 protein as indicated by loss of DNA binding and transcription activity in culture (PMID: 25840971).,295,,,www.uniprot.org,3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,26361
RUNX1 P398L lies within the proline/serine/threonine rich region at the C-terminus of the Runx1 protein (UniProt.org). P398L demonstrates DNA binding and transcription activity similar to wild type Runx1 protein in culture (PMID: 25840971).,295,,,www.uniprot.org,3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,26362
"RUNX1 E111_S114dup indicates the insertion of 4 duplicate amino acids, glutamic acid (E)-111 through serine(S)-114, in the Runt domain of the Runx1 protein (UniProt.org). E111_S114dup results in a loss of Runx1 transcription activity in culture (PMID: 25840971).",295,,,www.uniprot.org,3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,26363
"RUNX1 S268Gfs*311 is a missense mutation (S268G) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 268, followed by 311 nonsense amino acids (UniProt.org). S268Gfs*311
results in a loss of Runx1 transcription activity in culture (PMID: 25840971).",295,,,www.uniprot.org,3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,26364
"APC S1197* results in a premature truncation of the Apc protein at amino acid 1197 of 2843 (UniProt.org). Due to the loss of the 20-amino acid repeats involved in beta-catenin degradation (PMID: 28179481), S1197* is predicted to lead to a loss of Apc protein function.",8618,28179481,APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28179481,295,,,www.uniprot.org,26365
"RUNX1 G324Dfs*242 is a missense mutation (G324D) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 324, followed by 242 nonsense amino acids (UniProt.org). G324Dfs*242
results in a loss of Runx1 transcription activity in culture (PMID: 25840971).",295,,,www.uniprot.org,3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,26366
"RUNX1 P332Dfs*242 is a missense mutation (P332D) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 332, followed by 242 nonsense amino acids (UniProt.org). P332Dfs*242
results in a loss of Runx1 transcription activity in culture (PMID: 25840971).",3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,295,,,www.uniprot.org,26367
"RUNX1 M341Hfs*229 is a missense mutation (M341H) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 341, followed by 229 nonsense amino acids (UniProt.org). M341Hfs*229
results in a loss of Runx1 transcription activity in culture (PMID: 25840971).",3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,295,,,www.uniprot.org,26368
"RUNX1 F369Vfs*204 is a missense mutation (F369V) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 369, followed by 204 nonsense amino acids (UniProt.org). F369Vfs*204
results in a loss of RUnx1 transcription activity in culture (PMID: 25840971).",3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,295,,,www.uniprot.org,26369
"RUNX1 T18Nfs*93 is a missense mutation (T18N) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 18, followed by 93 nonsense amino acids (UniProt.org). T18Nfs*93
confers a loss of function to the Runx1 protein as indicated by loss of DNA binding and transcription activity in culture (PMID: 25840971).",3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,295,,,www.uniprot.org,26370
"RUNX1 V92Ffs*6 is a missense mutation (V92F) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 92, followed by 6 nonsense amino acids (UniProt.org). V92Ffs*6 confers a loss of function to the Runx1 protein as indicated by loss of DNA binding and transcription activity in culture (PMID: 25840971).",3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,295,,,www.uniprot.org,26371
RUNX1 Q245* results in a premature truncation of the Runx1 protein at amino acid 245 of 453 (UniProt.org). Q245* results in a loss of Runx1 transcription activity in culture (PMID: 25840971).,3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,295,,,www.uniprot.org,26372
RUNX1 M283* results in a premature truncation of the Runx1 protein at amino acid 283 of 453 (UniProt.org). M283* results in a loss of Runx1 transcription activity in culture (PMID: 25840971).,295,,,www.uniprot.org,3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,26373
RUNX1 S383* results in a premature truncation of the Runx1 protein at amino acid 383 of 453 (UniProt.org). S383* results in a loss of Runx1 transcription activity in culture (PMID: 25840971).,295,,,www.uniprot.org,3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,26374
RUNX1 S73F lies within the Runt domain of the Runx1 protein (UniProt.org). S73F results in a loss of Runx1 transcription activity in culture (PMID: 25840971).,295,,,www.uniprot.org,3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,26375
RUNX1 R139Q lies within the Runt domain of the Runx1 protein (UniProt.org). R139Q confers a loss of function to the Runx1 protein as indicated by loss of DNA binding and transcription activity in culture (PMID: 25840971).,295,,,www.uniprot.org,3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,26376
RUNX1 G141V lies within the Runt domain of the Runx1 protein (UniProt.org). G141V confers a loss of function to the Runx1 protein as indicated by loss of DNA binding and transcription activity in culture (PMID: 25840971).,295,,,www.uniprot.org,3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,26378
"RUNX1 S329Lfs*244 is a missense mutation (S329L) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 329, followed by 244 nonsense amino acids (UniProt.org). S329Lfs*244 demonstrates DNA binding and transcription activity similar to wild type Runx1 protein in culture (PMID: 25840971).",295,,,www.uniprot.org,3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,26379
"RUNX1 D424Gfs*149 is a missense mutation (D424G) in conjunction with a likely truncation of the 453 aa Runx1 protein at aa 424, followed by 149 nonsense amino acids (UniProt.org). D424Gfs*149 demonstrates DNA binding and transcription activity similar to wild type Runx1 protein in culture (PMID: 25840971).",295,,,www.uniprot.org,3333,25840971,Biological Activities of RUNX1 Mutants Predict Secondary Acute Leukemia Transformation from Chronic Myelomonocytic Leukemia and Myelodysplastic Syndromes.,http://www.ncbi.nlm.nih.gov/pubmed/25840971,26380
"APC L665* results in a premature truncation of the Apc protein at amino acid 665 of 2843 of the Apc protein (UniProt.org). L665* has not been characterized, however, Apc truncation mutations downstream of L665 are inactivating (PMID: 18199528, PMID: 16798748), thus, L665* is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,8619,16798748,Adenomatous polyposis coli (APC) differentially regulates beta-catenin phosphorylation and ubiquitination in colon cancer cells.,http://www.ncbi.nlm.nih.gov/pubmed/16798748,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,26381
"PTEN G143fs*4 likely results in a truncation of the 403 aa Pten protein at aa 143, followed by 4 nonsense amino acids within the phosphatase tensin-type domain (UniProt.org). G143fs*4 has not been characterized, however, other C-terminal deletion mutants downstream of G143 are inactivating (PMID: 10468583), thus G143fs*4 is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,26382
"APC N1819fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1819 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). N1819fs has not been characterized, and therefore its effect on Apc protein function is unknown (PubMed, Sep 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26383
"TP53 S90fs*33 likely results in a premature truncation of the 393 aa Tp53 protein at aa 90, followed by 33 nonsense amino acids (UniProt.org). Due to the loss of the DNA-binding domain as well as several other functional domains (UniProt.org), S90fs*33 is predicted to lead to a loss of Tp53 protein function. ",295,,,www.uniprot.org,26384
"RET C515W lies within the extracellular domain of the Ret protein (UniProt.org). C515W results in increased cell proliferation, S-phase progression, colony formation, cell migration, Ret autophosphorylation, and ERK1/2 and S6 phosphorylation in vitro relative to wild-type Ret (PMID: 25725622).",8620,25725622,Identification and characterization of two novel germline RET variants associated with medullary thyroid carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25725622,295,,,www.uniprot.org,26385
"RET G533C lies within the extracellular domain of the Ret protein (UniProt.org). G553C results in increased Ret autophosphorylation, Erk phosphorylation, cell proliferation, micronuclei formation, and colony formation in vitro, decreased apoptosis and expression of thyroid-specific genes in vitro, and increased liver metastasis in vivo relative to wild-type Ret (PMID: 21834681).",295,,,www.uniprot.org,8621,21834681,The RET p.G533C mutation confers predisposition to multiple endocrine neoplasia type 2A in a Brazilian kindred and is able to induce a malignant phenotype in vitro and in vivo.,http://www.ncbi.nlm.nih.gov/pubmed/21834681,26386
"RET C609R lies within the extracellular domain of the Ret protein (UniProt.org). C609R has been identified in the scientific literature (PMID: 8807338), but has not been biochemically characterized and therefore, its effect on Ret protein function is unknown (PubMed, Apr 2017).",8622,8807338,"Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations.",http://www.ncbi.nlm.nih.gov/pubmed/8807338,295,,,www.uniprot.org,26387
"ATM V278fs results in a change in the amino acid sequence of the Atm protein beginning at aa 278 of 3056, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of all known functional domains (UniProt.org), V278fs is predicted to lead to a loss of Atm function.",295,,,www.uniprot.org,26388
"RB1 E48* results in a premature truncation of the Rb1 protein at amino acid 48 of 928 (UniProt.org). Due to the loss of all known functional domains (UniProt.org), E48* is predicted to lead to a loss of Rb1 protein function.",295,,,www.uniprot.org,26389
"ERBB2 (HER2) F616L lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). F616L has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26392
"GATA1 G5V lies within the transcriptional activation domain of the Gata1 protein (PMID: 22556427). G5V has not been characterized in the scientific literature and therefore, its effect on Gata1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,3109,22556427,N- and C-terminal transactivation domains of GATA1 protein coordinate hematopoietic program.,http://www.ncbi.nlm.nih.gov/pubmed/22556427,26393
"JAK3 Q743L lies within the protein kinase domain 1 of the Jak3 protein (UniProt.org). Q743L has not been characterized in the scientific literature and therefore, its effect on Jak3 protein function is unknown (PubMed, Apr 2017).",295,,,www.uniprot.org,26394
"KIT F811L lies within the protein kinase domain of the Kit protein (UniProt.org). F811L has not been characterized in the scientific literature and therefore, its effect on Kit protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26395
"ROS1 Y1700* results in a premature truncation of the Ros1 protein at amino acid 1700 of 2347 (UniProt.org). Due to the loss of the protein kinase domain (UniProt.org), Y1700* is predicted to result in a loss of Ros1 function.",295,,,www.uniprot.org,26396
"CDH1 W409fs results in a change in the amino acid sequence of the Cdh1 protein beginning at aa 409 of 882, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the catenin-binding region (UniProt.org), W409fs is predicted to lead to a loss of Cdh1 protein function.",295,,,www.uniprot.org,26397
"TP53 L130R lies within the DNA binding domain and the HIPK1, ZNF385A, FBXO42 and AXIN1 interaction region of the Tp53 protein (UniProt.org). L130R has been identified in the scientific literature (PMID: 26070072, PMID: 8916968, PMID: 12637159), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Apr 2017).",8624,8916968,p21/WAF1 cyclin-kinase inhibitor expression in non-Hodgkin's lymphomas: a potential marker of p53 tumor-suppressor gene function.,http://www.ncbi.nlm.nih.gov/pubmed/8916968,8623,26070072,Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment.,http://www.ncbi.nlm.nih.gov/pubmed/26070072,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8625,12637159,ING1 and p53 tumor suppressor gene alterations in adenocarcinomas of the esophagogastric junction.,http://www.ncbi.nlm.nih.gov/pubmed/12637159,26398
"ABL1 A337V lies within the protein kinase domain of the Abl1 protein (UniProt.org). A337V has not been biochemically characterized, but has been demonstrated to confer resistance to allosteric Abl1 inhibitors (PMID: 25849130).",295,,,www.uniprot.org,8640,25849130,Studying clonal dynamics in response to cancer therapy using high-complexity barcoding.,http://www.ncbi.nlm.nih.gov/pubmed/25849130,26408
"ABL1 P465S lies within the protein kinase domain of the Abl1 protein (UniProt.org). P465S has not been biochemically characterized, but has been demonstrated to confer resistance to allosteric Abl1 inhibitors (PMID: 25849130).",295,,,www.uniprot.org,1250,23811600,Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells.,http://www.ncbi.nlm.nih.gov/pubmed/23811600,26409
"APC I1164fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1164 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). I1164fs has not been characterized, however Apc truncation mutants downstream of I1164 are inactivating (PMID: 18199528, PMID: 10346819), thus, I1164fs is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,26410
"APC W553* results in a premature truncation of the Apc protein at amino acid 553 of 2843 (UniProt.org). Due to disruption of the Armadillo domain and loss of the beta-catenin binding and down-regulation domains (PMID: 19573802), W553* is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,8641,19573802,Gardner's syndrome (familial adenomatous polyposis): a cilia-related disorder.,http://www.ncbi.nlm.nih.gov/pubmed/19573802,26411
"ABL1 V468F lies within the protein kinase domain of the Abl1 protein (UniProt.org). V468F has not been biochemically characterized, but has been demonstrated to confer resistance to allosteric Abl1 inhibitors (PMID: 28329763).",8633,28329763,The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.,http://www.ncbi.nlm.nih.gov/pubmed/28329763,295,,,www.uniprot.org,26412
"ABL1 I502L does not lie within any known functional domains of the Abl1 protein (UniProt.org). I502L has not been biochemically characterized, but has been demonstrated to confer resistance to allosteric Abl1 inhibitors (PMID: 28329763).",8633,28329763,The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.,http://www.ncbi.nlm.nih.gov/pubmed/28329763,295,,,www.uniprot.org,26413
"ABL1 P223S does not lie within any known functional domains of the Abl1 protein (UniProt.org). P223S has not been biochemically characterized, but has been demonstrated to confer resistance to allosteric Abl1 inhibitors (PMID: 28329763).",295,,,www.uniprot.org,8633,28329763,The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.,http://www.ncbi.nlm.nih.gov/pubmed/28329763,26423
"ABL1 K294E lies within the protein kinase domain of the Abl1 protein (UniProt.org). K294E has not been biochemically characterized, but has been demonstrated to confer resistance to allosteric Abl1 inhibitors (PMID: 28329763).",295,,,www.uniprot.org,8633,28329763,The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.,http://www.ncbi.nlm.nih.gov/pubmed/28329763,26424
"ABL1 G250H lies within the protein kinase domain of the Abl1 protein (UniProt.org). G250H has been identified in the scientific literature (PMID: 28329763), but has not been biochemically characterized and therefore, its effect on Btk protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8633,28329763,The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.,http://www.ncbi.nlm.nih.gov/pubmed/28329763,26425
"ERBB2 (HER2) E770delinsEAYVM results in a deletion of glutamate (E) at amino acid 770 within the Erbb2 (Her2) protein, combined with the insertion of a glutamate (E), alanine (A), tyrosine (Y), valine (V), and a methionine (M) (UniProt.org). E770delinsEAYVM has been identified in the literature (PMID: 26582655), but its effect on Erbb2 (Her2) protein function is unknown (PubMed, Apr 2017).",8669,26582655,Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/26582655,295,,,www.uniprot.org,26427
"ATM L804fs*4 likely results in a truncation of the 3056 aa Atm protein at aa 804, followed by 4 nonsense amino acids (UniProt.org). Due to the loss of all known functional domains (UniProt.org), L804fs*4 is predicted to lead to a loss of Atm protein function.",295,,,www.uniprot.org,26428
"ATM S978fs*12 likely results in a truncation of the 3056 aa Atm protein at aa 978, followed by 12 nonsense amino acids (UniProt.org). Due to the loss of all known functional domains (UniProt.org), S978fs*12 is predicted to lead to a loss of Atm function.",295,,,www.uniprot.org,26429
"PTEN R173S lies within the phosphatase tensin-type domain of the Pten protein (UniProt.org). R173S has been identified in the scientific literature (PMID: 23434733), but has not been biochemically characterized and therefore, its effect on Pten protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,1066,23434733,Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.,http://www.ncbi.nlm.nih.gov/pubmed/23434733,26430
"KDR (VEGFR2) P1147S lies within the protein kinase domain of the Kdr (Vegfr2) protein (UniProt.org). Y822C has been identified in the scientific literature (PMID: 11807987), but has not been biochemically characterized and therefore, its effect on Kdr (Vegfr2) protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,8701,11807987,Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma.,http://www.ncbi.nlm.nih.gov/pubmed/11807987,26431
"ABL1 A1121P (corresponds to A1102 in the canonical isoform) lies within the F-actin binding region of the Abl1 protein (UniProt.org). A1121P has not been characterized in the scientific literature and therefore, its effect on Abl1 protein function is unknown (PubMed, Apr 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26434
"MET L1333V lies within the protein kinase domain of the Met protein (UniProt.org). L1333V has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26435
"APC I1926M lies within the beta-catenin binding and down-regulation region of the Apc protein (PMID: 14672538). I1926M has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Apr 2017). ",2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,285,,,http://www.ncbi.nlm.nih.gov/pubmed,26437
"APC V2112I does not lie within any known functional domains of the Apc protein (UniProt.org). V2112I has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Apr 2017). ",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,26438
"MET M357V lies within the Sema domain of the Met protein (UniProt.org). M357V has not been characterized in the scientific literature and therefore, its effect on Met protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26441
"ATM G2023R lies within the FAT domain of the Atm protein (UniProt.org). G2023R has been identified in the scientific literature (PMID: 25625042, PMID: 12149228, PMID: 23091097), but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Apr 2017).",8704,23091097,Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.,http://www.ncbi.nlm.nih.gov/pubmed/23091097,8703,12149228,ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/12149228,285,,,http://www.ncbi.nlm.nih.gov/pubmed,6937,25625042,ATM gene mutations in sporadic breast cancer patients from Brazil.,http://www.ncbi.nlm.nih.gov/pubmed/25625042,295,,,www.uniprot.org,26445
"FGFR3 P91L lies within the Ig-like C2-type domain 2 of the Fgfr3 protein (UniProt.org). P91L has not been characterized in the scientific literature and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26447
"BRCA1 K739E does not lie within any known functional domains of the Brca1 protein (UniProt.org). K739E has not been characterized in the scientific literature and therefore, its effect on Brca1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26448
"BRCA2 N1784fs results in a change in the amino acid sequence of the Brca2 protein beginning at aa 1784 of 3418, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the nuclear localization sequence (PMID: 10570174), N1784fs is predicted to lead to a loss of Brca2 protein function.",295,,,www.uniprot.org,3274,10570174,Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations.,http://www.ncbi.nlm.nih.gov/pubmed/10570174,26451
"CSF1R N255I lies within the Ig-like C2-type 3 domain of the Csfr1 protein (UniProt.org). N255I has been identified in the scientific literature (PMID: 23889897), but has not been biochemically characterized and therefore, its effect on Csf1r protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,7275,23889897,Colony stimulation factor 1 receptor (CSF1R) is not a common cause of multiple sclerosis.,http://www.ncbi.nlm.nih.gov/pubmed/23889897,26457
"EGFR D994Y lies within the cytoplasmic domain of the Egfr protein (UniProt.org). D994Y has not been characterized in the scientific literature and therefore, its effect on Egfr protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26461
"ERBB4 A1136D lies within the cytoplasmic domain of the Erbb4 protein (UniProt.org). A1136D has not been characterized in the scientific literature and therefore, its effect on Erbb4 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26463
"SMO S574C does not lie within any known functional domains of the Smo protein (UniProt.org). S574C has not been characterized in the scientific literature and therefore, its effect on Smo protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26478
"ROS1 R77W lies within the extracellular domain of the Ros1 protein (UniProt.org). R77W has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Apr 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26480
"PTPN11 T337M lies within the tyrosine-protein phosphatase domain of the Ptpn11 protein (UniProt.org). T337M has not been characterized in the scientific literature and therefore, its effect on Ptpn11 protein function is unknown (PubMed, Apr 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26483
"TP53 G334W lies within the hinge residue of the oligomerization domain of the Tp53 protein (PMID: 16007150). G334W has not been characterized in human cells, but results in a loss of Tp53 transactivation activity in yeast (PMID: 16007150).",500,16007150,"The relationship among p53 oligomer formation, structure and transcriptional activity using a comprehensive missense mutation library.",http://www.ncbi.nlm.nih.gov/pubmed/16007150,26484
"TP53 C124fs results in a change in the amino acid sequence of the Tp53 protein beginning at aa 124 of 393, likely resulting in premature truncation of the functional protein (UniProt.org). Due to disruption of the DNA binding region and loss of the oligomerization domain (UniProt.org), C124fs is predicted to lead to a loss of Tp53 protein function.",295,,,www.uniprot.org,26487
"CDKN2A G23C lies within the ANK repeat 1 of the Cdk2na protein (UniProt.org). G23C has been identified in the scientific literature (PMID: 12001124), but not been characterized and therefore, its effect on Cdk2na protein function is unknown (PubMed, Apr 2017).",8763,12001124,Multiple primary melanoma revisited.,http://www.ncbi.nlm.nih.gov/pubmed/12001124,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26499
"TP53 P190S lies within the DNA binding domain of the Tp53 protein (UniProt.org). P190S confers a loss of function to the Tp53 protein, as demonstrated by decreased suppression of Vimentin mRNA expression, decreased ability to suppress cell viability, increased cell migration, and increased cell invasion in cell culture (PMID: 28408749).",295,,,www.uniprot.org,8764,28408749,High prevalence of TP53 mutations is associated with poor survival and an EMT signature in gliosarcoma patients.,http://www.ncbi.nlm.nih.gov/pubmed/28408749,26500
TP53 R273W is a hotspot mutation that lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). R273W results in decreased gene transcription in response to Tgf-beta treatment in cell culture (PMID: 17875924).,8776,17875924,Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II.,http://www.ncbi.nlm.nih.gov/pubmed/17875924,2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,26501
"PTEN R130fs results in a change in the amino acid sequence of the Pten protein beginning at aa 130 of 403, likely resulting in premature truncation of the functional protein (UniProt.org). R130fs has not been characterized, however, other C-terminal deletion mutants downstream of R130 are inactivating (PMID: 10468583), thus R130fs is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,26525
"PIK3CA E978K lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). E978K has been identified in the scientific literature (PMID: 28119489), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017). ",8811,28119489,PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2(mutant) Endometrial Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/28119489,26526
"PIK3CA I20M lies within the PI3K-ABD domain of the Pik3ca protein (UniProt.org). I20M has been identified in the scientific literature (PMID: 28119489), but has not been biochemically characterized and therefore, its effect on Pik3ca protein function is unknown (PubMed, May 2017). ",8811,28119489,PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2(mutant) Endometrial Cancers.,http://www.ncbi.nlm.nih.gov/pubmed/28119489,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26528
"PTEN T321fs*23 likely results in a truncation of the 403 aa Pten protein at aa 321, followed by 23 nonsense amino acids (UniProt.org). T321fs*23 has not been characterized, however, other C-terminal deletion mutants downstream of T321 are inactivating (PMID: 10468583), thus, T321fs*23 is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,26529
"RAD21 amplification indicates an increased number of copies of the RAD21 gene. However, the mechanism causing the increase is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,26564
"APC T1496fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1496 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). T1496fs has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), T1496fs is predicted to reduce the ability of Apc to regulate beta-catenin.",295,,,www.uniprot.org,2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,26566
"PTEN Y155fs results in a change in the amino acid sequence of the PTEN protein beginning at aa 155 of 403, likely resulting in premature truncation of the functional protein (UniProt.org). Y155fsfs has not been characterized, however other C-terminal deletion mutants downstream of Y155 are inactivating (PMID: 10468583), thus Y155fs is predicted to lead to a loss of Pten protein function.",2371,10468583,The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region.,http://www.ncbi.nlm.nih.gov/pubmed/10468583,295,,,www.uniprot.org,26575
"TP53 N131fs results in a change in the amino acid sequence of the Tp53 protein beginning at aa 131 of 393, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the disruption of the DNA binding domain and the loss of the oligomerization domain (PMID: 21561095), N131fs is predicted to lead to a loss of Tp53 protein function.",2155,21561095,"Structural effects of the L145Q, V157F, and R282W cancer-associated mutations in the p53 DNA-binding core domain.",http://www.ncbi.nlm.nih.gov/pubmed/21561095,295,,,www.uniprot.org,26577
"MLH1 R389Q does not lie within any known functional domains of Mlh1 protein (UniProt.org). R389Q has been identified in sequencing studies (PMID: 26817999), but has not been biochemically characterized and therefore, its effect on Mlh1 protein function is unknown (PubMed, May 2017). ",8904,26817999,Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion in Glioblastoma.,http://www.ncbi.nlm.nih.gov/pubmed/26817999,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26578
HNF1A del indicates a deletion of the HNF1A gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,26582
"NOTCH1 S1970P lies within ANK repeat 3 of the Notch1 protein (UniProt.org). S1970P has not been characterized in the scientific literature and therefore, its effect on Notch1 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26583
"JAK3 R172W lies within the FERM domain of the Jak3 protein (UniProt.org). R172W has been identified in sequencing studies (PMID: 25822088), but has not been biochemically characterized and therefore, its effect on Jak3 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,7022,25822088,Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.,http://www.ncbi.nlm.nih.gov/pubmed/25822088,295,,,www.uniprot.org,26584
"RET V125F lies within the extracellular domain of the Ret protein (UniProt.org). V125F has not been characterized in the scientific literature and therefore, its effect on Ret protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26585
"SMO R290H lies within an extracellular domain of the Smo protein (UniProt.org). D25G has not been characterized in the scientific literature and therefore, its effect on Smo protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26586
"ATM T2743M lies within the PI3K/PI4K domain of the Atm protein (UniProt.org). T2743M has not been characterized in the scientific literature and therefore, its effect on Atm protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26587
"TET2 Q1524H does not lie within any known functional domains of the Tet2 protein (UniProt.org). Q1524H has not been characterized in the scientific literature and therefore, its effect on Tet2 protein function is unknown (PubMed, May 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26591
TP53 E339K lies within the tetramerization domain of the Tp53 protein (PMID: 20978130). E339K demonstrates similar ability to regulate expression of Tp53 targets and induce apoptosis to wild-type Tp53 in culture (PMID: 24076587).,498,20978130,Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20978130,8913,24076587,Mapping the p53 transcriptome universe using p53 natural polymorphs.,http://www.ncbi.nlm.nih.gov/pubmed/24076587,26592
"EGFR V654E (present in isoform 3) lies within the helical domain of the Egfr protein (UniProt.org). V654E has not been characterized in the scientific literature and therefore, its effect on Egfr protein function is unknown (PubMed, May 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26593
"KIT exon 11 deletions are deletions in exon 11 of the KIT gene, which affect the juxtamembrane domain of the Kit protein and are associated with increased KIT activity (PMID: 18312355, PMID: 15365079).",2054,15365079,Biology of gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/15365079,8916,18312355,Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.,http://www.ncbi.nlm.nih.gov/pubmed/18312355,26594
"EGFR I744_K745insKIPVAI is an exon 19 mutation that results in the insertion of six amino acids in the protein kinase domain of the Egfr protein between amino acids 744 and 745 (UniProt.org). I744_K745insKIPVAI has not been biochemically characterized, but is predicted to result in a gain of function due to sensitivity to Egfr inhibitors (PMID: 22190593). ",439,22190593,EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22190593,295,,,www.uniprot.org,26595
"EGFR K745_E746insIPVAIK is an exon 19 mutation that results in the insertion of six amino acids in the protein kinase domain of the Egfr protein between amino acids 745 and 746 (UniProt.org). K745_E746insIPVAIK has not been biochemically characterized, but is predicted to result in a gain of function due to sensitivity to Egfr inhibitors (PMID: 22190593). ",295,,,www.uniprot.org,439,22190593,EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22190593,26596
"EGFR K745_E746insTPVAIK is an exon 19 mutation that results in the insertion of six amino acids in the protein kinase domain of the Egfr protein between amino acids 745 and 746 (UniProt.org). K745_E746insTPVAIK has not been biochemically characterized, but is predicted to result in a gain of function due to sensitivity to Egfr inhibitors (PMID: 22190593). ",439,22190593,EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/22190593,295,,,www.uniprot.org,26597
"JAK3 R172Q lies within the FERM domain of the Jak3 protein (UniProt.org). R172Q confers a gain of function to the Jak3 protein as demonstrated by constitutive autophosphorylation of Jak3 and increased phosphorylation of Stat5a, and is transforming in cultured cells (PMID: 21821710).",295,,,www.uniprot.org,8930,21821710,FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/21821710,26600
JAK3 L156P lies within the FERM domain of the Jak3 protein (UniProt.org). L156P results in a gain of function of the Jak3 protein as demonstrated by increased protein stability and transformation in cell culture (PMID: 21821710). ,295,,,www.uniprot.org,8930,21821710,FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/21821710,26601
"JAK3 E183G lies within the FERM domain of the Jak3 protein (UniProt.org). E183G confers a gain of function to the Jak3 protein as demonstrated by increased protein stability compared to wild-type, increased Stat5a phosphorylation, and transformation in cultured cells (PMID: 21821710). ",295,,,www.uniprot.org,8930,21821710,FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/21821710,26602
EZH2 mutant indicates an unspecified mutation in the EZH2 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,26605
"ABL1 G250R lies within the protein kinase domain of the Abl1 protein (UniProt.org). G250R has been identified in the scientific literature (PMID: 20369050), but has not been biochemically characterized and therefore, its effect on Abl1 protein function is unknown (PubMed, Jun 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9044,20369050,Coexisting with clonal evolution and BCR-ABL mutant in CML patients treated with second-generation tyrosine kinase inhibitors predict the discrepancy of in vitro drug sensitivity.,http://www.ncbi.nlm.nih.gov/pubmed/20369050,26635
"ABL1 G251D lies within the protein kinase domain of the Abl1 protein (UniProt.org). G251D has been identified in the scientific literature (PMID: 17947479), but has not been biochemically characterized and therefore, its effect on Abl1 protein function is unknown (PubMed, Jun 2017). ",9045,17947479,A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response.,http://www.ncbi.nlm.nih.gov/pubmed/17947479,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26636
"TP53 Q192K lies within the AXIN1-interacting region of the Tp53 protein (UniProt.org). Q192K has not been characterized in the scientific literature and therefore, its effect on Tp53 protein function is unknown (PubMed, Jun 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26637
"SMAD4 Q249H does not lie within any known functional domains of the Smad4 protein (UniProt.org). Q249H has not been characterized in the scientific literature and therefore, its effect on Smad4 protein function is unknown (PubMed, Jun 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26638
"ERBB2 (HER2) D277Y lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). D277Y did not demonstrate Erbb2 (Her2) gain of function activity in a cell culture assay (J Clin Oncol 35, 2017 (suppl; abstr e23150)).",9077,,In vitro functional analysis of HER2 variants in lung cancers to evaluate their oncogenic activity and predict clinical response to HER2 targeted therapies.,http://abstracts.asco.org/199/AbstView_199_190816.html,26643
"EZH2 F120L lies within the DNMT1, DNMT3B, and DNMT3A-interacting regions of the Ezh2 protein (UniProt.org). F120L has not been biochemically characterized, however, has been demonstrated to occur as a drug resistant mutation in the context of EZH2 Y111N (PMID: 28135235).",295,,,www.uniprot.org,9115,28135235,An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.,http://www.ncbi.nlm.nih.gov/pubmed/28135235,26647
"EGFR L833F lies within the protein kinase domain of the Egfr protein (UniProt.org). L833F has been identified in the scientific literature (PMID: 26762747, PMID: 25130612), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Jun 2017).",9126,26762747,Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients.,http://www.ncbi.nlm.nih.gov/pubmed/26762747,8112,25130612,Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations.,http://www.ncbi.nlm.nih.gov/pubmed/25130612,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26649
"RET I788N lies within the protein kinase domain of the Ret protein (UniProt.org). I788N has not been biochemically characterized, but has been associated with Ret inhibitor resistance in the context of Ret fusions (PMID: 28615362).",9186,28615362,Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.,http://www.ncbi.nlm.nih.gov/pubmed/28615362,295,,,www.uniprot.org,26650
"CDKN2A L65P lies within the ANK repeat 2 of the Cdkn2a protein (UniProt.org). L65P has been identified in the scientific literature (PMID: 15860862, PMID: 22368299), but has not been biochemically characterized and therefore, its effect on Cdkn2a protein function is unknown (PubMed, Jun 2017). ",9225,15860862,Role of the CDKN2A locus in patients with multiple primary melanomas.,http://www.ncbi.nlm.nih.gov/pubmed/15860862,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9226,22368299,CDKN2A is the main susceptibility gene in Italian pancreatic cancer families.,http://www.ncbi.nlm.nih.gov/pubmed/22368299,26663
"KMT2A-ELL results from the fusion of KMT2A (MLL) and ELL, resulting in the transformation of primary myeloid progenitor cells, which eventually leads to acute myeloid leukemia in mouse models (PMID: 10995463).",9251,10995463,Retrovirus-mediated gene transfer of MLL-ELL transforms primary myeloid progenitors and causes acute myeloid leukemias in mice.,http://www.ncbi.nlm.nih.gov/pubmed/10995463,26669
"BRAF F247L lies within the phorbol-ester/DAG-type zinc finger region of the Braf protein (UniProt.org). F247L confers a gain of function to Braf, as indicated by activation of downstream MAPK signaling and is transforming in cultured cells (PMID: 28512244).",9257,28512244,Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28512244,26677
"KMT2A-SEPT6 results from the fusion of KMT2A (MLL) and ELLSEPT6, resulting in the transformation of myeloid cells in culture and leukemogenesis in mouse models (PMID: 16314519).",9269,16314519,"Disruption of Sept6, a fusion partner gene of MLL, does not affect ontogeny, leukemogenesis induced by MLL-SEPT6, or phenotype induced by the loss of Sept4.",http://www.ncbi.nlm.nih.gov/pubmed/16314519,26678
"KMT2A fusion indicates a fusion of the KMT2A gene, but the fusion partner is unknown.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,26680
"ALK M1166V lies within the protein kinase domain of the Alk protein (UniProt.org). M1166V has not been characterized in the scientific literature and therefore, its effect on Alk protein function is unknown (PubMed, Jul 2017). ",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,26703
"CALR N158D lies within the N-domain region of the Calr protein (UniProt.org). N158D has not been characterized in the scientific literature and therefore, its effect on Calr protein function is unknown (PubMed, Jul 2017). ",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,26704
ATRX mutant indicates an unspecified mutation in the ATRX gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,26707
"APC P1439fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1439 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). P1439fs has not been characterized, however, Apc truncation mutants downstream of P1439 are inactivating (PMID: 18199528) and thus, P1439fs is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,26817
"STAG2 E1005D does not lie within any known functional domains of the Stag2 protein (UniProt.org). E1005D has not been characterized in the scientific literature and therefore, its effect on Stag2 protein function is unknown (PubMed, Jul 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26823
"FBXW7 Q631* results in a premature truncation of the Fbxw7 protein at amino acid 631 of 707 (UniProt.org). Q631* has been identified in sequencing studies (PMID: 24390348), but has not been characterized and therefore, its effect on Fbxw7 protein function is unknown (PubMed, Jul 2017). ",9612,24390348,Landscape of genomic alterations in cervical carcinomas.,http://www.ncbi.nlm.nih.gov/pubmed/24390348,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26824
"TP53 L111fs results in a change in the amino acid sequence of the Tp53 protein beginning at aa 111 of 393, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the disruption of the DNA binding domain and the loss of the oligomerization domain (PMID: 21561095), L111fs is predicted to lead to a loss of Tp53 protein function.",295,,,www.uniprot.org,2155,21561095,"Structural effects of the L145Q, V157F, and R282W cancer-associated mutations in the p53 DNA-binding core domain.",http://www.ncbi.nlm.nih.gov/pubmed/21561095,26825
"SMAD4 Q83* results in a premature truncation of the Smad4 protein at amino acid 83 of 552 (UniProt.org).  Q83* has not been characterized however, due to the effects of other truncation mutations downstream of Q83, Q83* is predicted to lead to a loss of Smad4 protein function (PMID: 11553622, PMID: 22316667).",3669,22316667,Germline mutations in SMAD4 disrupt bone morphogenetic protein signaling.,http://www.ncbi.nlm.nih.gov/pubmed/22316667,295,,,www.uniprot.org,3668,11553622,Loss of Smad4 function in pancreatic tumors: C-terminal truncation leads to decreased stability.,http://www.ncbi.nlm.nih.gov/pubmed/11553622,26826
"EZH2 T678_R679delinsKK results in a deletion of two amino acids in the SET domain of the Ezh2 protein from amino acids 678 to 679, combined with the insertion of two lysines (K) at the same site (UniProt.org). T678_R679delinsKK has not been fully biochemically characterized but has been demonstrated to confer Tazemetostat (EPZ-6438) resistance in culture (PMID: 28231254).",9725,28231254,Rapid generation of drug-resistance alleles at endogenous loci using CRISPR-Cas9 indel mutagenesis.,http://www.ncbi.nlm.nih.gov/pubmed/28231254,26871
"PIK3CA K944N lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). K944N results in activation of Pik3ca signaling as indicated by increased phosphorylation of Akt and Mapk3/Mapk1 (Erk1/2), and confers resistance to Erbitux (cetuximab) in culture (PMID: 28424201).",9728,28424201,PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28424201,295,,,www.uniprot.org,26872
"PIK3CA V955G lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). V955G results in activation of Pik3ca signaling as indicated by increased phosphorylation of Akt and Mapk3/Mapk1 (Erk1/2), and confers resistance to Erbitux (cetuximab) in culture (PMID: 28424201).",9728,28424201,PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28424201,295,,,www.uniprot.org,26873
"PIK3CA V955I lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). V955I results in activation of Pik3ca signaling as indicated by increased phosphorylation of Akt and Mapk3/Mapk1 (Erk1/2), and confers resistance to Erbitux (cetuximab) in culture (PMID: 28424201).",295,,,www.uniprot.org,9728,28424201,PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28424201,26874
"PIK3CA K966E lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). K966E results in activation of Pik3ca signaling as indicated by increased phosphorylation of Akt and Mapk3/Mapk1 (Erk1/2), and confers resistance to Erbitux (cetuximab) in culture (PMID: 28424201).",295,,,www.uniprot.org,9728,28424201,PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28424201,26875
"PIK3CA F930S lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). F930S results in activation of Pik3ca signaling as indicated by increased phosphorylation of Akt and Mapk3/Mapk1 (Erk1/2), and confers resistance to Erbitux (cetuximab) in culture (PMID: 28424201).",9728,28424201,PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28424201,295,,,www.uniprot.org,26876
"PIK3CA V952A lies within the PI3K/PI4K domain of the Pik3ca protein (UniProt.org). V952A results in activation of Pik3ca signaling as indicated by increased phosphorylation of Akt and Mapk3/Mapk1 (Erk1/2), and confers resistance to Erbitux (cetuximab) in culture (PMID: 28424201).",9728,28424201,PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28424201,295,,,www.uniprot.org,26877
PIK3CA L938* results in a premature truncation of the Pik3ca protein at amino acid 938 of 1068 (UniProt.org). L938* results in activation of Pik3ca signaling as indicated by increased phosphorylation of Akt and Mapk3/Mapk1 (Erk1/2) in culture (PMID: 28424201).,9728,28424201,PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/28424201,295,,,www.uniprot.org,26878
"FLT3 positive indicates the presence of the FLT3 gene, mRNA, and/or protein.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,26881
"ALK V66A lies within the extracellular domain of the Alk protein (UniProt.org). V66A has not been characterized in the scientific literature and therefore, its effect on Alk protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26886
"FGFR3 R112Q lies within the Ig-like C2-type domain 1 of the Fgfr3 protein (UniProt.org). R112Q has not been characterized in the scientific literature and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26889
"MET G1163R lies within the protein kinase domain of the Met protein (UniProt.org). G1163R has been described as a secondary drug resistance mutation due to its inability to bind some Met inhibitors (PMID: 21697284, PMID: 28765324). ",8018,21697284,A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.,http://www.ncbi.nlm.nih.gov/pubmed/21697284,9757,28765324,Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-Mediated Resistance to Type I MET Inhibitors in Nonclinical Models.,http://www.ncbi.nlm.nih.gov/pubmed/28765324,295,,,www.uniprot.org,26893
"MET Y1230S lies within the protein kinase domain of the Met protein (UniProt.org). Y1230S has been identified in the scientific literature (PMID: 28522754), but has not been characterized and therefore, its effect on Met protein function is unknown (PubMed, Aug 2017). ",9758,28522754,MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28522754,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26894
"TP53 I255del results in the deletion of one amino acid in the DNA-binding domain of the Tp53 protein at amino acid 255 (PMID: 15510160). I255del has been identified in the scientific literature (PMID: 27998224), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Aug 2017).",9762,27998224,Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.,http://www.ncbi.nlm.nih.gov/pubmed/27998224,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,26895
"TP53 P98fs results in a change in the amino acid sequence of the Tp53 protein beginning at aa 98 of 393, likely resulting in premature truncation of the functional protein. Due to the loss of the DNA binding region (UniProt.org), P98fs is predicted to lead to a loss of Tp53 protein function.",295,,,www.uniprot.org,26896
TP53 A159V lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). A159V results decreased Tp53 transactivation activity and leads to reduced apoptosis relative to wild type Tp53 in cell culture (PMID: 22862161).,609,22862161,Roscovitine-induced apoptosis of H1299 cells depends on functional status of p53.,http://www.ncbi.nlm.nih.gov/pubmed/22862161,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,26897
TP53 S215G lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). S215G results in decreased Tp53 transactivation activity and leads to reduced apoptosis relative to wild type Tp53 in cell culture (PMID: 22862161).,609,22862161,Roscovitine-induced apoptosis of H1299 cells depends on functional status of p53.,http://www.ncbi.nlm.nih.gov/pubmed/22862161,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,26898
"TP53 Y163* results in a premature truncation of the Tp53 protein at amino acid 163 of 393 (UniProt.org). Due to the loss of several functional domains (UniProt.org), Y163* is predicted to lead to a loss of Tp53 protein function.",295,,,www.uniprot.org,26899
"TP53 L114fs results in a change in the amino acid sequence of the Tp53 protein beginning at aa 114 of 393, likely resulting in premature truncation of the functional protein (UniProt.org). Due to disruption of the DNA binding region and loss of the oligomerization domain (UniProt.org), L114fs is predicted to lead to a loss of Tp53 protein function.",295,,,www.uniprot.org,26901
"TP53 V157fs results in a change in the amino acid sequence of the Tp53 protein beginning at aa 157 of 393, likely resulting in premature truncation of the functional protein (UniProt.org). Due to disruption of the DNA binding region and loss of the oligomerization domain (UniProt.org), V157fs is predicted to lead to a loss of Tp53 protein function.",295,,,www.uniprot.org,26902
"TP53 H193Y lies within the DNA binding domain of the Tp53 protein (UniProt.org). H193Y has been identified in sequencing studies (PMID: 27998224), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Aug 2017).",295,,,www.uniprot.org,9762,27998224,Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.,http://www.ncbi.nlm.nih.gov/pubmed/27998224,26903
TP53 exon 7 indicates an unspecified mutation has occurred in exon 7 of the TP53 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,26904
TP53 exon 5 indicates an unspecified mutation has occurred in exon 5 of the TP53 gene.,275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,26905
"MET F1200L lies within the protein kinase domain of the Met protein (UniProt.org). F1200L has not been biochemically characterized, however, has been described as a secondary drug resistance mutation (PMID: 28765324). ",295,,,www.uniprot.org,9757,28765324,Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-Mediated Resistance to Type I MET Inhibitors in Nonclinical Models.,http://www.ncbi.nlm.nih.gov/pubmed/28765324,26906
"BRAF D287H does not lie within any known functional domains of the Braf protein (UniProt.org). D287H results in impaired Braf kinase activity, and leads to Ras-dependent activation of Erk in cell culture (PMID: 26343582, PMID: 28783719).",295,,,www.uniprot.org,7141,26343582,BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/26343582,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,26912
"BRAF V459L lies with protein kinase domain of the Braf protein (UniProt.org). V459L results in impaired Braf kinase activity, and leads to Ras-dependent activation of Erk in cell culture (PMID: 28783719).",295,,,www.uniprot.org,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,26916
"BRAF S467L lies with protein kinase domain of the Braf protein (UniProt.org). S467L results in impaired Braf kinase activity, and leads to Ras-dependent activation of Erk in cell culture (PMID: 28783719).",295,,,www.uniprot.org,9692,28783719,Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.,http://www.ncbi.nlm.nih.gov/pubmed/28783719,26917
"ALK V198M lies within the extracellular domain of the Alk protein (UniProt.org). V198M has not been characterized in the scientific literature and therefore, its effect on Alk protein function is unknown (PubMed, Aug 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26934
"APC D1022G lies within a region of the Apc protein responsible for down-regulation mediated by ubiquitination (UniProt.org). D1022G has not been characterized in the scientific literature and therefore, its effect on Apc protein function is unknown (PubMed, Aug 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26935
"APC Q1480* results in a premature truncation of the Apc protein at amino acid 1480 of 2843 (UniProt.org). Q1480* has not been characterized, however, due to the effects of an Apc truncation at I1572 (PMID: 10346819), Q1480* is predicted to reduce the ability of Apc to regulate beta-catenin.",2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,26936
"ATM S2407* results in a premature truncation of the Atm protein at amino acid 2407 of 3056 (UniProt.org). Due to the loss of the PI3K/PI4K protein kinase and FATC domains (UniProt.org), S2407* is predicted to lead to a loss of Atm protein function.",295,,,www.uniprot.org,26939
"ATM C532Y does not lie within any known functional domains of the Atm protein (UniProt.org). C532Y has been identified in the scientific literature (PMID: 11756177), but has not been characterized and therefore, its effect on Atm protein function is unknown (PubMed, Aug 2017). ",295,,,www.uniprot.org,7870,11756177,ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances.,http://www.ncbi.nlm.nih.gov/pubmed/11756177,285,,,http://www.ncbi.nlm.nih.gov/pubmed,26942
"PIK3CA P377R lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). P377R has not been characterized in the scientific literature and therefore, its effect on Pik3ca protein function is unknown (PubMed, Aug 2017).",295,,,www.uniprot.org,285,,,http://www.ncbi.nlm.nih.gov/pubmed,26943
"RET G446R lies within the extracellular domain of the Ret protein (UniProt.org). G446R has not been characterized in the scientific literature and therefore, its effect on Ret protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26947
"ROS1 R2083G lies within the protein kinase domain of the Ros1 protein (UniProt.org). R2083G has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26950
"TP53 V203M lies within the DNA binding domain and HIPK1, ZNF385A, FBXO42, and AXIN1 interacting region of the Tp53 protein (UniProt.org). V203M has been identified in sequencing studies (PMID: 16061860), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Aug 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,9815,16061860,FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis.,http://www.ncbi.nlm.nih.gov/pubmed/16061860,295,,,www.uniprot.org,26954
"TP53 E204fs results in a change in the amino acid sequence of the Tp53 protein beginning at aa 204 of 393, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the loss of the oligomerization domain (UniProt.org), E204fs is predicted to lead to a loss of Tp53 protein function.",295,,,www.uniprot.org,26955
MSH6 S503C does not lie within any known functional domains of the Msh6 protein (UniProt.org). S503C demonstrates mismatch repair activity similar to wild-type Msh6 in a cell-free assay (PMID: 22102614).,4989,22102614,A rapid and cell-free assay to test the activity of lynch syndrome-associated MSH2 and MSH6 missense variants.,http://www.ncbi.nlm.nih.gov/pubmed/22102614,295,,,www.uniprot.org,26962
"RET R600Q lies within the extracellular domain of the Ret protein (UniProt.org). R600Q has been identified in the scientific literature (PMID: 10612852), but has not been biochemically characterized and therefore, its effect on Ret protein function is unknown (PubMed, Aug 2017).",295,,,www.uniprot.org,9820,10612852,"A new germline mutation, R600Q, within the coding region of RET proto-oncogene: a rare polymorphism or a MEN 2 causing mutation?",http://www.ncbi.nlm.nih.gov/pubmed/10612852,26964
"KIT M552_V559del results in the deletion of 8 amino acids in the juxtamembrane domain of the Kit protein from amino acids 552 to 559 (PMID: 20633291). K550_K558del confers a gain of function to Kit, as indicated by constitutive Kit phosphorylation in cell culture (PMID: 20633291).",9827,20633291,Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors.,http://www.ncbi.nlm.nih.gov/pubmed/20633291,26967
"KIT S628N lies within the protein kinase domain of the Kit protein (UniProt.org). S628N results in constitutive Kit phosphorylation and activation of downstream STAT3, AKT and ERK1/2, and is transforming in cell culture (PMID: 25317746).",9868,25317746,Characterization of S628N: a novel KIT mutation found in a metastatic melanoma.,http://www.ncbi.nlm.nih.gov/pubmed/25317746,295,,,www.uniprot.org,26968
"KIT R634L lies within the protein kinase domain of the Kit protein (UniProt.org). R634L has been identified in the scientific literature (PMID: 28843487), but has not been biochemically characterized and therefore, its effect on Kit protein function is unknown (PubMed, Sep 2017).",9871,28843487,STAT3 mediates Nilotinib response in KIT-altered Melanoma: a Phase II Multicenter Trial of the French Skin Cancer Network.,http://www.ncbi.nlm.nih.gov/pubmed/28843487,295,,,www.uniprot.org,26969
"KIT L576R lies within the juxtamembrane domain of the Kit protein (PMID: 17372901). L576R has been identified in the scientific literature (PMID: 28843487), but has not been biochemically characterized and therefore, its effect on Kit protein function is unknown (PubMed, Sep 2017). ",9871,28843487,STAT3 mediates Nilotinib response in KIT-altered Melanoma: a Phase II Multicenter Trial of the French Skin Cancer Network.,http://www.ncbi.nlm.nih.gov/pubmed/28843487,285,,,http://www.ncbi.nlm.nih.gov/pubmed,695,17372901,L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition.,http://www.ncbi.nlm.nih.gov/pubmed/17372901,26970
"KIT L631F lies within the protein kinase domain of the Kit protein (UniProt.org). L631F has been identified in the scientific literature (PMID: 28843487), but has not been biochemically characterized and therefore, its effect on Kit protein function is unknown (PubMed, Sep 2017).",9871,28843487,STAT3 mediates Nilotinib response in KIT-altered Melanoma: a Phase II Multicenter Trial of the French Skin Cancer Network.,http://www.ncbi.nlm.nih.gov/pubmed/28843487,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26971
"KIT G565V lies within the cytoplasmic domain of the Kit protein (UniProt.org). G565V has been identified in the scientific literature (PMID: 28843487), but has not been biochemically characterized and therefore, its effect on Kit protein function is unknown (PubMed, Sep 2017).",9871,28843487,STAT3 mediates Nilotinib response in KIT-altered Melanoma: a Phase II Multicenter Trial of the French Skin Cancer Network.,http://www.ncbi.nlm.nih.gov/pubmed/28843487,285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,26972
"BRCA1 L392Qfs*5 is a missense mutation (L392Q) in conjunction with a likely truncation of the 1863 aa Brca1 protein at aa 392, followed by 5 nonsense amino acids (UniProt.org). L392Qfs*5 has not been characterized, however, C-terminal deletion mutants downstream of L392 are inactivating (PMID: 16618730), thus, L392Qfs*5 is predicted to lead to a loss of Brca1 protein function.",295,,,www.uniprot.org,2575,16618730,Identification of domains of BRCA1 critical for the ubiquitin-dependent inhibition of centrosome function.,http://www.ncbi.nlm.nih.gov/pubmed/16618730,26973
"BRCA1 W1782* results in a premature truncation of the Brca1 protein at amino acid 1782 of 1863 (UniProt.org). W1782* has not been characterized, however, other BRCT domain deletion mutants downstream of W1782 are destablizing (PMID: 14534301), thus W1782* is predicted to lead to a loss of Brca1 protein function.",295,,,www.uniprot.org,2590,14534301,Detection of protein folding defects caused by BRCA1-BRCT truncation and missense mutations.,http://www.ncbi.nlm.nih.gov/pubmed/14534301,26974
"BRCA1 L631Qfs*4 is a missense mutation (L631Q) in conjunction with a likely truncation of the 1863 aa Brca1 protein at aa 631, followed by 4 nonsense amino acids (UniProt.org). L631Qfs*4 has not been characterized, however, C-terminal deletion mutants downstream of L631 are inactivating (PMID: 16618730), thus, L631Qfs*4 is predicted to lead to a loss of Brca1 protein function.",295,,,www.uniprot.org,2575,16618730,Identification of domains of BRCA1 critical for the ubiquitin-dependent inhibition of centrosome function.,http://www.ncbi.nlm.nih.gov/pubmed/16618730,26975
"BRCA1 N682* results in a premature truncation of the Brca1 protein at amino acid 682 of 1863 (UniProt.org). N682* has not been characterized, however, other C-terminal deletion mutants downstream of N682 are inactivating (PMID: 16618730), thus N682* is predicted to lead to a loss of Brca1 protein function.",295,,,www.uniprot.org,2575,16618730,Identification of domains of BRCA1 critical for the ubiquitin-dependent inhibition of centrosome function.,http://www.ncbi.nlm.nih.gov/pubmed/16618730,26976
"BRCA1 S377_N417del results in the deletion of 41 amino acids in the Brca1 protein (UniProt.org). S377_N417del has been identified in the scientific literature (PMID: 28588062), but has not been biochemically characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Sep 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9883,28588062,Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28588062,26980
"BRCA1 E427_S713del results in the deletion of 287 amino acids in the Brca1 protein (UniProt.org). E427_S713del has been identified in the scientific literature (PMID: 28588062), but has not been biochemically characterized and therefore, its effect on Brca1 protein function is unknown (PubMed, Sep 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,9883,28588062,Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/28588062,26981
"ABL1 amplification indicates an increased number of copies of the ABL1 gene. However, the mechanism causing the increase is unspecified.",275,10,,http://www.ncbi.nlm.nih.gov/pubmed/10,26990
"BRAF I463T lies within the protein kinase domain of the BRAF protein (UniProt.org). I463T has been identified in the scientific literature (PMID: 28829677), but has not been biochemically characterized and therefore, its effect on Braf protein function is unknown (PubMed, Sep 2017).",295,,,www.uniprot.org,9957,28829677,BRAF mutation as a novel driver of eosinophilic cystitis.,http://www.ncbi.nlm.nih.gov/pubmed/28829677,285,,,http://www.ncbi.nlm.nih.gov/pubmed,27006
"MYD88 V217F lies within the TIR domain of the Myd88 protein (PMID: 25359991). V217F has been identified in the scientific literature (PMID: 27923841, PMID: 25359991, PMID: 28619981), but has not been biochemically characterized and therefore, its effect on Myd88 protein function is unknown (PubMed, Oct 2017). ",10035,28619981,Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/28619981,10041,27923841,Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.,http://www.ncbi.nlm.nih.gov/pubmed/27923841,285,,,http://www.ncbi.nlm.nih.gov/pubmed,10040,25359991,Activation of lymphoma-associated MyD88 mutations via allostery-induced TIR-domain oligomerization.,http://www.ncbi.nlm.nih.gov/pubmed/25359991,27026
"MYD88 M232T lies within the TIR domain of the Myd88 protein (PMID: 27102345). M232T results in high activity of NF-kappaB compared to MYD88 wild-type in vitro and therefore, is predicted to result in a gain of function (PMID: 21179087). ",2809,21179087,Oncogenically active MYD88 mutations in human lymphoma.,http://www.ncbi.nlm.nih.gov/pubmed/21179087,10043,27102345,Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies.,http://www.ncbi.nlm.nih.gov/pubmed/27102345,27027
"TP53 A159P lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). A159P has not been fully biochemically characterized, but demonstrates binding to ZBP-89 at similar level of wild-type Tp53 in culture (PMID: 12759240).",10052,12759240,Mutation of p53 in recurrent hepatocellular carcinoma and its association with the expression of ZBP-89.,http://www.ncbi.nlm.nih.gov/pubmed/12759240,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,27033
"TP53 V157P lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). V157P has not been fully biochemically characterized, but demonstrated binding to ZBP-89 at similar level of wild-type Tp53 in culture (PMID: 12759240).",10052,12759240,Mutation of p53 in recurrent hepatocellular carcinoma and its association with the expression of ZBP-89.,http://www.ncbi.nlm.nih.gov/pubmed/12759240,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,27034
TP53 C242Y lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). C242Y confers a loss of function to the Tp52 protein as indicated by abolished ZBP-89 interaction in culture (PMID: 12759240).,10052,12759240,Mutation of p53 in recurrent hepatocellular carcinoma and its association with the expression of ZBP-89.,http://www.ncbi.nlm.nih.gov/pubmed/12759240,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,27035
"TP53 D281E lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). D281E results in a loss of Tp53 transactivation activity in an yeast assay and loss of ZBP-89 binding in cell culture (PMID: 20407015, PMID: ",10052,12759240,Mutation of p53 in recurrent hepatocellular carcinoma and its association with the expression of ZBP-89.,http://www.ncbi.nlm.nih.gov/pubmed/12759240,643,20407015,Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20407015,27036
TP53 R181P lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). R181P results in a loss of Tp53 transactivation activity in cell culture (PMID: 23149933).,10053,23149933,Oxidized DJ-1 inhibits p53 by sequestering p53 from promoters in a DNA-binding affinity-dependent manner.,http://www.ncbi.nlm.nih.gov/pubmed/23149933,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,27037
TP53 S183L lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). S183L results in a loss of Tp53 transactivation activity in a yeast assay (PMID: 20407015).,643,20407015,Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20407015,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,27038
TP53 N239D lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). N239D results in a loss of Tp53 transactivation activity in a yeast assay (PMID: 20407015).,643,20407015,Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20407015,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,27039
TP53 N239T lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). N239T results in a loss of Tp53 transactivation activity in a yeast assay (PMID: 20407015).,643,20407015,Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20407015,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,27040
TP53 C242S lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). C242S results in a loss of Tp53 transactivation activity in a yeast assay (PMID: 20407015).,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,643,20407015,Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20407015,27041
TP53 M243T lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). M243T results in a loss of Tp53 transactivation activity in a yeast assay (PMID: 20407015).,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,643,20407015,Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20407015,27042
TP53 G244V lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). G244V results in a loss of Tp53 transactivation activity in a yeast assay (PMID: 20407015).,643,20407015,Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20407015,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,27043
TP53 M246A lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). M246A results in a loss of Tp53 transactivation activity in a yeast assay (PMID: 20407015).,643,20407015,Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20407015,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,27044
TP53 M246T lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). M246T results in a loss of Tp53 transactivation activity in a yeast assay (PMID: 20407015).,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,643,20407015,Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20407015,27045
TP53 D259V lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). D259V results in a loss of Tp53 transactivation activity in a yeast assay (PMID: 20407015).,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,643,20407015,Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20407015,27046
TP53 G266R lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). G266R results in decreased Tp53 transactivation activity in cell culture (PMID: 16827139).,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,10057,16827139,P53 mutants suppress ZBP-89 function.,http://www.ncbi.nlm.nih.gov/pubmed/16827139,27047
TP53 V143A lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). V143A results in decreased Tp53 transactivation activity in cell culture (PMID: 16827139).,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,10057,16827139,P53 mutants suppress ZBP-89 function.,http://www.ncbi.nlm.nih.gov/pubmed/16827139,27048
TP53 Y236C lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). Y236C results in decreased Tp53 transactivation activity in cell culture (PMID: 16827139).,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,10057,16827139,P53 mutants suppress ZBP-89 function.,http://www.ncbi.nlm.nih.gov/pubmed/16827139,27049
"TP53 K305M lies within the nuclear localization signal domain of the Tp53 protein (PMID: 15510160). K305M results in a loss of Tp53 transactivation activity in a yeast assay and loss of nuclear Tp53 in a tumor sample (PMID: 20407015, PMID: 10719737).",10058,10719737,Distinct prognostic values of p53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancers.,http://www.ncbi.nlm.nih.gov/pubmed/10719737,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,643,20407015,Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20407015,27050
TP53 C135S lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). C135S confers a loss of function to the Tp53 protein as indicated by decreased DNA binding in cell culture (PMID: 12034820).,7605,12034820,Redox state of tumor suppressor p53 regulates its sequence-specific DNA binding in DNA-damaged cells by cysteine 277.,http://www.ncbi.nlm.nih.gov/pubmed/12034820,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,27051
"MYD88 F270S lies within the TIR domain of the Myd88 protein (UniProt.org). F270S has not been fully biochemically characterized, however, demonstrates disrupted binding of Myd88 to Mal in vitro (PMID: 26876098).",10059,26876098,Reconstructing the TIR Side of the Myddosome: a Paradigm for TIR-TIR Interactions.,http://www.ncbi.nlm.nih.gov/pubmed/26876098,295,,,www.uniprot.org,27052
"MYD88 P245S lies within the TIR domain of the Myd88 protein (UniProt.org). P245S has not been fully biochemically characterized, however, demonstrates disrupted binding of Myd88 to Mal in vitro (PMID: 26876098).",295,,,www.uniprot.org,10059,26876098,Reconstructing the TIR Side of the Myddosome: a Paradigm for TIR-TIR Interactions.,http://www.ncbi.nlm.nih.gov/pubmed/26876098,27053
"MYD88 T272H lies within the TIR domain of the Myd88 protein (UniProt.org). T272H has not been fully biochemically characterized, however, demonstrates disrupted binding of Myd88 to Mal in vitro (PMID: 26876098).",295,,,www.uniprot.org,10059,26876098,Reconstructing the TIR Side of the Myddosome: a Paradigm for TIR-TIR Interactions.,http://www.ncbi.nlm.nih.gov/pubmed/26876098,27054
TP53 C277S lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). C277S demonstrates enhanced DNA binding capacity comparing to wild-type Tp53 in cell culture (PMID: 12034820).,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,7605,12034820,Redox state of tumor suppressor p53 regulates its sequence-specific DNA binding in DNA-damaged cells by cysteine 277.,http://www.ncbi.nlm.nih.gov/pubmed/12034820,27055
TP53 C124S lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). C124S demonstrates enhanced DNA binding capacity comparing to wild-type Tp53 in cell culture (PMID: 12034820).,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,7605,12034820,Redox state of tumor suppressor p53 regulates its sequence-specific DNA binding in DNA-damaged cells by cysteine 277.,http://www.ncbi.nlm.nih.gov/pubmed/12034820,27056
"TP53 Y234S lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). Y234S has been identified in sequencing studies (PMID: 24667986), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,285,,,http://www.ncbi.nlm.nih.gov/pubmed,10060,24667986,Novel insight into mutational landscape of head and neck squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/24667986,27057
"MYD88 S244A lies within the TIR domain of the Myd88 protein (UniProt.org). S244A confers a loss of function to the Myd88 protein as demonstrated by decreased NF-kappaB activity compared to wild-type, and disruption of both Myd88 homodimerization and recruitment of IL-1 receptor-associated kinases in culture (PMID: 24019529).",10061,24019529,Mutational analysis identifies residues crucial for homodimerization of myeloid differentiation factor 88 (MyD88) and for its function in immune cells.,http://www.ncbi.nlm.nih.gov/pubmed/24019529,295,,,www.uniprot.org,27058
"MYD88 S244D lies within the TIR domain of the Myd88 (UniProt.org).  S244D has not been fully biochemically characterized, however, does not result in disrupted binding of Myd88 to Mal in vitro (PMID: 26876098).",10059,26876098,Reconstructing the TIR Side of the Myddosome: a Paradigm for TIR-TIR Interactions.,http://www.ncbi.nlm.nih.gov/pubmed/26876098,295,,,www.uniprot.org,27059
"TP53 R283P lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). R283P has not been fully biochemically characterized, but results in decreased transactivation activity in a yeast assay (PMID: 20407015).",643,20407015,Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20407015,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,27060
"MYD88 L211F lies within the TIR domain of the Myd88 protein (UniProt.org). L211F has not been fully biochemically characterized, however, demonstrates disrupted binding of Myd88 to Mal in vitro (PMID: 26876098).",10059,26876098,Reconstructing the TIR Side of the Myddosome: a Paradigm for TIR-TIR Interactions.,http://www.ncbi.nlm.nih.gov/pubmed/26876098,295,,,www.uniprot.org,27061
"MYD88 N278Y lies within the TIR domain of the Myd88 protein (UniProt.org). N278Y has not been fully biochemically characterized, however, demonstrates disrupted binding of Myd88 to Mal in vitro (PMID: 26876098).",10059,26876098,Reconstructing the TIR Side of the Myddosome: a Paradigm for TIR-TIR Interactions.,http://www.ncbi.nlm.nih.gov/pubmed/26876098,295,,,www.uniprot.org,27062
"MYD88 P279L lies within the TIR domain of the Myd88 protein (UniProt.org). P279L has not been fully biochemically characterized, however, demonstrates disrupted binding of Myd88 to Mal in vitro (PMID: 26876098).",10059,26876098,Reconstructing the TIR Side of the Myddosome: a Paradigm for TIR-TIR Interactions.,http://www.ncbi.nlm.nih.gov/pubmed/26876098,295,,,www.uniprot.org,27063
"MYD88 W205R lies within the TIR domain of the Myd88 protein (UniProt.org). W205R has not been characterized in the scientific literature and therefore, its effect on Myd88 protein function is unknown (PubMed, Oct 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,27064
"TP53 R280T lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). R280T results in a loss of Tp53 transactivation activity and is transforming in cell culture (PMID: 16616891, PMID: 8464896).",10062,16616891,A dominant negative form of p63 inhibits apoptosis in a p53-independent manner.,http://www.ncbi.nlm.nih.gov/pubmed/16616891,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,10063,8464896,Progression toward tumor cell phenotype is enhanced by overexpression of a mutant p53 tumor-suppressor gene isolated from nasopharyngeal carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/8464896,27065
TP53 R213Q lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). R213Q is predicted to lead to a loss of Tp53 protein function as indicated by increased cell proliferation in culture and tumor growth in animal models (PMID: 8080050).,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,10064,8080050,Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness.,http://www.ncbi.nlm.nih.gov/pubmed/8080050,27066
"TP53 R213G lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). R213G has been identified in sequencing studies (PMID: 26319365), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,10066,26319365,Mutational Analysis of BRAF Inhibitor-Associated Squamoproliferative Lesions.,http://www.ncbi.nlm.nih.gov/pubmed/26319365,27067
"APC E1408* results in a premature truncation of the Apc protein at amino acid 1408 of 2843 (UniProt.org). E1408* has not been characterized, however, due to the effects of Apc truncation mutations downstream of E1408 (PMID: 18199528, PMID: 10346819), E1408* is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,27068
"TP53 Q317* results in a premature truncation of the Tp53 protein at amino acid 317 of 393 (UniProt.org). Due to the loss of the tetramerization domain (PMID: 22713868), Q317* is predicted to lead to a loss of Tp53 function.",2397,22713868,"Mutant p53: one name, many proteins.",http://www.ncbi.nlm.nih.gov/pubmed/22713868,295,,,www.uniprot.org,27069
"TP53 P278H lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). P278H has been identified in sequencing studies (PMID: 25151357), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,1252,25151357,Genetic landscape of esophageal squamous cell carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/25151357,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,27070
"TP53 P250L lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). P250L has been identified in sequencing studies (PMID: 21232794), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,285,,,http://www.ncbi.nlm.nih.gov/pubmed,556,21232794,A comprehensive study of TP53 mutations in chronic lymphocytic leukemia: Analysis of 1287 diagnostic and 1148 follow-up CLL samples.,http://www.ncbi.nlm.nih.gov/pubmed/21232794,27071
"APC R499* results in a premature truncation of the Apc protein at amino acid 499 of 2843 (UniProt.org). Due to the loss of the beta-catenin binding and down-regulation regions (PMID: 14672538), R499* is predicted to lead to a loss of Apc protein function.",295,,,www.uniprot.org,2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,27072
"TP53 P177L lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). P177L has not been biochemically characterized, but demonstrates transactivation activity similar to wild-type Tp53 in a yeast assay (PMID: 9627118).",4345,9627118,Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay.,http://www.ncbi.nlm.nih.gov/pubmed/9627118,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,27073
"TP53 P152fs results in a change in the amino acid sequence of the Tp53 protein beginning at aa 152 of 393, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the disruption of the DNA binding domain and the loss of the oligomerization domain (PMID: 21561095), P152fs is predicted to lead to a loss of Tp53 protein function.",295,,,www.uniprot.org,2155,21561095,"Structural effects of the L145Q, V157F, and R282W cancer-associated mutations in the p53 DNA-binding core domain.",http://www.ncbi.nlm.nih.gov/pubmed/21561095,27074
"APC R805* results in a premature truncation of the Apc protein at amino acid 805 of 2843 (UniProt.org). R805* is transforming in cell culture, and due to the loss of multiple functional domains important for beta-catenin regulation, is predicted to result in a loss of Apc protein function (PMID: 28769798).",10069,28769798,Molecular Characterization of Somatic Alterations in Dukes' B and C Colorectal Cancers by Targeted Sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/28769798,295,,,www.uniprot.org,27075
"TP53 I195S lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). I195S has not been biochemically characterized, but demonstrates a loss of Tp53 transactivation activity in a yeast assay (PMID: 23897043).",10070,23897043,Validation of a yeast functional assay for p53 mutations using clonal sequencing.,http://www.ncbi.nlm.nih.gov/pubmed/23897043,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,27076
"TP53 H214R lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). H214R has not been fully biochemically characterized, but results in decreased transactivation activity in a yeast assay (PMID: 20407015).",5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,643,20407015,Altered-function p53 missense mutations identified in breast cancers can have subtle effects on transactivation.,http://www.ncbi.nlm.nih.gov/pubmed/20407015,27077
"APC S1411fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1411 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). S1411fs has not been characterized, however, due to the effects of Apc truncation mutations downstream of S1411 (PMID: 10346819, PMID: 18199528), S1411fs is predicted to result in a loss in Apc protein function.",2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,27078
"APC T1487fs results in a change in the amino acid sequence of the Apc protein beginning at aa 1487 of 2843, likely resulting in premature truncation of the functional protein (UniProt.org). T1487fs has not been characterized, however, due to the effects of Apc truncation mutations downstream of T1487 (PMID: 10346819, PMID: 18199528), T1487fs is predicted to result in a loss in Apc protein function.",2395,18199528,Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas.,http://www.ncbi.nlm.nih.gov/pubmed/18199528,2409,10346819,Apc1638T: a mouse model delineating critical domains of the adenomatous polyposis coli protein involved in tumorigenesis and development.,http://www.ncbi.nlm.nih.gov/pubmed/10346819,295,,,www.uniprot.org,27079
"APC Y935* results in a premature truncation of the Apc protein at amino acid 935 of 2843 (UniProt.org). Y935* has not been characterized, however, due to the loss of the beta-catenin binding and down-regulation regions (PMID: 14672538), Y935* is predicted to lead to a loss of Apc protein function.",2392,14672538,Role of APC and DNA mismatch repair genes in the development of colorectal cancers.,http://www.ncbi.nlm.nih.gov/pubmed/14672538,295,,,www.uniprot.org,27080
"TP53 H193L lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). H193L has been identified in the scientific literature (PMID: 21056685), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,285,,,http://www.ncbi.nlm.nih.gov/pubmed,4320,21056685,Co-localization of mutant p53 and amyloid-like protein aggregates in breast tumors.,http://www.ncbi.nlm.nih.gov/pubmed/21056685,27081
TP53 H179Y lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). H179Y confers a loss of function to the Tp53 protein as indicated by increased Ccna1 and Cdk4 expression and cell proliferation in culture (PMID: 17530187).,10074,17530187,The over-expression of p53 H179Y residue mutation causes the increase of cyclin A1 and Cdk4 expression in HELF cells.,http://www.ncbi.nlm.nih.gov/pubmed/17530187,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,27082
TP53 H179L lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). H179L confers a loss of function to the Tp53 protein as indicated by transformation in culture and promoting tumor formation and invasion in animal models (PMID: 9049183).,10078,9049183,Functional characterization in vivo of mutant p53 molecules derived from squamous cell carcinomas of the head and neck.,http://www.ncbi.nlm.nih.gov/pubmed/9049183,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,27083
"TP53 G266V lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). G266V has been identified in sequencing studies (PMID: 21094160), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",10079,21094160,Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma.,http://www.ncbi.nlm.nih.gov/pubmed/21094160,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,27084
"TP53 G266E lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). G266E has not been fully biochemically characterized, but has been shown to promote cell motility in culture (PMID: 22114072).",378,22114072,Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.,http://www.ncbi.nlm.nih.gov/pubmed/22114072,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,27085
"TP53 G244fs results in a change in the amino acid sequence of the Tp53 protein beginning at aa 244 of 393, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the disruption of the DNA binding domain and the loss of the oligomerization domain (PMID: 21561095), G244fs is predicted to lead to a loss of Tp53 protein function.",295,,,www.uniprot.org,2155,21561095,"Structural effects of the L145Q, V157F, and R282W cancer-associated mutations in the p53 DNA-binding core domain.",http://www.ncbi.nlm.nih.gov/pubmed/21561095,27086
"TET2 Q544* results in a premature truncation of the Tet2 protein at amino acid 544 of 2002 (UniProt.org). Q544* has been identified in the scientific literature (PMID: 20008300), but has not been biochemically characterized, however, due to the loss of the DNA binding and substrate binding regions (UniProt.org), Q544* is predicted to lead to a loss of Tet2 protein function.",10083,20008300,Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm.,http://www.ncbi.nlm.nih.gov/pubmed/20008300,295,,,www.uniprot.org,27087
"TP53 G244D lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). G244D has not been biochemically characterized however, has been demonstrated to inhibit wild-type Tp53 function in a yeast assay (PMID: 8633021).",5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,10084,8633021,Dominant-negative p53 mutations selected in yeast hit cancer hot spots.,http://www.ncbi.nlm.nih.gov/pubmed/8633021,27088
"TP53 G154fs results in a change in the amino acid sequence of the Tp53 protein beginning at aa 154 of 393, likely resulting in premature truncation of the functional protein (UniProt.org). Due to the disruption of the DNA binding domain and the loss of the oligomerization domain (PMID: 21561095), G154fs is predicted to lead to a loss of Tp53 protein function.",295,,,www.uniprot.org,2155,21561095,"Structural effects of the L145Q, V157F, and R282W cancer-associated mutations in the p53 DNA-binding core domain.",http://www.ncbi.nlm.nih.gov/pubmed/21561095,27090
TP53 C141Y lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). C141Y results in a loss of transcription activity in a subset of Tp53-target genes and increased expression of genes downregulated by wild-type Tp53 in culture (PMID: 12725534).,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,10102,12725534,Differentially expressed downstream genes in cells with normal or mutated p53.,http://www.ncbi.nlm.nih.gov/pubmed/12725534,27091
TP53 A138T lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). A138T results in a loss of transcription activity in a subset of Tp53-targeted genes in culture (PMID: 12725534).,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,10102,12725534,Differentially expressed downstream genes in cells with normal or mutated p53.,http://www.ncbi.nlm.nih.gov/pubmed/12725534,27092
"TP53 C176Y lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). C176Y has been identified in sequencing studies (PMID: 19759556), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",10105,19759556,TP53 mutations in myeloid malignancies are either homozygous or hemizygous due to copy number-neutral loss of heterozygosity or deletion of 17p.,http://www.ncbi.nlm.nih.gov/pubmed/19759556,5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,285,,,http://www.ncbi.nlm.nih.gov/pubmed,27093
"TP53 E286K lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). E286K has not been fully biochemically characterized, but results in decreased transactivation activity in a yeast assay (PMID: 17724467).",5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,3143,17724467,Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast.,http://www.ncbi.nlm.nih.gov/pubmed/17724467,27094
"TP53 G154V lies within the DNA-binding domain of the Tp53 protein (PMID: 15510160). G154V has been identified in the scientific literature (PMID: 26288819), but has not been biochemically characterized and therefore, its effect on Tp53 protein function is unknown (PubMed, Oct 2017).",5145,15510160,Post-translational modification of p53 in tumorigenesis.,http://www.ncbi.nlm.nih.gov/pubmed/15510160,10107,26288819,Characterization of Somatic Mutations in Air Pollution-Related Lung Cancer.,http://www.ncbi.nlm.nih.gov/pubmed/26288819,285,,,http://www.ncbi.nlm.nih.gov/pubmed,27095
"ROS1 G1027D lies within the fibronectin type-III domain 4 of the Ros1 protein (UniProt.org). G1027D has not been characterized in the scientific literature and therefore, its effect on Ros1 protein function is unknown (PubMed, Oct 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,27097
"ATM V2439A lies within the FAT domain of the Atm protein (UniProt.org). V2439A has been identified in the scientific literature (PMID: 12810666), but has not been biochemically characterized and therefore, its effect on Atm protein function is unknown (PubMed, Oct 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,27098
"DNMT3A Y735S lies within the SAM-dependent C5-type MTase domain of the Dnmt3a protein (UniProt.org). Y735S has been identified in the scientific literature (PMID: 26290145), but has not been biochemically characterized and therefore, its effect on Dnmt3a protein function is unknown (PubMed, Oct 2017).",295,,,www.uniprot.org,10121,26290145,Distribution of mutations in DNMT3A gene and the suitability of mutations in R882 codon for MRD monitoring in patients with AML.,http://www.ncbi.nlm.nih.gov/pubmed/26290145,285,,,http://www.ncbi.nlm.nih.gov/pubmed,27100
"CSF3R L23M does not lie within any known functional domains of the Csf3r protein (Uniprot.org). L23M has not been characterized in the scientific literature and therefore, its effect on Csf3r protien function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,27101
"ERBB2 (HER2) D277G lies within the extracellular domain of the Erbb2 (Her2) protein (UniProt.org). D277G has not been characterized in the scientific literature and therefore, its effect on Erbb2 (Her2) protein function is unknown (PubMed, Oct 2017). ",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,27102
"CDH1 D805* results in a premature truncation of the Cdh1 protein at amino acid 805 of 882 (UniProt.org). Due to the loss of the catenin-binding region (UniProt.org), D805* is predicted to lead to a loss of Cdh1 protein.",295,,,www.uniprot.org,27103
ERBB2 (HER2) R966C lies within the protein kinase domain of the Erbb2 (Her2) protein (UniProt.org). R966C results in decreased Erbb2 (Her2) and Mapk phosphorylation in cell culture (PMID: 28743916).,295,,,www.uniprot.org,10127,28743916,Analysis of somatic mutations across the kinome reveals loss-of-function mutations in multiple cancer types.,http://www.ncbi.nlm.nih.gov/pubmed/28743916,27105
"NPM1 E226* results in a premature truncation of the Npm1 protein at amino acid 226 of 294 (UniProt.org). E226* has not been characterized in the scientific literature and therefore, its effect on Npm1 protein function is unknown (PubMed, Oct 2017).",285,,,http://www.ncbi.nlm.nih.gov/pubmed,295,,,www.uniprot.org,27106
